docid|source|sourcetype|target|targettype|type
0|Early Phase Clinical Trial|Topic|Phase I Trials|Topic|RELATED_TO
0|Phase I Trials|Topic|Cytotoxic Agents|Topic|RELATED_TO
0|Bayesian Early Phase Trial Designs|Topic|Peter F. Thall|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Tianyu Zhan|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Yiwang Zhou|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Ziqian Geng|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Yihua Gu|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Jian Kang|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Li Wang|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Xiaohong Huang|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Elizabeth H. Slate|Author|AUTHORED
2|Pilot Studies Of Structured Treatment Interruptions (Sti) In Hiv Therapy|Topic|Hiv Therapy|Topic|RELATED_TO
2|Hiv Therapy|Topic|Virologic Failure|Topic|RELATED_TO
2|Novel Hypothesis|Topic|Virologic Failure|Topic|RELATED_TO
2|Mathematical Model Of Hiv Within-Host Viral Dynamics|Topic|Nonlinear Parametric Resonance|Topic|RELATED_TO
2|Nonlinear Parametric Resonance|Topic|Virologic Failure|Topic|RELATED_TO
2|Clinical Trial Data|Topic|Patient-Specific Resonant Spectra|Topic|RELATED_TO
2|Heterogeneity Of Patient Response|Topic|Virologic Failure|Topic|RELATED_TO
2|Immunologic And Virologic Parameters|Topic|Patient-Specific Resonant Spectra|Topic|RELATED_TO
2|Romulus Breban|Author|Pilot Studies Of Structured Treatment Interruptions (Sti) In Hiv Therapy|Topic|AUTHORED
2|Sally Blower|Author|Pilot Studies Of Structured Treatment Interruptions (Sti) In Hiv Therapy|Topic|AUTHORED
3|Preventive Vaccines|Topic|Hiv|Topic|RELATED_TO
3|Hiv|Topic|Immune Response Markers|Topic|RELATED_TO
3|Immune Response Markers|Topic|Two-Phase Sampling|Topic|RELATED_TO
3|Two-Phase Sampling|Topic|Nonparametric Methodology|Topic|RELATED_TO
3|Nonparametric Methodology|Topic|Txshift R Package|Topic|RELATED_TO
3|Txshift R Package|Topic|Nima S. Hejazi|Author|AUTHORED
3|Txshift R Package|Topic|Mark J. Van Der Laan|Author|AUTHORED
3|Txshift R Package|Topic|Holly E. Janes|Author|AUTHORED
3|Txshift R Package|Topic|Peter B. Gilbert|Author|AUTHORED
3|Txshift R Package|Topic|David C. Benkeser|Author|AUTHORED
4|Phase 1-2 Designs|Topic|Generalized Phase 1-2 Design|Topic|RELATED_TO
4|Generalized Phase 1-2 Design|Topic|Biological Outcome|Topic|RELATED_TO
4|Biological Outcome|Topic|Therapeutically Optimal Dose|Topic|RELATED_TO
4|Demo|Paper|Cheng-Han Yang|Author|AUTHORED
4|Demo|Paper|Peter F. Thall|Author|AUTHORED
4|Demo|Paper|Ruitao Lin|Author|AUTHORED
5|Align|Topic|Large Language Models|Topic|RELATED_TO
5|Align|Topic|Anatomical Therapeutic Chemical|Topic|RELATED_TO
5|Align|Topic|Medical Dictionary For Regulatory Activities|Topic|RELATED_TO
5|Align|Topic|Clinical Trial Data|Topic|RELATED_TO
5|Align|Topic|Drug Development|Topic|RELATED_TO
5|Nabeel Seedat|Author|Align|Topic|AUTHORED
5|Caterina Tozzi|Author|Align|Topic|AUTHORED
5|Andrea Hita Ardiaca|Author|Align|Topic|AUTHORED
5|Mihaela Van Der Schaar|Author|Align|Topic|AUTHORED
5|James Weatherall|Author|Align|Topic|AUTHORED
5|Adam Taylor|Author|Align|Topic|AUTHORED
6|Ross M. Kedl|Author|An Immunological Autobiography|Paper|AUTHORED
6|An Immunological Autobiography|Paper|Sars-Cov2 And Variants Of Concern|Topic|DISCUSSES
6|An Immunological Autobiography|Paper|Moderna Phase Iii Clinical Trial|Topic|DISCUSSES
6|An Immunological Autobiography|Paper|Longitudinal Evaluation Of T And B Cell Immunity|Topic|DISCUSSES
6|An Immunological Autobiography|Paper|Covid-19 Vaccine Trial|Topic|RELATED_TO
7|Sleep Monitoring Algorithm|Topic|Hao He|Author|AUTHORED
7|Sleep Monitoring Algorithm|Topic|Chao Li|Author|AUTHORED
7|Sleep Monitoring Algorithm|Topic|Wolfgang Ganglberger|Author|AUTHORED
7|Sleep Monitoring Algorithm|Topic|Kaileigh Gallagher|Author|AUTHORED
7|Sleep Monitoring Algorithm|Topic|Rumen Hristov|Author|AUTHORED
7|Sleep Monitoring Algorithm|Topic|Michail Ouroutzoglou|Author|AUTHORED
7|Sleep Monitoring Algorithm|Topic|Haoqi Sun|Author|AUTHORED
7|Sleep Monitoring Algorithm|Topic|Jimeng Sun|Author|AUTHORED
7|Sleep Monitoring Algorithm|Topic|Brandon Westover|Author|AUTHORED
7|Sleep Monitoring Algorithm|Topic|Dina Katabi|Author|AUTHORED
8|Vaccine Efficacy Estimands|Topic|Mats Stensrud|Author|AUTHORED
8|Vaccine Efficacy Estimands|Topic|Daniel Nevo|Author|AUTHORED
8|Vaccine Efficacy Estimands|Topic|Uri Obolski|Author|AUTHORED
8|Vaccine Efficacy Estimands|Topic|Influenza Vaccine Trial|Topic|RELATED_TO
9|Panacea|Topic|Trialalign|Topic|RELATED_TO
9|Panacea|Topic|Trialinstruct|Topic|RELATED_TO
9|Panacea|Topic|Trialpanorama|Topic|RELATED_TO
9|Jiacheng Lin|Author|Panacea|Topic|AUTHORED
9|Hanwen Xu|Author|Panacea|Topic|AUTHORED
9|Zifeng Wang|Author|Panacea|Topic|AUTHORED
9|Sheng Wang|Author|Panacea|Topic|AUTHORED
9|Jimeng Sun|Author|Panacea|Topic|AUTHORED
10|Immune Correlates Of Protection|Topic|Correlates Of Risk|Topic|RELATED_TO
10|Correlates Of Risk|Topic|Controlled Vaccine Efficacy Curve|Topic|RELATED_TO
10|Controlled Vaccine Efficacy Curve|Topic|Controlled-Risk Curve|Topic|RELATED_TO
10|Controlled Vaccine Efficacy Curve|Topic|50% Neutralizing Antibody Titer|Topic|RELATED_TO
10|50% Neutralizing Antibody Titer|Topic|Virologically Confirmed Dengue|Topic|RELATED_TO
10|Peter B. Gilbert|Author|Cyd14|Paper|AUTHORED
10|Youyi Fong|Author|Cyd14|Paper|AUTHORED
10|Marco Carone|Author|Cyd14|Paper|AUTHORED
10|Peter B. Gilbert|Author|Cyd15|Paper|AUTHORED
10|Youyi Fong|Author|Cyd15|Paper|AUTHORED
10|Marco Carone|Author|Cyd15|Paper|AUTHORED
11|Trial2Vec|Topic|Zifeng Wang|Author|AUTHORED
11|Trial2Vec|Topic|Jimeng Sun|Author|AUTHORED
11|Trial2Vec|Topic|Clinical Trials|Topic|DISCUSSES
11|Trial2Vec|Topic|Umls Knowledge Base|Topic|RELATED_TO
12|Clinical Trials|Topic|Drug Development|Topic|RELATED_TO
12|Trial Outcome Prediction|Topic|Spot|Paper|AUTHORED
12|Spot|Paper|Drug Development|Topic|DISCUSSES
13|Clinical Trial Outcome (Cto) Dataset|Paper|Chufan Gao|Author|AUTHORED
13|Clinical Trial Outcome (Cto) Dataset|Paper|Jathurshan Pradeepkumar|Author|AUTHORED
13|Clinical Trial Outcome (Cto) Dataset|Paper|Trisha Das|Author|AUTHORED
13|Clinical Trial Outcome (Cto) Dataset|Paper|Shivashankar Thati|Author|AUTHORED
13|Clinical Trial Outcome (Cto) Dataset|Paper|Jimeng Sun|Author|AUTHORED
13|Drug Discovery And Development|Topic|Clinical Trials|Topic|RELATED_TO
13|Clinical Trials|Topic|Clinical Trial Outcome (Cto) Dataset|Paper|DISCUSSES
14|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|Matrix-Valued Time-Series Data Clustering|Topic|DISCUSSES
14|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|Low-Dimensional Embedding|Topic|DISCUSSES
14|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|Static Clinical Covariates|Topic|DISCUSSES
14|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|High-Dimensional Longitudinal Features|Topic|DISCUSSES
14|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|Sparse And Irregular Nature Of Sample Collection|Topic|DISCUSSES
15|World Health Organization|Topic|Hiv Treatment Monitoring|Topic|RELATED_TO
15|Hiv Treatment Monitoring|Topic|Viral Load Testing|Topic|RELATED_TO
15|Hiv Treatment Monitoring|Topic|Diagnostic Algorithm|Topic|RELATED_TO
15|Diagnostic Algorithm|Topic|Miriam Hospital Immunology Clinic|Topic|RELATED_TO
15|Tao Liu|Author|Diagnostic Algorithm|Topic|AUTHORED
15|Joseph W. Hogan|Author|Diagnostic Algorithm|Topic|AUTHORED
15|Lisa Wang|Author|Diagnostic Algorithm|Topic|AUTHORED
15|Shangxuan Zhang|Author|Diagnostic Algorithm|Topic|AUTHORED
15|Rami Kantor|Author|Diagnostic Algorithm|Topic|AUTHORED
16|Clinical Trials|Topic|Nlp|Topic|RELATED_TO
16|Nlp|Topic|Eligibility Classification|Topic|RELATED_TO
16|Eligibility Classification|Topic|Phase 3 Cancer Trials|Topic|RELATED_TO
16|Eligibility Classification|Topic|Phase 1 And 2 Cancer Trials|Topic|RELATED_TO
16|Eligibility Classification|Topic|Heart Disease Trials|Topic|RELATED_TO
16|Eligibility Classification|Topic|Type 2 Diabetes Trials|Topic|RELATED_TO
16|Eligibility Classification|Topic|Observational Trials|Topic|RELATED_TO
16|Yumeng Yang|Author|Annotated Eligibility Criteria Dataset|Topic|AUTHORED
16|Ashley Gilliam|Author|Annotated Eligibility Criteria Dataset|Topic|AUTHORED
16|Ethan B Ludmir|Author|Annotated Eligibility Criteria Dataset|Topic|AUTHORED
16|Kirk Roberts|Author|Annotated Eligibility Criteria Dataset|Topic|AUTHORED
17|Trialsynth|Topic|Chufan Gao|Author|AUTHORED
17|Trialsynth|Topic|Mandis Beigi|Author|AUTHORED
17|Trialsynth|Topic|Afrah Shafquat|Author|AUTHORED
17|Trialsynth|Topic|Jacob Aptekar|Author|AUTHORED
17|Trialsynth|Topic|Jimeng Sun|Author|AUTHORED
18|Ct-Bert|Topic|Natural Language Processing (Nlp) Of Clinical Trial Documents|Topic|RELATED_TO
18|Ct-Bert|Topic|Named Entity Recognition (Ner) Models|Topic|RELATED_TO
18|Ct-Bert|Topic|Clinical Trial Nlp|Topic|RELATED_TO
18|Ct-Bert|Topic|Attention-Based Bilstm|Topic|RELATED_TO
18|Ct-Bert|Topic|Criteria2Query|Topic|RELATED_TO
18|Xiong Liu|Author|Ct-Bert|Topic|AUTHORED
18|Greg L. Hersch|Author|Ct-Bert|Topic|AUTHORED
18|Iya Khalil|Author|Ct-Bert|Topic|AUTHORED
18|Murthy Devarakonda|Author|Ct-Bert|Topic|AUTHORED
19|Ctp-Llm|Topic|Clinical Trial Outcome Prediction (Ctop)|Topic|RELATED_TO
19|Ctp-Llm|Topic|Phasetransition Dataset|Topic|RELATED_TO
19|Michael Reinisch|Author|Ctp-Llm|Topic|AUTHORED
19|Jianfeng He|Author|Ctp-Llm|Topic|AUTHORED
19|Chenxi Liao|Author|Ctp-Llm|Topic|AUTHORED
19|Sauleh Ahmad Siddiqui|Author|Ctp-Llm|Topic|AUTHORED
19|Bei Xiao|Author|Ctp-Llm|Topic|AUTHORED
20|Machine Learning|Topic|Clinical Domain|Topic|RELATED_TO
20|Data Scarcity|Topic|Clinical Trials|Topic|RELATED_TO
20|Ethical Considerations|Topic|Clinical Trials|Topic|RELATED_TO
20|Clinical Trials|Topic|Privacy Regulations|Topic|RELATED_TO
20|Clinical Trials|Topic|High Costs|Topic|RELATED_TO
20|Clinical Trials|Topic|Extended Duration|Topic|RELATED_TO
20|Large Language Models|Topic|Synthetic Clinical Trials|Topic|RELATED_TO
20|Retrieval-Reasoning Few-Shot Framework|Topic|Synthetic Clinical Trials|Topic|RELATED_TO
20|Synthetic Clinical Trials|Topic|Binary Success/Failure Labels|Topic|RELATED_TO
20|Clinicaltrials.Gov|Topic|Synthetic Data|Topic|RELATED_TO
20|Pre-Trained Model|Topic|Binary Classifier|Topic|RELATED_TO
20|Synthetic Clinical Trials|Topic|Trial Outcome Prediction|Topic|RELATED_TO
20|Zerui Xu|Author|Https://Anonymous.4Open.Science/R/Retrieval_Reasoning_Clinical_Trial_Generation-3Ec4|Paper|AUTHORED
20|Fang Wu|Author|Https://Anonymous.4Open.Science/R/Retrieval_Reasoning_Clinical_Trial_Generation-3Ec4|Paper|AUTHORED
20|Yuanyuan Zhang|Author|Https://Anonymous.4Open.Science/R/Retrieval_Reasoning_Clinical_Trial_Generation-3Ec4|Paper|AUTHORED
20|Yue Zhao|Author|Https://Anonymous.4Open.Science/R/Retrieval_Reasoning_Clinical_Trial_Generation-3Ec4|Paper|AUTHORED
21|Clinical Trials|Topic|Drug Development|Topic|RELATED_TO
21|Drug Development|Topic|Phase I|Topic|RELATED_TO
21|Drug Development|Topic|Phase Ii|Topic|RELATED_TO
21|Drug Development|Topic|Phase Iii|Topic|RELATED_TO
21|Drug Development|Topic|Phase Iv|Topic|RELATED_TO
21|Drug Development|Topic|Challenges In Clinical Trials|Topic|RELATED_TO
21|Drug Development|Topic|Innovative Technologies|Topic|RELATED_TO
21|Drug Development|Topic|Emerging Therapies|Topic|RELATED_TO
21|Drug Development|Topic|Regulatory Reforms|Topic|RELATED_TO
21|Drug Development|Topic|Global Collaboration|Topic|RELATED_TO
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Tianyang Wang|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Ming Liu|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Benji Peng|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Xinyuan Song|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Charles Zhang|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Xintian Sun|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Qian Niu|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Junyu Liu|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Silin Chen|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Keyu Chen|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Ming Li|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Pohsun Feng|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Ziqian Bi|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Yunze Wang|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Yichao Zhang|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Cheng Fei|Author|AUTHORED
21|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Lawrence Kq Yan|Author|AUTHORED
22|Bayesian Adaptive Designs|Topic|Clinical Trials|Topic|RELATED_TO
22|Covid-19 Pandemic|Topic|Clinical Trials|Topic|RELATED_TO
22|Shirin Golchi|Author|Designing Bayesian Adaptive Trials|Topic|AUTHORED
22|Designing Bayesian Adaptive Trials|Topic|Efficient Estimation And Uncertainty Quantification|Topic|RELATED_TO
22|Efficient Estimation And Uncertainty Quantification|Topic|Sampling Distribution Of Bayesian Probability Statements|Topic|RELATED_TO
22|Designing Bayesian Adaptive Trials|Topic|Ordinal Disease-Progression Scale Endpoint|Topic|RELATED_TO
22|Design Operating Characteristics|Topic|Bayesian Adaptive Designs|Topic|RELATED_TO
23|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Zifeng Wang|Author|AUTHORED
23|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Chufan Gao|Author|AUTHORED
23|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Lucas M. Glass|Author|AUTHORED
23|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Jimeng Sun|Author|AUTHORED
23|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Clinical Simulation|Topic|RELATED_TO
23|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Individualized Predictive Modeling|Topic|RELATED_TO
23|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Computer-Aided Trial Design|Topic|RELATED_TO
24|Clinical Trial Outcome Prediction|Topic|Language Interaction Network (Lint)|Topic|RELATED_TO
24|Language Interaction Network (Lint)|Topic|Chufan Gao|Author|AUTHORED
24|Language Interaction Network (Lint)|Topic|Tianfan Fu|Author|AUTHORED
24|Language Interaction Network (Lint)|Topic|Jimeng Sun|Author|AUTHORED
24|Language Interaction Network (Lint)|Topic|Biologics|Topic|RELATED_TO
24|Language Interaction Network (Lint)|Topic|Small-Molecule Drugs|Topic|RELATED_TO
24|Language Interaction Network (Lint)|Topic|Roc-Auc Scores|Topic|RELATED_TO
24|Language Interaction Network (Lint)|Topic|Clinical Trials|Topic|RELATED_TO
24|Language Interaction Network (Lint)|Topic|Drug Portfolio|Topic|RELATED_TO
25|Rats|Topic|Random Dot Motion Task|Topic|RELATED_TO
25|Random Dot Motion Task|Topic|Stimulus Integration|Topic|DISCUSSES
25|Rats|Topic|Trial Difficulty|Topic|DISCUSSES
25|Rats|Topic|Reward-Related Parameters|Topic|DISCUSSES
25|Pamela Reinagel|Author|Rats|Topic|AUTHORED
25|Emily Mankin|Author|Rats|Topic|AUTHORED
25|Adam Calhoun|Author|Rats|Topic|AUTHORED
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Yanxun Xu|Author|AUTHORED
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Yuan Ji|Author|AUTHORED
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Bayesian Trial Monitoring Scheme|Topic|DISCUSSES
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Latent Gaussian Process|Topic|DISCUSSES
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Clinical Trials|Topic|DISCUSSES
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Repeated Outcomes|Topic|DISCUSSES
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Binary Outcomes|Topic|DISCUSSES
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Posterior Inference|Topic|DISCUSSES
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Monte Carlo Algorithm|Topic|DISCUSSES
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Simulation Studies|Topic|DISCUSSES
26|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|Case Study|Topic|DISCUSSES
27|Clinical Trial Site Matching With Improved Diversity Using Fair Policy Learning|Paper|Clinical Trials|Topic|DISCUSSES
27|Clinical Trial Site Matching With Improved Diversity Using Fair Policy Learning|Paper|Diversity And Inclusion|Topic|DISCUSSES
28|Ongoing Vaccine And Monoclonal Antibody Hiv Prevention Efficacy Trials And Considerations For Sequel Efficacy Trial Designs|Paper|Hvtn 702|Topic|DISCUSSES
28|Ongoing Vaccine And Monoclonal Antibody Hiv Prevention Efficacy Trials And Considerations For Sequel Efficacy Trial Designs|Paper|Hvtn 705|Topic|DISCUSSES
28|Ongoing Vaccine And Monoclonal Antibody Hiv Prevention Efficacy Trials And Considerations For Sequel Efficacy Trial Designs|Paper|Hvtn 703/Hptn 081|Topic|DISCUSSES
28|Ongoing Vaccine And Monoclonal Antibody Hiv Prevention Efficacy Trials And Considerations For Sequel Efficacy Trial Designs|Paper|Hvtn 704/Hptn 085|Topic|DISCUSSES
28|Ongoing Vaccine And Monoclonal Antibody Hiv Prevention Efficacy Trials And Considerations For Sequel Efficacy Trial Designs|Paper|Hiv-1 Infection|Topic|RELATED_TO
28|Ongoing Vaccine And Monoclonal Antibody Hiv Prevention Efficacy Trials And Considerations For Sequel Efficacy Trial Designs|Paper|Sequel Efficacy Trials|Topic|RELATED_TO
28|Ongoing Vaccine And Monoclonal Antibody Hiv Prevention Efficacy Trials And Considerations For Sequel Efficacy Trial Designs|Paper|Correlates Of Protection|Topic|RELATED_TO
28|Ongoing Vaccine And Monoclonal Antibody Hiv Prevention Efficacy Trials And Considerations For Sequel Efficacy Trial Designs|Paper|Monoclonal Antibody Trials|Topic|RELATED_TO
29|Adaptive Immune System|Topic|B- And T-Cell Receptors|Topic|RELATED_TO
29|Human Immune System|Topic|Immunoengineers|Topic|RELATED_TO
29|Quantitative Resolution|Topic|Immunotherapy|Topic|RELATED_TO
29|Quantitative Resolution|Topic|Autoimmunity|Topic|RELATED_TO
29|Quantitative Resolution|Topic|Vaccine Design|Topic|RELATED_TO
29|Immunoengineers|Topic|Biopharmaceutical Drugs|Topic|RELATED_TO
29|Immunoengineers|Topic|Immunological Phenomena|Topic|RELATED_TO
29|Computational Immunology|Topic|Immunological Phenomena|Topic|RELATED_TO
29|Alex J. Brown|Author|Biopharmaceutical Drugs|Topic|AUTHORED
29|Igor Snapkov|Author|Biopharmaceutical Drugs|Topic|AUTHORED
29|Rahmad Akbar|Author|Biopharmaceutical Drugs|Topic|AUTHORED
29|Enkelejda Miho|Author|Biopharmaceutical Drugs|Topic|AUTHORED
29|Geir K. Sandve|Author|Biopharmaceutical Drugs|Topic|AUTHORED
29|Victor Greiff|Author|Biopharmaceutical Drugs|Topic|AUTHORED
30|Competing Risks Model|Topic|Non-Inferiority Clinical Trials|Topic|RELATED_TO
30|Non-Inferiority Clinical Trials|Topic|Parpia Et Al.|Author|DISCUSSES
30|Parpia Et Al.|Author|Proportional Sub-Distribution Hazard Model|Topic|DISCUSSES
30|Sample Size Formula|Topic|Non-Inferiority Clinical Trials|Topic|RELATED_TO
30|Sub-Distribution Hazard Ratio|Topic|Sample Size Formula|Topic|RELATED_TO
30|Weibull Distribution|Topic|Non-Inferiority Clinical Trials|Topic|RELATED_TO
30|Dong Han|Author|Sample Size Formula|Topic|AUTHORED
30|Zheng Chen|Author|Sample Size Formula|Topic|AUTHORED
30|Yawen Hou|Author|Sample Size Formula|Topic|AUTHORED
31|Clinical Trial Recommendations Using Semantics-Based Inductive Inference And Knowledge Graph Embeddings|Paper|Clinical Trial|Topic|RELATED_TO
31|Clinical Trial Recommendations Using Semantics-Based Inductive Inference And Knowledge Graph Embeddings|Paper|Knowledge Graph|Topic|RELATED_TO
31|Clinical Trial Recommendations Using Semantics-Based Inductive Inference And Knowledge Graph Embeddings|Paper|Neural Embeddings|Topic|RELATED_TO
31|Clinical Trial Recommendations Using Semantics-Based Inductive Inference And Knowledge Graph Embeddings|Paper|Kge Methods|Topic|RELATED_TO
31|Clinical Trial Recommendations Using Semantics-Based Inductive Inference And Knowledge Graph Embeddings|Paper|Clinical Trials Data|Topic|RELATED_TO
31|Clinical Trial Recommendations Using Semantics-Based Inductive Inference And Knowledge Graph Embeddings|Paper|Clinicaltrials.Gov|Topic|RELATED_TO
31|Clinical Trial Recommendations Using Semantics-Based Inductive Inference And Knowledge Graph Embeddings|Paper|Recommendations|Topic|RELATED_TO
32|Matchminer-Ai|Topic|Ethan Cerami|Author|AUTHORED
32|Matchminer-Ai|Topic|Pavel Trukhanov|Author|AUTHORED
32|Matchminer-Ai|Topic|Morgan A. Paul|Author|AUTHORED
32|Matchminer-Ai|Topic|Michael J. Hassett|Author|AUTHORED
32|Matchminer-Ai|Topic|Irbaz B. Riaz|Author|AUTHORED
32|Matchminer-Ai|Topic|James Lindsay|Author|AUTHORED
32|Matchminer-Ai|Topic|Emily Mallaber|Author|AUTHORED
32|Matchminer-Ai|Topic|Harry Klein|Author|AUTHORED
32|Matchminer-Ai|Topic|Gufran Gungor|Author|AUTHORED
32|Matchminer-Ai|Topic|Matthew Galvin|Author|AUTHORED
32|Matchminer-Ai|Topic|Stephen C. Van Nostrand|Author|AUTHORED
32|Matchminer-Ai|Topic|Joyce Yu|Author|AUTHORED
32|Matchminer-Ai|Topic|Tali Mazor|Author|AUTHORED
32|Matchminer-Ai|Topic|Kenneth L. Kehl|Author|AUTHORED
33|Trialdura|Paper|Ling Yue|Author|AUTHORED
33|Trialdura|Paper|Jonathan Li|Author|AUTHORED
33|Trialdura|Paper|Sixue Xing|Author|AUTHORED
33|Trialdura|Paper|Md Zabirul Islam|Author|AUTHORED
33|Trialdura|Paper|Bolun Xia|Author|AUTHORED
33|Trialdura|Paper|Tianfan Fu|Author|AUTHORED
33|Trialdura|Paper|Jintai Chen|Author|AUTHORED
34|Clinical Trials|Topic|Adaptive Clinical Trials|Topic|RELATED_TO
34|Adaptive Clinical Trials|Topic|Bayesian Framework|Topic|RELATED_TO
34|Bayesian Framework|Topic|Gastroenteritis Vaccine Trial|Paper|DISCUSSES
34|Gastroenteritis Vaccine Trial|Paper|James M. Mcgree|Author|AUTHORED
34|Gastroenteritis Vaccine Trial|Paper|Antony M. Overstall|Author|AUTHORED
34|Gastroenteritis Vaccine Trial|Paper|Mark Jones|Author|AUTHORED
34|Gastroenteritis Vaccine Trial|Paper|Robert K. Mahar|Author|AUTHORED
35|Trial Level General Surrogate|Topic|Bayesian Non-Parametric Modeling|Topic|RELATED_TO
35|Bayesian Non-Parametric Modeling|Topic|Pentavalent Rotavirus Vaccine|Topic|RELATED_TO
35|Erin E. Gabriel|Author|Trial Level General Surrogate|Topic|AUTHORED
35|Michael J. Daniels|Author|Trial Level General Surrogate|Topic|AUTHORED
35|M. Elizabeth Halloran|Author|Trial Level General Surrogate|Topic|AUTHORED
36|Spx|Topic|Rheumatoid Arthritis Clinical Trial|Topic|RELATED_TO
36|Daniel E. Schwartz|Author|Spx|Topic|AUTHORED
36|Yuan Ji|Author|Spx|Topic|AUTHORED
36|Li Wang|Author|Spx|Topic|AUTHORED
37|Adversity Index For Clinical Trials: An Inclusive Approach For Analysis Of Safety Data|Paper|Sharayu Paranjpe|Author|AUTHORED
37|Adversity Index For Clinical Trials: An Inclusive Approach For Analysis Of Safety Data|Paper|Anil Gore|Author|AUTHORED
38|Self-Centered Model|Topic|Adaptive Immune System|Topic|RELATED_TO
38|Classical Nonself-Centered Model|Topic|Adaptive Immune System|Topic|RELATED_TO
38|Humoral Immunity|Topic|Adaptive Immune System|Topic|RELATED_TO
38|Mistimm|Paper|Tamás Szabados|Author|AUTHORED
38|Mistimm|Paper|Csaba Kerepesi|Author|AUTHORED
38|Mistimm|Paper|Tibor Bakács|Author|AUTHORED
39|Relational Dynamics In Perception: Impacts On Trial-To-Trial Variation|Paper|Shimon Marom|Author|AUTHORED
39|Relational Dynamics In Perception: Impacts On Trial-To-Trial Variation|Paper|Avner Wallach|Author|AUTHORED
40|Pytrial|Topic|Clinical Trials|Topic|RELATED_TO
40|Pytrial|Topic|Machine Learning|Topic|RELATED_TO
40|Zifeng Wang|Author|Pytrial|Topic|AUTHORED
40|Brandon Theodorou|Author|Pytrial|Topic|AUTHORED
40|Tianfan Fu|Author|Pytrial|Topic|AUTHORED
40|Cao Xiao|Author|Pytrial|Topic|AUTHORED
40|Jimeng Sun|Author|Pytrial|Topic|AUTHORED
41|Artificial Intelligence|Topic|Deep Learning|Topic|RELATED_TO
41|Artificial Intelligence|Topic|Predictive Modelling|Topic|RELATED_TO
41|Deep Learning|Topic|Natural Language Processing|Topic|RELATED_TO
41|Sydney Anuyah|Author|Advancing Clinical Trial Outcomes Using Deep Learning And Predictive Modelling: Bridging Precision Medicine And Patient-Centered Care|Paper|AUTHORED
41|Mallika K Singh|Author|Advancing Clinical Trial Outcomes Using Deep Learning And Predictive Modelling: Bridging Precision Medicine And Patient-Centered Care|Paper|AUTHORED
41|Hope Nyavor|Author|Advancing Clinical Trial Outcomes Using Deep Learning And Predictive Modelling: Bridging Precision Medicine And Patient-Centered Care|Paper|AUTHORED
42|Trialbench|Paper|Clinical Trials|Topic|DISCUSSES
42|Trialbench|Paper|Artificial Intelligence|Topic|DISCUSSES
42|Trialbench|Paper|Ai-Ready Datasets|Topic|DISCUSSES
42|Trialbench|Paper|Trial Duration Prediction|Topic|DISCUSSES
42|Trialbench|Paper|Patient Dropout Rate Prediction|Topic|DISCUSSES
42|Trialbench|Paper|Serious Adverse Event Prediction|Topic|DISCUSSES
42|Trialbench|Paper|Mortality Rate Prediction|Topic|DISCUSSES
42|Trialbench|Paper|Trial Approval Outcome Prediction|Topic|DISCUSSES
42|Trialbench|Paper|Trial Failure Reason Prediction|Topic|DISCUSSES
42|Trialbench|Paper|Drug Dose Finding Prediction|Topic|DISCUSSES
42|Trialbench|Paper|Eligibility Criteria Design Prediction|Topic|DISCUSSES
42|Trialbench|Paper|Jintai Chen|Author|AUTHORED
42|Trialbench|Paper|Yaojun Hu|Author|AUTHORED
42|Trialbench|Paper|Yue Wang|Author|AUTHORED
42|Trialbench|Paper|Yingzhou Lu|Author|AUTHORED
42|Trialbench|Paper|Xu Cao|Author|AUTHORED
42|Trialbench|Paper|Miao Lin|Author|AUTHORED
42|Trialbench|Paper|Hongxia Xu|Author|AUTHORED
42|Trialbench|Paper|Jian Wu|Author|AUTHORED
42|Trialbench|Paper|Cao Xiao|Author|AUTHORED
42|Trialbench|Paper|Jimeng Sun|Author|AUTHORED
42|Trialbench|Paper|Lucas Glass|Author|AUTHORED
42|Trialbench|Paper|Kexin Huang|Author|AUTHORED
42|Trialbench|Paper|Marinka Zitnik|Author|AUTHORED
42|Trialbench|Paper|Tianfan Fu|Author|AUTHORED
43|Autotrial|Paper|Clinical Trials|Topic|DISCUSSES
43|Autotrial|Paper|Drug Development|Topic|RELATED_TO
43|Autotrial|Paper|Eligibility Criteria|Topic|RELATED_TO
44|Clinical Trials|Topic|Oncology|Topic|RELATED_TO
44|Oncology|Topic|Drug Development|Topic|RELATED_TO
44|Large Language Models|Topic|Gpt-3.5|Author|RELATED_TO
44|Large Language Models|Topic|Gpt-4|Author|RELATED_TO
44|Large Language Models|Topic|Hint|Author|RELATED_TO
44|Clinicaltrials.Gov|Topic|Large Language Models|Topic|RELATED_TO
44|Matthews Correlation Coefficient|Topic|Large Language Models|Topic|RELATED_TO
44|Neoplasms|Topic|Trial Duration|Topic|RELATED_TO
44|Trial Duration|Topic|Disease Categories|Topic|RELATED_TO
44|Shuyi Jin|Author|Clinical Trials|Topic|AUTHORED
44|Lu Chen|Author|Clinical Trials|Topic|AUTHORED
44|Hongru Ding|Author|Clinical Trials|Topic|AUTHORED
44|Meijie Wang|Author|Clinical Trials|Topic|AUTHORED
44|Lun Yu|Author|Clinical Trials|Topic|AUTHORED
45|Motor-Evoked Potentials (Meps)|Topic|Input-Output (Io) Curves|Topic|RELATED_TO
45|Triple-Variability-Source Model|Topic|Logarithmic Logistic Function|Topic|RELATED_TO
45|Triple-Variability-Source Model|Topic|Bayesian Information Criterion|Topic|RELATED_TO
45|Triple-Variability-Source Model|Topic|Physiological Variability|Topic|RELATED_TO
45|Triple-Variability-Source Model|Topic|Background Noise|Topic|RELATED_TO
45|Triple-Variability-Source Model|Topic|Neural Recruitment Curve|Topic|RELATED_TO
45|Triple-Variability-Source Model|Topic|Cortical Excitability|Topic|RELATED_TO
45|Triple-Variability-Source Model|Topic|Neuromodulation Effects|Topic|RELATED_TO
45|Ke Ma|Author|Triple-Variability-Source Model|Topic|AUTHORED
45|Siwei Liu|Author|Triple-Variability-Source Model|Topic|AUTHORED
45|Mengjie Qin|Author|Triple-Variability-Source Model|Topic|AUTHORED
45|Stefan Goetz|Author|Triple-Variability-Source Model|Topic|AUTHORED
46|Clinical Trial Result Prediction|Topic|Evidence-Based Medicine|Topic|RELATED_TO
46|Clinical Trial Result Prediction|Topic|Pico|Topic|RELATED_TO
46|Clinical Trial Result Prediction|Topic|Evidence Integration Dataset|Topic|RELATED_TO
46|Clinical Trial Result Prediction|Topic|Biobert|Topic|RELATED_TO
46|Clinical Trial Result Prediction|Topic|Covid-19 Clinical Trials|Topic|RELATED_TO
46|Qiao Jin|Author|Clinical Trial Result Prediction|Topic|AUTHORED
46|Chuanqi Tan|Author|Clinical Trial Result Prediction|Topic|AUTHORED
46|Mosha Chen|Author|Clinical Trial Result Prediction|Topic|AUTHORED
46|Xiaozhong Liu|Author|Clinical Trial Result Prediction|Topic|AUTHORED
46|Songfang Huang|Author|Clinical Trial Result Prediction|Topic|AUTHORED
47|Leaf Clinical Trials Corpus|Topic|Nicholas J Dobbins|Author|AUTHORED
47|Leaf Clinical Trials Corpus|Topic|Tony Mullen|Author|AUTHORED
47|Leaf Clinical Trials Corpus|Topic|Ozlem Uzuner|Author|AUTHORED
47|Leaf Clinical Trials Corpus|Topic|Meliha Yetisgen|Author|AUTHORED
48|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|Clinical Trials|Topic|DISCUSSES
48|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|Drug Discovery Process|Topic|DISCUSSES
48|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|Clinical Model Development|Topic|DISCUSSES
48|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|Protocol Design|Topic|DISCUSSES
48|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|Quantum Computing|Topic|DISCUSSES
48|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|Clinical Trial Simulations|Topic|DISCUSSES
48|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|Site Selection|Topic|DISCUSSES
48|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|Cohort Identification|Topic|DISCUSSES
48|Hakan Doga|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|M. Emre Sahin|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Joao Bettencourt-Silva|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Anh Pham|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Eunyoung Kim|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Alan Andress|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Sudhir Saxena|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Aritra Bose|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Laxmi Parida|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Jan Lukas Robertus|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Hideaki Kawaguchi|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Radwa Soliman|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
48|Daniel Blankenberg|Author|Towards Quantum Computing For Clinical Trial Design And Optimization: A Perspective On New Opportunities And Challenges|Paper|AUTHORED
49|Adaptive Cohort Size Determination Method For Bayesian Optimal Interval Phase I/Ii Design To Shorten Clinical Trial Duration|Paper|Masahiro Kojima|Author|AUTHORED
49|Adaptive Cohort Size Determination Method For Bayesian Optimal Interval Phase I/Ii Design To Shorten Clinical Trial Duration|Paper|Dose Optimization In Oncology|Topic|RELATED_TO
50|Clinicalagent|Paper|Large Language Models|Topic|RELATED_TO
50|Clinicalagent|Paper|Multi-Agent Systems|Topic|RELATED_TO
50|Clinicalagent|Paper|Gpt-4|Topic|RELATED_TO
50|Clinicalagent|Paper|Least-To-Most|Topic|RELATED_TO
50|Clinicalagent|Paper|React Reasoning Technology|Topic|RELATED_TO
50|Clinicalagent|Paper|Clinical Trial Outcome Prediction|Topic|RELATED_TO
50|Clinicalagent|Paper|Ling Yue|Author|AUTHORED
50|Clinicalagent|Paper|Sixue Xing|Author|AUTHORED
50|Clinicalagent|Paper|Jintai Chen|Author|AUTHORED
50|Clinicalagent|Paper|Tianfan Fu|Author|AUTHORED
51|Predictive Directions For Individualized Treatment Selection In Clinical Trials|Paper|Debashis Ghosh|Author|AUTHORED
51|Predictive Directions For Individualized Treatment Selection In Clinical Trials|Paper|Youngjoo Cho|Author|AUTHORED
51|Predictive Directions For Individualized Treatment Selection In Clinical Trials|Paper|Clinical Trials|Topic|RELATED_TO
51|Predictive Directions For Individualized Treatment Selection In Clinical Trials|Paper|Colorectal Cancer|Topic|RELATED_TO
52|Clinical Trials Ontology Engineering With Large Language Models|Paper|Clinical Trial Information Management|Topic|DISCUSSES
52|Clinical Trials Ontology Engineering With Large Language Models|Paper|Large Language Models|Topic|DISCUSSES
53|Conditional Approval|Topic|Post-Market Clinical Trial|Topic|RELATED_TO
53|Harmonic Mean Chi-Squared Test|Topic|Post-Market Clinical Trial|Topic|RELATED_TO
53|Harmonic Mean Chi-Squared Test|Topic|Two-Trials Rule|Topic|RELATED_TO
53|Harmonic Mean Chi-Squared Test|Topic|Fisher'S Criterion|Topic|RELATED_TO
53|Harmonic Mean Chi-Squared Test|Topic|Stouffer'S Method|Topic|RELATED_TO
53|Simulation Study|Topic|Harmonic Mean Chi-Squared Test|Topic|RELATED_TO
53|Manja Deforth|Author|Harmonic Mean Chi-Squared Test|Topic|AUTHORED
53|Charlotte Micheloud|Author|Harmonic Mean Chi-Squared Test|Topic|AUTHORED
53|Kit C Roes|Author|Harmonic Mean Chi-Squared Test|Topic|AUTHORED
53|Leonhard Held|Author|Harmonic Mean Chi-Squared Test|Topic|AUTHORED
54|February 2023 Meeting|Topic|Medical Digital Twins|Topic|DISCUSSES
54|February 2023 Meeting|Topic|Immune System|Topic|DISCUSSES
54|February 2023 Meeting|Topic|Reinhard Laubenbacher|Author|AUTHORED
54|February 2023 Meeting|Topic|Fred Adler|Author|AUTHORED
54|February 2023 Meeting|Topic|Gary An|Author|AUTHORED
54|February 2023 Meeting|Topic|Filippo Castiglione|Author|AUTHORED
54|February 2023 Meeting|Topic|Stephen Eubank|Author|AUTHORED
54|February 2023 Meeting|Topic|Luis L. Fonseca|Author|AUTHORED
54|February 2023 Meeting|Topic|James Glazier|Author|AUTHORED
54|February 2023 Meeting|Topic|Tomas Helikar|Author|AUTHORED
54|February 2023 Meeting|Topic|Marti Jett-Tilton|Author|AUTHORED
54|February 2023 Meeting|Topic|Denise Kirschner|Author|AUTHORED
54|February 2023 Meeting|Topic|Paul Macklin|Author|AUTHORED
54|February 2023 Meeting|Topic|Borna Mehrad|Author|AUTHORED
54|February 2023 Meeting|Topic|Beth Moore|Author|AUTHORED
54|February 2023 Meeting|Topic|Virginia Pasour|Author|AUTHORED
54|February 2023 Meeting|Topic|Ilya Shmulevich|Author|AUTHORED
54|February 2023 Meeting|Topic|Amber Smith|Author|AUTHORED
54|February 2023 Meeting|Topic|Isabel Voigt|Author|AUTHORED
54|February 2023 Meeting|Topic|Thomas E. Yankeelov|Author|AUTHORED
54|February 2023 Meeting|Topic|Tjalf Ziemssen|Author|AUTHORED
55|Machine Learning|Topic|Healthcare|Topic|RELATED_TO
55|Fairness In Machine Learning|Topic|Clinical Trials|Topic|RELATED_TO
55|Isabel Chien|Author|Multi-Disciplinary Fairness Considerations In Machine Learning For Clinical Trials|Paper|AUTHORED
55|Nina Deliu|Author|Multi-Disciplinary Fairness Considerations In Machine Learning For Clinical Trials|Paper|AUTHORED
55|Richard E. Turner|Author|Multi-Disciplinary Fairness Considerations In Machine Learning For Clinical Trials|Paper|AUTHORED
55|Adrian Weller|Author|Multi-Disciplinary Fairness Considerations In Machine Learning For Clinical Trials|Paper|AUTHORED
55|Sofia S. Villar|Author|Multi-Disciplinary Fairness Considerations In Machine Learning For Clinical Trials|Paper|AUTHORED
55|Niki Kilbertus|Author|Multi-Disciplinary Fairness Considerations In Machine Learning For Clinical Trials|Paper|AUTHORED
56|Clinical Trials|Topic|Medical Device Validation|Topic|RELATED_TO
56|Model-Based Pre-Clinical Trial Framework|Paper|Statistical Model Checking|Topic|DISCUSSES
56|Model-Based Pre-Clinical Trial Framework|Paper|Physiological Models|Topic|DISCUSSES
56|Model-Based Pre-Clinical Trial Framework|Paper|Implantable Cardioverter Defibrillators|Topic|DISCUSSES
57|Drug Development|Topic|Phase Ii / Iii Cancer Clinical Trials|Topic|RELATED_TO
57|Seamless Clinical Trials|Topic|Master Protocols|Topic|RELATED_TO
57|Seamless Clinical Trials|Topic|Phase Ii / Iii Cancer Clinical Trials|Topic|DISCUSSES
57|Master Protocols|Topic|Phase Ii / Iii Cancer Clinical Trials|Topic|DISCUSSES
57|Abigail Burdon|Author|Next Generation Clinical Trials: Seamless Designs And Master Protocols|Paper|AUTHORED
57|Thomas Jaki|Author|Next Generation Clinical Trials: Seamless Designs And Master Protocols|Paper|AUTHORED
57|Xijin Chen|Author|Next Generation Clinical Trials: Seamless Designs And Master Protocols|Paper|AUTHORED
57|Pavel Mozgunov|Author|Next Generation Clinical Trials: Seamless Designs And Master Protocols|Paper|AUTHORED
57|Haiyan Zheng|Author|Next Generation Clinical Trials: Seamless Designs And Master Protocols|Paper|AUTHORED
57|Richard Baird|Author|Next Generation Clinical Trials: Seamless Designs And Master Protocols|Paper|AUTHORED
58|Hint|Topic|Clinical Trials|Topic|DISCUSSES
58|Hint|Topic|Tianfan Fu|Author|AUTHORED
58|Hint|Topic|Kexin Huang|Author|AUTHORED
58|Hint|Topic|Cao Xiao|Author|AUTHORED
58|Hint|Topic|Lucas M. Glass|Author|AUTHORED
58|Hint|Topic|Jimeng Sun|Author|AUTHORED
59|Text Classification Of Cancer Clinical Trial Eligibility Criteria|Paper|Cancer Trials|Topic|RELATED_TO
60|Clinical Trial Active Learning|Paper|Zoe Fowler|Author|AUTHORED
60|Clinical Trial Active Learning|Paper|Kiran Kokilepersaud|Author|AUTHORED
60|Clinical Trial Active Learning|Paper|Mohit Prabhushankar|Author|AUTHORED
60|Clinical Trial Active Learning|Paper|Ghassan Alregib|Author|AUTHORED
60|Clinical Trial Active Learning|Paper|Active Learning|Topic|RELATED_TO
60|Clinical Trial Active Learning|Paper|Clinical Trials|Topic|RELATED_TO
60|Clinical Trial Active Learning|Paper|Optical Coherence Tomography|Topic|RELATED_TO
60|Clinical Trial Active Learning|Paper|Prospective Active Learning|Topic|RELATED_TO
60|Clinical Trial Active Learning|Paper|Retrospective Active Learning|Topic|RELATED_TO
61|Accept|Topic|Clinical Trials|Topic|RELATED_TO
61|Michelle N. Clements|Author|Accept|Topic|AUTHORED
61|Ian R. White|Author|Accept|Topic|AUTHORED
61|Andrew J. Copas|Author|Accept|Topic|AUTHORED
61|Victoria Cornelius|Author|Accept|Topic|AUTHORED
61|Suzie Cro|Author|Accept|Topic|AUTHORED
61|David T Dunn|Author|Accept|Topic|AUTHORED
61|Matteo Quartagno|Author|Accept|Topic|AUTHORED
61|Rebecca M. Turner|Author|Accept|Topic|AUTHORED
61|Conor D. Tweed|Author|Accept|Topic|AUTHORED
61|A. Sarah Walker|Author|Accept|Topic|AUTHORED
62|Statistical Methods For Clinical Trial Design|Topic|Adequately Powered Study|Topic|RELATED_TO
62|Adequately Powered Study|Topic|Statistical Significance|Topic|RELATED_TO
62|Adequately Powered Study|Topic|Clinical Interpretability|Topic|RELATED_TO
62|Calibrate Randomised Trial Designs|Topic|Strong Clinical Equipoise Imbalance|Topic|RELATED_TO
62|Least Informed Population Distribution|Topic|Pre-Trial Odds Of The Design Hypotheses|Topic|RELATED_TO
62|Primary Analysis Outcomes|Topic|Phase 3 Superiority Designs|Topic|RELATED_TO
62|95% Power At 5% False Positive Rate|Topic|Robustly Powered Study|Topic|RELATED_TO
62|Clinical Development Plans|Topic|Randomised Phase 2 And Phase 3 Studies|Topic|RELATED_TO
62|Randomised Phase 2 And Phase 3 Studies|Topic|Oncology Clinical Endpoints|Topic|RELATED_TO
62|Positive Outcomes|Topic|Phase 2|Topic|RELATED_TO
62|Negative Primary Outcome|Topic|Large Sample Sizes|Topic|RELATED_TO
62|Large Sample Sizes|Topic|Clinically Meaningful Effect Sizes|Topic|RELATED_TO
62|Equipoise Calibration|Topic|Fabio Rigat|Author|AUTHORED
63|Combining Real-World And Randomized Control Trial Data Using Data-Adaptive Weighting Via The On-Trial Score|Paper|Joanna Harton|Author|AUTHORED
63|Combining Real-World And Randomized Control Trial Data Using Data-Adaptive Weighting Via The On-Trial Score|Paper|Brian Segal|Author|AUTHORED
63|Combining Real-World And Randomized Control Trial Data Using Data-Adaptive Weighting Via The On-Trial Score|Paper|Ronac Mamtani|Author|AUTHORED
63|Combining Real-World And Randomized Control Trial Data Using Data-Adaptive Weighting Via The On-Trial Score|Paper|Nandita Mitra|Author|AUTHORED
63|Combining Real-World And Randomized Control Trial Data Using Data-Adaptive Weighting Via The On-Trial Score|Paper|Rebecca Hubbard|Author|AUTHORED
63|Clinical Trials With A Hybrid Control Arm|Topic|Combining Real-World And Randomized Control Trial Data Using Data-Adaptive Weighting Via The On-Trial Score|Paper|RELATED_TO
64|Clinidigest|Topic|Clinical Trial|Topic|DISCUSSES
64|Renee D. White|Author|Clinidigest|Topic|AUTHORED
64|Tristan Peng|Author|Clinidigest|Topic|AUTHORED
64|Pann Sripitak|Author|Clinidigest|Topic|AUTHORED
64|Alexander Rosenberg Johansen|Author|Clinidigest|Topic|AUTHORED
64|Michael Snyder|Author|Clinidigest|Topic|AUTHORED
65|Clinical Trial Matching|Topic|Large Language Models|Topic|RELATED_TO
65|Large Language Models|Topic|Oncollm|Topic|RELATED_TO
65|Oncollm|Topic|Shashi Kant Gupta|Author|AUTHORED
65|Oncollm|Topic|Aditya Basu|Author|AUTHORED
65|Oncollm|Topic|Mauro Nievas|Author|AUTHORED
65|Oncollm|Topic|Jerrin Thomas|Author|AUTHORED
65|Oncollm|Topic|Nathan Wolfrath|Author|AUTHORED
65|Oncollm|Topic|Adhitya Ramamurthi|Author|AUTHORED
65|Oncollm|Topic|Bradley Taylor|Author|AUTHORED
65|Oncollm|Topic|Anai N. Kothari|Author|AUTHORED
65|Oncollm|Topic|Regina Schwind|Author|AUTHORED
65|Oncollm|Topic|Therica M. Miller|Author|AUTHORED
65|Oncollm|Topic|Sorena Nadaf-Rahrov|Author|AUTHORED
65|Oncollm|Topic|Yanshan Wang|Author|AUTHORED
65|Oncollm|Topic|Hrituraj Singh|Author|AUTHORED
65|Real-World Ehrs|Topic|Clinical Notes|Topic|RELATED_TO
65|Real-World Ehrs|Topic|Clinical Trials|Topic|RELATED_TO
65|Clinical Trials|Topic|Cancer Center In The United States|Topic|RELATED_TO
66|Twin-Gpt|Paper|Clinical Trials|Topic|RELATED_TO
66|Twin-Gpt|Paper|Medical Research|Topic|RELATED_TO
66|Twin-Gpt|Paper|New Treatments|Topic|RELATED_TO
66|Twin-Gpt|Paper|Virtual Clinical Trials|Topic|RELATED_TO
66|Twin-Gpt|Paper|Patient Safety|Topic|RELATED_TO
66|Twin-Gpt|Paper|Cost Reduction|Topic|RELATED_TO
66|Twin-Gpt|Paper|Scientific Knowledge|Topic|RELATED_TO
66|Twin-Gpt|Paper|Electronic Health Records|Topic|RELATED_TO
66|Twin-Gpt|Paper|Clinical Trial Outcome Prediction|Topic|RELATED_TO
66|Twin-Gpt|Paper|Large Language Models|Topic|RELATED_TO
67|Immune Response Model|Paper|Covid-19 Epidemiological Models|Topic|DISCUSSES
67|Immune Response Model|Paper|Immunological Assay|Topic|RELATED_TO
67|Immune Response Model|Paper|Sars-Cov-2 Vaccines|Topic|RELATED_TO
68|Towards More Flexible False Positive Control In Phase Iii Randomized Clinical Trials|Paper|Phase Iii Randomized Clinical Trials|Topic|DISCUSSES
68|Towards More Flexible False Positive Control In Phase Iii Randomized Clinical Trials|Paper|New Medical Products|Topic|DISCUSSES
68|Towards More Flexible False Positive Control In Phase Iii Randomized Clinical Trials|Paper|Statistical Principles|Topic|DISCUSSES
68|Towards More Flexible False Positive Control In Phase Iii Randomized Clinical Trials|Paper|Statistical Hypothesis Testing|Topic|DISCUSSES
68|Towards More Flexible False Positive Control In Phase Iii Randomized Clinical Trials|Paper|Frequentist Paradigm|Topic|DISCUSSES
68|Towards More Flexible False Positive Control In Phase Iii Randomized Clinical Trials|Paper|Bayesian Perspectives|Topic|DISCUSSES
68|Towards More Flexible False Positive Control In Phase Iii Randomized Clinical Trials|Paper|Effect Sizes|Topic|DISCUSSES
68|Towards More Flexible False Positive Control In Phase Iii Randomized Clinical Trials|Paper|Clinicaltrials.Gov|Topic|DISCUSSES
68|Changyu Shen|Author|Towards More Flexible False Positive Control In Phase Iii Randomized Clinical Trials|Paper|AUTHORED
68|Xiaochun Li|Author|Towards More Flexible False Positive Control In Phase Iii Randomized Clinical Trials|Paper|AUTHORED
69|A Machine Learning Approach For Recruitment Prediction In Clinical Trial Design|Paper|Jingshu Liu|Author|AUTHORED
69|A Machine Learning Approach For Recruitment Prediction In Clinical Trial Design|Paper|Patricia J Allen|Author|AUTHORED
69|A Machine Learning Approach For Recruitment Prediction In Clinical Trial Design|Paper|Luke Benz|Author|AUTHORED
69|A Machine Learning Approach For Recruitment Prediction In Clinical Trial Design|Paper|Daniel Blickstein|Author|AUTHORED
69|A Machine Learning Approach For Recruitment Prediction In Clinical Trial Design|Paper|Evon Okidi|Author|AUTHORED
69|A Machine Learning Approach For Recruitment Prediction In Clinical Trial Design|Paper|Xiao Shi|Author|AUTHORED
70|Web Application For Sample Size Calculation|Paper|Multi-Arm Clinical Trials|Topic|RELATED_TO
70|Michael J Grayling|Author|Web Application For Sample Size Calculation|Paper|AUTHORED
70|James Ms Wason|Author|Web Application For Sample Size Calculation|Paper|AUTHORED
71|Bevacizumab Colorectal Cancer Treatment Trials|Topic|Cptg Scores|Topic|RELATED_TO
71|Cptg Scores|Topic|Serious Adverse Events|Topic|RELATED_TO
71|Oneflorida Consortium|Topic|Patient-Level Data|Topic|AUTHORED
71|Qian Li|Author|Bevacizumab Colorectal Cancer Treatment Trials|Topic|AUTHORED
71|Zhe He|Author|Bevacizumab Colorectal Cancer Treatment Trials|Topic|AUTHORED
71|Yi Guo|Author|Bevacizumab Colorectal Cancer Treatment Trials|Topic|AUTHORED
71|Hansi Zhang|Author|Bevacizumab Colorectal Cancer Treatment Trials|Topic|AUTHORED
71|Thomas J George Jr|Author|Bevacizumab Colorectal Cancer Treatment Trials|Topic|AUTHORED
71|William Hogan|Author|Bevacizumab Colorectal Cancer Treatment Trials|Topic|AUTHORED
71|Neil Charness|Author|Bevacizumab Colorectal Cancer Treatment Trials|Topic|AUTHORED
71|Jiang Bian|Author|Bevacizumab Colorectal Cancer Treatment Trials|Topic|AUTHORED
72|Bayesian Sequential Clinical Trial Designs|Paper|Tianjian Zhou|Author|AUTHORED
72|Bayesian Sequential Clinical Trial Designs|Paper|Yuan Ji|Author|AUTHORED
73|Multi-Arm, Multi-Stage (Mams) Clinical Trial Designs|Topic|Adaptive Designs (Ad)|Topic|RELATED_TO
73|Multi-Arm, Multi-Stage (Mams) Clinical Trial Designs|Topic|Multi-Arm (Ma) Designs|Topic|RELATED_TO
73|Factorial Clinical Trials Designs|Topic|Multi-Arm, Multi-Stage (Mams) Clinical Trial Designs|Topic|RELATED_TO
73|Factorial Adaptive Multi-Arm Multi-Stage (Fast) Designs|Topic|Factorial Clinical Trials Designs|Topic|RELATED_TO
73|Factorial Adaptive Multi-Arm Multi-Stage (Fast) Designs|Topic|Multi-Arm, Multi-Stage (Mams) Clinical Trial Designs|Topic|RELATED_TO
73|Design Considerations For Factorial Adaptive Multi-Arm Multi-Stage (Fast) Clinical Trials|Topic|Jonathan Beall|Author|AUTHORED
73|Design Considerations For Factorial Adaptive Multi-Arm Multi-Stage (Fast) Clinical Trials|Topic|Jordan Elm|Author|AUTHORED
73|Design Considerations For Factorial Adaptive Multi-Arm Multi-Stage (Fast) Clinical Trials|Topic|Mathew W Semler|Author|AUTHORED
73|Design Considerations For Factorial Adaptive Multi-Arm Multi-Stage (Fast) Clinical Trials|Topic|Li Wang|Author|AUTHORED
73|Design Considerations For Factorial Adaptive Multi-Arm Multi-Stage (Fast) Clinical Trials|Topic|Todd Rice|Author|AUTHORED
73|Design Considerations For Factorial Adaptive Multi-Arm Multi-Stage (Fast) Clinical Trials|Topic|Hooman Kamel|Author|AUTHORED
73|Design Considerations For Factorial Adaptive Multi-Arm Multi-Stage (Fast) Clinical Trials|Topic|William Mack|Author|AUTHORED
73|Design Considerations For Factorial Adaptive Multi-Arm Multi-Stage (Fast) Clinical Trials|Topic|Akshitkumar M. Mistry|Author|AUTHORED
74|Monitoring Fidelity Of Online Reinforcement Learning Algorithms In Clinical Trials|Paper|Anna L. Trella|Author|AUTHORED
74|Monitoring Fidelity Of Online Reinforcement Learning Algorithms In Clinical Trials|Paper|Kelly W. Zhang|Author|AUTHORED
74|Monitoring Fidelity Of Online Reinforcement Learning Algorithms In Clinical Trials|Paper|Inbal Nahum-Shani|Author|AUTHORED
74|Monitoring Fidelity Of Online Reinforcement Learning Algorithms In Clinical Trials|Paper|Vivek Shetty|Author|AUTHORED
74|Monitoring Fidelity Of Online Reinforcement Learning Algorithms In Clinical Trials|Paper|Iris Yan|Author|AUTHORED
74|Monitoring Fidelity Of Online Reinforcement Learning Algorithms In Clinical Trials|Paper|Finale Doshi-Velez|Author|AUTHORED
74|Monitoring Fidelity Of Online Reinforcement Learning Algorithms In Clinical Trials|Paper|Susan A. Murphy|Author|AUTHORED
74|Oralytics Clinical Trial|Topic|Monitoring Fidelity Of Online Reinforcement Learning Algorithms In Clinical Trials|Paper|RELATED_TO
75|Augmented Binary Method For Basket Trials (Abba)|Topic|Clinical Trials|Topic|RELATED_TO
75|Augmented Binary Method For Basket Trials (Abba)|Topic|Basket Trials|Topic|RELATED_TO
75|Augmented Binary Method For Basket Trials (Abba)|Topic|Bayesian Hierarchical Modelling|Topic|RELATED_TO
75|Svetlana Cherlin|Author|Augmented Binary Method For Basket Trials (Abba)|Topic|AUTHORED
75|James M S Wason|Author|Augmented Binary Method For Basket Trials (Abba)|Topic|AUTHORED
75|Augmented Binary Method For Basket Trials (Abba)|Topic|Treatment Effect|Topic|RELATED_TO
75|Augmented Binary Method For Basket Trials (Abba)|Topic|Subtrials|Topic|RELATED_TO
75|Augmented Binary Method For Basket Trials (Abba)|Topic|Log Odds Ratio|Topic|RELATED_TO
75|Augmented Binary Method For Basket Trials (Abba)|Topic|High Density Interval|Topic|RELATED_TO
75|Augmented Binary Method For Basket Trials (Abba)|Topic|Rheumatology|Topic|RELATED_TO
76|On An Approach To Bayesian Sample Sizing In Clinical Trials|Paper|Robb J. Muirhead|Author|AUTHORED
76|On An Approach To Bayesian Sample Sizing In Clinical Trials|Paper|Adina I. Soaita|Author|AUTHORED
76|On An Approach To Bayesian Sample Sizing In Clinical Trials|Paper|Bayesian Sample Size Determination|Topic|RELATED_TO
76|On An Approach To Bayesian Sample Sizing In Clinical Trials|Paper|Clinical Trials|Topic|RELATED_TO
76|On An Approach To Bayesian Sample Sizing In Clinical Trials|Paper|Posterior Probability|Topic|RELATED_TO
76|On An Approach To Bayesian Sample Sizing In Clinical Trials|Paper|Marginal Distribution Of The Data|Topic|RELATED_TO
76|On An Approach To Bayesian Sample Sizing In Clinical Trials|Paper|Superiority Of A New Drug Over A Control|Topic|RELATED_TO
77|Assurance For Clinical Trial Design With Normally Distributed Outcomes: Eliciting Uncertainty About Variances|Paper|Ziyad A. Alhussain|Author|AUTHORED
77|Assurance For Clinical Trial Design With Normally Distributed Outcomes: Eliciting Uncertainty About Variances|Paper|Jeremy E. Oakley|Author|AUTHORED
77|Assurance For Clinical Trial Design With Normally Distributed Outcomes: Eliciting Uncertainty About Variances|Paper|Clinical Trial Planning|Topic|RELATED_TO
77|Assurance For Clinical Trial Design With Normally Distributed Outcomes: Eliciting Uncertainty About Variances|Paper|Elicitation Method|Topic|RELATED_TO
78|Clinical Trials|Topic|Deep Learning Frameworks|Topic|RELATED_TO
78|Deep Learning Frameworks|Topic|Fair Patient-Trial Matching Framework|Topic|RELATED_TO
78|Fair Patient-Trial Matching Framework|Topic|Chia-Yuan Chang|Author|AUTHORED
78|Fair Patient-Trial Matching Framework|Topic|Jiayi Yuan|Author|AUTHORED
78|Fair Patient-Trial Matching Framework|Topic|Sirui Ding|Author|AUTHORED
78|Fair Patient-Trial Matching Framework|Topic|Qiaoyu Tan|Author|AUTHORED
78|Fair Patient-Trial Matching Framework|Topic|Kai Zhang|Author|AUTHORED
78|Fair Patient-Trial Matching Framework|Topic|Xiaoqian Jiang|Author|AUTHORED
78|Fair Patient-Trial Matching Framework|Topic|Xia Hu|Author|AUTHORED
78|Fair Patient-Trial Matching Framework|Topic|Na Zou|Author|AUTHORED
79|Clinical Trials|Topic|Part 11 Of Title 21 Of The Code Of Federal Regulations|Topic|RELATED_TO
79|Clinical Trials|Topic|Iso 27789|Topic|RELATED_TO
79|Clinical Trials|Topic|Context-Aware Smart Devices|Topic|RELATED_TO
79|Clinical Trials|Topic|Wearable Iot Devices|Topic|RELATED_TO
79|Clinical Trials|Topic|Electronic Data Capture (Edc)|Topic|RELATED_TO
79|Clinical Trials|Topic|Clinical Data Management Systems (Cdms)|Topic|RELATED_TO
79|Healthcare Digital Threat Landscape|Topic|Sensor Fusion|Topic|RELATED_TO
79|Scrybe|Paper|Part 11 Of Title 21 Of The Code Of Federal Regulations|Topic|DISCUSSES
79|Scrybe|Paper|Iso 27789|Topic|DISCUSSES
79|Scrybe|Paper|Electronic Data Capture (Edc)|Topic|DISCUSSES
79|Scrybe|Paper|Clinical Data Management Systems (Cdms)|Topic|DISCUSSES
80|Local Explanations For Clinical Search Engine Results|Paper|Edeline Contempré|Author|AUTHORED
80|Local Explanations For Clinical Search Engine Results|Paper|Zoltán Szlávik|Author|AUTHORED
80|Local Explanations For Clinical Search Engine Results|Paper|Majid Mohammadi|Author|AUTHORED
80|Local Explanations For Clinical Search Engine Results|Paper|Erick Velazquez|Author|AUTHORED
80|Local Explanations For Clinical Search Engine Results|Paper|Annette Ten Teije|Author|AUTHORED
80|Local Explanations For Clinical Search Engine Results|Paper|Ilaria Tiddi|Author|AUTHORED
81|Clinical Trials|Topic|Evidence-Based Medicine|Topic|RELATED_TO
81|Meta-Analyses|Topic|Clinical Practice Guidelines|Topic|RELATED_TO
81|Data Science|Topic|Big Data|Topic|RELATED_TO
81|Data Science|Topic|Visual Analytics|Topic|RELATED_TO
81|Trial Registries|Topic|Platform For Analyzing Safety Events|Paper|RELATED_TO
81|Ontological Model|Topic|Platform For Analyzing Safety Events|Paper|RELATED_TO
81|Adverse Drug Events (Ade)|Topic|Platform For Analyzing Safety Events|Paper|RELATED_TO
81|Pain Treatments|Topic|Platform For Analyzing Safety Events|Paper|RELATED_TO
81|Platform For Analyzing Safety Events|Paper|Drug Safety Experts|Author|AUTHORED
82|Trend-Adaptive Design With A Synthetic-Intervention-Based Estimator|Topic|Secrets|Topic|RELATED_TO
82|Trend-Adaptive Design With A Synthetic-Intervention-Based Estimator|Topic|Tad|Topic|RELATED_TO
82|Sayeri Lala|Author|Trend-Adaptive Design With A Synthetic-Intervention-Based Estimator|Topic|AUTHORED
82|Niraj K. Jha|Author|Trend-Adaptive Design With A Synthetic-Intervention-Based Estimator|Topic|AUTHORED
83|Biomarker Clustering Of Colorectal Cancer Data To Complement Clinical Classification|Paper|Chris Roadknight|Author|AUTHORED
83|Biomarker Clustering Of Colorectal Cancer Data To Complement Clinical Classification|Paper|Uwe Aickelin|Author|AUTHORED
83|Biomarker Clustering Of Colorectal Cancer Data To Complement Clinical Classification|Paper|Alex Ladas|Author|AUTHORED
83|Biomarker Clustering Of Colorectal Cancer Data To Complement Clinical Classification|Paper|Daniele Soria|Author|AUTHORED
83|Biomarker Clustering Of Colorectal Cancer Data To Complement Clinical Classification|Paper|John Scholefield|Author|AUTHORED
83|Biomarker Clustering Of Colorectal Cancer Data To Complement Clinical Classification|Paper|Lindy Durrant|Author|AUTHORED
84|Baskexact|Paper|Basket Trials|Topic|DISCUSSES
84|Baskexact|Paper|R Package|Topic|RELATED_TO
84|Baskexact|Paper|Empirical Bayes Techniques|Topic|RELATED_TO
84|Baskexact|Paper|Single-Stage Designs|Topic|RELATED_TO
84|Baskexact|Paper|Two-Stage Designs|Topic|RELATED_TO
85|Improving Patient Pre-Screening For Clinical Trials: Assisting Physicians With Large Language Models|Paper|Instructgpt|Topic|DISCUSSES
85|Improving Patient Pre-Screening For Clinical Trials: Assisting Physicians With Large Language Models|Paper|Large Language Models|Topic|DISCUSSES
85|Improving Patient Pre-Screening For Clinical Trials: Assisting Physicians With Large Language Models|Paper|Clinical Trials|Topic|RELATED_TO
85|Improving Patient Pre-Screening For Clinical Trials: Assisting Physicians With Large Language Models|Paper|Physicians|Topic|RELATED_TO
86|Virtual Clinical Trial|Topic|Tobias K. S. Ritschel|Author|AUTHORED
86|Virtual Clinical Trial|Topic|Asbjørn Thode Reenberg|Author|AUTHORED
86|Virtual Clinical Trial|Topic|John Bagterp Jørgensen|Author|AUTHORED
87|Confirmatory Clinical Trials|Topic|Experimental Treatments|Topic|RELATED_TO
87|Confirmatory Clinical Trials|Topic|Control|Topic|RELATED_TO
87|Randomised Controlled Trials|Topic|Hypothesis Testing Methods|Topic|RELATED_TO
87|Hypothesis Testing Methods|Topic|Error Rate|Topic|RELATED_TO
87|Hypothesis Testing Methods|Topic|Power|Topic|RELATED_TO
87|Hypothesis Testing Methods|Topic|Bonferroni Adjustment|Topic|RELATED_TO
87|Multi-Stage Adaptive Trials|Topic|Clinical Trials Setting|Topic|RELATED_TO
87|Thomas Burnett|Author|Hypothesis Testing Methods|Topic|AUTHORED
87|Thomas Jaki|Author|Hypothesis Testing Methods|Topic|AUTHORED
88|Inspire Project|Topic|T. Friede|Author|AUTHORED
88|Inspire Project|Topic|M. Posch|Author|AUTHORED
88|Inspire Project|Topic|S. Zohar|Author|AUTHORED
88|Inspire Project|Topic|C. Alberti|Author|AUTHORED
88|Inspire Project|Topic|N. Benda|Author|AUTHORED
88|Inspire Project|Topic|E. Comets|Author|AUTHORED
88|Inspire Project|Topic|S. Day|Author|AUTHORED
88|Inspire Project|Topic|A. Dmitrenko|Author|AUTHORED
88|Inspire Project|Topic|A. Graf|Author|AUTHORED
88|Inspire Project|Topic|B. K. Günhan|Author|AUTHORED
88|Inspire Project|Topic|S. W. Hee|Author|AUTHORED
88|Inspire Project|Topic|F. Lentz|Author|AUTHORED
88|Inspire Project|Topic|J. Madan|Author|AUTHORED
88|Inspire Project|Topic|F. Miller|Author|AUTHORED
88|Inspire Project|Topic|T. Ondra|Author|AUTHORED
88|Inspire Project|Topic|M. Pearce|Author|AUTHORED
88|Inspire Project|Topic|C. Röver|Author|AUTHORED
88|Inspire Project|Topic|A. Tournazi|Author|AUTHORED
88|Inspire Project|Topic|S. Unkel|Author|AUTHORED
88|Inspire Project|Topic|M. Ursino|Author|AUTHORED
88|Inspire Project|Topic|G. Wassmer|Author|AUTHORED
88|Inspire Project|Topic|N. Stallard|Author|AUTHORED
89|Defining The Inclusion/Exclusion (I/E) Criteria Of A Trial|Paper|Selection Induced Contrast Estimate (Sice) Effect|Topic|DISCUSSES
89|Defining The Inclusion/Exclusion (I/E) Criteria Of A Trial|Paper|Junshui Ma|Author|AUTHORED
89|Defining The Inclusion/Exclusion (I/E) Criteria Of A Trial|Paper|Daniel J. Holder|Author|AUTHORED
90|Covid-19|Topic|Sars-Cov-2|Topic|RELATED_TO
90|Sars-Cov-2|Topic|World Health Organization|Author|DISCUSSES
90|Covid-19|Topic|Data Monitoring Committee|Topic|RELATED_TO
90|Data Monitoring Committee|Topic|Clinical Trials|Topic|RELATED_TO
90|Covid-19|Topic|Vaccination|Topic|RELATED_TO
90|Covid-19|Topic|Diagnostics|Topic|RELATED_TO
90|Covid-19|Topic|Mortality|Topic|RELATED_TO
90|Data Monitoring Committee|Topic|Platform Trials|Topic|RELATED_TO
90|Data Monitoring Committee|Topic|Adaptive Designs|Topic|RELATED_TO
90|Data Monitoring Committee|Topic|Simulation Study|Topic|RELATED_TO
90|Tobias Mütze|Author|Clinical Trials|Topic|AUTHORED
90|Tim Friede|Author|Clinical Trials|Topic|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Silvia Calderazzo|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Sergey Tarima|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Carissa Reid|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Nancy Flournoy|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Tim Friede|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Nancy Geller|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|James L Rosenberger|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Nigel Stallard|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Moreno Ursino|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Marc Vandemeulebroecke|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Kelly Van Lancker|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Sarah Zohar|Author|AUTHORED
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Sars-Cov-2|Topic|RELATED_TO
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Covid-19|Topic|RELATED_TO
91|Coping With Information Loss And The Use Of Auxiliary Sources Of Data: A Report From The Niss Ingram Olkin Forum Series On Unplanned Clinical Trial Disruptions|Paper|Primary Care Pediatrics Learning Activity Nutrition (Plan) Study|Topic|RELATED_TO
92|Oncology Clinical Trial Design Planning Based On A Multistate Model That Jointly Models Progression-Free And Overall Survival Endpoints|Paper|Alexandra Erdmann|Author|AUTHORED
92|Oncology Clinical Trial Design Planning Based On A Multistate Model That Jointly Models Progression-Free And Overall Survival Endpoints|Paper|Jan Beyersmann|Author|AUTHORED
92|Oncology Clinical Trial Design Planning Based On A Multistate Model That Jointly Models Progression-Free And Overall Survival Endpoints|Paper|Kaspar Rufibach|Author|AUTHORED
92|Oncology Clinical Trial Design Planning Based On A Multistate Model That Jointly Models Progression-Free And Overall Survival Endpoints|Paper|Overall Survival (Os)|Topic|RELATED_TO
92|Oncology Clinical Trial Design Planning Based On A Multistate Model That Jointly Models Progression-Free And Overall Survival Endpoints|Paper|Progression-Free Survival (Pfs)|Topic|RELATED_TO
92|Oncology Clinical Trial Design Planning Based On A Multistate Model That Jointly Models Progression-Free And Overall Survival Endpoints|Paper|Multistate Model|Topic|RELATED_TO
92|Oncology Clinical Trial Design Planning Based On A Multistate Model That Jointly Models Progression-Free And Overall Survival Endpoints|Paper|Non-Small-Cell Lung Cancer|Topic|RELATED_TO
92|Oncology Clinical Trial Design Planning Based On A Multistate Model That Jointly Models Progression-Free And Overall Survival Endpoints|Paper|Clinical Trial Design|Topic|RELATED_TO
92|Oncology Clinical Trial Design Planning Based On A Multistate Model That Jointly Models Progression-Free And Overall Survival Endpoints|Paper|R Package|Topic|RELATED_TO
93|Hierarchical Bayesian Inference|Topic|Cortical Hierarchies|Topic|RELATED_TO
93|Cortical Hierarchies|Topic|Anatomical Accounts Of Cortical Organisation|Topic|RELATED_TO
93|Andreea O. Diaconescu|Author|Neuroimaging And Electrophysiological Data|Topic|AUTHORED
93|Vladimir Litvak|Author|Neuroimaging And Electrophysiological Data|Topic|AUTHORED
93|Christoph Mathys|Author|Neuroimaging And Electrophysiological Data|Topic|AUTHORED
93|Lars Kasper|Author|Neuroimaging And Electrophysiological Data|Topic|AUTHORED
93|Karl J. Friston|Author|Neuroimaging And Electrophysiological Data|Topic|AUTHORED
93|Klaas E. Stephan|Author|Neuroimaging And Electrophysiological Data|Topic|AUTHORED
93|Social Learning Task|Topic|Neuroimaging And Electrophysiological Data|Topic|RELATED_TO
93|Disorders Of Perception|Topic|Schizophrenia|Topic|RELATED_TO
93|Disorders Of Perception|Topic|Autism|Topic|RELATED_TO
94|Bayesian Neural Networks|Topic|Alzheimer'S Disease|Topic|RELATED_TO
94|Quantitative Eeg Markers|Topic|Alzheimer'S Disease|Topic|RELATED_TO
94|Wolfgang Fruehwirt|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Adam D. Cobb|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Martin Mairhofer|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Leonard Weydemann|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Heinrich Garn|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Reinhold Schmidt|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Thomas Benke|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Peter Dal-Bianco|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Gerhard Ransmayr|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Markus Waser|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Dieter Grossegger|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Pengfei Zhang|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Georg Dorffner|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
94|Stephen Roberts|Author|Bayesian Deep Neural Networks For Low-Cost Neurophysiological Markers Of Alzheimer'S Disease Severity|Paper|AUTHORED
95|Clinical Trials|Topic|Randomization|Topic|RELATED_TO
95|Randomization|Topic|Treatment Efficacies|Topic|RELATED_TO
95|Post Hoc Studies|Topic|Supervised-Learning Methods|Topic|RELATED_TO
95|Reinforcement-Learning Methods|Topic|Multi-Arm Bandits|Topic|RELATED_TO
95|Multi-Arm Bandits|Topic|Contextual-Bandit-Based Online Treatment Optimization Algorithm|Topic|RELATED_TO
95|Contextual-Bandit-Based Online Treatment Optimization Algorithm|Topic|International Stroke Trial|Topic|RELATED_TO
95|Yogatheesan Varatharajah|Author|Contextual-Bandit-Based Online Treatment Optimization Algorithm|Topic|AUTHORED
95|Brent Berry|Author|Contextual-Bandit-Based Online Treatment Optimization Algorithm|Topic|AUTHORED
95|Sanmi Koyejo|Author|Contextual-Bandit-Based Online Treatment Optimization Algorithm|Topic|AUTHORED
95|Ravishankar Iyer|Author|Contextual-Bandit-Based Online Treatment Optimization Algorithm|Topic|AUTHORED
96|C3T-Budget|Topic|Clinical Trials|Topic|RELATED_TO
96|C3T-Budget|Topic|Hyun-Suk Lee|Author|AUTHORED
96|C3T-Budget|Topic|Cong Shen|Author|AUTHORED
96|C3T-Budget|Topic|James Jordon|Author|AUTHORED
96|C3T-Budget|Topic|Mihaela Van Der Schaar|Author|AUTHORED
97|Clinical Trial|Topic|Treatment Effect|Topic|RELATED_TO
97|Helicobacter Pylori Infection|Topic|External Control Data|Topic|RELATED_TO
97|Xinyu Li|Author|Clinical Trial|Topic|AUTHORED
97|Wang Miao|Author|Clinical Trial|Topic|AUTHORED
97|Fang Lu|Author|Clinical Trial|Topic|AUTHORED
97|Xiao-Hua Zhou|Author|Clinical Trial|Topic|AUTHORED
97|External Control Data|Topic|Doubly Robust Estimator|Topic|RELATED_TO
97|External Control Data|Topic|Locally Efficient Estimator|Topic|RELATED_TO
97|Clinical Trial|Topic|Average Treatment Effect|Topic|RELATED_TO
97|Simulation|Topic|Doubly Robust Estimator|Topic|RELATED_TO
97|Simulation|Topic|Locally Efficient Estimator|Topic|RELATED_TO
97|Combination Treatment|Topic|Triple Therapy|Topic|RELATED_TO
98|Causal Inference|Topic|Estimand Framework|Topic|RELATED_TO
98|Causal Inference|Topic|Target Trial Framework|Topic|RELATED_TO
98|Estimand Framework|Topic|Patient-Level Clinical Trials|Topic|RELATED_TO
98|Estimand Framework|Topic|Observational Data|Topic|RELATED_TO
98|Target Trial Framework|Topic|Baseline Confounding|Topic|RELATED_TO
98|Long-Term Outcomes|Topic|Metastatic Non-Small Cell Lung Cancer|Topic|RELATED_TO
98|Letizia Polito|Author|Causal Inference|Topic|AUTHORED
98|Qixing Liang|Author|Causal Inference|Topic|AUTHORED
98|Navdeep Pal|Author|Causal Inference|Topic|AUTHORED
98|Philani Mpofu|Author|Causal Inference|Topic|AUTHORED
98|Ahmed Sawas|Author|Causal Inference|Topic|AUTHORED
98|Olivier Humblet|Author|Causal Inference|Topic|AUTHORED
98|Kaspar Rufibach|Author|Causal Inference|Topic|AUTHORED
98|Dominik Heinzmann|Author|Causal Inference|Topic|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Cliff Wong|Author|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Sheng Zhang|Author|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Yu Gu|Author|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Christine Moung|Author|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Jacob Abel|Author|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Naoto Usuyama|Author|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Roshanthi Weerasinghe|Author|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Brian Piening|Author|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Tristan Naumann|Author|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Carlo Bifulco|Author|AUTHORED
99|Scaling Clinical Trial Matching Using Large Language Models: A Case Study In Oncology|Paper|Hoifung Poon|Author|AUTHORED
100|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|Pragmatic Clinical Trials|Topic|DISCUSSES
100|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|Health Interventions|Topic|DISCUSSES
100|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|Negative Spillover|Topic|DISCUSSES
100|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|Control Group|Topic|DISCUSSES
100|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|Treatment Effect|Topic|DISCUSSES
100|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|Social Welfare Interventions|Topic|DISCUSSES
100|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|Public Health Interventions|Topic|DISCUSSES
100|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|Patient Navigation|Topic|DISCUSSES
100|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|Ai-Based Physiological Alarms|Topic|DISCUSSES
100|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|Elective Induction Of Labor|Topic|DISCUSSES
100|Sean Mann|Author|Negative Spillover: A Potential Source Of Bias In Pragmatic Clinical Trials|Paper|AUTHORED
101|Incorporating External Data For Analyzing Randomized Clinical Trials: A Transfer Learning Approach|Paper|Randomized Clinical Trials|Topic|DISCUSSES
101|Incorporating External Data For Analyzing Randomized Clinical Trials: A Transfer Learning Approach|Paper|Transfer Learning|Topic|DISCUSSES
102|A Conservative Approach To Leveraging External Evidence For Effective Clinical Trial Design|Paper|Fabio Rigat|Author|AUTHORED
102|A Conservative Approach To Leveraging External Evidence For Effective Clinical Trial Design|Paper|Clinical Trial Design|Topic|DISCUSSES
102|A Conservative Approach To Leveraging External Evidence For Effective Clinical Trial Design|Paper|Bayesian Trial Design|Topic|DISCUSSES
102|A Conservative Approach To Leveraging External Evidence For Effective Clinical Trial Design|Paper|Clinical Equipoise|Topic|DISCUSSES
102|A Conservative Approach To Leveraging External Evidence For Effective Clinical Trial Design|Paper|Phase Ii Study Sample Size|Topic|DISCUSSES
102|A Conservative Approach To Leveraging External Evidence For Effective Clinical Trial Design|Paper|Group Sequential Confirmatory Designs|Topic|DISCUSSES
103|Leveraging Historical Data For High-Dimensional Regression Adjustment, A Composite Covariate Approach|Paper|Samuel Branders|Author|AUTHORED
103|Leveraging Historical Data For High-Dimensional Regression Adjustment, A Composite Covariate Approach|Paper|Alvaro Pereira|Author|AUTHORED
103|Leveraging Historical Data For High-Dimensional Regression Adjustment, A Composite Covariate Approach|Paper|Guillaume Bernard|Author|AUTHORED
103|Leveraging Historical Data For High-Dimensional Regression Adjustment, A Composite Covariate Approach|Paper|Marie Ernst|Author|AUTHORED
103|Leveraging Historical Data For High-Dimensional Regression Adjustment, A Composite Covariate Approach|Paper|Adelin Albert|Author|AUTHORED
104|Clinical Trials|Topic|Electronic Health Records|Topic|RELATED_TO
104|Electronic Health Records|Topic|Chatgpt|Topic|RELATED_TO
104|Chatgpt|Topic|Georgios Peikos|Author|AUTHORED
104|Chatgpt|Topic|Symeon Symeonidis|Author|AUTHORED
104|Chatgpt|Topic|Pranav Kasela|Author|AUTHORED
104|Chatgpt|Topic|Gabriella Pasi|Author|AUTHORED
105|Multivariate Rank-Based Analysis Of Multiple Endpoints In Clinical Trials: A Global Test Approach|Paper|Kexuan Li|Author|AUTHORED
105|Multivariate Rank-Based Analysis Of Multiple Endpoints In Clinical Trials: A Global Test Approach|Paper|Lingli Yang|Author|AUTHORED
105|Multivariate Rank-Based Analysis Of Multiple Endpoints In Clinical Trials: A Global Test Approach|Paper|Shaofei Zhao|Author|AUTHORED
105|Multivariate Rank-Based Analysis Of Multiple Endpoints In Clinical Trials: A Global Test Approach|Paper|Susie Sinks|Author|AUTHORED
105|Multivariate Rank-Based Analysis Of Multiple Endpoints In Clinical Trials: A Global Test Approach|Paper|Luan Lin|Author|AUTHORED
105|Multivariate Rank-Based Analysis Of Multiple Endpoints In Clinical Trials: A Global Test Approach|Paper|Peng Sun|Author|AUTHORED
106|Team Ielab|Topic|Csiro|Topic|RELATED_TO
106|Team Ielab|Topic|The University Of Queensland|Topic|RELATED_TO
106|Team Ielab|Topic|2023 Trec Clinical Trials Track|Topic|RELATED_TO
106|Team Ielab|Topic|Chatgpt|Topic|RELATED_TO
106|Team Ielab|Topic|Pubmedbert|Topic|RELATED_TO
106|Team Ielab|Topic|Gpt-4|Topic|RELATED_TO
106|Shengyao Zhuang|Author|Team Ielab|Topic|AUTHORED
106|Bevan Koopman|Author|Team Ielab|Topic|AUTHORED
106|Guido Zuccon|Author|Team Ielab|Topic|AUTHORED
107|Tables, Figures, And Listings (Tfls)|Topic|Clinical Trial Data|Topic|RELATED_TO
107|Large Language Models (Llms)|Topic|Prompt Engineering|Topic|RELATED_TO
107|Large Language Models (Llms)|Topic|Few-Shot Transfer Learning|Topic|RELATED_TO
107|Public Clinical Trial Data In Adam Format|Topic|Large Language Models (Llms)|Topic|RELATED_TO
107|Clinical Trial Tfl Generation Agent|Topic|Large Language Models (Llms)|Topic|RELATED_TO
107|Yumeng Yang|Author|Using Large Language Models To Generate Clinical Trial Tables And Figures|Paper|AUTHORED
107|Peter Krusche|Author|Using Large Language Models To Generate Clinical Trial Tables And Figures|Paper|AUTHORED
107|Kristyn Pantoja|Author|Using Large Language Models To Generate Clinical Trial Tables And Figures|Paper|AUTHORED
107|Cheng Shi|Author|Using Large Language Models To Generate Clinical Trial Tables And Figures|Paper|AUTHORED
107|Ethan Ludmir|Author|Using Large Language Models To Generate Clinical Trial Tables And Figures|Paper|AUTHORED
107|Kirk Roberts|Author|Using Large Language Models To Generate Clinical Trial Tables And Figures|Paper|AUTHORED
107|Gen Zhu|Author|Using Large Language Models To Generate Clinical Trial Tables And Figures|Paper|AUTHORED
108|Comprehensive Cancer Center|Topic|Clinical Trials|Topic|RELATED_TO
108|Clinical Trials|Topic|Oncologists|Topic|RELATED_TO
108|Oncologists|Topic|Most Responsible Physicians|Topic|RELATED_TO
108|Patient Movements|Topic|Social Network Analysis|Topic|RELATED_TO
108|Social Network Analysis|Topic|Community Detection Algorithms|Topic|RELATED_TO
108|Community Detection Algorithms|Topic|Girvan-Newman|Topic|RELATED_TO
108|Community Detection Algorithms|Topic|Louvain|Topic|RELATED_TO
108|Community Detection Algorithms|Topic|Author'S Algorithm|Topic|RELATED_TO
108|Author'S Algorithm|Topic|Epidemiological Research|Topic|RELATED_TO
108|Centrality In Collaboration: A Novel Algorithm For Social Partitioning Gradients In Community Detection For Multiple Oncology Clinical Trial Enrollments|Paper|Benjamin Smith|Author|AUTHORED
108|Centrality In Collaboration: A Novel Algorithm For Social Partitioning Gradients In Community Detection For Multiple Oncology Clinical Trial Enrollments|Paper|Tyler Pittman|Author|AUTHORED
108|Centrality In Collaboration: A Novel Algorithm For Social Partitioning Gradients In Community Detection For Multiple Oncology Clinical Trial Enrollments|Paper|Wei Xu|Author|AUTHORED
109|Clinical Trials|Topic|Binary Outcomes|Topic|RELATED_TO
109|Minge Xie|Author|Clinical Trials|Topic|AUTHORED
109|Regina Y. Liu|Author|Clinical Trials|Topic|AUTHORED
109|C. V. Damaraju|Author|Clinical Trials|Topic|AUTHORED
109|William H. Olson|Author|Clinical Trials|Topic|AUTHORED
109|Discrepant Posterior Phenomenon|Topic|Bayesian Approach|Topic|RELATED_TO
109|Bayesian Approach|Topic|Confidence Distribution|Topic|RELATED_TO
110|Sample Size Calculation For Clinical Trials|Topic|Rmtld|Topic|RELATED_TO
110|Sample Size Calculation For Clinical Trials|Topic|Weibull Distribution|Topic|RELATED_TO
110|Rmtld|Topic|Weibull Distribution|Topic|RELATED_TO
110|Xiang Geng|Author|Sample Size Calculation For Clinical Trials|Topic|AUTHORED
110|Zhaojin Li|Author|Sample Size Calculation For Clinical Trials|Topic|AUTHORED
110|Chengfeng Zhang|Author|Sample Size Calculation For Clinical Trials|Topic|AUTHORED
110|Yanjie Wang|Author|Sample Size Calculation For Clinical Trials|Topic|AUTHORED
110|Haoning Shen|Author|Sample Size Calculation For Clinical Trials|Topic|AUTHORED
110|Zhiheng Huang|Author|Sample Size Calculation For Clinical Trials|Topic|AUTHORED
110|Yawen Hou|Author|Sample Size Calculation For Clinical Trials|Topic|AUTHORED
110|Zheng Chen|Author|Sample Size Calculation For Clinical Trials|Topic|AUTHORED
111|Bayesian Predictive Probabilities Of Success (Ppos)|Topic|Interim Trial Data|Topic|RELATED_TO
111|Bayesian Predictive Probabilities Of Success (Ppos)|Topic|Simulation-Based Approach|Topic|RELATED_TO
111|Simulation-Based Approach|Topic|Clinical Trials|Topic|RELATED_TO
111|Clinical Trials|Topic|Competing Event Data|Topic|RELATED_TO
111|Joint Distribution Of Time To Event And Event Type|Topic|Competing Event Data|Topic|RELATED_TO
111|I-Spy Covid Phase Ii Trial|Paper|Nct04488081|Topic|RELATED_TO
111|Sthlm3 Prostate Cancer Diagnostic Trial|Paper|Isrctn84445406|Topic|RELATED_TO
111|I-Spy Covid Phase Ii Trial|Paper|Simulation-Based Approach|Topic|DISCUSSES
111|Sthlm3 Prostate Cancer Diagnostic Trial|Paper|Simulation-Based Approach|Topic|DISCUSSES
112|Electronic Health Records|Topic|Patient Information|Topic|RELATED_TO
112|Structured Data|Topic|Patient Information|Topic|RELATED_TO
112|Unstructured Data|Topic|Patient Information|Topic|RELATED_TO
112|Unstructured Data|Topic|Clinical Applications|Topic|RELATED_TO
112|Eligibility Criteria|Topic|Chronic Lymphocytic Leukemia|Topic|RELATED_TO
112|Eligibility Criteria|Topic|Prostate Cancer|Topic|RELATED_TO
112|Temporal Reasoning|Topic|Unstructured Data|Topic|RELATED_TO
112|Information Integration|Topic|Unstructured Data|Topic|RELATED_TO
112|Preethi Raghavan|Author|Electronic Health Records|Topic|AUTHORED
112|James L. Chen|Author|Electronic Health Records|Topic|AUTHORED
112|Eric Fosler-Lussier|Author|Electronic Health Records|Topic|AUTHORED
112|Albert M. Lai|Author|Electronic Health Records|Topic|AUTHORED
113|Failures In Phase 3 Clinical Trials|Topic|Drug Development In Oncology|Topic|RELATED_TO
113|Responders To An Oncology Treatment|Topic|Deep-Learning Derived Digital Pathology Scores|Topic|RELATED_TO
113|Deep-Learning Derived Digital Pathology Scores|Topic|Immunohistochemistry Images|Topic|RELATED_TO
113|Deep-Learning Derived Digital Pathology Scores|Topic|Tumor Biopsy Samples|Topic|RELATED_TO
113|Deep-Learning Derived Digital Pathology Scores|Topic|Phase 1 Non-Small Cell Lung Cancer Clinical Trial|Paper|AUTHORED
113|Auc Of Roc Curve|Topic|Auc Of Precision-Recall Curve|Topic|RELATED_TO
113|Tumor Proportion Score (Tps)|Topic|Auc Of Roc Curve|Topic|RELATED_TO
113|Independent Testing Set Of Patients|Topic|Deep-Learning Derived Score|Topic|RELATED_TO
113|Deep-Learning Derived Score|Topic|Tumor Proportion Score (Tps)|Topic|RELATED_TO
113|Phase 1 Non-Small Cell Lung Cancer Clinical Trial|Paper|Qi Tang|Author|AUTHORED
113|Phase 1 Non-Small Cell Lung Cancer Clinical Trial|Paper|Vardaan Kishore Kumar|Author|AUTHORED
114|Clinical Trials|Topic|Large Language Models|Topic|RELATED_TO
114|Large Language Models|Topic|Clinical Trial Protocols|Topic|RELATED_TO
114|Large Language Models|Topic|Document Quality Improvement|Topic|RELATED_TO
114|Nigel Markey|Author|From Rags To Riches: Using Large Language Models To Write Documents For Clinical Trials|Paper|AUTHORED
114|Ilyass El-Mansouri|Author|From Rags To Riches: Using Large Language Models To Write Documents For Clinical Trials|Paper|AUTHORED
114|Gaetan Rensonnet|Author|From Rags To Riches: Using Large Language Models To Write Documents For Clinical Trials|Paper|AUTHORED
114|Casper Van Langen|Author|From Rags To Riches: Using Large Language Models To Write Documents For Clinical Trials|Paper|AUTHORED
114|Christoph Meier|Author|From Rags To Riches: Using Large Language Models To Write Documents For Clinical Trials|Paper|AUTHORED
114|Retrieval-Augmented Generation|Topic|Large Language Models|Topic|RELATED_TO
115|Information Theory|Topic|Shannon Entropy|Topic|RELATED_TO
115|Information Theory|Topic|Kullback-Leibler Divergence|Topic|RELATED_TO
115|Information Theory|Topic|Mutual Information|Topic|RELATED_TO
115|Estimation Of Information-Theoretic Quantities|Paper|Information Theory|Topic|DISCUSSES
115|Applications Of Information-Theoretic Quantities In Neuroscience|Paper|Information Theory|Topic|DISCUSSES
115|Estimation Of Information-Theoretic Quantities|Paper|Robin A. A. Ince|Author|AUTHORED
115|Estimation Of Information-Theoretic Quantities|Paper|Stefano Panzeri|Author|AUTHORED
115|Estimation Of Information-Theoretic Quantities|Paper|Simon R. Schultz|Author|AUTHORED
115|Applications Of Information-Theoretic Quantities In Neuroscience|Paper|Robin A. A. Ince|Author|AUTHORED
115|Applications Of Information-Theoretic Quantities In Neuroscience|Paper|Stefano Panzeri|Author|AUTHORED
115|Applications Of Information-Theoretic Quantities In Neuroscience|Paper|Simon R. Schultz|Author|AUTHORED
116|Inverse Probability Weighting (Ipsw)|Topic|Population Average Treatment Effect|Topic|RELATED_TO
116|Missing Data|Topic|Inverse Probability Weighting (Ipsw)|Topic|RELATED_TO
116|Multiple Imputation (Mi)|Topic|Inverse Probability Weighting (Ipsw)|Topic|RELATED_TO
116|Frequent Hemodialysis Network (Fhn) Daily Trial|Topic|United States Renal Stage System (Usrds)|Topic|RELATED_TO
116|Albee Y. Ling|Author|Multiple Imputation (Mi)|Topic|AUTHORED
116|Maria E. Montez-Rath|Author|Multiple Imputation (Mi)|Topic|AUTHORED
116|Kris Kapphahn|Author|Multiple Imputation (Mi)|Topic|AUTHORED
116|Manisha Desai|Author|Multiple Imputation (Mi)|Topic|AUTHORED
117|Adaptive Randomization Methods For Sequential Multiple Assignment Randomized Trials (Smarts) Via Thompson Sampling|Paper|Response-Adaptive Randomization|Topic|DISCUSSES
117|Adaptive Randomization Methods For Sequential Multiple Assignment Randomized Trials (Smarts) Via Thompson Sampling|Paper|Sequential Multiple Assignment Randomized Trials|Topic|DISCUSSES
117|Adaptive Randomization Methods For Sequential Multiple Assignment Randomized Trials (Smarts) Via Thompson Sampling|Paper|Thompson Sampling|Topic|DISCUSSES
117|Adaptive Randomization Methods For Sequential Multiple Assignment Randomized Trials (Smarts) Via Thompson Sampling|Paper|Peter Norwood|Author|AUTHORED
117|Adaptive Randomization Methods For Sequential Multiple Assignment Randomized Trials (Smarts) Via Thompson Sampling|Paper|Marie Davidian|Author|AUTHORED
117|Adaptive Randomization Methods For Sequential Multiple Assignment Randomized Trials (Smarts) Via Thompson Sampling|Paper|Eric Laber|Author|AUTHORED
118|Single-Cell Technologies|Topic|Immune Cell-Types|Topic|RELATED_TO
118|Machine Learning Approaches|Topic|Immunological Summaries|Topic|RELATED_TO
118|Cytocoset|Topic|Per-Sample Featurizations|Topic|AUTHORED
118|Chi-Jane Chen|Author|Cytocoset|Topic|AUTHORED
118|Haidong Yi|Author|Cytocoset|Topic|AUTHORED
118|Natalie Stanley|Author|Cytocoset|Topic|AUTHORED
118|Clinical Covariates|Topic|Clinical Outcome|Topic|RELATED_TO
118|Loss Function|Topic|Triplet Term|Topic|RELATED_TO
118|Embedding Results|Topic|Per-Sample Featurizations|Topic|RELATED_TO
119|Utilising High-Dimensional Data In Randomised Clinical Trials: A Review Of Methods And Practice|Paper|Svetlana Cherlin|Author|AUTHORED
119|Utilising High-Dimensional Data In Randomised Clinical Trials: A Review Of Methods And Practice|Paper|Theophile Bigirumurame|Author|AUTHORED
119|Utilising High-Dimensional Data In Randomised Clinical Trials: A Review Of Methods And Practice|Paper|Michael J Grayling|Author|AUTHORED
119|Utilising High-Dimensional Data In Randomised Clinical Trials: A Review Of Methods And Practice|Paper|Jérémie Nsengimana|Author|AUTHORED
119|Utilising High-Dimensional Data In Randomised Clinical Trials: A Review Of Methods And Practice|Paper|Luke Ouma|Author|AUTHORED
119|Utilising High-Dimensional Data In Randomised Clinical Trials: A Review Of Methods And Practice|Paper|Aida Santaolalla|Author|AUTHORED
119|Utilising High-Dimensional Data In Randomised Clinical Trials: A Review Of Methods And Practice|Paper|Fang Wan|Author|AUTHORED
119|Utilising High-Dimensional Data In Randomised Clinical Trials: A Review Of Methods And Practice|Paper|S Faye Williamson|Author|AUTHORED
119|Utilising High-Dimensional Data In Randomised Clinical Trials: A Review Of Methods And Practice|Paper|James M S Wason|Author|AUTHORED
120|How Biomedical Papers Accumulated Their Clinical Citations: A Large-Scale Retrospective Analysis Based On Pubmed|Paper|Xin Li|Author|AUTHORED
120|How Biomedical Papers Accumulated Their Clinical Citations: A Large-Scale Retrospective Analysis Based On Pubmed|Paper|Xuli Tang|Author|AUTHORED
120|How Biomedical Papers Accumulated Their Clinical Citations: A Large-Scale Retrospective Analysis Based On Pubmed|Paper|Wei Lu|Author|AUTHORED
121|Ibex|Topic|Ibex Knowledge-Base|Topic|RELATED_TO
121|Ibex Knowledge-Base|Topic|Open Science|Topic|RELATED_TO
121|Ibex Knowledge-Base|Topic|Andrea J. Radtke|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Ifeanyichukwu Anidi|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Leanne Arakkal|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Armando Arroyo-Mejias|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Rebecca T. Beuschel|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Katy Borner|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Colin J. Chu|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Beatrice Clark|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Menna R. Clatworthy|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Jake Colautti|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Joshua Croteau|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Saven Denha|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Rose Dever|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Walderez O. Dutra|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Sonja Fritzsche|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Spencer Fullam|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Michael Y. Gerner|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Anita Gola|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Kenneth J. Gollob|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Jonathan M. Hernandez|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Jyh Liang Hor|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Hiroshi Ichise|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Zhixin Jing|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Danny Jonigk|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Evelyn Kandov|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Wolfgang Kastenmueller|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Joshua F. E. Koenig|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Aanandita Kothurkar|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Alexandra Y. Kreins|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Ian Lamborn|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Yuri Lin|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Katia Luciano Pereira Morais|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Aleksandra Lunich|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Jean C. S. Luz|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Ryan B. Macdonald|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Chen Makranz|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Vivien I. Maltez|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Ryan V. Moriaty|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Juan M. Ocampo-Godinez|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Vitoria M. Olyntho|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Kartika Padhan|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Kirsten Remmert|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Nathan Richoz|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Edward C. Schrom|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Wanjing Shang|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Lihong Shi|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Rochelle M. Shih|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Emily Speranza|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Salome Stierli|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Sarah A. Teichmann|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Tibor Z. Veres|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Megan Vierhout|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Brianna T. Wachter|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Adam K. Wade-Vallance|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Margaret Williams|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Nathan Zangger|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Ronald N. Germain|Author|AUTHORED
121|Ibex Knowledge-Base|Topic|Ziv Yaniv|Author|AUTHORED
122|Neural Latent Aligner|Topic|Cheol Jun Cho|Author|AUTHORED
122|Neural Latent Aligner|Topic|Edward F. Chang|Author|AUTHORED
122|Neural Latent Aligner|Topic|Gopala K. Anumanchipalli|Author|AUTHORED
122|Neural Latent Aligner|Topic|Intracranial Electrocorticography|Topic|RELATED_TO
122|Neural Latent Aligner|Topic|Complex Human Behaviors|Topic|RELATED_TO
122|Neural Latent Aligner|Topic|Neural Representations|Topic|RELATED_TO
122|Neural Latent Aligner|Topic|Time Warping Model|Topic|RELATED_TO
122|Neural Latent Aligner|Topic|Behavioral Coherence|Topic|RELATED_TO
122|Neural Latent Aligner|Topic|Cross-Trial Consistent Representations|Topic|RELATED_TO
123|Neurocave|Topic|Clinical Neuroscience|Topic|RELATED_TO
123|Connectomes|Topic|Clinical Neuroscience|Topic|RELATED_TO
123|Clinical Neuroscience|Topic|Neuropsychiatric Disorders|Topic|RELATED_TO
123|Johnson J. G. Keiriz|Author|Neurocave|Topic|AUTHORED
123|Liang Zhan|Author|Neurocave|Topic|AUTHORED
123|Morris Chukhman|Author|Neurocave|Topic|AUTHORED
123|Olu Ajilore|Author|Neurocave|Topic|AUTHORED
123|Alex D. Leow|Author|Neurocave|Topic|AUTHORED
123|Angus G. Forbes|Author|Neurocave|Topic|AUTHORED
124|Pranab K. Sen|Author|Sequential Nonparametrics|Topic|RELATED_TO
124|Pranab K. Sen|Author|Semiparametrics|Topic|RELATED_TO
124|Pranab K. Sen|Author|Clinical Trials|Topic|RELATED_TO
124|Tze Leung Lai|Author|Clinical Trials|Topic|AUTHORED
124|Zheng Su|Author|Clinical Trials|Topic|AUTHORED
124|Nonparametric Inference|Topic|Time-Sequential Clinical Trials|Topic|RELATED_TO
124|Semiparametric Inference|Topic|Time-Sequential Clinical Trials|Topic|RELATED_TO
124|Computational Methods|Topic|Time-Sequential Clinical Trials|Topic|RELATED_TO
124|Time-Sequential Clinical Trials|Topic|Survival Endpoints|Topic|RELATED_TO
125|Generalized Likelihood Ratio Statistics And Uncertainty Adjustments In Efficient Adaptive Design Of Clinical Trials|Paper|Jay Bartroff|Author|AUTHORED
125|Generalized Likelihood Ratio Statistics And Uncertainty Adjustments In Efficient Adaptive Design Of Clinical Trials|Paper|Tze Leung Lai|Author|AUTHORED
126|Toronto Metropolitan University|Topic|Trec Clinical Trials Track 2023|Topic|RELATED_TO
126|Aritra Kumar Lahiri|Author|Team - V-Torontomu|Topic|AUTHORED
126|Emrul Hasan|Author|Team - V-Torontomu|Topic|AUTHORED
126|Qinmin Vivian Hu|Author|Team - V-Torontomu|Topic|AUTHORED
126|Cherie Ding|Author|Team - V-Torontomu|Topic|AUTHORED
127|Interim Analyses In Clinical Trials|Topic|Elina Asikanius|Author|DISCUSSES
127|Interim Analyses In Clinical Trials|Topic|Benjamin Hofner|Author|DISCUSSES
127|Interim Analyses In Clinical Trials|Topic|Lisa V. Hampson|Author|DISCUSSES
127|Interim Analyses In Clinical Trials|Topic|Gernot Wassmer|Author|DISCUSSES
127|Interim Analyses In Clinical Trials|Topic|Christopher Jennison|Author|DISCUSSES
127|Interim Analyses In Clinical Trials|Topic|Tobias Mielke|Author|DISCUSSES
127|Interim Analyses In Clinical Trials|Topic|Cornelia Ursula Kunz|Author|DISCUSSES
127|Interim Analyses In Clinical Trials|Topic|Kaspar Rufibach|Author|DISCUSSES
128|New Two-Stage Design|Topic|Drug Combinations In Clinical Trials|Topic|RELATED_TO
128|New Two-Stage Design|Topic|Phase I Clinical Trials|Topic|RELATED_TO
128|New Two-Stage Design|Topic|Phase Ii Clinical Trials|Topic|RELATED_TO
128|New Two-Stage Design|Topic|Two-Stage Designs|Topic|RELATED_TO
128|New Two-Stage Design|Topic|José L. Jiménez|Author|AUTHORED
128|New Two-Stage Design|Topic|Sungjin Kim|Author|AUTHORED
128|New Two-Stage Design|Topic|Mourad Tighiouart|Author|AUTHORED
129|On The Relevance Of Prognostic Information For Clinical Trials: A Theoretical Quantification|Paper|Bayesian Information Borrowing|Topic|DISCUSSES
129|On The Relevance Of Prognostic Information For Clinical Trials: A Theoretical Quantification|Paper|Propensity Score Methods|Topic|DISCUSSES
129|On The Relevance Of Prognostic Information For Clinical Trials: A Theoretical Quantification|Paper|Stratification|Topic|DISCUSSES
129|On The Relevance Of Prognostic Information For Clinical Trials: A Theoretical Quantification|Paper|Covariate Adjustment|Topic|DISCUSSES
129|On The Relevance Of Prognostic Information For Clinical Trials: A Theoretical Quantification|Paper|Prognostic Score|Topic|DISCUSSES
129|On The Relevance Of Prognostic Information For Clinical Trials: A Theoretical Quantification|Paper|Machine Learning|Topic|DISCUSSES
129|On The Relevance Of Prognostic Information For Clinical Trials: A Theoretical Quantification|Paper|Sample Size Reduction Formula|Topic|DISCUSSES
129|On The Relevance Of Prognostic Information For Clinical Trials: A Theoretical Quantification|Paper|Historical Data|Topic|DISCUSSES
129|On The Relevance Of Prognostic Information For Clinical Trials: A Theoretical Quantification|Paper|Randomised Clinical Trials|Topic|DISCUSSES
130|Cancer Clinical Trials|Topic|Large Language Models|Topic|RELATED_TO
130|Large Language Models|Topic|Gpt4|Topic|RELATED_TO
130|Gpt4|Topic|Clinicaltrials.Gov|Topic|RELATED_TO
130|Gpt4|Topic|Mingye Gao|Author|AUTHORED
130|Gpt4|Topic|Aman Varshney|Author|AUTHORED
130|Gpt4|Topic|Shan Chen|Author|AUTHORED
130|Gpt4|Topic|Vikram Goddla|Author|AUTHORED
130|Gpt4|Topic|Jack Gallifant|Author|AUTHORED
130|Gpt4|Topic|Patrick Doyle|Author|AUTHORED
130|Gpt4|Topic|Claire Novack|Author|AUTHORED
130|Gpt4|Topic|Maeve Dillon-Martin|Author|AUTHORED
130|Gpt4|Topic|Teresia Perkins|Author|AUTHORED
130|Gpt4|Topic|Xinrong Correia|Author|AUTHORED
130|Gpt4|Topic|Erik Duhaime|Author|AUTHORED
130|Gpt4|Topic|Howard Isenstein|Author|AUTHORED
130|Gpt4|Topic|Elad Sharon|Author|AUTHORED
130|Gpt4|Topic|Lisa Soleymani Lehmann|Author|AUTHORED
130|Gpt4|Topic|David Kozono|Author|AUTHORED
130|Gpt4|Topic|Brian Anthony|Author|AUTHORED
130|Gpt4|Topic|Dmitriy Dligach|Author|AUTHORED
130|Gpt4|Topic|Danielle S. Bitterman|Author|AUTHORED
131|Treement|Topic|Brandon Theodorou|Author|AUTHORED
131|Treement|Topic|Cao Xiao|Author|AUTHORED
131|Treement|Topic|Jimeng Sun|Author|AUTHORED
131|Clinical Trials|Topic|Machine Learning Models|Topic|RELATED_TO
131|Machine Learning Models|Topic|Patient Electronic Health Records|Topic|RELATED_TO
132|Deep Learning|Topic|Neuroscience|Topic|RELATED_TO
132|Deep Learning|Topic|Biomedical Data Analysis|Topic|RELATED_TO
132|Neuroscience|Topic|Neuroinformatic Toolboxes|Topic|RELATED_TO
132|Louis Fabrice Tshimanga|Author|Deep Learning|Topic|AUTHORED
132|Manfredo Atzori|Author|Deep Learning|Topic|AUTHORED
132|Federico Del Pup|Author|Deep Learning|Topic|AUTHORED
132|Maurizio Corbetta|Author|Deep Learning|Topic|AUTHORED
133|Lifted|Topic|Clinical Trial Outcome Prediction|Topic|RELATED_TO
133|Wenhao Zheng|Author|Lifted|Topic|AUTHORED
133|Liaoyaqi Wang|Author|Lifted|Topic|AUTHORED
133|Dongshen Peng|Author|Lifted|Topic|AUTHORED
133|Hongxia Xu|Author|Lifted|Topic|AUTHORED
133|Yun Li|Author|Lifted|Topic|AUTHORED
133|Hongtu Zhu|Author|Lifted|Topic|AUTHORED
133|Tianfan Fu|Author|Lifted|Topic|AUTHORED
133|Huaxiu Yao|Author|Lifted|Topic|AUTHORED
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Ali Akram|Author|AUTHORED
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Marija Stanojevic|Author|AUTHORED
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Malikeh Ehghaghi|Author|AUTHORED
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Jekaterina Novikova|Author|AUTHORED
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Clinical Trials|Topic|RELATED_TO
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Speaker Verification|Topic|RELATED_TO
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Cognitive And Mental Health Disorders|Topic|RELATED_TO
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Titanet|Topic|RELATED_TO
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Ecapa-Tdnn|Topic|RELATED_TO
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Speakernet|Topic|RELATED_TO
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Speech Data|Topic|RELATED_TO
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|European Languages|Topic|RELATED_TO
134|Zero-Shot Multi-Lingual Speaker Verification In Clinical Trials|Paper|Arabic|Topic|RELATED_TO
135|Linkedct|Topic|Oktie Hassanzadeh|Author|AUTHORED
135|Linkedct|Topic|Anastasios Kementsietsidis|Author|AUTHORED
135|Linkedct|Topic|Lipyeow Lim|Author|AUTHORED
135|Linkedct|Topic|Renee J. Miller|Author|AUTHORED
135|Linkedct|Topic|Min Wang|Author|AUTHORED
136|Active Clinical Trials For Personalized Medicine|Paper|Individualized Treatment Rules (Itrs)|Topic|DISCUSSES
136|Active Clinical Trials For Personalized Medicine|Paper|Patient Care|Topic|DISCUSSES
136|Active Clinical Trials For Personalized Medicine|Paper|Randomized Clinical Trials|Topic|DISCUSSES
136|Active Clinical Trials For Personalized Medicine|Paper|Cost-Effective Estimation Method|Topic|DISCUSSES
136|Active Clinical Trials For Personalized Medicine|Paper|Active Learning Perspective|Topic|DISCUSSES
136|Active Clinical Trials For Personalized Medicine|Paper|Most Informative Patients|Topic|DISCUSSES
136|Active Clinical Trials For Personalized Medicine|Paper|Simulation Studies|Topic|DISCUSSES
136|Active Clinical Trials For Personalized Medicine|Paper|Real-Data Examples|Topic|DISCUSSES
136|Active Clinical Trials For Personalized Medicine|Paper|Risk Bounds|Topic|DISCUSSES
136|Stanislav Minsker|Author|Active Clinical Trials For Personalized Medicine|Paper|AUTHORED
136|Ying-Qi Zhao|Author|Active Clinical Trials For Personalized Medicine|Paper|AUTHORED
136|Guang Cheng|Author|Active Clinical Trials For Personalized Medicine|Paper|AUTHORED
137|A Blockchain Framework For Managing And Monitoring Data In Multi-Site Clinical Trials|Paper|Olivia Choudhury|Author|AUTHORED
137|A Blockchain Framework For Managing And Monitoring Data In Multi-Site Clinical Trials|Paper|Noor Fairoza|Author|AUTHORED
137|A Blockchain Framework For Managing And Monitoring Data In Multi-Site Clinical Trials|Paper|Issa Sylla|Author|AUTHORED
137|A Blockchain Framework For Managing And Monitoring Data In Multi-Site Clinical Trials|Paper|Amar Das|Author|AUTHORED
138|Safe Efficacy Exploration Dose Allocation (Seeda)|Topic|Cumulative Efficacy|Topic|RELATED_TO
138|Safe Efficacy Exploration Dose Allocation (Seeda)|Topic|Toxicity Violation Probability|Topic|RELATED_TO
138|Safe Efficacy Exploration Dose Allocation (Seeda)|Topic|Sample Efficiency|Topic|RELATED_TO
138|Seeda-Plateau Algorithm|Topic|Safe Efficacy Exploration Dose Allocation (Seeda)|Topic|RELATED_TO
138|Cong Shen|Author|Learning For Dose Allocation In Adaptive Clinical Trials With Safety Constraints|Paper|AUTHORED
138|Zhiyang Wang|Author|Learning For Dose Allocation In Adaptive Clinical Trials With Safety Constraints|Paper|AUTHORED
138|Sofia S. Villar|Author|Learning For Dose Allocation In Adaptive Clinical Trials With Safety Constraints|Paper|AUTHORED
138|Mihaela Van Der Schaar|Author|Learning For Dose Allocation In Adaptive Clinical Trials With Safety Constraints|Paper|AUTHORED
139|Clinical Trials|Topic|New Treatments|Topic|RELATED_TO
139|Clinical Trials|Topic|Medical Knowledge|Topic|RELATED_TO
139|Intervention Effectiveness Prediction Method|Topic|Pubmed Articles|Topic|RELATED_TO
139|Intervention Effectiveness Prediction Method|Topic|Evidence Sentences|Topic|RELATED_TO
139|Intervention Effectiveness Prediction Method|Topic|Bert-Based Classifier|Topic|RELATED_TO
139|Dataset Of Clinical Trials|Topic|Pubmed Articles|Topic|RELATED_TO
139|Short Informative Summaries|Topic|Intervention Effectiveness Prediction Method|Topic|RELATED_TO
139|Georgios Katsimpras|Author|Intervention Effectiveness Prediction Method|Topic|AUTHORED
139|Georgios Paliouras|Author|Intervention Effectiveness Prediction Method|Topic|AUTHORED
140|Pragmatic Clinical Trials In The Rubric Of Structural Causal Models|Paper|Explanatory Studies|Topic|DISCUSSES
140|Pragmatic Clinical Trials In The Rubric Of Structural Causal Models|Paper|Observational Studies|Topic|DISCUSSES
140|Pragmatic Clinical Trials In The Rubric Of Structural Causal Models|Paper|Structural Causal Model (Scm)|Topic|DISCUSSES
140|Pragmatic Clinical Trials In The Rubric Of Structural Causal Models|Paper|Do-Calculus|Topic|DISCUSSES
140|Pragmatic Clinical Trials In The Rubric Of Structural Causal Models|Paper|Pragmatic Clinical Trials (Pct)|Topic|DISCUSSES
140|Pragmatic Clinical Trials In The Rubric Of Structural Causal Models|Paper|Generalized Representation Of Pct|Topic|DISCUSSES
140|Pragmatic Clinical Trials In The Rubric Of Structural Causal Models|Paper|Analysis Techniques In Pct|Topic|DISCUSSES
140|Pragmatic Clinical Trials In The Rubric Of Structural Causal Models|Paper|Experimental Dataset From A Pragmatic Clinical Trial|Topic|DISCUSSES
141|Robust Detection Of Covariate-Treatment Interactions In Clinical Trials|Paper|Baptiste Goujaud|Author|AUTHORED
141|Robust Detection Of Covariate-Treatment Interactions In Clinical Trials|Paper|Eric W. Tramel|Author|AUTHORED
141|Robust Detection Of Covariate-Treatment Interactions In Clinical Trials|Paper|Pierre Courtiol|Author|AUTHORED
141|Robust Detection Of Covariate-Treatment Interactions In Clinical Trials|Paper|Mikhail Zaslavskiy|Author|AUTHORED
141|Robust Detection Of Covariate-Treatment Interactions In Clinical Trials|Paper|Gilles Wainrib|Author|AUTHORED
142|Prognostic Model|Topic|Mild Cognitive Impairment|Topic|RELATED_TO
142|Prognostic Model|Topic|Baseline Cognitive Scores|Topic|RELATED_TO
142|Prognostic Model|Topic|Mri-Based Features|Topic|RELATED_TO
142|Cognitive Decline|Topic|Cdr-Sb|Topic|RELATED_TO
142|Clinical Trials|Topic|Cohort Enrichment Tool|Topic|RELATED_TO
142|Neda Shafiee|Author|Clinical Trials|Topic|AUTHORED
142|Mahsa Dadar|Author|Clinical Trials|Topic|AUTHORED
142|Simon Ducharme|Author|Clinical Trials|Topic|AUTHORED
142|D. Louis Collins|Author|Clinical Trials|Topic|AUTHORED
143|Incorporating External Data Into The Analysis Of Clinical Trials Via Bayesian Additive Regression Trees|Paper|Bayesian Additive Regression Trees|Topic|DISCUSSES
143|Incorporating External Data Into The Analysis Of Clinical Trials Via Bayesian Additive Regression Trees|Paper|Clinical Trials|Topic|RELATED_TO
144|High-Performance Uncertainty Quantification In Large-Scale Virtual Clinical Trials Of Closed-Loop Diabetes Treatment|Paper|Asbjørn Thode Reenberg|Author|AUTHORED
144|High-Performance Uncertainty Quantification In Large-Scale Virtual Clinical Trials Of Closed-Loop Diabetes Treatment|Paper|Tobias K. S. Ritschel|Author|AUTHORED
144|High-Performance Uncertainty Quantification In Large-Scale Virtual Clinical Trials Of Closed-Loop Diabetes Treatment|Paper|Bernd Dammann|Author|AUTHORED
144|High-Performance Uncertainty Quantification In Large-Scale Virtual Clinical Trials Of Closed-Loop Diabetes Treatment|Paper|John Bagterp Jørgensen|Author|AUTHORED
145|Clinical Trial Aggregation Program|Topic|Randomized Controlled Trial|Topic|RELATED_TO
145|Randomized Controlled Trial|Topic|Frantiek Barto|Author|AUTHORED
145|Randomized Controlled Trial|Topic|Eric-Jan Wagenmakers|Author|AUTHORED
145|Randomized Controlled Trial|Topic|Christiaan H. Vinkers|Author|AUTHORED
145|Randomized Controlled Trial|Topic|Kees P. J. Braun|Author|AUTHORED
145|Randomized Controlled Trial|Topic|Willem M. Otte|Author|AUTHORED
146|Modern Randomization Methods In Clinical Trials|Topic|Adaptive Randomization Methods|Topic|RELATED_TO
146|Adaptive Randomization Methods|Topic|Mathematical Programming|Topic|RELATED_TO
146|Adaptive Randomization Methods|Topic|Energy Distance Measure|Topic|RELATED_TO
146|Energy Distance Measure|Topic|Small Clinical Trials|Topic|RELATED_TO
146|Alan R. Vazquez|Author|Two-Arm Clinical Trials|Topic|AUTHORED
146|Weng Kee Wong|Author|Two-Arm Clinical Trials|Topic|AUTHORED
146|R Codes|Topic|Two-Arm Clinical Trials|Topic|RELATED_TO
146|Two-Arm Clinical Trials|Topic|Real Data|Topic|RELATED_TO
147|Clinical Trials Protocol Authoring Using Llms|Paper|Gpt-4|Topic|DISCUSSES
147|Clinical Trials Protocol Authoring Using Llms|Paper|Clinical Trial Protocols|Topic|RELATED_TO
148|Design Of Bayesian Clinical Trials With Clustered Data And Multiple Endpoints|Paper|Bayesian Clinical Trials|Topic|RELATED_TO
148|Design Of Bayesian Clinical Trials With Clustered Data And Multiple Endpoints|Paper|Operating Characteristics|Topic|RELATED_TO
148|Design Of Bayesian Clinical Trials With Clustered Data And Multiple Endpoints|Paper|Monte Carlo Simulation|Topic|RELATED_TO
148|Design Of Bayesian Clinical Trials With Clustered Data And Multiple Endpoints|Paper|Clustered Data|Topic|RELATED_TO
148|Design Of Bayesian Clinical Trials With Clustered Data And Multiple Endpoints|Paper|Sample Sizes|Topic|RELATED_TO
148|Design Of Bayesian Clinical Trials With Clustered Data And Multiple Endpoints|Paper|Posterior Probabilities|Topic|RELATED_TO
148|Design Of Bayesian Clinical Trials With Clustered Data And Multiple Endpoints|Paper|Simulation Variability|Topic|RELATED_TO
148|Design Of Bayesian Clinical Trials With Clustered Data And Multiple Endpoints|Paper|Current Clinical Trial|Topic|RELATED_TO
148|Luke Hagar|Author|Design Of Bayesian Clinical Trials With Clustered Data And Multiple Endpoints|Paper|AUTHORED
148|Shirin Golchi|Author|Design Of Bayesian Clinical Trials With Clustered Data And Multiple Endpoints|Paper|AUTHORED
149|Choriocapillaris Flow Signal Impairment In Sorsby Fundus Dystrophy|Paper|Sorsby Fundus Dystrophy|Topic|RELATED_TO
149|Choriocapillaris Flow Signal Impairment In Sorsby Fundus Dystrophy|Paper|Oct-A|Topic|DISCUSSES
149|Choriocapillaris Flow Signal Impairment In Sorsby Fundus Dystrophy|Paper|Choriocapillaris|Topic|DISCUSSES
150|Estimands In Hematologic Oncology Trials|Paper|Ich E9 Guideline|Topic|RELATED_TO
150|Estimands In Hematologic Oncology Trials|Paper|Hematological Malignancies|Topic|RELATED_TO
151|Clinical Trial|Topic|Survival Outcome|Topic|RELATED_TO
151|Clinical Trial|Topic|Interim Analysis|Topic|RELATED_TO
151|Interim Analysis|Topic|New Treatment|Topic|RELATED_TO
151|Interim Analysis|Topic|Placebo|Topic|RELATED_TO
151|Interim Analysis|Topic|Kaplan-Meier Curves|Topic|RELATED_TO
151|Marianne A Jonker|Author|Clinical Trial|Topic|AUTHORED
151|Steven Teerenstra|Author|Clinical Trial|Topic|AUTHORED
152|Active Learning For Developing Personalized Treatment|Paper|Kun Deng|Author|AUTHORED
152|Active Learning For Developing Personalized Treatment|Paper|Joelle Pineau|Author|AUTHORED
152|Active Learning For Developing Personalized Treatment|Paper|Susan A. Murphy|Author|AUTHORED
152|Active Learning For Developing Personalized Treatment|Paper|Personalized Treatment|Topic|RELATED_TO
152|Active Learning For Developing Personalized Treatment|Paper|Active Learning Techniques|Topic|RELATED_TO
152|Active Learning For Developing Personalized Treatment|Paper|Clinical Trials|Topic|RELATED_TO
152|Active Learning For Developing Personalized Treatment|Paper|Minimax Bandit Model|Topic|RELATED_TO
152|Active Learning For Developing Personalized Treatment|Paper|Computational Challenges|Topic|RELATED_TO
152|Active Learning For Developing Personalized Treatment|Paper|Simulated Data|Topic|RELATED_TO
152|Active Learning For Developing Personalized Treatment|Paper|Depressed Individuals|Topic|RELATED_TO
153|Medical Research|Topic|Randomized Clinical Trials|Topic|RELATED_TO
153|Randomized Clinical Trials|Topic|Hypothesis Testing|Topic|RELATED_TO
153|Bayesians|Topic|Subjective Expected Utility|Topic|RELATED_TO
153|Bayesians|Topic|Treatment Response|Topic|RELATED_TO
153|Frequentist Statistical Decision Theory|Topic|Wald (1950)|Author|RELATED_TO
153|Charles F. Manski|Author|Aleksey Tetenov|Author|AUTHORED
154|Covid-19 Clinical Trial Design|Topic|Deep Learning Approach|Topic|RELATED_TO
154|Deep Learning Approach|Topic|Att-Bilstm|Topic|RELATED_TO
154|Att-Bilstm|Topic|Ontology-Based Method|Topic|DISCUSSES
154|Att-Bilstm|Topic|Benchmark Dataset|Topic|RELATED_TO
154|Xiong Liu|Author|Attention-Based Lstm Network For Covid-19 Clinical Trial Parsing|Paper|AUTHORED
154|Luca A. Finelli|Author|Attention-Based Lstm Network For Covid-19 Clinical Trial Parsing|Paper|AUTHORED
154|Greg L. Hersch|Author|Attention-Based Lstm Network For Covid-19 Clinical Trial Parsing|Paper|AUTHORED
154|Iya Khalil|Author|Attention-Based Lstm Network For Covid-19 Clinical Trial Parsing|Paper|AUTHORED
155|Clinical Trial Enrollment Success Prediction|Topic|Ling Yue|Author|AUTHORED
155|Clinical Trial Enrollment Success Prediction|Topic|Sixue Xing|Author|AUTHORED
155|Clinical Trial Enrollment Success Prediction|Topic|Jintai Chen|Author|AUTHORED
155|Clinical Trial Enrollment Success Prediction|Topic|Tianfan Fu|Author|AUTHORED
156|Trail Making Test|Topic|Executive Functions|Topic|RELATED_TO
156|Trail Making Test|Topic|Ctmt|Topic|RELATED_TO
156|Ctmt|Topic|Traditional Tmt|Topic|RELATED_TO
156|Ignacio Linari|Author|Trail Making Test|Topic|AUTHORED
156|Gustavo Juantorena|Author|Trail Making Test|Topic|AUTHORED
156|Agustin Ibañez|Author|Trail Making Test|Topic|AUTHORED
156|Agustin Petroni|Author|Trail Making Test|Topic|AUTHORED
156|Juan E. Kamienkowski|Author|Trail Making Test|Topic|AUTHORED
157|Multinomial Sequential Unbiased Estimators|Topic|Binomial Samples|Topic|RELATED_TO
157|Unbiased Estimators|Topic|Multidimensional Random Walks|Topic|RELATED_TO
157|Unbiased Estimators|Topic|Multinomial Random Walks|Topic|RELATED_TO
157|Multinomial Random Walks|Topic|Boundary Crossing Random Walks|Topic|RELATED_TO
157|Clinical Trials|Topic|Boundary Crossing Random Walks|Topic|RELATED_TO
157|Enrico Bibbona|Author|Clinical Trials|Topic|AUTHORED
157|Alessandro Rubba|Author|Clinical Trials|Topic|AUTHORED
158|Multivariate Bayesian Logistic Regression For Analysis Of Clinical Trial Safety Issues|Paper|W. Dumouchel|Author|AUTHORED
158|Multivariate Bayesian Logistic Regression For Analysis Of Clinical Trial Safety Issues|Paper|Bradley W. Mcevoy|Author|AUTHORED
158|Multivariate Bayesian Logistic Regression For Analysis Of Clinical Trial Safety Issues|Paper|Ram C. Tiwari|Author|AUTHORED
159|Multivariate Bayesian Logistic Regression For Analysis Of Clinical Trial Safety Issues|Paper|Don Berry|Author|DISCUSSES
161|N2C2 2018 Challenge Task 1|Topic|Generic Rule-Based Natural Language Pipeline|Topic|DISCUSSES
161|Generic Rule-Based Natural Language Pipeline|Topic|Jianlin Shi|Author|AUTHORED
161|Generic Rule-Based Natural Language Pipeline|Topic|Kevin Graves|Author|AUTHORED
161|Generic Rule-Based Natural Language Pipeline|Topic|John F. Hurdle|Author|AUTHORED
162|Uschner Et Al. (2023)|Paper|Disruptions In Clinical Trials|Topic|DISCUSSES
163|Fda|Topic|Aducanumab|Topic|RELATED_TO
163|Fda|Topic|Lecanemab|Topic|RELATED_TO
163|Donanemab|Topic|Fda|Topic|RELATED_TO
163|Leonardino A. Digma Md|Author|Anti-Amyloid Therapies|Topic|DISCUSSES
163|Joseph R. Winer Phd|Author|Anti-Amyloid Therapies|Topic|DISCUSSES
163|Michael D. Greicius Md|Author|Anti-Amyloid Therapies|Topic|DISCUSSES
164|App-Based N-Of-1 Trials|Topic|Potential Outcomes Framework|Topic|RELATED_TO
164|Potential Outcomes Framework|Topic|Valid Confidence Sequences|Topic|RELATED_TO
164|Valid Confidence Sequences|Topic|Anytime-Valid Inference|Topic|RELATED_TO
164|Anytime-Valid Inference|Topic|N-Of-1 Trials|Topic|RELATED_TO
164|Ivana Malenica|Author|App-Based N-Of-1 Trials|Topic|AUTHORED
164|Yongyi Guo|Author|App-Based N-Of-1 Trials|Topic|AUTHORED
164|Kyra Gan|Author|App-Based N-Of-1 Trials|Topic|AUTHORED
164|Stefan Konigorski|Author|App-Based N-Of-1 Trials|Topic|AUTHORED
165|21St Century Cures Act|Topic|Bayesian Statistics|Topic|RELATED_TO
165|21St Century Cures Act|Topic|Historical Data|Topic|RELATED_TO
165|Historical Data|Topic|Bayesian Meta-Analytic Approach|Topic|RELATED_TO
165|Bayesian Meta-Analytic Approach|Topic|Time-To-Event Endpoints|Topic|RELATED_TO
165|Bayesian Meta-Analytic Approach|Topic|Piecewise Exponential Data|Topic|RELATED_TO
165|Satrajit Roychoudhury|Author|Bayesian Leveraging Of Historical Control Data For A Clinical Trial With Time-To-Event Endpoint|Paper|AUTHORED
165|Beat Neuenschwander|Author|Bayesian Leveraging Of Historical Control Data For A Clinical Trial With Time-To-Event Endpoint|Paper|AUTHORED
165|Ovarian Carcinoma Trial|Topic|Bayesian Meta-Analytic Approach|Topic|RELATED_TO
165|Non-Small-Cell Cancer Trial|Topic|Bayesian Meta-Analytic Approach|Topic|RELATED_TO
166|Trialstreamer|Topic|Benjamin E. Nye|Author|AUTHORED
166|Trialstreamer|Topic|Ani Nenkova|Author|AUTHORED
166|Trialstreamer|Topic|Iain J. Marshall|Author|AUTHORED
166|Trialstreamer|Topic|Byron C. Wallace|Author|AUTHORED
166|Trialstreamer|Topic|Medline|Topic|RELATED_TO
166|Trialstreamer|Topic|Randomized Controlled Trials|Topic|RELATED_TO
166|Trialstreamer|Topic|Evidence Maps|Topic|RELATED_TO
167|Clinical Evidence Engine|Topic|Clinical Decision Support Systems|Topic|RELATED_TO
167|Clinical Evidence Engine|Topic|Clinical Biobert|Topic|RELATED_TO
167|Clinical Evidence Engine|Topic|Cardiovascular Diseases|Topic|RELATED_TO
167|Clinical Evidence Engine|Topic|Autism|Topic|RELATED_TO
167|Clinical Evidence Engine|Topic|Cancer|Topic|RELATED_TO
167|Clinical Evidence Engine|Topic|Clinical Trial Reports|Topic|RELATED_TO
167|Clinical Evidence Engine|Topic|Povidone Iodine-Alcohol|Topic|RELATED_TO
167|Clinical Evidence Engine|Topic|Risks Of Catheter Infection|Topic|RELATED_TO
167|Clinical Evidence Engine|Topic|Adult Patients In Intensive Care Unit Who Require Arterial Catheters|Topic|RELATED_TO
167|Bojian Hou|Author|Clinical Evidence Engine|Topic|AUTHORED
167|Hao Zhang|Author|Clinical Evidence Engine|Topic|AUTHORED
167|Gur Ladizhinsky|Author|Clinical Evidence Engine|Topic|AUTHORED
167|Stephen Yang|Author|Clinical Evidence Engine|Topic|AUTHORED
167|Volodymyr Kuleshov|Author|Clinical Evidence Engine|Topic|AUTHORED
167|Fei Wang|Author|Clinical Evidence Engine|Topic|AUTHORED
167|Qian Yang|Author|Clinical Evidence Engine|Topic|AUTHORED
168|Compose|Topic|Junyi Gao|Author|AUTHORED
168|Compose|Topic|Cao Xiao|Author|AUTHORED
168|Compose|Topic|Lucas M. Glass|Author|AUTHORED
168|Compose|Topic|Jimeng Sun|Author|AUTHORED
168|Clinical Trials|Topic|Compose|Topic|RELATED_TO
169|Doctor2Vec|Topic|Siddharth Biswal|Author|AUTHORED
169|Doctor2Vec|Topic|Cao Xiao|Author|AUTHORED
169|Doctor2Vec|Topic|Lucas M. Glass|Author|AUTHORED
169|Doctor2Vec|Topic|Elizabeth Milkovits|Author|AUTHORED
169|Doctor2Vec|Topic|Jimeng Sun|Author|AUTHORED
169|Doctor2Vec|Topic|Ehrs|Topic|RELATED_TO
170|Covid-19 Vaccine Efficacy Trials|Topic|Preventive Vaccines|Topic|RELATED_TO
170|Covid-19 Vaccine Efficacy Trials|Topic|Immunological Marker|Topic|RELATED_TO
170|Covid-19 Vaccine Efficacy Trials|Topic|Case-Cohort Sampling Design|Topic|RELATED_TO
170|Covid-19 Vaccine Efficacy Trials|Topic|Mediation Parameters|Topic|RELATED_TO
170|Covid-19 Vaccine Efficacy Trials|Topic|Natural Mediation Effects|Topic|RELATED_TO
170|Covid-19 Vaccine Efficacy Trials|Topic|Correlates Of Protection|Topic|RELATED_TO
170|David Benkeser|Author|Covid-19 Vaccine Efficacy Trials|Topic|AUTHORED
170|Iván Díaz|Author|Covid-19 Vaccine Efficacy Trials|Topic|AUTHORED
170|Jialu Ran|Author|Covid-19 Vaccine Efficacy Trials|Topic|AUTHORED
171|Mondrian Processes For Flow Cytometry Analysis|Paper|Disi Ji|Author|AUTHORED
171|Mondrian Processes For Flow Cytometry Analysis|Paper|Eric Nalisnick|Author|AUTHORED
171|Mondrian Processes For Flow Cytometry Analysis|Paper|Padhraic Smyth|Author|AUTHORED
172|Transient Recurring Phenomena|Topic|Neuroscience|Topic|RELATED_TO
172|Transient Recurring Phenomena|Topic|Meteorology|Topic|RELATED_TO
172|Time Inhomogenous Vector Autoregressive Models (Var)|Topic|Multi-Trial Data|Topic|DISCUSSES
172|Multi-Trial Data|Topic|Akaike Information Criteria (Aic)|Topic|DISCUSSES
172|Multi-Trial Data|Topic|Bayesian Information Criteria (Bic)|Topic|DISCUSSES
172|Multi-Trial Bic|Topic|Multi-Trial Data|Topic|DISCUSSES
172|Multi-Trial Bic|Topic|Kaidi Shao|Author|AUTHORED
172|Multi-Trial Bic|Topic|Nikos K. Logothetis|Author|AUTHORED
172|Multi-Trial Bic|Topic|Michel Besserve|Author|AUTHORED
173|Statistical Neuroscience In The Single Trial Limit|Paper|Neural Activity|Topic|DISCUSSES
173|Statistical Neuroscience In The Single Trial Limit|Paper|Neural Variability|Topic|DISCUSSES
173|Statistical Neuroscience In The Single Trial Limit|Paper|Cognitive And Behavioral State|Topic|DISCUSSES
173|Statistical Neuroscience In The Single Trial Limit|Paper|Statistical Modeling|Topic|DISCUSSES
173|Statistical Neuroscience In The Single Trial Limit|Paper|Neural Circuits|Topic|DISCUSSES
174|Adding Flexibility To Clinical Trial Designs: An Example-Based Guide To The Practical Use Of Adaptive Designs|Paper|Adaptive Designs For Clinical Trials|Topic|DISCUSSES
174|Adding Flexibility To Clinical Trial Designs: An Example-Based Guide To The Practical Use Of Adaptive Designs|Paper|Thomas Burnett|Author|AUTHORED
174|Adding Flexibility To Clinical Trial Designs: An Example-Based Guide To The Practical Use Of Adaptive Designs|Paper|Pavel Mozgunov|Author|AUTHORED
174|Adding Flexibility To Clinical Trial Designs: An Example-Based Guide To The Practical Use Of Adaptive Designs|Paper|Philip Pallmann|Author|AUTHORED
174|Adding Flexibility To Clinical Trial Designs: An Example-Based Guide To The Practical Use Of Adaptive Designs|Paper|Sofia S. Villar|Author|AUTHORED
174|Adding Flexibility To Clinical Trial Designs: An Example-Based Guide To The Practical Use Of Adaptive Designs|Paper|Graham M. Wheeler|Author|AUTHORED
174|Adding Flexibility To Clinical Trial Designs: An Example-Based Guide To The Practical Use Of Adaptive Designs|Paper|Thomas Jaki|Author|AUTHORED
175|Covid-19 Pandemic|Topic|Clinical Trials|Topic|RELATED_TO
175|Clinical Trials|Topic|Ich E9(R1) Addendum|Topic|RELATED_TO
175|Ich E9(R1) Addendum|Topic|Estimands|Topic|RELATED_TO
175|Ich E9(R1) Addendum|Topic|Sensitivity Analyses|Topic|RELATED_TO
175|Niss Ingram Olkin Forum Series|Topic|Estimands|Topic|RELATED_TO
175|Niss Ingram Olkin Forum Series|Topic|Sensitivity Analyses|Topic|RELATED_TO
175|Stylized Trial|Topic|Covid-19 Pandemic|Topic|RELATED_TO
175|Unforeseen Disruptions|Topic|Clinical Trials|Topic|RELATED_TO
175|Kelly Van Lancker|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
175|Sergey Tarima|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
175|Jonathan Bartlett|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
175|Madeline Bauer|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
175|Bharani Bharani-Dharan|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
175|Frank Bretz|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
175|Nancy Flournoy|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
175|Hege Michiels|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
175|Camila Olarte Parra|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
175|James L Rosenberger|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
175|Suzie Cro|Author|Niss Ingram Olkin Forum Series|Topic|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Jie Chen|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Junrui Di|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Nadia Daizadeh|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Ying Lu|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Hongwei Wang|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Yuan-Li Shen|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Jennifer Kirk|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Frank W. Rockhold|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Herbert Pang|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Jing Zhao|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Weili He|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Andrew Potter|Author|AUTHORED
176|Decentralized Clinical Trials In The Era Of Real-World Evidence: A Statistical Perspective|Paper|Hana Lee|Author|AUTHORED
177|Information Extraction Approach To Prescreen Heart Failure Patients For Clinical Trials|Paper|Abhishek Kalyan Adupa|Author|AUTHORED
177|Information Extraction Approach To Prescreen Heart Failure Patients For Clinical Trials|Paper|Ravi Prakash Garg|Author|AUTHORED
177|Information Extraction Approach To Prescreen Heart Failure Patients For Clinical Trials|Paper|Jessica Corona-Cox|Author|AUTHORED
177|Information Extraction Approach To Prescreen Heart Failure Patients For Clinical Trials|Paper|Sanjiv. J. Shah|Author|AUTHORED
177|Information Extraction Approach To Prescreen Heart Failure Patients For Clinical Trials|Paper|Siddhartha R. Jonnalagadda|Author|AUTHORED
178|Automating The Compilation Of Potential Core-Outcomes For Clinical Trials|Paper|Natural Language Processing|Topic|DISCUSSES
178|Automating The Compilation Of Potential Core-Outcomes For Clinical Trials|Paper|Biobert|Topic|DISCUSSES
178|Automating The Compilation Of Potential Core-Outcomes For Clinical Trials|Paper|Cosine Similarity|Topic|DISCUSSES
178|Automating The Compilation Of Potential Core-Outcomes For Clinical Trials|Paper|Jaccard Similarity|Topic|DISCUSSES
179|Hecix-Kg|Topic|Clinicaltrials.Gov|Topic|RELATED_TO
179|Hecix-Kg|Topic|Hetionet|Topic|RELATED_TO
179|Hecix|Topic|Hecix-Kg|Topic|AUTHORED
179|Hecix|Topic|Prerana Sanjay Kulkarni|Author|AUTHORED
179|Hecix|Topic|Muskaan Jain|Author|AUTHORED
179|Hecix|Topic|Disha Sheshanarayana|Author|AUTHORED
179|Hecix|Topic|Srinivasan Parthiban|Author|AUTHORED
180|Diabetes|Topic|Uva/Padova Type 1 Diabetes Simulator|Topic|RELATED_TO
180|Uva/Padova Type 1 Diabetes Simulator|Topic|Uva Virtual Lab (Uvlab)|Topic|RELATED_TO
180|Uva Virtual Lab (Uvlab)|Topic|Distribution-Based Population Selection (Dsps)|Topic|RELATED_TO
180|Distribution-Based Population Selection (Dsps)|Topic|Insulin Degludec (Ideg)|Topic|RELATED_TO
180|Distribution-Based Population Selection (Dsps)|Topic|Mohammadreza Ganji|Author|AUTHORED
180|Distribution-Based Population Selection (Dsps)|Topic|Anas El Fathi|Author|AUTHORED
180|Distribution-Based Population Selection (Dsps)|Topic|Chiara Fabris|Author|AUTHORED
180|Distribution-Based Population Selection (Dsps)|Topic|Dayu Lv|Author|AUTHORED
180|Distribution-Based Population Selection (Dsps)|Topic|Boris Kovatchev|Author|AUTHORED
180|Distribution-Based Population Selection (Dsps)|Topic|Marc Breton|Author|AUTHORED
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Trisha Das|Author|AUTHORED
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Zifeng Wang|Author|AUTHORED
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Afrah Shafquat|Author|AUTHORED
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Mandis Beigi|Author|AUTHORED
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Jason Mezey|Author|AUTHORED
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Jimeng Sun|Author|AUTHORED
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Synthetic Patient Data|Topic|RELATED_TO
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Reinforcement Learning|Topic|RELATED_TO
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Clinical Trials|Topic|RELATED_TO
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Data Generation|Topic|RELATED_TO
181|Synrl: Aligning Synthetic Clinical Trial Data With Human-Preferred Clinical Endpoints Using Reinforcement Learning|Paper|Privacy Concerns|Topic|RELATED_TO
182|Gan-Biobert|Topic|Clinical Trial Abstracts|Topic|RELATED_TO
182|Joshua J Myszewski|Author|Gan-Biobert|Topic|AUTHORED
182|Emily Klossowski|Author|Gan-Biobert|Topic|AUTHORED
182|Patrick Meyer|Author|Gan-Biobert|Topic|AUTHORED
182|Kristin Bevil|Author|Gan-Biobert|Topic|AUTHORED
182|Lisa Klesius|Author|Gan-Biobert|Topic|AUTHORED
182|Kristopher M Schroeder|Author|Gan-Biobert|Topic|AUTHORED
183|Clinical Trial Registries|Topic|Systematic Reviews|Topic|RELATED_TO
183|Systematic Reviews|Topic|Type 2 Diabetes|Topic|RELATED_TO
183|Didi Surian|Author|Matrix Factorisation Approach|Topic|AUTHORED
183|Adam G. Dunn|Author|Matrix Factorisation Approach|Topic|AUTHORED
183|Liat Orenstein|Author|Matrix Factorisation Approach|Topic|AUTHORED
183|Rabia Bashir|Author|Matrix Factorisation Approach|Topic|AUTHORED
183|Enrico Coiera|Author|Matrix Factorisation Approach|Topic|AUTHORED
183|Florence T. Bourgeois|Author|Matrix Factorisation Approach|Topic|AUTHORED
183|Matrix Factorisation Approach|Topic|Document Similarity Approach|Topic|RELATED_TO
183|Clinicaltrials.Gov|Topic|Trial Registrations|Topic|RELATED_TO
183|Cochrane Database Of Systematic Reviews|Topic|Systematic Reviews|Topic|RELATED_TO
183|Matrix Factorisation Approach|Topic|Semi-Automated Pipeline|Topic|RELATED_TO
184|Ebola Research|Topic|David Fajardo-Ortiz|Author|AUTHORED
184|Ebola Research|Topic|Josw Ortega-Sanchez-De-Tagle|Author|AUTHORED
184|Ebola Research|Topic|Victor-M Castano|Author|AUTHORED
184|Ebola Research|Topic|Ebola Virus Proteins|Topic|RELATED_TO
184|Ebola Research|Topic|Vaccines|Topic|RELATED_TO
184|Ebola Research|Topic|Clinical-Epidemiology Research|Topic|RELATED_TO
184|Ebola Research|Topic|Basic Research|Topic|RELATED_TO
184|Ebola Research|Topic|Patent Families Network|Topic|RELATED_TO
184|Ebola Research|Topic|Us Army|Topic|RELATED_TO
184|Research Fronts|Topic|Basic Research|Topic|RELATED_TO
184|Research Fronts|Topic|Clinical-Epidemiology Research|Topic|RELATED_TO
185|Phase Ii Trials|Topic|Statistical Significance|Topic|RELATED_TO
185|Phase Ii Trials|Topic|Clinical Relevance|Topic|RELATED_TO
185|Dual-Criterion Designs|Topic|Statistical Significance|Topic|RELATED_TO
185|Dual-Criterion Designs|Topic|Clinical Relevance|Topic|RELATED_TO
185|Dual-Criterion Designs|Topic|Satrajit Roychoudhury|Author|AUTHORED
185|Dual-Criterion Designs|Topic|Nicolas Scheuer|Author|AUTHORED
185|Dual-Criterion Designs|Topic|Beat Neuenschwander|Author|AUTHORED
186|National Research Council|Topic|Primary Analysis Method|Topic|DISCUSSES
186|Impi Trial|Topic|Cd4 Count Data|Topic|RELATED_TO
186|Impi Trial|Topic|Effectiveness Estimand Hypothesis|Topic|RELATED_TO
186|Abdul-Karim Iddrisu|Author|Primary Analysis Method|Topic|AUTHORED
186|Abukari Alhassan|Author|Primary Analysis Method|Topic|AUTHORED
186|Primary Analysis Method|Topic|Sensitivity Analysis|Topic|RELATED_TO
186|Primary Analysis Method|Topic|Maximum Likelihood Method|Topic|RELATED_TO
186|Primary Analysis Method|Topic|Multiple Imputation Method|Topic|RELATED_TO
186|Simple Imputation Methods|Topic|Treatment Effect|Topic|DISCUSSES
186|Complete Case Analysis|Topic|Treatment Effect|Topic|DISCUSSES
187|Clinical Trials|Topic|Blinding|Topic|RELATED_TO
187|Clinical Trials|Topic|Placebo Effects|Topic|RELATED_TO
187|Instrumental Variables|Topic|Treatment Effects|Topic|RELATED_TO
187|Elias Chaibub Neto|Author|Randomized Clinical Trials|Topic|AUTHORED
187|Randomized Clinical Trials|Topic|Confounders|Topic|RELATED_TO
187|Randomized Clinical Trials|Topic|Psychological Encouragement Messages|Topic|RELATED_TO
187|Unblinded Trials|Topic|Placebo Effects|Topic|RELATED_TO
187|Blinded Studies|Topic|Treatment Effects|Topic|RELATED_TO
188|Covid-19|Topic|Sars-Cov-2|Topic|RELATED_TO
188|World Health Organization|Author|Covid-19|Topic|DISCUSSES
188|Clinical Trials|Topic|Covid-19|Topic|RELATED_TO
188|Adaptive Designs|Topic|Clinical Trials|Topic|RELATED_TO
188|Bayesian Techniques|Topic|Clinical Trials|Topic|RELATED_TO
188|R Shiny App|Topic|Clinical Trials|Topic|RELATED_TO
188|Data Monitoring Committees|Topic|Clinical Trials|Topic|RELATED_TO
188|Cornelia Ursula Kunz|Author|Clinical Trials|Topic|AUTHORED
188|Silke Jörgens|Author|Clinical Trials|Topic|AUTHORED
188|Frank Bretz|Author|Clinical Trials|Topic|AUTHORED
188|Nigel Stallard|Author|Clinical Trials|Topic|AUTHORED
188|Kelly Van Lancker|Author|Clinical Trials|Topic|AUTHORED
188|Dong Xi|Author|Clinical Trials|Topic|AUTHORED
188|Sarah Zohar|Author|Clinical Trials|Topic|AUTHORED
188|Christoph Gerlinger|Author|Clinical Trials|Topic|AUTHORED
188|Tim Friede|Author|Clinical Trials|Topic|AUTHORED
189|Clinical Trials|Topic|Adaptive Designs|Topic|RELATED_TO
189|Adaptive Designs|Topic|Multi-Arm Phase Ii Clinical Trials|Topic|RELATED_TO
189|Multi-Arm Phase Ii Clinical Trials|Topic|Treatment Allocation|Topic|RELATED_TO
189|Treatment Allocation|Topic|Fixed Block Randomization|Topic|RELATED_TO
189|Fixed Block Randomization|Topic|Posterior Distribution|Topic|RELATED_TO
189|Posterior Distribution|Topic|Model Parameter|Topic|RELATED_TO
189|Multi-Arm Phase Ii Clinical Trials|Topic|Treatment Arms|Topic|RELATED_TO
189|Treatment Arms|Topic|Pre-Defined Criteria|Topic|RELATED_TO
189|Pre-Defined Criteria|Topic|Joint Posterior|Topic|RELATED_TO
189|Joint Posterior|Topic|Treatment|Topic|RELATED_TO
189|Treatment|Topic|Participant Accrual|Topic|RELATED_TO
189|Participant Accrual|Topic|Adaptive Treatment Selection|Topic|RELATED_TO
189|Adaptive Treatment Selection|Topic|Early Stopping|Topic|RELATED_TO
189|Multi-Arm Phase Ii Clinical Trials|Topic|Binary Outcomes|Topic|RELATED_TO
189|Binary Outcomes|Topic|Time-To-Event Data|Topic|RELATED_TO
189|Elja Arjas|Author|Adaptive Treatment Allocation And Selection In Multi-Arm Clinical Trials: A Bayesian Perspective|Paper|AUTHORED
189|Dario Gasbarra|Author|Adaptive Treatment Allocation And Selection In Multi-Arm Clinical Trials: A Bayesian Perspective|Paper|AUTHORED
190|Trialr|Topic|Kristian Brock|Author|AUTHORED
190|Trialr|Topic|Continual Reassessment Method|Topic|RELATED_TO
190|Trialr|Topic|Efftox|Topic|RELATED_TO
190|Trialr|Topic|Augmented Binary Method|Topic|RELATED_TO
191|Finding Translational Biomarkers|Topic|Personalized Medicine|Topic|RELATED_TO
191|The Future Will Be Different Than Today: Model Evaluation Considerations When Developing Translational Clinical Biomarker|Paper|Yichen Lu|Author|AUTHORED
191|The Future Will Be Different Than Today: Model Evaluation Considerations When Developing Translational Clinical Biomarker|Paper|Jane Fridlyand|Author|AUTHORED
191|The Future Will Be Different Than Today: Model Evaluation Considerations When Developing Translational Clinical Biomarker|Paper|Tiffany Tang|Author|AUTHORED
191|The Future Will Be Different Than Today: Model Evaluation Considerations When Developing Translational Clinical Biomarker|Paper|Ting Qi|Author|AUTHORED
191|The Future Will Be Different Than Today: Model Evaluation Considerations When Developing Translational Clinical Biomarker|Paper|Noah Simon|Author|AUTHORED
191|The Future Will Be Different Than Today: Model Evaluation Considerations When Developing Translational Clinical Biomarker|Paper|Ning Leng|Author|AUTHORED
191|Leave-One-Study-Out (Loso)|Topic|Cross-Validation (Cv) Methods|Topic|RELATED_TO
191|K-Fold|Topic|Leave-One-Study-Out (Loso)|Topic|RELATED_TO
191|Clinical Trials|Topic|Biomarkers|Topic|RELATED_TO
191|Evaluation Metrics|Topic|Statistical Methods|Topic|RELATED_TO
192|Natural Language Processing Team|Topic|Australian Research Council Industrial Transformation Training Centre|Topic|RELATED_TO
192|Australian Research Council Industrial Transformation Training Centre|Topic|Cognitive Computing In Medical Technologies|Topic|RELATED_TO
192|Cognitive Computing In Medical Technologies|Topic|Trec 2021 Clinical Trials Track|Topic|RELATED_TO
192|Trec 2021 Clinical Trials Track|Topic|Thinh Hung Truong|Author|AUTHORED
192|Trec 2021 Clinical Trials Track|Topic|Yulia Otmakhova|Author|AUTHORED
192|Trec 2021 Clinical Trials Track|Topic|Rahmad Mahendra|Author|AUTHORED
192|Trec 2021 Clinical Trials Track|Topic|Timothy Baldwin|Author|AUTHORED
192|Trec 2021 Clinical Trials Track|Topic|Jey Han Lau|Author|AUTHORED
192|Trec 2021 Clinical Trials Track|Topic|Trevor Cohn|Author|AUTHORED
192|Trec 2021 Clinical Trials Track|Topic|Lawrence Cavedon|Author|AUTHORED
192|Trec 2021 Clinical Trials Track|Topic|Damiano Spina|Author|AUTHORED
192|Trec 2021 Clinical Trials Track|Topic|Karin Verspoor|Author|AUTHORED
193|A Matching Design For Augmenting A Randomized Clinical Trial With External Control|Paper|U.S. Food And Drug Administration|Author|DISCUSSES
194|Large Language Models For Healthcare Data Augmentation: An Example On Patient-Trial Matching|Paper|Jiayi Yuan|Author|AUTHORED
194|Large Language Models For Healthcare Data Augmentation: An Example On Patient-Trial Matching|Paper|Ruixiang Tang|Author|AUTHORED
194|Large Language Models For Healthcare Data Augmentation: An Example On Patient-Trial Matching|Paper|Xiaoqian Jiang|Author|AUTHORED
194|Large Language Models For Healthcare Data Augmentation: An Example On Patient-Trial Matching|Paper|Xia Hu|Author|AUTHORED
195|Bayesian Statistics|Topic|Medical Science|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Healthcare Companies|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Regulators|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Stakeholders|Topic|RELATED_TO
195|Bayesian Statistics|Topic|New Treatments|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Interventions|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Medical Procedures|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Classical Framework|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Prior Information|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Quality External Data|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Historical Data|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Co-Data|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Regulatory Submissions|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Decision-Making|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Clinical Trials|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Frequentist Trials|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Frequentist Operating Characteristics|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Frequentist Type I Error Rate|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Power|Topic|RELATED_TO
195|Bayesian Statistics|Topic|Bayesian Sample Size Determination|Topic|RELATED_TO
195|Se Yoon Lee|Author|Using Bayesian Statistics In Confirmatory Clinical Trials In The Regulatory Setting|Paper|AUTHORED
196|Randomized Clinical Trials|Topic|Longitudinal Rank-Sum Test|Topic|RELATED_TO
196|Longitudinal Rank-Sum Test|Topic|Multi-Arm Lrst|Topic|RELATED_TO
196|Multi-Arm Lrst|Topic|Bapineuzumab 301 Trial|Topic|RELATED_TO
196|Dhrubajyoti Ghosh|Author|Multi-Arm Lrst|Topic|AUTHORED
196|Sheng Luo|Author|Multi-Arm Lrst|Topic|AUTHORED
197|Information Theory|Topic|Neuroscience|Topic|RELATED_TO
197|Simon R. Schultz|Author|Information Theory|Topic|AUTHORED
197|Robin A. A. Ince|Author|Information Theory|Topic|AUTHORED
197|Stefano Panzeri|Author|Information Theory|Topic|AUTHORED
198|Spatial Auditory Attention Decoding|Topic|Prototype Training|Topic|RELATED_TO
198|Prototype Training|Topic|Eegwavenet|Topic|RELATED_TO
198|Zelin Qiu|Author|Spatial Auditory Attention Decoding|Topic|AUTHORED
198|Jianjun Gu|Author|Spatial Auditory Attention Decoding|Topic|AUTHORED
198|Dingding Yao|Author|Spatial Auditory Attention Decoding|Topic|AUTHORED
198|Junfeng Li|Author|Spatial Auditory Attention Decoding|Topic|AUTHORED
199|Academic Research|Topic|Sources Of Knowledge|Topic|RELATED_TO
199|Academic Research|Topic|Sinks Of Knowledge|Topic|RELATED_TO
199|Human Knowledge|Topic|Diaspora Of Knowledge|Topic|RELATED_TO
199|Diaspora Of Knowledge|Topic|Medicine|Topic|RELATED_TO
199|Diaspora Of Knowledge|Topic|Physics|Topic|RELATED_TO
199|Diaspora Of Knowledge|Topic|Chemistry|Topic|RELATED_TO
199|Diaspora Of Knowledge|Topic|Material Science|Topic|RELATED_TO
199|Diaspora Of Knowledge|Topic|Chemical Engineering|Topic|RELATED_TO
199|Diaspora Of Knowledge|Topic|Neuroscience|Topic|RELATED_TO
199|Diaspora Of Knowledge|Topic|Immunology|Topic|RELATED_TO
199|Diaspora Of Knowledge|Topic|Microbiology|Topic|RELATED_TO
199|Diaspora Of Knowledge|Topic|Environmental Science|Topic|RELATED_TO
199|Manlio De Domenico|Author|Diaspora Of Knowledge|Topic|AUTHORED
199|Elisa Omodei|Author|Diaspora Of Knowledge|Topic|AUTHORED
199|Alex Arenas|Author|Diaspora Of Knowledge|Topic|AUTHORED
200|Comparing Trial Evidence To Target Populations|Topic|Hiv Interventions|Topic|RELATED_TO
200|Comparing Trial Evidence To Target Populations|Topic|Aids Clinical Trials Group (Actg)|Topic|RELATED_TO
200|Fan Li|Author|Generalizability Of Trial Evidence|Topic|AUTHORED
200|Ashley L. Buchanan|Author|Generalizability Of Trial Evidence|Topic|AUTHORED
200|Stephen R. Cole|Author|Generalizability Of Trial Evidence|Topic|AUTHORED
200|Generalizability Of Trial Evidence|Topic|Causal Effects Estimation|Topic|RELATED_TO
200|Generalizability Of Trial Evidence|Topic|Simulation Study|Topic|RELATED_TO
201|Trialgpt|Topic|Trialgpt-Retrieval|Topic|RELATED_TO
201|Trialgpt|Topic|Trialgpt-Matching|Topic|RELATED_TO
201|Trialgpt|Topic|Trialgpt-Ranking|Topic|RELATED_TO
201|Trialgpt-Retrieval|Topic|Trialgpt-Matching|Topic|RELATED_TO
201|Trialgpt-Matching|Topic|Trialgpt-Ranking|Topic|RELATED_TO
201|Trialgpt|Topic|Qiao Jin|Author|AUTHORED
201|Trialgpt|Topic|Zifeng Wang|Author|AUTHORED
201|Trialgpt|Topic|Charalampos S. Floudas|Author|AUTHORED
201|Trialgpt|Topic|Fangyuan Chen|Author|AUTHORED
201|Trialgpt|Topic|Changlin Gong|Author|AUTHORED
201|Trialgpt|Topic|Dara Bracken-Clarke|Author|AUTHORED
201|Trialgpt|Topic|Elisabetta Xue|Author|AUTHORED
201|Trialgpt|Topic|Yifan Yang|Author|AUTHORED
201|Trialgpt|Topic|Jimeng Sun|Author|AUTHORED
201|Trialgpt|Topic|Zhiyong Lu|Author|AUTHORED
202|Quant-Ph/0208006|Topic|Alexander Yu. Vlasov|Author|DISCUSSES
203|Stochastic Multi-Armed Bandit Problem|Topic|Adaptive Clinical Trials|Topic|RELATED_TO
203|Adaptive Clinical Trials|Topic|Regret|Topic|DISCUSSES
203|Regret|Topic|Besa Algorithm|Topic|RELATED_TO
203|Besa Algorithm|Topic|Hossein Aboutalebi|Author|AUTHORED
203|Besa Algorithm|Topic|Doina Precup|Author|AUTHORED
203|Besa Algorithm|Topic|Tibor Schuster|Author|AUTHORED
204|Two-Stage Penalized Regression Screening To Detect Biomarker-Treatment Interactions In Randomized Clinical Trials|Paper|Jixiong Wang|Author|AUTHORED
204|Two-Stage Penalized Regression Screening To Detect Biomarker-Treatment Interactions In Randomized Clinical Trials|Paper|Ashish Patel|Author|AUTHORED
204|Two-Stage Penalized Regression Screening To Detect Biomarker-Treatment Interactions In Randomized Clinical Trials|Paper|James M. S. Wason|Author|AUTHORED
204|Two-Stage Penalized Regression Screening To Detect Biomarker-Treatment Interactions In Randomized Clinical Trials|Paper|Paul J. Newcombe|Author|AUTHORED
204|Randomized Clinical Trials|Topic|Biomarker-Treatment Interactions|Topic|RELATED_TO
204|Biomarker-Treatment Interactions|Topic|Two-Stage Interaction Detecting Procedures|Topic|RELATED_TO
204|Two-Stage Interaction Detecting Procedures|Topic|Multivariate Screening Strategy|Topic|RELATED_TO
204|Multivariate Screening Strategy|Topic|Ridge Regression|Topic|RELATED_TO
204|Ridge Regression|Topic|Family-Wise Error Rate Control|Topic|RELATED_TO
204|Asymptotic Between-Stage Independence|Topic|Family-Wise Error Rate Control|Topic|RELATED_TO
204|Simulation Results|Topic|Traditional One-Biomarker-At-A-Time Screening Procedure|Topic|RELATED_TO
204|Traditional One-Biomarker-At-A-Time Screening Procedure|Topic|Real Clinical Trial Data Applications|Topic|RELATED_TO
205|Bayesian Optimal Phase Ii Trial Design With Dual-Criterion Decision Making (Bop2-Dc)|Topic|Yujie Zhao|Author|AUTHORED
205|Bayesian Optimal Phase Ii Trial Design With Dual-Criterion Decision Making (Bop2-Dc)|Topic|Daniel Li|Author|AUTHORED
205|Bayesian Optimal Phase Ii Trial Design With Dual-Criterion Decision Making (Bop2-Dc)|Topic|Rong Liu|Author|AUTHORED
205|Bayesian Optimal Phase Ii Trial Design With Dual-Criterion Decision Making (Bop2-Dc)|Topic|Ying Yuan|Author|AUTHORED
206|Seme At Semeval-2024 Task 2|Paper|Safe Biomedical Natural Language Inference For Clinical Trials|Topic|RELATED_TO
206|Seme At Semeval-2024 Task 2|Paper|Multi-Evidence Natural Language Inference For Clinical Trial Data (Nli4Ct)|Topic|RELATED_TO
206|Seme At Semeval-2024 Task 2|Paper|Textual Entailment (Te) Task|Topic|RELATED_TO
206|Seme At Semeval-2024 Task 2|Paper|Clinical Trial Reports (Ctr)|Topic|RELATED_TO
206|Seme At Semeval-2024 Task 2|Paper|Masked Language Models|Topic|RELATED_TO
206|Seme At Semeval-2024 Task 2|Paper|Large Language Models|Topic|RELATED_TO
206|Seme At Semeval-2024 Task 2|Paper|Chain-Of-Thought|Topic|RELATED_TO
206|Seme At Semeval-2024 Task 2|Paper|Contrastive Chain-Of-Thought|Topic|RELATED_TO
206|Seme At Semeval-2024 Task 2|Paper|Flan-T5-Large|Topic|RELATED_TO
206|Seme At Semeval-2024 Task 2|Paper|Mathilde Aguiar|Author|AUTHORED
206|Seme At Semeval-2024 Task 2|Paper|Pierre Zweigenbaum|Author|AUTHORED
206|Seme At Semeval-2024 Task 2|Paper|Nona Naderi|Author|AUTHORED
207|Method For Assigning High-Quality Labels To Unstructured Text|Topic|Open-Source Language Model|Topic|RELATED_TO
207|Method For Assigning High-Quality Labels To Unstructured Text|Topic|Proprietary Language Model|Topic|RELATED_TO
207|Method For Assigning High-Quality Labels To Unstructured Text|Topic|Census Of Published Clinical Trials|Topic|RELATED_TO
207|Census Of Published Clinical Trials|Topic|Pharmaceutical Sector Productivity|Topic|DISCUSSES
207|Census Of Published Clinical Trials|Topic|Clinical Trials Data Since 2010|Topic|RELATED_TO
207|Previous Measurements Of Clinical Trials|Topic|Pharmaceutical Sector Productivity|Topic|DISCUSSES
207|Maya M. Durvasula|Author|Counting Clinical Trials: New Evidence On Pharmaceutical Sector Productivity|Paper|AUTHORED
207|Sabri Eyuboglu|Author|Counting Clinical Trials: New Evidence On Pharmaceutical Sector Productivity|Paper|AUTHORED
207|David M. Ritzwoller|Author|Counting Clinical Trials: New Evidence On Pharmaceutical Sector Productivity|Paper|AUTHORED
208|Clinical Trial Cohort Selection Using Large Language Models On N2C2 Challenges|Paper|Clinical Trials|Topic|DISCUSSES
208|Clinical Trial Cohort Selection Using Large Language Models On N2C2 Challenges|Paper|Cohort Selection|Topic|DISCUSSES
208|Clinical Trial Cohort Selection Using Large Language Models On N2C2 Challenges|Paper|Natural Language Processing (Nlp)|Topic|DISCUSSES
208|Clinical Trial Cohort Selection Using Large Language Models On N2C2 Challenges|Paper|Large Language Models (Llms)|Topic|DISCUSSES
209|Maximum Matchings In Graphs For Allocating Kidney Paired Donation|Paper|Sommer Gentry|Author|AUTHORED
209|Maximum Matchings In Graphs For Allocating Kidney Paired Donation|Paper|Michal Mankowski|Author|AUTHORED
209|Maximum Matchings In Graphs For Allocating Kidney Paired Donation|Paper|T. S. Michael|Author|AUTHORED
209|Maximum Matchings In Graphs For Allocating Kidney Paired Donation|Paper|Dorry Segev|Author|AUTHORED
209|Kidney Paired Donation|Topic|Maximum Matchings In Graphs For Allocating Kidney Paired Donation|Paper|RELATED_TO
210|On Preparing A List Of Random Treatment Assigns|Paper|N. S. Santos-Magalhaes|Author|AUTHORED
210|On Preparing A List Of Random Treatment Assigns|Paper|H. M. De Oliveira|Author|AUTHORED
210|On Preparing A List Of Random Treatment Assigns|Paper|A. J. Alves|Author|AUTHORED
211|Insertus.Jl|Topic|Yevgen Ryeznik|Author|AUTHORED
211|Insertus.Jl|Topic|Oleksandr Sverdlov|Author|AUTHORED
212|A Clinical Trial Design Approach To Auditing Language Models In Healthcare Setting|Paper|Language Models|Topic|RELATED_TO
212|A Clinical Trial Design Approach To Auditing Language Models In Healthcare Setting|Paper|Healthcare Setting|Topic|RELATED_TO
212|A Clinical Trial Design Approach To Auditing Language Models In Healthcare Setting|Paper|Audit Mechanism|Topic|RELATED_TO
212|A Clinical Trial Design Approach To Auditing Language Models In Healthcare Setting|Paper|Clinical Trial Design|Topic|RELATED_TO
212|A Clinical Trial Design Approach To Auditing Language Models In Healthcare Setting|Paper|Subject Matter Experts|Topic|RELATED_TO
212|A Clinical Trial Design Approach To Auditing Language Models In Healthcare Setting|Paper|Sample Size And Power Calculations|Topic|RELATED_TO
212|A Clinical Trial Design Approach To Auditing Language Models In Healthcare Setting|Paper|Audit Integrity|Topic|RELATED_TO
212|A Clinical Trial Design Approach To Auditing Language Models In Healthcare Setting|Paper|Statistical Soundness|Topic|RELATED_TO
212|A Clinical Trial Design Approach To Auditing Language Models In Healthcare Setting|Paper|Public Health Network|Topic|RELATED_TO
213|Sample-Targeted Clinical Trial Adaptation|Paper|Ognjen Arandjelovic|Author|AUTHORED
213|Sample-Targeted Clinical Trial Adaptation|Paper|Clinical Trial Adaptation|Topic|DISCUSSES
214|Principal Stratification|Topic|Randomized Experiments|Topic|RELATED_TO
214|Randomized Experiments|Topic|Post-Treatment Variable|Topic|RELATED_TO
214|Post-Treatment Variable|Topic|Treatment Variable|Topic|RELATED_TO
214|Treatment Variable|Topic|Endpoint Variable|Topic|RELATED_TO
214|Phase Iii Adjuvant Colon Clinical Trials|Topic|Principal Causal Effects|Topic|RELATED_TO
214|Exclusion Restriction Assumption|Topic|Principal Causal Effects|Topic|RELATED_TO
214|Monotonicity Assumption|Topic|Principal Causal Effects|Topic|RELATED_TO
214|Disease-Free Survival|Topic|Overall Survival|Topic|RELATED_TO
214|Zhichao Jiang|Author|Principal Causal Effects|Topic|AUTHORED
214|Peng Ding|Author|Principal Causal Effects|Topic|AUTHORED
214|Zhi Geng|Author|Principal Causal Effects|Topic|AUTHORED
215|Optimizing Trial Designs For Targeted Therapies|Paper|Thomas Ondra|Author|AUTHORED
215|Optimizing Trial Designs For Targeted Therapies|Paper|Sebastian Jobjörnsson|Author|AUTHORED
215|Optimizing Trial Designs For Targeted Therapies|Paper|Robert A. Beckman|Author|AUTHORED
215|Optimizing Trial Designs For Targeted Therapies|Paper|Carl-Fredrik Burman|Author|AUTHORED
215|Optimizing Trial Designs For Targeted Therapies|Paper|Franz König|Author|AUTHORED
215|Optimizing Trial Designs For Targeted Therapies|Paper|Nigel Stallard|Author|AUTHORED
215|Optimizing Trial Designs For Targeted Therapies|Paper|Martin Posch|Author|AUTHORED
216|Randomization|Topic|Clinical Trials|Topic|RELATED_TO
216|Superiority Trials|Topic|Randomization|Topic|RELATED_TO
216|Non-Inferiority Trials|Topic|Randomization|Topic|RELATED_TO
216|Imbalanced Randomization In Clinical Trials|Paper|Non-Inferiority Trials|Topic|DISCUSSES
216|Imbalanced Randomization In Clinical Trials|Paper|Superiority Trials|Topic|DISCUSSES
217|Novel Adaptive Design Algorithm|Topic|N-Of-1 Clinical Trials|Topic|RELATED_TO
217|Laplace Approximations|Topic|Novel Adaptive Design Algorithm|Topic|RELATED_TO
217|Multi-Armed Bandit Approach|Topic|Novel Adaptive Design Algorithm|Topic|DISCUSSES
217|Randomised N-Of-1 Trial Design|Topic|Novel Adaptive Design Algorithm|Topic|DISCUSSES
217|S. G. Jagath Senarathne|Author|Novel Adaptive Design Algorithm|Topic|AUTHORED
217|Antony M. Overstall|Author|Novel Adaptive Design Algorithm|Topic|AUTHORED
217|James M. Mcgree|Author|Novel Adaptive Design Algorithm|Topic|AUTHORED
218|A Scalable Ai Approach For Clinical Trial Cohort Optimization|Paper|Cohort Optimization|Topic|DISCUSSES
218|A Scalable Ai Approach For Clinical Trial Cohort Optimization|Paper|Clinical Trials|Topic|RELATED_TO
218|A Scalable Ai Approach For Clinical Trial Cohort Optimization|Paper|Breast Cancer Trial Design|Topic|RELATED_TO
218|Xiong Liu|Author|A Scalable Ai Approach For Clinical Trial Cohort Optimization|Paper|AUTHORED
218|Cheng Shi|Author|A Scalable Ai Approach For Clinical Trial Cohort Optimization|Paper|AUTHORED
218|Uday Deore|Author|A Scalable Ai Approach For Clinical Trial Cohort Optimization|Paper|AUTHORED
218|Yingbo Wang|Author|A Scalable Ai Approach For Clinical Trial Cohort Optimization|Paper|AUTHORED
218|Myah Tran|Author|A Scalable Ai Approach For Clinical Trial Cohort Optimization|Paper|AUTHORED
218|Iya Khalil|Author|A Scalable Ai Approach For Clinical Trial Cohort Optimization|Paper|AUTHORED
218|Murthy Devarakonda|Author|A Scalable Ai Approach For Clinical Trial Cohort Optimization|Paper|AUTHORED
219|Trialview|Paper|Randomized Controlled Trials|Topic|RELATED_TO
219|Trialview|Paper|Graph Artificial Intelligence|Topic|RELATED_TO
219|Trialview|Paper|Visual Analytics|Topic|RELATED_TO
219|Trialview|Paper|Clinical Trials|Topic|RELATED_TO
219|Trialview|Paper|Temporal Event Data|Topic|RELATED_TO
219|Trialview|Paper|Knowledge-Guided Clustering|Topic|RELATED_TO
219|Trialview|Paper|Explanatory Modeling|Topic|RELATED_TO
219|Trialview|Paper|Graph-Based Agglomeration Algorithms|Topic|RELATED_TO
220|Biomarker-Guided Adaptive Enrichment Design With Threshold Detection For Clinical Trials With Time-To-Event Outcome|Paper|Kaiyuan Hua|Author|AUTHORED
220|Biomarker-Guided Adaptive Enrichment Design With Threshold Detection For Clinical Trials With Time-To-Event Outcome|Paper|Hwanhee Hong|Author|AUTHORED
220|Biomarker-Guided Adaptive Enrichment Design With Threshold Detection For Clinical Trials With Time-To-Event Outcome|Paper|Xiaofei Wang|Author|AUTHORED
221|Predictive Probabilities Made Simple: A Fast And Accurate Method For Clinical Trial Decision Making|Paper|Joe Marion|Author|AUTHORED
221|Predictive Probabilities Made Simple: A Fast And Accurate Method For Clinical Trial Decision Making|Paper|Liz Lorenzi|Author|AUTHORED
221|Predictive Probabilities Made Simple: A Fast And Accurate Method For Clinical Trial Decision Making|Paper|Cora Allen-Savietta|Author|AUTHORED
221|Predictive Probabilities Made Simple: A Fast And Accurate Method For Clinical Trial Decision Making|Paper|Scott Berry|Author|AUTHORED
221|Predictive Probabilities Made Simple: A Fast And Accurate Method For Clinical Trial Decision Making|Paper|Kert Viele|Author|AUTHORED
221|Bayesian Predictive Probabilities|Topic|Clinical Trials|Topic|RELATED_TO
221|Predictive Probabilities|Topic|Approximation For Computing Predictive Probabilities|Topic|RELATED_TO
221|Approximation For Computing Predictive Probabilities|Topic|Monte Carlo Imputation Methods|Topic|RELATED_TO
221|Dichotomous Endpoints|Topic|Predictive Probabilities Made Simple: A Fast And Accurate Method For Clinical Trial Decision Making|Paper|RELATED_TO
221|Time-To-Event Endpoints|Topic|Predictive Probabilities Made Simple: A Fast And Accurate Method For Clinical Trial Decision Making|Paper|RELATED_TO
221|Ordinal Endpoints|Topic|Predictive Probabilities Made Simple: A Fast And Accurate Method For Clinical Trial Decision Making|Paper|RELATED_TO
221|Historical Borrowing|Topic|Predictive Probabilities Made Simple: A Fast And Accurate Method For Clinical Trial Decision Making|Paper|RELATED_TO
221|Longitudinal Modeling|Topic|Predictive Probabilities Made Simple: A Fast And Accurate Method For Clinical Trial Decision Making|Paper|RELATED_TO
222|Confidence Intervals For Adaptive Trial Designs I: A Methodological Review|Paper|David S. Robertson|Author|AUTHORED
222|Confidence Intervals For Adaptive Trial Designs I: A Methodological Review|Paper|Thomas Burnett|Author|AUTHORED
222|Confidence Intervals For Adaptive Trial Designs I: A Methodological Review|Paper|Babak Choodari-Oskooei|Author|AUTHORED
222|Confidence Intervals For Adaptive Trial Designs I: A Methodological Review|Paper|Munya Dimairo|Author|AUTHORED
222|Confidence Intervals For Adaptive Trial Designs I: A Methodological Review|Paper|Michael Grayling|Author|AUTHORED
222|Confidence Intervals For Adaptive Trial Designs I: A Methodological Review|Paper|Philip Pallmann|Author|AUTHORED
222|Confidence Intervals For Adaptive Trial Designs I: A Methodological Review|Paper|Thomas Jaki|Author|AUTHORED
223|Confidence Intervals For Adaptive Trial Designs Ii: Case Study And Practical Guidance|Paper|David S. Robertson|Author|AUTHORED
223|Confidence Intervals For Adaptive Trial Designs Ii: Case Study And Practical Guidance|Paper|Thomas Burnett|Author|AUTHORED
223|Confidence Intervals For Adaptive Trial Designs Ii: Case Study And Practical Guidance|Paper|Babak Choodari-Oskooei|Author|AUTHORED
223|Confidence Intervals For Adaptive Trial Designs Ii: Case Study And Practical Guidance|Paper|Munya Dimairo|Author|AUTHORED
223|Confidence Intervals For Adaptive Trial Designs Ii: Case Study And Practical Guidance|Paper|Michael Grayling|Author|AUTHORED
223|Confidence Intervals For Adaptive Trial Designs Ii: Case Study And Practical Guidance|Paper|Philip Pallmann|Author|AUTHORED
223|Confidence Intervals For Adaptive Trial Designs Ii: Case Study And Practical Guidance|Paper|Thomas Jaki|Author|AUTHORED
224|End-To-End Clinical Trial Matching With Large Language Models|Paper|Large Language Models|Topic|RELATED_TO
224|End-To-End Clinical Trial Matching With Large Language Models|Paper|Clinicaltrials.Gov|Topic|RELATED_TO
224|End-To-End Clinical Trial Matching With Large Language Models|Paper|Electronic Health Records|Topic|RELATED_TO
224|End-To-End Clinical Trial Matching With Large Language Models|Paper|Oncology|Topic|RELATED_TO
224|End-To-End Clinical Trial Matching With Large Language Models|Paper|Gpt-4O|Topic|RELATED_TO
225|Ich E9|Topic|Estimands|Topic|RELATED_TO
225|Ich E9|Topic|Sensitivity Analyses|Topic|RELATED_TO
225|Estimands|Topic|Kaspar Rufibach|Author|AUTHORED
225|Sensitivity Analyses|Topic|Kaspar Rufibach|Author|AUTHORED
226|Covid-19 Pandemic|Topic|Clinical Research Activity|Topic|RELATED_TO
226|Clinical Research Activity|Topic|Randomized Controlled Clinical Trials|Topic|RELATED_TO
226|Randomized Controlled Clinical Trials|Topic|Adaptive Designs For Clinical Trials|Topic|RELATED_TO
226|Adaptive Designs For Clinical Trials|Topic|Nigel Stallard|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Lisa Hampson|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Norbert Benda|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Werner Brannath|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Tom Burnett|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Tim Friede|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Peter K. Kimani|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Franz Koenig|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Johannes Krisam|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Pavel Mozgunov|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Martin Posch|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|James Wason|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Gernot Wassmer|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|John Whitehead|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|S. Faye Williamson|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Sarah Zohar|Author|AUTHORED
226|Adaptive Designs For Clinical Trials|Topic|Thomas Jaki|Author|AUTHORED
227|Leveraging External Data In The Analysis Of Randomized Controlled Trials: A Comparative Analysis|Paper|Gopal Kotecha|Author|AUTHORED
227|Leveraging External Data In The Analysis Of Randomized Controlled Trials: A Comparative Analysis|Paper|Daniel E. Schwartz|Author|AUTHORED
227|Leveraging External Data In The Analysis Of Randomized Controlled Trials: A Comparative Analysis|Paper|Steffen Ventz|Author|AUTHORED
227|Leveraging External Data In The Analysis Of Randomized Controlled Trials: A Comparative Analysis|Paper|Lorenzo Trippa|Author|AUTHORED
228|Designing And Evaluating Advanced Adaptive Randomised Clinical Trials: A Practical Guide|Paper|Advanced Adaptive Randomised Clinical Trials|Topic|RELATED_TO
228|Designing And Evaluating Advanced Adaptive Randomised Clinical Trials: A Practical Guide|Paper|Bayesian Statistical Framework|Topic|RELATED_TO
228|Designing And Evaluating Advanced Adaptive Randomised Clinical Trials: A Practical Guide|Paper|Adaptr R Package|Topic|RELATED_TO
228|Designing And Evaluating Advanced Adaptive Randomised Clinical Trials: A Practical Guide|Paper|Anders Granholm|Author|AUTHORED
228|Designing And Evaluating Advanced Adaptive Randomised Clinical Trials: A Practical Guide|Paper|Aksel Karl Georg Jensen|Author|AUTHORED
228|Designing And Evaluating Advanced Adaptive Randomised Clinical Trials: A Practical Guide|Paper|Theis Lange|Author|AUTHORED
228|Designing And Evaluating Advanced Adaptive Randomised Clinical Trials: A Practical Guide|Paper|Anders Perner|Author|AUTHORED
228|Designing And Evaluating Advanced Adaptive Randomised Clinical Trials: A Practical Guide|Paper|Morten Hylander Møller|Author|AUTHORED
228|Designing And Evaluating Advanced Adaptive Randomised Clinical Trials: A Practical Guide|Paper|Benjamin Skov Kaas-Hansen|Author|AUTHORED
229|Multi-Center Clinical Trials: Randomization And Ancillary Statistics|Paper|Lu Zheng|Author|AUTHORED
229|Multi-Center Clinical Trials: Randomization And Ancillary Statistics|Paper|Marvin Zelen|Author|AUTHORED
230|Framm|Topic|Clinical Trials|Topic|RELATED_TO
230|Framm|Topic|Diversity In Clinical Trials|Topic|RELATED_TO
230|Framm|Topic|Enrollment In Clinical Trials|Topic|RELATED_TO
230|Brandon Theodorou|Author|Framm|Topic|AUTHORED
230|Lucas Glass|Author|Framm|Topic|AUTHORED
230|Cao Xiao|Author|Framm|Topic|AUTHORED
230|Jimeng Sun|Author|Framm|Topic|AUTHORED
231|Indolent Cancers|Topic|Overall Survival (Os)|Topic|RELATED_TO
231|Indolent Cancers|Topic|Progression-Free Survival (Pfs)|Topic|RELATED_TO
231|Us Food And Drug Administration|Author|Overall Survival (Os)|Topic|RELATED_TO
231|American Association For Cancer Research|Author|Overall Survival (Os)|Topic|RELATED_TO
231|American Statistical Association|Author|Overall Survival (Os)|Topic|RELATED_TO
231|Thomas R Fleming|Author|Overall Survival (Os)|Topic|AUTHORED
231|Lisa V Hampson|Author|Overall Survival (Os)|Topic|AUTHORED
231|Bharani Bharani-Dharan|Author|Overall Survival (Os)|Topic|AUTHORED
231|Frank Bretz|Author|Overall Survival (Os)|Topic|AUTHORED
231|Arunava Chakravartty|Author|Overall Survival (Os)|Topic|AUTHORED
231|Thibaud Coroller|Author|Overall Survival (Os)|Topic|AUTHORED
231|Evanthia Koukouli|Author|Overall Survival (Os)|Topic|AUTHORED
231|Janet Wittes|Author|Overall Survival (Os)|Topic|AUTHORED
231|Nigel Yateman|Author|Overall Survival (Os)|Topic|AUTHORED
231|Emmanuel Zuber|Author|Overall Survival (Os)|Topic|AUTHORED
232|Estimand Framework|Topic|Time-To-Event Estimands|Topic|RELATED_TO
232|Oncology Clinical Trials|Topic|Time-To-Event Estimands|Topic|RELATED_TO
232|Jonathan Siegel|Author|Time-To-Event Estimands|Topic|AUTHORED
232|Hans-Jochen Weber|Author|Time-To-Event Estimands|Topic|AUTHORED
232|Stefan Englert|Author|Time-To-Event Estimands|Topic|AUTHORED
232|Feng Liu|Author|Time-To-Event Estimands|Topic|AUTHORED
233|Single-World Intervention Graph (Swig)|Topic|Estimand|Topic|RELATED_TO
233|Single-World Intervention Graph (Swig)|Topic|Clinical Trial|Topic|RELATED_TO
233|Alex Ocampo|Author|Single-World Intervention Graph (Swig)|Topic|AUTHORED
233|Jemar R. Bather|Author|Single-World Intervention Graph (Swig)|Topic|AUTHORED
234|Sequentially Monitor Response-Adaptive Randomized Clinical Trial|Paper|Clinical Trials|Topic|DISCUSSES
234|Sequentially Monitor Response-Adaptive Randomized Clinical Trial|Paper|Response-Adaptive Randomization (Rar)|Topic|DISCUSSES
234|Sequentially Monitor Response-Adaptive Randomized Clinical Trial|Paper|Sequential Monitoring|Topic|DISCUSSES
234|Sequentially Monitor Response-Adaptive Randomized Clinical Trial|Paper|Brownian Motion|Topic|DISCUSSES
234|Sequentially Monitor Response-Adaptive Randomized Clinical Trial|Paper|Canonical Joint Distribution|Topic|DISCUSSES
234|Sequentially Monitor Response-Adaptive Randomized Clinical Trial|Paper|Maternal-Infant Hiv Transmission|Topic|DISCUSSES
235|Multi-Armed Bandit Problems|Topic|Optimal Control Problem|Topic|RELATED_TO
235|Multi-Armed Bandit Problems|Topic|Resource Allocation Under Uncertainty|Topic|RELATED_TO
235|Multi-Armed Bandit Problems|Topic|Clinical Trials|Topic|RELATED_TO
235|Infinite-Horizon Bayesian Bernoulli Mabp|Topic|Clinical Trials|Topic|RELATED_TO
235|Finite-Horizon Variant|Topic|Clinical Trials|Topic|RELATED_TO
235|Fixed Randomization|Topic|Clinical Trials|Topic|RELATED_TO
235|Bandit-Based Patient Allocation Rule|Topic|Clinical Trials|Topic|RELATED_TO
235|Multi-Armed Bandit Models For The Optimal Design Of Clinical Trials: Benefits And Challenges|Paper|Sofía S. Villar|Author|AUTHORED
235|Multi-Armed Bandit Models For The Optimal Design Of Clinical Trials: Benefits And Challenges|Paper|Jack Bowden|Author|AUTHORED
235|Multi-Armed Bandit Models For The Optimal Design Of Clinical Trials: Benefits And Challenges|Paper|James Wason|Author|AUTHORED
236|Osteoarthritis Clinical Trials|Topic|Patient Selection Problem|Topic|RELATED_TO
236|Patient Selection Problem|Topic|Multi-Class Classification Task|Topic|RELATED_TO
236|Oai|Topic|Check|Topic|RELATED_TO
236|Paco M. J. Welsing|Author|Multi-Class Classification Task|Topic|AUTHORED
236|Christoph Ladel|Author|Multi-Class Classification Task|Topic|AUTHORED
236|John Loughlin|Author|Multi-Class Classification Task|Topic|AUTHORED
236|Floris P. J. G. Lafeber|Author|Multi-Class Classification Task|Topic|AUTHORED
236|Florence Petit Dop|Author|Multi-Class Classification Task|Topic|AUTHORED
236|Jonathan Larkin|Author|Multi-Class Classification Task|Topic|AUTHORED
236|Harrie Weinans|Author|Multi-Class Classification Task|Topic|AUTHORED
236|Ali Mobasheri|Author|Multi-Class Classification Task|Topic|AUTHORED
236|Jaume Bacardit|Author|Multi-Class Classification Task|Topic|AUTHORED
237|Personalized Medicine|Topic|Biomarker|Topic|RELATED_TO
237|Biomarker|Topic|Clinical Trial Design|Topic|RELATED_TO
237|Clinical Trial Design|Topic|Optimization Problem|Topic|RELATED_TO
237|Optimization Problem|Topic|Monte-Carlo And Smoothing Methods|Topic|RELATED_TO
237|Monte-Carlo And Smoothing Methods|Topic|General-Purpose Computing On Graphics Processing Units|Topic|RELATED_TO
237|Yitao Lu|Author|Optimal Design Of Clinical Trials With Potential Biomarker Effects, A Novel Computational Approach|Paper|AUTHORED
237|Julie Zhou|Author|Optimal Design Of Clinical Trials With Potential Biomarker Effects, A Novel Computational Approach|Paper|AUTHORED
237|Li Xing|Author|Optimal Design Of Clinical Trials With Potential Biomarker Effects, A Novel Computational Approach|Paper|AUTHORED
237|Xuekui Zhang|Author|Optimal Design Of Clinical Trials With Potential Biomarker Effects, A Novel Computational Approach|Paper|AUTHORED
238|Zero-Shot Clinical Trial Patient Matching With Llms|Paper|Michael Wornow|Author|AUTHORED
238|Zero-Shot Clinical Trial Patient Matching With Llms|Paper|Alejandro Lozano|Author|AUTHORED
238|Zero-Shot Clinical Trial Patient Matching With Llms|Paper|Dev Dash|Author|AUTHORED
238|Zero-Shot Clinical Trial Patient Matching With Llms|Paper|Jenelle Jindal|Author|AUTHORED
238|Zero-Shot Clinical Trial Patient Matching With Llms|Paper|Kenneth W. Mahaffey|Author|AUTHORED
238|Zero-Shot Clinical Trial Patient Matching With Llms|Paper|Nigam H. Shah|Author|AUTHORED
239|Ctbench|Topic|Clinical Trial|Topic|RELATED_TO
239|Ctbench|Topic|Ct-Repo|Topic|RELATED_TO
239|Ctbench|Topic|Ct-Pub|Topic|RELATED_TO
239|Ctbench|Topic|Listmatch-Lm|Topic|RELATED_TO
239|Ctbench|Topic|Listmatch-Bert|Topic|RELATED_TO
239|Listmatch-Lm|Topic|Ct-Pub|Topic|DISCUSSES
239|Listmatch-Bert|Topic|Ct-Pub|Topic|DISCUSSES
239|Nafis Neehal|Author|Ctbench|Topic|AUTHORED
239|Bowen Wang|Author|Ctbench|Topic|AUTHORED
239|Shayom Debopadhaya|Author|Ctbench|Topic|AUTHORED
239|Soham Dan|Author|Ctbench|Topic|AUTHORED
239|Keerthiram Murugesan|Author|Ctbench|Topic|AUTHORED
239|Vibha Anand|Author|Ctbench|Topic|AUTHORED
239|Kristin P. Bennett|Author|Ctbench|Topic|AUTHORED
240|Mantel-Haenszel Risk Difference Estimator|Topic|Xiaoyu Qiu|Author|AUTHORED
240|Mantel-Haenszel Risk Difference Estimator|Topic|Yuhan Qian|Author|AUTHORED
240|Mantel-Haenszel Risk Difference Estimator|Topic|Jaehwan Yi|Author|AUTHORED
240|Mantel-Haenszel Risk Difference Estimator|Topic|Jinqiu Wang|Author|AUTHORED
240|Mantel-Haenszel Risk Difference Estimator|Topic|Yu Du|Author|AUTHORED
240|Mantel-Haenszel Risk Difference Estimator|Topic|Yanyao Yi|Author|AUTHORED
240|Mantel-Haenszel Risk Difference Estimator|Topic|Ting Ye|Author|AUTHORED
241|Covid-19 Pandemic|Topic|Decentralized Clinical Trials|Topic|RELATED_TO
241|Decentralized Clinical Trials|Topic|Blockchain Technology|Topic|RELATED_TO
241|Blockchain Technology|Topic|Zero-Trust Architecture Blockchain|Paper|RELATED_TO
241|Internet Of Things|Topic|Zero-Trust Architecture Blockchain|Paper|RELATED_TO
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Jiaqi Tong|Author|AUTHORED
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Chao Cheng|Author|AUTHORED
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Guangyu Tong|Author|AUTHORED
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Michael O. Harhay|Author|AUTHORED
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Fan Li|Author|AUTHORED
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Clinical Trials|Topic|RELATED_TO
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Survivor Average Causal Effect|Topic|RELATED_TO
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Principal Stratification|Topic|RELATED_TO
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Multi-Arm Clinical Trials|Topic|RELATED_TO
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Doubly Robust Estimators|Topic|RELATED_TO
242|Doubly Robust Estimation And Sensitivity Analysis With Outcomes Truncated By Death In Multi-Arm Clinical Trials|Paper|Sensitivity Analysis|Topic|RELATED_TO
243|Accurate Immunological Models|Topic|Immunological Memory|Topic|RELATED_TO
243|Experimental Immunological Simulator|Topic|Theory Of Immunological Memory|Topic|RELATED_TO
243|Simon Garret|Author|Experimental Immunological Simulator|Topic|AUTHORED
243|Martin Robbins|Author|Experimental Immunological Simulator|Topic|AUTHORED
243|Joanne Walker|Author|Experimental Immunological Simulator|Topic|AUTHORED
243|William Wilson|Author|Experimental Immunological Simulator|Topic|AUTHORED
243|Uwe Aickelin|Author|Experimental Immunological Simulator|Topic|AUTHORED
244|Naplib-Python|Topic|Gavin Mischler|Author|AUTHORED
244|Naplib-Python|Topic|Vinay Raghavan|Author|AUTHORED
244|Naplib-Python|Topic|Menoua Keshishian|Author|AUTHORED
244|Naplib-Python|Topic|Nima Mesgarani|Author|AUTHORED
245|Group Sequential Clinical Trial Design|Topic|Pivotal Trial|Topic|RELATED_TO
245|Group Sequential Clinical Trial Design|Topic|Regulatory Review|Topic|RELATED_TO
245|Group Sequential Clinical Trial Design|Topic|Single Stage Design|Topic|RELATED_TO
245|Group Sequential Clinical Trial Design|Topic|Group Sequential Methodology|Topic|RELATED_TO
245|Group Sequential Methodology|Topic|Key Operating Characteristics|Topic|RELATED_TO
245|Key Operating Characteristics|Topic|Decision Makers|Topic|RELATED_TO
245|Fraser I Lewis|Author|Introduction To Group Sequential Methods: Planning And Multi-Aspect Optimization|Paper|AUTHORED
246|T Cell Receptors|Topic|Causal Effects Of Tcrs|Topic|RELATED_TO
246|Eli N. Weinstein|Author|Causal Effects Of Tcrs|Topic|AUTHORED
246|Elizabeth B. Wood|Author|Causal Effects Of Tcrs|Topic|AUTHORED
246|David M. Blei|Author|Causal Effects Of Tcrs|Topic|AUTHORED
246|Tcr Repertoire Sequencing|Topic|Causal Effects Of Tcrs|Topic|RELATED_TO
246|Covid-19 Severity|Topic|Causal Effects Of Tcrs|Topic|RELATED_TO
247|Learning Eligibility In Cancer Clinical Trials Using Deep Neural Networks|Paper|Aurelia Bustos|Author|AUTHORED
247|Learning Eligibility In Cancer Clinical Trials Using Deep Neural Networks|Paper|Antonio Pertusa|Author|AUTHORED
247|Learning Eligibility In Cancer Clinical Trials Using Deep Neural Networks|Paper|Interventional Cancer Clinical Trials|Topic|DISCUSSES
248|Blinded Sample Size Re-Estimation|Topic|Gold Standard Design|Topic|RELATED_TO
248|Gold Standard Design|Topic|Three-Arm Clinical Trial|Topic|RELATED_TO
248|Tobias Mütze|Author|Blinded Sample Size Re-Estimation|Topic|AUTHORED
248|Tim Friede|Author|Blinded Sample Size Re-Estimation|Topic|AUTHORED
248|Sample Size Re-Estimation Procedures|Topic|Operating Characteristics|Topic|RELATED_TO
248|Outcome Variance|Topic|Nuisance Parameters|Topic|RELATED_TO
248|Internal Pilot Study|Topic|Sample Size Re-Estimation Procedures|Topic|RELATED_TO
248|Power|Topic|Type I Error|Topic|RELATED_TO
248|Xing-Ganju Variance Estimator|Topic|Inflation Factor|Topic|RELATED_TO
248|Overpowered Trials|Topic|Sample Size Re-Estimation Procedures|Topic|RELATED_TO
248|Underpowered Trials|Topic|Sample Size Re-Estimation Procedures|Topic|RELATED_TO
249|Deepenroll|Topic|Clinical Trials|Topic|RELATED_TO
249|Deepenroll|Topic|Xingyao Zhang|Author|AUTHORED
249|Deepenroll|Topic|Cao Xiao|Author|AUTHORED
249|Deepenroll|Topic|Lucas M. Glass|Author|AUTHORED
249|Deepenroll|Topic|Jimeng Sun|Author|AUTHORED
250|Platform Trial|Topic|Estimand|Topic|RELATED_TO
250|Platform Trial|Topic|Entire Concurrently Eligible (Ece) Population|Topic|RELATED_TO
250|Platform Trial|Topic|Treatment Effects|Topic|RELATED_TO
250|Platform Trial|Topic|Simplify Trial|Topic|RELATED_TO
250|Yuhan Qian|Author|Platform Trial|Topic|AUTHORED
250|Yifan Yi|Author|Platform Trial|Topic|AUTHORED
250|Jun Shao|Author|Platform Trial|Topic|AUTHORED
250|Yanyao Yi|Author|Platform Trial|Topic|AUTHORED
250|Gregory Levin|Author|Platform Trial|Topic|AUTHORED
250|Nicole Mayer-Hamblett|Author|Platform Trial|Topic|AUTHORED
250|Patrick J. Heagerty|Author|Platform Trial|Topic|AUTHORED
250|Ting Ye|Author|Platform Trial|Topic|AUTHORED
251|Bayesian Adaptive Cluster-Randomized Trials|Topic|Junwei Shen|Author|AUTHORED
251|Bayesian Adaptive Cluster-Randomized Trials|Topic|Shirin Golchi|Author|AUTHORED
251|Bayesian Adaptive Cluster-Randomized Trials|Topic|Erica E. M. Moodie|Author|AUTHORED
251|Bayesian Adaptive Cluster-Randomized Trials|Topic|David Benrimoh|Author|AUTHORED
251|Machine-Learning Based Clinical Decision Support System|Topic|Depression|Topic|RELATED_TO
251|Adaptive Designs For Cluster-Randomized Trials|Topic|Two Bayesian Adaptive Designs|Topic|RELATED_TO
251|Two Bayesian Adaptive Designs|Topic|Early Stopping For Efficacy|Topic|RELATED_TO
251|Two Bayesian Adaptive Designs|Topic|Simulation Results|Topic|RELATED_TO
252|Prognostic Adjustment With Efficient Estimators To Unbiasedly Leverage Historical Data In Randomized Trials|Paper|Randomized Controlled Trials|Topic|DISCUSSES
252|Prognostic Adjustment With Efficient Estimators To Unbiasedly Leverage Historical Data In Randomized Trials|Paper|Observational Studies|Topic|DISCUSSES
252|Prognostic Adjustment With Efficient Estimators To Unbiasedly Leverage Historical Data In Randomized Trials|Paper|Historical Data|Topic|DISCUSSES
252|Prognostic Adjustment With Efficient Estimators To Unbiasedly Leverage Historical Data In Randomized Trials|Paper|Prognostic Covariate Adjustment|Topic|DISCUSSES
252|Novo Nordisk A/S|Author|Prognostic Adjustment With Efficient Estimators To Unbiasedly Leverage Historical Data In Randomized Trials|Paper|AUTHORED
253|Dengue|Topic|Denv|Topic|RELATED_TO
253|Asymptomatic Viremic Individuals|Topic|Clinical Dengue Patients|Topic|RELATED_TO
253|Etienne Simon-Loriere|Author|Dengue|Topic|AUTHORED
253|Veasna Duong|Author|Dengue|Topic|AUTHORED
253|Ahmed Tawfik|Author|Dengue|Topic|AUTHORED
253|Sivlin Ung|Author|Dengue|Topic|AUTHORED
253|Sowath Ly|Author|Dengue|Topic|AUTHORED
253|Isabelle Casademont|Author|Dengue|Topic|AUTHORED
253|Matthieu Prot|Author|Dengue|Topic|AUTHORED
253|Noémie Courtejoie|Author|Dengue|Topic|AUTHORED
253|Kevin Bleakley|Author|Dengue|Topic|AUTHORED
253|Philippe Buchy|Author|Dengue|Topic|AUTHORED
253|Arnaud Tarantola|Author|Dengue|Topic|AUTHORED
253|Philippe Dussart|Author|Dengue|Topic|AUTHORED
253|Tineke Cantaert|Author|Dengue|Topic|AUTHORED
253|Anavaj Sakuntabhai|Author|Dengue|Topic|AUTHORED
254|Sars-Cov-2|Topic|Covid-19|Topic|RELATED_TO
254|Covid-19|Topic|Cytokine Storm|Topic|RELATED_TO
254|Cytokine Storm|Topic|Nf-Kappab|Topic|RELATED_TO
254|Nf-Kappab|Topic|Proteasome Inhibitors|Topic|RELATED_TO
254|Ralf Kircheis|Author|Proteasome Inhibitors|Topic|AUTHORED
254|Emanuel Haasbach|Author|Proteasome Inhibitors|Topic|AUTHORED
254|Daniel Lueftenegger|Author|Proteasome Inhibitors|Topic|AUTHORED
254|Willm T. Heyken|Author|Proteasome Inhibitors|Topic|AUTHORED
254|Matthias Ocker|Author|Proteasome Inhibitors|Topic|AUTHORED
254|Oliver Planz|Author|Proteasome Inhibitors|Topic|AUTHORED
255|Trialgraph|Topic|Clinical Trial|Topic|RELATED_TO
255|Trialgraph|Topic|Machine Learning|Topic|RELATED_TO
255|Metapath2Vec|Topic|Roc-Auc|Topic|RELATED_TO
255|Ct.Gov|Topic|Trialgraph|Topic|RELATED_TO
255|Aact|Topic|Trialgraph|Topic|RELATED_TO
255|Trialtrove|Topic|Trialgraph|Topic|RELATED_TO
255|Christopher Yacoumatos|Author|Trialgraph|Topic|AUTHORED
255|Stefano Bragaglia|Author|Trialgraph|Topic|AUTHORED
255|Anshul Kanakia|Author|Trialgraph|Topic|AUTHORED
255|Nils Svangård|Author|Trialgraph|Topic|AUTHORED
255|Jonathan Mangion|Author|Trialgraph|Topic|AUTHORED
255|Claire Donoghue|Author|Trialgraph|Topic|AUTHORED
255|Jim Weatherall|Author|Trialgraph|Topic|AUTHORED
255|Faisal M. Khan|Author|Trialgraph|Topic|AUTHORED
255|Khader Shameer|Author|Trialgraph|Topic|AUTHORED
256|Dose Finding With Escalation With Overdose Control (Ewoc) In Cancer Clinical Trials|Paper|Mourad Tighiouart|Author|AUTHORED
256|Dose Finding With Escalation With Overdose Control (Ewoc) In Cancer Clinical Trials|Paper|André Rogatko|Author|AUTHORED
256|Dose Finding With Escalation With Overdose Control (Ewoc) In Cancer Clinical Trials|Paper|Maximum Tolerated Dose (Mtd)|Topic|DISCUSSES
256|Dose Finding With Escalation With Overdose Control (Ewoc) In Cancer Clinical Trials|Paper|Bayesian Adaptive Design|Topic|DISCUSSES
256|Dose Finding With Escalation With Overdose Control (Ewoc) In Cancer Clinical Trials|Paper|Escalation With Overdose Control (Ewoc)|Topic|DISCUSSES
256|Dose Finding With Escalation With Overdose Control (Ewoc) In Cancer Clinical Trials|Paper|Abr-217620 (Naptumomab Estafenatox) Trial|Topic|DISCUSSES
257|Active Controlled Noninferiority Trials|Topic|Bias In Clinical Trials|Topic|DISCUSSES
257|Likelihood Reweighting Method|Topic|Active Controlled Noninferiority Trials|Topic|RELATED_TO
257|Likelihood Reweighting Method|Topic|Historically Controlled Trials|Topic|RELATED_TO
257|Likelihood Reweighting Method|Topic|Meta-Analyses|Topic|RELATED_TO
257|Likelihood Reweighting Method|Topic|Comparative Effectiveness Analyses|Topic|RELATED_TO
257|Lei Nie|Author|Likelihood Reweighting Method|Topic|AUTHORED
257|Zhiwei Zhang|Author|Likelihood Reweighting Method|Topic|AUTHORED
257|Daniel Rubin|Author|Likelihood Reweighting Method|Topic|AUTHORED
257|Jianxiong Chu|Author|Likelihood Reweighting Method|Topic|AUTHORED
258|Non-Alcoholic Steatohepatitis (Nash)|Topic|Nonalcoholic Fatty Liver Disease (Nafld)|Topic|RELATED_TO
258|Eu-Pearl Consortium|Topic|Non-Alcoholic Steatohepatitis (Nash)|Topic|RELATED_TO
258|Elias Laurin Meyer|Author|Eu-Pearl Consortium|Topic|AUTHORED
258|Peter Mesenbrink|Author|Eu-Pearl Consortium|Topic|AUTHORED
258|Nicholas A. Di Prospero|Author|Eu-Pearl Consortium|Topic|AUTHORED
258|Juan M. Pericàs|Author|Eu-Pearl Consortium|Topic|AUTHORED
258|Ekkehard Glimm|Author|Eu-Pearl Consortium|Topic|AUTHORED
258|Vlad Ratziu|Author|Eu-Pearl Consortium|Topic|AUTHORED
258|Elena Sena|Author|Eu-Pearl Consortium|Topic|AUTHORED
258|Franz König|Author|Eu-Pearl Consortium|Topic|AUTHORED
259|An Empirical Likelihood Approach To Nonparametric Covariate Adjustment In Randomized Clinical Trials|Paper|Covariate Adjustment|Topic|DISCUSSES
259|An Empirical Likelihood Approach To Nonparametric Covariate Adjustment In Randomized Clinical Trials|Paper|Empirical Likelihood Method|Topic|DISCUSSES
259|An Empirical Likelihood Approach To Nonparametric Covariate Adjustment In Randomized Clinical Trials|Paper|Gusto-I Trial|Topic|DISCUSSES
260|C-Pass-Pc|Topic|Haibin Wang|Author|AUTHORED
260|C-Pass-Pc|Topic|Cloud Computing|Topic|RELATED_TO
260|C-Pass-Pc|Topic|Clinical Trials|Topic|RELATED_TO
260|C-Pass-Pc|Topic|Google App Engine|Topic|RELATED_TO
260|C-Pass-Pc|Topic|Google Cloud Sql-Mysql|Topic|RELATED_TO
260|C-Pass-Pc|Topic|Php|Topic|RELATED_TO
260|C-Pass-Pc|Topic|Jquery|Topic|RELATED_TO
260|C-Pass-Pc|Topic|Css|Topic|RELATED_TO
260|C-Pass-Pc|Topic|Oracle|Topic|RELATED_TO
260|Clinical Trials|Topic|Data Coordinating Center|Topic|RELATED_TO
261|Use Of Historical Individual Patient Data In Analysis Of Clinical Trials|Paper|Bayesian Framework|Topic|DISCUSSES
261|Use Of Historical Individual Patient Data In Analysis Of Clinical Trials|Paper|Informative Prior|Topic|DISCUSSES
261|Use Of Historical Individual Patient Data In Analysis Of Clinical Trials|Paper|Historical Data|Topic|DISCUSSES
261|Use Of Historical Individual Patient Data In Analysis Of Clinical Trials|Paper|Individual Patient Data|Topic|DISCUSSES
261|Use Of Historical Individual Patient Data In Analysis Of Clinical Trials|Paper|Non-Small Cell Lung Cancer|Topic|DISCUSSES
262|Vaccsc|Topic|Sars-Cov-2|Topic|RELATED_TO
262|Ivan Da Silva Sendin|Author|Vaccsc|Topic|AUTHORED
262|Rodrigo Sanches Miani|Author|Vaccsc|Topic|AUTHORED
263|Clinical Trials|Topic|Treatments|Topic|RELATED_TO
263|Clinical Trials|Topic|Outcomes|Topic|RELATED_TO
263|Medical Experts|Topic|Clinical Trials|Topic|DISCUSSES
263|Benjamin E. Nye|Author|Understanding Clinical Trial Reports: Extracting Medical Entities And Their Relations|Paper|AUTHORED
263|Jay Deyoung|Author|Understanding Clinical Trial Reports: Extracting Medical Entities And Their Relations|Paper|AUTHORED
263|Eric Lehman|Author|Understanding Clinical Trial Reports: Extracting Medical Entities And Their Relations|Paper|AUTHORED
263|Ani Nenkova|Author|Understanding Clinical Trial Reports: Extracting Medical Entities And Their Relations|Paper|AUTHORED
263|Iain J. Marshall|Author|Understanding Clinical Trial Reports: Extracting Medical Entities And Their Relations|Paper|AUTHORED
263|Byron C. Wallace|Author|Understanding Clinical Trial Reports: Extracting Medical Entities And Their Relations|Paper|AUTHORED
263|End-To-End Evidence Extraction Systems|Topic|Cancer|Topic|RELATED_TO
263|Natural Language Processing|Topic|Data-Driven Baselines|Topic|RELATED_TO
263|Fielded Evaluation|Topic|End-To-End Evidence Extraction Systems|Topic|RELATED_TO
264|Custom2Vec|Topic|Clinical_Trials|Topic|RELATED_TO
264|Custom2Vec|Topic|Non-Small_Cell_Lung_Cancer|Topic|RELATED_TO
264|Xiong Liu|Author|Custom2Vec|Topic|AUTHORED
264|Iya Khalil|Author|Custom2Vec|Topic|AUTHORED
264|Murthy Devarakonda|Author|Custom2Vec|Topic|AUTHORED
265|A Connection Between Covariate Adjustment And Stratified Randomization In Randomized Clinical Trials|Paper|Randomized Clinical Trials|Topic|DISCUSSES
265|A Connection Between Covariate Adjustment And Stratified Randomization In Randomized Clinical Trials|Paper|Covariate Adjustment|Topic|DISCUSSES
265|A Connection Between Covariate Adjustment And Stratified Randomization In Randomized Clinical Trials|Paper|Stratified Randomization|Topic|DISCUSSES
265|A Connection Between Covariate Adjustment And Stratified Randomization In Randomized Clinical Trials|Paper|Baseline Covariates|Topic|DISCUSSES
265|A Connection Between Covariate Adjustment And Stratified Randomization In Randomized Clinical Trials|Paper|Asymptotically Linear Estimators|Topic|DISCUSSES
265|A Connection Between Covariate Adjustment And Stratified Randomization In Randomized Clinical Trials|Paper|Optimal Augmentation Function|Topic|DISCUSSES
265|A Connection Between Covariate Adjustment And Stratified Randomization In Randomized Clinical Trials|Paper|Prognostic Information|Topic|DISCUSSES
265|A Connection Between Covariate Adjustment And Stratified Randomization In Randomized Clinical Trials|Paper|Simulation Study|Topic|DISCUSSES
265|A Connection Between Covariate Adjustment And Stratified Randomization In Randomized Clinical Trials|Paper|Real Clinical Trial Data|Topic|DISCUSSES
266|Dental Disease|Topic|Oralytics|Paper|RELATED_TO
266|Oralytics|Paper|Mhealth Intervention System|Topic|RELATED_TO
266|Oralytics|Paper|Online Reinforcement Learning Algorithm|Topic|RELATED_TO
266|Oralytics|Paper|Clinical Trial|Topic|RELATED_TO
266|Oralytics|Paper|Randomized Control Trial|Topic|RELATED_TO
266|Randomized Control Trial|Topic|Spring 2025|Topic|RELATED_TO
267|Controlled Llm-Based Reasoning For Clinical Trial Retrieval|Paper|Trec 2022 Clinical Trials|Topic|DISCUSSES
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Julia Camps|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Lucas Arantes Berg|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Zhinuo Jenny Wang|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Rafael Sebastian|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Leto Luana Riebel|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Ruben Doste|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Xin Zhou|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Rafael Sachetto|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|James Coleman|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Brodie Lawson|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Vicente Grau|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Kevin Burrage|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Alfonso Bueno-Orovio|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Rodrigo Weber|Author|AUTHORED
268|Digital Twinning Of The Human Ventricular Activation Sequence To Clinical 12-Lead Ecgs And Magnetic Resonance Imaging Using Realistic Purkinje Networks For In Silico Clinical Trials|Paper|Blanca Rodriguez|Author|AUTHORED
269|Estimation Framework Of Mcid|Paper|Minimum Clinically Important Difference|Topic|RELATED_TO
269|Estimation Framework Of Mcid|Paper|A. S. Hedayat|Author|AUTHORED
269|Estimation Framework Of Mcid|Paper|Junhui Wang|Author|AUTHORED
269|Estimation Framework Of Mcid|Paper|Tu Xu|Author|AUTHORED
270|A Statistical Inference Framework For The Minimal Clinically Important Difference|Paper|Minimal Clinically Important Difference|Topic|DISCUSSES
270|A Statistical Inference Framework For The Minimal Clinically Important Difference|Paper|Champ Trial|Topic|DISCUSSES
271|The Use Of External Controls: To What Extent Can It Currently Be Recommended?|Paper|Hans Ulrich Burger|Author|AUTHORED
271|The Use Of External Controls: To What Extent Can It Currently Be Recommended?|Paper|Christoph Gerlinger|Author|AUTHORED
271|The Use Of External Controls: To What Extent Can It Currently Be Recommended?|Paper|Chris Harbron|Author|AUTHORED
271|The Use Of External Controls: To What Extent Can It Currently Be Recommended?|Paper|Armin Koch|Author|AUTHORED
271|The Use Of External Controls: To What Extent Can It Currently Be Recommended?|Paper|Martin Posch|Author|AUTHORED
271|The Use Of External Controls: To What Extent Can It Currently Be Recommended?|Paper|Justine Rochon|Author|AUTHORED
271|The Use Of External Controls: To What Extent Can It Currently Be Recommended?|Paper|Anja Schiel|Author|AUTHORED
272|Esource|Topic|Learning Health System|Topic|RELATED_TO
272|Transform Project|Topic|Clinical Research Information Model|Topic|RELATED_TO
272|Transform Project|Topic|Clinical Data Integration Model|Topic|RELATED_TO
272|Transform Project|Topic|Cdisc Operational Data Model|Topic|RELATED_TO
272|Jean-Francois Ethier|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Vasa Curcin|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Mark M. Mcgilchrist|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Sarah N. Lim Choi Keung|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Lei Zhao|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Anna Andreasson|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Piotr Bródka|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Radoslaw Michalski|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Theodoros N. Arvanitis|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Nikolaos Mastellos|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Anita Burgun|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
272|Brendan C. Delaney|Author|Esource For Clinical Trials: Implementation And Evaluation Of A Standards-Based Approach In A Real World Trial|Paper|AUTHORED
273|N-Of-1 Trials|Topic|T-Tests|Topic|DISCUSSES
273|T-Tests|Topic|Serial Correlation|Topic|DISCUSSES
273|Jillian Tang|Author|T-Tests|Topic|AUTHORED
273|Reid D. Landes|Author|T-Tests|Topic|AUTHORED
273|Fibromyalgia Patients|Topic|N-Of-1 Trials|Topic|RELATED_TO
273|Behavioral Health Setting|Topic|N-Of-1 Trials|Topic|RELATED_TO
274|A Model Of A Randomized Experiment With An Application To The Prowess Clinical Trial|Paper|Amanda Kowalski|Author|AUTHORED
274|A Model Of A Randomized Experiment With An Application To The Prowess Clinical Trial|Paper|Prowess Trial|Topic|RELATED_TO
275|Individualizing Treatment Assignment|Topic|Diseases With Patient-To-Patient Variability|Topic|RELATED_TO
275|Individualizing Treatment Assignment|Topic|Treatment Effect Heterogeneity|Topic|RELATED_TO
275|Covariate Data|Topic|Treatment Effect Heterogeneity|Topic|RELATED_TO
275|Major Depressive Disorder|Topic|Summary Statistics|Topic|RELATED_TO
275|Summary Statistics|Topic|Depression Treatment Trial|Topic|RELATED_TO
275|Rct2Otrbounds R Package|Topic|Summary Statistics|Topic|RELATED_TO
275|Nina Galanter|Author|Rct2Otrbounds R Package|Topic|AUTHORED
275|Marco Carone|Author|Rct2Otrbounds R Package|Topic|AUTHORED
275|Ronald C. Kessler|Author|Rct2Otrbounds R Package|Topic|AUTHORED
275|Alex Luedtke|Author|Rct2Otrbounds R Package|Topic|AUTHORED
276|Anscombe'S Classical Model|Topic|N|Topic|RELATED_TO
276|Anscombe'S Classical Model|Topic|Conjugate Normal Priors|Topic|RELATED_TO
276|Anscombe'S Classical Model|Topic|General Form Priors|Topic|RELATED_TO
276|Anscombe'S Classical Model|Topic|Numerical Solutions|Topic|RELATED_TO
276|Asymmetric Treatments|Topic|Conjugate Normal Priors|Topic|RELATED_TO
276|Random Variable N|Topic|N|Topic|RELATED_TO
276|Sebastian Jobjörnsson|Author|Anscombe'S Classical Model|Topic|AUTHORED
276|Sören Christensen|Author|Anscombe'S Classical Model|Topic|AUTHORED
277|Guidelines For Estimating Causal Effects In Pragmatic Randomized Trials|Paper|Eleanor J. Murray|Author|AUTHORED
277|Guidelines For Estimating Causal Effects In Pragmatic Randomized Trials|Paper|Sonja A. Swanson|Author|AUTHORED
277|Guidelines For Estimating Causal Effects In Pragmatic Randomized Trials|Paper|Miguel A. Hernán|Author|AUTHORED
278|Alzheimer'S Disease|Topic|Participant Selection|Topic|RELATED_TO
278|Participant Selection|Topic|Cognitive Trajectories|Topic|RELATED_TO
278|Cognitive Trajectories|Topic|Machine Learning Models|Topic|RELATED_TO
278|Machine Learning Models|Topic|Early Alzheimer'S Disease|Topic|RELATED_TO
278|Machine Learning Models|Topic|Presymptomatic Individuals|Topic|RELATED_TO
278|Early Alzheimer'S Disease|Topic|Magnetic Resonance Imaging|Topic|RELATED_TO
278|Early Alzheimer'S Disease|Topic|Cognitive Tests|Topic|RELATED_TO
278|Early Alzheimer'S Disease|Topic|Demographics|Topic|RELATED_TO
278|Early Alzheimer'S Disease|Topic|Apoe Genotype|Topic|RELATED_TO
278|Cognitive Trajectories|Topic|Cdr-Sum Of Boxes|Topic|RELATED_TO
278|Angela Tam|Author|Machine Learning Models|Topic|AUTHORED
278|César Laurent|Author|Machine Learning Models|Topic|AUTHORED
278|Serge Gauthier|Author|Machine Learning Models|Topic|AUTHORED
278|Christian Dansereau|Author|Machine Learning Models|Topic|AUTHORED
279|Randomized Clinical Trials|Topic|Exclusion Criteria|Topic|RELATED_TO
279|Observational Datasets|Topic|Confounding|Topic|RELATED_TO
279|Optimum In Convex Hulls (Och)|Topic|Treatment Effect|Topic|AUTHORED
279|Eric V. Strobl|Author|Generalizing Clinical Trials With Convex Hulls|Paper|AUTHORED
279|Thomas A. Lasko|Author|Generalizing Clinical Trials With Convex Hulls|Paper|AUTHORED
279|Treatment Response|Topic|Observational Datasets|Topic|RELATED_TO
279|Confounding|Topic|Treatment Response|Topic|RELATED_TO
280|Multi-Agents For Knowledge Augmentation (Maka)|Topic|Patient-Trial Matching|Topic|RELATED_TO
280|Multi-Agents For Knowledge Augmentation (Maka)|Topic|Knowledge Augmentation|Topic|RELATED_TO
280|Multi-Agents For Knowledge Augmentation (Maka)|Topic|Clinical Trials|Topic|RELATED_TO
280|Multi-Agents For Knowledge Augmentation (Maka)|Topic|Knowledge Probing Agent|Topic|RELATED_TO
280|Multi-Agents For Knowledge Augmentation (Maka)|Topic|Navigation Agent|Topic|RELATED_TO
280|Multi-Agents For Knowledge Augmentation (Maka)|Topic|Supervision Agent|Topic|RELATED_TO
280|Multi-Agents For Knowledge Augmentation (Maka)|Topic|Matching Agent|Topic|RELATED_TO
280|Multi-Agents For Knowledge Augmentation (Maka)|Topic|Knowledge Augmentation Agent|Topic|RELATED_TO
280|Hanwen Shi|Author|Multi-Agents For Knowledge Augmentation (Maka)|Topic|AUTHORED
280|Jin Zhang|Author|Multi-Agents For Knowledge Augmentation (Maka)|Topic|AUTHORED
280|Kunpeng Zhang|Author|Multi-Agents For Knowledge Augmentation (Maka)|Topic|AUTHORED
281|Two-Arm Clinical Trials|Topic|Scalar Treatment Effect Parameter|Topic|RELATED_TO
281|Scalar Treatment Effect Parameter|Topic|Treatment-Specific Means|Topic|RELATED_TO
281|Scalar Treatment Effect Parameter|Topic|Risk Difference|Topic|RELATED_TO
281|Scalar Treatment Effect Parameter|Topic|Risk Ratio|Topic|RELATED_TO
281|Scalar Treatment Effect Parameter|Topic|Odds Ratio|Topic|RELATED_TO
281|Interim Analysis|Topic|Censoring|Topic|RELATED_TO
281|Interim Analysis|Topic|Baseline Covariates|Topic|RELATED_TO
281|Interim Analysis|Topic|Time-Dependent Covariates|Topic|RELATED_TO
281|Group Sequential Framework|Topic|Interim Analysis|Topic|RELATED_TO
281|Semiparametric Theory|Topic|Group Sequential Framework|Topic|RELATED_TO
281|Anastasios A. Tsiatis|Author|Group Sequential Framework|Topic|AUTHORED
281|Marie Davidian|Author|Group Sequential Framework|Topic|AUTHORED
282|Participation Incentives|Topic|Randomized Controlled Trials|Topic|RELATED_TO
282|Randomized Controlled Trials|Topic|Medicine|Topic|RELATED_TO
282|Randomized Controlled Trials|Topic|User Dissatisfaction|Topic|RELATED_TO
282|Exploration-Exploitation Tradeoff|Topic|Randomized Controlled Trials|Topic|DISCUSSES
282|Agents|Topic|Exploration-Exploitation Tradeoff|Topic|RELATED_TO
282|Incentive-Compatible Mechanism|Topic|Statistical Performance|Topic|RELATED_TO
282|Statistical Performance|Topic|Worst-Case Estimation Error|Topic|RELATED_TO
282|Worst-Case Estimation Error|Topic|Adversarially Generated Outcomes|Topic|RELATED_TO
282|Homogeneous Agents|Topic|Randomized Controlled Trials|Topic|RELATED_TO
282|Heterogeneous Agents|Topic|Randomized Controlled Trials|Topic|RELATED_TO
282|Estimated Type Frequencies|Topic|Randomized Controlled Trials|Topic|RELATED_TO
282|Yingkai Li|Author|Incentive-Compatible Mechanism|Topic|AUTHORED
282|Aleksandrs Slivkins|Author|Incentive-Compatible Mechanism|Topic|AUTHORED
283|Fda Guidance On Covariate Adjustment|Topic|Covariate Adjustment|Topic|DISCUSSES
283|Covariate Adjustment|Topic|Machine Learning Algorithms|Topic|RELATED_TO
283|Kelly Van Lancker|Author|Fda Guidance On Covariate Adjustment|Topic|AUTHORED
283|Iván Díaz|Author|Fda Guidance On Covariate Adjustment|Topic|AUTHORED
283|Stijn Vansteelandt|Author|Fda Guidance On Covariate Adjustment|Topic|AUTHORED
284|Adaptive Designs For Multi-Armed Clinical Trials|Topic|Multi-Armed Bandit Problems|Topic|RELATED_TO
284|Multi-Armed Bandit Problems|Topic|Normally Distributed Endpoint|Topic|RELATED_TO
284|Adam Smith|Author|Bayesian Adaptive Bandit-Based Designs Using The Gittins Index For Multi-Armed Trials With Normally Distributed Endpoints|Paper|AUTHORED
284|Sofia S. Villar|Author|Bayesian Adaptive Bandit-Based Designs Using The Gittins Index For Multi-Armed Trials With Normally Distributed Endpoints|Paper|AUTHORED
284|Simulation-Based Testing Procedure|Topic|Type I Error|Topic|RELATED_TO
284|Simulation-Based Testing Procedure|Topic|Power|Topic|RELATED_TO
284|Simulation-Based Testing Procedure|Topic|Bias|Topic|RELATED_TO
284|Simulation-Based Testing Procedure|Topic|Patient Benefit|Topic|RELATED_TO
284|Rare Disease Context|Topic|Patient Benefit|Topic|RELATED_TO
284|Common Diseases|Topic|Simulation-Based Testing Procedure|Topic|RELATED_TO
285|Copd|Topic|Exacerbation Rates|Topic|RELATED_TO
285|Exacerbation Rates|Topic|Meta-Regression|Topic|RELATED_TO
285|Meta-Regression|Topic|Randomized Controlled Trials|Topic|RELATED_TO
285|Meta-Regression|Topic|Bayesian Negative Binomial Model|Topic|RELATED_TO
285|Meta-Regression|Topic|Systematic Review|Topic|RELATED_TO
285|Randomized Controlled Trials|Topic|Placebo Groups|Topic|RELATED_TO
285|Exacerbation Rates|Topic|Adjunct Therapy|Topic|RELATED_TO
285|Exacerbation Rates|Topic|Forced Expiratory Volume In 1 S (Fev1)|Topic|RELATED_TO
285|Exacerbation Rates|Topic|Decline Of Copd Exacerbations|Topic|RELATED_TO
285|Stefan Andreas|Author|Meta-Regression|Topic|AUTHORED
285|Christian Röver|Author|Meta-Regression|Topic|AUTHORED
285|Judith Heinz|Author|Meta-Regression|Topic|AUTHORED
285|Sebastian Straube|Author|Meta-Regression|Topic|AUTHORED
285|Henrik Watz|Author|Meta-Regression|Topic|AUTHORED
285|Tim Friede|Author|Meta-Regression|Topic|AUTHORED
286|Information Extraction Of Clinical Trial Eligibility Criteria|Topic|Yitong Tseo|Author|AUTHORED
286|Information Extraction Of Clinical Trial Eligibility Criteria|Topic|M. I. Salkola|Author|AUTHORED
286|Information Extraction Of Clinical Trial Eligibility Criteria|Topic|Ahmed Mohamed|Author|AUTHORED
286|Information Extraction Of Clinical Trial Eligibility Criteria|Topic|Anuj Kumar|Author|AUTHORED
286|Information Extraction Of Clinical Trial Eligibility Criteria|Topic|Freddy Abnousi|Author|AUTHORED
287|Use Of Historical Data And Real-World Evidence|Topic|Clinical Trials|Topic|RELATED_TO
287|Elastic Prior Approach|Topic|Clinical Trials|Topic|RELATED_TO
287|Clinically Meaningful Difference|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Liyun Jiang|Author|Elastic Prior Approach|Topic|AUTHORED
287|Lei Nie|Author|Elastic Prior Approach|Topic|AUTHORED
287|Ying Yuan|Author|Elastic Prior Approach|Topic|AUTHORED
287|Simulation Study|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Type I Error|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Type Ii Error|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Information Borrowing|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Data Dredging|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Bias|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Power|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Information-Borrowing Constraints|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Congruence Measure|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Historical Data|Topic|Elastic Prior Approach|Topic|RELATED_TO
287|Trial Data|Topic|Elastic Prior Approach|Topic|RELATED_TO
288|Trialmdp|Topic|Response-Adaptive Randomization|Topic|RELATED_TO
288|Trialmdp|Topic|Blocked Rar|Topic|RELATED_TO
288|Trialmdp|Topic|David Merrell|Author|AUTHORED
288|Trialmdp|Topic|Thevaa Chandereng|Author|AUTHORED
288|Trialmdp|Topic|Yeonhee Park|Author|AUTHORED
289|Estimating Treatment Effects From Observational Data|Topic|Causal Inference|Topic|RELATED_TO
289|Causal Inference|Topic|Basket Trial|Topic|RELATED_TO
289|Basket Trial|Topic|Multi-Task Adversarial Learning (Mtal)|Topic|RELATED_TO
289|Multi-Task Adversarial Learning (Mtal)|Topic|Ihdp|Topic|RELATED_TO
289|Multi-Task Adversarial Learning (Mtal)|Topic|News|Topic|RELATED_TO
289|Zhixuan Chu|Author|Multi-Task Adversarial Learning (Mtal)|Topic|AUTHORED
289|Stephen L. Rathbun|Author|Multi-Task Adversarial Learning (Mtal)|Topic|AUTHORED
289|Sheng Li|Author|Multi-Task Adversarial Learning (Mtal)|Topic|AUTHORED
290|Modeling Restricted Enrollment And Optimal Cost-Efficient Design In Multicenter Clinical Trials|Paper|Vladimir Anisimov|Author|AUTHORED
290|Modeling Restricted Enrollment And Optimal Cost-Efficient Design In Multicenter Clinical Trials|Paper|Matthew Austin|Author|AUTHORED
290|Modeling Restricted Enrollment And Optimal Cost-Efficient Design In Multicenter Clinical Trials|Paper|Clinical Research|Topic|DISCUSSES
290|Modeling Restricted Enrollment And Optimal Cost-Efficient Design In Multicenter Clinical Trials|Paper|Statistical Methodology|Topic|DISCUSSES
290|Modeling Restricted Enrollment And Optimal Cost-Efficient Design In Multicenter Clinical Trials|Paper|Artificial Intelligence|Topic|DISCUSSES
291|Bayesian Inference|Topic|Decision Making|Topic|RELATED_TO
291|Posterior Probabilities|Topic|Decision Making|Topic|RELATED_TO
291|Posterior Predictive Probabilities|Topic|Decision Making|Topic|RELATED_TO
291|Clinical Trials|Topic|Bayesian Clinical Trials|Topic|RELATED_TO
291|Bayesian Clinical Trials|Topic|Hybrid Bayesian-Frequentist Approach|Topic|RELATED_TO
291|Hybrid Bayesian-Frequentist Approach|Topic|Frequentist Operating Characteristics|Topic|RELATED_TO
291|Frequentist Operating Characteristics|Topic|Power|Topic|RELATED_TO
291|Frequentist Operating Characteristics|Topic|Type I Error Rate|Topic|RELATED_TO
291|Bayesian Measures|Topic|Assurance|Topic|RELATED_TO
291|Assurance|Topic|Decision Making|Topic|RELATED_TO
291|Computational Burden|Topic|Bayesian Measures|Topic|RELATED_TO
291|Methodology|Topic|Large Sample Theory|Topic|RELATED_TO
291|Large Sample Theory|Topic|Posterior Distribution|Topic|RELATED_TO
291|Posterior Distribution|Topic|Parametric Models|Topic|RELATED_TO
291|Parametric Models|Topic|Sampling Distribution|Topic|RELATED_TO
291|Sampling Distribution|Topic|Posterior Summaries|Topic|RELATED_TO
291|Small Number Of Simulation Scenarios|Topic|Sampling Distribution|Topic|RELATED_TO
291|Conditional Operating Characteristics|Topic|Sample Size Determination|Topic|RELATED_TO
291|Marginal Operating Characteristics|Topic|Sample Size Determination|Topic|RELATED_TO
291|Design Prior|Topic|Bayesian Trials|Topic|RELATED_TO
291|Shirin Golchi|Author|Estimating The Sampling Distribution Of Posterior Decision Summaries In Bayesian Clinical Trials|Paper|AUTHORED
291|James Willard|Author|Estimating The Sampling Distribution Of Posterior Decision Summaries In Bayesian Clinical Trials|Paper|AUTHORED
292|Assurance Methods For Designing A Clinical Trial With A Delayed Treatment Effect|Paper|Immuno-Oncology|Topic|RELATED_TO
293|Large Language Models|Topic|Healthcare|Topic|RELATED_TO
293|Patient-Trial Matching|Topic|Healthcare|Topic|RELATED_TO
293|Gpt-3.5|Author|Patient-Trial Matching|Topic|AUTHORED
293|Gpt-4|Author|Patient-Trial Matching|Topic|AUTHORED
293|Llama 7B|Author|Patient-Trial Matching|Topic|AUTHORED
293|Llama 13B|Author|Patient-Trial Matching|Topic|AUTHORED
293|Llama 70B|Author|Patient-Trial Matching|Topic|AUTHORED
293|Mauro Nievas|Author|Patient-Trial Matching|Topic|AUTHORED
293|Aditya Basu|Author|Patient-Trial Matching|Topic|AUTHORED
293|Yanshan Wang|Author|Patient-Trial Matching|Topic|AUTHORED
293|Hrituraj Singh|Author|Patient-Trial Matching|Topic|AUTHORED
293|Trial-Llama|Topic|Evaluation Dataset|Topic|RELATED_TO
293|Synthetic Dataset|Topic|Trial-Llama|Topic|RELATED_TO
294|Biosimilars Development|Topic|Ryuji Uozumi|Author|AUTHORED
294|Biosimilars Development|Topic|Chikuma Hamada|Author|AUTHORED
295|Rheumatoid Arthritis Clinical Trials|Topic|Das28 Scores|Topic|RELATED_TO
295|Das28 Scores|Topic|Bayesian Joint Model|Topic|DISCUSSES
295|Etanercept|Topic|Tempo|Topic|RELATED_TO
295|Methotrexate|Topic|Tempo|Topic|RELATED_TO
295|Tempo|Topic|Violeta G. Hennessey|Author|AUTHORED
295|Tempo|Topic|Luis G. Leon-Novelo|Author|AUTHORED
295|Tempo|Topic|Juan Li|Author|AUTHORED
295|Tempo|Topic|Li Zhu|Author|AUTHORED
295|Tempo|Topic|Eric Chi|Author|AUTHORED
295|Tempo|Topic|Joseph G. Ibrahim|Author|AUTHORED
295|Informative Dropout|Topic|Longitudinal Data Collection|Topic|RELATED_TO
296|Prognostic Model|Topic|Patients|Topic|RELATED_TO
296|Prognostic Model|Topic|Clinicians|Topic|RELATED_TO
296|Decision Rule|Topic|Randomized Trial|Topic|RELATED_TO
296|Observational Data|Topic|Decision Rule|Topic|RELATED_TO
296|Michael C Sachs|Author|Decision Rule|Topic|AUTHORED
296|Arvid Sjölander|Author|Decision Rule|Topic|AUTHORED
296|Erin E Gabriel|Author|Decision Rule|Topic|AUTHORED
297|Antioxidants|Topic|Cancer Therapy|Topic|RELATED_TO
297|Free Radicals|Topic|Oxidative Stress|Topic|RELATED_TO
297|Oxidative Stress|Topic|Cancer Therapy|Topic|RELATED_TO
297|Emerging Classes Of Antioxidant To Cancer Therapy: A Review Of Clinical And Experimental Studies|Paper|Qurat-Ul-Ain|Author|AUTHORED
297|Emerging Classes Of Antioxidant To Cancer Therapy: A Review Of Clinical And Experimental Studies|Paper|M. Iqbal Choudhary|Author|AUTHORED
298|Machine Learning For Health: Personalized Models For Forecasting Of Alzheimer Disease Progression|Paper|Alzheimer Disease|Topic|RELATED_TO
298|Machine Learning For Health: Personalized Models For Forecasting Of Alzheimer Disease Progression|Paper|Tadpole Challenge|Topic|RELATED_TO
298|Machine Learning For Health: Personalized Models For Forecasting Of Alzheimer Disease Progression|Paper|Adas-Cog13 Scores|Topic|RELATED_TO
298|Machine Learning For Health: Personalized Models For Forecasting Of Alzheimer Disease Progression|Paper|Cox Model|Topic|RELATED_TO
298|Machine Learning For Health: Personalized Models For Forecasting Of Alzheimer Disease Progression|Paper|Mit Medialab|Author|AUTHORED
299|Ct-Ade|Topic|Adverse Drug Events|Topic|RELATED_TO
299|Ct-Ade|Topic|Anthony Yazdani|Author|AUTHORED
299|Ct-Ade|Topic|Alban Bornet|Author|AUTHORED
299|Ct-Ade|Topic|Philipp Khlebnikov|Author|AUTHORED
299|Ct-Ade|Topic|Boya Zhang|Author|AUTHORED
299|Ct-Ade|Topic|Hossein Rouhizadeh|Author|AUTHORED
299|Ct-Ade|Topic|Poorya Amini|Author|AUTHORED
299|Ct-Ade|Topic|Douglas Teodoro|Author|AUTHORED
300|Watch|Topic|Treatment Effect Heterogeneity|Topic|RELATED_TO
300|Konstantinos Sechidis|Author|Watch|Topic|AUTHORED
300|Sophie Sun|Author|Watch|Topic|AUTHORED
300|Yao Chen|Author|Watch|Topic|AUTHORED
300|Jiarui Lu|Author|Watch|Topic|AUTHORED
300|Cong Zhang|Author|Watch|Topic|AUTHORED
300|Mark Baillie|Author|Watch|Topic|AUTHORED
300|David Ohlssen|Author|Watch|Topic|AUTHORED
300|Marc Vandemeulebroecke|Author|Watch|Topic|AUTHORED
300|Rob Hemmings|Author|Watch|Topic|AUTHORED
300|Stephen Ruberg|Author|Watch|Topic|AUTHORED
300|Björn Bornkamp|Author|Watch|Topic|AUTHORED
301|Cox Proportional Hazards Models|Topic|St-Segment Elevation Myocardial Infarction (Stemi)|Topic|RELATED_TO
301|Cox Proportional Hazards Models|Topic|Non-Stemi|Topic|RELATED_TO
301|Thomas Mcandrew|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Bjorn Redfors|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Aaron Crowley|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Yiran Zhang|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Shmuel Chen|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Mordechai Golomb|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Maria Alu|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Dominic Francese|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Ori Ben-Yehuda|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Akiko Maehara|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Gary Mintz|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Gregg Stone|Author|Cox Proportional Hazards Models|Topic|AUTHORED
301|Paul Jenkins|Author|Cox Proportional Hazards Models|Topic|AUTHORED
302|Pediatric Rare Diseases|Topic|Clinical Research|Topic|RELATED_TO
302|Pediatric Regulation|Topic|Clinical Research|Topic|RELATED_TO
302|Orphan Regulation|Topic|Clinical Research|Topic|RELATED_TO
302|Victoria Hedley|Author|Pediatric Rare Diseases|Topic|AUTHORED
302|Rebecca Leary|Author|Pediatric Rare Diseases|Topic|AUTHORED
302|Anando Sen|Author|Pediatric Rare Diseases|Topic|AUTHORED
302|Anna Irvin|Author|Pediatric Rare Diseases|Topic|AUTHORED
302|Emma Heslop|Author|Pediatric Rare Diseases|Topic|AUTHORED
302|Volker Straub|Author|Pediatric Rare Diseases|Topic|AUTHORED
303|Phase I Clinical Trial Design|Topic|Xiaojun Zhu|Author|AUTHORED
304|Optimal Allocation Strategies In Platform Trials|Paper|Platform Trials|Topic|DISCUSSES
304|Optimal Allocation Strategies In Platform Trials|Paper|Marta Bofill Roig|Author|AUTHORED
304|Optimal Allocation Strategies In Platform Trials|Paper|Ekkehard Glimm|Author|AUTHORED
304|Optimal Allocation Strategies In Platform Trials|Paper|Tobias Mielke|Author|AUTHORED
304|Optimal Allocation Strategies In Platform Trials|Paper|Martin Posch|Author|AUTHORED
305|Surrogate Endpoint For Overall Survival In Cancer Patients|Topic|Oncology Drug Development|Topic|RELATED_TO
305|Patient Level Association With Survival|Topic|Clinical Or Biological Features|Topic|RELATED_TO
305|Discovery Cohort|Topic|Trial Level Association|Topic|RELATED_TO
305|Trial Level Association|Topic|Meta-Analysis|Topic|RELATED_TO
305|Causal Biological Trajectories|Topic|Bi-Exponential Functions|Topic|RELATED_TO
305|Simulated Discovery Cohorts|Topic|C Index|Topic|RELATED_TO
305|Simulated Discovery Cohorts|Topic|Integrated Brier Score|Topic|RELATED_TO
305|Simulated Discovery Cohorts|Topic|Log Hazard Ratio|Topic|RELATED_TO
305|Simulated Studies|Topic|Trial Level Metric|Topic|RELATED_TO
305|Wei Zou|Author|Metrics To Find A Surrogate Endpoint Of Os In Metastatic Oncology Trials: A Simulation Study|Paper|AUTHORED
306|Analysis Of An Incomplete Binary Outcome Dichotomized From An Underlying Continuous Variable In Clinical Trials|Paper|Chenchen Ma|Author|AUTHORED
306|Analysis Of An Incomplete Binary Outcome Dichotomized From An Underlying Continuous Variable In Clinical Trials|Paper|Xin Shen|Author|AUTHORED
306|Analysis Of An Incomplete Binary Outcome Dichotomized From An Underlying Continuous Variable In Clinical Trials|Paper|Yongming Qu|Author|AUTHORED
306|Analysis Of An Incomplete Binary Outcome Dichotomized From An Underlying Continuous Variable In Clinical Trials|Paper|Yu Du|Author|AUTHORED
306|Analysis Of An Incomplete Binary Outcome Dichotomized From An Underlying Continuous Variable In Clinical Trials|Paper|Glmm|Topic|RELATED_TO
306|Analysis Of An Incomplete Binary Outcome Dichotomized From An Underlying Continuous Variable In Clinical Trials|Paper|Mi|Topic|RELATED_TO
306|Analysis Of An Incomplete Binary Outcome Dichotomized From An Underlying Continuous Variable In Clinical Trials|Paper|Clinical Trials|Topic|RELATED_TO
307|Alzheimer'S Disease|Topic|Mild Cognitive Impairment|Topic|RELATED_TO
307|Alzheimer'S Disease|Topic|Conditional Restricted Boltzmann Machines|Topic|RELATED_TO
307|Alzheimer'S Disease|Topic|Digital Twins|Topic|RELATED_TO
307|Digital Twins|Topic|Daniele Bertolini|Author|AUTHORED
307|Digital Twins|Topic|Anton D. Loukianov|Author|AUTHORED
307|Digital Twins|Topic|Aaron M. Smith|Author|AUTHORED
307|Digital Twins|Topic|David Li-Bland|Author|AUTHORED
307|Digital Twins|Topic|Yannick Pouliot|Author|AUTHORED
307|Digital Twins|Topic|Jonathan R. Walsh|Author|AUTHORED
307|Digital Twins|Topic|Charles K. Fisher|Author|AUTHORED
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Automated Speaker Verification|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Alzheimer'S Disease|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|659 Participants|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Male Speakers|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Female Speakers|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Non-Native English Speakers|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Native English Speakers|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Clinician Interference|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Noisy Background|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Unclear Participant Speech|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Severity Level Of Alzheimer'S Disease|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Voice Biometrics|Topic|DISCUSSES
308|Factors Affecting The Performance Of Automated Speaker Verification In Alzheimer'S Disease Clinical Trials|Paper|Data Collection Settings|Topic|DISCUSSES
309|Trialscope|Topic|Javier González|Author|AUTHORED
309|Trialscope|Topic|Cliff Wong|Author|AUTHORED
309|Trialscope|Topic|Zelalem Gero|Author|AUTHORED
309|Trialscope|Topic|Jass Bagga|Author|AUTHORED
309|Trialscope|Topic|Risa Ueno|Author|AUTHORED
309|Trialscope|Topic|Isabel Chien|Author|AUTHORED
309|Trialscope|Topic|Eduard Oravkin|Author|AUTHORED
309|Trialscope|Topic|Emre Kiciman|Author|AUTHORED
309|Trialscope|Topic|Aditya Nori|Author|AUTHORED
309|Trialscope|Topic|Roshanthi Weerasinghe|Author|AUTHORED
309|Trialscope|Topic|Rom S. Leidner|Author|AUTHORED
309|Trialscope|Topic|Brian Piening|Author|AUTHORED
309|Trialscope|Topic|Tristan Naumann|Author|AUTHORED
309|Trialscope|Topic|Carlo Bifulco|Author|AUTHORED
309|Trialscope|Topic|Hoifung Poon|Author|AUTHORED
310|Gather|Topic|David Narganes-Carlon|Author|AUTHORED
310|Gather|Topic|Anniek Myatt|Author|AUTHORED
310|Gather|Topic|Mani Mudaliar|Author|AUTHORED
310|Gather|Topic|Daniel J. Crowther|Author|AUTHORED
310|Gather|Topic|Pharmaceutical Drug Discovery|Topic|RELATED_TO
310|Gather|Topic|Clinical Trial|Topic|RELATED_TO
310|Gather|Topic|Gatv3|Topic|RELATED_TO
310|Gather|Topic|Gatv3Heteroconv|Topic|RELATED_TO
310|Gather|Topic|Captum|Topic|RELATED_TO
311|Causal Inferences|Topic|Generalizability|Topic|RELATED_TO
311|Causal Inferences|Topic|Transportability|Topic|RELATED_TO
311|Sensitivity Analysis|Topic|Randomized Trial|Topic|RELATED_TO
311|Sensitivity Analysis|Topic|Non-Randomized Individuals|Topic|RELATED_TO
311|Sensitivity Analysis|Topic|Chronic Hepatitis C Infection|Topic|RELATED_TO
311|Issa J. Dahabreh|Author|Sensitivity Analysis|Topic|AUTHORED
311|James M. Robins|Author|Sensitivity Analysis|Topic|AUTHORED
311|Sebastien J-P. A. Haneuse|Author|Sensitivity Analysis|Topic|AUTHORED
311|Iman Saeed|Author|Sensitivity Analysis|Topic|AUTHORED
311|Sarah E. Robertson|Author|Sensitivity Analysis|Topic|AUTHORED
311|Elisabeth A. Stuart|Author|Sensitivity Analysis|Topic|AUTHORED
311|Miguel A. Hernán|Author|Sensitivity Analysis|Topic|AUTHORED
312|Basket Trials|Topic|R-Package Basket|Topic|RELATED_TO
312|R-Package Basket|Topic|Michael J. Kane|Author|AUTHORED
312|R-Package Basket|Topic|Nan Chen|Author|AUTHORED
312|R-Package Basket|Topic|Alexander M. Kaizer|Author|AUTHORED
312|R-Package Basket|Topic|Xun Jiang|Author|AUTHORED
312|R-Package Basket|Topic|H. Amy Xia|Author|AUTHORED
312|R-Package Basket|Topic|Brian P. Hobbs|Author|AUTHORED
313|Results From Clinical Trials|Topic|P-Hacking|Topic|RELATED_TO
313|Pre-Spec Framework|Topic|P-Hacking|Topic|RELATED_TO
313|Spirit Statement|Topic|Pre-Spec Framework|Topic|RELATED_TO
313|Brennan C Kahan|Author|Pre-Spec Framework|Topic|AUTHORED
313|Gordon Forbes|Author|Pre-Spec Framework|Topic|AUTHORED
313|Suzie Cro|Author|Pre-Spec Framework|Topic|AUTHORED
314|Dose-Finding Clinical Trials In Oncology|Topic|Maximum Tolerated Dose (Mtd)|Topic|RELATED_TO
314|Dose-Finding Clinical Trials In Oncology|Topic|Patient-Reported Outcomes (Pros)|Topic|RELATED_TO
314|Pro Continual Reassessment Method (Pro-Crm)|Topic|Maximum Tolerated Dose (Mtd)|Topic|RELATED_TO
314|Tite-Pro-Crm|Topic|Pro Continual Reassessment Method (Pro-Crm)|Topic|RELATED_TO
314|Tite-Crm+Pro|Topic|Pro Continual Reassessment Method (Pro-Crm)|Topic|RELATED_TO
314|Anaïs Andrillon|Author|Tite-Pro-Crm|Topic|AUTHORED
314|Lucie Biard|Author|Tite-Pro-Crm|Topic|AUTHORED
314|Shing M. Lee|Author|Tite-Pro-Crm|Topic|AUTHORED
315|Phase I Dose Escalation Trials|Topic|Maximum Tolerated Dose (Mtd)|Topic|RELATED_TO
315|Optimal Biological Dose (Obd)|Topic|Maximum Tolerated Dose (Mtd)|Topic|RELATED_TO
315|Estimand Framework|Topic|Ich E9(R1) Guidelines|Topic|RELATED_TO
315|Estimand Framework|Topic|Pharmacokinetics (Pk) Data|Topic|RELATED_TO
315|Estimand Framework|Topic|Toxicity Data|Topic|RELATED_TO
315|Estimand Framework|Topic|Efficacy Data|Topic|RELATED_TO
315|Estimand Framework|Topic|Utility Functions|Topic|RELATED_TO
315|Intercurrent Events|Topic|Estimand Framework|Topic|RELATED_TO
315|Ayon Mukherjee|Author|Estimand Framework|Topic|AUTHORED
315|Jonathan L. Moscovici|Author|Estimand Framework|Topic|AUTHORED
315|Zheng Liu|Author|Estimand Framework|Topic|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Amir A Toor|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Jared D Kobulnicky|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Salman Salman|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Catherine H Roberts|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Max Jameson-Lee|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Jeremy Meier|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Allison Scalora|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Nihar Sheth|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Vishal Koparde|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Myrna Serrano|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Gregory A Buck|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|William Clark|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|John Mccarty|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Harold Chung|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Masoud H Manjili|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Roy T Sabo|Author|AUTHORED
316|Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic?|Paper|Michael C Neale|Author|AUTHORED
317|Artificial Intelligence|Topic|Clinical Practice|Topic|RELATED_TO
317|Evaluation Methodologies|Topic|Artificial Intelligence|Topic|RELATED_TO
317|Dc-Ai Rcts|Topic|Evaluation Methodologies|Topic|RELATED_TO
317|Vc-Medai|Topic|Evaluation Methodologies|Topic|RELATED_TO
317|Wanling Gao|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Yunyou Huang|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Dandan Cui|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Zhuoming Yu|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Wenjing Liu|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Xiaoshuang Liang|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Jiahui Zhao|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Jiyue Xie|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Hao Li|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Li Ma|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Ning Ye|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Yumiao Kang|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Dingfeng Luo|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Peng Pan|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Wei Huang|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Zhongmou Liu|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Jizhong Hu|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Gangyuan Zhao|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Chongrong Jiang|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Fan Huang|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Tianyi Wei|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Suqin Tang|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Bingjie Xia|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Zhifei Zhang|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
317|Jianfeng Zhan|Author|Establishing Rigorous And Cost-Effective Clinical Trials For Artificial Intelligence Models|Paper|AUTHORED
318|A Hassle-Free Machine Learning Method For Cohort Selection Of Clinical Trials|Paper|Liu Man|Author|AUTHORED
319|Heterogeneous Clinical Trial Outcomes Via Multi-Output Gaussian Processes|Paper|Owen Thomas|Author|AUTHORED
319|Heterogeneous Clinical Trial Outcomes Via Multi-Output Gaussian Processes|Paper|Leiv Rønneberg|Author|AUTHORED
319|Heterogeneous Clinical Trial Outcomes Via Multi-Output Gaussian Processes|Paper|Gaussian Process Models|Topic|RELATED_TO
319|Heterogeneous Clinical Trial Outcomes Via Multi-Output Gaussian Processes|Paper|Clinical Data Sets|Topic|RELATED_TO
319|Heterogeneous Clinical Trial Outcomes Via Multi-Output Gaussian Processes|Paper|Bayesian Nonparametric Models|Topic|RELATED_TO
319|Heterogeneous Clinical Trial Outcomes Via Multi-Output Gaussian Processes|Paper|Stan|Topic|RELATED_TO
319|Heterogeneous Clinical Trial Outcomes Via Multi-Output Gaussian Processes|Paper|Brms|Topic|RELATED_TO
319|Heterogeneous Clinical Trial Outcomes Via Multi-Output Gaussian Processes|Paper|Radiological Image Quality|Topic|RELATED_TO
319|Heterogeneous Clinical Trial Outcomes Via Multi-Output Gaussian Processes|Paper|Parametric Models|Topic|RELATED_TO
319|Heterogeneous Clinical Trial Outcomes Via Multi-Output Gaussian Processes|Paper|Random Effects|Topic|RELATED_TO
320|Space Biology Research|Topic|Artificial Intelligence|Topic|RELATED_TO
320|Space Biology Research|Topic|Machine Learning|Topic|RELATED_TO
320|Space Biology Research|Topic|Modeling Applications|Topic|RELATED_TO
320|National Aeronautics And Space Administration|Author|Artificial Intelligence|Topic|DISCUSSES
320|National Aeronautics And Space Administration|Author|Machine Learning|Topic|DISCUSSES
320|National Aeronautics And Space Administration|Author|Modeling Applications|Topic|DISCUSSES
321|Beyond Low Earth Orbit: Biomonitoring, Artificial Intelligence, And Precision Space Health|Paper|National Aeronautics And Space Administration|Topic|DISCUSSES
322|Interadapt R Package|Topic|Aaron Fisher|Author|AUTHORED
322|Interadapt R Package|Topic|Harris Jaffee|Author|AUTHORED
322|Interadapt R Package|Topic|Michael Rosenblum|Author|AUTHORED
323|Nonlinear Regression Models|Topic|Dose-Finding Trials|Topic|RELATED_TO
323|Dose-Finding Trials|Topic|Pharmaceutical Drug Development|Topic|RELATED_TO
323|Optimal Designs|Topic|Efficacy And Toxicity|Topic|RELATED_TO
323|Bivariate Continuous Outcomes|Topic|Optimal Designs|Topic|RELATED_TO
323|Polynomials|Topic|Optimal Designs|Topic|RELATED_TO
323|Michaelis-Menten Model|Topic|Optimal Designs|Topic|RELATED_TO
323|Emax Model|Topic|Optimal Designs|Topic|RELATED_TO
323|D-Optimal Designs|Topic|Efficacy And Toxicity|Topic|RELATED_TO
323|Holger Dette|Author|Optimal Designs|Topic|AUTHORED
323|Katrin Kettelhake|Author|Optimal Designs|Topic|AUTHORED
323|Kirsten Schorning|Author|Optimal Designs|Topic|AUTHORED
323|Weng Kee Wong|Author|Optimal Designs|Topic|AUTHORED
323|Frank Bretz|Author|Optimal Designs|Topic|AUTHORED
324|Comparedesign|Topic|Composite Endpoints|Topic|RELATED_TO
324|Comparedesign|Topic|Time-To-Event Endpoints|Topic|RELATED_TO
324|Jordi Cortés Martinez|Author|Comparedesign|Topic|AUTHORED
324|Marta Bofill Roig|Author|Comparedesign|Topic|AUTHORED
324|Guadalupe Gómez Melis|Author|Comparedesign|Topic|AUTHORED
325|Information Theory|Topic|Communication Over Noisy Channels|Topic|RELATED_TO
325|Information Theory|Topic|Nervous System|Topic|RELATED_TO
325|Robin A. A. Ince|Author|Information Theory|Topic|AUTHORED
325|Simon R. Schultz|Author|Information Theory|Topic|AUTHORED
325|Stefano Panzeri|Author|Information Theory|Topic|AUTHORED
326|Ibex Knowledge-Base|Topic|Ziv Yaniv|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Ifeanyichukwu U. Anidi|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Leanne Arakkal|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Armando J. Arroyo-Mejías|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Rebecca T. Beuschel|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Katy Börner|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Colin J. Chu|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Beatrice Clark|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Menna R. Clatworthy|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Jake Colautti|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Fabian Coscia|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Joshua Croteau|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Saven Denha|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Rose Dever|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Walderez O. Dutra|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Sonja Fritzsche|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Spencer Fullam|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Michael Y. Gerner|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Anita Gola|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Kenneth J. Gollob|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Jonathan M. Hernandez|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Jyh Liang Hor|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Hiroshi Ichise|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Zhixin Jing|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Danny Jonigk|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Evelyn Kandov|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Wolfgang Kastenmüller|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Joshua F. E. Koenig|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Aanandita Kothurkar|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Rosa K. Kortekaas|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Alexandra Y. Kreins|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Ian T. Lamborn|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Yuri Lin|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Katia Luciano Pereira Morais|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Aleksandra Lunich|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Jean C. S. Luz|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Ryan B. Macdonald|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Chen Makranz|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Vivien I. Maltez|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|John E. Mcdonough|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Ryan V. Moriarty|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Juan M. Ocampo-Godinez|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Vitoria M. Olyntho|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Annette Oxenius|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Kartika Padhan|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Kirsten Remmert|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Nathan Richoz|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Edward C. Schrom|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Wanjing Shang|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Lihong Shi|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Rochelle M. Shih|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Emily Speranza|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Salome Stierli|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Sarah A. Teichmann|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Tibor Z. Veres|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Megan Vierhout|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Brianna T. Wachter|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Margaret Williams|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Nathan Zangger|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Ronald N. Germain|Author|AUTHORED
326|Ibex Knowledge-Base|Topic|Andrea J. Radtke|Author|AUTHORED
327|Rheumatoid Arthritis Clinical Trial|Topic|Accountable Care Organization|Topic|RELATED_TO
327|Rheumatoid Arthritis Clinical Trial|Topic|Clinical Trials|Topic|RELATED_TO
327|Andrew J Mcmurry|Author|Rheumatoid Arthritis Clinical Trial|Topic|AUTHORED
327|Richen Zhang|Author|Rheumatoid Arthritis Clinical Trial|Topic|AUTHORED
327|Alex Foxman|Author|Rheumatoid Arthritis Clinical Trial|Topic|AUTHORED
327|Lawrence Reiter|Author|Rheumatoid Arthritis Clinical Trial|Topic|AUTHORED
327|Ronny Schnel|Author|Rheumatoid Arthritis Clinical Trial|Topic|AUTHORED
327|Deleys Brandman|Author|Rheumatoid Arthritis Clinical Trial|Topic|AUTHORED
327|Electronic Health Record Systems|Topic|Patient Privacy|Topic|RELATED_TO
327|Hipaa Privacy Rules|Topic|Patient Privacy|Topic|RELATED_TO
327|Clinical Documentation Extraction|Topic|Patient Cohort Development|Topic|RELATED_TO
327|Prevalence Of Ra|Topic|Study Population|Topic|RELATED_TO
327|De-Identification Of Phi|Topic|Patient Privacy|Topic|RELATED_TO
327|Clinical Study Planning|Topic|Clinical Trials|Topic|RELATED_TO
328|Immersive Virtual Reality|Topic|Cognitive Neuroscience|Topic|RELATED_TO
328|Vr Induced Adverse Symptoms And Effects|Topic|Health And Safety Standards|Topic|RELATED_TO
328|Vr Induced Adverse Symptoms And Effects|Topic|Scientific Results|Topic|RELATED_TO
328|New Generation Hmds|Topic|Vr Induced Adverse Symptoms And Effects|Topic|RELATED_TO
328|Commercial Versions Of Hmds|Topic|Adverse Symptomatology|Topic|RELATED_TO
328|Technological Competency|Topic|Neuroscientific Results|Topic|RELATED_TO
328|Meta-Analysis Of Vr Studies|Topic|New Generation Hmds|Topic|DISCUSSES
328|Technological Systematic Literature|Topic|Ergonomic Interactions|Topic|DISCUSSES
328|Panagiotis Kourtesis|Author|Technological Competency|Topic|AUTHORED
328|Simona Collina|Author|Technological Competency|Topic|AUTHORED
328|Leonidas A. A. Doumas|Author|Technological Competency|Topic|AUTHORED
328|Sarah E. Macpherson|Author|Technological Competency|Topic|AUTHORED
329|Adaptive Allocation Theory In Clinical Trials|Paper|Adaptive Designs|Topic|DISCUSSES
329|Adaptive Allocation Theory In Clinical Trials|Paper|Play-The-Winner Rule|Topic|DISCUSSES
329|Adaptive Allocation Theory In Clinical Trials|Paper|Markov Chain Model|Topic|DISCUSSES
329|Adaptive Allocation Theory In Clinical Trials|Paper|Randomized Play-The-Winner Rule|Topic|DISCUSSES
329|Adaptive Allocation Theory In Clinical Trials|Paper|Urn Models|Topic|DISCUSSES
329|Adaptive Allocation Theory In Clinical Trials|Paper|Drop-The-Loser Rule|Topic|DISCUSSES
329|Adaptive Allocation Theory In Clinical Trials|Paper|Doubly Biased Coin Adaptive Design|Topic|DISCUSSES
329|Adaptive Allocation Theory In Clinical Trials|Paper|Asymptotic Theories|Topic|DISCUSSES
329|Adaptive Allocation Theory In Clinical Trials|Paper|Delayed Responses|Topic|DISCUSSES
329|Adaptive Allocation Theory In Clinical Trials|Paper|Power And Variability Comparison|Topic|DISCUSSES
330|Application Of The Signature Method To Pattern Recognition In The Cequel Clinical Trial|Paper|A. B. Kormilitzin|Author|AUTHORED
330|Application Of The Signature Method To Pattern Recognition In The Cequel Clinical Trial|Paper|K. E. A. Saunders|Author|AUTHORED
330|Application Of The Signature Method To Pattern Recognition In The Cequel Clinical Trial|Paper|P. J. Harrison|Author|AUTHORED
330|Application Of The Signature Method To Pattern Recognition In The Cequel Clinical Trial|Paper|J. R. Geddes|Author|AUTHORED
330|Application Of The Signature Method To Pattern Recognition In The Cequel Clinical Trial|Paper|T. J. Lyons|Author|AUTHORED
331|Group Sequential Clinical Trial Designs For Normally Distributed Outcome Variables|Paper|Michael Grayling|Author|AUTHORED
331|Group Sequential Clinical Trial Designs For Normally Distributed Outcome Variables|Paper|James Wason|Author|AUTHORED
331|Group Sequential Clinical Trial Designs For Normally Distributed Outcome Variables|Paper|Adrian Mander|Author|AUTHORED
332|Itzhaky Et Al|Paper|Statistical Methods|Topic|DISCUSSES
333|Aducanumab|Topic|Tommaso Costa|Author|AUTHORED
333|Aducanumab|Topic|Franco Cauda|Author|AUTHORED
334|Adaptive Experiments And A Rigorous Framework For Type I Error Verification And Computational Experiment Design|Paper|Adaptive Experiment Design|Topic|RELATED_TO
334|Adaptive Experiments And A Rigorous Framework For Type I Error Verification And Computational Experiment Design|Paper|Clinical Trial Designs|Topic|RELATED_TO
334|Adaptive Experiments And A Rigorous Framework For Type I Error Verification And Computational Experiment Design|Paper|Multi-Armed Bandit Theory|Topic|RELATED_TO
334|Adaptive Experiments And A Rigorous Framework For Type I Error Verification And Computational Experiment Design|Paper|Bandit And Covariate Processes|Topic|RELATED_TO
334|Adaptive Experiments And A Rigorous Framework For Type I Error Verification And Computational Experiment Design|Paper|Simulation-Based Verification|Topic|RELATED_TO
334|Michael Sklar|Author|Adaptive Experiments And A Rigorous Framework For Type I Error Verification And Computational Experiment Design|Paper|AUTHORED
335|Robust Variance Estimation For Covariate-Adjusted Unconditional Treatment Effect In Randomized Clinical Trials With Binary Outcomes|Paper|Ting Ye|Author|AUTHORED
335|Robust Variance Estimation For Covariate-Adjusted Unconditional Treatment Effect In Randomized Clinical Trials With Binary Outcomes|Paper|Marlena Bannick|Author|AUTHORED
335|Robust Variance Estimation For Covariate-Adjusted Unconditional Treatment Effect In Randomized Clinical Trials With Binary Outcomes|Paper|Yanyao Yi|Author|AUTHORED
335|Robust Variance Estimation For Covariate-Adjusted Unconditional Treatment Effect In Randomized Clinical Trials With Binary Outcomes|Paper|Jun Shao|Author|AUTHORED
336|Drug Supply Chain Optimization For Adaptive Clinical Trials|Paper|Jincheng Pang|Author|AUTHORED
336|Drug Supply Chain Optimization For Adaptive Clinical Trials|Paper|Hong Yan|Author|AUTHORED
336|Drug Supply Chain Optimization For Adaptive Clinical Trials|Paper|Zoe Hua|Author|AUTHORED
337|Nph2Ph-Transform|Topic|Sean M. Devlin|Author|AUTHORED
337|Nph2Ph-Transform|Topic|John O'Quigley|Author|AUTHORED
338|Uncertainty Quantification On Clinical Trial Outcome Prediction|Paper|Hierarchical Interaction Network (Hint)|Topic|RELATED_TO
338|Uncertainty Quantification On Clinical Trial Outcome Prediction|Paper|Selective Classification|Topic|RELATED_TO
339|The Power Of A Large Clinical Trial|Topic|Low Recruitment, Follow-Up And Adherence Rates|Topic|RELATED_TO
339|External Pilot Trials|Topic|Definitive Trial|Topic|RELATED_TO
339|Hypothesis Test Of The Feasibility Of A Definitive Trial|Topic|Definitive Trial|Topic|RELATED_TO
339|Tiga-Cub|Paper|Hypothesis Test Of The Feasibility Of A Definitive Trial|Topic|DISCUSSES
340|Hptn 084|Topic|Long-Acting Cabotegravir|Topic|RELATED_TO
340|Hptn 084|Topic|Tenofovir Disoproxil Fumarate Plus Emtricitabine|Topic|RELATED_TO
340|Qijia He|Author|Hptn 084|Topic|AUTHORED
340|Fei Gao|Author|Hptn 084|Topic|AUTHORED
340|Oliver Dukes|Author|Hptn 084|Topic|AUTHORED
340|Sinead Delany-Moretlwe|Author|Hptn 084|Topic|AUTHORED
340|Bo Zhang|Author|Hptn 084|Topic|AUTHORED
341|Gated Group Sequential Design|Topic|Phase Ii/Iii Trial Design|Topic|RELATED_TO
341|Guanhong Miao|Author|Gated Group Sequential Design|Topic|AUTHORED
341|Jason J. Z. Liao|Author|Gated Group Sequential Design|Topic|AUTHORED
341|Jing Yang|Author|Gated Group Sequential Design|Topic|AUTHORED
341|Keaven Anderson|Author|Gated Group Sequential Design|Topic|AUTHORED
342|Three-Arm Non-Inferiority Trials|Topic|Placebo Group|Topic|RELATED_TO
342|Three-Arm Non-Inferiority Trials|Topic|Koch-Röhmel Design|Topic|RELATED_TO
342|Koch-Röhmel Design|Topic|Non-Inferiority|Topic|RELATED_TO
342|Koch-Röhmel Design|Topic|Assay Sensitivity|Topic|RELATED_TO
342|Martin Scharpenberg|Author|Non-Inferiority|Topic|AUTHORED
342|Werner Brannath|Author|Non-Inferiority|Topic|AUTHORED
342|Non-Inferiority|Topic|Superiority To Placebo|Topic|RELATED_TO
342|Non-Inferiority|Topic|$	Heta$-Superiority|Topic|RELATED_TO
342|Non-Inferiority|Topic|Simultaneous Confidence Intervals|Topic|RELATED_TO
342|Simultaneous Confidence Intervals|Topic|Clinical Trial Example|Topic|RELATED_TO
343|Oncology Clinical Trials|Topic|Master Protocols|Topic|RELATED_TO
343|Master Protocols|Topic|External Controls|Topic|RELATED_TO
343|Jie Chen|Author|Master Protocols|Topic|AUTHORED
343|Xiaoyun|Author|Master Protocols|Topic|AUTHORED
343|Li|Author|Master Protocols|Topic|AUTHORED
343|Chengxing|Author|Master Protocols|Topic|AUTHORED
343|Lu|Author|Master Protocols|Topic|AUTHORED
343|Sammy Yuan|Author|Master Protocols|Topic|AUTHORED
343|Godwin Yung|Author|Master Protocols|Topic|AUTHORED
343|Jingjing Ye|Author|Master Protocols|Topic|AUTHORED
343|Hong Tian|Author|Master Protocols|Topic|AUTHORED
343|Jianchang Lin|Author|Master Protocols|Topic|AUTHORED
344|Non-Inferiority Trials|Topic|Estimands Framework|Topic|RELATED_TO
344|Katy E Morgan|Author|Non-Inferiority Trials|Topic|AUTHORED
344|Ian R White|Author|Non-Inferiority Trials|Topic|AUTHORED
344|Clémence Leyrat|Author|Non-Inferiority Trials|Topic|AUTHORED
344|Simon Stanworth|Author|Non-Inferiority Trials|Topic|AUTHORED
344|Brennan C Kahan|Author|Non-Inferiority Trials|Topic|AUTHORED
344|Per Protocol Analyses|Topic|Estimands Framework|Topic|RELATED_TO
344|Inverse Probability Weighting|Topic|Hypothetical Estimand|Topic|RELATED_TO
344|Instrumental Variable Approaches|Topic|Hypothetical Estimand|Topic|RELATED_TO
345|Bayesian Trial Designs|Topic|Frequentist Type I Error Rate|Topic|RELATED_TO
345|2-Arm Superiority Trial|Topic|Dichotomous Outcomes|Topic|RELATED_TO
345|False Discovery Probability (Fdp)|Topic|False Futility Probability (Ffp)|Topic|RELATED_TO
345|Elja Arjas|Author|Bayesian Trial Designs|Topic|AUTHORED
345|Dario Gasbarra|Author|Bayesian Trial Designs|Topic|AUTHORED
346|Algorithms For Multi-Armed Bandit Problems|Paper|Volodymyr Kuleshov|Author|AUTHORED
346|Algorithms For Multi-Armed Bandit Problems|Paper|Doina Precup|Author|AUTHORED
346|Algorithms For Multi-Armed Bandit Problems|Paper|Multi-Armed Bandit Algorithms|Topic|RELATED_TO
346|Algorithms For Multi-Armed Bandit Problems|Paper|Clinical Trials|Topic|RELATED_TO
347|Prior Information Incorporation|Topic|Nuisance Parameter|Topic|RELATED_TO
347|Prior Information Incorporation|Topic|Bayesian Meta-Analytic-Predictive Approach|Topic|RELATED_TO
347|Prior Information Incorporation|Topic|Simulation Study|Topic|RELATED_TO
347|Simulation Study|Topic|Nuisance Parameter|Topic|DISCUSSES
347|Tobias Mütze|Author|Prior Information Incorporation|Topic|AUTHORED
347|Heinz Schmidli|Author|Prior Information Incorporation|Topic|AUTHORED
347|Tim Friede|Author|Prior Information Incorporation|Topic|AUTHORED
348|Graphical Approaches For The Control Of Generalised Error Rates|Paper|David S. Robertson|Author|AUTHORED
348|Graphical Approaches For The Control Of Generalised Error Rates|Paper|James M. S. Wason|Author|AUTHORED
348|Graphical Approaches For The Control Of Generalised Error Rates|Paper|Frank Bretz|Author|AUTHORED
349|Clinical Research|Topic|Ethical And Scientific Integrity|Topic|RELATED_TO
349|Human Lives|Topic|Ethical And Scientific Integrity|Topic|RELATED_TO
349|Economic Incentives|Topic|Conflicts Of Interest|Topic|RELATED_TO
349|Investigators|Topic|Unfavorable Results|Topic|RELATED_TO
349|Investigators|Topic|Data Tampering|Topic|RELATED_TO
349|Clinical Trial Results|Topic|P-Values|Topic|RELATED_TO
349|Phase Ii Drug Trials|Topic|Clinicaltrials.Gov Registry|Topic|RELATED_TO
349|Phase Iii Drug Trials|Topic|Clinicaltrials.Gov Registry|Topic|RELATED_TO
349|5% Threshold|Topic|Significant Results|Topic|RELATED_TO
349|Density Discontinuity Test|Topic|5% Threshold|Topic|RELATED_TO
349|Early Favorable Results|Topic|Selective Continuation|Topic|RELATED_TO
349|Jérôme Adda|Author|Clinical Trial Results|Topic|AUTHORED
349|Christian Decker|Author|Clinical Trial Results|Topic|AUTHORED
349|Marco Ottaviani|Author|Clinical Trial Results|Topic|AUTHORED
350|Estimating Causal Effects From Randomized Experiments|Topic|Clinical Research|Topic|RELATED_TO
350|Reducing The Statistical Uncertainty|Topic|Statistical Uncertainty|Topic|DISCUSSES
350|Historical Data|Topic|Prognostic Model|Topic|RELATED_TO
350|Prognostic Model|Topic|Treatment Effect|Topic|DISCUSSES
350|Treatment Effect|Topic|Linear Regression|Topic|DISCUSSES
350|Alzheimer'S Disease Clinical Trial|Topic|Prognostic Model|Topic|DISCUSSES
350|Alejandro Schuler|Author|Estimating Causal Effects From Randomized Experiments|Topic|AUTHORED
350|David Walsh|Author|Estimating Causal Effects From Randomized Experiments|Topic|AUTHORED
350|Diana Hall|Author|Estimating Causal Effects From Randomized Experiments|Topic|AUTHORED
350|Jon Walsh|Author|Estimating Causal Effects From Randomized Experiments|Topic|AUTHORED
350|Charles Fisher|Author|Estimating Causal Effects From Randomized Experiments|Topic|AUTHORED
351|Sent2Span: Span Detection For Pico Extraction In The Biomedical Text Without Span Annotations|Paper|Shifeng Liu|Author|AUTHORED
351|Sent2Span: Span Detection For Pico Extraction In The Biomedical Text Without Span Annotations|Paper|Yifang Sun|Author|AUTHORED
351|Sent2Span: Span Detection For Pico Extraction In The Biomedical Text Without Span Annotations|Paper|Bing Li|Author|AUTHORED
351|Sent2Span: Span Detection For Pico Extraction In The Biomedical Text Without Span Annotations|Paper|Wei Wang|Author|AUTHORED
351|Sent2Span: Span Detection For Pico Extraction In The Biomedical Text Without Span Annotations|Paper|Florence T. Bourgeois|Author|AUTHORED
351|Sent2Span: Span Detection For Pico Extraction In The Biomedical Text Without Span Annotations|Paper|Adam G. Dunn|Author|AUTHORED
351|Pico Span Detection|Topic|Sent2Span: Span Detection For Pico Extraction In The Biomedical Text Without Span Annotations|Paper|RELATED_TO
352|A Bayesian Precision Response-Adaptive Phase Ii Clinical Trial Design For Radiotherapies With Competing Risk Survival Outcomes|Paper|Radiotherapy|Topic|DISCUSSES
352|A Bayesian Precision Response-Adaptive Phase Ii Clinical Trial Design For Radiotherapies With Competing Risk Survival Outcomes|Paper|Competing Risk Survival Outcomes|Topic|DISCUSSES
353|Factive|Topic|Hta|Topic|RELATED_TO
353|Cornelia Dunger-Baldauf|Author|Factive|Topic|AUTHORED
353|Rob Hemmings|Author|Factive|Topic|AUTHORED
353|Frank Bretz|Author|Factive|Topic|AUTHORED
353|Byron Jones|Author|Factive|Topic|AUTHORED
353|Anja Schiel|Author|Factive|Topic|AUTHORED
353|Chris Holmes|Author|Factive|Topic|AUTHORED
354|Broadening Eligibility Criteria In Cancer Trials|Topic|Precision Dose-Finding Design|Topic|RELATED_TO
354|Precision Dose-Finding Design|Topic|Phase I Cancer Clinical Trials|Topic|RELATED_TO
354|Rebecca B. Silva|Author|Precision Dose-Finding Design|Topic|AUTHORED
354|Bin Cheng|Author|Precision Dose-Finding Design|Topic|AUTHORED
354|Richard D. Carvajal|Author|Precision Dose-Finding Design|Topic|AUTHORED
354|Shing M. Lee|Author|Precision Dose-Finding Design|Topic|AUTHORED
355|Precision Medicine|Topic|Individual Heterogeneity|Topic|RELATED_TO
355|Treatment Effect Heterogeneity|Topic|Statistical Methods|Topic|RELATED_TO
355|Patient Stratification|Topic|Multi-Arm Trial|Topic|RELATED_TO
355|Bayesian Nonparametric Framework|Topic|Bayesian Additive Regression Trees (Bart)|Topic|RELATED_TO
355|Bayesian Nonparametric Framework|Topic|Bayesian Profile Regression|Topic|RELATED_TO
355|Variable Selection Procedure|Topic|Patient Stratification|Topic|RELATED_TO
355|Simulation Studies|Topic|Uk-Based Multi-Arm Blood Donation Trial|Topic|RELATED_TO
355|Yuejia Xu|Author|Patient Stratification|Topic|AUTHORED
355|Angela M. Wood|Author|Patient Stratification|Topic|AUTHORED
355|Brian D. M. Tom|Author|Patient Stratification|Topic|AUTHORED
356|Rct|Topic|Cross-Over Trial|Topic|RELATED_TO
356|Secrets|Topic|Synthetic Intervention|Topic|RELATED_TO
356|Secrets|Topic|Rct|Topic|DISCUSSES
356|Sayeri Lala|Author|Secrets|Topic|AUTHORED
356|Niraj K. Jha|Author|Secrets|Topic|AUTHORED
357|Biomarker-Guided Clinical Trials|Topic|Precision Medicine|Topic|RELATED_TO
357|Mixture Distributions|Topic|Biomarker-Guided Clinical Trials|Topic|RELATED_TO
357|Detest|Topic|Mixture Distributions|Topic|AUTHORED
357|Hong Zhang|Author|Detest|Topic|AUTHORED
357|Jie Pu|Author|Detest|Topic|AUTHORED
357|Shibing Deng|Author|Detest|Topic|AUTHORED
357|Satrajit Roychoudhury|Author|Detest|Topic|AUTHORED
357|Haitao Chu|Author|Detest|Topic|AUTHORED
357|Douglas Robinson|Author|Detest|Topic|AUTHORED
358|Chauhan Weighted Trajectory Analysis|Topic|Kaplan-Meier Analysis|Topic|RELATED_TO
358|Chauhan Weighted Trajectory Analysis|Topic|Progression Free Survival|Topic|RELATED_TO
358|Chauhan Weighted Trajectory Analysis|Topic|Overall Survival|Topic|RELATED_TO
358|Utkarsh Chauhan|Author|Chauhan Weighted Trajectory Analysis|Topic|AUTHORED
358|Daylen Mackey|Author|Chauhan Weighted Trajectory Analysis|Topic|AUTHORED
358|John R. Mackey|Author|Chauhan Weighted Trajectory Analysis|Topic|AUTHORED
359|Oncology|Topic|Phase Ii Trials|Topic|RELATED_TO
359|Phase Ii Trials|Topic|Clinical Development Plans|Topic|RELATED_TO
359|Phase Ii Trials|Topic|Potent Agents|Topic|RELATED_TO
359|Phase Ii Trials|Topic|Short-Term Treatment Efficacy|Topic|RELATED_TO
359|Response Evaluation Criteria In Solid Tumors|Topic|Phase Ii Trials|Topic|RELATED_TO
359|Generalized Bayes' Theorem|Topic|Phase Ii Trials|Topic|RELATED_TO
359|Takuya Yoshimoto|Author|Optimal Bayesian Predictive Probability For Delayed Response In Single-Arm Clinical Trials With Binary Efficacy Outcome|Paper|AUTHORED
359|Satoru Shinoda|Author|Optimal Bayesian Predictive Probability For Delayed Response In Single-Arm Clinical Trials With Binary Efficacy Outcome|Paper|AUTHORED
359|Kouji Yamamoto|Author|Optimal Bayesian Predictive Probability For Delayed Response In Single-Arm Clinical Trials With Binary Efficacy Outcome|Paper|AUTHORED
359|Kouji Tahata|Author|Optimal Bayesian Predictive Probability For Delayed Response In Single-Arm Clinical Trials With Binary Efficacy Outcome|Paper|AUTHORED
360|Mexa-Ctp|Topic|Yiqing Zhang|Author|AUTHORED
360|Mexa-Ctp|Topic|Xiaozhong Liu|Author|AUTHORED
360|Mexa-Ctp|Topic|Fabricio Murai|Author|AUTHORED
360|Mexa-Ctp|Topic|Clinical Trials|Topic|RELATED_TO
360|Mexa-Ctp|Topic|Deep Learning|Topic|RELATED_TO
360|Mexa-Ctp|Topic|Trial Outcome Prediction (Top)|Topic|RELATED_TO
361|Ultrasonic Actuation Of A Fine-Needle Improves Biopsy Yield|Paper|Emanuele Perra|Author|AUTHORED
361|Ultrasonic Actuation Of A Fine-Needle Improves Biopsy Yield|Paper|Eetu Lampsijärvi|Author|AUTHORED
361|Ultrasonic Actuation Of A Fine-Needle Improves Biopsy Yield|Paper|Gonçalo Barreto|Author|AUTHORED
361|Ultrasonic Actuation Of A Fine-Needle Improves Biopsy Yield|Paper|Muhammad Arif|Author|AUTHORED
361|Ultrasonic Actuation Of A Fine-Needle Improves Biopsy Yield|Paper|Tuomas Puranen|Author|AUTHORED
361|Ultrasonic Actuation Of A Fine-Needle Improves Biopsy Yield|Paper|Edward Hæggström|Author|AUTHORED
361|Ultrasonic Actuation Of A Fine-Needle Improves Biopsy Yield|Paper|Kenneth P. H. Pritzker|Author|AUTHORED
361|Ultrasonic Actuation Of A Fine-Needle Improves Biopsy Yield|Paper|Heikki J. Nieminen|Author|AUTHORED
361|Ultrasonic Actuation Of A Fine-Needle Improves Biopsy Yield|Paper|Sonolancet|Topic|RELATED_TO
362|Baysize|Topic|Xiaolei Lin|Author|AUTHORED
362|Baysize|Topic|Jiaying Lyu|Author|AUTHORED
362|Baysize|Topic|Shijie Yuan|Author|AUTHORED
362|Baysize|Topic|Sue-Jane Wang|Author|AUTHORED
362|Baysize|Topic|Yuan Ji|Author|AUTHORED
363|Treatments For Pregestational Chronic Conditions During Pregnancy: Emulating A Target Trial With A Treatment Decision Design|Paper|Causal Effects Of Early-Pregnancy Pharmacotherapies On Pregnancy Outcomes|Topic|DISCUSSES
363|Treatments For Pregestational Chronic Conditions During Pregnancy: Emulating A Target Trial With A Treatment Decision Design|Paper|Target Trial|Topic|DISCUSSES
363|Treatments For Pregestational Chronic Conditions During Pregnancy: Emulating A Target Trial With A Treatment Decision Design|Paper|Treatment Decision Design|Topic|DISCUSSES
363|Treatments For Pregestational Chronic Conditions During Pregnancy: Emulating A Target Trial With A Treatment Decision Design|Paper|Antidepressant Use For Pre-Existing Depressive Disorder|Topic|DISCUSSES
363|Treatments For Pregestational Chronic Conditions During Pregnancy: Emulating A Target Trial With A Treatment Decision Design|Paper|Antihypertensive Medication Use For Mild-To-Moderate Chronic Hypertension|Topic|DISCUSSES
363|Mollie E. Wood|Author|Treatments For Pregestational Chronic Conditions During Pregnancy: Emulating A Target Trial With A Treatment Decision Design|Paper|AUTHORED
363|Chase D. Latour|Author|Treatments For Pregestational Chronic Conditions During Pregnancy: Emulating A Target Trial With A Treatment Decision Design|Paper|AUTHORED
363|Lucia C. Petito|Author|Treatments For Pregestational Chronic Conditions During Pregnancy: Emulating A Target Trial With A Treatment Decision Design|Paper|AUTHORED
364|American Academy Of Clinical Neuropsychology|Author|Computerized Neuropsychological Assessment Devices|Topic|DISCUSSES
364|National Academy Of Neuropsychology|Author|Computerized Neuropsychological Assessment Devices|Topic|DISCUSSES
364|Vr Everyday Assessment Lab|Topic|Cognitive Neuroscience|Topic|RELATED_TO
364|Vr Everyday Assessment Lab|Topic|Neuropsychology|Topic|RELATED_TO
364|Panagiotis Kourtesis|Author|Vr Everyday Assessment Lab|Topic|AUTHORED
364|Sarah E. Macpherson|Author|Vr Everyday Assessment Lab|Topic|AUTHORED
365|Statistical Research Regarding Health-Related Quality Of Life (Hrqol)|Topic|Mixed Models From The Item Response Theory|Topic|RELATED_TO
365|Mixed Models From The Item Response Theory|Topic|Generalized Linear Models For Categorical Data|Topic|RELATED_TO
365|Generalized Linear Models For Categorical Data|Topic|Cancer Clinical Trials|Topic|RELATED_TO
365|Cancer Clinical Trials|Topic|Antoine Barbieri|Author|AUTHORED
365|Cancer Clinical Trials|Topic|Jean Peyhardi|Author|AUTHORED
365|Cancer Clinical Trials|Topic|Thierry Conroy|Author|AUTHORED
365|Cancer Clinical Trials|Topic|Sophie Gourgou|Author|AUTHORED
365|Cancer Clinical Trials|Topic|Christian Lavergne|Author|AUTHORED
365|Cancer Clinical Trials|Topic|Caroline Mollevi|Author|AUTHORED
366|Count Data And Recurrent Events In Clinical Trials|Topic|Negative Binomial Distributions|Topic|RELATED_TO
366|Negative Binomial Distributions|Topic|Group Sequential Designs|Topic|RELATED_TO
366|Group Sequential Designs|Topic|Wald Statistics|Topic|RELATED_TO
366|Group Sequential Designs|Topic|Maximum Likelihood Estimators|Topic|RELATED_TO
366|Group Sequential Designs|Topic|Asymptotic Normal Theory|Topic|RELATED_TO
366|Group Sequential Designs|Topic|Student'S T-Distribution|Topic|RELATED_TO
366|Group Sequential Designs|Topic|Resampling|Topic|RELATED_TO
366|Gscounts|Paper|Negative Binomial Distributions|Topic|AUTHORED
367|Prospective Registration Of Study Protocols In Clinical Trial Registries|Topic|Publication Bias|Topic|RELATED_TO
367|Publication Bias|Topic|Meta-Analysis|Topic|RELATED_TO
367|Sensitivity Analysis|Topic|Copas Selection Model|Topic|RELATED_TO
367|Funnel-Plot|Topic|Publication Bias|Topic|RELATED_TO
367|Trim-And-Fill Method|Topic|Publication Bias|Topic|RELATED_TO
367|Alternative Inference Procedure|Topic|Copas Selection Model|Topic|RELATED_TO
367|Simulation Study|Topic|Alternative Inference Procedure|Topic|RELATED_TO
367|Clinical Trial Registries|Topic|Copas Selection Model|Topic|RELATED_TO
367|Ao Huang|Author|Alternative Inference Procedure|Topic|AUTHORED
367|Sho Komukai|Author|Alternative Inference Procedure|Topic|AUTHORED
367|Tim Friede|Author|Alternative Inference Procedure|Topic|AUTHORED
367|Satoshi Hattori|Author|Alternative Inference Procedure|Topic|AUTHORED
368|Covid-19|Topic|Oncology Clinical Trials|Topic|RELATED_TO
368|Oncology Clinical Trials|Topic|Estimand Framework|Topic|RELATED_TO
368|Evgeny Degtyarev|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Kaspar Rufibach|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Yue Shentu|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Godwin Yung|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Michelle Casey|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Stefan Englert|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Feng Liu|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Yi Liu|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Oliver Sailer|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Jonathan Siegel|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Steven Sun|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Rui Tang|Author|Oncology Clinical Trials|Topic|AUTHORED
368|Jiangxiu Zhou|Author|Oncology Clinical Trials|Topic|AUTHORED
369|Long-Term Effect Estimation When Combining Clinical Trial And Observational Follow-Up Datasets|Paper|Combining Experimental And Observational Follow-Up Datasets|Topic|DISCUSSES
370|Concept Normalization|Topic|Text-Mining Pipeline|Topic|RELATED_TO
370|Bidirectional Encoder Representations From Transformers (Bert)|Topic|Biomedical Domain|Topic|RELATED_TO
370|Drug Discovery And Development|Topic|Clinical Trials|Topic|RELATED_TO
370|Zulfat Miftahutdinov|Author|Two-Stage Neural Approach|Topic|AUTHORED
370|Artur Kadurin|Author|Two-Stage Neural Approach|Topic|AUTHORED
370|Roman Kudrin|Author|Two-Stage Neural Approach|Topic|AUTHORED
370|Elena Tutubalina|Author|Two-Stage Neural Approach|Topic|AUTHORED
370|Two-Stage Neural Approach|Topic|Metric Learning Model|Topic|RELATED_TO
370|Metric Learning Model|Topic|Triplet Loss|Topic|RELATED_TO
370|Metric Learning Model|Topic|Vector Embeddings|Topic|RELATED_TO
370|Embedding Space|Topic|Clinical Trials|Topic|RELATED_TO
370|Dataset Of Abstracts|Topic|Real-World Dataset Of Trial Records|Topic|RELATED_TO
370|Drug And Disease Terminologies|Topic|Knowledge Transfer|Topic|RELATED_TO
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Lingjing Jiang|Author|AUTHORED
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Michael Rosenblum|Author|AUTHORED
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Yu Du|Author|AUTHORED
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Diabetes Clinical Trials|Topic|RELATED_TO
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Mmrm|Topic|RELATED_TO
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Glmm|Topic|RELATED_TO
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Tmle|Topic|RELATED_TO
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Longitudinal Continuous Outcome|Topic|RELATED_TO
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Longitudinal Binary Outcome|Topic|RELATED_TO
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Average Treatment Effect|Topic|RELATED_TO
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Missing Data Scenarios|Topic|RELATED_TO
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Real Data Sets|Topic|RELATED_TO
371|Using Targeted Maximum Likelihood Estimation To Estimate Treatment Effect With Longitudinal Continuous Or Binary Data: A Systematic Evaluation Of 28 Diabetes Clinical Trials|Paper|Cumbersome Covariance Fitting Procedure|Topic|RELATED_TO
372|Confirmatory Clinical Trials|Topic|Survival Outcomes|Topic|RELATED_TO
372|Confirmatory Clinical Trials|Topic|Interim Analyses|Topic|RELATED_TO
372|Survival Outcomes|Topic|Log Rank Test|Topic|RELATED_TO
372|Survival Outcomes|Topic|Cox Regression Model|Topic|RELATED_TO
372|Log Rank Test|Topic|Proportional Hazards Assumption|Topic|RELATED_TO
372|Cox Regression Model|Topic|Proportional Hazards Assumption|Topic|RELATED_TO
372|Proportional Hazards Assumption|Topic|Type I Error Rate|Topic|RELATED_TO
372|Proportional Hazards Assumption|Topic|Loss Of Power|Topic|RELATED_TO
372|Immunotherapy|Topic|Chemotherapy|Topic|RELATED_TO
372|Group Sequential Tests|Topic|Survival Curves|Topic|RELATED_TO
372|Group Sequential Tests|Topic|Covariate Adjustment|Topic|RELATED_TO
372|Test Statistics|Topic|Marginal Comparisons|Topic|RELATED_TO
372|Clinical Trial Dataset|Topic|Blood And Marrow Transplant Clinical Trials Network 1101 Trial|Topic|RELATED_TO
372|Peter Zhang|Author|Covariate-Adjusted Group Sequential Comparisons Of Survival Probabilities|Paper|AUTHORED
372|Brent Logan|Author|Covariate-Adjusted Group Sequential Comparisons Of Survival Probabilities|Paper|AUTHORED
372|Michael Martens|Author|Covariate-Adjusted Group Sequential Comparisons Of Survival Probabilities|Paper|AUTHORED
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Madhusudan Ghosh|Author|AUTHORED
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Shrimon Mukherjee|Author|AUTHORED
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Asmit Ganguly|Author|AUTHORED
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Partha Basuchowdhuri|Author|AUTHORED
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Sudip Kumar Naskar|Author|AUTHORED
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Debasis Ganguly|Author|AUTHORED
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Pico|Topic|RELATED_TO
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Clinical Trial Documents|Topic|RELATED_TO
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Large Language Models|Topic|RELATED_TO
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|In-Context Learning|Topic|RELATED_TO
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Instruction Tuning|Topic|RELATED_TO
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Low Rank Adaptation|Topic|RELATED_TO
373|Alpapico: Extraction Of Pico Frames From Clinical Trial Documents Using Llms|Paper|Ebm-Nlp Datasets|Topic|RELATED_TO
374|Fragility Index For Time-To-Event Endpoints In Single-Arm Clinical Trials|Paper|Arnab Kumar Maity|Author|AUTHORED
374|Fragility Index For Time-To-Event Endpoints In Single-Arm Clinical Trials|Paper|Jhanvi Garg|Author|AUTHORED
374|Fragility Index For Time-To-Event Endpoints In Single-Arm Clinical Trials|Paper|Cynthia Basu|Author|AUTHORED
375|A Simple Cellular Automaton Model For Influenza A Viral Infections|Paper|Catherine Beauchemin|Author|AUTHORED
375|A Simple Cellular Automaton Model For Influenza A Viral Infections|Paper|John Samuel|Author|AUTHORED
375|A Simple Cellular Automaton Model For Influenza A Viral Infections|Paper|Jack Tuszynski|Author|AUTHORED
375|A Simple Cellular Automaton Model For Influenza A Viral Infections|Paper|Viral Kinetics|Topic|RELATED_TO
375|A Simple Cellular Automaton Model For Influenza A Viral Infections|Paper|Influenza A|Topic|RELATED_TO
376|Systemic Lupus Erythematosus (Sle)|Topic|Natural Igm Autoantibodies|Topic|RELATED_TO
376|Systemic Lupus Erythematosus (Sle)|Topic|Igm Responses|Topic|RELATED_TO
376|Systemic Lupus Erythematosus (Sle)|Topic|Hla-Drb1*03|Topic|RELATED_TO
376|Systemic Lupus Erythematosus (Sle)|Topic|Cardiovascular Disease|Topic|RELATED_TO
376|Caroline Gronwall|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Uta Hardt|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Johanna T. Gustafsson|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Kerstin Elvin|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Kerstin Jensen-Urstad|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Marika Kvarnstrom|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Giorgia Grosso|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Johan Ronnelid|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Leonid Padyukov|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Iva Gunnarsson|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Gregg J. Silverman|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
376|Elisabet Svenungsson|Author|Systemic Lupus Erythematosus (Sle)|Topic|AUTHORED
377|Head And Neck Squamous Cell Carcinoma|Topic|Alcohol|Topic|RELATED_TO
377|Head And Neck Squamous Cell Carcinoma|Topic|Tobacco|Topic|RELATED_TO
377|Head And Neck Squamous Cell Carcinoma|Topic|Human Papillomavirus|Topic|RELATED_TO
377|Human Papillomavirus|Topic|Hpv Status|Topic|RELATED_TO
377|Triplet-Ranking Loss Function|Topic|Hpv Detection|Topic|RELATED_TO
377|Multiple Instance Learning Pipeline|Topic|Hpv Detection|Topic|RELATED_TO
377|Tumour Microenvironment Profiling|Topic|T Cells|Topic|RELATED_TO
377|Tumour Microenvironment Profiling|Topic|Macrophages|Topic|RELATED_TO
377|Tumour Microenvironment Profiling|Topic|Fibroblast|Topic|RELATED_TO
377|Gene Expression Profiles|Topic|Human Papillomavirus|Topic|RELATED_TO
377|Ruoyu Wang|Author|Triplet-Ranking Loss Function|Topic|AUTHORED
377|Syed Ali Khurram|Author|Triplet-Ranking Loss Function|Topic|AUTHORED
377|Amina Asif|Author|Triplet-Ranking Loss Function|Topic|AUTHORED
377|Lawrence Young|Author|Triplet-Ranking Loss Function|Topic|AUTHORED
377|Nasir Rajpoot|Author|Triplet-Ranking Loss Function|Topic|AUTHORED
378|Model-Based Recursive Partitioning (Mob)|Topic|Subgroup Identification|Topic|RELATED_TO
378|Metamob|Topic|Subgroup Identification|Topic|RELATED_TO
378|Metamob|Topic|Generalized Mixed-Effects Model Tree (Glmm Tree)|Topic|RELATED_TO
378|Randomized Controlled Clinical Trials|Topic|Metamob|Topic|RELATED_TO
378|Cynthia Huber|Author|Subgroup Identification|Topic|AUTHORED
378|Norbert Benda|Author|Subgroup Identification|Topic|AUTHORED
378|Tim Friede|Author|Subgroup Identification|Topic|AUTHORED
379|Vaccine Efficacy For Binary Post-Infection Outcomes Under Misclassification Without Monotonicity|Paper|Regulatory Approval|Topic|DISCUSSES
379|Vaccine Efficacy For Binary Post-Infection Outcomes Under Misclassification Without Monotonicity|Paper|Pharmaceutical Companies|Topic|DISCUSSES
379|Vaccine Efficacy For Binary Post-Infection Outcomes Under Misclassification Without Monotonicity|Paper|Vaccines|Topic|DISCUSSES
379|Vaccine Efficacy For Binary Post-Infection Outcomes Under Misclassification Without Monotonicity|Paper|Principal Stratification|Topic|DISCUSSES
379|Vaccine Efficacy For Binary Post-Infection Outcomes Under Misclassification Without Monotonicity|Paper|Causal Effect|Topic|DISCUSSES
379|Vaccine Efficacy For Binary Post-Infection Outcomes Under Misclassification Without Monotonicity|Paper|Vaccine Efficacy|Topic|DISCUSSES
379|Vaccine Efficacy For Binary Post-Infection Outcomes Under Misclassification Without Monotonicity|Paper|Clinical Trial Settings|Topic|DISCUSSES
379|Vaccine Efficacy For Binary Post-Infection Outcomes Under Misclassification Without Monotonicity|Paper|Measurement Error|Topic|DISCUSSES
379|Vaccine Efficacy For Binary Post-Infection Outcomes Under Misclassification Without Monotonicity|Paper|Multi-Arm Clinical Trials|Topic|DISCUSSES
380|Oncology Dose Finding Using Approximate Bayesian Computation Design|Paper|Huaqing Jin|Author|AUTHORED
380|Oncology Dose Finding Using Approximate Bayesian Computation Design|Paper|Wenbin Du|Author|AUTHORED
380|Oncology Dose Finding Using Approximate Bayesian Computation Design|Paper|Guosheng Yin|Author|AUTHORED
381|Information-Adaptive Clinical Trials: A Selective Recruitment Design|Paper|Clinical Trials|Topic|RELATED_TO
381|Information-Adaptive Clinical Trials: A Selective Recruitment Design|Paper|Time-To-Event Outcomes|Topic|RELATED_TO
381|Information-Adaptive Clinical Trials: A Selective Recruitment Design|Paper|Covariates|Topic|RELATED_TO
381|Information-Adaptive Clinical Trials: A Selective Recruitment Design|Paper|Biomarkers|Topic|RELATED_TO
381|Information-Adaptive Clinical Trials: A Selective Recruitment Design|Paper|Proportional Hazards Model|Topic|RELATED_TO
381|Information-Adaptive Clinical Trials: A Selective Recruitment Design|Paper|Expected Entropy|Topic|RELATED_TO
381|Information-Adaptive Clinical Trials: A Selective Recruitment Design|Paper|German Breast Cancer Study Group|Topic|RELATED_TO
381|Information-Adaptive Clinical Trials: A Selective Recruitment Design|Paper|Biomarker Validation Trial|Topic|RELATED_TO
382|Combining Survival Trials Using Aggregate Data Based On Misspecified Models|Paper|Tinghui Yu|Author|AUTHORED
382|Combining Survival Trials Using Aggregate Data Based On Misspecified Models|Paper|Yabing Mai|Author|AUTHORED
382|Combining Survival Trials Using Aggregate Data Based On Misspecified Models|Paper|Sherry Liu|Author|AUTHORED
382|Combining Survival Trials Using Aggregate Data Based On Misspecified Models|Paper|Xiaofei Hu|Author|AUTHORED
383|Stopped Negative Binomial Distribution|Topic|Michelle Deveaux|Author|AUTHORED
383|Stopped Negative Binomial Distribution|Topic|Michael J. Kane|Author|AUTHORED
383|Stopped Negative Binomial Distribution|Topic|Daniel Zelterman|Author|AUTHORED
384|Selective Recruitment Designs|Topic|Information-Adaptive Design|Topic|RELATED_TO
384|Statistical Information Methods|Topic|Selective Recruitment Designs|Topic|DISCUSSES
384|James E. Barrett|Author|Statistical Information Methods|Topic|AUTHORED
385|Aaa|Topic|Jiaying Lyu|Author|AUTHORED
385|Aaa|Topic|Yuan Ji|Author|AUTHORED
385|Aaa|Topic|Naiqing Zhao|Author|AUTHORED
385|Aaa|Topic|Daniel V. T. Catenacci|Author|AUTHORED
386|Power Priors Based On Multiple Historical Studies For Binary Outcomes|Paper|Clinical Trial|Topic|DISCUSSES
386|Power Priors Based On Multiple Historical Studies For Binary Outcomes|Paper|Antibiotics|Topic|DISCUSSES
386|Power Priors Based On Multiple Historical Studies For Binary Outcomes|Paper|Empirical Bayes|Topic|DISCUSSES
386|Power Priors Based On Multiple Historical Studies For Binary Outcomes|Paper|Bayesian Approaches|Topic|DISCUSSES
386|Power Priors Based On Multiple Historical Studies For Binary Outcomes|Paper|Historical Trials|Topic|DISCUSSES
386|Power Priors Based On Multiple Historical Studies For Binary Outcomes|Paper|Drug Resistant Infections|Topic|DISCUSSES
387|Optimizing Interim Analysis Timing For Bayesian Adaptive Commensurate Designs|Paper|Xiao Wu|Author|AUTHORED
387|Optimizing Interim Analysis Timing For Bayesian Adaptive Commensurate Designs|Paper|Yi Xu|Author|AUTHORED
387|Optimizing Interim Analysis Timing For Bayesian Adaptive Commensurate Designs|Paper|Bradley P. Carlin|Author|AUTHORED
388|Recruitment Prediction Framework|Topic|Szymon Urbas|Author|AUTHORED
388|Recruitment Prediction Framework|Topic|Chris Sherlock|Author|AUTHORED
388|Recruitment Prediction Framework|Topic|Paul Metcalfe|Author|AUTHORED
388|Recruitment Prediction Framework|Topic|Inhomogeneous Poisson Process|Topic|RELATED_TO
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Covid-19 Pandemic|Topic|DISCUSSES
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|R. Daniel Meyer|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Bohdana Ratitch|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Marcel Wolbers|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Olga Marchenko|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Hui Quan|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Daniel Li|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Chrissie Fletcher|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Xin Li|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|David Wright|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Yue Shentu|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Stefan Englert|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Wei Shen|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Jyotirmoy Dey|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Thomas Liu|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Ming Zhou|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Norman Bohidar|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Peng-Liang Zhao|Author|AUTHORED
389|Statistical Issues And Recommendations For Clinical Trials Conducted During The Covid-19 Pandemic|Paper|Michael Hale|Author|AUTHORED
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Kaplan-Meier Curves|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Hazard Ratio|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Log-Rank Test|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Cox Proportional Hazard Model|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Non-Proportional Hazards|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Equivalence Trials|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Non-Inferiority Trials|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Parametric Framework|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Pointwise Confidence Bands|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Test Procedure|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Clinical Trial Example|Topic|DISCUSSES
390|Survival Analysis Under Non-Proportional Hazards: Investigating Non-Inferiority Or Equivalence In Time-To-Event Data|Paper|Simulation Results|Topic|DISCUSSES
391|Identifying Heterogeneous Treatment Effects In Randomized Controlled Trials|Topic|Erin Craig|Author|AUTHORED
391|Identifying Heterogeneous Treatment Effects In Randomized Controlled Trials|Topic|Donald A Redelmeier|Author|AUTHORED
391|Identifying Heterogeneous Treatment Effects In Randomized Controlled Trials|Topic|Robert J Tibshirani|Author|AUTHORED
392|Bayesian Prognostic Covariate Adjustment|Topic|David Walsh|Author|AUTHORED
392|Bayesian Prognostic Covariate Adjustment|Topic|Alejandro Schuler|Author|AUTHORED
392|Bayesian Prognostic Covariate Adjustment|Topic|Diana Hall|Author|AUTHORED
392|Bayesian Prognostic Covariate Adjustment|Topic|Jon Walsh|Author|AUTHORED
392|Bayesian Prognostic Covariate Adjustment|Topic|Charles Fisher|Author|AUTHORED
393|Bnt162B2 Mrna Covid-19 Vaccine Trial|Topic|Bayesian Design And Analysis|Topic|RELATED_TO
393|Bayesian Design And Analysis|Topic|Bayesian Statistics|Topic|RELATED_TO
393|Bayesian Statistics|Topic|Bayesian Credible Intervals|Topic|RELATED_TO
393|Bayesian Statistics|Topic|Confidence Intervals|Topic|RELATED_TO
393|Bayesian Statistics|Topic|Posterior Probabilities|Topic|RELATED_TO
393|Lessons Learned From The Bayesian Design And Analysis For The Bnt162B2 Covid-19 Vaccine Phase 3 Trial|Paper|Yuan Ji|Author|AUTHORED
393|Lessons Learned From The Bayesian Design And Analysis For The Bnt162B2 Covid-19 Vaccine Phase 3 Trial|Paper|Shijie Yuan|Author|AUTHORED
393|Bayesian Design And Analysis|Topic|Regulatory Decision Making|Topic|RELATED_TO
393|Bayesian Credible Intervals|Topic|Bi|Topic|RELATED_TO
393|Confidence Intervals|Topic|Ci|Topic|RELATED_TO
394|Multi-Armed Bandits|Topic|Model-Assisted Designs|Topic|RELATED_TO
394|Model-Assisted Designs|Topic|Dose-Finding Clinical Trials|Topic|RELATED_TO
394|Multi-Armed Bandits|Topic|Thompson Sampling|Topic|RELATED_TO
394|Thompson Sampling|Topic|Regularized Thompson Sampling|Topic|RELATED_TO
394|Thompson Sampling|Topic|Greedy Algorithm|Topic|RELATED_TO
394|Greedy Algorithm|Topic|Posterior Mean|Topic|RELATED_TO
394|Thompson Sampling|Topic|Posterior Median|Topic|RELATED_TO
394|Masahiro Kojima|Author|Multi-Armed Bandits|Topic|AUTHORED
394|Simulation Studies|Topic|Dose-Finding Clinical Trials|Topic|RELATED_TO
395|Priors From Envisioned Posterior Judgments: A Novel Elicitation Approach With Application To Bayesian Clinical Trials|Paper|Yongdong Ouyang|Author|AUTHORED
395|Priors From Envisioned Posterior Judgments: A Novel Elicitation Approach With Application To Bayesian Clinical Trials|Paper|Janice J Eng|Author|AUTHORED
395|Priors From Envisioned Posterior Judgments: A Novel Elicitation Approach With Application To Bayesian Clinical Trials|Paper|Denghuang Zhan|Author|AUTHORED
395|Priors From Envisioned Posterior Judgments: A Novel Elicitation Approach With Application To Bayesian Clinical Trials|Paper|Hubert Wong|Author|AUTHORED
396|Multiple Sclerosis|Topic|Andy A. Shen|Author|AUTHORED
396|Multiple Sclerosis|Topic|Aidan Mcloughlin|Author|AUTHORED
396|Multiple Sclerosis|Topic|Zoe Vernon|Author|AUTHORED
396|Multiple Sclerosis|Topic|Jonathan Lin|Author|AUTHORED
396|Multiple Sclerosis|Topic|Richard A. D. Carano|Author|AUTHORED
396|Multiple Sclerosis|Topic|Peter J. Bickel|Author|AUTHORED
396|Multiple Sclerosis|Topic|Zhuang Song|Author|AUTHORED
396|Multiple Sclerosis|Topic|Haiyan Huang|Author|AUTHORED
397|Handling Covariates In The Design Of Clinical Trials|Paper|Clinical Trial Design|Topic|DISCUSSES
397|Handling Covariates In The Design Of Clinical Trials|Paper|Stratification And Covariate-Adaptive Randomization|Topic|DISCUSSES
397|Handling Covariates In The Design Of Clinical Trials|Paper|Covariate-Adjusted Response-Adaptive Randomization|Topic|DISCUSSES
398|Hypothesis Tests Based On Linear Models|Topic|Organizations That Regulate Clinical Trials|Topic|RELATED_TO
398|Permutation Tests|Topic|Parametric Distributions|Topic|RELATED_TO
398|Analysis Of Covariance (Ancova)|Topic|Permutation Tests|Topic|RELATED_TO
398|Kellie Ottoboni|Author|An Empirical Comparison Of Parametric And Permutation Tests For Regression Analysis Of Randomized Experiments|Paper|AUTHORED
398|Fraser Lewis|Author|An Empirical Comparison Of Parametric And Permutation Tests For Regression Analysis Of Randomized Experiments|Paper|AUTHORED
398|Luigi Salmaso|Author|An Empirical Comparison Of Parametric And Permutation Tests For Regression Analysis Of Randomized Experiments|Paper|AUTHORED
398|Gastroesophageal Reflux Disease|Topic|An Empirical Comparison Of Parametric And Permutation Tests For Regression Analysis Of Randomized Experiments|Paper|RELATED_TO
399|Quantifying And Detecting Individual Level 'Always Survivor' Causal Effects Under 'Truncation By Death' And Censoring Through Time|Paper|Jaffer M. Zaidi|Author|AUTHORED
399|Quantifying And Detecting Individual Level 'Always Survivor' Causal Effects Under 'Truncation By Death' And Censoring Through Time|Paper|Eric J. Tchetgen Tchetgen|Author|AUTHORED
399|Quantifying And Detecting Individual Level 'Always Survivor' Causal Effects Under 'Truncation By Death' And Censoring Through Time|Paper|Tyler J. Vanderweele|Author|AUTHORED
400|Clinical Trial Records|Topic|Patients|Topic|RELATED_TO
400|Clinical Trial Records|Topic|Diseases|Topic|RELATED_TO
400|Eligibility Criteria|Topic|Computer-Based Eligibility Query Formulation|Topic|RELATED_TO
400|Summary Of Results|Topic|Conclusions|Topic|RELATED_TO
400|Previous Research|Topic|Eligibility Criteria|Topic|RELATED_TO
400|Knowledge-Guided Text Structuring Framework|Topic|Knowledge Base|Topic|RELATED_TO
400|Knowledge-Guided Text Structuring Framework|Topic|Word Dependency Relations|Topic|RELATED_TO
400|Knowledge-Guided Text Structuring Framework|Topic|Formal Representations|Topic|RELATED_TO
400|High Precision And Recall|Topic|Knowledge-Guided Text Structuring Framework|Topic|RELATED_TO
400|Yingcheng Sun|Author|Knowledge-Guided Text Structuring Framework|Topic|AUTHORED
400|Kenneth Loparo|Author|Knowledge-Guided Text Structuring Framework|Topic|AUTHORED
401|Response Adaptive Randomization|Topic|Response Adaptive Block Randomization|Topic|RELATED_TO
401|Response Adaptive Block Randomization|Topic|Doubly Adaptive Biased Coin Design|Topic|RELATED_TO
401|Tianyu Zhan|Author|Response Adaptive Block Randomization|Topic|AUTHORED
401|Lu Cui|Author|Response Adaptive Block Randomization|Topic|AUTHORED
401|Ziqian Geng|Author|Response Adaptive Block Randomization|Topic|AUTHORED
401|Lanju Zhang|Author|Response Adaptive Block Randomization|Topic|AUTHORED
401|Yihua Gu|Author|Response Adaptive Block Randomization|Topic|AUTHORED
401|Ivan S. F. Chan|Author|Response Adaptive Block Randomization|Topic|AUTHORED
402|Response-Adaptive Randomization|Topic|Clinical Trials|Topic|RELATED_TO
402|Response-Adaptive Randomization|Topic|Data-Dependent Sampling Algorithms|Topic|RELATED_TO
402|Response-Adaptive Randomization|Topic|Biostatistical Literature|Topic|RELATED_TO
402|Response-Adaptive Randomization|Topic|Machine Learning|Topic|RELATED_TO
402|Response-Adaptive Randomization In Clinical Trials: From Myths To Practical Considerations|Paper|David S. Robertson|Author|AUTHORED
402|Response-Adaptive Randomization In Clinical Trials: From Myths To Practical Considerations|Paper|Kim May Lee|Author|AUTHORED
402|Response-Adaptive Randomization In Clinical Trials: From Myths To Practical Considerations|Paper|Boryana C. Lopez-Kolkovska|Author|AUTHORED
402|Response-Adaptive Randomization In Clinical Trials: From Myths To Practical Considerations|Paper|Sofia S. Villar|Author|AUTHORED
403|Randomised Clinical Trial Results|Topic|Intercurrent Events|Topic|RELATED_TO
403|Intercurrent Events|Topic|Rescue Medication|Topic|RELATED_TO
403|Rescue Medication|Topic|Intention-To-Treat Analysis|Topic|RELATED_TO
403|Intention-To-Treat Analysis|Topic|Estimand|Topic|RELATED_TO
403|Estimand|Topic|Treatment Effect|Topic|RELATED_TO
403|Estimand|Topic|Inverse Probability Weighting Method|Topic|RELATED_TO
403|Inverse Probability Weighting Method|Topic|Sensitivity Analysis|Topic|RELATED_TO
403|Sensitivity Analysis|Topic|Clinical Trial|Topic|RELATED_TO
403|Clinical Trial|Topic|Janssen Pharmaceuticals|Author|RELATED_TO
403|Hege Michiels|Author|Clinical Trial|Topic|AUTHORED
403|Cristina Sotto|Author|Clinical Trial|Topic|AUTHORED
403|An Vandebosch|Author|Clinical Trial|Topic|AUTHORED
403|Stijn Vansteelandt|Author|Clinical Trial|Topic|AUTHORED
404|Semeval-2023 Task 7|Topic|Nlp Solutions|Topic|RELATED_TO
404|Semeval-2023 Task 7|Topic|Evidence Retrieval|Topic|RELATED_TO
404|Semeval-2023 Task 7|Topic|Natural Language Inference|Topic|RELATED_TO
404|Semeval-2023 Task 7|Topic|Pipeline System|Topic|RELATED_TO
404|Semeval-2023 Task 7|Topic|Joint System|Topic|RELATED_TO
404|Semeval-2023 Task 7|Topic|Ensemble System|Topic|RELATED_TO
404|Juraj Vladika|Author|Semeval-2023 Task 7|Topic|AUTHORED
404|Florian Matthes|Author|Semeval-2023 Task 7|Topic|AUTHORED
404|Clinical Trial Reports|Topic|Nlp Solutions|Topic|RELATED_TO
405|Stratification In Randomized Clinical Trials|Topic|Misclassification Errors|Topic|RELATED_TO
405|Misclassification Errors|Topic|Corrected Values|Topic|RELATED_TO
405|Likelihood Function|Topic|Corrected Values|Topic|DISCUSSES
405|Standard Errors|Topic|Misclassification Errors|Topic|DISCUSSES
405|Unbiased Linear Estimation|Topic|Misclassification Errors|Topic|DISCUSSES
405|Neal Thomas|Author|Stratification In Randomized Clinical Trials|Topic|AUTHORED
406|Using Recursive Partitioning To Find And Estimate Heterogenous Treatment Effects In Randomized Clinical Trials|Paper|Heterogeneous Treatment Effects|Topic|DISCUSSES
406|Using Recursive Partitioning To Find And Estimate Heterogenous Treatment Effects In Randomized Clinical Trials|Paper|Randomized Clinical Trials|Topic|DISCUSSES
406|Using Recursive Partitioning To Find And Estimate Heterogenous Treatment Effects In Randomized Clinical Trials|Paper|Richard Berk|Author|AUTHORED
406|Using Recursive Partitioning To Find And Estimate Heterogenous Treatment Effects In Randomized Clinical Trials|Paper|Matthew Olson|Author|AUTHORED
406|Using Recursive Partitioning To Find And Estimate Heterogenous Treatment Effects In Randomized Clinical Trials|Paper|Andreas Buja|Author|AUTHORED
406|Using Recursive Partitioning To Find And Estimate Heterogenous Treatment Effects In Randomized Clinical Trials|Paper|Aurelie Ouss|Author|AUTHORED
407|A Simulation Study Evaluating Phase I Clinical Trial Designs For Combinational Agents|Paper|Shu Wang|Author|AUTHORED
407|A Simulation Study Evaluating Phase I Clinical Trial Designs For Combinational Agents|Paper|Ji-Hyun Lee|Author|AUTHORED
407|A Simulation Study Evaluating Phase I Clinical Trial Designs For Combinational Agents|Paper|Phase I Clinical Trial Designs|Topic|DISCUSSES
408|Bayesian Optimization|Topic|Design Selection Process|Topic|RELATED_TO
408|Clinical Trials|Topic|Design Selection Process|Topic|RELATED_TO
408|Adaptive Seamless Designs|Topic|Bayesian Optimization|Topic|RELATED_TO
408|Jakob Richter|Author|Adaptive Seamless Designs|Topic|AUTHORED
408|Tim Friede|Author|Adaptive Seamless Designs|Topic|AUTHORED
408|Jörg Rahnenführer|Author|Adaptive Seamless Designs|Topic|AUTHORED
409|The Predictive Individual Effect For Survival Data|Paper|Beat Neuenschwander|Author|AUTHORED
409|The Predictive Individual Effect For Survival Data|Paper|Satrajit Roychoudhury|Author|AUTHORED
409|The Predictive Individual Effect For Survival Data|Paper|Simon Wandel|Author|AUTHORED
409|The Predictive Individual Effect For Survival Data|Paper|Kannan Natarajan|Author|AUTHORED
409|The Predictive Individual Effect For Survival Data|Paper|Emmanuel Zuber|Author|AUTHORED
409|The Predictive Individual Effect For Survival Data|Paper|Patient-Focused Drug Development|Topic|DISCUSSES
409|The Predictive Individual Effect For Survival Data|Paper|Oncology Trials|Topic|DISCUSSES
410|Statistical Modelling And Prediction Of Patient Recruitment In Clinical Trials|Paper|Vladimir Anisimov|Author|AUTHORED
410|Statistical Modelling And Prediction Of Patient Recruitment In Clinical Trials|Paper|Guillaume Mijoule|Author|AUTHORED
410|Statistical Modelling And Prediction Of Patient Recruitment In Clinical Trials|Paper|Armando Turchetta|Author|AUTHORED
410|Statistical Modelling And Prediction Of Patient Recruitment In Clinical Trials|Paper|Nicolas Savy|Author|AUTHORED
410|Statistical Modelling And Prediction Of Patient Recruitment In Clinical Trials|Paper|Poisson-Gamma Model|Topic|RELATED_TO
410|Statistical Modelling And Prediction Of Patient Recruitment In Clinical Trials|Paper|Dropout Process|Topic|RELATED_TO
410|Statistical Modelling And Prediction Of Patient Recruitment In Clinical Trials|Paper|Recruitment Forecasting|Topic|RELATED_TO
411|Missing Data Imputation For A Multivariate Outcome Of Mixed Variable Types|Paper|Tuo Wang|Author|AUTHORED
411|Missing Data Imputation For A Multivariate Outcome Of Mixed Variable Types|Paper|Rachel Zilinskas|Author|AUTHORED
411|Missing Data Imputation For A Multivariate Outcome Of Mixed Variable Types|Paper|Ying Li|Author|AUTHORED
411|Missing Data Imputation For A Multivariate Outcome Of Mixed Variable Types|Paper|Yongming Qu|Author|AUTHORED
412|Unimib Team|Topic|Trec 2021 Clinical Trials Track|Topic|RELATED_TO
412|Unimib Team|Topic|Georgios Peikos|Author|AUTHORED
412|Unimib Team|Topic|Oscar Espitia|Author|AUTHORED
412|Unimib Team|Topic|Gabriella Pasi|Author|AUTHORED
412|Trec 2021 Clinical Trials Track|Topic|Neural Re-Ranking Approach|Topic|DISCUSSES
412|Trec 2021 Clinical Trials Track|Topic|Decision-Theoretic Model|Topic|DISCUSSES
412|Decision-Theoretic Model|Topic|Relevance Estimation|Topic|RELATED_TO
412|Keyword Extraction Method|Topic|Bm25 Model|Topic|RELATED_TO
412|Ndcg@10|Topic|Trec 2021 Clinical Trials Track|Topic|DISCUSSES
412|Rpec@10|Topic|Trec 2021 Clinical Trials Track|Topic|DISCUSSES
413|Mixed Model Repeated Measures (Mmrm)|Topic|Alzheimer'S Disease|Topic|RELATED_TO
413|Constrained Longitudinal Data Analysis|Topic|Alzheimer'S Disease|Topic|RELATED_TO
413|Natural Cubic Splines|Topic|Alzheimer'S Disease|Topic|RELATED_TO
413|M. C. Donohue|Author|Natural Cubic Splines|Topic|AUTHORED
413|O. Langford|Author|Natural Cubic Splines|Topic|AUTHORED
413|P. Insel|Author|Natural Cubic Splines|Topic|AUTHORED
413|C. H. Van Dyck|Author|Natural Cubic Splines|Topic|AUTHORED
413|R. C. Petersen|Author|Natural Cubic Splines|Topic|AUTHORED
413|S. Craft|Author|Natural Cubic Splines|Topic|AUTHORED
413|G. Sethuraman|Author|Natural Cubic Splines|Topic|AUTHORED
413|R. Raman|Author|Natural Cubic Splines|Topic|AUTHORED
413|P. S. Aisen|Author|Natural Cubic Splines|Topic|AUTHORED
414|Modern Approaches For Evaluating Treatment Effect Heterogeneity From Clinical Trials And Observational Data|Paper|Ilya Lipkovich|Author|AUTHORED
414|Modern Approaches For Evaluating Treatment Effect Heterogeneity From Clinical Trials And Observational Data|Paper|David Svensson|Author|AUTHORED
414|Modern Approaches For Evaluating Treatment Effect Heterogeneity From Clinical Trials And Observational Data|Paper|Bohdana Ratitch|Author|AUTHORED
414|Modern Approaches For Evaluating Treatment Effect Heterogeneity From Clinical Trials And Observational Data|Paper|Alex Dmitrienko|Author|AUTHORED
415|Non-Proportional Hazards|Topic|Clinical Trials|Topic|RELATED_TO
415|Clinical Trials|Topic|Time-To-Event Endpoints|Topic|RELATED_TO
415|Immunotherapy For Cancer|Topic|Clinical Trials|Topic|RELATED_TO
415|Group Sequential Design|Topic|Non-Proportional Hazards|Topic|RELATED_TO
415|Average Hazard Ratio|Topic|Group Sequential Design|Topic|RELATED_TO
415|Weighted Logrank Test|Topic|Group Sequential Design|Topic|RELATED_TO
415|Maxcombo Combination Test|Topic|Group Sequential Design|Topic|RELATED_TO
415|Gsdesign2 R Package|Topic|Group Sequential Design|Topic|RELATED_TO
415|Yujie Zhao|Author|Group Sequential Design|Topic|AUTHORED
415|Yilong Zhang|Author|Group Sequential Design|Topic|AUTHORED
415|Larry Leon|Author|Group Sequential Design|Topic|AUTHORED
415|Keaven M. Anderson|Author|Group Sequential Design|Topic|AUTHORED
416|Large Language Models|Topic|Conversational Ai|Topic|RELATED_TO
416|Large Language Models|Topic|Content Generation|Topic|RELATED_TO
416|Large Language Models|Topic|Information Retrieval|Topic|RELATED_TO
416|Large Language Models|Topic|Business Intelligence|Topic|RELATED_TO
416|Large Language Models|Topic|Medical|Topic|RELATED_TO
416|Medical|Topic|Clinical Trials|Topic|RELATED_TO
416|Large Language Models|Topic|Shortcut Learning|Topic|RELATED_TO
416|Large Language Models|Topic|Factual Inconsistency|Topic|RELATED_TO
416|Large Language Models|Topic|Performance Degradation|Topic|RELATED_TO
416|Large Language Models|Topic|Adversarial Testing|Topic|RELATED_TO
416|Large Language Models|Topic|Robust Testing|Topic|RELATED_TO
416|Large Language Models|Topic|Ambiguity|Topic|RELATED_TO
416|Large Language Models|Topic|Reasoning Integrity|Topic|RELATED_TO
416|Large Language Models|Topic|Syntactic Understanding|Topic|RELATED_TO
416|Large Language Models|Topic|Semantic Understanding|Topic|RELATED_TO
416|Sci-Five Model|Topic|Mnestic Probing|Topic|RELATED_TO
416|Mnestic Probing|Topic|Natural Logic|Topic|RELATED_TO
416|Task Specific Probes|Topic|Final Layers Of Trained Model|Topic|RELATED_TO
416|Iterative Null Projection|Topic|Model Accuracy|Topic|RELATED_TO
416|Probe Size|Topic|Fine Tuning Process|Topic|RELATED_TO
416|Ata Mustafa|Author|Enhancing Robustness In Biomedical Nli Models: A Probing Approach For Clinical Trials|Paper|AUTHORED
417|Large Language Models|Topic|Natural Language Processing|Topic|RELATED_TO
417|Natural Language Processing|Topic|Natural Language Inference|Topic|RELATED_TO
417|Natural Language Inference|Topic|Breast Cancer Clinical Trial Reports|Topic|RELATED_TO
417|Breast Cancer Clinical Trial Reports|Topic|Semeval 2024 Task 2|Topic|RELATED_TO
417|Semeval 2024 Task 2|Topic|Retrieval-Augmented Generation|Topic|RELATED_TO
417|Iitk|Author|Semeval 2024 Task 2|Topic|AUTHORED
417|Shreyasi Mandal|Author|Semeval 2024 Task 2|Topic|AUTHORED
417|Ashutosh Modi|Author|Semeval 2024 Task 2|Topic|AUTHORED
417|Gpt-3.5|Paper|Retrieval-Augmented Generation|Topic|RELATED_TO
417|Gemini Pro|Paper|Retrieval-Augmented Generation|Topic|RELATED_TO
417|Evaluation Results|Topic|Semeval 2024 Task 2|Topic|DISCUSSES
418|Considerations For Single-Arm Trials To Support Accelerated Approval Of Oncology Drugs|Paper|Feinan Lu|Author|AUTHORED
418|Considerations For Single-Arm Trials To Support Accelerated Approval Of Oncology Drugs|Paper|Tao Wang|Author|AUTHORED
418|Considerations For Single-Arm Trials To Support Accelerated Approval Of Oncology Drugs|Paper|Ying Lu|Author|AUTHORED
418|Considerations For Single-Arm Trials To Support Accelerated Approval Of Oncology Drugs|Paper|Jie Chen|Author|AUTHORED
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Yizhen Zheng|Author|AUTHORED
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Huan Yee Koh|Author|AUTHORED
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Maddie Yang|Author|AUTHORED
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Li Li|Author|AUTHORED
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Lauren T. May|Author|AUTHORED
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Geoffrey I. Webb|Author|AUTHORED
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Shirui Pan|Author|AUTHORED
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|George Church|Author|AUTHORED
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Computational Biology|Topic|RELATED_TO
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Pharmacology|Topic|RELATED_TO
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Ai4Science|Topic|RELATED_TO
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Drug Discovery|Topic|RELATED_TO
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Drug Development|Topic|RELATED_TO
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Disease Mechanisms|Topic|RELATED_TO
419|Large Language Models In Drug Discovery And Development: From Disease Mechanisms To Clinical Trials|Paper|Clinical Trials|Topic|RELATED_TO
420|Improve Sensitivity Analysis Synthesizing Randomized Clinical Trials With Limited Overlap|Paper|Randomized Clinical Trials|Topic|DISCUSSES
420|Improve Sensitivity Analysis Synthesizing Randomized Clinical Trials With Limited Overlap|Paper|Observational Studies|Topic|DISCUSSES
420|Improve Sensitivity Analysis Synthesizing Randomized Clinical Trials With Limited Overlap|Paper|Sensitivity Analysis|Topic|DISCUSSES
420|Improve Sensitivity Analysis Synthesizing Randomized Clinical Trials With Limited Overlap|Paper|Synthesis Estimator|Topic|DISCUSSES
420|Improve Sensitivity Analysis Synthesizing Randomized Clinical Trials With Limited Overlap|Paper|Average Treatment Effect|Topic|DISCUSSES
420|Kuan Jiang|Author|Improve Sensitivity Analysis Synthesizing Randomized Clinical Trials With Limited Overlap|Paper|AUTHORED
420|Wenjie Hu|Author|Improve Sensitivity Analysis Synthesizing Randomized Clinical Trials With Limited Overlap|Paper|AUTHORED
420|Shu Yang|Author|Improve Sensitivity Analysis Synthesizing Randomized Clinical Trials With Limited Overlap|Paper|AUTHORED
420|Xinxing Lai|Author|Improve Sensitivity Analysis Synthesizing Randomized Clinical Trials With Limited Overlap|Paper|AUTHORED
420|Xiaohua Zhou|Author|Improve Sensitivity Analysis Synthesizing Randomized Clinical Trials With Limited Overlap|Paper|AUTHORED
421|Ich E9(R1) Addendum|Topic|Intercurrent Events|Topic|RELATED_TO
421|G-Estimation|Topic|Intercurrent Events|Topic|DISCUSSES
421|G-Estimation|Topic|Alzheimer Disease|Topic|DISCUSSES
421|Florian Lasch|Author|G-Estimation|Topic|AUTHORED
421|Lorenzo Guizzaro|Author|G-Estimation|Topic|AUTHORED
421|Wen Wei Loh|Author|G-Estimation|Topic|AUTHORED
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Pattern-Mixture Models|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Treatment Effects|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Clinical Trials|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Nonignorable Missing Data|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Multiple Imputation|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Rubin'S Approach|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Bootstrap Methods|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Direct Likelihood-Based Approaches|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Analytical Framework|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Return-To-Baseline|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Jump-To-Reference|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Placebo Washout|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Retrieved Dropout Imputations|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Tipping Point Analysis|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Simulation Studies|Topic|DISCUSSES
422|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|Clinical Trial Evaluating A Treatment For Type 2 Diabetes|Topic|DISCUSSES
422|Jitong Lou|Author|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|AUTHORED
422|Mallikarjuna Rettiganti|Author|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|AUTHORED
422|Yongming Qu|Author|Direct Estimation For Commonly Used Pattern-Mixture Models In Clinical Trials|Paper|AUTHORED
423|Pkg2.0|Topic|Biomedical Literature|Topic|RELATED_TO
423|Pkg2.0|Topic|Jian Xu|Author|AUTHORED
423|Pkg2.0|Topic|Chao Yu|Author|AUTHORED
423|Pkg2.0|Topic|Jiawei Xu|Author|AUTHORED
423|Pkg2.0|Topic|Ying Ding|Author|AUTHORED
423|Pkg2.0|Topic|Vetle I. Torvik|Author|AUTHORED
423|Pkg2.0|Topic|Jaewoo Kang|Author|AUTHORED
423|Pkg2.0|Topic|Mujeen Sung|Author|AUTHORED
423|Pkg2.0|Topic|Min Song|Author|AUTHORED
424|A Novel Longitudinal Rank-Sum Test For Multiple Primary Endpoints In Clinical Trials: Applications To Neurodegenerative Disorders|Paper|Xiaoming Xu|Author|AUTHORED
424|A Novel Longitudinal Rank-Sum Test For Multiple Primary Endpoints In Clinical Trials: Applications To Neurodegenerative Disorders|Paper|Dhrubajyoti Ghosh|Author|AUTHORED
424|A Novel Longitudinal Rank-Sum Test For Multiple Primary Endpoints In Clinical Trials: Applications To Neurodegenerative Disorders|Paper|Sheng Luo|Author|AUTHORED
424|Longitudinal Rank Sum Test|Topic|Neurodegenerative Disorders|Topic|RELATED_TO
424|Longitudinal Rank Sum Test|Topic|Alzheimer'S Disease|Topic|RELATED_TO
425|G-Computation For Increasing Performances Of Clinical Trials With Individual Randomization And Binary Response|Paper|Clinical Trials|Topic|RELATED_TO
425|G-Computation For Increasing Performances Of Clinical Trials With Individual Randomization And Binary Response|Paper|Machine Learning|Topic|RELATED_TO
425|G-Computation For Increasing Performances Of Clinical Trials With Individual Randomization And Binary Response|Paper|Penalized Regressions|Topic|RELATED_TO
425|G-Computation For Increasing Performances Of Clinical Trials With Individual Randomization And Binary Response|Paper|Algorithm-Based Methods|Topic|RELATED_TO
426|Sparsevm|Topic|3D Mr Scans|Topic|RELATED_TO
426|Sparsevm|Topic|Voxelmorph Package|Topic|RELATED_TO
426|Sparsevm|Topic|Kathleen M. Lewis|Author|AUTHORED
426|Sparsevm|Topic|Natalia S. Rost|Author|AUTHORED
426|Sparsevm|Topic|John Guttag|Author|AUTHORED
426|Sparsevm|Topic|Adrian V. Dalca|Author|AUTHORED
427|Multi-Arm Multi-Stage Trial|Topic|Allocation Ratio|Topic|RELATED_TO
427|Allocation Ratio|Topic|Optimal Allocation Ratio|Topic|RELATED_TO
427|Optimal Allocation Ratio|Topic|Martin Law|Author|AUTHORED
428|Leafai|Topic|Nicholas J Dobbins|Author|AUTHORED
428|Leafai|Topic|Bin Han|Author|AUTHORED
428|Leafai|Topic|Weipeng Zhou|Author|AUTHORED
428|Leafai|Topic|Kristine Lan|Author|AUTHORED
428|Leafai|Topic|H. Nina Kim|Author|AUTHORED
428|Leafai|Topic|Robert Harrington|Author|AUTHORED
428|Leafai|Topic|Ozlem Uzuner|Author|AUTHORED
428|Leafai|Topic|Meliha Yetisgen|Author|AUTHORED
428|Leafai|Topic|Clinical Trials|Topic|RELATED_TO
429|Sex Differences In Severity And Mortality Among Patients With Covid-19: Evidence From Pooled Literature Analysis And Insights From Integrated Bioinformatic Analysis|Paper|Covid-19|Topic|RELATED_TO
430|Bapofi|Topic|Bapofi-Tte|Topic|RELATED_TO
430|Bapofi-Tte|Topic|Satoshi Morita|Author|AUTHORED
430|Bapofi-Tte|Topic|Peter Müller|Author|AUTHORED
430|Bapofi-Tte|Topic|Hiroyasu Abe|Author|AUTHORED
430|Bapofi-Tte|Topic|Biometrics|Topic|RELATED_TO
431|Monte Carlo Simulations Of Stroke|Topic|3D Stroke Simulations|Topic|RELATED_TO
431|3D Stroke Simulations|Topic|In-Silico Trials|Topic|RELATED_TO
431|3D Stroke Simulations|Topic|Probabilistic Lesion Overlap Maps|Topic|RELATED_TO
431|3D Stroke Simulations|Topic|Equation For Sizing Emboli|Topic|RELATED_TO
431|James P. Hague|Author|3D Stroke Simulations|Topic|AUTHORED
431|Jonathan Keelan|Author|3D Stroke Simulations|Topic|AUTHORED
431|Lucy Beishon|Author|3D Stroke Simulations|Topic|AUTHORED
431|David Swienton|Author|3D Stroke Simulations|Topic|AUTHORED
431|Thompson G. Robinson|Author|3D Stroke Simulations|Topic|AUTHORED
431|Emma M. L. Chung|Author|3D Stroke Simulations|Topic|AUTHORED
432|Misclassification Of Vaccination Status In Electronic Health Records: A Bayesian Approach In Cluster Randomized Trials|Paper|Misclassification|Topic|DISCUSSES
432|Misclassification Of Vaccination Status In Electronic Health Records: A Bayesian Approach In Cluster Randomized Trials|Paper|Public Health|Topic|DISCUSSES
432|Misclassification Of Vaccination Status In Electronic Health Records: A Bayesian Approach In Cluster Randomized Trials|Paper|Vaccinations|Topic|DISCUSSES
432|Misclassification Of Vaccination Status In Electronic Health Records: A Bayesian Approach In Cluster Randomized Trials|Paper|Cluster Controlled Randomized Trial (Ccrt)|Topic|DISCUSSES
432|Misclassification Of Vaccination Status In Electronic Health Records: A Bayesian Approach In Cluster Randomized Trials|Paper|Bayesian Logistic Regression|Topic|DISCUSSES
432|Misclassification Of Vaccination Status In Electronic Health Records: A Bayesian Approach In Cluster Randomized Trials|Paper|Behavioral Intervention|Topic|DISCUSSES
432|Misclassification Of Vaccination Status In Electronic Health Records: A Bayesian Approach In Cluster Randomized Trials|Paper|Vaccination Uptake|Topic|DISCUSSES
432|Misclassification Of Vaccination Status In Electronic Health Records: A Bayesian Approach In Cluster Randomized Trials|Paper|U.S. Veterans|Topic|DISCUSSES
433|Clinical Trials|Topic|Patient Recruitment|Topic|RELATED_TO
433|Patient Recruitment|Topic|Poisson-Gamma Model|Topic|RELATED_TO
433|Poisson-Gamma Model|Topic|Time-Dependent Rates|Topic|RELATED_TO
433|Patient Recruitment|Topic|Homogeneity Testing|Topic|RELATED_TO
433|Volodymyr Anisimov|Author|Patient Recruitment|Topic|AUTHORED
433|Lucas Oliver|Author|Patient Recruitment|Topic|AUTHORED
433|Poisson-Gamma Model|Topic|Analytic Methodology|Topic|RELATED_TO
434|Cure Proportion Model|Topic|Overall Survival|Topic|RELATED_TO
434|Phase 1 Trial|Topic|Phase 3 Trial|Topic|RELATED_TO
434|Futility Interim Analysis|Topic|Phase 3 Trial|Topic|RELATED_TO
434|Intermediate Endpoint|Topic|Overall Survival|Topic|RELATED_TO
434|Acute Myeloid Leukemia|Topic|Intermediate Endpoint|Topic|RELATED_TO
434|Kaspar Rufibach|Author|Acute Myeloid Leukemia|Topic|AUTHORED
434|Dominik Heinzmann|Author|Acute Myeloid Leukemia|Topic|AUTHORED
434|Annabelle Monnet|Author|Acute Myeloid Leukemia|Topic|AUTHORED
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Daniel H. Baker|Author|AUTHORED
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Greta Vilidaite|Author|AUTHORED
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Freya A. Lygo|Author|AUTHORED
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Anika K. Smith|Author|AUTHORED
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Tessa R. Flack|Author|AUTHORED
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Andre D. Gouws|Author|AUTHORED
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Timothy J. Andrews|Author|AUTHORED
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Statistical Power|Topic|RELATED_TO
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Experimental Studies|Topic|RELATED_TO
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Human Participants|Topic|RELATED_TO
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Variance|Topic|RELATED_TO
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Power Contour Plots|Topic|RELATED_TO
435|Power Contours: Optimising Sample Size And Precision In Experimental Psychology And Human Neuroscience|Paper|Online Tool|Topic|RELATED_TO
436|Time-Frequency Analysis|Topic|Brain Rhythms|Topic|RELATED_TO
436|Event-Related Protocols|Topic|Brain Rhythms|Topic|RELATED_TO
436|Avgamp|Topic|Relationship Between Powavg And Itc|Topic|RELATED_TO
436|Itc|Topic|Relationship Between Powavg And Itc|Topic|RELATED_TO
436|Powavg|Topic|Relationship Between Powavg And Itc|Topic|RELATED_TO
436|Jonas Benhamou|Author|Time-Frequency Analysis Of Event-Related Brain Recordings: Connecting Power Of Evoked Potential And Inter-Trial Coherence|Paper|AUTHORED
436|Michel Le Van Quyen|Author|Time-Frequency Analysis Of Event-Related Brain Recordings: Connecting Power Of Evoked Potential And Inter-Trial Coherence|Paper|AUTHORED
436|Guillaume Marrelec|Author|Time-Frequency Analysis Of Event-Related Brain Recordings: Connecting Power Of Evoked Potential And Inter-Trial Coherence|Paper|AUTHORED
437|Covid-19 Pandemic|Topic|Long Covid|Topic|RELATED_TO
437|Long Covid|Topic|Immune Dysregulation|Topic|RELATED_TO
437|Post-Covid-19 Patients|Topic|2022|Topic|RELATED_TO
437|Post-Covid-19 Patients|Topic|2023|Topic|RELATED_TO
437|Machine Learning Techniques|Topic|Immunophenotyping|Topic|RELATED_TO
437|Clinical Information|Topic|Immunological Information|Topic|RELATED_TO
437|Clinical Information|Topic|Demographic Information|Topic|RELATED_TO
437|Long Covid|Topic|Persistent Inflammation|Topic|RELATED_TO
437|Long Covid|Topic|Altered Cytokine Profiles|Topic|RELATED_TO
437|Long Covid|Topic|Abnormal Immune Cell Subsets|Topic|RELATED_TO
437|Long Covid|Topic|Personalized Interventions|Topic|RELATED_TO
437|Long Covid|Topic|Targeted Therapies|Topic|RELATED_TO
437|Long Covid|Topic|Clinical Management|Topic|RELATED_TO
437|Unraveling Post-Covid-19 Immune Dysregulation Using Machine Learning-Based Immunophenotyping|Paper|Maitham G. Yousif|Author|AUTHORED
437|Unraveling Post-Covid-19 Immune Dysregulation Using Machine Learning-Based Immunophenotyping|Paper|Ghizal Fatima|Author|AUTHORED
437|Unraveling Post-Covid-19 Immune Dysregulation Using Machine Learning-Based Immunophenotyping|Paper|Hector J. Castro|Author|AUTHORED
437|Unraveling Post-Covid-19 Immune Dysregulation Using Machine Learning-Based Immunophenotyping|Paper|Fadhil G. Al-Amran|Author|AUTHORED
437|Unraveling Post-Covid-19 Immune Dysregulation Using Machine Learning-Based Immunophenotyping|Paper|Salman Rawaf|Author|AUTHORED
438|Laboratory Values Estimation And Monitoring From Electrocardiogram Signals -- A Multimodal Deep Learning Approach|Paper|Mimic-Iv Dataset|Topic|RELATED_TO
438|Laboratory Values Estimation And Monitoring From Electrocardiogram Signals -- A Multimodal Deep Learning Approach|Paper|Ecg Waveforms|Topic|RELATED_TO
438|Laboratory Values Estimation And Monitoring From Electrocardiogram Signals -- A Multimodal Deep Learning Approach|Paper|Laboratory Value Abnormalities|Topic|RELATED_TO
438|Laboratory Values Estimation And Monitoring From Electrocardiogram Signals -- A Multimodal Deep Learning Approach|Paper|Auroc Scores|Topic|RELATED_TO
438|Laboratory Values Estimation And Monitoring From Electrocardiogram Signals -- A Multimodal Deep Learning Approach|Paper|Cardiac Abnormalities|Topic|RELATED_TO
438|Laboratory Values Estimation And Monitoring From Electrocardiogram Signals -- A Multimodal Deep Learning Approach|Paper|Renal Abnormalities|Topic|RELATED_TO
438|Laboratory Values Estimation And Monitoring From Electrocardiogram Signals -- A Multimodal Deep Learning Approach|Paper|Hematological Abnormalities|Topic|RELATED_TO
438|Laboratory Values Estimation And Monitoring From Electrocardiogram Signals -- A Multimodal Deep Learning Approach|Paper|Metabolic Abnormalities|Topic|RELATED_TO
438|Laboratory Values Estimation And Monitoring From Electrocardiogram Signals -- A Multimodal Deep Learning Approach|Paper|Immunological Abnormalities|Topic|RELATED_TO
438|Laboratory Values Estimation And Monitoring From Electrocardiogram Signals -- A Multimodal Deep Learning Approach|Paper|Coagulation Abnormalities|Topic|RELATED_TO
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Lori E Dodd|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Dean Follmann|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Jing Wang|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Franz Koenig|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Lisa L Korn|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Christian Schoergenhofer|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Michael Proschan|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Sally Hunsberger|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Tyler Bonnett|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Mat Makowski|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Drifa Belhadi|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Yeming Wang|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Bin Cao|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|France Mentre|Author|AUTHORED
439|Endpoint Choice For Randomized Controlled Trials Of Treatments For Covid-19|Topic|Thomas Jaki|Author|AUTHORED
440|Medical Trials|Topic|Patients' Health Conditions|Topic|DISCUSSES
440|Demographic Factors|Topic|Death Rate|Topic|DISCUSSES
440|Bertillon Effect|Topic|Death Rate|Topic|RELATED_TO
440|Age Of The Oldest Patients|Topic|Death Rate|Topic|RELATED_TO
440|Gompertz'S Law|Topic|Death Rate|Topic|RELATED_TO
440|Marital Status|Topic|Clinical Trials|Topic|RELATED_TO
440|Age Distribution Of Those Over 65|Topic|Clinical Trials|Topic|RELATED_TO
440|Bertrand M. Roehner|Author|Clinical Trials|Topic|AUTHORED
440|Reliability And Accuracy Of Trial'S Conclusions|Topic|Clinical Trials|Topic|DISCUSSES
441|Phase 1 Clinical Trials|Topic|Dose-Escalation Practices|Topic|RELATED_TO
441|Precautionary Coherence Principle|Topic|Phase 1 Clinical Trials|Topic|DISCUSSES
441|Afm11|Topic|Bayesian Dose-Response Model|Topic|DISCUSSES
441|Bayesian Dose-Response Model|Topic|Afm11|Topic|RELATED_TO
441|David C. Norris|Author|Afm11|Topic|AUTHORED
443|Bayesian Response Adaptive Clinical Trials|Topic|Experimental Therapies|Topic|RELATED_TO
443|Bayesian Response Adaptive Clinical Trials|Topic|Diseases|Topic|RELATED_TO
443|Adaptive Decisions|Topic|Randomization Probabilities|Topic|RELATED_TO
443|Randomization Probabilities|Topic|New Treatments|Topic|RELATED_TO
443|Response Adaptive Trials|Topic|Simulation Studies|Topic|RELATED_TO
443|Simulation Studies|Topic|Operating Characteristics|Topic|RELATED_TO
443|Operating Characteristics|Topic|Type I/Ii Error Rates|Topic|RELATED_TO
443|Bayesian Uncertainty Directed Trial Designs (Buds)|Topic|Metric U|Topic|RELATED_TO
443|Metric U|Topic|Information Accrued|Topic|RELATED_TO
443|Information Accrued|Topic|Treatment Effects|Topic|RELATED_TO
443|Asymptotic Analysis|Topic|Allocation Of Patients|Topic|RELATED_TO
443|Allocation Of Patients|Topic|Treatment Arms|Topic|RELATED_TO
443|Asymptotic Normality|Topic|Power Of The Bud|Topic|RELATED_TO
443|Marta Bonsaglio|Author|Approximating The Operating Characteristics Of Bayesian Uncertainty Directed Trial Designs|Paper|AUTHORED
443|Sandra Fortini|Author|Approximating The Operating Characteristics Of Bayesian Uncertainty Directed Trial Designs|Paper|AUTHORED
443|Steffen Ventz|Author|Approximating The Operating Characteristics Of Bayesian Uncertainty Directed Trial Designs|Paper|AUTHORED
443|Lorenzo Trippa|Author|Approximating The Operating Characteristics Of Bayesian Uncertainty Directed Trial Designs|Paper|AUTHORED
444|Modeling Synergism In Early Phase Cancer Trials With Drug Combination With Continuous Dose Levels: Is There An Added Value?|Paper|Mourad Tighiouart|Author|AUTHORED
444|Modeling Synergism In Early Phase Cancer Trials With Drug Combination With Continuous Dose Levels: Is There An Added Value?|Paper|José L. Jiménez|Author|AUTHORED
444|Modeling Synergism In Early Phase Cancer Trials With Drug Combination With Continuous Dose Levels: Is There An Added Value?|Paper|Marcio A. Diniz|Author|AUTHORED
444|Modeling Synergism In Early Phase Cancer Trials With Drug Combination With Continuous Dose Levels: Is There An Added Value?|Paper|André Rogatko|Author|AUTHORED
445|Randomized Clinical Trials|Topic|In Silico Imaging Trials|Topic|RELATED_TO
445|In Silico Imaging Trials|Topic|Medical Device|Topic|RELATED_TO
445|In Silico Imaging Trials|Topic|Digital Representations Of Humans|Topic|RELATED_TO
445|Digital Representations Of Humans|Topic|Digital Human Models|Topic|RELATED_TO
445|Digital Human Models|Topic|Digital Cohorts|Topic|RELATED_TO
445|A Badano|Author|In Silico Imaging Trials|Topic|AUTHORED
445|M Lago|Author|In Silico Imaging Trials|Topic|AUTHORED
445|E Sizikova|Author|In Silico Imaging Trials|Topic|AUTHORED
445|Jg Delfino|Author|In Silico Imaging Trials|Topic|AUTHORED
445|S Guan|Author|In Silico Imaging Trials|Topic|AUTHORED
445|Ma Anastasio|Author|In Silico Imaging Trials|Topic|AUTHORED
445|B Sahiner|Author|In Silico Imaging Trials|Topic|AUTHORED
446|Molecular Targeted Oncology Drug Development|Topic|Clinical Trial Methodologies|Topic|RELATED_TO
446|Clinical Trial Methodologies|Topic|Basket Trial|Topic|RELATED_TO
446|Basket Trial|Topic|Bayesian Approach|Topic|RELATED_TO
446|Basket Trial|Topic|Frequentist Approach|Topic|RELATED_TO
446|Frequentist Approach|Topic|Mantel-Haenszel Procedure|Topic|RELATED_TO
446|Frequentist Approach|Topic|Dually Consistent Variance Estimators|Topic|RELATED_TO
446|Satoshi Hattori|Author|Frequentist Approach|Topic|AUTHORED
446|Satoshi Morita|Author|Frequentist Approach|Topic|AUTHORED
446|Basket Trial|Topic|Efficacy Evaluation|Topic|RELATED_TO
446|Basket Trial|Topic|Type 1 Error Control|Topic|RELATED_TO
446|Basket Trial|Topic|Information Criterion Approach|Topic|RELATED_TO
447|Implementing Response-Adaptive Randomisation In Stratified Rare-Disease Trials: Design Challenges And Practical Solutions|Paper|Rajenki Das|Author|AUTHORED
447|Implementing Response-Adaptive Randomisation In Stratified Rare-Disease Trials: Design Challenges And Practical Solutions|Paper|Nina Deliu|Author|AUTHORED
447|Implementing Response-Adaptive Randomisation In Stratified Rare-Disease Trials: Design Challenges And Practical Solutions|Paper|Mark Toshner|Author|AUTHORED
447|Implementing Response-Adaptive Randomisation In Stratified Rare-Disease Trials: Design Challenges And Practical Solutions|Paper|Sofía S Villar|Author|AUTHORED
448|A Comparative Evaluation Of Bayesian Model-Assisted Two-Stage Designs For Phase I/Ii Clinical Trials|Paper|Phase I/Ii Trial|Topic|DISCUSSES
448|A Comparative Evaluation Of Bayesian Model-Assisted Two-Stage Designs For Phase I/Ii Clinical Trials|Paper|Optimal Biological Dose|Topic|DISCUSSES
448|A Comparative Evaluation Of Bayesian Model-Assisted Two-Stage Designs For Phase I/Ii Clinical Trials|Paper|Recommended Phase Ii Doses|Topic|DISCUSSES
448|A Comparative Evaluation Of Bayesian Model-Assisted Two-Stage Designs For Phase I/Ii Clinical Trials|Paper|Go/No-Go Decision|Topic|DISCUSSES
448|A Comparative Evaluation Of Bayesian Model-Assisted Two-Stage Designs For Phase I/Ii Clinical Trials|Paper|Recommended Phase Iii Dose|Topic|DISCUSSES
448|A Comparative Evaluation Of Bayesian Model-Assisted Two-Stage Designs For Phase I/Ii Clinical Trials|Paper|Bayesian Model-Assisted Designs|Topic|DISCUSSES
448|A Comparative Evaluation Of Bayesian Model-Assisted Two-Stage Designs For Phase I/Ii Clinical Trials|Paper|Tite-Boin12 + Top|Topic|DISCUSSES
449|Robbins And Monro|Author|Stochastic Approximation|Topic|RELATED_TO
449|Stochastic Approximation|Topic|Dose-Finding Studies|Topic|RELATED_TO
449|Ying Kuen Cheung|Author|Arxiv.Result|Paper|AUTHORED
449|Stochastic Approximation Literature|Topic|Dose-Finding Literature|Topic|RELATED_TO
449|Dose-Finding Literature|Topic|Clinical Studies|Topic|RELATED_TO
450|Extracting Factual Min/Max Age Information From Clinical Trial Studies|Paper|Yufang Hou|Author|AUTHORED
450|Extracting Factual Min/Max Age Information From Clinical Trial Studies|Paper|Debasis Ganguly|Author|AUTHORED
450|Extracting Factual Min/Max Age Information From Clinical Trial Studies|Paper|Lea A. Deleris|Author|AUTHORED
450|Extracting Factual Min/Max Age Information From Clinical Trial Studies|Paper|Francesca Bonin|Author|AUTHORED
451|Tripartite Estimands|Topic|Adverse Events|Topic|RELATED_TO
451|Tripartite Estimands|Topic|Lack Of Efficacy|Topic|RELATED_TO
451|Tripartite Estimands|Topic|Primary Efficacy Outcome|Topic|RELATED_TO
451|Tripartite Estimands|Topic|Causal Inference Framework|Topic|RELATED_TO
451|Yongming Qu|Author|Implementation Of Tripartite Estimands Using Adherence Causal Estimators Under The Causal Inference Framework|Paper|AUTHORED
451|Junxiang Luo|Author|Implementation Of Tripartite Estimands Using Adherence Causal Estimators Under The Causal Inference Framework|Paper|AUTHORED
451|Stephen J. Ruberg|Author|Implementation Of Tripartite Estimands Using Adherence Causal Estimators Under The Causal Inference Framework|Paper|AUTHORED
451|Phase 3 Clinical Study|Topic|Basal Insulin Treatment|Topic|RELATED_TO
451|Basal Insulin Treatment|Topic|Type 1 Diabetes|Topic|RELATED_TO
452|A Nonparametric Method For Value Function Guided Subgroup Identification Via Gradient Tree Boosting For Censored Survival Data|Paper|Subgroup Identification|Topic|DISCUSSES
452|A Nonparametric Method For Value Function Guided Subgroup Identification Via Gradient Tree Boosting For Censored Survival Data|Paper|Individualized Treatment Regime|Topic|DISCUSSES
452|A Nonparametric Method For Value Function Guided Subgroup Identification Via Gradient Tree Boosting For Censored Survival Data|Paper|Gradient Tree Boosting|Topic|DISCUSSES
452|A Nonparametric Method For Value Function Guided Subgroup Identification Via Gradient Tree Boosting For Censored Survival Data|Paper|Censored Survival Data|Topic|DISCUSSES
452|A Nonparametric Method For Value Function Guided Subgroup Identification Via Gradient Tree Boosting For Censored Survival Data|Paper|Aids Clinical Trial|Topic|DISCUSSES
453|Utilizing Win Ratio Approaches And Two-Stage Enrichment Designs For Small-Sized Clinical Trials|Paper|Conventional Methods For Analyzing Composite Endpoints In Clinical Trials|Topic|DISCUSSES
453|Utilizing Win Ratio Approaches And Two-Stage Enrichment Designs For Small-Sized Clinical Trials|Paper|Win Ratio (Wr)|Topic|DISCUSSES
453|Jialu Wang|Author|Utilizing Win Ratio Approaches And Two-Stage Enrichment Designs For Small-Sized Clinical Trials|Paper|AUTHORED
453|Yeh-Fong Chen|Author|Utilizing Win Ratio Approaches And Two-Stage Enrichment Designs For Small-Sized Clinical Trials|Paper|AUTHORED
453|Thomas Gwise|Author|Utilizing Win Ratio Approaches And Two-Stage Enrichment Designs For Small-Sized Clinical Trials|Paper|AUTHORED
454|Sequential Knockoffs For Continuous And Categorical Predictors: With Application To A Large Psoriatic Arthritis Clinical Trial Pool|Paper|Knockoffs|Topic|DISCUSSES
455|In Silico Clinical Trials|Topic|Pharmacological Treatment|Topic|RELATED_TO
455|In Silico Clinical Trials|Topic|Precision Medicine|Topic|RELATED_TO
455|Stefano Sinisi|Author|In Silico Clinical Trials|Topic|AUTHORED
455|Vadim Alimguzhin|Author|In Silico Clinical Trials|Topic|AUTHORED
455|Toni Mancini|Author|In Silico Clinical Trials|Topic|AUTHORED
455|Enrico Tronci|Author|In Silico Clinical Trials|Topic|AUTHORED
455|Federico Mari|Author|In Silico Clinical Trials|Topic|AUTHORED
455|Brigitte Leeners|Author|In Silico Clinical Trials|Topic|AUTHORED
456|Automated Approach To Extracting Positive And Negative Clinical Research Results|Paper|Picoe Framework|Topic|DISCUSSES
456|Automated Approach To Extracting Positive And Negative Clinical Research Results|Paper|Covid-19 Related Intervention-Outcomes Pairs|Topic|DISCUSSES
456|Automated Approach To Extracting Positive And Negative Clinical Research Results|Paper|Xuanyu Shi|Author|AUTHORED
456|Automated Approach To Extracting Positive And Negative Clinical Research Results|Paper|Shiyao Xie|Author|AUTHORED
456|Automated Approach To Extracting Positive And Negative Clinical Research Results|Paper|Wenjia Wang|Author|AUTHORED
456|Automated Approach To Extracting Positive And Negative Clinical Research Results|Paper|Ting Chen|Author|AUTHORED
456|Automated Approach To Extracting Positive And Negative Clinical Research Results|Paper|Jian Du|Author|AUTHORED
457|Estimands In Real-World Evidence Studies|Paper|Jie Chen|Author|AUTHORED
457|Estimands In Real-World Evidence Studies|Paper|Daniel Scharfstein|Author|AUTHORED
457|Estimands In Real-World Evidence Studies|Paper|Hongwei Wang|Author|AUTHORED
457|Estimands In Real-World Evidence Studies|Paper|Binbing Yu|Author|AUTHORED
457|Estimands In Real-World Evidence Studies|Paper|Yang Song|Author|AUTHORED
457|Estimands In Real-World Evidence Studies|Paper|Weili He|Author|AUTHORED
457|Estimands In Real-World Evidence Studies|Paper|John Scott|Author|AUTHORED
457|Estimands In Real-World Evidence Studies|Paper|Xiwu Lin|Author|AUTHORED
457|Estimands In Real-World Evidence Studies|Paper|Hana Lee|Author|AUTHORED
458|N4U Analysis Base|Topic|Neugrid For Users (N4U)|Topic|RELATED_TO
458|N4U Analysis Base|Topic|Neurodegenerative Diseases|Topic|RELATED_TO
458|Kamran Munir|Author|N4U Analysis Base|Topic|AUTHORED
458|Saad Liaquat Kiani|Author|N4U Analysis Base|Topic|AUTHORED
458|Khawar Hasham|Author|N4U Analysis Base|Topic|AUTHORED
458|Richard Mcclatchey|Author|N4U Analysis Base|Topic|AUTHORED
458|Andrew Branson|Author|N4U Analysis Base|Topic|AUTHORED
458|Jetendr Shamdasani|Author|N4U Analysis Base|Topic|AUTHORED
458|N4U Consortium|Author|N4U Analysis Base|Topic|AUTHORED
459|Covid-19 Vaccine Trials|Topic|Rob Johnson|Author|AUTHORED
459|Covid-19 Vaccine Trials|Topic|Chris Jackson|Author|AUTHORED
459|Covid-19 Vaccine Trials|Topic|Anne Presanis|Author|AUTHORED
459|Covid-19 Vaccine Trials|Topic|Sofia S. Villar|Author|AUTHORED
459|Covid-19 Vaccine Trials|Topic|Daniela De Angelis|Author|AUTHORED
460|Trials|Topic|Sample Size Calculations|Topic|RELATED_TO
460|Sample Size Calculations|Topic|Semiparametric Efficient Estimator|Topic|RELATED_TO
460|Semiparametric Efficient Estimator|Topic|Power|Topic|RELATED_TO
460|Alejandro Schuler|Author|Clinical Trial|Topic|AUTHORED
460|Clinical Trial|Topic|Design Power|Topic|RELATED_TO
460|Design Power|Topic|Type I Error|Topic|RELATED_TO
460|Two-Arm, Single-Timepoint Trial|Topic|Semiparametric Efficient Estimator|Topic|RELATED_TO
460|Nominal Values|Topic|Power|Topic|RELATED_TO
461|Covariate Adjustment|Topic|Clinical Trials|Topic|RELATED_TO
461|Covariate Adjustment|Topic|Group Sequential Designs|Topic|RELATED_TO
461|Covariate Adjustment|Topic|Information Adaptive Design|Topic|RELATED_TO
461|Kelly Van Lancker|Author|Combining Covariate Adjustment With Group Sequential, Information Adaptive Designs To Improve Randomized Trial Efficiency|Paper|AUTHORED
461|Joshua Betz|Author|Combining Covariate Adjustment With Group Sequential, Information Adaptive Designs To Improve Randomized Trial Efficiency|Paper|AUTHORED
461|Michael Rosenblum|Author|Combining Covariate Adjustment With Group Sequential, Information Adaptive Designs To Improve Randomized Trial Efficiency|Paper|AUTHORED
461|Estimator Performance|Topic|Stroke Trial|Topic|RELATED_TO
462|Basket Trials|Topic|Bayesian Approach|Topic|RELATED_TO
462|Bayesian Approach|Topic|Sample Size Determination|Topic|RELATED_TO
462|Haiyan Zheng|Author|Sample Size Determination|Topic|AUTHORED
462|Michael J. Grayling|Author|Sample Size Determination|Topic|AUTHORED
462|Pavel Mozgunov|Author|Sample Size Determination|Topic|AUTHORED
462|Thomas Jaki|Author|Sample Size Determination|Topic|AUTHORED
462|James M. S. Wason|Author|Sample Size Determination|Topic|AUTHORED
463|Actg 175 Hiv Trial|Topic|Us Early-Stage Hiv Patients|Topic|RELATED_TO
463|Actg 175 Hiv Trial|Topic|Thailand Hiv Patients|Topic|RELATED_TO
463|Actg 175 Hiv Trial|Topic|Southern Ethiopia Hiv Patients|Topic|RELATED_TO
463|Actg 175 Hiv Trial|Topic|Treatment Effect|Topic|DISCUSSES
463|Cox Proportional Hazard Model|Topic|Treatment Effect|Topic|DISCUSSES
463|Inverse Probability Weighting Method|Topic|Treatment Effect|Topic|DISCUSSES
463|Augmented Calibration Weighting Method|Topic|Treatment Effect|Topic|DISCUSSES
463|Linear Spline-Based Hazard Regression Model|Topic|Augmented Calibration Weighting Method|Topic|RELATED_TO
463|Dasom Lee|Author|Actg 175 Hiv Trial|Topic|AUTHORED
463|Sujit Ghosh|Author|Actg 175 Hiv Trial|Topic|AUTHORED
463|Shu Yang|Author|Actg 175 Hiv Trial|Topic|AUTHORED
464|Using Limited Trial Evidence To Credibly Choose Treatment Dosage When Efficacy And Adverse Effects Weakly Increase With Dose|Paper|Charles F. Manski|Author|AUTHORED
464|Using Limited Trial Evidence To Credibly Choose Treatment Dosage When Efficacy And Adverse Effects Weakly Increase With Dose|Paper|Dosage|Topic|RELATED_TO
464|Using Limited Trial Evidence To Credibly Choose Treatment Dosage When Efficacy And Adverse Effects Weakly Increase With Dose|Paper|Efficacy|Topic|RELATED_TO
464|Using Limited Trial Evidence To Credibly Choose Treatment Dosage When Efficacy And Adverse Effects Weakly Increase With Dose|Paper|Adverse Effects|Topic|RELATED_TO
464|Using Limited Trial Evidence To Credibly Choose Treatment Dosage When Efficacy And Adverse Effects Weakly Increase With Dose|Paper|Trial Evidence|Topic|RELATED_TO
464|Using Limited Trial Evidence To Credibly Choose Treatment Dosage When Efficacy And Adverse Effects Weakly Increase With Dose|Paper|Patient Care|Topic|RELATED_TO
464|Using Limited Trial Evidence To Credibly Choose Treatment Dosage When Efficacy And Adverse Effects Weakly Increase With Dose|Paper|Treatment Cost|Topic|RELATED_TO
464|Using Limited Trial Evidence To Credibly Choose Treatment Dosage When Efficacy And Adverse Effects Weakly Increase With Dose|Paper|Minimax-Regret Criterion|Topic|RELATED_TO
464|Using Limited Trial Evidence To Credibly Choose Treatment Dosage When Efficacy And Adverse Effects Weakly Increase With Dose|Paper|Convex Polygon|Topic|RELATED_TO
465|Design Considerations For A Phase Ii Platform Trial In Major Depressive Disorder|Paper|Major Depressive Disorder (Mdd)|Topic|DISCUSSES
465|Design Considerations For A Phase Ii Platform Trial In Major Depressive Disorder|Paper|Michaela Maria Freitag|Author|AUTHORED
465|Design Considerations For A Phase Ii Platform Trial In Major Depressive Disorder|Paper|Dario Zocholl|Author|AUTHORED
465|Design Considerations For A Phase Ii Platform Trial In Major Depressive Disorder|Paper|Elias Laurin Meyer|Author|AUTHORED
465|Design Considerations For A Phase Ii Platform Trial In Major Depressive Disorder|Paper|Stefan M. Gold|Author|AUTHORED
465|Design Considerations For A Phase Ii Platform Trial In Major Depressive Disorder|Paper|Marta Bofill Roig|Author|AUTHORED
465|Design Considerations For A Phase Ii Platform Trial In Major Depressive Disorder|Paper|Heidi De Smedt|Author|AUTHORED
465|Design Considerations For A Phase Ii Platform Trial In Major Depressive Disorder|Paper|Martin Posch|Author|AUTHORED
465|Design Considerations For A Phase Ii Platform Trial In Major Depressive Disorder|Paper|Franz König|Author|AUTHORED
466|Ai-Probe|Topic|Intra-Cranial Hemorrhage|Topic|RELATED_TO
466|Ai-Probe|Topic|Turn-Around Time|Topic|RELATED_TO
466|Intra-Cranial Hemorrhage|Topic|Turn-Around Time|Topic|RELATED_TO
466|Aidoc|Author|Intra-Cranial Hemorrhage|Topic|RELATED_TO
466|Axel Wismüller|Author|Ai-Probe|Topic|AUTHORED
466|Larry Stockmaster|Author|Ai-Probe|Topic|AUTHORED
467|Neurosciences|Topic|Brain Signals|Topic|RELATED_TO
467|Brain Signals|Topic|Wavelets|Topic|RELATED_TO
467|Wavelets|Topic|Replicate Locally Stationary Wavelet (Rlsw) Process|Topic|RELATED_TO
467|Replicate Locally Stationary Wavelet (Rlsw) Process|Topic|Nonstationary Behaviour|Topic|RELATED_TO
467|Replicate Locally Stationary Wavelet (Rlsw) Process|Topic|Spectral Estimation Framework|Topic|RELATED_TO
467|Jonathan Embleton|Author|Simulation Studies|Topic|AUTHORED
467|Marina I. Knight|Author|Simulation Studies|Topic|AUTHORED
467|Hernando Ombao|Author|Simulation Studies|Topic|AUTHORED
467|Hippocampus|Topic|Associative Learning Experiment|Topic|RELATED_TO
467|Nucleus Accumbens|Topic|Associative Learning Experiment|Topic|RELATED_TO
468|Brain|Topic|Neuroscience|Topic|RELATED_TO
468|Monkey_Local_Field_Potentials|Topic|Go_No-Go_Task|Topic|RELATED_TO
468|Go_No-Go_Task|Topic|Bandt-Pompe_Symbolization|Topic|RELATED_TO
468|Go_No-Go_Task|Topic|Asymmetry_Index|Topic|RELATED_TO
468|Go_No-Go_Task|Topic|Multi-Scale_Approach|Topic|RELATED_TO
468|Helena_B_Lucas|Author|Monkey_Local_Field_Potentials|Topic|AUTHORED
468|Steven_L_Bressler|Author|Monkey_Local_Field_Potentials|Topic|AUTHORED
468|Fernanda_S_Matias|Author|Monkey_Local_Field_Potentials|Topic|AUTHORED
468|Osvaldo_A_Rosso|Author|Monkey_Local_Field_Potentials|Topic|AUTHORED
469|Clinical Connectivity Map Framework|Topic|Laboratory Tests|Topic|RELATED_TO
469|Clinical Connectivity Map Framework|Topic|Clinical Drug Effect Vectors|Topic|RELATED_TO
469|Clinical Connectivity Map Framework|Topic|Clinical Disease Sign Vectors|Topic|RELATED_TO
469|Clinical Drug Effect Vectors|Topic|Dot Product-Based Scoring Function|Topic|RELATED_TO
469|Clinical Disease Sign Vectors|Topic|Dot Product-Based Scoring Function|Topic|RELATED_TO
469|Asthma|Topic|Clinical Connectivity Map Framework|Topic|RELATED_TO
469|Coronary Heart Disease|Topic|Clinical Connectivity Map Framework|Topic|RELATED_TO
469|Type 2 Diabetes|Topic|Clinical Connectivity Map Framework|Topic|RELATED_TO
469|Qianlong Wen|Author|Clinical Connectivity Map Framework|Topic|AUTHORED
469|Ruoqi Liu|Author|Clinical Connectivity Map Framework|Topic|AUTHORED
469|Ping Zhang|Author|Clinical Connectivity Map Framework|Topic|AUTHORED
470|Mpnn Model|Topic|Biomedical Papers|Topic|RELATED_TO
470|Clinical Citation Count|Topic|Biomedical Papers|Topic|RELATED_TO
470|Mpnn Model|Topic|Xin Li|Author|AUTHORED
470|Mpnn Model|Topic|Xuli Tang|Author|AUTHORED
470|Mpnn Model|Topic|Qikai Cheng|Author|AUTHORED
471|Crocs|Topic|Dani Kiyasseh|Author|AUTHORED
471|Crocs|Topic|Tingting Zhu|Author|AUTHORED
471|Crocs|Topic|David A. Clifton|Author|AUTHORED
471|Crocs|Topic|Clinical Tasks|Topic|RELATED_TO
471|Crocs|Topic|Clinical Databases|Topic|RELATED_TO
471|Crocs|Topic|Dtc|Topic|RELATED_TO
472|Cluster Randomized Trials|Topic|Connectivity-Informed Trial Designs|Topic|RELATED_TO
472|Connectivity-Informed Trial Designs|Topic|Public Health Impact|Topic|RELATED_TO
472|Connectivity-Informed Trial Designs|Topic|Epidemic Control|Topic|RELATED_TO
472|Connectivity-Informed Trial Designs|Topic|Vaccine Effect Performance|Topic|RELATED_TO
472|Seir-Type Epidemic|Topic|Network-Structured Agent-Based Model|Topic|RELATED_TO
472|Guy Harling|Author|Cluster Randomized Trials|Topic|AUTHORED
472|Rui Wang|Author|Cluster Randomized Trials|Topic|AUTHORED
472|Jukka-Pekka Onnela|Author|Cluster Randomized Trials|Topic|AUTHORED
472|Victor De Gruttola|Author|Cluster Randomized Trials|Topic|AUTHORED
473|Fusing Trial Data For Treatment Comparisons: Single Versus Multi-Span Bridging|Paper|Bonnie E. Shook-Sa|Author|AUTHORED
473|Fusing Trial Data For Treatment Comparisons: Single Versus Multi-Span Bridging|Paper|Paul N. Zivich|Author|AUTHORED
473|Fusing Trial Data For Treatment Comparisons: Single Versus Multi-Span Bridging|Paper|Samuel P. Rosin|Author|AUTHORED
473|Fusing Trial Data For Treatment Comparisons: Single Versus Multi-Span Bridging|Paper|Jessie K. Edwards|Author|AUTHORED
473|Fusing Trial Data For Treatment Comparisons: Single Versus Multi-Span Bridging|Paper|Adaora A. Adimora|Author|AUTHORED
473|Fusing Trial Data For Treatment Comparisons: Single Versus Multi-Span Bridging|Paper|Michael G. Hudgens|Author|AUTHORED
473|Fusing Trial Data For Treatment Comparisons: Single Versus Multi-Span Bridging|Paper|Stephen R. Cole|Author|AUTHORED
474|Observational Studies|Topic|Randomized Controlled Trials (Rcts)|Topic|RELATED_TO
474|Target Trial Emulation|Topic|Causal Inference|Topic|RELATED_TO
474|Novel Framework For Target Trial Emulation|Topic|Causal Inference|Topic|RELATED_TO
474|Dimitris Bertsimas|Author|Novel Framework For Target Trial Emulation|Topic|AUTHORED
474|Angelos G. Koulouras|Author|Novel Framework For Target Trial Emulation|Topic|AUTHORED
474|Hiroshi Nagata|Author|Novel Framework For Target Trial Emulation|Topic|AUTHORED
474|Carol Gao|Author|Novel Framework For Target Trial Emulation|Topic|AUTHORED
474|Junki Mizusawa|Author|Novel Framework For Target Trial Emulation|Topic|AUTHORED
474|Yukihide Kanemitsu|Author|Novel Framework For Target Trial Emulation|Topic|AUTHORED
474|Georgios Antonios Margonis|Author|Novel Framework For Target Trial Emulation|Topic|AUTHORED
475|Hidden Markov Models For Alcoholism Treatment Trial Data|Paper|Markov Models|Topic|DISCUSSES
475|Hidden Markov Models For Alcoholism Treatment Trial Data|Paper|Hidden Markov Models|Topic|DISCUSSES
475|Hidden Markov Models For Alcoholism Treatment Trial Data|Paper|Naltrexone|Topic|DISCUSSES
476|Small-Sample Behavior Of Novel Phase I Cancer Trial Designs|Paper|Bayesian Phase I|Topic|DISCUSSES
476|Small-Sample Behavior Of Novel Phase I Cancer Trial Designs|Paper|Lmp1S|Topic|DISCUSSES
476|Small-Sample Behavior Of Novel Phase I Cancer Trial Designs|Paper|U&D|Topic|DISCUSSES
476|Small-Sample Behavior Of Novel Phase I Cancer Trial Designs|Paper|Assaf P. Oron|Author|AUTHORED
476|Small-Sample Behavior Of Novel Phase I Cancer Trial Designs|Paper|Peter D. Hoff|Author|AUTHORED
477|Mathematical Model Of Colorectal Cancer With Monoclonal Antibody Treatments|Paper|Colorectal Cancer|Topic|RELATED_TO
477|Mathematical Model Of Colorectal Cancer With Monoclonal Antibody Treatments|Paper|Monoclonal Antibody Therapy|Topic|RELATED_TO
477|Mathematical Model Of Colorectal Cancer With Monoclonal Antibody Treatments|Paper|Irinotecan|Topic|RELATED_TO
477|Mathematical Model Of Colorectal Cancer With Monoclonal Antibody Treatments|Paper|Cetuximab|Topic|RELATED_TO
477|Mathematical Model Of Colorectal Cancer With Monoclonal Antibody Treatments|Paper|Panitumumab|Topic|RELATED_TO
477|Mathematical Model Of Colorectal Cancer With Monoclonal Antibody Treatments|Paper|Nonlinear Ordinary Differential Equations|Topic|RELATED_TO
477|Mathematical Model Of Colorectal Cancer With Monoclonal Antibody Treatments|Paper|Tumor Growth Rate|Topic|RELATED_TO
477|Mathematical Model Of Colorectal Cancer With Monoclonal Antibody Treatments|Paper|Carrying Capacity|Topic|RELATED_TO
477|Mathematical Model Of Colorectal Cancer With Monoclonal Antibody Treatments|Paper|Pk/Pd Parameters|Topic|RELATED_TO
478|Response-Adaptive Randomisation (Rar)|Topic|Response Adaptive Designs For Binary Responses: How To Offer Patient Benefit While Being Robust To Time Trends?|Paper|DISCUSSES
478|Sofia S. Villar|Author|Response Adaptive Designs For Binary Responses: How To Offer Patient Benefit While Being Robust To Time Trends?|Paper|AUTHORED
478|Jack Bowden|Author|Response Adaptive Designs For Binary Responses: How To Offer Patient Benefit While Being Robust To Time Trends?|Paper|AUTHORED
478|James Wason|Author|Response Adaptive Designs For Binary Responses: How To Offer Patient Benefit While Being Robust To Time Trends?|Paper|AUTHORED
479|Phase I|Topic|Phase Ii|Topic|RELATED_TO
479|Phase I/Ii Clinical Trials|Topic|Cytotoxic Agents|Topic|RELATED_TO
479|Phase I/Ii Clinical Trials|Topic|Molecularly Targeted Agents|Topic|RELATED_TO
479|Molecularly Targeted Agents|Topic|Dose-Efficacy Relationship|Topic|RELATED_TO
479|Regimen-Finding Design|Topic|Molecularly Targeted Agents|Topic|RELATED_TO
479|Pavel Mozgunov|Author|Phase I/Ii Clinical Trials|Topic|AUTHORED
479|Thomas Jaki|Author|Phase I/Ii Clinical Trials|Topic|AUTHORED
480|Strituvad Project|Topic|Universal Immune System Simulator|Topic|RELATED_TO
480|Universal Immune System Simulator|Topic|Bayesian Adaptive Design|Topic|RELATED_TO
480|Universal Immune System Simulator|Topic|Digital Patients|Topic|RELATED_TO
480|Digital Patients|Topic|Marzio Pennisi|Author|AUTHORED
480|Digital Patients|Topic|Miguel A. Juarez|Author|AUTHORED
480|Digital Patients|Topic|Giulia Russo|Author|AUTHORED
480|Digital Patients|Topic|Marco Viceconti|Author|AUTHORED
480|Digital Patients|Topic|Francesco Pappalardo|Author|AUTHORED
481|Event-Driven Clinical Trials|Topic|Clinical Events|Topic|RELATED_TO
481|Clinical Events|Topic|Oncology|Topic|RELATED_TO
481|Clinical Events|Topic|Cardiovascular Trials|Topic|RELATED_TO
481|Patient Recruitment|Topic|Event Counts|Topic|RELATED_TO
481|Analytic Approach|Topic|Poisson-Gamma Model|Topic|RELATED_TO
481|Analytic Approach|Topic|Exponential Distribution|Topic|RELATED_TO
481|Analytic Approach|Topic|Weibull Distribution|Topic|RELATED_TO
481|Analytic Approach|Topic|Log-Normal Distribution|Topic|RELATED_TO
481|Simulation|Topic|Real Dataset|Topic|RELATED_TO
481|Vladimir Anisimov|Author|Analytic Approach|Topic|AUTHORED
481|Stephen Gormley|Author|Analytic Approach|Topic|AUTHORED
481|Rosalind Baverstock|Author|Analytic Approach|Topic|AUTHORED
481|Cynthia Kineza|Author|Analytic Approach|Topic|AUTHORED
482|A Bayesian Hierarchical Model For Bridging Across Patient Subgroups In Phase I Clinical Trials With Animal Data|Paper|Haiyan Zheng|Author|AUTHORED
482|A Bayesian Hierarchical Model For Bridging Across Patient Subgroups In Phase I Clinical Trials With Animal Data|Paper|Lisa V. Hampson|Author|AUTHORED
482|A Bayesian Hierarchical Model For Bridging Across Patient Subgroups In Phase I Clinical Trials With Animal Data|Paper|Thomas Jaki|Author|AUTHORED
483|Covariate Adjustment In Randomized Clinical Trials With Missing Covariate And Outcome Data|Paper|Chia-Rui Chang|Author|AUTHORED
483|Covariate Adjustment In Randomized Clinical Trials With Missing Covariate And Outcome Data|Paper|Yue Song|Author|AUTHORED
483|Covariate Adjustment In Randomized Clinical Trials With Missing Covariate And Outcome Data|Paper|Fan Li|Author|AUTHORED
483|Covariate Adjustment In Randomized Clinical Trials With Missing Covariate And Outcome Data|Paper|Rui Wang|Author|AUTHORED
483|Covariate Adjustment In Randomized Clinical Trials With Missing Covariate And Outcome Data|Paper|Childhood Adenotonsillectomy Trial|Topic|RELATED_TO
484|Sensitivity Analyses Of Clinical Trial Designs: Selecting Scenarios And Summarizing Operating Characteristics|Paper|Simulation-Based Sensitivity Analyses|Topic|DISCUSSES
484|Sensitivity Analyses Of Clinical Trial Designs: Selecting Scenarios And Summarizing Operating Characteristics|Paper|Candidate Designs For Future Clinical Trials|Topic|DISCUSSES
484|Sensitivity Analyses Of Clinical Trial Designs: Selecting Scenarios And Summarizing Operating Characteristics|Paper|Design Operating Characteristics|Topic|DISCUSSES
484|Sensitivity Analyses Of Clinical Trial Designs: Selecting Scenarios And Summarizing Operating Characteristics|Paper|Unknown Parameters|Topic|DISCUSSES
484|Sensitivity Analyses Of Clinical Trial Designs: Selecting Scenarios And Summarizing Operating Characteristics|Paper|Plausible Simulation Scenarios|Topic|DISCUSSES
484|Sensitivity Analyses Of Clinical Trial Designs: Selecting Scenarios And Summarizing Operating Characteristics|Paper|Optimization Techniques|Topic|DISCUSSES
485|Adaptive Identification Of Populations With Treatment Benefit In Clinical Trials: Machine Learning Challenges And Solutions|Paper|Patient Subpopulations|Topic|DISCUSSES
485|Adaptive Identification Of Populations With Treatment Benefit In Clinical Trials: Machine Learning Challenges And Solutions|Paper|Adaptive Clinical Trial|Topic|DISCUSSES
485|Adaptive Identification Of Populations With Treatment Benefit In Clinical Trials: Machine Learning Challenges And Solutions|Paper|Biostatistics|Topic|DISCUSSES
485|Adaptive Identification Of Populations With Treatment Benefit In Clinical Trials: Machine Learning Challenges And Solutions|Paper|Machine Learning|Topic|DISCUSSES
485|Adaptive Identification Of Populations With Treatment Benefit In Clinical Trials: Machine Learning Challenges And Solutions|Paper|Adaggi|Topic|RELATED_TO
485|Adaptive Identification Of Populations With Treatment Benefit In Clinical Trials: Machine Learning Challenges And Solutions|Paper|Adagcpi|Topic|RELATED_TO
486|Enrollment Forecast For Clinical Trials At The Portfolio Planning Phase Based On Site-Level Historical Data|Paper|Sheng Zhong|Author|AUTHORED
486|Enrollment Forecast For Clinical Trials At The Portfolio Planning Phase Based On Site-Level Historical Data|Paper|Yunzhao Xing|Author|AUTHORED
486|Enrollment Forecast For Clinical Trials At The Portfolio Planning Phase Based On Site-Level Historical Data|Paper|Mengjia Yu|Author|AUTHORED
486|Enrollment Forecast For Clinical Trials At The Portfolio Planning Phase Based On Site-Level Historical Data|Paper|Li Wang|Author|AUTHORED
486|Enrollment Forecast For Clinical Trials At The Portfolio Planning Phase Based On Site-Level Historical Data|Paper|Clinical Trial Enrollment|Topic|RELATED_TO
486|Enrollment Forecast For Clinical Trials At The Portfolio Planning Phase Based On Site-Level Historical Data|Paper|Statistical Approaches|Topic|RELATED_TO
486|Enrollment Forecast For Clinical Trials At The Portfolio Planning Phase Based On Site-Level Historical Data|Paper|Generalized Linear Mixed-Effects Models|Topic|RELATED_TO
487|The Clinical Trials Puzzle: How Network Effects Limit Drug Discovery|Paper|Kishore Vasan|Author|AUTHORED
487|The Clinical Trials Puzzle: How Network Effects Limit Drug Discovery|Paper|Deisy Gysi|Author|AUTHORED
487|The Clinical Trials Puzzle: How Network Effects Limit Drug Discovery|Paper|Albert-Laszlo Barabasi|Author|AUTHORED
487|The Clinical Trials Puzzle: How Network Effects Limit Drug Discovery|Paper|Post-Genomic Medicine|Topic|RELATED_TO
487|The Clinical Trials Puzzle: How Network Effects Limit Drug Discovery|Paper|Clinical Trials|Topic|RELATED_TO
487|The Clinical Trials Puzzle: How Network Effects Limit Drug Discovery|Paper|Drug Discovery|Topic|RELATED_TO
487|The Clinical Trials Puzzle: How Network Effects Limit Drug Discovery|Paper|Human Interactome|Topic|RELATED_TO
487|The Clinical Trials Puzzle: How Network Effects Limit Drug Discovery|Paper|Network-Based Model|Topic|RELATED_TO
487|The Clinical Trials Puzzle: How Network Effects Limit Drug Discovery|Paper|Druggable Proteins|Topic|RELATED_TO
488|Pulsar|Topic|Immunotherapy|Topic|RELATED_TO
488|Pulsar|Topic|Mathematical Model|Topic|RELATED_TO
488|Samiha Rouf|Author|Mathematical Model|Topic|AUTHORED
488|Casey Moore|Author|Mathematical Model|Topic|AUTHORED
488|Debabrata Saha|Author|Mathematical Model|Topic|AUTHORED
488|Dan Nguyen|Author|Mathematical Model|Topic|AUTHORED
488|Marylena Bleile|Author|Mathematical Model|Topic|AUTHORED
488|Robert Timmerman|Author|Mathematical Model|Topic|AUTHORED
488|Hao Peng|Author|Mathematical Model|Topic|AUTHORED
488|Steve Jiang|Author|Mathematical Model|Topic|AUTHORED
489|Gentwoarmstrialsize|Topic|Clinical Trials|Topic|RELATED_TO
489|Gentwoarmstrialsize|Topic|R Statistical Software|Topic|RELATED_TO
489|Gentwoarmstrialsize|Topic|Pharmaceutical Statisticians|Topic|RELATED_TO
490|Top-Down Multilevel Simulation Of Tumor Response To Treatment In The Context Of In Silico Oncology|Paper|Georgios Stamatakos|Author|AUTHORED
490|Top-Down Multilevel Simulation Of Tumor Response To Treatment In The Context Of In Silico Oncology|Paper|Tumor Dynamics Modeling Method|Topic|RELATED_TO
490|Top-Down Multilevel Simulation Of Tumor Response To Treatment In The Context Of In Silico Oncology|Paper|Oncosimulator|Topic|RELATED_TO
491|Patients|Topic|Clinical Trial|Topic|RELATED_TO
491|Clinical Trial|Topic|Medication'S Efficacy|Topic|DISCUSSES
491|Missing Data Problem|Topic|Medication'S Efficacy|Topic|DISCUSSES
491|Trimmed Means Approach|Topic|Missing Data Problem|Topic|RELATED_TO
491|Average Population Treatment Effect|Topic|Trimmed Means Approach|Topic|RELATED_TO
491|Missing Not At Random (Mnar)|Topic|Trimmed Means Approach|Topic|RELATED_TO
491|Missing At Random (Mar)|Topic|Trimmed Means Approach|Topic|RELATED_TO
491|Multiple Imputation (Mi)|Topic|Trimmed Means Approach|Topic|RELATED_TO
491|Permutt 2017|Paper|Alex Ocampo|Author|AUTHORED
491|Permutt 2017|Paper|Heinz Schmidli|Author|AUTHORED
491|Permutt 2017|Paper|Peter Quarg|Author|AUTHORED
491|Permutt 2017|Paper|Francesca Callegari|Author|AUTHORED
491|Permutt 2017|Paper|Marcello Pagano|Author|AUTHORED
492|Model-Robust Inference For Clinical Trials That Improve Precision By Stratified Randomization And Covariate Adjustment|Paper|Bingkai Wang|Author|AUTHORED
492|Model-Robust Inference For Clinical Trials That Improve Precision By Stratified Randomization And Covariate Adjustment|Paper|Ryoko Susukida|Author|AUTHORED
492|Model-Robust Inference For Clinical Trials That Improve Precision By Stratified Randomization And Covariate Adjustment|Paper|Ramin Mojtabai|Author|AUTHORED
492|Model-Robust Inference For Clinical Trials That Improve Precision By Stratified Randomization And Covariate Adjustment|Paper|Masoumeh Amin-Esmaeili|Author|AUTHORED
492|Model-Robust Inference For Clinical Trials That Improve Precision By Stratified Randomization And Covariate Adjustment|Paper|Michael Rosenblum|Author|AUTHORED
492|Model-Robust Inference For Clinical Trials That Improve Precision By Stratified Randomization And Covariate Adjustment|Paper|Stratified Randomization|Topic|RELATED_TO
492|Model-Robust Inference For Clinical Trials That Improve Precision By Stratified Randomization And Covariate Adjustment|Paper|Covariate Adjustment|Topic|RELATED_TO
492|Model-Robust Inference For Clinical Trials That Improve Precision By Stratified Randomization And Covariate Adjustment|Paper|Clinical Trials|Topic|RELATED_TO
493|Adaptive Enrichment|Topic|Clinical Trial|Topic|RELATED_TO
493|Longitudinal And Time-To-Event Data|Topic|Clinical Trial|Topic|RELATED_TO
493|Biomarkers|Topic|Clinical Trial|Topic|RELATED_TO
493|Metastatic Breast Cancer|Topic|Clinical Trial|Topic|RELATED_TO
493|Abigail J. Burdon|Author|Longitudinal And Time-To-Event Data|Topic|AUTHORED
493|Richard D. Baird|Author|Longitudinal And Time-To-Event Data|Topic|AUTHORED
493|Thomas Jaki|Author|Longitudinal And Time-To-Event Data|Topic|AUTHORED
494|Exact Statistical Analysis For Response-Adaptive Clinical Trials: A General And Computationally Tractable Approach|Paper|Stef Baas|Author|AUTHORED
494|Exact Statistical Analysis For Response-Adaptive Clinical Trials: A General And Computationally Tractable Approach|Paper|Peter Jacko|Author|AUTHORED
494|Exact Statistical Analysis For Response-Adaptive Clinical Trials: A General And Computationally Tractable Approach|Paper|Sofía S. Villar|Author|AUTHORED
494|Exact Statistical Analysis For Response-Adaptive Clinical Trials: A General And Computationally Tractable Approach|Paper|Response-Adaptive Clinical Trials|Topic|RELATED_TO
495|Decoding The Circuitry Of Consciousness: From Local Microcircuits To Brain-Scale Networks|Paper|Julien Modolo|Author|AUTHORED
495|Decoding The Circuitry Of Consciousness: From Local Microcircuits To Brain-Scale Networks|Paper|Mahmoud Hassan|Author|AUTHORED
495|Decoding The Circuitry Of Consciousness: From Local Microcircuits To Brain-Scale Networks|Paper|Fabrice Wendling|Author|AUTHORED
495|Decoding The Circuitry Of Consciousness: From Local Microcircuits To Brain-Scale Networks|Paper|Pascal Benquet|Author|AUTHORED
495|Decoding The Circuitry Of Consciousness: From Local Microcircuits To Brain-Scale Networks|Paper|Consciousness|Topic|RELATED_TO
495|Decoding The Circuitry Of Consciousness: From Local Microcircuits To Brain-Scale Networks|Paper|Disorders Of Consciousness|Topic|RELATED_TO
495|Disorders Of Consciousness|Topic|Neuroscience|Topic|RELATED_TO
496|Fome (Foundation Model For Eeg)|Paper|Enze Shi|Author|AUTHORED
496|Fome (Foundation Model For Eeg)|Paper|Kui Zhao|Author|AUTHORED
496|Fome (Foundation Model For Eeg)|Paper|Qilong Yuan|Author|AUTHORED
496|Fome (Foundation Model For Eeg)|Paper|Jiaqi Wang|Author|AUTHORED
496|Fome (Foundation Model For Eeg)|Paper|Huawen Hu|Author|AUTHORED
496|Fome (Foundation Model For Eeg)|Paper|Sigang Yu|Author|AUTHORED
496|Fome (Foundation Model For Eeg)|Paper|Shu Zhang|Author|AUTHORED
496|Electroencephalography (Eeg)|Topic|Fome (Foundation Model For Eeg)|Paper|RELATED_TO
497|Eeg Signal Denoising Using Pix2Pix Gan: Enhancing Neurological Data Analysis|Paper|Haoyi Wang|Author|AUTHORED
497|Eeg Signal Denoising Using Pix2Pix Gan: Enhancing Neurological Data Analysis|Paper|Xufang Chen|Author|AUTHORED
497|Eeg Signal Denoising Using Pix2Pix Gan: Enhancing Neurological Data Analysis|Paper|Yue Yang|Author|AUTHORED
497|Eeg Signal Denoising Using Pix2Pix Gan: Enhancing Neurological Data Analysis|Paper|Kewei Zhou|Author|AUTHORED
497|Eeg Signal Denoising Using Pix2Pix Gan: Enhancing Neurological Data Analysis|Paper|Meining Lv|Author|AUTHORED
497|Eeg Signal Denoising Using Pix2Pix Gan: Enhancing Neurological Data Analysis|Paper|Dongrui Wang|Author|AUTHORED
497|Eeg Signal Denoising Using Pix2Pix Gan: Enhancing Neurological Data Analysis|Paper|Wenjie Zhang|Author|AUTHORED
497|Pix2Pixgan|Topic|Electroencephalography (Eeg)|Topic|RELATED_TO
497|Eegdenoisenet Dataset|Topic|Pix2Pixgan|Topic|RELATED_TO
498|Real-Time Machine Learning Strategies For A New Kind Of Neuroscience Experiments|Paper|Ayesha Vermani|Author|AUTHORED
498|Real-Time Machine Learning Strategies For A New Kind Of Neuroscience Experiments|Paper|Matthew Dowling|Author|AUTHORED
498|Real-Time Machine Learning Strategies For A New Kind Of Neuroscience Experiments|Paper|Hyungju Jeon|Author|AUTHORED
498|Real-Time Machine Learning Strategies For A New Kind Of Neuroscience Experiments|Paper|Ian Jordan|Author|AUTHORED
498|Real-Time Machine Learning Strategies For A New Kind Of Neuroscience Experiments|Paper|Josue Nassar|Author|AUTHORED
498|Real-Time Machine Learning Strategies For A New Kind Of Neuroscience Experiments|Paper|Yves Bernaerts|Author|AUTHORED
498|Real-Time Machine Learning Strategies For A New Kind Of Neuroscience Experiments|Paper|Yuan Zhao|Author|AUTHORED
498|Real-Time Machine Learning Strategies For A New Kind Of Neuroscience Experiments|Paper|Steven Van Vaerenbergh|Author|AUTHORED
498|Real-Time Machine Learning Strategies For A New Kind Of Neuroscience Experiments|Paper|Il Memming Park|Author|AUTHORED
499|Human Decision Making Behavior|Topic|Choice-Response Time Data|Topic|RELATED_TO
499|Drift-Diffusion Models|Topic|Wiener First-Passage Time (Wfpt) Distribution|Topic|RELATED_TO
499|Drift-Diffusion Models|Topic|Cognitive Parameters|Topic|RELATED_TO
499|Cognitive Parameters|Topic|Drift Rate|Topic|RELATED_TO
499|Cognitive Parameters|Topic|Boundary Separation|Topic|RELATED_TO
499|Cognitive Parameters|Topic|Starting Point|Topic|RELATED_TO
499|Neuroscientists|Topic|Cognitive Processes Of Decision Making|Topic|RELATED_TO
499|Neuroscientists|Topic|Brain Activity|Topic|RELATED_TO
499|Sincnet-Based Shallow Neural Network Architecture|Topic|Eeg Signals|Topic|RELATED_TO
499|Sincnet-Based Shallow Neural Network Architecture|Topic|Drift-Diffusion Models|Topic|RELATED_TO
499|Sincnet Layer|Topic|Eeg Signals|Topic|RELATED_TO
499|Sincnet Layer|Topic|Drift Rate|Topic|RELATED_TO
499|Sincnet Layer|Topic|Boundary Separation|Topic|RELATED_TO
499|Negative Log Likelihood Function|Topic|Wiener First-Passage Time (Wfpt) Distribution|Topic|RELATED_TO
499|Two-Alternative Forced-Choice Task|Topic|Sincnet-Based Shallow Neural Network Architecture|Topic|RELATED_TO
499|Qinhua Jenny Sun|Author|Decision Sincnet: Neurocognitive Models Of Decision Making That Predict Cognitive Processes From Neural Signals|Paper|AUTHORED
499|Khuong Vo|Author|Decision Sincnet: Neurocognitive Models Of Decision Making That Predict Cognitive Processes From Neural Signals|Paper|AUTHORED
499|Kitty Lui|Author|Decision Sincnet: Neurocognitive Models Of Decision Making That Predict Cognitive Processes From Neural Signals|Paper|AUTHORED
499|Michael Nunez|Author|Decision Sincnet: Neurocognitive Models Of Decision Making That Predict Cognitive Processes From Neural Signals|Paper|AUTHORED
499|Joachim Vandekerckhove|Author|Decision Sincnet: Neurocognitive Models Of Decision Making That Predict Cognitive Processes From Neural Signals|Paper|AUTHORED
499|Ramesh Srinivasan|Author|Decision Sincnet: Neurocognitive Models Of Decision Making That Predict Cognitive Processes From Neural Signals|Paper|AUTHORED
500|Biophysical Effects And Neuromodulatory Dose Of Transcranial Ultrasonic Stimulation|Paper|Transcranial Ultrasonic Stimulation|Topic|DISCUSSES
500|Biophysical Effects And Neuromodulatory Dose Of Transcranial Ultrasonic Stimulation|Paper|Tulika Nandi|Author|AUTHORED
500|Biophysical Effects And Neuromodulatory Dose Of Transcranial Ultrasonic Stimulation|Paper|Benjamin R. Kop|Author|AUTHORED
500|Biophysical Effects And Neuromodulatory Dose Of Transcranial Ultrasonic Stimulation|Paper|Kasra Naftchi-Ardebili|Author|AUTHORED
500|Biophysical Effects And Neuromodulatory Dose Of Transcranial Ultrasonic Stimulation|Paper|Charlotte J. Stagg|Author|AUTHORED
500|Biophysical Effects And Neuromodulatory Dose Of Transcranial Ultrasonic Stimulation|Paper|Kim Butts Pauly|Author|AUTHORED
500|Biophysical Effects And Neuromodulatory Dose Of Transcranial Ultrasonic Stimulation|Paper|Lennart Verhagen|Author|AUTHORED
501|Umbilical Cord Blood|Topic|Cord Blood Banking|Topic|RELATED_TO
501|Nivethika Sivakumaran|Author|Umbilical Cord Blood|Topic|AUTHORED
501|Imesha Rashmini Rathnayaka|Author|Umbilical Cord Blood|Topic|AUTHORED
501|Rashida Shabbir|Author|Umbilical Cord Blood|Topic|AUTHORED
501|Sasini Sandareka Wimalsinghe|Author|Umbilical Cord Blood|Topic|AUTHORED
501|J. A. Sumalimina Jayakody|Author|Umbilical Cord Blood|Topic|AUTHORED
501|Mahisha Chandrasekaran|Author|Umbilical Cord Blood|Topic|AUTHORED
501|Mawatha|Author|Umbilical Cord Blood|Topic|AUTHORED
501|Sri Lanka|Author|Umbilical Cord Blood|Topic|AUTHORED
502|A Bayesian Hierarchical Model For The Analysis Of A Longitudinal Dynamic Contrast-Enhanced Mri Cancer Study|Paper|Dce-Mri|Topic|DISCUSSES
503|Evaluation Of Treatment Effect Modification By Biomarkers Measured Pre- And Post-Randomization In The Presence Of Non-Monotone Missingness|Paper|Yingying Zhuang|Author|AUTHORED
503|Evaluation Of Treatment Effect Modification By Biomarkers Measured Pre- And Post-Randomization In The Presence Of Non-Monotone Missingness|Paper|Ying Huang|Author|AUTHORED
503|Evaluation Of Treatment Effect Modification By Biomarkers Measured Pre- And Post-Randomization In The Presence Of Non-Monotone Missingness|Paper|Peter B. Gilbert|Author|AUTHORED
504|Sars-Cov-2|Topic|Covid-19|Topic|RELATED_TO
504|Covid-19|Topic|Drug Repurposing|Topic|RELATED_TO
504|Drug Repurposing|Topic|Mpro|Topic|RELATED_TO
504|Mpro|Topic|Oxytetracycline|Topic|RELATED_TO
504|Mpro|Topic|Ribavirin|Topic|RELATED_TO
504|Mpro|Topic|Codeine|Topic|RELATED_TO
504|Emilio Angelina|Author|Drug Repurposing|Topic|AUTHORED
504|Sebastian Andujar|Author|Drug Repurposing|Topic|AUTHORED
504|Oscar Parravicini|Author|Drug Repurposing|Topic|AUTHORED
504|Daniel Enriz|Author|Drug Repurposing|Topic|AUTHORED
504|Nelida Peruchena|Author|Drug Repurposing|Topic|AUTHORED
505|A Bias Correction Method In Meta-Analysis Of Randomized Clinical Trials With No Adjustments For Zero-Inflated Outcomes|Paper|Zero-Inflation Bias Correction (Zibc) Method|Topic|DISCUSSES
505|A Bias Correction Method In Meta-Analysis Of Randomized Clinical Trials With No Adjustments For Zero-Inflated Outcomes|Paper|Zhengyang Zhou|Author|AUTHORED
505|A Bias Correction Method In Meta-Analysis Of Randomized Clinical Trials With No Adjustments For Zero-Inflated Outcomes|Paper|Minge Xie|Author|AUTHORED
505|A Bias Correction Method In Meta-Analysis Of Randomized Clinical Trials With No Adjustments For Zero-Inflated Outcomes|Paper|David Huh|Author|AUTHORED
505|A Bias Correction Method In Meta-Analysis Of Randomized Clinical Trials With No Adjustments For Zero-Inflated Outcomes|Paper|Eun-Young Mun|Author|AUTHORED
506|Covid-19 Pandemic|Topic|Clinical Trials|Topic|RELATED_TO
506|Covid-19 Pandemic|Topic|Estimands|Topic|RELATED_TO
506|Clinical Trials|Topic|Ich E9 (R1)|Topic|RELATED_TO
506|Yongming Qu|Author|Ich E9 (R1)|Topic|AUTHORED
506|Ilya Lipkovich|Author|Ich E9 (R1)|Topic|AUTHORED
507|Automated Causal Inference In Application To Randomized Controlled Clinical Trials|Paper|Autoci|Topic|DISCUSSES
507|Automated Causal Inference In Application To Randomized Controlled Clinical Trials|Paper|Rcts|Topic|DISCUSSES
508|Semeval 2023 Task 7|Topic|Natural Language Inference Task|Topic|RELATED_TO
508|Semeval 2023 Task 7|Topic|Evidence Selection Task|Topic|RELATED_TO
508|Natural Language Inference Task|Topic|Maël Jullien|Author|AUTHORED
508|Natural Language Inference Task|Topic|Marco Valentino|Author|AUTHORED
508|Natural Language Inference Task|Topic|Hannah Frost|Author|AUTHORED
508|Natural Language Inference Task|Topic|Paul O'Regan|Author|AUTHORED
508|Natural Language Inference Task|Topic|Donal Landers|Author|AUTHORED
508|Natural Language Inference Task|Topic|André Freitas|Author|AUTHORED
508|Evidence Selection Task|Topic|Maël Jullien|Author|AUTHORED
508|Evidence Selection Task|Topic|Marco Valentino|Author|AUTHORED
508|Evidence Selection Task|Topic|Hannah Frost|Author|AUTHORED
508|Evidence Selection Task|Topic|Paul O'Regan|Author|AUTHORED
508|Evidence Selection Task|Topic|Donal Landers|Author|AUTHORED
508|Evidence Selection Task|Topic|André Freitas|Author|AUTHORED
509|Nli4Ct|Topic|Clinical Trial Reports|Topic|RELATED_TO
509|Nli4Ct|Topic|Natural Language Inference|Topic|RELATED_TO
509|Nli4Ct|Topic|Maël Jullien|Author|AUTHORED
509|Nli4Ct|Topic|Marco Valentino|Author|AUTHORED
509|Nli4Ct|Topic|Hannah Frost|Author|AUTHORED
509|Nli4Ct|Topic|Paul O'Regan|Author|AUTHORED
509|Nli4Ct|Topic|Donal Landers|Author|AUTHORED
509|Nli4Ct|Topic|André Freitas|Author|AUTHORED
510|Aumcf|Topic|Mcc|Topic|RELATED_TO
510|Aumcf|Topic|Beta-Blocker Evaluation Of Survival Trial|Topic|DISCUSSES
510|Mcc|Topic|Beta-Blocker Evaluation Of Survival Trial|Topic|DISCUSSES
510|Jessica Gronsbell|Author|Aumcf|Topic|AUTHORED
510|Zachary R. Mccaw|Author|Aumcf|Topic|AUTHORED
510|Isabelle-Emmanuella Nogues|Author|Aumcf|Topic|AUTHORED
510|Xiangshan Kong|Author|Aumcf|Topic|AUTHORED
510|Tianxi Cai|Author|Aumcf|Topic|AUTHORED
510|Lu Tian|Author|Aumcf|Topic|AUTHORED
510|Lj Wei|Author|Aumcf|Topic|AUTHORED
511|Artificial Intelligence Transfer Learning Algorithms|Topic|Covid-19|Topic|DISCUSSES
511|Clinical Trial|Topic|Mexico|Topic|RELATED_TO
511|Clinical Trial|Topic|Spain|Topic|RELATED_TO
511|Clinical Trial|Topic|Usa|Topic|RELATED_TO
511|Longitudinal Audio Test|Topic|Covid-19|Topic|DISCUSSES
511|Icu Allocation|Topic|Covid-19|Topic|DISCUSSES
511|Open Collective Approach|Topic|Covid-19|Topic|DISCUSSES
511|Https://Opensigma.Mit.Edu|Topic|Open Collective Approach|Topic|RELATED_TO
511|Brian Subirana|Author|Covid-19|Topic|AUTHORED
511|Ferran Hueto|Author|Covid-19|Topic|AUTHORED
511|Prithvi Rajasekaran|Author|Covid-19|Topic|AUTHORED
511|Jordi Laguarta|Author|Covid-19|Topic|AUTHORED
511|Susana Puig|Author|Covid-19|Topic|AUTHORED
511|Josep Malvehy|Author|Covid-19|Topic|AUTHORED
511|Oriol Mitja|Author|Covid-19|Topic|AUTHORED
511|Antoni Trilla|Author|Covid-19|Topic|AUTHORED
511|Carlos Iván Moreno|Author|Covid-19|Topic|AUTHORED
511|José Francisco Muñoz Valle|Author|Covid-19|Topic|AUTHORED
511|Ana Esther Mercado González|Author|Covid-19|Topic|AUTHORED
511|Barbara Vizmanos|Author|Covid-19|Topic|AUTHORED
511|Sanjay Sarma|Author|Covid-19|Topic|AUTHORED
512|Bacterial Infections|Topic|Antimicrobial Resistance|Topic|RELATED_TO
512|Acute Bacterial Skin And Skin Structure Infection (Absssi)|Topic|Methicillin-Resistant Staphylococcus Aureus (Mrsa)|Topic|RELATED_TO
512|Vancomycin|Topic|Acute Bacterial Skin And Skin Structure Infection (Absssi)|Topic|RELATED_TO
512|Inyoung Jun|Author|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|AUTHORED
512|Simone Marini|Author|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|AUTHORED
512|Christina A. Boucher|Author|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|AUTHORED
512|J. Glenn Morris|Author|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|AUTHORED
512|Jiang Bian|Author|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|AUTHORED
512|Mattia Prosperi|Author|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|AUTHORED
512|Propensity Score Matching|Topic|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|RELATED_TO
512|Boosted/Lasso Logistic Regression|Topic|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|RELATED_TO
512|Support Vector Machines|Topic|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|RELATED_TO
512|Random Forest|Topic|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|RELATED_TO
512|Area Under The Receiver Characteristic (Auc)|Topic|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|RELATED_TO
512|Counterfactuals|Topic|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|RELATED_TO
512|Treatment Heterogeneity|Topic|Machine Learning Model Of Mortality Prediction And Ite Estimation|Topic|RELATED_TO
513|Blinatumomab|Topic|B-Cell All|Topic|RELATED_TO
513|Single-Arm Trial|Topic|External Control Data|Topic|DISCUSSES
513|Jérôme Lambert|Author|Single-Arm Trial|Topic|AUTHORED
513|Etienne Lengline|Author|Single-Arm Trial|Topic|AUTHORED
513|Raphaël Porcher|Author|Single-Arm Trial|Topic|AUTHORED
513|Rodolphe Thiébaut|Author|Single-Arm Trial|Topic|AUTHORED
513|Sarah Zohar|Author|Single-Arm Trial|Topic|AUTHORED
513|Sylvie Chevret|Author|Single-Arm Trial|Topic|AUTHORED
514|Seventy-Seven Patients|Paper|Functional Motor Disorder|Topic|RELATED_TO
514|Seventy-Seven Patients|Paper|Health-Related Quality Of Life|Topic|RELATED_TO
514|Seventy-Seven Patients|Paper|Sf-36 Questionnaire|Topic|RELATED_TO
514|Seventy-Seven Patients|Paper|Martin Jirásek|Author|AUTHORED
514|Seventy-Seven Patients|Paper|Tomá Sieger|Author|AUTHORED
514|Seventy-Seven Patients|Paper|Gabriela Chaloupková|Author|AUTHORED
514|Seventy-Seven Patients|Paper|Lucia Nováková|Author|AUTHORED
514|Seventy-Seven Patients|Paper|Petr Sojka|Author|AUTHORED
514|Seventy-Seven Patients|Paper|Mark J Edwards|Author|AUTHORED
514|Seventy-Seven Patients|Paper|Tereza Serranová|Author|AUTHORED
515|Named Clinical Entity Recognition Benchmark|Paper|Wadood M Abdul|Author|AUTHORED
515|Named Clinical Entity Recognition Benchmark|Paper|Marco Af Pimentel|Author|AUTHORED
515|Named Clinical Entity Recognition Benchmark|Paper|Muhammad Umar Salman|Author|AUTHORED
515|Named Clinical Entity Recognition Benchmark|Paper|Tathagata Raha|Author|AUTHORED
515|Named Clinical Entity Recognition Benchmark|Paper|Clément Christophe|Author|AUTHORED
515|Named Clinical Entity Recognition Benchmark|Paper|Praveen K Kanithi|Author|AUTHORED
515|Named Clinical Entity Recognition Benchmark|Paper|Nasir Hayat|Author|AUTHORED
515|Named Clinical Entity Recognition Benchmark|Paper|Ronnie Rajan|Author|AUTHORED
515|Named Clinical Entity Recognition Benchmark|Paper|Shadab Khan|Author|AUTHORED
515|Named Clinical Entity Recognition Benchmark|Paper|Natural Language Processing|Topic|RELATED_TO
515|Named Clinical Entity Recognition Benchmark|Paper|Clinical Entity Recognition|Topic|RELATED_TO
515|Named Clinical Entity Recognition Benchmark|Paper|Healthcare|Topic|RELATED_TO
515|Named Clinical Entity Recognition Benchmark|Paper|F1-Score|Topic|RELATED_TO
515|Named Clinical Entity Recognition Benchmark|Paper|Observational Medical Outcomes Partnership|Topic|RELATED_TO
516|Efficient Adaptive Designs With Mid-Course Sample Size Adjustment In Clinical Trials|Paper|Jay Bartroff|Author|AUTHORED
516|Efficient Adaptive Designs With Mid-Course Sample Size Adjustment In Clinical Trials|Paper|Tze Leung Lai|Author|AUTHORED
516|Efficient Adaptive Designs With Mid-Course Sample Size Adjustment In Clinical Trials|Paper|Adaptive Designs For Clinical Trials|Topic|RELATED_TO
517|Bayesian Decision-Optimal Interval Designs For Phase I Clinical Trials|Paper|Interval Designs|Topic|DISCUSSES
518|Mid-Study Design Modifications|Topic|Confirmatory Clinical Trials|Topic|RELATED_TO
518|Confirmatory Clinical Trials|Topic|Time-To-Event Endpoints|Topic|RELATED_TO
518|Interim Data|Topic|Final Test Statistic|Topic|RELATED_TO
518|Final Test Statistic|Topic|Long-Term Survival|Topic|RELATED_TO
518|Adaptive Survival Trials|Topic|Dominic Magirr|Author|AUTHORED
518|Adaptive Survival Trials|Topic|Thomas Jaki|Author|AUTHORED
518|Adaptive Survival Trials|Topic|Franz Koenig|Author|AUTHORED
518|Adaptive Survival Trials|Topic|Martin Posch|Author|AUTHORED
519|Doctors|Topic|Statistical Inference|Topic|DISCUSSES
519|Personalized Medicine|Topic|Individualized Treatment|Topic|RELATED_TO
519|Keli Liu|Author|Individualized Treatment|Topic|AUTHORED
519|Xiao-Li Meng|Author|Individualized Treatment|Topic|AUTHORED
521|On Multi-Armed Bandit Designs For Dose-Finding Clinical Trials|Paper|Maryam Aziz|Author|AUTHORED
521|On Multi-Armed Bandit Designs For Dose-Finding Clinical Trials|Paper|Emilie Kaufmann|Author|AUTHORED
521|On Multi-Armed Bandit Designs For Dose-Finding Clinical Trials|Paper|Marie-Karelle Riviere|Author|AUTHORED
522|Inferring Which Medical Treatments Work From Reports Of Clinical Trials|Paper|Clinical Trials|Topic|RELATED_TO
522|Inferring Which Medical Treatments Work From Reports Of Clinical Trials|Paper|Randomized Controlled Trials|Topic|RELATED_TO
523|Bayesian Models For Survival Data Of Clinical Trials: Comparison Of Implementations Using R Software|Paper|Allozithro Trial|Topic|DISCUSSES
523|Bayesian Models For Survival Data Of Clinical Trials: Comparison Of Implementations Using R Software|Paper|Lucie Biard|Author|AUTHORED
523|Bayesian Models For Survival Data Of Clinical Trials: Comparison Of Implementations Using R Software|Paper|Anne Bergeron|Author|AUTHORED
523|Bayesian Models For Survival Data Of Clinical Trials: Comparison Of Implementations Using R Software|Paper|Sylvie Chevret|Author|AUTHORED
524|Causal Intervention Effects|Topic|Transmissible Infectious Disease Outcomes|Topic|RELATED_TO
524|Vaccine|Topic|Transmissible Infectious Disease Outcomes|Topic|RELATED_TO
524|Epidemiologists|Topic|Causal Estimands|Topic|RELATED_TO
524|Causal Estimands|Topic|Two-Person Partnership Model|Topic|RELATED_TO
524|Two-Person Partnership Model|Topic|Infectious Disease Transmission Dynamics|Topic|RELATED_TO
524|Empirical Intervention Trials|Topic|Causal Intervention Effects|Topic|RELATED_TO
524|Time-To-Infection Data|Topic|Causal Intervention Effects|Topic|RELATED_TO
524|Binary Outcome Data|Topic|Causal Intervention Effects|Topic|RELATED_TO
524|Hiv Vaccine Trial|Topic|Causal Intervention Effects|Topic|RELATED_TO
524|Xiaoxuan Cai|Author|Causal Intervention Effects|Topic|AUTHORED
524|Wen Wei Loh|Author|Causal Intervention Effects|Topic|AUTHORED
524|Forrest W. Crawford|Author|Causal Intervention Effects|Topic|AUTHORED
525|Trialverify|Topic|Observational Studies|Topic|DISCUSSES
525|Trialverify|Topic|Clinical Trial Reports|Topic|RELATED_TO
525|Trialverify|Topic|Inverse Propensity Score Weighting|Topic|DISCUSSES
525|Ethan Steinberg|Author|Trialverify|Topic|AUTHORED
525|Nikolaos Ignatiadis|Author|Trialverify|Topic|AUTHORED
525|Steve Yadlowsky|Author|Trialverify|Topic|AUTHORED
525|Yizhe Xu|Author|Trialverify|Topic|AUTHORED
525|Nigam H. Shah|Author|Trialverify|Topic|AUTHORED
525|Trialverify|Topic|National Insurance Claims Dataset|Topic|RELATED_TO
526|Causal Inference Methods For Small Non-Randomized Studies: Methods And An Application In Covid-19|Paper|Sarah Friedrich|Author|AUTHORED
526|Causal Inference Methods For Small Non-Randomized Studies: Methods And An Application In Covid-19|Paper|Tim Friede|Author|AUTHORED
526|Causal Inference Methods For Small Non-Randomized Studies: Methods And An Application In Covid-19|Paper|Sars-Cov-2 Pandemic|Topic|RELATED_TO
526|Causal Inference Methods For Small Non-Randomized Studies: Methods And An Application In Covid-19|Paper|Propensity Score Methods|Topic|RELATED_TO
526|Causal Inference Methods For Small Non-Randomized Studies: Methods And An Application In Covid-19|Paper|G-Computation Approach|Topic|RELATED_TO
526|Causal Inference Methods For Small Non-Randomized Studies: Methods And An Application In Covid-19|Paper|Doubly Robust Estimators|Topic|RELATED_TO
527|Sample Size Calculation For Cluster Randomized Trials With Zero-Inflated Count Outcomes|Paper|Zhengyang Zhou|Author|AUTHORED
527|Sample Size Calculation For Cluster Randomized Trials With Zero-Inflated Count Outcomes|Paper|Dateng Li|Author|AUTHORED
527|Sample Size Calculation For Cluster Randomized Trials With Zero-Inflated Count Outcomes|Paper|Song Zhang|Author|AUTHORED
527|Sample Size Calculation For Cluster Randomized Trials With Zero-Inflated Count Outcomes|Paper|Cluster Randomized Trials|Topic|RELATED_TO
527|Sample Size Calculation For Cluster Randomized Trials With Zero-Inflated Count Outcomes|Paper|Zero-Inflated Count Outcomes|Topic|RELATED_TO
527|Sample Size Calculation For Cluster Randomized Trials With Zero-Inflated Count Outcomes|Paper|Generalized Estimating Equations|Topic|RELATED_TO
527|Sample Size Calculation For Cluster Randomized Trials With Zero-Inflated Count Outcomes|Paper|Power Analysis Methods|Topic|RELATED_TO
527|Sample Size Calculation For Cluster Randomized Trials With Zero-Inflated Count Outcomes|Paper|Simulation Studies|Topic|RELATED_TO
528|A Novel Statistical Test For Treatment Differences In Clinical Trials Using A Response Adaptive Forward Looking Gittins Index Rule|Paper|Helen Yvette Barnett|Author|AUTHORED
528|A Novel Statistical Test For Treatment Differences In Clinical Trials Using A Response Adaptive Forward Looking Gittins Index Rule|Paper|Sofia S Villar|Author|AUTHORED
528|A Novel Statistical Test For Treatment Differences In Clinical Trials Using A Response Adaptive Forward Looking Gittins Index Rule|Paper|Helena Geys|Author|AUTHORED
528|A Novel Statistical Test For Treatment Differences In Clinical Trials Using A Response Adaptive Forward Looking Gittins Index Rule|Paper|Thomas Jaki|Author|AUTHORED
529|Multiple Type I Error Criterion|Topic|Clinical Trials|Topic|RELATED_TO
529|Clinical Trials|Topic|Precision Medicine|Topic|RELATED_TO
529|Population-Wise Error Rate|Topic|Clinical Trials|Topic|RELATED_TO
529|Werner Brannath|Author|Multiple Type I Error Criterion|Topic|AUTHORED
529|Charlie Hillner|Author|Multiple Type I Error Criterion|Topic|AUTHORED
529|Kornelius Rohmeyer|Author|Multiple Type I Error Criterion|Topic|AUTHORED
530|Unit Information Prior For Adaptive Information Borrowing From Multiple Historical Datasets|Paper|Huaqing Jin|Author|AUTHORED
530|Unit Information Prior For Adaptive Information Borrowing From Multiple Historical Datasets|Paper|Guosheng Yin|Author|AUTHORED
530|Unit Information Prior For Adaptive Information Borrowing From Multiple Historical Datasets|Paper|Clinical Trials|Topic|RELATED_TO
530|Unit Information Prior For Adaptive Information Borrowing From Multiple Historical Datasets|Paper|Historical Studies|Topic|RELATED_TO
530|Unit Information Prior For Adaptive Information Borrowing From Multiple Historical Datasets|Paper|Informative Prior|Topic|RELATED_TO
530|Unit Information Prior For Adaptive Information Borrowing From Multiple Historical Datasets|Paper|Uip|Topic|RELATED_TO
530|Unit Information Prior For Adaptive Information Borrowing From Multiple Historical Datasets|Paper|Alzheimer'S Disease|Topic|RELATED_TO
530|Unit Information Prior For Adaptive Information Borrowing From Multiple Historical Datasets|Paper|Memantine|Topic|RELATED_TO
531|Multi-Armed Parallel Group Clinical Trials|Topic|Personalized Treatment Rules|Topic|RELATED_TO
531|David Azriel|Author|Multi-Armed Parallel Group Clinical Trials|Topic|AUTHORED
531|Yosef Rinott|Author|Multi-Armed Parallel Group Clinical Trials|Topic|AUTHORED
531|Martin Posch|Author|Multi-Armed Parallel Group Clinical Trials|Topic|AUTHORED
531|Dietary Clinical Trial|Topic|Personalized Treatment Rules|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Emily K. Roberts|Author|AUTHORED
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Michael R. Elliott|Author|AUTHORED
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Jeremy M. G. Taylor|Author|AUTHORED
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Intermediate Endpoint|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Causal Association Paradigm|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Time-To-Event Outcomes|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Bayesian Method|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Localized Prostate Cancer Clinical Trial|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Surrogate S|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|True Endpoint T|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Censored And Semi-Competing Risk Structure|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Markov Chain Monte Carlo|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Time To Distant Metastasis|Topic|RELATED_TO
532|Surrogacy Validation For Time-To-Event Outcomes With Illness-Death Frailty Models|Paper|Time To Death|Topic|RELATED_TO
533|Semiparametric Inference Of The Complier Average Causal Effect With Nonignorable Missing Outcomes|Paper|Hua Chen|Author|AUTHORED
533|Semiparametric Inference Of The Complier Average Causal Effect With Nonignorable Missing Outcomes|Paper|Peng Ding|Author|AUTHORED
533|Semiparametric Inference Of The Complier Average Causal Effect With Nonignorable Missing Outcomes|Paper|Zhi Geng|Author|AUTHORED
533|Semiparametric Inference Of The Complier Average Causal Effect With Nonignorable Missing Outcomes|Paper|Xiao-Hua Zhou|Author|AUTHORED
534|Deep Neural Networks Guided Ensemble Learning For Point Estimation|Paper|Tianyu Zhan|Author|AUTHORED
534|Deep Neural Networks Guided Ensemble Learning For Point Estimation|Paper|Haoda Fu|Author|AUTHORED
534|Deep Neural Networks Guided Ensemble Learning For Point Estimation|Paper|Jian Kang|Author|AUTHORED
534|Deep Neural Networks Guided Ensemble Learning For Point Estimation|Paper|Mean Squared Error|Topic|RELATED_TO
534|Deep Neural Networks Guided Ensemble Learning For Point Estimation|Paper|Shrinkage Based Estimation|Topic|RELATED_TO
534|Deep Neural Networks Guided Ensemble Learning For Point Estimation|Paper|Adaptive Covid-19 Treatment Trial|Topic|RELATED_TO
534|Deep Neural Networks Guided Ensemble Learning For Point Estimation|Paper|Prediction Accuracy|Topic|RELATED_TO
534|Deep Neural Networks Guided Ensemble Learning For Point Estimation|Paper|Statistical Research|Topic|RELATED_TO
535|Suppression Of Disability Progression|Topic|Multiple Sclerosis|Topic|RELATED_TO
535|Multiple Sclerosis|Topic|Time To The First Confirmed Disability Progression|Topic|RELATED_TO
535|Time To The First Confirmed Disability Progression|Topic|Expanded Disability Status Scale|Topic|RELATED_TO
535|Multiple Sclerosis|Topic|Recurrent Disability Progression Events|Topic|RELATED_TO
535|Recurrent Disability Progression Events|Topic|Recurrent Event Analyses|Topic|RELATED_TO
535|Recurrent Event Analyses|Topic|Negative Binomial Model|Topic|RELATED_TO
535|Recurrent Event Analyses|Topic|Andersen-Gill Model|Topic|RELATED_TO
535|Recurrent Event Analyses|Topic|Lin-Wei-Ying-Yang Model|Topic|RELATED_TO
536|A Critical Review Of Methods For Real-World Applications To Generalize Or Transport Clinical Trial Findings To Target Populations Of Interest|Paper|Albee Y. Ling|Author|AUTHORED
536|A Critical Review Of Methods For Real-World Applications To Generalize Or Transport Clinical Trial Findings To Target Populations Of Interest|Paper|Maria E. Montez-Rath|Author|AUTHORED
536|A Critical Review Of Methods For Real-World Applications To Generalize Or Transport Clinical Trial Findings To Target Populations Of Interest|Paper|Paulo Carita|Author|AUTHORED
536|A Critical Review Of Methods For Real-World Applications To Generalize Or Transport Clinical Trial Findings To Target Populations Of Interest|Paper|Karen Chandross|Author|AUTHORED
536|A Critical Review Of Methods For Real-World Applications To Generalize Or Transport Clinical Trial Findings To Target Populations Of Interest|Paper|Laurence Lucats|Author|AUTHORED
536|A Critical Review Of Methods For Real-World Applications To Generalize Or Transport Clinical Trial Findings To Target Populations Of Interest|Paper|Zhaoling Meng|Author|AUTHORED
536|A Critical Review Of Methods For Real-World Applications To Generalize Or Transport Clinical Trial Findings To Target Populations Of Interest|Paper|Bernard Sebastien|Author|AUTHORED
536|A Critical Review Of Methods For Real-World Applications To Generalize Or Transport Clinical Trial Findings To Target Populations Of Interest|Paper|Kris Kapphahn|Author|AUTHORED
536|A Critical Review Of Methods For Real-World Applications To Generalize Or Transport Clinical Trial Findings To Target Populations Of Interest|Paper|Manisha Desai|Author|AUTHORED
537|Intensity-Based Multistate Models|Topic|Disease Processes|Topic|RELATED_TO
537|Intensity-Based Multistate Models|Topic|Interventions|Topic|RELATED_TO
537|Intensity-Based Multistate Models|Topic|Loss To Follow-Up|Topic|RELATED_TO
537|Intensity-Based Multistate Models|Topic|Randomized Trials|Topic|RELATED_TO
537|Intensity-Based Multistate Models|Topic|Complex Life History Processes|Topic|RELATED_TO
537|Intensity-Based Multistate Models|Topic|Estimands|Topic|RELATED_TO
537|Intensity-Based Multistate Models|Topic|Cumulative Incidence Function Regression Models|Topic|RELATED_TO
537|Intensity-Based Multistate Models|Topic|Intercurrent Events|Topic|RELATED_TO
537|Intensity-Based Multistate Models|Topic|Clinical Trials|Topic|RELATED_TO
537|Intensity-Based Multistate Models|Topic|Protocols|Topic|RELATED_TO
537|Multistate Models As A Framework For Estimand Specification In Clinical Trials Of Complex Processes|Paper|Alexandra Bühler|Author|AUTHORED
537|Multistate Models As A Framework For Estimand Specification In Clinical Trials Of Complex Processes|Paper|Richard J. Cook|Author|AUTHORED
537|Multistate Models As A Framework For Estimand Specification In Clinical Trials Of Complex Processes|Paper|Jerald F. Lawless|Author|AUTHORED
538|Estimands And Estimators In Randomized Clinical Trials|Topic|Intercurrent Events|Topic|RELATED_TO
538|Estimands And Estimators In Randomized Clinical Trials|Topic|Oncology Case Study|Topic|RELATED_TO
538|Oncology Case Study|Topic|Survival Risk Ratio Estimator|Topic|RELATED_TO
538|Survival Risk Ratio Estimator|Topic|Hege Michiels|Author|AUTHORED
538|Survival Risk Ratio Estimator|Topic|An Vandebosch|Author|AUTHORED
538|Survival Risk Ratio Estimator|Topic|Stijn Vansteelandt|Author|AUTHORED
539|Enrollment Forecast For Clinical Trials At The Planning Phase With Study-Level Historical Data|Paper|Mengjia Yu|Author|AUTHORED
539|Enrollment Forecast For Clinical Trials At The Planning Phase With Study-Level Historical Data|Paper|Sheng Zhong|Author|AUTHORED
539|Enrollment Forecast For Clinical Trials At The Planning Phase With Study-Level Historical Data|Paper|Yunzhao Xing|Author|AUTHORED
539|Enrollment Forecast For Clinical Trials At The Planning Phase With Study-Level Historical Data|Paper|Li Wang|Author|AUTHORED
539|Enrollment Forecast For Clinical Trials At The Planning Phase With Study-Level Historical Data|Paper|Clinical Trials|Topic|RELATED_TO
539|Enrollment Forecast For Clinical Trials At The Planning Phase With Study-Level Historical Data|Paper|Statistical Approaches|Topic|RELATED_TO
539|Enrollment Forecast For Clinical Trials At The Planning Phase With Study-Level Historical Data|Paper|Enrollment Timeline Forecasting|Topic|RELATED_TO
540|Phase Ii Studies|Topic|Phase Iii Trials|Topic|RELATED_TO
540|Phase Ii Studies|Topic|Bayesian Monitoring Strategies|Topic|RELATED_TO
540|Bayesian Monitoring Strategies|Topic|New Index Vector|Topic|RELATED_TO
540|New Index Vector|Topic|Takuya Yoshimoto|Author|AUTHORED
540|New Index Vector|Topic|Satoru Shinoda|Author|AUTHORED
540|New Index Vector|Topic|Kouji Yamamoto|Author|AUTHORED
540|New Index Vector|Topic|Kouji Tahata|Author|AUTHORED
541|Type 2 Diabetes Clinical Trial|Paper|Ich E9 Addendum|Topic|DISCUSSES
541|Type 2 Diabetes Clinical Trial|Paper|Camila Olarte Parra|Author|AUTHORED
541|Type 2 Diabetes Clinical Trial|Paper|Rhian M. Daniel|Author|AUTHORED
541|Type 2 Diabetes Clinical Trial|Paper|David Wright|Author|AUTHORED
541|Type 2 Diabetes Clinical Trial|Paper|Jonathan W. Bartlett|Author|AUTHORED
542|Pam-Hc: A Bayesian Nonparametric Construction Of Hybrid Control For Randomized Clinical Trials Using External Data|Paper|Dehua Bi|Author|AUTHORED
542|Pam-Hc: A Bayesian Nonparametric Construction Of Hybrid Control For Randomized Clinical Trials Using External Data|Paper|Tianjian Zhou|Author|AUTHORED
542|Pam-Hc: A Bayesian Nonparametric Construction Of Hybrid Control For Randomized Clinical Trials Using External Data|Paper|Wei Zhong|Author|AUTHORED
542|Pam-Hc: A Bayesian Nonparametric Construction Of Hybrid Control For Randomized Clinical Trials Using External Data|Paper|Yuan Ji|Author|AUTHORED
542|Pam-Hc: A Bayesian Nonparametric Construction Of Hybrid Control For Randomized Clinical Trials Using External Data|Paper|Bayesian Nonparametric Model|Topic|DISCUSSES
542|Pam-Hc: A Bayesian Nonparametric Construction Of Hybrid Control For Randomized Clinical Trials Using External Data|Paper|Atopic Dermatitis Dataset|Topic|DISCUSSES
542|Pam-Hc: A Bayesian Nonparametric Construction Of Hybrid Control For Randomized Clinical Trials Using External Data|Paper|Hybrid Control|Topic|DISCUSSES
542|Pam-Hc: A Bayesian Nonparametric Construction Of Hybrid Control For Randomized Clinical Trials Using External Data|Paper|Randomized Clinical Trial|Topic|DISCUSSES
543|Adaptive Experiments Toward Learning Treatment Effect Heterogeneity|Paper|Waverly Wei|Author|AUTHORED
543|Adaptive Experiments Toward Learning Treatment Effect Heterogeneity|Paper|Xinwei Ma|Author|AUTHORED
543|Adaptive Experiments Toward Learning Treatment Effect Heterogeneity|Paper|Jingshen Wang|Author|AUTHORED
543|Understanding Treatment Effect Heterogeneity|Topic|Adaptive Experiments Toward Learning Treatment Effect Heterogeneity|Paper|RELATED_TO
544|Executable Specification Of Oncology Dose-Escalation Protocols With Prolog|Paper|David C. Norris|Author|AUTHORED
544|Executable Specification Of Oncology Dose-Escalation Protocols With Prolog|Paper|Markus Triska|Author|AUTHORED
544|Executable Specification Of Oncology Dose-Escalation Protocols With Prolog|Paper|3 + 3 Dose-Escalation Protocol|Topic|RELATED_TO
545|Bayesian Hybrid Design With Borrowing From Historical Study|Paper|Bayesian Dynamic Power Prior (Dpp) Framework|Topic|DISCUSSES
545|Bayesian Hybrid Design With Borrowing From Historical Study|Paper|Combination Therapy|Topic|DISCUSSES
545|Bayesian Hybrid Design With Borrowing From Historical Study|Paper|Uncontrolled Single-Arm Trials|Topic|DISCUSSES
545|Bayesian Hybrid Design With Borrowing From Historical Study|Paper|Hybrid Design|Topic|DISCUSSES
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Dennis Shen|Author|AUTHORED
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Anish Agarwal|Author|AUTHORED
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Vishal Misra|Author|AUTHORED
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Bjoern Schelter|Author|AUTHORED
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Devavrat Shah|Author|AUTHORED
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Helen Shiells|Author|AUTHORED
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Claude Wischik|Author|AUTHORED
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Synthetic Nearest Neighbors (Snn) Estimator|Topic|DISCUSSES
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Alzheimer'S Disease|Topic|DISCUSSES
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Randomized Control Trials (Rcts)|Topic|DISCUSSES
546|Personalized Predictions From Population Level Experiments: A Study On Alzheimer'S Disease|Paper|Precision Medicine|Topic|DISCUSSES
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Jie Chen|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Susan Gruber|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Hana Lee|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Haitao Chu|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Shiowjen Lee|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Haijun Tian|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Yan Wang|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Weili He|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Thomas Jemielita|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Yang Song|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Roy Tamura|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Lu Tian|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Yihua Zhao|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Yong Chen|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Mark Van Der Laan|Author|AUTHORED
547|Use Of Real-World Data And Real-World Evidence In Rare Disease Drug Development: A Statistical Perspective|Paper|Lei Nie|Author|AUTHORED
548|Censored Survival Data|Topic|Clinical Trials|Topic|RELATED_TO
548|Small Control Groups|Topic|Rare Diseases|Topic|RELATED_TO
548|Small Control Groups|Topic|Balanced Randomization|Topic|RELATED_TO
548|External Controls|Topic|Historical Studies|Topic|RELATED_TO
548|External Controls|Topic|Real-World Data|Topic|RELATED_TO
548|Treatment Evaluation|Topic|Survival Outcomes|Topic|RELATED_TO
548|Doubly Protected Estimator|Topic|Treatment-Specific Restricted Mean Survival Time Difference|Topic|RELATED_TO
548|Doubly Protected Estimator|Topic|Trial-Only Estimators|Topic|RELATED_TO
548|Covariate Shifts|Topic|Doubly Robust Estimation|Topic|RELATED_TO
548|Outcome Drift|Topic|Dr-Learner|Topic|RELATED_TO
548|Machine Learning|Topic|Survival Curves|Topic|RELATED_TO
548|Outcome Drifts|Topic|Comparable External Controls|Topic|RELATED_TO
548|Simulation Studies|Topic|Real-Data Application|Topic|RELATED_TO
548|Real-Data Application|Topic|Galcanezumab|Topic|RELATED_TO
548|Real-Data Application|Topic|Migraine Headaches|Topic|RELATED_TO
548|Chenyin Gao|Author|Doubly Protected Estimator|Topic|AUTHORED
548|Shu Yang|Author|Doubly Protected Estimator|Topic|AUTHORED
548|Mingyang Shan|Author|Doubly Protected Estimator|Topic|AUTHORED
548|Wenyu Wendy Ye|Author|Doubly Protected Estimator|Topic|AUTHORED
548|Ilya Lipkovich|Author|Doubly Protected Estimator|Topic|AUTHORED
548|Douglas Faries|Author|Doubly Protected Estimator|Topic|AUTHORED
549|Leveraging Large Language Models For Medical Information Extraction And Query Generation|Paper|Large Language Models|Topic|RELATED_TO
549|Leveraging Large Language Models For Medical Information Extraction And Query Generation|Paper|Clinical Trial Retrieval|Topic|RELATED_TO
550|Interpretable Deep Neural Networks For Single-Trial Eeg Classification|Paper|Irene Sturm|Author|AUTHORED
550|Interpretable Deep Neural Networks For Single-Trial Eeg Classification|Paper|Sebastian Bach|Author|AUTHORED
550|Interpretable Deep Neural Networks For Single-Trial Eeg Classification|Paper|Wojciech Samek|Author|AUTHORED
550|Interpretable Deep Neural Networks For Single-Trial Eeg Classification|Paper|Klaus-Robert Müller|Author|AUTHORED
550|Interpretable Deep Neural Networks For Single-Trial Eeg Classification|Paper|Deep Neural Networks|Topic|RELATED_TO
550|Interpretable Deep Neural Networks For Single-Trial Eeg Classification|Paper|Layer-Wise Relevance Propagation|Topic|RELATED_TO
550|Interpretable Deep Neural Networks For Single-Trial Eeg Classification|Paper|Eeg Data Analysis|Topic|RELATED_TO
550|Interpretable Deep Neural Networks For Single-Trial Eeg Classification|Paper|Csp-Lda|Topic|RELATED_TO
551|Autoreject|Topic|Mainak Jas|Author|AUTHORED
551|Autoreject|Topic|Denis A. Engemann|Author|AUTHORED
551|Autoreject|Topic|Yousra Bekhti|Author|AUTHORED
551|Autoreject|Topic|Federico Raimondo|Author|AUTHORED
551|Autoreject|Topic|Alexandre Gramfort|Author|AUTHORED
551|Autoreject|Topic|Meg|Topic|RELATED_TO
551|Autoreject|Topic|Eeg|Topic|RELATED_TO
551|Autoreject|Topic|Human Connectome Project|Topic|RELATED_TO
551|Autoreject|Topic|Public Datasets|Topic|RELATED_TO
551|Autoreject|Topic|Bad Trials|Topic|RELATED_TO
551|Autoreject|Topic|Cross-Validation|Topic|RELATED_TO
551|Autoreject|Topic|Peak-To-Peak Threshold|Topic|RELATED_TO
551|Autoreject|Topic|Trial-Wise Bad Sensors|Topic|RELATED_TO
551|Autoreject|Topic|Interpolation|Topic|RELATED_TO
551|Autoreject|Topic|Human Inspection|Topic|RELATED_TO
551|Autoreject|Topic|Data Analysis|Topic|RELATED_TO
552|Neuroscience|Topic|Neural Spiking Dynamics|Topic|RELATED_TO
552|Neural Spiking Dynamics|Topic|Separable 2D Random Field Model|Topic|RELATED_TO
552|Separable 2D Random Field Model|Topic|Yingzhuo Zhang|Author|AUTHORED
552|Separable 2D Random Field Model|Topic|Noa Malem-Shinitski|Author|AUTHORED
552|Separable 2D Random Field Model|Topic|Stephen A Allsop|Author|AUTHORED
552|Separable 2D Random Field Model|Topic|Kay Tye|Author|AUTHORED
552|Separable 2D Random Field Model|Topic|Demba Ba|Author|AUTHORED
552|Pre-Frontal Cortex|Topic|Associative Learning Of Fear In Mice|Topic|RELATED_TO
553|N-Of-1 Trials|Topic|Multimodal Outcomes|Topic|RELATED_TO
553|Automated Approach|Topic|N-Of-1 Trials|Topic|DISCUSSES
553|Autoencoder|Topic|Automated Approach|Topic|RELATED_TO
553|Principal Component Analysis|Topic|Automated Approach|Topic|RELATED_TO
553|Treatment Effect|Topic|Multimodal N-Of-1 Trials|Topic|RELATED_TO
553|Acne Severity|Topic|Treatment Effect|Topic|RELATED_TO
553|Juliana Schneider|Author|Multimodal N-Of-1 Trials|Topic|AUTHORED
553|Thomas Gärtner|Author|Multimodal N-Of-1 Trials|Topic|AUTHORED
553|Stefan Konigorski|Author|Multimodal N-Of-1 Trials|Topic|AUTHORED
554|Novel Development Of Llm Driven Mcode Data Model For Improved Clinical Trial Matching To Enable Standardization And Interoperability In Oncology Research|Paper|Aarsh Shekhar|Author|AUTHORED
554|Novel Development Of Llm Driven Mcode Data Model For Improved Clinical Trial Matching To Enable Standardization And Interoperability In Oncology Research|Paper|Mincheol Kim|Author|AUTHORED
554|Novel Development Of Llm Driven Mcode Data Model For Improved Clinical Trial Matching To Enable Standardization And Interoperability In Oncology Research|Paper|Cancer Care|Topic|DISCUSSES
554|Novel Development Of Llm Driven Mcode Data Model For Improved Clinical Trial Matching To Enable Standardization And Interoperability In Oncology Research|Paper|Clinical Trial Enrollment|Topic|DISCUSSES
554|Novel Development Of Llm Driven Mcode Data Model For Improved Clinical Trial Matching To Enable Standardization And Interoperability In Oncology Research|Paper|Data Standardization|Topic|DISCUSSES
554|Novel Development Of Llm Driven Mcode Data Model For Improved Clinical Trial Matching To Enable Standardization And Interoperability In Oncology Research|Paper|Llm|Topic|DISCUSSES
554|Novel Development Of Llm Driven Mcode Data Model For Improved Clinical Trial Matching To Enable Standardization And Interoperability In Oncology Research|Paper|Mcode Profiles|Topic|DISCUSSES
554|Novel Development Of Llm Driven Mcode Data Model For Improved Clinical Trial Matching To Enable Standardization And Interoperability In Oncology Research|Paper|Ai And Ml-Based Clinical Trial Matching Engine|Topic|DISCUSSES
555|Assessing Immune Responses To Study Vaccines As Surrogates Of Protection|Topic|Hiv Vaccine Efficacy Trials|Topic|RELATED_TO
555|Assessing Immune Responses To Study Vaccines As Surrogates Of Protection|Topic|Cox Proportional Hazards Model|Topic|RELATED_TO
555|Frangakis And Rubin|Author|Cox Proportional Hazards Model|Topic|DISCUSSES
555|Gilbert And Hudgens|Author|Cox Proportional Hazards Model|Topic|DISCUSSES
555|Li Qin|Author|Assessing Immune Responses To Study Vaccines As Surrogates Of Protection|Topic|AUTHORED
555|Peter B. Gilbert|Author|Assessing Immune Responses To Study Vaccines As Surrogates Of Protection|Topic|AUTHORED
555|Dean Follmann|Author|Assessing Immune Responses To Study Vaccines As Surrogates Of Protection|Topic|AUTHORED
555|Dongfeng Li|Author|Assessing Immune Responses To Study Vaccines As Surrogates Of Protection|Topic|AUTHORED
556|Propatria|Topic|Experimental Probiotica Treatment|Topic|RELATED_TO
556|Experimental Probiotica Treatment|Topic|Acute Pancreatitis|Topic|RELATED_TO
556|Richard D. Gill|Author|Propatria|Topic|AUTHORED
556|New Treatment|Topic|Standard Therapy|Topic|RELATED_TO
556|Data Monitoring Committee|Topic|Propatria|Topic|RELATED_TO
556|Spss|Topic|Data Monitoring Committee|Topic|RELATED_TO
556|Clinical Trial|Topic|Life-Threatening Medical Condition|Topic|RELATED_TO
557|Point Estimation For Adaptive Trial Designs Ii: Practical Considerations And Guidance|Paper|David S. Robertson|Author|AUTHORED
557|Point Estimation For Adaptive Trial Designs Ii: Practical Considerations And Guidance|Paper|Babak Choodari-Oskooei|Author|AUTHORED
557|Point Estimation For Adaptive Trial Designs Ii: Practical Considerations And Guidance|Paper|Munya Dimairo|Author|AUTHORED
557|Point Estimation For Adaptive Trial Designs Ii: Practical Considerations And Guidance|Paper|Laura Flight|Author|AUTHORED
557|Point Estimation For Adaptive Trial Designs Ii: Practical Considerations And Guidance|Paper|Philip Pallmann|Author|AUTHORED
557|Point Estimation For Adaptive Trial Designs Ii: Practical Considerations And Guidance|Paper|Thomas Jaki|Author|AUTHORED
558|Composite Binary Endpoints|Topic|Clinical Trials|Topic|RELATED_TO
558|Sample Size|Topic|Clinical Trials|Topic|RELATED_TO
558|Marta Bofill Roig|Author|Compare|Topic|AUTHORED
558|Guadalupe Gómez Melis|Author|Compare|Topic|AUTHORED
558|Compare|Topic|Simulation Study|Topic|RELATED_TO
558|Compare|Topic|Real Case Study|Topic|RELATED_TO
559|Phase I Oncology Trials|Topic|Dose-Toxicity Model|Topic|RELATED_TO
559|Animal Data|Topic|Decision-Theoretic Approach|Topic|RELATED_TO
559|Haiyan Zheng|Author|Bayesian Decision-Theoretic Approach|Topic|AUTHORED
559|Lisa V. Hampson|Author|Bayesian Decision-Theoretic Approach|Topic|AUTHORED
559|Bayesian Decision-Theoretic Approach|Topic|Preclinical Information|Topic|RELATED_TO
559|Model-Based Dose-Escalation Procedure|Topic|Animal Data|Topic|RELATED_TO
559|Utility Of Optimal Prior Predictions|Topic|Commensurability|Topic|RELATED_TO
559|Commensurability|Topic|Dose-Escalation Procedure|Topic|RELATED_TO
559|Simulation Study|Topic|Bayesian Decision-Theoretic Approach|Topic|RELATED_TO
560|Hi3+3|Topic|Yunshan Duan|Author|AUTHORED
560|Hi3+3|Topic|Sue-Jane Wang|Author|AUTHORED
560|Hi3+3|Topic|Yuan Ji|Author|AUTHORED
561|Studyu Platform|Topic|Studyu Designer|Topic|RELATED_TO
561|Studyu Platform|Topic|Studyu App|Topic|RELATED_TO
561|Studyu Designer|Topic|N-Of-1 Trials|Topic|DISCUSSES
561|Studyu App|Topic|N-Of-1 Trials|Topic|DISCUSSES
561|Studyu Platform|Topic|Stefan Konigorski|Author|AUTHORED
561|Studyu Platform|Topic|Sarah Wernicke|Author|AUTHORED
561|Studyu Platform|Topic|Tamara Slosarek|Author|AUTHORED
561|Studyu Platform|Topic|Alexander M. Zenner|Author|AUTHORED
561|Studyu Platform|Topic|Nils Strelow|Author|AUTHORED
561|Studyu Platform|Topic|Ferenc D. Ruether|Author|AUTHORED
561|Studyu Platform|Topic|Florian Henschel|Author|AUTHORED
561|Studyu Platform|Topic|Manisha Manaswini|Author|AUTHORED
561|Studyu Platform|Topic|Fabian Pottbäcker|Author|AUTHORED
561|Studyu Platform|Topic|Jonathan A. Edelman|Author|AUTHORED
561|Studyu Platform|Topic|Babajide Owoyele|Author|AUTHORED
561|Studyu Platform|Topic|Matteo Danieletto|Author|AUTHORED
561|Studyu Platform|Topic|Eddye Golden|Author|AUTHORED
561|Studyu Platform|Topic|Micol Zweig|Author|AUTHORED
561|Studyu Platform|Topic|Girish Nadkarni|Author|AUTHORED
561|Studyu Platform|Topic|Erwin Böttinger|Author|AUTHORED
562|Recent Fda Guidance On Adaptive Clinical Trial Designs|Topic|Bias|Topic|RELATED_TO
562|Point Estimation For Adaptive Trial Designs I: A Methodological Review|Paper|Adaptive Clinical Trial Designs|Topic|DISCUSSES
562|Point Estimation For Adaptive Trial Designs I: A Methodological Review|Paper|Methods To Remove Or Reduce Potential Bias|Topic|DISCUSSES
563|Contemporary Scientific Research|Topic|Statistical Methods|Topic|RELATED_TO
563|Statistical Methods|Topic|Hypothesis Testing|Topic|RELATED_TO
563|Agent|Topic|Principal|Topic|RELATED_TO
563|Stephen Bates|Author|Incentive-Theoretic Bayesian Inference For Collaborative Science|Paper|AUTHORED
563|Michael I. Jordan|Author|Incentive-Theoretic Bayesian Inference For Collaborative Science|Paper|AUTHORED
563|Michael Sklar|Author|Incentive-Theoretic Bayesian Inference For Collaborative Science|Paper|AUTHORED
563|Jake A. Soloff|Author|Incentive-Theoretic Bayesian Inference For Collaborative Science|Paper|AUTHORED
563|Significance Threshold|Topic|Type-I Error Level|Topic|RELATED_TO
563|Type-I Error Level|Topic|Cost Of The Trial|Topic|RELATED_TO
563|Cost Of The Trial|Topic|Firm'S Profit|Topic|RELATED_TO
564|Meta-Analysis|Topic|Randomized Controlled Trials|Topic|RELATED_TO
564|Large Language Models|Topic|Evaluation Dataset|Topic|DISCUSSES
564|Hye Sun Yun|Author|Automatically Extracting Numerical Results From Randomized Controlled Trials With Large Language Models|Paper|AUTHORED
564|David Pogrebitskiy|Author|Automatically Extracting Numerical Results From Randomized Controlled Trials With Large Language Models|Paper|AUTHORED
564|Iain J. Marshall|Author|Automatically Extracting Numerical Results From Randomized Controlled Trials With Large Language Models|Paper|AUTHORED
564|Byron C. Wallace|Author|Automatically Extracting Numerical Results From Randomized Controlled Trials With Large Language Models|Paper|AUTHORED
565|Virtual Lung Screening Trial (Vlst)|Topic|National Lung Screening Trial (Nlst)|Topic|RELATED_TO
565|Fakrul Islam Tushar|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Liesbeth Vancoillie|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Cindy Mccabe|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Amareswararao Kavuri|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Lavsen Dahal|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Brian Harrawood|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Milo Fryling|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Mojtaba Zarei|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Saman Sotoudeh-Paima|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Fong Chi Ho|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Dhrubajyoti Ghosh|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Michael R. Harowicz|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Tina D. Tailor|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Sheng Luo|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|W. Paul Segars|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Ehsan Abadi|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Kyle J. Lafata|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Joseph Y. Lo|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
565|Ehsan Samei|Author|Virtual Lung Screening Trial (Vlst)|Topic|AUTHORED
566|Multiscale Bayesian State Space Model For Granger Causality Analysis Of Brain Signal|Paper|Cekic, S.|Author|AUTHORED
566|Multiscale Bayesian State Space Model For Granger Causality Analysis Of Brain Signal|Paper|Grandjean, D.|Author|AUTHORED
566|Multiscale Bayesian State Space Model For Granger Causality Analysis Of Brain Signal|Paper|Renaud, O.|Author|AUTHORED
567|Weighted Trajectory Analysis|Topic|Kaplan-Meier Estimator|Topic|RELATED_TO
567|Weighted Trajectory Analysis|Topic|Logrank Test|Topic|RELATED_TO
567|Weighted Trajectory Analysis|Topic|Generalized Estimating Equations|Topic|RELATED_TO
567|Weighted Trajectory Analysis|Topic|Melanoma Patients|Topic|RELATED_TO
567|Weighted Trajectory Analysis|Topic|Metastatic Breast Cancer Patients|Topic|RELATED_TO
567|Utkarsh Chauhan|Author|Weighted Trajectory Analysis|Topic|AUTHORED
567|Kaiqiong Zhao|Author|Weighted Trajectory Analysis|Topic|AUTHORED
567|John Walker|Author|Weighted Trajectory Analysis|Topic|AUTHORED
567|John R. Mackey|Author|Weighted Trajectory Analysis|Topic|AUTHORED
568|Probabilistic Temporal Prediction Of Continuous Disease Trajectories And Treatment Effects Using Neural Sdes|Paper|Personalized Medicine Based On Medical Images|Topic|RELATED_TO
568|Probabilistic Temporal Prediction Of Continuous Disease Trajectories And Treatment Effects Using Neural Sdes|Paper|Multiple Sclerosis (Ms)|Topic|RELATED_TO
568|Probabilistic Temporal Prediction Of Continuous Disease Trajectories And Treatment Effects Using Neural Sdes|Paper|Neural Stochastic Differential Equations (Nsde)|Topic|RELATED_TO
568|Probabilistic Temporal Prediction Of Continuous Disease Trajectories And Treatment Effects Using Neural Sdes|Paper|Joshua Durso-Finley|Author|AUTHORED
568|Probabilistic Temporal Prediction Of Continuous Disease Trajectories And Treatment Effects Using Neural Sdes|Paper|Berardino Barile|Author|AUTHORED
568|Probabilistic Temporal Prediction Of Continuous Disease Trajectories And Treatment Effects Using Neural Sdes|Paper|Jean-Pierre Falet|Author|AUTHORED
568|Probabilistic Temporal Prediction Of Continuous Disease Trajectories And Treatment Effects Using Neural Sdes|Paper|Douglas L. Arnold|Author|AUTHORED
568|Probabilistic Temporal Prediction Of Continuous Disease Trajectories And Treatment Effects Using Neural Sdes|Paper|Nick Pawlowski|Author|AUTHORED
568|Probabilistic Temporal Prediction Of Continuous Disease Trajectories And Treatment Effects Using Neural Sdes|Paper|Tal Arbel|Author|AUTHORED
569|Easy-Icd|Topic|Norway|Topic|RELATED_TO
569|Easy-Icd|Topic|Sweden|Topic|RELATED_TO
569|Mann-Whitney U Test|Topic|123 Seconds|Topic|DISCUSSES
569|Clinical Workflows|Topic|Easy-Icd|Topic|DISCUSSES
569|Taridzo Chomutare|Author|Easy-Icd|Topic|AUTHORED
569|Therese Olsen Svenning|Author|Easy-Icd|Topic|AUTHORED
569|Miguel Ángel Tejedor Hernández|Author|Easy-Icd|Topic|AUTHORED
569|Phuong Dinh Ngo|Author|Easy-Icd|Topic|AUTHORED
569|Andrius Budrionis|Author|Easy-Icd|Topic|AUTHORED
569|Kaisa Markljung|Author|Easy-Icd|Topic|AUTHORED
569|Lill Irene Hind|Author|Easy-Icd|Topic|AUTHORED
569|Torbjørn Torsvik|Author|Easy-Icd|Topic|AUTHORED
569|Karl Øyvind Mikalsen|Author|Easy-Icd|Topic|AUTHORED
569|Aleksandar Babic|Author|Easy-Icd|Topic|AUTHORED
569|Hercules Dalianis|Author|Easy-Icd|Topic|AUTHORED
570|Neuroscience Datasets|Topic|Hierarchical Bootstrap|Topic|RELATED_TO
570|Hierarchical Bootstrap|Topic|Traditional Statistical Tests|Topic|DISCUSSES
570|Hierarchical Bootstrap|Topic|Bengalese Finches|Topic|DISCUSSES
570|Hierarchical Bootstrap|Topic|Drosophila Melanogaster|Topic|DISCUSSES
570|Varun Saravanan|Author|Hierarchical Bootstrap|Topic|AUTHORED
570|Gordon J Berman|Author|Hierarchical Bootstrap|Topic|AUTHORED
570|Samuel J Sober|Author|Hierarchical Bootstrap|Topic|AUTHORED
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Rui Song|Author|AUTHORED
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Weiwei Wang|Author|AUTHORED
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Donglin Zeng|Author|AUTHORED
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Michael R. Kosorok|Author|AUTHORED
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Dynamic Treatment Regimes|Topic|RELATED_TO
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Reinforcement Learning|Topic|RELATED_TO
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Statistical Inference|Topic|RELATED_TO
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Clinical Trials|Topic|RELATED_TO
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Longitudinal Data|Topic|RELATED_TO
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Numerical Studies|Topic|RELATED_TO
571|Penalized Q-Learning For Dynamic Treatment Regimes|Paper|Depression Clinical Trial Study|Topic|RELATED_TO
572|Medis|Topic|Clinical Trial Process|Topic|RELATED_TO
572|Daniela Luzi|Author|Medis|Topic|AUTHORED
572|Fabrizio Pecoraro|Author|Medis|Topic|AUTHORED
573|A Two-Stage Patient-Focused Study Design For Rare Disease Controlled Trials|Paper|Rare Disease Clinical Trials|Topic|DISCUSSES
573|A Two-Stage Patient-Focused Study Design For Rare Disease Controlled Trials|Paper|Jian Yong|Author|AUTHORED
573|A Two-Stage Patient-Focused Study Design For Rare Disease Controlled Trials|Paper|Sohaib H. Mohammad|Author|AUTHORED
573|A Two-Stage Patient-Focused Study Design For Rare Disease Controlled Trials|Paper|Yan Yuan|Author|AUTHORED
574|Transform Mobile Ehealth Solution For Remote Patient Monitoring During Clinical Trials|Paper|Mobile Devices|Topic|DISCUSSES
574|Transform Mobile Ehealth Solution For Remote Patient Monitoring During Clinical Trials|Paper|Clinical Trials|Topic|RELATED_TO
574|Transform Mobile Ehealth Solution For Remote Patient Monitoring During Clinical Trials|Paper|Usability Evaluation|Topic|DISCUSSES
575|Escalation With Overdose Control|Topic|Continuous Dose Scheme|Topic|RELATED_TO
575|Escalation With Overdose Control|Topic|Discrete Dose Scheme|Topic|RELATED_TO
575|Monte Carlo Simulation Study|Topic|Continuous Dose Scheme|Topic|DISCUSSES
575|Monte Carlo Simulation Study|Topic|Discrete Dose Scheme|Topic|DISCUSSES
575|Cancer Phase I Clinical Trial Design|Topic|Discrete Dose Scheme|Topic|RELATED_TO
575|Cancer Phase I Clinical Trial Design|Topic|Continuous Dose Scheme|Topic|RELATED_TO
575|Operating Characteristics|Topic|Monte Carlo Simulation Study|Topic|RELATED_TO
575|True Mtd Value|Topic|Continuous Dose Scheme|Topic|RELATED_TO
575|True Mtd Value|Topic|Discrete Dose Scheme|Topic|RELATED_TO
575|Márcio Augusto Diniz|Author|Monte Carlo Simulation Study|Topic|AUTHORED
575|Mourad Tighiouart|Author|Monte Carlo Simulation Study|Topic|AUTHORED
575|André Rogatko|Author|Monte Carlo Simulation Study|Topic|AUTHORED
576|Personalized Medicine|Topic|Dirac Delta Regression|Topic|RELATED_TO
576|Dirac Delta Regression|Topic|Rct|Topic|RELATED_TO
576|Eric V. Strobl|Author|Https://Github.Com/Ericstrobl/Ddr|Paper|AUTHORED
576|Shyam Visweswaran|Author|Https://Github.Com/Ericstrobl/Ddr|Paper|AUTHORED
577|Clinical Trials|Topic|Outcome Variables|Topic|RELATED_TO
577|Outcome Variables|Topic|Treatment|Topic|RELATED_TO
577|Bayesian Model|Topic|Outcome Variables|Topic|DISCUSSES
577|Multivariate Bernoulli Distribution|Topic|Bayesian Model|Topic|RELATED_TO
577|Decision Criterion|Topic|Outcome Variables|Topic|DISCUSSES
577|X. M. Kavelaars|Author|Clinical Trials|Topic|AUTHORED
577|J. Mulder|Author|Clinical Trials|Topic|AUTHORED
577|M. C. Kaptein|Author|Clinical Trials|Topic|AUTHORED
577|Simulation Study|Topic|Type I Error Rates|Topic|DISCUSSES
577|Fixed Designs|Topic|Simulation Study|Topic|RELATED_TO
577|Group Sequential Designs|Topic|Simulation Study|Topic|RELATED_TO
577|Adaptive Designs|Topic|Simulation Study|Topic|RELATED_TO
577|Non-Informative Prior Distributions|Topic|Simulation Study|Topic|RELATED_TO
577|Informative Prior Distributions|Topic|Simulation Study|Topic|RELATED_TO
578|Multiple Sclerosis|Topic|Conditional Restricted Boltzmann Machine|Topic|RELATED_TO
578|Conditional Restricted Boltzmann Machine|Topic|Jonathan R. Walsh|Author|AUTHORED
578|Conditional Restricted Boltzmann Machine|Topic|Aaron M. Smith|Author|AUTHORED
578|Conditional Restricted Boltzmann Machine|Topic|Yannick Pouliot|Author|AUTHORED
578|Conditional Restricted Boltzmann Machine|Topic|David Li-Bland|Author|AUTHORED
578|Conditional Restricted Boltzmann Machine|Topic|Anton Loukianov|Author|AUTHORED
578|Conditional Restricted Boltzmann Machine|Topic|Charles K. Fisher|Author|AUTHORED
579|Prediction Interval|Topic|Tolerance Interval|Topic|RELATED_TO
579|Non-Normal Models|Topic|Prediction Interval|Topic|DISCUSSES
579|Non-Normal Models|Topic|Tolerance Interval|Topic|DISCUSSES
579|Geoffrey S Johnson|Author|Non-Normal Models|Topic|AUTHORED
580|Similarity Networks|Topic|Recommender Systems|Topic|RELATED_TO
580|Similarity Networks|Topic|Corpora Analysis|Topic|RELATED_TO
580|Similarity Networks|Topic|Medical Informatics|Topic|RELATED_TO
580|Hammock Paths|Topic|Similarity Networks|Topic|RELATED_TO
580|M. Shahriar Hossain|Author|Efficiently Discovering Hammock Paths From Induced Similarity Networks|Paper|AUTHORED
580|Michael Narayan|Author|Efficiently Discovering Hammock Paths From Induced Similarity Networks|Paper|AUTHORED
580|Naren Ramakrishnan|Author|Efficiently Discovering Hammock Paths From Induced Similarity Networks|Paper|AUTHORED
580|Netflix Dataset|Topic|Hammock Paths|Topic|RELATED_TO
580|Pubmed Corpus|Topic|Hammock Paths|Topic|RELATED_TO
580|Clinical Trials Database|Topic|Hammock Paths|Topic|RELATED_TO
581|Neoadjuvant Trials On Early-Stage Breast Cancer|Topic|Binary Pathological Complete Response (Pcr)|Topic|DISCUSSES
581|Neoadjuvant Trials On Early-Stage Breast Cancer|Topic|Survival|Topic|DISCUSSES
581|Xiaoqing Tan|Author|Recent Clinical Trial|Topic|AUTHORED
581|Judah Abberbock|Author|Recent Clinical Trial|Topic|AUTHORED
581|Priya Rastogi|Author|Recent Clinical Trial|Topic|AUTHORED
581|Gong Tang|Author|Recent Clinical Trial|Topic|AUTHORED
581|Sensitivity Analyses|Topic|Causal Estimand|Topic|RELATED_TO
581|Censored Outcome Data|Topic|Causal Estimand|Topic|RELATED_TO
581|Simulation Studies|Topic|Recent Clinical Trial|Topic|RELATED_TO
582|Covid-19 Pandemic|Topic|Biomedical Literature|Topic|RELATED_TO
582|Clinical Trials|Topic|Pico Criteria|Topic|RELATED_TO
582|Standard Search Engine|Topic|Relational Concept Selection|Topic|DISCUSSES
582|Trec-Covid Shared Task|Topic|Relational Concept Selection|Topic|DISCUSSES
582|Simon uster|Author|Relational Concept Selection|Topic|AUTHORED
582|Karin Verspoor|Author|Relational Concept Selection|Topic|AUTHORED
582|Timothy Baldwin|Author|Relational Concept Selection|Topic|AUTHORED
582|Jey Han Lau|Author|Relational Concept Selection|Topic|AUTHORED
582|Antonio Jimeno Yepes|Author|Relational Concept Selection|Topic|AUTHORED
582|David Martinez|Author|Relational Concept Selection|Topic|AUTHORED
582|Yulia Otmakhova|Author|Relational Concept Selection|Topic|AUTHORED
583|Ich E9(R1) Addendum|Topic|Principal Stratification|Topic|RELATED_TO
583|Principal Stratification|Topic|Ilya Lipkovich|Author|AUTHORED
583|Principal Stratification|Topic|Bohdana Ratitch|Author|AUTHORED
583|Principal Stratification|Topic|Yongming Qu|Author|AUTHORED
583|Principal Stratification|Topic|Xiang Zhang|Author|AUTHORED
583|Principal Stratification|Topic|Mingyang Shan|Author|AUTHORED
583|Principal Stratification|Topic|Craig Mallinckrodt|Author|AUTHORED
584|Pplasso|Topic|Prognostic Biomarkers|Topic|RELATED_TO
584|Pplasso|Topic|Predictive Biomarkers|Topic|RELATED_TO
584|Pplasso|Topic|Traditional Lasso|Topic|DISCUSSES
584|Pplasso|Topic|Pplasso R Package|Topic|AUTHORED
585|Clustered Multistate Process Data|Topic|Marginal Probability Of Being In A Particular Transient State|Topic|RELATED_TO
585|Marginal Probability Of Being In A Particular Transient State|Topic|Weighted Functional Generalized Estimating Equations Approach|Topic|RELATED_TO
585|Weighted Functional Generalized Estimating Equations Approach|Topic|Informative Cluster Size (Ics)|Topic|RELATED_TO
585|Weighted Functional Generalized Estimating Equations Approach|Topic|Functional Regression Coefficients|Topic|RELATED_TO
585|Weighted Functional Generalized Estimating Equations Approach|Topic|Nonparametric Hypothesis Testing Procedure|Topic|RELATED_TO
585|Weighted Functional Generalized Estimating Equations Approach|Topic|Multicenter Clinical Trial On Recurrent Or Metastatic Squamous-Cell Carcinoma Of The Head And Neck|Topic|RELATED_TO
585|Wenxian Zhou|Author|Weighted Functional Generalized Estimating Equations Approach|Topic|AUTHORED
585|Giorgos Bakoyannis|Author|Weighted Functional Generalized Estimating Equations Approach|Topic|AUTHORED
585|Ying Zhang|Author|Weighted Functional Generalized Estimating Equations Approach|Topic|AUTHORED
585|Constantin T Yiannoutsos|Author|Weighted Functional Generalized Estimating Equations Approach|Topic|AUTHORED
586|Semeval-2024 Task 2|Paper|Nli4Ct-P Dataset|Topic|RELATED_TO
586|Semeval-2024 Task 2|Paper|Interventional Reasoning Tasks|Topic|RELATED_TO
586|Semeval-2024 Task 2|Paper|Causal Reasoning Tasks|Topic|RELATED_TO
586|Semeval-2024 Task 2|Paper|106 Participants|Topic|RELATED_TO
586|Semeval-2024 Task 2|Paper|1200 Individual Submissions|Topic|RELATED_TO
586|Semeval-2024 Task 2|Paper|25 System Overview Papers|Topic|RELATED_TO
586|Semeval-2024 Task 2|Paper|Healthcare|Topic|RELATED_TO
586|Semeval-2024 Task 2|Paper|Biomedical Nli|Topic|RELATED_TO
586|Semeval-2024 Task 2|Paper|Competition Leaderboard|Topic|RELATED_TO
586|Semeval-2024 Task 2|Paper|Website|Topic|RELATED_TO
586|Large Language Models|Topic|Nlp Achievements|Topic|RELATED_TO
586|Large Language Models|Topic|Shortcut Learning|Topic|RELATED_TO
586|Large Language Models|Topic|Factual Inconsistency|Topic|RELATED_TO
586|Large Language Models|Topic|Adversarial Inputs|Topic|RELATED_TO
588|Advances In Anticancer Therapies|Topic|Declining Death Rates|Topic|RELATED_TO
588|Advances In Anticancer Therapies|Topic|Clinical Trial|Topic|RELATED_TO
588|Clinical Trial|Topic|Overall Survival (Os)|Topic|RELATED_TO
588|Statistical Approaches|Topic|Overall Survival (Os)|Topic|RELATED_TO
588|Statistical Approaches|Topic|Shan, 2023|Author|RELATED_TO
588|Statistical Approaches|Topic|Fleming Et Al., 2024|Author|RELATED_TO
588|Statistical Approaches|Topic|Rodriguez Et Al., 2024|Author|RELATED_TO
588|Framework|Topic|Statistical Approaches|Topic|RELATED_TO
588|Framework|Topic|Stakeholders|Topic|RELATED_TO
588|Framework|Topic|Fit-For-Purpose Os Data Collection And Assessment Of Harm|Topic|RELATED_TO
588|American Association For Cancer Research, 2024|Author|Framework|Topic|RELATED_TO
588|Framework|Topic|Large B-Cell Lymphoma|Topic|RELATED_TO
588|Recommendations And Open Questions|Topic|Framework|Topic|RELATED_TO
588|Godwin Yung|Author|Framework|Topic|AUTHORED
588|Kaspar Rufibach|Author|Framework|Topic|AUTHORED
588|Marcel Wolbers|Author|Framework|Topic|AUTHORED
588|Mark Yan|Author|Framework|Topic|AUTHORED
588|Jue Wang|Author|Framework|Topic|AUTHORED
589|Clinical Trials|Topic|Overall Survival (Os)|Topic|RELATED_TO
589|Clinical Trials|Topic|Progression-Free Survival (Pfs)|Topic|RELATED_TO
589|Clinical Trials|Topic|Response To Treatment (Rt)|Topic|RELATED_TO
589|Bayesian Decision-Theoretic Framework|Topic|Clinical Trials|Topic|DISCUSSES
589|Massimiliano Russo|Author|Bayesian Decision-Theoretic Framework|Topic|AUTHORED
589|Steffen Ventz|Author|Bayesian Decision-Theoretic Framework|Topic|AUTHORED
589|Lorenzo Trippa|Author|Bayesian Decision-Theoretic Framework|Topic|AUTHORED
590|Bayesian Phase I/Ii Adaptively Randomized Oncology Trials With Combined Drugs|Paper|Ying Yuan|Author|AUTHORED
590|Bayesian Phase I/Ii Adaptively Randomized Oncology Trials With Combined Drugs|Paper|Guosheng Yin|Author|AUTHORED
590|Bayesian Phase I/Ii Adaptively Randomized Oncology Trials With Combined Drugs|Paper|Phase I/Ii Trial Design|Topic|RELATED_TO
590|Bayesian Phase I/Ii Adaptively Randomized Oncology Trials With Combined Drugs|Paper|Bayesian Copula-Type Model|Topic|RELATED_TO
590|Bayesian Phase I/Ii Adaptively Randomized Oncology Trials With Combined Drugs|Paper|Adaptive Randomization Scheme|Topic|RELATED_TO
590|Bayesian Phase I/Ii Adaptively Randomized Oncology Trials With Combined Drugs|Paper|Melanoma Clinical Trial|Topic|RELATED_TO
591|Crossover Clinical Trials|Topic|Optimal Crossover Trial With 30 Periods|Paper|DISCUSSES
591|Clot Prevention In Children Undergoing Haemodialysis|Topic|Optimal Crossover Trial With 30 Periods|Paper|DISCUSSES
592|Drug Combination Trials|Topic|Toxicity Attributions|Topic|RELATED_TO
592|Toxicity Attributions|Topic|Bayesian Adaptive Design|Topic|RELATED_TO
592|Bayesian Adaptive Design|Topic|Copula Regression|Topic|RELATED_TO
592|Bayesian Adaptive Design|Topic|Maximum Tolerated Dose (Mtd) Curve|Topic|RELATED_TO
592|Dose Escalation Algorithm|Topic|Continual Reassessment Method (Crm) Scheme|Topic|RELATED_TO
592|Bayesian Adaptive Design|Topic|Operating Characteristics|Topic|RELATED_TO
592|Bayesian Adaptive Design|Topic|Discrete Dose Combinations|Topic|RELATED_TO
592|Cancer Phase I Trial Design|Topic|Jose L. Jimenez|Author|AUTHORED
592|Cancer Phase I Trial Design|Topic|Mourad Tighiouart|Author|AUTHORED
592|Cancer Phase I Trial Design|Topic|Mauro Gasparini|Author|AUTHORED
593|Optimality Of Testing Procedures For Survival Data|Paper|Andrea Arfé|Author|AUTHORED
593|Optimality Of Testing Procedures For Survival Data|Paper|Brian Alexander|Author|AUTHORED
593|Optimality Of Testing Procedures For Survival Data|Paper|Lorenzo Trippa|Author|AUTHORED
594|A Nonparametric Bayesian Design For Drug Combination Cancer Trials|Paper|Zahra S. Razaee|Author|AUTHORED
594|A Nonparametric Bayesian Design For Drug Combination Cancer Trials|Paper|Galen Wien-Cook|Author|AUTHORED
594|A Nonparametric Bayesian Design For Drug Combination Cancer Trials|Paper|Mourad Tighiouart|Author|AUTHORED
594|A Nonparametric Bayesian Design For Drug Combination Cancer Trials|Paper|Maximum Tolerated Dose (Mtd)|Topic|RELATED_TO
594|A Nonparametric Bayesian Design For Drug Combination Cancer Trials|Paper|Dose Limiting Toxicity (Dlt)|Topic|RELATED_TO
594|A Nonparametric Bayesian Design For Drug Combination Cancer Trials|Paper|Phase I Clinical Trial Of Cb-839 And Gemcitabine|Topic|RELATED_TO
595|Design And Analysis Of Group-Sequential Clinical Trials Based On A Modestly-Weighted Log-Rank Test In Anticipation Of A Delayed Separation Of Survival Curves: A Practical Guidance|Paper|Immunotherapy|Topic|DISCUSSES
595|Design And Analysis Of Group-Sequential Clinical Trials Based On A Modestly-Weighted Log-Rank Test In Anticipation Of A Delayed Separation Of Survival Curves: A Practical Guidance|Paper|Survival|Topic|DISCUSSES
595|Design And Analysis Of Group-Sequential Clinical Trials Based On A Modestly-Weighted Log-Rank Test In Anticipation Of A Delayed Separation Of Survival Curves: A Practical Guidance|Paper|Non-Small-Cell Lung Cancer|Topic|DISCUSSES
595|Design And Analysis Of Group-Sequential Clinical Trials Based On A Modestly-Weighted Log-Rank Test In Anticipation Of A Delayed Separation Of Survival Curves: A Practical Guidance|Paper|Poplar Trial|Topic|DISCUSSES
595|Design And Analysis Of Group-Sequential Clinical Trials Based On A Modestly-Weighted Log-Rank Test In Anticipation Of A Delayed Separation Of Survival Curves: A Practical Guidance|Paper|Weighted Log-Rank Tests|Topic|DISCUSSES
595|Design And Analysis Of Group-Sequential Clinical Trials Based On A Modestly-Weighted Log-Rank Test In Anticipation Of A Delayed Separation Of Survival Curves: A Practical Guidance|Paper|Group-Sequential Methods|Topic|DISCUSSES
595|Design And Analysis Of Group-Sequential Clinical Trials Based On A Modestly-Weighted Log-Rank Test In Anticipation Of A Delayed Separation Of Survival Curves: A Practical Guidance|Paper|R Package|Topic|DISCUSSES
596|Estimating The Efficiency Gain Of Covariate-Adjusted Analyses In Future Clinical Trials Using External Data|Paper|Covariate-Adjusted Estimator|Topic|DISCUSSES
596|Estimating The Efficiency Gain Of Covariate-Adjusted Analyses In Future Clinical Trials Using External Data|Paper|Marginal Treatment Effect|Topic|DISCUSSES
596|Estimating The Efficiency Gain Of Covariate-Adjusted Analyses In Future Clinical Trials Using External Data|Paper|Randomized Trial|Topic|DISCUSSES
596|Estimating The Efficiency Gain Of Covariate-Adjusted Analyses In Future Clinical Trials Using External Data|Paper|Relative Efficiency|Topic|DISCUSSES
596|Estimating The Efficiency Gain Of Covariate-Adjusted Analyses In Future Clinical Trials Using External Data|Paper|Semiparametrically Efficient Estimator|Topic|DISCUSSES
596|Estimating The Efficiency Gain Of Covariate-Adjusted Analyses In Future Clinical Trials Using External Data|Paper|Wald-Type Confidence Interval|Topic|DISCUSSES
596|Estimating The Efficiency Gain Of Covariate-Adjusted Analyses In Future Clinical Trials Using External Data|Paper|Double Bootstrap Scheme|Topic|DISCUSSES
596|Estimating The Efficiency Gain Of Covariate-Adjusted Analyses In Future Clinical Trials Using External Data|Paper|Covid-19 Therapeutic Trials|Topic|DISCUSSES
597|Causal Analysis Of The Topcat Trial: Spironolactone For Preserved Cardiac Function Heart Failure|Paper|Francesca E. D. Raimondi|Author|AUTHORED
597|Causal Analysis Of The Topcat Trial: Spironolactone For Preserved Cardiac Function Heart Failure|Paper|Tadhg O'Keeffe|Author|AUTHORED
597|Causal Analysis Of The Topcat Trial: Spironolactone For Preserved Cardiac Function Heart Failure|Paper|Hana Chockler|Author|AUTHORED
597|Causal Analysis Of The Topcat Trial: Spironolactone For Preserved Cardiac Function Heart Failure|Paper|Andrew R. Lawrence|Author|AUTHORED
597|Causal Analysis Of The Topcat Trial: Spironolactone For Preserved Cardiac Function Heart Failure|Paper|Tamara Stemberga|Author|AUTHORED
597|Causal Analysis Of The Topcat Trial: Spironolactone For Preserved Cardiac Function Heart Failure|Paper|Andre Franca|Author|AUTHORED
597|Causal Analysis Of The Topcat Trial: Spironolactone For Preserved Cardiac Function Heart Failure|Paper|Maksim Sipos|Author|AUTHORED
597|Causal Analysis Of The Topcat Trial: Spironolactone For Preserved Cardiac Function Heart Failure|Paper|Javed Butler|Author|AUTHORED
597|Causal Analysis Of The Topcat Trial: Spironolactone For Preserved Cardiac Function Heart Failure|Paper|Shlomo Ben-Haim|Author|AUTHORED
598|Time-To-Event Model-Assisted Designs To Accelerate Phase I Clinical Trials|Paper|Ruitao Lin|Author|AUTHORED
598|Time-To-Event Model-Assisted Designs To Accelerate Phase I Clinical Trials|Paper|Ying Yuan|Author|AUTHORED
598|Time-To-Event Model-Assisted Designs To Accelerate Phase I Clinical Trials|Paper|Drug Development Strategies|Topic|DISCUSSES
598|Time-To-Event Model-Assisted Designs To Accelerate Phase I Clinical Trials|Paper|Toxicity Data Handling|Topic|DISCUSSES
598|Time-To-Event Model-Assisted Designs To Accelerate Phase I Clinical Trials|Paper|Phase I Dose-Finding Trials|Topic|DISCUSSES
599|Group Sequential Designs|Topic|Interim Efficacy Monitoring|Topic|RELATED_TO
599|Group Sequential Designs|Topic|Futility Monitoring|Topic|RELATED_TO
599|Group Sequential Designs|Topic|Baseline Covariates|Topic|RELATED_TO
599|Group Sequential Designs|Topic|Type I Error|Topic|RELATED_TO
599|Group Sequential Designs|Topic|Point Estimates|Topic|RELATED_TO
599|Group Sequential Designs|Topic|Confidence Intervals|Topic|RELATED_TO
599|Marlena S. Bannick|Author|Correct Interim Monitoring|Topic|AUTHORED
599|Sonya L. Heltshe|Author|Correct Interim Monitoring|Topic|AUTHORED
599|Noah Simon|Author|Correct Interim Monitoring|Topic|AUTHORED
599|Correct Interim Monitoring|Topic|Estimation|Topic|RELATED_TO
599|Correct Interim Monitoring|Topic|Inference|Topic|RELATED_TO
599|Correct Interim Monitoring|Topic|Two-Arm Trials|Topic|RELATED_TO
599|Two-Arm Trials|Topic|Balanced Randomization|Topic|RELATED_TO
599|Two-Arm Trials|Topic|Continuous Outcomes|Topic|RELATED_TO
599|Correct Interim Monitoring|Topic|Simulation Studies|Topic|RELATED_TO
599|Correct Interim Monitoring|Topic|Recommendations|Topic|RELATED_TO
600|Trialssummarizer|Topic|Automatically Summarizing Evidence From Clinical Trials: A Prototype Highlighting Current Challenges|Paper|RELATED_TO
600|Automatically Summarizing Evidence From Clinical Trials: A Prototype Highlighting Current Challenges|Paper|Sanjana Ramprasad|Author|AUTHORED
600|Automatically Summarizing Evidence From Clinical Trials: A Prototype Highlighting Current Challenges|Paper|Denis Jered Mcinerney|Author|AUTHORED
600|Automatically Summarizing Evidence From Clinical Trials: A Prototype Highlighting Current Challenges|Paper|Iain J. Marshal|Author|AUTHORED
600|Automatically Summarizing Evidence From Clinical Trials: A Prototype Highlighting Current Challenges|Paper|Byron C. Wallace|Author|AUTHORED
601|The Use Of Covariate Adjustment In Randomized Controlled Trials: An Overview|Paper|Kelly Van Lancker|Author|AUTHORED
601|The Use Of Covariate Adjustment In Randomized Controlled Trials: An Overview|Paper|Frank Bretz|Author|AUTHORED
601|The Use Of Covariate Adjustment In Randomized Controlled Trials: An Overview|Paper|Oliver Dukes|Author|AUTHORED
601|The Use Of Covariate Adjustment In Randomized Controlled Trials: An Overview|Paper|Covariate Adjustment|Topic|RELATED_TO
601|The Use Of Covariate Adjustment In Randomized Controlled Trials: An Overview|Paper|Randomized Controlled Trials|Topic|RELATED_TO
601|The Use Of Covariate Adjustment In Randomized Controlled Trials: An Overview|Paper|Conditional And Marginal Treatment Effects|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Masahiro Kojima|Author|AUTHORED
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Hirotaka Mano|Author|AUTHORED
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Kana Yamada|Author|AUTHORED
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Keisuke Hanada|Author|AUTHORED
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Yuji Tanaka|Author|AUTHORED
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Junji Moriya|Author|AUTHORED
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Permutation Tests|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Randomization Tests|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Type-I Error Rate|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Covariate-Adaptive Randomization|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Randomized Clinical Trials|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Non-Inferiority Trials|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Equivalence Trials|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Normal Variables|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Binary Variables|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Time-To-Event Variables|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Simulation Results|Topic|RELATED_TO
602|Adjusted Confidence Intervals Under Covariate-Adaptive Randomization In Non-Inferiority And Equivalence Trials|Paper|Performance Evaluation|Topic|RELATED_TO
603|Clinical Trials|Topic|Heterogeneity In Patient Responses|Topic|RELATED_TO
603|Heterogeneity In Patient Responses|Topic|Syntax|Topic|DISCUSSES
603|Syntax|Topic|Alihan Hüyük|Author|AUTHORED
603|Syntax|Topic|Zhaozhi Qian|Author|AUTHORED
603|Syntax|Topic|Mihaela Van Der Schaar|Author|AUTHORED
604|Machine Learning Assisted Adjustment Boosts Efficiency Of Exact Inference In Randomized Controlled Trials|Paper|Han Yu|Author|AUTHORED
604|Machine Learning Assisted Adjustment Boosts Efficiency Of Exact Inference In Randomized Controlled Trials|Paper|Alan D. Hutson|Author|AUTHORED
604|Machine Learning Assisted Adjustment Boosts Efficiency Of Exact Inference In Randomized Controlled Trials|Paper|Xiaoyi Ma|Author|AUTHORED
604|Machine Learning Assisted Adjustment Boosts Efficiency Of Exact Inference In Randomized Controlled Trials|Paper|Randomized Controlled Trials|Topic|RELATED_TO
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|Randomized Controlled Trial|Topic|DISCUSSES
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|Drug Effectiveness|Topic|DISCUSSES
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|Internal Validity|Topic|DISCUSSES
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|External Validity|Topic|DISCUSSES
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|Treatment Effects|Topic|DISCUSSES
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|Real-World Population|Topic|DISCUSSES
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|Statistical Methods|Topic|DISCUSSES
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|Augmented Inversed Probability Of Sampling Weighting|Topic|DISCUSSES
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|Omitted Variable Bias|Topic|DISCUSSES
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|Songling Xuemaikang Capsule|Topic|DISCUSSES
605|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|Losartan|Topic|DISCUSSES
605|Kuan Jiang|Author|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|AUTHORED
605|Xin-Xing Lai|Author|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|AUTHORED
605|Shu Yang|Author|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|AUTHORED
605|Ying Gao|Author|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|AUTHORED
605|Xiao-Hua Zhou|Author|A Practical Analysis Procedure On Generalizing Comparative Effectiveness In The Randomized Clinical Trial To The Real-World Trialeligible Population|Paper|AUTHORED
606|Bayesian Adaptive Trials Simulator Software|Topic|R|Topic|RELATED_TO
606|Dominique-Laurent Couturier|Author|Bayesian Adaptive Trials Simulator Software|Topic|AUTHORED
606|Elizabeth G Ryan|Author|Bayesian Adaptive Trials Simulator Software|Topic|AUTHORED
606|Rainer Puhr|Author|Bayesian Adaptive Trials Simulator Software|Topic|AUTHORED
606|Thomas Jaki|Author|Bayesian Adaptive Trials Simulator Software|Topic|AUTHORED
606|Stephane Heritier|Author|Bayesian Adaptive Trials Simulator Software|Topic|AUTHORED
607|Zikq: An Innovative Centile Chart Method For Utilizing Natural History Data In Rare Disease Clinical Development|Paper|Tianying Wang|Author|AUTHORED
607|Zikq: An Innovative Centile Chart Method For Utilizing Natural History Data In Rare Disease Clinical Development|Paper|Wenfei Zhang|Author|AUTHORED
607|Zikq: An Innovative Centile Chart Method For Utilizing Natural History Data In Rare Disease Clinical Development|Paper|Ying Wei|Author|AUTHORED
607|Zikq: An Innovative Centile Chart Method For Utilizing Natural History Data In Rare Disease Clinical Development|Paper|Duchenne Muscular Dystrophy|Topic|RELATED_TO
608|Cognitive Science|Topic|Behavioural Neuroscience|Topic|RELATED_TO
608|Cognitive Science|Topic|Machine Learning|Topic|RELATED_TO
608|Cognitive Science|Topic|Artificial Intelligence|Topic|RELATED_TO
608|Visual Object Recognition|Topic|Convolutional Neural Networks|Topic|RELATED_TO
608|Trial-By-Trial Error Consistency|Topic|Convolutional Neural Networks|Topic|RELATED_TO
608|Trial-By-Trial Error Consistency|Topic|Visual Object Recognition|Topic|RELATED_TO
608|Cornet-S|Topic|Visual Object Recognition|Topic|RELATED_TO
608|Resnet-50|Topic|Visual Object Recognition|Topic|RELATED_TO
608|Robert Geirhos|Author|Trial-By-Trial Error Consistency|Topic|AUTHORED
608|Kristof Meding|Author|Trial-By-Trial Error Consistency|Topic|AUTHORED
608|Felix A. Wichmann|Author|Trial-By-Trial Error Consistency|Topic|AUTHORED
609|Batched Bandit Problems|Topic|Vianney Perchet|Author|AUTHORED
609|Batched Bandit Problems|Topic|Philippe Rigollet|Author|AUTHORED
609|Batched Bandit Problems|Topic|Sylvain Chassang|Author|AUTHORED
609|Batched Bandit Problems|Topic|Erik Snowberg|Author|AUTHORED
610|Compliance-Aware Bandits|Paper|Nicolás Della Penna|Author|AUTHORED
610|Compliance-Aware Bandits|Paper|Mark D. Reid|Author|AUTHORED
610|Compliance-Aware Bandits|Paper|David Balduzzi|Author|AUTHORED
610|Compliance-Aware Bandits|Paper|Bandits|Topic|RELATED_TO
610|Compliance-Aware Bandits|Paper|Non-Compliance|Topic|RELATED_TO
610|Compliance-Aware Bandits|Paper|Regret|Topic|RELATED_TO
610|Compliance-Aware Bandits|Paper|International Stoke Trial|Topic|RELATED_TO
611|Random Measures, Anova Models And Quantifying Uncertainty In Randomized Controlled Trials|Paper|Global Sensitivity Analysis|Topic|DISCUSSES
611|Random Measures, Anova Models And Quantifying Uncertainty In Randomized Controlled Trials|Paper|Variance-Covariance Structure|Topic|DISCUSSES
611|Random Measures, Anova Models And Quantifying Uncertainty In Randomized Controlled Trials|Paper|Information-Theoretic Rules|Topic|DISCUSSES
611|Random Measures, Anova Models And Quantifying Uncertainty In Randomized Controlled Trials|Paper|Variance Decomposition|Topic|DISCUSSES
611|Random Measures, Anova Models And Quantifying Uncertainty In Randomized Controlled Trials|Paper|Randomized Controlled Trials|Topic|DISCUSSES
611|Caleb Deen Bastian|Author|Random Measures, Anova Models And Quantifying Uncertainty In Randomized Controlled Trials|Paper|AUTHORED
611|Herschel Rabitz|Author|Random Measures, Anova Models And Quantifying Uncertainty In Randomized Controlled Trials|Paper|AUTHORED
611|Grzegorz A Rempala|Author|Random Measures, Anova Models And Quantifying Uncertainty In Randomized Controlled Trials|Paper|AUTHORED
612|Testing For Similarity Of Dose Response In Multi-Regional Clinical Trials|Paper|Holger Dette|Author|AUTHORED
612|Testing For Similarity Of Dose Response In Multi-Regional Clinical Trials|Paper|Lukas Koletzko|Author|AUTHORED
612|Testing For Similarity Of Dose Response In Multi-Regional Clinical Trials|Paper|Frank Bretz|Author|AUTHORED
613|Broad Versus Narrow Research Questions In Evidence Synthesis: A Parallel To (And Plea For) Estimands|Paper|Antonio Remiro-Azócar|Author|AUTHORED
613|Broad Versus Narrow Research Questions In Evidence Synthesis: A Parallel To (And Plea For) Estimands|Paper|Anders Gorst-Rasmussen|Author|AUTHORED
613|Network Meta-Analysis|Topic|Estimand Framework|Topic|RELATED_TO
614|Mining Brain Networks Using Multiple Side Views For Neurological Disorder Identification|Paper|Subgraph Mining|Topic|DISCUSSES
614|Mining Brain Networks Using Multiple Side Views For Neurological Disorder Identification|Paper|Graph Classification|Topic|DISCUSSES
614|Mining Brain Networks Using Multiple Side Views For Neurological Disorder Identification|Paper|Neurological Disorder Identification|Topic|DISCUSSES
615|Cd8+ T Cell|Topic|Influenza A Virus|Topic|DISCUSSES
615|Mathematical Model Of Influenza Viral Dynamics|Topic|Influenza A Virus|Topic|RELATED_TO
615|Pengxing Cao|Author|Mathematical Model Of Influenza Viral Dynamics|Topic|AUTHORED
615|Zhongfang Wang|Author|Mathematical Model Of Influenza Viral Dynamics|Topic|AUTHORED
615|Ada W. C. Yan|Author|Mathematical Model Of Influenza Viral Dynamics|Topic|AUTHORED
615|Jodie Mcvernon|Author|Mathematical Model Of Influenza Viral Dynamics|Topic|AUTHORED
615|Jianqing Xu|Author|Mathematical Model Of Influenza Viral Dynamics|Topic|AUTHORED
615|Jane M. Heffernan|Author|Mathematical Model Of Influenza Viral Dynamics|Topic|AUTHORED
615|Katherine Kedzierska|Author|Mathematical Model Of Influenza Viral Dynamics|Topic|AUTHORED
615|James M. Mccaw|Author|Mathematical Model Of Influenza Viral Dynamics|Topic|AUTHORED
616|Maternal Sars-Cov-2 Status|Topic|Placental Pathology|Topic|RELATED_TO
616|Retrospective Case-Control Study|Topic|Covid-19|Topic|RELATED_TO
616|Mai He|Author|Study Results|Topic|AUTHORED
616|Priya Skaria|Author|Study Results|Topic|AUTHORED
616|Kasey Kreutz|Author|Study Results|Topic|AUTHORED
616|Ling Chen|Author|Study Results|Topic|AUTHORED
616|Ian Hagemann|Author|Study Results|Topic|AUTHORED
616|Ebony B. Carter|Author|Study Results|Topic|AUTHORED
616|Indira U. Mysorekar|Author|Study Results|Topic|AUTHORED
616|D Michael Nelson|Author|Study Results|Topic|AUTHORED
616|John Pfeifer|Author|Study Results|Topic|AUTHORED
616|Louis P. Dehner|Author|Study Results|Topic|AUTHORED
616|Placentas From Sars-Cov-2-Positive Women|Topic|Placentas From Sars-Cov-2-Negative Women|Topic|RELATED_TO
617|Estimating Waning Of Vaccine Effectiveness: A Simulation Study|Paper|Ariel Nikas|Author|AUTHORED
617|Estimating Waning Of Vaccine Effectiveness: A Simulation Study|Paper|Hasan Ahmed|Author|AUTHORED
617|Estimating Waning Of Vaccine Effectiveness: A Simulation Study|Paper|Veronika I. Zarnitsyna|Author|AUTHORED
617|Estimating Waning Of Vaccine Effectiveness: A Simulation Study|Paper|Vaccine Effectiveness|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Cancer Cell Line Encyclopedia (Ccle)|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Genotype-Tissue Expression Project (Gtex)|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|The Cancer Genome Atlas (Tcga)|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Cbioportal|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Tisdb|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Tumor Immune Estimation Resource (Timer)|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Gene Set Enrichment Analysis (Gsea)|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Tumor Mutation Burden (Tmb)|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Microsatellite Instability (Msi)|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Mismatch Repair (Mmr)|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Dna Methyltransferase (Dnmt)|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Colon Adenocarcinoma|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Kidney Renal Clear Cell Carcinoma|Topic|RELATED_TO
618|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|Liver Hepatocellular Carcinoma|Topic|RELATED_TO
618|Shuqiang Huang|Author|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|AUTHORED
618|Cuiyu Tan|Author|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|AUTHORED
618|Jinzhen Zheng|Author|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|AUTHORED
618|Zhugu Huang|Author|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|AUTHORED
618|Zhihong Li|Author|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|AUTHORED
618|Ziyin Lv|Author|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|AUTHORED
618|Wanru Chen|Author|Rna Guanine-7 Methyltransferase (Rnmt)|Topic|AUTHORED
619|Colorectal Cancer Liver Metastases|Topic|Cd3Lowmhchigh Immunological Profile|Topic|RELATED_TO
619|Cd3Lowmhchigh Immunological Profile|Topic|Ensemble Network|Topic|RELATED_TO
619|Ensemble Network|Topic|Attentive Interpretable Tabular Learning|Topic|RELATED_TO
619|Ensemble Network|Topic|Ct-Derived Radiomic Features|Topic|RELATED_TO
619|Ralph Saber|Author|Colorectal Cancer Liver Metastases|Topic|AUTHORED
619|David Henault|Author|Colorectal Cancer Liver Metastases|Topic|AUTHORED
619|Rolando Rebolledo|Author|Colorectal Cancer Liver Metastases|Topic|AUTHORED
619|Simon Turcotte|Author|Colorectal Cancer Liver Metastases|Topic|AUTHORED
619|Samuel Kadoury|Author|Colorectal Cancer Liver Metastases|Topic|AUTHORED
619|Colorectal Cancer Liver Metastases|Topic|70.0% Accuracy|Topic|RELATED_TO
619|Colorectal Cancer Liver Metastases|Topic|69.4% Area Under The Curve|Topic|RELATED_TO
619|Cd3Lowmhchigh Immunological Profile|Topic|Shorter Disease-Specific Survival|Topic|RELATED_TO
619|Cd3Lowmhchigh Immunological Profile|Topic|Time-To-Recurrence|Topic|RELATED_TO
620|A Two-Stage Approach For Segmenting Spatial Point Patterns Applied To Multiplex Imaging|Paper|Alvin Sheng|Author|AUTHORED
620|A Two-Stage Approach For Segmenting Spatial Point Patterns Applied To Multiplex Imaging|Paper|Brian J. Reich|Author|AUTHORED
620|A Two-Stage Approach For Segmenting Spatial Point Patterns Applied To Multiplex Imaging|Paper|Ana-Maria Staicu|Author|AUTHORED
620|A Two-Stage Approach For Segmenting Spatial Point Patterns Applied To Multiplex Imaging|Paper|Santhoshi N. Krishnan|Author|AUTHORED
620|A Two-Stage Approach For Segmenting Spatial Point Patterns Applied To Multiplex Imaging|Paper|Arvind Rao|Author|AUTHORED
620|A Two-Stage Approach For Segmenting Spatial Point Patterns Applied To Multiplex Imaging|Paper|Timothy L. Frankel|Author|AUTHORED
621|Randomized Clinical Trials|Topic|Evidence Table|Topic|RELATED_TO
621|Evidence Table|Topic|Maximum Entropy Classifier|Topic|RELATED_TO
621|Evidence Table|Topic|Integer Linear Programming|Topic|RELATED_TO
621|Maximum Entropy Classifier|Topic|Antonio Trenta|Author|AUTHORED
621|Maximum Entropy Classifier|Topic|Anthony Hunter|Author|AUTHORED
621|Maximum Entropy Classifier|Topic|Sebastian Riedel|Author|AUTHORED
622|A Semiparametric Joint Model For Terminal Trend Of Quality Of Life And Survival In Palliative Care Research|Paper|Zhigang Li|Author|AUTHORED
622|A Semiparametric Joint Model For Terminal Trend Of Quality Of Life And Survival In Palliative Care Research|Paper|H. R. Frost|Author|AUTHORED
622|A Semiparametric Joint Model For Terminal Trend Of Quality Of Life And Survival In Palliative Care Research|Paper|Tor D. Tosteson|Author|AUTHORED
622|A Semiparametric Joint Model For Terminal Trend Of Quality Of Life And Survival In Palliative Care Research|Paper|Lihui Zhao|Author|AUTHORED
622|A Semiparametric Joint Model For Terminal Trend Of Quality Of Life And Survival In Palliative Care Research|Paper|Lei Liu|Author|AUTHORED
622|A Semiparametric Joint Model For Terminal Trend Of Quality Of Life And Survival In Palliative Care Research|Paper|Kathleen Lyons|Author|AUTHORED
622|A Semiparametric Joint Model For Terminal Trend Of Quality Of Life And Survival In Palliative Care Research|Paper|Huaihou Chen|Author|AUTHORED
622|A Semiparametric Joint Model For Terminal Trend Of Quality Of Life And Survival In Palliative Care Research|Paper|Bernard Cole|Author|AUTHORED
622|A Semiparametric Joint Model For Terminal Trend Of Quality Of Life And Survival In Palliative Care Research|Paper|David Currow|Author|AUTHORED
622|A Semiparametric Joint Model For Terminal Trend Of Quality Of Life And Survival In Palliative Care Research|Paper|Marie Bakitas|Author|AUTHORED
623|3+3 Design|Topic|I3+3 Design|Topic|RELATED_TO
623|I3+3 Design|Topic|Phase I Clinical Trials|Topic|RELATED_TO
623|Meizi Liu|Author|I3+3 Design|Topic|AUTHORED
623|Sue-Jane Wang|Author|I3+3 Design|Topic|AUTHORED
623|Yuan Ji|Author|I3+3 Design|Topic|AUTHORED
624|Adaptive Seamless Designs|Topic|Confirmatory Testing|Topic|RELATED_TO
624|Adaptive Seamless Designs|Topic|Phase Iii Trials|Topic|RELATED_TO
624|Adaptive Seamless Designs|Topic|Treatment Selection|Topic|RELATED_TO
624|Adaptive Seamless Designs|Topic|Subgroup Selection|Topic|RELATED_TO
624|Adaptive Seamless Designs|Topic|Development Programmes Of New Drugs|Topic|RELATED_TO
624|Adaptive Seamless Designs|Topic|Sample Size|Topic|RELATED_TO
624|Adaptive Seamless Designs|Topic|Development Time|Topic|RELATED_TO
624|Adaptive Seamless Designs|Topic|Logistical Perspective|Topic|RELATED_TO
624|Adaptive Seamless Designs|Topic|Upfront Planning|Topic|RELATED_TO
624|Adaptive Seamless Designs|Topic|Simulation Studies|Topic|RELATED_TO
624|Adaptive Seamless Designs|Topic|Framework For Adaptive Treatment And Subgroup Selection|Topic|RELATED_TO
624|R Package Asd|Author|Adaptive Enrichment Designs|Topic|AUTHORED
624|R Package Asd|Author|Interim Analyses|Topic|AUTHORED
624|R Package Asd|Author|Primary Outcome|Topic|AUTHORED
624|R Package Asd|Author|Early Outcome|Topic|AUTHORED
624|R Package Asd|Author|Operating Characteristics Of Adaptive Seamless Studies|Topic|AUTHORED
624|R Package Asd|Author|Seamless Phase Ii/Iii Clinical Trials|Topic|AUTHORED
624|R Package Asd|Author|Methods And Aspects Of Their Implementation|Topic|AUTHORED
624|Tim Friede|Author|R Package Asd|Author|AUTHORED
624|Nigel Stallard|Author|R Package Asd|Author|AUTHORED
624|Nicholas Parsons|Author|R Package Asd|Author|AUTHORED
625|Stride Trial|Topic|Ascertainment Bias|Topic|RELATED_TO
625|E. J. Greene|Author|Ascertainment Bias|Topic|AUTHORED
625|P. Peduzzi|Author|Ascertainment Bias|Topic|AUTHORED
625|J. Dziura|Author|Ascertainment Bias|Topic|AUTHORED
625|C. Meng|Author|Ascertainment Bias|Topic|AUTHORED
625|M. E. Miller|Author|Ascertainment Bias|Topic|AUTHORED
625|T. G. Travison|Author|Ascertainment Bias|Topic|AUTHORED
625|D. Esserman|Author|Ascertainment Bias|Topic|AUTHORED
626|Efficient, Doubly Robust Estimation Of The Effect Of Dose Switching For Switchers In A Randomised Clinical Trial|Paper|Janssen Pharmaceuticals|Topic|RELATED_TO
626|Efficient, Doubly Robust Estimation Of The Effect Of Dose Switching For Switchers In A Randomised Clinical Trial|Paper|Flexible Dosing Regimen|Topic|RELATED_TO
626|Efficient, Doubly Robust Estimation Of The Effect Of Dose Switching For Switchers In A Randomised Clinical Trial|Paper|Placebo|Topic|RELATED_TO
626|Efficient, Doubly Robust Estimation Of The Effect Of Dose Switching For Switchers In A Randomised Clinical Trial|Paper|Low Dose|Topic|RELATED_TO
626|Efficient, Doubly Robust Estimation Of The Effect Of Dose Switching For Switchers In A Randomised Clinical Trial|Paper|Higher Dose|Topic|RELATED_TO
626|Efficient, Doubly Robust Estimation Of The Effect Of Dose Switching For Switchers In A Randomised Clinical Trial|Paper|Fixed Dosing Trial|Topic|RELATED_TO
626|Efficient, Doubly Robust Estimation Of The Effect Of Dose Switching For Switchers In A Randomised Clinical Trial|Paper|Outcome Model|Topic|RELATED_TO
626|Efficient, Doubly Robust Estimation Of The Effect Of Dose Switching For Switchers In A Randomised Clinical Trial|Paper|Propensity Score Model|Topic|RELATED_TO
626|Efficient, Doubly Robust Estimation Of The Effect Of Dose Switching For Switchers In A Randomised Clinical Trial|Paper|Monte Carlo Simulations|Topic|RELATED_TO
627|Doubly-Robust Imputation Framework|Topic|Yuqi Qiu|Author|AUTHORED
627|Doubly-Robust Imputation Framework|Topic|Karen Messer|Author|AUTHORED
627|Doubly-Robust Imputation Framework|Topic|Alzheimer'S Disease Cooperative Study|Topic|RELATED_TO
628|Prognostic Stratum Matching Framework|Topic|Optimal Policy Trees (Opts)|Topic|RELATED_TO
628|Gastrointestinal Stromal Tumors (Gist)|Topic|Optimal Policy Trees (Opts)|Topic|RELATED_TO
628|Extremity Sarcomas|Topic|Optimal Policy Trees (Opts)|Topic|RELATED_TO
628|Dimitris Bertsimas|Author|Prognostic Stratum Matching Framework|Topic|AUTHORED
628|Angelos G. Koulouras|Author|Prognostic Stratum Matching Framework|Topic|AUTHORED
628|Georgios Antonios Margonis|Author|Prognostic Stratum Matching Framework|Topic|AUTHORED
629|Randomized Controlled Trial Transportability|Topic|Scoping Review|Topic|DISCUSSES
629|Scoping Review|Topic|Rcts|Topic|RELATED_TO
629|Scoping Review|Topic|Observational Cohorts|Topic|RELATED_TO
629|Scoping Review|Topic|Cardiovascular Diseases|Topic|RELATED_TO
629|Scoping Review|Topic|Infectious Diseases|Topic|RELATED_TO
629|Scoping Review|Topic|Psychiatry|Topic|RELATED_TO
629|Scoping Review|Topic|Oncology|Topic|RELATED_TO
629|Scoping Review|Topic|Orthopedics|Topic|RELATED_TO
629|Scoping Review|Topic|Anesthesiology|Topic|RELATED_TO
629|Scoping Review|Topic|Hematology|Topic|RELATED_TO
629|Guanbo Wang|Author|Randomized Controlled Trial Transportability|Topic|AUTHORED
629|Ting-Wei Ernie Liao|Author|Randomized Controlled Trial Transportability|Topic|AUTHORED
629|David Furfaro|Author|Randomized Controlled Trial Transportability|Topic|AUTHORED
629|Leo Anthony Celi|Author|Randomized Controlled Trial Transportability|Topic|AUTHORED
629|Kevin Sheng-Kai Ma|Author|Randomized Controlled Trial Transportability|Topic|AUTHORED
630|Traditional Phase I Dose Finding Cancer Clinical Trial Designs|Topic|Maximum Tolerated Dose (Mtd)|Topic|DISCUSSES
630|Traditional Phase I Dose Finding Cancer Clinical Trial Designs|Topic|Immuno-Oncology Therapies|Topic|DISCUSSES
630|Traditional Phase I Dose Finding Cancer Clinical Trial Designs|Topic|Molecularly Targeted Therapies|Topic|DISCUSSES
630|Model-Assisted Dose Finding Designs|Topic|Optimal Biological Dose (Obd)|Topic|DISCUSSES
630|Model-Assisted Dose Finding Designs|Topic|Boin-Et|Topic|RELATED_TO
630|Model-Assisted Dose Finding Designs|Topic|Boin12|Topic|RELATED_TO
630|Model-Assisted Dose Finding Designs|Topic|Ubi|Topic|RELATED_TO
630|Model-Assisted Dose Finding Designs|Topic|Tepi-2|Topic|RELATED_TO
630|Model-Assisted Dose Finding Designs|Topic|Printe|Topic|RELATED_TO
630|Model-Assisted Dose Finding Designs|Topic|Stein|Topic|RELATED_TO
630|Model-Assisted Dose Finding Designs|Topic|Utpi|Topic|RELATED_TO
630|Car T-Cell Therapy Phase I Trial|Topic|Model-Assisted Dose Finding Designs|Topic|DISCUSSES
630|Hao Sun|Author|Statistical Operating Characteristics Of Current Early Phase Dose Finding Designs With Toxicity And Efficacy In Oncology|Paper|AUTHORED
630|Hsin-Yu Lin|Author|Statistical Operating Characteristics Of Current Early Phase Dose Finding Designs With Toxicity And Efficacy In Oncology|Paper|AUTHORED
630|Jieqi Tu|Author|Statistical Operating Characteristics Of Current Early Phase Dose Finding Designs With Toxicity And Efficacy In Oncology|Paper|AUTHORED
630|Revathi Ananthakrishnan|Author|Statistical Operating Characteristics Of Current Early Phase Dose Finding Designs With Toxicity And Efficacy In Oncology|Paper|AUTHORED
630|Eunhee Kim|Author|Statistical Operating Characteristics Of Current Early Phase Dose Finding Designs With Toxicity And Efficacy In Oncology|Paper|AUTHORED
631|Markov Chain Model|Topic|Multiple Sclerosis|Topic|RELATED_TO
631|Expanded Disability Status Scale|Topic|Markov Chain Model|Topic|RELATED_TO
631|Uma Sthanu|Author|Clinical Trial Endpoints|Topic|AUTHORED
631|Gary Cutter Phd|Author|Clinical Trial Endpoints|Topic|AUTHORED
632|A Framework For Generating Realistic Synthetic Tabular Data In A Randomized Controlled Trial Setting|Paper|Niki Z. Petrakos|Author|AUTHORED
632|A Framework For Generating Realistic Synthetic Tabular Data In A Randomized Controlled Trial Setting|Paper|Erica E. M. Moodie|Author|AUTHORED
632|A Framework For Generating Realistic Synthetic Tabular Data In A Randomized Controlled Trial Setting|Paper|Nicolas Savy|Author|AUTHORED
632|A Framework For Generating Realistic Synthetic Tabular Data In A Randomized Controlled Trial Setting|Paper|Synthetic Data Generation|Topic|RELATED_TO
632|A Framework For Generating Realistic Synthetic Tabular Data In A Randomized Controlled Trial Setting|Paper|Randomized Controlled Trials|Topic|RELATED_TO
633|Test Sensitivity In The Computer-Aided Detection Of Breast Cancer From Clinical Mammographic Screening: A Meta-Analysis|Paper|Computer-Aided Detection Technologies|Topic|DISCUSSES
633|Test Sensitivity In The Computer-Aided Detection Of Breast Cancer From Clinical Mammographic Screening: A Meta-Analysis|Paper|Breast Cancer Screening|Topic|DISCUSSES
633|Test Sensitivity In The Computer-Aided Detection Of Breast Cancer From Clinical Mammographic Screening: A Meta-Analysis|Paper|Meta-Analysis|Topic|DISCUSSES
633|Test Sensitivity In The Computer-Aided Detection Of Breast Cancer From Clinical Mammographic Screening: A Meta-Analysis|Paper|Clinical Studies|Topic|DISCUSSES
634|Alzheimer'S Disease|Topic|Machine Learning|Topic|RELATED_TO
634|Machine Learning|Topic|Alzheimer'S Disease Neuroimaging Initiative (Adni)|Topic|RELATED_TO
634|Vipul Satone|Author|Alzheimer'S Disease|Topic|AUTHORED
634|Rachneet Kaur|Author|Alzheimer'S Disease|Topic|AUTHORED
634|Faraz Faghri|Author|Alzheimer'S Disease|Topic|AUTHORED
634|Mike A Nalls|Author|Alzheimer'S Disease|Topic|AUTHORED
634|Andrew B Singleton|Author|Alzheimer'S Disease|Topic|AUTHORED
634|Roy H Campbell|Author|Alzheimer'S Disease|Topic|AUTHORED
635|Age-Related Macular Degeneration|Topic|Yifan Peng|Author|AUTHORED
635|Age-Related Macular Degeneration|Topic|Tiarnan D. Keenan|Author|AUTHORED
635|Age-Related Macular Degeneration|Topic|Qingyu Chen|Author|AUTHORED
635|Age-Related Macular Degeneration|Topic|Elvira Agrón|Author|AUTHORED
635|Age-Related Macular Degeneration|Topic|Alexis Allot|Author|AUTHORED
635|Age-Related Macular Degeneration|Topic|Wai T. Wong|Author|AUTHORED
635|Age-Related Macular Degeneration|Topic|Emily Y. Chew|Author|AUTHORED
635|Age-Related Macular Degeneration|Topic|Zhiyong Lu|Author|AUTHORED
635|Areds|Topic|Areds2|Topic|RELATED_TO
635|Deep Learning|Topic|Age-Related Macular Degeneration|Topic|DISCUSSES
635|Retinal Specialists|Topic|Clinical Standards|Topic|RELATED_TO
635|Independent Test Dataset|Topic|Prognostic Accuracy|Topic|RELATED_TO
636|Artificial Intelligence Language Models|Topic|Clinical Decision-Making|Topic|RELATED_TO
636|Large Language Models|Topic|Medical Licensure Exams|Topic|RELATED_TO
636|Gpt4|Author|Complex Clinical Cases|Topic|AUTHORED
636|Gpt3.5|Author|Complex Clinical Cases|Topic|AUTHORED
636|Case Records Of The Massachusetts General Hospital|Topic|January 1, 2022|Topic|RELATED_TO
636|Case Records Of The Massachusetts General Hospital|Topic|April 16, 2022|Topic|RELATED_TO
636|Timothy Poterucha|Author|The Case Records Of Chatgpt: Language Models And Complex Clinical Questions|Paper|AUTHORED
636|Pierre Elias|Author|The Case Records Of Chatgpt: Language Models And Complex Clinical Questions|Paper|AUTHORED
636|Christopher M. Haggerty|Author|The Case Records Of Chatgpt: Language Models And Complex Clinical Questions|Paper|AUTHORED
637|Trialmind|Topic|Trialreviewbench|Topic|RELATED_TO
637|Zifeng Wang|Author|Trialmind|Topic|AUTHORED
637|Lang Cao|Author|Trialmind|Topic|AUTHORED
637|Benjamin Danek|Author|Trialmind|Topic|AUTHORED
637|Qiao Jin|Author|Trialmind|Topic|AUTHORED
637|Zhiyong Lu|Author|Trialmind|Topic|AUTHORED
637|Jimeng Sun|Author|Trialmind|Topic|AUTHORED
638|Comparing Approaches To Treatment Effect Estimation For Subgroups In Clinical Trials|Paper|Marius Thomas|Author|AUTHORED
638|Comparing Approaches To Treatment Effect Estimation For Subgroups In Clinical Trials|Paper|Björn Bornkamp|Author|AUTHORED
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|Randomly Censored Survival Data|Topic|DISCUSSES
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|Applied Sciences|Topic|DISCUSSES
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|Biomedical Applications|Topic|DISCUSSES
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|Reliability Applications|Topic|DISCUSSES
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|Clinical Trial Analyses|Topic|DISCUSSES
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|Statistical Hypotheses|Topic|DISCUSSES
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|Likelihood Based Tests|Topic|DISCUSSES
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|M-Estimators|Topic|DISCUSSES
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|Minimum Density Power Divergence Estimators|Topic|DISCUSSES
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|Asymptotic Variance|Topic|DISCUSSES
639|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|Wald-Type Tests|Topic|DISCUSSES
639|Abhik Ghosh|Author|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|AUTHORED
639|Ayanendranath Basu|Author|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|AUTHORED
639|Leandro Pardo|Author|Robust Wald-Type Tests Under Random Censoring With Applications To Clinical Trial Analyses|Paper|AUTHORED
640|Mild Cognitive Impairment|Topic|Alzheimers Disease|Topic|RELATED_TO
640|Fengyi Tang|Author|Improving Mild Cognitive Impairment Prediction Via Reinforcement Learning And Dialogue Simulation|Paper|AUTHORED
640|Kaixiang Lin|Author|Improving Mild Cognitive Impairment Prediction Via Reinforcement Learning And Dialogue Simulation|Paper|AUTHORED
640|Ikechukwu Uchendu|Author|Improving Mild Cognitive Impairment Prediction Via Reinforcement Learning And Dialogue Simulation|Paper|AUTHORED
640|Hiroko H. Dodge|Author|Improving Mild Cognitive Impairment Prediction Via Reinforcement Learning And Dialogue Simulation|Paper|AUTHORED
640|Jiayu Zhou|Author|Improving Mild Cognitive Impairment Prediction Via Reinforcement Learning And Dialogue Simulation|Paper|AUTHORED
640|Reinforcement Learning Framework|Topic|Mci Diagnosis|Topic|RELATED_TO
640|Dialogue Agent|Topic|Mci Diagnosis|Topic|RELATED_TO
640|Clinical Trial|Topic|Mci Diagnosis|Topic|RELATED_TO
640|Supervised Learning Approaches|Topic|Mci Diagnosis|Topic|RELATED_TO
641|Loss Of Power And Clear Description Of Treatment Differences|Topic|Clinical Trial|Topic|RELATED_TO
641|Clinical Trial|Topic|Non-Proportional Hazard|Topic|RELATED_TO
641|Non-Proportional Hazard|Topic|Log-Rank Test|Topic|RELATED_TO
641|Non-Proportional Hazard|Topic|Hazard Ratio|Topic|RELATED_TO
641|Hazard Ratio|Topic|Cox Regression|Topic|RELATED_TO
641|Clinical Trial|Topic|Ich E9 (R1) Addendum|Topic|RELATED_TO
641|Ich E9 (R1) Addendum|Topic|Clinically Relevant Estimand|Topic|RELATED_TO
641|Clinically Relevant Estimand|Topic|Expected Life Gain|Topic|RELATED_TO
641|Cross-Pharma Working Group|Topic|Combination Test|Topic|RELATED_TO
641|Combination Test|Topic|Robust Design And Analysis Of Clinical Trials With Non-Proportional Hazards: A Straw Man Guidance From A Cross-Pharma Working Group|Paper|RELATED_TO
642|Recruitment Prediction For Multi-Centre Clinical Trials Based On A Hierarchical Poisson-Gamma Model: Asymptotic Analysis And Improved Intervals|Paper|Hierarchical Poisson-Gamma Model|Topic|DISCUSSES
642|Recruitment Prediction For Multi-Centre Clinical Trials Based On A Hierarchical Poisson-Gamma Model: Asymptotic Analysis And Improved Intervals|Paper|Quantile Predictions|Topic|DISCUSSES
642|Recruitment Prediction For Multi-Centre Clinical Trials Based On A Hierarchical Poisson-Gamma Model: Asymptotic Analysis And Improved Intervals|Paper|Simulation Studies|Topic|DISCUSSES
642|Recruitment Prediction For Multi-Centre Clinical Trials Based On A Hierarchical Poisson-Gamma Model: Asymptotic Analysis And Improved Intervals|Paper|Gamma Random Variables|Topic|DISCUSSES
642|Recruitment Prediction For Multi-Centre Clinical Trials Based On A Hierarchical Poisson-Gamma Model: Asymptotic Analysis And Improved Intervals|Paper|Gaussian Approximation|Topic|DISCUSSES
643|Evidence Inference 2.0: More Data, Better Models|Paper|Jay Deyoung|Author|AUTHORED
643|Evidence Inference 2.0: More Data, Better Models|Paper|Eric Lehman|Author|AUTHORED
643|Evidence Inference 2.0: More Data, Better Models|Paper|Ben Nye|Author|AUTHORED
643|Evidence Inference 2.0: More Data, Better Models|Paper|Iain J. Marshall|Author|AUTHORED
643|Evidence Inference 2.0: More Data, Better Models|Paper|Byron C. Wallace|Author|AUTHORED
643|Evidence Inference 2.0: More Data, Better Models|Paper|Nlp|Topic|RELATED_TO
643|Evidence Inference 2.0: More Data, Better Models|Paper|Clinical Trials|Topic|RELATED_TO
643|Evidence Inference 2.0: More Data, Better Models|Paper|Systematic Reviews|Topic|RELATED_TO
643|Evidence Inference 2.0: More Data, Better Models|Paper|Evidence Inference Dataset|Topic|RELATED_TO
643|Evidence Inference 2.0: More Data, Better Models|Paper|Comparative Performance|Topic|RELATED_TO
643|Evidence Inference 2.0: More Data, Better Models|Paper|Treatments|Topic|RELATED_TO
643|Evidence Inference 2.0: More Data, Better Models|Paper|Outcome|Topic|RELATED_TO
643|Evidence Inference 2.0: More Data, Better Models|Paper|Five-Year Survival Rates|Topic|RELATED_TO
643|Evidence Inference 2.0: More Data, Better Models|Paper|Operable Cancers|Topic|RELATED_TO
644|Clinical Trial Drug Safety Assessment For Studies And Submissions Impacted By Covid-19|Paper|Mary Nilsson|Author|AUTHORED
644|Clinical Trial Drug Safety Assessment For Studies And Submissions Impacted By Covid-19|Paper|Brenda Crowe|Author|AUTHORED
644|Clinical Trial Drug Safety Assessment For Studies And Submissions Impacted By Covid-19|Paper|Greg Anglin|Author|AUTHORED
644|Clinical Trial Drug Safety Assessment For Studies And Submissions Impacted By Covid-19|Paper|Greg Ball|Author|AUTHORED
644|Clinical Trial Drug Safety Assessment For Studies And Submissions Impacted By Covid-19|Paper|Melvin Munsaka|Author|AUTHORED
644|Clinical Trial Drug Safety Assessment For Studies And Submissions Impacted By Covid-19|Paper|Seta Shahin|Author|AUTHORED
644|Clinical Trial Drug Safety Assessment For Studies And Submissions Impacted By Covid-19|Paper|Wei Wang|Author|AUTHORED
645|Linear Regression|Topic|Randomized Clinical Trials|Topic|RELATED_TO
645|Regression Models|Topic|Treatment Effect|Topic|RELATED_TO
645|Wei Ma|Author|Regression Models|Topic|AUTHORED
645|Fuyi Tu|Author|Regression Models|Topic|AUTHORED
645|Hanzhong Liu|Author|Regression Models|Topic|AUTHORED
646|Nonparametric Statistical Test Of Quasi-Independence|Paper|Quasi-(In)Dependence|Topic|DISCUSSES
646|Nonparametric Statistical Test Of Quasi-Independence|Paper|Tamara Fernández|Author|AUTHORED
646|Nonparametric Statistical Test Of Quasi-Independence|Paper|Wenkai Xu|Author|AUTHORED
646|Nonparametric Statistical Test Of Quasi-Independence|Paper|Marc Ditzhaus|Author|AUTHORED
646|Nonparametric Statistical Test Of Quasi-Independence|Paper|Arthur Gretton|Author|AUTHORED
647|Assessing Contribution Of Treatment Phases Through Tipping Point Analyses Using Rank Preserving Structural Failure Time Models|Paper|Sudipta Bhattacharya|Author|AUTHORED
647|Assessing Contribution Of Treatment Phases Through Tipping Point Analyses Using Rank Preserving Structural Failure Time Models|Paper|Jyotirmoy Dey|Author|AUTHORED
647|Assessing Contribution Of Treatment Phases Through Tipping Point Analyses Using Rank Preserving Structural Failure Time Models|Paper|Clinical Trials|Topic|RELATED_TO
647|Assessing Contribution Of Treatment Phases Through Tipping Point Analyses Using Rank Preserving Structural Failure Time Models|Paper|Tipping Point Analysis|Topic|RELATED_TO
647|Assessing Contribution Of Treatment Phases Through Tipping Point Analyses Using Rank Preserving Structural Failure Time Models|Paper|Rank-Preserving-Structural-Failure-Time Modeling|Topic|RELATED_TO
648|Optimal Multiple Testing And Design In Clinical Trials|Paper|Ruth Heller|Author|AUTHORED
648|Optimal Multiple Testing And Design In Clinical Trials|Paper|Abba Krieger|Author|AUTHORED
648|Optimal Multiple Testing And Design In Clinical Trials|Paper|Saharon Rosset|Author|AUTHORED
648|Optimal Multiple Testing And Design In Clinical Trials|Paper|Power|Topic|DISCUSSES
648|Optimal Multiple Testing And Design In Clinical Trials|Paper|Type I Error|Topic|DISCUSSES
648|Optimal Multiple Testing And Design In Clinical Trials|Paper|Optimization Problem|Topic|DISCUSSES
648|Optimal Multiple Testing And Design In Clinical Trials|Paper|Hommel'S Procedure|Topic|DISCUSSES
648|Optimal Multiple Testing And Design In Clinical Trials|Paper|Bittman Et Al. (2009)|Topic|DISCUSSES
648|Optimal Multiple Testing And Design In Clinical Trials|Paper|Apex Study|Topic|DISCUSSES
648|Optimal Multiple Testing And Design In Clinical Trials|Paper|Simulation|Topic|DISCUSSES
649|A Permutation Test For Assessing The Presence Of Individual Differences In Treatment Effects|Paper|Chi Chang|Author|AUTHORED
649|A Permutation Test For Assessing The Presence Of Individual Differences In Treatment Effects|Paper|Thomas Jaki|Author|AUTHORED
649|A Permutation Test For Assessing The Presence Of Individual Differences In Treatment Effects|Paper|Muhammad Saad Sadiq|Author|AUTHORED
649|A Permutation Test For Assessing The Presence Of Individual Differences In Treatment Effects|Paper|Alena A. Kuhlemeier|Author|AUTHORED
649|A Permutation Test For Assessing The Presence Of Individual Differences In Treatment Effects|Paper|Daniel Feaster|Author|AUTHORED
649|A Permutation Test For Assessing The Presence Of Individual Differences In Treatment Effects|Paper|Nathan Cole|Author|AUTHORED
649|A Permutation Test For Assessing The Presence Of Individual Differences In Treatment Effects|Paper|Andrea Lamont|Author|AUTHORED
649|A Permutation Test For Assessing The Presence Of Individual Differences In Treatment Effects|Paper|Daniel Oberski|Author|AUTHORED
649|A Permutation Test For Assessing The Presence Of Individual Differences In Treatment Effects|Paper|Yasin Desai|Author|AUTHORED
649|A Permutation Test For Assessing The Presence Of Individual Differences In Treatment Effects|Paper|M. Lee Van Horn|Author|AUTHORED
650|Advanced Lung Cancer|Topic|Immunotherapy|Topic|RELATED_TO
650|Cimavaxegf|Topic|Advanced Lung Cancer|Topic|RELATED_TO
650|Lizet Sanchez|Author|Mixture Survival Model|Topic|AUTHORED
650|Patricia Lorenzo-Luaces|Author|Mixture Survival Model|Topic|AUTHORED
650|Claudia Fonte|Author|Mixture Survival Model|Topic|AUTHORED
650|Agustin Lage|Author|Mixture Survival Model|Topic|AUTHORED
650|Mixture Survival Model|Topic|Randomized Clinical Trials|Topic|RELATED_TO
650|Mixture Survival Model|Topic|Survival Analysis|Topic|RELATED_TO
650|Therapeutic Vaccine|Topic|Advanced Lung Cancer|Topic|RELATED_TO
650|Best Supportive Care|Topic|Advanced Lung Cancer|Topic|RELATED_TO
651|Transformer Query-Target Knowledge Discovery (Tend): Drug Discovery From Cord-19|Paper|Roberta|Topic|DISCUSSES
651|Transformer Query-Target Knowledge Discovery (Tend): Drug Discovery From Cord-19|Paper|Word2Vec|Topic|RELATED_TO
651|Transformer Query-Target Knowledge Discovery (Tend): Drug Discovery From Cord-19|Paper|Covid-19 Open Research Dataset Challenge (Cord-19)|Topic|RELATED_TO
651|Transformer Query-Target Knowledge Discovery (Tend): Drug Discovery From Cord-19|Paper|Influenza Drug Clinical Trials Dataset|Topic|RELATED_TO
651|Transformer Query-Target Knowledge Discovery (Tend): Drug Discovery From Cord-19|Paper|Influenza Clinical Trials And Antiviral Analogies Dataset|Topic|RELATED_TO
652|Motor Disturbances|Topic|Catching A Ball|Topic|RELATED_TO
652|Clinical Catching Trials|Topic|Arm And Ball Movements|Topic|RELATED_TO
652|Decision Confidence|Topic|Accuracy|Topic|RELATED_TO
652|Decision Confidence|Topic|Earliness|Topic|RELATED_TO
652|Decision Confidence|Topic|Decision-Making Confidence|Topic|RELATED_TO
652|Predictive Sequential Classification (Psc)|Topic|Predictive, Generative Recurrent Neural Network (Rnn)|Topic|RELATED_TO
652|Predictive Sequential Classification (Psc)|Topic|Discriminative Rnn|Topic|RELATED_TO
652|Predictive Sequential Classification (Psc)|Topic|Temporal Convolutional Network (Tcn)|Topic|RELATED_TO
652|Jana Lang|Author|Predictive Sequential Classification (Psc)|Topic|AUTHORED
652|Martin A. Giese|Author|Predictive Sequential Classification (Psc)|Topic|AUTHORED
652|Matthis Synofzik|Author|Predictive Sequential Classification (Psc)|Topic|AUTHORED
652|Winfried Ilg|Author|Predictive Sequential Classification (Psc)|Topic|AUTHORED
652|Sebastian Otte|Author|Predictive Sequential Classification (Psc)|Topic|AUTHORED
653|Broadly Neutralizing Antibodies (Bnabs)|Topic|Hiv|Topic|RELATED_TO
653|Bnab Therapy|Topic|Viral Escape|Topic|RELATED_TO
653|Hiv Sequence Data|Topic|Bnab Therapy|Topic|RELATED_TO
653|Clinical Trials|Topic|Bnab Therapy|Topic|RELATED_TO
653|Optimal Bnab Cocktail|Topic|Bnab Therapy|Topic|RELATED_TO
653|Mutational Target Size|Topic|Fitness Cost Of Hiv-1 Escape|Topic|RELATED_TO
653|Rebound Times|Topic|Clinical Trials|Topic|RELATED_TO
653|Pre-Treatment Standing Variation|Topic|Rebound Times|Topic|RELATED_TO
653|Colin Lamont|Author|Bnab Therapy|Topic|AUTHORED
653|Jakub Otwinowski|Author|Bnab Therapy|Topic|AUTHORED
653|Kanika Vanshylla|Author|Bnab Therapy|Topic|AUTHORED
653|Henning Gruell|Author|Bnab Therapy|Topic|AUTHORED
653|Florian Klein|Author|Bnab Therapy|Topic|AUTHORED
653|Armita Nourmohammad|Author|Bnab Therapy|Topic|AUTHORED
654|Missing Data In Longitudinal Clinical Trials|Topic|Sensitivity Analysis|Topic|RELATED_TO
654|Sensitivity Analysis|Topic|Imputation Models|Topic|RELATED_TO
654|Imputation Models|Topic|Distributional Imputation (Di)|Topic|RELATED_TO
654|Distributional Imputation (Di)|Topic|Weighted Bootstrap|Topic|RELATED_TO
654|Distributional Imputation (Di)|Topic|Antidepressant Longitudinal Clinical Trial|Topic|RELATED_TO
654|Siyi Liu|Author|Sensitivity Analysis|Topic|AUTHORED
654|Shu Yang|Author|Sensitivity Analysis|Topic|AUTHORED
654|Yilong Zhang|Author|Sensitivity Analysis|Topic|AUTHORED
654|Guanghan|Author|Sensitivity Analysis|Topic|AUTHORED
654|Liu|Author|Sensitivity Analysis|Topic|AUTHORED
655|Robust Analyses For Longitudinal Clinical Trials With Missing And Non-Normal Continuous Outcomes|Paper|Siyi Liu|Author|AUTHORED
655|Robust Analyses For Longitudinal Clinical Trials With Missing And Non-Normal Continuous Outcomes|Paper|Yilong Zhang|Author|AUTHORED
655|Robust Analyses For Longitudinal Clinical Trials With Missing And Non-Normal Continuous Outcomes|Paper|Gregory T Golm|Author|AUTHORED
655|Robust Analyses For Longitudinal Clinical Trials With Missing And Non-Normal Continuous Outcomes|Paper|Guanghan Liu|Author|AUTHORED
655|Robust Analyses For Longitudinal Clinical Trials With Missing And Non-Normal Continuous Outcomes|Paper|Shu Yang|Author|AUTHORED
656|Towards Assessing Data Bias In Clinical Trials|Paper|Algorithms And Technologies|Topic|RELATED_TO
656|Towards Assessing Data Bias In Clinical Trials|Paper|Health Care Research|Topic|RELATED_TO
656|Towards Assessing Data Bias In Clinical Trials|Paper|Data Bias|Topic|RELATED_TO
656|Towards Assessing Data Bias In Clinical Trials|Paper|Cardiovascular Diseases|Topic|RELATED_TO
656|Chiara Criscuolo|Author|Towards Assessing Data Bias In Clinical Trials|Paper|AUTHORED
656|Tommaso Dolci|Author|Towards Assessing Data Bias In Clinical Trials|Paper|AUTHORED
656|Mattia Salnitri|Author|Towards Assessing Data Bias In Clinical Trials|Paper|AUTHORED
657|Dual Cox Model Theory|Topic|Powei Chen|Author|AUTHORED
657|Dual Cox Model Theory|Topic|Siying Hu|Author|AUTHORED
657|Dual Cox Model Theory|Topic|Haojin Zhou|Author|AUTHORED
658|A Comprehensive Analysis Of Hiv Treatment Efficacy In The Actg 175 Trial Through Multiple-Endpoint Approaches|Paper|María Paula Cantarini|Author|AUTHORED
658|A Comprehensive Analysis Of Hiv Treatment Efficacy In The Actg 175 Trial Through Multiple-Endpoint Approaches|Paper|Florencia Ayelén Hernández|Author|AUTHORED
658|A Comprehensive Analysis Of Hiv Treatment Efficacy In The Actg 175 Trial Through Multiple-Endpoint Approaches|Paper|Hiv-1|Topic|RELATED_TO
658|A Comprehensive Analysis Of Hiv Treatment Efficacy In The Actg 175 Trial Through Multiple-Endpoint Approaches|Paper|Cd4 Cell Counts|Topic|RELATED_TO
658|A Comprehensive Analysis Of Hiv Treatment Efficacy In The Actg 175 Trial Through Multiple-Endpoint Approaches|Paper|Zidovudine|Topic|RELATED_TO
658|A Comprehensive Analysis Of Hiv Treatment Efficacy In The Actg 175 Trial Through Multiple-Endpoint Approaches|Paper|Didanosine|Topic|RELATED_TO
658|A Comprehensive Analysis Of Hiv Treatment Efficacy In The Actg 175 Trial Through Multiple-Endpoint Approaches|Paper|Zalcitabine|Topic|RELATED_TO
659|Novomol|Topic|Ishir Rao|Author|AUTHORED
659|Novomol|Topic|Imatinib|Topic|RELATED_TO
660|Dementia Research|Topic|Matilda Beinat|Author|AUTHORED
660|Dementia Research|Topic|Julian Beinat|Author|AUTHORED
660|Dementia Research|Topic|Mohammed Shoaib|Author|AUTHORED
660|Dementia Research|Topic|Jorge Gomez Magenti|Author|AUTHORED
660|Dementia Research|Topic|Dimensions Database|Topic|RELATED_TO
660|Dementia Research|Topic|Catboost Classifier|Topic|RELATED_TO
660|Dementia Research|Topic|Machine Learning|Topic|RELATED_TO
660|Dementia Research|Topic|Uk Dementia Research Publications|Topic|RELATED_TO
660|Dementia Research|Topic|2023|Topic|RELATED_TO
660|Dementia Research|Topic|2040|Topic|RELATED_TO
660|Dementia Research|Topic|1.6 Million People|Topic|RELATED_TO
660|Dementia Research|Topic|£25 Billion|Topic|RELATED_TO
661|Savvy|Topic|Kaspar Rufibach|Author|AUTHORED
661|Savvy|Topic|Jan Beyersmann|Author|AUTHORED
661|Savvy|Topic|Tim Friede|Author|AUTHORED
661|Savvy|Topic|Claudia Schmoor|Author|AUTHORED
661|Savvy|Topic|Regina Stegherr|Author|AUTHORED
662|Power Prior Distributions|Topic|Clinical Trials|Topic|RELATED_TO
662|Power Prior Distributions|Topic|Treatment Effect|Topic|RELATED_TO
662|Weight Parameter|Topic|Historical Information|Topic|RELATED_TO
662|Prior Distribution|Topic|Weight Parameter|Topic|RELATED_TO
662|Calibrated Bayes Factor Procedure|Topic|Weight Parameter|Topic|RELATED_TO
662|Roberto Macrì Demartino|Author|Calibrated Bayes Factor Procedure|Topic|AUTHORED
662|Leonardo Egidi|Author|Calibrated Bayes Factor Procedure|Topic|AUTHORED
662|Nicola Torelli|Author|Calibrated Bayes Factor Procedure|Topic|AUTHORED
662|Ioannis Ntzoufras|Author|Calibrated Bayes Factor Procedure|Topic|AUTHORED
663|Stedr|Topic|Drug Repurposing|Topic|RELATED_TO
663|Stedr|Topic|Alzheimer'S Disease|Topic|RELATED_TO
663|Seungyeon Lee|Author|Stedr|Topic|AUTHORED
663|Ruoqi Liu|Author|Stedr|Topic|AUTHORED
663|Feixiong Cheng|Author|Stedr|Topic|AUTHORED
663|Ping Zhang|Author|Stedr|Topic|AUTHORED
664|Experimental Treatments|Topic|Familywise Type I Error Rate (Fwer)|Topic|DISCUSSES
664|Familywise Type I Error Rate (Fwer)|Topic|Dunnett Probability|Topic|RELATED_TO
664|Babak Choodari-Oskooei|Author|Adding New Experimental Arms To Randomised Clinical Trials: Impact On Error Rates|Paper|AUTHORED
664|Daniel J Bratton|Author|Adding New Experimental Arms To Randomised Clinical Trials: Impact On Error Rates|Paper|AUTHORED
664|Melissa R Gannon|Author|Adding New Experimental Arms To Randomised Clinical Trials: Impact On Error Rates|Paper|AUTHORED
664|Angela M Meade|Author|Adding New Experimental Arms To Randomised Clinical Trials: Impact On Error Rates|Paper|AUTHORED
664|Matthew R Sydes|Author|Adding New Experimental Arms To Randomised Clinical Trials: Impact On Error Rates|Paper|AUTHORED
664|Mahesh Kb Parmar|Author|Adding New Experimental Arms To Randomised Clinical Trials: Impact On Error Rates|Paper|AUTHORED
666|European Medicines Agency|Topic|An Efficient Method For Computing Expected Value Of Sample Information For Survival Data From An Ongoing Trial|Paper|RELATED_TO
666|Expected Value Of Sample Information|Topic|An Efficient Method For Computing Expected Value Of Sample Information For Survival Data From An Ongoing Trial|Paper|RELATED_TO
666|Mathyn Vervaart|Author|An Efficient Method For Computing Expected Value Of Sample Information For Survival Data From An Ongoing Trial|Paper|AUTHORED
666|Mark Strong|Author|An Efficient Method For Computing Expected Value Of Sample Information For Survival Data From An Ongoing Trial|Paper|AUTHORED
666|Karl P. Claxton|Author|An Efficient Method For Computing Expected Value Of Sample Information For Survival Data From An Ongoing Trial|Paper|AUTHORED
666|Nicky J. Welton|Author|An Efficient Method For Computing Expected Value Of Sample Information For Survival Data From An Ongoing Trial|Paper|AUTHORED
666|Torbjørn Wisløff|Author|An Efficient Method For Computing Expected Value Of Sample Information For Survival Data From An Ongoing Trial|Paper|AUTHORED
666|Eline Aas|Author|An Efficient Method For Computing Expected Value Of Sample Information For Survival Data From An Ongoing Trial|Paper|AUTHORED
667|Biomarker-Targeted Anti-Cancer Therapies|Topic|Programmed Death Ligand 1|Topic|RELATED_TO
667|Biomarker-Targeted Anti-Cancer Therapies|Topic|Programmed Death 1|Topic|RELATED_TO
667|Biomarker-Targeted Anti-Cancer Therapies|Topic|Cancer Indications|Topic|RELATED_TO
667|Biomarker-Targeted Anti-Cancer Therapies|Topic|Accelerated Approval|Topic|RELATED_TO
667|Biomarker-Targeted Anti-Cancer Therapies|Topic|Single-Arm Phase Ii Trials|Topic|RELATED_TO
667|Biomarker-Targeted Anti-Cancer Therapies|Topic|Randomized Trials|Topic|RELATED_TO
667|Atezolizumab|Author|Phase Iii Trial|Topic|AUTHORED
667|Emily C. Zabor|Author|Optimal Efficiency Predictive Probability Method|Topic|AUTHORED
667|Alexander M. Kaizer|Author|Futility Stopping|Topic|AUTHORED
667|Nathan A. Pennell|Author|Simulation Study|Topic|AUTHORED
667|Brian P. Hobbs|Author|Comparative Efficacy|Topic|AUTHORED
667|Comparative Efficacy|Topic|Phase Iii Confirmatory Trial|Topic|RELATED_TO
668|Bayesian Adaptive Trial|Topic|Integrated Nested Laplace Approximations|Topic|RELATED_TO
668|Bayesian Adaptive Trial|Topic|Markov Chain Monte Carlo Methods|Topic|RELATED_TO
668|Bayesian Adaptive Trial|Topic|Reyhaneh Hosseini|Author|AUTHORED
668|Bayesian Adaptive Trial|Topic|Ziming Chen|Author|AUTHORED
668|Bayesian Adaptive Trial|Topic|Ewan Goligher|Author|AUTHORED
668|Bayesian Adaptive Trial|Topic|Eddy Fan|Author|AUTHORED
668|Bayesian Adaptive Trial|Topic|Niall D. Ferguson|Author|AUTHORED
668|Bayesian Adaptive Trial|Topic|Michael O. Harhay|Author|AUTHORED
668|Bayesian Adaptive Trial|Topic|Sarina Sahetya|Author|AUTHORED
668|Bayesian Adaptive Trial|Topic|Martin Urner|Author|AUTHORED
668|Bayesian Adaptive Trial|Topic|Christopher J. Yarnell|Author|AUTHORED
668|Bayesian Adaptive Trial|Topic|Anna Heath|Author|AUTHORED
669|Randomized Clinical Trials|Topic|Composite Endpoints|Topic|RELATED_TO
669|Sample Size Calculations|Topic|Composite Endpoints|Topic|RELATED_TO
669|Adaptive Clinical Trial Designs|Topic|Composite Endpoints|Topic|RELATED_TO
669|Marta Bofill Roig|Author|Adaptive Clinical Trial Designs|Topic|AUTHORED
669|Guadalupe Gómez Melis|Author|Adaptive Clinical Trial Designs|Topic|AUTHORED
669|Martin Posch|Author|Adaptive Clinical Trial Designs|Topic|AUTHORED
669|Franz Koenig|Author|Adaptive Clinical Trial Designs|Topic|AUTHORED
670|Three-Photon Fluorescence Microscopy|Topic|Deep-Tissue Imaging|Topic|RELATED_TO
670|Three-Photon Fluorescence Microscopy|Topic|Neuroscience|Topic|RELATED_TO
670|Three-Photon Fluorescence Microscopy|Topic|Immunology|Topic|RELATED_TO
670|Three-Photon Fluorescence Microscopy|Topic|Cancer Biology|Topic|RELATED_TO
670|Femtosecond Pulses|Topic|Hollow-Core Fiber|Topic|RELATED_TO
670|Mouse Brain|Topic|Femtosecond Pulses|Topic|DISCUSSES
670|Yishai Eisenberg|Author|Femtosecond Pulses|Topic|AUTHORED
670|Wenchao Wang|Author|Femtosecond Pulses|Topic|AUTHORED
670|Shitong Zhao|Author|Femtosecond Pulses|Topic|AUTHORED
670|Eric S. Hebert|Author|Femtosecond Pulses|Topic|AUTHORED
670|Yi-Hao Chen|Author|Femtosecond Pulses|Topic|AUTHORED
670|Dimitre G. Ouzounov|Author|Femtosecond Pulses|Topic|AUTHORED
670|Hazuki Takahashi|Author|Femtosecond Pulses|Topic|AUTHORED
670|Anna Gruzdeva|Author|Femtosecond Pulses|Topic|AUTHORED
670|Aaron K. Laviolette|Author|Femtosecond Pulses|Topic|AUTHORED
670|Moshe Labaz|Author|Femtosecond Pulses|Topic|AUTHORED
670|Pavel Sidorenko|Author|Femtosecond Pulses|Topic|AUTHORED
670|Enrique Antonio-Lopez|Author|Femtosecond Pulses|Topic|AUTHORED
670|Rodrigo Amezcua-Correa|Author|Femtosecond Pulses|Topic|AUTHORED
670|Nilay Yapici|Author|Femtosecond Pulses|Topic|AUTHORED
670|Chris Xu|Author|Femtosecond Pulses|Topic|AUTHORED
670|Frank Wise|Author|Femtosecond Pulses|Topic|AUTHORED
671|Clinica|Topic|Alexandre Routier|Author|AUTHORED
671|Clinica|Topic|Ninon Burgos|Author|AUTHORED
671|Clinica|Topic|Mauricio Díaz|Author|AUTHORED
671|Clinica|Topic|Michael Bacci|Author|AUTHORED
671|Clinica|Topic|Simona Bottani|Author|AUTHORED
671|Clinica|Topic|Omar El-Rifai|Author|AUTHORED
671|Clinica|Topic|Sabrina Fontanella|Author|AUTHORED
671|Clinica|Topic|Pietro Gori|Author|AUTHORED
671|Clinica|Topic|Jérémy Guillon|Author|AUTHORED
671|Clinica|Topic|Alexis Guyot|Author|AUTHORED
671|Clinica|Topic|Ravi Hassanaly|Author|AUTHORED
671|Clinica|Topic|Thomas Jacquemont|Author|AUTHORED
671|Clinica|Topic|Pascal Lu|Author|AUTHORED
671|Clinica|Topic|Arnaud Marcoux|Author|AUTHORED
671|Clinica|Topic|Tristan Moreau|Author|AUTHORED
671|Clinica|Topic|Jorge Samper-González|Author|AUTHORED
671|Clinica|Topic|Marc Teichmann|Author|AUTHORED
671|Clinica|Topic|Elina Thibeau--Sutre|Author|AUTHORED
671|Clinica|Topic|Ghislain Vaillant|Author|AUTHORED
671|Clinica|Topic|Junhao Wen|Author|AUTHORED
671|Clinica|Topic|Adam Wild|Author|AUTHORED
671|Clinica|Topic|Marie-Odile Habert|Author|AUTHORED
671|Clinica|Topic|Stanley Durrleman|Author|AUTHORED
671|Clinica|Topic|Olivier Colliot|Author|AUTHORED
672|Women'S Health Initiative|Topic|Hormone Therapy|Topic|RELATED_TO
672|Hormone Therapy|Topic|Myocardial Infarction|Topic|RELATED_TO
672|Hormone Therapy|Topic|Ischemic Stroke|Topic|RELATED_TO
672|Diana B. Petitti|Author|Hormone Therapy|Topic|AUTHORED
672|Wansu Chen|Author|Hormone Therapy|Topic|AUTHORED
673|Multivariate Bayesian Logistic Regression For Analysis Of Clinical Trial Safety Issues|Paper|Stephen Evans|Author|DISCUSSES
674|Asymptotic Normality Of Linear Rank Statistics|Topic|Randomization Rules|Topic|RELATED_TO
674|Asymptotic Normality Of Linear Rank Statistics|Topic|Clinical Trials|Topic|RELATED_TO
674|Patients' Allocation Into Treatment And Placebo Arms|Topic|Clinical Trials|Topic|RELATED_TO
674|General Limit Theorem|Topic|Mcleish (1974)|Author|DISCUSSES
674|Asymptotic Normality Of Linear Rank Statistics|Topic|Viktor Skorniakov|Author|AUTHORED
674|Well Known Results|Topic|Asymptotic Normality Of Linear Rank Statistics|Topic|RELATED_TO
674|Several New Results|Topic|Asymptotic Normality Of Linear Rank Statistics|Topic|RELATED_TO
675|Regulation Of Interferon Production As A Potential Strategy For Covid-19 Treatment|Paper|Xiaobing Deng|Author|AUTHORED
675|Regulation Of Interferon Production As A Potential Strategy For Covid-19 Treatment|Paper|Xiaoyu Yu|Author|AUTHORED
675|Regulation Of Interferon Production As A Potential Strategy For Covid-19 Treatment|Paper|Jianfeng Pei|Author|AUTHORED
676|Youth Experiencing Homelessness|Topic|Hiv Infection|Topic|RELATED_TO
676|Health Equity|Topic|Peer Leaders|Topic|RELATED_TO
676|Peer Leaders|Topic|Artificial Intelligence System|Topic|RELATED_TO
676|Artificial Intelligence System|Topic|Clinical Trial|Topic|RELATED_TO
676|Clinical Trial|Topic|Ai-Augmented Intervention For Hiv Prevention|Paper|AUTHORED
677|Randomized Clinical Trials|Topic|Multiple Primary Endpoints|Topic|RELATED_TO
677|Multiple Primary Endpoints|Topic|Closed Testing Principle|Topic|RELATED_TO
677|Closed Testing Principle|Topic|Max(Maxt) Tests|Topic|RELATED_TO
677|Max(Maxt) Tests|Topic|Simulation Study|Topic|RELATED_TO
677|Simulation Study|Topic|Treatment-Versus-Control Comparisons|Topic|RELATED_TO
677|Treatment-Versus-Control Comparisons|Topic|Multiple Correlated Endpoint|Topic|RELATED_TO
677|Ludwig A. Hothorn|Author|Multiple Correlated Endpoint|Topic|AUTHORED
677|Siegfried Kropf|Author|Multiple Correlated Endpoint|Topic|AUTHORED
678|Artificial Pancreas System|Topic|Openaps|Topic|RELATED_TO
678|Artificial Pancreas System|Topic|Basal Bolus|Topic|RELATED_TO
678|Artificial Pancreas System|Topic|Type 1 Diabetes|Topic|RELATED_TO
678|Artificial Pancreas System|Topic|Glucose Levels|Topic|RELATED_TO
678|Artificial Pancreas System|Topic|Control Algorithms|Topic|RELATED_TO
678|Artificial Pancreas System|Topic|Synthetic Data|Topic|RELATED_TO
678|Artificial Pancreas System|Topic|Testbed|Topic|RELATED_TO
678|Testbed|Topic|Xugui Zhou|Author|AUTHORED
678|Testbed|Topic|Maxfield Kouzel|Author|AUTHORED
678|Testbed|Topic|Haotian Ren|Author|AUTHORED
678|Testbed|Topic|Homa Alemzadeh|Author|AUTHORED
679|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|Alzheimer'S Disease|Topic|RELATED_TO
679|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|Amyotrophic Lateral Sclerosis|Topic|RELATED_TO
679|Jessica L. Ross|Author|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|AUTHORED
679|Arman Sabbaghi|Author|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|AUTHORED
679|Run Zhuang|Author|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|AUTHORED
679|Daniele Bertolini|Author|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|AUTHORED
679|The Alzheimer'S Disease Cooperative Study|Author|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|AUTHORED
679|Alzheimer'S Disease Neuroimaging Initiative|Author|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|AUTHORED
679|The Critical Path For Alzheimer'S Disease Database|Author|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|AUTHORED
679|The European Prevention Of Alzheimer'S Disease Consortium|Author|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|AUTHORED
679|The Pooled Resource Open-Access Als Clinical Trials Consortium|Author|Prognostic Covariate-Adjusted Mixed Models For Repeated Measures (Procova-Mmrm)|Topic|AUTHORED
680|Semeval 2024 Task 2|Topic|Prompt Optimization Techniques|Topic|RELATED_TO
680|Prompt Optimization Techniques|Topic|Language Model-As-A-Service|Topic|RELATED_TO
680|Prompt Optimization Techniques|Topic|Synthetic Cot Prompts|Topic|RELATED_TO
680|Clément Brutti-Mairesse|Author|Semeval 2024 Task 2|Topic|AUTHORED
680|Loïc Verlingue|Author|Semeval 2024 Task 2|Topic|AUTHORED
681|Arges|Topic|Ulcerative Colitis|Topic|RELATED_TO
681|Arges|Topic|Mayo Endoscopic Subscore|Topic|RELATED_TO
681|Arges|Topic|Ulcerative Colitis Endoscopic Index Of Severity|Topic|RELATED_TO
681|Krishna Chaitanya|Author|Arges|Topic|AUTHORED
681|Pablo F. Damasceno|Author|Arges|Topic|AUTHORED
681|Shreyas Fadnavis|Author|Arges|Topic|AUTHORED
681|Pooya Mobadersany|Author|Arges|Topic|AUTHORED
681|Chaitanya Parmar|Author|Arges|Topic|AUTHORED
681|Emily Scherer|Author|Arges|Topic|AUTHORED
681|Natalia Zemlianskaia|Author|Arges|Topic|AUTHORED
681|Lindsey Surace|Author|Arges|Topic|AUTHORED
681|Louis R. Ghanem|Author|Arges|Topic|AUTHORED
681|Oana Gabriela Cula|Author|Arges|Topic|AUTHORED
681|Tommaso Mansi|Author|Arges|Topic|AUTHORED
681|Kristopher Standish|Author|Arges|Topic|AUTHORED
682|Spatiotemporal Dissociation Of Brain Activity Underlying Subjective Awareness, Objective Performance And Confidence|Paper|Qi Li|Author|AUTHORED
682|Spatiotemporal Dissociation Of Brain Activity Underlying Subjective Awareness, Objective Performance And Confidence|Paper|Zachary Hill|Author|AUTHORED
682|Spatiotemporal Dissociation Of Brain Activity Underlying Subjective Awareness, Objective Performance And Confidence|Paper|Biyu J. He|Author|AUTHORED
683|Lfads|Paper|Neuroscience|Topic|RELATED_TO
683|Lfads|Paper|Variational Auto-Encoder|Topic|RELATED_TO
683|Lfads|Paper|Synthetic Data|Topic|DISCUSSES
683|Lfads|Paper|Neural Firing Rates|Topic|DISCUSSES
683|Lfads|Paper|Latent Dynamics|Topic|DISCUSSES
684|Lfads|Topic|Neural Population Dynamics|Topic|RELATED_TO
684|Lfads|Topic|Field Programmable Gate Arrays|Topic|RELATED_TO
684|Field Programmable Gate Arrays|Topic|Xilinx U55C|Topic|RELATED_TO
684|Xiaohan Liu|Author|Lfads|Topic|AUTHORED
684|Chijui Chen|Author|Lfads|Topic|AUTHORED
684|Yanlun Huang|Author|Lfads|Topic|AUTHORED
684|Lingchi Yang|Author|Lfads|Topic|AUTHORED
684|Elham E Khoda|Author|Lfads|Topic|AUTHORED
684|Yihui Chen|Author|Lfads|Topic|AUTHORED
684|Scott Hauck|Author|Lfads|Topic|AUTHORED
684|Shih-Chieh Hsu|Author|Lfads|Topic|AUTHORED
684|Bo-Cheng Lai|Author|Lfads|Topic|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Cenyuan Zhang|Author|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Xiaoqing Zheng|Author|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Ruicheng Yin|Author|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Shujie Geng|Author|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Jianhan Xu|Author|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Xuan Gao|Author|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Changze Lv|Author|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Zixuan Ling|Author|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Xuanjing Huang|Author|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Miao Cao|Author|AUTHORED
685|Decoding Continuous Character-Based Language From Non-Invasive Brain Recordings|Paper|Jianfeng Feng|Author|AUTHORED
686|Stacked Ca|Topic|Common Terminology Criteria For Adverse Events (Ctcae)|Topic|RELATED_TO
686|Stacked Ca|Topic|Shiny App|Topic|RELATED_TO
686|Nsabp R-04|Paper|Stacked Ca|Topic|DISCUSSES
686|Nsabp B-35|Paper|Stacked Ca|Topic|DISCUSSES
686|Márcio A. Diniz|Author|Nsabp R-04|Paper|AUTHORED
686|Gillian Gresham|Author|Nsabp R-04|Paper|AUTHORED
686|Sungjin Kim|Author|Nsabp R-04|Paper|AUTHORED
686|Michael Luu|Author|Nsabp R-04|Paper|AUTHORED
686|N. Lynn Henry|Author|Nsabp R-04|Paper|AUTHORED
686|Mourad Tighiouart|Author|Nsabp R-04|Paper|AUTHORED
686|Greg Yothers|Author|Nsabp R-04|Paper|AUTHORED
686|Patricia A. Ganz|Author|Nsabp R-04|Paper|AUTHORED
686|André Rogatko|Author|Nsabp R-04|Paper|AUTHORED
687|Effective Matching Of Patients To Clinical Trials Using Entity Extraction And Neural Re-Ranking|Paper|Clinical Trials|Topic|DISCUSSES
687|Effective Matching Of Patients To Clinical Trials Using Entity Extraction And Neural Re-Ranking|Paper|Transformer Network|Topic|DISCUSSES
687|Effective Matching Of Patients To Clinical Trials Using Entity Extraction And Neural Re-Ranking|Paper|Data Enrichment Technique|Topic|DISCUSSES
687|Effective Matching Of Patients To Clinical Trials Using Entity Extraction And Neural Re-Ranking|Paper|Named Entity Recognition|Topic|DISCUSSES
687|Effective Matching Of Patients To Clinical Trials Using Entity Extraction And Neural Re-Ranking|Paper|Negation Detection|Topic|DISCUSSES
687|Effective Matching Of Patients To Clinical Trials Using Entity Extraction And Neural Re-Ranking|Paper|Patient Descriptions|Topic|DISCUSSES
687|Effective Matching Of Patients To Clinical Trials Using Entity Extraction And Neural Re-Ranking|Paper|Ct Eligibility Criteria|Topic|DISCUSSES
688|Measurement Efficient Randomized Controlled Trials Using Transformers With Input Masking|Paper|Clinical Randomized Controlled Trials|Topic|DISCUSSES
688|Measurement Efficient Randomized Controlled Trials Using Transformers With Input Masking|Paper|Planned Missing Design|Topic|RELATED_TO
688|Measurement Efficient Randomized Controlled Trials Using Transformers With Input Masking|Paper|Imputation Algorithms|Topic|RELATED_TO
688|Measurement Efficient Randomized Controlled Trials Using Transformers With Input Masking|Paper|Rct Datasets|Topic|RELATED_TO
688|Measurement Efficient Randomized Controlled Trials Using Transformers With Input Masking|Paper|Transformer Architecture|Topic|RELATED_TO
688|Measurement Efficient Randomized Controlled Trials Using Transformers With Input Masking|Paper|Sampling Efficiency|Topic|RELATED_TO
688|Measurement Efficient Randomized Controlled Trials Using Transformers With Input Masking|Paper|Imputation Performance|Topic|RELATED_TO
689|Machine Learning|Topic|Clinical Neuroscience|Topic|RELATED_TO
689|Machine Learning|Topic|Cancer Imaging|Topic|RELATED_TO
689|Neurologic Diseases|Topic|Disease Subtyping|Topic|RELATED_TO
689|Neuropsychiatric Diseases|Topic|Disease Subtyping|Topic|RELATED_TO
689|Alzheimer Disease|Topic|Disease Subtyping|Topic|RELATED_TO
689|Psychosis|Topic|Disease Subtyping|Topic|RELATED_TO
689|Depression|Topic|Disease Subtyping|Topic|RELATED_TO
689|Autism|Topic|Disease Subtyping|Topic|RELATED_TO
689|Brain Cancer|Topic|Disease Subtyping|Topic|RELATED_TO
689|Junhao Wen|Author|Disease Subtyping|Topic|AUTHORED
689|Erdem Varol|Author|Disease Subtyping|Topic|AUTHORED
689|Zhijian Yang|Author|Disease Subtyping|Topic|AUTHORED
689|Gyujoon Hwang|Author|Disease Subtyping|Topic|AUTHORED
689|Dominique Dwyer|Author|Disease Subtyping|Topic|AUTHORED
689|Anahita Fathi Kazerooni|Author|Disease Subtyping|Topic|AUTHORED
689|Paris Alexandros Lalousis|Author|Disease Subtyping|Topic|AUTHORED
689|Christos Davatzikos|Author|Disease Subtyping|Topic|AUTHORED
690|Investigating The Use Of Mastery-Style Online Homework Exercises In Introductory Algebra-Based Mechanics In A Controlled Clinical Study|Paper|William R. Evans|Author|AUTHORED
690|Investigating The Use Of Mastery-Style Online Homework Exercises In Introductory Algebra-Based Mechanics In A Controlled Clinical Study|Paper|Mats A. Selen|Author|AUTHORED
690|Investigating The Use Of Mastery-Style Online Homework Exercises In Introductory Algebra-Based Mechanics In A Controlled Clinical Study|Paper|Mastery-Style Homework|Topic|RELATED_TO
690|Investigating The Use Of Mastery-Style Online Homework Exercises In Introductory Algebra-Based Mechanics In A Controlled Clinical Study|Paper|Traditional-Style Homework|Topic|RELATED_TO
690|Investigating The Use Of Mastery-Style Online Homework Exercises In Introductory Algebra-Based Mechanics In A Controlled Clinical Study|Paper|Introductory Physics|Topic|RELATED_TO
690|Investigating The Use Of Mastery-Style Online Homework Exercises In Introductory Algebra-Based Mechanics In A Controlled Clinical Study|Paper|Algebra-Based Mechanics|Topic|RELATED_TO
690|Investigating The Use Of Mastery-Style Online Homework Exercises In Introductory Algebra-Based Mechanics In A Controlled Clinical Study|Paper|Calculus-Based Mechanics|Topic|RELATED_TO
690|Mastery-Style Homework|Topic|Weaker Students|Topic|RELATED_TO
690|Clinical Trials|Topic|Mastery-Style Homework|Topic|RELATED_TO
690|Clinical Trials|Topic|Traditional-Style Homework|Topic|RELATED_TO
691|Statistical Inference Methods For Cumulative Incidence Function Curves At A Fixed Point In Time|Paper|Jinbao Chen|Author|AUTHORED
691|Statistical Inference Methods For Cumulative Incidence Function Curves At A Fixed Point In Time|Paper|Yawen Hou|Author|AUTHORED
691|Statistical Inference Methods For Cumulative Incidence Function Curves At A Fixed Point In Time|Paper|Zheng Chen|Author|AUTHORED
692|Revolutionizing Pharma: Unveiling The Ai And Llm Trends In The Pharmaceutical Industry|Paper|Artificial Intelligence|Topic|DISCUSSES
692|Revolutionizing Pharma: Unveiling The Ai And Llm Trends In The Pharmaceutical Industry|Paper|Pharmaceutical Industry|Topic|DISCUSSES
692|Yu Han|Author|Revolutionizing Pharma: Unveiling The Ai And Llm Trends In The Pharmaceutical Industry|Paper|AUTHORED
692|Jingwen Tao|Author|Revolutionizing Pharma: Unveiling The Ai And Llm Trends In The Pharmaceutical Industry|Paper|AUTHORED
693|Major Depressive Disorder (Mdd)|Topic|Differential Prototypes Neural Network (Dpnn)|Topic|RELATED_TO
693|Differential Prototypes Neural Network (Dpnn)|Topic|David Benrimoh|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Akiva Kleinerman|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Toshi A. Furukawa|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Charles F. Reynolds Iii|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Eric Lenze|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Jordan Karp|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Benoit Mulsant|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Caitrin Armstrong|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Joseph Mehltretter|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Robert Fratila|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Kelly Perlman|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Sonia Israel|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Myriam Tanguay-Sela|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Christina Popescu|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Grace Golden|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Sabrina Qassim|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Alexandra Anacleto|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Adam Kapelner|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Ariel Rosenfeld|Author|AUTHORED
693|Differential Prototypes Neural Network (Dpnn)|Topic|Gustavo Turecki|Author|AUTHORED
694|Single-Arm Phase Ii Oncology Trials|Topic|Simon'S Two-Stage Design|Topic|RELATED_TO
694|Single-Arm Phase Ii Oncology Trials|Topic|Curtailment|Topic|RELATED_TO
694|Curtailment|Topic|Stochastic Curtailment|Topic|RELATED_TO
694|Curtailment|Topic|Non-Stochastic Curtailment|Topic|RELATED_TO
694|Single-Arm Phase Ii Oncology Trials|Topic|Optimal Stopping Boundaries|Topic|RELATED_TO
694|Optimal Stopping Boundaries|Topic|Optimal Curtailed Designs|Topic|RELATED_TO
694|Optimal Curtailed Designs|Topic|Expected Sample Size|Topic|RELATED_TO
694|Optimal Curtailed Designs|Topic|Loss Function|Topic|RELATED_TO
694|Martin Law|Author|Optimal Curtailed Designs|Topic|AUTHORED
694|Michael J. Grayling|Author|Optimal Curtailed Designs|Topic|AUTHORED
694|Adrian P. Mander|Author|Optimal Curtailed Designs|Topic|AUTHORED
695|Bayesian Nonparametric Common Atoms Regression For Generating Synthetic Controls In Clinical Trials|Paper|Noirrit Kiran Chandra|Author|AUTHORED
695|Bayesian Nonparametric Common Atoms Regression For Generating Synthetic Controls In Clinical Trials|Paper|Abhra Sarkar|Author|AUTHORED
695|Bayesian Nonparametric Common Atoms Regression For Generating Synthetic Controls In Clinical Trials|Paper|John F. De Groot|Author|AUTHORED
695|Bayesian Nonparametric Common Atoms Regression For Generating Synthetic Controls In Clinical Trials|Paper|Ying Yuan|Author|AUTHORED
695|Bayesian Nonparametric Common Atoms Regression For Generating Synthetic Controls In Clinical Trials|Paper|Peter Müller|Author|AUTHORED
696|Bi3+3|Topic|Jiaxin Liu|Author|AUTHORED
696|Bi3+3|Topic|Shijie Yuan|Author|AUTHORED
696|Bi3+3|Topic|B. Nebiyou Bekele|Author|AUTHORED
696|Bi3+3|Topic|Yuan Ji|Author|AUTHORED
697|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|Randomized Controlled Clinical Trials|Topic|DISCUSSES
697|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|Bayesian Paradigm|Topic|DISCUSSES
697|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|Discounting Factor|Topic|DISCUSSES
697|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|Nonmonotonicity|Topic|DISCUSSES
697|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|Weights|Topic|DISCUSSES
697|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|Analytical Sample Size Formula|Topic|DISCUSSES
697|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|Linearization Technique|Topic|DISCUSSES
697|Lou E. Whitehead|Author|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|AUTHORED
697|James M. S. Wason|Author|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|AUTHORED
697|Oliver Sailer|Author|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|AUTHORED
697|Haiyan Zheng|Author|Bayesian Sample Size Determination Using Robust Commensurate Priors With Interpretable Discrepancy Weights|Paper|AUTHORED
698|Ebm-Comet|Topic|Micheal Abaho|Author|AUTHORED
698|Ebm-Comet|Topic|Danushka Bollegala|Author|AUTHORED
698|Ebm-Comet|Topic|Paula R Williamson|Author|AUTHORED
698|Ebm-Comet|Topic|Susanna Dodd|Author|AUTHORED
698|Biobert|Topic|Ebm-Comet|Topic|RELATED_TO
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Mengzhou Li|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Chuang Niu|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Ge Wang|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Maya R Amma|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Krishna M Chapagain|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Stefan Gabrielson|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Andrew Li|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Kevin Jonker|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Niels De Ruiter|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Jennifer A Clark|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Phil Butler|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Anthony Butler|Author|AUTHORED
699|Deep Few-View High-Resolution Photon-Counting Extremity Ct At Halved Dose For A Clinical Trial|Paper|Hengyong Yu|Author|AUTHORED
700|National Nlp Clinical Challenges (N2C2)|Topic|Cohort Selection|Topic|RELATED_TO
700|Cohort Selection|Topic|Clinical Trial Cohort Selection|Topic|RELATED_TO
700|Cohort Selection|Topic|Machine Learning Model|Topic|RELATED_TO
700|Cohort Selection|Topic|Lexicon Development|Topic|RELATED_TO
700|Cohort Selection|Topic|F Measure|Topic|RELATED_TO
700|Samarth Rawal|Author|Cohort Selection|Topic|AUTHORED
700|Ashok Prakash|Author|Cohort Selection|Topic|AUTHORED
700|Soumya Adhya|Author|Cohort Selection|Topic|AUTHORED
700|Sidharth Kulkarni|Author|Cohort Selection|Topic|AUTHORED
700|Saadat Anwar|Author|Cohort Selection|Topic|AUTHORED
700|Chitta Baral|Author|Cohort Selection|Topic|AUTHORED
700|Murthy Devarakonda|Author|Cohort Selection|Topic|AUTHORED
701|Alzheimer'S Disease|Topic|Machine Learning|Topic|RELATED_TO
701|Machine Learning|Topic|Neural Network Model|Topic|RELATED_TO
701|Neural Network Model|Topic|Clinical Trials|Topic|RELATED_TO
701|Jack Albright|Author|Forecasting The Progression Of Alzheimer'S Disease Using Neural Networks And A Novel Pre-Processing Algorithm|Paper|AUTHORED
701|Alzheimer'S Disease Neuroimaging Initiative|Topic|1737 Patients|Topic|RELATED_TO
701|1737 Patients|Topic|All-Pairs Technique|Topic|RELATED_TO
701|All-Pairs Technique|Topic|Machine Learning|Topic|RELATED_TO
701|110 Patients|Topic|Neural Network Model|Topic|RELATED_TO
701|Mauc|Topic|Neural Network Model|Topic|RELATED_TO
702|Proportional Hazards|Topic|Confirmatory Clinical Trials|Topic|RELATED_TO
702|Confirmatory Clinical Trials|Topic|Oncology|Topic|RELATED_TO
702|Non-Proportional Hazards|Topic|Hazard Ratio|Topic|RELATED_TO
702|Non-Proportional Hazards|Topic|Log-Rank Test|Topic|RELATED_TO
702|Non-Proportional Hazards|Topic|Weighed Log-Rank Test|Topic|RELATED_TO
702|Non-Proportional Hazards|Topic|Restricted Mean Survival Time (Rmst)|Topic|RELATED_TO
702|José L. Jiménez|Author|Simulation Study|Topic|AUTHORED
703|Ultrasound Computed Tomography (Usct)|Topic|Breast Imaging|Topic|RELATED_TO
703|Computer-Simulation Studies|Topic|Realistic Numerical Phantoms|Topic|RELATED_TO
703|Three-Dimensional (3D) Numerical Breast Phantoms|Topic|Computer-Simulation Studies|Topic|RELATED_TO
703|Fu Li|Author|Three-Dimensional (3D) Numerical Breast Phantoms|Topic|AUTHORED
703|Umberto Villa|Author|Three-Dimensional (3D) Numerical Breast Phantoms|Topic|AUTHORED
703|Seonyeong Park|Author|Three-Dimensional (3D) Numerical Breast Phantoms|Topic|AUTHORED
703|Mark A. Anastasio|Author|Three-Dimensional (3D) Numerical Breast Phantoms|Topic|AUTHORED
704|Model-Informed Precision Dosing (Mipd)|Topic|Paclitaxel|Topic|RELATED_TO
704|Corinna Maier|Author|Model-Informed Precision Dosing (Mipd)|Topic|AUTHORED
704|Jana De Wiljes|Author|Model-Informed Precision Dosing (Mipd)|Topic|AUTHORED
704|Niklas Hartung|Author|Model-Informed Precision Dosing (Mipd)|Topic|AUTHORED
704|Charlotte Kloft|Author|Model-Informed Precision Dosing (Mipd)|Topic|AUTHORED
704|Wilhelm Huisinga|Author|Model-Informed Precision Dosing (Mipd)|Topic|AUTHORED
705|Assessing Contribution Of Treatment Phases Through Tipping Point Analyses Via Counterfactual Elicitation Using Rank Preserving Structural Failure Time Models|Paper|Tipping Point Analyses|Topic|DISCUSSES
705|Assessing Contribution Of Treatment Phases Through Tipping Point Analyses Via Counterfactual Elicitation Using Rank Preserving Structural Failure Time Models|Paper|Rank-Preserving-Structural-Failure-Time Modelling|Topic|DISCUSSES
705|Assessing Contribution Of Treatment Phases Through Tipping Point Analyses Via Counterfactual Elicitation Using Rank Preserving Structural Failure Time Models|Paper|Oncology Clinical Research|Topic|DISCUSSES
705|Assessing Contribution Of Treatment Phases Through Tipping Point Analyses Via Counterfactual Elicitation Using Rank Preserving Structural Failure Time Models|Paper|Statistical Approaches|Topic|DISCUSSES
706|P2T2|Topic|Hadas Ben-Atya|Author|AUTHORED
706|P2T2|Topic|Moti Freiman|Author|AUTHORED
706|T2 Relaxation Time Distributions|Topic|Mri|Topic|RELATED_TO
706|T2 Relaxation Time Distributions|Topic|Neurodegenerative Disorders|Topic|RELATED_TO
706|T2 Relaxation Time Distributions|Topic|Osteoarthritis|Topic|RELATED_TO
706|T2 Relaxation Time Distributions|Topic|Tumors|Topic|RELATED_TO
707|Benchmarking Drug Efficacy|Topic|Clinical Trial Design|Topic|RELATED_TO
707|Scientific Papers|Topic|Efficacy Endpoints|Topic|RELATED_TO
707|Machine Learning Approach|Topic|Efficacy Endpoints|Topic|RELATED_TO
707|Efficacy Endpoints|Topic|Aline Gendrin-Brokmann|Author|AUTHORED
707|Efficacy Endpoints|Topic|Eden Harrison|Author|AUTHORED
707|Efficacy Endpoints|Topic|Julianne Noveras|Author|AUTHORED
707|Efficacy Endpoints|Topic|Leonidas Souliotis|Author|AUTHORED
707|Efficacy Endpoints|Topic|Harris Vince|Author|AUTHORED
707|Efficacy Endpoints|Topic|Ines Smit|Author|AUTHORED
707|Efficacy Endpoints|Topic|Francisco Costa|Author|AUTHORED
707|Efficacy Endpoints|Topic|David Milward|Author|AUTHORED
707|Efficacy Endpoints|Topic|Sashka Dimitrievska|Author|AUTHORED
707|Efficacy Endpoints|Topic|Paul Metcalfe|Author|AUTHORED
707|Efficacy Endpoints|Topic|Emilie Louvet|Author|AUTHORED
708|Intracranial Arterial Calcification|Topic|Ischaemic Stroke|Topic|RELATED_TO
708|Ct Head Scans|Topic|Ischaemic Stroke|Topic|RELATED_TO
708|Artificial Intelligence Methods|Topic|Intracranial Arterial Calcification|Topic|RELATED_TO
708|International Stroke Trial (Ist-3)|Paper|Intracranial Arterial Calcification|Topic|RELATED_TO
708|International Stroke Trial (Ist-3)|Paper|Ct Head Scans|Topic|RELATED_TO
708|Benjamin Jin|Author|International Stroke Trial (Ist-3)|Paper|AUTHORED
708|Maria Del C. Valdés Hernández|Author|International Stroke Trial (Ist-3)|Paper|AUTHORED
708|Alessandro Fontanella|Author|International Stroke Trial (Ist-3)|Paper|AUTHORED
708|Wenwen Li|Author|International Stroke Trial (Ist-3)|Paper|AUTHORED
708|Eleanor Platt|Author|International Stroke Trial (Ist-3)|Paper|AUTHORED
708|Paul Armitage|Author|International Stroke Trial (Ist-3)|Paper|AUTHORED
708|Amos Storkey|Author|International Stroke Trial (Ist-3)|Paper|AUTHORED
708|Joanna M. Wardlaw|Author|International Stroke Trial (Ist-3)|Paper|AUTHORED
708|Grant Mair|Author|International Stroke Trial (Ist-3)|Paper|AUTHORED
709|Understanding The Function Of Complex Cortical Circuits|Topic|Action Potentials|Topic|RELATED_TO
709|Action Potentials|Topic|Neurons|Topic|RELATED_TO
709|Neurons|Topic|Awake And Behaving Animals|Topic|RELATED_TO
709|Extracellularly Recording|Topic|Single Wire Electrodes|Topic|RELATED_TO
709|Human Hippocampus|Topic|Analytic Techniques|Topic|RELATED_TO
709|Offline Spike Sorting Approaches|Topic|Human Brain|Topic|RELATED_TO
709|Online Sorting And Detection Algorithms|Topic|Response Properties Of The Recorded Neurons|Topic|RELATED_TO
709|Method For Detecting And Sorting Extracellular Single-Wire Recordings|Topic|Data Set From Chronically-Implanted Depth Electrodes|Topic|RELATED_TO
709|Data Set From Chronically-Implanted Depth Electrodes|Topic|Human Epilepsy Patients|Topic|RELATED_TO
709|Noisy Clinical Environment|Topic|Closed-Loop Experiments|Topic|RELATED_TO
709|Ueli Rutishauser|Author|Method For Detecting And Sorting Extracellular Single-Wire Recordings|Topic|AUTHORED
709|Erin M. Schuman|Author|Method For Detecting And Sorting Extracellular Single-Wire Recordings|Topic|AUTHORED
709|Adam N. Mamelak|Author|Method For Detecting And Sorting Extracellular Single-Wire Recordings|Topic|AUTHORED
710|Artificial Intelligence|Topic|Intracranial Electroencephalography|Topic|RELATED_TO
710|Intracranial Electroencephalography|Topic|Ai-Ieeg For Neuroscience|Topic|RELATED_TO
710|Intracranial Electroencephalography|Topic|Ai-Ieeg For Neurotechnology|Topic|RELATED_TO
710|Ai-Ieeg For Neuroscience|Topic|Julia Berezutskaya|Author|AUTHORED
710|Ai-Ieeg For Neuroscience|Topic|Anne-Lise Saive|Author|AUTHORED
710|Ai-Ieeg For Neuroscience|Topic|Karim Jerbi|Author|AUTHORED
710|Ai-Ieeg For Neuroscience|Topic|Marcel Van Gerven|Author|AUTHORED
710|Ai-Ieeg For Neurotechnology|Topic|Julia Berezutskaya|Author|AUTHORED
710|Ai-Ieeg For Neurotechnology|Topic|Anne-Lise Saive|Author|AUTHORED
710|Ai-Ieeg For Neurotechnology|Topic|Karim Jerbi|Author|AUTHORED
710|Ai-Ieeg For Neurotechnology|Topic|Marcel Van Gerven|Author|AUTHORED
711|Pennsieve|Topic|Zack Goldblum|Author|AUTHORED
711|Pennsieve|Topic|Zhongchuan Xu|Author|AUTHORED
711|Pennsieve|Topic|Haoer Shi|Author|AUTHORED
711|Pennsieve|Topic|Patryk Orzechowski|Author|AUTHORED
711|Pennsieve|Topic|Jamaal Spence|Author|AUTHORED
711|Pennsieve|Topic|Kathryn A Davis|Author|AUTHORED
711|Pennsieve|Topic|Brian Litt|Author|AUTHORED
711|Pennsieve|Topic|Nishant Sinha|Author|AUTHORED
711|Pennsieve|Topic|Joost Wagenaar|Author|AUTHORED
711|Pennsieve|Topic|Nih Sparc Initiative|Topic|RELATED_TO
711|Pennsieve|Topic|Nih Heal Initiative'S Precision Human Pain Network|Topic|RELATED_TO
711|Pennsieve|Topic|Nih Heal Re-Join Initiative|Topic|RELATED_TO
711|Pennsieve|Topic|University Of Pennsylvania|Topic|RELATED_TO
711|Pennsieve|Topic|Sparc.Science|Topic|RELATED_TO
711|Pennsieve|Topic|Epilepsy.Science|Topic|RELATED_TO
711|Pennsieve|Topic|Pennsieve Discover|Topic|RELATED_TO
712|Testing The Odds Of Inherent Versus Observed Over-Dispersion In Neural Spike Counts|Paper|Negative-Binomial Distribution Model|Topic|DISCUSSES
712|Testing The Odds Of Inherent Versus Observed Over-Dispersion In Neural Spike Counts|Paper|Poisson Process|Topic|RELATED_TO
712|Testing The Odds Of Inherent Versus Observed Over-Dispersion In Neural Spike Counts|Paper|Over-Dispersion|Topic|RELATED_TO
712|Testing The Odds Of Inherent Versus Observed Over-Dispersion In Neural Spike Counts|Paper|Neurophysiological Data|Topic|RELATED_TO
712|Testing The Odds Of Inherent Versus Observed Over-Dispersion In Neural Spike Counts|Paper|Wahiba Taouali|Author|AUTHORED
712|Testing The Odds Of Inherent Versus Observed Over-Dispersion In Neural Spike Counts|Paper|Giacomo Benvenuti|Author|AUTHORED
712|Testing The Odds Of Inherent Versus Observed Over-Dispersion In Neural Spike Counts|Paper|Pascal Wallisch|Author|AUTHORED
712|Testing The Odds Of Inherent Versus Observed Over-Dispersion In Neural Spike Counts|Paper|Frédéric Chavane|Author|AUTHORED
712|Testing The Odds Of Inherent Versus Observed Over-Dispersion In Neural Spike Counts|Paper|Laurent Perrinet|Author|AUTHORED
713|Neuroscience Data Analysis|Topic|Stimuli Bundle|Topic|DISCUSSES
713|Dapp Model|Topic|Neuroscience Data Analysis|Topic|RELATED_TO
713|Dapp Model|Topic|Stimuli Bundle|Topic|RELATED_TO
713|Chris Glynn|Author|Dapp Model|Topic|AUTHORED
713|Surya T Tokdar|Author|Dapp Model|Topic|AUTHORED
713|Azeem Zaman|Author|Dapp Model|Topic|AUTHORED
713|Valeria C Caruso|Author|Dapp Model|Topic|AUTHORED
713|Jeffrey T Mohl|Author|Dapp Model|Topic|AUTHORED
713|Shawn M Willett|Author|Dapp Model|Topic|AUTHORED
713|Jennifer M Groh|Author|Dapp Model|Topic|AUTHORED
714|Sars-Cov-2|Topic|Covid-19|Topic|RELATED_TO
714|Elizabeth Krieger|Author|Covid-19|Topic|AUTHORED
714|Nicole Vissichelli|Author|Covid-19|Topic|AUTHORED
714|Stefan Leichtle|Author|Covid-19|Topic|AUTHORED
714|Markos Kashioris|Author|Covid-19|Topic|AUTHORED
714|Roy Sabo|Author|Covid-19|Topic|AUTHORED
714|Don Brophy|Author|Covid-19|Topic|AUTHORED
714|Xiang-Yang Wang|Author|Covid-19|Topic|AUTHORED
714|Pamela Kimbal|Author|Covid-19|Topic|AUTHORED
714|Michael Neale|Author|Covid-19|Topic|AUTHORED
714|Myrna G. Serrano|Author|Covid-19|Topic|AUTHORED
714|Gregory A. Buck|Author|Covid-19|Topic|AUTHORED
714|Catherine Roberts|Author|Covid-19|Topic|AUTHORED
714|Rehan Qayyum|Author|Covid-19|Topic|AUTHORED
714|Daniel Nixon|Author|Covid-19|Topic|AUTHORED
714|Steven Grossman|Author|Covid-19|Topic|AUTHORED
714|Amir A. Toor|Author|Covid-19|Topic|AUTHORED
715|Network Neuroscience|Topic|Cognitive Deficits|Topic|RELATED_TO
715|Network Neuroscience|Topic|Mental Abilities|Topic|RELATED_TO
715|Network Control Theory|Topic|Human Brain|Topic|RELATED_TO
715|John D. Medaglia|Author|Mind Control|Topic|AUTHORED
715|Perry Zurn|Author|Mind Control|Topic|AUTHORED
715|Walter Sinnott-Armstrong|Author|Mind Control|Topic|AUTHORED
715|Danielle S. Bassett|Author|Mind Control|Topic|AUTHORED
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Gesture Recognition|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Event Based Camera|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Mobile Phone|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Time-Surfaces|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Dynamic Backgrounds|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|High Temporal Resolution|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Dynamic Scenarios|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Uncontrolled Lighting Conditions|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Publicly Available Event-Based Dataset|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Human-Machine Interactions|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Visually-Impaired|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Elderly|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Prior Works|Topic|DISCUSSES
716|Event-Based Gesture Recognition With Dynamic Background Suppression Using Smartphone Computational Capabilities|Paper|Computational And Memory Constraints|Topic|DISCUSSES
717|Computational Models|Topic|Electroencephalography (Eeg)|Topic|RELATED_TO
717|Katharina Glomb|Author|Computational Models|Topic|AUTHORED
717|Joana Cabral|Author|Computational Models|Topic|AUTHORED
717|Anna Cattani|Author|Computational Models|Topic|AUTHORED
717|Alberto Mazzoni|Author|Computational Models|Topic|AUTHORED
717|Ashish Raj|Author|Computational Models|Topic|AUTHORED
717|Benedetta Franceschiello|Author|Computational Models|Topic|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|George Papagiannakis|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Walter Greenleaf|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Michael Cole|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Mark Zhang|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Rabi Datta|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Mathias Delahaye|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Eleni Grigoriou|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Manos Kamarianakis|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Antonis Protopsaltis|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Philippe Bijlenga|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Nadia Magnenat-Thalmann|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Eleftherios Tsiridis|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Eustathios Kenanidis|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Kyriakos Vamvakidis|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Ioannis Koutelidakis|Author|AUTHORED
718|Computational Medical Extended Reality (Cmxr)|Topic|Oliver A Kannape|Author|AUTHORED
719|Neuroscience|Topic|Spatiotemporal Alignment Of Multimodal Brain Activity|Paper|RELATED_TO
719|Electrophysiological Recordings|Topic|Eeg|Topic|RELATED_TO
719|Hemodynamic Modalities|Topic|Fmri|Topic|RELATED_TO
719|Spatiotemporal Alignment Of Multimodal Brain Activity|Paper|Electrophysiological Recordings|Topic|DISCUSSES
719|Spatiotemporal Alignment Of Multimodal Brain Activity|Paper|Hemodynamic Modalities|Topic|DISCUSSES
720|Treatment Regime|Topic|Patient Outcomes|Topic|RELATED_TO
720|Statisticians|Topic|Clinical Scientists|Topic|RELATED_TO
720|If-Then Statements|Topic|Optimal Regime|Topic|RELATED_TO
720|Optimal Regime|Topic|Simulation Experiments|Topic|RELATED_TO
720|Simulation Experiments|Topic|Clinical Trials|Topic|RELATED_TO
720|Yichi Zhang|Author|Clinical Trials|Topic|AUTHORED
720|Eric B. Laber|Author|Clinical Trials|Topic|AUTHORED
720|Anastasios Tsiatis|Author|Clinical Trials|Topic|AUTHORED
720|Marie Davidian|Author|Clinical Trials|Topic|AUTHORED
721|Correlational Dueling Bandits With Application To Clinical Treatment In Large Decision Spaces|Paper|Corrduel|Topic|DISCUSSES
721|Correlational Dueling Bandits With Application To Clinical Treatment In Large Decision Spaces|Paper|Dueling Bandits Problem|Topic|DISCUSSES
722|Unstructured Clinical Text In Ehrs|Topic|Decision Support|Topic|RELATED_TO
722|Unstructured Clinical Text In Ehrs|Topic|Trial Matching|Topic|RELATED_TO
722|Unstructured Clinical Text In Ehrs|Topic|Retrospective Research|Topic|RELATED_TO
722|Bert-Based Models|Topic|Snipbert|Topic|RELATED_TO
722|Snipbert|Topic|An Interpretable End-To-End Fine-Tuning Approach For Long Clinical Text|Paper|AUTHORED
722|Kexin Huang|Author|An Interpretable End-To-End Fine-Tuning Approach For Long Clinical Text|Paper|AUTHORED
722|Sankeerth Garapati|Author|An Interpretable End-To-End Fine-Tuning Approach For Long Clinical Text|Paper|AUTHORED
722|Alexander S. Rich|Author|An Interpretable End-To-End Fine-Tuning Approach For Long Clinical Text|Paper|AUTHORED
723|Parkinson'S Disease|Topic|Gait Impairment|Topic|RELATED_TO
723|Model|Topic|Clinical Measures|Topic|RELATED_TO
723|Model|Topic|Biomechanical Measures|Topic|RELATED_TO
723|Pd Subjects|Topic|Model|Topic|RELATED_TO
723|Xgboost|Topic|Model|Topic|RELATED_TO
723|Feed Forward Neural Networks|Topic|Model|Topic|RELATED_TO
723|Neural Network|Topic|Ppv|Topic|RELATED_TO
723|Neural Network|Topic|Variance|Topic|RELATED_TO
723|Vyom Raval|Author|Model|Topic|AUTHORED
723|Kevin P. Nguyen|Author|Model|Topic|AUTHORED
723|Ashley Gerald|Author|Model|Topic|AUTHORED
723|Richard B. Dewey Jr.|Author|Model|Topic|AUTHORED
723|Albert Montillo|Author|Model|Topic|AUTHORED
724|Clinical Data|Topic|Machine Learning Methods|Topic|RELATED_TO
724|Machine Learning Methods|Topic|Precision Medicine|Topic|RELATED_TO
724|Precision Medicine|Topic|Disease Phenotypes|Topic|RELATED_TO
724|Precision Medicine|Topic|Individual Disease Prediction|Topic|RELATED_TO
724|Deep Learning Methods|Topic|Clinical Data|Topic|RELATED_TO
724|Adaptivenet|Paper|Fully-Connected Neural Networks|Topic|DISCUSSES
724|Adaptivenet|Paper|Classical Machine Learning Methods|Topic|DISCUSSES
724|Adaptivenet|Paper|Disease Progression Prediction|Topic|DISCUSSES
724|Disease Progression Prediction|Topic|Rheumatoid Arthritis|Topic|RELATED_TO
724|Swiss Clinical Quality Management Registry|Topic|10.000 Patients|Topic|RELATED_TO
724|Swiss Clinical Quality Management Registry|Topic|65.000 Patient Visits|Topic|RELATED_TO
725|Adaptive Therapy|Topic|Metastatic Castrate Resistant Prostate Cancer|Topic|RELATED_TO
725|Adaptive Therapy|Topic|Ovarian Cancer|Topic|RELATED_TO
725|Adaptive Therapy|Topic|Braf-Mutant Melanoma|Topic|RELATED_TO
725|Adaptive Therapy|Topic|Jeffrey West|Author|AUTHORED
725|Adaptive Therapy|Topic|Fred Adler|Author|AUTHORED
725|Adaptive Therapy|Topic|Jill Gallaher|Author|AUTHORED
725|Adaptive Therapy|Topic|Maximilian Strobl|Author|AUTHORED
725|Adaptive Therapy|Topic|Renee Brady-Nicholls|Author|AUTHORED
725|Adaptive Therapy|Topic|Joel S. Brown|Author|AUTHORED
725|Adaptive Therapy|Topic|Mark Robertson-Tessi|Author|AUTHORED
725|Adaptive Therapy|Topic|Eunjung Kim|Author|AUTHORED
725|Adaptive Therapy|Topic|Robert Noble|Author|AUTHORED
725|Adaptive Therapy|Topic|Yannick Viossat|Author|AUTHORED
725|Adaptive Therapy|Topic|David Basanta|Author|AUTHORED
725|Adaptive Therapy|Topic|Alexander R. A. Anderson|Author|AUTHORED
726|Anonymising Clinical Data For Secondary Use|Paper|Irene Ferreira|Author|AUTHORED
726|Anonymising Clinical Data For Secondary Use|Paper|Chris Harbron|Author|AUTHORED
726|Anonymising Clinical Data For Secondary Use|Paper|Alex Hughes|Author|AUTHORED
726|Anonymising Clinical Data For Secondary Use|Paper|Tamsin Sargood|Author|AUTHORED
726|Anonymising Clinical Data For Secondary Use|Paper|Christoph Gerlinger|Author|AUTHORED
727|Tldr|Paper|Natural Language Inference For Clinical Trials|Topic|RELATED_TO
727|Tldr|Paper|Spandan Das|Author|AUTHORED
727|Tldr|Paper|Vinay Samuel|Author|AUTHORED
727|Tldr|Paper|Shahriar Noroozizadeh|Author|AUTHORED
728|Causal Machine Learning For Predicting Treatment Outcomes|Paper|Stefan Feuerriegel|Author|AUTHORED
728|Causal Machine Learning For Predicting Treatment Outcomes|Paper|Dennis Frauen|Author|AUTHORED
728|Causal Machine Learning For Predicting Treatment Outcomes|Paper|Valentyn Melnychuk|Author|AUTHORED
728|Causal Machine Learning For Predicting Treatment Outcomes|Paper|Jonas Schweisthal|Author|AUTHORED
728|Causal Machine Learning For Predicting Treatment Outcomes|Paper|Konstantin Hess|Author|AUTHORED
728|Causal Machine Learning For Predicting Treatment Outcomes|Paper|Alicia Curth|Author|AUTHORED
728|Causal Machine Learning For Predicting Treatment Outcomes|Paper|Stefan Bauer|Author|AUTHORED
728|Causal Machine Learning For Predicting Treatment Outcomes|Paper|Niki Kilbertus|Author|AUTHORED
728|Causal Machine Learning For Predicting Treatment Outcomes|Paper|Isaac S. Kohane|Author|AUTHORED
728|Causal Machine Learning For Predicting Treatment Outcomes|Paper|Mihaela Van Der Schaar|Author|AUTHORED
729|Tuh Eeg Seizure Corpus|Topic|Vinit Shah|Author|AUTHORED
729|Tuh Eeg Seizure Corpus|Topic|Eva Von Weltin|Author|AUTHORED
729|Tuh Eeg Seizure Corpus|Topic|Silvia Lopez|Author|AUTHORED
729|Tuh Eeg Seizure Corpus|Topic|James Riley Mchugh|Author|AUTHORED
729|Tuh Eeg Seizure Corpus|Topic|Lily Veloso|Author|AUTHORED
729|Tuh Eeg Seizure Corpus|Topic|Meysam Golmohammadi|Author|AUTHORED
729|Tuh Eeg Seizure Corpus|Topic|Iyad Obeid|Author|AUTHORED
729|Tuh Eeg Seizure Corpus|Topic|Joseph Picone|Author|AUTHORED
730|Effective And Interpretable Fmri Analysis Via Functional Brain Network Generation|Paper|Xuan Kan|Author|AUTHORED
730|Effective And Interpretable Fmri Analysis Via Functional Brain Network Generation|Paper|Hejie Cui|Author|AUTHORED
730|Effective And Interpretable Fmri Analysis Via Functional Brain Network Generation|Paper|Ying Guo|Author|AUTHORED
730|Effective And Interpretable Fmri Analysis Via Functional Brain Network Generation|Paper|Carl Yang|Author|AUTHORED
731|Clinical Diagnosis Of The Eye|Topic|Diabetic Retinopathy|Topic|RELATED_TO
731|Clinical Diagnosis Of The Eye|Topic|Diabetic Macular Edema|Topic|RELATED_TO
731|Ophthalmic Labels For Investigating Visual Eye Semantics|Paper|Olives Dataset|Topic|AUTHORED
731|Olives Dataset|Topic|Optical Coherence Tomography|Topic|RELATED_TO
731|Olives Dataset|Topic|Near-Ir Fundus Images|Topic|RELATED_TO
731|Olives Dataset|Topic|Biomarker Labels|Topic|RELATED_TO
731|Olives Dataset|Topic|Clinical Labels|Topic|RELATED_TO
731|Olives Dataset|Topic|Disease Labels|Topic|RELATED_TO
731|Olives Dataset|Topic|Time-Series Patient Treatment Information|Topic|RELATED_TO
731|Olives Dataset|Topic|1268 Near-Ir Fundus Images|Topic|RELATED_TO
731|Olives Dataset|Topic|49 Oct Scans|Topic|RELATED_TO
731|Olives Dataset|Topic|16 Biomarkers|Topic|RELATED_TO
731|Olives Dataset|Topic|4 Clinical Labels|Topic|RELATED_TO
731|Olives Dataset|Topic|96 Eyes' Data|Topic|RELATED_TO
731|Olives Dataset|Topic|66 Weeks|Topic|RELATED_TO
731|Olives Dataset|Topic|7 Injections|Topic|RELATED_TO
731|Olives Dataset|Topic|Two Years|Topic|RELATED_TO
732|Hold-Out Sets|Topic|Clinical Prediction Models|Topic|RELATED_TO
732|Ethical Principles|Topic|Hold-Out Sets|Topic|RELATED_TO
732|Informed Consent|Topic|Hold-Out Sets|Topic|RELATED_TO
732|Clinical Equipoise|Topic|Hold-Out Sets|Topic|RELATED_TO
732|Truth-Telling|Topic|Hold-Out Sets|Topic|RELATED_TO
732|Louis Chislett|Author|Hold-Out Sets|Topic|AUTHORED
732|Louis Jm Aslett|Author|Hold-Out Sets|Topic|AUTHORED
732|Alisha R Davies|Author|Hold-Out Sets|Topic|AUTHORED
732|Catalina A Vallejos|Author|Hold-Out Sets|Topic|AUTHORED
732|James Liley|Author|Hold-Out Sets|Topic|AUTHORED
733|Transcranial Ultrasonic Stimulation|Topic|Tulika Nandi|Author|AUTHORED
733|Transcranial Ultrasonic Stimulation|Topic|Benjamin R. Kop|Author|AUTHORED
733|Transcranial Ultrasonic Stimulation|Topic|Kim Butts Pauly|Author|AUTHORED
733|Transcranial Ultrasonic Stimulation|Topic|Charlotte J. Stagg|Author|AUTHORED
733|Transcranial Ultrasonic Stimulation|Topic|Lennart Verhagen|Author|AUTHORED
734|A Scoping Review Of Publicly Available Language Tasks In Clinical Natural Language Processing|Paper|Clinical Natural Language Processing|Topic|RELATED_TO
735|Efron|Author|Biased Coin Design|Topic|RELATED_TO
735|Biometrika 58 (1971) 403--417|Paper|Efron|Author|AUTHORED
735|Biometrika 58 (1971) 403--417|Paper|Tigran Markaryan|Author|AUTHORED
735|Biometrika 58 (1971) 403--417|Paper|William F. Rosenberger|Author|AUTHORED
735|Biased Coin Design|Topic|Biometrika 58 (1971) 403--417|Paper|DISCUSSES
736|Randomized Urn Models Revisited Using Stochastic Approximation|Paper|Sophie Laruelle|Author|AUTHORED
736|Randomized Urn Models Revisited Using Stochastic Approximation|Paper|Gilles Pagès|Author|AUTHORED
737|Addressing Missing Data Mechanism Uncertainty Using Multiple-Model Multiple Imputation: Application To A Longitudinal Clinical Trial|Paper|Juned Siddique|Author|AUTHORED
737|Addressing Missing Data Mechanism Uncertainty Using Multiple-Model Multiple Imputation: Application To A Longitudinal Clinical Trial|Paper|Ofer Harel|Author|AUTHORED
737|Addressing Missing Data Mechanism Uncertainty Using Multiple-Model Multiple Imputation: Application To A Longitudinal Clinical Trial|Paper|Catherine M. Crespi|Author|AUTHORED
738|A Two-Stage, Phase Ii Clinical Trial Design With Nested Criteria For Early Stopping And Efficacy|Paper|Daniel Zelterman|Author|AUTHORED
738|A Two-Stage, Phase Ii Clinical Trial Design With Nested Criteria For Early Stopping And Efficacy|Paper|Clinical Trial|Topic|RELATED_TO
738|A Two-Stage, Phase Ii Clinical Trial Design With Nested Criteria For Early Stopping And Efficacy|Paper|Early Stopping Rule|Topic|RELATED_TO
738|A Two-Stage, Phase Ii Clinical Trial Design With Nested Criteria For Early Stopping And Efficacy|Paper|Efficacy|Topic|RELATED_TO
738|A Two-Stage, Phase Ii Clinical Trial Design With Nested Criteria For Early Stopping And Efficacy|Paper|Lung Cancer|Topic|RELATED_TO
738|A Two-Stage, Phase Ii Clinical Trial Design With Nested Criteria For Early Stopping And Efficacy|Paper|Novel Drug Combination|Topic|RELATED_TO
738|A Two-Stage, Phase Ii Clinical Trial Design With Nested Criteria For Early Stopping And Efficacy|Paper|Progression-Free Survival (Pfs)|Topic|RELATED_TO
738|A Two-Stage, Phase Ii Clinical Trial Design With Nested Criteria For Early Stopping And Efficacy|Paper|Phase Ii Design|Topic|RELATED_TO
739|Variable Selection For Optimal Treatment Regime|Topic|Sequential Advantage Selection For Optimal Treatment Regimes|Paper|DISCUSSES
739|Gunter Et Al. (2011)|Author|Sequential Advantage Selection For Optimal Treatment Regimes|Paper|RELATED_TO
739|Ailin Fan|Author|Sequential Advantage Selection For Optimal Treatment Regimes|Paper|AUTHORED
739|Wenbin Lu|Author|Sequential Advantage Selection For Optimal Treatment Regimes|Paper|AUTHORED
739|Rui Song|Author|Sequential Advantage Selection For Optimal Treatment Regimes|Paper|AUTHORED
740|Generalized Pólya Urn|Topic|Adaptive Randomly Reinforced Urn Model|Topic|RELATED_TO
740|Adaptive Randomly Reinforced Urn Model|Topic|Law Of Large Numbers|Topic|DISCUSSES
740|Adaptive Randomly Reinforced Urn Model|Topic|Central Limit Theorem|Topic|DISCUSSES
740|Adaptive Randomly Reinforced Urn Model|Topic|Response-Adaptive Randomization|Topic|RELATED_TO
740|Andrea Ghiglietti|Author|Central Limit Theorem|Topic|AUTHORED
740|Anand N. Vidyashankar|Author|Central Limit Theorem|Topic|AUTHORED
740|William F. Rosenberger|Author|Central Limit Theorem|Topic|AUTHORED
741|Dynamic Prediction For Multiple Repeated Measures And Event Time Data: An Application To Parkinson'S Disease|Paper|Parkinson'S Disease|Topic|RELATED_TO
742|Pairwise Sequential Randomization|Topic|Causal Inference|Topic|RELATED_TO
742|Pairwise Sequential Randomization|Topic|Clinical Trials|Topic|RELATED_TO
742|Pairwise Sequential Randomization|Topic|Covariate Imbalance|Topic|RELATED_TO
742|Pairwise Sequential Randomization|Topic|Big Data|Topic|RELATED_TO
742|Yichen Qin|Author|Pairwise Sequential Randomization|Topic|AUTHORED
742|Yang Li|Author|Pairwise Sequential Randomization|Topic|AUTHORED
742|Wei Ma|Author|Pairwise Sequential Randomization|Topic|AUTHORED
742|Feifang Hu|Author|Pairwise Sequential Randomization|Topic|AUTHORED
743|An Information-Theoretic Approach For Selecting Arms In Clinical Trials|Paper|Pavel Mozgunov|Author|AUTHORED
743|An Information-Theoretic Approach For Selecting Arms In Clinical Trials|Paper|Thomas Jaki|Author|AUTHORED
744|Bayesian Nonparametric Inference For Panel Count Data With An Informative Observation Process|Paper|Ye Liang|Author|AUTHORED
744|Bayesian Nonparametric Inference For Panel Count Data With An Informative Observation Process|Paper|Yang Li|Author|AUTHORED
744|Bayesian Nonparametric Inference For Panel Count Data With An Informative Observation Process|Paper|Bin Zhang|Author|AUTHORED
745|Learning Disentangled Representations Of Texts With Application To Biomedical Abstracts|Paper|Sarthak Jain|Author|AUTHORED
745|Learning Disentangled Representations Of Texts With Application To Biomedical Abstracts|Paper|Edward Banner|Author|AUTHORED
745|Learning Disentangled Representations Of Texts With Application To Biomedical Abstracts|Paper|Jan-Willem Van De Meent|Author|AUTHORED
745|Learning Disentangled Representations Of Texts With Application To Biomedical Abstracts|Paper|Iain J. Marshall|Author|AUTHORED
745|Learning Disentangled Representations Of Texts With Application To Biomedical Abstracts|Paper|Byron C. Wallace|Author|AUTHORED
745|Learning Disentangled Representations Of Texts With Application To Biomedical Abstracts|Paper|Biomedical Abstracts|Topic|RELATED_TO
746|Subgroup Identification Using Covariate Adjusted Interaction Trees|Paper|Jon Arni Steingrimsson|Author|AUTHORED
746|Subgroup Identification Using Covariate Adjusted Interaction Trees|Paper|Jiabei Yang|Author|AUTHORED
746|Subgroup Identification Using Covariate Adjusted Interaction Trees|Paper|Recursive Partitioning Methods|Topic|RELATED_TO
746|Subgroup Identification Using Covariate Adjusted Interaction Trees|Paper|Classification And Regression Tree Algorithm|Topic|RELATED_TO
746|Subgroup Identification Using Covariate Adjusted Interaction Trees|Paper|Covariate Adjusted Estimators|Topic|RELATED_TO
746|Subgroup Identification Using Covariate Adjusted Interaction Trees|Paper|Clinical Trial|Topic|RELATED_TO
746|Subgroup Identification Using Covariate Adjusted Interaction Trees|Paper|Motivational Interviews|Topic|RELATED_TO
746|Subgroup Identification Using Covariate Adjusted Interaction Trees|Paper|Substance Abusers|Topic|RELATED_TO
748|Oncology Clinical Trials|Topic|Experimental Drug|Topic|RELATED_TO
748|Experimental Drug|Topic|Control Group|Topic|RELATED_TO
748|Control Group|Topic|Overall Survival Benefit|Topic|RELATED_TO
748|Statistical Methods|Topic|Overall Survival Benefit|Topic|RELATED_TO
748|Inverse Probability Of Censoring Weighting (Ipcw)|Topic|Statistical Methods|Topic|RELATED_TO
748|Iterative Parameter Estimation (Ipe)|Topic|Statistical Methods|Topic|RELATED_TO
748|Rank-Preserving Structural Failure Time Models (Rpsftm)|Topic|Statistical Methods|Topic|RELATED_TO
748|Stratified Rpsftm|Topic|Statistical Methods|Topic|RELATED_TO
748|Random-Forest-Based Prediction|Topic|Statistical Methods|Topic|RELATED_TO
748|Simulation Study|Topic|Statistical Methods|Topic|RELATED_TO
748|Yuqing Xu|Author|Simulation Study|Topic|AUTHORED
748|Meijing Wu|Author|Simulation Study|Topic|AUTHORED
748|Weili He|Author|Simulation Study|Topic|AUTHORED
748|Qiming Liao|Author|Simulation Study|Topic|AUTHORED
748|Yabing Mai|Author|Simulation Study|Topic|AUTHORED
749|Simulation-Based Sample Size Determination|Topic|Duncan T. Wilson|Author|AUTHORED
749|Simulation-Based Sample Size Determination|Topic|Rebecca E. A. Walwyn|Author|AUTHORED
749|Simulation-Based Sample Size Determination|Topic|Richard Hooper|Author|AUTHORED
749|Simulation-Based Sample Size Determination|Topic|Julia Brown|Author|AUTHORED
749|Simulation-Based Sample Size Determination|Topic|Amanda J. Farrin|Author|AUTHORED
750|Rct Conclusion Generation Task|Topic|Pubmed 200K Rct Sentence Classification Dataset|Topic|RELATED_TO
750|Pointer-Generator Baseline Model|Topic|Rct Conclusion Generation Task|Topic|RELATED_TO
750|Gpt-2 Language Model|Topic|Rct Conclusion Generation Task|Topic|RELATED_TO
750|Alexander Te-Wei Shieh|Author|Rct Conclusion Generation Task|Topic|AUTHORED
750|Yung-Sung Chuang|Author|Rct Conclusion Generation Task|Topic|AUTHORED
750|Shang-Yu Su|Author|Rct Conclusion Generation Task|Topic|AUTHORED
750|Yun-Nung Chen|Author|Rct Conclusion Generation Task|Topic|AUTHORED
751|Hodgkin Lymphoma|Topic|Ahod0031 Trial|Topic|RELATED_TO
751|Cédric Beaulac|Author|Ahod0031 Trial|Topic|AUTHORED
751|Jeffrey S. Rosenthal|Author|Ahod0031 Trial|Topic|AUTHORED
751|Qinglin Pei|Author|Ahod0031 Trial|Topic|AUTHORED
751|Debra Friedman|Author|Ahod0031 Trial|Topic|AUTHORED
751|Suzanne Wolden|Author|Ahod0031 Trial|Topic|AUTHORED
751|David Hodgson|Author|Ahod0031 Trial|Topic|AUTHORED
751|Cox Proportional Hazard Model|Topic|Machine Learning Algorithms|Topic|DISCUSSES
751|Machine Learning Algorithms|Topic|Survival Analysis|Topic|RELATED_TO
751|Machine Learning Algorithms|Topic|Concordance Index|Topic|RELATED_TO
751|Machine Learning Algorithms|Topic|Brier Score|Topic|RELATED_TO
751|Machine Learning Algorithms|Topic|Artificial Intelligence|Topic|RELATED_TO
752|On The Theory Of Covariate-Adaptive Designs|Paper|Pocock And Simon'S Marginal Procedure|Topic|DISCUSSES
752|On The Theory Of Covariate-Adaptive Designs|Paper|Feifang Hu|Author|AUTHORED
752|On The Theory Of Covariate-Adaptive Designs|Paper|Li-Xin Zhang|Author|AUTHORED
753|Power Calculations For Replication Studies|Paper|Charlotte Micheloud|Author|AUTHORED
753|Power Calculations For Replication Studies|Paper|Leonhard Held|Author|AUTHORED
753|Power Calculations For Replication Studies|Paper|Replication Studies|Topic|RELATED_TO
753|Power Calculations For Replication Studies|Paper|Bayesian Methods|Topic|RELATED_TO
753|Power Calculations For Replication Studies|Paper|Predictive Power|Topic|RELATED_TO
753|Power Calculations For Replication Studies|Paper|Conditional Power|Topic|RELATED_TO
753|Power Calculations For Replication Studies|Paper|Social Sciences|Topic|RELATED_TO
754|Functional Additive Model|Topic|Randomized Clinical Trial|Topic|RELATED_TO
754|Functional Additive Model|Topic|Depression Clinical Trial|Topic|RELATED_TO
754|Hyung Park|Author|Functional Additive Model|Topic|AUTHORED
754|Eva Petkova|Author|Functional Additive Model|Topic|AUTHORED
754|Thaddeus Tarpey|Author|Functional Additive Model|Topic|AUTHORED
754|R. Todd Ogden|Author|Functional Additive Model|Topic|AUTHORED
755|Ivist|Topic|Multi-Point Plastic Scintillator Dosimeter|Topic|RELATED_TO
755|Ivist|Topic|Photomultiplier Tubes Assembly|Topic|RELATED_TO
755|Ivist|Topic|Python-Based Graphical User Interface|Topic|RELATED_TO
755|Ivist|Topic|Clinical Trial|Topic|RELATED_TO
755|Clinical Trial|Topic|Haydee M. Linares Rosales|Author|AUTHORED
755|Clinical Trial|Topic|Audrey Cantin|Author|AUTHORED
755|Clinical Trial|Topic|Sylviane Aubin|Author|AUTHORED
755|Clinical Trial|Topic|Sam Beddar|Author|AUTHORED
755|Clinical Trial|Topic|Luc Beaulieu|Author|AUTHORED
756|Smim|Paper|Censored Survival Data|Topic|RELATED_TO
756|Smim|Paper|Sensitivity Analysis|Topic|RELATED_TO
756|Smim|Paper|Multiple Imputation|Topic|RELATED_TO
756|Smim|Paper|Martingale|Topic|RELATED_TO
757|Adaptive Dose-Response Studies To Establish Proof-Of-Concept In Learning-Phase Clinical Trials|Paper|Shiyang Ma|Author|AUTHORED
757|Adaptive Dose-Response Studies To Establish Proof-Of-Concept In Learning-Phase Clinical Trials|Paper|Michael P. Mcdermott|Author|AUTHORED
758|Multicenter Clinical Trials|Topic|Data Sharing Barriers|Topic|RELATED_TO
758|Data Use Agreement|Topic|Data Sharing Barriers|Topic|RELATED_TO
758|Causal Inference Framework|Topic|Summary Statistics|Topic|RELATED_TO
758|Collaborative Inference|Topic|Summary Statistics|Topic|RELATED_TO
758|Statistical Power|Topic|Collaborative Inference|Topic|RELATED_TO
758|Mengtong Hu|Author|Collaborative Inference|Topic|AUTHORED
758|Xu Shi|Author|Collaborative Inference|Topic|AUTHORED
758|Peter X. -K. Song|Author|Collaborative Inference|Topic|AUTHORED
758|Basal Insulin Treatment|Topic|Post-Transplantation Diabetes|Topic|RELATED_TO
758|Post-Transplantation Diabetes|Topic|Kidney-Transplant Patients|Topic|RELATED_TO
759|Multistate Process Data|Topic|Chronic Diseases|Topic|RELATED_TO
759|Chronic Diseases|Topic|Cancer|Topic|RELATED_TO
759|Multistate Process Data|Topic|Precision Medicine|Topic|RELATED_TO
759|Optimal Individualized Treatment Rules|Topic|Nonparametric Outcome Weighted Learning Approach|Topic|AUTHORED
759|Randomized Clinical Trial|Topic|Nonparametric Outcome Weighted Learning Approach|Topic|RELATED_TO
759|Fisher Consistency|Topic|Nonparametric Outcome Weighted Learning Approach|Topic|RELATED_TO
759|Asymptotic Normality|Topic|Nonparametric Outcome Weighted Learning Approach|Topic|RELATED_TO
759|Variance Estimator|Topic|Nonparametric Outcome Weighted Learning Approach|Topic|RELATED_TO
759|Confidence Intervals|Topic|Nonparametric Outcome Weighted Learning Approach|Topic|RELATED_TO
759|Simulation Studies|Topic|Nonparametric Outcome Weighted Learning Approach|Topic|RELATED_TO
759|Randomized Clinical Trial|Topic|Metastatic Squamous-Cell Carcinoma Of The Head And Neck|Topic|RELATED_TO
759|Giorgos Bakoyannis|Author|Nonparametric Outcome Weighted Learning Approach|Topic|AUTHORED
761|Joint Modelling Of Longitudinal And Time-To-Event Data Applied To Group Sequential Clinical Trials|Paper|Abigail J. Burdon|Author|AUTHORED
761|Joint Modelling Of Longitudinal And Time-To-Event Data Applied To Group Sequential Clinical Trials|Paper|Lisa V. Hampson|Author|AUTHORED
761|Joint Modelling Of Longitudinal And Time-To-Event Data Applied To Group Sequential Clinical Trials|Paper|Christopher Jennison|Author|AUTHORED
762|Predicting Subgroup Treatment Effects For A New Study: Motivations, Results And Learnings From Running A Data Challenge In A Pharmaceutical Corporation|Paper|Subgroup Identification|Topic|DISCUSSES
762|Predicting Subgroup Treatment Effects For A New Study: Motivations, Results And Learnings From Running A Data Challenge In A Pharmaceutical Corporation|Paper|Phase Iii Clinical Trials|Topic|DISCUSSES
762|Predicting Subgroup Treatment Effects For A New Study: Motivations, Results And Learnings From Running A Data Challenge In A Pharmaceutical Corporation|Paper|Data Challenge|Topic|DISCUSSES
764|Optimal Benchmark|Topic|O'Quigley Et Al. 2002|Paper|RELATED_TO
764|Optimal Benchmark|Topic|Cheung 2014|Paper|RELATED_TO
764|Optimal Benchmark|Topic|Phase I Clinical Trial|Topic|DISCUSSES
764|Optimal Benchmark|Topic|Phase I/Ii Clinical Trial|Topic|DISCUSSES
765|Photobiomodulation Against Alzheimer'S Disease: A Systematic Review|Paper|Alzheimer'S Disease|Topic|DISCUSSES
765|Photobiomodulation Against Alzheimer'S Disease: A Systematic Review|Paper|Photobiomodulation|Topic|DISCUSSES
765|Photobiomodulation Against Alzheimer'S Disease: A Systematic Review|Paper|Joachim Enengl|Author|AUTHORED
765|Photobiomodulation Against Alzheimer'S Disease: A Systematic Review|Paper|Peter Dungel|Author|AUTHORED
766|Random Allocation Models|Topic|Clinical Trials|Topic|RELATED_TO
766|Play The Winner|Topic|Random Allocation Models|Topic|RELATED_TO
766|Randomized Play The Winner Rule|Topic|Random Allocation Models|Topic|RELATED_TO
766|Bayesian Method Using Decreasingly Informative Priors|Topic|Random Allocation Models|Topic|RELATED_TO
766|Dynamic Linear Model (Dlm)|Topic|Bayesian Method Using Decreasingly Informative Priors|Topic|RELATED_TO
766|Sensitivity Analysis|Topic|Bayesian Method Using Decreasingly Informative Priors|Topic|RELATED_TO
766|Bayes Factor|Topic|Sensitivity Analysis|Topic|RELATED_TO
766|Albert. H. Lee Iii|Author|Bayesian Method Using Decreasingly Informative Priors|Topic|AUTHORED
766|Edward L Boone|Author|Bayesian Method Using Decreasingly Informative Priors|Topic|AUTHORED
766|Roy T. Sabo|Author|Bayesian Method Using Decreasingly Informative Priors|Topic|AUTHORED
766|Erin Donahue|Author|Bayesian Method Using Decreasingly Informative Priors|Topic|AUTHORED
767|Hopes|Topic|Beiwe|Topic|RELATED_TO
767|Hopes|Topic|Sars-Cov-2 Pandemic|Topic|DISCUSSES
767|Hopes|Topic|Xuancong Wang|Author|AUTHORED
767|Hopes|Topic|Nikola Vouk|Author|AUTHORED
767|Hopes|Topic|Creighton Heaukulani|Author|AUTHORED
767|Hopes|Topic|Thisum Buddhika|Author|AUTHORED
767|Hopes|Topic|Wijaya Martanto|Author|AUTHORED
767|Hopes|Topic|Jimmy Lee|Author|AUTHORED
767|Hopes|Topic|Robert Jt Morris|Author|AUTHORED
768|Testing The Equality Of Proportions For Combined Unilateral And Bilateral Data|Paper|Chang-Xing Ma|Author|AUTHORED
768|Testing The Equality Of Proportions For Combined Unilateral And Bilateral Data|Paper|Kejia Wang|Author|AUTHORED
768|Testing The Equality Of Proportions For Combined Unilateral And Bilateral Data|Paper|Bilateral Data|Topic|RELATED_TO
768|Testing The Equality Of Proportions For Combined Unilateral And Bilateral Data|Paper|Unilateral Data|Topic|RELATED_TO
768|Testing The Equality Of Proportions For Combined Unilateral And Bilateral Data|Paper|Statistical Tests|Topic|RELATED_TO
768|Testing The Equality Of Proportions For Combined Unilateral And Bilateral Data|Paper|Intra-Class Correlation|Topic|RELATED_TO
768|Testing The Equality Of Proportions For Combined Unilateral And Bilateral Data|Paper|Likelihood Estimate Algorithm|Topic|RELATED_TO
768|Testing The Equality Of Proportions For Combined Unilateral And Bilateral Data|Paper|Score Test|Topic|RELATED_TO
769|Cauchycp|Topic|Cox Proportional Hazards Model|Topic|RELATED_TO
769|Cauchycp|Topic|Randomized Clinical Trials|Topic|RELATED_TO
769|Cauchycp|Topic|Cauchycp Test|Topic|AUTHORED
770|Clinical Interventions|Topic|Vaccine Efficacy|Topic|RELATED_TO
770|Covid-19 Vaccines|Topic|Vaccine Efficacy|Topic|RELATED_TO
770|Yasin Memari|Author|Vaccine Efficacy|Topic|AUTHORED
771|Randomized Block Factorial Experiments|Topic|Linear Model And Analysis Of Covariance|Topic|RELATED_TO
771|Finite Population Joint Central Limit Theorem|Topic|Factorial Effect Estimators|Topic|RELATED_TO
771|Covariate Adjustment Methods|Topic|Factorial Effect Estimators|Topic|RELATED_TO
771|Neyman-Type Conservative Estimators|Topic|Covariate Adjustment Methods|Topic|RELATED_TO
771|Hanzhong Liu|Author|Randomization-Based Joint Central Limit Theorem And Efficient Covariate Adjustment In Stratified $2^K$ Factorial Experiments|Paper|AUTHORED
771|Jiyang Ren|Author|Randomization-Based Joint Central Limit Theorem And Efficient Covariate Adjustment In Stratified $2^K$ Factorial Experiments|Paper|AUTHORED
771|Yuehan Yang|Author|Randomization-Based Joint Central Limit Theorem And Efficient Covariate Adjustment In Stratified $2^K$ Factorial Experiments|Paper|AUTHORED
772|Group Sequential Design (Gsd)|Topic|Multiple Hypotheses|Topic|RELATED_TO
772|Weighted Parametric Group Sequential Design (Wpgsd)|Topic|Type I Error Rate (Fwer)|Topic|RELATED_TO
772|Weighted Parametric Group Sequential Design (Wpgsd)|Topic|Clinical Trials|Topic|RELATED_TO
772|Keaven M. Anderson|Author|Weighted Parametric Group Sequential Design (Wpgsd)|Topic|AUTHORED
772|Zifang Guo|Author|Weighted Parametric Group Sequential Design (Wpgsd)|Topic|AUTHORED
772|Jing Zhao|Author|Weighted Parametric Group Sequential Design (Wpgsd)|Topic|AUTHORED
772|Linda Z. Sun|Author|Weighted Parametric Group Sequential Design (Wpgsd)|Topic|AUTHORED
773|Classification Of Hierarchical Text Using Geometric Deep Learning: The Case Of Clinical Trials Corpus|Paper|Geometric Deep Learning|Topic|DISCUSSES
773|Classification Of Hierarchical Text Using Geometric Deep Learning: The Case Of Clinical Trials Corpus|Paper|Graph Neural Networks|Topic|DISCUSSES
773|Classification Of Hierarchical Text Using Geometric Deep Learning: The Case Of Clinical Trials Corpus|Paper|Selective Graph Pooling|Topic|DISCUSSES
773|Classification Of Hierarchical Text Using Geometric Deep Learning: The Case Of Clinical Trials Corpus|Paper|Clinical Trial Protocols|Topic|DISCUSSES
773|Clinical Trial Protocols|Topic|Completed Category|Topic|RELATED_TO
773|Clinical Trial Protocols|Topic|Terminated Category|Topic|RELATED_TO
773|Classification Of Hierarchical Text Using Geometric Deep Learning: The Case Of Clinical Trials Corpus|Paper|F1-Scores|Topic|DISCUSSES
773|F1-Scores|Topic|Ct Registry|Topic|RELATED_TO
773|Ct Registry|Topic|360K Protocols|Topic|RELATED_TO
773|Classification Of Hierarchical Text Using Geometric Deep Learning: The Case Of Clinical Trials Corpus|Paper|Ct Termination Status Prediction|Topic|DISCUSSES
774|Return-To-Baseline|Topic|Missing Values|Topic|RELATED_TO
774|Return-To-Baseline|Topic|Clinical Trials|Topic|RELATED_TO
774|Yongming Qu|Author|Novel Return-To-Baseline Imputation Method|Topic|AUTHORED
774|Biyue Dai|Author|Novel Return-To-Baseline Imputation Method|Topic|AUTHORED
775|Temporal Subtyping Of Alzheimer'S Disease Using Medical Conditions Preceding Alzheimer'S Disease Onset In Electronic Health Records|Paper|Alzheimer'S Disease|Topic|RELATED_TO
775|Temporal Subtyping Of Alzheimer'S Disease Using Medical Conditions Preceding Alzheimer'S Disease Onset In Electronic Health Records|Paper|Oneflorida Data Trust|Topic|RELATED_TO
775|Temporal Subtyping Of Alzheimer'S Disease Using Medical Conditions Preceding Alzheimer'S Disease Onset In Electronic Health Records|Paper|Zhe He|Author|AUTHORED
775|Temporal Subtyping Of Alzheimer'S Disease Using Medical Conditions Preceding Alzheimer'S Disease Onset In Electronic Health Records|Paper|Shubo Tian|Author|AUTHORED
775|Temporal Subtyping Of Alzheimer'S Disease Using Medical Conditions Preceding Alzheimer'S Disease Onset In Electronic Health Records|Paper|Arslan Erdengasileng|Author|AUTHORED
775|Temporal Subtyping Of Alzheimer'S Disease Using Medical Conditions Preceding Alzheimer'S Disease Onset In Electronic Health Records|Paper|Neil Charness|Author|AUTHORED
775|Temporal Subtyping Of Alzheimer'S Disease Using Medical Conditions Preceding Alzheimer'S Disease Onset In Electronic Health Records|Paper|Jiang Bian|Author|AUTHORED
776|Biotechnologies|Topic|74 Biotech Startups|Paper|DISCUSSES
776|2020|Topic|74 Biotech Startups|Paper|DISCUSSES
776|2021|Topic|60 Biotech Startups|Paper|DISCUSSES
776|Leadership|Topic|74 Biotech Startups|Paper|RELATED_TO
776|Technological Focus|Topic|74 Biotech Startups|Paper|RELATED_TO
776|Clinical Trials|Topic|74 Biotech Startups|Paper|RELATED_TO
776|Financing|Topic|74 Biotech Startups|Paper|RELATED_TO
776|Advanced Degrees|Topic|74 Biotech Startups|Paper|RELATED_TO
776|Intellectual Property|Topic|74 Biotech Startups|Paper|RELATED_TO
776|Large Private Rounds|Topic|74 Biotech Startups|Paper|RELATED_TO
776|Time-To-Ipo|Topic|74 Biotech Startups|Paper|RELATED_TO
776|Post-Ipo Stock Performance|Topic|74 Biotech Startups|Paper|RELATED_TO
776|Covid|Topic|138 Biotech Ipos|Paper|DISCUSSES
776|Sebastian G. Huayamares|Author|74 Biotech Startups|Paper|AUTHORED
776|Melissa P. Lokugamage|Author|74 Biotech Startups|Paper|AUTHORED
776|Alejandro J. Da Silva Sanchez|Author|74 Biotech Startups|Paper|AUTHORED
776|James E. Dahlman|Author|74 Biotech Startups|Paper|AUTHORED
777|Covariate Adjustment|Topic|Randomized Clinical Trials|Topic|RELATED_TO
777|Covariate Adjustment|Topic|Treatment Effects|Topic|RELATED_TO
777|Covariate Adjusted Pseudovalue Regression|Topic|Restricted Mean Survival Times (Rmst)|Topic|RELATED_TO
777|Yunfan Li|Author|Covariate Adjusted Pseudovalue Regression|Topic|AUTHORED
777|Jessica L. Ross|Author|Covariate Adjusted Pseudovalue Regression|Topic|AUTHORED
777|Aaron M. Smith|Author|Covariate Adjusted Pseudovalue Regression|Topic|AUTHORED
777|David P. Miller|Author|Covariate Adjusted Pseudovalue Regression|Topic|AUTHORED
778|Bayesian Arc Length Survival Analysis Model (Balsam)|Paper|Hiv/Aids Clinical Trial|Topic|RELATED_TO
778|Bayesian Arc Length Survival Analysis Model (Balsam)|Paper|Cumulative Variations|Topic|DISCUSSES
778|Bayesian Arc Length Survival Analysis Model (Balsam)|Paper|Cd4 Count|Topic|DISCUSSES
778|Cox Proportional Hazards Model|Topic|Hazard Rate|Topic|RELATED_TO
778|Arc Length|Topic|Cumulative Variations|Topic|RELATED_TO
778|Stochastic Volatility|Topic|Cumulative Variations|Topic|RELATED_TO
779|Pro Development|Topic|Qualitative Research|Topic|RELATED_TO
779|Qualitative Research|Topic|Saturation|Topic|RELATED_TO
779|Saturation|Topic|Fda Guidance|Topic|RELATED_TO
779|Chris Barker|Author|Saturation|Topic|AUTHORED
779|Francis 2010|Author|Saturation|Topic|AUTHORED
779|Mason 2010|Author|Saturation|Topic|AUTHORED
779|Marshall 2013|Author|Saturation|Topic|AUTHORED
779|Guest 2006|Author|Saturation|Topic|AUTHORED
780|Ulrich Schimmack|Author|False Positive Risk|Topic|AUTHORED
780|Frantiek Barto|Author|False Positive Risk|Topic|AUTHORED
780|False Positive Risk|Topic|Publication Bias|Topic|RELATED_TO
780|False Positive Risk|Topic|Medical Research|Topic|RELATED_TO
780|Clinical Trials|Topic|Medical Research|Topic|RELATED_TO
780|Significance Criterion|Topic|False Positive Risk|Topic|RELATED_TO
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Heterogeneous Treatment Effects|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Precision Medicine|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Randomized Clinical Trials|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|High-Dimensional Predictive Markers|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Two-Stage Statistical Learning Procedure|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Optimal Efficiency Augmentation|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Extreme Gradient Boosting Trees|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Mean Difference|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Risk Ratio|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Specialized Loss Functions|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Permutation Test|Topic|DISCUSSES
781|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|Prostate Cancer Prevention Trial|Topic|DISCUSSES
781|Heng Chen|Author|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|AUTHORED
781|Michael L. Leblanc|Author|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|AUTHORED
781|James Y. Dai|Author|Augmented Learning Of Heterogeneous Treatment Effects Via Gradient Boosting Trees|Paper|AUTHORED
782|Dynamic Borrowing Method For Historical Information Using A Frequentist Approach For Hybrid Control Design|Paper|Bayesian Information Borrowing Methods|Topic|RELATED_TO
782|Dynamic Borrowing Method For Historical Information Using A Frequentist Approach For Hybrid Control Design|Paper|Test-Then-Pool Methods|Topic|RELATED_TO
782|Dynamic Borrowing Method For Historical Information Using A Frequentist Approach For Hybrid Control Design|Paper|Equivalence-Based Test-Then-Pool Methods|Topic|RELATED_TO
782|Dynamic Borrowing Method For Historical Information Using A Frequentist Approach For Hybrid Control Design|Paper|Monte Carlo Simulations|Topic|RELATED_TO
782|Dynamic Borrowing Method For Historical Information Using A Frequentist Approach For Hybrid Control Design|Paper|Clinical Trial Data|Topic|RELATED_TO
782|Dynamic Borrowing Method For Historical Information Using A Frequentist Approach For Hybrid Control Design|Paper|Rare And Pediatric Diseases|Topic|RELATED_TO
782|Dynamic Borrowing Method For Historical Information Using A Frequentist Approach For Hybrid Control Design|Paper|Statistical Hypothesis Testing|Topic|RELATED_TO
783|Aipw Estimator|Topic|Marlena S. Bannick|Author|AUTHORED
783|Aipw Estimator|Topic|Jun Shao|Author|AUTHORED
783|Aipw Estimator|Topic|Jingyi Liu|Author|AUTHORED
783|Aipw Estimator|Topic|Yu Du|Author|AUTHORED
783|Aipw Estimator|Topic|Yanyao Yi|Author|AUTHORED
783|Aipw Estimator|Topic|Ting Ye|Author|AUTHORED
783|Aipw Estimator|Topic|R Package Robincar|Topic|RELATED_TO
784|Prognostic Model For Ich|Paper|Intracerebral Hemorrhage|Topic|DISCUSSES
784|Wenao Ma|Author|Prognostic Model For Ich|Paper|AUTHORED
784|Cheng Chen|Author|Prognostic Model For Ich|Paper|AUTHORED
784|Jill Abrigo|Author|Prognostic Model For Ich|Paper|AUTHORED
784|Calvin Hoi-Kwan Mak|Author|Prognostic Model For Ich|Paper|AUTHORED
784|Yuqi Gong|Author|Prognostic Model For Ich|Paper|AUTHORED
784|Nga Yan Chan|Author|Prognostic Model For Ich|Paper|AUTHORED
784|Chu Han|Author|Prognostic Model For Ich|Paper|AUTHORED
784|Zaiyi Liu|Author|Prognostic Model For Ich|Paper|AUTHORED
784|Qi Dou|Author|Prognostic Model For Ich|Paper|AUTHORED
785|Randomized Clinical Trials|Topic|Difference In Proportions|Topic|RELATED_TO
785|Difference In Proportions|Topic|Treatment Effect|Topic|DISCUSSES
785|Prognostic Baseline Covariates|Topic|Standardization|Topic|RELATED_TO
785|Standardization|Topic|G-Computation|Topic|RELATED_TO
785|G-Computation|Topic|Unconditional Difference In Proportions|Topic|RELATED_TO
785|Uncertainty And Confidence Intervals|Topic|Small Sample Sizes|Topic|RELATED_TO
785|Robust Sandwich Estimator|Topic|Finite Sample Performance|Topic|RELATED_TO
785|Jialuo Liu|Author|Randomized Clinical Trials|Topic|AUTHORED
785|Dong Xi|Author|Randomized Clinical Trials|Topic|AUTHORED
786|N-Of-1 Trial Study Design|Topic|Personalized Adaptive Interventions|Topic|RELATED_TO
786|Online Reinforcement Learning Agent|Topic|N-Of-1 Trial Study Design|Topic|RELATED_TO
786|Physical Exercise Recommendations|Topic|Endometriosis|Topic|RELATED_TO
786|Dominik Meier|Author|N-Of-1 Trial Study Design|Topic|AUTHORED
786|Ipek Ensari|Author|N-Of-1 Trial Study Design|Topic|AUTHORED
786|Stefan Konigorski|Author|N-Of-1 Trial Study Design|Topic|AUTHORED
787|Estimands And Cumulative Incidence Function Regression In Clinical Trials: Some New Results On Interpretability And Robustness|Paper|Fine-Gray Model|Topic|DISCUSSES
787|Estimands And Cumulative Incidence Function Regression In Clinical Trials: Some New Results On Interpretability And Robustness|Paper|Direct Binomial Regression|Topic|DISCUSSES
787|Estimands And Cumulative Incidence Function Regression In Clinical Trials: Some New Results On Interpretability And Robustness|Paper|Cumulative Incidence Function Regression|Topic|DISCUSSES
787|Estimands And Cumulative Incidence Function Regression In Clinical Trials: Some New Results On Interpretability And Robustness|Paper|Breast Cancer Metastatic To Bone|Topic|RELATED_TO
788|Constrained Markov Decision Process (Cmdp)|Topic|Stef Baas|Author|AUTHORED
788|Constrained Markov Decision Process (Cmdp)|Topic|Aleida Braaksma|Author|AUTHORED
788|Constrained Markov Decision Process (Cmdp)|Topic|Richard J. Boucherie|Author|AUTHORED
789|Publication Bias Adjustment In Network Meta-Analysis: An Inverse Probability Weighting Approach Using Clinical Trial Registries|Paper|Network Meta-Analysis|Topic|DISCUSSES
789|Publication Bias Adjustment In Network Meta-Analysis: An Inverse Probability Weighting Approach Using Clinical Trial Registries|Paper|Publication Bias|Topic|DISCUSSES
789|Publication Bias Adjustment In Network Meta-Analysis: An Inverse Probability Weighting Approach Using Clinical Trial Registries|Paper|Inverse Probability Weighting|Topic|DISCUSSES
789|Publication Bias Adjustment In Network Meta-Analysis: An Inverse Probability Weighting Approach Using Clinical Trial Registries|Paper|Ao Huang|Author|AUTHORED
789|Publication Bias Adjustment In Network Meta-Analysis: An Inverse Probability Weighting Approach Using Clinical Trial Registries|Paper|Yi Zhou|Author|AUTHORED
789|Publication Bias Adjustment In Network Meta-Analysis: An Inverse Probability Weighting Approach Using Clinical Trial Registries|Paper|Satoshi Hattori|Author|AUTHORED
790|Log-Rank Test|Topic|Cox Proportional Hazards Model|Topic|RELATED_TO
790|Time-To-Event Data|Topic|Clinical Trials|Topic|RELATED_TO
790|Proportional Hazards|Topic|Log-Rank Test|Topic|DISCUSSES
790|Proportional Hazards|Topic|Cox Proportional Hazards Model|Topic|DISCUSSES
790|Immunotherapies|Topic|Proportional Hazards|Topic|RELATED_TO
790|Two-Stage Test Procedure|Topic|Permutation Test Framework|Topic|RELATED_TO
790|Two-Stage Test Procedure|Topic|Log-Rank Test|Topic|DISCUSSES
790|Two-Stage Test Procedure|Topic|Cox Proportional Hazards Model|Topic|DISCUSSES
790|Jonas Brugger|Author|Two-Stage Test Procedure|Topic|AUTHORED
790|Tim Friede|Author|Two-Stage Test Procedure|Topic|AUTHORED
790|Florian Klinglmüller|Author|Two-Stage Test Procedure|Topic|AUTHORED
790|Martin Posch|Author|Two-Stage Test Procedure|Topic|AUTHORED
790|Robin Ristl|Author|Two-Stage Test Procedure|Topic|AUTHORED
790|Franz König|Author|Two-Stage Test Procedure|Topic|AUTHORED
791|American Statistical Association|Topic|Interval Null Hypothesis Framework|Topic|DISCUSSES
791|Interval Null Hypothesis Framework|Topic|Bayes Factor-Based Tests|Topic|RELATED_TO
791|Bayesian Hypothesis Testing|Topic|Bayes Factor-Based Tests|Topic|RELATED_TO
791|Abhisek Chakraborty|Author|Interval Null Hypothesis Framework|Topic|AUTHORED
791|Megan H. Murray|Author|Interval Null Hypothesis Framework|Topic|AUTHORED
791|Ilya Lipkovich|Author|Interval Null Hypothesis Framework|Topic|AUTHORED
791|Yu Du|Author|Interval Null Hypothesis Framework|Topic|AUTHORED
792|Clinical Trial|Topic|Continuous Glucose Monitoring|Topic|RELATED_TO
792|Type 1 Diabetes|Topic|Glycemic Control|Topic|RELATED_TO
792|Multilevel Functional Model|Topic|Cgm Distributions|Topic|RELATED_TO
792|The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Group|Author|Clinical Trial|Topic|AUTHORED
792|Marcos Matabuena|Author|Clinical Trial|Topic|AUTHORED
792|Ciprian M. Crainiceanu|Author|Clinical Trial|Topic|AUTHORED
792|Multilevel Functional Model|Topic|Github|Topic|RELATED_TO
793|Clinical Trials|Topic|Drug Development|Topic|RELATED_TO
793|Global Win Probability|Topic|Winp|Topic|RELATED_TO
793|Sample Size Formula|Topic|Global Win Probability|Topic|DISCUSSES
793|Confidence Interval|Topic|Sample Size Formula|Topic|DISCUSSES
793|Probability|Topic|Sample Size Formula|Topic|DISCUSSES
793|Receiver Operating Characteristic Curve|Topic|Auc|Topic|RELATED_TO
793|Auc|Topic|Global Win Probability|Topic|RELATED_TO
793|Parkinson'S Disease Clinical Trial|Topic|Sample Size Formula|Topic|DISCUSSES
793|Di Shu|Author|Sample Size Formula|Topic|AUTHORED
793|Guangyong Zou|Author|Sample Size Formula|Topic|AUTHORED
794|Multi-Regional Clinical Trials (Mrcts)|Topic|Restricted Mean Survival Time|Topic|DISCUSSES
794|Restricted Mean Survival Time|Topic|Acute Coronary Syndromes|Topic|RELATED_TO
794|Kaiyuan Hua|Author|Multi-Regional Clinical Trials (Mrcts)|Topic|AUTHORED
794|Hwanhee Hong|Author|Multi-Regional Clinical Trials (Mrcts)|Topic|AUTHORED
794|Xiaofei Wang|Author|Multi-Regional Clinical Trials (Mrcts)|Topic|AUTHORED
795|Safe And Reliable Natural Language Inference|Topic|Clinical Trial Reports|Topic|RELATED_TO
795|Data Augmentation Technique|Topic|Biomedical Natural Language Inference|Topic|RELATED_TO
795|Synthetic Examples|Topic|Semantic Perturbations|Topic|RELATED_TO
795|Synthetic Examples|Topic|Domain-Specific Vocabulary Replacement|Topic|RELATED_TO
795|Biomedical Natural Language Inference|Topic|Numerical And Quantitative Reasoning|Topic|RELATED_TO
795|Data Augmentation Technique|Topic|Multi-Task Learning|Topic|RELATED_TO
795|Multi-Task Learning|Topic|Deberta Architecture|Topic|RELATED_TO
795|Deberta Architecture|Topic|Nli4Ct 2024 Benchmark|Topic|RELATED_TO
795|Dke-Research|Author|Yuqi Wang|Author|AUTHORED
795|Dke-Research|Author|Zeqiang Wang|Author|AUTHORED
795|Dke-Research|Author|Wei Wang|Author|AUTHORED
795|Dke-Research|Author|Qi Chen|Author|AUTHORED
795|Dke-Research|Author|Kaizhu Huang|Author|AUTHORED
795|Dke-Research|Author|Anh Nguyen|Author|AUTHORED
795|Dke-Research|Author|Suparna De|Author|AUTHORED
796|Piecewise Exponential Hazard Model|Topic|Parametric Assumptions|Topic|RELATED_TO
796|Pwexp Package|Topic|Piecewise Exponential Hazard Model|Topic|AUTHORED
796|Tianchen Xu|Author|Pwexp Package|Topic|AUTHORED
796|Rachael Wen|Author|Pwexp Package|Topic|AUTHORED
797|Covariate-Adaptive Randomization|Topic|Interventional Studies|Topic|RELATED_TO
797|Covariate-Adaptive Randomization|Topic|Clinical Trials|Topic|RELATED_TO
797|Covariate-Adaptive Randomization|Topic|Development Economics|Topic|RELATED_TO
797|Bugni Et Al. (2018, 2019)|Author|Covariate-Adaptive Randomization|Topic|DISCUSSES
797|Jiahui Xin|Author|Inference Under Covariate-Adaptive Randomization|Topic|AUTHORED
797|Hanzhong Liu|Author|Inference Under Covariate-Adaptive Randomization|Topic|AUTHORED
797|Wei Ma|Author|Inference Under Covariate-Adaptive Randomization|Topic|AUTHORED
797|Inference Under Covariate-Adaptive Randomization|Topic|Weighted Regression Adjustment|Topic|RELATED_TO
797|Inference Under Covariate-Adaptive Randomization|Topic|Asymptotic Theory|Topic|RELATED_TO
797|Inference Under Covariate-Adaptive Randomization|Topic|Practical Algorithms|Topic|RELATED_TO
797|Stratified Block Randomization|Topic|Covariate-Adaptive Randomization|Topic|RELATED_TO
797|Simple Randomization|Topic|Stratified Block Randomization|Topic|RELATED_TO
798|Average Hazard|Topic|Cox'S Hazard Ratio|Topic|RELATED_TO
798|Uno And Horiguchi|Author|Average Hazard|Topic|AUTHORED
798|Comparative Effectiveness Research|Topic|Average Hazard|Topic|RELATED_TO
798|Hong Xiong|Author|Comparative Effectiveness Research With Average Hazard For Censored Time-To-Event Outcomes: A Numerical Study|Paper|AUTHORED
798|Jean Connors|Author|Comparative Effectiveness Research With Average Hazard For Censored Time-To-Event Outcomes: A Numerical Study|Paper|AUTHORED
798|Deb Schrag|Author|Comparative Effectiveness Research With Average Hazard For Censored Time-To-Event Outcomes: A Numerical Study|Paper|AUTHORED
798|Hajime Uno|Author|Comparative Effectiveness Research With Average Hazard For Censored Time-To-Event Outcomes: A Numerical Study|Paper|AUTHORED
799|Win Ratio With Multiple Thresholds|Topic|Cardiovascular Clinical Trials|Topic|RELATED_TO
799|Pocock Et Al. (2012)|Author|Win Ratio With Multiple Thresholds|Topic|DISCUSSES
799|Yunhan Mou|Author|Win Ratio With Multiple Thresholds|Topic|AUTHORED
799|Tassos Kyriakides|Author|Win Ratio With Multiple Thresholds|Topic|AUTHORED
799|Scott Hummel|Author|Win Ratio With Multiple Thresholds|Topic|AUTHORED
799|Fan Li|Author|Win Ratio With Multiple Thresholds|Topic|AUTHORED
799|Yuan Huang|Author|Win Ratio With Multiple Thresholds|Topic|AUTHORED
800|Semeval-2024 Safe Biomedical Natural Language Inference For Clinical Trials|Topic|Mistral-7B|Topic|RELATED_TO
800|Semeval-2024 Safe Biomedical Natural Language Inference For Clinical Trials|Topic|Clinical Trial Reports|Topic|RELATED_TO
800|Mistral-7B|Topic|Artur Guimarães|Author|AUTHORED
800|Mistral-7B|Topic|Bruno Martins|Author|AUTHORED
800|Mistral-7B|Topic|João Magalhães|Author|AUTHORED
801|International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use (Ich) E9 (R1) Addendum|Topic|Treatment Policy Strategy|Topic|RELATED_TO
801|Treatment Policy Strategy|Topic|Missing Values|Topic|RELATED_TO
801|Missing Values|Topic|Hypothetical Strategy|Topic|RELATED_TO
801|Hypothetical Strategy|Topic|Retrieved Dropout Imputation|Topic|RELATED_TO
801|Retrieved Dropout Imputation|Topic|Anti-Diabetes Treatment|Topic|RELATED_TO
801|Rong Liu|Author|Retrieved Dropout Imputation|Topic|AUTHORED
801|Yongming Qu|Author|Retrieved Dropout Imputation|Topic|AUTHORED
802|Covid-19|Topic|Drug Repurposing|Topic|RELATED_TO
802|Covid-19|Topic|Dexamethasone|Topic|RELATED_TO
802|Covid-19|Topic|Resveratrol|Topic|RELATED_TO
802|Covid-19|Topic|Methotrexate|Topic|RELATED_TO
802|Covid-19|Topic|Indomethacin|Topic|RELATED_TO
802|Covid-19|Topic|Quercetin|Topic|RELATED_TO
802|Dgdr-Net|Topic|Covid-19|Topic|RELATED_TO
802|Comorbidities|Topic|Covid-19|Topic|RELATED_TO
802|Clinical Trials|Topic|Covid-19|Topic|RELATED_TO
802|Yonghyun Nam|Author|Dgdr-Net|Topic|AUTHORED
802|Jae-Seung Yun|Author|Dgdr-Net|Topic|AUTHORED
802|Seung Mi Lee|Author|Dgdr-Net|Topic|AUTHORED
802|Ji Won Park|Author|Dgdr-Net|Topic|AUTHORED
802|Ziqi Chen|Author|Dgdr-Net|Topic|AUTHORED
802|Brian Lee|Author|Dgdr-Net|Topic|AUTHORED
802|Anurag Verma|Author|Dgdr-Net|Topic|AUTHORED
802|Xia Ning|Author|Dgdr-Net|Topic|AUTHORED
802|Li Shen|Author|Dgdr-Net|Topic|AUTHORED
802|Dokyoon Kim|Author|Dgdr-Net|Topic|AUTHORED
803|Measuring Disease Progression In Clinical Trials For Testing Novel Treatments For Multifaceted Diseases As Progressive Supranuclear Palsy (Psp)|Topic|Progressive Supranuclear Palsy Rating Scale (Psprs)|Topic|RELATED_TO
803|Progressive Supranuclear Palsy Rating Scale (Psprs)|Topic|Item Response Theory Models|Topic|RELATED_TO
803|Item Response Theory Models|Topic|Abbv-8E12 Clinical Trial|Topic|RELATED_TO
803|Elham Yousefi|Author|Measuring Disease Progression In Clinical Trials For Testing Novel Treatments For Multifaceted Diseases As Progressive Supranuclear Palsy (Psp)|Topic|AUTHORED
803|Mohamed Gewily|Author|Measuring Disease Progression In Clinical Trials For Testing Novel Treatments For Multifaceted Diseases As Progressive Supranuclear Palsy (Psp)|Topic|AUTHORED
803|Franz König|Author|Measuring Disease Progression In Clinical Trials For Testing Novel Treatments For Multifaceted Diseases As Progressive Supranuclear Palsy (Psp)|Topic|AUTHORED
803|Günter Höglinger|Author|Measuring Disease Progression In Clinical Trials For Testing Novel Treatments For Multifaceted Diseases As Progressive Supranuclear Palsy (Psp)|Topic|AUTHORED
803|Franziska Hopfner|Author|Measuring Disease Progression In Clinical Trials For Testing Novel Treatments For Multifaceted Diseases As Progressive Supranuclear Palsy (Psp)|Topic|AUTHORED
803|Mats O. Karlsson|Author|Measuring Disease Progression In Clinical Trials For Testing Novel Treatments For Multifaceted Diseases As Progressive Supranuclear Palsy (Psp)|Topic|AUTHORED
803|Robin Ristl|Author|Measuring Disease Progression In Clinical Trials For Testing Novel Treatments For Multifaceted Diseases As Progressive Supranuclear Palsy (Psp)|Topic|AUTHORED
803|Sonja Zehetmayer|Author|Measuring Disease Progression In Clinical Trials For Testing Novel Treatments For Multifaceted Diseases As Progressive Supranuclear Palsy (Psp)|Topic|AUTHORED
803|Martin Posch|Author|Measuring Disease Progression In Clinical Trials For Testing Novel Treatments For Multifaceted Diseases As Progressive Supranuclear Palsy (Psp)|Topic|AUTHORED
804|Estimands Using The Treatment Policy Strategy For Addressing Intercurrent Events|Topic|Phase Iii Clinical Trials|Topic|RELATED_TO
804|Retrieved Dropout|Topic|Likelihood-Based Methods|Topic|RELATED_TO
804|Pioneer 1 Phase Iii Clinical Trial|Topic|Likelihood-Based Methods|Topic|RELATED_TO
804|James Bell|Author|Estimands Using The Treatment Policy Strategy For Addressing Intercurrent Events|Topic|AUTHORED
804|Thomas Drury|Author|Estimands Using The Treatment Policy Strategy For Addressing Intercurrent Events|Topic|AUTHORED
804|Tobias Mütze|Author|Estimands Using The Treatment Policy Strategy For Addressing Intercurrent Events|Topic|AUTHORED
804|Christian Bressen Pipper|Author|Estimands Using The Treatment Policy Strategy For Addressing Intercurrent Events|Topic|AUTHORED
804|Lorenzo Guizzaro|Author|Estimands Using The Treatment Policy Strategy For Addressing Intercurrent Events|Topic|AUTHORED
804|Marian Mitroiu|Author|Estimands Using The Treatment Policy Strategy For Addressing Intercurrent Events|Topic|AUTHORED
804|Khadija Rerhou Rantell|Author|Estimands Using The Treatment Policy Strategy For Addressing Intercurrent Events|Topic|AUTHORED
804|Marcel Wolbers|Author|Estimands Using The Treatment Policy Strategy For Addressing Intercurrent Events|Topic|AUTHORED
804|David Wright|Author|Estimands Using The Treatment Policy Strategy For Addressing Intercurrent Events|Topic|AUTHORED
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Rachael Fleurence|Author|AUTHORED
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Jiang Bian|Author|AUTHORED
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Xiaoyan Wang|Author|AUTHORED
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Hua Xu|Author|AUTHORED
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Dalia Dawoud|Author|AUTHORED
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Mitch Higashi|Author|AUTHORED
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Jagpreet Chhatwal|Author|AUTHORED
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Generative Ai|Topic|RELATED_TO
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Health Technology Assessment|Topic|RELATED_TO
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Large Language Models|Topic|RELATED_TO
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Evidence Synthesis|Topic|RELATED_TO
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Evidence Generation|Topic|RELATED_TO
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Clinical Trials|Topic|RELATED_TO
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Economic Modeling|Topic|RELATED_TO
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Real-World Data|Topic|RELATED_TO
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Real-World Evidence|Topic|RELATED_TO
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Health Economic Models|Topic|RELATED_TO
805|Generative Ai For Health Technology Assessment: Opportunities, Challenges, And Policy Considerations|Paper|Policy Landscape|Topic|RELATED_TO
806|Asymptotics In Randomized Urn Models|Paper|Zhi-Dong Bai|Author|AUTHORED
806|Asymptotics In Randomized Urn Models|Paper|Feifang Hu|Author|AUTHORED
807|Statistical Methodology For Non-Inferiority Trials|Topic|Non-Inferiority Trials|Topic|RELATED_TO
807|Statistical Methodology For Non-Inferiority Trials|Topic|Wald-Type Test Procedure|Topic|DISCUSSES
807|Statistical Methodology For Non-Inferiority Trials|Topic|Sample Size Allocation Rule|Topic|DISCUSSES
807|Statistical Methodology For Non-Inferiority Trials|Topic|Clinical Trials For Depression|Topic|DISCUSSES
807|Statistical Methodology For Non-Inferiority Trials|Topic|Clinical Trials For Epilepsy|Topic|DISCUSSES
807|M. Mielke|Author|Statistical Methodology For Non-Inferiority Trials|Topic|AUTHORED
807|A. Munk|Author|Statistical Methodology For Non-Inferiority Trials|Topic|AUTHORED
807|Statistical Methodology For Non-Inferiority Trials|Topic|R Software|Topic|RELATED_TO
808|Optimal Design Of A Phase I Cancer Trial|Topic|Approximate Dynamic Programming And Its Applications To The Design Of Phase I Cancer Trials|Paper|DISCUSSES
808|Approximate Dynamic Programming And Its Applications To The Design Of Phase I Cancer Trials|Paper|Treatment Design|Topic|RELATED_TO
808|Approximate Dynamic Programming And Its Applications To The Design Of Phase I Cancer Trials|Paper|Learning Design|Topic|RELATED_TO
808|Treatment Design|Topic|Babb Et Al.'S Escalation With Overdose Control|Topic|RELATED_TO
808|Learning Design|Topic|Haines Et Al.'S $C$-Optimal Design|Topic|RELATED_TO
808|Optimal Design Of A Phase I Cancer Trial|Topic|Bayesian Optimal Design|Topic|RELATED_TO
808|Optimal Design Of A Phase I Cancer Trial|Topic|Phase I Trials|Topic|RELATED_TO
808|Approximate Dynamic Programming And Its Applications To The Design Of Phase I Cancer Trials|Paper|Simulation Study|Topic|DISCUSSES
808|Approximate Dynamic Programming And Its Applications To The Design Of Phase I Cancer Trials|Paper|Nonparametric Step-Up/Down Schemes|Topic|RELATED_TO
808|Approximate Dynamic Programming And Its Applications To The Design Of Phase I Cancer Trials|Paper|Bayesian Parametric Model|Topic|RELATED_TO
809|Bayesian Hypothesis Assessment In Two-Arm Trials Using Relative Belief Ratios|Paper|Saman Muthukumarana|Author|AUTHORED
809|Bayesian Hypothesis Assessment In Two-Arm Trials Using Relative Belief Ratios|Paper|Michael Evans|Author|AUTHORED
810|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|Critically Ill Patients|Topic|DISCUSSES
810|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|Treatment|Topic|DISCUSSES
810|Hospital Monitoring Devices|Topic|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|RELATED_TO
810|Spontaneous Breathing Trial|Topic|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|RELATED_TO
810|Spontaneous Breathing Trial|Topic|Critically Ill Patients|Topic|RELATED_TO
810|Personalized Critical Care|Topic|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|RELATED_TO
810|Heart Rate Response|Topic|Spontaneous Breathing Trial|Topic|RELATED_TO
810|Man Chen|Author|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|AUTHORED
810|Liang Ren Niestemski|Author|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|AUTHORED
810|Robert Prevost|Author|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|AUTHORED
810|Michael Mcrae|Author|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|AUTHORED
810|Sharath Cholleti|Author|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|AUTHORED
810|Gabriel Najarro|Author|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|AUTHORED
810|Timothy G. Buchman|Author|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|AUTHORED
810|Michael W. Deem|Author|Non-Equilibrium Fluctuation Dissipation Theorem|Topic|AUTHORED
811|Clinical Trial|Topic|Treatment Effect|Topic|RELATED_TO
811|Treatment Effect|Topic|Odds Ratio|Topic|RELATED_TO
811|Odds Ratio|Topic|Logistic Regression|Topic|RELATED_TO
811|Logistic Regression|Topic|J. N. S. Matthews|Author|AUTHORED
811|Logistic Regression|Topic|Nuri H. Badi|Author|AUTHORED
812|Targeted Therapies On The Basis Of Genomic Aberrations Analysis|Topic|Cancer Prognosis And Treatment|Topic|RELATED_TO
812|Adaptive Bayesian Clinical Trial Design|Topic|Cancer Prognosis And Treatment|Topic|RELATED_TO
812|Yanxun Xu|Author|Adaptive Bayesian Clinical Trial Design|Topic|AUTHORED
812|Peter Mueller|Author|Adaptive Bayesian Clinical Trial Design|Topic|AUTHORED
812|Apostolia M Tsimberidou|Author|Adaptive Bayesian Clinical Trial Design|Topic|AUTHORED
812|Donald Berry|Author|Adaptive Bayesian Clinical Trial Design|Topic|AUTHORED
813|Interval-Based Dose-Finding Designs|Paper|Idesigns|Topic|DISCUSSES
813|Interval-Based Dose-Finding Designs|Paper|Ib-Designs|Topic|DISCUSSES
813|Idesigns|Topic|Tpi|Topic|RELATED_TO
813|Idesigns|Topic|Mtpi|Topic|RELATED_TO
813|Idesigns|Topic|Mtpi-2|Topic|RELATED_TO
813|Ib-Designs|Topic|Ccd|Topic|RELATED_TO
813|Ib-Designs|Topic|Boin|Topic|RELATED_TO
813|Interval-Based Dose-Finding Designs|Paper|Crm|Topic|DISCUSSES
813|Interval-Based Dose-Finding Designs|Paper|3+3|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Multi-Arm Multi-Stage Trial Designs|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Drug Development Process|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Patient Variance In Response|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|T-Test Statistics|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Quantile Substitution Procedure|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Familywise Error-Rate|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Monte Carlo Simulation|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Group Size|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Stopping Boundaries|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Optimality Criteria|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|R Code|Topic|DISCUSSES
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Michael Grayling|Author|AUTHORED
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|James Wason|Author|AUTHORED
814|Optimised Multi-Arm Multi-Stage Clinical Trial Design For Unknown Variance|Paper|Adrian Mander|Author|AUTHORED
815|Noniterative Sample Size Procedure|Topic|T Distribution|Topic|RELATED_TO
815|Noniterative Sample Size Procedure|Topic|Guenther'S Approach|Topic|RELATED_TO
815|Noniterative Sample Size Procedure|Topic|Ancova|Topic|RELATED_TO
815|Noniterative Sample Size Procedure|Topic|Mmrm|Topic|RELATED_TO
815|Noniterative Sample Size Procedure|Topic|Superiority Tests|Topic|RELATED_TO
815|Noniterative Sample Size Procedure|Topic|Noninferiority Tests|Topic|RELATED_TO
815|Noniterative Sample Size Procedure|Topic|Equivalence Tests|Topic|RELATED_TO
815|Noniterative Sample Size Procedure|Topic|Yongqiang Tang|Author|AUTHORED
816|Sample Size Determination In Superiority Or Non-Inferiority Clinical Trials With Time-To-Event Data Under Exponential, Weibull And Gompertz Distributions|Paper|Dong Han|Author|AUTHORED
816|Sample Size Determination In Superiority Or Non-Inferiority Clinical Trials With Time-To-Event Data Under Exponential, Weibull And Gompertz Distributions|Paper|Yawen Hou|Author|AUTHORED
816|Sample Size Determination In Superiority Or Non-Inferiority Clinical Trials With Time-To-Event Data Under Exponential, Weibull And Gompertz Distributions|Paper|Zheng Chen|Author|AUTHORED
817|Case-Mix Heterogeneity|Topic|Meta-Analyses|Topic|RELATED_TO
817|Treatment Effect|Topic|Meta-Analyses|Topic|RELATED_TO
817|Individual Patient Data (Ipd)|Topic|Treatment Effect|Topic|RELATED_TO
817|Outcome Regression (Ocr)|Topic|Treatment Effect|Topic|RELATED_TO
817|Inverse Probability Weighting (Ipw)|Topic|Treatment Effect|Topic|RELATED_TO
817|Random-Effect Meta-Analysis Models|Topic|Meta-Analyses|Topic|RELATED_TO
817|Tat-Thang Vo|Author|Random-Effect Meta-Analysis Models|Topic|AUTHORED
817|Raphael Porcher|Author|Random-Effect Meta-Analysis Models|Topic|AUTHORED
817|Anna Chaimani|Author|Random-Effect Meta-Analysis Models|Topic|AUTHORED
817|Stijn Vansteelandt|Author|Random-Effect Meta-Analysis Models|Topic|AUTHORED
818|Dose-Finding Studies|Topic|Dose-Limiting Toxicity (Dlt)|Topic|RELATED_TO
818|Oncology Dose-Finding Trials|Topic|Advanced Soft-Tissue Sarcoma|Topic|RELATED_TO
818|Time-To-Event Continual Reassessment Method (Tite-Crm)|Topic|Dose-Limiting Toxicity (Dlt)|Topic|RELATED_TO
818|Lucie Biard|Author|Simulation Study|Topic|AUTHORED
818|Bin Cheng|Author|Simulation Study|Topic|AUTHORED
818|Gulam A. Manji|Author|Simulation Study|Topic|AUTHORED
818|Shing M. Lee|Author|Simulation Study|Topic|AUTHORED
819|Interim Monitoring In Sequential Multiple Assignment Randomized Trials|Paper|Sequential Multiple Assignment Randomized Trial|Topic|RELATED_TO
820|Hierarchical Random Effect Models|Topic|Population Parameters|Topic|RELATED_TO
820|Hierarchical Random Effect Models|Topic|Treatment Effects|Topic|RELATED_TO
820|Hierarchical Random Effect Models|Topic|Group Differences|Topic|RELATED_TO
820|Optimal Design|Topic|Population Parameters|Topic|RELATED_TO
820|Individual Predictions|Topic|Multi-Center Trials|Topic|RELATED_TO
820|Balanced Design|Topic|Treatment Allocation|Topic|RELATED_TO
820|Maryna Prus|Author|Optimal Design In Hierarchical Models With Application In Multi-Center Trials|Paper|AUTHORED
820|Norbert Benda|Author|Optimal Design In Hierarchical Models With Application In Multi-Center Trials|Paper|AUTHORED
820|Rainer Schwabe|Author|Optimal Design In Hierarchical Models With Application In Multi-Center Trials|Paper|AUTHORED
821|Design Aspects Of Covid-19 Treatment Trials: Improving Probability And Time Of Favourable Events|Paper|Jan Beyersmann|Author|AUTHORED
821|Design Aspects Of Covid-19 Treatment Trials: Improving Probability And Time Of Favourable Events|Paper|Tim Friede|Author|AUTHORED
821|Design Aspects Of Covid-19 Treatment Trials: Improving Probability And Time Of Favourable Events|Paper|Claudia Schmoor|Author|AUTHORED
821|Covid-19 Treatment Trials|Topic|Sars-Cov-2|Topic|RELATED_TO
822|Dose-Finding Clinical Trials In Oncology|Topic|Maximum Tolerated Dose (Mtd)|Topic|RELATED_TO
822|Dose-Finding Clinical Trials In Oncology|Topic|Dose-Limiting Toxicities (Dlts)|Topic|RELATED_TO
822|Bayesian Cumulative Modeling Approach|Topic|Dice (Dose-Finding Cumulative)|Topic|RELATED_TO
822|Dice (Dose-Finding Cumulative)|Topic|Time-To-Event Continual Reassessment Method (Tite-Crm)|Topic|RELATED_TO
822|Dice (Dose-Finding Cumulative)|Topic|Moreno Ursino|Author|AUTHORED
822|Dice (Dose-Finding Cumulative)|Topic|Lucie Biard|Author|AUTHORED
822|Dice (Dose-Finding Cumulative)|Topic|Sylvie Chevret|Author|AUTHORED
823|Ci3+3 Design For Dual-Agent Combination Dose-Finding Clinical Trials|Paper|Shijie Yuan|Author|AUTHORED
823|Ci3+3 Design For Dual-Agent Combination Dose-Finding Clinical Trials|Paper|Tianjian Zhou|Author|AUTHORED
823|Ci3+3 Design For Dual-Agent Combination Dose-Finding Clinical Trials|Paper|Yawen Lin|Author|AUTHORED
823|Ci3+3 Design For Dual-Agent Combination Dose-Finding Clinical Trials|Paper|Yuan Ji|Author|AUTHORED
824|Estimating The Distribution Of Ratio Of Paired Event Times In Phase Ii Oncology Trials|Paper|Li Chen|Author|AUTHORED
824|Estimating The Distribution Of Ratio Of Paired Event Times In Phase Ii Oncology Trials|Paper|Mark Burkard|Author|AUTHORED
824|Estimating The Distribution Of Ratio Of Paired Event Times In Phase Ii Oncology Trials|Paper|Jianrong Wu|Author|AUTHORED
824|Estimating The Distribution Of Ratio Of Paired Event Times In Phase Ii Oncology Trials|Paper|Jill M. Kolesar|Author|AUTHORED
824|Estimating The Distribution Of Ratio Of Paired Event Times In Phase Ii Oncology Trials|Paper|Chi Wang|Author|AUTHORED
825|Caden|Topic|Cvrs|Topic|RELATED_TO
826|Rct Duplicate Initiative|Topic|Franklin Et Al.|Author|AUTHORED
826|Statistical Matching Algorithm|Topic|Real-World Evidence (Rwe)|Topic|RELATED_TO
826|Statistical Matching Algorithm|Topic|Randomized Controlled Trials (Rcts)|Topic|RELATED_TO
826|Hormone Replacement Therapy (Hrt)|Topic|Women'S Health Initiative (Whi)|Topic|RELATED_TO
826|R Package Match2C|Topic|Statistical Matching Algorithm|Topic|RELATED_TO
826|Bo Zhang|Author|Statistical Matching Algorithm|Topic|AUTHORED
827|Borrowing Of Information From Historical Or External Data|Topic|Precision Medicine|Topic|RELATED_TO
827|Borrowing Of Information From Historical Or External Data|Topic|Bayesian Approaches|Topic|RELATED_TO
827|Borrowing Of Information From Historical Or External Data|Topic|Frequentist Operating Characteristics|Topic|RELATED_TO
827|Frequentist Operating Characteristics|Topic|Type I Error|Topic|RELATED_TO
827|Frequentist Operating Characteristics|Topic|Power|Topic|RELATED_TO
827|Annette Kopp-Schneider|Author|Borrowing Of Information From Historical Or External Data|Topic|AUTHORED
827|Manuel Wiesenfarth|Author|Borrowing Of Information From Historical Or External Data|Topic|AUTHORED
827|Leonhard Held|Author|Borrowing Of Information From Historical Or External Data|Topic|AUTHORED
827|Silvia Calderazzo|Author|Borrowing Of Information From Historical Or External Data|Topic|AUTHORED
828|Basket Trials|Topic|Bayesian Methods|Topic|DISCUSSES
828|Fujikawa Et Al. (2020)|Author|Bayesian Methods|Topic|AUTHORED
828|Fujikawa Et Al. (2020)|Author|Power Priors|Topic|DISCUSSES
828|Lukas Baumann|Author|Basket Trials|Topic|AUTHORED
828|Lukas Sauer|Author|Basket Trials|Topic|AUTHORED
828|Meinhard Kieser|Author|Basket Trials|Topic|AUTHORED
829|Mci3+3|Topic|Jiaxin Liu|Author|AUTHORED
829|Mci3+3|Topic|Shijie Yuan|Author|AUTHORED
829|Mci3+3|Topic|Qiqi Deng|Author|AUTHORED
829|Mci3+3|Topic|Yuan Ji|Author|AUTHORED
830|Mediation Analysis In Sw-Crts|Topic|R Package Mediateswcrt|Topic|RELATED_TO
831|Tw-Bag|Paper|Diffusion Weighted Imaging|Topic|DISCUSSES
831|Tw-Bag|Paper|Diffusion Tensor Imaging|Topic|DISCUSSES
831|Tw-Bag|Paper|Human Connectome Project|Topic|RELATED_TO
831|Tw-Bag|Paper|Zihao Tang|Author|AUTHORED
831|Tw-Bag|Paper|Xinyi Wang|Author|AUTHORED
831|Tw-Bag|Paper|Lihaowen Zhu|Author|AUTHORED
831|Tw-Bag|Paper|Mariano Cabezas|Author|AUTHORED
831|Tw-Bag|Paper|Dongnan Liu|Author|AUTHORED
831|Tw-Bag|Paper|Michael Barnett|Author|AUTHORED
831|Tw-Bag|Paper|Weidong Cai|Author|AUTHORED
831|Tw-Bag|Paper|Chengyu Wang|Author|AUTHORED
832|Blended Survival Curves: A New Approach To Extrapolation For Time-To-Event Outcomes From Clinical Trial In Health Technology Assessment|Paper|Zhaojing Che|Author|AUTHORED
832|Blended Survival Curves: A New Approach To Extrapolation For Time-To-Event Outcomes From Clinical Trial In Health Technology Assessment|Paper|Nathan Green|Author|AUTHORED
832|Blended Survival Curves: A New Approach To Extrapolation For Time-To-Event Outcomes From Clinical Trial In Health Technology Assessment|Paper|Gianluca Baio|Author|AUTHORED
832|Blended Survival Curves: A New Approach To Extrapolation For Time-To-Event Outcomes From Clinical Trial In Health Technology Assessment|Paper|Chronic Lymphocytic Leukemia|Topic|RELATED_TO
833|Bayesian Approach For Exploratory Clinical Trials|Topic|John Whitehead|Author|AUTHORED
833|Bayesian Approach For Exploratory Clinical Trials|Topic|Faye Cleary|Author|AUTHORED
833|Bayesian Approach For Exploratory Clinical Trials|Topic|Amanda Turner|Author|AUTHORED
834|Bayesian Meta-Analysis Of Multiple Continuous Treatments: An Application To Antipsychotic Drugs|Paper|Jacob Spertus|Author|AUTHORED
834|Bayesian Meta-Analysis Of Multiple Continuous Treatments: An Application To Antipsychotic Drugs|Paper|Marcela Horvitz-Lennon|Author|AUTHORED
834|Bayesian Meta-Analysis Of Multiple Continuous Treatments: An Application To Antipsychotic Drugs|Paper|Sharon-Lise Normand|Author|AUTHORED
834|Paliperidone|Topic|Schizophrenia|Topic|RELATED_TO
834|Risperidone|Topic|Schizophrenia|Topic|RELATED_TO
834|Olanzapine|Topic|Schizophrenia|Topic|RELATED_TO
835|Robust Optimal Design Of Two-Armed Trials With Side Information|Paper|Personalized Medicine|Topic|DISCUSSES
835|Robust Optimal Design Of Two-Armed Trials With Side Information|Paper|Clinical Trials|Topic|DISCUSSES
835|Robust Optimal Design Of Two-Armed Trials With Side Information|Paper|Patient Covariates|Topic|DISCUSSES
835|Robust Optimal Design Of Two-Armed Trials With Side Information|Paper|Robust Optimization|Topic|DISCUSSES
836|Randomized Clinical Trials|Topic|Chance Imbalance In Baseline Characteristics|Topic|RELATED_TO
836|Regression Adjustment|Topic|Analysis Of Covariance (Ancova)|Topic|DISCUSSES
836|Inverse Probability Weighting (Ipw)|Topic|Propensity Scores|Topic|DISCUSSES
836|Overlap Weighting (Ow)|Topic|Propensity Scores|Topic|DISCUSSES
836|Best Apnea Interventions For Research (Bestair)|Topic|Overlap Weighting (Ow)|Topic|DISCUSSES
836|Shuxi Zeng|Author|Propensity Score Weighting For Covariate Adjustment In Randomized Clinical Trials|Paper|AUTHORED
836|Fan Li|Author|Propensity Score Weighting For Covariate Adjustment In Randomized Clinical Trials|Paper|AUTHORED
836|Rui Wang|Author|Propensity Score Weighting For Covariate Adjustment In Randomized Clinical Trials|Paper|AUTHORED
836|Psweight|Topic|Propensity Score Weighting For Covariate Adjustment In Randomized Clinical Trials|Paper|RELATED_TO
837|Incorporating Historical Information To Improve Phase I Clinical Trial Designs|Paper|Model-Based Designs|Topic|DISCUSSES
837|Incorporating Historical Information To Improve Phase I Clinical Trial Designs|Paper|Model-Assisted Designs|Topic|DISCUSSES
837|Incorporating Historical Information To Improve Phase I Clinical Trial Designs|Paper|Skeleton Approach|Topic|DISCUSSES
837|Incorporating Historical Information To Improve Phase I Clinical Trial Designs|Paper|Bayesian Optimal Interval|Topic|DISCUSSES
837|Incorporating Historical Information To Improve Phase I Clinical Trial Designs|Paper|Continuous Reassessment Method|Topic|DISCUSSES
837|Incorporating Historical Information To Improve Phase I Clinical Trial Designs|Paper|Modified Toxicity Probability Interval|Topic|DISCUSSES
837|Incorporating Historical Information To Improve Phase I Clinical Trial Designs|Paper|Prior Effective Sample Size|Topic|DISCUSSES
837|Incorporating Historical Information To Improve Phase I Clinical Trial Designs|Paper|Dose Limiting Toxicity|Topic|DISCUSSES
838|Randomized Clinical Trials|Topic|Test Treatment|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Control Treatment|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Patient Heterogeneity|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Statistical Approaches|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Regulatory Approval|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Safe And Efficacious Therapies|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Baseline Covariates|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Analysis Plan|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Survival Times|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Noise Covariates|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Elastic Net Cox Regression|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Conditional Inference Tree Algorithm|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Risk Strata|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Treatment Comparison|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Stratum-Level Results|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Statistical Inference|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|5-Step Stratified Testing And Amalgamation Routine|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|5-Star|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Logrank Test|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Personalized Medicine|Topic|RELATED_TO
838|Randomized Clinical Trials|Topic|Fivestar R Package|Topic|RELATED_TO
838|Fivestar R Package|Topic|Https://Github.Com/Rmarceauwest/Fivestar|Paper|RELATED_TO
838|Devan V. Mehrotra|Author|Https://Github.Com/Rmarceauwest/Fivestar|Paper|AUTHORED
838|Rachel Marceau West|Author|Https://Github.Com/Rmarceauwest/Fivestar|Paper|AUTHORED
839|Randomized Controlled Trials|Topic|Estimand|Topic|RELATED_TO
839|Intercurrent Events|Topic|Estimand|Topic|RELATED_TO
839|International Council For Harmonisation E9 (R1)|Topic|Treatment Policy|Topic|RELATED_TO
839|International Council For Harmonisation E9 (R1)|Topic|Hypothetical|Topic|RELATED_TO
839|International Council For Harmonisation E9 (R1)|Topic|Composite Variable|Topic|RELATED_TO
839|International Council For Harmonisation E9 (R1)|Topic|While On Treatment|Topic|RELATED_TO
839|International Council For Harmonisation E9 (R1)|Topic|Principal Stratum|Topic|RELATED_TO
839|Yongming Qu|Author|Estimand|Topic|AUTHORED
839|Linda Shurzinske|Author|Estimand|Topic|AUTHORED
839|Shanthi Sethuraman|Author|Estimand|Topic|AUTHORED
840|Breakthroughs In Cancer Biology|Topic|Therapies That Target Specific Pathways In Tumor Cells|Topic|RELATED_TO
840|Clinical Trial Design|Topic|Master Protocols|Topic|RELATED_TO
840|Subpopulation Heterogeneity|Topic|Statistical Designs Of Master Protocols|Topic|RELATED_TO
840|Statistical Designs Of Master Protocols|Topic|Master Protocols|Topic|RELATED_TO
840|Alexander M. Kaizer|Author|Statistical Designs Of Master Protocols|Topic|AUTHORED
840|Joseph S. Koopmeiners|Author|Statistical Designs Of Master Protocols|Topic|AUTHORED
840|Nan Chen|Author|Statistical Designs Of Master Protocols|Topic|AUTHORED
840|Brian P. Hobbs|Author|Statistical Designs Of Master Protocols|Topic|AUTHORED
841|Toward Better Practice Of Covariate Adjustment In Analyzing Randomized Clinical Trials|Paper|Ting Ye|Author|AUTHORED
841|Toward Better Practice Of Covariate Adjustment In Analyzing Randomized Clinical Trials|Paper|Jun Shao|Author|AUTHORED
841|Toward Better Practice Of Covariate Adjustment In Analyzing Randomized Clinical Trials|Paper|Yanyao Yi|Author|AUTHORED
841|Toward Better Practice Of Covariate Adjustment In Analyzing Randomized Clinical Trials|Paper|Qingyuan Zhao|Author|AUTHORED
841|Toward Better Practice Of Covariate Adjustment In Analyzing Randomized Clinical Trials|Paper|Model-Assisted Approach|Topic|DISCUSSES
841|Toward Better Practice Of Covariate Adjustment In Analyzing Randomized Clinical Trials|Paper|Covariate Adjustment|Topic|DISCUSSES
841|Toward Better Practice Of Covariate Adjustment In Analyzing Randomized Clinical Trials|Paper|Statistical Efficiency|Topic|DISCUSSES
842|Patient-Level Health Economic Data|Topic|Technology Appraisal|Topic|RELATED_TO
842|Technology Appraisal|Topic|Resource Allocation Decisions|Topic|RELATED_TO
842|End Of Life Treatments|Topic|Cancer Treatments|Topic|RELATED_TO
842|Cancer Treatments|Topic|Partitioned Survival Analysis|Topic|RELATED_TO
842|Partitioned Survival Analysis|Topic|Health-Related Quality Of Life|Topic|RELATED_TO
842|Partitioned Survival Analysis|Topic|Survival Time|Topic|RELATED_TO
842|Health-Related Quality Of Life|Topic|Quality-Adjusted Survival|Topic|RELATED_TO
842|Resource Use Data|Topic|Health Records|Topic|RELATED_TO
842|Health Records|Topic|Cost Components|Topic|RELATED_TO
842|Bayesian Modelling|Topic|Health Economics|Topic|RELATED_TO
842|Bayesian Modelling|Topic|Statistical Literature|Topic|RELATED_TO
842|Bayesian Framework|Topic|Policymakers|Topic|RELATED_TO
842|Bayesian Framework|Topic|Decision-Making Process|Topic|RELATED_TO
842|Advanced Non-Small-Cell Lung Cancer|Topic|Bayesian Framework|Topic|RELATED_TO
842|Bayesian Framework|Topic|Andrea Gabrio|Author|AUTHORED
843|New Medicine|Topic|Quantitative Risk Metrics|Topic|RELATED_TO
843|Pharmaceutical Companies|Topic|Regulatory Approval|Topic|RELATED_TO
843|Probability Of Success (Pos)|Topic|Phase Ii|Topic|RELATED_TO
843|Phase Iib Studies|Topic|Probability Of Success (Pos)|Topic|RELATED_TO
843|Phase Iii Trials|Topic|Probability Of Success (Pos)|Topic|RELATED_TO
843|Accelerated Drug Development Pathways|Topic|Probability Of Success (Pos)|Topic|RELATED_TO
843|Lisa V Hampson|Author|New Medicine|Topic|AUTHORED
843|Björn Bornkamp|Author|New Medicine|Topic|AUTHORED
843|Björn Holzhauer|Author|New Medicine|Topic|AUTHORED
843|Joseph Kahn|Author|New Medicine|Topic|AUTHORED
843|Markus R Lange|Author|New Medicine|Topic|AUTHORED
843|Wen-Lin Luo|Author|New Medicine|Topic|AUTHORED
843|Giovanni Della Cioppa|Author|New Medicine|Topic|AUTHORED
843|Kelvin Stott|Author|New Medicine|Topic|AUTHORED
843|Steffen Ballerstedt|Author|New Medicine|Topic|AUTHORED
844|Studentized Permutation Method For Comparing Restricted Mean Survival Times With Small Sample From Randomized Trials|Paper|Marc Ditzhaus|Author|AUTHORED
844|Studentized Permutation Method For Comparing Restricted Mean Survival Times With Small Sample From Randomized Trials|Paper|Menggang Yu|Author|AUTHORED
844|Studentized Permutation Method For Comparing Restricted Mean Survival Times With Small Sample From Randomized Trials|Paper|Jin Xu|Author|AUTHORED
844|Studentized Permutation Method For Comparing Restricted Mean Survival Times With Small Sample From Randomized Trials|Paper|Restricted Mean Survival Time (Rmst)|Topic|RELATED_TO
844|Studentized Permutation Method For Comparing Restricted Mean Survival Times With Small Sample From Randomized Trials|Paper|Cancer Immunotherapy Clinical Trials|Topic|RELATED_TO
845|Determination Of Posterior Probability For Go-No-Go Decision And Predictive Power|Topic|Probability Of Success Measures|Topic|RELATED_TO
845|Probability Of Success Measures|Topic|Frequentist And Bayesian Paradigms|Topic|RELATED_TO
845|Probability Of Success Measures|Topic|Conditional Power (Cp)|Topic|RELATED_TO
845|Probability Of Success Measures|Topic|Predictive Power Of Success (Ppos)|Topic|RELATED_TO
845|Probability Of Success Measures|Topic|Probability Of Success (Pos)|Topic|RELATED_TO
845|Madan G. Kundu|Author|Determination Of Posterior Probability For Go-No-Go Decision And Predictive Power|Topic|AUTHORED
845|Sandipan Samanta|Author|Determination Of Posterior Probability For Go-No-Go Decision And Predictive Power|Topic|AUTHORED
845|Shoubhik Mondal|Author|Determination Of Posterior Probability For Go-No-Go Decision And Predictive Power|Topic|AUTHORED
845|Longcart Package|Topic|Conditional Power (Cp)|Topic|RELATED_TO
845|R Shiny App|Topic|Https://Ppos.Herokuapp.Com/|Topic|RELATED_TO
846|Hazard Ratio|Topic|Treatment Effect|Topic|RELATED_TO
846|Composite Endpoint|Topic|Hazard Ratio|Topic|RELATED_TO
846|Zodiac Trial|Topic|Composite Endpoint|Topic|RELATED_TO
846|Jordi Cortés Martínez|Author|Zodiac Trial|Topic|AUTHORED
846|Moisès Gómez Mateu|Author|Zodiac Trial|Topic|AUTHORED
846|Kyungmann Kim|Author|Zodiac Trial|Topic|AUTHORED
846|Guadalupe Gómez Melis|Author|Zodiac Trial|Topic|AUTHORED
847|Kaplan-Meier Estimator|Topic|Sample Size Calculation|Topic|RELATED_TO
847|Sample Size Calculation|Topic|Small Sample Properties|Topic|DISCUSSES
847|Sample Size Calculation|Topic|Arcsine Square-Root Transformation|Topic|RELATED_TO
847|Kengo Nagashima|Author|Sample Size Calculation|Topic|AUTHORED
847|Hisashi Noma|Author|Sample Size Calculation|Topic|AUTHORED
847|Yasunori Sato|Author|Sample Size Calculation|Topic|AUTHORED
847|Masahiko Gosho|Author|Sample Size Calculation|Topic|AUTHORED
848|Causal Inference Methods|Topic|Pharmaceutical Drug Development|Topic|RELATED_TO
848|E9 Guideline|Topic|International Council For Harmonisation|Topic|RELATED_TO
848|Instrumental Variables Methods|Topic|Causal Inference Methods|Topic|RELATED_TO
848|Graphical Diagrams|Topic|Causal Inference Methods|Topic|RELATED_TO
848|Potential Outcomes|Topic|Causal Inference Methods|Topic|RELATED_TO
848|Treatment Policy|Topic|Hypothetical Estimand Strategies|Topic|RELATED_TO
848|Principal Stratum|Topic|Hypothetical Estimand Strategies|Topic|RELATED_TO
848|Standard Regression Models|Topic|Causal Inference Methods|Topic|RELATED_TO
848|Sensitivity Analyses|Topic|Causal Inference Methods|Topic|RELATED_TO
848|Simulated Data|Topic|Pharmaceutical Drug Development|Topic|RELATED_TO
848|Jack Bowden|Author|Causal Inference Methods|Topic|AUTHORED
848|Bjoern Bornkamp|Author|Causal Inference Methods|Topic|AUTHORED
848|Ekkehard Glimm|Author|Causal Inference Methods|Topic|AUTHORED
848|Frank Bretz|Author|Causal Inference Methods|Topic|AUTHORED
849|Sdf-Bayes|Paper|Phase I Clinical Trials|Topic|DISCUSSES
850|Nonparametric Efficient Estimator|Topic|Threshold-Response Function|Topic|RELATED_TO
850|Sequential Regression Estimator|Topic|Threshold-Response Function|Topic|RELATED_TO
850|Inverse-Probability-Weighting|Topic|Nonparametric Efficient Estimator|Topic|RELATED_TO
850|Lars Van Der Laan|Author|Nonparametric Efficient Estimator|Topic|AUTHORED
850|Wenbo Zhang|Author|Nonparametric Efficient Estimator|Topic|AUTHORED
850|Peter B. Gilbert|Author|Nonparametric Efficient Estimator|Topic|AUTHORED
850|Dengue Vaccine Trials|Topic|Threshold-Response Function|Topic|DISCUSSES
851|Publication Bias Adjustment In Meta-Analysis|Topic|Ao Huang|Author|AUTHORED
851|Publication Bias Adjustment In Meta-Analysis|Topic|Kosuke Morikawa|Author|AUTHORED
851|Publication Bias Adjustment In Meta-Analysis|Topic|Tim Friede|Author|AUTHORED
851|Publication Bias Adjustment In Meta-Analysis|Topic|Satoshi Hattori|Author|AUTHORED
852|Intercurrent Events|Topic|Randomized Trials|Topic|RELATED_TO
852|Randomized Trials|Topic|Treatment Effects|Topic|RELATED_TO
852|Estimand|Topic|Decision Maker|Topic|RELATED_TO
852|Estimand|Topic|Drug Developer|Topic|RELATED_TO
852|Research Question|Topic|Estimand|Topic|RELATED_TO
852|Mats J. Stensrud|Author|Estimand|Topic|AUTHORED
852|Oliver Dukes|Author|Estimand|Topic|AUTHORED
852|Conditional Effects|Topic|Estimand|Topic|RELATED_TO
852|Sequential Regime Effects|Topic|Estimand|Topic|RELATED_TO
852|Separable Effects|Topic|Estimand|Topic|RELATED_TO
852|Principal Stratum Effects|Topic|Estimand|Topic|RELATED_TO
853|2X2 Cross-Over Study|Paper|Principal Causal Effect|Topic|DISCUSSES
853|2X2 Cross-Over Study|Paper|Monotonicity|Topic|DISCUSSES
853|2X2 Cross-Over Study|Paper|Principal Ignorability|Topic|DISCUSSES
853|2X2 Cross-Over Study|Paper|Cross-World Principal Ignorability|Topic|DISCUSSES
853|2X2 Cross-Over Study|Paper|Cross-World Principal Stratum Independence|Topic|DISCUSSES
853|2X2 Cross-Over Study|Paper|Yongming Qu|Author|AUTHORED
853|2X2 Cross-Over Study|Paper|Ilya Lipkovich|Author|AUTHORED
853|2X2 Cross-Over Study|Paper|Stephen J. Ruberg|Author|AUTHORED
854|Predictive Biomarker Discovery|Topic|Precision Medicine|Topic|RELATED_TO
854|Predictive Biomarker Discovery|Topic|Treatment Rule Estimation|Topic|RELATED_TO
854|False Discovery Rates|Topic|Treatment Rule Estimation|Topic|RELATED_TO
854|Variable Importance Parameter|Topic|Predictive Biomarker Discovery|Topic|RELATED_TO
854|Nonparametric Inference Procedure|Topic|Variable Importance Parameter|Topic|RELATED_TO
854|Tumor Gene Expression Data|Topic|Metastatic Renal Cell Carcinoma|Topic|RELATED_TO
854|Unicate R Package|Topic|Predictive Biomarker Discovery|Topic|RELATED_TO
854|Philippe Boileau|Author|A Flexible Approach For Predictive Biomarker Discovery|Paper|AUTHORED
854|Nina Ting Qi|Author|A Flexible Approach For Predictive Biomarker Discovery|Paper|AUTHORED
854|Mark J. Van Der Laan|Author|A Flexible Approach For Predictive Biomarker Discovery|Paper|AUTHORED
854|Sandrine Dudoit|Author|A Flexible Approach For Predictive Biomarker Discovery|Paper|AUTHORED
854|Ning Leng|Author|A Flexible Approach For Predictive Biomarker Discovery|Paper|AUTHORED
855|Whole-Body Model Of The Metabolism In Man|Topic|Metabolic Networks|Topic|RELATED_TO
855|Whole-Body Model Of The Metabolism In Man|Topic|Carbohydrates|Topic|RELATED_TO
855|Whole-Body Model Of The Metabolism In Man|Topic|Proteins|Topic|RELATED_TO
855|Whole-Body Model Of The Metabolism In Man|Topic|Lipids|Topic|RELATED_TO
855|Whole-Body Model Of The Metabolism In Man|Topic|7 Organs|Topic|RELATED_TO
855|Whole-Body Model Of The Metabolism In Man|Topic|16 Metabolites|Topic|RELATED_TO
855|Whole-Body Model Of The Metabolism In Man|Topic|31 Enzymatic Reactions|Topic|RELATED_TO
855|31 Enzymatic Reactions|Topic|Michaelis-Menten Kinetics|Topic|RELATED_TO
855|31 Enzymatic Reactions|Topic|Insulin|Topic|RELATED_TO
855|31 Enzymatic Reactions|Topic|Glucagon|Topic|RELATED_TO
855|Whole-Body Model Of The Metabolism In Man|Topic|Glycogen|Topic|RELATED_TO
855|Whole-Body Model Of The Metabolism In Man|Topic|Muscle Protein|Topic|RELATED_TO
855|Whole-Body Model Of The Metabolism In Man|Topic|Lipid Droplets|Topic|RELATED_TO
855|Whole-Body Model Of The Metabolism In Man|Topic|Virtual Clinical Trials|Topic|RELATED_TO
855|Virtual Clinical Trials|Topic|Medicine Development|Topic|RELATED_TO
855|Virtual Clinical Trials|Topic|Control Algorithms|Topic|RELATED_TO
855|Peter Emil Carstensen|Author|Whole-Body Model Of The Metabolism In Man|Topic|AUTHORED
855|Jacob Bendsen|Author|Whole-Body Model Of The Metabolism In Man|Topic|AUTHORED
855|Asbjørn Thode Reenberg|Author|Whole-Body Model Of The Metabolism In Man|Topic|AUTHORED
855|Tobias K. S. Ritschel|Author|Whole-Body Model Of The Metabolism In Man|Topic|AUTHORED
855|John Bagterp Jørgensen|Author|Whole-Body Model Of The Metabolism In Man|Topic|AUTHORED
856|Antihistamines|Topic|Bruno L. Travi|Author|AUTHORED
856|Antihistamines|Topic|Infectious Diseases|Topic|RELATED_TO
857|Quantification Of Follow-Up Time In Oncology Clinical Trials With A Time-To-Event Endpoint: Asking The Right Questions|Paper|Kaspar Rufibach|Author|AUTHORED
857|Quantification Of Follow-Up Time In Oncology Clinical Trials With A Time-To-Event Endpoint: Asking The Right Questions|Paper|Lynda Grinsted|Author|AUTHORED
857|Quantification Of Follow-Up Time In Oncology Clinical Trials With A Time-To-Event Endpoint: Asking The Right Questions|Paper|Jiang Li|Author|AUTHORED
857|Quantification Of Follow-Up Time In Oncology Clinical Trials With A Time-To-Event Endpoint: Asking The Right Questions|Paper|Hans-Jochen Weber|Author|AUTHORED
857|Quantification Of Follow-Up Time In Oncology Clinical Trials With A Time-To-Event Endpoint: Asking The Right Questions|Paper|Cheng Zheng|Author|AUTHORED
857|Quantification Of Follow-Up Time In Oncology Clinical Trials With A Time-To-Event Endpoint: Asking The Right Questions|Paper|Jiangxiu Zhou|Author|AUTHORED
858|Towards Optimal Use Of Surrogate Markers To Improve Power|Paper|Xuan Wang|Author|AUTHORED
858|Towards Optimal Use Of Surrogate Markers To Improve Power|Paper|Layla Parast|Author|AUTHORED
858|Towards Optimal Use Of Surrogate Markers To Improve Power|Paper|Lu Tian|Author|AUTHORED
858|Towards Optimal Use Of Surrogate Markers To Improve Power|Paper|Tianxi Cai|Author|AUTHORED
858|Towards Optimal Use Of Surrogate Markers To Improve Power|Paper|Surrogate Marker|Topic|RELATED_TO
858|Towards Optimal Use Of Surrogate Markers To Improve Power|Paper|Treatment Effect|Topic|RELATED_TO
858|Towards Optimal Use Of Surrogate Markers To Improve Power|Paper|Diabetes Prevention Program|Topic|RELATED_TO
859|Confirmatory Adaptive Group Sequential Designs For Clinical Trials With Multiple Time-To-Event Outcomes In Markov Models|Paper|Moritz Fabian Danzer|Author|AUTHORED
859|Confirmatory Adaptive Group Sequential Designs For Clinical Trials With Multiple Time-To-Event Outcomes In Markov Models|Paper|Andreas Faldum|Author|AUTHORED
859|Confirmatory Adaptive Group Sequential Designs For Clinical Trials With Multiple Time-To-Event Outcomes In Markov Models|Paper|Thorsten Simon|Author|AUTHORED
859|Confirmatory Adaptive Group Sequential Designs For Clinical Trials With Multiple Time-To-Event Outcomes In Markov Models|Paper|Barbara Hero|Author|AUTHORED
859|Confirmatory Adaptive Group Sequential Designs For Clinical Trials With Multiple Time-To-Event Outcomes In Markov Models|Paper|Rene Schmidt|Author|AUTHORED
860|Bayesian Hierarchical Mixture Cure Modelling Framework|Topic|Nathan Green|Author|AUTHORED
860|Bayesian Hierarchical Mixture Cure Modelling Framework|Topic|Murat Kurt|Author|AUTHORED
860|Bayesian Hierarchical Mixture Cure Modelling Framework|Topic|Andriy Moshyk|Author|AUTHORED
860|Bayesian Hierarchical Mixture Cure Modelling Framework|Topic|James Larkin|Author|AUTHORED
860|Bayesian Hierarchical Mixture Cure Modelling Framework|Topic|Gianluca Baio|Author|AUTHORED
860|Checkmate 067 Phase 3 Trial|Topic|Bayesian Hierarchical Mixture Cure Modelling Framework|Topic|RELATED_TO
861|Gene Therapies|Topic|Rare Genetic Defects|Topic|RELATED_TO
861|Gene Therapies|Topic|Long-Term Effectiveness|Topic|RELATED_TO
861|Long-Term Effectiveness|Topic|Bayesian Framework|Topic|RELATED_TO
861|Bayesian Framework|Topic|Long-Term Efficacy|Topic|RELATED_TO
861|Long-Term Efficacy|Topic|Factor Ix (Fix) Levels|Topic|RELATED_TO
861|Hemgenix|Paper|Fda-Approved Gene Therapy|Topic|RELATED_TO
861|Hemgenix|Paper|Severe Hemophilia B|Topic|RELATED_TO
861|Hemgenix|Paper|Phase 3 Study|Topic|RELATED_TO
861|Hemgenix|Paper|5-Year Fix Levels|Topic|RELATED_TO
861|Hemgenix|Paper|Posterior Convergence Properties|Topic|RELATED_TO
862|Adaptive Interventions|Topic|Clustered Adaptive Interventions (Cais)|Topic|RELATED_TO
862|Clustered Adaptive Interventions (Cais)|Topic|Clustered, Sequential Multiple-Assignment Randomized Trials (Csmarts)|Topic|RELATED_TO
862|Clustered, Sequential Multiple-Assignment Randomized Trials (Csmarts)|Topic|Finite-Sample Adjustment (Fsa) Methods|Topic|RELATED_TO
862|Finite-Sample Adjustment (Fsa) Methods|Topic|Adaptive School-Based Implementation Of Cbt (Asic) Study|Paper|DISCUSSES
863|Systematic Review|Paper|Immunotherapy|Topic|DISCUSSES
863|Systematic Review|Paper|Glioblastoma|Topic|DISCUSSES
863|Systematic Review|Paper|Radiogenomics|Topic|DISCUSSES
863|Systematic Review|Paper|Biomarkers|Topic|DISCUSSES
863|Systematic Review|Paper|Prajwal Ghimire|Author|AUTHORED
863|Systematic Review|Paper|Ben Kinnersley|Author|AUTHORED
863|Systematic Review|Paper|Golestan Karami|Author|AUTHORED
863|Systematic Review|Paper|Prabhu Arumugam|Author|AUTHORED
863|Systematic Review|Paper|Richard Houlston|Author|AUTHORED
863|Systematic Review|Paper|Keyoumars Ashkan|Author|AUTHORED
863|Systematic Review|Paper|Marc Modat|Author|AUTHORED
863|Systematic Review|Paper|Thomas C Booth|Author|AUTHORED
864|Adaptive Treatment Assignment Algorithms|Topic|Digital Health Intervention Clinical Trials|Topic|RELATED_TO
864|Causal Inference|Topic|Digital Health Intervention Clinical Trials|Topic|RELATED_TO
864|Statistical Analyses|Topic|Replicability|Topic|RELATED_TO
864|Replicable Bandit Algorithm|Topic|Statistical Analyses|Topic|RELATED_TO
864|Mobile Health Oral Health Self-Care Intervention|Topic|Replicable Bandit Algorithm|Topic|RELATED_TO
864|Kelly W. Zhang|Author|Replicable Bandit Algorithm|Topic|AUTHORED
864|Nowell Closser|Author|Replicable Bandit Algorithm|Topic|AUTHORED
864|Anna L. Trella|Author|Replicable Bandit Algorithm|Topic|AUTHORED
864|Susan A. Murphy|Author|Replicable Bandit Algorithm|Topic|AUTHORED
865|Artificial Intelligence-Based Decision Support Systems|Topic|Post-Hepatectomy Liver Failure|Topic|RELATED_TO
865|Post-Hepatectomy Liver Failure|Topic|Hepatocellular Carcinoma|Topic|RELATED_TO
865|Variational Autoencoder-Multilayer Perceptron Model|Topic|Post-Hepatectomy Liver Failure|Topic|RELATED_TO
865|Counterfactuals|Topic|Variational Autoencoder-Multilayer Perceptron Model|Topic|RELATED_TO
865|Layerwise Relevance Propagation|Topic|Variational Autoencoder-Multilayer Perceptron Model|Topic|RELATED_TO
865|Methodological Framework For Evaluating Explainability|Topic|Variational Autoencoder-Multilayer Perceptron Model|Topic|RELATED_TO
865|Xian Zhong|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Zohaib Salahuddin|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Yi Chen|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Henry C Woodruff|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Haiyi Long|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Jianyun Peng|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Nuwan Udawatte|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Roberto Casale|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Ayoub Mokhtari|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Xiaoer Zhang|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Jiayao Huang|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Qingyu Wu|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Li Tan|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Lili Chen|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Dongming Li|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Xiaoyan Xie|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Manxia Lin|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
865|Philippe Lambin|Author|Methodological Framework For Evaluating Explainability|Topic|AUTHORED
866|Response-Adaptive Design|Topic|Continuous Endpoints|Topic|RELATED_TO
866|Gianmarco Caruso|Author|Response-Adaptive Design|Topic|AUTHORED
866|Pavel Mozgunov|Author|Response-Adaptive Design|Topic|AUTHORED
866|Response-Adaptive Design|Topic|Phase Iia Proof-Of-Concept Oncology Clinical Trials|Topic|RELATED_TO
867|Robin|Topic|Abel Corrêa Dias|Author|AUTHORED
867|Robin|Topic|Viviane Pereira Moreira|Author|AUTHORED
867|Robin|Topic|João Luiz Dihl Comba|Author|AUTHORED
867|Robin|Topic|Cochrane Database Of Systematic Reviews|Topic|RELATED_TO
867|Robin|Topic|Pubmed|Topic|RELATED_TO
867|Robin|Topic|Robinext|Topic|RELATED_TO
867|Robin|Topic|Robingen|Topic|RELATED_TO
868|Information Borrowing In Bayesian Clinical Trials: Choice Of Tuning Parameters For The Robust Mixture Prior|Paper|Bayesian Framework|Topic|DISCUSSES
868|Information Borrowing In Bayesian Clinical Trials: Choice Of Tuning Parameters For The Robust Mixture Prior|Paper|Robust Mixture Prior|Topic|DISCUSSES
868|Information Borrowing In Bayesian Clinical Trials: Choice Of Tuning Parameters For The Robust Mixture Prior|Paper|Informative Prior Distributions|Topic|DISCUSSES
868|Information Borrowing In Bayesian Clinical Trials: Choice Of Tuning Parameters For The Robust Mixture Prior|Paper|Operating Characteristics|Topic|DISCUSSES
868|Information Borrowing In Bayesian Clinical Trials: Choice Of Tuning Parameters For The Robust Mixture Prior|Paper|Type I Error Rate|Topic|DISCUSSES
868|Information Borrowing In Bayesian Clinical Trials: Choice Of Tuning Parameters For The Robust Mixture Prior|Paper|Mse|Topic|DISCUSSES
869|External Data In Clinical Trials|Topic|Bayesian Inference|Topic|RELATED_TO
869|Heterogeneity|Topic|Clustering|Topic|RELATED_TO
869|Overlapping Clustering Index (Oci)|Topic|K-Means Algorithm|Topic|RELATED_TO
869|Overlapping Evidence Index (Oei)|Topic|K-Means Algorithm|Topic|RELATED_TO
869|K-Means Algorithm|Topic|Prior Synthesis Framework|Topic|RELATED_TO
869|Prior Synthesis Framework|Topic|Bayesian Clustering Map Priors|Topic|RELATED_TO
869|Xuetao Lu|Author|Bayesian Clustering Map Priors|Topic|AUTHORED
869|J. Jack Lee|Author|Bayesian Clustering Map Priors|Topic|AUTHORED
870|Ich E9 (R1) Estimands Framework|Topic|Causal Inference|Topic|RELATED_TO
870|Thomas Drury|Author|Ich E9 (R1) Estimands Framework|Topic|AUTHORED
870|Jonathan W. Bartlett|Author|Ich E9 (R1) Estimands Framework|Topic|AUTHORED
870|David Wright|Author|Ich E9 (R1) Estimands Framework|Topic|AUTHORED
870|Oliver N. Keene|Author|Ich E9 (R1) Estimands Framework|Topic|AUTHORED
871|Malignant Gliomas|Topic|Chemotherapy|Topic|RELATED_TO
871|Malignant Gliomas|Topic|Car-T Cells Therapy|Topic|RELATED_TO
871|Dmitry Sinelshchikov|Author|Mathematical Model|Topic|AUTHORED
871|Juan Belmonte-Beitia|Author|Mathematical Model|Topic|AUTHORED
871|Matteo Italia|Author|Mathematical Model|Topic|AUTHORED
871|Mathematical Model|Topic|Tumor Growth Rate|Topic|RELATED_TO
871|Mathematical Model|Topic|Tumor Immunosuppression|Topic|RELATED_TO
871|Mathematical Model|Topic|Survival Time|Topic|RELATED_TO
871|Mathematical Model|Topic|In Silico Trials|Topic|RELATED_TO
871|Mathematical Model|Topic|Optimal Protocols|Topic|RELATED_TO
872|Automatic Estimation Of Ulcerative Colitis Severity From Endoscopy Videos Using Ordinal Multi-Instance Learning|Paper|Ulcerative Colitis|Topic|DISCUSSES
872|Automatic Estimation Of Ulcerative Colitis Severity From Endoscopy Videos Using Ordinal Multi-Instance Learning|Paper|Mayo Endoscopic Subscore|Topic|DISCUSSES
872|Automatic Estimation Of Ulcerative Colitis Severity From Endoscopy Videos Using Ordinal Multi-Instance Learning|Paper|Evan Schwab|Author|AUTHORED
872|Automatic Estimation Of Ulcerative Colitis Severity From Endoscopy Videos Using Ordinal Multi-Instance Learning|Paper|Gabriela Oana Cula|Author|AUTHORED
872|Automatic Estimation Of Ulcerative Colitis Severity From Endoscopy Videos Using Ordinal Multi-Instance Learning|Paper|Kristopher Standish|Author|AUTHORED
872|Automatic Estimation Of Ulcerative Colitis Severity From Endoscopy Videos Using Ordinal Multi-Instance Learning|Paper|Stephen S. F. Yip|Author|AUTHORED
872|Automatic Estimation Of Ulcerative Colitis Severity From Endoscopy Videos Using Ordinal Multi-Instance Learning|Paper|Aleksandar Stojmirovic|Author|AUTHORED
872|Automatic Estimation Of Ulcerative Colitis Severity From Endoscopy Videos Using Ordinal Multi-Instance Learning|Paper|Louis Ghanem|Author|AUTHORED
872|Automatic Estimation Of Ulcerative Colitis Severity From Endoscopy Videos Using Ordinal Multi-Instance Learning|Paper|Christel Chehoud|Author|AUTHORED
873|Metastatic Clear Cell Renal Cell Carcinoma|Topic|Angiogenesis Inhibitors|Topic|RELATED_TO
873|Metastatic Clear Cell Renal Cell Carcinoma|Topic|Immune Checkpoint Inhibitors|Topic|RELATED_TO
873|Metastatic Clear Cell Renal Cell Carcinoma|Topic|Mtor Inhibitors|Topic|RELATED_TO
873|Metastatic Clear Cell Renal Cell Carcinoma|Topic|Hif2 Inhibitor|Topic|RELATED_TO
873|Angioscore|Topic|Deep Learning Model|Topic|RELATED_TO
873|Deep Learning Model|Topic|Angioscore|Topic|DISCUSSES
873|Deep Learning Model|Topic|Cd31|Topic|RELATED_TO
873|Jay Jasti|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Hua Zhong|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Vandana Panwar|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Vipul Jarmale|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Jeffrey Miyata|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Deyssy Carrillo|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Alana Christie|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Dinesh Rakheja|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Zora Modrusan|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Edward Ernest Kadel Iii|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Niha Beig|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Mahrukh Huseni|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|James Brugarolas|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Payal Kapur|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
873|Satwik Rajaram|Author|Histopathology Based Ai Model Predicts Anti-Angiogenic Therapy Response In Renal Cancer Clinical Trial|Paper|AUTHORED
874|Artificial Intelligence In Depression Medication Enhancement Study|Topic|Deep Learning Model|Topic|RELATED_TO
874|Deep Learning Model|Topic|Major Depressive Disorder|Topic|RELATED_TO
874|David Benrimoh|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Caitrin Armstrong|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Joseph Mehltretter|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Robert Fratila|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Kelly Perlman|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Sonia Israel|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Adam Kapelner|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Sagar V. Parikh|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Jordan F. Karp|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Katherine Heller|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Gustavo Turecki|Author|Artificial Intelligence In Depression Medication Enhancement Study|Topic|AUTHORED
874|Deep Learning Model|Topic|Escitalopram|Topic|RELATED_TO
875|Giorgio Parisi|Author|Introduction To Modern Immunology|Topic|AUTHORED
875|Giorgio Parisi|Author|Idiotypic Network Among Antibodies|Topic|AUTHORED
875|Giorgio Parisi|Author|Immunological Memory|Topic|AUTHORED
875|Giorgio Parisi|Author|Memory Capacity Model|Topic|AUTHORED
876|Hepatitis C Virus (Hcv) Coinfection|Topic|Hiv-Infected Patients|Topic|RELATED_TO
876|Hiv-Infected Patients|Topic|Highly Active Antiretroviral Therapy (Haart)|Topic|RELATED_TO
876|Highly Active Antiretroviral Therapy (Haart)|Topic|Hiv Dynamics|Topic|RELATED_TO
876|Hiv Dynamics|Topic|Aids Clinical Trials|Topic|RELATED_TO
876|Hiv Dynamics|Topic|Hiv Epidemiology Research Study (Hers)|Topic|RELATED_TO
876|Hiv Epidemiology Research Study (Hers)|Topic|Li Su|Author|AUTHORED
876|Hiv Epidemiology Research Study (Hers)|Topic|Joseph W. Hogan|Author|AUTHORED
877|Clinical Trial For Jaw Fractures|Paper|Principal Stratification|Topic|DISCUSSES
877|Clinical Trial For Jaw Fractures|Paper|Causal Effects|Topic|DISCUSSES
877|Clinical Trial For Jaw Fractures|Paper|Complier Average Causal Effect (Cace)|Topic|DISCUSSES
877|Clinical Trial For Jaw Fractures|Paper|Bayesian Perspective|Topic|DISCUSSES
877|Clinical Trial For Jaw Fractures|Paper|Markov Chain Monte Carlo|Topic|DISCUSSES
877|Clinical Trial For Jaw Fractures|Paper|Injury Severity|Topic|DISCUSSES
877|Clinical Trial For Jaw Fractures|Paper|Corwin M. Zigler|Author|AUTHORED
877|Clinical Trial For Jaw Fractures|Paper|Thomas R. Belin|Author|AUTHORED
878|Common Medical Conditions|Topic|Sleep Abnormalities|Topic|RELATED_TO
878|Patients With Medical Disorders|Topic|Poor Sleep Quality|Topic|RELATED_TO
878|Poor Sleep Quality|Topic|Healthy Individuals|Topic|RELATED_TO
878|Sleep/Wake Patterns|Topic|Personalized Digital Markers|Topic|RELATED_TO
878|Personalized Digital Markers|Topic|Objective Measurements|Topic|RELATED_TO
878|Personalized Digital Markers|Topic|Efficient Disease Management|Topic|RELATED_TO
878|Big Data Technologies|Topic|Advanced Analytics Methods|Topic|RELATED_TO
878|Advanced Analytics Methods|Topic|Clinical Research Processes|Topic|RELATED_TO
878|Digital Data|Topic|Clinical Trials|Topic|RELATED_TO
878|Actigraphy|Topic|Non-Invasive Activity Monitoring Method|Topic|RELATED_TO
878|Non-Invasive Activity Monitoring Method|Topic|Activities And Movement Disorders|Topic|RELATED_TO
878|Non-Invasive Activity Monitoring Method|Topic|Sleep/Wake Behavior|Topic|RELATED_TO
878|Cluster Headache Disorder|Topic|Wearable Device|Topic|RELATED_TO
878|Wearable Device|Topic|Clinical Trial|Topic|RELATED_TO
878|Deep Convolutional Neural Networks|Topic|Cnn|Topic|RELATED_TO
878|Cnn|Topic|Sequential Cnn|Topic|RELATED_TO
878|Cnn|Topic|Multi-Task Learning|Topic|RELATED_TO
878|Multi-Task Learning|Topic|Mtl Based Model|Topic|RELATED_TO
878|Sleep/Wake States|Topic|Falling Asleep|Topic|RELATED_TO
878|Sleep/Wake States|Topic|Siesta|Topic|RELATED_TO
878|Sleep/Wake Patterns|Topic|Cluster Headache Attacks|Topic|RELATED_TO
878|Lena Granovsky|Author|Actigraphy-Based Sleep/Wake Pattern Detection Using Convolutional Neural Networks|Paper|AUTHORED
878|Gabi Shalev|Author|Actigraphy-Based Sleep/Wake Pattern Detection Using Convolutional Neural Networks|Paper|AUTHORED
878|Nancy Yacovzada|Author|Actigraphy-Based Sleep/Wake Pattern Detection Using Convolutional Neural Networks|Paper|AUTHORED
878|Yotam Frank|Author|Actigraphy-Based Sleep/Wake Pattern Detection Using Convolutional Neural Networks|Paper|AUTHORED
878|Shai Fine|Author|Actigraphy-Based Sleep/Wake Pattern Detection Using Convolutional Neural Networks|Paper|AUTHORED
879|Percutaneous Coronary Interventions|Topic|Catheter|Topic|RELATED_TO
879|Catheter|Topic|Stent|Topic|RELATED_TO
879|Wrist Access|Topic|Groin Access|Topic|RELATED_TO
879|Clinical Trials|Topic|Wrist Access|Topic|RELATED_TO
879|Hospitalization Charges|Topic|Wrist Access|Topic|RELATED_TO
879|Hospitalization Charges|Topic|Groin Access|Topic|RELATED_TO
879|Samrachana Adhikari|Author|Bayesian Instrumental Variable Analysis|Topic|AUTHORED
879|Sherri Rose|Author|Bayesian Instrumental Variable Analysis|Topic|AUTHORED
879|Sharon-Lise Normand|Author|Bayesian Instrumental Variable Analysis|Topic|AUTHORED
879|Bayesian Instrumental Variable Analysis|Topic|Latent Index Modeling|Topic|RELATED_TO
879|Bayesian Instrumental Variable Analysis|Topic|Dirichlet Process Mixture Models|Topic|RELATED_TO
879|7,963 Patients|Topic|Bayesian Instrumental Variable Analysis|Topic|RELATED_TO
880|Lesionvis|Topic|Pls|Topic|RELATED_TO
880|Pls|Topic|Siba-Net|Topic|RELATED_TO
880|Siba-Net|Topic|P-Siba|Topic|RELATED_TO
880|P-Siba|Topic|Lesionvis|Topic|DISCUSSES
880|Bo Zhou|Author|P-Siba|Topic|AUTHORED
880|Randolph Crawford|Author|P-Siba|Topic|AUTHORED
880|Belma Dogdas|Author|P-Siba|Topic|AUTHORED
880|Gregory Goldmacher|Author|P-Siba|Topic|AUTHORED
880|Antong Chen|Author|P-Siba|Topic|AUTHORED
881|Covid 19|Topic|Ards|Topic|RELATED_TO
881|Mscs|Topic|Mesenchymal Stem Cell Therapy|Topic|RELATED_TO
881|Mesenchymal Stem Cell Therapy|Topic|Covid Induced Ards|Topic|RELATED_TO
881|Adrita Chanda|Author|Current Landscape Of Mesenchymal Stem Cell Therapy In Covid Induced Acute Respiratory Distress Syndrome|Paper|AUTHORED
881|Adrija Aich|Author|Current Landscape Of Mesenchymal Stem Cell Therapy In Covid Induced Acute Respiratory Distress Syndrome|Paper|AUTHORED
881|Arka Sanyal|Author|Current Landscape Of Mesenchymal Stem Cell Therapy In Covid Induced Acute Respiratory Distress Syndrome|Paper|AUTHORED
881|Anantika Chandra|Author|Current Landscape Of Mesenchymal Stem Cell Therapy In Covid Induced Acute Respiratory Distress Syndrome|Paper|AUTHORED
881|Saumyadeep Goswami|Author|Current Landscape Of Mesenchymal Stem Cell Therapy In Covid Induced Acute Respiratory Distress Syndrome|Paper|AUTHORED
882|Mixed Models For Repeated Measures|Topic|Progression Models For Repeated Measures|Topic|RELATED_TO
882|Progression Models For Repeated Measures|Topic|Lars Lau Raket|Author|AUTHORED
882|Progression Models For Repeated Measures|Topic|Alzheimer'S Disease|Topic|RELATED_TO
882|Progression Models For Repeated Measures|Topic|Clinical Trials|Topic|RELATED_TO
882|Progression Models For Repeated Measures|Topic|Treatment Effects|Topic|RELATED_TO
882|Progression Models For Repeated Measures|Topic|Disease Progression Models|Topic|RELATED_TO
882|Progression Models For Repeated Measures|Topic|Longitudinal Data Analysis|Topic|RELATED_TO
883|Mission Imputable: Correcting For Berkson Error When Imputing A Censored Covariate|Paper|Kyle F. Grosser|Author|AUTHORED
883|Mission Imputable: Correcting For Berkson Error When Imputing A Censored Covariate|Paper|Sarah C. Lotspeich|Author|AUTHORED
883|Mission Imputable: Correcting For Berkson Error When Imputing A Censored Covariate|Paper|Tanya P. Garcia|Author|AUTHORED
883|Ace Imputation|Topic|Huntington Disease|Topic|RELATED_TO
884|Image-Based Precision Medicine|Topic|Bayesian Deep Learning|Topic|DISCUSSES
884|Joshua Durso-Finley|Author|Image-Based Precision Medicine|Topic|AUTHORED
884|Jean-Pierre Falet|Author|Image-Based Precision Medicine|Topic|AUTHORED
884|Raghav Mehta|Author|Image-Based Precision Medicine|Topic|AUTHORED
884|Douglas L. Arnold|Author|Image-Based Precision Medicine|Topic|AUTHORED
884|Nick Pawlowski|Author|Image-Based Precision Medicine|Topic|AUTHORED
884|Tal Arbel|Author|Image-Based Precision Medicine|Topic|AUTHORED
885|Data Science Roundtable Meeting|Topic|Boin Design|Topic|DISCUSSES
885|Boin Design|Topic|Accelerated Boin Design|Topic|RELATED_TO
885|Accelerated Boin Design|Topic|3+3 Design|Topic|RELATED_TO
885|Accelerated Boin Design|Topic|Clinical Phase I Trial|Topic|RELATED_TO
885|Masahiro Kojima|Author|Accelerated Boin Design|Topic|AUTHORED
885|Wu Wende|Author|Accelerated Boin Design|Topic|AUTHORED
885|Henry Zhao|Author|Accelerated Boin Design|Topic|AUTHORED
885|Accelerated Boin Design|Topic|Simulation Study|Topic|RELATED_TO
885|Simulation Study|Topic|Mtd Selection|Topic|DISCUSSES
885|Accelerated Boin Design|Topic|Case Study|Topic|RELATED_TO
885|Clinical Oncology Dose Escalation Trials|Topic|3+3 Design|Topic|RELATED_TO
886|Corticospinal Tract|Topic|Diffusion Tensor Tractography|Topic|RELATED_TO
886|Intracerebral Haemorrhage|Topic|Diffusion Tensor Tractography|Topic|RELATED_TO
886|Nnu-Net|Topic|Corticospinal Tract|Topic|RELATED_TO
886|Mistie Iii|Topic|Nnu-Net|Topic|RELATED_TO
886|Mistie Iii|Topic|Corticospinal Tract|Topic|RELATED_TO
886|Olivia N Murray|Author|Mistie Iii|Topic|AUTHORED
886|Hamied Haroon|Author|Mistie Iii|Topic|AUTHORED
886|Paul Ryu|Author|Mistie Iii|Topic|AUTHORED
886|Hiren Patel|Author|Mistie Iii|Topic|AUTHORED
886|George Harston|Author|Mistie Iii|Topic|AUTHORED
886|Marieke Wermer|Author|Mistie Iii|Topic|AUTHORED
886|Wilmar Jolink|Author|Mistie Iii|Topic|AUTHORED
886|Daniel Hanley|Author|Mistie Iii|Topic|AUTHORED
886|Catharina Klijn|Author|Mistie Iii|Topic|AUTHORED
886|Ulrike Hammerbeck|Author|Mistie Iii|Topic|AUTHORED
886|Adrian Parry-Jones|Author|Mistie Iii|Topic|AUTHORED
886|Timothy Cootes|Author|Mistie Iii|Topic|AUTHORED
887|Simulation Study|Topic|Estimands Framework|Topic|RELATED_TO
887|Treatment Switching|Topic|Simulation Study|Topic|RELATED_TO
887|Randomized Clinical Trials (Rcts)|Topic|Simulation Study|Topic|RELATED_TO
887|Overall Survival Data|Topic|Randomized Clinical Trials (Rcts)|Topic|RELATED_TO
887|Treatment Policy Estimand|Topic|Simulation Study|Topic|RELATED_TO
887|Hypothetical Estimand|Topic|Simulation Study|Topic|RELATED_TO
887|Quang Vuong|Author|Simulation Study|Topic|AUTHORED
887|Rebecca K. Metcalfe|Author|Simulation Study|Topic|AUTHORED
887|Antonio Remiro-Azócar|Author|Simulation Study|Topic|AUTHORED
887|Anders Gorst-Rasmussen|Author|Simulation Study|Topic|AUTHORED
887|Oliver Keene|Author|Simulation Study|Topic|AUTHORED
887|Jay J. H. Park|Author|Simulation Study|Topic|AUTHORED
888|Joint Modeling Of Longitudinal Covariates And Partly-Interval Censored Time-To-Event Data|Topic|Cox Model For Time-To-Event Data|Topic|RELATED_TO
888|Joint Modeling Of Longitudinal Covariates And Partly-Interval Censored Time-To-Event Data|Topic|Penalised Likelihood Approach|Topic|RELATED_TO
888|Penalised Likelihood Approach|Topic|Anti-Pd1 Brain Collaboration Clinical Trial|Topic|RELATED_TO
888|Anti-Pd1 Brain Collaboration Clinical Trial|Topic|Annabel Webb|Author|AUTHORED
888|Anti-Pd1 Brain Collaboration Clinical Trial|Topic|Nan Zou|Author|AUTHORED
888|Anti-Pd1 Brain Collaboration Clinical Trial|Topic|Serigne Lo|Author|AUTHORED
888|Anti-Pd1 Brain Collaboration Clinical Trial|Topic|Jun Ma|Author|AUTHORED
889|Restricted Mean Survival Time (Rmst)|Topic|Adarmst|Topic|RELATED_TO
889|Jinghao Sun|Author|Restricted Mean Survival Time (Rmst)|Topic|AUTHORED
889|Douglas E. Schaubel|Author|Restricted Mean Survival Time (Rmst)|Topic|AUTHORED
889|Eric J. Tchetgen Tchetgen|Author|Restricted Mean Survival Time (Rmst)|Topic|AUTHORED
890|Cerebral Cortex|Topic|Neurons|Topic|RELATED_TO
890|Vmt Method|Topic|Neurons|Topic|DISCUSSES
890|Vmt Method|Topic|Guinea-Pig Visual Cortex Neurons|Topic|DISCUSSES
890|Martin Pospischil|Author|Vmt Method|Topic|AUTHORED
890|Zuzanna Piwkowska|Author|Vmt Method|Topic|AUTHORED
890|Thierry Bal|Author|Vmt Method|Topic|AUTHORED
890|Alain Destexhe|Author|Vmt Method|Topic|AUTHORED
890|Guinea-Pig Visual Cortex Neurons|Topic|Dynamic-Clamp Experiments|Topic|RELATED_TO
891|Multivariate Pattern Analysis|Topic|Fmri Data|Topic|RELATED_TO
891|Multivariate Pattern Analysis|Topic|Brain Computing Interfaces|Topic|RELATED_TO
891|Multivariate Pattern Analysis|Topic|Time-Series Neuroimaging Data|Topic|RELATED_TO
891|Time-Series Neuroimaging Data|Topic|Meg|Topic|RELATED_TO
891|Time-Series Neuroimaging Data|Topic|Eeg|Topic|RELATED_TO
891|Time-Series Neuroimaging Data|Topic|Cognitive Neuroscience|Topic|RELATED_TO
891|Decoding Analysis Pipeline|Topic|Decoding Dynamic Brain Patterns|Topic|RELATED_TO
891|Decoding Dynamic Brain Patterns|Topic|Representational Similarity Analysis|Topic|RELATED_TO
891|Decoding Dynamic Brain Patterns|Topic|Temporal Generalisation|Topic|RELATED_TO
891|Decoding Dynamic Brain Patterns|Topic|Classifier Weight Maps|Topic|RELATED_TO
891|Time-Series Decoding Experiments|Topic|Tijl Grootswagers|Author|AUTHORED
891|Time-Series Decoding Experiments|Topic|Susan G. Wardle|Author|AUTHORED
891|Time-Series Decoding Experiments|Topic|Thomas A. Carlson|Author|AUTHORED
892|A Goal-Based Movement Model For Continuous Multi-Agent Tasks|Paper|Shariq Iqbal|Author|AUTHORED
892|A Goal-Based Movement Model For Continuous Multi-Agent Tasks|Paper|John Pearson|Author|AUTHORED
892|A Goal-Based Movement Model For Continuous Multi-Agent Tasks|Paper|Neuroscience Data|Topic|DISCUSSES
892|A Goal-Based Movement Model For Continuous Multi-Agent Tasks|Paper|Behavioral Analysis|Topic|DISCUSSES
892|A Goal-Based Movement Model For Continuous Multi-Agent Tasks|Paper|Decision Paradigms|Topic|DISCUSSES
892|A Goal-Based Movement Model For Continuous Multi-Agent Tasks|Paper|Machine Learning Methods|Topic|DISCUSSES
893|Deep Learning As A Tool For Neural Data Analysis: Speech Classification And Cross-Frequency Coupling In Human Sensorimotor Cortex|Paper|Neuroscience|Topic|RELATED_TO
893|Deep Learning As A Tool For Neural Data Analysis: Speech Classification And Cross-Frequency Coupling In Human Sensorimotor Cortex|Paper|Neural Activity|Topic|RELATED_TO
893|Deep Learning As A Tool For Neural Data Analysis: Speech Classification And Cross-Frequency Coupling In Human Sensorimotor Cortex|Paper|Deep Networks|Topic|RELATED_TO
893|Deep Learning As A Tool For Neural Data Analysis: Speech Classification And Cross-Frequency Coupling In Human Sensorimotor Cortex|Paper|Speech Syllables|Topic|RELATED_TO
893|Deep Learning As A Tool For Neural Data Analysis: Speech Classification And Cross-Frequency Coupling In Human Sensorimotor Cortex|Paper|Cortical Surface Electric Potentials|Topic|RELATED_TO
893|Deep Learning As A Tool For Neural Data Analysis: Speech Classification And Cross-Frequency Coupling In Human Sensorimotor Cortex|Paper|Human Sensorimotor Cortex|Topic|RELATED_TO
893|Deep Networks|Topic|High-Gamma Band|Topic|RELATED_TO
893|Deep Networks|Topic|Lower-Frequencies|Topic|RELATED_TO
894|Kawato|Author|Computational Neuroscience Model Of Metacognition|Paper|AUTHORED
894|Aurelio Cortese|Author|Computational Neuroscience Model Of Metacognition|Paper|AUTHORED
894|Computational Neuroscience Model Of Metacognition|Paper|Biological Cybernetics|Topic|RELATED_TO
895|Phase I Clinical Trial|Topic|Maximum Tolerated Dose (Mtd)|Topic|RELATED_TO
895|Maximum Tolerated Dose (Mtd)|Topic|Dose-Escalation Study|Topic|RELATED_TO
895|Dose-Escalation Study|Topic|Continual Reassessment Method (Crm)|Topic|RELATED_TO
895|Continual Reassessment Method (Crm)|Topic|Randomized Crm (Rcrm)|Topic|RELATED_TO
895|Randomized Crm (Rcrm)|Topic|Joseph S. Koopmeiners|Author|AUTHORED
895|Randomized Crm (Rcrm)|Topic|Andrew Wey|Author|AUTHORED
896|Estimating The Sample Mean And Standard Deviation From The Sample Size, Median, Range And/Or Interquartile Range|Paper|Xiang Wan|Author|AUTHORED
896|Estimating The Sample Mean And Standard Deviation From The Sample Size, Median, Range And/Or Interquartile Range|Paper|Wenqian Wang|Author|AUTHORED
896|Estimating The Sample Mean And Standard Deviation From The Sample Size, Median, Range And/Or Interquartile Range|Paper|Jiming Liu|Author|AUTHORED
896|Estimating The Sample Mean And Standard Deviation From The Sample Size, Median, Range And/Or Interquartile Range|Paper|Tiejun Tong|Author|AUTHORED
897|Improved Precision In The Analysis Of Randomized Trials With Survival Outcomes, Without Assuming Proportional Hazards|Paper|Iván Díaz|Author|AUTHORED
897|Improved Precision In The Analysis Of Randomized Trials With Survival Outcomes, Without Assuming Proportional Hazards|Paper|Elizabeth Colantuoni|Author|AUTHORED
897|Improved Precision In The Analysis Of Randomized Trials With Survival Outcomes, Without Assuming Proportional Hazards|Paper|Daniel F. Hanley|Author|AUTHORED
897|Improved Precision In The Analysis Of Randomized Trials With Survival Outcomes, Without Assuming Proportional Hazards|Paper|Michael Rosenblum|Author|AUTHORED
898|Clinicaltrials.Gov|Topic|Pubmed|Topic|RELATED_TO
898|Document Similarity Methods|Topic|Unreported Links|Topic|DISCUSSES
898|Reporting Biases|Topic|Systematic Reviews|Topic|RELATED_TO
898|Trial Registrations|Topic|Corresponding Articles|Topic|RELATED_TO
898|Adam G. Dunn|Author|Document Similarity Methods|Topic|AUTHORED
898|Enrico Coiera|Author|Document Similarity Methods|Topic|AUTHORED
898|Florence Bourgeois|Author|Document Similarity Methods|Topic|AUTHORED
899|Randomized Clinical Trials|Topic|Subgroup Treatment Effect|Topic|RELATED_TO
899|Subgroup Treatment Effect|Topic|Principal Stratification Framework|Topic|RELATED_TO
899|Principal Stratification Framework|Topic|Bayesian Methods|Topic|RELATED_TO
899|Siponimod|Topic|Secondary Progressive Multiple Sclerosis|Topic|RELATED_TO
899|Siponimod|Topic|Placebo-Controlled Trial|Topic|RELATED_TO
899|Placebo-Controlled Trial|Topic|Disability Progression|Topic|RELATED_TO
899|Disability Progression|Topic|Regulatory Guidance Ich E9(R1)|Topic|RELATED_TO
899|Baldur P. Magnusson|Author|Placebo-Controlled Trial|Topic|AUTHORED
899|Heinz Schmidli|Author|Placebo-Controlled Trial|Topic|AUTHORED
899|Nicolas Rouyrre|Author|Placebo-Controlled Trial|Topic|AUTHORED
899|Daniel O. Scharfstein|Author|Placebo-Controlled Trial|Topic|AUTHORED
900|Identifying Treatment Effect Heterogeneity In Dose-Finding Trials Using Bayesian Hierarchical Models|Paper|Bayesian Hierarchical Dose-Response Model|Topic|DISCUSSES
900|Identifying Treatment Effect Heterogeneity In Dose-Finding Trials Using Bayesian Hierarchical Models|Paper|Predictive Covariates|Topic|DISCUSSES
900|Identifying Treatment Effect Heterogeneity In Dose-Finding Trials Using Bayesian Hierarchical Models|Paper|Prognostic Covariates|Topic|DISCUSSES
900|Identifying Treatment Effect Heterogeneity In Dose-Finding Trials Using Bayesian Hierarchical Models|Paper|Treatment Effect Heterogeneity|Topic|DISCUSSES
900|Identifying Treatment Effect Heterogeneity In Dose-Finding Trials Using Bayesian Hierarchical Models|Paper|Dose-Finding Trials|Topic|DISCUSSES
900|Identifying Treatment Effect Heterogeneity In Dose-Finding Trials Using Bayesian Hierarchical Models|Paper|Shrinkage Priors|Topic|DISCUSSES
900|Identifying Treatment Effect Heterogeneity In Dose-Finding Trials Using Bayesian Hierarchical Models|Paper|Phase Ii Dose-Finding Trial|Topic|DISCUSSES
901|Causal Inference For Comprehensive Cohort Studies|Paper|Yi Lu|Author|AUTHORED
901|Causal Inference For Comprehensive Cohort Studies|Paper|Daniel O. Scharfstein|Author|AUTHORED
901|Causal Inference For Comprehensive Cohort Studies|Paper|Maria M. Brooks|Author|AUTHORED
901|Causal Inference For Comprehensive Cohort Studies|Paper|Kevin Quach|Author|AUTHORED
901|Causal Inference For Comprehensive Cohort Studies|Paper|Edward H. Kennedy|Author|AUTHORED
901|Causal Inference For Comprehensive Cohort Studies|Paper|Bypass Angioplasty Revascularization Investigation|Topic|RELATED_TO
902|Novel Model For The Analysis Of Clustered Observations|Paper|Clustered Observations|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Marginal Distributions|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Linear Transformation Model|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Joint Multivariate Normal Distribution|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Marginal Odds Ratios|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Toe Nail Data|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Clinical Trials|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Bounded Visual Analog Scale|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Marginal Proportional-Odds Models|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Disease-Free Survival In Rectal Cancer Patients|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Marginal Hazard Ratio|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Weibull And Cox Models|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Tram Add-On Package|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|R System|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|General Estimation Equations|Topic|DISCUSSES
902|Novel Model For The Analysis Of Clustered Observations|Paper|Conditional Mixed-Effects Models|Topic|DISCUSSES
903|Confirmatory Cancer Clinical Trials|Topic|Overall Survival|Topic|RELATED_TO
903|Confirmatory Cancer Clinical Trials|Topic|Intention-To-Treat Analysis|Topic|RELATED_TO
903|Treatment Switching|Topic|Modified Weighted Log-Rank Test|Topic|RELATED_TO
903|Record-1 Trial|Topic|Everolimus|Topic|RELATED_TO
903|Record-1 Trial|Topic|Placebo|Topic|RELATED_TO
903|Modified Weighted Log-Rank Test|Topic|José L. Jiménez|Author|AUTHORED
903|Modified Weighted Log-Rank Test|Topic|Julia Niewczas|Author|AUTHORED
903|Modified Weighted Log-Rank Test|Topic|Alexander Bore|Author|AUTHORED
903|Modified Weighted Log-Rank Test|Topic|Carl-Fredrik Burman|Author|AUTHORED
904|Sample Size Derivation|Topic|Confirmatory Trial|Topic|RELATED_TO
904|Sample Size Derivation|Topic|Type I Error Rate|Topic|RELATED_TO
904|Sample Size Derivation|Topic|Power|Topic|RELATED_TO
904|Power|Topic|Effect Size|Topic|RELATED_TO
904|Bayesian Perspective|Topic|Sample Size Derivation|Topic|RELATED_TO
904|Hybrid Approaches|Topic|Sample Size Derivation|Topic|RELATED_TO
904|Assurance|Topic|Sample Size Derivation|Topic|RELATED_TO
904|Probability Of Success|Topic|Sample Size Derivation|Topic|RELATED_TO
904|Expected Power|Topic|Sample Size Derivation|Topic|RELATED_TO
904|Sample Size Derivation|Topic|Clinical Trials|Topic|RELATED_TO
904|Kevin Kunzmann|Author|Sample Size Derivation|Topic|AUTHORED
904|Michael J. Grayling|Author|Sample Size Derivation|Topic|AUTHORED
904|Kim May Lee|Author|Sample Size Derivation|Topic|AUTHORED
904|David S. Robertson|Author|Sample Size Derivation|Topic|AUTHORED
904|Kaspar Rufibach|Author|Sample Size Derivation|Topic|AUTHORED
904|James M. S. Wason|Author|Sample Size Derivation|Topic|AUTHORED
905|A Bayesian Machine Learning Approach For Estimating Heterogeneous Survivor Causal Effects: Applications To A Critical Care Trial|Paper|Xinyuan Chen|Author|AUTHORED
905|A Bayesian Machine Learning Approach For Estimating Heterogeneous Survivor Causal Effects: Applications To A Critical Care Trial|Paper|Michael O. Harhay|Author|AUTHORED
905|A Bayesian Machine Learning Approach For Estimating Heterogeneous Survivor Causal Effects: Applications To A Critical Care Trial|Paper|Guangyu Tong|Author|AUTHORED
905|A Bayesian Machine Learning Approach For Estimating Heterogeneous Survivor Causal Effects: Applications To A Critical Care Trial|Paper|Fan Li|Author|AUTHORED
905|Arma Trial|Topic|Ardsnetwork|Topic|RELATED_TO
905|Bayesian Additive Regression Trees (Bart)|Topic|A Bayesian Machine Learning Approach For Estimating Heterogeneous Survivor Causal Effects: Applications To A Critical Care Trial|Paper|DISCUSSES
905|Low Tidal Volume Treatment|Topic|A Bayesian Machine Learning Approach For Estimating Heterogeneous Survivor Causal Effects: Applications To A Critical Care Trial|Paper|DISCUSSES
905|Sex|Topic|A Bayesian Machine Learning Approach For Estimating Heterogeneous Survivor Causal Effects: Applications To A Critical Care Trial|Paper|DISCUSSES
905|Alveolar-Arterial Oxygen Gradient|Topic|A Bayesian Machine Learning Approach For Estimating Heterogeneous Survivor Causal Effects: Applications To A Critical Care Trial|Paper|DISCUSSES
906|Clinical Trial|Topic|Frequentist Analysis|Topic|DISCUSSES
906|Clinical Trial|Topic|Interim Analyses|Topic|DISCUSSES
906|Clinical Trial|Topic|Rao-Blackwellisation|Topic|DISCUSSES
906|Clinical Trial|Topic|Sepsis Treatments Comparison|Topic|DISCUSSES
906|John Whitehead|Author|Sepsis Treatments Comparison|Topic|AUTHORED
906|Yasin Desai|Author|Sepsis Treatments Comparison|Topic|AUTHORED
906|Thomas Jaki|Author|Sepsis Treatments Comparison|Topic|AUTHORED
907|Obstetrics And Gynecology Trials|Topic|Reproducibility In Scientific Research|Topic|RELATED_TO
907|Aaron Bowers|Author|Obstetrics And Gynecology Trials|Topic|AUTHORED
907|Shelby Rauh|Author|Obstetrics And Gynecology Trials|Topic|AUTHORED
907|Drayton Rorah|Author|Obstetrics And Gynecology Trials|Topic|AUTHORED
907|Daniel Tritz|Author|Obstetrics And Gynecology Trials|Topic|AUTHORED
907|Lance Frye|Author|Obstetrics And Gynecology Trials|Topic|AUTHORED
907|Matt Vassar|Author|Obstetrics And Gynecology Trials|Topic|AUTHORED
908|Tissue-Agnostic Trials|Topic|Bayesian Hierarchical Model (Bhm)|Topic|RELATED_TO
908|Bayesian Hierarchical Model (Bhm)|Topic|Optimal Bhm (Obhm)|Topic|RELATED_TO
908|Optimal Bhm (Obhm)|Topic|Clustered Obhm (Cobhm)|Topic|RELATED_TO
908|Optimal Bhm (Obhm)|Topic|Adaptive Obhm (Aobhm)|Topic|RELATED_TO
908|Liyun Jiang|Author|Optimal Bhm (Obhm)|Topic|AUTHORED
908|Lei Nie|Author|Optimal Bhm (Obhm)|Topic|AUTHORED
908|Fangrong Yan|Author|Optimal Bhm (Obhm)|Topic|AUTHORED
908|Ying Yuan|Author|Optimal Bhm (Obhm)|Topic|AUTHORED
909|Bayesian Estimation|Topic|Parametric Survival Analysis|Topic|RELATED_TO
909|Hypothesis Testing|Topic|Parametric Survival Analysis|Topic|RELATED_TO
909|Model-Averaging|Topic|Parametric Survival Analysis|Topic|RELATED_TO
909|Frequentist Approach|Topic|Parametric Survival Analysis|Topic|RELATED_TO
909|Colon Cancer Trial|Topic|Bayesian Estimation|Topic|DISCUSSES
909|Colon Cancer Trial|Topic|Hypothesis Testing|Topic|DISCUSSES
909|Colon Cancer Trial|Topic|Model-Averaging|Topic|DISCUSSES
909|Frantiek Barto|Author|Colon Cancer Trial|Topic|AUTHORED
909|Frederik Aust|Author|Colon Cancer Trial|Topic|AUTHORED
909|Julia M. Haaf|Author|Colon Cancer Trial|Topic|AUTHORED
909|Robsa R Package|Topic|Parametric Survival Analysis|Topic|RELATED_TO
910|Statistical Methods For Analysis Of Clinical And Virus Genetics Data|Topic|Covid-19|Topic|RELATED_TO
910|Covid-19|Topic|Sars-Cov-2|Topic|RELATED_TO
910|Phase 3 Randomized, Placebo-Controlled Trials|Topic|Covid-19|Topic|RELATED_TO
910|Vaccine Efficacy (Ve)|Topic|Covid-19|Topic|RELATED_TO
910|Strain-Specific Ve|Topic|Vaccine Efficacy (Ve)|Topic|RELATED_TO
910|Cox Proportional Hazards Model|Topic|Strain-Specific Ve|Topic|RELATED_TO
910|Inverse Probability Weighted Complete-Case (Ipw) Estimator|Topic|Strain-Specific Ve|Topic|RELATED_TO
910|Augmented Inverse Probability Weighted Complete-Case (Aipw) Estimator|Topic|Strain-Specific Ve|Topic|RELATED_TO
910|Estimation And Hypothesis Testing Of Strain-Specific Vaccine Efficacy With Missing Strain Types|Paper|Fei Heng|Author|AUTHORED
910|Estimation And Hypothesis Testing Of Strain-Specific Vaccine Efficacy With Missing Strain Types|Paper|Yanqing Sun|Author|AUTHORED
910|Estimation And Hypothesis Testing Of Strain-Specific Vaccine Efficacy With Missing Strain Types|Paper|Peter B. Gilbert|Author|AUTHORED
911|Heterogeneous Treatment Effects|Topic|Cluster-Randomized Trials|Topic|RELATED_TO
911|Cluster-Randomized Trials|Topic|Multilevel Multiple Imputation|Topic|RELATED_TO
911|Cluster-Randomized Trials|Topic|Bayesian Mmi|Topic|RELATED_TO
911|Cluster-Randomized Trials|Topic|Work, Family, And Health Study|Topic|RELATED_TO
911|Bryan S. Blette|Author|Cluster-Randomized Trials|Topic|AUTHORED
911|Scott D. Halpern|Author|Cluster-Randomized Trials|Topic|AUTHORED
911|Fan Li|Author|Cluster-Randomized Trials|Topic|AUTHORED
911|Michael O. Harhay|Author|Cluster-Randomized Trials|Topic|AUTHORED
912|Sequential Multiple Assignment Randomized Trial (Smart)|Topic|Wu Et Al. (2021)|Author|DISCUSSES
912|Sequential Multiple Assignment Randomized Trial (Smart)|Topic|Cole Manschot|Author|AUTHORED
912|Sequential Multiple Assignment Randomized Trial (Smart)|Topic|Eric Laber|Author|AUTHORED
912|Sequential Multiple Assignment Randomized Trial (Smart)|Topic|Marie Davidian|Author|AUTHORED
912|Sequential Multiple Assignment Randomized Trial (Smart)|Topic|Behavioral Pain Interventions For Breast Cancer Patients|Topic|RELATED_TO
913|Dynamic Treatment Regimes (Dtrs)|Topic|Sequential Multiple Assignment Randomized Trial (Smart)|Topic|RELATED_TO
913|Sequential Multiple Assignment Randomized Trial (Smart)|Topic|Smart-Exam|Topic|RELATED_TO
913|Smart-Exam|Topic|Xinru Wang|Author|AUTHORED
913|Smart-Exam|Topic|Nina Deliu|Author|AUTHORED
913|Smart-Exam|Topic|Yusuke Narita|Author|AUTHORED
913|Smart-Exam|Topic|Bibhas Chakraborty|Author|AUTHORED
913|Smart-Exam|Topic|Attention-Deficit/Hyperactivity Disorder (Adhd)|Topic|RELATED_TO
914|Covariate Adjustment And Methods Of Incorporating Historical Data In Randomized Clinical Trials|Topic|Cochran-Mantel-Haenszel Test|Topic|RELATED_TO
914|Cochran-Mantel-Haenszel Test|Topic|Procova-Cmh|Topic|RELATED_TO
914|Procova-Cmh|Topic|Alyssa M. Vanderbeek|Author|AUTHORED
914|Procova-Cmh|Topic|Jessica L. Ross|Author|AUTHORED
914|Procova-Cmh|Topic|David P. Miller|Author|AUTHORED
914|Procova-Cmh|Topic|Alejandro Schuler|Author|AUTHORED
914|Procova-Cmh|Topic|Alzheimer'S Disease|Topic|DISCUSSES
915|A Brief Wellbeing Training Session Delivered By A Humanoid Social Robot: A Pilot Randomized Controlled Trial|Paper|Nicole Robinson|Author|AUTHORED
915|A Brief Wellbeing Training Session Delivered By A Humanoid Social Robot: A Pilot Randomized Controlled Trial|Paper|Jennifer Connolly|Author|AUTHORED
915|A Brief Wellbeing Training Session Delivered By A Humanoid Social Robot: A Pilot Randomized Controlled Trial|Paper|Gavin Suddrey|Author|AUTHORED
915|A Brief Wellbeing Training Session Delivered By A Humanoid Social Robot: A Pilot Randomized Controlled Trial|Paper|David J. Kavanagh|Author|AUTHORED
915|Pilot Randomised Controlled Trial|Topic|Autonomous Humanoid Social Robot|Topic|RELATED_TO
915|Pilot Randomised Controlled Trial|Topic|Mindful Breathing Technique|Topic|RELATED_TO
915|Pilot Randomised Controlled Trial|Topic|Simple Rapport|Topic|RELATED_TO
915|Participants|Topic|Convenience Sampling|Topic|RELATED_TO
915|Technique Enjoyment|Topic|Perceived Usefulness|Topic|RELATED_TO
915|Technique Enjoyment|Topic|Likelihood To Repeat The Technique|Topic|RELATED_TO
915|Gender|Topic|Distress Levels|Topic|RELATED_TO
915|Autonomous Wellbeing Intervention|Topic|Robot-Delivered Mindfulness Training Program|Topic|RELATED_TO
915|Robot-Delivered Mindfulness Training Program|Topic|Sub-Clinical Population|Topic|RELATED_TO
916|Stepped Wedge Cluster Randomized Trials (Sw-Crts)|Topic|Stratified Marginal Cox Model|Topic|RELATED_TO
916|Stratified Marginal Cox Model|Topic|Power Calculation|Topic|RELATED_TO
916|Power Calculation|Topic|R Shiny Application|Topic|RELATED_TO
916|Power Calculation|Topic|New Electronic Reminder System|Topic|RELATED_TO
916|New Electronic Reminder System|Topic|Time To Catheter Removal|Topic|RELATED_TO
916|Mary M. Ryan|Author|Power Calculation|Topic|AUTHORED
916|Denise Esserman|Author|Power Calculation|Topic|AUTHORED
916|Monica Taljaard|Author|Power Calculation|Topic|AUTHORED
916|Fan Li|Author|Power Calculation|Topic|AUTHORED
916|Power Calculation|Topic|Censored Time-To-Event Outcomes|Topic|RELATED_TO
916|Power Calculation|Topic|Wald And Robust Score Tests|Topic|RELATED_TO
916|Power Calculation|Topic|Robust Sandwich Variance|Topic|RELATED_TO
916|Power Calculation|Topic|Cross-Sectional Sw-Crts|Topic|RELATED_TO
916|Power Calculation|Topic|Clinically Meaningful Effect Size|Topic|RELATED_TO
917|Phase I Clinical Trials|Topic|3+3 Method|Topic|RELATED_TO
917|Phase I Clinical Trials|Topic|Continual Reassessment Method (Crm)|Topic|RELATED_TO
917|Partial Ordering Crm (Pocrm)|Topic|Bayesian Model Averaged Pocrm (Bma-Pocrm)|Topic|RELATED_TO
917|Luka Kovacevic|Author|Bayesian Model Averaged Pocrm (Bma-Pocrm)|Topic|AUTHORED
917|Thomas Jaki|Author|Bayesian Model Averaged Pocrm (Bma-Pocrm)|Topic|AUTHORED
917|Helen Barnett|Author|Bayesian Model Averaged Pocrm (Bma-Pocrm)|Topic|AUTHORED
917|Pavel Mozgunov|Author|Bayesian Model Averaged Pocrm (Bma-Pocrm)|Topic|AUTHORED
918|Patient-Centered Outcomes|Topic|Survivor Average Causal Effect (Sace)|Topic|RELATED_TO
918|Survivor Average Causal Effect (Sace)|Topic|Cluster-Randomized Trials (Crts)|Topic|RELATED_TO
918|Dane Isenberg|Author|Survivor Average Causal Effect (Sace)|Topic|AUTHORED
918|Michael Harhay|Author|Survivor Average Causal Effect (Sace)|Topic|AUTHORED
918|Nandita Mitra|Author|Survivor Average Causal Effect (Sace)|Topic|AUTHORED
918|Fan Li|Author|Survivor Average Causal Effect (Sace)|Topic|AUTHORED
919|Online Ai Decision-Making Algorithms|Topic|Digital Interventions|Topic|RELATED_TO
919|Digital Interventions|Topic|Treatment|Topic|RELATED_TO
919|Guidelines For Monitoring|Topic|Oralytics|Topic|RELATED_TO
919|Guidelines For Monitoring|Topic|Miwaves|Topic|RELATED_TO
919|Guidelines For Monitoring|Topic|Anna L. Trella|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Susobhan Ghosh|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Erin E. Bonar|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Lara Coughlin|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Finale Doshi-Velez|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Yongyi Guo|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Pei-Yao Hung|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Inbal Nahum-Shani|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Vivek Shetty|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Maureen Walton|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Iris Yan|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Kelly W. Zhang|Author|AUTHORED
919|Guidelines For Monitoring|Topic|Susan A. Murphy|Author|AUTHORED
920|Phase I Clinical Trial Designs|Topic|Maximum Tolerated Doses|Topic|RELATED_TO
920|Phase I Clinical Trial Designs|Topic|Dose-Escalation Designs|Topic|RELATED_TO
920|Dose-Escalation Designs|Topic|Continual Reassessment Method|Topic|RELATED_TO
920|Dose-Escalation Designs|Topic|Partial Ordering Crm|Topic|RELATED_TO
920|Weishi Chen|Author|On The Consistency Of Partial Ordering Continual Reassessment Method With Model And Ordering Misspecification|Paper|AUTHORED
920|Pavel Mozgunov|Author|On The Consistency Of Partial Ordering Continual Reassessment Method With Model And Ordering Misspecification|Paper|AUTHORED
921|Restricted Win Probability With Bayesian Estimation For Implementing The Estimand Framework In Clinical Trials With A Time-To-Event Outcome|Paper|Michelle Leeberg|Author|AUTHORED
921|Restricted Win Probability With Bayesian Estimation For Implementing The Estimand Framework In Clinical Trials With A Time-To-Event Outcome|Paper|Xianghua Luo|Author|AUTHORED
921|Restricted Win Probability With Bayesian Estimation For Implementing The Estimand Framework In Clinical Trials With A Time-To-Event Outcome|Paper|Thomas A. Murray|Author|AUTHORED
921|Restricted Win Probability With Bayesian Estimation For Implementing The Estimand Framework In Clinical Trials With A Time-To-Event Outcome|Paper|Bayesian Estimation|Topic|RELATED_TO
921|Restricted Win Probability With Bayesian Estimation For Implementing The Estimand Framework In Clinical Trials With A Time-To-Event Outcome|Paper|Time-To-Event Outcome|Topic|RELATED_TO
921|Restricted Win Probability With Bayesian Estimation For Implementing The Estimand Framework In Clinical Trials With A Time-To-Event Outcome|Paper|Estimand Framework|Topic|RELATED_TO
921|Restricted Win Probability With Bayesian Estimation For Implementing The Estimand Framework In Clinical Trials With A Time-To-Event Outcome|Paper|Oncology Trials|Topic|RELATED_TO
922|Phase I Trial|Topic|Dose-Finding Design|Topic|RELATED_TO
922|Dose-Finding Design|Topic|Bayesian Logistic Regression Model|Topic|DISCUSSES
922|Sandrine Boulet|Author|Dose-Finding Design|Topic|AUTHORED
922|Emmanuelle Comets|Author|Dose-Finding Design|Topic|AUTHORED
922|Antoine Guillon|Author|Dose-Finding Design|Topic|AUTHORED
922|Linda B. S. Aulin|Author|Dose-Finding Design|Topic|AUTHORED
922|Robin Michelet|Author|Dose-Finding Design|Topic|AUTHORED
922|Charlotte Kloft|Author|Dose-Finding Design|Topic|AUTHORED
922|Sarah Zohar|Author|Dose-Finding Design|Topic|AUTHORED
922|Moreno Ursino|Author|Dose-Finding Design|Topic|AUTHORED
923|Bupd|Topic|Ryo Kitabayashi|Author|AUTHORED
923|Bupd|Topic|Hiroyuki Sato|Author|AUTHORED
923|Bupd|Topic|Akihiro Hirakawa|Author|AUTHORED
924|Personalized Medicine|Topic|Individualized Treatment Rules (Itrs)|Topic|RELATED_TO
924|Individualized Treatment Rules (Itrs)|Topic|Outcome Weighted Learning (Owl)|Topic|RELATED_TO
924|Outcome Weighted Learning (Owl)|Topic|Residual Weighted Learning (Rwl)|Topic|RELATED_TO
924|Zhao Et Al. (2012)|Author|Outcome Weighted Learning (Owl)|Topic|AUTHORED
924|Xin Zhou|Author|Residual Weighted Learning (Rwl)|Topic|AUTHORED
924|Nicole Mayer-Hamblett|Author|Residual Weighted Learning (Rwl)|Topic|AUTHORED
924|Umer Khan|Author|Residual Weighted Learning (Rwl)|Topic|AUTHORED
924|Michael R. Kosorok|Author|Residual Weighted Learning (Rwl)|Topic|AUTHORED
924|Residual Weighted Learning (Rwl)|Topic|Cystic Fibrosis Clinical Trial Data|Topic|RELATED_TO
925|Deepradiologynet|Topic|Ct Head Scans|Topic|RELATED_TO
925|Deepradiologynet|Topic|Deep Convolutional Neural Networks|Topic|RELATED_TO
925|Deepradiologynet|Topic|Clinical Trial|Topic|RELATED_TO
925|Clinical Trial|Topic|Us Board Certified Radiologists|Topic|RELATED_TO
926|Clinical Disease Registries|Topic|Causal Inference|Topic|RELATED_TO
926|Causal Inference|Topic|Emory Als Clinic Registry|Topic|RELATED_TO
926|Emory Als Clinic Registry|Topic|Percutaneous Endoscopic Gastrostomy (Peg)|Topic|RELATED_TO
926|Percutaneous Endoscopic Gastrostomy (Peg)|Topic|Body Mass Index (Bmi)|Topic|RELATED_TO
926|Pallavi Mishra-Kalyani|Author|Emory Als Clinic Registry|Topic|AUTHORED
926|Brent A. Johnson|Author|Emory Als Clinic Registry|Topic|AUTHORED
926|Jonathan D. Glass|Author|Emory Als Clinic Registry|Topic|AUTHORED
926|Qi Long|Author|Emory Als Clinic Registry|Topic|AUTHORED
927|Real-World Multi-Domain Data Applications For Generalizations To Clinical Settings|Paper|Nooshin Mojab|Author|AUTHORED
927|Real-World Multi-Domain Data Applications For Generalizations To Clinical Settings|Paper|Vahid Noroozi|Author|AUTHORED
927|Real-World Multi-Domain Data Applications For Generalizations To Clinical Settings|Paper|Darvin Yi|Author|AUTHORED
927|Real-World Multi-Domain Data Applications For Generalizations To Clinical Settings|Paper|Manoj Prabhakar Nallabothula|Author|AUTHORED
927|Real-World Multi-Domain Data Applications For Generalizations To Clinical Settings|Paper|Abdullah Aleem|Author|AUTHORED
927|Real-World Multi-Domain Data Applications For Generalizations To Clinical Settings|Paper|Phillip S. Yu|Author|AUTHORED
927|Real-World Multi-Domain Data Applications For Generalizations To Clinical Settings|Paper|Joelle A. Hallak|Author|AUTHORED
928|Test Of Significance For High-Dimensional Thresholds With Application To Individualized Minimal Clinically Important Difference|Paper|Huijie Feng|Author|AUTHORED
928|Test Of Significance For High-Dimensional Thresholds With Application To Individualized Minimal Clinically Important Difference|Paper|Jingyi Duan|Author|AUTHORED
928|Test Of Significance For High-Dimensional Thresholds With Application To Individualized Minimal Clinically Important Difference|Paper|Yang Ning|Author|AUTHORED
928|Test Of Significance For High-Dimensional Thresholds With Application To Individualized Minimal Clinically Important Difference|Paper|Jiwei Zhao|Author|AUTHORED
929|Imputed Clinical Data|Topic|Skander Kazdaghli|Author|AUTHORED
929|Imputed Clinical Data|Topic|Iordanis Kerenidis|Author|AUTHORED
929|Imputed Clinical Data|Topic|Jens Kieckbusch|Author|AUTHORED
929|Imputed Clinical Data|Topic|Philip Teare|Author|AUTHORED
930|Anti-Gravity Therapy|Topic|Exonet|Topic|RELATED_TO
930|Exonet|Topic|Post-Stroke Rehabilitation|Topic|RELATED_TO
930|Courtney Celian|Author|Anti-Gravity Therapy|Topic|AUTHORED
930|Partha Ryali|Author|Anti-Gravity Therapy|Topic|AUTHORED
930|Valentino Wilson|Author|Anti-Gravity Therapy|Topic|AUTHORED
930|Adith Srivatsaa|Author|Anti-Gravity Therapy|Topic|AUTHORED
930|James L. Patton|Author|Anti-Gravity Therapy|Topic|AUTHORED
930|Chronic Stroke Survivors|Topic|Exonet|Topic|RELATED_TO
930|Box And Blocks Scores|Topic|Anti-Gravity Therapy|Topic|DISCUSSES
930|Arat Scores|Topic|Anti-Gravity Therapy|Topic|DISCUSSES
930|Muscle Activity|Topic|Anti-Gravity Therapy|Topic|DISCUSSES
930|Clinical Metrics|Topic|Anti-Gravity Therapy|Topic|DISCUSSES
931|Nih-Funded Bridge2Ai Project|Topic|High-Quality Biomedical Datasets|Topic|RELATED_TO
931|1,699 Dataset Papers|Topic|Nucleic Acids Research (Nar) Database|Topic|RELATED_TO
931|1,699 Dataset Papers|Topic|Bridge2Ai Talent Knowledge Graph|Topic|RELATED_TO
931|Team Attributes|Topic|Dataset Success|Topic|DISCUSSES
931|Scientific Impact|Topic|Relative Citation Ratio Percentile|Topic|RELATED_TO
931|Clinical Translation Power|Topic|Apt|Topic|RELATED_TO
931|Shap Explainable Ai Framework|Topic|Dataset Success|Topic|DISCUSSES
931|Dataset Success|Topic|Principal Investigator Leadership|Topic|RELATED_TO
931|Dataset Success|Topic|Team Academic Prowess|Topic|RELATED_TO
931|Scientific Impact|Topic|Team Size|Topic|RELATED_TO
931|Scientific Impact|Topic|Career Age|Topic|RELATED_TO
931|Dataset Success|Topic|Female Representation|Topic|RELATED_TO
931|Jiawei Xu|Author|Decoding Patterns Of Data Generation Teams For Clinical And Scientific Success: Insights From The Bridge2Ai Talent Knowledge Graph|Paper|AUTHORED
931|Qingnan Xie|Author|Decoding Patterns Of Data Generation Teams For Clinical And Scientific Success: Insights From The Bridge2Ai Talent Knowledge Graph|Paper|AUTHORED
931|Meijun Liu|Author|Decoding Patterns Of Data Generation Teams For Clinical And Scientific Success: Insights From The Bridge2Ai Talent Knowledge Graph|Paper|AUTHORED
931|Zhandos Sembay|Author|Decoding Patterns Of Data Generation Teams For Clinical And Scientific Success: Insights From The Bridge2Ai Talent Knowledge Graph|Paper|AUTHORED
931|Swathi Thaker|Author|Decoding Patterns Of Data Generation Teams For Clinical And Scientific Success: Insights From The Bridge2Ai Talent Knowledge Graph|Paper|AUTHORED
931|Pamela Payne-Foster|Author|Decoding Patterns Of Data Generation Teams For Clinical And Scientific Success: Insights From The Bridge2Ai Talent Knowledge Graph|Paper|AUTHORED
931|Jake Chen|Author|Decoding Patterns Of Data Generation Teams For Clinical And Scientific Success: Insights From The Bridge2Ai Talent Knowledge Graph|Paper|AUTHORED
931|Ying Ding|Author|Decoding Patterns Of Data Generation Teams For Clinical And Scientific Success: Insights From The Bridge2Ai Talent Knowledge Graph|Paper|AUTHORED
932|Machine Learning|Topic|Neuroscience|Topic|RELATED_TO
932|Neuroscience|Topic|Diagnostics|Topic|RELATED_TO
932|Neuroscience|Topic|Characterization|Topic|RELATED_TO
932|Neuroscience|Topic|Treatment Outcome Prediction|Topic|RELATED_TO
932|Psychiatric Disorders|Topic|Diagnostics|Topic|RELATED_TO
932|Neurological Disorders|Topic|Diagnostics|Topic|RELATED_TO
932|Epilepsy|Topic|Psychiatric Disorders|Topic|RELATED_TO
932|Depression|Topic|Psychiatric Disorders|Topic|RELATED_TO
932|Data-Driven Approaches|Topic|Clinical Conclusions|Topic|RELATED_TO
932|Structural Neuroimaging|Topic|Data-Driven Approaches|Topic|RELATED_TO
932|Functional Neuroimaging|Topic|Data-Driven Approaches|Topic|RELATED_TO
932|Neuroimaging Markers|Topic|Data Preparation Pipeline|Topic|RELATED_TO
932|Data Preparation Pipeline|Topic|Artifactual Signal Fluctuations|Topic|RELATED_TO
932|Pattern Recognition Approaches|Topic|Clinical Applications|Topic|RELATED_TO
932|Graph-Based Pattern Recognition Approaches|Topic|Pattern Recognition Approaches|Topic|RELATED_TO
932|Noise-Aware Neuroimaging Data Processing Pipeline|Topic|Data Preparation Pipeline|Topic|RELATED_TO
932|Pilot Study|Topic|Classification Accuracy|Topic|RELATED_TO
932|Maxim Sharaev|Author|Pilot Study|Topic|AUTHORED
932|Alexander Andreev|Author|Pilot Study|Topic|AUTHORED
932|Alexey Artemov|Author|Pilot Study|Topic|AUTHORED
932|Alexander Bernstein|Author|Pilot Study|Topic|AUTHORED
932|Evgeny Burnaev|Author|Pilot Study|Topic|AUTHORED
932|Ekaterina Kondratyeva|Author|Pilot Study|Topic|AUTHORED
932|Svetlana Sushchinskaya|Author|Pilot Study|Topic|AUTHORED
932|Renat Akzhigitov|Author|Pilot Study|Topic|AUTHORED
933|Deep Learning Image Analysis Methods|Topic|Imaging Neuroscience|Topic|RELATED_TO
933|Large-Scale Imaging Datasets|Topic|Imaging Neuroscience|Topic|RELATED_TO
933|Large-Scale Imaging Datasets|Topic|Epidemiology|Topic|RELATED_TO
933|Clinical Translation|Topic|Big Data Deep Learning Approaches|Topic|RELATED_TO
933|Data Availability|Topic|Big Data Deep Learning Approaches|Topic|RELATED_TO
933|Interpretability|Topic|Big Data Deep Learning Approaches|Topic|RELATED_TO
933|Evaluation|Topic|Big Data Deep Learning Approaches|Topic|RELATED_TO
933|Logistical Challenges|Topic|Big Data Deep Learning Approaches|Topic|RELATED_TO
933|Big Data Deep Learning Approaches|Topic|Clinical Translation|Topic|DISCUSSES
933|Nicola K Dinsdale|Author|Big Data Deep Learning Approaches|Topic|AUTHORED
933|Emma Bluemke|Author|Big Data Deep Learning Approaches|Topic|AUTHORED
933|Vaanathi Sundaresan|Author|Big Data Deep Learning Approaches|Topic|AUTHORED
933|Mark Jenkinson|Author|Big Data Deep Learning Approaches|Topic|AUTHORED
933|Stephen Smith|Author|Big Data Deep Learning Approaches|Topic|AUTHORED
933|Ana Il Namburete|Author|Big Data Deep Learning Approaches|Topic|AUTHORED
934|Deep Learning|Topic|Computer Vision|Topic|RELATED_TO
934|Deep Learning|Topic|Natural Language Processing|Topic|RELATED_TO
934|Deep Learning|Topic|Biomedical Research|Topic|RELATED_TO
934|Neuroscience|Topic|Electrophysiological Neuroimaging|Topic|RELATED_TO
934|Large-Scale Clinical Eeg Dataset|Paper|Deep Learning|Topic|AUTHORED
935|Mri Dataset Nigeria|Topic|Eberechi Wogu|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Patrick Filima|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Bradley Caron|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Daniel Levitas|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Peer Herholz|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Catherine Leal|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Mohammed F. Mehboob|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Soichi Hayashi|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Simisola Akintoye|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|George Ogoh|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Tawe Godwin|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Damian Eke|Author|AUTHORED
935|Mri Dataset Nigeria|Topic|Franco Pestilli|Author|AUTHORED
936|Summit|Topic|Quantitative Magnetic Resonance Imaging|Topic|RELATED_TO
936|Guoyan Lao|Author|Summit|Topic|AUTHORED
936|Ruimin Feng|Author|Summit|Topic|AUTHORED
936|Haikun Qi|Author|Summit|Topic|AUTHORED
936|Zhenfeng Lv|Author|Summit|Topic|AUTHORED
936|Qiangqiang Liu|Author|Summit|Topic|AUTHORED
936|Chunlei Liu|Author|Summit|Topic|AUTHORED
936|Yuyao Zhang|Author|Summit|Topic|AUTHORED
936|Hongjiang Wei|Author|Summit|Topic|AUTHORED
937|Electroencephalogram (Eeg)|Topic|Graph Signal Processing (Gsp)|Topic|RELATED_TO
937|Graph Signal Processing (Gsp)|Topic|Eeg Graph Mutual Attention Convolutional Network (Eeg-Gmacn)|Topic|RELATED_TO
937|Eeg Graph Mutual Attention Convolutional Network (Eeg-Gmacn)|Topic|Haili Ye|Author|AUTHORED
937|Eeg Graph Mutual Attention Convolutional Network (Eeg-Gmacn)|Topic|Stephan Goerttler|Author|AUTHORED
937|Eeg Graph Mutual Attention Convolutional Network (Eeg-Gmacn)|Topic|Fei He|Author|AUTHORED
938|Standardization Of Data Items In Paediatric Clinical Trials|Topic|Clinical Data Interchange Standards Consortium (Cdisc)|Topic|RELATED_TO
938|Clinical Data Interchange Standards Consortium (Cdisc)|Topic|Conect4Children Consortium|Topic|RELATED_TO
938|Conect4Children Consortium|Topic|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|RELATED_TO
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Anando Sen|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Victoria Hedley|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|John Owen|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Ronald Cornet|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Dipak Kalra|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Corinna Engel|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Avril Palmeri|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Joanne Lee|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Jean-Christophe Roze|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Joseph F Standing|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Adilia Warris|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Claudia Pansieri|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Rebecca Leary|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Mark Turner|Author|AUTHORED
938|Cross-Cutting Paediatric Data Dictionary (Ccpdd)|Topic|Volker Straub|Author|AUTHORED
939|Orient-Covid|Paper|Covid-19 Management|Topic|RELATED_TO
939|Orient-Covid|Paper|Clinical Decision Support Systems|Topic|RELATED_TO
939|Orient-Covid|Paper|Decision Tree Navigation|Topic|RELATED_TO
939|Orient-Covid|Paper|Randomized Controlled Trial|Topic|RELATED_TO
939|Orient-Covid|Paper|Guideline Adherence|Topic|RELATED_TO
939|Orient-Covid|Paper|Medical Students|Topic|RELATED_TO
939|Paper Guidelines|Topic|Guideline Adherence|Topic|DISCUSSES
940|Abimed|Topic|Medication Review|Topic|RELATED_TO
940|Abimed|Topic|Abdelmalek Mouazer|Author|AUTHORED
940|Abimed|Topic|Sophie Dubois|Author|AUTHORED
940|Abimed|Topic|Romain Léguillon|Author|AUTHORED
940|Abimed|Topic|Nada Boudegzdame|Author|AUTHORED
940|Abimed|Topic|Thibaud Levrard|Author|AUTHORED
940|Abimed|Topic|Yoann Le Bars|Author|AUTHORED
940|Abimed|Topic|Christian Simon|Author|AUTHORED
940|Abimed|Topic|Brigitte Séroussi|Author|AUTHORED
940|Abimed|Topic|Julien Grosjean|Author|AUTHORED
940|Abimed|Topic|Romain Lelong|Author|AUTHORED
940|Abimed|Topic|Catherine Letord|Author|AUTHORED
940|Abimed|Topic|Stéfan Darmoni|Author|AUTHORED
940|Abimed|Topic|Karima Sedki|Author|AUTHORED
940|Abimed|Topic|Pierre Meneton|Author|AUTHORED
940|Abimed|Topic|Rosy Tsopra|Author|AUTHORED
940|Abimed|Topic|Hector Falcoff|Author|AUTHORED
940|Abimed|Topic|Jean-Baptiste Lamy|Author|AUTHORED
941|Information Theory|Topic|Transfer Entropy|Topic|RELATED_TO
941|Gomez-Herrero|Author|Transfer Entropy|Topic|DISCUSSES
941|Patricia Wollstadt|Author|Transfer Entropy|Topic|AUTHORED
941|Mario Martínez-Zarzuela|Author|Transfer Entropy|Topic|AUTHORED
941|Raul Vicente|Author|Transfer Entropy|Topic|AUTHORED
941|Francisco J. Díaz-Pernas|Author|Transfer Entropy|Topic|AUTHORED
941|Michael Wibral|Author|Transfer Entropy|Topic|AUTHORED
942|Survival-Agreement Plot|Topic|Survival Analysis|Topic|RELATED_TO
942|Chronic Hepatitis C|Topic|B. De B. Pereira|Author|AUTHORED
942|Chronic Hepatitis C|Topic|E. M. Nascimento|Author|AUTHORED
942|Chronic Hepatitis C|Topic|F. Felix|Author|AUTHORED
942|Chronic Hepatitis C|Topic|G. F. M. Rezende|Author|AUTHORED
942|Chorda Tympani Nerve Involvement|Topic|B. De B. Pereira|Author|AUTHORED
942|Chorda Tympani Nerve Involvement|Topic|E. M. Nascimento|Author|AUTHORED
942|Chorda Tympani Nerve Involvement|Topic|F. Felix|Author|AUTHORED
942|Chorda Tympani Nerve Involvement|Topic|G. F. M. Rezende|Author|AUTHORED
943|Optimal Treatment Regimes|Topic|Runchao Jiang|Author|AUTHORED
943|Optimal Treatment Regimes|Topic|Wenbin Lu|Author|AUTHORED
943|Optimal Treatment Regimes|Topic|Rui Song|Author|AUTHORED
943|Optimal Treatment Regimes|Topic|Marie Davidian|Author|AUTHORED
944|Speech-Language Pathologists|Topic|Speech Disorders|Topic|RELATED_TO
944|Technology For Speech Analysis|Topic|Mixed Speech Signals|Topic|RELATED_TO
944|Mixed Speech Signals|Topic|Loudness|Topic|RELATED_TO
944|Mixed Speech Signals|Topic|Pitch|Topic|RELATED_TO
944|Mixed Speech Signals|Topic|Shimmer|Topic|RELATED_TO
944|Mixed Speech Signals|Topic|Jitter|Topic|RELATED_TO
944|Mixed Speech Signals|Topic|Semitone Standard Deviation|Topic|RELATED_TO
944|Mixed Speech Signals|Topic|Sharpness|Topic|RELATED_TO
944|Parkinson Disease|Topic|Healthy Controls|Topic|RELATED_TO
944|Multi-Smartwatch System For Assessing Speech Characteristics Of People With Dysarthria In Group Settings|Paper|Speech Disorders|Topic|DISCUSSES
945|Precision Medicine|Topic|Optimal Treatment Regime|Topic|RELATED_TO
945|Optimal Treatment Regime|Topic|Residual Weighted Learning (Rwl)|Topic|RELATED_TO
945|Residual Weighted Learning (Rwl)|Topic|Augmented Outcome-Weighted Learning (Aol)|Topic|RELATED_TO
945|Zhou Et Al. (2017)|Author|Residual Weighted Learning (Rwl)|Topic|AUTHORED
945|Xin Zhou|Author|Augmented Outcome-Weighted Learning (Aol)|Topic|AUTHORED
945|Michael R. Kosorok|Author|Augmented Outcome-Weighted Learning (Aol)|Topic|AUTHORED
945|Augmented Outcome-Weighted Learning (Aol)|Topic|Nefazodone-Cbasp Clinical Trial Data|Topic|RELATED_TO
946|A Likelihood-Based Alternative To Null Hypothesis Significance Testing|Paper|P-Value|Topic|DISCUSSES
946|A Likelihood-Based Alternative To Null Hypothesis Significance Testing|Paper|Null Hypothesis Significance Testing|Topic|DISCUSSES
946|A Likelihood-Based Alternative To Null Hypothesis Significance Testing|Paper|Likelihood Function|Topic|DISCUSSES
946|A Likelihood-Based Alternative To Null Hypothesis Significance Testing|Paper|S-Value|Topic|DISCUSSES
946|A Likelihood-Based Alternative To Null Hypothesis Significance Testing|Paper|Woman Trial|Topic|DISCUSSES
946|A Likelihood-Based Alternative To Null Hypothesis Significance Testing|Paper|Relief Trial|Topic|DISCUSSES
947|Hybrid Sequential Deep Learning Model|Topic|Amd Progression|Topic|RELATED_TO
947|Rnn Model|Topic|Amd Progression|Topic|RELATED_TO
947|Rnn Model|Topic|Random Forest Model|Topic|RELATED_TO
947|Clinical Trial Dataset|Topic|Rnn Model|Topic|RELATED_TO
948|Prism|Topic|Thomas O. Jemielita|Author|AUTHORED
948|Prism|Topic|Devan V. Mehrotra|Author|AUTHORED
949|Predictimand Framework|Topic|Clinical Prediction Model|Topic|RELATED_TO
949|Clinical Prediction Model|Topic|End-Stage Kidney Disease|Topic|RELATED_TO
949|Nan Van Geloven|Author|Predictimand Framework|Topic|AUTHORED
949|Sonja Swanson|Author|Predictimand Framework|Topic|AUTHORED
949|Chava Ramspek|Author|Predictimand Framework|Topic|AUTHORED
949|Kim Luijken|Author|Predictimand Framework|Topic|AUTHORED
949|Merel Van Diepen|Author|Predictimand Framework|Topic|AUTHORED
949|Tim Morris|Author|Predictimand Framework|Topic|AUTHORED
949|Rolf Groenwold|Author|Predictimand Framework|Topic|AUTHORED
949|Hans Van Houwelingen|Author|Predictimand Framework|Topic|AUTHORED
949|Hein Putter|Author|Predictimand Framework|Topic|AUTHORED
949|Saskia Le Cessie|Author|Predictimand Framework|Topic|AUTHORED
950|Medical Reports|Topic|Lambr|Topic|RELATED_TO
950|Lambr|Topic|Chen-Han Tsai|Author|AUTHORED
950|Lambr|Topic|Nahum Kiryati|Author|AUTHORED
950|Lambr|Topic|Eli Konen|Author|AUTHORED
950|Lambr|Topic|Miri Sklair-Levy|Author|AUTHORED
950|Lambr|Topic|Arnaldo Mayer|Author|AUTHORED
951|Identifying And Analyzing Sepsis States: A Retrospective Study On Patients With Sepsis In Icus|Paper|Sepsis|Topic|DISCUSSES
951|Identifying And Analyzing Sepsis States: A Retrospective Study On Patients With Sepsis In Icus|Paper|Mimic-Iii Database|Topic|DISCUSSES
951|Identifying And Analyzing Sepsis States: A Retrospective Study On Patients With Sepsis In Icus|Paper|Chih-Hao Fang|Author|AUTHORED
951|Identifying And Analyzing Sepsis States: A Retrospective Study On Patients With Sepsis In Icus|Paper|Vikram Ravindra|Author|AUTHORED
951|Identifying And Analyzing Sepsis States: A Retrospective Study On Patients With Sepsis In Icus|Paper|Salma Akhter|Author|AUTHORED
951|Identifying And Analyzing Sepsis States: A Retrospective Study On Patients With Sepsis In Icus|Paper|Mohammad Adibuzzaman|Author|AUTHORED
951|Identifying And Analyzing Sepsis States: A Retrospective Study On Patients With Sepsis In Icus|Paper|Paul Griffin|Author|AUTHORED
951|Identifying And Analyzing Sepsis States: A Retrospective Study On Patients With Sepsis In Icus|Paper|Shankar Subramaniam|Author|AUTHORED
951|Identifying And Analyzing Sepsis States: A Retrospective Study On Patients With Sepsis In Icus|Paper|Ananth Grama|Author|AUTHORED
952|Bayesian Nonparametric Utility-Based Group Sequential Design|Topic|Randomized Clinical Trial|Topic|RELATED_TO
952|Randomized Clinical Trial|Topic|Gel Sealant|Topic|RELATED_TO
952|Randomized Clinical Trial|Topic|Standard Care|Topic|RELATED_TO
952|Randomized Clinical Trial|Topic|Air Leaks|Topic|RELATED_TO
952|Randomized Clinical Trial|Topic|Pulmonary Resection|Topic|RELATED_TO
952|Decision-Theoretic Comparison Of Treatments To Resolve Air Leaks After Lung Surgery Based On Nonparametric Modeling|Paper|Yanxun Xu|Author|AUTHORED
952|Decision-Theoretic Comparison Of Treatments To Resolve Air Leaks After Lung Surgery Based On Nonparametric Modeling|Paper|Peter F. Thall|Author|AUTHORED
952|Decision-Theoretic Comparison Of Treatments To Resolve Air Leaks After Lung Surgery Based On Nonparametric Modeling|Paper|Peter Mueller|Author|AUTHORED
952|Decision-Theoretic Comparison Of Treatments To Resolve Air Leaks After Lung Surgery Based On Nonparametric Modeling|Paper|Mehran J. Reza|Author|AUTHORED
953|Gastrointestinal Cancers|Topic|Esd Cyclops System|Paper|RELATED_TO
953|Endoscopic Submucosal Dissection|Topic|Esd Cyclops System|Paper|RELATED_TO
954|Proposed Approach|Paper|Medical Imaging|Topic|RELATED_TO
954|Proposed Approach|Paper|Radiology Reports|Topic|RELATED_TO
954|Proposed Approach|Paper|Artificial Intelligence|Topic|RELATED_TO
954|Proposed Approach|Paper|Memory-Driven Transformer|Topic|RELATED_TO
954|Proposed Approach|Paper|Iu X-Ray|Topic|RELATED_TO
954|Proposed Approach|Paper|Mimic-Cxr|Topic|RELATED_TO
954|Proposed Approach|Paper|Zhihong Chen|Author|AUTHORED
954|Proposed Approach|Paper|Yan Song|Author|AUTHORED
954|Proposed Approach|Paper|Tsung-Hui Chang|Author|AUTHORED
954|Proposed Approach|Paper|Xiang Wan|Author|AUTHORED
955|Incorporating External Knowledge Into Named Entity Recognition (Ner) Systems|Topic|Clinical Domain|Topic|RELATED_TO
955|Clinical Domain|Topic|Zero-Shot Ner Systems|Topic|RELATED_TO
955|Zero-Shot Ner Systems|Topic|Auxiliary Gazetteer Model|Topic|RELATED_TO
955|Auxiliary Gazetteer Model|Topic|Neural Entity Recognition With Gazetteer Based Fusion|Paper|AUTHORED
955|Neural Entity Recognition With Gazetteer Based Fusion|Paper|Qing Sun|Author|AUTHORED
955|Neural Entity Recognition With Gazetteer Based Fusion|Paper|Parminder Bhatia|Author|AUTHORED
955|I2B2 Dataset|Topic|Zero-Shot Ner Systems|Topic|RELATED_TO
956|Automatic Detection Of Covid-19 And Pneumonia From Chest X-Ray Using Deep Learning|Paper|X-Ray Images|Topic|DISCUSSES
956|Automatic Detection Of Covid-19 And Pneumonia From Chest X-Ray Using Deep Learning|Paper|Transfer Learning|Topic|DISCUSSES
956|Automatic Detection Of Covid-19 And Pneumonia From Chest X-Ray Using Deep Learning|Paper|Deep Learning|Topic|DISCUSSES
957|Longitudinal Patient Stratification Of Electronic Health Records With Flexible Adjustment For Clinical Outcomes|Paper|Oliver Carr|Author|AUTHORED
957|Longitudinal Patient Stratification Of Electronic Health Records With Flexible Adjustment For Clinical Outcomes|Paper|Avelino Javer|Author|AUTHORED
957|Longitudinal Patient Stratification Of Electronic Health Records With Flexible Adjustment For Clinical Outcomes|Paper|Patrick Rockenschaub|Author|AUTHORED
957|Longitudinal Patient Stratification Of Electronic Health Records With Flexible Adjustment For Clinical Outcomes|Paper|Owen Parsons|Author|AUTHORED
957|Longitudinal Patient Stratification Of Electronic Health Records With Flexible Adjustment For Clinical Outcomes|Paper|Robert Dürichen|Author|AUTHORED
958|Flexible Inference Of Optimal Individualized Treatment Strategy In Covariate Adjusted Randomization With Multiple Covariates|Paper|Trinetri Ghosh|Author|AUTHORED
958|Flexible Inference Of Optimal Individualized Treatment Strategy In Covariate Adjusted Randomization With Multiple Covariates|Paper|Yanyuan Ma|Author|AUTHORED
958|Flexible Inference Of Optimal Individualized Treatment Strategy In Covariate Adjusted Randomization With Multiple Covariates|Paper|Rui Song|Author|AUTHORED
958|Flexible Inference Of Optimal Individualized Treatment Strategy In Covariate Adjusted Randomization With Multiple Covariates|Paper|Pingshou Zhong|Author|AUTHORED
959|Digital Therapeutics For Mental Health: Is Attrition The Achilles Heel?|Paper|Adaora Nwosu|Author|AUTHORED
959|Digital Therapeutics For Mental Health: Is Attrition The Achilles Heel?|Paper|Samantha Boardman|Author|AUTHORED
959|Digital Therapeutics For Mental Health: Is Attrition The Achilles Heel?|Paper|Mustafa M. Husain|Author|AUTHORED
959|Digital Therapeutics For Mental Health: Is Attrition The Achilles Heel?|Paper|P. Murali Doraiswamy|Author|AUTHORED
959|Digital Therapeutics For Mental Health: Is Attrition The Achilles Heel?|Paper|Digital Therapeutics|Topic|RELATED_TO
959|Digital Therapeutics For Mental Health: Is Attrition The Achilles Heel?|Paper|Mental Health Care|Topic|RELATED_TO
959|Digital Therapeutics For Mental Health: Is Attrition The Achilles Heel?|Paper|User Engagement|Topic|RELATED_TO
959|Digital Therapeutics For Mental Health: Is Attrition The Achilles Heel?|Paper|Clinical Trials|Topic|RELATED_TO
960|Duration Of Response (Dor)|Topic|Estimand Framework|Topic|RELATED_TO
960|Time To Response (Ttr)|Topic|Estimand Framework|Topic|RELATED_TO
960|Best Overall Response (Bor)|Topic|Overall Response Rate (Orr)|Topic|RELATED_TO
960|Mantle Cell Lymphoma|Topic|Estimand Framework|Topic|RELATED_TO
960|Hans-Jochen Weber|Author|Duration Of Response (Dor)|Topic|AUTHORED
960|Stephen Corson|Author|Duration Of Response (Dor)|Topic|AUTHORED
960|Jiang Li|Author|Duration Of Response (Dor)|Topic|AUTHORED
960|Francois Mercier|Author|Duration Of Response (Dor)|Topic|AUTHORED
960|Satrajit Roychoudhury|Author|Duration Of Response (Dor)|Topic|AUTHORED
960|Martin Oliver Sailer|Author|Duration Of Response (Dor)|Topic|AUTHORED
960|Stephen Sun|Author|Duration Of Response (Dor)|Topic|AUTHORED
960|Alexander Todd|Author|Duration Of Response (Dor)|Topic|AUTHORED
960|Godwin Yung|Author|Duration Of Response (Dor)|Topic|AUTHORED
961|Smart Data Extractor|Topic|Manual Data Collection|Topic|RELATED_TO
961|Sophie Quennelle|Author|Smart Data Extractor|Topic|AUTHORED
961|Maxime Douillet|Author|Smart Data Extractor|Topic|AUTHORED
961|Lisa Friedlander|Author|Smart Data Extractor|Topic|AUTHORED
961|Olivia Boyer|Author|Smart Data Extractor|Topic|AUTHORED
961|Anita Burgun|Author|Smart Data Extractor|Topic|AUTHORED
961|Antoine Neuraz|Author|Smart Data Extractor|Topic|AUTHORED
961|Nicolas Garcelon|Author|Smart Data Extractor|Topic|AUTHORED
962|Nlp Model Generalization|Topic|Aparna Elangovan|Author|AUTHORED
962|Nlp Model Generalization|Topic|Jiayuan He|Author|AUTHORED
962|Nlp Model Generalization|Topic|Yuan Li|Author|AUTHORED
962|Nlp Model Generalization|Topic|Karin Verspoor|Author|AUTHORED
963|Care|Topic|Biomedicine|Topic|RELATED_TO
963|Care|Topic|Clinical Trials|Topic|RELATED_TO
963|Care|Topic|Case Reports|Topic|RELATED_TO
963|Care|Topic|Computer Science|Topic|RELATED_TO
963|Care|Topic|Materials Science|Topic|RELATED_TO
963|Care|Topic|Gpt4|Topic|DISCUSSES
963|Aakanksha Naik|Author|Care|Topic|AUTHORED
963|Bailey Kuehl|Author|Care|Topic|AUTHORED
963|Erin Bransom|Author|Care|Topic|AUTHORED
963|Doug Downey|Author|Care|Topic|AUTHORED
963|Tom Hope|Author|Care|Topic|AUTHORED
964|Clinical Trials In Nsclc|Topic|Non-Small Cell Lung Cancer|Topic|RELATED_TO
964|Benjamin Schneider|Author|Comprehensive Joint Modeling Of First-Line Therapeutics In Non-Small Cell Lung Cancer|Paper|AUTHORED
964|Sébastien Benzekry|Author|Comprehensive Joint Modeling Of First-Line Therapeutics In Non-Small Cell Lung Cancer|Paper|AUTHORED
964|Jonathan Mochel|Author|Comprehensive Joint Modeling Of First-Line Therapeutics In Non-Small Cell Lung Cancer|Paper|AUTHORED
964|Bevacizumab-Antiproliferative Combination Therapy|Topic|Clinical Model Of Nsclc Growth|Topic|RELATED_TO
964|Acquired Resistance To Pharmaceuticals|Topic|Clinical Model Of Nsclc Growth|Topic|RELATED_TO
964|Anti-Vegf Therapy|Topic|Clinical Model Of Nsclc Growth|Topic|RELATED_TO
964|5-Year Survival Rate For Metastatic Disease|Topic|Non-Small Cell Lung Cancer|Topic|RELATED_TO
964|Late-Stage Disease Diagnosis|Topic|Non-Small Cell Lung Cancer|Topic|RELATED_TO
965|Large Language Models|Topic|Oncology|Topic|RELATED_TO
965|Openai Models|Topic|Adjuvant Radiation Therapy|Topic|RELATED_TO
965|Openai Models|Topic|Chemotherapy|Topic|RELATED_TO
965|Adjuvant Radiation Therapy|Topic|Breast Cancer|Topic|RELATED_TO
965|Chemotherapy|Topic|Breast Cancer|Topic|RELATED_TO
965|Tristen Pool|Author|A Large Language Model Pipeline For Breast Cancer Oncology|Paper|AUTHORED
965|Dennis Trujillo|Author|A Large Language Model Pipeline For Breast Cancer Oncology|Paper|AUTHORED
965|Langchain Prompt Engineering Pipeline|Topic|Openai Models|Topic|RELATED_TO
965|Clinical Trial|Topic|Oncology|Topic|RELATED_TO
965|U.S. Cancer Patients|Topic|Quality Care|Topic|RELATED_TO
966|Intervention Calculus When The Dag Is Absent (Ida)|Topic|Peter Clarks (Pc)-Algorithm|Topic|RELATED_TO
966|Peter Clarks (Pc)-Algorithm|Topic|Chronologically Ordered Pc-Algorithm (Copc-Algorithm)|Topic|RELATED_TO
966|Chronologically Ordered Pc-Algorithm (Copc-Algorithm)|Topic|Completed Partially Directed Acyclic Graphs (Cpdags)|Topic|RELATED_TO
966|Completed Partially Directed Acyclic Graphs (Cpdags)|Topic|Time-Dependent Immunological Biomarkers|Topic|RELATED_TO
966|Time-Dependent Immunological Biomarkers|Topic|Metastatic Melanoma|Topic|RELATED_TO
966|Vahé Asvatourian|Author|Intervention Calculus When The Dag Is Absent (Ida)|Topic|AUTHORED
966|Clélia Coutzac|Author|Intervention Calculus When The Dag Is Absent (Ida)|Topic|AUTHORED
966|Nathalie Chaput|Author|Intervention Calculus When The Dag Is Absent (Ida)|Topic|AUTHORED
966|Caroline Robert|Author|Intervention Calculus When The Dag Is Absent (Ida)|Topic|AUTHORED
966|Stefan Michiels|Author|Intervention Calculus When The Dag Is Absent (Ida)|Topic|AUTHORED
966|Emilie Lanoy|Author|Intervention Calculus When The Dag Is Absent (Ida)|Topic|AUTHORED
967|Glomerulosclerosis|Topic|Interstitial Fibrosis|Topic|RELATED_TO
967|Glomerulosclerosis|Topic|Tubular Atrophy|Topic|RELATED_TO
967|Interstitial Fibrosis|Topic|Tubular Atrophy|Topic|RELATED_TO
967|Artificial Intelligence|Topic|Computer Vision|Topic|RELATED_TO
967|Convolutional Neural Networks|Topic|Renal Biopsies|Topic|RELATED_TO
967|Brandon Ginley|Author|Neural Network Segmentation Of Interstitial Fibrosis, Tubular Atrophy, And Glomerulosclerosis In Renal Biopsies|Paper|AUTHORED
967|Kuang-Yu Jen|Author|Neural Network Segmentation Of Interstitial Fibrosis, Tubular Atrophy, And Glomerulosclerosis In Renal Biopsies|Paper|AUTHORED
967|Avi Rosenberg|Author|Neural Network Segmentation Of Interstitial Fibrosis, Tubular Atrophy, And Glomerulosclerosis In Renal Biopsies|Paper|AUTHORED
967|Felicia Yen|Author|Neural Network Segmentation Of Interstitial Fibrosis, Tubular Atrophy, And Glomerulosclerosis In Renal Biopsies|Paper|AUTHORED
967|Sanjay Jain|Author|Neural Network Segmentation Of Interstitial Fibrosis, Tubular Atrophy, And Glomerulosclerosis In Renal Biopsies|Paper|AUTHORED
967|Agnes Fogo|Author|Neural Network Segmentation Of Interstitial Fibrosis, Tubular Atrophy, And Glomerulosclerosis In Renal Biopsies|Paper|AUTHORED
967|Pinaki Sarder|Author|Neural Network Segmentation Of Interstitial Fibrosis, Tubular Atrophy, And Glomerulosclerosis In Renal Biopsies|Paper|AUTHORED
968|Haplo-Identical Transplantation|Topic|Hla Mismatches|Topic|RELATED_TO
968|Gramm|Topic|Alleles Imputation Accuracy|Topic|RELATED_TO
968|Gramm|Topic|Recombination Events|Topic|RELATED_TO
968|Gramm|Topic|False Positive Rate|Topic|RELATED_TO
968|Gramm|Topic|Israeli Population Dataset|Topic|RELATED_TO
968|Gramm|Topic|Australian Population Dataset|Topic|RELATED_TO
968|Zuriya Ansbacher-Feldman|Author|Gramm|Topic|AUTHORED
968|Sapir Israeli|Author|Gramm|Topic|AUTHORED
968|Martin Maiers|Author|Gramm|Topic|AUTHORED
968|Loren Gragert|Author|Gramm|Topic|AUTHORED
968|Dianne De Santis|Author|Gramm|Topic|AUTHORED
968|Moshe Israeli|Author|Gramm|Topic|AUTHORED
968|Yoram Louzoun|Author|Gramm|Topic|AUTHORED
969|Modular Sparse Distributed Code (Msdc)|Topic|Neuroscience|Topic|RELATED_TO
969|Modular Sparse Distributed Code (Msdc)|Topic|Sparse Distributed Codes (Sdcs)|Topic|RELATED_TO
969|Modular Sparse Distributed Code (Msdc)|Topic|Neocortex|Topic|RELATED_TO
969|Modular Sparse Distributed Code (Msdc)|Topic|Hippocampus|Topic|RELATED_TO
969|Modular Sparse Distributed Code (Msdc)|Topic|Wta Competitive Modules (Cms)|Topic|RELATED_TO
969|Modular Sparse Distributed Code (Msdc)|Topic|Binary Units|Topic|RELATED_TO
969|Modular Sparse Distributed Code (Msdc)|Topic|Single-Trial Unsupervised Learning Algorithm|Topic|RELATED_TO
969|Modular Sparse Distributed Code (Msdc)|Topic|Fixed Time Best-Match Retrieval|Topic|RELATED_TO
969|Modular Sparse Distributed Code (Msdc)|Topic|Fixed Time Belief Update|Topic|RELATED_TO
969|Modular Sparse Distributed Code (Msdc)|Topic|Novelty Of The Input|Topic|RELATED_TO
969|Modular Sparse Distributed Code (Msdc)|Topic|Spatial Patterns|Topic|RELATED_TO
970|Advances In Power Electronics|Topic|High Power Levels|Topic|RELATED_TO
970|Advances In Power Electronics|Topic|High Output Bandwidths|Topic|RELATED_TO
970|High Power Levels|Topic|Multichannel Wireless Power Transfer|Topic|RELATED_TO
970|High Output Bandwidths|Topic|Medical Applications|Topic|RELATED_TO
970|High Output Bandwidths|Topic|Neuroscience Applications|Topic|RELATED_TO
970|Conventional Inverters|Topic|High Power Levels|Topic|DISCUSSES
970|Resonant Circuits|Topic|High Output Bandwidths|Topic|DISCUSSES
970|Gallium-Nitride (Gan) Transistors|Topic|Modular Cascaded Double-H Bridge Circuits|Topic|RELATED_TO
970|Lightweight Embedded Control Solution|Topic|Look-Up-Table Digital Synthesizer|Topic|RELATED_TO
970|Lightweight Embedded Control Solution|Topic|Adaptive-Bias-Elimination Nearest-Level Modulation|Topic|RELATED_TO
970|Prototype|Topic|High Power Levels|Topic|DISCUSSES
970|Prototype|Topic|High Output Bandwidths|Topic|DISCUSSES
970|Jinshui Zhang|Author|Design And Implementation Of Dc-To-5~Mhz Wide-Bandwidth High-Power High-Fidelity Converter|Paper|AUTHORED
970|Boshuo Wang|Author|Design And Implementation Of Dc-To-5~Mhz Wide-Bandwidth High-Power High-Fidelity Converter|Paper|AUTHORED
970|Xiaoyang Tian|Author|Design And Implementation Of Dc-To-5~Mhz Wide-Bandwidth High-Power High-Fidelity Converter|Paper|AUTHORED
970|Angel Peterchev|Author|Design And Implementation Of Dc-To-5~Mhz Wide-Bandwidth High-Power High-Fidelity Converter|Paper|AUTHORED
970|Stefan Goetz|Author|Design And Implementation Of Dc-To-5~Mhz Wide-Bandwidth High-Power High-Fidelity Converter|Paper|AUTHORED
971|Neuro-Vision To Language: Enhancing Brain Recording-Based Visual Reconstruction And Language Interaction|Paper|Guobin Shen|Author|AUTHORED
971|Neuro-Vision To Language: Enhancing Brain Recording-Based Visual Reconstruction And Language Interaction|Paper|Dongcheng Zhao|Author|AUTHORED
971|Neuro-Vision To Language: Enhancing Brain Recording-Based Visual Reconstruction And Language Interaction|Paper|Xiang He|Author|AUTHORED
971|Neuro-Vision To Language: Enhancing Brain Recording-Based Visual Reconstruction And Language Interaction|Paper|Linghao Feng|Author|AUTHORED
971|Neuro-Vision To Language: Enhancing Brain Recording-Based Visual Reconstruction And Language Interaction|Paper|Yiting Dong|Author|AUTHORED
971|Neuro-Vision To Language: Enhancing Brain Recording-Based Visual Reconstruction And Language Interaction|Paper|Jihang Wang|Author|AUTHORED
971|Neuro-Vision To Language: Enhancing Brain Recording-Based Visual Reconstruction And Language Interaction|Paper|Qian Zhang|Author|AUTHORED
971|Neuro-Vision To Language: Enhancing Brain Recording-Based Visual Reconstruction And Language Interaction|Paper|Yi Zeng|Author|AUTHORED
971|Decoding Non-Invasive Brain Recordings|Topic|Vision Transformer 3D|Topic|RELATED_TO
971|Decoding Non-Invasive Brain Recordings|Topic|Large Language Models (Llms)|Topic|RELATED_TO
972|Gaussian Processes|Topic|Dimensionality Reduction|Topic|RELATED_TO
972|Dimensionality Reduction|Topic|Neuroscience|Topic|RELATED_TO
972|Multi-Population Interactions|Topic|Multi-Group Gaussian Process Factor Models|Topic|RELATED_TO
972|Multi-Group Gaussian Process Factor Models|Topic|Inducing Variables|Topic|RELATED_TO
972|Multi-Group Gaussian Process Factor Models|Topic|Frequency Domain|Topic|RELATED_TO
972|Evren Gokcen|Author|Multi-Group Gaussian Process Factor Models|Topic|AUTHORED
972|Anna I. Jasper|Author|Multi-Group Gaussian Process Factor Models|Topic|AUTHORED
972|Adam Kohn|Author|Multi-Group Gaussian Process Factor Models|Topic|AUTHORED
972|Christian K. Machens|Author|Multi-Group Gaussian Process Factor Models|Topic|AUTHORED
972|Byron M. Yu|Author|Multi-Group Gaussian Process Factor Models|Topic|AUTHORED
973|Savvy Project|Topic|Aalen-Johansen Estimator|Topic|RELATED_TO
973|Savvy Project|Topic|Kaplan-Meier Estimator|Topic|RELATED_TO
973|Savvy Project|Topic|Adverse Event|Topic|RELATED_TO
973|Savvy Project|Topic|Competing Events|Topic|RELATED_TO
974|Estimands Framework|Topic|Ich E9 (R1)|Topic|RELATED_TO
974|Treatment Policy Strategy|Topic|Mixed Model For Repeated Measures (Mmrm)|Topic|RELATED_TO
974|Treatment Policy Strategy|Topic|Multiple Imputation (Mi)|Topic|RELATED_TO
974|Phase 3 Trial|Topic|Respiratory Disease|Topic|RELATED_TO
974|Thomas Drury|Author|Estimands Framework|Topic|AUTHORED
974|Juan J Abellan|Author|Estimands Framework|Topic|AUTHORED
974|Nicky Best|Author|Estimands Framework|Topic|AUTHORED
974|Ian R. White|Author|Estimands Framework|Topic|AUTHORED
975|Prognostic Model For Relapses In Rrms|Topic|Relapsing-Remitting Multiple Sclerosis (Rrms)|Topic|RELATED_TO
975|Prognostic Model For Relapses In Rrms|Topic|Konstantina Chalkou|Author|AUTHORED
975|Prognostic Model For Relapses In Rrms|Topic|Ewout Steyerberg|Author|AUTHORED
975|Prognostic Model For Relapses In Rrms|Topic|Patrick Bossuyt|Author|AUTHORED
975|Prognostic Model For Relapses In Rrms|Topic|Suvitha Subramanian|Author|AUTHORED
975|Prognostic Model For Relapses In Rrms|Topic|Pascal Benkert|Author|AUTHORED
975|Prognostic Model For Relapses In Rrms|Topic|Jens Kuhle|Author|AUTHORED
975|Prognostic Model For Relapses In Rrms|Topic|Giulio Disanto|Author|AUTHORED
975|Prognostic Model For Relapses In Rrms|Topic|Ludwig Kappos|Author|AUTHORED
975|Prognostic Model For Relapses In Rrms|Topic|Matthias Egger|Author|AUTHORED
975|Prognostic Model For Relapses In Rrms|Topic|Georgia Salanti|Author|AUTHORED
976|Machine Learning Methods|Topic|Multi-Parametric Biomarkers|Topic|RELATED_TO
976|Machine Learning Methods|Topic|Neuroimaging|Topic|RELATED_TO
976|Machine Learning Methods|Topic|Dementia|Topic|RELATED_TO
976|Machine Learning Methods|Topic|Early Diagnosis Of Dementia|Topic|RELATED_TO
976|Machine Learning Methods|Topic|Individuals At-Risk Of Developing Dementia|Topic|RELATED_TO
976|Seven Grand Challenges|Topic|Screening|Topic|RELATED_TO
976|Seven Grand Challenges|Topic|Clinical Status Estimation|Topic|RELATED_TO
976|Seven Grand Challenges|Topic|Prediction|Topic|RELATED_TO
976|Seven Grand Challenges|Topic|Monitoring In (Pre-Clinical) Dementia|Topic|RELATED_TO
976|Seven Grand Challenges|Topic|Clinical Questions|Topic|RELATED_TO
976|Seven Grand Challenges|Topic|Performance Metrics|Topic|RELATED_TO
976|Validation Process|Topic|Data Preprocessing|Topic|RELATED_TO
976|Validation Process|Topic|Input Features|Topic|RELATED_TO
976|State-Of-The-Art Performances|Topic|Methods Evaluated By The Challenges|Topic|RELATED_TO
976|Statistical Analysis|Topic|Clinical Questions Beyond Alzheimer'S Disease|Topic|RELATED_TO
976|Testing Data Beyond The Alzheimer'S Disease Neuroimaging Initiative|Topic|Generalizability Of Algorithm Performance|Topic|RELATED_TO
976|Larger Testing Data Sizes|Topic|Sharing Algorithms Rather Than Data|Topic|RELATED_TO
976|Esther E. Bron|Author|Seven Grand Challenges|Topic|AUTHORED
976|Stefan Klein|Author|Seven Grand Challenges|Topic|AUTHORED
976|Annika Reinke|Author|Seven Grand Challenges|Topic|AUTHORED
976|Janne M. Papma|Author|Seven Grand Challenges|Topic|AUTHORED
976|Lena Maier-Hein|Author|Seven Grand Challenges|Topic|AUTHORED
976|Daniel C. Alexander|Author|Seven Grand Challenges|Topic|AUTHORED
976|Neil P. Oxtoby|Author|Seven Grand Challenges|Topic|AUTHORED
977|Sensing Danger: Innate Immunology For Intrusion Detection|Paper|Uwe Aickelin|Author|AUTHORED
977|Sensing Danger: Innate Immunology For Intrusion Detection|Paper|Julie Greensmith|Author|AUTHORED
978|Theoretical Immunology|Topic|Disordered Statistical Mechanics|Topic|RELATED_TO
978|Theoretical Immunology|Topic|Quantitative Theoretical Immunology|Topic|RELATED_TO
978|Disordered Statistical Mechanics|Topic|Quantitative Theoretical Immunology|Topic|RELATED_TO
978|Adaptive Immune Response|Topic|Disordered Statistical Mechanics|Topic|RELATED_TO
978|Research Article|Paper|Adriano Barra|Author|AUTHORED
978|Research Article|Paper|Elena Agliari|Author|AUTHORED
979|A Beginners Guide To Systems Simulation In Immunology|Paper|Monte Carlo Simulations|Topic|DISCUSSES
979|A Beginners Guide To Systems Simulation In Immunology|Paper|System Dynamics|Topic|DISCUSSES
979|A Beginners Guide To Systems Simulation In Immunology|Paper|Discrete-Event Simulation|Topic|DISCUSSES
979|A Beginners Guide To Systems Simulation In Immunology|Paper|Agent-Based Simulation|Topic|DISCUSSES
979|A Beginners Guide To Systems Simulation In Immunology|Paper|Immunology Research|Topic|RELATED_TO
979|A Beginners Guide To Systems Simulation In Immunology|Paper|Simulation Models|Topic|RELATED_TO
979|A Beginners Guide To Systems Simulation In Immunology|Paper|Modelling And Simulation|Topic|RELATED_TO
979|A Beginners Guide To Systems Simulation In Immunology|Paper|Simulation Problem|Topic|RELATED_TO
980|T-Cell Receptors|Topic|Antigenic Peptides|Topic|RELATED_TO
980|Artificial Neural Networks|Topic|Immunological Recognition|Topic|DISCUSSES
980|Jin Xu|Author|Immunological Recognition|Topic|AUTHORED
980|Junghyo Jo|Author|Immunological Recognition|Topic|AUTHORED
981|Covid-19 Vaccines|Topic|Sars-Cov-2 Infection|Topic|RELATED_TO
981|Vaccine-Induced Immunological Memory|Topic|Neutralizing Antibodies|Topic|RELATED_TO
981|Mathematical Model|Topic|Vaccine-Induced Immune Response|Topic|AUTHORED
981|Coronavac|Topic|Vaccine-Induced Immunological Memory|Topic|RELATED_TO
981|Booster Shot|Topic|Neutralizing Antibodies|Topic|RELATED_TO
981|Maximum Viral Load|Topic|Recovery Time|Topic|RELATED_TO
981|Vaccination Regimen|Topic|Fourth Dose|Topic|RELATED_TO
981|Virus Transmission|Topic|Public Health Policies|Topic|RELATED_TO
981|Xin Gao|Author|Mathematical Model|Topic|AUTHORED
981|Jianwei Li|Author|Mathematical Model|Topic|AUTHORED
981|Dianjie Li|Author|Mathematical Model|Topic|AUTHORED
982|Natural Language Processing|Topic|Clinical Trials|Topic|RELATED_TO
982|N2C2 Challenge|Topic|Clinical Trials|Topic|RELATED_TO
982|Mimic|Topic|Weakly Supervised Method|Topic|RELATED_TO
982|Weakly Supervised Method|Topic|N2C2 Challenge|Topic|RELATED_TO
982|Terminology-Based Approach|Topic|N2C2 Challenge|Topic|RELATED_TO
982|N2C2 Dataset|Topic|F1-Measure|Topic|RELATED_TO
982|Xavier Tannier|Author|N2C2 Challenge|Topic|AUTHORED
982|Nicolas Paris|Author|N2C2 Challenge|Topic|AUTHORED
982|Hugo Cisneros|Author|N2C2 Challenge|Topic|AUTHORED
982|Christel Daniel|Author|N2C2 Challenge|Topic|AUTHORED
982|Matthieu Doutreligne|Author|N2C2 Challenge|Topic|AUTHORED
982|Catherine Duclos|Author|N2C2 Challenge|Topic|AUTHORED
982|Nicolas Griffon|Author|N2C2 Challenge|Topic|AUTHORED
982|Claire Hassen-Khodja|Author|N2C2 Challenge|Topic|AUTHORED
982|Ivan Lerner|Author|N2C2 Challenge|Topic|AUTHORED
982|Adrien Parrot|Author|N2C2 Challenge|Topic|AUTHORED
982|Éric Sadou|Author|N2C2 Challenge|Topic|AUTHORED
982|Cyrina Saussol|Author|N2C2 Challenge|Topic|AUTHORED
982|Pascal Vaillant|Author|N2C2 Challenge|Topic|AUTHORED
983|Acute Neuroprotection In Clinical Trials|Topic|Clinical Trial Issues|Topic|RELATED_TO
983|Clinical Trial Issues|Topic|Neuroprotective Moiety Issues|Topic|RELATED_TO
983|Conditioning Strategies|Topic|Neuroprotective Framework|Topic|RELATED_TO
983|Tauskela Joseph S.|Author|Neuroprotective Framework|Topic|AUTHORED
983|Blondeau Nicolas|Author|Neuroprotective Framework|Topic|AUTHORED
984|Clinical Trial Results|Topic|Public Pharma Market Value|Topic|RELATED_TO
984|Bert-Based Model|Topic|Public Pharma Market Value|Topic|RELATED_TO
984|Temporal Fusion Transformer|Topic|Public Pharma Market Value|Topic|RELATED_TO
984|Graph Convolution Network|Topic|Public Pharma Market Value|Topic|RELATED_TO
984|Gradient Boosting|Topic|Public Pharma Market Value|Topic|RELATED_TO
984|Drug Portfolio Size|Topic|Public Pharma Market Value|Topic|RELATED_TO
984|Network Effect|Topic|Public Pharma Market Value|Topic|RELATED_TO
984|Fda Announcement Dataset|Topic|Public Pharma Market Value|Topic|RELATED_TO
984|Semen Budennyy|Author|New Drugs And Stock Market: How To Predict Pharma Market Reaction To Clinical Trial Announcements|Paper|AUTHORED
984|Alexey Kazakov|Author|New Drugs And Stock Market: How To Predict Pharma Market Reaction To Clinical Trial Announcements|Paper|AUTHORED
984|Elizaveta Kovtun|Author|New Drugs And Stock Market: How To Predict Pharma Market Reaction To Clinical Trial Announcements|Paper|AUTHORED
984|Leonid Zhukov|Author|New Drugs And Stock Market: How To Predict Pharma Market Reaction To Clinical Trial Announcements|Paper|AUTHORED
985|Drug Repurposing Network|Topic|Breast Cancer|Topic|RELATED_TO
985|Chatgpt|Author|Drug Repurposing Network|Topic|AUTHORED
985|Ahmed Abdeen Hamed|Author|Drug Repurposing Network|Topic|AUTHORED
985|Tamer E. Fandy|Author|Drug Repurposing Network|Topic|AUTHORED
985|Kegg Database|Topic|Drug Repurposing Network|Topic|RELATED_TO
985|Signaling Pathway Id Hsa:2064|Topic|Drug Repurposing Network|Topic|RELATED_TO
985|Signaling Pathway Id Hsa:1499|Topic|Drug Repurposing Network|Topic|RELATED_TO
986|Leads|Topic|Systematic Literature Review|Topic|RELATED_TO
986|Leads|Topic|Artificial Intelligence|Topic|RELATED_TO
986|Leads|Topic|Clinical Trials|Topic|RELATED_TO
986|Leads|Topic|Expert Workflows|Topic|RELATED_TO
986|Zifeng Wang|Author|Leads|Topic|AUTHORED
986|Lang Cao|Author|Leads|Topic|AUTHORED
986|Qiao Jin|Author|Leads|Topic|AUTHORED
986|Joey Chan|Author|Leads|Topic|AUTHORED
986|Nicholas Wan|Author|Leads|Topic|AUTHORED
986|Behdad Afzali|Author|Leads|Topic|AUTHORED
986|Hyun-Jin Cho|Author|Leads|Topic|AUTHORED
986|Chang-In Choi|Author|Leads|Topic|AUTHORED
986|Mehdi Emamverdi|Author|Leads|Topic|AUTHORED
986|Manjot K. Gill|Author|Leads|Topic|AUTHORED
986|Sun-Hyung Kim|Author|Leads|Topic|AUTHORED
986|Yijia Li|Author|Leads|Topic|AUTHORED
986|Yi Liu|Author|Leads|Topic|AUTHORED
986|Hanley Ong|Author|Leads|Topic|AUTHORED
986|Justin Rousseau|Author|Leads|Topic|AUTHORED
986|Irfan Sheikh|Author|Leads|Topic|AUTHORED
986|Jenny J. Wei|Author|Leads|Topic|AUTHORED
986|Ziyang Xu|Author|Leads|Topic|AUTHORED
986|Christopher M. Zallek|Author|Leads|Topic|AUTHORED
986|Kyungsang Kim|Author|Leads|Topic|AUTHORED
986|Yifan Peng|Author|Leads|Topic|AUTHORED
986|Zhiyong Lu|Author|Leads|Topic|AUTHORED
986|Jimeng Sun|Author|Leads|Topic|AUTHORED
987|Blockchain Technology|Topic|Healthcare Industry|Topic|RELATED_TO
987|Healthcare Industry|Topic|Electronic Health Records (Ehr)|Topic|RELATED_TO
987|Healthcare Industry|Topic|Medical Supply Chain Management System|Topic|RELATED_TO
987|Healthcare Industry|Topic|Genomic Market|Topic|RELATED_TO
987|Healthcare Industry|Topic|Neuroscience Technology|Topic|RELATED_TO
987|Healthcare Industry|Topic|Clinical Research|Topic|RELATED_TO
987|Healthcare Industry|Topic|Pharmaceutical Medicine|Topic|RELATED_TO
987|Blockchain In Healthcare And Medicine: A Contemporary Research Of Applications, Challenges, And Future Perspectives|Paper|H. Sami Ullah|Author|AUTHORED
987|Blockchain In Healthcare And Medicine: A Contemporary Research Of Applications, Challenges, And Future Perspectives|Paper|S. Aslam|Author|AUTHORED
988|Standard Model (Sm)|Topic|Diffusion Mri (Dmri)|Topic|RELATED_TO
988|Estimating Intra- And Extra-Axonal Microstructure Parameters|Topic|Standard Model (Sm)|Topic|DISCUSSES
988|20 Healthy Volunteers|Topic|Standard Model (Sm)|Topic|RELATED_TO
988|Santiago Coelho|Author|Standard Model (Sm)|Topic|AUTHORED
988|Steven H. Baete|Author|Standard Model (Sm)|Topic|AUTHORED
988|Gregory Lemberskiy|Author|Standard Model (Sm)|Topic|AUTHORED
988|Benjamin Ades-Aaron|Author|Standard Model (Sm)|Topic|AUTHORED
988|Genevieve Barrol|Author|Standard Model (Sm)|Topic|AUTHORED
988|Jelle Veraart|Author|Standard Model (Sm)|Topic|AUTHORED
988|Dmitry S. Novikov|Author|Standard Model (Sm)|Topic|AUTHORED
988|Els Fieremans|Author|Standard Model (Sm)|Topic|AUTHORED
989|Generative Adversarial Networks|Topic|Deep Learning|Topic|RELATED_TO
989|Generative Adversarial Networks|Topic|Generative Methods|Topic|RELATED_TO
989|Applications Of Generative Adversarial Networks In Neuroimaging And Clinical Neuroscience|Paper|Neurological Conditions|Topic|DISCUSSES
990|Neural Electrical Activity|Topic|Brain Function|Topic|RELATED_TO
990|Brain Function|Topic|Cognitive And Behavioral Processes|Topic|RELATED_TO
990|Brainwave|Paper|Brain Diseases|Topic|DISCUSSES
990|Brainwave|Paper|Neurological Disorders|Topic|DISCUSSES
990|Brainwave|Paper|Ai-Driven Approaches|Topic|RELATED_TO
990|Brainwave|Paper|Neuroscience Research|Topic|RELATED_TO
991|5Th Workshop On Machine Learning And Interpretation In Neuroimaging (Mlini)|Topic|Neural Information Processing Systems (Nips 2015)|Topic|RELATED_TO
991|5Th Workshop On Machine Learning And Interpretation In Neuroimaging (Mlini)|Topic|I. Rish|Author|AUTHORED
991|5Th Workshop On Machine Learning And Interpretation In Neuroimaging (Mlini)|Topic|L. Wehbe|Author|AUTHORED
991|5Th Workshop On Machine Learning And Interpretation In Neuroimaging (Mlini)|Topic|G. Langs|Author|AUTHORED
991|5Th Workshop On Machine Learning And Interpretation In Neuroimaging (Mlini)|Topic|M. Grosse-Wentrup|Author|AUTHORED
991|5Th Workshop On Machine Learning And Interpretation In Neuroimaging (Mlini)|Topic|B. Murphy|Author|AUTHORED
991|5Th Workshop On Machine Learning And Interpretation In Neuroimaging (Mlini)|Topic|G. Cecchi|Author|AUTHORED
992|Computational Logic For Biomedicine And Neurosciences|Paper|Systems Biology|Topic|DISCUSSES
992|Computational Logic For Biomedicine And Neurosciences|Paper|Neuroscience|Topic|DISCUSSES
992|Computational Logic For Biomedicine And Neurosciences|Paper|Biomedicine|Topic|DISCUSSES
992|Computational Logic For Biomedicine And Neurosciences|Paper|Calculus Of Inductive Constructions (Cic)|Topic|DISCUSSES
992|Computational Logic For Biomedicine And Neurosciences|Paper|Coq|Topic|DISCUSSES
992|Computational Logic For Biomedicine And Neurosciences|Paper|Drug Discovery|Topic|DISCUSSES
992|Computational Logic For Biomedicine And Neurosciences|Paper|Disease Diagnosis|Topic|DISCUSSES
993|Simple Rgc|Topic|Rgc Counter|Paper|RELATED_TO
993|Simple Rgc|Topic|Rgc Transduction|Paper|RELATED_TO
993|Simple Rgc|Topic|Rgc Batch|Paper|RELATED_TO
993|Rgc Counter|Paper|Tiger Cross|Author|AUTHORED
993|Rgc Counter|Paper|Rasika Navarange|Author|AUTHORED
993|Rgc Counter|Paper|Joon-Ho Son|Author|AUTHORED
993|Rgc Counter|Paper|William Burr|Author|AUTHORED
993|Rgc Counter|Paper|Arjun Singh|Author|AUTHORED
993|Rgc Counter|Paper|Kelvin Zhang|Author|AUTHORED
993|Rgc Counter|Paper|Miruna Rusu|Author|AUTHORED
993|Rgc Counter|Paper|Konstantinos Gkoutzis|Author|AUTHORED
993|Rgc Counter|Paper|Andrew Osborne|Author|AUTHORED
993|Rgc Counter|Paper|Bart Nieuwenhuis|Author|AUTHORED
994|Portiloop|Paper|Closed-Loop Brain Stimulation|Topic|RELATED_TO
995|Human Brain|Topic|Neuroscience Research|Topic|RELATED_TO
995|Neuroscience Research|Topic|Graph Neural Networks|Topic|RELATED_TO
995|Graph Neural Networks|Topic|Deep Models|Topic|RELATED_TO
995|Deep Models|Topic|Interpretable Framework|Topic|RELATED_TO
995|Interpretable Framework|Topic|Regions Of Interest|Topic|RELATED_TO
995|Interpretable Framework|Topic|Biomarkers|Topic|RELATED_TO
995|Ibgnn|Paper|Hejie Cui|Author|AUTHORED
995|Ibgnn|Paper|Wei Dai|Author|AUTHORED
995|Ibgnn|Paper|Yanqiao Zhu|Author|AUTHORED
995|Ibgnn|Paper|Xiaoxiao Li|Author|AUTHORED
995|Ibgnn|Paper|Lifang He|Author|AUTHORED
995|Ibgnn|Paper|Carl Yang|Author|AUTHORED
996|Noninvasive Brain Stimulation And Neuroimaging|Topic|Brain Biomarkers|Topic|RELATED_TO
996|Brain Biomarkers|Topic|Reliability|Topic|RELATED_TO
996|Brain Biomarkers|Topic|Validity|Topic|RELATED_TO
996|Tms-Eeg Biomarkers|Topic|Reliability|Topic|RELATED_TO
996|Tms-Eeg Biomarkers|Topic|Validity|Topic|RELATED_TO
996|Tms-Eeg Biomarkers|Topic|Sara Parmigiani|Author|AUTHORED
996|Tms-Eeg Biomarkers|Topic|Jessica M. Ross|Author|AUTHORED
996|Tms-Eeg Biomarkers|Topic|Christopher Cline|Author|AUTHORED
996|Tms-Eeg Biomarkers|Topic|Christopher B. Minasi|Author|AUTHORED
996|Tms-Eeg Biomarkers|Topic|Juha Gogulski|Author|AUTHORED
996|Tms-Eeg Biomarkers|Topic|Corey J Keller|Author|AUTHORED
997|Neuralizer|Topic|Neuroimage Processing Tasks|Topic|RELATED_TO
997|Steffen Czolbe|Author|Neuralizer|Topic|AUTHORED
997|Adrian V. Dalca|Author|Neuralizer|Topic|AUTHORED
998|Foundation Models|Topic|Medical Image Analysis|Topic|RELATED_TO
998|Foundation Models|Topic|Neuroscience Research|Topic|RELATED_TO
998|Brain Network Foundation Models|Topic|Neuroscience Research|Topic|RELATED_TO
998|Dataset|Topic|Brain Network Foundation Models|Topic|RELATED_TO
998|Brainmass Framework|Topic|Brain Network Foundation Models|Topic|AUTHORED
998|Brainmass Framework|Topic|Mask-Roi Modeling|Topic|RELATED_TO
998|Brainmass Framework|Topic|Latent Representation Alignment|Topic|RELATED_TO
998|Yanwu Yang|Author|Brainmass Framework|Topic|AUTHORED
998|Chenfei Ye|Author|Brainmass Framework|Topic|AUTHORED
998|Guinan Su|Author|Brainmass Framework|Topic|AUTHORED
998|Ziyao Zhang|Author|Brainmass Framework|Topic|AUTHORED
998|Zhikai Chang|Author|Brainmass Framework|Topic|AUTHORED
998|Hairui Chen|Author|Brainmass Framework|Topic|AUTHORED
998|Piu Chan|Author|Brainmass Framework|Topic|AUTHORED
998|Yue Yu|Author|Brainmass Framework|Topic|AUTHORED
998|Ting Ma|Author|Brainmass Framework|Topic|AUTHORED
999|Precision Medicine|Topic|Treatment Regime|Topic|RELATED_TO
999|Treatment Regime|Topic|Optimal Treatment Regime|Topic|RELATED_TO
999|Optimal Treatment Regime|Topic|Exploratory Analysis|Topic|RELATED_TO
999|Optimal Treatment Regime|Topic|Black-Box Estimation Methods|Topic|RELATED_TO
999|Yichi Zhang|Author|Interpretable Dynamic Treatment Regimes|Paper|AUTHORED
999|Eric B. Laber|Author|Interpretable Dynamic Treatment Regimes|Paper|AUTHORED
999|Anastasios Tsiatis|Author|Interpretable Dynamic Treatment Regimes|Paper|AUTHORED
999|Marie Davidian|Author|Interpretable Dynamic Treatment Regimes|Paper|AUTHORED
999|Interpretable Dynamic Treatment Regimes|Paper|Bipolar Disorder|Topic|RELATED_TO
999|Interpretable Dynamic Treatment Regimes|Paper|Sequential Clinical Trial|Topic|RELATED_TO
999|Interpretable Dynamic Treatment Regimes|Paper|Decision Rules|Topic|RELATED_TO
999|Decision Rules|Topic|If-Then Statements|Topic|RELATED_TO
999|Interpretable Dynamic Treatment Regimes|Paper|Simulation Examples|Topic|RELATED_TO
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Pranav Rajpurkar|Author|AUTHORED
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Anirudh Joshi|Author|AUTHORED
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Anuj Pareek|Author|AUTHORED
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Phil Chen|Author|AUTHORED
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Amirhossein Kiani|Author|AUTHORED
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Jeremy Irvin|Author|AUTHORED
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Andrew Y. Ng|Author|AUTHORED
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Matthew P. Lungren|Author|AUTHORED
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Chexpert|Topic|RELATED_TO
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Deep Learning Algorithms|Topic|RELATED_TO
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Chest X-Ray Interpretation|Topic|RELATED_TO
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Tb Detection|Topic|RELATED_TO
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Pathology Detection|Topic|RELATED_TO
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Auc|Topic|RELATED_TO
1000|Chexpedition: Investigating Generalization Challenges For Translation Of Chest X-Ray Algorithms To The Clinical Setting|Paper|Clinical Decision Support Tools|Topic|RELATED_TO
1001|Reinforcement Learning Framework|Topic|Intensive Care Units|Topic|RELATED_TO
1001|Sepsis Treatment|Topic|Intensive Care Units|Topic|RELATED_TO
1001|Luchen Li|Author|Sepsis Treatment|Topic|AUTHORED
1001|Ignacio Albert-Smet|Author|Sepsis Treatment|Topic|AUTHORED
1001|Aldo A. Faisal|Author|Sepsis Treatment|Topic|AUTHORED
1002|High-Throughput Sequencing|Topic|Personalized Medicine|Topic|RELATED_TO
1002|Targeted Therapies|Topic|Personalized Medicine|Topic|RELATED_TO
1002|Treatment Assignment Algorithm|Topic|Personalized Medicine|Topic|RELATED_TO
1002|Causal Framework|Topic|Precision Medicine Strategies|Topic|RELATED_TO
1002|Clinical Trials|Topic|Precision Medicine Strategies|Topic|RELATED_TO
1002|Gold Standard Treatment|Topic|Treatment Assignment Algorithm|Topic|RELATED_TO
1002|Observed Treatments|Topic|Treatment Assignment Algorithm|Topic|RELATED_TO
1002|Random Assignment Of Targeted Treatments|Topic|Treatment Assignment Algorithm|Topic|RELATED_TO
1002|Rshiny Interactive Application|Topic|Precision Medicine Strategies|Topic|RELATED_TO
1002|Patient-Derived Xenografts (Pdx)|Topic|Precision Medicine Strategies|Topic|RELATED_TO
1002|Jonas Béal|Author|Causal Inference With Multiple Versions Of Treatment And Application To Personalized Medicine|Paper|AUTHORED
1002|Aurélien Latouche|Author|Causal Inference With Multiple Versions Of Treatment And Application To Personalized Medicine|Paper|AUTHORED
1003|Virdocd|Topic|Dengue|Topic|RELATED_TO
1003|Virdocd|Topic|Clinical Eye|Topic|RELATED_TO
1003|Virdocd|Topic|Statistical And Machine Intelligence Tools (Smi)|Topic|RELATED_TO
1003|Virdocd|Topic|Multiple Linear Regression (Mlr)|Topic|RELATED_TO
1003|Virdocd|Topic|Random Forest Classification (Rf)|Topic|RELATED_TO
1003|Virdocd|Topic|Covid-19|Topic|RELATED_TO
1003|Amit K Chattopadhyay|Author|Virdocd|Topic|AUTHORED
1003|Subhagata Chattopadhyay|Author|Virdocd|Topic|AUTHORED
1004|Predicting Clinical Outcome Of Stroke Patients With Tractographic Feature|Paper|Po-Yu Kao|Author|AUTHORED
1004|Predicting Clinical Outcome Of Stroke Patients With Tractographic Feature|Paper|Jefferson W. Chen|Author|AUTHORED
1004|Predicting Clinical Outcome Of Stroke Patients With Tractographic Feature|Paper|B. S. Manjunath|Author|AUTHORED
1004|Predicting Clinical Outcome Of Stroke Patients With Tractographic Feature|Paper|Modified Rankin Scale|Topic|DISCUSSES
1004|Predicting Clinical Outcome Of Stroke Patients With Tractographic Feature|Paper|Stroke Lesion|Topic|DISCUSSES
1004|Predicting Clinical Outcome Of Stroke Patients With Tractographic Feature|Paper|Tractographic Feature|Topic|DISCUSSES
1004|Tractographic Feature|Topic|Ischemic Stroke Lesion Segmentation 2017|Topic|RELATED_TO
1005|Quality Assessment Tool For Machine Learning With Clinical Ct|Paper|Riqiang Gao|Author|AUTHORED
1005|Quality Assessment Tool For Machine Learning With Clinical Ct|Paper|Mirza S. Khan|Author|AUTHORED
1005|Quality Assessment Tool For Machine Learning With Clinical Ct|Paper|Yucheng Tang|Author|AUTHORED
1005|Quality Assessment Tool For Machine Learning With Clinical Ct|Paper|Kaiwen Xu|Author|AUTHORED
1005|Quality Assessment Tool For Machine Learning With Clinical Ct|Paper|Steve Deppen|Author|AUTHORED
1005|Quality Assessment Tool For Machine Learning With Clinical Ct|Paper|Yuankai Huo|Author|AUTHORED
1005|Quality Assessment Tool For Machine Learning With Clinical Ct|Paper|Kim L. Sandler|Author|AUTHORED
1005|Quality Assessment Tool For Machine Learning With Clinical Ct|Paper|Pierre P. Massion|Author|AUTHORED
1005|Quality Assessment Tool For Machine Learning With Clinical Ct|Paper|Bennett A. Landman|Author|AUTHORED
1005|Image Quality Assessment|Topic|Medical Imaging|Topic|RELATED_TO
1005|Image Quality Assessment|Topic|Machine Learning|Topic|RELATED_TO
1005|Image Quality Assessment|Topic|Computed Tomography|Topic|RELATED_TO
1005|Image Quality Assessment|Topic|National Lung Screening Trial|Topic|RELATED_TO
1006|Stroke|Topic|Neurological Injury|Topic|RELATED_TO
1006|Stroke|Topic|Cognition|Topic|RELATED_TO
1006|Stroke|Topic|Language|Topic|RELATED_TO
1006|Stroke|Topic|Sensory Functions|Topic|RELATED_TO
1006|Stroke|Topic|Motor Functions|Topic|RELATED_TO
1006|Stroke|Topic|Clinical Recovery|Topic|RELATED_TO
1006|Ninds Tpa Trial|Paper|Trajectory Profile Clustering (Tpc)|Topic|DISCUSSES
1006|Trajectory Profile Clustering (Tpc)|Topic|Stroke Recovery Phenotyping|Topic|RELATED_TO
1006|Graph Neural Networks|Topic|Trajectory Profile Clustering (Tpc)|Topic|RELATED_TO
1006|Sanjukta Krishnagopal|Author|Ninds Tpa Trial|Paper|AUTHORED
1006|Keith Lohse|Author|Ninds Tpa Trial|Paper|AUTHORED
1006|Robynne Braun|Author|Ninds Tpa Trial|Paper|AUTHORED
1007|Artificial Intelligence (Ai)-Based Methods|Topic|Oncologic Positron Emission Tomography (Pet) Images|Topic|RELATED_TO
1007|Dice Score|Topic|Metabolic Tumor Volume (Mtv)|Topic|RELATED_TO
1007|Dice Score|Topic|Total Lesion Glycolysis (Tlg)|Topic|RELATED_TO
1007|Non-Small Cell Lung Cancer|Topic|Ecog-Acrin 6668/Rtog 0235|Topic|RELATED_TO
1007|Ziping Liu|Author|Ecog-Acrin 6668/Rtog 0235|Topic|AUTHORED
1007|Joyce C. Mhlanga|Author|Ecog-Acrin 6668/Rtog 0235|Topic|AUTHORED
1007|Barry A. Siegel|Author|Ecog-Acrin 6668/Rtog 0235|Topic|AUTHORED
1007|Abhinav K. Jha|Author|Ecog-Acrin 6668/Rtog 0235|Topic|AUTHORED
1008|Machine Learning|Topic|Dementia Research|Topic|RELATED_TO
1008|Magda Bucholc|Author|Dementia Research|Topic|AUTHORED
1008|Charlotte James|Author|Dementia Research|Topic|AUTHORED
1008|Ahmad Al Khleifat|Author|Dementia Research|Topic|AUTHORED
1008|Amanpreet Badhwar|Author|Dementia Research|Topic|AUTHORED
1008|Natasha Clarke|Author|Dementia Research|Topic|AUTHORED
1008|Amir Dehsarvi|Author|Dementia Research|Topic|AUTHORED
1008|Christopher R. Madan|Author|Dementia Research|Topic|AUTHORED
1008|Sarah J. Marzi|Author|Dementia Research|Topic|AUTHORED
1008|Cameron Shand|Author|Dementia Research|Topic|AUTHORED
1008|Brian M. Schilder|Author|Dementia Research|Topic|AUTHORED
1008|Stefano Tamburin|Author|Dementia Research|Topic|AUTHORED
1008|Hanz M. Tantiangco|Author|Dementia Research|Topic|AUTHORED
1008|Ilianna Lourida|Author|Dementia Research|Topic|AUTHORED
1008|David J. Llewellyn|Author|Dementia Research|Topic|AUTHORED
1008|Janice M. Ranson|Author|Dementia Research|Topic|AUTHORED
1009|Harmonization Across Imaging Locations(Hail): One-Shot Learning For Brain Mri|Paper|Abhijeet Parida|Author|AUTHORED
1009|Harmonization Across Imaging Locations(Hail): One-Shot Learning For Brain Mri|Paper|Zhifan Jiang|Author|AUTHORED
1009|Harmonization Across Imaging Locations(Hail): One-Shot Learning For Brain Mri|Paper|Syed Muhammad Anwar|Author|AUTHORED
1009|Harmonization Across Imaging Locations(Hail): One-Shot Learning For Brain Mri|Paper|Nicholas Foreman|Author|AUTHORED
1009|Harmonization Across Imaging Locations(Hail): One-Shot Learning For Brain Mri|Paper|Nicholas Stence|Author|AUTHORED
1009|Harmonization Across Imaging Locations(Hail): One-Shot Learning For Brain Mri|Paper|Michael J. Fisher|Author|AUTHORED
1009|Harmonization Across Imaging Locations(Hail): One-Shot Learning For Brain Mri|Paper|Roger J. Packer|Author|AUTHORED
1009|Harmonization Across Imaging Locations(Hail): One-Shot Learning For Brain Mri|Paper|Robert A. Avery|Author|AUTHORED
1009|Harmonization Across Imaging Locations(Hail): One-Shot Learning For Brain Mri|Paper|Marius George Linguraru|Author|AUTHORED
1010|Chatgpt Advanced Data Analysis|Topic|Machine Learning|Topic|RELATED_TO
1010|Chatgpt Advanced Data Analysis|Topic|Clinical Data Analysis|Topic|RELATED_TO
1010|Soroosh Tayebi Arasteh|Author|Large Language Models Streamline Automated Machine Learning For Clinical Studies|Paper|AUTHORED
1010|Tianyu Han|Author|Large Language Models Streamline Automated Machine Learning For Clinical Studies|Paper|AUTHORED
1010|Mahshad Lotfinia|Author|Large Language Models Streamline Automated Machine Learning For Clinical Studies|Paper|AUTHORED
1010|Christiane Kuhl|Author|Large Language Models Streamline Automated Machine Learning For Clinical Studies|Paper|AUTHORED
1010|Jakob Nikolas Kather|Author|Large Language Models Streamline Automated Machine Learning For Clinical Studies|Paper|AUTHORED
1010|Daniel Truhn|Author|Large Language Models Streamline Automated Machine Learning For Clinical Studies|Paper|AUTHORED
1010|Sven Nebelung|Author|Large Language Models Streamline Automated Machine Learning For Clinical Studies|Paper|AUTHORED
1011|Chronic Itch|Topic|Us Population|Topic|RELATED_TO
1011|Home Radio Device|Topic|Artificial Intelligence|Topic|RELATED_TO
1011|Chronic Pruritus Patients|Topic|Clinical Study|Topic|AUTHORED
1011|Sleep Quality|Topic|Sleep Efficiency|Topic|RELATED_TO
1011|Sleep Quality|Topic|Sleep Latency|Topic|RELATED_TO
1011|Quantifying Itch|Topic|Machine Learning|Topic|RELATED_TO
1011|Quantifying Itch|Topic|Radio Signals|Topic|RELATED_TO
1011|Michail Ouroutzoglou|Author|Clinical Study|Topic|AUTHORED
1011|Mingmin Zhao|Author|Clinical Study|Topic|AUTHORED
1011|Joshua Hellerstein|Author|Clinical Study|Topic|AUTHORED
1011|Hariharan Rahul|Author|Clinical Study|Topic|AUTHORED
1011|Asima Badic|Author|Clinical Study|Topic|AUTHORED
1011|Brian S. Kim|Author|Clinical Study|Topic|AUTHORED
1011|Dina Katabi|Author|Clinical Study|Topic|AUTHORED
1012|Randomized Controlled Trials|Topic|Single-Arm Studies|Topic|RELATED_TO
1012|Hybrid Controlled Trials|Topic|Real-World Data|Topic|RELATED_TO
1012|Hybrid Controlled Trials|Topic|Randomized Controlled Trials|Topic|RELATED_TO
1012|Hybrid Controlled Trials|Topic|Single-Arm Studies|Topic|RELATED_TO
1012|W. Katherine Tan|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|Brian D. Segal|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|Melissa D. Curtis|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|Shrujal S. Baxi|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|William B. Capra|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|Elizabeth Garrett-Mayer|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|Brian P. Hobbs|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|David S. Hong|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|Rebecca A. Hubbard|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|Jiawen Zhu|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|Somnath Sarkar|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1012|Meghna Samant|Author|Augmenting Control Arms With Real-World Data For Cancer Trials: Hybrid Control Arm Methods And Considerations|Paper|AUTHORED
1013|Testing For Treatment Effect Twice Using Internal And External Controls In Clinical Trials|Paper|Yanyao Yi|Author|AUTHORED
1013|Testing For Treatment Effect Twice Using Internal And External Controls In Clinical Trials|Paper|Ying Zhang|Author|AUTHORED
1013|Testing For Treatment Effect Twice Using Internal And External Controls In Clinical Trials|Paper|Yu Du|Author|AUTHORED
1013|Testing For Treatment Effect Twice Using Internal And External Controls In Clinical Trials|Paper|Ting Ye|Author|AUTHORED
1014|A Wavelet Based Algorithm For The Identification Of Oscillatory Event-Related Potential Components|Paper|Event Related Potentials (Erps)|Topic|DISCUSSES
1014|A Wavelet Based Algorithm For The Identification Of Oscillatory Event-Related Potential Components|Paper|N170 Erp|Topic|DISCUSSES
1014|A Wavelet Based Algorithm For The Identification Of Oscillatory Event-Related Potential Components|Paper|Asymmetry Method|Topic|DISCUSSES
1014|Asymmetry Method|Topic|Matching Wavelet Algorithm|Topic|RELATED_TO
1014|Asymmetry Method|Topic|T-Cwt Method|Topic|RELATED_TO
1015|The Right Time To Learn: Mechanisms And Optimization Of Spaced Learning|Paper|Paul Smolen|Author|AUTHORED
1015|The Right Time To Learn: Mechanisms And Optimization Of Spaced Learning|Paper|Yili Zhang|Author|AUTHORED
1015|The Right Time To Learn: Mechanisms And Optimization Of Spaced Learning|Paper|John H. Byrne|Author|AUTHORED
1015|The Right Time To Learn: Mechanisms And Optimization Of Spaced Learning|Paper|Spaced Training|Topic|DISCUSSES
1015|The Right Time To Learn: Mechanisms And Optimization Of Spaced Learning|Paper|Massed Training|Topic|DISCUSSES
1015|The Right Time To Learn: Mechanisms And Optimization Of Spaced Learning|Paper|Cognitive Theories|Topic|DISCUSSES
1015|The Right Time To Learn: Mechanisms And Optimization Of Spaced Learning|Paper|Cellular And Molecular Mechanisms|Topic|DISCUSSES
1015|The Right Time To Learn: Mechanisms And Optimization Of Spaced Learning|Paper|Computational Models|Topic|DISCUSSES
1015|The Right Time To Learn: Mechanisms And Optimization Of Spaced Learning|Paper|Pharmacotherapy|Topic|DISCUSSES
1016|Neural Circuits|Topic|Decision-Making Theory|Topic|RELATED_TO
1016|Neural Circuits|Topic|Neural Activity|Topic|RELATED_TO
1016|Decision-Making Theory|Topic|Drift-Diffusion Model|Topic|RELATED_TO
1016|Drift-Diffusion Model|Topic|Recurrent State-Space Models|Topic|RELATED_TO
1016|Recurrent State-Space Models|Topic|Variational Laplace-Em Inference Algorithm|Topic|RELATED_TO
1016|Variational Laplace-Em Inference Algorithm|Topic|Monkey Parietal Cortex|Topic|RELATED_TO
1016|Monkey Parietal Cortex|Topic|Parietal Neurons|Topic|RELATED_TO
1016|Lip Neuron|Topic|Decision-Making Theory|Topic|RELATED_TO
1016|David M. Zoltowski|Author|Neural Circuits|Topic|AUTHORED
1016|Jonathan W. Pillow|Author|Neural Circuits|Topic|AUTHORED
1016|Scott W. Linderman|Author|Neural Circuits|Topic|AUTHORED
1017|Reinforcement Learning Framework For Deep Brain Stimulation Study|Paper|Dmitrii Krylov|Author|AUTHORED
1017|Reinforcement Learning Framework For Deep Brain Stimulation Study|Paper|Remi Tachet|Author|AUTHORED
1017|Reinforcement Learning Framework For Deep Brain Stimulation Study|Paper|Romain Laroche|Author|AUTHORED
1017|Reinforcement Learning Framework For Deep Brain Stimulation Study|Paper|Michael Rosenblum|Author|AUTHORED
1017|Reinforcement Learning Framework For Deep Brain Stimulation Study|Paper|Dmitry V. Dylov|Author|AUTHORED
1018|Characterizing Spreading Dynamics Of Subsampled Systems With Non-Stationary External Input|Paper|Jorge De Heuvel|Author|AUTHORED
1018|Characterizing Spreading Dynamics Of Subsampled Systems With Non-Stationary External Input|Paper|Jens Wilting|Author|AUTHORED
1018|Characterizing Spreading Dynamics Of Subsampled Systems With Non-Stationary External Input|Paper|Moritz Becker|Author|AUTHORED
1018|Characterizing Spreading Dynamics Of Subsampled Systems With Non-Stationary External Input|Paper|Viola Priesemann|Author|AUTHORED
1018|Characterizing Spreading Dynamics Of Subsampled Systems With Non-Stationary External Input|Paper|Johannes Zierenberg|Author|AUTHORED
1019|Quantifying Similarity Between Neural Representations|Topic|Stochastic Representations|Topic|DISCUSSES
1019|Quantifying Similarity Between Neural Representations|Topic|Deterministic Responses|Topic|DISCUSSES
1019|Quantifying Similarity Between Neural Representations|Topic|Neurobiological Representations|Topic|DISCUSSES
1019|Quantifying Similarity Between Neural Representations|Topic|Deep Network Representations|Topic|DISCUSSES
1019|Quantifying Similarity Between Neural Representations|Topic|Training Hyperparameters|Topic|DISCUSSES
1019|Lyndon R. Duong|Author|Quantifying Similarity Between Neural Representations|Topic|AUTHORED
1019|Jingyang Zhou|Author|Quantifying Similarity Between Neural Representations|Topic|AUTHORED
1019|Josue Nassar|Author|Quantifying Similarity Between Neural Representations|Topic|AUTHORED
1019|Jules Berman|Author|Quantifying Similarity Between Neural Representations|Topic|AUTHORED
1019|Jeroen Olieslagers|Author|Quantifying Similarity Between Neural Representations|Topic|AUTHORED
1019|Alex H. Williams|Author|Quantifying Similarity Between Neural Representations|Topic|AUTHORED
1020|Fluctuation Theorem|Topic|Motor Proteins|Topic|RELATED_TO
1020|Fluctuation Theorem|Topic|F1-Atpase|Topic|RELATED_TO
1020|Fluctuation Theorem|Topic|Kinesin|Topic|RELATED_TO
1020|Fluctuation Theorem|Topic|Dynein|Topic|RELATED_TO
1020|Kumiko Hayashi|Author|Fluctuation Theorem|Topic|AUTHORED
1021|Decoding Spiking Mechanism With Dynamic Learning On Neuron Population|Paper|Neuron Activation Network|Topic|DISCUSSES
1021|Decoding Spiking Mechanism With Dynamic Learning On Neuron Population|Paper|Retinal Ganglion Cells|Topic|DISCUSSES
1021|Zhijie Chen|Author|Decoding Spiking Mechanism With Dynamic Learning On Neuron Population|Paper|AUTHORED
1021|Junchi Yan|Author|Decoding Spiking Mechanism With Dynamic Learning On Neuron Population|Paper|AUTHORED
1021|Longyuan Li|Author|Decoding Spiking Mechanism With Dynamic Learning On Neuron Population|Paper|AUTHORED
1021|Xiaokang Yang|Author|Decoding Spiking Mechanism With Dynamic Learning On Neuron Population|Paper|AUTHORED
1022|Technological Advancements|Topic|Spiking Activities|Topic|RELATED_TO
1022|Spiking Activities|Topic|Neuron Ensembles|Topic|RELATED_TO
1022|Neuron Ensembles|Topic|Statistical Analysis|Topic|RELATED_TO
1022|Neuroscience Experiments|Topic|Randomized Interventions|Topic|RELATED_TO
1022|Groups Of Neurons|Topic|Stimulation Responses|Topic|RELATED_TO
1022|Observed Data|Topic|Neural Responses|Topic|RELATED_TO
1022|Neural Responses|Topic|Response Latencies|Topic|RELATED_TO
1022|Additive Shape Invariant Model|Topic|Model Parameters|Topic|RELATED_TO
1022|Model Parameters|Topic|Future Experiments|Topic|RELATED_TO
1022|Simulation Studies|Topic|Neural Data|Topic|RELATED_TO
1022|Neural Data|Topic|Mice|Topic|RELATED_TO
1022|Zitong Zhang|Author|Shizhe Chen|Author|AUTHORED
1023|Tadpole Challenge|Topic|Alzheimer'S Disease Neuroimaging Initiative|Topic|RELATED_TO
1023|Tadpole Challenge|Topic|Adni-3 Rollover Participants|Topic|RELATED_TO
1023|Team Frog|Author|Tadpole Challenge|Topic|AUTHORED
1023|Team Emc1|Author|Tadpole Challenge|Topic|AUTHORED
1023|Benchmarkme|Topic|Tadpole Challenge|Topic|RELATED_TO
1023|Razvan V. Marinescu|Author|Tadpole Challenge|Topic|AUTHORED
1023|Neil P. Oxtoby|Author|Tadpole Challenge|Topic|AUTHORED
1023|Alexandra L. Young|Author|Tadpole Challenge|Topic|AUTHORED
1023|Esther E. Bron|Author|Tadpole Challenge|Topic|AUTHORED
1023|Arthur W. Toga|Author|Tadpole Challenge|Topic|AUTHORED
1023|Michael W. Weiner|Author|Tadpole Challenge|Topic|AUTHORED
1023|Frederik Barkhof|Author|Tadpole Challenge|Topic|AUTHORED
1023|Nick C. Fox|Author|Tadpole Challenge|Topic|AUTHORED
1023|Polina Golland|Author|Tadpole Challenge|Topic|AUTHORED
1023|Stefan Klein|Author|Tadpole Challenge|Topic|AUTHORED
1023|Daniel C. Alexander|Author|Tadpole Challenge|Topic|AUTHORED
1024|Smart Devices|Topic|Thermistors|Topic|RELATED_TO
1024|Thermistors|Topic|Temperature Monitoring|Topic|RELATED_TO
1024|Temperature Monitoring|Topic|Core Body Temperature|Topic|RELATED_TO
1024|Joseph Breda|Author|Smartphone Fever Monitoring|Topic|AUTHORED
1024|Shwetak Patel|Author|Smartphone Fever Monitoring|Topic|AUTHORED
1024|Clinical Study|Topic|Smartphone Fever Monitoring|Topic|RELATED_TO
1025|Radiation-Induced Erectile Dysfunction (Ried)|Topic|Prostate Cancer|Topic|RELATED_TO
1025|Internal-Pudendal-Arteries (Ipa)|Topic|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|RELATED_TO
1025|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|Ct And Mri|Topic|RELATED_TO
1025|86 Patients|Topic|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|RELATED_TO
1025|Squeeze-And-Excite Blocks|Topic|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|RELATED_TO
1025|Novel Loss Function|Topic|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|RELATED_TO
1025|Modality Dropout Strategy|Topic|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|RELATED_TO
1025|Dsc|Topic|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|RELATED_TO
1025|Asd|Topic|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|RELATED_TO
1025|Hd95|Topic|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|RELATED_TO
1025|Ai Contours|Topic|Expert Physicians|Author|RELATED_TO
1025|Ai Contours|Topic|Inexperienced Physicians|Author|RELATED_TO
1025|Anjali Balagopal|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Michael Dohopolski|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Young Suk Kwon|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Steven Montalvo|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Howard Morgan|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Ti Bai|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Dan Nguyen|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Xiao Liang|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Xinran Zhong|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Mu-Han Lin|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Neil Desai|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1025|Steve Jiang|Author|Deep Learning (Dl)-Based Auto-Segmentation Model|Topic|AUTHORED
1026|Virtual Imaging Trials|Topic|Artificial Intelligence|Topic|RELATED_TO
1026|Covid-19|Topic|Artificial Intelligence|Topic|RELATED_TO
1026|3D Resnet-Like|Topic|Covid-19|Topic|RELATED_TO
1026|2D Efficientnetv2|Topic|Covid-19|Topic|RELATED_TO
1026|Auc|Topic|Virtual Imaging Trials|Topic|RELATED_TO
1026|Delong Method|Topic|Auc|Topic|RELATED_TO
1026|Fakrul Islam Tushar|Author|Virtual Imaging Trials|Topic|AUTHORED
1026|Lavsen Dahal|Author|Virtual Imaging Trials|Topic|AUTHORED
1026|Saman Sotoudeh-Paima|Author|Virtual Imaging Trials|Topic|AUTHORED
1026|Ehsan Abadi|Author|Virtual Imaging Trials|Topic|AUTHORED
1026|W. Paul Segars|Author|Virtual Imaging Trials|Topic|AUTHORED
1026|Ehsan Samei|Author|Virtual Imaging Trials|Topic|AUTHORED
1026|Joseph Y. Lo|Author|Virtual Imaging Trials|Topic|AUTHORED
1027|Resotran|Topic|Resovist|Topic|RELATED_TO
1027|Resotran|Topic|Ferrotran|Topic|RELATED_TO
1027|Resotran|Topic|Perimag|Topic|RELATED_TO
1027|Fabian Mohn|Author|Resotran|Topic|AUTHORED
1027|Konrad Scheffler|Author|Resotran|Topic|AUTHORED
1027|Justin Ackers|Author|Resotran|Topic|AUTHORED
1027|Agnes Weimer|Author|Resotran|Topic|AUTHORED
1027|Franz Wegner|Author|Resotran|Topic|AUTHORED
1027|Florian Thieben|Author|Resotran|Topic|AUTHORED
1027|Mandy Ahlborg|Author|Resotran|Topic|AUTHORED
1027|Patrick Vogel|Author|Resotran|Topic|AUTHORED
1027|Matthias Graeser|Author|Resotran|Topic|AUTHORED
1027|Tobias Knopp|Author|Resotran|Topic|AUTHORED
1028|Prostate Sbrt Treatment Survey|Topic|Proton Therapy Centers|Topic|RELATED_TO
1028|Proton Therapy Centers|Topic|Survey Results|Topic|DISCUSSES
1028|Survey Results|Topic|Reasons For Not Offering Sbrt|Topic|DISCUSSES
1028|Survey Results|Topic|Common Practices In Sbrt|Topic|DISCUSSES
1028|Common Practices In Sbrt|Topic|Patient-Specific Qa|Topic|RELATED_TO
1028|Common Practices In Sbrt|Topic|Treatment Planning|Topic|RELATED_TO
1029|Systematic Review And Meta-Analysis|Paper|Stereotactic Arrhythmia Radioablation (Star)|Topic|DISCUSSES
1029|Systematic Review And Meta-Analysis|Paper|Refractory Ventricular Tachycardia (Vt)|Topic|DISCUSSES
1029|Systematic Review And Meta-Analysis|Paper|Keyur D. Shah|Author|AUTHORED
1029|Systematic Review And Meta-Analysis|Paper|Chih-Wei Chang|Author|AUTHORED
1029|Systematic Review And Meta-Analysis|Paper|Sibo Tian|Author|AUTHORED
1029|Systematic Review And Meta-Analysis|Paper|Pretesh Patel|Author|AUTHORED
1029|Systematic Review And Meta-Analysis|Paper|Richard Qiu|Author|AUTHORED
1029|Systematic Review And Meta-Analysis|Paper|Justin Roper|Author|AUTHORED
1029|Systematic Review And Meta-Analysis|Paper|Jun Zhou|Author|AUTHORED
1029|Systematic Review And Meta-Analysis|Paper|Zhen Tian|Author|AUTHORED
1029|Systematic Review And Meta-Analysis|Paper|Xiaofeng Yang|Author|AUTHORED
1030|Vrnq|Topic|Vrise|Topic|RELATED_TO
1030|Vrnq|Topic|Vr_Session_Duration|Topic|RELATED_TO
1030|Participants|Topic|Vrnq|Topic|AUTHORED
1030|Panagiotis Kourtesis|Author|Vrnq|Topic|AUTHORED
1030|Simona Collina|Author|Vrnq|Topic|AUTHORED
1030|Leonidas A. A. Doumas|Author|Vrnq|Topic|AUTHORED
1030|Sarah E. Macpherson|Author|Vrnq|Topic|AUTHORED
1031|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|Cognitive Neuroscience|Topic|RELATED_TO
1031|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|Neuropsychology|Topic|RELATED_TO
1031|Panagiotis Kourtesis|Author|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|AUTHORED
1031|Danai Korre|Author|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|AUTHORED
1031|Simona Collina|Author|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|AUTHORED
1031|Leonidas A. A. Doumas|Author|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|AUTHORED
1031|Sarah E. Macpherson|Author|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|AUTHORED
1031|Vr Induced Symptoms And Effects (Vrise)|Topic|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|RELATED_TO
1031|Unity|Topic|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|RELATED_TO
1031|Vr Neuroscience Questionnaire (Vrnq)|Topic|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|RELATED_TO
1031|Participants|Topic|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|RELATED_TO
1031|User Experience|Topic|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|RELATED_TO
1031|Game Mechanics|Topic|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|RELATED_TO
1031|In-Game Assistance|Topic|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|RELATED_TO
1031|Graphics|Topic|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|RELATED_TO
1031|Vrise|Topic|Virtual Reality Everyday Assessment Lab (Vr-Eal)|Topic|RELATED_TO
1032|A Mutagenetic Tree Hidden Markov Model For Longitudinal Clonal Hiv Sequence Data|Paper|Niko Beerenwinkel|Author|AUTHORED
1032|A Mutagenetic Tree Hidden Markov Model For Longitudinal Clonal Hiv Sequence Data|Paper|Mathias Drton|Author|AUTHORED
1033|Didemnins|Topic|Jonathan L. Belof|Author|AUTHORED
1034|A New Family Of Covariate-Adjusted Response Adaptive Designs And Their Asymptotic Properties|Paper|Li-Xin Zhang|Author|AUTHORED
1034|A New Family Of Covariate-Adjusted Response Adaptive Designs And Their Asymptotic Properties|Paper|Feifang Hu|Author|AUTHORED
1035|Odds Theorem|Topic|Odds Algorithm|Topic|RELATED_TO
1035|Odds Theorem|Topic|Optimal Stopping Problems|Topic|DISCUSSES
1035|Odds Algorithm|Topic|Optimal Stopping Problems|Topic|DISCUSSES
1035|2000|Topic|Odds Theorem|Topic|RELATED_TO
1035|2000|Topic|Odds Algorithm|Topic|RELATED_TO
1035|Rémi Dendievel|Author|New Developments|Topic|AUTHORED
1035|New Developments|Topic|Gnew Developments|Topic|RELATED_TO
1035|Optimal Stopping Problems|Topic|Secretary Problems|Topic|RELATED_TO
1035|Optimal Stopping Problems|Topic|Robotic Maintenance Problems|Topic|RELATED_TO
1035|Optimal Stopping Problems|Topic|Compassionate Use Clinical Trials|Topic|RELATED_TO
1036|Human Dynamics|Topic|Stochastic Processes|Topic|RELATED_TO
1036|Stochastic Processes|Topic|Survival Analysis|Topic|RELATED_TO
1036|Survival Analysis|Topic|Generative Model|Topic|RELATED_TO
1036|Generative Model|Topic|Trevor Fenner|Author|AUTHORED
1036|Generative Model|Topic|Mark Levene|Author|AUTHORED
1036|Generative Model|Topic|George Loizou|Author|AUTHORED
1037|Online Learning Of Finite Markov Decision Process (Mdp) Problems|Topic|Applications Such As Clinical Trials And Recommendation Systems|Topic|RELATED_TO
1037|Yasin Abbasi-Yadkori|Author|Online Learning Of Finite Markov Decision Process (Mdp) Problems|Topic|AUTHORED
1037|Gergely Neu|Author|Online Learning Of Finite Markov Decision Process (Mdp) Problems|Topic|AUTHORED
1037|Computationally Efficient Algorithm|Topic|Regret Bound|Topic|DISCUSSES
1037|Regret Bound|Topic|Optimal Dynamic Policy|Topic|DISCUSSES
1037|Episodic Structure|Topic|Applications Such As Clinical Trials And Recommendation Systems|Topic|RELATED_TO
1037|Number Of Rounds|Topic|Regret Bound|Topic|DISCUSSES
1038|Gaussian Comparison Inequalities|Topic|Multivariate Gaussian Random Vectors|Topic|RELATED_TO
1038|Cumulative Distribution Function|Topic|Multivariate Normal Random Vector|Topic|RELATED_TO
1038|Cumulative Distribution Function|Topic|Standard Normal Random Variable|Topic|RELATED_TO
1038|Bayesian Design Of A Clinical Trial|Topic|Multivariate Normal Random Vector|Topic|RELATED_TO
1038|Amanda Turner|Author|Gaussian Comparison Inequalities|Topic|AUTHORED
1038|John Whitehead|Author|Gaussian Comparison Inequalities|Topic|AUTHORED
1039|A Statistical Model For Stroke Outcome Prediction And Treatment Planning|Paper|Stroke|Topic|RELATED_TO
1039|A Statistical Model For Stroke Outcome Prediction And Treatment Planning|Paper|Abhishek Sengupta|Author|AUTHORED
1039|A Statistical Model For Stroke Outcome Prediction And Treatment Planning|Paper|Vaibhav Rajan|Author|AUTHORED
1039|A Statistical Model For Stroke Outcome Prediction And Treatment Planning|Paper|Sakyajit Bhattacharya|Author|AUTHORED
1039|A Statistical Model For Stroke Outcome Prediction And Treatment Planning|Paper|G R K Sarma|Author|AUTHORED
1040|Thresholding Bandit For Dose-Ranging: The Impact Of Monotonicity|Paper|Aurélien Garivier|Author|AUTHORED
1040|Thresholding Bandit For Dose-Ranging: The Impact Of Monotonicity|Paper|Pierre Ménard|Author|AUTHORED
1040|Thresholding Bandit For Dose-Ranging: The Impact Of Monotonicity|Paper|Laurent Rossi|Author|AUTHORED
1040|Thresholding Bandit For Dose-Ranging: The Impact Of Monotonicity|Paper|Pierre Menard|Author|AUTHORED
1041|Vrc01|Topic|Hiv Infection Rate|Topic|RELATED_TO
1041|Lily Zhang|Author|Pharmacokinetics Simulations For Studying Correlates Of Prevention Efficacy Of Passive Hiv-1 Antibody Prophylaxis In The Antibody Mediated Prevention (Amp) Study|Paper|AUTHORED
1041|Peter B. Gilbert|Author|Pharmacokinetics Simulations For Studying Correlates Of Prevention Efficacy Of Passive Hiv-1 Antibody Prophylaxis In The Antibody Mediated Prevention (Amp) Study|Paper|AUTHORED
1041|Edmund Capparelli|Author|Pharmacokinetics Simulations For Studying Correlates Of Prevention Efficacy Of Passive Hiv-1 Antibody Prophylaxis In The Antibody Mediated Prevention (Amp) Study|Paper|AUTHORED
1041|Yunda Huang|Author|Pharmacokinetics Simulations For Studying Correlates Of Prevention Efficacy Of Passive Hiv-1 Antibody Prophylaxis In The Antibody Mediated Prevention (Amp) Study|Paper|AUTHORED
1042|Learning Patient Representations From Text|Paper|Dmitriy Dligach|Author|AUTHORED
1042|Learning Patient Representations From Text|Paper|Timothy Miller|Author|AUTHORED
1042|Learning Patient Representations From Text|Paper|Phenotyping|Topic|DISCUSSES
1042|Phenotyping|Topic|Applications Of Phenotyping|Topic|RELATED_TO
1042|Supervised Machine Learning|Topic|Phenotyping|Topic|RELATED_TO
1042|Neural Network Model|Topic|Supervised Machine Learning|Topic|RELATED_TO
1042|Neural Network Model|Topic|Comorbidity Detection Task|Topic|RELATED_TO
1043|Phi Scrubber: A Deep Learning Approach|Paper|Abhai Kollara Dilip|Author|AUTHORED
1043|Phi Scrubber: A Deep Learning Approach|Paper|Kamal Raj K|Author|AUTHORED
1043|Phi Scrubber: A Deep Learning Approach|Paper|Malaikannan Sankarasubbu|Author|AUTHORED
1043|Patient Information|Topic|Electronic Health Record System|Topic|RELATED_TO
1043|Deep Learning Model|Topic|Patient Information|Topic|RELATED_TO
1043|De-Convolutional Neural Network|Topic|Deep Learning Model|Topic|RELATED_TO
1043|Bi-Directional Lstm-Cnn|Topic|Deep Learning Model|Topic|RELATED_TO
1043|Regular Expressions|Topic|Deep Learning Model|Topic|RELATED_TO
1044|Risk-Averse Stochastic Convex Bandit|Paper|Online Convex Optimization|Topic|RELATED_TO
1045|Multi-Parameter Regression Model For Interval Censored Survival Data|Paper|Defen Peng|Author|AUTHORED
1045|Multi-Parameter Regression Model For Interval Censored Survival Data|Paper|Gilbert Mackenzie|Author|AUTHORED
1045|Multi-Parameter Regression Model For Interval Censored Survival Data|Paper|Kevin Burke|Author|AUTHORED
1046|Energy Distance And Kernel Mean Embeddings For Two-Sample Survival Testing|Paper|Marcos Matabuena|Author|AUTHORED
1046|Energy Distance And Kernel Mean Embeddings For Two-Sample Survival Testing|Paper|Oscar Hernan Madrid Padilla|Author|AUTHORED
1047|A Comparison Of Prior Elicitation Aggregation Using The Classical Method And Shelf|Paper|Subjective Bayesian Prior Distributions|Topic|DISCUSSES
1047|A Comparison Of Prior Elicitation Aggregation Using The Classical Method And Shelf|Paper|Equal Weight Aggregation|Topic|DISCUSSES
1047|A Comparison Of Prior Elicitation Aggregation Using The Classical Method And Shelf|Paper|Classical Method|Topic|DISCUSSES
1047|A Comparison Of Prior Elicitation Aggregation Using The Classical Method And Shelf|Paper|Sheffield Elicitation Framework|Topic|DISCUSSES
1047|A Comparison Of Prior Elicitation Aggregation Using The Classical Method And Shelf|Paper|Clinical Trial|Topic|DISCUSSES
1047|Cameron J. Williams|Author|A Comparison Of Prior Elicitation Aggregation Using The Classical Method And Shelf|Paper|AUTHORED
1047|Kevin J. Wilson|Author|A Comparison Of Prior Elicitation Aggregation Using The Classical Method And Shelf|Paper|AUTHORED
1047|Nina Wilson|Author|A Comparison Of Prior Elicitation Aggregation Using The Classical Method And Shelf|Paper|AUTHORED
1048|Corrupted Contextual Bandits|Topic|Djallel Bouneffouf|Author|AUTHORED
1049|Andersen-Gill Model|Topic|Recurrent Events|Topic|RELATED_TO
1049|Wald Test|Topic|Andersen-Gill Model|Topic|DISCUSSES
1049|Wald Test|Topic|Superiority Trials|Topic|DISCUSSES
1049|Wald Test|Topic|Noninferiority Trials|Topic|DISCUSSES
1049|Wald Test|Topic|Equivalence Trials|Topic|DISCUSSES
1049|Yongqiang Tang|Author|Wald Test|Topic|AUTHORED
1049|Ronan Fitzpatrick|Author|Wald Test|Topic|AUTHORED
1050|Sudeep Pasricha|Author|Ai Ethics In Smart Healthcare|Topic|AUTHORED
1051|Blended Mastery Learning In Mathematics|Paper|Teaching Cycle Based On Bloom'S Learning For Mastery|Topic|DISCUSSES
1051|Blended Mastery Learning In Mathematics|Paper|Stack Online Assessment System|Topic|DISCUSSES
1051|Blended Mastery Learning In Mathematics|Paper|University Level Engineering Students|Topic|DISCUSSES
1051|Blended Mastery Learning In Mathematics|Paper|Timo Pelkola|Author|AUTHORED
1051|Blended Mastery Learning In Mathematics|Paper|Antti Rasila|Author|AUTHORED
1051|Blended Mastery Learning In Mathematics|Paper|Christopher Sangwin|Author|AUTHORED
1052|Identifying Mediating Variables With Graphical Models: An Application To The Study Of Causal Pathways In People Living With Hiv|Paper|Adrian Dobra|Author|AUTHORED
1052|Identifying Mediating Variables With Graphical Models: An Application To The Study Of Causal Pathways In People Living With Hiv|Paper|Katherine Buhikire|Author|AUTHORED
1052|Identifying Mediating Variables With Graphical Models: An Application To The Study Of Causal Pathways In People Living With Hiv|Paper|Joachim G. Voss|Author|AUTHORED
1052|Identifying Mediating Variables With Graphical Models: An Application To The Study Of Causal Pathways In People Living With Hiv|Paper|Graphical Models|Topic|RELATED_TO
1052|Identifying Mediating Variables With Graphical Models: An Application To The Study Of Causal Pathways In People Living With Hiv|Paper|Causal Pathways|Topic|RELATED_TO
1052|Identifying Mediating Variables With Graphical Models: An Application To The Study Of Causal Pathways In People Living With Hiv|Paper|Hiv|Topic|RELATED_TO
1052|Identifying Mediating Variables With Graphical Models: An Application To The Study Of Causal Pathways In People Living With Hiv|Paper|Mediation|Topic|RELATED_TO
1053|Novel Non-Parametric Method|Topic|Sudipta Bhattacharya|Author|AUTHORED
1053|Novel Non-Parametric Method|Topic|Recurrent Events|Topic|RELATED_TO
1054|Chemistry42|Topic|Insilico Medicine Pharma.Ai|Topic|RELATED_TO
1054|Chemistry42|Topic|Yan A. Ivanenkov|Author|AUTHORED
1054|Chemistry42|Topic|Alex Zhebrak|Author|AUTHORED
1054|Chemistry42|Topic|Dmitry Bezrukov|Author|AUTHORED
1054|Chemistry42|Topic|Bogdan Zagribelnyy|Author|AUTHORED
1054|Chemistry42|Topic|Vladimir Aladinskiy|Author|AUTHORED
1054|Chemistry42|Topic|Daniil Polykovskiy|Author|AUTHORED
1054|Chemistry42|Topic|Evgeny Putin|Author|AUTHORED
1054|Chemistry42|Topic|Petrina Kamya|Author|AUTHORED
1054|Chemistry42|Topic|Alexander Aliper|Author|AUTHORED
1054|Chemistry42|Topic|Alex Zhavoronkov|Author|AUTHORED
1055|What Clinical Trials Can Teach Us About The Development Of More Resilient Ai For Cybersecurity|Paper|Edmon Begoli|Author|AUTHORED
1055|What Clinical Trials Can Teach Us About The Development Of More Resilient Ai For Cybersecurity|Paper|Robert A. Bridges|Author|AUTHORED
1055|What Clinical Trials Can Teach Us About The Development Of More Resilient Ai For Cybersecurity|Paper|Sean Oesch|Author|AUTHORED
1055|What Clinical Trials Can Teach Us About The Development Of More Resilient Ai For Cybersecurity|Paper|Kathryn E. Knight|Author|AUTHORED
1056|Ai-Based Medical Consultation System|Topic|Knowledge Graph Embedding|Topic|RELATED_TO
1056|Ai-Based Medical Consultation System|Topic|Reinforcement Learning|Topic|RELATED_TO
1056|Yining Huang|Author|Training Like Playing: A Reinforcement Learning And Knowledge Graph-Based Framework For Building Automatic Consultation System In Medical Field|Paper|AUTHORED
1056|Meilian Chen|Author|Training Like Playing: A Reinforcement Learning And Knowledge Graph-Based Framework For Building Automatic Consultation System In Medical Field|Paper|AUTHORED
1056|Keke Tang|Author|Training Like Playing: A Reinforcement Learning And Knowledge Graph-Based Framework For Building Automatic Consultation System In Medical Field|Paper|AUTHORED
1057|Data Integration In Causal Inference|Paper|Xu Shi|Author|AUTHORED
1057|Data Integration In Causal Inference|Paper|Ziyang Pan|Author|AUTHORED
1057|Data Integration In Causal Inference|Paper|Wang Miao|Author|AUTHORED
1057|Data Integration In Causal Inference|Paper|Causal Inference Methods|Topic|DISCUSSES
1057|Data Integration In Causal Inference|Paper|Data Integration|Topic|DISCUSSES
1057|Data Integration In Causal Inference|Paper|Mendelian Randomization|Topic|DISCUSSES
1057|Data Integration In Causal Inference|Paper|Bayesian Causal Inference|Topic|DISCUSSES
1057|Data Integration In Causal Inference|Paper|Causal Discovery Methods|Topic|DISCUSSES
1058|The Role Of Pairwise Matching In Experimental Design For An Incidence Outcome|Paper|Adam Kapelner|Author|AUTHORED
1058|The Role Of Pairwise Matching In Experimental Design For An Incidence Outcome|Paper|Abba M. Krieger|Author|AUTHORED
1058|The Role Of Pairwise Matching In Experimental Design For An Incidence Outcome|Paper|David Azriel|Author|AUTHORED
1059|Testing Homogeneity Of Proportion Ratios For Stratified Bilateral Correlated Data|Paper|Bilateral Data|Topic|DISCUSSES
1059|Testing Homogeneity Of Proportion Ratios For Stratified Bilateral Correlated Data|Paper|Statistical Methods|Topic|DISCUSSES
1059|Testing Homogeneity Of Proportion Ratios For Stratified Bilateral Correlated Data|Paper|Control Variables|Topic|DISCUSSES
1059|Testing Homogeneity Of Proportion Ratios For Stratified Bilateral Correlated Data|Paper|Monte Carlo Simulations|Topic|DISCUSSES
1059|Monte Carlo Simulations|Topic|Type I Error|Topic|RELATED_TO
1059|Monte Carlo Simulations|Topic|Power|Topic|RELATED_TO
1060|Confidence Intervals For Ratios Of Proportions In Stratified Bilateral Correlated Data|Paper|Wanqing Tian|Author|AUTHORED
1060|Confidence Intervals For Ratios Of Proportions In Stratified Bilateral Correlated Data|Paper|Chang-Xing Ma|Author|AUTHORED
1061|Randomized Play-The-Winner Model|Topic|Pólya Urn Process|Topic|RELATED_TO
1061|Randomized Play-The-Winner Model|Topic|Sars-Cov-2|Topic|RELATED_TO
1061|Randomized Play-The-Winner Model|Topic|Ivan Specht|Author|AUTHORED
1061|Randomized Play-The-Winner Model|Topic|Michael Mitzenmacher|Author|AUTHORED
1062|Causal Rule Ensemble Method|Paper|Heterogeneous Treatment Effect (Hte)|Topic|DISCUSSES
1062|Causal Rule Ensemble Method|Paper|Rulefit Method|Topic|DISCUSSES
1062|Causal Rule Ensemble Method|Paper|S-Learner|Topic|DISCUSSES
1062|Causal Rule Ensemble Method|Paper|Mayu Hiraishi|Author|AUTHORED
1062|Causal Rule Ensemble Method|Paper|Ke Wan|Author|AUTHORED
1062|Causal Rule Ensemble Method|Paper|Kensuke Tanioka|Author|AUTHORED
1062|Causal Rule Ensemble Method|Paper|Hiroshi Yadohisa|Author|AUTHORED
1062|Causal Rule Ensemble Method|Paper|Toshio Shimokawa|Author|AUTHORED
1063|Extracting Scalar Measures From Curves|Paper|Functional Outcomes|Topic|DISCUSSES
1063|Extracting Scalar Measures From Curves|Paper|Average Rate Of Change|Topic|DISCUSSES
1063|Extracting Scalar Measures From Curves|Paper|Change Score|Topic|DISCUSSES
1063|Extracting Scalar Measures From Curves|Paper|Analysis Of Covariance|Topic|DISCUSSES
1063|Extracting Scalar Measures From Curves|Paper|Depression Clinical Trial|Topic|DISCUSSES
1063|Lanqiu Yao|Author|Extracting Scalar Measures From Curves|Paper|AUTHORED
1063|Thaddeus Tarpey|Author|Extracting Scalar Measures From Curves|Paper|AUTHORED
1064|Nli4Ct|Topic|Mistral|Topic|RELATED_TO
1064|Nli4Ct|Topic|Dfki-Nlp|Author|AUTHORED
1065|Fzi-Wim At Semeval-2024 Task 2|Paper|Jin Liu|Author|AUTHORED
1065|Fzi-Wim At Semeval-2024 Task 2|Paper|Steffen Thoma|Author|AUTHORED
1065|Fzi-Wim At Semeval-2024 Task 2|Paper|Safe Biomedical Natural Language Inference For Clinical Trials|Topic|RELATED_TO
1065|Fzi-Wim At Semeval-2024 Task 2|Paper|Chain Of Thought (Cot)|Topic|RELATED_TO
1065|Fzi-Wim At Semeval-2024 Task 2|Paper|Self-Consistency|Topic|RELATED_TO
1065|Fzi-Wim At Semeval-2024 Task 2|Paper|Majority Voting|Topic|RELATED_TO
1065|Fzi-Wim At Semeval-2024 Task 2|Paper|Baseline F1 Score|Topic|RELATED_TO
1065|Fzi-Wim At Semeval-2024 Task 2|Paper|Faithfulness Score|Topic|RELATED_TO
1065|Fzi-Wim At Semeval-2024 Task 2|Paper|Consistency Score|Topic|RELATED_TO
1066|Experimental Design For Causal Inference Through An Optimization Lens|Paper|Jinglong Zhao|Author|AUTHORED
1067|Categorical Data Analysis|Paper|Dandan Chen|Author|AUTHORED
1067|Categorical Data Analysis|Paper|Carolyn Anderson|Author|AUTHORED
1068|Generative Ai In Medicine|Topic|Divya Shanmugam|Author|AUTHORED
1068|Generative Ai In Medicine|Topic|Monica Agrawal|Author|AUTHORED
1068|Generative Ai In Medicine|Topic|Rajiv Movva|Author|AUTHORED
1068|Generative Ai In Medicine|Topic|Irene Y. Chen|Author|AUTHORED
1068|Generative Ai In Medicine|Topic|Marzyeh Ghassemi|Author|AUTHORED
1068|Generative Ai In Medicine|Topic|Maia Jacobs|Author|AUTHORED
1068|Generative Ai In Medicine|Topic|Emma Pierson|Author|AUTHORED
1069|Bhandari Et Al. (2009)|Topic|Adaptive Sequential Procedure|Topic|RELATED_TO
1069|Sampurna Kundu|Author|Adaptive Sequential Procedure|Topic|AUTHORED
1069|Jayant Jha|Author|Adaptive Sequential Procedure|Topic|AUTHORED
1069|Subir Kumar Bhandari|Author|Adaptive Sequential Procedure|Topic|AUTHORED
1069|Adaptive Sequential Procedure|Topic|Two-Treatment Clinical Trials|Topic|RELATED_TO
1069|Adaptive Sequential Procedure|Topic|Less Effective Drug|Topic|RELATED_TO
1069|Adaptive Sequential Procedure|Topic|Expected Number Of Applications|Topic|RELATED_TO
1069|Expected Number Of Applications|Topic|Discrepancy In Sample Size|Topic|RELATED_TO
1070|France|Topic|National Plan For Open Science|Topic|RELATED_TO
1070|National Plan For Open Science|Topic|French Open Science Monitor|Topic|RELATED_TO
1070|French Open Science Monitor|Topic|Laetitia Bracco|Author|AUTHORED
1070|French Open Science Monitor|Topic|Eric Jeangirard|Author|AUTHORED
1070|French Open Science Monitor|Topic|Anne L'Hôte|Author|AUTHORED
1070|French Open Science Monitor|Topic|Laurent Romary|Author|AUTHORED
1072|Dynamics Of Multi-Stable States During Ongoing And Evoked Cortical Activity|Paper|Cortical Circuits Dynamics|Topic|DISCUSSES
1072|Dynamics Of Multi-Stable States During Ongoing And Evoked Cortical Activity|Paper|Metastability|Topic|DISCUSSES
1072|Dynamics Of Multi-Stable States During Ongoing And Evoked Cortical Activity|Paper|Sensory Coding|Topic|DISCUSSES
1072|Dynamics Of Multi-Stable States During Ongoing And Evoked Cortical Activity|Paper|Memory|Topic|DISCUSSES
1072|Dynamics Of Multi-Stable States During Ongoing And Evoked Cortical Activity|Paper|Decision-Making|Topic|DISCUSSES
1072|Dynamics Of Multi-Stable States During Ongoing And Evoked Cortical Activity|Paper|Gustatory Cortex|Topic|DISCUSSES
1072|Dynamics Of Multi-Stable States During Ongoing And Evoked Cortical Activity|Paper|Recurrent Spiking Network Model|Topic|DISCUSSES
1072|Dynamics Of Multi-Stable States During Ongoing And Evoked Cortical Activity|Paper|Neural Clusters|Topic|DISCUSSES
1072|Dynamics Of Multi-Stable States During Ongoing And Evoked Cortical Activity|Paper|External Stimuli|Topic|DISCUSSES
1073|Human Brain|Topic|Cognitive Tasks|Topic|RELATED_TO
1073|Cognitive Tasks|Topic|Information Theory|Topic|RELATED_TO
1073|Information Theory|Topic|Electrocorticography (Ecog)|Topic|RELATED_TO
1073|Ícaro Rodolfo Soares Coelho Da Paz|Author|Electrocorticography (Ecog)|Topic|AUTHORED
1073|Pedro F. A. Silva|Author|Electrocorticography (Ecog)|Topic|AUTHORED
1073|Helena Bordini De Lucas|Author|Electrocorticography (Ecog)|Topic|AUTHORED
1073|Sérgio H. A. Lira|Author|Electrocorticography (Ecog)|Topic|AUTHORED
1073|Osvaldo A. Rosso|Author|Electrocorticography (Ecog)|Topic|AUTHORED
1073|Fernanda Selingardi Matias|Author|Electrocorticography (Ecog)|Topic|AUTHORED
1074|Nonlinear Mixed-Effect Models For Prostate-Specific Antigen Kinetics And Link With Survival In The Context Of Metastatic Prostate Cancer: A Comparison By Simulation Of Two-Stage And Joint Approaches|Paper|Soléne Desmée|Author|AUTHORED
1074|Nonlinear Mixed-Effect Models For Prostate-Specific Antigen Kinetics And Link With Survival In The Context Of Metastatic Prostate Cancer: A Comparison By Simulation Of Two-Stage And Joint Approaches|Paper|France Mentré|Author|AUTHORED
1074|Nonlinear Mixed-Effect Models For Prostate-Specific Antigen Kinetics And Link With Survival In The Context Of Metastatic Prostate Cancer: A Comparison By Simulation Of Two-Stage And Joint Approaches|Paper|Christine Veyrat-Follet|Author|AUTHORED
1074|Nonlinear Mixed-Effect Models For Prostate-Specific Antigen Kinetics And Link With Survival In The Context Of Metastatic Prostate Cancer: A Comparison By Simulation Of Two-Stage And Joint Approaches|Paper|Jérémie Guedj|Author|AUTHORED
1074|Mcrpc|Topic|Psa|Topic|RELATED_TO
1074|Joint Modelling|Topic|Stochastic Approximation Expectation-Maximization Algorithm|Topic|RELATED_TO
1074|Clinical Trial|Topic|Mcrpc|Topic|RELATED_TO
1075|Dynamic Path Analysis - A Useful Tool To Investigate Mediation Processes In Clinical Survival Trials|Paper|Susanne Strohmaier|Author|AUTHORED
1075|Dynamic Path Analysis - A Useful Tool To Investigate Mediation Processes In Clinical Survival Trials|Paper|Kjetil Røysland|Author|AUTHORED
1075|Dynamic Path Analysis - A Useful Tool To Investigate Mediation Processes In Clinical Survival Trials|Paper|Rune Hoff|Author|AUTHORED
1075|Dynamic Path Analysis - A Useful Tool To Investigate Mediation Processes In Clinical Survival Trials|Paper|Ørnulf Borgan|Author|AUTHORED
1075|Dynamic Path Analysis - A Useful Tool To Investigate Mediation Processes In Clinical Survival Trials|Paper|Terje Pedersen|Author|AUTHORED
1075|Dynamic Path Analysis - A Useful Tool To Investigate Mediation Processes In Clinical Survival Trials|Paper|Odd O. Aalen|Author|AUTHORED
1075|Dynamic Path Analysis - A Useful Tool To Investigate Mediation Processes In Clinical Survival Trials|Paper|Clinical Survival Trials|Topic|RELATED_TO
1075|Dynamic Path Analysis - A Useful Tool To Investigate Mediation Processes In Clinical Survival Trials|Paper|Lipid Lowering Treatments|Topic|RELATED_TO
1075|Lipid Lowering Treatments|Topic|Myocardial Infarctions|Topic|RELATED_TO
1076|Big Data|Topic|Evidence-Based Medicine|Topic|RELATED_TO
1076|Evidence-Based Medicine|Topic|Meta-Analysis|Topic|RELATED_TO
1076|Meta-Analysis|Topic|Sample Mean|Topic|RELATED_TO
1076|Meta-Analysis|Topic|Standard Deviation|Topic|RELATED_TO
1076|Meta-Analysis|Topic|Clinical Trials|Topic|RELATED_TO
1076|Sample Mean|Topic|Optimal Estimation|Topic|RELATED_TO
1076|Optimal Estimation|Topic|Dehui Luo|Author|AUTHORED
1076|Optimal Estimation|Topic|Xiang Wan|Author|AUTHORED
1076|Optimal Estimation|Topic|Jiming Liu|Author|AUTHORED
1076|Optimal Estimation|Topic|Tiejun Tong|Author|AUTHORED
1076|Optimal Estimation|Topic|Real Data Application|Topic|RELATED_TO
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Correlation And Regression Analysis|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Dose Volume Histogram (Dvh)|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Local Injury Model|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Radiation-Induced Damage|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Functional Loss|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Risk|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Sigmoid Cumulative Distribution|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Bernoulli Function|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Homogeneous Patient Cohort|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Dvh Metrics|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Smoothness Regularization|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Integral Lung Damage|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Ventilation|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Perfusion|Topic|DISCUSSES
1077|Outcome Modeling Using Clinical Dvh Data|Paper|Radiographic Damage|Topic|DISCUSSES
1078|Individual Treatment Effect Prediction For Als Patients|Paper|Riluzole|Topic|DISCUSSES
1078|Individual Treatment Effect Prediction For Als Patients|Paper|Amyotrophic Lateral Sclerosis|Topic|RELATED_TO
1078|Individual Treatment Effect Prediction For Als Patients|Paper|Pro-Act Database|Topic|RELATED_TO
1079|Empirical Biomarker-Based Calculator For Autosomal Recessive Polycystic Kidney Disease - The Nieto-Narayan Formula|Paper|Jake A. Nieto|Author|AUTHORED
1079|Empirical Biomarker-Based Calculator For Autosomal Recessive Polycystic Kidney Disease - The Nieto-Narayan Formula|Paper|Michael A. Yamin|Author|AUTHORED
1079|Empirical Biomarker-Based Calculator For Autosomal Recessive Polycystic Kidney Disease - The Nieto-Narayan Formula|Paper|Itzhak D. Goldberg|Author|AUTHORED
1079|Empirical Biomarker-Based Calculator For Autosomal Recessive Polycystic Kidney Disease - The Nieto-Narayan Formula|Paper|Prakash Narayan|Author|AUTHORED
1079|Autosomal Polycystic Kidney Disease (Arpkd)|Topic|Empirical Biomarker-Based Calculator For Autosomal Recessive Polycystic Kidney Disease - The Nieto-Narayan Formula|Paper|RELATED_TO
1080|Devices And Sensors For Identification Of Fallers|Topic|Timed Up And Go Test|Topic|RELATED_TO
1080|Timed Up And Go Test|Topic|Accelerometer Data|Topic|RELATED_TO
1080|Community Dwelling Healthy Older Persons|Topic|Fallers|Topic|RELATED_TO
1080|Community Dwelling Healthy Older Persons|Topic|Non-Fallers|Topic|RELATED_TO
1080|Moacir Ponti|Author|Better Than Counting Seconds: Identifying Fallers Among Healthy Elderly Using Fusion Of Accelerometer Features And Dual-Task Timed Up And Go|Paper|AUTHORED
1080|Patricia Bet|Author|Better Than Counting Seconds: Identifying Fallers Among Healthy Elderly Using Fusion Of Accelerometer Features And Dual-Task Timed Up And Go|Paper|AUTHORED
1080|Caroline Oliveira|Author|Better Than Counting Seconds: Identifying Fallers Among Healthy Elderly Using Fusion Of Accelerometer Features And Dual-Task Timed Up And Go|Paper|AUTHORED
1080|Paula C. Castro|Author|Better Than Counting Seconds: Identifying Fallers Among Healthy Elderly Using Fusion Of Accelerometer Features And Dual-Task Timed Up And Go|Paper|AUTHORED
1080|Timed Up And Go Test|Topic|Auc Of 0.84|Topic|RELATED_TO
1080|Timed Up And Go Test|Topic|Sensitivity=Specificity=0.83|Topic|RELATED_TO
1080|Timed Up And Go Test|Topic|95% Ci 0.62-0.91|Topic|RELATED_TO
1080|Timed Up And Go Test|Topic|Dual Tasks Tug|Topic|RELATED_TO
1081|Optimal Exact Tests For Multiple Binary Endpoints|Paper|Robin Ristl|Author|AUTHORED
1081|Optimal Exact Tests For Multiple Binary Endpoints|Paper|Dong Xi|Author|AUTHORED
1081|Optimal Exact Tests For Multiple Binary Endpoints|Paper|Ekkehard Glimm|Author|AUTHORED
1081|Optimal Exact Tests For Multiple Binary Endpoints|Paper|Martin Posch|Author|AUTHORED
1082|Immune Interventions|Topic|Interleukine-7 (Il-7) Injections|Topic|RELATED_TO
1082|Interleukine-7 (Il-7) Injections|Topic|Hiv-Infected Patients|Topic|RELATED_TO
1082|Hiv-Infected Patients|Topic|Cd4+ T Lymphocytes|Topic|RELATED_TO
1082|Chloé Pasin|Author|Hiv-Infected Patients|Topic|AUTHORED
1082|François Dufour|Author|Hiv-Infected Patients|Topic|AUTHORED
1082|Laura Villain|Author|Hiv-Infected Patients|Topic|AUTHORED
1082|Huilong Zhang|Author|Hiv-Infected Patients|Topic|AUTHORED
1082|Rodolphe Thiébaut|Author|Hiv-Infected Patients|Topic|AUTHORED
1083|Meta-Analytic Methods|Topic|Normal-Normal Hierarchical Model (Nnhm)|Topic|RELATED_TO
1083|Normal-Normal Hierarchical Model (Nnhm)|Topic|Random-Effect|Topic|RELATED_TO
1083|Random-Effect|Topic|Between-Study Heterogeneity|Topic|RELATED_TO
1083|Normal-Normal Hierarchical Model (Nnhm)|Topic|Shrinkage Estimate|Topic|RELATED_TO
1083|Small-Scale Randomized Controlled Trial|Topic|Non-Randomized Study|Topic|RELATED_TO
1083|Non-Randomized Study|Topic|Clinical Registry|Topic|RELATED_TO
1083|Rare Diseases|Topic|Creutzfeld-Jakob Disease|Topic|RELATED_TO
1083|Bayesian Random-Effects Meta-Analysis|Topic|Shrinkage Estimate|Topic|RELATED_TO
1083|Immunosuppression Following Liver Transplantation In Children|Topic|Bayesian Random-Effects Meta-Analysis|Topic|RELATED_TO
1083|Christian Röver|Author|Tim Friede|Author|AUTHORED
1084|Optimizing Adaptive Cancer Therapy: Dynamic Programming And Evolutionary Game Theory|Paper|Adaptive Drug Therapy|Topic|DISCUSSES
1084|Optimizing Adaptive Cancer Therapy: Dynamic Programming And Evolutionary Game Theory|Paper|Standard Mtd-Based Policy|Topic|DISCUSSES
1084|Optimizing Adaptive Cancer Therapy: Dynamic Programming And Evolutionary Game Theory|Paper|Evolutionary Game Theory|Topic|DISCUSSES
1084|Optimizing Adaptive Cancer Therapy: Dynamic Programming And Evolutionary Game Theory|Paper|Dynamic Programming|Topic|DISCUSSES
1084|Optimizing Adaptive Cancer Therapy: Dynamic Programming And Evolutionary Game Theory|Paper|Hamilton-Jacobi-Bellman Equation|Topic|DISCUSSES
1084|Optimizing Adaptive Cancer Therapy: Dynamic Programming And Evolutionary Game Theory|Paper|Cancer Treatment|Topic|RELATED_TO
1085|Estimation Of Group Means In Generalized Linear Mixed Models|Paper|Generalized Linear Models|Topic|DISCUSSES
1085|Estimation Of Group Means In Generalized Linear Mixed Models|Paper|Generalized Linear Mixed Model (Glmm)|Topic|DISCUSSES
1085|Estimation Of Group Means In Generalized Linear Mixed Models|Paper|Healthcare Professionals|Topic|RELATED_TO
1086|Optimizing Graphical Procedures For Multiplicity Control In A Confirmatory Clinical Trial Via Deep Learning|Paper|Tianyu Zhan|Author|AUTHORED
1086|Optimizing Graphical Procedures For Multiplicity Control In A Confirmatory Clinical Trial Via Deep Learning|Paper|Alan H Hartford|Author|AUTHORED
1086|Optimizing Graphical Procedures For Multiplicity Control In A Confirmatory Clinical Trial Via Deep Learning|Paper|Jian Kang|Author|AUTHORED
1086|Optimizing Graphical Procedures For Multiplicity Control In A Confirmatory Clinical Trial Via Deep Learning|Paper|Walter W Offen|Author|AUTHORED
1086|Optimizing Graphical Procedures For Multiplicity Control In A Confirmatory Clinical Trial Via Deep Learning|Paper|Phase Ii Study|Topic|RELATED_TO
1086|Optimizing Graphical Procedures For Multiplicity Control In A Confirmatory Clinical Trial Via Deep Learning|Paper|Phase Iii Study|Topic|RELATED_TO
1086|Optimizing Graphical Procedures For Multiplicity Control In A Confirmatory Clinical Trial Via Deep Learning|Paper|Deep Learning|Topic|RELATED_TO
1086|Optimizing Graphical Procedures For Multiplicity Control In A Confirmatory Clinical Trial Via Deep Learning|Paper|Fnns|Topic|RELATED_TO
1086|Optimizing Graphical Procedures For Multiplicity Control In A Confirmatory Clinical Trial Via Deep Learning|Paper|Stochastic Search Method|Topic|RELATED_TO
1086|Optimizing Graphical Procedures For Multiplicity Control In A Confirmatory Clinical Trial Via Deep Learning|Paper|Multiple Testing Procedure|Topic|RELATED_TO
1087|Theory On Covariate-Adaptive Randomized Clinical Trials: Efficiency, Selection Bias And Randomization Methods|Paper|Li-Xin Zhang|Author|AUTHORED
1087|Theory On Covariate-Adaptive Randomized Clinical Trials: Efficiency, Selection Bias And Randomization Methods|Paper|Covariate-Adaptive Randomized Clinical Trials|Topic|RELATED_TO
1087|Theory On Covariate-Adaptive Randomized Clinical Trials: Efficiency, Selection Bias And Randomization Methods|Paper|Hypothesis Testing|Topic|RELATED_TO
1087|Theory On Covariate-Adaptive Randomized Clinical Trials: Efficiency, Selection Bias And Randomization Methods|Paper|Selection Bias|Topic|RELATED_TO
1087|Theory On Covariate-Adaptive Randomized Clinical Trials: Efficiency, Selection Bias And Randomization Methods|Paper|Power Of Hypothesis Testing|Topic|RELATED_TO
1087|Theory On Covariate-Adaptive Randomized Clinical Trials: Efficiency, Selection Bias And Randomization Methods|Paper|Randomization Procedures|Topic|RELATED_TO
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Lena Schmidt|Author|AUTHORED
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Julie Weeds|Author|AUTHORED
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Julian P. T. Higgins|Author|AUTHORED
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Natural Language Processing|Topic|RELATED_TO
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Pico Framework|Topic|RELATED_TO
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Transformers|Topic|RELATED_TO
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Data Extraction|Topic|RELATED_TO
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Systematic Review Automation|Topic|RELATED_TO
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Named Entity Recognition|Topic|RELATED_TO
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Transfer Learning|Topic|RELATED_TO
1088|Data Mining In Clinical Trial Text: Transformers For Classification And Question Answering Tasks|Paper|Biomedical Literature|Topic|RELATED_TO
1089|Concorde Clinical Trial|Topic|Zidovudine|Topic|RELATED_TO
1089|Alessandra Mattei|Author|Concorde Clinical Trial|Topic|AUTHORED
1089|Peng Ding|Author|Concorde Clinical Trial|Topic|AUTHORED
1089|Veronica Ballerini|Author|Concorde Clinical Trial|Topic|AUTHORED
1089|Fabrizia Mealli|Author|Concorde Clinical Trial|Topic|AUTHORED
1090|Testing For Treatment Effect In Covariate-Adaptive Randomized Clinical Trials With Generalized Linear Models And Omitted Covariates|Paper|Li Yang|Author|AUTHORED
1090|Testing For Treatment Effect In Covariate-Adaptive Randomized Clinical Trials With Generalized Linear Models And Omitted Covariates|Paper|Wei Ma|Author|AUTHORED
1090|Testing For Treatment Effect In Covariate-Adaptive Randomized Clinical Trials With Generalized Linear Models And Omitted Covariates|Paper|Yichen Qin|Author|AUTHORED
1090|Testing For Treatment Effect In Covariate-Adaptive Randomized Clinical Trials With Generalized Linear Models And Omitted Covariates|Paper|Feifang Hu|Author|AUTHORED
1091|Optical Character Recognition Software|Topic|Data Extraction Method|Topic|RELATED_TO
1091|Data Extraction Method|Topic|Macular Degeneration|Topic|RELATED_TO
1091|Automated Data Extraction|Topic|Manual Data Extraction|Topic|RELATED_TO
1091|Bland-Altman Analysis|Topic|Automated Data Extraction|Topic|RELATED_TO
1091|Bland-Altman Analysis|Topic|Manual Data Extraction|Topic|RELATED_TO
1091|Alex Carderas|Author|Automated Data Extraction|Topic|AUTHORED
1091|Ye Yuan|Author|Automated Data Extraction|Topic|AUTHORED
1091|Itamar Livnat|Author|Automated Data Extraction|Topic|AUTHORED
1091|Ryan Yanagihara|Author|Automated Data Extraction|Topic|AUTHORED
1091|Rosita Saul|Author|Automated Data Extraction|Topic|AUTHORED
1091|Gabrielle Montes De Oca|Author|Automated Data Extraction|Topic|AUTHORED
1091|Kai Zheng|Author|Automated Data Extraction|Topic|AUTHORED
1091|Andrew W. Browne|Author|Automated Data Extraction|Topic|AUTHORED
1092|Sars-Cov-2|Topic|Covid-19|Topic|RELATED_TO
1092|Covid-19|Topic|Monoclonal Antibody Therapies|Topic|RELATED_TO
1092|U.S. Fda|Author|Monoclonal Antibody Therapies|Topic|AUTHORED
1092|Regeneron|Author|Monoclonal Antibody Therapies|Topic|AUTHORED
1092|Eli Elly|Author|Monoclonal Antibody Therapies|Topic|AUTHORED
1092|Topological Ai-Designed Mabs|Topic|Covid-19|Topic|DISCUSSES
1092|Jiahui Chen|Author|Topological Ai-Designed Mabs|Topic|AUTHORED
1092|Guo-Wei Wei|Author|Topological Ai-Designed Mabs|Topic|AUTHORED
1093|Improving Safety Of The Continual Reassessment Method Via A Modified Allocation Rule|Paper|Pavel Mozgunov|Author|AUTHORED
1093|Improving Safety Of The Continual Reassessment Method Via A Modified Allocation Rule|Paper|Thomas Jaki|Author|AUTHORED
1094|Surrogate Endpoints|Topic|Regulatory Decision-Making|Topic|RELATED_TO
1094|Surrogate Endpoints|Topic|Healthcare|Topic|RELATED_TO
1094|Bivariate Meta-Analysis Methods|Topic|Treatment Effect|Topic|DISCUSSES
1094|Bivariate Meta-Analysis Methods|Topic|Final Outcome|Topic|DISCUSSES
1094|Bivariate Network Meta-Analysis (Bvnma)|Topic|Treatment Effect|Topic|DISCUSSES
1094|Bivariate Network Meta-Analysis (Bvnma)|Topic|Final Outcome|Topic|DISCUSSES
1094|Bivariate Network Meta-Analysis (Bvnma)|Topic|Advanced Colorectal Cancer|Topic|DISCUSSES
1094|Sylwia Bujkiewicz|Author|Bivariate Network Meta-Analysis (Bvnma)|Topic|AUTHORED
1094|Dan Jackson|Author|Bivariate Network Meta-Analysis (Bvnma)|Topic|AUTHORED
1094|John R Thompson|Author|Bivariate Network Meta-Analysis (Bvnma)|Topic|AUTHORED
1094|Rebecca Turner|Author|Bivariate Network Meta-Analysis (Bvnma)|Topic|AUTHORED
1094|Keith R Abrams|Author|Bivariate Network Meta-Analysis (Bvnma)|Topic|AUTHORED
1094|Ian R White|Author|Bivariate Network Meta-Analysis (Bvnma)|Topic|AUTHORED
1095|Empirical Likelihood Weighted Estimation Of Average Treatment Effects|Paper|Yuanyao Tan|Author|AUTHORED
1095|Empirical Likelihood Weighted Estimation Of Average Treatment Effects|Paper|Xialing Wen|Author|AUTHORED
1095|Empirical Likelihood Weighted Estimation Of Average Treatment Effects|Paper|Wei Liang|Author|AUTHORED
1095|Empirical Likelihood Weighted Estimation Of Average Treatment Effects|Paper|Ying Yan|Author|AUTHORED
1095|Empirical Likelihood Weighted Estimation Of Average Treatment Effects|Paper|Average Treatment Effect|Topic|RELATED_TO
1095|Empirical Likelihood Weighted Estimation Of Average Treatment Effects|Paper|Empirical Likelihood Method|Topic|RELATED_TO
1095|Empirical Likelihood Weighted Estimation Of Average Treatment Effects|Paper|Constrained Empirical Likelihood Estimation|Topic|RELATED_TO
1095|Empirical Likelihood Weighted Estimation Of Average Treatment Effects|Paper|Aids Clinical Trials Group Protocol 175|Topic|RELATED_TO
1096|Scale Transformed Power Prior|Topic|Power Prior|Topic|RELATED_TO
1096|Scale Transformed Power Prior|Topic|Historical Data|Topic|RELATED_TO
1096|Scale Transformed Power Prior|Topic|Current Data|Topic|RELATED_TO
1096|Scale Transformed Power Prior|Topic|Fisher Information Matrices|Topic|RELATED_TO
1096|Brady Nifong|Author|Scale Transformed Power Prior|Topic|AUTHORED
1096|Matthew A. Psioda|Author|Scale Transformed Power Prior|Topic|AUTHORED
1096|Joseph G. Ibrahim|Author|Scale Transformed Power Prior|Topic|AUTHORED
1096|Clinical Trials|Topic|Scale Transformed Power Prior|Topic|RELATED_TO
1096|Real Dataset|Topic|Transitional Care Model For Stroke Survivors|Topic|RELATED_TO
1096|Simulation Studies|Topic|Performance Advantages|Topic|RELATED_TO
1097|Covid-19 Therapeutics Trials|Topic|Ordinal Categorical Variable|Topic|RELATED_TO
1097|Covid-19 Therapeutics Trials|Topic|Odds Ratio|Topic|RELATED_TO
1097|Covid-19 Therapeutics Trials|Topic|Proportional Odds Model|Topic|RELATED_TO
1097|Covid-19 Therapeutics Trials|Topic|Censored Outcome|Topic|RELATED_TO
1097|Covid-19 Therapeutics Trials|Topic|Interim Analysis|Topic|RELATED_TO
1097|Anastasios A. Tsiatis|Author|Odds Ratio|Topic|AUTHORED
1097|Marie Davidian|Author|Odds Ratio|Topic|AUTHORED
1097|Shannon T. Holloway|Author|Odds Ratio|Topic|AUTHORED
1097|Odds Ratio|Topic|Covariate-Adjusted Estimator|Topic|RELATED_TO
1097|Randomized Clinical Trial|Topic|Odds Ratio|Topic|RELATED_TO
1098|A Comparison Of Various Aggregation Functions In Multi-Criteria Decision Analysis For Drug Benefit-Risk Assessment|Paper|Tom Menzies|Author|AUTHORED
1098|A Comparison Of Various Aggregation Functions In Multi-Criteria Decision Analysis For Drug Benefit-Risk Assessment|Paper|Gaelle Saint-Hilary|Author|AUTHORED
1098|A Comparison Of Various Aggregation Functions In Multi-Criteria Decision Analysis For Drug Benefit-Risk Assessment|Paper|Pavel Mozgunov|Author|AUTHORED
1098|Multi-Criteria Decision Analysis (Mcda)|Topic|Drug Benefit-Risk Assessment (Bra)|Topic|RELATED_TO
1098|Utility Score Function|Topic|Multi-Criteria Decision Analysis (Mcda)|Topic|RELATED_TO
1098|Linear Utility Score|Topic|Utility Score Function|Topic|RELATED_TO
1098|Product Model|Topic|Utility Score Function|Topic|RELATED_TO
1098|Multi-Linear Model|Topic|Utility Score Function|Topic|RELATED_TO
1098|Scale Loss Score Model|Topic|Utility Score Function|Topic|RELATED_TO
1099|Phase I-Ii Cancer Clinical Trial Designs|Topic|Drug Development|Topic|RELATED_TO
1099|Two-Stage Design|Topic|Cytotoxic Agents|Topic|RELATED_TO
1099|Two-Stage Design|Topic|Single Patient Population|Topic|RELATED_TO
1099|Conditional Escalation With Overdose Control (Ewoc)|Topic|Two-Stage Design|Topic|RELATED_TO
1099|Adaptive Randomization Approach|Topic|Two-Stage Design|Topic|RELATED_TO
1099|José L. Jiménez|Author|Drug Development|Topic|AUTHORED
1099|Mourad Tighiouart|Author|Drug Development|Topic|AUTHORED
1100|Combination Chemotherapy Optimization With Discrete Dosing|Paper|Chemotherapy|Topic|RELATED_TO
1101|Explainable Artificial Intelligence (Xai)|Topic|Deep Learning|Topic|RELATED_TO
1101|Deep Learning|Topic|Autism Spectrum Disorder (Asd)|Topic|RELATED_TO
1101|Convolutional Neural Network (Cnn)|Topic|Electroencephalography (Eeg)|Topic|RELATED_TO
1101|Remove-And-Retrain (Roar) Methodology|Topic|Convolutional Neural Network (Cnn)|Topic|RELATED_TO
1101|Layer-Wise Relevance Propagation (Lrp)|Topic|Convolutional Neural Network (Cnn)|Topic|RELATED_TO
1101|Patternnet|Topic|Convolutional Neural Network (Cnn)|Topic|RELATED_TO
1101|Pattern-Attribution|Topic|Convolutional Neural Network (Cnn)|Topic|RELATED_TO
1101|Smooth-Grad Squared|Topic|Convolutional Neural Network (Cnn)|Topic|RELATED_TO
1101|Juan Manuel Mayor-Torres|Author|Evaluation Of Interpretability For Deep Learning Algorithms In Eeg Emotion Recognition: A Case Study In Autism|Paper|AUTHORED
1101|Sara Medina-Devilliers|Author|Evaluation Of Interpretability For Deep Learning Algorithms In Eeg Emotion Recognition: A Case Study In Autism|Paper|AUTHORED
1101|Tessa Clarkson|Author|Evaluation Of Interpretability For Deep Learning Algorithms In Eeg Emotion Recognition: A Case Study In Autism|Paper|AUTHORED
1101|Matthew D. Lerner|Author|Evaluation Of Interpretability For Deep Learning Algorithms In Eeg Emotion Recognition: A Case Study In Autism|Paper|AUTHORED
1101|Giuseppe Riccardi|Author|Evaluation Of Interpretability For Deep Learning Algorithms In Eeg Emotion Recognition: A Case Study In Autism|Paper|AUTHORED
1103|Cox Proportional Hazards Model|Topic|Change-Points|Topic|RELATED_TO
1103|Cox Proportional Hazards Model|Topic|Aic-Type Information Criteria|Topic|RELATED_TO
1103|Change-Points|Topic|Aic-Type Information Criteria|Topic|RELATED_TO
1103|Ryoto Ozaki|Author|Aic-Type Information Criteria|Topic|AUTHORED
1103|Yoshiyuki Ninomiya|Author|Aic-Type Information Criteria|Topic|AUTHORED
1104|Clinical Trials|Topic|Wald Statistics|Topic|RELATED_TO
1104|Wald Statistics|Topic|Anovas|Topic|RELATED_TO
1104|Wald Statistics|Topic|Manovas|Topic|RELATED_TO
1104|Wald Statistics|Topic|Multiple Comparison Tests|Topic|RELATED_TO
1104|Wald Statistics|Topic|Multivariate Covariance Generalized Linear Models (Mcglms)|Topic|RELATED_TO
1104|Multivariate Covariance Generalized Linear Models (Mcglms)|Topic|R Language|Topic|RELATED_TO
1104|Probiotics|Topic|Addiction And Binge Eating Disorder|Topic|RELATED_TO
1104|Lineu Alberto Cavazani De Freitas|Author|Hypothesis Tests For Multiple Responses Regression: Effect Of Probiotics On Addiction And Binge Eating Disorder|Paper|AUTHORED
1104|Ligia De Oliveira Carlos|Author|Hypothesis Tests For Multiple Responses Regression: Effect Of Probiotics On Addiction And Binge Eating Disorder|Paper|AUTHORED
1104|Antônio Carlos Ligocki Campos|Author|Hypothesis Tests For Multiple Responses Regression: Effect Of Probiotics On Addiction And Binge Eating Disorder|Paper|AUTHORED
1104|Wagner Hugo Bonat|Author|Hypothesis Tests For Multiple Responses Regression: Effect Of Probiotics On Addiction And Binge Eating Disorder|Paper|AUTHORED
1105|Drug Effects On Chronic Diseases|Topic|Randomized Clinical Trials|Topic|RELATED_TO
1105|Kidney Disease Study|Topic|Average Treatment Effects|Topic|RELATED_TO
1105|Average Treatment Effects|Topic|Semiparametric Efficiency Bound|Topic|RELATED_TO
1105|Doubly Robust Estimator|Topic|Semiparametric Efficiency Bound|Topic|RELATED_TO
1105|Inverse Probability Weighted Estimator|Topic|Semiparametric Efficiency Bound|Topic|RELATED_TO
1105|Oral Hydroxychloroquine|Topic|Renal Failure|Topic|RELATED_TO
1105|Wenjie Hu|Author|Identification And Estimation Of Treatment Effects On Long-Term Outcomes In Clinical Trials With External Observational Data|Paper|AUTHORED
1105|Xiaohua Zhou|Author|Identification And Estimation Of Treatment Effects On Long-Term Outcomes In Clinical Trials With External Observational Data|Paper|AUTHORED
1105|Peng Wu|Author|Identification And Estimation Of Treatment Effects On Long-Term Outcomes In Clinical Trials With External Observational Data|Paper|AUTHORED
1106|Modeling Symptom Progression To Identify Informative Subjects For A New Huntington'S Disease Clinical Trial|Topic|Huntington'S Disease|Topic|RELATED_TO
1106|Sarah C. Lotspeich|Author|Modeling Symptom Progression To Identify Informative Subjects For A New Huntington'S Disease Clinical Trial|Topic|AUTHORED
1106|Tanya P. Garcia|Author|Modeling Symptom Progression To Identify Informative Subjects For A New Huntington'S Disease Clinical Trial|Topic|AUTHORED
1106|Hybrid Approach|Topic|Semiparametric Survival Estimator|Topic|RELATED_TO
1106|Hybrid Approach|Topic|Parametric Extension|Topic|RELATED_TO
1106|Extrapolation Then Imputation|Topic|Censored Covariates|Topic|RELATED_TO
1106|Extrapolation Then Imputation|Topic|Conditional Means|Topic|RELATED_TO
1106|Survival Function|Topic|Cox Model|Topic|RELATED_TO
1106|Survival Function|Topic|Breslow'S Estimator|Topic|RELATED_TO
1106|Simulation Studies|Topic|Clinical Trials|Topic|RELATED_TO
1107|Sample Size Determination For Restricted Mean Survival Time-Based Tests In Randomized Clinical Trials|Paper|Restricted Mean Survival Time (Rmst)|Topic|DISCUSSES
1107|Sample Size Determination For Restricted Mean Survival Time-Based Tests In Randomized Clinical Trials|Paper|Satoshi Hattori|Author|AUTHORED
1107|Sample Size Determination For Restricted Mean Survival Time-Based Tests In Randomized Clinical Trials|Paper|Hajime Uno|Author|AUTHORED
1108|Causal Inference Under Data Restrictions|Paper|Neoadjuvant Clinical Trials|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Distributed Data Networks|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Robust Individualized Decision Making|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Principal Stratification Framework|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Censored Outcome Data|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Tree-Based Model Averaging|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Conditional Average Treatment Effects|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Oxygen Therapy|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Hospital Survival Rates|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Robust Individualized Decision Learning Framework|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Sensitive Variables|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Quantile-Optimal Decision Rule|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Conditional Fairness|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Synthetic Experiments|Topic|RELATED_TO
1108|Causal Inference Under Data Restrictions|Paper|Real-Data Applications|Topic|RELATED_TO
1109|Maximum Penalised Likelihood Approach|Topic|Semiparametric Aft Model|Topic|RELATED_TO
1109|Semiparametric Aft Model|Topic|Survival Data|Topic|RELATED_TO
1109|Randomised Clinical Trial Dataset|Topic|Advanced Melanoma|Topic|RELATED_TO
1109|Aishwarya Bhaskaran|Author|Maximum Penalised Likelihood Approach|Topic|AUTHORED
1109|Ding Ma|Author|Maximum Penalised Likelihood Approach|Topic|AUTHORED
1109|Benoit Liquet|Author|Maximum Penalised Likelihood Approach|Topic|AUTHORED
1109|Angela Hong|Author|Maximum Penalised Likelihood Approach|Topic|AUTHORED
1109|Stephane Heritier|Author|Maximum Penalised Likelihood Approach|Topic|AUTHORED
1109|Serigne N Lo|Author|Maximum Penalised Likelihood Approach|Topic|AUTHORED
1109|Jun Ma|Author|Maximum Penalised Likelihood Approach|Topic|AUTHORED
1110|Autism Spectrum Disorder|Topic|Asd Mouse Models|Topic|RELATED_TO
1110|Asd Mouse Models|Topic|Social Circuit|Topic|RELATED_TO
1110|Egr1|Topic|Molecular Markers|Topic|RELATED_TO
1110|Foxp1|Topic|Molecular Markers|Topic|RELATED_TO
1110|Homer1A|Topic|Molecular Markers|Topic|RELATED_TO
1110|Oxt|Topic|Molecular Markers|Topic|RELATED_TO
1110|Oxtr|Topic|Molecular Markers|Topic|RELATED_TO
1110|Caroline Gora|Author|Autism Spectrum Disorder|Topic|AUTHORED
1110|Ana Dudas|Author|Autism Spectrum Disorder|Topic|AUTHORED
1110|Océane Vaugrente|Author|Autism Spectrum Disorder|Topic|AUTHORED
1110|Lucile Drobecq|Author|Autism Spectrum Disorder|Topic|AUTHORED
1110|Emmanuel Pecnard|Author|Autism Spectrum Disorder|Topic|AUTHORED
1110|Gaëlle Lefort|Author|Autism Spectrum Disorder|Topic|AUTHORED
1110|Lucie P. Pellissier|Author|Autism Spectrum Disorder|Topic|AUTHORED
1111|Non-Linear Mixed Effects Modeling And Simulation (Nlme M&S)|Topic|Standardization|Topic|RELATED_TO
1111|Standardization|Topic|Causal Inference|Topic|RELATED_TO
1111|Pharmacometrics|Topic|Non-Linear Mixed Effects Modeling And Simulation (Nlme M&S)|Topic|RELATED_TO
1111|Causal Prediction|Topic|Non-Linear Mixed Effects Modeling And Simulation (Nlme M&S)|Topic|RELATED_TO
1111|Christian Bartels|Author|Correcting For Confounding In Longitudinal Experiments: Positioning Non-Linear Mixed Effects Modeling As Implementation Of Standardization Using Latent Conditional Exchangeability|Paper|AUTHORED
1111|Martina Scauda|Author|Correcting For Confounding In Longitudinal Experiments: Positioning Non-Linear Mixed Effects Modeling As Implementation Of Standardization Using Latent Conditional Exchangeability|Paper|AUTHORED
1111|Neva Coello|Author|Correcting For Confounding In Longitudinal Experiments: Positioning Non-Linear Mixed Effects Modeling As Implementation Of Standardization Using Latent Conditional Exchangeability|Paper|AUTHORED
1111|Thomas Dumortier|Author|Correcting For Confounding In Longitudinal Experiments: Positioning Non-Linear Mixed Effects Modeling As Implementation Of Standardization Using Latent Conditional Exchangeability|Paper|AUTHORED
1111|Bjoern Bornkamp|Author|Correcting For Confounding In Longitudinal Experiments: Positioning Non-Linear Mixed Effects Modeling As Implementation Of Standardization Using Latent Conditional Exchangeability|Paper|AUTHORED
1111|Giusi Moffa|Author|Correcting For Confounding In Longitudinal Experiments: Positioning Non-Linear Mixed Effects Modeling As Implementation Of Standardization Using Latent Conditional Exchangeability|Paper|AUTHORED
1112|Randomized Play-The-Winner Rule|Topic|Elephant Random Walk|Topic|RELATED_TO
1112|Elephant Random Walk|Topic|Recursive Stochastic Algorithm|Topic|RELATED_TO
1112|Recursive Stochastic Algorithm|Topic|Gaussian Approximation|Topic|RELATED_TO
1112|Gaussian Approximation|Topic|Li-Xin Zhang|Author|AUTHORED
1113|Bayesian Generalized Method Of Moments Applied To Pseudo-Observations In Survival Analysis|Paper|Bayesian Approach|Topic|DISCUSSES
1113|Bayesian Generalized Method Of Moments Applied To Pseudo-Observations In Survival Analysis|Paper|Generalized Methods Of Moments (Gmm)|Topic|DISCUSSES
1113|Bayesian Generalized Method Of Moments Applied To Pseudo-Observations In Survival Analysis|Paper|Pseudo-Observations|Topic|DISCUSSES
1113|Bayesian Generalized Method Of Moments Applied To Pseudo-Observations In Survival Analysis|Paper|Cox Model|Topic|RELATED_TO
1113|Bayesian Generalized Method Of Moments Applied To Pseudo-Observations In Survival Analysis|Paper|Generalized Estimating Equation (Gee)|Topic|RELATED_TO
1113|Bayesian Generalized Method Of Moments Applied To Pseudo-Observations In Survival Analysis|Paper|Bayesian Piecewise Exponential Models|Topic|RELATED_TO
1113|Bayesian Generalized Method Of Moments Applied To Pseudo-Observations In Survival Analysis|Paper|Ewing Sarcoma|Topic|RELATED_TO
1114|Semiparametric Piecewise Accelerated Failure Time Model For The Analysis Of Immune-Oncology Clinical Trials|Paper|Immune-Oncology Chemotherapies|Topic|DISCUSSES
1114|Semiparametric Piecewise Accelerated Failure Time Model For The Analysis Of Immune-Oncology Clinical Trials|Paper|Clinical Trials|Topic|RELATED_TO
1114|Semiparametric Piecewise Accelerated Failure Time Model For The Analysis Of Immune-Oncology Clinical Trials|Paper|Hazard Ratio|Topic|RELATED_TO
1114|Semiparametric Piecewise Accelerated Failure Time Model For The Analysis Of Immune-Oncology Clinical Trials|Paper|Restricted Mean Survival Time|Topic|RELATED_TO
1114|Semiparametric Piecewise Accelerated Failure Time Model For The Analysis Of Immune-Oncology Clinical Trials|Paper|Lag-Time|Topic|RELATED_TO
1115|Identifying Treatment Response Subgroups In Observational Time-To-Event Data|Paper|Vincent Jeanselme|Author|AUTHORED
1115|Identifying Treatment Response Subgroups In Observational Time-To-Event Data|Paper|Chang Ho Yoon|Author|AUTHORED
1115|Identifying Treatment Response Subgroups In Observational Time-To-Event Data|Paper|Fabian Falck|Author|AUTHORED
1115|Identifying Treatment Response Subgroups In Observational Time-To-Event Data|Paper|Brian Tom|Author|AUTHORED
1115|Identifying Treatment Response Subgroups In Observational Time-To-Event Data|Paper|Jessica Barrett|Author|AUTHORED
1116|Stratification In Randomised Clinical Trials And Analysis Of Covariance: Some Simple Theory And Recommendations|Paper|Continuous Covariate|Topic|DISCUSSES
1116|Stratification In Randomised Clinical Trials And Analysis Of Covariance: Some Simple Theory And Recommendations|Paper|Treatment Effect|Topic|DISCUSSES
1116|Stratification In Randomised Clinical Trials And Analysis Of Covariance: Some Simple Theory And Recommendations|Paper|Variance Inflation Factor|Topic|DISCUSSES
1116|Stratification In Randomised Clinical Trials And Analysis Of Covariance: Some Simple Theory And Recommendations|Paper|Mean Square Error Effect|Topic|DISCUSSES
1116|Stratification In Randomised Clinical Trials And Analysis Of Covariance: Some Simple Theory And Recommendations|Paper|Second Order Precision|Topic|DISCUSSES
1117|Aranet|Paper|Cervical Cancer|Topic|RELATED_TO
1117|Aranet|Paper|Radiation Therapy|Topic|RELATED_TO
1117|Aranet|Paper|Lu Wen|Author|AUTHORED
1117|Aranet|Paper|Wenxia Yin|Author|AUTHORED
1117|Aranet|Paper|Zhenghao Feng|Author|AUTHORED
1117|Aranet|Paper|Xi Wu|Author|AUTHORED
1117|Aranet|Paper|Deng Xiong|Author|AUTHORED
1117|Aranet|Paper|Yan Wang|Author|AUTHORED
1118|Nonparametric Inference Methods|Topic|Survival Data|Topic|RELATED_TO
1118|Nonparametric Inference Methods|Topic|Cancer Therapies|Topic|RELATED_TO
1118|Mixture Cure Framework|Topic|Survival Data|Topic|RELATED_TO
1118|Kaplan-Meier Estimator|Topic|Survival Data|Topic|RELATED_TO
1118|Checkmate 067|Paper|Yi-Cheng Tai|Author|AUTHORED
1118|Checkmate 067|Paper|Weijing Wang|Author|AUTHORED
1118|Checkmate 067|Paper|Martin T. Wells|Author|AUTHORED
1119|Marker-Based Optical Motion Capture (Omc)|Topic|Markerless Motion Capture (Mmc)|Topic|RELATED_TO
1119|Markerless Motion Capture (Mmc)|Topic|Biomechanical Modeling|Topic|RELATED_TO
1119|Biomechanical Modeling|Topic|Stroke Patients|Topic|RELATED_TO
1119|Stroke Patients|Topic|Drinking Task|Topic|RELATED_TO
1119|Tim Unger|Author|Differentiable Biomechanics For Markerless Motion Capture In Upper Limb Stroke Rehabilitation: A Comparison With Optical Motion Capture|Paper|AUTHORED
1119|Arash Sal Moslehian|Author|Differentiable Biomechanics For Markerless Motion Capture In Upper Limb Stroke Rehabilitation: A Comparison With Optical Motion Capture|Paper|AUTHORED
1119|J. D. Peiffer|Author|Differentiable Biomechanics For Markerless Motion Capture In Upper Limb Stroke Rehabilitation: A Comparison With Optical Motion Capture|Paper|AUTHORED
1119|Johann Ullrich|Author|Differentiable Biomechanics For Markerless Motion Capture In Upper Limb Stroke Rehabilitation: A Comparison With Optical Motion Capture|Paper|AUTHORED
1119|Roger Gassert|Author|Differentiable Biomechanics For Markerless Motion Capture In Upper Limb Stroke Rehabilitation: A Comparison With Optical Motion Capture|Paper|AUTHORED
1119|Olivier Lambercy|Author|Differentiable Biomechanics For Markerless Motion Capture In Upper Limb Stroke Rehabilitation: A Comparison With Optical Motion Capture|Paper|AUTHORED
1119|R. James Cotton|Author|Differentiable Biomechanics For Markerless Motion Capture In Upper Limb Stroke Rehabilitation: A Comparison With Optical Motion Capture|Paper|AUTHORED
1119|Chris Awai Easthope|Author|Differentiable Biomechanics For Markerless Motion Capture In Upper Limb Stroke Rehabilitation: A Comparison With Optical Motion Capture|Paper|AUTHORED
1120|Computer Assisted Technologies Based On Algorithmic Software Segmentation|Topic|Growcut (Gc)|Topic|RELATED_TO
1120|Jürgen Wallner|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Kerstin Hochegger|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Xiaojun Chen|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Irene Mischak|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Knut Reinbacher|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Mauro Pau|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Tomislav Zrnc|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Katja Schwenzer-Zimmerer|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Wolfgang Zemann|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Dieter Schmalstieg|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Jan Egger|Author|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|AUTHORED
1120|Ct Lower Jaw Data-Sets|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Mandibular Bone|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Clinical Practice|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Surgical Treatment Planning|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Postoperative Results|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Segmentation Time|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Volume|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Voxel Number|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Dice Score (Dsc)|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Hausdorff Distance (Hd)|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Statistical Differences|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Correlation Coefficients|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Functional Stable|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Time Saving Segmentations|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|High Accuracy|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|High Positive Correlation|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Algorithmic Alternative|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Image-Based Segmentation|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Systematic Comparisons|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1120|Future Works|Topic|Clinical Evaluation Of Semi-Automatic Opensource Algorithmic Software Segmentation Of The Mandibular Bone: Practical Feasibility And Assessment Of A New Course Of Action|Paper|RELATED_TO
1121|Oropharyngeal Squamous Cell Carcinoma|Topic|Probabilistic Model For Ipsilateral Lymphatic Spread|Topic|RELATED_TO
1121|Probabilistic Model For Ipsilateral Lymphatic Spread|Topic|Hidden Markov Model|Topic|RELATED_TO
1121|Hidden Markov Model|Topic|Opscc Patients|Topic|RELATED_TO
1121|Opscc Patients|Topic|Roman Ludwig|Author|AUTHORED
1121|Opscc Patients|Topic|Adrian Schubert|Author|AUTHORED
1121|Opscc Patients|Topic|Dorothea Barbatei|Author|AUTHORED
1121|Opscc Patients|Topic|Lauence Bauwens|Author|AUTHORED
1121|Opscc Patients|Topic|Jean-Marc Hoffmann|Author|AUTHORED
1121|Opscc Patients|Topic|Sandrine Werlen|Author|AUTHORED
1121|Opscc Patients|Topic|Olgun Elicin|Author|AUTHORED
1121|Opscc Patients|Topic|Matthias Dettmer|Author|AUTHORED
1121|Opscc Patients|Topic|Philippe Zrounba|Author|AUTHORED
1121|Opscc Patients|Topic|Bertrand Pouymayou|Author|AUTHORED
1121|Opscc Patients|Topic|Panagiotis Balermpas|Author|AUTHORED
1121|Opscc Patients|Topic|Vincent Grégoire|Author|AUTHORED
1121|Opscc Patients|Topic|Roland Giger|Author|AUTHORED
1121|Opscc Patients|Topic|Jan Unkelbach|Author|AUTHORED
1122|Current Clinical Decision Support Systems|Topic|Observational Data|Topic|RELATED_TO
1122|Current Clinical Decision Support Systems|Topic|Randomized Clinical Trial|Topic|RELATED_TO
1122|Rct Data|Topic|Multi-Armed Rct|Topic|RELATED_TO
1122|Multi-Armed Rct|Topic|Tinnitus Patients|Topic|RELATED_TO
1122|Treatment|Topic|Tinnitus Patients|Topic|RELATED_TO
1122|Vishnu Unnikrishnan|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Clara Puga|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Miro Schleicher|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Uli Niemann|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Berthod Langguth|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Stefan Schoisswohl|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Birgit Mazurek|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Rilana Cima|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Jose Antonio Lopez-Escamez|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Dimitris Kikidis|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Eleftheria Vellidou|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Ruediger Pryss|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Winfried Schlee|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1122|Myra Spiliopoulou|Author|Training And Validating A Treatment Recommender With Partial Verification Evidence|Paper|AUTHORED
1123|Personalized Treatment Evaluator|Topic|Personalized Medicine|Topic|RELATED_TO
1123|Adam Kapelner|Author|Personalized Treatment Evaluator|Topic|AUTHORED
1123|Justin Bleich|Author|Personalized Treatment Evaluator|Topic|AUTHORED
1123|Alina Levine|Author|Personalized Treatment Evaluator|Topic|AUTHORED
1123|Zachary D. Cohen|Author|Personalized Treatment Evaluator|Topic|AUTHORED
1123|Robert J. Derubeis|Author|Personalized Treatment Evaluator|Topic|AUTHORED
1123|Richard Berk|Author|Personalized Treatment Evaluator|Topic|AUTHORED
1124|Causal Mediation Analysis|Topic|Ordinary Least Squares (Ols)|Topic|DISCUSSES
1124|Causal Mediation Analysis|Topic|Instrumental Variables (Iv)|Topic|DISCUSSES
1124|Instrumental Variables (Iv)|Topic|Two-Stage Least Squares (Tsls)|Topic|RELATED_TO
1124|Two-Stage Least Squares (Tsls)|Topic|Semi-Parametric Stein-Like (Spsl) Estimator|Topic|RELATED_TO
1124|Semi-Parametric Stein-Like (Spsl) Estimator|Topic|Randomized Controlled Trials|Topic|DISCUSSES
1124|Simulation Study|Topic|Mental Health Trial|Topic|RELATED_TO
1124|Cedric E. Ginestet|Author|Stein-Like Estimators For Causal Mediation Analysis In Randomized Trials|Paper|AUTHORED
1124|Richard Emsley|Author|Stein-Like Estimators For Causal Mediation Analysis In Randomized Trials|Paper|AUTHORED
1124|Sabine Landau|Author|Stein-Like Estimators For Causal Mediation Analysis In Randomized Trials|Paper|AUTHORED
1125|Health Economic Evaluations|Topic|Patient-Level Data|Topic|RELATED_TO
1125|Patient-Level Data|Topic|Clinical Trials|Topic|RELATED_TO
1125|Clinical Trials|Topic|Resource Allocation Decisions|Topic|RELATED_TO
1125|Missing Data|Topic|Qalys|Topic|RELATED_TO
1125|Joint Longitudinal Models|Topic|Cost-Effectiveness Analysis|Topic|RELATED_TO
1125|Joint Longitudinal Models|Topic|Missing Data|Topic|RELATED_TO
1125|Andrea Gabrio|Author|Joint Longitudinal Models|Topic|AUTHORED
1125|Rachael Hunter|Author|Joint Longitudinal Models|Topic|AUTHORED
1125|Alexina J. Mason|Author|Joint Longitudinal Models|Topic|AUTHORED
1125|Gianluca Baio|Author|Joint Longitudinal Models|Topic|AUTHORED
1126|Proportional Hazards|Topic|Confirmatory Clinical Trials|Topic|RELATED_TO
1126|Confirmatory Clinical Trials|Topic|Oncology|Topic|RELATED_TO
1126|Hazard Ratio|Topic|Weighted Log-Rank Test|Topic|RELATED_TO
1126|Weighted Log-Rank Test|Topic|Fleming And Harrington Class Of Weights|Topic|RELATED_TO
1126|Sample Size Calculation|Topic|Power|Topic|RELATED_TO
1126|Sample Size Calculation|Topic|Type-I Error Rate|Topic|RELATED_TO
1126|Weighted Log-Rank Test|Topic|Jose L Jimenez|Author|AUTHORED
1126|Weighted Log-Rank Test|Topic|Viktoriya Stalbovskaya|Author|AUTHORED
1126|Weighted Log-Rank Test|Topic|Byron Jones|Author|AUTHORED
1127|Knowledge Gradient For Randomized Controlled Trials|Topic|Randomized Controlled Trials|Topic|RELATED_TO
1127|Onur Atan|Author|Knowledge Gradient For Randomized Controlled Trials|Topic|AUTHORED
1127|William R. Zame|Author|Knowledge Gradient For Randomized Controlled Trials|Topic|AUTHORED
1127|Mihaela Van Der Schaar|Author|Knowledge Gradient For Randomized Controlled Trials|Topic|AUTHORED
1128|Conditional Power Calculations|Topic|Interim Decision Procedure|Topic|RELATED_TO
1128|Interim Decision Procedure|Topic|Treatment Effect Estimation|Topic|RELATED_TO
1128|Treatment Effect Estimation|Topic|Prediction Models|Topic|RELATED_TO
1128|Prediction Models|Topic|Efficiency Gain|Topic|RELATED_TO
1128|Efficiency Gain|Topic|Adaptive Designs|Topic|RELATED_TO
1128|Adaptive Designs|Topic|Monte Carlo Simulations|Topic|RELATED_TO
1128|Kelly Van Lancker|Author|Interim Decision Procedure|Topic|AUTHORED
1128|An Vandebosch|Author|Interim Decision Procedure|Topic|AUTHORED
1128|Stijn Vansteelandt|Author|Interim Decision Procedure|Topic|AUTHORED
1129|Sample Size Estimation Using A Latent Variable Model For Mixed Outcome Co-Primary, Multiple Primary And Composite Endpoints|Paper|Martina Mcmenamin|Author|AUTHORED
1129|Sample Size Estimation Using A Latent Variable Model For Mixed Outcome Co-Primary, Multiple Primary And Composite Endpoints|Paper|Jessica K. Barrett|Author|AUTHORED
1129|Sample Size Estimation Using A Latent Variable Model For Mixed Outcome Co-Primary, Multiple Primary And Composite Endpoints|Paper|Anna Berglind|Author|AUTHORED
1129|Sample Size Estimation Using A Latent Variable Model For Mixed Outcome Co-Primary, Multiple Primary And Composite Endpoints|Paper|James M. S. Wason|Author|AUTHORED
1129|Sample Size Estimation Using A Latent Variable Model For Mixed Outcome Co-Primary, Multiple Primary And Composite Endpoints|Paper|Mixed Outcome Endpoints|Topic|RELATED_TO
1129|Sample Size Estimation Using A Latent Variable Model For Mixed Outcome Co-Primary, Multiple Primary And Composite Endpoints|Paper|Latent Variable Model|Topic|RELATED_TO
1129|Sample Size Estimation Using A Latent Variable Model For Mixed Outcome Co-Primary, Multiple Primary And Composite Endpoints|Paper|Sample Size Estimation|Topic|RELATED_TO
1129|Sample Size Estimation Using A Latent Variable Model For Mixed Outcome Co-Primary, Multiple Primary And Composite Endpoints|Paper|Muse Trial|Topic|RELATED_TO
1130|Cvrs|Topic|Cvrs2|Topic|RELATED_TO
1130|Cvrs2|Topic|Psychiatry Trial|Topic|DISCUSSES
1130|Cvrs2|Topic|Psychology Clinical Trial|Topic|DISCUSSES
1130|Svetlana Cherlin|Author|Cvrs2|Topic|AUTHORED
1130|James M. S. Wason|Author|Cvrs2|Topic|AUTHORED
1131|Bayesian Sample Size Calculations For Smart Studies|Paper|Armando Turchetta|Author|AUTHORED
1131|Bayesian Sample Size Calculations For Smart Studies|Paper|Erica E. M. Moodie|Author|AUTHORED
1131|Bayesian Sample Size Calculations For Smart Studies|Paper|David A. Stephens|Author|AUTHORED
1131|Bayesian Sample Size Calculations For Smart Studies|Paper|Sylvie D. Lambert|Author|AUTHORED
1131|Bayesian Sample Size Calculations For Smart Studies|Paper|Adaptive Treatment Strategies|Topic|RELATED_TO
1131|Bayesian Sample Size Calculations For Smart Studies|Paper|Sequential Multiple Assignment Randomized Trials|Topic|RELATED_TO
1131|Bayesian Sample Size Calculations For Smart Studies|Paper|Bayesian Framework|Topic|RELATED_TO
1132|A Review Of Available Software For Adaptive Clinical Trial Design|Paper|Adaptive Designs|Topic|DISCUSSES
1132|A Review Of Available Software For Adaptive Clinical Trial Design|Paper|Drug Development|Topic|RELATED_TO
1133|Use Of Historical Data In Clinical Trial Design And Analysis|Topic|Meta-Analytic-Predictive (Map) Approach|Topic|RELATED_TO
1133|Meta-Analytic-Predictive (Map) Approach|Topic|Rbest (R Bayesian Evidence Synthesis Tools)|Paper|DISCUSSES
1134|Strituvad|Topic|Ruti|Topic|RELATED_TO
1134|Strituvad|Topic|Id93/Gla-Se|Topic|RELATED_TO
1134|Ruti|Topic|Tuberculosis|Topic|RELATED_TO
1134|Id93/Gla-Se|Topic|Tuberculosis|Topic|RELATED_TO
1134|Giulia Russo|Author|Strituvad|Topic|AUTHORED
1134|Francesco Pappalardo|Author|Strituvad|Topic|AUTHORED
1134|Miguel A. Juarez|Author|Strituvad|Topic|AUTHORED
1134|Marzio Pennisi|Author|Strituvad|Topic|AUTHORED
1134|Pere Joan Cardona|Author|Strituvad|Topic|AUTHORED
1134|Rhea Coler|Author|Strituvad|Topic|AUTHORED
1134|Epifanio Fichera|Author|Strituvad|Topic|AUTHORED
1134|Marco Viceconti|Author|Strituvad|Topic|AUTHORED
1135|A Simulation-Free Group Sequential Design With Max-Combo Tests In The Presence Of Non-Proportional Hazards|Paper|Non-Proportional Hazards|Topic|DISCUSSES
1135|A Simulation-Free Group Sequential Design With Max-Combo Tests In The Presence Of Non-Proportional Hazards|Paper|Weighted Log-Rank Tests|Topic|DISCUSSES
1135|A Simulation-Free Group Sequential Design With Max-Combo Tests In The Presence Of Non-Proportional Hazards|Paper|Maxcombo Test|Topic|DISCUSSES
1135|A Simulation-Free Group Sequential Design With Max-Combo Tests In The Presence Of Non-Proportional Hazards|Paper|Interim Analyses|Topic|DISCUSSES
1135|A Simulation-Free Group Sequential Design With Max-Combo Tests In The Presence Of Non-Proportional Hazards|Paper|Simulation-Free Approach|Topic|DISCUSSES
1135|Lili Wang|Author|A Simulation-Free Group Sequential Design With Max-Combo Tests In The Presence Of Non-Proportional Hazards|Paper|AUTHORED
1135|Xiaodong Luo|Author|A Simulation-Free Group Sequential Design With Max-Combo Tests In The Presence Of Non-Proportional Hazards|Paper|AUTHORED
1135|Cheng Zheng|Author|A Simulation-Free Group Sequential Design With Max-Combo Tests In The Presence Of Non-Proportional Hazards|Paper|AUTHORED
1136|Statistical Methodology|Topic|Fda|Topic|RELATED_TO
1136|Statistical Methodology|Topic|Ema|Topic|RELATED_TO
1136|Two-Trials Rule|Topic|Statistical Methodology|Topic|RELATED_TO
1136|Harmonic Mean Of The Squared Study-Specific Test Statistics|Topic|Statistical Methodology|Topic|RELATED_TO
1136|Null Distribution|Topic|Harmonic Mean Of The Squared Study-Specific Test Statistics|Topic|RELATED_TO
1136|P-Values|Topic|Harmonic Mean Of The Squared Study-Specific Test Statistics|Topic|RELATED_TO
1136|Confidence Intervals|Topic|Overall Treatment Effect|Topic|RELATED_TO
1136|Carvedilol|Topic|Clinical Trials|Topic|RELATED_TO
1136|Clinical Trials|Topic|Moderate To Severe Heart Failure|Topic|RELATED_TO
1136|Leonhard Held|Author|Harmonic Mean Of The Squared Study-Specific Test Statistics|Topic|AUTHORED
1137|Network Meta-Analysis|Topic|Individual Patient Data|Topic|RELATED_TO
1137|Penalized Poisson Regression Model|Topic|Individual Patient Data|Topic|RELATED_TO
1137|Edouard Ollier|Author|Penalized Poisson Regression Model|Topic|AUTHORED
1137|Pierre Blanchard|Author|Penalized Poisson Regression Model|Topic|AUTHORED
1137|Gwénaël Le Teuff|Author|Penalized Poisson Regression Model|Topic|AUTHORED
1137|Stefan Michiels|Author|Penalized Poisson Regression Model|Topic|AUTHORED
1137|Penalized Poisson Regression Model|Topic|Nasopharyngeal Carcinoma|Topic|RELATED_TO
1137|Penalized Poisson Regression Model|Topic|Overall Survival|Topic|RELATED_TO
1137|Penalized Poisson Regression Model|Topic|Chemotherapy|Topic|RELATED_TO
1137|Penalized Poisson Regression Model|Topic|Radiotherapy|Topic|RELATED_TO
1138|Two-Stage Targeted Minimum Loss-Based Estimator|Topic|Cluster Randomized Trials|Topic|RELATED_TO
1138|Search Community Randomized Trial|Topic|Two-Stage Targeted Minimum Loss-Based Estimator|Topic|RELATED_TO
1138|Laura B. Balzer|Author|Two-Stage Targeted Minimum Loss-Based Estimator|Topic|AUTHORED
1138|Mark Van Der Laan|Author|Two-Stage Targeted Minimum Loss-Based Estimator|Topic|AUTHORED
1138|James Ayieko|Author|Two-Stage Targeted Minimum Loss-Based Estimator|Topic|AUTHORED
1138|Moses Kamya|Author|Two-Stage Targeted Minimum Loss-Based Estimator|Topic|AUTHORED
1138|Gabriel Chamie|Author|Two-Stage Targeted Minimum Loss-Based Estimator|Topic|AUTHORED
1138|Joshua Schwab|Author|Two-Stage Targeted Minimum Loss-Based Estimator|Topic|AUTHORED
1138|Diane V. Havlir|Author|Two-Stage Targeted Minimum Loss-Based Estimator|Topic|AUTHORED
1138|Maya L. Petersen|Author|Two-Stage Targeted Minimum Loss-Based Estimator|Topic|AUTHORED
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Nicholas Williams|Author|AUTHORED
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Michael Rosenblum|Author|AUTHORED
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Iván Díaz|Author|AUTHORED
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Covid-19 Trials|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Weill Cornell Medicine New York Presbyterian Hospital|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|L1-Regularization|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Random Forests|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Xgboost|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Multivariate Adaptive Regression Splines|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Covariate Adjustment|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Asymptotic Normality|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Asymptotic Variance|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Longitudinal Data|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Type 1 Error|Topic|RELATED_TO
1139|Optimizing Precision And Power By Machine Learning In Randomized Trials, With An Application To Covid-19|Paper|Adjrct|Topic|RELATED_TO
1140|A Comparison Of Estimand And Estimation Strategies For Clinical Trials In Early Parkinson'S Disease|Paper|Alessandro Noci|Author|AUTHORED
1140|A Comparison Of Estimand And Estimation Strategies For Clinical Trials In Early Parkinson'S Disease|Paper|Marcel Wolbers|Author|AUTHORED
1140|A Comparison Of Estimand And Estimation Strategies For Clinical Trials In Early Parkinson'S Disease|Paper|Markus Abt|Author|AUTHORED
1140|A Comparison Of Estimand And Estimation Strategies For Clinical Trials In Early Parkinson'S Disease|Paper|Corine Baayen|Author|AUTHORED
1140|A Comparison Of Estimand And Estimation Strategies For Clinical Trials In Early Parkinson'S Disease|Paper|Hans Ulrich Burger|Author|AUTHORED
1140|A Comparison Of Estimand And Estimation Strategies For Clinical Trials In Early Parkinson'S Disease|Paper|Man Jin|Author|AUTHORED
1140|A Comparison Of Estimand And Estimation Strategies For Clinical Trials In Early Parkinson'S Disease|Paper|Weining Zhao Robieson|Author|AUTHORED
1140|Mds-Unified Parkinson'S Disease Rating Scale|Topic|Parkinson'S Disease|Topic|RELATED_TO
1141|Covid-19 Prophylaxis And Treatment Smart|Paper|Smart|Topic|DISCUSSES
1141|Covid-19 Prophylaxis And Treatment Smart|Paper|Q-Learning|Topic|RELATED_TO
1142|Comparisons Of Treatments, Interventions, Or Exposures|Topic|Epidemiology|Topic|RELATED_TO
1142|Aids Clinical Trial Group (Actg) 175|Paper|Mono Antiretroviral Therapy|Topic|DISCUSSES
1142|Aids Clinical Trial Group (Actg) 320|Paper|Triple Antiretroviral Therapy|Topic|DISCUSSES
1142|Risk Difference|Topic|Inverse Probability Weighting Estimator|Topic|RELATED_TO
1142|Shared Trial Arms|Topic|Fusion Diagnostic|Topic|RELATED_TO
1142|Paul N Zivich|Author|Aids Clinical Trial Group (Actg) 175|Paper|AUTHORED
1142|Stephen R Cole|Author|Aids Clinical Trial Group (Actg) 175|Paper|AUTHORED
1142|Jessie K Edwards|Author|Aids Clinical Trial Group (Actg) 175|Paper|AUTHORED
1142|Bonnie E Shook-Sa|Author|Aids Clinical Trial Group (Actg) 175|Paper|AUTHORED
1142|Alexander Breskin|Author|Aids Clinical Trial Group (Actg) 175|Paper|AUTHORED
1142|Michael G Hudgens|Author|Aids Clinical Trial Group (Actg) 175|Paper|AUTHORED
1143|Analysis Of Two Binomial Proportions In Non-Inferiority Confirmatory Trials|Paper|Hassan Lakkis|Author|AUTHORED
1143|Analysis Of Two Binomial Proportions In Non-Inferiority Confirmatory Trials|Paper|Andrew Lakkis|Author|AUTHORED
1143|Analysis Of Two Binomial Proportions In Non-Inferiority Confirmatory Trials|Paper|Exact Likelihood Score Test|Topic|DISCUSSES
1143|Analysis Of Two Binomial Proportions In Non-Inferiority Confirmatory Trials|Paper|Non-Inferiority Comparison|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Two-Arm Superiority Cluster Randomised Controlled Trial|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Bayesian Inference|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Linear Mixed-Effects Model|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Treatment Effect|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Sample Size|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Monte Carlo Sampling Scheme|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Prior Distribution|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Post-Stroke Incontinence|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Wald Test|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Parameter Mis-Specification|Topic|DISCUSSES
1144|Bayesian Design And Analysis Of Two-Arm Cluster Randomised Trials Using Assurance|Paper|Clinically Important Difference|Topic|DISCUSSES
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Suzanne M. Dufault|Author|AUTHORED
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Angela M. Crook|Author|AUTHORED
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Katie Rolfe|Author|AUTHORED
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Patrick P. J. Phillips|Author|AUTHORED
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Multi-Arm Multi-Stage Phase Ii Clinical Trials|Topic|RELATED_TO
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Bayesian Framework|Topic|RELATED_TO
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Target Product Profile|Topic|RELATED_TO
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Novel Tb Arms|Topic|RELATED_TO
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Intermediate Outcomes|Topic|RELATED_TO
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Primary Outcome|Topic|RELATED_TO
1145|A Flexible Multi-Metric Bayesian Framework For Decision-Making In Phase Ii Multi-Arm Multi-Stage Studies|Paper|Drug Development|Topic|RELATED_TO
1146|Jointly Extracting Interventions, Outcomes, And Findings From Rct Reports With Llms|Paper|Somin Wadhwa|Author|AUTHORED
1146|Jointly Extracting Interventions, Outcomes, And Findings From Rct Reports With Llms|Paper|Jay Deyoung|Author|AUTHORED
1146|Jointly Extracting Interventions, Outcomes, And Findings From Rct Reports With Llms|Paper|Benjamin Nye|Author|AUTHORED
1146|Jointly Extracting Interventions, Outcomes, And Findings From Rct Reports With Llms|Paper|Silvio Amir|Author|AUTHORED
1146|Jointly Extracting Interventions, Outcomes, And Findings From Rct Reports With Llms|Paper|Byron C. Wallace|Author|AUTHORED
1147|Causal Effect Of Chemotherapy Received Dose Intensity On Survival Outcome: A Retrospective Study In Osteosarcoma|Paper|Marta Spreafico|Author|AUTHORED
1147|Causal Effect Of Chemotherapy Received Dose Intensity On Survival Outcome: A Retrospective Study In Osteosarcoma|Paper|Francesca Ieva|Author|AUTHORED
1147|Causal Effect Of Chemotherapy Received Dose Intensity On Survival Outcome: A Retrospective Study In Osteosarcoma|Paper|Marta Fiocco|Author|AUTHORED
1147|Causal Effect Of Chemotherapy Received Dose Intensity On Survival Outcome: A Retrospective Study In Osteosarcoma|Paper|Osteosarcoma|Topic|RELATED_TO
1148|Causal Inference Under Transportability Assumptions For Conditional Relative Effect Measures|Paper|Transportability Condition|Topic|DISCUSSES
1148|Causal Inference Under Transportability Assumptions For Conditional Relative Effect Measures|Paper|Conditional Difference Effect Measures|Topic|DISCUSSES
1148|Causal Inference Under Transportability Assumptions For Conditional Relative Effect Measures|Paper|Marginal Causal Mean Difference|Topic|DISCUSSES
1148|Causal Inference Under Transportability Assumptions For Conditional Relative Effect Measures|Paper|Conditional Relative Effect Measures|Topic|DISCUSSES
1148|Causal Inference Under Transportability Assumptions For Conditional Relative Effect Measures|Paper|Marginal Counterfactual Mean Difference|Topic|DISCUSSES
1148|Causal Inference Under Transportability Assumptions For Conditional Relative Effect Measures|Paper|Marginal Counterfactual Ratio|Topic|DISCUSSES
1148|Causal Inference Under Transportability Assumptions For Conditional Relative Effect Measures|Paper|Simulation Studies|Topic|DISCUSSES
1148|Causal Inference Under Transportability Assumptions For Conditional Relative Effect Measures|Paper|Paliperidone|Topic|DISCUSSES
1148|Causal Inference Under Transportability Assumptions For Conditional Relative Effect Measures|Paper|Schizophrenia|Topic|DISCUSSES
1149|Instrumental Variables|Topic|Switcher Average Treatment Effect|Topic|RELATED_TO
1149|Switcher Average Treatment Effect|Topic|Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial|Paper|DISCUSSES
1149|Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial|Paper|Rui Wang|Author|AUTHORED
1149|Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial|Paper|Ying-Qi Zhao|Author|AUTHORED
1149|Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial|Paper|Oliver Dukes|Author|AUTHORED
1149|Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial|Paper|Bo Zhang|Author|AUTHORED
1150|Bayesian Adaptive Enrichment Design|Topic|Precision Medicine|Topic|RELATED_TO
1150|Lara Maleyeff|Author|Bayesian Adaptive Enrichment Design|Topic|AUTHORED
1150|Shirin Golchi|Author|Bayesian Adaptive Enrichment Design|Topic|AUTHORED
1150|Erica E. M. Moodie|Author|Bayesian Adaptive Enrichment Design|Topic|AUTHORED
1150|Marie Hudson|Author|Bayesian Adaptive Enrichment Design|Topic|AUTHORED
1151|Single-Arm Clinical Trials|Topic|Average Treatment Effect On The Treated (Att)|Topic|RELATED_TO
1151|Single-Arm Clinical Trials|Topic|Average Treatment Effect (Ate)|Topic|RELATED_TO
1151|Average Treatment Effect On The Treated (Att)|Topic|Regression Model|Topic|RELATED_TO
1151|Average Treatment Effect On The Treated (Att)|Topic|Propensity Score Matching|Topic|RELATED_TO
1151|Average Treatment Effect On The Treated (Att)|Topic|Mahalanobis Distance Matching|Topic|RELATED_TO
1151|Average Treatment Effect On The Treated (Att)|Topic|Coarsened Exact Matching|Topic|RELATED_TO
1151|Average Treatment Effect On The Treated (Att)|Topic|Inverse Probability Weighting|Topic|RELATED_TO
1151|Average Treatment Effect On The Treated (Att)|Topic|Augmented Inverse Probability Weighting (Aipw)|Topic|RELATED_TO
1151|Average Treatment Effect On The Treated (Att)|Topic|Aipw With Superlearner|Topic|RELATED_TO
1151|Average Treatment Effect On The Treated (Att)|Topic|Targeted Maximum Likelihood Estimator (Tmle) With Superlearner|Topic|RELATED_TO
1151|Huan Wang|Author|Average Treatment Effect On The Treated (Att)|Topic|AUTHORED
1151|Fei Wu|Author|Average Treatment Effect On The Treated (Att)|Topic|AUTHORED
1151|Yeh-Fong Chen|Author|Average Treatment Effect On The Treated (Att)|Topic|AUTHORED
1152|Dose Selection|Topic|Pharmaceutical Drug Development|Topic|RELATED_TO
1152|Therapeutic Efficacy|Topic|Patient Safety|Topic|RELATED_TO
1152|Generalized Multiple Comparison Procedures And Modeling (Mcp-Mod)|Topic|Phase Ii Trials|Topic|RELATED_TO
1152|Generalized Multiple Comparison Procedures And Modeling (Mcp-Mod)|Topic|Dose-Response Relationships|Topic|RELATED_TO
1152|Penalized Maximum Likelihood Estimation (Mle)|Topic|Randomization-Based Inference|Topic|RELATED_TO
1152|Logistic Regression|Topic|Penalized Maximum Likelihood Estimation (Mle)|Topic|RELATED_TO
1152|Type-I Error Rates|Topic|Randomization-Based Inference|Topic|RELATED_TO
1152|Residual-Based Randomization Tests|Topic|Penalized Maximum Likelihood Estimation (Mle)|Topic|RELATED_TO
1152|Lukas Pin|Author|Randomization-Based Inference For Mcp-Mod|Paper|AUTHORED
1152|Oleksandr Sverdlov|Author|Randomization-Based Inference For Mcp-Mod|Paper|AUTHORED
1152|Frank Bretz|Author|Randomization-Based Inference For Mcp-Mod|Paper|AUTHORED
1152|Björn Bornkamp|Author|Randomization-Based Inference For Mcp-Mod|Paper|AUTHORED
1153|Cluster Or Group Randomized Trials (Crts)|Topic|Hiv Prevention Crt|Topic|RELATED_TO
1153|Shubhadeep Chakraborty|Author|Hiv Prevention Crt|Topic|AUTHORED
1153|Bo Wang|Author|Hiv Prevention Crt|Topic|AUTHORED
1153|Ram Tiwari|Author|Hiv Prevention Crt|Topic|AUTHORED
1153|Samiran Ghosh|Author|Hiv Prevention Crt|Topic|AUTHORED
1154|Machine Learning|Topic|Medical Research|Topic|RELATED_TO
1154|Machine Learning|Topic|Diagnostic Accuracy|Topic|RELATED_TO
1154|Machine Learning|Topic|Personalized Treatments|Topic|RELATED_TO
1154|General Ml Model|Topic|Subject-Specific Models|Topic|RELATED_TO
1154|Random Forest (Rf) Model|Topic|Novel Validation Approach|Topic|RELATED_TO
1154|Novel Validation Approach|Topic|Feature Importance|Topic|RELATED_TO
1154|Novel Validation Approach|Topic|Clinical Research|Topic|RELATED_TO
1154|Gideon Vos|Author|Novel Validation Approach|Topic|AUTHORED
1154|Liza Van Eijk|Author|Novel Validation Approach|Topic|AUTHORED
1154|Zoltan Sarnyai|Author|Novel Validation Approach|Topic|AUTHORED
1154|Mostafa Rahimi Azghadi|Author|Novel Validation Approach|Topic|AUTHORED
1155|Sequential Tests And Estimates After Overrunning Based On P-Value Combination|Paper|Brownian Motion With Drift|Topic|DISCUSSES
1155|Sequential Tests And Estimates After Overrunning Based On P-Value Combination|Paper|Adding Weighted Zs Method|Topic|DISCUSSES
1155|Sequential Tests And Estimates After Overrunning Based On P-Value Combination|Paper|Sequential Clinical Trials|Topic|DISCUSSES
1156|The Future Of Indirect Evidence|Paper|Bradley Efron|Author|AUTHORED
1156|The Future Of Indirect Evidence|Paper|Familiar Statistical Tests And Estimates|Topic|DISCUSSES
1156|The Future Of Indirect Evidence|Paper|Clinical Trial Of A New Drug|Topic|DISCUSSES
1156|The Future Of Indirect Evidence|Paper|New Scientific Devices Such As Microarrays|Topic|DISCUSSES
1156|The Future Of Indirect Evidence|Paper|Empirical Bayes Methodology|Topic|DISCUSSES
1157|Cara Design|Topic|Treatment Effect|Topic|DISCUSSES
1157|Yuan-Chin Ivan Chang|Author|Cara Design|Topic|AUTHORED
1157|Eunsik Park|Author|Cara Design|Topic|AUTHORED
1158|Q-Learning Algorithm|Topic|Censored Data|Topic|RELATED_TO
1158|Q-Learning Algorithm|Topic|Multistage Decision Problem|Topic|RELATED_TO
1158|Yair Goldberg|Author|Q-Learning Algorithm|Topic|AUTHORED
1158|Michael R. Kosorok|Author|Q-Learning Algorithm|Topic|AUTHORED
1158|Q-Learning Algorithm|Topic|Finite Sample Bounds|Topic|RELATED_TO
1158|Q-Learning Algorithm|Topic|Optimal Q-Function|Topic|RELATED_TO
1158|Q-Learning Algorithm|Topic|Expected Survival Time|Topic|RELATED_TO
1158|Multistage Clinical Trial|Topic|Individualized Treatment Regimens|Topic|RELATED_TO
1158|Multistage Clinical Trial|Topic|Personalized Medicine Trials|Topic|RELATED_TO
1158|Personalized Medicine Trials|Topic|Cancer|Topic|RELATED_TO
1158|Personalized Medicine Trials|Topic|Life-Threatening Diseases|Topic|RELATED_TO
1159|Testing For Efficacy In Single-Subject Trials With Intervention Analysis|Paper|A. Savenkov|Author|AUTHORED
1159|Testing For Efficacy In Single-Subject Trials With Intervention Analysis|Paper|S. Wu|Author|AUTHORED
1159|Testing For Efficacy In Single-Subject Trials With Intervention Analysis|Paper|D. Neal|Author|AUTHORED
1159|Testing For Efficacy In Single-Subject Trials With Intervention Analysis|Paper|Intervention Analysis Model|Topic|RELATED_TO
1159|Testing For Efficacy In Single-Subject Trials With Intervention Analysis|Paper|Single-Subject Data|Topic|RELATED_TO
1159|Testing For Efficacy In Single-Subject Trials With Intervention Analysis|Paper|Type I Error|Topic|RELATED_TO
1159|Testing For Efficacy In Single-Subject Trials With Intervention Analysis|Paper|Constraint Induced Language Therapy|Topic|RELATED_TO
1159|Testing For Efficacy In Single-Subject Trials With Intervention Analysis|Paper|Aphasia Patients|Topic|RELATED_TO
1160|Conventional Approaches To Statistical Inference|Topic|Hierarchical Model Structure|Topic|DISCUSSES
1160|Perfusion Computed Tomography|Topic|Functional Imaging Biomarkers|Topic|RELATED_TO
1160|Functional Imaging Biomarkers|Topic|Cancerous Regions Of The Liver|Topic|RELATED_TO
1160|Cancerous Regions Of The Liver|Topic|Noncancerous Regions|Topic|RELATED_TO
1160|Hierarchical Model Structure|Topic|Nonparametric Regression|Topic|DISCUSSES
1160|Nonparametric Regression|Topic|Liver Cancer Data|Topic|RELATED_TO
1160|Semiparametric Hazard Model|Topic|Clinical Trial|Topic|DISCUSSES
1160|Clinical Trial|Topic|Colorectal Cancer Treatments|Topic|RELATED_TO
1160|Clinical Trial|Topic|Previous Trial|Topic|RELATED_TO
1160|Generalized Mixture Commensurate Priors|Topic|Hierarchical Model Structure|Topic|RELATED_TO
1160|Thomas A. Murray|Author|Hierarchical Model Structure|Topic|AUTHORED
1160|Brian P. Hobbs|Author|Hierarchical Model Structure|Topic|AUTHORED
1160|Bradley P. Carlin|Author|Hierarchical Model Structure|Topic|AUTHORED
1161|Mmrm|Topic|Missing Data Imputation Algorithm|Topic|DISCUSSES
1161|Pmm|Topic|Missing Data Imputation Algorithm|Topic|DISCUSSES
1161|Sas Proc Mi|Topic|Missing Data Imputation Algorithm|Topic|RELATED_TO
1161|Yongqiang Tang|Author|Antidepressant Trial|Topic|AUTHORED
1161|Pmm|Topic|Mmrm|Topic|RELATED_TO
1161|Multiple Imputation Algorithm|Topic|Pmm|Topic|DISCUSSES
1162|Function Driven Diffusion For Personalized Counterfactual Inference|Paper|High Dimensional Data|Topic|DISCUSSES
1162|Function Driven Diffusion For Personalized Counterfactual Inference|Paper|Counterfactual Functions|Topic|DISCUSSES
1162|Function Driven Diffusion For Personalized Counterfactual Inference|Paper|Individualized Treatment Effectiveness|Topic|DISCUSSES
1162|Function Driven Diffusion For Personalized Counterfactual Inference|Paper|Diffusion Metric|Topic|DISCUSSES
1162|Function Driven Diffusion For Personalized Counterfactual Inference|Paper|Localized Filtration|Topic|DISCUSSES
1162|Function Driven Diffusion For Personalized Counterfactual Inference|Paper|Drug Trials|Topic|DISCUSSES
1162|Function Driven Diffusion For Personalized Counterfactual Inference|Paper|Synthetic And Real World Clinical Trials|Topic|DISCUSSES
1162|Function Driven Diffusion For Personalized Counterfactual Inference|Paper|Individualized Notions Of Benefit From Treatment|Topic|DISCUSSES
1163|Causal Modelling Framework For Reference-Based Imputation And Tipping Point Analysis|Paper|Ian R. White|Author|AUTHORED
1163|Causal Modelling Framework For Reference-Based Imputation And Tipping Point Analysis|Paper|Royes Joseph|Author|AUTHORED
1163|Causal Modelling Framework For Reference-Based Imputation And Tipping Point Analysis|Paper|Nicky Best|Author|AUTHORED
1164|Instrument-Armed Bandits|Topic|Nathan Kallus|Author|AUTHORED
1164|Multi-Armed Bandit Model|Topic|Noncompliance|Topic|RELATED_TO
1164|Noncompliance|Topic|Instrument-Armed Bandit Problem|Topic|RELATED_TO
1164|Instrument-Armed Bandit Problem|Topic|Regret|Topic|RELATED_TO
1164|Dynamic Clinical Trials|Topic|Instrument-Armed Bandit Problem|Topic|RELATED_TO
1164|Controlled Trials|Topic|Instrument-Armed Bandit Problem|Topic|RELATED_TO
1164|Regret|Topic|New Algorithms For The Iab Problem|Topic|RELATED_TO
1164|New Algorithms For The Iab Problem|Topic|Regret Bounds|Topic|RELATED_TO
1164|Standard Mab Algorithms|Topic|Regret|Topic|RELATED_TO
1165|Stanford Health Care|Topic|Electronic Medical Records|Topic|RELATED_TO
1165|Electronic Medical Records|Topic|Personalized Treatment Recommendations|Topic|RELATED_TO
1165|Personalized Treatment Recommendations|Topic|Treatment Effect Estimation Methods|Topic|RELATED_TO
1165|Treatment Effect Estimation Methods|Topic|The Sprint Data Analysis Challenge|Topic|RELATED_TO
1165|Scott Powers|Author|Treatment Effect Estimation Methods|Topic|AUTHORED
1165|Junyang Qian|Author|Treatment Effect Estimation Methods|Topic|AUTHORED
1165|Kenneth Jung|Author|Treatment Effect Estimation Methods|Topic|AUTHORED
1165|Alejandro Schuler|Author|Treatment Effect Estimation Methods|Topic|AUTHORED
1165|Nigam H. Shah|Author|Treatment Effect Estimation Methods|Topic|AUTHORED
1165|Trevor Hastie|Author|Treatment Effect Estimation Methods|Topic|AUTHORED
1165|Robert Tibshirani|Author|Treatment Effect Estimation Methods|Topic|AUTHORED
1166|Diagnosing Glaucoma Progression With Visual Field Data Using A Spatiotemporal Boundary Detection Method|Paper|Samuel I. Berchuck|Author|AUTHORED
1166|Diagnosing Glaucoma Progression With Visual Field Data Using A Spatiotemporal Boundary Detection Method|Paper|Jean-Claude Mwanza|Author|AUTHORED
1166|Diagnosing Glaucoma Progression With Visual Field Data Using A Spatiotemporal Boundary Detection Method|Paper|Joshua L. Warren|Author|AUTHORED
1166|Diagnosing Glaucoma Progression With Visual Field Data Using A Spatiotemporal Boundary Detection Method|Paper|Vein Pulsation Study Trial In Glaucoma|Topic|RELATED_TO
1166|Diagnosing Glaucoma Progression With Visual Field Data Using A Spatiotemporal Boundary Detection Method|Paper|Lions Eye Institute Trial Registry|Topic|RELATED_TO
1166|Diagnosing Glaucoma Progression With Visual Field Data Using A Spatiotemporal Boundary Detection Method|Paper|Womblr|Topic|RELATED_TO
1167|Joint Distribution Of Progression-Free And Overall Survival|Topic|Pearson'S Correlation Coefficient|Topic|DISCUSSES
1167|Progression-Free Survival|Topic|Overall Survival|Topic|RELATED_TO
1167|Joint Distribution Of Progression-Free And Overall Survival|Topic|Breast Cancer Clinical Trial|Topic|RELATED_TO
1167|Matthias Meller|Author|Joint Distribution Of Progression-Free And Overall Survival|Topic|AUTHORED
1167|Jan Beyersmann|Author|Joint Distribution Of Progression-Free And Overall Survival|Topic|AUTHORED
1167|Kaspar Rufibach|Author|Joint Distribution Of Progression-Free And Overall Survival|Topic|AUTHORED
1168|Partial Effectiveness Of Drugs|Topic|Pharmaceutical Industry|Topic|RELATED_TO
1168|Randomized Controlled Trials|Topic|Subgroup Sensitive To Treatment|Topic|RELATED_TO
1168|Model Of Treatment Response|Topic|Placebo Responders|Topic|RELATED_TO
1168|Model Of Treatment Response|Topic|Drug Responders|Topic|RELATED_TO
1168|Treatment-Specific Effect|Topic|Prevalence Of Drug Responders|Topic|RELATED_TO
1168|One-Stage Rct Designs|Topic|Sensitive Subgroup|Topic|DISCUSSES
1168|Two-Stage Rct Designs|Topic|Sensitive Subgroup|Topic|DISCUSSES
1168|Multicenter Rcts|Topic|Hochberg'S Step-Up Procedure|Topic|RELATED_TO
1168|Numerical Optimization Methods|Topic|Adaptive Multicenter Designs|Topic|RELATED_TO
1168|Daria Rukina|Author|Partial Effectiveness Of Drugs|Topic|AUTHORED
1169|Estimating Malaria Vaccine Efficacy In The Absence Of A Gold Standard Case Definition: Mendelian Factorial Design|Paper|Raiden B. Hasegawa|Author|AUTHORED
1169|Estimating Malaria Vaccine Efficacy In The Absence Of A Gold Standard Case Definition: Mendelian Factorial Design|Paper|Dylan S. Small|Author|AUTHORED
1170|Prognostic Score Matching|Topic|Conditional Inference Trees|Topic|RELATED_TO
1170|Randomized Binary Treatment|Topic|Tehtrees|Topic|RELATED_TO
1170|Type I Error Rate|Topic|Clinical Trials|Topic|RELATED_TO
1170|Tehtrees|Topic|Nutrition Trial Dataset|Topic|RELATED_TO
1170|Ashwini Venkatasubramaniam|Author|Randomized Binary Treatment|Topic|AUTHORED
1170|Brandon Koch|Author|Randomized Binary Treatment|Topic|AUTHORED
1170|Lauren Erickson|Author|Randomized Binary Treatment|Topic|AUTHORED
1170|Simone French|Author|Randomized Binary Treatment|Topic|AUTHORED
1170|David Vock|Author|Randomized Binary Treatment|Topic|AUTHORED
1170|Julian Wolfson|Author|Randomized Binary Treatment|Topic|AUTHORED
1171|Finite-Sample Two-Group Composite Hypothesis Testing Via Machine Learning|Paper|Composite Hypothesis Testing|Topic|DISCUSSES
1171|Finite-Sample Two-Group Composite Hypothesis Testing Via Machine Learning|Paper|Uniformly Most Powerful (Ump) Unbiased Test|Topic|DISCUSSES
1171|Finite-Sample Two-Group Composite Hypothesis Testing Via Machine Learning|Paper|Covid-19 Pandemic|Topic|DISCUSSES
1171|Finite-Sample Two-Group Composite Hypothesis Testing Via Machine Learning|Paper|Adaptive Clinical Trials|Topic|DISCUSSES
1171|Finite-Sample Two-Group Composite Hypothesis Testing Via Machine Learning|Paper|Machine Learning Methods|Topic|DISCUSSES
1171|Finite-Sample Two-Group Composite Hypothesis Testing Via Machine Learning|Paper|Deep Neural Networks (Dnn)|Topic|DISCUSSES
1171|Tianyu Zhan|Author|Finite-Sample Two-Group Composite Hypothesis Testing Via Machine Learning|Paper|AUTHORED
1171|Jian Kang|Author|Finite-Sample Two-Group Composite Hypothesis Testing Via Machine Learning|Paper|AUTHORED
1172|Approximate Bayesian Bootstrap Procedures To Estimate Multilevel Treatment Effects In Observational Studies With Application To Type 2 Diabetes Treatment Regimens|Paper|Anthony D. Scotina|Author|AUTHORED
1172|Approximate Bayesian Bootstrap Procedures To Estimate Multilevel Treatment Effects In Observational Studies With Application To Type 2 Diabetes Treatment Regimens|Paper|Andrew R. Zullo|Author|AUTHORED
1172|Approximate Bayesian Bootstrap Procedures To Estimate Multilevel Treatment Effects In Observational Studies With Application To Type 2 Diabetes Treatment Regimens|Paper|Robert J. Smith|Author|AUTHORED
1172|Approximate Bayesian Bootstrap Procedures To Estimate Multilevel Treatment Effects In Observational Studies With Application To Type 2 Diabetes Treatment Regimens|Paper|Roee Gutman|Author|AUTHORED
1172|Observational Studies|Topic|Generalized Propensity Scores|Topic|RELATED_TO
1172|Generalized Propensity Scores|Topic|Treatment Effects|Topic|RELATED_TO
1172|Approximate Bayesian Bootstrap Algorithm|Topic|Point And Interval Estimates|Topic|RELATED_TO
1172|Point And Interval Estimates|Topic|Categorical Outcomes|Topic|RELATED_TO
1172|Unconfoundedness Assumption|Topic|Sensitivity Analysis|Topic|RELATED_TO
1172|Cardiovascular Safety|Topic|Anti-Diabetic Treatment Regimens|Topic|RELATED_TO
1172|Anti-Diabetic Treatment Regimens|Topic|Type 2 Diabetes Mellitus|Topic|RELATED_TO
1173|Borrowing From Supplemental Sources To Estimate Causal Effects From A Primary Data Source|Paper|Causal Effect Estimators|Topic|DISCUSSES
1173|Borrowing From Supplemental Sources To Estimate Causal Effects From A Primary Data Source|Paper|Bayesian Linear Model|Topic|DISCUSSES
1173|Borrowing From Supplemental Sources To Estimate Causal Effects From A Primary Data Source|Paper|Bayesian Additive Regression Trees|Topic|DISCUSSES
1173|Borrowing From Supplemental Sources To Estimate Causal Effects From A Primary Data Source|Paper|Very Low Nicotine Content Cigarettes|Topic|RELATED_TO
1173|Borrowing From Supplemental Sources To Estimate Causal Effects From A Primary Data Source|Paper|Smoking Behavior|Topic|RELATED_TO
1174|Unstructured Primary Outcome In Randomized Controlled Trials|Paper|Daniel Taylor-Rodriguez|Author|AUTHORED
1174|Unstructured Primary Outcome In Randomized Controlled Trials|Paper|David Lovitz|Author|AUTHORED
1174|Unstructured Primary Outcome In Randomized Controlled Trials|Paper|Nora Mattek|Author|AUTHORED
1174|Unstructured Primary Outcome In Randomized Controlled Trials|Paper|Chao-Yi Wu|Author|AUTHORED
1174|Unstructured Primary Outcome In Randomized Controlled Trials|Paper|Hiroko Dodge|Author|AUTHORED
1174|Unstructured Primary Outcome In Randomized Controlled Trials|Paper|Jeffrey Kaye|Author|AUTHORED
1174|Unstructured Primary Outcome In Randomized Controlled Trials|Paper|Bruno M. Jedynak|Author|AUTHORED
1175|Nonparametric Analysis Of Delayed Treatment Effects Using Single-Crossing Constraints|Paper|Nicholas C. Henderson|Author|AUTHORED
1175|Nonparametric Analysis Of Delayed Treatment Effects Using Single-Crossing Constraints|Paper|Kijoeng Nam|Author|AUTHORED
1175|Nonparametric Analysis Of Delayed Treatment Effects Using Single-Crossing Constraints|Paper|Dai Feng|Author|AUTHORED
1175|Nonparametric Analysis Of Delayed Treatment Effects Using Single-Crossing Constraints|Paper|Immuno-Oncology Therapies|Topic|RELATED_TO
1176|Randomized Controlled Trials|Topic|Treatment Effect|Topic|RELATED_TO
1176|International Council On Harmonisation (Ich)-E9 Addendum (R1)|Topic|Intercurrent Events (Ices)|Topic|DISCUSSES
1176|Intercurrent Events (Ices)|Topic|Principal Stratum|Topic|RELATED_TO
1176|Qu Et Al. (2020)|Author|Adherer Average Causal Effect (Adace)|Topic|AUTHORED
1176|Adherer Average Causal Effect (Adace)|Topic|Multiple Imputation (Mi)|Topic|RELATED_TO
1176|Multiple Imputation (Mi)|Topic|Bootstrapping|Topic|RELATED_TO
1176|Real Clinical Trial|Topic|Type 1 Diabetes|Topic|RELATED_TO
1176|Junxiang Luo|Author|Qu Et Al. (2020)|Author|AUTHORED
1176|Stephen J. Ruberg|Author|Qu Et Al. (2020)|Author|AUTHORED
1176|Yongming Qu|Author|Qu Et Al. (2020)|Author|AUTHORED
1177|Shortcomings Of Randomized Clinical Trials|Topic|Urgent Health Crises|Topic|RELATED_TO
1177|Urgent Health Crises|Topic|Effective Treatments|Topic|RELATED_TO
1177|Short-Term Surrogates|Topic|Real-World Data (Rwd)|Topic|RELATED_TO
1177|Proportion Of Treatment Effect (Pte)|Topic|Novel Estimators|Topic|RELATED_TO
1177|Inverse Probability Weighted And Doubly Robust (Dr) Estimators|Topic|Optimal Transformation Of The Surrogate|Topic|RELATED_TO
1177|Baseline Covariates|Topic|Asymptotically Normal|Topic|RELATED_TO
1177|Propensity Score Model|Topic|Outcome Regression Model|Topic|RELATED_TO
1177|Cross-Trial Comparison|Topic|Biologic Therapies For Ulcerative Colitis|Topic|RELATED_TO
1177|Larry Han|Author|Novel Estimators|Topic|AUTHORED
1177|Xuan Wang|Author|Novel Estimators|Topic|AUTHORED
1177|Tianxi Cai|Author|Novel Estimators|Topic|AUTHORED
1178|Planner|Topic|Policy|Topic|DISCUSSES
1178|Policy|Topic|Local Population|Topic|RELATED_TO
1178|Intervention Studies|Topic|Policy|Topic|RELATED_TO
1178|Manski (2020)|Author|Minimax-Regret Criterion|Topic|AUTHORED
1178|Minimax-Regret Criterion|Topic|Active Labor Market Policy|Topic|DISCUSSES
1178|Minimax-Regret Criterion|Topic|Remdesivir|Topic|DISCUSSES
1178|Remdesivir|Topic|Covid-19 Treatment|Topic|RELATED_TO
1178|Takuya Ishihara|Author|Active Labor Market Policy|Topic|AUTHORED
1178|Toru Kitagawa|Author|Remdesivir|Topic|AUTHORED
1179|Response-Adaptive Randomization|Topic|Type I Error Rate|Topic|RELATED_TO
1179|Response-Adaptive Randomization|Topic|Familywise Error Rate|Topic|RELATED_TO
1179|Robertson And Wason|Author|Familywise Error Rate|Topic|DISCUSSES
1179|Ekkehard Glimm|Author|Robertson And Wason|Author|AUTHORED
1179|David Robertson|Author|Robertson And Wason|Author|AUTHORED
1179|Block-Randomised Trials|Topic|Negative Weights For Blocks Of Data|Topic|RELATED_TO
1179|Block-Randomised Trials|Topic|Power Advantage|Topic|RELATED_TO
1180|Randomized Controlled Trials|Topic|Causal Inference|Topic|RELATED_TO
1180|Randomized Controlled Trials|Topic|Evidence-Based Medicine|Topic|RELATED_TO
1180|Observational Data|Topic|Bias|Topic|RELATED_TO
1180|Power Likelihood Approach|Topic|Treatment Effect Estimation|Topic|RELATED_TO
1180|Expected Log Predictive Density|Topic|Power Likelihood Approach|Topic|RELATED_TO
1180|Simulation Study|Topic|Power Likelihood Approach|Topic|RELATED_TO
1180|Real-World Data Fusion Study|Topic|Pioneer 6 Clinical Trial|Topic|RELATED_TO
1180|Real-World Data Fusion Study|Topic|Us Health Claims Dataset|Topic|RELATED_TO
1180|Xi Lin|Author|Power Likelihood Approach|Topic|AUTHORED
1180|Jens Magelund Tarp|Author|Power Likelihood Approach|Topic|AUTHORED
1180|Robin J. Evans|Author|Power Likelihood Approach|Topic|AUTHORED
1181|Randomized Experiments|Topic|Data-Driven Decision Making|Topic|RELATED_TO
1181|Medicine|Topic|Randomized Controlled Trials (Rcts)|Topic|RELATED_TO
1181|Randomized Controlled Trials (Rcts)|Topic|Clinical Trial Methodology|Topic|RELATED_TO
1181|Clinical Trial Methodology|Topic|New Drugs And Therapies|Topic|RELATED_TO
1181|Clinical Trial Methodology|Topic|Existing Treatments|Topic|RELATED_TO
1181|Clinical Trial Methodology|Topic|Placebo|Topic|RELATED_TO
1181|Business And Marketing|Topic|A/B Tests|Topic|RELATED_TO
1181|A/B Tests|Topic|Multivariate A/B Tests|Topic|RELATED_TO
1181|A/B Tests|Topic|Ad Campaigns|Topic|RELATED_TO
1181|A/B Tests|Topic|Website Layouts|Topic|RELATED_TO
1181|A/B Tests|Topic|Customer Subpopulations|Topic|RELATED_TO
1181|Multivariate A/B Testing|Paper|Sequential Monitoring|Topic|DISCUSSES
1181|Multivariate A/B Testing|Paper|Multiple Comparisons|Topic|DISCUSSES
1181|Multivariate A/B Testing|Paper|Standard Statistical Software|Topic|DISCUSSES
1181|Multivariate A/B Testing|Paper|Simulation Studies|Topic|DISCUSSES
1181|Bayesian Sequentially Monitored Multi-Arm Experiments With Multiple Comparison Adjustments|Paper|Andrew W. Correia|Author|AUTHORED
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Adam Kapelner|Author|AUTHORED
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Abba Krieger|Author|AUTHORED
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Average Treatment Effect|Topic|DISCUSSES
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Sequential Randomized Trials|Topic|DISCUSSES
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Dynamic Allocation Procedure|Topic|DISCUSSES
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Seqexpmatch|Topic|DISCUSSES
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Dynamic Matching Criterion|Topic|DISCUSSES
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Estimators|Topic|DISCUSSES
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Exact Test|Topic|DISCUSSES
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Clinical Trial Dataset|Topic|DISCUSSES
1182|A Matching Procedure For Sequential Experiments That Iteratively Learns Which Covariates Improve Power|Paper|Simulated Scenarios|Topic|DISCUSSES
1183|Targeted Therapeutics For Cancer Treatment|Topic|Drug Resistance Factors|Topic|RELATED_TO
1183|Drug Resistance Factors|Topic|Combination Cancer Therapies (Ccts)|Topic|RELATED_TO
1183|Combination Cancer Therapies (Ccts)|Topic|Mathematical Modeling In Cancer Treatment|Topic|RELATED_TO
1183|Mathematical Modeling In Cancer Treatment|Topic|Joseph Malinzi|Author|AUTHORED
1183|Mathematical Modeling In Cancer Treatment|Topic|Kevin Bosire Basita|Author|AUTHORED
1183|Mathematical Modeling In Cancer Treatment|Topic|Sara Padidar|Author|AUTHORED
1183|Mathematical Modeling In Cancer Treatment|Topic|Henry A. Adeola|Author|AUTHORED
1184|Sample Size Re-Estimation In Phase 2 Dose-Finding: Conditional Power Vs. Bayesian Predictive Power|Paper|Unblinded Sample Size Re-Estimation (Ssr)|Topic|DISCUSSES
1184|Sample Size Re-Estimation In Phase 2 Dose-Finding: Conditional Power Vs. Bayesian Predictive Power|Paper|Proof-Of Concept (Poc)|Topic|DISCUSSES
1184|Sample Size Re-Estimation In Phase 2 Dose-Finding: Conditional Power Vs. Bayesian Predictive Power|Paper|Phase Ii Dose Finding Study|Topic|DISCUSSES
1184|Sample Size Re-Estimation In Phase 2 Dose-Finding: Conditional Power Vs. Bayesian Predictive Power|Paper|Frequentist Conditional Power|Topic|DISCUSSES
1184|Sample Size Re-Estimation In Phase 2 Dose-Finding: Conditional Power Vs. Bayesian Predictive Power|Paper|Bayesian Posterior Predictive Power|Topic|DISCUSSES
1184|Qingyang Liu|Author|Sample Size Re-Estimation In Phase 2 Dose-Finding: Conditional Power Vs. Bayesian Predictive Power|Paper|AUTHORED
1184|Guanyu Hu|Author|Sample Size Re-Estimation In Phase 2 Dose-Finding: Conditional Power Vs. Bayesian Predictive Power|Paper|AUTHORED
1184|Binqi Ye|Author|Sample Size Re-Estimation In Phase 2 Dose-Finding: Conditional Power Vs. Bayesian Predictive Power|Paper|AUTHORED
1184|Susan Wang|Author|Sample Size Re-Estimation In Phase 2 Dose-Finding: Conditional Power Vs. Bayesian Predictive Power|Paper|AUTHORED
1184|Yaoshi Wu|Author|Sample Size Re-Estimation In Phase 2 Dose-Finding: Conditional Power Vs. Bayesian Predictive Power|Paper|AUTHORED
1185|Shape-Constrained Methods|Topic|Immune Response Profiles|Topic|RELATED_TO
1185|Hvtn 097|Topic|Igg Binding Immune Responses|Topic|RELATED_TO
1185|Hvtn 100|Topic|Igg Binding Immune Responses|Topic|RELATED_TO
1185|Stochastic Dominance|Topic|Hellinger Distance|Topic|RELATED_TO
1185|Nilanjana Laha|Author|Shape-Constrained Methods|Topic|AUTHORED
1185|Zoe Moodie|Author|Shape-Constrained Methods|Topic|AUTHORED
1185|Ying Huang|Author|Shape-Constrained Methods|Topic|AUTHORED
1185|Alex Luedtke|Author|Shape-Constrained Methods|Topic|AUTHORED
1186|Clinical Trials With Longitudinal Outcomes|Topic|Bayesian Random Multiple Imputation|Topic|RELATED_TO
1186|Clinical Trials With Longitudinal Outcomes|Topic|Rubin'S Rule|Topic|RELATED_TO
1186|Bayesian Random Multiple Imputation|Topic|Deterministic Conditional Mean Imputation|Topic|RELATED_TO
1186|Deterministic Conditional Mean Imputation|Topic|Jackknife For Inference|Topic|RELATED_TO
1186|Deterministic Conditional Mean Imputation|Topic|Missing-At-Random Assumption|Topic|RELATED_TO
1186|Marcel Wolbers|Author|Clinical Trials With Longitudinal Outcomes|Topic|AUTHORED
1186|Alessandro Noci|Author|Clinical Trials With Longitudinal Outcomes|Topic|AUTHORED
1186|Paul Delmar|Author|Clinical Trials With Longitudinal Outcomes|Topic|AUTHORED
1186|Craig Gower-Page|Author|Clinical Trials With Longitudinal Outcomes|Topic|AUTHORED
1186|Sean Yiu|Author|Clinical Trials With Longitudinal Outcomes|Topic|AUTHORED
1186|Jonathan W. Bartlett|Author|Clinical Trials With Longitudinal Outcomes|Topic|AUTHORED
1187|Schmookler, 1966|Author|Markets For Innovation|Topic|RELATED_TO
1187|Acemoglu And Linn, 2004|Author|Markets For Innovation|Topic|RELATED_TO
1187|Bryan And Williams, 2021|Author|Markets For Innovation|Topic|RELATED_TO
1187|Acemoglu And Linn, 2004|Author|Demographical Shifts|Topic|DISCUSSES
1187|Demographical Shifts|Topic|New Drugs|Topic|RELATED_TO
1187|Cerda Et Al., 2007|Author|Market Size|Topic|DISCUSSES
1187|Market Size|Topic|Active Clinical Trials|Topic|RELATED_TO
1187|Product Recalls|Topic|Market Size|Topic|RELATED_TO
1187|Us Market Size|Topic|Active Clinical Trials|Topic|RELATED_TO
1187|Wooldridge Et Al., 2019|Author|Active Clinical Trials|Topic|DISCUSSES
1187|Federico Nutarelli|Author|Product Recalls|Topic|AUTHORED
1187|Massimo Riccaboni|Author|Product Recalls|Topic|AUTHORED
1187|Andrea Morescalchi|Author|Product Recalls|Topic|AUTHORED
1188|Statistical Methods For Accommodating Immortal Time: A Selective Review And Comparison|Paper|Immortal Time|Topic|DISCUSSES
1188|Statistical Methods For Accommodating Immortal Time: A Selective Review And Comparison|Paper|Biased Estimation|Topic|DISCUSSES
1188|Statistical Methods For Accommodating Immortal Time: A Selective Review And Comparison|Paper|Time-Varying Treatment Modeling|Topic|DISCUSSES
1188|Statistical Methods For Accommodating Immortal Time: A Selective Review And Comparison|Paper|Sequential Trial Methods|Topic|DISCUSSES
1188|Statistical Methods For Accommodating Immortal Time: A Selective Review And Comparison|Paper|Causal Inference|Topic|DISCUSSES
1189|Phase Ii Basket Trials|Topic|Treatment Targeting Genetic Alteration|Topic|RELATED_TO
1189|Bayesian Hierarchical Modelling|Topic|Variance Parameter|Topic|RELATED_TO
1189|Variance Parameter|Topic|Shrinkage|Topic|RELATED_TO
1189|Prior Choice On The Variance|Topic|Shrinkage|Topic|RELATED_TO
1189|Penalized Complexity (Pc) Priors|Topic|Half-T Prior|Topic|RELATED_TO
1189|Massimo Ventrucci|Author|Treatment Targeting Genetic Alteration|Topic|AUTHORED
1189|Alessandro Vagheggini|Author|Treatment Targeting Genetic Alteration|Topic|AUTHORED
1190|Modeling And Predictive Control For The Treatment Of Hyperthyroidism|Paper|Tobias M. Wolff|Author|AUTHORED
1190|Modeling And Predictive Control For The Treatment Of Hyperthyroidism|Paper|Maylin Menzel|Author|AUTHORED
1190|Modeling And Predictive Control For The Treatment Of Hyperthyroidism|Paper|Johannes W. Dietrich|Author|AUTHORED
1190|Modeling And Predictive Control For The Treatment Of Hyperthyroidism|Paper|Matthias A. Müller|Author|AUTHORED
1190|Modeling And Predictive Control For The Treatment Of Hyperthyroidism|Paper|Hyperthyroidism|Topic|RELATED_TO
1191|Principal Stratification With Time-To-Event Outcomes|Paper|Bo Liu|Author|AUTHORED
1191|Principal Stratification With Time-To-Event Outcomes|Paper|Lisa Wruck|Author|AUTHORED
1191|Principal Stratification With Time-To-Event Outcomes|Paper|Fan Li|Author|AUTHORED
1191|Principal Stratification With Time-To-Event Outcomes|Paper|Adaptable Trial|Topic|DISCUSSES
1192|Chromium Supplementation And The Essentiality Of Chromium To Human Nutrition: A Narrative Review|Paper|Chromium|Topic|DISCUSSES
1192|Chromium Supplementation And The Essentiality Of Chromium To Human Nutrition: A Narrative Review|Paper|Type 2 Diabetes Mellitus|Topic|DISCUSSES
1193|Projection-Based Testing For Mean Trajectory Differences|Topic|Wang (2021)|Author|RELATED_TO
1193|Fpass|Topic|Salil Koner|Author|AUTHORED
1193|Fpass|Topic|Sheng Luo|Author|AUTHORED
1193|Fpass|Topic|Parkinson'S Disease|Topic|RELATED_TO
1193|Fpass|Topic|Biostatistical Applications|Topic|RELATED_TO
1193|Fpass|Topic|Clinical Trials|Topic|RELATED_TO
1194|Hidden Yet Quantifiable: A Lower Bound For Confounding Strength Using Randomized Trials|Paper|Observational Studies|Topic|DISCUSSES
1194|Hidden Yet Quantifiable: A Lower Bound For Confounding Strength Using Randomized Trials|Paper|Randomized Trials|Topic|DISCUSSES
1194|Hidden Yet Quantifiable: A Lower Bound For Confounding Strength Using Randomized Trials|Paper|Unobserved Confounding|Topic|DISCUSSES
1194|Hidden Yet Quantifiable: A Lower Bound For Confounding Strength Using Randomized Trials|Paper|Statistical Test|Topic|DISCUSSES
1194|Hidden Yet Quantifiable: A Lower Bound For Confounding Strength Using Randomized Trials|Paper|Causal Conclusions|Topic|DISCUSSES
1195|Optimal Adaptive Smart Designs With Binary Outcomes|Paper|Rik Ghosh|Author|AUTHORED
1195|Optimal Adaptive Smart Designs With Binary Outcomes|Paper|Bibhas Chakraborty|Author|AUTHORED
1195|Optimal Adaptive Smart Designs With Binary Outcomes|Paper|Inbal Nahum-Shani|Author|AUTHORED
1195|Optimal Adaptive Smart Designs With Binary Outcomes|Paper|Megan E. Patrick|Author|AUTHORED
1195|Optimal Adaptive Smart Designs With Binary Outcomes|Paper|Palash Ghosh|Author|AUTHORED
1195|Optimal Adaptive Smart Designs With Binary Outcomes|Paper|Smart|Topic|DISCUSSES
1195|Optimal Adaptive Smart Designs With Binary Outcomes|Paper|M-Bridge|Topic|RELATED_TO
1196|Unified Three-State Model Framework For Analysis Of Treatment Crossover In Survival Trials|Paper|Treatment Effect|Topic|DISCUSSES
1196|Unified Three-State Model Framework For Analysis Of Treatment Crossover In Survival Trials|Paper|Treatment Crossover|Topic|DISCUSSES
1196|Unified Three-State Model Framework For Analysis Of Treatment Crossover In Survival Trials|Paper|Statistical Methodologies|Topic|DISCUSSES
1196|Unified Three-State Model Framework For Analysis Of Treatment Crossover In Survival Trials|Paper|Tsm Framework|Topic|DISCUSSES
1196|Tsm Framework|Topic|Imputation Method|Topic|RELATED_TO
1197|Rank-Based Approach For Univariate Two-Sample Testing|Topic|Wilcoxon-Mann-Whitney Test|Topic|RELATED_TO
1197|Yijin Zeng|Author|Rank-Based Approach For Univariate Two-Sample Testing|Topic|AUTHORED
1197|Niall M. Adams|Author|Rank-Based Approach For Univariate Two-Sample Testing|Topic|AUTHORED
1197|Dean A. Bodenham|Author|Rank-Based Approach For Univariate Two-Sample Testing|Topic|AUTHORED
1197|Rank-Based Approach For Univariate Two-Sample Testing|Topic|Complex Clinical Trial Data|Topic|DISCUSSES
1198|Bayesian Estimator Of Sample Size|Topic|Oncology Dose Optimization Clinical Trials|Topic|RELATED_TO
1198|Dehua Bi|Author|Bayesian Estimator Of Sample Size|Topic|AUTHORED
1198|Yuan Ji|Author|Bayesian Estimator Of Sample Size|Topic|AUTHORED
1199|Oncology Drug Development|Topic|Dose Escalation Phase|Topic|RELATED_TO
1199|Dose Escalation Phase|Topic|Maximal Tolerable Dose (Mtd)|Topic|RELATED_TO
1199|Dose Escalation Phase|Topic|Dose Limiting Toxicity (Dlt)|Topic|RELATED_TO
1199|Model-Based Dose Escalation Trial Designs|Topic|Dose Limiting Toxicity (Dlt)|Topic|RELATED_TO
1199|Pharmacokinetic (Pk) Data|Topic|Dose Escalation Phase|Topic|RELATED_TO
1199|Bayesian Joint Modeling Framework|Topic|Dose Escalation Phase|Topic|RELATED_TO
1199|Bayesian Joint Modeling Framework|Topic|Dose-Pk Relationship|Topic|RELATED_TO
1199|Bayesian Joint Modeling Framework|Topic|Pk-Dlt Relationship|Topic|RELATED_TO
1199|Real-Life Case Study|Topic|Bayesian Joint Modeling Framework|Topic|RELATED_TO
1199|Simulation|Topic|Bayesian Joint Modeling Framework|Topic|RELATED_TO
1199|Arnab Kumar Maity|Author|Pharmacokinetic Measurements In Dose Finding Model Guided By Escalation With Overdose Control|Paper|AUTHORED
1199|Satrajit Roy Chowdhury|Author|Pharmacokinetic Measurements In Dose Finding Model Guided By Escalation With Overdose Control|Paper|AUTHORED
1199|Ray Li|Author|Pharmacokinetic Measurements In Dose Finding Model Guided By Escalation With Overdose Control|Paper|AUTHORED
1199|Lada Markovtsova|Author|Pharmacokinetic Measurements In Dose Finding Model Guided By Escalation With Overdose Control|Paper|AUTHORED
1199|Roberto Bugarini|Author|Pharmacokinetic Measurements In Dose Finding Model Guided By Escalation With Overdose Control|Paper|AUTHORED
1200|Randomized Trials|Topic|Observational Studies|Topic|RELATED_TO
1200|Benchmarking Strategy|Topic|Observational Studies|Topic|DISCUSSES
1200|Benchmarking Strategy|Topic|Randomized Trials|Topic|DISCUSSES
1200|Piersilvio De Bartolomeis|Author|Benchmarking Strategy|Topic|AUTHORED
1200|Javier Abad|Author|Benchmarking Strategy|Topic|AUTHORED
1200|Konstantin Donhauser|Author|Benchmarking Strategy|Topic|AUTHORED
1200|Fanny Yang|Author|Benchmarking Strategy|Topic|AUTHORED
1200|Treatment Effect Bias|Topic|Benchmarking Strategy|Topic|RELATED_TO
1201|Transportability Of Principal Causal Effects|Paper|Justin M. Clark|Author|AUTHORED
1201|Transportability Of Principal Causal Effects|Paper|Kollin W. Rott|Author|AUTHORED
1201|Transportability Of Principal Causal Effects|Paper|James S. Hodges|Author|AUTHORED
1201|Transportability Of Principal Causal Effects|Paper|Jared D. Huling|Author|AUTHORED
1202|Starting Small: Prioritizing Safety Over Efficacy In Randomized Experiments Using The Exact Finite Sample Likelihood|Paper|Neil Christy|Author|AUTHORED
1202|Starting Small: Prioritizing Safety Over Efficacy In Randomized Experiments Using The Exact Finite Sample Likelihood|Paper|A. E. Kowalski|Author|AUTHORED
1203|Bootstrap Matching|Topic|A/B Testing|Topic|RELATED_TO
1203|Bootstrap Matching|Topic|Difference-In-Differences|Topic|RELATED_TO
1203|Bootstrap Matching|Topic|Propensity Score Matching|Topic|RELATED_TO
1203|Bootstrap Matching|Topic|Online Advertising|Topic|RELATED_TO
1203|Bootstrap Matching|Topic|Digital Marketing|Topic|RELATED_TO
1203|Bootstrap Matching|Topic|Empirical Economics|Topic|RELATED_TO
1203|Bootstrap Matching|Topic|Clinical Trials|Topic|RELATED_TO
1203|Bootstrap Matching|Topic|High-Dimensional Bioinformatics|Topic|RELATED_TO
1203|Zihao Zheng|Author|Bootstrap Matching|Topic|AUTHORED
1203|Carol Liu|Author|Bootstrap Matching|Topic|AUTHORED
1204|Covid-19 Pandemic|Topic|Vaccine Policies|Topic|RELATED_TO
1204|Vaccine Policies|Topic|Traditional Clinical Trials|Topic|RELATED_TO
1204|Traditional Clinical Trials|Topic|Public Health Strategies|Topic|RELATED_TO
1204|Ethical Concerns|Topic|Vaccine Policy Development|Topic|RELATED_TO
1204|Reinforcement Learning|Topic|Vaccine Policy Development|Topic|RELATED_TO
1204|Tabular Q-Learning|Topic|Microsimulation|Topic|RELATED_TO
1204|Microsimulation|Topic|Recurrent Neural Network|Topic|RELATED_TO
1204|Public Health Vaccine Policymaking|Topic|Q-Learning Model|Topic|RELATED_TO
1204|Q-Learning Model|Topic|Covid-19 Booster Policies|Topic|RELATED_TO
1204|Covid-19 Booster Policies|Topic|Guoxuan Ma|Author|AUTHORED
1204|Covid-19 Booster Policies|Topic|Lili Zhao|Author|AUTHORED
1204|Covid-19 Booster Policies|Topic|Jian Kang|Author|AUTHORED
1205|Intercurrent Events|Topic|Final Outcomes|Topic|DISCUSSES
1205|Principal Stratification|Topic|Latent Subpopulations|Topic|DISCUSSES
1205|Principal Stratification|Topic|Monotonicity|Topic|DISCUSSES
1205|Principal Stratification|Topic|Counterfactual Intermediate Independence|Topic|DISCUSSES
1205|Semiparametric Framework|Topic|Principal Ignorability|Topic|DISCUSSES
1205|Nonparametric Identification Formulas|Topic|Conditionally Doubly Robust Parametric Estimator|Topic|DISCUSSES
1205|Nonparametric Identification Formulas|Topic|De-Biased Machine Learning Estimator|Topic|DISCUSSES
1205|De-Biased Machine Learning Estimator|Topic|Data-Adaptive Nuisance Estimators|Topic|DISCUSSES
1205|Semiparametric Sensitivity Analysis|Topic|Principal Ignorability|Topic|DISCUSSES
1205|Semiparametric Principal Stratification Analysis Beyond Monotonicity|Paper|Jiaqi Tong|Author|AUTHORED
1205|Semiparametric Principal Stratification Analysis Beyond Monotonicity|Paper|Brennan Kahan|Author|AUTHORED
1205|Semiparametric Principal Stratification Analysis Beyond Monotonicity|Paper|Michael O. Harhay|Author|AUTHORED
1205|Semiparametric Principal Stratification Analysis Beyond Monotonicity|Paper|Fan Li|Author|AUTHORED
1206|Machine Learning|Topic|Healthcare|Topic|RELATED_TO
1206|Machine Learning|Topic|Reproducibility Crisis|Topic|RELATED_TO
1206|Reproducibility Crisis|Topic|Medicine|Topic|RELATED_TO
1206|Neuroimaging|Topic|Alzheimer'S Disease|Topic|RELATED_TO
1206|Neuroimaging|Topic|Schizophrenia|Topic|RELATED_TO
1206|Neuroimaging|Topic|Brain Aging|Topic|RELATED_TO
1206|Weighted Empirical Risk Minimization|Topic|Alzheimer'S Disease|Topic|RELATED_TO
1206|Weighted Empirical Risk Minimization|Topic|Schizophrenia|Topic|RELATED_TO
1206|Weighted Empirical Risk Minimization|Topic|Brain Aging|Topic|RELATED_TO
1206|15,363 Individuals|Topic|20 Neuroimaging Studies|Topic|RELATED_TO
1206|Rongguang Wang|Author|Weighted Empirical Risk Minimization|Topic|AUTHORED
1206|Guray Erus|Author|Weighted Empirical Risk Minimization|Topic|AUTHORED
1206|Pratik Chaudhari|Author|Weighted Empirical Risk Minimization|Topic|AUTHORED
1206|Christos Davatzikos|Author|Weighted Empirical Risk Minimization|Topic|AUTHORED
1207|Threshold-Free Summary Index For Quantifying The Capacity Of Covariates To Yield Efficient Treatment Rules|Paper|Covariates|Topic|DISCUSSES
1207|Threshold-Free Summary Index For Quantifying The Capacity Of Covariates To Yield Efficient Treatment Rules|Paper|Treatment Rules|Topic|DISCUSSES
1207|Threshold-Free Summary Index For Quantifying The Capacity Of Covariates To Yield Efficient Treatment Rules|Paper|Randomized Trial|Topic|DISCUSSES
1207|Threshold-Free Summary Index For Quantifying The Capacity Of Covariates To Yield Efficient Treatment Rules|Paper|Decision Theory|Topic|DISCUSSES
1207|Threshold-Free Summary Index For Quantifying The Capacity Of Covariates To Yield Efficient Treatment Rules|Paper|Clinical Trial Of Preventive Antibiotic Therapy For Reducing Exacerbation Rate In Chronic Obstructive Pulmonary Disease|Topic|DISCUSSES
1208|Covariate Adjustment In Subgroup Analyses Of Randomized Clinical Trials: A Propensity Score Approach|Paper|Siyun Yang|Author|AUTHORED
1208|Covariate Adjustment In Subgroup Analyses Of Randomized Clinical Trials: A Propensity Score Approach|Paper|Fan Li|Author|AUTHORED
1208|Covariate Adjustment In Subgroup Analyses Of Randomized Clinical Trials: A Propensity Score Approach|Paper|Laine E. Thomas|Author|AUTHORED
1208|Covariate Adjustment In Subgroup Analyses Of Randomized Clinical Trials: A Propensity Score Approach|Paper|Fan Li|Author|AUTHORED
1209|Savvy|Topic|Adverse Events|Topic|RELATED_TO
1209|Savvy|Topic|Randomized Clinical Trials|Topic|RELATED_TO
1209|Kaspar Rufibach|Author|Savvy|Topic|AUTHORED
1209|Regina Stegherr|Author|Savvy|Topic|AUTHORED
1209|Claudia Schmoor|Author|Savvy|Topic|AUTHORED
1209|Valentine Jehl|Author|Savvy|Topic|AUTHORED
1209|Arthur Allignol|Author|Savvy|Topic|AUTHORED
1209|Annette Boeckenhoff|Author|Savvy|Topic|AUTHORED
1209|Cornelia Dunger-Baldauf|Author|Savvy|Topic|AUTHORED
1209|Lewin Eisele|Author|Savvy|Topic|AUTHORED
1209|Thomas Künzel|Author|Savvy|Topic|AUTHORED
1209|Katrin Kupas|Author|Savvy|Topic|AUTHORED
1209|Friedhelm Leverkus|Author|Savvy|Topic|AUTHORED
1209|Matthias Trampisch|Author|Savvy|Topic|AUTHORED
1209|Yumin Zhao|Author|Savvy|Topic|AUTHORED
1209|Tim Friede|Author|Savvy|Topic|AUTHORED
1209|Jan Beyersmann|Author|Savvy|Topic|AUTHORED
1210|Randomised Controlled Trials|Topic|Ordinal Outcome|Topic|RELATED_TO
1210|Ordinal Outcome|Topic|Scoping Review|Topic|RELATED_TO
1210|Scoping Review|Topic|Chris J. Selman|Author|AUTHORED
1210|Scoping Review|Topic|Katherine J. Lee|Author|AUTHORED
1210|Scoping Review|Topic|Robert K. Mahar|Author|AUTHORED
1210|Scoping Review|Topic|Bmj|Topic|RELATED_TO
1210|Scoping Review|Topic|Nejm|Topic|RELATED_TO
1210|Scoping Review|Topic|The Lancet|Topic|RELATED_TO
1210|Scoping Review|Topic|Jama|Topic|RELATED_TO
1210|Scoping Review|Topic|Pubmed|Topic|RELATED_TO
1210|Scoping Review|Topic|Prisma-Scr Checklist|Topic|RELATED_TO
1210|1 January 2012|Topic|Scoping Review|Topic|RELATED_TO
1210|31 July 2022|Topic|Scoping Review|Topic|RELATED_TO
1211|Clinical Trials|Topic|Electronic Health Records|Topic|RELATED_TO
1211|Natural Language Processing|Topic|Generative Pre-Trained Transformer|Topic|RELATED_TO
1211|Mojdeh Rahmanian|Author|Clinical Trials|Topic|AUTHORED
1211|Seyed Mostafa Fakhrahmad|Author|Clinical Trials|Topic|AUTHORED
1211|Seyedeh Zahra Mousavi|Author|Clinical Trials|Topic|AUTHORED
1211|2018 N2C2 Challenge|Topic|Natural Language Processing|Topic|RELATED_TO
1211|Snomed Ct|Topic|Eligibility Criteria|Topic|RELATED_TO
1211|Cohort Selection Task|Topic|Eligibility Criteria|Topic|RELATED_TO
1211|Micro F Measure|Topic|Cohort Selection Task|Topic|RELATED_TO
1211|Macro F Measure|Topic|Cohort Selection Task|Topic|RELATED_TO
1212|Randomized Controlled Trials|Topic|Forest Plots|Topic|RELATED_TO
1212|Forest Plots|Topic|Treatment Effect Estimates|Topic|DISCUSSES
1212|Treatment Effect Estimates|Topic|Subgroups|Topic|RELATED_TO
1212|Bayesian Shrinkage Methods|Topic|Subgroups|Topic|DISCUSSES
1212|Cox Model|Topic|Subgroups|Topic|DISCUSSES
1212|Penalized Partial Likelihood Estimation|Topic|Cox Model|Topic|RELATED_TO
1212|Bayesian Estimation|Topic|Cox Model|Topic|RELATED_TO
1212|Credible Intervals|Topic|Bayesian Estimation|Topic|RELATED_TO
1212|Treatment Effect Estimators|Topic|Subgroups|Topic|DISCUSSES
1212|R Package Bonsaiforest|Topic|Bayesian Shrinkage Methods|Topic|RELATED_TO
1212|Marcel Wolbers|Author|Randomized Controlled Trials|Topic|AUTHORED
1212|Mar Vázquez Rabuñal|Author|Randomized Controlled Trials|Topic|AUTHORED
1212|Ke Li|Author|Randomized Controlled Trials|Topic|AUTHORED
1212|Kaspar Rufibach|Author|Randomized Controlled Trials|Topic|AUTHORED
1212|Daniel Sabanés Bové|Author|Randomized Controlled Trials|Topic|AUTHORED
1213|Chauhan Weighted Trajectory Analysis|Topic|Risk Benefit Analysis|Topic|RELATED_TO
1213|Chauhan Weighted Trajectory Analysis|Topic|Randomized Controlled Trials|Topic|RELATED_TO
1213|Chauhan Weighted Trajectory Analysis|Topic|Advanced Cancer Trial|Topic|RELATED_TO
1213|Chauhan Weighted Trajectory Analysis|Topic|Dose Escalation Phase I Trial|Topic|RELATED_TO
1213|Chauhan Weighted Trajectory Analysis|Topic|Ctcae Scale|Topic|RELATED_TO
1213|Chauhan Weighted Trajectory Analysis|Topic|Recist 1.1 Health Statuses|Topic|RELATED_TO
1213|Utkarsh Chauhan|Author|Chauhan Weighted Trajectory Analysis|Topic|AUTHORED
1213|Daylen Mackey|Author|Chauhan Weighted Trajectory Analysis|Topic|AUTHORED
1213|John R Mackey|Author|Chauhan Weighted Trajectory Analysis|Topic|AUTHORED
1214|Semiparametric Joint Modeling To Estimate The Treatment Effect On A Longitudinal Surrogate With Application To Chronic Kidney Disease Trials|Paper|Xuan Wang|Author|AUTHORED
1214|Semiparametric Joint Modeling To Estimate The Treatment Effect On A Longitudinal Surrogate With Application To Chronic Kidney Disease Trials|Paper|Jie Zhou|Author|AUTHORED
1214|Semiparametric Joint Modeling To Estimate The Treatment Effect On A Longitudinal Surrogate With Application To Chronic Kidney Disease Trials|Paper|Layla Parast|Author|AUTHORED
1214|Semiparametric Joint Modeling To Estimate The Treatment Effect On A Longitudinal Surrogate With Application To Chronic Kidney Disease Trials|Paper|Tom Greene|Author|AUTHORED
1214|Semiparametric Joint Modeling To Estimate The Treatment Effect On A Longitudinal Surrogate With Application To Chronic Kidney Disease Trials|Paper|Chronic Kidney Disease|Topic|RELATED_TO
1214|Semiparametric Joint Modeling To Estimate The Treatment Effect On A Longitudinal Surrogate With Application To Chronic Kidney Disease Trials|Paper|Glomerular Filtration Rate|Topic|RELATED_TO
1214|Semiparametric Joint Modeling To Estimate The Treatment Effect On A Longitudinal Surrogate With Application To Chronic Kidney Disease Trials|Paper|Losartan|Topic|RELATED_TO
1214|Semiparametric Joint Modeling To Estimate The Treatment Effect On A Longitudinal Surrogate With Application To Chronic Kidney Disease Trials|Paper|Renaal Trial|Topic|RELATED_TO
1215|Asymptotic Properties Of Covariate-Adjusted Adaptive Designs|Paper|Response-Adaptive Designs|Topic|DISCUSSES
1215|Asymptotic Properties Of Covariate-Adjusted Adaptive Designs|Paper|Covariate-Adjusted Response-Adaptive Designs|Topic|DISCUSSES
1215|Asymptotic Properties Of Covariate-Adjusted Adaptive Designs|Paper|K Treatments|Topic|DISCUSSES
1215|Asymptotic Properties Of Covariate-Adjusted Adaptive Designs|Paper|Generalized Linear Models|Topic|DISCUSSES
1215|Asymptotic Properties Of Covariate-Adjusted Adaptive Designs|Paper|Linear Model|Topic|DISCUSSES
1215|Asymptotic Properties Of Covariate-Adjusted Adaptive Designs|Paper|Logistic Regression Model|Topic|DISCUSSES
1215|Asymptotic Properties Of Covariate-Adjusted Adaptive Designs|Paper|Li-Xin Zhang|Author|AUTHORED
1215|Asymptotic Properties Of Covariate-Adjusted Adaptive Designs|Paper|Feifang Hu|Author|AUTHORED
1215|Asymptotic Properties Of Covariate-Adjusted Adaptive Designs|Paper|Siu Hung Cheung|Author|AUTHORED
1215|Asymptotic Properties Of Covariate-Adjusted Adaptive Designs|Paper|Wai Sum Chan|Author|AUTHORED
1216|Nonparametric Estimators Of The Mean Total Cost|Topic|Clinical Trials|Topic|RELATED_TO
1216|Longitudinal Framework|Topic|Net Present Value|Topic|RELATED_TO
1216|Medical Cost Data|Topic|Regression Model|Topic|RELATED_TO
1216|Regression Model|Topic|Heteroscedasticity|Topic|RELATED_TO
1216|Regression Model|Topic|Skewness|Topic|RELATED_TO
1216|Regression Model|Topic|Censoring In Cost Data|Topic|RELATED_TO
1216|Joseph C. Gardiner|Author|Medical Cost Data|Topic|AUTHORED
1216|Lin Liu|Author|Medical Cost Data|Topic|AUTHORED
1216|Zhehui Luo|Author|Medical Cost Data|Topic|AUTHORED
1217|Urn Models|Topic|Immigrated Urn (Imu) Models|Topic|RELATED_TO
1217|Clinical Studies|Topic|Treatment Allocation Schemes|Topic|RELATED_TO
1217|Immigrated Urn (Imu) Models|Topic|Statistical Inferences|Topic|RELATED_TO
1217|Classical Urn Models|Topic|Immigrated Urn (Imu) Models|Topic|RELATED_TO
1217|Imu Framework|Topic|Classical Urn Models|Topic|RELATED_TO
1217|Li-Xin Zhang|Author|Immigrated Urn (Imu) Models|Topic|AUTHORED
1217|Feifang Hu|Author|Immigrated Urn (Imu) Models|Topic|AUTHORED
1217|Siu Hung Cheung|Author|Immigrated Urn (Imu) Models|Topic|AUTHORED
1217|Wei Sum Chan|Author|Immigrated Urn (Imu) Models|Topic|AUTHORED
1218|A New Latent Cure Rate Marker Model For Survival Data|Paper|Sungduk Kim|Author|AUTHORED
1218|A New Latent Cure Rate Marker Model For Survival Data|Paper|Yingmei Xi|Author|AUTHORED
1218|A New Latent Cure Rate Marker Model For Survival Data|Paper|Ming-Hui Chen|Author|AUTHORED
1219|Twitter|Topic|Medical Papers|Topic|RELATED_TO
1219|Jens Peter Andersen|Author|Medical Papers|Topic|AUTHORED
1219|Stefanie Haustein|Author|Medical Papers|Topic|AUTHORED
1219|Embase|Topic|Medical Papers|Topic|RELATED_TO
1219|Meta-Analyses|Topic|Medical Papers|Topic|RELATED_TO
1219|Systematic Reviews|Topic|Medical Papers|Topic|RELATED_TO
1219|Clinical Trials|Topic|Medical Papers|Topic|RELATED_TO
1219|Basic Research|Topic|Medical Papers|Topic|RELATED_TO
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Phase Ii Dose Finding Studies|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Dose Response Relationship|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|New Drug|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Model Selection|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Model Averaging|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Mathematical Properties|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Simulations|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Asymptotic Properties Of Model Selection Criteria|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Sample Size|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Effect Size|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Large Scale Simulation Study|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Phase Ii Dosefinding Study|Topic|DISCUSSES
1220|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|Chronic Obstructive Pulmonary Disease|Topic|DISCUSSES
1220|Kirsten Schorning|Author|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|AUTHORED
1220|Björn Bornkamp|Author|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|AUTHORED
1220|Frank Bretz|Author|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|AUTHORED
1220|Holger Dette|Author|Model Selection Versus Model Averaging In Dose Finding Studies|Paper|AUTHORED
1221|Closed-Loop Deep Brain Stimulation|Topic|Neurological Movement Disorders|Topic|RELATED_TO
1221|Control Algorithms|Topic|Metric For System Performance|Topic|RELATED_TO
1221|Metric For System Performance|Topic|Parkinson'S Disease|Topic|RELATED_TO
1221|Parkinson'S Disease|Topic|Tremor Treatment|Topic|RELATED_TO
1221|Tremor Treatment|Topic|Power Savings|Topic|RELATED_TO
1221|Clinicaltrials.Gov Identifier: Nct02384421|Paper|Jeffrey Herron|Author|AUTHORED
1221|Clinicaltrials.Gov Identifier: Nct02384421|Paper|Anca Velisar|Author|AUTHORED
1221|Clinicaltrials.Gov Identifier: Nct02384421|Paper|Mahsa Malekmohammadi|Author|AUTHORED
1221|Clinicaltrials.Gov Identifier: Nct02384421|Paper|Helen Bronte-Stewart|Author|AUTHORED
1221|Clinicaltrials.Gov Identifier: Nct02384421|Paper|Howard Jay Chizeck|Author|AUTHORED
1222|Robotics|Topic|Endoscopes|Topic|RELATED_TO
1222|Endoscopes|Topic|Gi Tract|Topic|RELATED_TO
1222|Robotically Actuated Tendon Sheath Mechanisms|Topic|Endoscopes|Topic|RELATED_TO
1222|Surgical Endoscopy|Topic|Surgeon Movements|Topic|RELATED_TO
1222|Surgeon Movements|Topic|Tissue Manipulation|Topic|RELATED_TO
1222|Endoscopic Submucosal Dissection|Topic|Full-Thickness Resection|Topic|RELATED_TO
1222|Surgical Outcomes|Topic|Clinical And Pre-Clinical Trials|Topic|RELATED_TO
1222|Master-Slave Surgical Robotics|Topic|Position And Force Sensors|Topic|RELATED_TO
1222|Position And Force Sensors|Topic|Tactile Feedback|Topic|RELATED_TO
1222|Robotic Assisted Gi Luminal Surgeries|Topic|Gastroenterologists|Topic|RELATED_TO
1222|Notes Surgeries|Topic|Gastroenterologists|Topic|RELATED_TO
1222|Tian En Timothy Seah|Author|Future Of Flexible Robotic Endoscopy Systems|Paper|AUTHORED
1222|Thanh Nho Do|Author|Future Of Flexible Robotic Endoscopy Systems|Paper|AUTHORED
1222|Nobuyoshi Takeshita|Author|Future Of Flexible Robotic Endoscopy Systems|Paper|AUTHORED
1222|Khek Yu Ho|Author|Future Of Flexible Robotic Endoscopy Systems|Paper|AUTHORED
1222|Soo Jay Phee|Author|Future Of Flexible Robotic Endoscopy Systems|Paper|AUTHORED
1223|A Novel Method Of Subgroup Identification By Combining Virtual Twins With Guide (Vg) For Development Of Precision Medicines|Paper|Virtual Twins|Topic|DISCUSSES
1223|A Novel Method Of Subgroup Identification By Combining Virtual Twins With Guide (Vg) For Development Of Precision Medicines|Paper|Guide|Topic|DISCUSSES
1224|Alzheimer'S Disease|Topic|Quantitative Electroencephalography|Topic|RELATED_TO
1224|Quantitative Electroencephalography|Topic|Riemannian Tangent Space Mapping|Topic|RELATED_TO
1224|Quantitative Electroencephalography|Topic|Elastic Net Regression|Topic|RELATED_TO
1224|Riemannian Tangent Space Mapping|Topic|Brain Atrophy Markers|Topic|RELATED_TO
1224|Elastic Net Regression|Topic|Brain Atrophy Markers|Topic|RELATED_TO
1224|Brain Atrophy Markers|Topic|Wolfgang Fruehwirt|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Matthias Gerstgrasser|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Pengfei Zhang|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Leonard Weydemann|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Markus Waser|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Reinhold Schmidt|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Thomas Benke|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Peter Dal-Bianco|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Gerhard Ransmayr|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Dieter Grossegger|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Heinrich Garn|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Gareth W. Peters|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Stephen Roberts|Author|AUTHORED
1224|Brain Atrophy Markers|Topic|Georg Dorffner|Author|AUTHORED
1225|Biomarker Measurements|Topic|Compound|Topic|RELATED_TO
1225|Patients|Topic|Drug|Topic|RELATED_TO
1225|Treatment Effect|Topic|Subgroup|Topic|RELATED_TO
1225|Subgroup|Topic|Causal Conclusions|Topic|RELATED_TO
1225|Causal Conclusions|Topic|Causal Inference|Topic|RELATED_TO
1225|Subgroup Effects|Topic|Simulations|Topic|RELATED_TO
1225|Subgroup Effects|Topic|Case-Study|Topic|RELATED_TO
1225|Randomized Clinical Trials|Topic|Time-To-Event Endpoint|Topic|RELATED_TO
1225|Björn Bornkamp|Author|Biomarker Measurements|Topic|AUTHORED
1225|Georgina Bermann|Author|Biomarker Measurements|Topic|AUTHORED
1226|Inverse Probability Of Treatment Weighting (Iptw)|Topic|Sample Average Treatment Effects (Sate)|Topic|RELATED_TO
1226|Sample Average Treatment Effects (Sate)|Topic|Observational Data|Topic|RELATED_TO
1226|Positivity Assumption|Topic|Treatment Assignment Model|Topic|RELATED_TO
1226|Truncation|Topic|Kernel Optimal Matching (Kom)|Topic|RELATED_TO
1226|Covariate-Balancing Propensity Scores|Topic|Kernel Optimal Matching (Kom)|Topic|RELATED_TO
1226|Stable Balancing Weights|Topic|Kernel Optimal Matching (Kom)|Topic|RELATED_TO
1226|Kernel Optimal Matching (Kom)|Topic|Spine Surgery|Topic|RELATED_TO
1226|Conditional Mean Squared Error|Topic|Kernel Optimal Matching (Kom)|Topic|RELATED_TO
1226|Clinical Registry|Topic|Kernel Optimal Matching (Kom)|Topic|RELATED_TO
1226|Nathan Kallus|Author|Kernel Optimal Matching (Kom)|Topic|AUTHORED
1226|Brenton Pennicooke|Author|Kernel Optimal Matching (Kom)|Topic|AUTHORED
1226|Michele Santacatterina|Author|Kernel Optimal Matching (Kom)|Topic|AUTHORED
1227|A Family-Based Graphical Approach For Testing Hierarchically Ordered Families Of Hypotheses|Paper|Zhiying Qiu|Author|AUTHORED
1227|A Family-Based Graphical Approach For Testing Hierarchically Ordered Families Of Hypotheses|Paper|Li Yu|Author|AUTHORED
1227|A Family-Based Graphical Approach For Testing Hierarchically Ordered Families Of Hypotheses|Paper|Wenge Guo|Author|AUTHORED
1227|A Family-Based Graphical Approach For Testing Hierarchically Ordered Families Of Hypotheses|Paper|Gatekeeping Strategies|Topic|DISCUSSES
1227|A Family-Based Graphical Approach For Testing Hierarchically Ordered Families Of Hypotheses|Paper|Familywise Error Rate|Topic|DISCUSSES
1228|Multi-Modal Machine Learning-Based Oa Progression Prediction Model|Topic|Knee Osteoarthritis|Topic|RELATED_TO
1228|Aleksei Tiulpin|Author|Multi-Modal Machine Learning-Based Oa Progression Prediction Model|Topic|AUTHORED
1228|Stefan Klein|Author|Multi-Modal Machine Learning-Based Oa Progression Prediction Model|Topic|AUTHORED
1228|Sita M. A. Bierma-Zeinstra|Author|Multi-Modal Machine Learning-Based Oa Progression Prediction Model|Topic|AUTHORED
1228|Jérôme Thevenot|Author|Multi-Modal Machine Learning-Based Oa Progression Prediction Model|Topic|AUTHORED
1228|Esa Rahtu|Author|Multi-Modal Machine Learning-Based Oa Progression Prediction Model|Topic|AUTHORED
1228|Joyce Van Meurs|Author|Multi-Modal Machine Learning-Based Oa Progression Prediction Model|Topic|AUTHORED
1228|Edwin H. G. Oei|Author|Multi-Modal Machine Learning-Based Oa Progression Prediction Model|Topic|AUTHORED
1228|Simo Saarakkala|Author|Multi-Modal Machine Learning-Based Oa Progression Prediction Model|Topic|AUTHORED
1229|Augmented Reality|Topic|Image Guided Surgery|Topic|RELATED_TO
1229|Image Guided Surgery|Topic|Surgical Landmarks|Topic|RELATED_TO
1229|Magnetic Resonance Elastography|Topic|Patient Specific Biomechanics|Topic|RELATED_TO
1229|Mre Data Driven Simulation|Topic|Traditional Method|Topic|RELATED_TO
1229|Michael Barrow|Author|Patient Specific Biomechanics|Topic|AUTHORED
1229|Alice Chao|Author|Patient Specific Biomechanics|Topic|AUTHORED
1229|Qizhi He|Author|Patient Specific Biomechanics|Topic|AUTHORED
1229|Sonia Ramamoorthy|Author|Patient Specific Biomechanics|Topic|AUTHORED
1229|Claude Sirlin|Author|Patient Specific Biomechanics|Topic|AUTHORED
1229|Ryan Kastner|Author|Patient Specific Biomechanics|Topic|AUTHORED
1230|Prediction Of Thrombectomy Functional Outcomes Using Multimodal Data|Paper|Zeynel A. Samak|Author|AUTHORED
1230|Prediction Of Thrombectomy Functional Outcomes Using Multimodal Data|Paper|Philip Clatworthy|Author|AUTHORED
1230|Prediction Of Thrombectomy Functional Outcomes Using Multimodal Data|Paper|Majid Mirmehdi|Author|AUTHORED
1230|Prediction Of Thrombectomy Functional Outcomes Using Multimodal Data|Paper|Ischaemic Stroke|Topic|RELATED_TO
1230|Prediction Of Thrombectomy Functional Outcomes Using Multimodal Data|Paper|Endovascular Thrombectomy|Topic|RELATED_TO
1230|Prediction Of Thrombectomy Functional Outcomes Using Multimodal Data|Paper|Deep Learning|Topic|RELATED_TO
1230|Prediction Of Thrombectomy Functional Outcomes Using Multimodal Data|Paper|Multimodal Data|Topic|RELATED_TO
1230|Prediction Of Thrombectomy Functional Outcomes Using Multimodal Data|Paper|Modified Rankin Scale Score|Topic|RELATED_TO
1230|Prediction Of Thrombectomy Functional Outcomes Using Multimodal Data|Paper|Auc|Topic|RELATED_TO
1230|Prediction Of Thrombectomy Functional Outcomes Using Multimodal Data|Paper|Classification Accuracy|Topic|RELATED_TO
1231|Causal Network Models Of Sars-Cov-2 Expression And Aging To Identify Candidates For Drug Repurposing|Paper|Anastasiya Belyaeva|Author|AUTHORED
1231|Causal Network Models Of Sars-Cov-2 Expression And Aging To Identify Candidates For Drug Repurposing|Paper|Louis Cammarata|Author|AUTHORED
1231|Causal Network Models Of Sars-Cov-2 Expression And Aging To Identify Candidates For Drug Repurposing|Paper|Adityanarayanan Radhakrishnan|Author|AUTHORED
1231|Causal Network Models Of Sars-Cov-2 Expression And Aging To Identify Candidates For Drug Repurposing|Paper|Chandler Squires|Author|AUTHORED
1231|Causal Network Models Of Sars-Cov-2 Expression And Aging To Identify Candidates For Drug Repurposing|Paper|Karren Dai Yang|Author|AUTHORED
1231|Causal Network Models Of Sars-Cov-2 Expression And Aging To Identify Candidates For Drug Repurposing|Paper|G. V. Shivashankar|Author|AUTHORED
1231|Causal Network Models Of Sars-Cov-2 Expression And Aging To Identify Candidates For Drug Repurposing|Paper|Caroline Uhler|Author|AUTHORED
1231|Causal Network Models Of Sars-Cov-2 Expression And Aging To Identify Candidates For Drug Repurposing|Paper|Sars-Cov-2|Topic|RELATED_TO
1231|Causal Network Models Of Sars-Cov-2 Expression And Aging To Identify Candidates For Drug Repurposing|Paper|Drug Repurposing|Topic|RELATED_TO
1231|Causal Network Models Of Sars-Cov-2 Expression And Aging To Identify Candidates For Drug Repurposing|Paper|Aging|Topic|RELATED_TO
1232|Pure-Exploration Problem In Stochastic Multi-Armed Bandits|Topic|Epsilon-Good Arm|Topic|RELATED_TO
1232|Pure-Exploration Problem In Stochastic Multi-Armed Bandits|Topic|Best-Arm Identification|Topic|RELATED_TO
1232|Pure-Exploration Problem In Stochastic Multi-Armed Bandits|Topic|Top-K Arm Identification|Topic|RELATED_TO
1232|Pure-Exploration Problem In Stochastic Multi-Armed Bandits|Topic|All Arms With Means Above A Specified Threshold|Topic|RELATED_TO
1232|Virologist|Author|Epsilon-Good Arm|Topic|DISCUSSES
1232|Blake Mason|Author|Pure-Exploration Problem In Stochastic Multi-Armed Bandits|Topic|AUTHORED
1232|Lalit Jain|Author|Pure-Exploration Problem In Stochastic Multi-Armed Bandits|Topic|AUTHORED
1232|Ardhendu Tripathy|Author|Pure-Exploration Problem In Stochastic Multi-Armed Bandits|Topic|AUTHORED
1232|Robert Nowak|Author|Pure-Exploration Problem In Stochastic Multi-Armed Bandits|Topic|AUTHORED
1232|Large-Scale Crowd-Sourced Dataset|Topic|Pure-Exploration Problem In Stochastic Multi-Armed Bandits|Topic|RELATED_TO
1232|Dataset Testing Hundreds Of Possible Cancer Drugs|Topic|Pure-Exploration Problem In Stochastic Multi-Armed Bandits|Topic|RELATED_TO
1233|Drug Repurposing|Topic|Framework For Drug Repurposing|Topic|RELATED_TO
1233|Real World Data|Topic|Framework For Drug Repurposing|Topic|RELATED_TO
1233|Coronary Artery Disease|Topic|Drug Candidates|Topic|RELATED_TO
1233|Ruoqi Liu|Author|Framework For Drug Repurposing|Topic|AUTHORED
1233|Lai Wei|Author|Framework For Drug Repurposing|Topic|AUTHORED
1233|Ping Zhang|Author|Framework For Drug Repurposing|Topic|AUTHORED
1233|Framework For Drug Repurposing|Topic|Causal Inference|Topic|RELATED_TO
1233|Framework For Drug Repurposing|Topic|Deep Learning|Topic|RELATED_TO
1234|The Impact Of The Covid-19 Pandemic On Scientific Research In The Life Sciences|Paper|Massimo Riccaboni|Author|AUTHORED
1234|The Impact Of The Covid-19 Pandemic On Scientific Research In The Life Sciences|Paper|Luca Verginer|Author|AUTHORED
1234|The Impact Of The Covid-19 Pandemic On Scientific Research In The Life Sciences|Paper|Covid-19|Topic|RELATED_TO
1234|The Impact Of The Covid-19 Pandemic On Scientific Research In The Life Sciences|Paper|Life Sciences|Topic|RELATED_TO
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Liudmila Voronina|Author|AUTHORED
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Cristina Leonardo|Author|AUTHORED
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Johannes B. Mueller-Reif|Author|AUTHORED
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Philipp E. Geyer|Author|AUTHORED
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Marinus Huber|Author|AUTHORED
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Michael Trubetskov|Author|AUTHORED
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Kosmas V. Kepesidis|Author|AUTHORED
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Jurgen Behr|Author|AUTHORED
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Matthias Mann|Author|AUTHORED
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Ferenc Krausz|Author|AUTHORED
1235|Molecular Origin Of Blood-Based Infrared Fingerprints|Paper|Mihaela Zigman|Author|AUTHORED
1236|Applications Of Artificial Intelligence To Aid Detection Of Dementia: A Narrative Review On Current Capabilities And Future Directions|Paper|Dementia|Topic|DISCUSSES
1236|Renjie Li|Author|Applications Of Artificial Intelligence To Aid Detection Of Dementia: A Narrative Review On Current Capabilities And Future Directions|Paper|AUTHORED
1236|Xinyi Wang|Author|Applications Of Artificial Intelligence To Aid Detection Of Dementia: A Narrative Review On Current Capabilities And Future Directions|Paper|AUTHORED
1236|Katherine Lawler|Author|Applications Of Artificial Intelligence To Aid Detection Of Dementia: A Narrative Review On Current Capabilities And Future Directions|Paper|AUTHORED
1236|Saurabh Garg|Author|Applications Of Artificial Intelligence To Aid Detection Of Dementia: A Narrative Review On Current Capabilities And Future Directions|Paper|AUTHORED
1236|Quan Bai|Author|Applications Of Artificial Intelligence To Aid Detection Of Dementia: A Narrative Review On Current Capabilities And Future Directions|Paper|AUTHORED
1236|Jane Alty|Author|Applications Of Artificial Intelligence To Aid Detection Of Dementia: A Narrative Review On Current Capabilities And Future Directions|Paper|AUTHORED
1237|Conservative Actor-Critic With Smooth Gradient (Casog)|Paper|Robot-Assisted Intervention|Topic|DISCUSSES
1237|Conservative Actor-Critic With Smooth Gradient (Casog)|Paper|Vascular Robotic Systems|Topic|DISCUSSES
1237|Conservative Actor-Critic With Smooth Gradient (Casog)|Paper|Clinical Trials|Topic|DISCUSSES
1237|Conservative Actor-Critic With Smooth Gradient (Casog)|Paper|Q-Function|Topic|DISCUSSES
1237|Conservative Actor-Critic With Smooth Gradient (Casog)|Paper|Convolution Layers|Topic|DISCUSSES
1237|Conservative Actor-Critic With Smooth Gradient (Casog)|Paper|Pre-Clinical Environment|Topic|DISCUSSES
1238|Mixed Effects Model For Repeated Measures|Topic|Multivariate Skew-T Distribution|Topic|RELATED_TO
1238|Multivariate Skew-T Distribution|Topic|Markov Chain Monte Carlo Algorithm|Topic|RELATED_TO
1238|Markov Chain Monte Carlo Algorithm|Topic|Longitudinal Clinical Trials|Topic|RELATED_TO
1238|Longitudinal Clinical Trials|Topic|Yongqiang Tang|Author|AUTHORED
1239|Warfarin|Topic|Fixed-Dose Approach|Topic|RELATED_TO
1239|Warfarin|Topic|Warfarin Clinical Algorithm|Topic|RELATED_TO
1239|Warfarin|Topic|Warfarin Clinical Dosing Algorithm|Topic|RELATED_TO
1239|Warfarin|Topic|Multi-Armed Bandit Algorithms|Topic|DISCUSSES
1239|Multi-Armed Bandit Algorithms|Topic|Pharmgkb|Topic|RELATED_TO
1239|Multi-Armed Bandit Algorithms|Topic|Hai Xiao|Author|AUTHORED
1240|Hand-Held Interface For Type 1 Diabetes|Topic|Type 1 Diabetes|Topic|RELATED_TO
1240|Hand-Held Interface For Type 1 Diabetes|Topic|Robert Spence|Author|AUTHORED
1240|Hand-Held Interface For Type 1 Diabetes|Topic|Chukwuma Uduku|Author|AUTHORED
1240|Hand-Held Interface For Type 1 Diabetes|Topic|Kezhi Li|Author|AUTHORED
1240|Hand-Held Interface For Type 1 Diabetes|Topic|Nick Oliver|Author|AUTHORED
1240|Hand-Held Interface For Type 1 Diabetes|Topic|Pantelis Georgiou|Author|AUTHORED
1241|Restricted Mean Time Lost|Topic|Sub-Distribution Hazard Ratio|Topic|RELATED_TO
1241|Sdiff|Topic|Diff|Topic|RELATED_TO
1241|Sdiff|Topic|Monte Carlo Simulations|Topic|RELATED_TO
1241|Sdiff|Topic|Real Examples|Topic|RELATED_TO
1241|Jingjing Lyu|Author|Sdiff|Topic|AUTHORED
1241|Yawen Hou|Author|Sdiff|Topic|AUTHORED
1241|Zheng Chen|Author|Sdiff|Topic|AUTHORED
1241|Treatment Effects|Topic|Restricted Mean Time Lost|Topic|RELATED_TO
1242|Social Robot Project|Topic|Mary Ellen Foster|Author|AUTHORED
1242|Social Robot Project|Topic|Ronald P. A. Petrick|Author|AUTHORED
1243|Digital Pathology Imaging|Topic|Deep Learning Methods|Topic|RELATED_TO
1243|Deep Learning Methods|Topic|Tumor Descriptors|Topic|RELATED_TO
1243|Tumor Descriptors|Topic|Lung Adenocarcinoma|Topic|RELATED_TO
1243|Lung Adenocarcinoma|Topic|Prognostic Model|Topic|RELATED_TO
1243|Esteban Fernández Morales|Author|Github Repository|Topic|AUTHORED
1243|Cong Zhang|Author|Github Repository|Topic|AUTHORED
1243|Guanghua Xiao|Author|Github Repository|Topic|AUTHORED
1243|Chul Moon|Author|Github Repository|Topic|AUTHORED
1243|Qiwei Li|Author|Github Repository|Topic|AUTHORED
1244|Multi-Center Clinical Trials|Topic|Summarized Clinical Data|Topic|RELATED_TO
1244|Summarized Clinical Data|Topic|Statistical Methods|Topic|RELATED_TO
1244|Statistical Methods|Topic|Big Data|Topic|RELATED_TO
1244|Jing Qin|Author|Statistical Methods|Topic|AUTHORED
1244|Yukun Liu|Author|Statistical Methods|Topic|AUTHORED
1244|Pengfei Li|Author|Statistical Methods|Topic|AUTHORED
1244|Statistical Methods|Topic|Generalized Method Of Moments|Topic|RELATED_TO
1244|Statistical Methods|Topic|Estimating Equations|Topic|RELATED_TO
1244|Estimating Equations|Topic|Empirical Likelihood Method|Topic|RELATED_TO
1244|Statistical Methods|Topic|Meta Analysis|Topic|RELATED_TO
1245|Meta-Analysis Of Censored Adverse Events|Paper|Xinyue Qi|Author|AUTHORED
1245|Meta-Analysis Of Censored Adverse Events|Paper|Shouhao Zhou|Author|AUTHORED
1245|Meta-Analysis Of Censored Adverse Events|Paper|Christine B. Peterson|Author|AUTHORED
1245|Meta-Analysis Of Censored Adverse Events|Paper|Yucai Wang|Author|AUTHORED
1245|Meta-Analysis Of Censored Adverse Events|Paper|Xinying Fang|Author|AUTHORED
1245|Meta-Analysis Of Censored Adverse Events|Paper|Michael L. Wang|Author|AUTHORED
1245|Meta-Analysis Of Censored Adverse Events|Paper|Chan Shen|Author|AUTHORED
1246|Estimating Conditional Average Treatment Effect|Topic|Randomized Clinical Trials|Topic|RELATED_TO
1246|Estimating Conditional Average Treatment Effect|Topic|Observational Datasets|Topic|RELATED_TO
1246|Estimating Conditional Average Treatment Effect|Topic|Difference In Differences|Topic|RELATED_TO
1246|Difference In Differences|Topic|Synthesized Difference In Differences|Topic|RELATED_TO
1246|Synthesized Difference In Differences|Topic|Eric V. Strobl|Author|AUTHORED
1246|Synthesized Difference In Differences|Topic|Thomas A. Lasko|Author|AUTHORED
1247|Machine Learning Applications For Therapeutic Tasks With Genomics Data|Paper|Kexin Huang|Author|AUTHORED
1247|Machine Learning Applications For Therapeutic Tasks With Genomics Data|Paper|Cao Xiao|Author|AUTHORED
1247|Machine Learning Applications For Therapeutic Tasks With Genomics Data|Paper|Lucas M. Glass|Author|AUTHORED
1247|Machine Learning Applications For Therapeutic Tasks With Genomics Data|Paper|Cathy W. Critchlow|Author|AUTHORED
1247|Machine Learning Applications For Therapeutic Tasks With Genomics Data|Paper|Greg Gibson|Author|AUTHORED
1247|Machine Learning Applications For Therapeutic Tasks With Genomics Data|Paper|Jimeng Sun|Author|AUTHORED
1248|Eb-Rmap|Topic|Box'S Prior Predictive P-Value|Topic|RELATED_TO
1248|Eb-Rmap|Topic|Binary|Topic|RELATED_TO
1248|Eb-Rmap|Topic|Normal|Topic|RELATED_TO
1248|Eb-Rmap|Topic|Time-To-Event|Topic|RELATED_TO
1248|Clinical Dataset|Topic|Eb-Rmap|Topic|RELATED_TO
1248|Hongtao Zhang|Author|Eb-Rmap|Topic|AUTHORED
1248|Yueqi Shen|Author|Eb-Rmap|Topic|AUTHORED
1248|Alan Y Chiang|Author|Eb-Rmap|Topic|AUTHORED
1248|Judy Li|Author|Eb-Rmap|Topic|AUTHORED
1249|Counterfactual Phenotyping With Censored Time-To-Events|Paper|Chirag Nagpal|Author|AUTHORED
1249|Counterfactual Phenotyping With Censored Time-To-Events|Paper|Mononito Goswami|Author|AUTHORED
1249|Counterfactual Phenotyping With Censored Time-To-Events|Paper|Keith Dufendach|Author|AUTHORED
1249|Counterfactual Phenotyping With Censored Time-To-Events|Paper|Artur Dubrawski|Author|AUTHORED
1249|Estimation Of Treatment Efficacy Of Real-World Clinical Interventions|Topic|Counterfactual Phenotyping With Censored Time-To-Events|Paper|RELATED_TO
1250|Pathologybert|Topic|Natural Language Understanding|Topic|RELATED_TO
1250|Pathologybert|Topic|Breast Cancer Diagnose Classification|Topic|RELATED_TO
1250|Thiago Santos|Author|Pathologybert|Topic|AUTHORED
1250|Amara Tariq|Author|Pathologybert|Topic|AUTHORED
1250|Susmita Das|Author|Pathologybert|Topic|AUTHORED
1250|Kavyasree Vayalpati|Author|Pathologybert|Topic|AUTHORED
1250|Geoffrey H. Smith|Author|Pathologybert|Topic|AUTHORED
1250|Hari Trivedi|Author|Pathologybert|Topic|AUTHORED
1250|Imon Banerjee|Author|Pathologybert|Topic|AUTHORED
1251|Treatment Discontinuation|Topic|Insulin Peglispro|Topic|RELATED_TO
1251|Yongming Qu|Author|Treatment Discontinuation|Topic|AUTHORED
1251|Robin D. White|Author|Treatment Discontinuation|Topic|AUTHORED
1251|Stephen J. Ruberg|Author|Treatment Discontinuation|Topic|AUTHORED
1251|Current Case Report Form|Topic|Treatment Discontinuation|Topic|RELATED_TO
1251|Phase 2 And Phase 3 Studies|Topic|Insulin Peglispro|Topic|RELATED_TO
1251|Clinical Data Interchange Standards Consortium|Topic|Treatment Discontinuation|Topic|RELATED_TO
1252|Biomarker|Topic|Selective Genotyping|Topic|RELATED_TO
1252|Selective Genotyping|Topic|Reverse-Regression Least Squares Estimator|Topic|RELATED_TO
1252|Reverse-Regression Least Squares Estimator|Topic|Monte Carlo Simulations|Topic|RELATED_TO
1252|Monte Carlo Simulations|Topic|Joint Normal Distribution Assumption|Topic|RELATED_TO
1252|Reverse-Regression Least Squares Estimator|Topic|Biomarker Testing Landscape|Topic|RELATED_TO
1252|Biomarker Testing Landscape|Topic|Biomarker Value|Topic|RELATED_TO
1252|Biomarker Testing Landscape|Topic|Response|Topic|RELATED_TO
1252|A. Adam Ding|Author|Statistical Methods For Selective Biomarker Testing|Paper|AUTHORED
1252|Natalie Delrocco|Author|Statistical Methods For Selective Biomarker Testing|Paper|AUTHORED
1252|Samuel Wu|Author|Statistical Methods For Selective Biomarker Testing|Paper|AUTHORED
1252|Statistical Methods For Selective Biomarker Testing|Paper|Chronic Pain Clinical Trial|Topic|DISCUSSES
1253|Perpetual Observational Studies|Topic|Ecraid|Topic|RELATED_TO
1253|Perpetual Observational Studies|Topic|N. Hassoun-Kheir|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|C. H. Van Werkhoven|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|J. Dunning|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|T. Jaenisch|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|J. Van Beek|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|J. Bielicki|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|C. Butler|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|B. Francois|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|S. Harbarth|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|A. C. Hernandez Padilla|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|P. Horby|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|M. Koopmans|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|J. Lee|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|J. Rodriguez-Baño|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|E. Tacconelli|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|Y. Themistocleous|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|A. W. Van Der Velden|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|M. Bonten|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|H. Goossens|Author|AUTHORED
1253|Perpetual Observational Studies|Topic|M. E. A. De Kraker|Author|AUTHORED
1254|Deep Learning Based Patient-Specific Computational Model|Paper|Patient-Specific Diagnosis|Topic|RELATED_TO
1254|Deep Learning Based Patient-Specific Computational Model|Paper|Therapy Stratification|Topic|RELATED_TO
1254|Deep Learning Based Patient-Specific Computational Model|Paper|Ventricular Activation Properties|Topic|RELATED_TO
1254|Deep Learning Based Patient-Specific Computational Model|Paper|Eikonal Model|Topic|RELATED_TO
1254|Deep Learning Based Patient-Specific Computational Model|Paper|Electrocardiogram (Ecg)|Topic|RELATED_TO
1254|Deep Learning Based Patient-Specific Computational Model|Paper|Simulated Data|Topic|RELATED_TO
1254|Deep Learning Based Patient-Specific Computational Model|Paper|Computational Time|Topic|RELATED_TO
1255|Echocardiographic Image Quality Assessment Using Deep Neural Networks|Paper|Robert B. Labs|Author|AUTHORED
1255|Echocardiographic Image Quality Assessment Using Deep Neural Networks|Paper|Massoud Zolgharni|Author|AUTHORED
1255|Echocardiographic Image Quality Assessment Using Deep Neural Networks|Paper|Jonathan P. Loo|Author|AUTHORED
1255|Echocardiographic Image Quality Assessment Using Deep Neural Networks|Paper|Echocardiography|Topic|RELATED_TO
1256|Medical Imaging Datasets|Topic|Precision Medicine|Topic|RELATED_TO
1256|Unsupervised Autoencoder Framework|Topic|Contrastive Loss|Topic|RELATED_TO
1256|Unsupervised Autoencoder Framework|Topic|Latent Space|Topic|RELATED_TO
1256|Unsupervised Autoencoder Framework|Topic|Benchmark Datasets|Topic|RELATED_TO
1256|Supervised Transfer Learning|Topic|Benchmark Datasets|Topic|RELATED_TO
1256|Matteo Ferrante|Author|Contrastive Learning For Unsupervised Medical Image Clustering And Reconstruction|Paper|AUTHORED
1256|Tommaso Boccato|Author|Contrastive Learning For Unsupervised Medical Image Clustering And Reconstruction|Paper|AUTHORED
1256|Simeon Spasov|Author|Contrastive Learning For Unsupervised Medical Image Clustering And Reconstruction|Paper|AUTHORED
1256|Andrea Duggento|Author|Contrastive Learning For Unsupervised Medical Image Clustering And Reconstruction|Paper|AUTHORED
1256|Nicola Toschi|Author|Contrastive Learning For Unsupervised Medical Image Clustering And Reconstruction|Paper|AUTHORED
1257|Deepvent|Paper|Mechanical Ventilation|Topic|DISCUSSES
1257|Deepvent|Paper|Conservative Q-Learning|Topic|RELATED_TO
1257|Deepvent|Paper|Deep Reinforcement Learning|Topic|RELATED_TO
1257|Deepvent|Paper|Mimic-Iii Dataset|Topic|RELATED_TO
1257|Deepvent|Paper|Fitted Q Evaluation|Topic|RELATED_TO
1257|Deepvent|Paper|Patients With Pulmonary Impairment|Topic|RELATED_TO
1257|Deepvent|Paper|Healthcare Workers|Topic|RELATED_TO
1258|Digital Health Twin|Topic|Computational Pathology|Topic|RELATED_TO
1258|Digital Health Twin|Topic|Privacy Safeguards|Topic|RELATED_TO
1258|Digital Health Twin|Topic|Real-World Evidence|Topic|RELATED_TO
1258|Manuel Cossio|Author|Digital Health Twin|Topic|AUTHORED
1259|Identifying Heterogeneous Treatment Effects In Multiple Outcomes Using Joint Confidence Intervals|Paper|Heterogeneous Treatment Effects|Topic|DISCUSSES
1259|Identifying Heterogeneous Treatment Effects In Multiple Outcomes Using Joint Confidence Intervals|Paper|Randomized Controlled Trials|Topic|DISCUSSES
1259|Identifying Heterogeneous Treatment Effects In Multiple Outcomes Using Joint Confidence Intervals|Paper|Precision Medicine|Topic|DISCUSSES
1259|Identifying Heterogeneous Treatment Effects In Multiple Outcomes Using Joint Confidence Intervals|Paper|Subgroups|Topic|DISCUSSES
1259|Identifying Heterogeneous Treatment Effects In Multiple Outcomes Using Joint Confidence Intervals|Paper|Framework For Partitioning The Covariate Space|Topic|DISCUSSES
1259|Identifying Heterogeneous Treatment Effects In Multiple Outcomes Using Joint Confidence Intervals|Paper|Algorithm|Topic|DISCUSSES
1259|Identifying Heterogeneous Treatment Effects In Multiple Outcomes Using Joint Confidence Intervals|Paper|Synthetic And Semi-Synthetic Data|Topic|DISCUSSES
1259|Peniel N. Argaw|Author|Identifying Heterogeneous Treatment Effects In Multiple Outcomes Using Joint Confidence Intervals|Paper|AUTHORED
1259|Elizabeth Healey|Author|Identifying Heterogeneous Treatment Effects In Multiple Outcomes Using Joint Confidence Intervals|Paper|AUTHORED
1259|Isaac S. Kohane|Author|Identifying Heterogeneous Treatment Effects In Multiple Outcomes Using Joint Confidence Intervals|Paper|AUTHORED
1260|Cart-Cell Therapy|Topic|Cancer|Topic|RELATED_TO
1260|Cart-Cell Therapy|Topic|Fda|Topic|RELATED_TO
1260|Cart-Cell Therapy|Topic|Clinical Trials|Topic|RELATED_TO
1260|Cart-Cell Therapy|Topic|Computational Frameworks|Topic|RELATED_TO
1260|Cart-Cell Therapy|Topic|Signaling Signatures|Topic|RELATED_TO
1260|Cart-Cell Therapy|Topic|Tumor Cells|Topic|RELATED_TO
1260|Cart-Cell Therapy|Topic|In Silico|Topic|RELATED_TO
1260|Viren Shah|Author|Cart-Cell Therapy|Topic|AUTHORED
1260|Justin Womack|Author|Cart-Cell Therapy|Topic|AUTHORED
1260|Anthony E. Zamora|Author|Cart-Cell Therapy|Topic|AUTHORED
1260|Scott S. Terhune|Author|Cart-Cell Therapy|Topic|AUTHORED
1260|Ranjan K. Dash|Author|Cart-Cell Therapy|Topic|AUTHORED
1261|Penalized Splines|Topic|Linear Mixed Effects Model (Lmm)|Topic|RELATED_TO
1261|Linear Mixed Effects Model (Lmm)|Topic|Permutation Tests|Topic|RELATED_TO
1261|Permutation Tests|Topic|Stimulant Use Disorder Psychosocial Clinical Trial|Topic|RELATED_TO
1261|Boyu Ren|Author|Permutation Tests|Topic|AUTHORED
1261|Stuart R. Lipsitz|Author|Permutation Tests|Topic|AUTHORED
1261|Garrett M. Fitzmaurice|Author|Permutation Tests|Topic|AUTHORED
1261|Roger D. Weiss|Author|Permutation Tests|Topic|AUTHORED
1262|Biodynamic Profiles|Topic|Canine B-Cell Lymphoma|Topic|RELATED_TO
1262|Fresh Tumor Biopsies|Topic|Flash-Frozen Biopsies|Topic|RELATED_TO
1262|Digital Speckle Holography|Topic|Thawed Samples|Topic|RELATED_TO
1262|Thawed Samples|Topic|Chemosensitivity Testing|Topic|RELATED_TO
1262|Zhen Hua|Author|Chemosensitivity Testing|Topic|AUTHORED
1262|John Turek|Author|Chemosensitivity Testing|Topic|AUTHORED
1262|Mike Childress|Author|Chemosensitivity Testing|Topic|AUTHORED
1262|David Nolte|Author|Chemosensitivity Testing|Topic|AUTHORED
1263|Bioequivalence Study|Topic|Clinical Trial|Topic|RELATED_TO
1263|Bioequivalence Study|Topic|Drug Formulation|Topic|RELATED_TO
1263|Bioequivalence Study|Topic|Pharmacokinetic Profiles|Topic|RELATED_TO
1263|Bioequivalence Study|Topic|Food And Drug Administration|Author|RELATED_TO
1263|Bioequivalence Study|Topic|Confidence Interval Approach|Topic|RELATED_TO
1263|Confidence Interval Approach|Topic|Kexuan Li|Author|AUTHORED
1263|Confidence Interval Approach|Topic|Susie Sinks|Author|AUTHORED
1263|Confidence Interval Approach|Topic|Peng Sun|Author|AUTHORED
1263|Confidence Interval Approach|Topic|Lingli Yang|Author|AUTHORED
1264|Guidance On Individualized Treatment Rule Estimation In High Dimensions|Paper|Philippe Boileau|Author|AUTHORED
1264|Guidance On Individualized Treatment Rule Estimation In High Dimensions|Paper|Ning Leng|Author|AUTHORED
1264|Guidance On Individualized Treatment Rule Estimation In High Dimensions|Paper|Sandrine Dudoit|Author|AUTHORED
1264|Guidance On Individualized Treatment Rule Estimation In High Dimensions|Paper|Individualized Treatment Rules|Topic|RELATED_TO
1264|Guidance On Individualized Treatment Rule Estimation In High Dimensions|Paper|Precision Medicine|Topic|RELATED_TO
1264|Guidance On Individualized Treatment Rule Estimation In High Dimensions|Paper|High-Dimensional Covariate Settings|Topic|RELATED_TO
1264|Guidance On Individualized Treatment Rule Estimation In High Dimensions|Paper|Data-Generating Processes|Topic|RELATED_TO
1264|Guidance On Individualized Treatment Rule Estimation In High Dimensions|Paper|Randomized Studies|Topic|RELATED_TO
1264|Guidance On Individualized Treatment Rule Estimation In High Dimensions|Paper|Observational Studies|Topic|RELATED_TO
1265|Drug Discovery|Topic|Data Science|Topic|RELATED_TO
1265|Drug Discovery|Topic|Informatics|Topic|RELATED_TO
1265|Drug Discovery|Topic|Artificial Intelligence (Ai)|Topic|RELATED_TO
1265|Drug Discovery|Topic|Small Molecule Drugs|Topic|RELATED_TO
1265|Drug Discovery|Topic|Generative Chemistry|Topic|RELATED_TO
1265|Drug Discovery|Topic|Machine Learning|Topic|RELATED_TO
1265|Drug Discovery|Topic|Multi-Property Optimization|Topic|RELATED_TO
1265|Drug Discovery|Topic|Reproducibility Crisis|Topic|RELATED_TO
1265|Catrin Hasselgren|Author|Artificial Intelligence For Drug Discovery: Are We There Yet?|Paper|AUTHORED
1265|Tudor I. Oprea|Author|Artificial Intelligence For Drug Discovery: Are We There Yet?|Paper|AUTHORED
1266|Heterogeneous Treatment Effects|Topic|Clinical Trial Analysis|Topic|RELATED_TO
1266|Causal Forests|Topic|Heterogeneous Treatment Effects|Topic|RELATED_TO
1266|Causal Forests|Topic|Relative Risk Causal Forests|Topic|RELATED_TO
1266|Vik Shirvaikar|Author|Relative Risk Causal Forests|Topic|AUTHORED
1266|Xi Lin|Author|Relative Risk Causal Forests|Topic|AUTHORED
1266|Chris Holmes|Author|Relative Risk Causal Forests|Topic|AUTHORED
1267|Recent Advances In Large Language Models|Topic|Clinical Applications|Topic|RELATED_TO
1267|Clinical Applications|Topic|Clinical Decision Support|Topic|RELATED_TO
1267|Clinical Applications|Topic|Trial Recommendations|Topic|RELATED_TO
1267|Gpt-4|Topic|Icd Codes|Topic|DISCUSSES
1267|Icd Codes|Topic|Medical Coding Tasks|Topic|RELATED_TO
1267|Llm-Codex|Topic|Icd Codes|Topic|RELATED_TO
1267|Llm-Codex|Topic|Lstm-Based Verification Stage|Topic|RELATED_TO
1267|Lstm-Based Verification Stage|Topic|Mimic Dataset|Topic|RELATED_TO
1267|Zhichao Yang|Author|Surpassing Gpt-4 Medical Coding With A Two-Stage Approach|Paper|AUTHORED
1267|Sanjit Singh Batra|Author|Surpassing Gpt-4 Medical Coding With A Two-Stage Approach|Paper|AUTHORED
1267|Joel Stremmel|Author|Surpassing Gpt-4 Medical Coding With A Two-Stage Approach|Paper|AUTHORED
1267|Eran Halperin|Author|Surpassing Gpt-4 Medical Coding With A Two-Stage Approach|Paper|AUTHORED
1268|Meta-Analysis Of Study Twins|Topic|Christian Röver|Author|AUTHORED
1268|Meta-Analysis Of Study Twins|Topic|Tim Friede|Author|AUTHORED
1269|Adaptive Experiment|Topic|Cate|Topic|RELATED_TO
1269|Adaptive Experiment|Topic|Social Welfare|Topic|RELATED_TO
1269|Social Welfare|Topic|Regret|Topic|RELATED_TO
1269|Regret|Topic|Contextual Bandit Framework|Topic|RELATED_TO
1269|Privacy Concerns|Topic|Treatment Allocation Mechanism|Topic|RELATED_TO
1269|Tradeoff|Topic|Social Welfare|Topic|RELATED_TO
1269|Tradeoff|Topic|Statistical Power|Topic|RELATED_TO
1269|Pareto Optimality|Topic|Tradeoff|Topic|RELATED_TO
1269|Differentially Private Algorithms|Topic|Privacy Concerns|Topic|RELATED_TO
1269|Asymptotic Normality|Topic|Statistical Inference|Topic|RELATED_TO
1269|Asymptotic Normality|Topic|Hypothesis Testing|Topic|RELATED_TO
1269|Jiachun Li|Author|Privacy Preserving Adaptive Experiment Design|Paper|AUTHORED
1269|Kaining Shi|Author|Privacy Preserving Adaptive Experiment Design|Paper|AUTHORED
1269|David Simchi-Levi|Author|Privacy Preserving Adaptive Experiment Design|Paper|AUTHORED
1270|Population-Based Biobanks|Topic|Epidemiological Research|Topic|RELATED_TO
1270|Population-Based Biobanks|Topic|Clinical Research|Topic|RELATED_TO
1270|Biobank Data|Topic|Cumulative Incidence Function (Cif) Estimator|Topic|RELATED_TO
1270|Cumulative Incidence Function (Cif) Estimator|Topic|Malka Gorfine|Author|AUTHORED
1270|Cumulative Incidence Function (Cif) Estimator|Topic|David M. Zucker|Author|AUTHORED
1270|Cumulative Incidence Function (Cif) Estimator|Topic|Shoval Shoham|Author|AUTHORED
1271|Nli4Ct Task|Topic|Large Language Models|Topic|DISCUSSES
1271|Large Language Models|Topic|Peft Method|Topic|DISCUSSES
1271|Peft Method|Topic|Gpt-4|Author|RELATED_TO
1271|Gpt-4|Author|Aryo Pradipta Gema|Author|AUTHORED
1271|Gpt-4|Author|Giwon Hong|Author|AUTHORED
1271|Gpt-4|Author|Pasquale Minervini|Author|AUTHORED
1271|Gpt-4|Author|Luke Daines|Author|AUTHORED
1271|Gpt-4|Author|Beatrice Alex|Author|AUTHORED
1272|D-Nlp At Semeval-2024 Task 2|Paper|Large Language Models (Llms)|Topic|DISCUSSES
1272|D-Nlp At Semeval-2024 Task 2|Paper|Transformers|Topic|RELATED_TO
1272|D-Nlp At Semeval-2024 Task 2|Paper|Natural Language Inference Capabilities|Topic|DISCUSSES
1272|D-Nlp At Semeval-2024 Task 2|Paper|Clinical Trial Reports|Topic|RELATED_TO
1272|Duygu Altinok|Author|D-Nlp At Semeval-2024 Task 2|Paper|AUTHORED
1272|Gemini|Author|D-Nlp At Semeval-2024 Task 2|Paper|AUTHORED
1273|Radex|Topic|Daniel Reichenpfader|Author|AUTHORED
1273|Radex|Topic|Jonas Knupp|Author|AUTHORED
1273|Radex|Topic|André Sander|Author|AUTHORED
1273|Radex|Topic|Kerstin Denecke|Author|AUTHORED
1274|Dynamic Treatment Regimes|Topic|Precision Medicine|Topic|RELATED_TO
1274|Optimal Regime|Topic|Scalar Outcome|Topic|RELATED_TO
1274|Multiple Outcomes|Topic|Optimal Regime|Topic|RELATED_TO
1274|Utility Functions|Topic|Optimal Regime|Topic|RELATED_TO
1274|Inverse Reinforcement Learning|Topic|Optimal Regime|Topic|RELATED_TO
1274|Hiv/Sti Prevention|Topic|Optimal Regime|Topic|RELATED_TO
1274|Kyle Duke|Author|Optimal Regime|Topic|AUTHORED
1274|Eric B. Laber|Author|Optimal Regime|Topic|AUTHORED
1274|Marie Davidian|Author|Optimal Regime|Topic|AUTHORED
1274|Michael Newcomb|Author|Optimal Regime|Topic|AUTHORED
1274|Brian Mustanski|Author|Optimal Regime|Topic|AUTHORED
1275|Outcome Reporting Bias|Topic|Meta-Analytic Findings|Topic|RELATED_TO
1275|Outcome Reporting Bias|Topic|Orb-Adjustment Techniques|Topic|RELATED_TO
1275|Orb-Adjustment Techniques|Topic|Clinical Trials|Topic|RELATED_TO
1275|Orb-Adjustment Techniques|Topic|Heterogeneity|Topic|RELATED_TO
1275|Treatment Effect Estimation|Topic|Simulation Study|Topic|RELATED_TO
1275|Alessandra Gaia Saracini|Author|Outcome Reporting Bias|Topic|AUTHORED
1275|Leonhard Held|Author|Outcome Reporting Bias|Topic|AUTHORED
1276|Dengue Virus|Topic|Dengvaxia|Paper|RELATED_TO
1276|Dengvaxia|Paper|Mrna-Based Vaccines|Topic|DISCUSSES
1276|Mrna-Based Vaccines|Topic|Dengue Virus|Topic|RELATED_TO
1276|Dengue Virus|Topic|Tak-003|Paper|RELATED_TO
1276|Tak-003|Paper|Who|Topic|DISCUSSES
1276|Who|Topic|Dengue Virus|Topic|RELATED_TO
1276|Dengue Virus|Topic|Xiaoyang Liu|Author|DISCUSSES
1276|Dengue Virus|Topic|Daniel Salmon|Author|DISCUSSES
1277|Comorbid Anxiety Disorders|Topic|Major Depressive Disorder (Mdd)|Topic|RELATED_TO
1277|Major Depressive Disorder (Mdd)|Topic|Machine Learning Techniques|Topic|DISCUSSES
1277|Gad-7 Questionnaire|Topic|Major Depressive Disorder (Mdd)|Topic|RELATED_TO
1277|Smartphone-Based Interventions|Topic|Major Depressive Disorder (Mdd)|Topic|RELATED_TO
1277|Morgan B. Talbot|Author|Clinical Trial|Topic|AUTHORED
1277|Jessica M. Lipschitz|Author|Clinical Trial|Topic|AUTHORED
1277|Omar Costilla-Reyes|Author|Clinical Trial|Topic|AUTHORED
1277|Treatment Response Prediction|Topic|Smartphone-Delivered Psychotherapy|Topic|RELATED_TO
1278|Large Language Models|Topic|Medical Applications|Topic|RELATED_TO
1278|Equityguard|Topic|Large Language Models|Topic|RELATED_TO
1278|Equityguard|Topic|Medical Applications|Topic|RELATED_TO
1278|Yuelyu Ji|Author|Mitigating The Risk Of Health Inequity Exacerbated By Large Language Models|Paper|AUTHORED
1278|Wenhe Ma|Author|Mitigating The Risk Of Health Inequity Exacerbated By Large Language Models|Paper|AUTHORED
1278|Sonish Sivarajkumar|Author|Mitigating The Risk Of Health Inequity Exacerbated By Large Language Models|Paper|AUTHORED
1278|Hang Zhang|Author|Mitigating The Risk Of Health Inequity Exacerbated By Large Language Models|Paper|AUTHORED
1278|Eugene Mathew Sadhu|Author|Mitigating The Risk Of Health Inequity Exacerbated By Large Language Models|Paper|AUTHORED
1278|Zhuochun Li|Author|Mitigating The Risk Of Health Inequity Exacerbated By Large Language Models|Paper|AUTHORED
1278|Xizhi Wu|Author|Mitigating The Risk Of Health Inequity Exacerbated By Large Language Models|Paper|AUTHORED
1278|Shyam Visweswaran|Author|Mitigating The Risk Of Health Inequity Exacerbated By Large Language Models|Paper|AUTHORED
1278|Yanshan Wang|Author|Mitigating The Risk Of Health Inequity Exacerbated By Large Language Models|Paper|AUTHORED
1279|Area Under The Curve (Auc)|Topic|Mean Cumulative Function (Mcf)|Topic|RELATED_TO
1279|Lin-Wei-Yang-Ying (Lwyy) Model|Topic|Area Under The Curve (Auc)|Topic|DISCUSSES
1279|Covariate Adjustment Approach|Topic|Area Under The Curve (Auc)|Topic|RELATED_TO
1279|Covariate Adjustment Approach|Topic|Lin-Wei-Yang-Yang (Lwyy) Model|Topic|RELATED_TO
1279|Jiren Sun|Author|Improve The Precision Of Area Under The Curve Estimation For Recurrent Events Through Covariate Adjustment|Paper|AUTHORED
1279|Tuo Wang|Author|Improve The Precision Of Area Under The Curve Estimation For Recurrent Events Through Covariate Adjustment|Paper|AUTHORED
1279|Yanyao Yi|Author|Improve The Precision Of Area Under The Curve Estimation For Recurrent Events Through Covariate Adjustment|Paper|AUTHORED
1279|Ting Ye|Author|Improve The Precision Of Area Under The Curve Estimation For Recurrent Events Through Covariate Adjustment|Paper|AUTHORED
1279|Jun Shao|Author|Improve The Precision Of Area Under The Curve Estimation For Recurrent Events Through Covariate Adjustment|Paper|AUTHORED
1279|Yu Du|Author|Improve The Precision Of Area Under The Curve Estimation For Recurrent Events Through Covariate Adjustment|Paper|AUTHORED
1280|Dynamic Treatment Regime|Topic|Bayesian Model|Topic|RELATED_TO
1280|Bayesian Model|Topic|Uncertainty Quantification|Topic|RELATED_TO
1280|Bayesian Model|Topic|Multi-Stage Variable Selection|Topic|RELATED_TO
1280|Bayesian Model|Topic|Dimensionality Reduction|Topic|RELATED_TO
1280|Bayesian Model|Topic|Prognostic Factors|Topic|RELATED_TO
1280|Bayesian Model|Topic|Optimal Decision Sequences|Topic|RELATED_TO
1280|Jiefeng Bi|Author|Bayesian Model|Topic|AUTHORED
1280|Matteo Borrotti|Author|Bayesian Model|Topic|AUTHORED
1280|Bernardo Nipoti|Author|Bayesian Model|Topic|AUTHORED
1280|Severe Acute Arterial Hypertension|Topic|Clinical Trial Data|Topic|RELATED_TO
1280|Simulation Studies|Topic|Bayesian Model|Topic|RELATED_TO
1281|Geometric-Based Nail Segmentation For Clinical Measurements|Paper|Toenail Segmentation Method|Topic|DISCUSSES
1281|Geometric-Based Nail Segmentation For Clinical Measurements|Paper|Hough Transform|Topic|DISCUSSES
1281|Geometric-Based Nail Segmentation For Clinical Measurements|Paper|Watershed Transform|Topic|DISCUSSES
1281|Geometric-Based Nail Segmentation For Clinical Measurements|Paper|348-Image Medical Dataset|Topic|DISCUSSES
1282|Sars-Cov-2 Spike Glycoprotein|Topic|Hiv Drugs|Topic|DISCUSSES
1282|Hiv Drugs|Topic|Covid-19 Disease|Topic|RELATED_TO
1282|Vini In Silico Model|Topic|Fda-Approved Antiviral Drugs|Topic|DISCUSSES
1282|Cobicistat_Abacavir_Rilpivirine|Topic|Sars-Cov-2 Spike Glycoprotein|Topic|DISCUSSES
1282|Karolj Skala|Author|Vini In Silico Model|Topic|AUTHORED
1282|Attila Marcel Szasz|Author|Vini In Silico Model|Topic|AUTHORED
1282|Melinda Rezeli|Author|Vini In Silico Model|Topic|AUTHORED
1282|Jozsef Petrik|Author|Vini In Silico Model|Topic|AUTHORED
1282|Branka Medved Rogina|Author|Vini In Silico Model|Topic|AUTHORED
1283|Technology Based Intervention Methodologies|Topic|Autism Spectrum Disorder|Topic|RELATED_TO
1283|Technology Based Intervention Methodologies|Topic|Computer Aided Systems|Topic|RELATED_TO
1283|Technology Based Intervention Methodologies|Topic|Computer Vision Assisted Technologies|Topic|RELATED_TO
1283|Technology Based Intervention Methodologies|Topic|Virtual Reality|Topic|RELATED_TO
1283|Technology Based Intervention Methodologies|Topic|Artificial Intelligence|Topic|RELATED_TO
1283|Muhammad Shoaib Jaliawala|Author|Technology Based Intervention Methodologies|Topic|AUTHORED
1283|Rizwan Ahmed Khan|Author|Technology Based Intervention Methodologies|Topic|AUTHORED
1284|Rapid-Eye-Movement Sleep Behaviour Disorder|Topic|Parkinson'S Disease|Topic|RELATED_TO
1284|Automated Sleep Staging|Topic|Rbd Detection|Topic|RELATED_TO
1284|Random Forest Classifier|Topic|Rbd Detection|Topic|RELATED_TO
1284|Polysomnography|Topic|Rbd Detection|Topic|RELATED_TO
1284|Electroencephalogram|Topic|Rbd Detection|Topic|RELATED_TO
1284|Electrooculogram|Topic|Rbd Detection|Topic|RELATED_TO
1284|Electromyogram|Topic|Rbd Detection|Topic|RELATED_TO
1284|Cohen'S Kappa Score|Topic|Automated Sleep Staging|Topic|RELATED_TO
1284|Wearable Take-Home Technology|Topic|Rbd Detection|Topic|RELATED_TO
1284|Navin Cooray|Author|Rbd Detection|Topic|AUTHORED
1284|Fernando Andreotti|Author|Rbd Detection|Topic|AUTHORED
1284|Christine Lo|Author|Rbd Detection|Topic|AUTHORED
1284|Mkael Symmonds|Author|Rbd Detection|Topic|AUTHORED
1284|Michele T. M. Hu|Author|Rbd Detection|Topic|AUTHORED
1284|Maarten De Vos|Author|Rbd Detection|Topic|AUTHORED
1285|Double Diffusion Encoding|Topic|Diffusion Magnetic Resonance Imaging|Topic|RELATED_TO
1285|Rafael N. Henriques|Author|Double Diffusion Encoding|Topic|AUTHORED
1285|Marco Palombo|Author|Double Diffusion Encoding|Topic|AUTHORED
1285|Sune N. Jespersen|Author|Double Diffusion Encoding|Topic|AUTHORED
1285|Noam Shemesh|Author|Double Diffusion Encoding|Topic|AUTHORED
1285|Henrik Lundell|Author|Double Diffusion Encoding|Topic|AUTHORED
1286|Brain Tissue Segmentation From Multimodal Mri|Topic|Deep Neural Networks (Dnns)|Topic|RELATED_TO
1286|Joint Tissue And Lesion Segmentation Model|Topic|Deep Neural Networks (Dnns)|Topic|RELATED_TO
1286|Joint Tissue And Lesion Segmentation Model|Topic|Reuben Dorent|Author|AUTHORED
1286|Joint Tissue And Lesion Segmentation Model|Topic|Wenqi Li|Author|AUTHORED
1286|Joint Tissue And Lesion Segmentation Model|Topic|Jinendra Ekanayake|Author|AUTHORED
1286|Joint Tissue And Lesion Segmentation Model|Topic|Sebastien Ourselin|Author|AUTHORED
1286|Joint Tissue And Lesion Segmentation Model|Topic|Tom Vercauteren|Author|AUTHORED
1287|Fbnetgen|Paper|Functional Magnetic Resonance Imaging (Fmri)|Topic|DISCUSSES
1287|Fbnetgen|Paper|Adolescent Brain Cognitive Development (Abcd)|Topic|RELATED_TO
1287|Fbnetgen|Paper|Pnc|Topic|RELATED_TO
1287|Fbnetgen|Paper|Xuan Kan|Author|AUTHORED
1287|Fbnetgen|Paper|Hejie Cui|Author|AUTHORED
1287|Fbnetgen|Paper|Joshua Lukemire|Author|AUTHORED
1287|Fbnetgen|Paper|Ying Guo|Author|AUTHORED
1287|Fbnetgen|Paper|Carl Yang|Author|AUTHORED
1288|Brainnet|Paper|Seeg|Topic|RELATED_TO
1288|Brainnet|Paper|Machine Learning|Topic|RELATED_TO
1288|Brainnet|Paper|Junru Chen|Author|AUTHORED
1288|Brainnet|Paper|Yang Yang|Author|AUTHORED
1288|Brainnet|Paper|Tao Yu|Author|AUTHORED
1288|Brainnet|Paper|Yingying Fan|Author|AUTHORED
1288|Brainnet|Paper|Xiaolong Mo|Author|AUTHORED
1288|Brainnet|Paper|Carl Yang|Author|AUTHORED
1289|Hierarchical Event Descriptor Library Schema For Eeg Data Annotation|Paper|Hierarchical Event Descriptor Library Schema For Eeg Data Annotation|Paper|RELATED_TO
1290|Hiv Rna Copies|Topic|Viral Load|Topic|RELATED_TO
1290|Viral Load|Topic|Arv Therapies|Topic|RELATED_TO
1290|Arv Therapies|Topic|Hiv Pathogenesis|Topic|RELATED_TO
1290|Long-Term Treatment|Topic|Drug Resistance|Topic|RELATED_TO
1290|Long-Term Treatment|Topic|Adherence|Topic|RELATED_TO
1290|Differential Equation Models|Topic|Long-Term Treatment|Topic|RELATED_TO
1290|Bayesian Nonlinear Mixed-Effects Modeling|Topic|Differential Equation Models|Topic|RELATED_TO
1290|Yangxin Huang|Author|Differential Equation Models|Topic|AUTHORED
1290|Tao Lu|Author|Differential Equation Models|Topic|AUTHORED
1291|Sepsis|Topic|Innate Immune Response Agent-Based Model (Iirabm)|Topic|RELATED_TO
1291|Innate Immune Response Agent-Based Model (Iirabm)|Topic|Adaptive, Personalized Multi-Cytokine Mediation Therapy|Topic|RELATED_TO
1291|Brenden K. Petersen|Author|Adaptive, Personalized Multi-Cytokine Mediation Therapy|Topic|AUTHORED
1291|Jiachen Yang|Author|Adaptive, Personalized Multi-Cytokine Mediation Therapy|Topic|AUTHORED
1291|Will S. Grathwohl|Author|Adaptive, Personalized Multi-Cytokine Mediation Therapy|Topic|AUTHORED
1291|Chase Cockrell|Author|Adaptive, Personalized Multi-Cytokine Mediation Therapy|Topic|AUTHORED
1291|Claudio Santiago|Author|Adaptive, Personalized Multi-Cytokine Mediation Therapy|Topic|AUTHORED
1291|Gary An|Author|Adaptive, Personalized Multi-Cytokine Mediation Therapy|Topic|AUTHORED
1291|Daniel M. Faissol|Author|Adaptive, Personalized Multi-Cytokine Mediation Therapy|Topic|AUTHORED
1292|Deepatrophy|Paper|Regional Deep Atrophy|Paper|RELATED_TO
1292|Alzheimer'S Disease|Topic|Deepatrophy|Paper|DISCUSSES
1292|Alzheimer'S Disease|Topic|Regional Deep Atrophy|Paper|DISCUSSES
1292|Deepatrophy|Paper|Mengjin Dong|Author|AUTHORED
1292|Deepatrophy|Paper|Long Xie|Author|AUTHORED
1292|Deepatrophy|Paper|Sandhitsu R. Das|Author|AUTHORED
1292|Deepatrophy|Paper|Jiancong Wang|Author|AUTHORED
1292|Deepatrophy|Paper|Laura E. M. Wisse|Author|AUTHORED
1292|Deepatrophy|Paper|Robin Deflores|Author|AUTHORED
1292|Deepatrophy|Paper|David A. Wolk|Author|AUTHORED
1292|Deepatrophy|Paper|Paul A. Yushkevich|Author|AUTHORED
1293|Two-Part Joint Models For A Longitudinal Semicontinuous Biomarker And A Terminal Event|Topic|Frequentist Estimation|Topic|RELATED_TO
1293|Two-Part Joint Models For A Longitudinal Semicontinuous Biomarker And A Terminal Event|Topic|Bayesian Estimation|Topic|RELATED_TO
1293|Bayesian Estimation|Topic|Integrated Nested Laplace Approximation|Topic|RELATED_TO
1293|Frequentist Estimation|Topic|Frailtypack|Topic|RELATED_TO
1293|Gercor|Topic|Prime|Topic|RELATED_TO
1293|Denis Rustand|Author|Bayesian Estimation|Topic|AUTHORED
1293|Janet Van Niekerk|Author|Bayesian Estimation|Topic|AUTHORED
1293|Håvard Rue|Author|Bayesian Estimation|Topic|AUTHORED
1293|Christophe Tournigand|Author|Bayesian Estimation|Topic|AUTHORED
1293|Virginie Rondeau|Author|Bayesian Estimation|Topic|AUTHORED
1293|Laurent Briollais|Author|Bayesian Estimation|Topic|AUTHORED
1294|Pressure Ulcers|Topic|Uk|Topic|RELATED_TO
1294|Pressure Ulcers|Topic|National Health Service|Topic|RELATED_TO
1294|Mersey Care Nhs Foundation Trust|Author|Clinical Trial|Topic|AUTHORED
1294|Paul Fergus|Author|Clinical Trial|Topic|AUTHORED
1294|Carl Chalmers|Author|Clinical Trial|Topic|AUTHORED
1294|William Henderson|Author|Clinical Trial|Topic|AUTHORED
1294|Danny Roberts|Author|Clinical Trial|Topic|AUTHORED
1294|Atif Waraich|Author|Clinical Trial|Topic|AUTHORED
1294|Clinical Trial|Topic|Convolutional Neural Network|Topic|DISCUSSES
1294|Clinical Trial|Topic|Deep Learning|Topic|DISCUSSES
1294|Clinical Trial|Topic|Pressure Ulcer Categorisation|Topic|DISCUSSES
1294|Mean Average Precision|Topic|Clinical Trial|Topic|RELATED_TO
1294|Recall|Topic|Clinical Trial|Topic|RELATED_TO
1294|F1-Score|Topic|Clinical Trial|Topic|RELATED_TO
1295|Error Rate Familywise|Topic|Error Rate Per Family|Topic|RELATED_TO
1295|Error Rate Familywise|Topic|False Approval Rate|Topic|RELATED_TO
1295|Regulatory Agency|Topic|False Approval Rate|Topic|RELATED_TO
1295|Platform Trials|Topic|False Approval Rate|Topic|RELATED_TO
1295|Xinping Cui|Author|Platform Trials|Topic|AUTHORED
1295|Emily Ouyang|Author|Platform Trials|Topic|AUTHORED
1295|Yi Liu|Author|Platform Trials|Topic|AUTHORED
1295|Jingjing Schneider|Author|Platform Trials|Topic|AUTHORED
1295|Hong Tian|Author|Platform Trials|Topic|AUTHORED
1295|Bushi Wang|Author|Platform Trials|Topic|AUTHORED
1295|Jason C. Hsu|Author|Platform Trials|Topic|AUTHORED
1296|Non-Small Cell Lung Cancer (Nsclc)|Topic|Therapeutics|Topic|RELATED_TO
1296|Non-Small Cell Lung Cancer (Nsclc)|Topic|Clinical Trials|Topic|RELATED_TO
1296|Non-Small Cell Lung Cancer (Nsclc)|Topic|Treatment Outcomes|Topic|RELATED_TO
1296|Non-Small Cell Lung Cancer (Nsclc)|Topic|Acquired Resistance|Topic|RELATED_TO
1296|Non-Small Cell Lung Cancer (Nsclc)|Topic|Vascular Remodeling|Topic|RELATED_TO
1296|Bevacizumab|Topic|Sequential Administration|Topic|RELATED_TO
1296|Bevacizumab|Topic|Pemetrexed-Cisplatin|Topic|RELATED_TO
1296|Benjamin K. Schneider|Author|Optimizing First-Line Therapeutics In Non-Small Cell Lung Cancer: Insights From Joint Modeling And Large-Scale Data Analysis|Paper|AUTHORED
1296|Sebastien Benzekry|Author|Optimizing First-Line Therapeutics In Non-Small Cell Lung Cancer: Insights From Joint Modeling And Large-Scale Data Analysis|Paper|AUTHORED
1296|Jonathan P. Mochel|Author|Optimizing First-Line Therapeutics In Non-Small Cell Lung Cancer: Insights From Joint Modeling And Large-Scale Data Analysis|Paper|AUTHORED
1297|Recent Technological Advances In Brain Recording And Artificial Intelligence|Topic|Naturalistic Neuroscience|Topic|RELATED_TO
1297|Naturalistic Neuroscience|Topic|Automated Approach For Analyzing Simultaneously Recorded Long-Term, Naturalistic Electrocorticography (Ecog) And Naturalistic Behavior Video Data|Topic|RELATED_TO
1297|Automated Approach For Analyzing Simultaneously Recorded Long-Term, Naturalistic Electrocorticography (Ecog) And Naturalistic Behavior Video Data|Topic|Computer Vision|Topic|RELATED_TO
1297|Automated Approach For Analyzing Simultaneously Recorded Long-Term, Naturalistic Electrocorticography (Ecog) And Naturalistic Behavior Video Data|Topic|Discrete Latent-Variable Modeling|Topic|RELATED_TO
1297|Automated Approach For Analyzing Simultaneously Recorded Long-Term, Naturalistic Electrocorticography (Ecog) And Naturalistic Behavior Video Data|Topic|String Pattern-Matching|Topic|RELATED_TO
1297|Automated Approach For Analyzing Simultaneously Recorded Long-Term, Naturalistic Electrocorticography (Ecog) And Naturalistic Behavior Video Data|Topic|Naturalistic Human Upper-Limb Movement Events|Topic|RELATED_TO
1297|Automated Approach For Analyzing Simultaneously Recorded Long-Term, Naturalistic Electrocorticography (Ecog) And Naturalistic Behavior Video Data|Topic|Brain-Computer Interfacing Applications|Topic|RELATED_TO
1297|Curated Dataset|Topic|Naturalistic Neuroscience|Topic|RELATED_TO
1297|Satpreet H. Singh|Author|Automated Approach For Analyzing Simultaneously Recorded Long-Term, Naturalistic Electrocorticography (Ecog) And Naturalistic Behavior Video Data|Topic|AUTHORED
1297|Steven M. Peterson|Author|Automated Approach For Analyzing Simultaneously Recorded Long-Term, Naturalistic Electrocorticography (Ecog) And Naturalistic Behavior Video Data|Topic|AUTHORED
1297|Rajesh P. N. Rao|Author|Automated Approach For Analyzing Simultaneously Recorded Long-Term, Naturalistic Electrocorticography (Ecog) And Naturalistic Behavior Video Data|Topic|AUTHORED
1297|Bingni W. Brunton|Author|Automated Approach For Analyzing Simultaneously Recorded Long-Term, Naturalistic Electrocorticography (Ecog) And Naturalistic Behavior Video Data|Topic|AUTHORED
1298|Paediatric Multiple Sclerosis|Topic|Randomized Controlled Trials|Topic|DISCUSSES
1298|Creutzfeldt-Jakob Disease|Topic|Randomized Controlled Trials|Topic|DISCUSSES
1298|Steffen Unkel|Author|Paediatric Multiple Sclerosis|Topic|AUTHORED
1298|Christian Röver|Author|Paediatric Multiple Sclerosis|Topic|AUTHORED
1298|Nigel Stallard|Author|Paediatric Multiple Sclerosis|Topic|AUTHORED
1298|Norbert Benda|Author|Paediatric Multiple Sclerosis|Topic|AUTHORED
1298|Martin Posch|Author|Paediatric Multiple Sclerosis|Topic|AUTHORED
1298|Sarah Zohar|Author|Paediatric Multiple Sclerosis|Topic|AUTHORED
1298|Tim Friede|Author|Paediatric Multiple Sclerosis|Topic|AUTHORED
1298|Steffen Unkel|Author|Creutzfeldt-Jakob Disease|Topic|AUTHORED
1298|Christian Röver|Author|Creutzfeldt-Jakob Disease|Topic|AUTHORED
1298|Nigel Stallard|Author|Creutzfeldt-Jakob Disease|Topic|AUTHORED
1298|Norbert Benda|Author|Creutzfeldt-Jakob Disease|Topic|AUTHORED
1298|Martin Posch|Author|Creutzfeldt-Jakob Disease|Topic|AUTHORED
1298|Sarah Zohar|Author|Creutzfeldt-Jakob Disease|Topic|AUTHORED
1298|Tim Friede|Author|Creutzfeldt-Jakob Disease|Topic|AUTHORED
1299|Vietnarms|Topic|Hepatitis C|Topic|RELATED_TO
1299|L. Mccabe|Author|Vietnarms|Topic|AUTHORED
1299|I. R. White|Author|Vietnarms|Topic|AUTHORED
1299|N. V. Vinh Chau|Author|Vietnarms|Topic|AUTHORED
1299|E. Barnes|Author|Vietnarms|Topic|AUTHORED
1299|S. L. Pett|Author|Vietnarms|Topic|AUTHORED
1299|G. S. Cooke|Author|Vietnarms|Topic|AUTHORED
1299|A. S. Walker|Author|Vietnarms|Topic|AUTHORED
1300|Sample Size Determination For Cluster Randomised Trials|Topic|Intra-Cluster Correlation Coefficient|Topic|RELATED_TO
1300|Sample Size Determination For Cluster Randomised Trials|Topic|Minimal Clinically Important Difference|Topic|RELATED_TO
1300|Sample Size Determination For Cluster Randomised Trials|Topic|Standard Deviation|Topic|RELATED_TO
1300|Sample Size Determination For Cluster Randomised Trials|Topic|Coefficient Of Variation Of The Cluster Size|Topic|RELATED_TO
1300|Sample Size Determination For Cluster Randomised Trials|Topic|Bayesian Assurance|Topic|RELATED_TO
1300|Sample Size Determination For Cluster Randomised Trials|Topic|Frequentist Analysis|Topic|RELATED_TO
1300|Sample Size Determination For Cluster Randomised Trials|Topic|Post-Stroke Incontinence|Topic|RELATED_TO
1300|S. Faye Williamson|Author|Hybrid Sample Size Calculations For Cluster Randomised Trials Using Assurance|Paper|AUTHORED
1300|Svetlana V. Tishkovskaya|Author|Hybrid Sample Size Calculations For Cluster Randomised Trials Using Assurance|Paper|AUTHORED
1300|Kevin J. Wilson|Author|Hybrid Sample Size Calculations For Cluster Randomised Trials Using Assurance|Paper|AUTHORED
1301|Cluster-Randomized Trials|Topic|Sample Size Methodology|Topic|RELATED_TO
1301|Cluster-Randomized Trials|Topic|Power Calculations|Topic|RELATED_TO
1301|Cluster-Randomized Trials|Topic|Treatment Effect Heterogeneity|Topic|RELATED_TO
1301|Cluster-Randomized Trials|Topic|Online R Shiny Calculator|Topic|RELATED_TO
1301|Cluster-Randomized Trials|Topic|Intracluster Correlation Coefficients|Topic|RELATED_TO
1301|Cluster-Randomized Trials|Topic|Real Crt Examples|Topic|RELATED_TO
1301|Mary Ryan Baumann|Author|Cluster-Randomized Trials|Topic|AUTHORED
1301|Monica Taljaard|Author|Cluster-Randomized Trials|Topic|AUTHORED
1301|Patrick J. Heagerty|Author|Cluster-Randomized Trials|Topic|AUTHORED
1301|Michael O. Harhay|Author|Cluster-Randomized Trials|Topic|AUTHORED
1301|Guangyu Tong|Author|Cluster-Randomized Trials|Topic|AUTHORED
1301|Rui Wang|Author|Cluster-Randomized Trials|Topic|AUTHORED
1301|Fan Li|Author|Cluster-Randomized Trials|Topic|AUTHORED
1302|Monitoring Fetal Electroencephalogram Intrapartum: A Systematic Literature Review|Paper|Fetal Electroencephalogram|Topic|DISCUSSES
1303|Ccs Explorer|Paper|Clinical Cohort Studies|Topic|RELATED_TO
1303|Ccs Explorer|Paper|Pubmed|Topic|RELATED_TO
1303|Ccs Explorer|Paper|Biobert|Topic|RELATED_TO
1303|Ccs Explorer|Paper|Pubmedbert|Topic|RELATED_TO
1304|Redwine|Paper|Electronic Health Records|Topic|RELATED_TO
1304|Redwine|Paper|Observational Health Data Sciences And Informatics|Topic|RELATED_TO
1304|Redwine|Paper|Open Health Natural Language Processing|Topic|RELATED_TO
1304|Redwine|Paper|David Oniani|Author|AUTHORED
1304|Redwine|Paper|Bambang Parmanto|Author|AUTHORED
1304|Redwine|Paper|Andi Saptono|Author|AUTHORED
1304|Redwine|Paper|Allyn Bove|Author|AUTHORED
1304|Redwine|Paper|Janet Freburger|Author|AUTHORED
1304|Redwine|Paper|Shyam Visweswaran Nickie Cappella|Author|AUTHORED
1304|Redwine|Paper|Brian Mclay|Author|AUTHORED
1304|Redwine|Paper|Jonathan C. Silverstein|Author|AUTHORED
1304|Redwine|Paper|Michael J. Becich|Author|AUTHORED
1304|Redwine|Paper|Anthony Delitto|Author|AUTHORED
1304|Redwine|Paper|Elizabeth Skidmore|Author|AUTHORED
1304|Redwine|Paper|Yanshan Wang|Author|AUTHORED
1305|Clinical Practice Guidelines|Topic|Research Studies|Topic|RELATED_TO
1305|Clinical Practice Guidelines|Topic|Study Cohorts|Topic|RELATED_TO
1305|Study Cohort Ontology|Topic|Table 1|Topic|RELATED_TO
1305|Semanticscience Integrated Ontology|Topic|Study Cohort Ontology|Topic|RELATED_TO
1305|Shruthi Chari|Author|Making Study Populations Visible Through Knowledge Graphs|Paper|AUTHORED
1305|Miao Qi|Author|Making Study Populations Visible Through Knowledge Graphs|Paper|AUTHORED
1305|Nkcheniyere N. Agu|Author|Making Study Populations Visible Through Knowledge Graphs|Paper|AUTHORED
1305|Oshani Seneviratne|Author|Making Study Populations Visible Through Knowledge Graphs|Paper|AUTHORED
1305|James P. Mccusker|Author|Making Study Populations Visible Through Knowledge Graphs|Paper|AUTHORED
1305|Kristin P. Bennett|Author|Making Study Populations Visible Through Knowledge Graphs|Paper|AUTHORED
1305|Amar K. Das|Author|Making Study Populations Visible Through Knowledge Graphs|Paper|AUTHORED
1305|Deborah L. Mcguinness|Author|Making Study Populations Visible Through Knowledge Graphs|Paper|AUTHORED
1306|Cvit-Covid Dataset|Topic|University Of Waterloo|Author|RELATED_TO
1306|Cvit-Covid Dataset|Topic|Mosmed|Topic|RELATED_TO
1306|Fakrul Islam Tushar|Author|Cvit-Covid Dataset|Topic|AUTHORED
1306|Ehsan Abadi|Author|Cvit-Covid Dataset|Topic|AUTHORED
1306|Saman Sotoudeh-Paima|Author|Cvit-Covid Dataset|Topic|AUTHORED
1306|Rafael B. Fricks|Author|Cvit-Covid Dataset|Topic|AUTHORED
1306|Maciej A. Mazurowski|Author|Cvit-Covid Dataset|Topic|AUTHORED
1306|W. Paul Segars|Author|Cvit-Covid Dataset|Topic|AUTHORED
1306|Ehsan Samei|Author|Cvit-Covid Dataset|Topic|AUTHORED
1306|Joseph Y. Lo|Author|Cvit-Covid Dataset|Topic|AUTHORED
1307|Common Average Referencing (Car)|Topic|Car By Least Anticorrelation (Carla)|Topic|RELATED_TO
1307|Car By Least Anticorrelation (Carla)|Topic|Simulated Ccep Data|Topic|DISCUSSES
1307|Car By Least Anticorrelation (Carla)|Topic|Real Ccep Data|Topic|DISCUSSES
1307|Car By Least Anticorrelation (Carla)|Topic|Four Human Participants|Topic|DISCUSSES
1307|Harvey Huang|Author|Car By Least Anticorrelation (Carla)|Topic|AUTHORED
1307|Gabriela Ojeda Valencia|Author|Car By Least Anticorrelation (Carla)|Topic|AUTHORED
1307|Nicholas M. Gregg|Author|Car By Least Anticorrelation (Carla)|Topic|AUTHORED
1307|Gamaleldin M. Osman|Author|Car By Least Anticorrelation (Carla)|Topic|AUTHORED
1307|Morgan N. Montoya|Author|Car By Least Anticorrelation (Carla)|Topic|AUTHORED
1307|Gregory A. Worrell|Author|Car By Least Anticorrelation (Carla)|Topic|AUTHORED
1307|Kai J. Miller|Author|Car By Least Anticorrelation (Carla)|Topic|AUTHORED
1307|Dora Hermes|Author|Car By Least Anticorrelation (Carla)|Topic|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Fahad Salman|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Abhisri Ramesh|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Thomas Jochmann|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Mirjam Prayer|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Ademola Adegbemigun|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Jack A. Reeves|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Gregory E. Wilding|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Junghun Cho|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Dejan Jakimovski|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Niels Bergsland|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Michael G. Dwyer|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Robert Zivadinov|Author|AUTHORED
1308|Quantitative Susceptibility Mapping|Topic|Ferdinand Schweser|Author|AUTHORED
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Yousuf M. Soliman|Author|AUTHORED
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Computer Science|Topic|RELATED_TO
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Medicine|Topic|RELATED_TO
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Personalized Treatment Policies|Topic|RELATED_TO
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Q-Learning Algorithm|Topic|RELATED_TO
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Censored Q-Learning Algorithm|Topic|RELATED_TO
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Chronic Depression Data|Topic|RELATED_TO
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Hypothetical Clinical Trial|Topic|RELATED_TO
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Algorithmic Framework|Topic|RELATED_TO
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Multistage Decision Problem|Topic|RELATED_TO
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Expected Survival Times|Topic|RELATED_TO
1309|Personalized Medical Treatments Using Novel Reinforcement Learning Algorithms|Paper|Optimal Treatment Path|Topic|RELATED_TO
1310|Nancy Flournoy|Author|Long Beach, California|Topic|RELATED_TO
1310|Nancy Flournoy|Author|Polytechnic School|Topic|RELATED_TO
1310|Nancy Flournoy|Author|Ucla|Topic|RELATED_TO
1310|Nancy Flournoy|Author|Southwest Laboratory For Education Research And Development|Topic|RELATED_TO
1310|Nancy Flournoy|Author|Fred Hutchinson Cancer Research Center|Topic|RELATED_TO
1310|Nancy Flournoy|Author|University Of Washington|Topic|RELATED_TO
1310|Nancy Flournoy|Author|National Science Foundation|Topic|RELATED_TO
1310|Nancy Flournoy|Author|Department Of Mathematics And Statistics At American University|Topic|RELATED_TO
1310|Nancy Flournoy|Author|University Of Missouri|Topic|RELATED_TO
1311|Computerized Detection Of Melanoma|Paper|Malignant Melanoma|Topic|DISCUSSES
1311|Computerized Detection Of Melanoma|Paper|Dermoscopy|Topic|DISCUSSES
1311|Computerized Detection Of Melanoma|Paper|Image Processing|Topic|DISCUSSES
1311|Computerized Detection Of Melanoma|Paper|Machine Learning|Topic|DISCUSSES
1311|Computerized Detection Of Melanoma|Paper|Nabin K. Mishra|Author|AUTHORED
1311|Computerized Detection Of Melanoma|Paper|M. Emre Celebi|Author|AUTHORED
1312|Warfarin Dosing|Topic|Machine Learning Algorithms|Topic|RELATED_TO
1312|Machine Learning Algorithms|Topic|Iwpc Algorithm|Topic|RELATED_TO
1312|Iwpc Algorithm|Topic|Stack 1|Topic|RELATED_TO
1312|Iwpc Algorithm|Topic|Stack 2|Topic|RELATED_TO
1312|Stack 1|Topic|Cyp2C9|Topic|RELATED_TO
1312|Stack 1|Topic|Vkorc1|Topic|RELATED_TO
1312|Zhiyuan Ma|Author|Estimate The Warfarin Dose By Ensemble Of Machine Learning Algorithms|Paper|AUTHORED
1312|Ping Wang|Author|Estimate The Warfarin Dose By Ensemble Of Machine Learning Algorithms|Paper|AUTHORED
1312|Zehui Gao|Author|Estimate The Warfarin Dose By Ensemble Of Machine Learning Algorithms|Paper|AUTHORED
1312|Ruobing Wang|Author|Estimate The Warfarin Dose By Ensemble Of Machine Learning Algorithms|Paper|AUTHORED
1312|Koroush Khalighi|Author|Estimate The Warfarin Dose By Ensemble Of Machine Learning Algorithms|Paper|AUTHORED
1313|Pre-Symptomatic Alzheimer'S Disease|Topic|Alzheimer'S Disease Neuroimaging Initiative|Topic|RELATED_TO
1313|Dan Li|Author|Pre-Symptomatic Alzheimer'S Disease|Topic|AUTHORED
1313|Samuel Iddi|Author|Pre-Symptomatic Alzheimer'S Disease|Topic|AUTHORED
1313|Paul S. Aisen|Author|Pre-Symptomatic Alzheimer'S Disease|Topic|AUTHORED
1313|Wesley K. Thompson|Author|Pre-Symptomatic Alzheimer'S Disease|Topic|AUTHORED
1313|Michael C. Donohue|Author|Pre-Symptomatic Alzheimer'S Disease|Topic|AUTHORED
1314|Artificial Intelligence For Pediatric Ophthalmology|Paper|Pediatric Ophthalmology|Topic|DISCUSSES
1315|Bioconjugated Oligonucleotides|Topic|Antisense Dna (Aso)|Topic|DISCUSSES
1315|Bioconjugated Oligonucleotides|Topic|Rna Interference (Rnai)|Topic|DISCUSSES
1315|Bioconjugated Oligonucleotides|Topic|Galnac|Topic|RELATED_TO
1315|Bioconjugated Oligonucleotides|Topic|Cell Penetrating Peptides|Topic|RELATED_TO
1315|Bioconjugated Oligonucleotides|Topic|Aptamers|Topic|RELATED_TO
1315|Bioconjugated Oligonucleotides|Topic|Antibodies|Topic|RELATED_TO
1315|Bioconjugated Oligonucleotides|Topic|Cholesterol|Topic|RELATED_TO
1315|Bioconjugated Oligonucleotides|Topic|Squalene|Topic|RELATED_TO
1315|Bioconjugated Oligonucleotides|Topic|Fatty Acids|Topic|RELATED_TO
1315|Bioconjugated Oligonucleotides|Topic|Nucleolipids|Topic|RELATED_TO
1315|Bioconjugation Chemistry|Topic|Bioconjugated Oligonucleotides|Topic|RELATED_TO
1315|Sébastien Benizri|Author|Bioconjugated Oligonucleotides|Topic|AUTHORED
1315|Arnaud Gissot|Author|Bioconjugated Oligonucleotides|Topic|AUTHORED
1315|Andrew Martin|Author|Bioconjugated Oligonucleotides|Topic|AUTHORED
1315|Brune Vialet|Author|Bioconjugated Oligonucleotides|Topic|AUTHORED
1315|Mark Grinstaff|Author|Bioconjugated Oligonucleotides|Topic|AUTHORED
1315|Philippe Barthélémy|Author|Bioconjugated Oligonucleotides|Topic|AUTHORED
1316|Vts Glove|Topic|Feasibility Study|Topic|RELATED_TO
1316|Chronic Stroke Survivors|Topic|Feasibility Study|Topic|RELATED_TO
1316|Caitlyn E. Seim|Author|Feasibility Study|Topic|AUTHORED
1316|Steven L. Wolf|Author|Feasibility Study|Topic|AUTHORED
1316|Thad E. Starner|Author|Feasibility Study|Topic|AUTHORED
1316|Vibrotactile Stimulation|Topic|Feasibility Study|Topic|RELATED_TO
1316|Semmes-Weinstein Monofilament Exam|Topic|Feasibility Study|Topic|RELATED_TO
1316|Modified Ashworth Measures|Topic|Feasibility Study|Topic|RELATED_TO
1316|Voluntary Finger Flexion|Topic|Feasibility Study|Topic|RELATED_TO
1316|Elbow And Shoulder Range Of Motion|Topic|Feasibility Study|Topic|RELATED_TO
1317|Causal Structure Discovery From Ehr Data|Paper|Xinpeng Shen|Author|AUTHORED
1317|Causal Structure Discovery From Ehr Data|Paper|Sisi Ma|Author|AUTHORED
1317|Causal Structure Discovery From Ehr Data|Paper|Prashanthi Vemuri|Author|AUTHORED
1317|Causal Structure Discovery From Ehr Data|Paper|M. Regina Castro|Author|AUTHORED
1317|Causal Structure Discovery From Ehr Data|Paper|Pedro J. Caraballo|Author|AUTHORED
1317|Causal Structure Discovery From Ehr Data|Paper|Gyorgy J. Simon|Author|AUTHORED
1317|Causal Structure Discovery From Ehr Data|Paper|Type-2 Diabetes Mellitus|Topic|DISCUSSES
1318|Causal Prediction Models|Topic|Prediction Models|Topic|RELATED_TO
1318|Causal Prediction Models|Topic|Causal Inference|Topic|RELATED_TO
1318|Causal Inference|Topic|Observational Data|Topic|RELATED_TO
1318|Causal Inference|Topic|Clinical Trials|Topic|RELATED_TO
1318|Causal Inference|Topic|Meta-Analyses|Topic|RELATED_TO
1318|Lijing Lin|Author|Causal Prediction Models|Topic|AUTHORED
1318|Matthew Sperrin|Author|Causal Prediction Models|Topic|AUTHORED
1318|David A. Jenkins|Author|Causal Prediction Models|Topic|AUTHORED
1318|Glen P. Martin|Author|Causal Prediction Models|Topic|AUTHORED
1318|Niels Peek|Author|Causal Prediction Models|Topic|AUTHORED
1319|Drug Discovery|Topic|Lead Optimization|Topic|RELATED_TO
1319|Lead Optimization|Topic|Machine Learning|Topic|RELATED_TO
1319|Lead Optimization|Topic|Molecular Modeling|Topic|RELATED_TO
1319|Molecular Modeling|Topic|Physics-Based Molecular Dynamics Simulation|Topic|RELATED_TO
1319|Physics-Based Molecular Dynamics Simulation|Topic|Temporal Dynamism Representation|Topic|RELATED_TO
1319|Temporal Dynamism Representation|Topic|Unsupervised Convolutional Variational Autoencoder|Topic|RELATED_TO
1319|Unsupervised Convolutional Variational Autoencoder|Topic|Conventional Clustering Method|Topic|RELATED_TO
1319|Unsupervised Convolutional Variational Autoencoder|Topic|Cvae-Based Clustering Method|Topic|RELATED_TO
1319|Leili Zhang|Author|Castelo: Clustered Atom Subtypes Aided Lead Optimization -- A Combined Machine Learning And Molecular Modeling Method|Paper|AUTHORED
1319|Giacomo Domeniconi|Author|Castelo: Clustered Atom Subtypes Aided Lead Optimization -- A Combined Machine Learning And Molecular Modeling Method|Paper|AUTHORED
1319|Chih-Chieh Yang|Author|Castelo: Clustered Atom Subtypes Aided Lead Optimization -- A Combined Machine Learning And Molecular Modeling Method|Paper|AUTHORED
1319|Seung-Gu Kang|Author|Castelo: Clustered Atom Subtypes Aided Lead Optimization -- A Combined Machine Learning And Molecular Modeling Method|Paper|AUTHORED
1319|Ruhong Zhou|Author|Castelo: Clustered Atom Subtypes Aided Lead Optimization -- A Combined Machine Learning And Molecular Modeling Method|Paper|AUTHORED
1319|Guojing Cong|Author|Castelo: Clustered Atom Subtypes Aided Lead Optimization -- A Combined Machine Learning And Molecular Modeling Method|Paper|AUTHORED
1320|Trecap|Topic|R. P. Bremm|Author|AUTHORED
1320|Trecap|Topic|A. Werle|Author|AUTHORED
1320|Trecap|Topic|C. Auer|Author|AUTHORED
1320|Trecap|Topic|F. Hertel|Author|AUTHORED
1320|Trecap|Topic|J. Gonçalves|Author|AUTHORED
1320|Trecap|Topic|K. P. Koch|Author|AUTHORED
1320|Trecap|Topic|Parkinson'S Disease|Topic|RELATED_TO
1320|Trecap|Topic|Wearable Sensors|Topic|RELATED_TO
1320|Trecap|Topic|Machine Learning|Topic|RELATED_TO
1320|Machine Learning|Topic|Support Vector Machine Algorithms|Topic|RELATED_TO
1320|Trecap|Topic|Clinical Trials|Topic|RELATED_TO
1321|Multiple Sclerosis|Topic|Neuroimaging Data|Topic|RELATED_TO
1321|Multiple Sclerosis|Topic|Clinical Laboratory Tests|Topic|RELATED_TO
1321|Multiple Sclerosis|Topic|Performance Outcome Measures|Topic|RELATED_TO
1321|Multiple Sclerosis|Topic|Demographic Data|Topic|RELATED_TO
1321|Subhrajit Roy|Author|Multiple Sclerosis|Topic|AUTHORED
1321|Diana Mincu|Author|Multiple Sclerosis|Topic|AUTHORED
1321|Lev Proleev|Author|Multiple Sclerosis|Topic|AUTHORED
1321|Negar Rostamzadeh|Author|Multiple Sclerosis|Topic|AUTHORED
1321|Chintan Ghate|Author|Multiple Sclerosis|Topic|AUTHORED
1321|Natalie Harris|Author|Multiple Sclerosis|Topic|AUTHORED
1321|Christina Chen|Author|Multiple Sclerosis|Topic|AUTHORED
1321|Jessica Schrouff|Author|Multiple Sclerosis|Topic|AUTHORED
1321|Nenad Tomasev|Author|Multiple Sclerosis|Topic|AUTHORED
1321|Fletcher Lee Hartsell|Author|Multiple Sclerosis|Topic|AUTHORED
1321|Katherine Heller|Author|Multiple Sclerosis|Topic|AUTHORED
1322|Chronic Cancer Pain Dataset|Topic|Catherine Ordun|Author|AUTHORED
1322|Chronic Cancer Pain Dataset|Topic|Alexandra N. Cha|Author|AUTHORED
1322|Chronic Cancer Pain Dataset|Topic|Edward Raff|Author|AUTHORED
1322|Chronic Cancer Pain Dataset|Topic|Byron Gaskin|Author|AUTHORED
1322|Chronic Cancer Pain Dataset|Topic|Alex Hanson|Author|AUTHORED
1322|Chronic Cancer Pain Dataset|Topic|Mason Rule|Author|AUTHORED
1322|Chronic Cancer Pain Dataset|Topic|Sanjay Purushotham|Author|AUTHORED
1322|Chronic Cancer Pain Dataset|Topic|James L. Gulley|Author|AUTHORED
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Artificial Intelligence Systems|Topic|DISCUSSES
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Scientific Methodology|Topic|DISCUSSES
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Decision Analysis|Topic|DISCUSSES
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Medical Research|Topic|DISCUSSES
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Influence Diagram|Topic|DISCUSSES
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Clinical Research Practices|Topic|DISCUSSES
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Clinical Epidemiological Advisory Systems|Topic|RELATED_TO
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Statistical Workstations|Topic|RELATED_TO
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Meta-Analytic Reviews|Topic|RELATED_TO
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Case-Control Studies|Topic|RELATED_TO
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Cohort Studies|Topic|RELATED_TO
1323|A Decision-Theoretic Model For Using Scientific Data|Paper|Controlled Clinical Trials|Topic|RELATED_TO
1324|Neutropenia|Topic|Acute Myeloid Leukemia|Topic|RELATED_TO
1324|Mathematical Modeling|Topic|Population Pk/Pd Model|Topic|RELATED_TO
1324|Population Pk/Pd Model|Topic|Cytarabine|Topic|RELATED_TO
1324|Population Pk/Pd Model|Topic|Granulocyte-Colony Stimulating Factor|Topic|RELATED_TO
1324|Clinical Trial|Topic|Population Pk/Pd Model|Topic|RELATED_TO
1324|Felix Jost|Author|Clinical Trial|Topic|AUTHORED
1324|Enrico Schalk|Author|Clinical Trial|Topic|AUTHORED
1324|Daniela Weber|Author|Clinical Trial|Topic|AUTHORED
1324|Hartmut Doehner|Author|Clinical Trial|Topic|AUTHORED
1324|Thomas Fischer|Author|Clinical Trial|Topic|AUTHORED
1324|Sebastian Sager|Author|Clinical Trial|Topic|AUTHORED
1325|Data-Adaptive Effect Estimators|Topic|Bioinformatic And Clinical Studies|Topic|RELATED_TO
1325|Refine2|Topic|Bioinformatic And Clinical Studies|Topic|RELATED_TO
1325|Refine2|Topic|Xiang Meng|Author|AUTHORED
1325|Refine2|Topic|Jonathan Huang|Author|AUTHORED
1326|Lung Cancer Risk Estimation With Incomplete Data: A Joint Missing Imputation Perspective|Paper|Conditional Pbigan|Topic|DISCUSSES
1327|Burn Resuscitation Protocols|Topic|Burn Pathophysiology|Topic|RELATED_TO
1327|Mathematical Model|Topic|Burn Resuscitation Protocols|Topic|RELATED_TO
1327|Mathematical Model|Topic|233 Burn Patients|Topic|AUTHORED
1327|Ghazal Arabidarrehdor|Author|Mathematical Model|Topic|AUTHORED
1327|Ali Tivay|Author|Mathematical Model|Topic|AUTHORED
1327|Chris Meador|Author|Mathematical Model|Topic|AUTHORED
1327|George C. Kramer|Author|Mathematical Model|Topic|AUTHORED
1327|Jin-Oh Hahn|Author|Mathematical Model|Topic|AUTHORED
1327|Jose Salinas|Author|Mathematical Model|Topic|AUTHORED
1327|Mathematical Model|Topic|Physiological Responses|Topic|RELATED_TO
1327|Inflammatory Response|Topic|Mortality Risk|Topic|RELATED_TO
1327|Inflammatory Response|Topic|Fluid Retention|Topic|RELATED_TO
1327|Demographic Characteristics|Topic|Injury Severity|Topic|RELATED_TO
1327|Inhalational Injury|Topic|Physiological Responses|Topic|RELATED_TO
1328|Pain Patient States|Topic|Chronic Pain Patients|Topic|RELATED_TO
1328|Pain Patient States|Topic|Clinical Trial|Topic|RELATED_TO
1328|Pain Patient States|Topic|Data-Driven Approach|Topic|RELATED_TO
1328|Pain Patient States|Topic|Clustering Analysis|Topic|RELATED_TO
1328|Pain Patient States|Topic|Quality-Of-Life Assessment|Topic|RELATED_TO
1328|Pain Patient States|Topic|Disability Assessment|Topic|RELATED_TO
1328|Pain Patient States|Topic|Mobile Device Monitoring|Topic|RELATED_TO
1328|Jenna M. Reinen|Author|Pain Patient States|Topic|AUTHORED
1328|Carla Agurto|Author|Pain Patient States|Topic|AUTHORED
1328|Guillermo Cecchi|Author|Pain Patient States|Topic|AUTHORED
1328|Jeffrey L. Rogers|Author|Pain Patient States|Topic|AUTHORED
1328|Navitas|Author|Pain Patient States|Topic|AUTHORED
1328|Envision Studies Physician Author Group|Author|Pain Patient States|Topic|AUTHORED
1328|Boston Scientific Research Scientists Consortium|Author|Pain Patient States|Topic|AUTHORED
1329|Alzheimer'S Disease|Topic|Amyloid-Beta Peptide|Topic|RELATED_TO
1329|Alzheimer'S Disease|Topic|Astrocytes|Topic|RELATED_TO
1329|Adni Data|Topic|Stochastic Models|Topic|AUTHORED
1329|Stochastic Models|Topic|Bayesian Inference|Topic|DISCUSSES
1329|Hina Shaheen|Author|Adni Data|Topic|AUTHORED
1329|Roderick Melnik|Author|Adni Data|Topic|AUTHORED
1329|The Alzheimer'S Disease Neuroimaging Initiative|Author|Adni Data|Topic|AUTHORED
1330|Is Attention All You Need In Medical Image Analysis? A Review|Paper|Giorgos Papanastasiou|Author|AUTHORED
1330|Is Attention All You Need In Medical Image Analysis? A Review|Paper|Nikolaos Dikaios|Author|AUTHORED
1330|Is Attention All You Need In Medical Image Analysis? A Review|Paper|Jiahao Huang|Author|AUTHORED
1330|Is Attention All You Need In Medical Image Analysis? A Review|Paper|Chengjia Wang|Author|AUTHORED
1330|Is Attention All You Need In Medical Image Analysis? A Review|Paper|Guang Yang|Author|AUTHORED
1330|Cnns|Topic|Medical Imaging|Topic|RELATED_TO
1330|Transformers|Topic|Medical Imaging|Topic|RELATED_TO
1330|Transf/Attention|Topic|Medical Imaging|Topic|RELATED_TO
1330|Hybrid Cnn-Transf/Attention Models|Topic|Medical Imaging|Topic|RELATED_TO
1331|Cancer|Topic|Personalized Treatment Strategies|Topic|RELATED_TO
1331|Genomic Profiling|Topic|Drug Response Prediction Models|Topic|RELATED_TO
1331|Transfer Learning|Topic|Drug Response Prediction Models|Topic|RELATED_TO
1331|Transformer Based Method|Topic|Drug Response Prediction Models|Topic|RELATED_TO
1331|Treatment Recommendation System|Topic|National University Hospital, Singapore|Topic|RELATED_TO
1331|Aishwarya Jayagopal|Author|Personalised Drug Identifier For Cancer Treatment With Transformers Using Auxiliary Information|Paper|AUTHORED
1331|Hansheng Xue|Author|Personalised Drug Identifier For Cancer Treatment With Transformers Using Auxiliary Information|Paper|AUTHORED
1331|Ziyang He|Author|Personalised Drug Identifier For Cancer Treatment With Transformers Using Auxiliary Information|Paper|AUTHORED
1331|Robert J. Walsh|Author|Personalised Drug Identifier For Cancer Treatment With Transformers Using Auxiliary Information|Paper|AUTHORED
1331|Krishna Kumar Hariprasannan|Author|Personalised Drug Identifier For Cancer Treatment With Transformers Using Auxiliary Information|Paper|AUTHORED
1331|David Shao Peng Tan|Author|Personalised Drug Identifier For Cancer Treatment With Transformers Using Auxiliary Information|Paper|AUTHORED
1331|Tuan Zea Tan|Author|Personalised Drug Identifier For Cancer Treatment With Transformers Using Auxiliary Information|Paper|AUTHORED
1331|Jason J. Pitt|Author|Personalised Drug Identifier For Cancer Treatment With Transformers Using Auxiliary Information|Paper|AUTHORED
1331|Anand D. Jeyasekharan|Author|Personalised Drug Identifier For Cancer Treatment With Transformers Using Auxiliary Information|Paper|AUTHORED
1331|Vaibhav Rajan|Author|Personalised Drug Identifier For Cancer Treatment With Transformers Using Auxiliary Information|Paper|AUTHORED
1332|Deepcre|Topic|Cross-Drug Response Evaluation|Topic|RELATED_TO
1332|Deepcre|Topic|Drug Research And Development|Topic|RELATED_TO
1332|Deepcre|Topic|Colorectal Cancer Organoids|Topic|RELATED_TO
1332|Yushuai Wu|Author|Deepcre|Topic|AUTHORED
1332|Ting Zhang|Author|Deepcre|Topic|AUTHORED
1332|Hao Zhou|Author|Deepcre|Topic|AUTHORED
1332|Hainan Wu|Author|Deepcre|Topic|AUTHORED
1332|Hanwen Sunchu|Author|Deepcre|Topic|AUTHORED
1332|Lei Hu|Author|Deepcre|Topic|AUTHORED
1332|Xiaofang Chen|Author|Deepcre|Topic|AUTHORED
1332|Suyuan Zhao|Author|Deepcre|Topic|AUTHORED
1332|Gaochao Liu|Author|Deepcre|Topic|AUTHORED
1332|Chao Sun|Author|Deepcre|Topic|AUTHORED
1332|Jiahuan Zhang|Author|Deepcre|Topic|AUTHORED
1332|Yizhen Luo|Author|Deepcre|Topic|AUTHORED
1332|Peng Liu|Author|Deepcre|Topic|AUTHORED
1332|Zaiqing Nie|Author|Deepcre|Topic|AUTHORED
1333|Tusnet|Paper|Kasra Naftchi-Ardebili|Author|AUTHORED
1333|Tusnet|Paper|Karanpartap Singh|Author|AUTHORED
1333|Tusnet|Paper|Gerald R. Popelka|Author|AUTHORED
1333|Tusnet|Paper|Kim Butts Pauly|Author|AUTHORED
1333|Transcranial Ultrasound|Topic|Opioid Addiction|Topic|RELATED_TO
1333|Transcranial Ultrasound|Topic|Alzheimer'S Disease|Topic|RELATED_TO
1333|Transcranial Ultrasound|Topic|Dementia|Topic|RELATED_TO
1333|Transcranial Ultrasound|Topic|Epilepsy|Topic|RELATED_TO
1333|Transcranial Ultrasound|Topic|Glioblastoma|Topic|RELATED_TO
1333|K-Wave|Topic|Tusnet|Paper|RELATED_TO
1334|Large Language Models|Topic|Medical Applications|Topic|RELATED_TO
1334|Medical Applications|Topic|Drug Discovery|Topic|RELATED_TO
1334|Medical Applications|Topic|Clinical Decision Support|Topic|RELATED_TO
1334|Medical Applications|Topic|Telemedicine|Topic|RELATED_TO
1334|Medical Applications|Topic|Medical Devices|Topic|RELATED_TO
1334|Medical Applications|Topic|Healthcare Insurance Applications|Topic|RELATED_TO
1334|Llm-Powered Medical Ai Applications|Topic|Three-Step Framework|Topic|RELATED_TO
1334|Three-Step Framework|Topic|Modeling|Topic|RELATED_TO
1334|Three-Step Framework|Topic|Optimization|Topic|RELATED_TO
1334|Three-Step Framework|Topic|System Engineering|Topic|RELATED_TO
1334|Llm-Powered Medical Ai Applications|Topic|Clinical Trial Design|Topic|RELATED_TO
1334|Llm-Powered Medical Ai Applications|Topic|Medical Imaging Analysis|Topic|RELATED_TO
1334|Zifeng Wang|Author|A Perspective For Adapting Generalist Ai To Specialized Medical Ai Applications And Their Challenges|Paper|AUTHORED
1334|Hanyin Wang|Author|A Perspective For Adapting Generalist Ai To Specialized Medical Ai Applications And Their Challenges|Paper|AUTHORED
1334|Benjamin Danek|Author|A Perspective For Adapting Generalist Ai To Specialized Medical Ai Applications And Their Challenges|Paper|AUTHORED
1334|Ying Li|Author|A Perspective For Adapting Generalist Ai To Specialized Medical Ai Applications And Their Challenges|Paper|AUTHORED
1334|Christina Mack|Author|A Perspective For Adapting Generalist Ai To Specialized Medical Ai Applications And Their Challenges|Paper|AUTHORED
1334|Hoifung Poon|Author|A Perspective For Adapting Generalist Ai To Specialized Medical Ai Applications And Their Challenges|Paper|AUTHORED
1334|Yajuan Wang|Author|A Perspective For Adapting Generalist Ai To Specialized Medical Ai Applications And Their Challenges|Paper|AUTHORED
1334|Pranav Rajpurkar|Author|A Perspective For Adapting Generalist Ai To Specialized Medical Ai Applications And Their Challenges|Paper|AUTHORED
1334|Jimeng Sun|Author|A Perspective For Adapting Generalist Ai To Specialized Medical Ai Applications And Their Challenges|Paper|AUTHORED
1335|Alzheimer'S Disease|Topic|Sustain Algorithm|Topic|RELATED_TO
1335|Sustain Algorithm|Topic|T1-Weighted Mri Data|Topic|RELATED_TO
1335|T1-Weighted Mri Data|Topic|Anmerge|Topic|RELATED_TO
1335|T1-Weighted Mri Data|Topic|Oasis|Topic|RELATED_TO
1335|T1-Weighted Mri Data|Topic|Adni|Topic|RELATED_TO
1335|Emma Prevot|Author|Alzheimer'S Disease Neuroimaging Initiative|Author|AUTHORED
1335|Cameron Shand|Author|Alzheimer'S Disease Neuroimaging Initiative|Author|AUTHORED
1335|Neil Oxtoby|Author|Alzheimer'S Disease Neuroimaging Initiative|Author|AUTHORED
1335|Alzheimer'S Disease Neuroimaging Initiative|Author|Typical Subtype|Topic|RELATED_TO
1335|Alzheimer'S Disease Neuroimaging Initiative|Author|Cortical Subtype|Topic|RELATED_TO
1335|Alzheimer'S Disease Neuroimaging Initiative|Author|Subcortical Subtype|Topic|RELATED_TO
1335|Alzheimer'S Disease Neuroimaging Initiative|Author|Posterior Cortical Atrophy|Topic|RELATED_TO
1335|Cohort Composition|Topic|Subcortical Subtype|Topic|RELATED_TO
1335|Dataset Diversity|Topic|Ethnic Representation|Topic|RELATED_TO
1336|Computational Modelling Of Biological Systems|Topic|Cardiovascular System|Topic|RELATED_TO
1336|Computational Modelling Of Biological Systems|Topic|Digital Twins|Topic|RELATED_TO
1336|Computational Modelling Of Biological Systems|Topic|In Silico Methods|Topic|RELATED_TO
1336|Axel Loewe|Author|Computational Modelling Of Biological Systems|Topic|AUTHORED
1336|Peter J. Hunter|Author|Computational Modelling Of Biological Systems|Topic|AUTHORED
1336|Peter Kohl|Author|Computational Modelling Of Biological Systems|Topic|AUTHORED
1337|Artificial Intelligence-Based Training System|Paper|Mental Disorders|Topic|DISCUSSES
1337|Artificial Intelligence-Based Training System|Paper|Psychiatrists|Topic|DISCUSSES
1337|Artificial Intelligence-Based Training System|Paper|Large Language Models|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Knowledge Graphs|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Expert Systems|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|B/S Architecture|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Vue.Js|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Node.Js|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Deep Learning Algorithms|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Clinical Trial|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|System Stability|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Ai Dialogue Accuracy|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Diagnostic Accuracy|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|User Satisfaction|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Knowledge Mastery|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Clinical Thinking|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Diagnostic Skills|Topic|RELATED_TO
1337|Artificial Intelligence-Based Training System|Paper|Psychiatrist Training|Topic|DISCUSSES
1337|Artificial Intelligence-Based Training System|Paper|Mental Health Professional Development|Topic|DISCUSSES
1338|Compressed Genotyping|Topic|Yaniv Erlich|Author|AUTHORED
1338|Compressed Genotyping|Topic|Assaf Gordon|Author|AUTHORED
1338|Compressed Genotyping|Topic|Michael Brand|Author|AUTHORED
1338|Compressed Genotyping|Topic|Gregory J. Hannon|Author|AUTHORED
1338|Compressed Genotyping|Topic|Partha P. Mitra|Author|AUTHORED
1338|Cystic Fibrosis|Topic|Compressed Genotyping|Topic|RELATED_TO
1338|Mental Retardation|Topic|Compressed Genotyping|Topic|RELATED_TO
1339|Hepatic Encephalopathy|Topic|Portacaval Shunt|Topic|RELATED_TO
1339|Portacaval Shunt|Topic|Morris Water Maze|Topic|RELATED_TO
1339|M. Méndez|Author|Hepatic Encephalopathy|Topic|AUTHORED
1339|M. Méndez-López|Author|Hepatic Encephalopathy|Topic|AUTHORED
1339|L. López|Author|Hepatic Encephalopathy|Topic|AUTHORED
1339|M. A. Aller|Author|Hepatic Encephalopathy|Topic|AUTHORED
1339|J. Arias|Author|Hepatic Encephalopathy|Topic|AUTHORED
1339|J. L. Arias|Author|Hepatic Encephalopathy|Topic|AUTHORED
1340|Computational Methods|Topic|Experimental And Clinical Neurosciences|Topic|RELATED_TO
1340|Experimental And Clinical Neurosciences|Topic|Nervous Systems|Topic|RELATED_TO
1340|Nervous Systems|Topic|Health|Topic|RELATED_TO
1340|Nervous Systems|Topic|Disease|Topic|RELATED_TO
1340|Neuromodulation|Topic|Electric And Magnetic Stimulation|Topic|RELATED_TO
1340|Neuromodulation|Topic|Chronic And Intractable Diseases|Topic|RELATED_TO
1340|Dynamical Network Biomarkers (Dnb)|Topic|Episodic Manifestations Of Chronic Disorders|Topic|RELATED_TO
1340|Dynamical Network Biomarkers (Dnb)|Topic|Migraine|Topic|RELATED_TO
1340|Early-Warning Signals|Topic|Neuromodulation|Topic|RELATED_TO
1340|Markus A. Dahlem|Author|Translational Computational Neuroscience|Topic|AUTHORED
1340|Sebastian Rode|Author|Translational Computational Neuroscience|Topic|AUTHORED
1340|Arne May|Author|Translational Computational Neuroscience|Topic|AUTHORED
1340|Naoya Fujiwara|Author|Translational Computational Neuroscience|Topic|AUTHORED
1340|Yoshito Hirata|Author|Translational Computational Neuroscience|Topic|AUTHORED
1340|Kazuyuki Aihara|Author|Translational Computational Neuroscience|Topic|AUTHORED
1340|Jürgen Kurths|Author|Translational Computational Neuroscience|Topic|AUTHORED
1341|The Potential Of The Human Connectome As A Biomarker Of Brain Disease|Paper|Marcus Kaiser|Author|AUTHORED
1341|The Potential Of The Human Connectome As A Biomarker Of Brain Disease|Paper|Connectome|Topic|RELATED_TO
1341|The Potential Of The Human Connectome As A Biomarker Of Brain Disease|Paper|Brain Disorders|Topic|RELATED_TO
1341|The Potential Of The Human Connectome As A Biomarker Of Brain Disease|Paper|Cognitive Deficits|Topic|RELATED_TO
1341|The Potential Of The Human Connectome As A Biomarker Of Brain Disease|Paper|Biomarkers|Topic|RELATED_TO
1341|The Potential Of The Human Connectome As A Biomarker Of Brain Disease|Paper|Dynamic Connectome|Topic|RELATED_TO
1341|The Potential Of The Human Connectome As A Biomarker Of Brain Disease|Paper|Structural Connectivity|Topic|RELATED_TO
1341|The Potential Of The Human Connectome As A Biomarker Of Brain Disease|Paper|Functional Connectivity|Topic|RELATED_TO
1341|The Potential Of The Human Connectome As A Biomarker Of Brain Disease|Paper|Effective Connectivity|Topic|RELATED_TO
1342|Electrical High Frequency Stimulation|Topic|Deep Brain Regions|Topic|RELATED_TO
1342|Deep Brain Regions|Topic|Movement Disorders|Topic|RELATED_TO
1342|Deep Brain Regions|Topic|Neurological Disorders|Topic|RELATED_TO
1342|Computational Model Of The Basal Ganglia Network|Topic|Electrical High Frequency Stimulation|Topic|RELATED_TO
1342|Computational Model Of The Basal Ganglia Network|Topic|Subthalamic Nucleus|Topic|RELATED_TO
1342|Subthalamic Nucleus|Topic|Sensorimotor Input|Topic|RELATED_TO
1342|Sensorimotor Input|Topic|Thalamo-Cortical Relay Cells|Topic|RELATED_TO
1342|Gaba|Topic|Subthalamic Nucleus|Topic|RELATED_TO
1342|Felix Njap|Author|J Comput Neurosci, 16, 211-223, 2004|Paper|AUTHORED
1342|Jens Christian Claussen|Author|J Comput Neurosci, 16, 211-223, 2004|Paper|AUTHORED
1342|Andreas Moser|Author|J Comput Neurosci, 16, 211-223, 2004|Paper|AUTHORED
1342|Ulrich G. Hofmann|Author|J Comput Neurosci, 16, 211-223, 2004|Paper|AUTHORED
1342|Rubin And Terman|Author|J Comput Neurosci, 16, 211-223, 2004|Paper|AUTHORED
1342|Simulated Parkinsonian State|Topic|Gaba|Topic|RELATED_TO
1343|Mathematical Modeling Approaches|Topic|Clinical Neuroscience|Topic|RELATED_TO
1343|Clinical Neuroscience|Topic|Migraine Generator Network|Topic|RELATED_TO
1343|Premonitory Symptoms|Topic|Tipping Point|Topic|RELATED_TO
1343|Neuronal And Autonomic Subnetworks|Topic|Dynamical Network Biomarker Of Migraine|Topic|RELATED_TO
1343|Markus A. Dahlem|Author|Dynamical Network Biomarker Of Migraine|Topic|AUTHORED
1343|Jürgen Kurths|Author|Dynamical Network Biomarker Of Migraine|Topic|AUTHORED
1343|Michel D. Ferrari|Author|Dynamical Network Biomarker Of Migraine|Topic|AUTHORED
1343|Kazuyuki Aihara|Author|Dynamical Network Biomarker Of Migraine|Topic|AUTHORED
1343|Marten Scheffer|Author|Dynamical Network Biomarker Of Migraine|Topic|AUTHORED
1343|Arne May|Author|Dynamical Network Biomarker Of Migraine|Topic|AUTHORED
1344|Bi-Directional Motion Detection: A Neural Intelligent Model For Perception Of Cognitive Robots|Paper|Spiking Neuronal Network Model|Topic|DISCUSSES
1344|Bi-Directional Motion Detection: A Neural Intelligent Model For Perception Of Cognitive Robots|Paper|Cognitive Robots|Topic|DISCUSSES
1344|Bi-Directional Motion Detection: A Neural Intelligent Model For Perception Of Cognitive Robots|Paper|Neuronal Circuit|Topic|DISCUSSES
1344|Bi-Directional Motion Detection: A Neural Intelligent Model For Perception Of Cognitive Robots|Paper|Blocking Problems|Topic|DISCUSSES
1344|Bi-Directional Motion Detection: A Neural Intelligent Model For Perception Of Cognitive Robots|Paper|Pioneer Cognitive Robot|Topic|DISCUSSES
1344|Bi-Directional Motion Detection: A Neural Intelligent Model For Perception Of Cognitive Robots|Paper|Sensory Networks|Topic|DISCUSSES
1344|Bi-Directional Motion Detection: A Neural Intelligent Model For Perception Of Cognitive Robots|Paper|Intrinsic Delay|Topic|DISCUSSES
1344|Bi-Directional Motion Detection: A Neural Intelligent Model For Perception Of Cognitive Robots|Paper|High-Speed Circuits|Topic|DISCUSSES
1345|Braitenberg Vehicles|Topic|Cognitive Studies|Topic|RELATED_TO
1345|Braitenberg Vehicles|Topic|Robotics|Topic|RELATED_TO
1345|Braitenberg Vehicles|Topic|Neurorobotics|Topic|RELATED_TO
1345|Motion Detection|Topic|Intelligent Braitenberg Vehicles|Topic|RELATED_TO
1345|Neuronal Circuit|Topic|Curved Movements|Topic|RELATED_TO
1345|Modular Structure|Topic|Sensory-Biosystems|Topic|RELATED_TO
1345|Neuronal Circuit|Topic|Epileptic Seizures|Topic|RELATED_TO
1345|Neuronal Circuit|Topic|Excitatory Stimuli|Topic|RELATED_TO
1345|Neuronal Circuit|Topic|Inhibitory Stimuli|Topic|RELATED_TO
1345|Straight Movements|Topic|Curved Movements|Topic|RELATED_TO
1345|Pioneer|Topic|Neurosensors|Topic|RELATED_TO
1345|Pioneer|Topic|Curved Trajectory Detector|Topic|RELATED_TO
1345|Curved Trajectory Detector|Topic|Curved Trajectory Detection : A Novel Neurocognitive Perception Approach For Autonomous Smart Robots|Paper|DISCUSSES
1346|Graph-Theoretical Analyses Of Complex Brain Networks|Topic|Weighted Functional Brain Networks|Topic|RELATED_TO
1346|Gerrit Ansmann|Author|Surrogate-Assisted Analysis Of Weighted Functional Brain Networks|Topic|AUTHORED
1346|Klaus Lehnertz|Author|Surrogate-Assisted Analysis Of Weighted Functional Brain Networks|Topic|AUTHORED
1346|Surrogate-Assisted Analysis Of Weighted Functional Brain Networks|Topic|Surrogate Networks|Topic|RELATED_TO
1346|Surrogate-Assisted Analysis Of Weighted Functional Brain Networks|Topic|Epilepsy Patients|Topic|RELATED_TO
1346|Surrogate-Assisted Analysis Of Weighted Functional Brain Networks|Topic|Control Subjects|Topic|RELATED_TO
1346|Surrogate-Assisted Analysis Of Weighted Functional Brain Networks|Topic|Eeg/Meg Recordings|Topic|RELATED_TO
1346|Surrogate-Assisted Analysis Of Weighted Functional Brain Networks|Topic|Behavioral States|Topic|RELATED_TO
1347|Curved Trajectory Detection|Topic|Depth Detection Module|Topic|RELATED_TO
1347|Depth Detection Module|Topic|Matin Macktoobian|Author|AUTHORED
1347|Depth Detection Module|Topic|Mohammad Jafari|Author|AUTHORED
1347|Depth Detection Module|Topic|Erfan Attarzadeh Gh|Author|AUTHORED
1347|Depth Detection Module|Topic|Pioneer Mobile Robot|Topic|RELATED_TO
1348|Statistical Machine Learning Methods|Topic|Neuroimaging Data Analysis|Topic|RELATED_TO
1348|Scikit-Learn|Topic|Neuroimaging Data Analysis|Topic|RELATED_TO
1348|Alexandre Abraham|Author|Machine Learning For Neuroimaging With Scikit-Learn|Paper|AUTHORED
1348|Fabian Pedregosa|Author|Machine Learning For Neuroimaging With Scikit-Learn|Paper|AUTHORED
1348|Michael Eickenberg|Author|Machine Learning For Neuroimaging With Scikit-Learn|Paper|AUTHORED
1348|Philippe Gervais|Author|Machine Learning For Neuroimaging With Scikit-Learn|Paper|AUTHORED
1348|Andreas Muller|Author|Machine Learning For Neuroimaging With Scikit-Learn|Paper|AUTHORED
1348|Jean Kossaifi|Author|Machine Learning For Neuroimaging With Scikit-Learn|Paper|AUTHORED
1348|Alexandre Gramfort|Author|Machine Learning For Neuroimaging With Scikit-Learn|Paper|AUTHORED
1348|Bertrand Thirion|Author|Machine Learning For Neuroimaging With Scikit-Learn|Paper|AUTHORED
1348|Gäel Varoquaux|Author|Machine Learning For Neuroimaging With Scikit-Learn|Paper|AUTHORED
1349|Functional Brain Imaging: A Comprehensive Survey|Paper|Functional Brain Imaging|Topic|DISCUSSES
1349|Functional Brain Imaging: A Comprehensive Survey|Paper|Functional Magnetic Resonance Imaging (Fmri)|Topic|RELATED_TO
1349|Functional Brain Imaging: A Comprehensive Survey|Paper|Functional Optical Imaging|Topic|RELATED_TO
1350|The Connected Brain: Causality, Models And Intrinsic Dynamics|Paper|Adeel Razi|Author|AUTHORED
1350|The Connected Brain: Causality, Models And Intrinsic Dynamics|Paper|Karl Friston|Author|AUTHORED
1350|The Connected Brain: Causality, Models And Intrinsic Dynamics|Paper|Brain Initiative|Topic|RELATED_TO
1350|The Connected Brain: Causality, Models And Intrinsic Dynamics|Paper|European Human Brain Project|Topic|RELATED_TO
1350|The Connected Brain: Causality, Models And Intrinsic Dynamics|Paper|Human Connectome Project|Topic|RELATED_TO
1350|The Connected Brain: Causality, Models And Intrinsic Dynamics|Paper|Functional Neuroimaging|Topic|RELATED_TO
1350|The Connected Brain: Causality, Models And Intrinsic Dynamics|Paper|Functional Connectivity|Topic|RELATED_TO
1350|The Connected Brain: Causality, Models And Intrinsic Dynamics|Paper|Causal Modeling|Topic|RELATED_TO
1350|The Connected Brain: Causality, Models And Intrinsic Dynamics|Paper|Connectomics|Topic|RELATED_TO
1350|The Connected Brain: Causality, Models And Intrinsic Dynamics|Paper|Multivariate Analyses Of Distributed Patterns Of Brain Responses|Topic|RELATED_TO
1351|On The Formal Development Of Behavioral Reactive Agents: A Systematic Braitenberg-Vehicle Approach|Paper|Braitenberg Vehicle|Topic|DISCUSSES
1351|On The Formal Development Of Behavioral Reactive Agents: A Systematic Braitenberg-Vehicle Approach|Paper|Reactive Agents|Topic|DISCUSSES
1352|Computational Psychiatry In Borderline Personality Disorder|Paper|Sarah K Fineberg|Author|AUTHORED
1352|Computational Psychiatry In Borderline Personality Disorder|Paper|Dylan Stahl|Author|AUTHORED
1352|Computational Psychiatry In Borderline Personality Disorder|Paper|Philip Corlett|Author|AUTHORED
1353|Data Assimilation|Topic|Neuroscience|Topic|RELATED_TO
1353|Data Assimilation|Topic|Electroencephalography (Eeg)|Topic|RELATED_TO
1353|Kalman Filtering|Topic|Electroencephalography (Eeg)|Topic|RELATED_TO
1353|Ary'S Model Of The Head|Topic|Electroencephalography (Eeg)|Topic|RELATED_TO
1353|Extracranial Electrodes|Topic|Neuroscience|Topic|RELATED_TO
1353|Lara Escuain-Poole|Author|Extracranial Electrodes|Topic|AUTHORED
1353|Jordi Garcia-Ojalvo|Author|Extracranial Electrodes|Topic|AUTHORED
1353|Antonio J. Pons|Author|Extracranial Electrodes|Topic|AUTHORED
1354|Machine Learning Models|Topic|Neuroimaging Data|Topic|RELATED_TO
1354|Weight Maps|Topic|Classifiers|Topic|RELATED_TO
1354|Weight Maps|Topic|Signal Differences|Topic|RELATED_TO
1354|False Positives|Topic|Weight Maps|Topic|DISCUSSES
1354|Electrocorticography (Ecog)|Topic|Signal-To-Noise Ratio|Topic|RELATED_TO
1354|Electrocorticography (Ecog)|Topic|Sparsity Of The Neural Signal|Topic|RELATED_TO
1354|Weight Maps|Topic|Cognitive Neuroscience|Topic|DISCUSSES
1354|Weight Maps|Topic|Clinical Neuroscience|Topic|DISCUSSES
1354|Jessica Schrouff|Author|Weight Maps|Topic|AUTHORED
1354|Janaina Mourao-Miranda|Author|Weight Maps|Topic|AUTHORED
1355|Mice Vocalizations|Topic|Ultrasonic Vocalizations (Usvs)|Topic|RELATED_TO
1355|Ultrasonic Vocalizations (Usvs)|Topic|Manual Analysis Of Usvs|Topic|RELATED_TO
1355|Manual Analysis Of Usvs|Topic|New Method For Usvs|Topic|RELATED_TO
1355|New Method For Usvs|Topic|Spectral Clustering|Topic|RELATED_TO
1355|New Method For Usvs|Topic|Performance Measures|Topic|RELATED_TO
1355|New Method For Usvs|Topic|Jiaxi Wang|Author|AUTHORED
1355|New Method For Usvs|Topic|Karel Mundnich|Author|AUTHORED
1355|New Method For Usvs|Topic|Allison T. Knoll|Author|AUTHORED
1355|New Method For Usvs|Topic|Pat Levitt|Author|AUTHORED
1355|New Method For Usvs|Topic|Shrikanth Narayanan|Author|AUTHORED
1356|Brain Stimulation|Topic|Non-Invasive Brain Stimulation (Nibs)|Topic|RELATED_TO
1356|Non-Invasive Brain Stimulation (Nibs)|Topic|Non-Human Primate (Nhp) Models|Topic|RELATED_TO
1356|Non-Human Primate (Nhp) Models|Topic|Oculomotor Network|Topic|RELATED_TO
1356|Sebastian J Lehmann|Author|Completing The Puzzle: Why Studies In Non-Human Primates Are Needed To Better Understand The Effects Of Non-Invasive Brain Stimulation|Paper|AUTHORED
1356|Brian D Corneil|Author|Completing The Puzzle: Why Studies In Non-Human Primates Are Needed To Better Understand The Effects Of Non-Invasive Brain Stimulation|Paper|AUTHORED
1357|Real Time Seizure Detection|Topic|Epileptic Disease|Topic|RELATED_TO
1357|Computational Method|Topic|Real Time Seizure Detection|Topic|AUTHORED
1357|Topological Analysis|Topic|Computational Method|Topic|RELATED_TO
1357|Persistent Homology|Topic|Topological Analysis|Topic|RELATED_TO
1357|Ximena Fernández|Author|Topological Biomarkers For Real-Time Detection Of Epileptic Seizures|Topic|AUTHORED
1357|Diego Mateos|Author|Topological Biomarkers For Real-Time Detection Of Epileptic Seizures|Topic|AUTHORED
1357|Scalp Electroencephalograms|Topic|Real Time Seizure Detection|Topic|RELATED_TO
1357|Intracranial Electroencephalograms|Topic|Real Time Seizure Detection|Topic|RELATED_TO
1357|Magnetoencephalograms|Topic|Real Time Seizure Detection|Topic|RELATED_TO
1357|Interictal States|Topic|Real Time Seizure Detection|Topic|RELATED_TO
1357|Ictal States|Topic|Real Time Seizure Detection|Topic|RELATED_TO
1358|Interdisciplinary Science Of Spontaneous Thought|Topic|Spontaneous Thought|Topic|RELATED_TO
1358|Kieran C. R. Fox|Author|Interdisciplinary Science Of Spontaneous Thought|Topic|AUTHORED
1358|Kalina Christoff|Author|Interdisciplinary Science Of Spontaneous Thought|Topic|AUTHORED
1359|Applications Of Machine Learning And Graph Theory Techniques To Neuroscience|Topic|Nav1.7|Topic|RELATED_TO
1359|Nav1.7|Topic|Chronic Painful Syndromes|Topic|RELATED_TO
1359|Computational Pipeline|Topic|Nav1.7|Topic|RELATED_TO
1359|Computational Pipeline|Topic|Alberto Toffano|Author|AUTHORED
1359|Computational Pipeline|Topic|Giacomo Chiarot|Author|AUTHORED
1359|Computational Pipeline|Topic|Stefano Zamuner|Author|AUTHORED
1359|Computational Pipeline|Topic|Margherita Marchi|Author|AUTHORED
1359|Computational Pipeline|Topic|Erika Salvi|Author|AUTHORED
1359|Computational Pipeline|Topic|Stephen G. Waxman|Author|AUTHORED
1359|Computational Pipeline|Topic|Catharina G. Faber|Author|AUTHORED
1359|Computational Pipeline|Topic|Giuseppe Lauria|Author|AUTHORED
1359|Computational Pipeline|Topic|Achille Giacometti|Author|AUTHORED
1359|Computational Pipeline|Topic|Marta Simeoni|Author|AUTHORED
1360|Few-Shot Learning|Topic|Neuroimaging Data|Topic|RELATED_TO
1360|Neuroimaging Data|Topic|Neuroimaging Benchmark Dataset|Topic|RELATED_TO
1360|Neuroimaging Benchmark Dataset|Topic|Brain Signals|Topic|RELATED_TO
1360|Brain Signals|Topic|Biomarkers|Topic|RELATED_TO
1360|Brain Signals|Topic|Brain Scans|Topic|RELATED_TO
1360|Brain Signals|Topic|Cognitive Tasks|Topic|RELATED_TO
1360|Myriam Bontonou|Author|Few-Shot Learning|Topic|AUTHORED
1360|Giulia Lioi|Author|Few-Shot Learning|Topic|AUTHORED
1360|Nicolas Farrugia|Author|Few-Shot Learning|Topic|AUTHORED
1360|Vincent Gripon|Author|Few-Shot Learning|Topic|AUTHORED
1361|Brain|Topic|Spatiotemporal Patterns|Topic|RELATED_TO
1361|Brain|Topic|Neuroscience|Topic|RELATED_TO
1361|Brain|Topic|Biologically-Inspired Engineering|Topic|RELATED_TO
1361|Electrophysiological Data|Topic|Brain|Topic|RELATED_TO
1361|Brain Connectivity Disorders|Topic|Brain|Topic|RELATED_TO
1361|Emmanuelle Tognoli|Author|A Blueprint For The Study Of The Brain'S Spatiotemporal Patterns|Paper|AUTHORED
1361|Daniela Benites|Author|A Blueprint For The Study Of The Brain'S Spatiotemporal Patterns|Paper|AUTHORED
1361|J. A. Scott Kelso|Author|A Blueprint For The Study Of The Brain'S Spatiotemporal Patterns|Paper|AUTHORED
1362|Statistical Challenges In Neuroimaging Data Analysis|Topic|Hongtu Zhu|Author|AUTHORED
1362|Statistical Challenges In Neuroimaging Data Analysis|Topic|Tengfei Li|Author|AUTHORED
1362|Statistical Challenges In Neuroimaging Data Analysis|Topic|Bingxin Zhao|Author|AUTHORED
1363|Dynamic Functional Connectivity|Topic|Christine Ahrends|Author|AUTHORED
1363|Dynamic Functional Connectivity|Topic|Diego Vidaurre|Author|AUTHORED
1364|Ptgb|Paper|Graph Neural Networks|Topic|RELATED_TO
1364|Ptgb|Paper|Human Brain|Topic|RELATED_TO
1364|Ptgb|Paper|Neuroscience|Topic|RELATED_TO
1364|Ptgb|Paper|Yi Yang|Author|AUTHORED
1364|Ptgb|Paper|Hejie Cui|Author|AUTHORED
1364|Ptgb|Paper|Carl Yang|Author|AUTHORED
1365|Bayesian Time-Series Classifier For Decoding Simple Visual Stimuli From Intracranial Neural Activity|Paper|Navid Ziaei|Author|AUTHORED
1365|Bayesian Time-Series Classifier For Decoding Simple Visual Stimuli From Intracranial Neural Activity|Paper|Reza Saadatifard|Author|AUTHORED
1365|Bayesian Time-Series Classifier For Decoding Simple Visual Stimuli From Intracranial Neural Activity|Paper|Ali Yousefi|Author|AUTHORED
1365|Bayesian Time-Series Classifier For Decoding Simple Visual Stimuli From Intracranial Neural Activity|Paper|Behzad Nazari|Author|AUTHORED
1365|Bayesian Time-Series Classifier For Decoding Simple Visual Stimuli From Intracranial Neural Activity|Paper|Sydney S. Cash|Author|AUTHORED
1365|Bayesian Time-Series Classifier For Decoding Simple Visual Stimuli From Intracranial Neural Activity|Paper|Angelique C. Paulk|Author|AUTHORED
1365|Bayesian Time-Series Classifier For Decoding Simple Visual Stimuli From Intracranial Neural Activity|Paper|Neural Data|Topic|DISCUSSES
1365|Neural Data|Topic|Visual Task|Topic|RELATED_TO
1366|Mapping Tissue Microstructure Of Brain White Matter In Vivo In Health And Disease Using Diffusion Mri|Topic|Ying Liao|Author|AUTHORED
1366|Mapping Tissue Microstructure Of Brain White Matter In Vivo In Health And Disease Using Diffusion Mri|Topic|Santiago Coelho|Author|AUTHORED
1366|Mapping Tissue Microstructure Of Brain White Matter In Vivo In Health And Disease Using Diffusion Mri|Topic|Jenny Chen|Author|AUTHORED
1366|Mapping Tissue Microstructure Of Brain White Matter In Vivo In Health And Disease Using Diffusion Mri|Topic|Benjamin Ades-Aron|Author|AUTHORED
1366|Mapping Tissue Microstructure Of Brain White Matter In Vivo In Health And Disease Using Diffusion Mri|Topic|Michelle Pang|Author|AUTHORED
1366|Mapping Tissue Microstructure Of Brain White Matter In Vivo In Health And Disease Using Diffusion Mri|Topic|Ricardo Osorio|Author|AUTHORED
1366|Mapping Tissue Microstructure Of Brain White Matter In Vivo In Health And Disease Using Diffusion Mri|Topic|Timothy Shepherd|Author|AUTHORED
1366|Mapping Tissue Microstructure Of Brain White Matter In Vivo In Health And Disease Using Diffusion Mri|Topic|Yvonne W. Lui|Author|AUTHORED
1366|Mapping Tissue Microstructure Of Brain White Matter In Vivo In Health And Disease Using Diffusion Mri|Topic|Dmitry S. Novikov|Author|AUTHORED
1366|Mapping Tissue Microstructure Of Brain White Matter In Vivo In Health And Disease Using Diffusion Mri|Topic|Els Fieremans|Author|AUTHORED
1367|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|Yongheng Sun|Author|AUTHORED
1367|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|Fan Wang|Author|AUTHORED
1367|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|Jun Shu|Author|AUTHORED
1367|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|Haifeng Wang|Author|AUTHORED
1367|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|Li Wang|Author|AUTHORED
1367|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|Deyu Meng|Author|AUTHORED
1367|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|Chunfeng Lian|Author|AUTHORED
1367|Brain Tissue Segmentation|Topic|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|RELATED_TO
1367|Longitudinal Data|Topic|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|RELATED_TO
1367|Iseg2019|Topic|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|RELATED_TO
1367|Adni|Topic|Dual Meta-Learning With Longitudinally Generalized Regularization For One-Shot Brain Tissue Segmentation Across The Human Lifespan|Paper|RELATED_TO
1368|Linking Fast And Slow: The Case For Generative Models|Paper|Neuronal Connectivity|Topic|DISCUSSES
1368|Linking Fast And Slow: The Case For Generative Models|Paper|Bayesian Inference|Topic|DISCUSSES
1368|Linking Fast And Slow: The Case For Generative Models|Paper|State-Space Modeling|Topic|DISCUSSES
1368|Linking Fast And Slow: The Case For Generative Models|Paper|Generative Models|Topic|DISCUSSES
1369|Noninvasive Brain Stimulation|Topic|Transcranial Stimulation Techniques|Topic|RELATED_TO
1369|Transcranial Stimulation Techniques|Topic|Depression|Topic|RELATED_TO
1369|Transcranial Stimulation Techniques|Topic|Anxiety|Topic|RELATED_TO
1369|Transcranial Stimulation Techniques|Topic|Chronic Pain|Topic|RELATED_TO
1369|Computer Science Semantic Reporting Methods|Topic|Neuroscience Nibs Studies|Topic|RELATED_TO
1369|Neuroscience Nibs Studies|Topic|Fair|Topic|RELATED_TO
1369|Repetitive Transcranial Magnetic Stimulation|Topic|Open Research Knowledge Graph|Topic|RELATED_TO
1369|Toward Semantic Publishing In Non-Invasive Brain Stimulation: A Comprehensive Analysis Of Rtms Studies|Paper|Repetitive Transcranial Magnetic Stimulation|Topic|DISCUSSES
1370|Michael W. Cole|Author|Activity Flow Models|Topic|AUTHORED
1370|Activity Flow Models|Topic|Brain Connectivity|Topic|RELATED_TO
1370|Activity Flow Models|Topic|Task-Evoked Brain Activation Patterns|Topic|RELATED_TO
1370|Activity Flow Models|Topic|Neurocognitive Functions|Topic|RELATED_TO
1370|Activity Flow Models|Topic|Brain Disorders|Topic|RELATED_TO
1370|Activity Flow Models|Topic|Computational Models|Topic|RELATED_TO
1370|Activity Flow Models|Topic|Activity Flow Modeling|Topic|RELATED_TO
1371|Wishart Process|Topic|Sequential Monte Carlo|Topic|RELATED_TO
1371|Sequential Monte Carlo|Topic|Mcmc|Topic|RELATED_TO
1371|Sequential Monte Carlo|Topic|Variational Inference|Topic|RELATED_TO
1371|Dynamic Covariance|Topic|Wishart Process|Topic|RELATED_TO
1371|Hester Huijsdens|Author|Robust Inference Of Dynamic Covariance Using Wishart Processes And Sequential Monte Carlo|Paper|AUTHORED
1371|David Leeftink|Author|Robust Inference Of Dynamic Covariance Using Wishart Processes And Sequential Monte Carlo|Paper|AUTHORED
1371|Linda Geerligs|Author|Robust Inference Of Dynamic Covariance Using Wishart Processes And Sequential Monte Carlo|Paper|AUTHORED
1371|Max Hinne|Author|Robust Inference Of Dynamic Covariance Using Wishart Processes And Sequential Monte Carlo|Paper|AUTHORED
1371|Clinical Depression|Topic|Robust Inference Of Dynamic Covariance Using Wishart Processes And Sequential Monte Carlo|Paper|RELATED_TO
1371|Econometrics|Topic|Robust Inference Of Dynamic Covariance Using Wishart Processes And Sequential Monte Carlo|Paper|RELATED_TO
1371|Neuroscience|Topic|Robust Inference Of Dynamic Covariance Using Wishart Processes And Sequential Monte Carlo|Paper|RELATED_TO
1371|Computational Psychology|Topic|Robust Inference Of Dynamic Covariance Using Wishart Processes And Sequential Monte Carlo|Paper|RELATED_TO
1372|Individual Brain Parcellation|Topic|Chengyi Li|Author|AUTHORED
1372|Individual Brain Parcellation|Topic|Shan Yu|Author|AUTHORED
1372|Individual Brain Parcellation|Topic|Yue Cui|Author|AUTHORED
1373|Eeg-Ssm|Topic|State-Space Models|Topic|RELATED_TO
1373|Eeg-Ssm|Topic|Dementia|Topic|RELATED_TO
1373|Eeg-Ssm|Topic|Healthy Control|Topic|DISCUSSES
1373|Eeg-Ssm|Topic|Frontotemporal Dementia|Topic|DISCUSSES
1373|Eeg-Ssm|Topic|Alzheimer'S Disease|Topic|DISCUSSES
1373|Xuan-The Tran|Author|Eeg-Ssm|Topic|AUTHORED
1373|Linh Le|Author|Eeg-Ssm|Topic|AUTHORED
1373|Quoc Toan Nguyen|Author|Eeg-Ssm|Topic|AUTHORED
1373|Thomas Do|Author|Eeg-Ssm|Topic|AUTHORED
1373|Chin-Teng Lin|Author|Eeg-Ssm|Topic|AUTHORED
1374|Chatgpt 4O-Mini|Topic|Research Excellence Framework 2021|Topic|DISCUSSES
1374|Chatgpt 4O-Mini|Topic|Journal Articles|Topic|DISCUSSES
1374|Mike Thelwall|Author|Chatgpt 4O-Mini|Topic|AUTHORED
1374|Abdallah Yaghi|Author|Chatgpt 4O-Mini|Topic|AUTHORED
1374|Chatgpt 4O-Mini|Topic|Large Language Models|Topic|RELATED_TO
1374|Chatgpt 4O-Mini|Topic|Citation-Based Indicators|Topic|RELATED_TO
1374|Chatgpt 4O-Mini|Topic|Philosophy|Topic|RELATED_TO
1374|Chatgpt 4O-Mini|Topic|Psychology, Psychiatry And Neuroscience|Topic|RELATED_TO
1374|Chatgpt 4O-Mini|Topic|Clinical Medicine|Topic|RELATED_TO
1374|Chatgpt 4O-Mini|Topic|Health Sciences|Topic|RELATED_TO
1374|Chatgpt 4O-Mini|Topic|Physical Sciences|Topic|RELATED_TO
1374|Chatgpt 4O-Mini|Topic|Engineering|Topic|RELATED_TO
1374|Chatgpt 4O-Mini|Topic|Multidisciplinary Assessments|Topic|RELATED_TO
1375|Cwa-T|Topic|Electroencephalogram (Eeg) Signals|Topic|DISCUSSES
1375|Cwa-T|Topic|Tuh Abnormal Eeg Corpus|Topic|DISCUSSES
1375|Cwa-T|Topic|Youshen Zhao|Author|AUTHORED
1375|Cwa-T|Topic|Keiji Iramina|Author|AUTHORED
1376|Human Brain|Topic|Sulcal Depth|Topic|RELATED_TO
1376|Maxime Dieudonné|Author|Sulcal Depth|Topic|AUTHORED
1376|Guillaume Auzias|Author|Sulcal Depth|Topic|AUTHORED
1376|Julien Lefèvre|Author|Sulcal Depth|Topic|AUTHORED
1376|Sulcal Depth|Topic|1,987 Subjects|Topic|RELATED_TO
1377|Effective Membrane Model Of The Immunological Synapse|Topic|Subhadip Raychaudhuri|Author|AUTHORED
1377|Effective Membrane Model Of The Immunological Synapse|Topic|Arup K. Chakraborty|Author|AUTHORED
1377|Effective Membrane Model Of The Immunological Synapse|Topic|Mehran Kardar|Author|AUTHORED
1378|Simmune|Topic|Immune System|Topic|RELATED_TO
1378|M. Meier-Schellersheim|Author|Simmune|Topic|AUTHORED
1378|G. Mack|Author|Simmune|Topic|AUTHORED
1379|Immune System|Topic|Cognitive System|Topic|RELATED_TO
1379|Immune System|Topic|Engineering Problems|Topic|DISCUSSES
1379|Immunological Principles|Topic|Anomaly Detection Algorithm|Topic|AUTHORED
1379|Anomaly Detection Algorithm|Topic|Applications|Topic|RELATED_TO
1379|Applications|Topic|Fault Detection|Topic|RELATED_TO
1379|P. J. Costa Branco|Author|Using Immunology Principles For Anomaly Detection In Electrical Systems|Paper|AUTHORED
1379|J. A. Dente|Author|Using Immunology Principles For Anomaly Detection In Electrical Systems|Paper|AUTHORED
1379|R. Vilela Mendes|Author|Using Immunology Principles For Anomaly Detection In Electrical Systems|Paper|AUTHORED
1380|Agent-Based Modeling Of Host-Pathogen Systems: The Successes And Challenges|Paper|Immunology|Topic|DISCUSSES
1380|Agent-Based Modeling Of Host-Pathogen Systems: The Successes And Challenges|Paper|Disease Pathology|Topic|DISCUSSES
1380|Agent-Based Modeling Of Host-Pathogen Systems: The Successes And Challenges|Paper|Host-Pathogen Systems|Topic|DISCUSSES
1380|Agent-Based Modeling Of Host-Pathogen Systems: The Successes And Challenges|Paper|Agent-Based Models|Topic|DISCUSSES
1380|Agent-Based Modeling Of Host-Pathogen Systems: The Successes And Challenges|Paper|Reproducibility|Topic|DISCUSSES
1380|Agent-Based Modeling Of Host-Pathogen Systems: The Successes And Challenges|Paper|Model Validation|Topic|DISCUSSES
1381|Immunological Memory|Topic|B And T Lymphocytes|Topic|RELATED_TO
1381|Immunological Memory|Topic|Monocytes|Topic|RELATED_TO
1381|Immunological Memory|Topic|Macrophages|Topic|RELATED_TO
1381|Immunological Memory|Topic|Dendritic Cells (Dcs)|Topic|RELATED_TO
1381|Dendritic Cells (Dcs)|Topic|Yiqiang Wang|Author|DISCUSSES
1381|Yiqiang Wang|Author|Shuyi|Author|AUTHORED
1382|Improved Immunological Assay|Topic|Quantum Dots|Topic|RELATED_TO
1382|Improved Immunological Assay|Topic|Antigen Detection|Topic|RELATED_TO
1382|Earl Bloch|Author|Improved Immunological Assay|Topic|AUTHORED
1382|Lou Massa|Author|Improved Immunological Assay|Topic|AUTHORED
1382|Kilian Dill|Author|Improved Immunological Assay|Topic|AUTHORED
1383|Towards A Mathematical Foundation Of Immunology And Amino Acid Chains|Paper|Wen-Jun Shen|Author|AUTHORED
1383|Towards A Mathematical Foundation Of Immunology And Amino Acid Chains|Paper|Hau-San Wong|Author|AUTHORED
1383|Towards A Mathematical Foundation Of Immunology And Amino Acid Chains|Paper|Quan-Wu Xiao|Author|AUTHORED
1383|Towards A Mathematical Foundation Of Immunology And Amino Acid Chains|Paper|Xin Guo|Author|AUTHORED
1383|Towards A Mathematical Foundation Of Immunology And Amino Acid Chains|Paper|Stephen Smale|Author|AUTHORED
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Chris Roadknight|Author|AUTHORED
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Uwe Aickelin|Author|AUTHORED
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Guoping Qiu|Author|AUTHORED
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|John Scholefield|Author|AUTHORED
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Lindy Durrant|Author|AUTHORED
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Colorectal Cancer|Topic|RELATED_TO
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Immunological Status|Topic|RELATED_TO
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Tumour Classification|Topic|RELATED_TO
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Post-Operative Survival|Topic|RELATED_TO
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Machine Learning|Topic|RELATED_TO
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Anti-Learning|Topic|RELATED_TO
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Dataset|Topic|RELATED_TO
1384|Supervised Learning And Anti-Learning Of Colorectal Cancer Classes And Survival Rates From Cellular Biology Parameters|Paper|Cancer Stage Prediction|Topic|RELATED_TO
1385|A Generation Method Of Immunological Memory In Clonal Selection Algorithm By Using Restricted Boltzmann Machines|Paper|Shin Kamada|Author|AUTHORED
1385|A Generation Method Of Immunological Memory In Clonal Selection Algorithm By Using Restricted Boltzmann Machines|Paper|Takumi Ichimura|Author|AUTHORED
1385|A Generation Method Of Immunological Memory In Clonal Selection Algorithm By Using Restricted Boltzmann Machines|Paper|Image Processing|Topic|RELATED_TO
1385|A Generation Method Of Immunological Memory In Clonal Selection Algorithm By Using Restricted Boltzmann Machines|Paper|Mobile Phone Based Participatory Sensing (Mpps) System|Topic|RELATED_TO
1385|A Generation Method Of Immunological Memory In Clonal Selection Algorithm By Using Restricted Boltzmann Machines|Paper|Clonal Selection Algorithm With Immunological Memory Cell (Csaim)|Topic|RELATED_TO
1385|A Generation Method Of Immunological Memory In Clonal Selection Algorithm By Using Restricted Boltzmann Machines|Paper|Restricted Boltzmann Machines|Topic|RELATED_TO
1385|A Generation Method Of Immunological Memory In Clonal Selection Algorithm By Using Restricted Boltzmann Machines|Paper|Deep Learning|Topic|RELATED_TO
1386|5G Networks|Topic|Network Security Architecture|Topic|RELATED_TO
1386|Immunology|Topic|Immune System|Topic|RELATED_TO
1386|Network Security Architecture|Topic|Security And Availability Balance|Topic|RELATED_TO
1386|Network Security Architecture|Topic|Situation-Awareness|Topic|RELATED_TO
1386|Network Security Architecture|Topic|Community Cooperation|Topic|RELATED_TO
1386|Network Security Architecture|Topic|Defense Capability|Topic|RELATED_TO
1386|Immunology-Inspired Network Security Architecture|Paper|Network Security Architecture|Topic|AUTHORED
1387|A Guideline For The Statistical Analysis Of Compositional Data In Immunology|Paper|Jinkyung Yoo|Author|AUTHORED
1387|A Guideline For The Statistical Analysis Of Compositional Data In Immunology|Paper|Zequn Sun|Author|AUTHORED
1387|A Guideline For The Statistical Analysis Of Compositional Data In Immunology|Paper|Michael Greenacre|Author|AUTHORED
1387|A Guideline For The Statistical Analysis Of Compositional Data In Immunology|Paper|Qin Ma|Author|AUTHORED
1387|A Guideline For The Statistical Analysis Of Compositional Data In Immunology|Paper|Dongjun Chung|Author|AUTHORED
1387|A Guideline For The Statistical Analysis Of Compositional Data In Immunology|Paper|Young Min Kim|Author|AUTHORED
1388|Sensory Cortex Of Alert Rats|Topic|Dimensionality Of Neural Space|Topic|DISCUSSES
1388|Dimensionality Of Neural Space|Topic|Spiking Network Model|Topic|DISCUSSES
1388|Spiking Network Model|Topic|Dimensionality Of Neural Space|Topic|RELATED_TO
1388|Luca Mazzucato|Author|Dimensionality Of Neural Space|Topic|AUTHORED
1388|Alfredo Fontanini|Author|Dimensionality Of Neural Space|Topic|AUTHORED
1388|Giancarlo La Camera|Author|Dimensionality Of Neural Space|Topic|AUTHORED
1389|Patient Monitoring In Intensive Care Units|Topic|Biosensors|Topic|RELATED_TO
1389|It Infrastructures|Topic|Clinical Decision Support Systems|Topic|RELATED_TO
1389|Clinical Decision Support Systems|Topic|Artifacts|Topic|RELATED_TO
1389|Video Recordings|Topic|Object Detection Methods|Topic|RELATED_TO
1389|Blurred Videos|Topic|Temporal Succession Of Video Frames|Topic|RELATED_TO
1389|Temporal Succession Of Video Frames|Topic|Yolov5 Baseline Model|Topic|RELATED_TO
1389|Raphael Emberger|Author|Video Object Detection For Privacy-Preserving Patient Monitoring In Intensive Care|Paper|AUTHORED
1389|Jens Michael Boss|Author|Video Object Detection For Privacy-Preserving Patient Monitoring In Intensive Care|Paper|AUTHORED
1389|Daniel Baumann|Author|Video Object Detection For Privacy-Preserving Patient Monitoring In Intensive Care|Paper|AUTHORED
1389|Marko Seric|Author|Video Object Detection For Privacy-Preserving Patient Monitoring In Intensive Care|Paper|AUTHORED
1389|Shufan Huo|Author|Video Object Detection For Privacy-Preserving Patient Monitoring In Intensive Care|Paper|AUTHORED
1389|Lukas Tuggener|Author|Video Object Detection For Privacy-Preserving Patient Monitoring In Intensive Care|Paper|AUTHORED
1389|Emanuela Keller|Author|Video Object Detection For Privacy-Preserving Patient Monitoring In Intensive Care|Paper|AUTHORED
1389|Thilo Stadelmann|Author|Video Object Detection For Privacy-Preserving Patient Monitoring In Intensive Care|Paper|AUTHORED
1390|Ep-Abc Algorithm|Topic|Approximate Bayesian Computation (Abc)|Topic|RELATED_TO
1390|Ep-Abc Algorithm|Topic|Expectation Propagation|Topic|RELATED_TO
1390|Simon Barthelmé|Author|Ep-Abc Algorithm|Topic|AUTHORED
1390|Nicolas Chopin|Author|Ep-Abc Algorithm|Topic|AUTHORED
1391|Phase Diagram Of Spiking Neural Networks|Paper|Spiking Neural Networks|Topic|DISCUSSES
1391|Phase Diagram Of Spiking Neural Networks|Paper|Parameters|Topic|DISCUSSES
1391|Phase Diagram Of Spiking Neural Networks|Paper|Dynamic Range|Topic|DISCUSSES
1391|Phase Diagram Of Spiking Neural Networks|Paper|Frequency|Topic|DISCUSSES
1391|Phase Diagram Of Spiking Neural Networks|Paper|Synaptic Weights|Topic|DISCUSSES
1391|Phase Diagram Of Spiking Neural Networks|Paper|Connections|Topic|DISCUSSES
1391|Phase Diagram Of Spiking Neural Networks|Paper|Excitatory Neurons|Topic|DISCUSSES
1391|Phase Diagram Of Spiking Neural Networks|Paper|Inhibitory Neurons|Topic|DISCUSSES
1392|Bayesian Multi-Dipole Localization Method|Topic|Magneto- And Electro-Encephalography|Topic|RELATED_TO
1392|Bayesian Multi-Dipole Localization Method|Topic|Dics|Topic|RELATED_TO
1392|Gianvittorio Luria|Author|Bayesian Multi-Dipole Localization Method|Topic|AUTHORED
1392|Dunja Duran|Author|Bayesian Multi-Dipole Localization Method|Topic|AUTHORED
1392|Elisa Visani|Author|Bayesian Multi-Dipole Localization Method|Topic|AUTHORED
1392|Sara Sommariva|Author|Bayesian Multi-Dipole Localization Method|Topic|AUTHORED
1392|Fabio Rotondi|Author|Bayesian Multi-Dipole Localization Method|Topic|AUTHORED
1392|Davide Rossi Sebastiano|Author|Bayesian Multi-Dipole Localization Method|Topic|AUTHORED
1392|Ferruccio Panzica|Author|Bayesian Multi-Dipole Localization Method|Topic|AUTHORED
1392|Michele Piana|Author|Bayesian Multi-Dipole Localization Method|Topic|AUTHORED
1392|Alberto Sorrentino|Author|Bayesian Multi-Dipole Localization Method|Topic|AUTHORED
1393|Factorized Neural Processes For Neural Processes: K-Shot Prediction Of Neural Responses|Paper|Artificial Neural Networks|Topic|DISCUSSES
1393|Factorized Neural Processes For Neural Processes: K-Shot Prediction Of Neural Responses|Paper|Visual Cortex|Topic|DISCUSSES
1393|Factorized Neural Processes For Neural Processes: K-Shot Prediction Of Neural Responses|Paper|Neural Process|Topic|DISCUSSES
1393|Factorized Neural Processes For Neural Processes: K-Shot Prediction Of Neural Responses|Paper|Factorized Neural Process|Topic|DISCUSSES
1394|Interval Timing Production Task|Topic|Trial-And-Error Learning|Topic|RELATED_TO
1394|Reward Sensitive Gaussian Process (Rsgp)|Topic|Interval Timing Production Task|Topic|RELATED_TO
1394|Recurrent Neural Networks|Topic|Reward Sensitive Gaussian Process (Rsgp)|Topic|RELATED_TO
1394|Jing Wang|Author|Neural Network Model For Timing Control With Reinforcement|Paper|AUTHORED
1394|Yousuf El-Jayyousi|Author|Neural Network Model For Timing Control With Reinforcement|Paper|AUTHORED
1394|Ilker Ozden|Author|Neural Network Model For Timing Control With Reinforcement|Paper|AUTHORED
1395|Erdiff|Topic|Extraction And Recovery Of Spatio-Temporal Structure In Latent Dynamics Alignment With Diffusion Models|Paper|RELATED_TO
1395|Yule Wang|Author|Extraction And Recovery Of Spatio-Temporal Structure In Latent Dynamics Alignment With Diffusion Models|Paper|AUTHORED
1395|Zijing Wu|Author|Extraction And Recovery Of Spatio-Temporal Structure In Latent Dynamics Alignment With Diffusion Models|Paper|AUTHORED
1395|Chengrui Li|Author|Extraction And Recovery Of Spatio-Temporal Structure In Latent Dynamics Alignment With Diffusion Models|Paper|AUTHORED
1395|Anqi Wu|Author|Extraction And Recovery Of Spatio-Temporal Structure In Latent Dynamics Alignment With Diffusion Models|Paper|AUTHORED
1396|Worm|Paper|Working Memory|Topic|RELATED_TO
1396|Ankur Sikarwar|Author|Worm|Paper|AUTHORED
1396|Mengmi Zhang|Author|Worm|Paper|AUTHORED
1397|Humans|Topic|Human-Object Interaction (Hoi)|Topic|RELATED_TO
1397|Neuroscience|Topic|Cognitive Science|Topic|RELATED_TO
1397|Graph Attention Networks|Topic|Human-Object Interaction (Hoi)|Topic|RELATED_TO
1397|Persistent-Transient Duality|Topic|Human-Object Interaction (Hoi)|Topic|RELATED_TO
1397|Hung Tran|Author|Persistent-Transient Duality|Topic|AUTHORED
1397|Vuong Le|Author|Persistent-Transient Duality|Topic|AUTHORED
1397|Svetha Venkatesh|Author|Persistent-Transient Duality|Topic|AUTHORED
1397|Truyen Tran|Author|Persistent-Transient Duality|Topic|AUTHORED
1398|Neuroassist|Topic|Eeshan G. Dandamudi|Author|AUTHORED
1398|Neuroassist|Topic|Brain-Computer Interface (Bci) Systems|Topic|RELATED_TO
1398|Neuroassist|Topic|Computational Neuroscience|Topic|RELATED_TO
1398|Neuroassist|Topic|Machine Learning (Ml)|Topic|RELATED_TO
1398|Neuroassist|Topic|Natural Language Processing (Nlp) Bert Model|Topic|RELATED_TO
1398|Neuroassist|Topic|Lstm Networks|Topic|RELATED_TO
1398|Neuroassist|Topic|Spiking Neural Networks (Snns)|Topic|RELATED_TO
1398|Neuroassist|Topic|Deep Q-Networks (Dqn)|Topic|RELATED_TO
1398|Neuroassist|Topic|Common Spatial Pattern (Csp)|Topic|RELATED_TO
1398|Neuroassist|Topic|Gigascience|Topic|RELATED_TO
1398|Neuroassist|Topic|Bci-Competition-Iv-2A Datasets|Topic|RELATED_TO
1398|Neuroassist|Topic|Eeg Data|Topic|RELATED_TO
1398|Neuroassist|Topic|Motor Imagery (Mi)|Topic|RELATED_TO
1398|Neuroassist|Topic|Eeg Temporal Characteristics|Topic|RELATED_TO
1398|Neuroassist|Topic|Classification Accuracy Of 99.17%|Topic|RELATED_TO
1398|Neuroassist|Topic|Assistive Technology|Topic|RELATED_TO
1399|Image-Guided Robotic System For Tms|Paper|Transcranial Magnetic Stimulation (Tms)|Topic|RELATED_TO
1400|Hiv Cure Research|Topic|Latency-Reversing Agents|Topic|RELATED_TO
1400|Latency-Reversing Agents|Topic|Stochastic Model|Topic|RELATED_TO
1400|Stochastic Model|Topic|Alison L. Hill|Author|AUTHORED
1400|Stochastic Model|Topic|Daniel I. S. Rosenbloom|Author|AUTHORED
1400|Stochastic Model|Topic|Feng Fu|Author|AUTHORED
1400|Stochastic Model|Topic|Martin A. Nowak|Author|AUTHORED
1400|Stochastic Model|Topic|Robert F. Siliciano|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Clinical Decision Support Systems|Topic|DISCUSSES
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Treatment Effectiveness Measure|Topic|DISCUSSES
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Secure Multiparty Computation|Topic|DISCUSSES
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Thomas Attema|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Emiliano Mancini|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Gabriele Spini|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Mark Abspoel|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Jan De Gier|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Serge Fehr|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Thijs Veugen|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Maran Van Heesch|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Daniël Worm|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Andrea De Luca|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Ronald Cramer|Author|AUTHORED
1401|A New Approach To Privacy-Preserving Clinical Decision Support Systems|Paper|Peter M. A. Sloot|Author|AUTHORED
1402|Tumor Segmentation In Oncological Pet|Topic|Bayesian Approach To Tissue-Fraction Estimation|Topic|RELATED_TO
1402|Bayesian Approach To Tissue-Fraction Estimation|Topic|Ziping Liu|Author|AUTHORED
1402|Bayesian Approach To Tissue-Fraction Estimation|Topic|Joyce C. Mhlanga|Author|AUTHORED
1402|Bayesian Approach To Tissue-Fraction Estimation|Topic|Richard Laforest|Author|AUTHORED
1402|Bayesian Approach To Tissue-Fraction Estimation|Topic|Paul-Robert Derenoncourt|Author|AUTHORED
1402|Bayesian Approach To Tissue-Fraction Estimation|Topic|Barry A. Siegel|Author|AUTHORED
1402|Bayesian Approach To Tissue-Fraction Estimation|Topic|Abhinav K. Jha|Author|AUTHORED
1402|Lung Cancer|Topic|Bayesian Approach To Tissue-Fraction Estimation|Topic|RELATED_TO
1402|Non-Small Cell Lung Cancer|Topic|Acrin 6668/Rtog 0235|Topic|RELATED_TO
1402|Dice Similarity Coefficient|Topic|Bayesian Approach To Tissue-Fraction Estimation|Topic|RELATED_TO
1403|Msbase Registry|Topic|Multiple Sclerosis|Topic|RELATED_TO
1403|Edward De Brouwer|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Thijs Becker|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Yves Moreau|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Eva Kubala Havrdova|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Maria Trojano|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Sara Eichau|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Serkan Ozakbas|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Marco Onofrj|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Pierre Grammond|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Jens Kuhle|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Ludwig Kappos|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Patrizia Sola|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Elisabetta Cartechini|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Jeannette Lechner-Scott|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Raed Alroughani|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Oliver Gerlach|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Tomas Kalincik|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Franco Granella|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Francois Grandmaison|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Roberto Bergamaschi|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Maria Jose Sa|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Bart Van Wijmeersch|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Aysun Soysal|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Jose Luis Sanchez-Menoyo|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Claudio Solaro|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Cavit Boz|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Gerardo Iuliano|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Katherine Buzzard|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Eduardo Aguera-Morales|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Murat Terzi|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Tamara Castillo Trivio|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Daniele Spitaleri|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Vincent Van Pesch|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Vahid Shaygannej|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Fraser Moore|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Celia Oreja Guevara|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Davide Maimone|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Riadh Gouider|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Tunde Csepany|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Cristina Ramo-Tello|Author|Multiple Sclerosis|Topic|AUTHORED
1403|Liesbet Peeters|Author|Multiple Sclerosis|Topic|AUTHORED
1404|Joint Modelling Of Longitudinal And Survival Data|Topic|Prostate Cancer|Topic|RELATED_TO
1404|Prostate Cancer|Topic|Prostate-Specific Antigen (Psa)|Topic|RELATED_TO
1404|Prostate Cancer|Topic|Relapse|Topic|RELATED_TO
1404|Multi-State Model|Topic|Linear Mixed Sub-Model|Topic|RELATED_TO
1404|Multi-State Model|Topic|Proportional Hazards|Topic|RELATED_TO
1404|Maximum Likelihood Framework|Topic|Em Algorithm|Topic|RELATED_TO
1404|Maximum Likelihood Framework|Topic|Quasi-Newton Algorithm|Topic|RELATED_TO
1404|R|Topic|Mstate Package|Topic|RELATED_TO
1404|R|Topic|Jm Package|Topic|RELATED_TO
1404|Loïc Ferrer|Author|Joint Modelling Of Longitudinal And Survival Data|Topic|AUTHORED
1404|Virginie Rondeau|Author|Joint Modelling Of Longitudinal And Survival Data|Topic|AUTHORED
1404|James J. Dignam|Author|Joint Modelling Of Longitudinal And Survival Data|Topic|AUTHORED
1404|Tom Pickles|Author|Joint Modelling Of Longitudinal And Survival Data|Topic|AUTHORED
1404|Hélène Jacqmin-Gadda|Author|Joint Modelling Of Longitudinal And Survival Data|Topic|AUTHORED
1404|Cécile Proust-Lima|Author|Joint Modelling Of Longitudinal And Survival Data|Topic|AUTHORED
1405|Self-Supervised Learning-Based Approach To Clustering Multivariate Time-Series Data With Missing Values (Slac-Time)|Paper|Traumatic Brain Injury (Tbi)|Topic|DISCUSSES
1405|Self-Supervised Learning-Based Approach To Clustering Multivariate Time-Series Data With Missing Values (Slac-Time)|Paper|Transforming Research And Clinical Knowledge In Traumatic Brain Injury (Track-Tbi) Study|Topic|RELATED_TO
1406|Artificial Intelligence-Based Methods|Topic|Nuclear Medicine|Topic|RELATED_TO
1406|Deep-Learning (Dl)-Based Approaches|Topic|Denoising Images|Topic|RELATED_TO
1406|Denoising Images|Topic|Fidelity-Based Figures Of Merit (Foms)|Topic|RELATED_TO
1406|Fidelity-Based Figures Of Merit (Foms)|Topic|Rmse|Topic|RELATED_TO
1406|Fidelity-Based Figures Of Merit (Foms)|Topic|Ssim|Topic|RELATED_TO
1406|Clinical Tasks|Topic|Fidelity-Based Figures Of Merit (Foms)|Topic|RELATED_TO
1406|Virtual Clinical Trials (Vcts)|Topic|Deep-Learning (Dl)-Based Approaches|Topic|RELATED_TO
1406|Myocardial Perfusion Spect (Mps) Images|Topic|Deep-Learning (Dl)-Based Approaches|Topic|RELATED_TO
1406|Zitong Yu|Author|Need For Objective Task-Based Evaluation Of Deep Learning-Based Denoising Methods: A Study In The Context Of Myocardial Perfusion Spect|Paper|AUTHORED
1406|Md Ashequr Rahman|Author|Need For Objective Task-Based Evaluation Of Deep Learning-Based Denoising Methods: A Study In The Context Of Myocardial Perfusion Spect|Paper|AUTHORED
1406|Richard Laforest|Author|Need For Objective Task-Based Evaluation Of Deep Learning-Based Denoising Methods: A Study In The Context Of Myocardial Perfusion Spect|Paper|AUTHORED
1406|Thomas H. Schindler|Author|Need For Objective Task-Based Evaluation Of Deep Learning-Based Denoising Methods: A Study In The Context Of Myocardial Perfusion Spect|Paper|AUTHORED
1406|Robert J. Gropler|Author|Need For Objective Task-Based Evaluation Of Deep Learning-Based Denoising Methods: A Study In The Context Of Myocardial Perfusion Spect|Paper|AUTHORED
1406|Richard L. Wahl|Author|Need For Objective Task-Based Evaluation Of Deep Learning-Based Denoising Methods: A Study In The Context Of Myocardial Perfusion Spect|Paper|AUTHORED
1406|Barry A. Siegel|Author|Need For Objective Task-Based Evaluation Of Deep Learning-Based Denoising Methods: A Study In The Context Of Myocardial Perfusion Spect|Paper|AUTHORED
1406|Abhinav K. Jha|Author|Need For Objective Task-Based Evaluation Of Deep Learning-Based Denoising Methods: A Study In The Context Of Myocardial Perfusion Spect|Paper|AUTHORED
1407|Circulating Tumour Dna (Ctdna) Detection Of Molecular Residual Disease (Mrd)|Topic|Patient Outcomes|Topic|RELATED_TO
1407|Circulating Tumour Dna (Ctdna) Detection Of Molecular Residual Disease (Mrd)|Topic|Tumor Volume|Topic|RELATED_TO
1407|Mrd Assays|Topic|0.01% Tumour Fraction|Topic|RELATED_TO
1407|Archer|Author|Mrd Assays|Topic|AUTHORED
1407|Signatera|Author|Mrd Assays|Topic|AUTHORED
1407|Astrazeneca Translational Medicine|Author|Mrd Assays|Topic|AUTHORED
1407|Dan Stetson|Author|Mrd Assays|Topic|AUTHORED
1407|Paul Labrousse|Author|Mrd Assays|Topic|AUTHORED
1407|Hugh Russell|Author|Mrd Assays|Topic|AUTHORED
1407|David Shera|Author|Mrd Assays|Topic|AUTHORED
1407|Chris Abbosh|Author|Mrd Assays|Topic|AUTHORED
1407|Brian Dougherty|Author|Mrd Assays|Topic|AUTHORED
1407|J. Carl Barrett|Author|Mrd Assays|Topic|AUTHORED
1407|Darren Hodgson|Author|Mrd Assays|Topic|AUTHORED
1407|James Hadfield|Author|Mrd Assays|Topic|AUTHORED
1408|High-Throughput Ai-Based System|Topic|Virchow2|Topic|RELATED_TO
1408|High-Throughput Ai-Based System|Topic|H&E Whole Slide Images|Topic|RELATED_TO
1408|High-Throughput Ai-Based System|Topic|Msk-Impact|Topic|RELATED_TO
1408|High-Throughput Ai-Based System|Topic|Biomarkers|Topic|RELATED_TO
1408|High-Throughput Ai-Based System|Topic|Cancer Types|Topic|RELATED_TO
1408|High-Throughput Ai-Based System|Topic|Ai In Cancer Screening|Topic|RELATED_TO
1408|Authors|Author|High-Throughput Ai-Based System|Topic|AUTHORED
1409|Influence Of Medical Foreign Bodies On Dark-Field Chest Radiographs: First Experiences|Paper|Chronic Obstructive Pulmonary Disease|Topic|RELATED_TO
1409|Influence Of Medical Foreign Bodies On Dark-Field Chest Radiographs: First Experiences|Paper|Covid-19|Topic|RELATED_TO
1409|Influence Of Medical Foreign Bodies On Dark-Field Chest Radiographs: First Experiences|Paper|Dark-Field Radiography|Topic|RELATED_TO
1409|Influence Of Medical Foreign Bodies On Dark-Field Chest Radiographs: First Experiences|Paper|Conventional Radiography|Topic|RELATED_TO
1410|O1-Preview|Topic|Peter G. Brodeur|Author|AUTHORED
1410|O1-Preview|Topic|Thomas A. Buckley|Author|AUTHORED
1410|O1-Preview|Topic|Zahir Kanjee|Author|AUTHORED
1410|O1-Preview|Topic|Ethan Goh|Author|AUTHORED
1410|O1-Preview|Topic|Evelyn Bin Ling|Author|AUTHORED
1410|O1-Preview|Topic|Priyank Jain|Author|AUTHORED
1410|O1-Preview|Topic|Stephanie Cabral|Author|AUTHORED
1410|O1-Preview|Topic|Raja-Elie Abdulnour|Author|AUTHORED
1410|O1-Preview|Topic|Adrian Haimovich|Author|AUTHORED
1410|O1-Preview|Topic|Jason A. Freed|Author|AUTHORED
1410|O1-Preview|Topic|Andrew Olson|Author|AUTHORED
1410|O1-Preview|Topic|Daniel J. Morgan|Author|AUTHORED
1410|O1-Preview|Topic|Jason Hom|Author|AUTHORED
1410|O1-Preview|Topic|Robert Gallo|Author|AUTHORED
1410|O1-Preview|Topic|Eric Horvitz|Author|AUTHORED
1410|O1-Preview|Topic|Jonathan Chen|Author|AUTHORED
1410|O1-Preview|Topic|Arjun K. Manrai|Author|AUTHORED
1410|O1-Preview|Topic|Adam Rodman|Author|AUTHORED
1411|Deep Learning|Topic|Least-Squares Fitting|Topic|RELATED_TO
1411|Deep Learning|Topic|Quantitative Mri|Topic|RELATED_TO
1411|Neural Controlled Differential Equations|Topic|Quantitative Mri|Topic|RELATED_TO
1411|Neural Controlled Differential Equations|Topic|Deep Learning|Topic|RELATED_TO
1411|Daan Kuppens|Author|Acquisition-Independent Deep Learning For Quantitative Mri Parameter Estimation Using Neural Controlled Differential Equations|Paper|AUTHORED
1411|Sebastiano Barbieri|Author|Acquisition-Independent Deep Learning For Quantitative Mri Parameter Estimation Using Neural Controlled Differential Equations|Paper|AUTHORED
1411|Daisy Van Den Berg|Author|Acquisition-Independent Deep Learning For Quantitative Mri Parameter Estimation Using Neural Controlled Differential Equations|Paper|AUTHORED
1411|Pepijn Schouten|Author|Acquisition-Independent Deep Learning For Quantitative Mri Parameter Estimation Using Neural Controlled Differential Equations|Paper|AUTHORED
1411|Harriet C. Thoeny|Author|Acquisition-Independent Deep Learning For Quantitative Mri Parameter Estimation Using Neural Controlled Differential Equations|Paper|AUTHORED
1411|Myrte Wennen|Author|Acquisition-Independent Deep Learning For Quantitative Mri Parameter Estimation Using Neural Controlled Differential Equations|Paper|AUTHORED
1411|Oliver J. Gurney-Champion|Author|Acquisition-Independent Deep Learning For Quantitative Mri Parameter Estimation Using Neural Controlled Differential Equations|Paper|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Pediatric Tumors Of The Central Nervous System|Topic|RELATED_TO
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|High-Grade Gliomas|Topic|RELATED_TO
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Anahita Fathi Kazerooni|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Nastaran Khalili|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Xinyang Liu|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Deep Gandhi|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Zhifan Jiang|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Syed Muhammed Anwar|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Jake Albrecht|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Maruf Adewole|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Udunna Anazodo|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Hannah Anderson|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Ujjwal Baid|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Timothy Bergquist|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Austin J. Borja|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Evan Calabrese|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Verena Chung|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Gian-Marco Conte|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Farouk Dako|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|James Eddy|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Ivan Ezhov|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Ariana Familiar|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Keyvan Farahani|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Andrea Franson|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Anurag Gottipati|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Shuvanjan Haldar|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Juan Eugenio Iglesias|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Anastasia Janas|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Elaine Johansen|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Blaise V Jones|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Neda Khalili|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Florian Kofler|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Dominic Labella|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Hollie Anne Lai|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Koen Van Leemput|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Hongwei Bran Li|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Nazanin Maleki|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Aaron S Mcallister|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Zeke Meier|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Bjoern Menze|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Ahmed W Moawad|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Khanak K Nandolia|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Julija Pavaine|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Marie Piraud|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Tina Poussaint|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Sanjay P Prabhu|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Zachary Reitman|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Jeffrey D Rudie|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Mariana Sanchez-Montano|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Ibraheem Salman Shaikh|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Nakul Sheth|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Wenxin Tu|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Chunhao Wang|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Jeffrey B Ware|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Benedikt Wiestler|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Anna Zapaishchykova|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Miriam Bornhorst|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Michelle Deutsch|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Maryam Fouladi|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Margot Lazow|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Leonie Mikael|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Trent Hummel|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Benjamin Kann|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Peter De Blank|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Lindsey Hoffman|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Mariam Aboian|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Ali Nabavizadeh|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Roger Packer|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Spyridon Bakas|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Adam Resnick|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Brian Rood|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Arastoo Vossough|Author|AUTHORED
1412|Cbtn-Connect-Dipgr-Asnr-Miccai Brats-Peds Challenge|Topic|Marius George Linguraru|Author|AUTHORED
1413|Brats-Peds 2023|Paper|Pediatric Central Nervous System Tumors|Topic|RELATED_TO
1413|Brats-Peds 2023|Paper|High-Grade Glioma|Topic|RELATED_TO
1413|Brats-Peds 2023|Paper|Pediatric Brain Tumors|Topic|RELATED_TO
1413|Brats-Peds 2023|Paper|Ai Approaches For Pediatric Tumor Analysis|Topic|RELATED_TO
1413|Brats-Peds 2023|Paper|Volumetric Segmentation Algorithms|Topic|RELATED_TO
1413|Brats-Peds 2023|Paper|Magnetic Resonance Imaging|Topic|RELATED_TO
1413|Brats-Peds 2023|Paper|Clinical Trials|Topic|RELATED_TO
1413|Brats-Peds 2023|Paper|Neuro-Oncologists|Topic|RELATED_TO
1413|Brats-Peds 2023|Paper|Neuroradiologists|Topic|RELATED_TO
1414|Multi-Levels Nonlinear Mixed Effects Models (Mnlmems)|Topic|Saem-Mcmc Algorithm|Topic|RELATED_TO
1414|Saem-Mcmc Algorithm|Topic|Pharmacokinetic Cross-Over Simulated Trials|Topic|RELATED_TO
1414|Tenofovir|Topic|Atazanavir|Topic|RELATED_TO
1414|Xavière Panhard|Author|Multi-Levels Nonlinear Mixed Effects Models (Mnlmems)|Topic|AUTHORED
1414|Adeline Samson|Author|Multi-Levels Nonlinear Mixed Effects Models (Mnlmems)|Topic|AUTHORED
1415|Clinical Trials|Topic|Binary Response|Topic|RELATED_TO
1415|Neyman Allocation|Topic|Adaptive Design|Topic|RELATED_TO
1415|Pitman Criterion|Topic|Balanced Allocation|Topic|RELATED_TO
1415|Bahadur Approach|Topic|Balanced Allocation|Topic|RELATED_TO
1415|David Azriel|Author|Clinical Trials|Topic|AUTHORED
1415|Micha Mandel|Author|Clinical Trials|Topic|AUTHORED
1415|Yosef Rinott|Author|Clinical Trials|Topic|AUTHORED
1416|Local Dynamic Stability|Topic|Gait|Topic|RELATED_TO
1416|Gait|Topic|Fall Risk|Topic|RELATED_TO
1416|Barefoot Walking|Topic|Shod Walking|Topic|RELATED_TO
1416|Philippe Terrier|Author|Healthy Individuals|Topic|AUTHORED
1416|Fabienne Reynard|Author|Healthy Individuals|Topic|AUTHORED
1416|Healthy Individuals|Topic|Intrasession Repeatability|Topic|RELATED_TO
1416|70 M Indoor Corridor|Topic|3D-Accelerometer|Topic|RELATED_TO
1416|3D-Accelerometer|Topic|Finite-Time Maximal Lyapunov Exponent Method|Topic|RELATED_TO
1416|Intrasession Repeatability|Topic|Intraclass Correlation Coefficient|Topic|RELATED_TO
1416|Average Standardized Effect Size|Topic|High In Sw|Topic|RELATED_TO
1416|Average Standardized Effect Size|Topic|Slightly Higher In Bw|Topic|RELATED_TO
1417|Haart|Topic|Cd4_Counts|Topic|RELATED_TO
1417|Cd4_Counts|Topic|Marginal_Structural_Models|Topic|RELATED_TO
1417|Marginal_Structural_Models|Topic|Dynamical_Models|Topic|RELATED_TO
1417|Dynamical_Models|Topic|Lim|Topic|RELATED_TO
1417|Lim|Topic|Ode_Nlme|Topic|RELATED_TO
1417|Anrs_Co3_Aquitaine_Cohort|Topic|Haart|Topic|RELATED_TO
1417|Swiss_Hiv_Cohort_Study|Topic|Haart|Topic|RELATED_TO
1417|M_Prague|Author|Haart|Topic|AUTHORED
1417|D_Commenges|Author|Haart|Topic|AUTHORED
1417|J_M_Gran|Author|Haart|Topic|AUTHORED
1417|B_Ledergerber|Author|Haart|Topic|AUTHORED
1417|J_Young|Author|Haart|Topic|AUTHORED
1417|H_Furrer|Author|Haart|Topic|AUTHORED
1417|R_Thiébaut|Author|Haart|Topic|AUTHORED
1418|Mycobacterium Bovis Bacille Calmette-Guérin (Bcg)|Topic|Tuberculosis (Tb)|Topic|RELATED_TO
1418|Masking Mechanism|Topic|Tuberculosis (Tb)|Topic|RELATED_TO
1418|Blocking Mechanism|Topic|Tuberculosis (Tb)|Topic|RELATED_TO
1418|Bcg-Revac Clinical Trials|Topic|Mycobacterium Bovis Bacille Calmette-Guérin (Bcg)|Topic|RELATED_TO
1418|Sergio Arregui|Author|Bcg-Revac Clinical Trials|Topic|AUTHORED
1418|Joaquín Sanz|Author|Bcg-Revac Clinical Trials|Topic|AUTHORED
1418|Dessislava Marinova|Author|Bcg-Revac Clinical Trials|Topic|AUTHORED
1418|Carlos Martín|Author|Bcg-Revac Clinical Trials|Topic|AUTHORED
1418|Yamir Moreno|Author|Bcg-Revac Clinical Trials|Topic|AUTHORED
1419|Assessing The Treatment Effect Heterogeneity With A Latent Variable|Paper|Yunjian Yin|Author|AUTHORED
1419|Assessing The Treatment Effect Heterogeneity With A Latent Variable|Paper|Lan Liu|Author|AUTHORED
1419|Assessing The Treatment Effect Heterogeneity With A Latent Variable|Paper|Zhi Geng|Author|AUTHORED
1420|Electroencephalography (Eeg)|Topic|Brain Connectivity|Topic|RELATED_TO
1420|Parafac2|Topic|Brain Connectivity|Topic|RELATED_TO
1420|Loukianos Spyrou|Author|Complex Tensor Factorisation|Topic|AUTHORED
1420|Mario Parra|Author|Complex Tensor Factorisation|Topic|AUTHORED
1420|Javier Escudero|Author|Complex Tensor Factorisation|Topic|AUTHORED
1420|Mild Cognitive Impairment|Topic|Brain Connectivity|Topic|RELATED_TO
1420|Alzheimer'S Disease|Topic|Brain Connectivity|Topic|RELATED_TO
1420|Traditional Tensor Analysis|Topic|Brain Connectivity|Topic|RELATED_TO
1420|Complex Tensor Factorisation|Topic|Brain Connectivity|Topic|RELATED_TO
1420|Eeg Dataset|Topic|Brain Connectivity|Topic|RELATED_TO
1421|Non-Parametric Accelerated Failure Time Model|Topic|Heterogeneous Treatment Effects (Hte)|Topic|DISCUSSES
1421|Non-Parametric Accelerated Failure Time Model|Topic|Bayesian Additive Regression Trees|Topic|RELATED_TO
1421|Non-Parametric Accelerated Failure Time Model|Topic|Mean-Constrained Dirichlet Process Mixture Model|Topic|RELATED_TO
1421|Non-Parametric Accelerated Failure Time Model|Topic|Individual Treatment Effect|Topic|DISCUSSES
1421|Two Large Clinical Trials|Topic|Congestive Heart Failure|Topic|RELATED_TO
1421|Two Large Clinical Trials|Topic|Angiotensin-Converting Enzyme Inhibitor|Topic|RELATED_TO
1421|Nicholas C. Henderson|Author|Individual Treatment Effect|Topic|AUTHORED
1421|Thomas A. Louis|Author|Individual Treatment Effect|Topic|AUTHORED
1421|Gary L. Rosner|Author|Individual Treatment Effect|Topic|AUTHORED
1421|Ravi Varadhan|Author|Individual Treatment Effect|Topic|AUTHORED
1422|Heart Rate Monitoring During Different Lung Volume Phases Using Seismocardiography|Paper|Seismocardiography|Topic|DISCUSSES
1422|Heart Rate Monitoring During Different Lung Volume Phases Using Seismocardiography|Paper|Electrocardiogram|Topic|DISCUSSES
1422|Heart Rate Monitoring During Different Lung Volume Phases Using Seismocardiography|Paper|Heart Rate|Topic|DISCUSSES
1422|Heart Rate Monitoring During Different Lung Volume Phases Using Seismocardiography|Paper|Lung Volume|Topic|DISCUSSES
1422|Heart Rate Monitoring During Different Lung Volume Phases Using Seismocardiography|Paper|Healthy Subjects|Topic|DISCUSSES
1422|Heart Rate Monitoring During Different Lung Volume Phases Using Seismocardiography|Paper|Postural Positions|Topic|DISCUSSES
1423|Treating Children With Autism Spectrum Disorders (Asd) With Behavioral Interventions|Topic|Pivotal Response Treatment (Prt)|Topic|RELATED_TO
1423|Nicha C. Dvornek|Author|Prediction Of Autism Treatment Response From Baseline Fmri Using Random Forests And Tree Bagging|Paper|AUTHORED
1423|Daniel Yang|Author|Prediction Of Autism Treatment Response From Baseline Fmri Using Random Forests And Tree Bagging|Paper|AUTHORED
1423|Archana Venkataraman|Author|Prediction Of Autism Treatment Response From Baseline Fmri Using Random Forests And Tree Bagging|Paper|AUTHORED
1423|Pamela Ventola|Author|Prediction Of Autism Treatment Response From Baseline Fmri Using Random Forests And Tree Bagging|Paper|AUTHORED
1423|Lawrence H. Staib|Author|Prediction Of Autism Treatment Response From Baseline Fmri Using Random Forests And Tree Bagging|Paper|AUTHORED
1423|Kevin A. Pelphrey|Author|Prediction Of Autism Treatment Response From Baseline Fmri Using Random Forests And Tree Bagging|Paper|AUTHORED
1423|James S. Duncan|Author|Prediction Of Autism Treatment Response From Baseline Fmri Using Random Forests And Tree Bagging|Paper|AUTHORED
1423|Random Forest And Tree Bagging Strategy|Topic|Baseline Task-Based Fmri|Topic|RELATED_TO
1423|19 Asd Children|Topic|16 Week Trial Of Prt|Topic|RELATED_TO
1423|16 Week Trial Of Prt|Topic|Leave-One-Out Cross-Validation Framework|Topic|RELATED_TO
1423|Leave-One-Out Cross-Validation Framework|Topic|Highest Prediction Accuracy|Topic|RELATED_TO
1424|Hvtn 505 Trial|Topic|Hiv Infection|Topic|DISCUSSES
1424|Hvtn 505 Trial|Topic|Vaccine|Topic|DISCUSSES
1424|Vaccine|Topic|Immune Response Markers|Topic|RELATED_TO
1424|Immune Response Markers|Topic|Qualitative Interaction|Topic|RELATED_TO
1424|Qualitative Interaction|Topic|Psem Methods|Topic|RELATED_TO
1424|Psem Methods|Topic|Sace Literature|Topic|RELATED_TO
1424|Sace Literature|Topic|Binary Intermediate Response Variable|Topic|RELATED_TO
1424|Peter B. Gilbert|Author|Hvtn 505 Trial|Topic|AUTHORED
1424|Bryan S. Blette|Author|Hvtn 505 Trial|Topic|AUTHORED
1424|Bryan E. Shepherd|Author|Hvtn 505 Trial|Topic|AUTHORED
1424|Michael G. Hudgens|Author|Hvtn 505 Trial|Topic|AUTHORED
1425|Composite Endpoints|Topic|Clinical Trials|Topic|RELATED_TO
1425|Clinical Trials|Topic|Chronic Conditions|Topic|RELATED_TO
1425|Systemic Lupus Erythematosus (Sle)|Topic|Composite Endpoints|Topic|RELATED_TO
1425|Latent Variable Model|Topic|Systemic Lupus Erythematosus (Sle)|Topic|RELATED_TO
1425|Phase Iib Muse Trial|Topic|Systemic Lupus Erythematosus (Sle)|Topic|RELATED_TO
1425|Martina Mcmenamin|Author|Phase Iib Muse Trial|Topic|AUTHORED
1425|Jessica K. Barrett|Author|Phase Iib Muse Trial|Topic|AUTHORED
1425|Anna Berglind|Author|Phase Iib Muse Trial|Topic|AUTHORED
1425|James M. S. Wason|Author|Phase Iib Muse Trial|Topic|AUTHORED
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Clinical Trials|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Observational Studies|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Multi-State Models|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Nonparametric Estimation|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Two-Sample Testing|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Population-Averaged Transition Probabilities|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|State Occupation Probabilities|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Right-Censored Observations|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Left-Truncated Observations|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Clustered Observations|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Markov Processes|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Non-Markov Processes|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Empirical Process Theory|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Simultaneous Confidence Bands|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Nonparametric Cluster Bootstrap|Topic|DISCUSSES
1426|Nonparametric Analysis Of Nonhomogeneous Multi-State Processes Based On Clustered Observations|Paper|Multicenter Randomized Controlled Trial|Topic|DISCUSSES
1427|Estimation And Validation Of Ratio-Based Conditional Average Treatment Effects Using Observational Data|Paper|Treatment-Covariate Interactions|Topic|DISCUSSES
1427|Estimation And Validation Of Ratio-Based Conditional Average Treatment Effects Using Observational Data|Paper|Precision Medicine|Topic|DISCUSSES
1427|Estimation And Validation Of Ratio-Based Conditional Average Treatment Effects Using Observational Data|Paper|Multiple Sclerosis|Topic|DISCUSSES
1427|Estimation And Validation Of Ratio-Based Conditional Average Treatment Effects Using Observational Data|Paper|Dimethyl Fumarate|Topic|DISCUSSES
1427|Estimation And Validation Of Ratio-Based Conditional Average Treatment Effects Using Observational Data|Paper|Teriflunomide|Topic|DISCUSSES
1428|Lung Lesion Response Prediction|Topic|Non-Small Cell Lung Cancer|Topic|RELATED_TO
1428|Lung Lesion Response Prediction|Topic|Response Evaluation Criteria In Solid Tumors|Topic|RELATED_TO
1428|Lung Lesion Response Prediction|Topic|Antong Chen|Author|AUTHORED
1428|Lung Lesion Response Prediction|Topic|Jennifer Saouaf|Author|AUTHORED
1428|Lung Lesion Response Prediction|Topic|Bo Zhou|Author|AUTHORED
1428|Lung Lesion Response Prediction|Topic|Randolph Crawford|Author|AUTHORED
1428|Lung Lesion Response Prediction|Topic|Jianda Yuan|Author|AUTHORED
1428|Lung Lesion Response Prediction|Topic|Junshui Ma|Author|AUTHORED
1428|Lung Lesion Response Prediction|Topic|Richard Baumgartner|Author|AUTHORED
1428|Lung Lesion Response Prediction|Topic|Shubing Wang|Author|AUTHORED
1428|Lung Lesion Response Prediction|Topic|Gregory Goldmacher|Author|AUTHORED
1429|Do-Search|Topic|Epidemiological Evidence|Topic|RELATED_TO
1429|Do-Search|Topic|Salt-Adding Behavior|Topic|RELATED_TO
1429|Juha Karvanen|Author|Do-Search|Topic|AUTHORED
1429|Santtu Tikka|Author|Do-Search|Topic|AUTHORED
1429|Antti Hyttinen|Author|Do-Search|Topic|AUTHORED
1429|Nhanes 2013--2016|Topic|Salt-Adding Behavior|Topic|RELATED_TO
1430|Bayesian Sample Size Determination Using Commensurate Priors To Leverage Pre-Experimental Data|Paper|Haiyan Zheng|Author|AUTHORED
1430|Bayesian Sample Size Determination Using Commensurate Priors To Leverage Pre-Experimental Data|Paper|Thomas Jaki|Author|AUTHORED
1430|Bayesian Sample Size Determination Using Commensurate Priors To Leverage Pre-Experimental Data|Paper|James M. S. Wason|Author|AUTHORED
1431|A Comparison Of Model-Free Phase I Dose Escalation Designs For Dual-Agent Combination Therapies|Paper|Helen Yvette Barnett|Author|AUTHORED
1431|A Comparison Of Model-Free Phase I Dose Escalation Designs For Dual-Agent Combination Therapies|Paper|Matthew George|Author|AUTHORED
1431|A Comparison Of Model-Free Phase I Dose Escalation Designs For Dual-Agent Combination Therapies|Paper|Donia Skanji|Author|AUTHORED
1431|A Comparison Of Model-Free Phase I Dose Escalation Designs For Dual-Agent Combination Therapies|Paper|Gaelle Saint-Hilary|Author|AUTHORED
1431|A Comparison Of Model-Free Phase I Dose Escalation Designs For Dual-Agent Combination Therapies|Paper|Thomas Jaki|Author|AUTHORED
1431|A Comparison Of Model-Free Phase I Dose Escalation Designs For Dual-Agent Combination Therapies|Paper|Pavel Mozgunov|Author|AUTHORED
1432|Pediatric Patients|Topic|Medicines|Topic|RELATED_TO
1432|Medicines|Topic|Safety And Efficacy|Topic|RELATED_TO
1432|Pediatric Clinical Development Plan|Topic|Safety Database|Topic|RELATED_TO
1432|Safety Database|Topic|Benefit-Risk Assessment|Topic|RELATED_TO
1432|Extrapolation From Adults|Topic|Safety Assessments|Topic|RELATED_TO
1432|Safety Assessments|Topic|Adverse Events (Aes)|Topic|RELATED_TO
1432|Bayesian Approaches|Topic|Safety Assessments|Topic|RELATED_TO
1432|Margaret Gamalo|Author|Extent Of Safety Database In Pediatric Drug Development: Types Of Assessment, Analytical Precision, And Pathway For Extrapolation Through On-Target Effects|Paper|AUTHORED
1432|Yihua Zhao|Author|Extent Of Safety Database In Pediatric Drug Development: Types Of Assessment, Analytical Precision, And Pathway For Extrapolation Through On-Target Effects|Paper|AUTHORED
1432|Aijun Gao|Author|Extent Of Safety Database In Pediatric Drug Development: Types Of Assessment, Analytical Precision, And Pathway For Extrapolation Through On-Target Effects|Paper|AUTHORED
1432|Jingjing Ye|Author|Extent Of Safety Database In Pediatric Drug Development: Types Of Assessment, Analytical Precision, And Pathway For Extrapolation Through On-Target Effects|Paper|AUTHORED
1432|Ralph Demasi|Author|Extent Of Safety Database In Pediatric Drug Development: Types Of Assessment, Analytical Precision, And Pathway For Extrapolation Through On-Target Effects|Paper|AUTHORED
1432|Eiji Eshida|Author|Extent Of Safety Database In Pediatric Drug Development: Types Of Assessment, Analytical Precision, And Pathway For Extrapolation Through On-Target Effects|Paper|AUTHORED
1432|Yj Choi|Author|Extent Of Safety Database In Pediatric Drug Development: Types Of Assessment, Analytical Precision, And Pathway For Extrapolation Through On-Target Effects|Paper|AUTHORED
1432|Robert Nelson|Author|Extent Of Safety Database In Pediatric Drug Development: Types Of Assessment, Analytical Precision, And Pathway For Extrapolation Through On-Target Effects|Paper|AUTHORED
1433|Bayesian Semi-Parametric Model|Topic|Pediatric Acute Myeloid Leukemia (Aml)|Topic|RELATED_TO
1433|Bayesian Semi-Parametric Model|Topic|Phase Iii Aaml1031 Clinical Trial|Topic|RELATED_TO
1433|Bayesian Semi-Parametric Model|Topic|Anthracyclines (Act)|Topic|RELATED_TO
1433|Bayesian Semi-Parametric Model|Topic|Survival Probability|Topic|RELATED_TO
1433|Bayesian Semi-Parametric Model|Topic|Gamma Process Priors|Topic|RELATED_TO
1433|Bayesian Semi-Parametric Model|Topic|G-Computation Procedure|Topic|RELATED_TO
1434|Estimating Marginal Treatment Effect In Cluster Randomized Trials With Multi-Level Missing Outcomes|Paper|Chia-Rui Chang|Author|AUTHORED
1434|Estimating Marginal Treatment Effect In Cluster Randomized Trials With Multi-Level Missing Outcomes|Paper|Rui Wang|Author|AUTHORED
1434|Estimating Marginal Treatment Effect In Cluster Randomized Trials With Multi-Level Missing Outcomes|Paper|Cluster Randomized Trials|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Clinical Trials|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Efficacy|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Strata-Specific Family Wise Error Rates|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Maximum-Likelihood Estimator|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Multinomial Distribution|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Simulations|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Expected Pwer|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Study-Specific Pwer|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Overlapping Populations|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Sample Sizes|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Maximum Strata-Wise Family Wise Error Rate|Topic|RELATED_TO
1435|Population-Wise Error Rate (Pwer)|Topic|Significance Level|Topic|RELATED_TO
1435|Remi Luschei|Author|Population-Wise Error Rate (Pwer)|Topic|AUTHORED
1435|Werner Brannath|Author|Population-Wise Error Rate (Pwer)|Topic|AUTHORED
1436|Predictively Consistent Prior Effective Sample Sizes|Paper|Prior Effective Sample Size|Topic|DISCUSSES
1436|Predictively Consistent Prior Effective Sample Sizes|Paper|Control Group|Topic|DISCUSSES
1436|Predictively Consistent Prior Effective Sample Sizes|Paper|Hierarchical Subgroup Analyses|Topic|DISCUSSES
1436|Predictively Consistent Prior Effective Sample Sizes|Paper|Prior Information|Topic|DISCUSSES
1436|Predictively Consistent Prior Effective Sample Sizes|Paper|Randomized Clinical Trials|Topic|DISCUSSES
1436|Predictively Consistent Prior Effective Sample Sizes|Paper|Expected Local-Information-Ratio Ess|Topic|DISCUSSES
1436|Predictively Consistent Prior Effective Sample Sizes|Paper|Current Methods|Topic|DISCUSSES
1436|Predictively Consistent Prior Effective Sample Sizes|Paper|Posterior Ess|Topic|DISCUSSES
1437|Knowledge Transfer Research|Topic|Translational Research|Topic|RELATED_TO
1437|Translational Research|Topic|Text Mining And Predictive Modeling|Topic|RELATED_TO
1437|Text Mining And Predictive Modeling|Topic|Scientific Concepts|Topic|RELATED_TO
1437|Scientific Concepts|Topic|Knowledge Transfer Mechanisms|Topic|RELATED_TO
1437|Hancheng Cao|Author|Knowledge Transfer Research|Topic|AUTHORED
1437|Mengjie Cheng|Author|Knowledge Transfer Research|Topic|AUTHORED
1437|Zhepeng Cen|Author|Knowledge Transfer Research|Topic|AUTHORED
1437|Daniel A. Mcfarland|Author|Knowledge Transfer Research|Topic|AUTHORED
1437|Xiang Ren|Author|Knowledge Transfer Research|Topic|AUTHORED
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Anti-Drug Antibody (Ada) Formation|Topic|DISCUSSES
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Biologic Treatment|Topic|DISCUSSES
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Randomized Controlled Trial|Topic|DISCUSSES
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Principal Stratum Estimand Strategy|Topic|DISCUSSES
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Treatment Effect|Topic|DISCUSSES
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Weighted Principal Stratum Approach|Topic|DISCUSSES
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Baseline Covariates|Topic|DISCUSSES
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Longitudinal Information|Topic|DISCUSSES
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Causal Conclusions|Topic|DISCUSSES
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Simulations|Topic|DISCUSSES
1438|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|Clinical Study|Topic|DISCUSSES
1438|Shengchun Kong|Author|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|AUTHORED
1438|Dominik Heinzmann|Author|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|AUTHORED
1438|Sabine Lauer|Author|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|AUTHORED
1438|Tian Lu|Author|Weighted Approach For Estimating Effects In Principal Strata With Missing Data For A Categorical Post-Baseline Variable In Randomized Controlled Trials|Paper|AUTHORED
1439|Data Science Task|Topic|Big Data|Topic|RELATED_TO
1439|Big Data|Topic|Healthcare Practitioners|Topic|RELATED_TO
1439|Healthcare Practitioners|Topic|Causality|Topic|RELATED_TO
1439|Causality|Topic|Observational Studies|Topic|RELATED_TO
1439|Observational Studies|Topic|Selection Bias|Topic|RELATED_TO
1439|Observational Studies|Topic|Confounding Bias|Topic|RELATED_TO
1439|Causal Inference|Topic|Healthcare Practitioners|Topic|RELATED_TO
1439|Causal Inference|Topic|Reinforcement Learning|Topic|RELATED_TO
1439|Wenhao Zhang|Author|Causal Inference|Topic|AUTHORED
1439|Ramin Ramezani|Author|Causal Inference|Topic|AUTHORED
1439|Arash Naeim|Author|Causal Inference|Topic|AUTHORED
1440|A Bayesian Adaptive Design For Dual-Agent Phase I-Ii Oncology Trials Integrating Efficacy Data Across Stages|Paper|José L. Jiménez|Author|AUTHORED
1440|A Bayesian Adaptive Design For Dual-Agent Phase I-Ii Oncology Trials Integrating Efficacy Data Across Stages|Paper|Haiyan Zheng|Author|AUTHORED
1441|All-In Meta-Analysis|Topic|Science|Topic|RELATED_TO
1441|Judith Ter Schure|Author|All-In Meta-Analysis|Topic|AUTHORED
1441|Peter Grünwald|Author|All-In Meta-Analysis|Topic|AUTHORED
1442|Evidence-Based Medicine|Topic|Systematic Reviews|Topic|RELATED_TO
1442|Systematic Reviews|Topic|Randomised Controlled Trial|Topic|RELATED_TO
1442|Named Entity Recognition|Topic|Relation Extraction|Topic|RELATED_TO
1442|Deep Neural Net Models|Topic|Transfer Learning|Topic|RELATED_TO
1442|Deep Neural Net Models|Topic|Transformer-Based Language Representations|Topic|RELATED_TO
1442|Gold-Standard Corpus|Topic|Clinical Trial Results|Topic|RELATED_TO
1442|Clinical Trial Results|Topic|Evidence Tables|Topic|RELATED_TO
1442|Jetsun Whitton|Author|Clinical Trial Results|Topic|AUTHORED
1442|Anthony Hunter|Author|Clinical Trial Results|Topic|AUTHORED
1443|Estimating Average Causal Effects From Patient Trajectories|Paper|Deepace|Topic|DISCUSSES
1443|Estimating Average Causal Effects From Patient Trajectories|Paper|Dennis Frauen|Author|AUTHORED
1443|Estimating Average Causal Effects From Patient Trajectories|Paper|Tobias Hatt|Author|AUTHORED
1443|Estimating Average Causal Effects From Patient Trajectories|Paper|Valentyn Melnychuk|Author|AUTHORED
1443|Estimating Average Causal Effects From Patient Trajectories|Paper|Stefan Feuerriegel|Author|AUTHORED
1444|Synthetic Control Method|Topic|Counterfactual Reality|Topic|RELATED_TO
1444|Synthetic Control Method|Topic|Donor Units|Topic|RELATED_TO
1444|Linear Model|Topic|Pre-Intervention Period|Topic|RELATED_TO
1444|Spatiotemporal Information|Topic|Counterfactual Sequence|Topic|RELATED_TO
1444|Transformer Model|Topic|Positional Embeddings|Topic|RELATED_TO
1444|Transformer Model|Topic|Decoder Attention Mask|Topic|RELATED_TO
1444|Transformer Model|Topic|Pre-Training Task|Topic|RELATED_TO
1444|Transformer Model|Topic|Spatiotemporal Sequence-To-Sequence Modeling|Topic|RELATED_TO
1444|Synthetic Data|Topic|Healthcare Insights|Topic|RELATED_TO
1444|Public Health Policy|Topic|Healthcare Insights|Topic|RELATED_TO
1444|Asthma Medications|Topic|Healthcare Insights|Topic|RELATED_TO
1444|Friedreich'S Ataxia|Topic|Healthcare Insights|Topic|RELATED_TO
1444|Bhishma Dedhia|Author|Scout: Synthetic Counterfactuals Via Spatiotemporal Transformers For Actionable Healthcare|Paper|AUTHORED
1444|Roshini Balasubramanian|Author|Scout: Synthetic Counterfactuals Via Spatiotemporal Transformers For Actionable Healthcare|Paper|AUTHORED
1444|Niraj K. Jha|Author|Scout: Synthetic Counterfactuals Via Spatiotemporal Transformers For Actionable Healthcare|Paper|AUTHORED
1445|Generalized Linear Mixed Models (Glmm)|Topic|Cluster-Randomized Trials (Crts)|Topic|RELATED_TO
1445|Hongxiang Qiu|Author|Generalized Linear Mixed Models (Glmm)|Topic|AUTHORED
1445|Andrea J. Cook|Author|Generalized Linear Mixed Models (Glmm)|Topic|AUTHORED
1445|Jennifer F. Bobb|Author|Generalized Linear Mixed Models (Glmm)|Topic|AUTHORED
1446|Strategy Training|Topic|Natural Language Processing|Topic|RELATED_TO
1446|Natural Language Processing|Topic|Bert Model|Topic|RELATED_TO
1446|Bert Model|Topic|Hunter Osterhoudt|Author|AUTHORED
1446|Bert Model|Topic|Courtney E. Schneider|Author|AUTHORED
1446|Bert Model|Topic|Haneef A Mohammad|Author|AUTHORED
1446|Bert Model|Topic|Minmei Shih|Author|AUTHORED
1446|Bert Model|Topic|Alexandra E. Harper|Author|AUTHORED
1446|Bert Model|Topic|Leming Zhou|Author|AUTHORED
1446|Bert Model|Topic|Elizabeth R Skidmore|Author|AUTHORED
1446|Bert Model|Topic|Yanshan Wang|Author|AUTHORED
1447|Surrogate Marker|Topic|Aids Clinical Trial|Topic|RELATED_TO
1447|Surrogate Marker|Topic|Cd4 Count|Topic|RELATED_TO
1447|Surrogate Marker|Topic|Rna|Topic|RELATED_TO
1447|Layla Parast|Author|Surrogate Marker|Topic|AUTHORED
1447|Tianxi Cai|Author|Surrogate Marker|Topic|AUTHORED
1447|Lu Tian|Author|Surrogate Marker|Topic|AUTHORED
1448|Hazard Ratios|Topic|Selection Bias|Topic|RELATED_TO
1448|Hazard Difference|Topic|Causal Hazard Differences|Topic|RELATED_TO
1448|Hazard Difference|Topic|Effect Heterogeneity|Topic|RELATED_TO
1448|Randomized Controlled Trial|Topic|Hazard Difference|Topic|DISCUSSES
1448|Chemotherapy|Topic|Survival Time|Topic|DISCUSSES
1448|Survival Time|Topic|Carcinoma Of The Oropharynx|Topic|DISCUSSES
1448|Richard Post|Author|Randomized Controlled Trial|Topic|AUTHORED
1448|Edwin Van Den Heuvel|Author|Randomized Controlled Trial|Topic|AUTHORED
1448|Hein Putter|Author|Randomized Controlled Trial|Topic|AUTHORED
1449|Multi-Document Summarization|Topic|Film Reviews|Topic|DISCUSSES
1449|Multi-Document Summarization|Topic|Biomedical Systematic Reviews|Topic|DISCUSSES
1449|Multi-Document Summarization|Topic|Opinion And Evidence Synthesis Datasets|Topic|DISCUSSES
1449|Opinion And Evidence Synthesis Datasets|Topic|Fine-Tuned Transformers|Topic|RELATED_TO
1449|Opinion And Evidence Synthesis Datasets|Topic|Gpt-4|Topic|RELATED_TO
1449|Jay Deyoung|Author|Do Multi-Document Summarization Models Synthesize?|Paper|AUTHORED
1449|Stephanie C. Martinez|Author|Do Multi-Document Summarization Models Synthesize?|Paper|AUTHORED
1449|Iain J. Marshall|Author|Do Multi-Document Summarization Models Synthesize?|Paper|AUTHORED
1449|Byron C. Wallace|Author|Do Multi-Document Summarization Models Synthesize?|Paper|AUTHORED
1450|Asymptotic Properties Of Multi-Treatment Covariate Adaptive Randomization Procedures For Balancing Observed And Unobserved Covariates|Paper|Li-Xin Zhang|Author|AUTHORED
1450|Asymptotic Properties Of Multi-Treatment Covariate Adaptive Randomization Procedures For Balancing Observed And Unobserved Covariates|Paper|Car|Topic|RELATED_TO
1450|Asymptotic Properties Of Multi-Treatment Covariate Adaptive Randomization Procedures For Balancing Observed And Unobserved Covariates|Paper|Multi-Treatment Clinical Trials|Topic|RELATED_TO
1450|Asymptotic Properties Of Multi-Treatment Covariate Adaptive Randomization Procedures For Balancing Observed And Unobserved Covariates|Paper|Covariate Features|Topic|RELATED_TO
1450|Asymptotic Properties Of Multi-Treatment Covariate Adaptive Randomization Procedures For Balancing Observed And Unobserved Covariates|Paper|Imbalance Vectors|Topic|RELATED_TO
1450|Asymptotic Properties Of Multi-Treatment Covariate Adaptive Randomization Procedures For Balancing Observed And Unobserved Covariates|Paper|Treatment Effect Test|Topic|RELATED_TO
1450|Asymptotic Properties Of Multi-Treatment Covariate Adaptive Randomization Procedures For Balancing Observed And Unobserved Covariates|Paper|Heteroscedastic Linear Model|Topic|RELATED_TO
1450|Asymptotic Properties Of Multi-Treatment Covariate Adaptive Randomization Procedures For Balancing Observed And Unobserved Covariates|Paper|Unobserved Covariates|Topic|RELATED_TO
1451|Bayesian Model-Averaged Meta-Analysis|Topic|Cochrane Database Of Systematic Reviews|Topic|RELATED_TO
1451|Bayesian Model-Averaged Meta-Analysis|Topic|Binary Outcomes|Topic|RELATED_TO
1451|Bayesian Model-Averaged Meta-Analysis|Topic|Time-To-Event Outcomes|Topic|RELATED_TO
1451|Frantiek Barto|Author|Bayesian Model-Averaged Meta-Analysis|Topic|AUTHORED
1451|Willem M. Otte|Author|Bayesian Model-Averaged Meta-Analysis|Topic|AUTHORED
1451|Quentin F. Gronau|Author|Bayesian Model-Averaged Meta-Analysis|Topic|AUTHORED
1451|Bram Timmers|Author|Bayesian Model-Averaged Meta-Analysis|Topic|AUTHORED
1451|Alexander Ly|Author|Bayesian Model-Averaged Meta-Analysis|Topic|AUTHORED
1451|Eric-Jan Wagenmakers|Author|Bayesian Model-Averaged Meta-Analysis|Topic|AUTHORED
1452|Machine Learning|Topic|Healthcare|Topic|RELATED_TO
1452|Alzheimer'S Disease|Topic|Adni Dataset|Topic|RELATED_TO
1452|3D Convolutional Neural Network|Topic|Alzheimer'S Disease|Topic|RELATED_TO
1452|Rosanna Turrisi|Author|Predictive Models|Topic|AUTHORED
1452|Alessandro Verri|Author|Predictive Models|Topic|AUTHORED
1452|Annalisa Barla|Author|Predictive Models|Topic|AUTHORED
1452|Data Augmentation|Topic|Model Complexity|Topic|RELATED_TO
1452|Model Complexity|Topic|Accuracy|Topic|RELATED_TO
1453|Intrusion Research|Topic|Causal Relationships|Topic|RELATED_TO
1453|Causal Relationships|Topic|Adaptive Design|Topic|RELATED_TO
1453|Adaptive Design|Topic|Honeypot Deployment Study|Topic|RELATED_TO
1453|Honeypot Deployment Study|Topic|Ssh Vulnerability|Topic|RELATED_TO
1453|Honeypot Deployment Study|Topic|Kate Highnam|Author|AUTHORED
1453|Honeypot Deployment Study|Topic|Zach Hanif|Author|AUTHORED
1453|Honeypot Deployment Study|Topic|Ellie Van Vogt|Author|AUTHORED
1453|Honeypot Deployment Study|Topic|Sonali Parbhoo|Author|AUTHORED
1453|Honeypot Deployment Study|Topic|Sergio Maffeis|Author|AUTHORED
1453|Honeypot Deployment Study|Topic|Nicholas R. Jennings|Author|AUTHORED
1454|Immunotherapies And Targeted Therapies|Topic|Optimal Biological Dose (Obd)|Topic|RELATED_TO
1454|Optimal Biological Dose (Obd)|Topic|Maximum Tolerated Dose (Mtd)|Topic|RELATED_TO
1454|Pkboin-12|Topic|Optimal Biological Dose (Obd)|Topic|AUTHORED
1454|Tite-Pkboin-12|Topic|Pkboin-12|Topic|RELATED_TO
1454|Hao Sun|Author|Pkboin-12|Topic|AUTHORED
1454|Jieqi Tu|Author|Pkboin-12|Topic|AUTHORED
1455|Uptime|Topic|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome|Topic|RELATED_TO
1455|Uptime|Topic|Long Covid|Topic|RELATED_TO
1455|Yifei Sun|Author|System And Method To Determine Me/Cfs And Long Covid Disease Severity Using A Wearable Sensor|Paper|AUTHORED
1455|Suzanne D. Vernon|Author|System And Method To Determine Me/Cfs And Long Covid Disease Severity Using A Wearable Sensor|Paper|AUTHORED
1455|Shad Roundy|Author|System And Method To Determine Me/Cfs And Long Covid Disease Severity Using A Wearable Sensor|Paper|AUTHORED
1455|Wearable Sensor|Topic|Uptime|Topic|RELATED_TO
1455|Inertial Measurement Unit|Topic|Wearable Sensor|Topic|RELATED_TO
1455|Clinical Research|Topic|Uptime|Topic|RELATED_TO
1456|Natural|Topic|Causal Effect Estimation|Topic|RELATED_TO
1456|Nikita Dhawan|Author|Natural|Topic|AUTHORED
1456|Leonardo Cotta|Author|Natural|Topic|AUTHORED
1456|Karen Ullrich|Author|Natural|Topic|AUTHORED
1456|Rahul G. Krishnan|Author|Natural|Topic|AUTHORED
1456|Chris J. Maddison|Author|Natural|Topic|AUTHORED
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Moritz Fabian Danzer|Author|AUTHORED
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Ina Dormuth|Author|AUTHORED
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Time-To-Event Endpoint|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Clinical Trial|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Effect Size|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Proportional Hazards|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Hazard Ratio|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Log-Rank Test|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Survival Data|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Multi-Stage Design|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Combination-Type Tests|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Royston-Parmar Spline Models|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Real-World Data Example|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Simulation Studies|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Power Performance|Topic|RELATED_TO
1457|Adaptive Weight Selection For Time-To-Event Data Under Non-Proportional Hazards|Paper|Flexibility|Topic|RELATED_TO
1458|Nonparametric Bayesian Approach For Dynamic Borrowing Of Historical Control Data|Paper|Historical Control Data|Topic|DISCUSSES
1458|Nonparametric Bayesian Approach For Dynamic Borrowing Of Historical Control Data|Paper|Randomized Controlled Trial Data|Topic|DISCUSSES
1458|Nonparametric Bayesian Approach For Dynamic Borrowing Of Historical Control Data|Paper|Dynamic Borrowing Method|Topic|DISCUSSES
1458|Nonparametric Bayesian Approach For Dynamic Borrowing Of Historical Control Data|Paper|Dependent Dirichlet Process Mixture|Topic|DISCUSSES
1458|Nonparametric Bayesian Approach For Dynamic Borrowing Of Historical Control Data|Paper|Simulation Study|Topic|DISCUSSES
1458|Nonparametric Bayesian Approach For Dynamic Borrowing Of Historical Control Data|Paper|Clinical Trial Examples|Topic|DISCUSSES
1459|Dynamic Indicators Of Adherence And Retention In Digital Health Studies: Insights From The Brighten Study|Paper|Dylan Hamitouche|Author|AUTHORED
1459|Dynamic Indicators Of Adherence And Retention In Digital Health Studies: Insights From The Brighten Study|Paper|Youcef Barkat|Author|AUTHORED
1459|Dynamic Indicators Of Adherence And Retention In Digital Health Studies: Insights From The Brighten Study|Paper|Deven Parekh|Author|AUTHORED
1459|Dynamic Indicators Of Adherence And Retention In Digital Health Studies: Insights From The Brighten Study|Paper|Eva Hammer|Author|AUTHORED
1459|Dynamic Indicators Of Adherence And Retention In Digital Health Studies: Insights From The Brighten Study|Paper|David Benrimoh|Author|AUTHORED
1459|Brighten Study|Topic|Dynamic Indicators Of Adherence And Retention In Digital Health Studies: Insights From The Brighten Study|Paper|RELATED_TO
1460|Hybrid Clinical Trials|Topic|Real-World Data|Topic|RELATED_TO
1460|Hybrid Clinical Trials|Topic|Rare Diseases|Topic|RELATED_TO
1460|Yuan Et Al. (2019)|Paper|Hybrid Clinical Trials|Topic|DISCUSSES
1461|Causal Inference Across Multiple Data Sources|Topic|Data Integration Methods For Time-To-Event Outcomes|Topic|RELATED_TO
1461|Data Integration Methods For Time-To-Event Outcomes|Topic|Survival Analysis|Topic|RELATED_TO
1461|Survival Analysis|Topic|Novel Approaches For Multi-Source Causal Survival Analysis|Topic|RELATED_TO
1461|Novel Approaches For Multi-Source Causal Survival Analysis|Topic|Semiparametric Efficient Estimator|Topic|RELATED_TO
1461|Novel Approaches For Multi-Source Causal Survival Analysis|Topic|Federated Learning Framework|Topic|RELATED_TO
1461|Novel Approaches For Multi-Source Causal Survival Analysis|Topic|Nonparametric Machine Learning Models|Topic|RELATED_TO
1461|Hvtn 704/Hptn 085|Paper|Hvtn 703/Hptn 081|Paper|RELATED_TO
1461|Hvtn 704/Hptn 085|Paper|Yi Liu|Author|AUTHORED
1461|Hvtn 704/Hptn 085|Paper|Alexander W. Levis|Author|AUTHORED
1461|Hvtn 704/Hptn 085|Paper|Ke Zhu|Author|AUTHORED
1461|Hvtn 704/Hptn 085|Paper|Shu Yang|Author|AUTHORED
1461|Hvtn 704/Hptn 085|Paper|Peter B. Gilbert|Author|AUTHORED
1461|Hvtn 704/Hptn 085|Paper|Larry Han|Author|AUTHORED
1461|Hvtn 703/Hptn 081|Paper|Yi Liu|Author|AUTHORED
1461|Hvtn 703/Hptn 081|Paper|Alexander W. Levis|Author|AUTHORED
1461|Hvtn 703/Hptn 081|Paper|Ke Zhu|Author|AUTHORED
1461|Hvtn 703/Hptn 081|Paper|Shu Yang|Author|AUTHORED
1461|Hvtn 703/Hptn 081|Paper|Peter B. Gilbert|Author|AUTHORED
1461|Hvtn 703/Hptn 081|Paper|Larry Han|Author|AUTHORED
1462|Cybernetical Neuroscience|Topic|Alexander Fradkov|Author|AUTHORED
1463|Analyzing Incomplete Discrete Longitudinal Clinical Trial Data|Paper|Complete Case Analysis|Topic|DISCUSSES
1463|Analyzing Incomplete Discrete Longitudinal Clinical Trial Data|Paper|Last Observation Carried Forward|Topic|DISCUSSES
1463|Analyzing Incomplete Discrete Longitudinal Clinical Trial Data|Paper|Missing Completely At Random|Topic|DISCUSSES
1463|Analyzing Incomplete Discrete Longitudinal Clinical Trial Data|Paper|Missing At Random|Topic|DISCUSSES
1463|Analyzing Incomplete Discrete Longitudinal Clinical Trial Data|Paper|Linear Mixed Model|Topic|DISCUSSES
1463|Analyzing Incomplete Discrete Longitudinal Clinical Trial Data|Paper|Generalized Linear Mixed-Effects Models|Topic|DISCUSSES
1463|Analyzing Incomplete Discrete Longitudinal Clinical Trial Data|Paper|Generalized Estimating Equations|Topic|DISCUSSES
1463|Analyzing Incomplete Discrete Longitudinal Clinical Trial Data|Paper|Sensitivity Analysis|Topic|DISCUSSES
1464|Clinical Research And Drug Development In Orphan Diseases|Topic|Bayesian Meta-Analytic Approach|Topic|RELATED_TO
1464|Phase Iii Study|Topic|Phase Ii Data|Topic|RELATED_TO
1464|Phase Iii Study|Topic|Fda Approval In Herpetic Keratitis|Topic|RELATED_TO
1464|Simon Wandel|Author|Phase Iii Study|Topic|AUTHORED
1464|Beat Neuenschwander|Author|Phase Iii Study|Topic|AUTHORED
1464|Tim Friede|Author|Phase Iii Study|Topic|AUTHORED
1464|Christian Röver|Author|Phase Iii Study|Topic|AUTHORED
1465|Analysis Of Adverse Events|Topic|Steffen Unkel|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Marjan Amiri|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Norbert Benda|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Jan Beyersmann|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Dietrich Knoerzer|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Katrin Kupas|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Frank Langer|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Friedhelm Leverkus|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Anja Loos|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Claudia Ose|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Tanja Proctor|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Claudia Schmoor|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Carsten Schwenke|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Guido Skipka|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Kristina Unnebrink|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Florian Voss|Author|AUTHORED
1465|Analysis Of Adverse Events|Topic|Tim Friede|Author|AUTHORED
1466|Electronic Health Records|Topic|Adverse Events|Topic|RELATED_TO
1466|Clozapine|Topic|Adverse Events|Topic|RELATED_TO
1466|Ehtesham Iqbal|Author|Clozapine|Topic|AUTHORED
1466|Risha Govind|Author|Clozapine|Topic|AUTHORED
1466|Alvin Romero|Author|Clozapine|Topic|AUTHORED
1466|Olubanke Dzahini|Author|Clozapine|Topic|AUTHORED
1466|Matthew Broadbent|Author|Clozapine|Topic|AUTHORED
1466|Robert Stewart|Author|Clozapine|Topic|AUTHORED
1466|Tanya Smith|Author|Clozapine|Topic|AUTHORED
1466|Chi-Hun Kim|Author|Clozapine|Topic|AUTHORED
1466|Nomi Werbeloff|Author|Clozapine|Topic|AUTHORED
1466|Richard Dobson|Author|Clozapine|Topic|AUTHORED
1466|Zina Ibrahim|Author|Clozapine|Topic|AUTHORED
1468|3D Augmented Reality-Assisted Ct-Guided Interventions: System Design And Preclinical Trial On An Abdominal Phantom Using Hololens 2|Paper|Brian J. Park|Author|AUTHORED
1468|3D Augmented Reality-Assisted Ct-Guided Interventions: System Design And Preclinical Trial On An Abdominal Phantom Using Hololens 2|Paper|Stephen J. Hunt|Author|AUTHORED
1468|3D Augmented Reality-Assisted Ct-Guided Interventions: System Design And Preclinical Trial On An Abdominal Phantom Using Hololens 2|Paper|Gregory J. Nadolski|Author|AUTHORED
1468|3D Augmented Reality-Assisted Ct-Guided Interventions: System Design And Preclinical Trial On An Abdominal Phantom Using Hololens 2|Paper|Terence P. Gade|Author|AUTHORED
1468|3D Augmented Reality-Assisted Ct-Guided Interventions: System Design And Preclinical Trial On An Abdominal Phantom Using Hololens 2|Paper|Augmented Reality|Topic|RELATED_TO
1468|3D Augmented Reality-Assisted Ct-Guided Interventions: System Design And Preclinical Trial On An Abdominal Phantom Using Hololens 2|Paper|Ct-Guided Interventions|Topic|RELATED_TO
1469|Mindfulness-Based Interventions|Topic|Post-Traumatic Stress Disorder (Ptsd)|Topic|RELATED_TO
1469|Mindfulness-Based Stress Reduction (Mbsr)|Topic|Post-Traumatic Stress Disorder (Ptsd)|Topic|RELATED_TO
1469|Randomized Clinical Trial (Rct)|Topic|Veterans|Topic|RELATED_TO
1469|Seung Suk Kang|Author|Randomized Clinical Trial (Rct)|Topic|AUTHORED
1469|Scott R. Sponheim|Author|Randomized Clinical Trial (Rct)|Topic|AUTHORED
1469|Kelvin O. Lim|Author|Randomized Clinical Trial (Rct)|Topic|AUTHORED
1469|Ptsd Checklist|Topic|Electroencephalography (Eeg)|Topic|RELATED_TO
1469|Electroencephalography (Eeg)|Topic|Anterior Cingulate Cortex|Topic|RELATED_TO
1469|Electroencephalography (Eeg)|Topic|Anterior Insular Cortex|Topic|RELATED_TO
1469|Electroencephalography (Eeg)|Topic|Lateral Prefrontal Cortex|Topic|RELATED_TO
1470|Adverse Drug Reactions|Topic|Randomized Clinical Trials|Topic|RELATED_TO
1470|Adverse Drug Reactions|Topic|Postmarketing Pharmacovigilance|Topic|RELATED_TO
1470|Knowledge Graphs|Topic|Drug Classifications|Topic|RELATED_TO
1470|Biomolecular Features|Topic|Drug Classifications|Topic|RELATED_TO
1470|Decision Trees|Topic|Classification Rules|Topic|RELATED_TO
1470|Gene Ontology Terms|Topic|Drug Targets|Topic|RELATED_TO
1470|Drug Targets|Topic|Pathway Names|Topic|RELATED_TO
1470|Dili|Topic|Scar|Topic|RELATED_TO
1470|Emmanuel Bresso|Author|Pierre Monnin|Author|AUTHORED
1470|Emmanuel Bresso|Author|Cédric Bousquet|Author|AUTHORED
1470|Emmanuel Bresso|Author|François-Elie Calvier|Author|AUTHORED
1470|Emmanuel Bresso|Author|Ndeye-Coumba Ndiaye|Author|AUTHORED
1470|Emmanuel Bresso|Author|Nadine Petitpain|Author|AUTHORED
1470|Emmanuel Bresso|Author|Malika Smaïl-Tabbone|Author|AUTHORED
1470|Emmanuel Bresso|Author|Adrien Coulet|Author|AUTHORED
1471|Dexamethasone|Paper|Covid-19|Topic|RELATED_TO
1471|Baricitinib|Paper|Covid-19|Topic|RELATED_TO
1471|Triamcinolone|Paper|Sars-Cov-2|Topic|RELATED_TO
1471|Gallopamil|Paper|Sars-Cov-2|Topic|RELATED_TO
1471|In Silico Approach|Topic|Covid-19|Topic|RELATED_TO
1471|Mechanism Of Action Analysis|Topic|Sars-Cov-2|Topic|RELATED_TO
1471|Méabh Macmahon|Author|Covid-19|Topic|AUTHORED
1471|Woochang Hwang|Author|Covid-19|Topic|AUTHORED
1471|Soorin Yim|Author|Covid-19|Topic|AUTHORED
1471|Eoghan Macmahon|Author|Covid-19|Topic|AUTHORED
1471|Alexandre Abraham|Author|Covid-19|Topic|AUTHORED
1471|Justin Barton|Author|Covid-19|Topic|AUTHORED
1471|Mukunthan Tharmakulasingam|Author|Covid-19|Topic|AUTHORED
1471|Paul Bilokon|Author|Covid-19|Topic|AUTHORED
1471|Vasanthi Priyadarshini Gaddi|Author|Covid-19|Topic|AUTHORED
1471|Namshik Han|Author|Covid-19|Topic|AUTHORED
1472|Evaluating Causal Effects On Time-To-Event Outcomes In An Rct In Oncology With Treatment Discontinuation|Paper|Veronica Ballerini|Author|AUTHORED
1472|Evaluating Causal Effects On Time-To-Event Outcomes In An Rct In Oncology With Treatment Discontinuation|Paper|Björn Bornkamp|Author|AUTHORED
1472|Evaluating Causal Effects On Time-To-Event Outcomes In An Rct In Oncology With Treatment Discontinuation|Paper|Alessandra Mattei|Author|AUTHORED
1472|Evaluating Causal Effects On Time-To-Event Outcomes In An Rct In Oncology With Treatment Discontinuation|Paper|Fabrizia Mealli|Author|AUTHORED
1472|Evaluating Causal Effects On Time-To-Event Outcomes In An Rct In Oncology With Treatment Discontinuation|Paper|Craig Wang|Author|AUTHORED
1472|Evaluating Causal Effects On Time-To-Event Outcomes In An Rct In Oncology With Treatment Discontinuation|Paper|Yufen Zhang|Author|AUTHORED
1473|Acute Lymphoblastic Leukemia (All)|Topic|Minimal Residual Disease (Mrd)|Topic|RELATED_TO
1473|Minimal Residual Disease (Mrd)|Topic|Bayesian Model|Topic|RELATED_TO
1473|Induction Phase|Topic|Minimal Residual Disease (Mrd)|Topic|RELATED_TO
1473|St. Jude Children'S Research Hospital|Topic|Bayesian Model|Topic|RELATED_TO
1473|Drug Sensitivity Profiles|Topic|Induction Phase|Topic|RELATED_TO
1473|Leukemic Subtypes|Topic|Induction Phase|Topic|RELATED_TO
1473|Andrea Cremaschi|Author|Bayesian Model|Topic|AUTHORED
1473|Wenjian Yang|Author|Bayesian Model|Topic|AUTHORED
1473|Maria De Iorio|Author|Bayesian Model|Topic|AUTHORED
1473|William E. Evans|Author|Bayesian Model|Topic|AUTHORED
1473|Jun J. Yang|Author|Bayesian Model|Topic|AUTHORED
1473|Gary L. Rosner|Author|Bayesian Model|Topic|AUTHORED
1474|Stability Basin|Topic|Sit-To-Stand (Sts)|Topic|RELATED_TO
1474|Patrick D. Holmes|Author|Stability Basin|Topic|AUTHORED
1474|Shannon M. Danforth|Author|Stability Basin|Topic|AUTHORED
1474|Xiao-Yu Fu|Author|Stability Basin|Topic|AUTHORED
1474|Talia Y. Moore|Author|Stability Basin|Topic|AUTHORED
1474|Ram Vasudevan|Author|Stability Basin|Topic|AUTHORED
1474|Falls|Topic|Sit-To-Stand (Sts)|Topic|RELATED_TO
1475|Biomedical Text Tagging Systems|Topic|Pre-Trained Encoders|Topic|RELATED_TO
1475|Pre-Trained Encoders|Topic|Pico Annotation|Topic|RELATED_TO
1475|Pico Annotation|Topic|Gaurav Singh|Author|AUTHORED
1475|Pico Annotation|Topic|Zahra Sabet|Author|AUTHORED
1475|Pico Annotation|Topic|John Shawe-Taylor|Author|AUTHORED
1475|Pico Annotation|Topic|James Thomas|Author|AUTHORED
1476|Clinical Trials Investigating Interventions On Physical Activity|Topic|Accelerometers|Topic|RELATED_TO
1476|Accelerometers|Topic|Step Count|Topic|RELATED_TO
1476|Epoch-Level Missingness|Topic|Parametric Approach|Topic|RELATED_TO
1476|Epoch-Level Missingness|Topic|Non-Parametric Approach|Topic|RELATED_TO
1476|Non-Parametric Approach|Topic|Multiple Imputation (Mi)|Topic|RELATED_TO
1476|Multiple Imputation (Mi)|Topic|2017 Pace-Up Trial|Topic|RELATED_TO
1476|Mia S. Tackney|Author|2017 Pace-Up Trial|Topic|AUTHORED
1476|Elizabeth Williamson|Author|2017 Pace-Up Trial|Topic|AUTHORED
1476|Derek G. Cook|Author|2017 Pace-Up Trial|Topic|AUTHORED
1476|Elizabeth Limb|Author|2017 Pace-Up Trial|Topic|AUTHORED
1476|Tess Harris|Author|2017 Pace-Up Trial|Topic|AUTHORED
1476|James Carpenter|Author|2017 Pace-Up Trial|Topic|AUTHORED
1477|Personalized Medicine|Topic|Individualized Treatment Rules (Itrs)|Topic|RELATED_TO
1477|Individualized Treatment Rules (Itrs)|Topic|Machine Learning Methods|Topic|RELATED_TO
1477|Machine Learning Methods|Topic|Randomized Control Trials|Topic|RELATED_TO
1477|Florie Bouvier|Author|Individualized Treatment Rules (Itrs)|Topic|AUTHORED
1477|Etienne Peyrot|Author|Individualized Treatment Rules (Itrs)|Topic|AUTHORED
1477|Alan Balendran|Author|Individualized Treatment Rules (Itrs)|Topic|AUTHORED
1477|Corentin Ségalas|Author|Individualized Treatment Rules (Itrs)|Topic|AUTHORED
1477|Ian Roberts|Author|Individualized Treatment Rules (Itrs)|Topic|AUTHORED
1477|François Petit|Author|Individualized Treatment Rules (Itrs)|Topic|AUTHORED
1477|Raphaël Porcher|Author|Individualized Treatment Rules (Itrs)|Topic|AUTHORED
1478|Digital Breast Tomosynthesis|Topic|Reconstruction Algorithms|Topic|RELATED_TO
1478|I. Reiser|Author|Digital Breast Tomosynthesis|Topic|AUTHORED
1478|J. Bian|Author|Digital Breast Tomosynthesis|Topic|AUTHORED
1478|R. M. Nishikawa|Author|Digital Breast Tomosynthesis|Topic|AUTHORED
1478|E. Y. Sidky|Author|Digital Breast Tomosynthesis|Topic|AUTHORED
1478|X. Pan|Author|Digital Breast Tomosynthesis|Topic|AUTHORED
1479|A Partitioning Deletion/Substitution/Addition Algorithm For Creating Survival Risk Groups|Paper|Cart|Topic|DISCUSSES
1479|A Partitioning Deletion/Substitution/Addition Algorithm For Creating Survival Risk Groups|Paper|Partdsa|Topic|DISCUSSES
1479|A Partitioning Deletion/Substitution/Addition Algorithm For Creating Survival Risk Groups|Paper|Censored Outcome Data|Topic|DISCUSSES
1479|A Partitioning Deletion/Substitution/Addition Algorithm For Creating Survival Risk Groups|Paper|Brain Cancer Patients|Topic|DISCUSSES
1480|Random Forest|Topic|Randomforestsrc Package|Topic|RELATED_TO
1480|Random Survival Forests|Topic|Randomforestsrc Package|Topic|RELATED_TO
1480|Ggrandomforests Package|Topic|Randomforestsrc Package|Topic|RELATED_TO
1480|Primary Biliary Cirrhosis Of The Liver Data|Topic|Ggrandomforests Package|Topic|RELATED_TO
1480|Ggrandomforests Package|Topic|John Ehrlinger|Author|AUTHORED
1481|A Machine Learning Approach To Drug Repositioning Based On Drug Expression Profiles: Applications To Schizophrenia And Depression/Anxiety Disorders|Paper|Drug Repositioning|Topic|DISCUSSES
1481|A Machine Learning Approach To Drug Repositioning Based On Drug Expression Profiles: Applications To Schizophrenia And Depression/Anxiety Disorders|Paper|Psychiatry|Topic|DISCUSSES
1481|A Machine Learning Approach To Drug Repositioning Based On Drug Expression Profiles: Applications To Schizophrenia And Depression/Anxiety Disorders|Paper|Schizophrenia|Topic|DISCUSSES
1481|A Machine Learning Approach To Drug Repositioning Based On Drug Expression Profiles: Applications To Schizophrenia And Depression/Anxiety Disorders|Paper|Depression|Topic|DISCUSSES
1481|A Machine Learning Approach To Drug Repositioning Based On Drug Expression Profiles: Applications To Schizophrenia And Depression/Anxiety Disorders|Paper|Anxiety Disorders|Topic|DISCUSSES
1481|A Machine Learning Approach To Drug Repositioning Based On Drug Expression Profiles: Applications To Schizophrenia And Depression/Anxiety Disorders|Paper|Machine Learning|Topic|DISCUSSES
1482|Variability In Drug Efficacy And Adverse Effects|Topic|Genetic Variability In Classical Pharmacokinetic Genes|Topic|RELATED_TO
1482|Variability In Drug Efficacy And Adverse Effects|Topic|Genetic Variation In Drug Targets|Topic|RELATED_TO
1482|Exac Dataset|Topic|Functional-Variants In Drug-Related Genes|Topic|RELATED_TO
1482|Functional-Variants In Drug-Related Genes|Topic|Fda Approved Drugs|Topic|RELATED_TO
1482|Functional-Variants In Drug-Related Genes|Topic|Oncological Drug Targets|Topic|RELATED_TO
1482|Charlotta P. I. Schärfe|Author|Functional-Variants In Drug-Related Genes|Topic|AUTHORED
1482|Roman Tremmel|Author|Functional-Variants In Drug-Related Genes|Topic|AUTHORED
1482|Matthias Schwab|Author|Functional-Variants In Drug-Related Genes|Topic|AUTHORED
1482|Oliver Kohlbacher|Author|Functional-Variants In Drug-Related Genes|Topic|AUTHORED
1482|Debora S. Marks|Author|Functional-Variants In Drug-Related Genes|Topic|AUTHORED
1483|Clinical Prediction Models|Topic|Marginal Structural Models|Topic|RELATED_TO
1483|Marginal Structural Models|Topic|Matthew Sperrin|Author|AUTHORED
1483|Marginal Structural Models|Topic|Glen Martin|Author|AUTHORED
1483|Marginal Structural Models|Topic|Tjeerd Van Staa|Author|AUTHORED
1483|Marginal Structural Models|Topic|Niels Peek|Author|AUTHORED
1483|Marginal Structural Models|Topic|Iain Buchan|Author|AUTHORED
1484|A Bayesian Mark Interaction Model For Analysis Of Tumor Pathology Images|Paper|Qiwei Li|Author|AUTHORED
1484|A Bayesian Mark Interaction Model For Analysis Of Tumor Pathology Images|Paper|Xinlei Wang|Author|AUTHORED
1484|A Bayesian Mark Interaction Model For Analysis Of Tumor Pathology Images|Paper|Faming Liang|Author|AUTHORED
1484|A Bayesian Mark Interaction Model For Analysis Of Tumor Pathology Images|Paper|Guanghua Xiao|Author|AUTHORED
1484|A Bayesian Mark Interaction Model For Analysis Of Tumor Pathology Images|Paper|Tumor Pathology Images|Topic|RELATED_TO
1484|A Bayesian Mark Interaction Model For Analysis Of Tumor Pathology Images|Paper|Deep-Learning Methods|Topic|RELATED_TO
1484|A Bayesian Mark Interaction Model For Analysis Of Tumor Pathology Images|Paper|Spatial Correlations|Topic|RELATED_TO
1484|A Bayesian Mark Interaction Model For Analysis Of Tumor Pathology Images|Paper|Cell-Cell Interactions|Topic|RELATED_TO
1484|A Bayesian Mark Interaction Model For Analysis Of Tumor Pathology Images|Paper|National Lung Screening Trial|Topic|RELATED_TO
1484|A Bayesian Mark Interaction Model For Analysis Of Tumor Pathology Images|Paper|Lung Cancer|Topic|RELATED_TO
1485|Artificial Intelligence|Topic|Medical Imaging|Topic|RELATED_TO
1485|Optical Coherence Tomography Angiography|Topic|Ai Algorithm|Topic|RELATED_TO
1485|Structural Optical Coherence Tomography|Topic|Ai Algorithm|Topic|RELATED_TO
1485|Deep Learning|Topic|Vasculature Maps|Topic|RELATED_TO
1485|Cecilia S. Lee|Author|Generating Retinal Flow Maps From Structural Optical Coherence Tomography With Artificial Intelligence|Paper|AUTHORED
1485|Ariel J. Tyring|Author|Generating Retinal Flow Maps From Structural Optical Coherence Tomography With Artificial Intelligence|Paper|AUTHORED
1485|Yue Wu|Author|Generating Retinal Flow Maps From Structural Optical Coherence Tomography With Artificial Intelligence|Paper|AUTHORED
1485|Sa Xiao|Author|Generating Retinal Flow Maps From Structural Optical Coherence Tomography With Artificial Intelligence|Paper|AUTHORED
1485|Ariel S. Rokem|Author|Generating Retinal Flow Maps From Structural Optical Coherence Tomography With Artificial Intelligence|Paper|AUTHORED
1485|Nicolaas P. Deruyter|Author|Generating Retinal Flow Maps From Structural Optical Coherence Tomography With Artificial Intelligence|Paper|AUTHORED
1485|Qinqin Zhang|Author|Generating Retinal Flow Maps From Structural Optical Coherence Tomography With Artificial Intelligence|Paper|AUTHORED
1485|Adnan Tufail|Author|Generating Retinal Flow Maps From Structural Optical Coherence Tomography With Artificial Intelligence|Paper|AUTHORED
1485|Ruikang K. Wang|Author|Generating Retinal Flow Maps From Structural Optical Coherence Tomography With Artificial Intelligence|Paper|AUTHORED
1485|Aaron Y. Lee|Author|Generating Retinal Flow Maps From Structural Optical Coherence Tomography With Artificial Intelligence|Paper|AUTHORED
1486|Natural Language Processing|Topic|Electronic Health Records|Topic|RELATED_TO
1486|Natural Language Processing|Topic|Computational Phenotyping|Topic|RELATED_TO
1486|Zexian Zeng|Author|Natural Language Processing|Topic|AUTHORED
1486|Yu Deng|Author|Natural Language Processing|Topic|AUTHORED
1486|Xiaoyu Li|Author|Natural Language Processing|Topic|AUTHORED
1486|Tristan Naumann|Author|Natural Language Processing|Topic|AUTHORED
1486|Yuan Luo|Author|Natural Language Processing|Topic|AUTHORED
1487|Virtual Reality Experience|Topic|Brian A. Cohn|Author|AUTHORED
1487|Virtual Reality Experience|Topic|Dilan D. Shah|Author|AUTHORED
1487|Virtual Reality Experience|Topic|Ali Marjaninejad|Author|AUTHORED
1487|Virtual Reality Experience|Topic|Martin Shapiro|Author|AUTHORED
1487|Virtual Reality Experience|Topic|Serhan Ulkumen|Author|AUTHORED
1487|Virtual Reality Experience|Topic|Christopher M. Laine|Author|AUTHORED
1487|Virtual Reality Experience|Topic|Francisco J. Valero-Cuevas|Author|AUTHORED
1487|Virtual Reality Experience|Topic|Kenneth H. Hayashida|Author|AUTHORED
1487|Virtual Reality Experience|Topic|Sarah Ingersoll|Author|AUTHORED
1488|High-Throughput, Semi-Autonomous Measurement Of Cavitation-Mediated Material Breakage|Paper|Engineered Microbubbles|Topic|DISCUSSES
1488|High-Throughput, Semi-Autonomous Measurement Of Cavitation-Mediated Material Breakage|Paper|Calcium-Containing Hydroxyapatite Substrate|Topic|DISCUSSES
1488|High-Throughput, Semi-Autonomous Measurement Of Cavitation-Mediated Material Breakage|Paper|Nephrolithiasis|Topic|DISCUSSES
1488|David G. Bell|Author|High-Throughput, Semi-Autonomous Measurement Of Cavitation-Mediated Material Breakage|Paper|AUTHORED
1488|Matthew A. Hopcroft|Author|High-Throughput, Semi-Autonomous Measurement Of Cavitation-Mediated Material Breakage|Paper|AUTHORED
1488|William M. Behnke-Parks|Author|High-Throughput, Semi-Autonomous Measurement Of Cavitation-Mediated Material Breakage|Paper|AUTHORED
1489|Mild Cognitive Impairment|Topic|Alzheimer'S Disease Dementia|Topic|RELATED_TO
1489|Deep Learning Model|Topic|Mild Cognitive Impairment|Topic|DISCUSSES
1489|Deep Learning Model|Topic|Mri Scans|Topic|DISCUSSES
1489|Deep Learning Model|Topic|C-Index|Topic|DISCUSSES
1489|Deep Learning Model|Topic|Clinical Trials|Topic|DISCUSSES
1489|Hongming Li|Author|Deep Learning Model|Topic|AUTHORED
1489|Mohamad Habes|Author|Deep Learning Model|Topic|AUTHORED
1489|David A. Wolk|Author|Deep Learning Model|Topic|AUTHORED
1489|Yong Fan|Author|Deep Learning Model|Topic|AUTHORED
1489|2146 Subjects|Topic|Deep Learning Model|Topic|RELATED_TO
1489|Adni Testing Mci Subjects|Topic|C-Index|Topic|RELATED_TO
1489|Aibl Testing Mci Subjects|Topic|C-Index|Topic|RELATED_TO
1490|Landmark Proportional Subdistribution Hazards Models For Dynamic Prediction Of Cumulative Incidence Functions|Paper|Qing Liu|Author|AUTHORED
1490|Landmark Proportional Subdistribution Hazards Models For Dynamic Prediction Of Cumulative Incidence Functions|Paper|Gong Tang|Author|AUTHORED
1490|Landmark Proportional Subdistribution Hazards Models For Dynamic Prediction Of Cumulative Incidence Functions|Paper|Joseph P. Costantino|Author|AUTHORED
1490|Landmark Proportional Subdistribution Hazards Models For Dynamic Prediction Of Cumulative Incidence Functions|Paper|Chung-Chou H. Chang|Author|AUTHORED
1491|Radiopathomics: Integration Of Radiographic And Histologic Characteristics For Prognostication In Glioblastoma|Paper|Glioblastoma|Topic|RELATED_TO
1491|Radiopathomics: Integration Of Radiographic And Histologic Characteristics For Prognostication In Glioblastoma|Paper|Rad Imaging|Topic|RELATED_TO
1491|Radiopathomics: Integration Of Radiographic And Histologic Characteristics For Prognostication In Glioblastoma|Paper|Path Images|Topic|RELATED_TO
1491|Radiopathomics: Integration Of Radiographic And Histologic Characteristics For Prognostication In Glioblastoma|Paper|The Cancer Imaging Archive|Topic|RELATED_TO
1491|Radiopathomics: Integration Of Radiographic And Histologic Characteristics For Prognostication In Glioblastoma|Paper|Support Vector Machine|Topic|RELATED_TO
1491|Radiopathomics: Integration Of Radiographic And Histologic Characteristics For Prognostication In Glioblastoma|Paper|Support Vector Regression|Topic|RELATED_TO
1492|Covid-19|Topic|Drug Design|Topic|RELATED_TO
1492|Hiv-1 Protease Inhibitors|Topic|Covid-19|Topic|RELATED_TO
1492|Anti Bronchitis Drugs|Topic|Covid-19|Topic|RELATED_TO
1492|Mohammad Reza Dayer|Author|Covid-19|Topic|AUTHORED
1493|Heterogeneous Treatment Effects Model|Topic|Multiple Sclerosis|Topic|RELATED_TO
1493|Heterogeneous Treatment Effects Model|Topic|Natalizumab|Topic|RELATED_TO
1493|Heterogeneous Treatment Effects Model|Topic|Glatiramer Acetate|Topic|RELATED_TO
1493|Heterogeneous Treatment Effects Model|Topic|Dimethyl Fumarate|Topic|RELATED_TO
1493|Heterogeneous Treatment Effects Model|Topic|Konstantina Chalkou|Author|AUTHORED
1493|Heterogeneous Treatment Effects Model|Topic|Ewout Steyerberg|Author|AUTHORED
1493|Heterogeneous Treatment Effects Model|Topic|Matthias Egger|Author|AUTHORED
1493|Heterogeneous Treatment Effects Model|Topic|Andrea Manca|Author|AUTHORED
1493|Heterogeneous Treatment Effects Model|Topic|Fabio Pellegrini|Author|AUTHORED
1493|Heterogeneous Treatment Effects Model|Topic|Georgia Salanti|Author|AUTHORED
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Zhiliang Wu|Author|AUTHORED
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Yinchong Yang|Author|AUTHORED
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Yunpu Ma|Author|AUTHORED
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Yushan Liu|Author|AUTHORED
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Rui Zhao|Author|AUTHORED
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Michael Moor|Author|AUTHORED
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Volker Tresp|Author|AUTHORED
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Individualized Treatment Rules|Topic|RELATED_TO
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Contextual Bandit Problem|Topic|RELATED_TO
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Intravenous Fluids|Topic|RELATED_TO
1494|Learning Individualized Treatment Rules With Estimated Translated Inverse Propensity Score|Paper|Vasopressors|Topic|RELATED_TO
1495|Smile-Gan|Topic|Alzheimer'S Disease|Topic|RELATED_TO
1495|Zhijian Yang|Author|Smile-Gan|Topic|AUTHORED
1495|Ilya M. Nasrallah|Author|Smile-Gan|Topic|AUTHORED
1495|Haochang Shou|Author|Smile-Gan|Topic|AUTHORED
1495|Junhao Wen|Author|Smile-Gan|Topic|AUTHORED
1495|Jimit Doshi|Author|Smile-Gan|Topic|AUTHORED
1495|Mohamad Habes|Author|Smile-Gan|Topic|AUTHORED
1495|Guray Erus|Author|Smile-Gan|Topic|AUTHORED
1495|Ahmed Abdulkadir|Author|Smile-Gan|Topic|AUTHORED
1495|Susan M. Resnick|Author|Smile-Gan|Topic|AUTHORED
1495|David Wolk|Author|Smile-Gan|Topic|AUTHORED
1495|Christos Davatzikos|Author|Smile-Gan|Topic|AUTHORED
1496|Human-Curated Disease Ontologies|Topic|Disease Modules (Dms)|Topic|RELATED_TO
1496|Disease Modules (Dms)|Topic|Human-Curated Disease Taxonomy|Topic|RELATED_TO
1496|Giorgio Grani|Author|Human-Curated Disease Taxonomy|Topic|AUTHORED
1496|Lorenzo Madeddu|Author|Human-Curated Disease Taxonomy|Topic|AUTHORED
1496|Paola Velardi|Author|Human-Curated Disease Taxonomy|Topic|AUTHORED
1496|Interactome|Topic|Disease Modules (Dms)|Topic|RELATED_TO
1497|Cohort Bias Adaptation In Aggregated Datasets For Lesion Segmentation|Paper|Source-Conditioned Instance Normalization (Scin)|Topic|DISCUSSES
1497|Cohort Bias Adaptation In Aggregated Datasets For Lesion Segmentation|Paper|Cohort Bias|Topic|DISCUSSES
1497|Cohort Bias Adaptation In Aggregated Datasets For Lesion Segmentation|Paper|Multiple Sclerosis (Ms)|Topic|DISCUSSES
1497|Brennan Nichyporuk|Author|Cohort Bias Adaptation In Aggregated Datasets For Lesion Segmentation|Paper|AUTHORED
1497|Jillian Cardinell|Author|Cohort Bias Adaptation In Aggregated Datasets For Lesion Segmentation|Paper|AUTHORED
1497|Justin Szeto|Author|Cohort Bias Adaptation In Aggregated Datasets For Lesion Segmentation|Paper|AUTHORED
1497|Raghav Mehta|Author|Cohort Bias Adaptation In Aggregated Datasets For Lesion Segmentation|Paper|AUTHORED
1497|Sotirios Tsaftaris|Author|Cohort Bias Adaptation In Aggregated Datasets For Lesion Segmentation|Paper|AUTHORED
1497|Douglas L. Arnold|Author|Cohort Bias Adaptation In Aggregated Datasets For Lesion Segmentation|Paper|AUTHORED
1497|Tal Arbel|Author|Cohort Bias Adaptation In Aggregated Datasets For Lesion Segmentation|Paper|AUTHORED
1498|Precision Medicine For Chronic Diseases|Topic|Multiple Sclerosis|Topic|RELATED_TO
1498|Multiple Sclerosis|Topic|Deep Neural Network Model|Topic|RELATED_TO
1498|Deep Neural Network Model|Topic|Baseline Magnetic Resonance Imaging|Topic|RELATED_TO
1498|Joshua Durso-Finley|Author|Deep Neural Network Model|Topic|AUTHORED
1498|Jean-Pierre R. Falet|Author|Deep Neural Network Model|Topic|AUTHORED
1498|Brennan Nichyporuk|Author|Deep Neural Network Model|Topic|AUTHORED
1498|Douglas L. Arnold|Author|Deep Neural Network Model|Topic|AUTHORED
1498|Tal Arbel|Author|Deep Neural Network Model|Topic|AUTHORED
1498|Deep Neural Network Model|Topic|Proprietary Federated Dataset|Topic|RELATED_TO
1498|Proprietary Federated Dataset|Topic|Multi-Sequence Mris|Topic|RELATED_TO
1498|Multi-Sequence Mris|Topic|Multi-Centre Randomized Clinical Trials|Topic|RELATED_TO
1498|Deep Neural Network Model|Topic|Average Precision|Topic|RELATED_TO
1498|Average Precision|Topic|Binarized Regression|Topic|RELATED_TO
1498|Deep Neural Network Model|Topic|Personalized Treatment Recommendation|Topic|RELATED_TO
1499|Pseudo-Survival Time Method|Topic|Restricted Mean Survival Time|Topic|RELATED_TO
1499|Inverse Probability Of Censoring Weighting (Ipcw) Method|Topic|Restricted Mean Survival Time|Topic|RELATED_TO
1499|Example Dataset|Topic|Pseudo-Survival Time Method|Topic|DISCUSSES
1499|Example Dataset|Topic|Inverse Probability Of Censoring Weighting (Ipcw) Method|Topic|DISCUSSES
1499|Computer Simulations|Topic|Pseudo-Survival Time Method|Topic|DISCUSSES
1499|Computer Simulations|Topic|Inverse Probability Of Censoring Weighting (Ipcw) Method|Topic|DISCUSSES
1499|Keisuke Hanada|Author|Comparison Of Baseline Covariate Adjustment Methods For Restricted Mean Survival Time|Paper|AUTHORED
1499|Junji Moriya|Author|Comparison Of Baseline Covariate Adjustment Methods For Restricted Mean Survival Time|Paper|AUTHORED
1499|Masahiro Kojima|Author|Comparison Of Baseline Covariate Adjustment Methods For Restricted Mean Survival Time|Paper|AUTHORED
1500|Randomized Controlled Trials|Topic|Real-World Evidence|Topic|RELATED_TO
1500|Real-World Evidence|Topic|Real-World Data|Topic|RELATED_TO
1500|Real-World Data|Topic|Electronic Health Records|Topic|RELATED_TO
1500|Electronic Health Records|Topic|Natural Language Processing|Topic|RELATED_TO
1500|Electronic Health Records|Topic|Computational Phenotyping|Topic|RELATED_TO
1500|Mass General Brigham|Topic|Real-World Evidence|Topic|RELATED_TO
1500|Jue Hou|Author|Real-World Evidence|Topic|AUTHORED
1500|Rachel Zhao|Author|Real-World Evidence|Topic|AUTHORED
1500|Jessica Gronsbell|Author|Real-World Evidence|Topic|AUTHORED
1500|Brett K. Beaulieu-Jones|Author|Real-World Evidence|Topic|AUTHORED
1500|Griffin Webber|Author|Real-World Evidence|Topic|AUTHORED
1500|Thomas Jemielita|Author|Real-World Evidence|Topic|AUTHORED
1500|Shuyan Wan|Author|Real-World Evidence|Topic|AUTHORED
1500|Chuan Hong|Author|Real-World Evidence|Topic|AUTHORED
1500|Yucong Lin|Author|Real-World Evidence|Topic|AUTHORED
1500|Tianrun Cai|Author|Real-World Evidence|Topic|AUTHORED
1500|Jun Wen|Author|Real-World Evidence|Topic|AUTHORED
1500|Vidul A. Panickan|Author|Real-World Evidence|Topic|AUTHORED
1500|Clara-Lea Bonzel|Author|Real-World Evidence|Topic|AUTHORED
1500|Kai-Li Liaw|Author|Real-World Evidence|Topic|AUTHORED
1500|Katherine P. Liao|Author|Real-World Evidence|Topic|AUTHORED
1500|Tianxi Cai|Author|Real-World Evidence|Topic|AUTHORED
1501|Clinical Research Studies|Topic|Internal Validity|Topic|RELATED_TO
1501|Clinical Research Studies|Topic|External Validity|Topic|RELATED_TO
1501|Prospective Observational Studies|Topic|External Validity|Topic|RELATED_TO
1501|Prospective Observational Studies|Topic|Confounding|Topic|RELATED_TO
1501|Transportability|Topic|Data-Fusion|Topic|RELATED_TO
1501|Calibration Method|Topic|Confounding|Topic|RELATED_TO
1501|Calibration Method|Topic|Target Population Average Treatment Effect|Topic|RELATED_TO
1501|Doubly-Robust Methods|Topic|Target Population Average Treatment Effect|Topic|RELATED_TO
1501|Simulation Study|Topic|Calibration Method|Topic|RELATED_TO
1501|Biguanides|Topic|Sulfonylureas|Topic|RELATED_TO
1501|Biguanides|Topic|All-Cause Mortality|Topic|RELATED_TO
1501|Sulfonylureas|Topic|All-Cause Mortality|Topic|RELATED_TO
1501|Kevin P. Josey|Author|Calibration Method|Topic|AUTHORED
1501|Fan Yang|Author|Calibration Method|Topic|AUTHORED
1501|Debashis Ghosh|Author|Calibration Method|Topic|AUTHORED
1501|Sridharan Raghavan|Author|Calibration Method|Topic|AUTHORED
1502|Ai In Healthcare|Topic|Radiology|Topic|RELATED_TO
1502|Ai In Healthcare|Topic|Dermatology|Topic|RELATED_TO
1502|Ai In Healthcare|Topic|Ophthalmology|Topic|RELATED_TO
1502|Ai In Healthcare|Topic|In Vitro Fertilization (Ivf)|Topic|RELATED_TO
1502|In Vitro Fertilization (Ivf)|Topic|Ethical Issues In Ivf|Topic|RELATED_TO
1502|In Vitro Fertilization (Ivf)|Topic|Interpretable Models|Topic|RELATED_TO
1502|In Vitro Fertilization (Ivf)|Topic|Clinical Effectiveness Trials|Topic|RELATED_TO
1502|Michael Anis Mihdi Afnan|Author|Ethical Implementation Of Artificial Intelligence To Select Embryos In In Vitro Fertilization|Paper|AUTHORED
1502|Cynthia Rudin|Author|Ethical Implementation Of Artificial Intelligence To Select Embryos In In Vitro Fertilization|Paper|AUTHORED
1502|Vincent Conitzer|Author|Ethical Implementation Of Artificial Intelligence To Select Embryos In In Vitro Fertilization|Paper|AUTHORED
1502|Julian Savulescu|Author|Ethical Implementation Of Artificial Intelligence To Select Embryos In In Vitro Fertilization|Paper|AUTHORED
1502|Abhishek Mishra|Author|Ethical Implementation Of Artificial Intelligence To Select Embryos In In Vitro Fertilization|Paper|AUTHORED
1502|Yanhe Liu|Author|Ethical Implementation Of Artificial Intelligence To Select Embryos In In Vitro Fertilization|Paper|AUTHORED
1502|Masoud Afnan|Author|Ethical Implementation Of Artificial Intelligence To Select Embryos In In Vitro Fertilization|Paper|AUTHORED
1503|Emergency Department|Topic|Hospital Admission|Topic|RELATED_TO
1503|Machine Learning|Topic|Hospital Admission|Topic|RELATED_TO
1503|Hospital Admission|Topic|Ed Visits|Topic|RELATED_TO
1503|Hospital Admission|Topic|Biomarkers|Topic|RELATED_TO
1503|F-Measure|Topic|Hospital Admission|Topic|RELATED_TO
1503|Roc Area|Topic|Hospital Admission|Topic|RELATED_TO
1503|Georgios Feretzakis|Author|Hospital Admission|Topic|AUTHORED
1503|George Karlis|Author|Hospital Admission|Topic|AUTHORED
1503|Evangelos Loupelis|Author|Hospital Admission|Topic|AUTHORED
1503|Dimitris Kalles|Author|Hospital Admission|Topic|AUTHORED
1503|Rea Chatzikyriakou|Author|Hospital Admission|Topic|AUTHORED
1503|Nikolaos Trakas|Author|Hospital Admission|Topic|AUTHORED
1503|Eugenia Karakou|Author|Hospital Admission|Topic|AUTHORED
1503|Aikaterini Sakagianni|Author|Hospital Admission|Topic|AUTHORED
1503|Lazaros Tzelves|Author|Hospital Admission|Topic|AUTHORED
1503|Stavroula Petropoulou|Author|Hospital Admission|Topic|AUTHORED
1503|Aikaterini Tika|Author|Hospital Admission|Topic|AUTHORED
1503|Ilias Dalainas|Author|Hospital Admission|Topic|AUTHORED
1503|Vasileios Kaldis|Author|Hospital Admission|Topic|AUTHORED
1504|Geoecg: Data Augmentation Via Wasserstein Geodesic Perturbation For Robust Electrocardiogram Prediction|Paper|Jiacheng Zhu|Author|AUTHORED
1504|Geoecg: Data Augmentation Via Wasserstein Geodesic Perturbation For Robust Electrocardiogram Prediction|Paper|Jielin Qiu|Author|AUTHORED
1504|Geoecg: Data Augmentation Via Wasserstein Geodesic Perturbation For Robust Electrocardiogram Prediction|Paper|Zhuolin Yang|Author|AUTHORED
1504|Geoecg: Data Augmentation Via Wasserstein Geodesic Perturbation For Robust Electrocardiogram Prediction|Paper|Douglas Weber|Author|AUTHORED
1504|Geoecg: Data Augmentation Via Wasserstein Geodesic Perturbation For Robust Electrocardiogram Prediction|Paper|Michael A. Rosenberg|Author|AUTHORED
1504|Geoecg: Data Augmentation Via Wasserstein Geodesic Perturbation For Robust Electrocardiogram Prediction|Paper|Emerson Liu|Author|AUTHORED
1504|Geoecg: Data Augmentation Via Wasserstein Geodesic Perturbation For Robust Electrocardiogram Prediction|Paper|Bo Li|Author|AUTHORED
1504|Geoecg: Data Augmentation Via Wasserstein Geodesic Perturbation For Robust Electrocardiogram Prediction|Paper|Ding Zhao|Author|AUTHORED
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Amar Kumar|Author|AUTHORED
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Anjun Hu|Author|AUTHORED
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Brennan Nichyporuk|Author|AUTHORED
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Jean-Pierre R. Falet|Author|AUTHORED
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Douglas L. Arnold|Author|AUTHORED
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Sotirios Tsaftaris|Author|AUTHORED
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Tal Arbel|Author|AUTHORED
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Multiple Sclerosis|Topic|RELATED_TO
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Deep Learning|Topic|RELATED_TO
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Biomarker Discovery|Topic|RELATED_TO
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Counterfactual Synthesis|Topic|RELATED_TO
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Magnetic Resonance Imaging|Topic|RELATED_TO
1505|Counterfactual Image Synthesis For Discovery Of Personalized Predictive Image Markers|Paper|Relapsing-Remitting Multiple Sclerosis|Topic|RELATED_TO
1506|Causally-Interpretable Meta-Analysis|Topic|Kollin W. Rott|Author|AUTHORED
1506|Causally-Interpretable Meta-Analysis|Topic|Gert Bronfort|Author|AUTHORED
1506|Causally-Interpretable Meta-Analysis|Topic|Haitao Chu|Author|AUTHORED
1506|Causally-Interpretable Meta-Analysis|Topic|Jared D. Huling|Author|AUTHORED
1506|Causally-Interpretable Meta-Analysis|Topic|Brent Leininger|Author|AUTHORED
1506|Causally-Interpretable Meta-Analysis|Topic|Mohammad Hassan Murad|Author|AUTHORED
1506|Causally-Interpretable Meta-Analysis|Topic|Zhen Wang|Author|AUTHORED
1506|Causally-Interpretable Meta-Analysis|Topic|James S. Hodges|Author|AUTHORED
1507|Multimodal And Multicontrast Image Fusion Via Deep Generative Models|Paper|Giovanna Maria Dimitri|Author|AUTHORED
1507|Multimodal And Multicontrast Image Fusion Via Deep Generative Models|Paper|Simeon Spasov|Author|AUTHORED
1507|Multimodal And Multicontrast Image Fusion Via Deep Generative Models|Paper|Andrea Duggento|Author|AUTHORED
1507|Multimodal And Multicontrast Image Fusion Via Deep Generative Models|Paper|Luca Passamonti|Author|AUTHORED
1507|Multimodal And Multicontrast Image Fusion Via Deep Generative Models|Paper|Pietro Li`O|Author|AUTHORED
1507|Multimodal And Multicontrast Image Fusion Via Deep Generative Models|Paper|Nicola Toschi|Author|AUTHORED
1508|Artificial Intelligence|Topic|Drug-Drug Interactions|Topic|RELATED_TO
1508|Deep Learning|Topic|Drug-Drug Interactions|Topic|RELATED_TO
1508|Graph Learning|Topic|Drug-Drug Interactions|Topic|RELATED_TO
1508|Xuan Lin|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Lichang Dai|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Yafang Zhou|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Zu-Guo Yu|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Wen Zhang|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Jian-Yu Shi|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Dong-Sheng Cao|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Li Zeng|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Haowen Chen|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Bosheng Song|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Philip S. Yu|Author|Drug-Drug Interactions|Topic|AUTHORED
1508|Xiangxiang Zeng|Author|Drug-Drug Interactions|Topic|AUTHORED
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Haoran Dou|Author|AUTHORED
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Nishant Ravikumar|Author|AUTHORED
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Alejandro F. Frangi|Author|AUTHORED
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Virtual Populations|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Conditional Variational Autoencoder|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Normalising Flows|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Cardiac Left Ventricles|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Demographic Information|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Clinical Measurements|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Generalisation Errors|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Specificity Errors|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Clinically Relevant Biomarkers|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Left Ventricular Blood Pool|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Myocardial Volume|Topic|RELATED_TO
1509|Conditional Flow Variational Autoencoder For Controllable Synthesis Of Virtual Populations Of Anatomy|Paper|Real Observed Population|Topic|RELATED_TO
1510|Opioids|Topic|Opioid Use Disorder|Topic|RELATED_TO
1510|Oud Risk Estimation Framework|Topic|Opioid Use Disorder|Topic|RELATED_TO
1510|Sybille Légitime|Author|Oud Risk Estimation Framework|Topic|AUTHORED
1510|Kaustubh Prabhu|Author|Oud Risk Estimation Framework|Topic|AUTHORED
1510|Devin Mcconnell|Author|Oud Risk Estimation Framework|Topic|AUTHORED
1510|Bing Wang|Author|Oud Risk Estimation Framework|Topic|AUTHORED
1510|Dipak K. Dey|Author|Oud Risk Estimation Framework|Topic|AUTHORED
1510|Derek Aguiar|Author|Oud Risk Estimation Framework|Topic|AUTHORED
1511|Histological Examination|Topic|Two-Color Stimulated Raman Histology|Topic|RELATED_TO
1511|Two-Color Stimulated Raman Histology|Topic|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|RELATED_TO
1511|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|Breast Tissue|Topic|RELATED_TO
1511|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|Fiber Laser-Based Srs Microscopy|Topic|RELATED_TO
1511|Nucleic Acid|Topic|Solid-State Ester|Topic|RELATED_TO
1511|Hongli Ni|Author|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|AUTHORED
1511|Chinmayee Prabhu Dessai|Author|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|AUTHORED
1511|Haonan Lin|Author|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|AUTHORED
1511|Wei Wang|Author|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|AUTHORED
1511|Shaoxiong Chen|Author|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|AUTHORED
1511|Yuhao Yuan|Author|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|AUTHORED
1511|Xiaowei Ge|Author|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|AUTHORED
1511|Jianpeng Ao|Author|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|AUTHORED
1511|Nolan Vild|Author|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|AUTHORED
1511|Ji-Xin Cheng|Author|High-Content Stimulated Raman Histology (Hc-Srh)|Topic|AUTHORED
1512|Visuospatial Neglect|Topic|Stroke|Topic|RELATED_TO
1512|Artificial Intelligence Solution|Topic|Visuospatial Neglect|Topic|RELATED_TO
1512|Gaussian Process Regression|Topic|Artificial Intelligence Solution|Topic|RELATED_TO
1512|Artificial Intelligence Solution|Topic|Gamification|Topic|RELATED_TO
1512|Artificial Intelligence Solution|Topic|Tele-Rehabilitation|Topic|RELATED_TO
1512|Artificial Intelligence Solution|Topic|Personalised Healthcare|Topic|RELATED_TO
1512|Clinical Trials|Topic|Ai-Based Assessment|Topic|RELATED_TO
1512|Ai-Based Assessment|Topic|Vr Application|Topic|RELATED_TO
1512|Ivan De Boi|Author|Clinical Trials|Topic|AUTHORED
1512|Elissa Embrechts|Author|Clinical Trials|Topic|AUTHORED
1512|Quirine Schatteman|Author|Clinical Trials|Topic|AUTHORED
1512|Rudi Penne|Author|Clinical Trials|Topic|AUTHORED
1512|Steven Truijen|Author|Clinical Trials|Topic|AUTHORED
1512|Wim Saeys|Author|Clinical Trials|Topic|AUTHORED
1513|Intracortical Brain-Computer Interfaces (Ibcis)|Topic|Amyotrophic Lateral Sclerosis (Als)|Topic|RELATED_TO
1513|Self-Recalibration Of Communication Ibcis|Topic|Large Language Models (Lms)|Topic|RELATED_TO
1513|Continual Online Recalibration With Pseudo-Labels (Corp)|Topic|93.84%|Topic|RELATED_TO
1513|Plug-And-Play Stability For Intracortical Brain-Computer Interfaces: A One-Year Demonstration Of Seamless Brain-To-Text Communication|Paper|Self-Recalibration Of Communication Ibcis|Topic|DISCUSSES
1514|Sp-Diffdose|Paper|Radiation Therapy|Topic|RELATED_TO
1514|Sp-Diffdose|Paper|Swintransformer|Topic|RELATED_TO
1514|Sp-Diffdose|Paper|Linjie Fu|Author|AUTHORED
1514|Sp-Diffdose|Paper|Xia Li|Author|AUTHORED
1514|Sp-Diffdose|Paper|Xiuding Cai|Author|AUTHORED
1514|Sp-Diffdose|Paper|Yingkai Wang|Author|AUTHORED
1514|Sp-Diffdose|Paper|Xueyao Wang|Author|AUTHORED
1514|Sp-Diffdose|Paper|Yu Yao|Author|AUTHORED
1514|Sp-Diffdose|Paper|Yali Shen|Author|AUTHORED
1515|Synthetic Data Generation|Topic|Clinical Cohort|Topic|RELATED_TO
1515|Heterogeneity|Topic|Variational Autoencoders|Topic|RELATED_TO
1515|Variational Autoencoders|Topic|Propensity Score Regression|Topic|RELATED_TO
1515|Kiana Farhadyar|Author|Synthetic Data Generation|Topic|AUTHORED
1515|Federico Bonofiglio|Author|Synthetic Data Generation|Topic|AUTHORED
1515|Maren Hackenberg|Author|Synthetic Data Generation|Topic|AUTHORED
1515|Daniela Zoeller|Author|Synthetic Data Generation|Topic|AUTHORED
1515|Harald Binder|Author|Synthetic Data Generation|Topic|AUTHORED
1515|International Stroke Trial|Topic|Heterogeneity|Topic|RELATED_TO
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Thiago Santos|Author|AUTHORED
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Harish Kamath|Author|AUTHORED
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Christopher R. Mcadams|Author|AUTHORED
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Mary S. Newell|Author|AUTHORED
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Marina Mosunjac|Author|AUTHORED
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Gabriela Oprea-Ilies|Author|AUTHORED
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Geoffrey Smith|Author|AUTHORED
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Constance Lehman|Author|AUTHORED
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Judy Gichoya|Author|AUTHORED
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Imon Banerjee|Author|AUTHORED
1516|Hierarchical Classification System For Breast Cancer Specimen Report (Hcsbc)|Topic|Hari Trivedi|Author|AUTHORED
1517|Qtnet|Topic|Dofetilide|Topic|RELATED_TO
1517|Qtnet|Topic|Massachusetts General Hospital|Topic|RELATED_TO
1517|Qtnet|Topic|Ecgrdvq-Dataset|Topic|RELATED_TO
1517|Qtnet|Topic|Ridwan Alam|Author|AUTHORED
1517|Qtnet|Topic|Aaron Aguirre|Author|AUTHORED
1517|Qtnet|Topic|Collin Stultz|Author|AUTHORED
1518|Cardiac Digital Twin|Topic|Automated Pipeline|Topic|RELATED_TO
1518|Automated Pipeline|Topic|Dofetilide|Topic|RELATED_TO
1518|Julia Camps|Author|Cardiac Digital Twin|Topic|AUTHORED
1518|Zhinuo Jenny Wang|Author|Cardiac Digital Twin|Topic|AUTHORED
1518|Ruben Doste|Author|Cardiac Digital Twin|Topic|AUTHORED
1518|Maxx Holmes|Author|Cardiac Digital Twin|Topic|AUTHORED
1518|Brodie Lawson|Author|Cardiac Digital Twin|Topic|AUTHORED
1518|Jakub Tomek|Author|Cardiac Digital Twin|Topic|AUTHORED
1518|Kevin Burrage|Author|Cardiac Digital Twin|Topic|AUTHORED
1518|Alfonso Bueno-Orovio|Author|Cardiac Digital Twin|Topic|AUTHORED
1518|Blanca Rodriguez|Author|Cardiac Digital Twin|Topic|AUTHORED
1519|Learning Optimal Dynamic Treatment Regimes From Longitudinal Data|Paper|Optimal Dynamic Treatment Rule|Topic|DISCUSSES
1520|Concurrency Of Transcranial Magnetic Stimulation With Electroencephalography|Topic|Tms-Eeg Methodology|Topic|RELATED_TO
1520|Tms-Eeg Methodology|Topic|Intermittent Theta-Burst Stimulation|Topic|RELATED_TO
1520|Tms-Eeg Methodology|Topic|Continuous Theta-Burst Stimulation|Topic|RELATED_TO
1520|Intermittent Theta-Burst Stimulation|Topic|Left Dorsolateral Prefrontal Cortex|Topic|RELATED_TO
1520|Continuous Theta-Burst Stimulation|Topic|Left Dorsolateral Prefrontal Cortex|Topic|RELATED_TO
1520|Brainstorm|Author|Tms-Eeg Methodology|Topic|AUTHORED
1520|Hua Cheng|Author|Tms-Eeg Methodology|Topic|AUTHORED
1521|Clinical Decision-Making|Topic|Randomized Controlled Trials|Topic|RELATED_TO
1521|Clinical Decision-Making|Topic|Machine Learning Models|Topic|RELATED_TO
1521|Clinical Decision Support System|Topic|Multiple Myeloma|Topic|RELATED_TO
1521|Interventional Study|Topic|Clinical Decision-Making|Topic|RELATED_TO
1521|Zeshan Hussain|Author|Evaluating Physician-Ai Interaction For Cancer Management: Paving The Path Towards Precision Oncology|Paper|AUTHORED
1521|Barbara D. Lam|Author|Evaluating Physician-Ai Interaction For Cancer Management: Paving The Path Towards Precision Oncology|Paper|AUTHORED
1521|Fernando A. Acosta-Perez|Author|Evaluating Physician-Ai Interaction For Cancer Management: Paving The Path Towards Precision Oncology|Paper|AUTHORED
1521|Irbaz Bin Riaz|Author|Evaluating Physician-Ai Interaction For Cancer Management: Paving The Path Towards Precision Oncology|Paper|AUTHORED
1521|Maia Jacobs|Author|Evaluating Physician-Ai Interaction For Cancer Management: Paving The Path Towards Precision Oncology|Paper|AUTHORED
1521|Andrew J. Yee|Author|Evaluating Physician-Ai Interaction For Cancer Management: Paving The Path Towards Precision Oncology|Paper|AUTHORED
1521|David Sontag|Author|Evaluating Physician-Ai Interaction For Cancer Management: Paving The Path Towards Precision Oncology|Paper|AUTHORED
1522|Digital Twin|Topic|Digital Twin Generators|Topic|RELATED_TO
1522|Digital Twin Generators|Topic|Machine Learning|Topic|RELATED_TO
1522|Machine Learning|Topic|Health Records|Topic|RELATED_TO
1522|Digital Twin Generators|Topic|Clinical Trials|Topic|RELATED_TO
1522|Digital Twin Generators|Topic|Personalized Treatment|Topic|RELATED_TO
1522|Authors|Author|Digital Twin Generators|Topic|AUTHORED
1523|Automated Pipeline|Topic|Rheumatoid Arthritis|Topic|RELATED_TO
1523|Van Der Heijde Modification Of The Sharp Score|Topic|Rheumatoid Arthritis|Topic|RELATED_TO
1523|Deep Learning Models To Automate The Scoring Of Hand Radiographs For Rheumatoid Arthritis|Paper|Automated Pipeline|Topic|AUTHORED
1524|Biobanks|Topic|Biomedical And Clinical Research|Topic|RELATED_TO
1524|Rodrigo Dorantes-Gilardi|Author|Quantifying The Impact Of Biobanks And Cohort Studies|Paper|AUTHORED
1524|Kerry Ivey|Author|Quantifying The Impact Of Biobanks And Cohort Studies|Paper|AUTHORED
1524|Lauren Costa|Author|Quantifying The Impact Of Biobanks And Cohort Studies|Paper|AUTHORED
1524|Rachael Matty|Author|Quantifying The Impact Of Biobanks And Cohort Studies|Paper|AUTHORED
1524|Kelly Cho|Author|Quantifying The Impact Of Biobanks And Cohort Studies|Paper|AUTHORED
1524|John Michael Gaziano|Author|Quantifying The Impact Of Biobanks And Cohort Studies|Paper|AUTHORED
1524|Albert-László Barabási|Author|Quantifying The Impact Of Biobanks And Cohort Studies|Paper|AUTHORED
1524|Scientific Articles|Topic|Biobanks|Topic|RELATED_TO
1524|Grants|Topic|Biobanks|Topic|RELATED_TO
1524|Patents|Topic|Biobanks|Topic|RELATED_TO
1524|Clinical Trials|Topic|Biobanks|Topic|RELATED_TO
1524|Public Policy Documents|Topic|Biobanks|Topic|RELATED_TO
1524|Obesity|Topic|Biobanks|Topic|RELATED_TO
1524|Alzheimer'S Disease|Topic|Biobanks|Topic|RELATED_TO
1524|Breast Cancer|Topic|Biobanks|Topic|RELATED_TO
1524|Diabetes|Topic|Biobanks|Topic|RELATED_TO
1524|Open-Access Web Application|Topic|Biobanks|Topic|RELATED_TO
1524|Impact Of Biobanks|Topic|Biobanks|Topic|RELATED_TO
1525|Objective Structured Assessments Of Technical Skills (Osats)|Topic|Global Rating Scale (Grs)|Topic|RELATED_TO
1525|Jigsaws Dataset|Topic|Global Rating Scale (Grs)|Topic|RELATED_TO
1525|Jigsaws Dataset|Topic|Objective Structured Assessments Of Technical Skills (Osats)|Topic|RELATED_TO
1525|Recurrent Transformer Model|Topic|Global Rating Scale (Grs)|Topic|DISCUSSES
1525|Recurrent Transformer Model|Topic|Objective Structured Assessments Of Technical Skills (Osats)|Topic|DISCUSSES
1525|Julien Quarez|Author|Recurrent Transformer Model|Topic|AUTHORED
1525|Marc Modat|Author|Recurrent Transformer Model|Topic|AUTHORED
1525|Sebastien Ourselin|Author|Recurrent Transformer Model|Topic|AUTHORED
1525|Jonathan Shapey|Author|Recurrent Transformer Model|Topic|AUTHORED
1525|Alejandro Granados|Author|Recurrent Transformer Model|Topic|AUTHORED
1525|Spearman'S Correlation Coefficients (Scc)|Topic|Recurrent Transformer Model|Topic|DISCUSSES
1525|Senior Surgeon|Topic|Recurrent Transformer Model|Topic|DISCUSSES
1525|Automated Surgical Skill Assessment Pipelines|Topic|Recurrent Transformer Model|Topic|DISCUSSES
1526|X-Ray Dark-Field Imaging|Topic|Xdfi Simulation|Topic|RELATED_TO
1526|Xdfi Simulation|Topic|Emphysema|Topic|RELATED_TO
1526|Xdfi Simulation|Topic|Fibrosis|Topic|RELATED_TO
1526|Xdfi Simulation|Topic|Atelectasis|Topic|RELATED_TO
1526|Xdfi Simulation|Topic|Edema|Topic|RELATED_TO
1526|Xdfi Simulation|Topic|Pneumonia|Topic|RELATED_TO
1526|Xdfi Simulation|Topic|Xcat Phantom|Topic|RELATED_TO
1526|Xcat Phantom|Topic|Voronoi Grids|Topic|RELATED_TO
1526|Voronoi Grids|Topic|Multi-Layer Wave-Optics Propagation|Topic|RELATED_TO
1526|Multi-Layer Wave-Optics Propagation|Topic|Realistic Xdfi Images|Topic|RELATED_TO
1526|Realistic Xdfi Images|Topic|Lung Pathologies|Topic|RELATED_TO
1526|Lung Pathologies|Topic|In-Silico Clinical Trials|Topic|RELATED_TO
1526|Lung Pathologies|Topic|Hardware And Software Optimization|Topic|RELATED_TO
1526|Yongjin Sung|Author|X-Ray Dark-Field Imaging|Topic|AUTHORED
1526|Brandon Nelson|Author|X-Ray Dark-Field Imaging|Topic|AUTHORED
1526|Rajiv Gupta|Author|X-Ray Dark-Field Imaging|Topic|AUTHORED
1528|Segmenting Brain Tumors In Multi-Parametric Magnetic Resonance Imaging|Topic|Brain Tumor Segmentation (Brats) Challenge|Topic|RELATED_TO
1528|Brain Tumor Segmentation (Brats) Challenge|Topic|Deep Learning-Based Ensemble Strategy|Topic|RELATED_TO
1528|Deep Learning-Based Ensemble Strategy|Topic|Pediatric Brain Tumors (Ped)|Topic|RELATED_TO
1528|Deep Learning-Based Ensemble Strategy|Topic|Intracranial Meningioma (Men)|Topic|RELATED_TO
1528|Deep Learning-Based Ensemble Strategy|Topic|Brain Metastases (Met)|Topic|RELATED_TO
1528|Deep Learning-Based Ensemble Strategy|Topic|Daniel Capellán-Martín|Author|AUTHORED
1528|Deep Learning-Based Ensemble Strategy|Topic|Zhifan Jiang|Author|AUTHORED
1528|Deep Learning-Based Ensemble Strategy|Topic|Abhijeet Parida|Author|AUTHORED
1528|Deep Learning-Based Ensemble Strategy|Topic|Xinyang Liu|Author|AUTHORED
1528|Deep Learning-Based Ensemble Strategy|Topic|Van Lam|Author|AUTHORED
1528|Deep Learning-Based Ensemble Strategy|Topic|Hareem Nisar|Author|AUTHORED
1528|Deep Learning-Based Ensemble Strategy|Topic|Austin Tapp|Author|AUTHORED
1528|Deep Learning-Based Ensemble Strategy|Topic|Sarah Elsharkawi|Author|AUTHORED
1528|Deep Learning-Based Ensemble Strategy|Topic|Maria J. Ledesma-Carbayo|Author|AUTHORED
1528|Deep Learning-Based Ensemble Strategy|Topic|Syed Muhammad Anwar|Author|AUTHORED
1528|Deep Learning-Based Ensemble Strategy|Topic|Marius George Linguraru|Author|AUTHORED
1529|Randomised Clinical Trial|Topic|Primary Endpoint|Topic|DISCUSSES
1529|Randomised Clinical Trial|Topic|Secondary Endpoints|Topic|DISCUSSES
1529|Secondary Endpoints|Topic|Type I Error Risk|Topic|RELATED_TO
1529|Secondary Endpoints|Topic|Co-Primary Endpoints|Topic|RELATED_TO
1529|Secondary Endpoints|Topic|Hierarchical Test Procedure|Topic|RELATED_TO
1529|Silvy Laporte|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Marine Diviné|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Danièle Girault|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Pierre Boutouyrie|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Olivier Chassany|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Michel Cucherat|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Hervé De Trogoff|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Sophie Dubois|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Cecile Fouret|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Natalie Hoog-Labouret|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Pascale Jolliet|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Patrick Mismetti|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Raphaël Porcher|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Cécile Rey-Coquais|Author|Randomised Clinical Trial|Topic|AUTHORED
1529|Eric Vicaut|Author|Randomised Clinical Trial|Topic|AUTHORED
1530|Real-World Evidence (Rwe) Scientific Working Group|Author|Challenges In Rare Disease Drug Development|Topic|DISCUSSES
1530|Challenges In Rare Disease Drug Development|Topic|Regulatory Agencies|Topic|RELATED_TO
1530|Challenges In Rare Disease Drug Development|Topic|Statistical Perspective|Topic|RELATED_TO
1530|Challenges In Rare Disease Drug Development|Topic|Development Pathway For Rare Disease Drugs|Topic|RELATED_TO
1530|Challenges In Rare Disease Drug Development|Topic|Evidence For Regulatory Decision-Making|Topic|RELATED_TO
1531|Target Aggregate Data Adjustment|Topic|Transportability Analysis|Topic|RELATED_TO
1531|Yichen Yan|Author|Target Aggregate Data Adjustment|Topic|AUTHORED
1531|Quang Vuong|Author|Target Aggregate Data Adjustment|Topic|AUTHORED
1531|Rebecca K Metcalfe|Author|Target Aggregate Data Adjustment|Topic|AUTHORED
1531|Tianyu Guan|Author|Target Aggregate Data Adjustment|Topic|AUTHORED
1531|Haolun Shi|Author|Target Aggregate Data Adjustment|Topic|AUTHORED
1531|Jay Jh Park|Author|Target Aggregate Data Adjustment|Topic|AUTHORED
1532|Finepico|Topic|Pico|Topic|RELATED_TO
1532|Finepico|Topic|Ner|Topic|RELATED_TO
1532|Finepico|Topic|Clinical Trial Literature|Topic|RELATED_TO
1532|Finepico|Topic|Public Datasets|Topic|RELATED_TO
1532|Finepico|Topic|Semi-Supervised Method|Topic|RELATED_TO
1532|Finepico|Topic|Annotated Data|Topic|RELATED_TO
1532|Finepico|Topic|Unlabeled Data|Topic|RELATED_TO
1532|Finepico|Topic|Performance Evaluation|Topic|RELATED_TO
1532|Finepico|Topic|Generalizability|Topic|RELATED_TO
1532|Finepico|Topic|Baseline Model|Topic|RELATED_TO
1532|Finepico|Topic|Experimental Settings|Topic|RELATED_TO
1532|Finepico|Topic|Precision|Topic|RELATED_TO
1532|Finepico|Topic|Recall|Topic|RELATED_TO
1532|Finepico|Topic|F1 Score|Topic|RELATED_TO
1532|Finepico|Topic|Fangyi Chen|Author|AUTHORED
1532|Finepico|Topic|Gongbo Zhang|Author|AUTHORED
1532|Finepico|Topic|Yilu Fang|Author|AUTHORED
1532|Finepico|Topic|Yifan Peng|Author|AUTHORED
1532|Finepico|Topic|Chunhua Weng|Author|AUTHORED
1533|Pso-Net|Paper|Pasi|Topic|DISCUSSES
1533|Sharif A. Kamran|Author|Pso-Net|Paper|AUTHORED
1533|Molly V. Lucas|Author|Pso-Net|Paper|AUTHORED
1533|Brendon Lutnick|Author|Pso-Net|Paper|AUTHORED
1533|Chaitanya Parmar|Author|Pso-Net|Paper|AUTHORED
1533|Basudha Pal|Author|Pso-Net|Paper|AUTHORED
1533|Asha Patel Shah|Author|Pso-Net|Paper|AUTHORED
1533|David Apfel|Author|Pso-Net|Paper|AUTHORED
1533|Steven Fakharzadeh|Author|Pso-Net|Paper|AUTHORED
1533|Lloyd Miller|Author|Pso-Net|Paper|AUTHORED
1533|Stephen Yip|Author|Pso-Net|Paper|AUTHORED
1533|Kristopher Standish|Author|Pso-Net|Paper|AUTHORED
1533|Gabriela Oana Cula|Author|Pso-Net|Paper|AUTHORED
1534|Arachidonic Acid|Topic|Cyclooxygenase|Topic|RELATED_TO
1534|Cyclooxygenase|Topic|Reactive Oxygen Species|Topic|RELATED_TO
1534|Reactive Oxygen Species|Topic|Ischemic Brain|Topic|RELATED_TO
1534|Cyclooxygenase-2|Topic|Neurodegeneration|Topic|RELATED_TO
1534|Neurodegeneration|Topic|Ischemic Injury|Topic|RELATED_TO
1534|Nimesulide|Author|Oxidative Stress|Topic|DISCUSSES
1534|Gerbils|Topic|Cerebral Ischemia|Topic|RELATED_TO
1534|Cerebral Ischemia|Topic|Oxidative Stress|Topic|RELATED_TO
1534|Hippocampus|Topic|Glutathione Depletion|Topic|RELATED_TO
1534|Hippocampus|Topic|Lipid Peroxidation|Topic|RELATED_TO
1534|Lipid Peroxidation|Topic|Malondialdehyde|Topic|RELATED_TO
1534|Lipid Peroxidation|Topic|4-Hydroxy-Alkenals|Topic|RELATED_TO
1534|Lipid Peroxidation|Topic|Lipid Hydroperoxides|Topic|RELATED_TO
1534|Fluoro-Jade B|Topic|Ca1 Region|Topic|RELATED_TO
1534|E. Candelario-Jalil|Author|Nimesulide|Author|AUTHORED
1534|D. Alvarez|Author|Nimesulide|Author|AUTHORED
1534|N. Merino|Author|Nimesulide|Author|AUTHORED
1534|O. S. Leon|Author|Nimesulide|Author|AUTHORED
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Brent J. Lance|Author|AUTHORED
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Scott E. Kerick|Author|AUTHORED
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Anthony J. Ries|Author|AUTHORED
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Kelvin S. Oie|Author|AUTHORED
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Kaleb Mcdowell|Author|AUTHORED
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Brain-Computer Interfaces|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Neuroscience Research|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Human-System Interactions|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Technological Advancements|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Flexible And Adaptive Brain-Based Neurotechnologies|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Clinical Populations|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Advanced Communications|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Prostheses|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Wheelchairs|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Task-Oriented Applications|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Pervasive Technologies|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Analytical Approaches|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Critical Brain Information|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Behavioral Information|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Task Information|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Environmental Information|Topic|RELATED_TO
1535|Brain Computer Interface Technologies In The Coming Decades|Paper|Communications Applications|Topic|RELATED_TO
1536|Percolation Under Noise: Detecting Explosive Percolation Using The Second Largest Component|Paper|Wes Viles|Author|AUTHORED
1536|Percolation Under Noise: Detecting Explosive Percolation Using The Second Largest Component|Paper|Cedric E. Ginestet|Author|AUTHORED
1536|Percolation Under Noise: Detecting Explosive Percolation Using The Second Largest Component|Paper|Ariana Tang|Author|AUTHORED
1536|Percolation Under Noise: Detecting Explosive Percolation Using The Second Largest Component|Paper|Mark A. Kramer|Author|AUTHORED
1536|Percolation Under Noise: Detecting Explosive Percolation Using The Second Largest Component|Paper|Eric D. Kolaczyk|Author|AUTHORED
1536|Percolation Under Noise: Detecting Explosive Percolation Using The Second Largest Component|Paper|Classical Percolation|Topic|RELATED_TO
1536|Percolation Under Noise: Detecting Explosive Percolation Using The Second Largest Component|Paper|Explosive Percolation|Topic|RELATED_TO
1536|Percolation Under Noise: Detecting Explosive Percolation Using The Second Largest Component|Paper|Noise In Observations|Topic|RELATED_TO
1536|Percolation Under Noise: Detecting Explosive Percolation Using The Second Largest Component|Paper|Hidden Markov Graph Model|Topic|RELATED_TO
1536|Percolation Under Noise: Detecting Explosive Percolation Using The Second Largest Component|Paper|Discriminatory Power|Topic|RELATED_TO
1537|Spatial Neural Networks And Their Functional Samples: Similarities And Differences|Paper|Neural Networks|Topic|DISCUSSES
1537|Spatial Neural Networks And Their Functional Samples: Similarities And Differences|Paper|Functional Networks|Topic|DISCUSSES
1537|Spatial Neural Networks And Their Functional Samples: Similarities And Differences|Paper|Mesoscopic Network Dynamics|Topic|DISCUSSES
1537|Spatial Neural Networks And Their Functional Samples: Similarities And Differences|Paper|Microscopic Network Structure|Topic|DISCUSSES
1537|Spatial Neural Networks And Their Functional Samples: Similarities And Differences|Paper|Eeg|Topic|DISCUSSES
1538|Neuroscience|Topic|Neuroimaging Technologies|Topic|RELATED_TO
1538|Neuroimaging Technologies|Topic|Diffusion Tensor Imaging|Topic|RELATED_TO
1538|Diffusion Tensor Imaging|Topic|Structural Graphs|Topic|RELATED_TO
1538|Neuroscience|Topic|Functional Graphs|Topic|RELATED_TO
1538|Functional Graphs|Topic|Functional Connectivity|Topic|RELATED_TO
1538|Cassiano O. Becker|Author|Functional Connectivity|Topic|AUTHORED
1538|Sergio Pequito|Author|Functional Connectivity|Topic|AUTHORED
1538|George J. Pappas|Author|Functional Connectivity|Topic|AUTHORED
1538|Michael B. Miller|Author|Functional Connectivity|Topic|AUTHORED
1538|Scott T. Grafton|Author|Functional Connectivity|Topic|AUTHORED
1538|Danielle S. Bassett|Author|Functional Connectivity|Topic|AUTHORED
1538|Victor M. Preciado|Author|Functional Connectivity|Topic|AUTHORED
1538|Functional Connectivity|Topic|Cognitive Systems|Topic|RELATED_TO
1538|Functional Connectivity|Topic|Clinical Populations|Topic|RELATED_TO
1538|Functional Connectivity|Topic|Developmental Populations|Topic|RELATED_TO
1539|Decnef|Topic|Rt-Fmri|Topic|RELATED_TO
1539|Aurelio Cortese|Author|Decnef|Topic|AUTHORED
1539|Kaoru Amano|Author|Decnef|Topic|AUTHORED
1539|Ai Koizumi|Author|Decnef|Topic|AUTHORED
1539|Hakwan Lau|Author|Decnef|Topic|AUTHORED
1539|Mitsuo Kawato|Author|Decnef|Topic|AUTHORED
1540|Contemporary Systems Biology|Topic|Network|Topic|RELATED_TO
1540|Network|Topic|Molecular Species|Topic|RELATED_TO
1540|Network|Topic|Cellular Species|Topic|RELATED_TO
1540|Network|Topic|Organismal Species|Topic|RELATED_TO
1540|Network|Topic|Graph Of Dependencies|Topic|RELATED_TO
1540|High-Throughput Data Acquisition Technologies|Topic|Genomics|Topic|RELATED_TO
1540|High-Throughput Data Acquisition Technologies|Topic|Metabolomics|Topic|RELATED_TO
1540|High-Throughput Data Acquisition Technologies|Topic|Neuroscience|Topic|RELATED_TO
1540|Reverse-Engineering|Topic|System Architectures|Topic|RELATED_TO
1540|Reverse-Engineering|Topic|Predictions|Topic|RELATED_TO
1540|Predictions|Topic|Drug Discovery|Topic|RELATED_TO
1540|Predictions|Topic|Disease Treatment|Topic|RELATED_TO
1540|Network Inference Algorithms|Topic|Reverse-Engineering|Topic|RELATED_TO
1540|Joseph L. Natale|Author|Reverse-Engineering Biological Networks From Large Data Sets|Paper|AUTHORED
1540|David Hofmann|Author|Reverse-Engineering Biological Networks From Large Data Sets|Paper|AUTHORED
1540|Damian G. Hernández|Author|Reverse-Engineering Biological Networks From Large Data Sets|Paper|AUTHORED
1540|Ilya Nemenman|Author|Reverse-Engineering Biological Networks From Large Data Sets|Paper|AUTHORED
1541|Morphospace Of Consciousness|Topic|Xerxes D. Arsiwalla|Author|AUTHORED
1541|Morphospace Of Consciousness|Topic|Ricard Sole|Author|AUTHORED
1541|Morphospace Of Consciousness|Topic|Clement Moulin-Frier|Author|AUTHORED
1541|Morphospace Of Consciousness|Topic|Ivan Herreros|Author|AUTHORED
1541|Morphospace Of Consciousness|Topic|Marti Sanchez-Fibla|Author|AUTHORED
1541|Morphospace Of Consciousness|Topic|Paul Verschure|Author|AUTHORED
1541|Morphospace Of Consciousness|Topic|Autonomous Complexity|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Cognitive Complexity|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Social Complexity|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Biological Consciousness|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Synthetic Consciousness|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Group Consciousness|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Simulated Consciousness|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Conscious Systems|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Synthetic Systems|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Artificially Intelligent Machines|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Synthetically Engineered Life Forms|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Cognitive Robotics|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Evolutionary Game-Theoretic Strategy|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Comparative Signatures Of Consciousness|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Design Principles For Conscious Machines|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Cognitive Neuroscience|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Biomedical Engineering|Topic|RELATED_TO
1541|Morphospace Of Consciousness|Topic|Biomimetics|Topic|RELATED_TO
1542|Hybrid Wavelet And Emd/Ica Approach For Artifact Suppression In Pervasive Eeg|Paper|Electroencephalogram (Eeg)|Topic|DISCUSSES
1542|Hybrid Wavelet And Emd/Ica Approach For Artifact Suppression In Pervasive Eeg|Paper|Wavelet Packet Transform Followed By Independent Component Analysis (Wptica)|Topic|DISCUSSES
1542|Hybrid Wavelet And Emd/Ica Approach For Artifact Suppression In Pervasive Eeg|Paper|Wavelet Packet Transform Followed By Empirical Mode Decomposition (Wptemd)|Topic|DISCUSSES
1542|Hybrid Wavelet And Emd/Ica Approach For Artifact Suppression In Pervasive Eeg|Paper|Root Mean Square Error (Rmse)|Topic|DISCUSSES
1542|Hybrid Wavelet And Emd/Ica Approach For Artifact Suppression In Pervasive Eeg|Paper|Artifact To Signal Ratio (Asr)|Topic|DISCUSSES
1542|Hybrid Wavelet And Emd/Ica Approach For Artifact Suppression In Pervasive Eeg|Paper|Enobio|Topic|DISCUSSES
1542|Hybrid Wavelet And Emd/Ica Approach For Artifact Suppression In Pervasive Eeg|Paper|Valentina Bono|Author|AUTHORED
1542|Hybrid Wavelet And Emd/Ica Approach For Artifact Suppression In Pervasive Eeg|Paper|Saptarshi Das|Author|AUTHORED
1542|Hybrid Wavelet And Emd/Ica Approach For Artifact Suppression In Pervasive Eeg|Paper|Wasifa Jamal|Author|AUTHORED
1542|Hybrid Wavelet And Emd/Ica Approach For Artifact Suppression In Pervasive Eeg|Paper|Koushik Maharatna|Author|AUTHORED
1543|Hint|Paper|Independent Component Analysis|Topic|DISCUSSES
1543|Hint|Paper|Joshua Lukemire|Author|AUTHORED
1543|Hint|Paper|Yikai Wang|Author|AUTHORED
1543|Hint|Paper|Amit Verma|Author|AUTHORED
1543|Hint|Paper|Ying Guo|Author|AUTHORED
1544|Spherical Harmonic Residual Network For Diffusion Signal Harmonization|Paper|Diffusion Imaging|Topic|DISCUSSES
1544|Spherical Harmonic Residual Network For Diffusion Signal Harmonization|Paper|Neuroscience|Topic|DISCUSSES
1544|Spherical Harmonic Residual Network For Diffusion Signal Harmonization|Paper|Mri|Topic|DISCUSSES
1544|Spherical Harmonic Residual Network For Diffusion Signal Harmonization|Paper|Deep Learning Residual Network|Topic|DISCUSSES
1545|Biomechanic And Motor Control Models|Topic|Bipedal Robots|Topic|RELATED_TO
1545|Biomechanic And Motor Control Models|Topic|Human Locomotion|Topic|RELATED_TO
1545|Potential Energy Model|Topic|Task-Space Planner|Topic|RELATED_TO
1545|Task-Space Planner|Topic|Rehabilitation Robotics|Topic|RELATED_TO
1545|Task-Space Planner|Topic|Computational Neuroscience|Topic|RELATED_TO
1545|Task-Space Planner|Topic|Centre Of Mass (Com) Trajectories|Topic|RELATED_TO
1545|Task-Space Planner|Topic|Foot Swing Trajectories|Topic|RELATED_TO
1545|Task-Space Planner|Topic|Base Of Support (Bos)|Topic|RELATED_TO
1545|Carlo Tiseo|Author|Motor Control Insights On Walking Planner And Its Stability|Paper|AUTHORED
1545|Kalyana C Veluvolu|Author|Motor Control Insights On Walking Planner And Its Stability|Paper|AUTHORED
1545|Wei Tech Ang|Author|Motor Control Insights On Walking Planner And Its Stability|Paper|AUTHORED
1546|Alzheimer'S Disease|Topic|Core-Periphery Structure|Topic|RELATED_TO
1546|Dwi|Topic|Core-Periphery Structure|Topic|RELATED_TO
1546|Fmri|Topic|Core-Periphery Structure|Topic|RELATED_TO
1546|Meg|Topic|Core-Periphery Structure|Topic|RELATED_TO
1546|Cognitive Impairment|Topic|Core-Periphery Structure|Topic|RELATED_TO
1546|Memory Impairment|Topic|Core-Periphery Structure|Topic|RELATED_TO
1546|Jeremy Guillon|Author|Core-Periphery Structure|Topic|AUTHORED
1546|Mario Chavez|Author|Core-Periphery Structure|Topic|AUTHORED
1546|Federico Battiston|Author|Core-Periphery Structure|Topic|AUTHORED
1546|Yohan Attal|Author|Core-Periphery Structure|Topic|AUTHORED
1546|Valentina La Corte|Author|Core-Periphery Structure|Topic|AUTHORED
1546|Michel Thiebaut De Schotten|Author|Core-Periphery Structure|Topic|AUTHORED
1546|Bruno Dubois|Author|Core-Periphery Structure|Topic|AUTHORED
1546|Denis Schwartz|Author|Core-Periphery Structure|Topic|AUTHORED
1546|Olivier Colliot|Author|Core-Periphery Structure|Topic|AUTHORED
1546|Fabrizio De Vico Fallani|Author|Core-Periphery Structure|Topic|AUTHORED
1547|Dynamic Causal Modelling (Dcm)|Topic|Fmri|Topic|RELATED_TO
1547|Dynamic Causal Modelling (Dcm)|Topic|Parametric Empirical Bayes|Topic|RELATED_TO
1547|Fmri|Topic|Parametric Empirical Bayes|Topic|RELATED_TO
1547|Peter Zeidman|Author|A Tutorial On Group Effective Connectivity Analysis, Part 1: First Level Analysis With Dcm For Fmri|Paper|AUTHORED
1547|Amirhossein Jafarian|Author|A Tutorial On Group Effective Connectivity Analysis, Part 1: First Level Analysis With Dcm For Fmri|Paper|AUTHORED
1547|Nadège Corbin|Author|A Tutorial On Group Effective Connectivity Analysis, Part 1: First Level Analysis With Dcm For Fmri|Paper|AUTHORED
1547|Mohamed L. Seghier|Author|A Tutorial On Group Effective Connectivity Analysis, Part 1: First Level Analysis With Dcm For Fmri|Paper|AUTHORED
1547|Adeel Razi|Author|A Tutorial On Group Effective Connectivity Analysis, Part 1: First Level Analysis With Dcm For Fmri|Paper|AUTHORED
1547|Cathy J. Price|Author|A Tutorial On Group Effective Connectivity Analysis, Part 1: First Level Analysis With Dcm For Fmri|Paper|AUTHORED
1547|Karl J. Friston|Author|A Tutorial On Group Effective Connectivity Analysis, Part 1: First Level Analysis With Dcm For Fmri|Paper|AUTHORED
1548|Modified Kalman Filter (Mkf)|Topic|Multi-Articulate Prostheses|Topic|RELATED_TO
1548|Modified Kalman Filter (Mkf)|Topic|Deka 'Luke' Arm|Topic|RELATED_TO
1548|Neural Firing Rates|Topic|Modified Kalman Filter (Mkf)|Topic|RELATED_TO
1548|Intramuscular Electromyographic (Emg) Recordings|Topic|Modified Kalman Filter (Mkf)|Topic|RELATED_TO
1548|Jacob A. George|Author|Modified Kalman Filter (Mkf)|Topic|AUTHORED
1548|Tyler S. Davis|Author|Modified Kalman Filter (Mkf)|Topic|AUTHORED
1548|Mark R. Brinton|Author|Modified Kalman Filter (Mkf)|Topic|AUTHORED
1548|Gregory A. Clark|Author|Modified Kalman Filter (Mkf)|Topic|AUTHORED
1549|T2-Buda-Gslider|Topic|Xiaozhi Cao|Author|AUTHORED
1549|T2-Buda-Gslider|Topic|Congyu Liao|Author|AUTHORED
1549|T2-Buda-Gslider|Topic|Zijing Zhang|Author|AUTHORED
1549|T2-Buda-Gslider|Topic|Siddharth Srinivasan Iyer|Author|AUTHORED
1549|T2-Buda-Gslider|Topic|Kang Wang|Author|AUTHORED
1549|T2-Buda-Gslider|Topic|Hongjian He|Author|AUTHORED
1549|T2-Buda-Gslider|Topic|Huafeng Liu|Author|AUTHORED
1549|T2-Buda-Gslider|Topic|Kawin Setsompop|Author|AUTHORED
1549|T2-Buda-Gslider|Topic|Jianhui Zhong|Author|AUTHORED
1549|T2-Buda-Gslider|Topic|Berkin Bilgic|Author|AUTHORED
1550|Inhibition And Set-Shifting Tasks In Central Executive Function Of Working Memory: An Event-Related Potential (Erp) Study|Paper|Pankaj|Author|AUTHORED
1550|Inhibition And Set-Shifting Tasks In Central Executive Function Of Working Memory: An Event-Related Potential (Erp) Study|Paper|Jamuna Rajeswaran|Author|AUTHORED
1550|Inhibition And Set-Shifting Tasks In Central Executive Function Of Working Memory: An Event-Related Potential (Erp) Study|Paper|Divya Sadana|Author|AUTHORED
1550|Working Memory|Topic|Central Executive Function|Topic|RELATED_TO
1550|Central Executive Function|Topic|Event-Related Potential|Topic|RELATED_TO
1551|Adaptive Behavior|Topic|Cognitive Agents|Topic|RELATED_TO
1551|Adaptive Behavior|Topic|Environmental Demands|Topic|RELATED_TO
1551|Information Processing|Topic|Adaptive Behavior|Topic|RELATED_TO
1551|Bayesian Model|Topic|Wisconsin Card Sorting Test|Topic|AUTHORED
1551|Bayesian Model|Topic|Bayesian Brain Theory|Topic|RELATED_TO
1551|Marco D'Alessandro|Author|Bayesian Model|Topic|AUTHORED
1551|Stefan T. Radev|Author|Bayesian Model|Topic|AUTHORED
1551|Andreas Voss|Author|Bayesian Model|Topic|AUTHORED
1551|Luigi Lombardi|Author|Bayesian Model|Topic|AUTHORED
1552|Review On Biophysical Modelling And Simulation Studies For Transcranial Magnetic Stimulation|Paper|Transcranial Magnetic Stimulation (Tms)|Topic|DISCUSSES
1552|Review On Biophysical Modelling And Simulation Studies For Transcranial Magnetic Stimulation|Paper|Computational Dosimetry|Topic|DISCUSSES
1552|Review On Biophysical Modelling And Simulation Studies For Transcranial Magnetic Stimulation|Paper|Jose Gomez-Tames|Author|AUTHORED
1552|Review On Biophysical Modelling And Simulation Studies For Transcranial Magnetic Stimulation|Paper|Ilkka Laakso|Author|AUTHORED
1552|Review On Biophysical Modelling And Simulation Studies For Transcranial Magnetic Stimulation|Paper|Akimasa Hirata|Author|AUTHORED
1553|Fiber Tractography|Topic|Diffusion Magnetic Resonance Imaging|Topic|RELATED_TO
1553|Dmri|Topic|Fiber Tractography|Topic|RELATED_TO
1553|Tomer Weiss|Author|Fiber Tractography|Topic|AUTHORED
1553|Sanketh Vedula|Author|Fiber Tractography|Topic|AUTHORED
1553|Ortal Senouf|Author|Fiber Tractography|Topic|AUTHORED
1553|Oleg Michailovich|Author|Fiber Tractography|Topic|AUTHORED
1553|Alex Bronstein|Author|Fiber Tractography|Topic|AUTHORED
1553|Human Connectome Project|Topic|Fiber Tractography|Topic|RELATED_TO
1554|Desire-Motivation Model|Topic|Recurrent Gating Desire-Motivation Model|Topic|RELATED_TO
1554|Recurrent Gating Desire-Motivation Model|Topic|Ventral Tegmental Area|Topic|DISCUSSES
1554|Recurrent Gating Desire-Motivation Model|Topic|Individual Personality|Topic|RELATED_TO
1554|Recurrent Gating Desire-Motivation Model|Topic|Depressive Disorder|Topic|RELATED_TO
1554|Yu Liu|Author|Desire-Motivation Model|Topic|AUTHORED
1554|Yinghong Zhao|Author|Desire-Motivation Model|Topic|AUTHORED
1554|Mo Chen|Author|Desire-Motivation Model|Topic|AUTHORED
1555|Epileptic Seizures|Topic|Percolation|Topic|RELATED_TO
1555|Random Graph Hidden Markov Models|Topic|Percolation|Topic|RELATED_TO
1555|Xiaojing Zhu|Author|Random Graph Hidden Markov Models|Topic|AUTHORED
1555|Heather Shappell|Author|Random Graph Hidden Markov Models|Topic|AUTHORED
1555|Mark A. Kramer|Author|Random Graph Hidden Markov Models|Topic|AUTHORED
1555|Catherine J. Chu|Author|Random Graph Hidden Markov Models|Topic|AUTHORED
1555|Eric D. Kolaczyk|Author|Random Graph Hidden Markov Models|Topic|AUTHORED
1556|Microstructure Estimation Using A Deep Network|Paper|Noddi Model|Topic|DISCUSSES
1556|Microstructure Estimation Using A Deep Network|Paper|Amico Algorithm|Topic|RELATED_TO
1556|Microstructure Estimation Using A Deep Network|Paper|Brain Dmri Scans|Topic|RELATED_TO
1556|Noddi Model|Topic|Diffusion Magnetic Resonance Imaging|Topic|RELATED_TO
1557|Retrospective Observational Study|Paper|Invasive Mechanical Ventilatory Therapy|Topic|DISCUSSES
1557|Retrospective Observational Study|Paper|Adult General Intensive Care Unit|Topic|RELATED_TO
1557|Retrospective Observational Study|Paper|Specialist Neurosciences Intensive Care Unit|Topic|RELATED_TO
1557|Retrospective Observational Study|Paper|Paediatric Intensive Care Unit|Topic|RELATED_TO
1557|Retrospective Observational Study|Paper|Tertiary Referral Hospital|Topic|RELATED_TO
1557|Retrospective Observational Study|Paper|Peep|Topic|DISCUSSES
1557|Retrospective Observational Study|Paper|Rr|Topic|DISCUSSES
1557|Retrospective Observational Study|Paper|Pinsp|Topic|DISCUSSES
1557|Retrospective Observational Study|Paper|Superstitions|Topic|DISCUSSES
1557|Superstitions|Topic|Number 13|Topic|RELATED_TO
1558|Functional Magnetic Resonance Imaging|Topic|Functional Connectivity|Topic|RELATED_TO
1558|Functional Connectivity|Topic|Multiple-View Clustering Method|Topic|RELATED_TO
1558|Multiple-View Clustering Method|Topic|Wishart Mixture Models|Topic|RELATED_TO
1558|Multiple-View Clustering Method|Topic|Tomoki Tokuda|Author|AUTHORED
1558|Multiple-View Clustering Method|Topic|Okito Yamashita|Author|AUTHORED
1558|Multiple-View Clustering Method|Topic|Junichiro Yoshimoto|Author|AUTHORED
1559|Few-Shot Learning|Topic|One-Shot Learning|Topic|RELATED_TO
1559|Graph Neural Networks|Topic|Neuroimaging Datasets|Topic|RELATED_TO
1559|One-Shot Learning|Topic|Connectional Brain Template|Topic|RELATED_TO
1559|Connectional Brain Template|Topic|Brain Connectivity Classification|Topic|RELATED_TO
1559|Connectional Brain Template|Topic|Evolution Prediction|Topic|RELATED_TO
1559|Umut Guvercin|Author|One-Shot Learning|Topic|AUTHORED
1559|Mohammed Amine Gharsallaoui|Author|One-Shot Learning|Topic|AUTHORED
1559|Islem Rekik|Author|One-Shot Learning|Topic|AUTHORED
1559|One-Shot Learning|Topic|Https://Github.Com/Basiralab/One-Representative-Shot-Learning|Topic|RELATED_TO
1560|Mental Health Research|Topic|Brain Function Measures|Topic|RELATED_TO
1560|Brain Function Measures|Topic|Mental Health Disorders|Topic|RELATED_TO
1560|Data-Driven Analyses|Topic|Population-Level Datasets|Topic|RELATED_TO
1560|Canonical Correlation Analysis (Cca)|Topic|Resting-State Mri Functional Connectivity|Topic|RELATED_TO
1560|Subject Measures Of Cognition And Behavior|Topic|Healthy Adults|Topic|RELATED_TO
1560|Well-Being|Topic|Developmental Dataset|Topic|RELATED_TO
1560|Primary Cca Mode|Topic|Variance Explained|Topic|RELATED_TO
1560|Neurotypical Relationship|Topic|Connectivity|Topic|RELATED_TO
1560|Nikhil Goyal|Author|Smith Et Al. 2015|Paper|AUTHORED
1560|Dustin Moraczewski|Author|Smith Et Al. 2015|Paper|AUTHORED
1560|Peter A. Bandettini|Author|Smith Et Al. 2015|Paper|AUTHORED
1560|Emily S. Finn|Author|Smith Et Al. 2015|Paper|AUTHORED
1560|Adam G. Thomas|Author|Smith Et Al. 2015|Paper|AUTHORED
1561|Deep Learning In Fnirs: A Review|Paper|Optical Neuroimaging|Topic|DISCUSSES
1561|Deep Learning In Fnirs: A Review|Paper|Functional Near-Infrared Spectroscopy (Fnirs)|Topic|DISCUSSES
1561|Deep Learning In Fnirs: A Review|Paper|Deep Learning (Dl)|Topic|DISCUSSES
1561|Deep Learning In Fnirs: A Review|Paper|Brain-Computer Interface|Topic|DISCUSSES
1561|Deep Learning In Fnirs: A Review|Paper|Neuro-Impairment Diagnosis|Topic|DISCUSSES
1561|Deep Learning In Fnirs: A Review|Paper|Neuroscience Discovery|Topic|DISCUSSES
1561|Condell Eastmond|Author|Deep Learning In Fnirs: A Review|Paper|AUTHORED
1561|Aseem Subedi|Author|Deep Learning In Fnirs: A Review|Paper|AUTHORED
1561|Suvranu De|Author|Deep Learning In Fnirs: A Review|Paper|AUTHORED
1561|Xavier Intes|Author|Deep Learning In Fnirs: A Review|Paper|AUTHORED
1562|Graph Neural Networks|Topic|Medical Imaging|Topic|RELATED_TO
1562|Graph Neural Networks|Topic|Network Neuroscience|Topic|RELATED_TO
1562|Graph Neural Networks|Topic|Autism|Topic|RELATED_TO
1562|Federated Learning|Topic|Graph Neural Networks|Topic|RELATED_TO
1562|Mehmet Yigit Balik|Author|Https://Github.Com/Basiralab/Reproduciblefedgnn|Paper|AUTHORED
1562|Arwa Rekik|Author|Https://Github.Com/Basiralab/Reproduciblefedgnn|Paper|AUTHORED
1562|Islem Rekik|Author|Https://Github.Com/Basiralab/Reproduciblefedgnn|Paper|AUTHORED
1562|Reproducibility Of Federated Gnn Models|Topic|Federated Learning|Topic|RELATED_TO
1562|Reproducibility Of Federated Gnn Models|Topic|Medical Imaging|Topic|RELATED_TO
1562|Reproducibility Of Federated Gnn Models|Topic|Connectomic Datasets|Topic|RELATED_TO
1563|Neural Perturbational Inference|Topic|Effective Connectivity|Topic|RELATED_TO
1563|Zixiang Luo|Author|Neural Perturbational Inference|Topic|AUTHORED
1563|Kaining Peng|Author|Neural Perturbational Inference|Topic|AUTHORED
1563|Zhichao Liang|Author|Neural Perturbational Inference|Topic|AUTHORED
1563|Shengyuan Cai|Author|Neural Perturbational Inference|Topic|AUTHORED
1563|Chenyu Xu|Author|Neural Perturbational Inference|Topic|AUTHORED
1563|Dan Li|Author|Neural Perturbational Inference|Topic|AUTHORED
1563|Yu Hu|Author|Neural Perturbational Inference|Topic|AUTHORED
1563|Changsong Zhou|Author|Neural Perturbational Inference|Topic|AUTHORED
1563|Quanying Liu|Author|Neural Perturbational Inference|Topic|AUTHORED
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Saurabh Sihag|Author|AUTHORED
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Gonzalo Mateos|Author|AUTHORED
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Corey Mcmillan|Author|AUTHORED
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Alejandro Ribeiro|Author|AUTHORED
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Computational Neuroscience|Topic|RELATED_TO
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Brain Age|Topic|RELATED_TO
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Brain Age Gap|Topic|RELATED_TO
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Alzheimer'S Disease|Topic|RELATED_TO
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Machine Learning Algorithms|Topic|RELATED_TO
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Brain Imaging Data|Topic|RELATED_TO
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Cortical Thickness Features|Topic|RELATED_TO
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Vnn|Topic|RELATED_TO
1564|Explainable Brain Age Prediction Using Covariance Neural Networks|Paper|Anatomical Covariance Matrix|Topic|RELATED_TO
1565|Immunotherapy|Topic|Cancer Treatment|Topic|RELATED_TO
1565|Fda Approval|Topic|Immunotherapy|Topic|RELATED_TO
1565|Magnetic Resonance Imaging|Topic|Molecular Mri|Topic|RELATED_TO
1565|Molecular Mri|Topic|Cancer Treatment|Topic|RELATED_TO
1565|Nikita Vladimirov|Author|Molecular Mri|Topic|AUTHORED
1565|Or Perlman|Author|Molecular Mri|Topic|AUTHORED
1565|Artificial Intelligence|Topic|Molecular Mri|Topic|RELATED_TO
1565|Preclinical Studies|Topic|Molecular Mri|Topic|RELATED_TO
1565|Clinical Studies|Topic|Molecular Mri|Topic|RELATED_TO
1566|Rvgp|Paper|Robert L. Peach|Author|AUTHORED
1566|Rvgp|Paper|Matteo Vinao-Carl|Author|AUTHORED
1566|Rvgp|Paper|Nir Grossman|Author|AUTHORED
1566|Rvgp|Paper|Michael David|Author|AUTHORED
1566|Rvgp|Paper|Emma Mallas|Author|AUTHORED
1566|Rvgp|Paper|David Sharp|Author|AUTHORED
1566|Rvgp|Paper|Paresh A. Malhotra|Author|AUTHORED
1566|Rvgp|Paper|Pierre Vandergheynst|Author|AUTHORED
1566|Rvgp|Paper|Adam Gosztolai|Author|AUTHORED
1567|Eeg Denoising Model|Topic|Electroencephalographic (Eeg) Signals|Topic|RELATED_TO
1567|Eeg Denoising Model|Topic|Eegdenoisenet Dataset|Topic|AUTHORED
1567|Matteo Gabardi|Author|Eeg Denoising Model|Topic|AUTHORED
1567|Aurora Saibene|Author|Eeg Denoising Model|Topic|AUTHORED
1567|Francesca Gasparini|Author|Eeg Denoising Model|Topic|AUTHORED
1567|Daniele Rizzo|Author|Eeg Denoising Model|Topic|AUTHORED
1567|Fabio Antonio Stella|Author|Eeg Denoising Model|Topic|AUTHORED
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Vi Thanh Pham|Author|AUTHORED
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Jonas Bille Nielsen|Author|AUTHORED
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Klaus Fuglsang Kofoed|Author|AUTHORED
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Jørgen Tobias Kühl|Author|AUTHORED
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Andreas Kryger Jensen|Author|AUTHORED
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Signal Processing|Topic|RELATED_TO
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Neuroscience|Topic|RELATED_TO
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Medicine|Topic|RELATED_TO
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Wearable Devices|Topic|RELATED_TO
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Deep Neural Networks|Topic|RELATED_TO
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Fisher-Rao Metric|Topic|RELATED_TO
1568|Joint Alignment Of Multivariate Quasi-Periodic Functional Data Using Deep Learning|Paper|Electrocardiogram|Topic|RELATED_TO
1569|Diffusion Mri With Machine Learning|Paper|Dmri|Topic|DISCUSSES
1569|Diffusion Mri With Machine Learning|Paper|Machine Learning|Topic|DISCUSSES
1570|Filter Average Short-Term (Fast) Functional Connectivity|Topic|Electroencephalogram (Eeg)|Topic|RELATED_TO
1570|Filter Average Short-Term (Fast) Functional Connectivity|Topic|Visual Short Term Memory (Vstm)|Topic|RELATED_TO
1570|Filter Average Short-Term (Fast) Functional Connectivity|Topic|Event-Related Potentials (Erps)|Topic|RELATED_TO
1570|Filter Average Short-Term (Fast) Functional Connectivity|Topic|Alzheimer'S Disease|Topic|RELATED_TO
1570|Om Roy|Author|Filter Average Short-Term (Fast) Functional Connectivity|Topic|AUTHORED
1570|Yashar Moshfeghi|Author|Filter Average Short-Term (Fast) Functional Connectivity|Topic|AUTHORED
1570|Agustin Ibanez|Author|Filter Average Short-Term (Fast) Functional Connectivity|Topic|AUTHORED
1570|Francisco Lopera|Author|Filter Average Short-Term (Fast) Functional Connectivity|Topic|AUTHORED
1570|Mario A Parra|Author|Filter Average Short-Term (Fast) Functional Connectivity|Topic|AUTHORED
1570|Keith M Smith|Author|Filter Average Short-Term (Fast) Functional Connectivity|Topic|AUTHORED
1571|Brain-Computer Interface (Bci) Systems|Topic|Severely Disabled Individuals|Topic|RELATED_TO
1571|Deep Learning And Riemannian Geometry-Based Classification Models|Topic|Motor Imagery (Mi) Based Bci|Topic|RELATED_TO
1571|Motor Imagery (Mi) Based Bci|Topic|Electroencephalography (Eeg)|Topic|RELATED_TO
1571|Optimal Transport Theory-Based Approach|Topic|Earth Mover'S Distance (Emd)|Topic|RELATED_TO
1571|Explainable Ai (Xai) Techniques|Topic|Earth Mover'S Distance (Emd)|Topic|RELATED_TO
1571|Riemannian Geometry-Based Classifier|Paper|Param Rajpura|Author|AUTHORED
1571|Eegnet|Paper|Hubert Cecotti|Author|AUTHORED
1571|Eeg Conformer|Paper|Yogesh Kumar Meena|Author|AUTHORED
1572|Endovascular Brain-Computer Interfaces (Ebcis)|Topic|Wireless Data And Power Transmission|Topic|RELATED_TO
1572|Endovascular Electrocorticography (Ecog)|Topic|Sensing Stent|Topic|RELATED_TO
1572|Endovascular Electrocorticography (Ecog)|Topic|Optical Telemetry Module|Topic|RELATED_TO
1572|Endovascular Electrocorticography (Ecog)|Topic|Focused Ultrasound (Fus) Power Transfer System|Topic|RELATED_TO
1572|Zhangyu Xu|Author|Leadless Power Transfer And Wireless Telemetry Solutions For An Endovascular Electrocorticography|Paper|AUTHORED
1572|Majid Khazaee|Author|Leadless Power Transfer And Wireless Telemetry Solutions For An Endovascular Electrocorticography|Paper|AUTHORED
1572|Nhan Duy Truong|Author|Leadless Power Transfer And Wireless Telemetry Solutions For An Endovascular Electrocorticography|Paper|AUTHORED
1572|Deniel Havenga|Author|Leadless Power Transfer And Wireless Telemetry Solutions For An Endovascular Electrocorticography|Paper|AUTHORED
1572|Armin Nikpour|Author|Leadless Power Transfer And Wireless Telemetry Solutions For An Endovascular Electrocorticography|Paper|AUTHORED
1572|Arman Ahnood|Author|Leadless Power Transfer And Wireless Telemetry Solutions For An Endovascular Electrocorticography|Paper|AUTHORED
1572|Omid Kavehei|Author|Leadless Power Transfer And Wireless Telemetry Solutions For An Endovascular Electrocorticography|Paper|AUTHORED
1573|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|Local Field Potential (Lfp)|Topic|DISCUSSES
1573|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|Nucleus Accumbens|Topic|DISCUSSES
1573|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|Hippocampus|Topic|DISCUSSES
1573|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|Morphine|Topic|DISCUSSES
1573|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|Natural Food|Topic|DISCUSSES
1573|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|Long Short Term Memory (Lstm)|Topic|DISCUSSES
1573|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|Echo State Network (Esn)|Topic|DISCUSSES
1573|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|Deep Echo State Network (Deepesn)|Topic|DISCUSSES
1573|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|Radial Basis Function (Rbf)|Topic|DISCUSSES
1573|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|Local Linear Model Tree (Llm)|Topic|DISCUSSES
1573|Lolimot|Topic|A Global Data-Driven Model For The Hippocampus And Nucleus Accumbens Of Rat From The Local Field Potential Recordings (Lfp)|Paper|RELATED_TO
1574|Loci-Diffcom|Paper|Zihao Zhu|Author|AUTHORED
1574|Loci-Diffcom|Paper|Tianli Tao|Author|AUTHORED
1574|Loci-Diffcom|Paper|Yitian Tao|Author|AUTHORED
1574|Loci-Diffcom|Paper|Haowen Deng|Author|AUTHORED
1574|Loci-Diffcom|Paper|Xinyi Cai|Author|AUTHORED
1574|Loci-Diffcom|Paper|Gaofeng Wu|Author|AUTHORED
1574|Loci-Diffcom|Paper|Kaidong Wang|Author|AUTHORED
1574|Loci-Diffcom|Paper|Haifeng Tang|Author|AUTHORED
1574|Loci-Diffcom|Paper|Lixuan Zhu|Author|AUTHORED
1574|Loci-Diffcom|Paper|Zhuoyang Gu|Author|AUTHORED
1574|Loci-Diffcom|Paper|Jiawei Huang|Author|AUTHORED
1574|Loci-Diffcom|Paper|Dinggang Shen|Author|AUTHORED
1574|Loci-Diffcom|Paper|Han Zhang|Author|AUTHORED
1575|High-Density Eeg (Hd Eeg) Devices|Topic|Neuroscience|Topic|RELATED_TO
1575|High-Density Eeg (Hd Eeg) Devices|Topic|Epilepsy Focus Localization|Topic|RELATED_TO
1575|Spatio-Temporal Adaptive Diffusion Models (Stad)|Topic|Low-Resolution Eeg|Topic|RELATED_TO
1575|Spatio-Temporal Adaptive Diffusion Models (Stad)|Topic|High-Resolution Eeg|Topic|RELATED_TO
1575|Multi-Scale Transformer Denoising Module|Topic|Spatio-Temporal Adaptive Diffusion Models (Stad)|Topic|RELATED_TO
1575|Tong Zhou|Author|Generative Ai Enables Eeg Super-Resolution Via Spatio-Temporal Adaptive Diffusion Learning|Paper|AUTHORED
1575|Shuqiang Wang|Author|Generative Ai Enables Eeg Super-Resolution Via Spatio-Temporal Adaptive Diffusion Learning|Paper|AUTHORED
1576|Quantum-Eegnet (Qeegnet)|Paper|Electroencephalography (Eeg)|Topic|RELATED_TO
1576|Quantum-Eegnet (Qeegnet)|Paper|Eegnet|Topic|RELATED_TO
1576|Quantum-Eegnet (Qeegnet)|Paper|Bci Competition Iv 2A|Topic|RELATED_TO
1577|T-Fake Dataset|Topic|Philipp Flotho|Author|AUTHORED
1577|T-Fake Dataset|Topic|Moritz Piening|Author|AUTHORED
1577|T-Fake Dataset|Topic|Anna Kukleva|Author|AUTHORED
1577|T-Fake Dataset|Topic|Gabriele Steidl|Author|AUTHORED
1577|T-Fake Dataset|Topic|Rgb2Thermal Loss Function|Topic|RELATED_TO
1577|T-Fake Dataset|Topic|Probabilistic Landmark Prediction|Topic|RELATED_TO
1577|T-Fake Dataset|Topic|Label Adaptation Networks|Topic|RELATED_TO
1578|Diffusion Tensor Imaging (Dti)|Topic|Dodti|Topic|RELATED_TO
1578|Dodti|Topic|Jialong Li|Author|AUTHORED
1578|Dodti|Topic|Zhicheng Zhang|Author|AUTHORED
1578|Dodti|Topic|Yunwei Chen|Author|AUTHORED
1578|Dodti|Topic|Qiqi Lu|Author|AUTHORED
1578|Dodti|Topic|Ye Wu|Author|AUTHORED
1578|Dodti|Topic|Xiaoming Liu|Author|AUTHORED
1578|Dodti|Topic|Qianjin Feng|Author|AUTHORED
1578|Dodti|Topic|Yanqiu Feng|Author|AUTHORED
1578|Dodti|Topic|Xinyuan Zhang|Author|AUTHORED
1579|Neural Transcoding Vision Transformer|Topic|Domain Matching|Topic|RELATED_TO
1579|Neural Transcoding Vision Transformer|Topic|Romeo Lanzino|Author|AUTHORED
1579|Neural Transcoding Vision Transformer|Topic|Federico Fontana|Author|AUTHORED
1579|Neural Transcoding Vision Transformer|Topic|Luigi Cinque|Author|AUTHORED
1579|Neural Transcoding Vision Transformer|Topic|Francesco Scarcello|Author|AUTHORED
1579|Neural Transcoding Vision Transformer|Topic|Atsuto Maki|Author|AUTHORED
1580|Tumsyn|Paper|Multimodal Brain Magnetic Resonance Imaging|Topic|RELATED_TO
1581|Hyperbrain|Topic|Sadaf Sadeghian|Author|AUTHORED
1581|Hyperbrain|Topic|Xiaoxiao Li|Author|AUTHORED
1581|Hyperbrain|Topic|Margo Seltzer|Author|AUTHORED
1581|Hyperbrain|Topic|Autism Spectrum Disorder|Topic|RELATED_TO
1581|Hyperbrain|Topic|Attention Deficit Hyperactivity Disorder|Topic|RELATED_TO
1582|Block-Term Tensor Regression|Topic|Healthcare|Topic|RELATED_TO
1582|Block-Term Tensor Regression|Topic|Neuroscience|Topic|RELATED_TO
1582|Federated Block-Term Tensor Regression|Topic|Healthcare|Topic|RELATED_TO
1582|Federated Block-Term Tensor Regression|Topic|Finger Movement Decoding|Topic|RELATED_TO
1582|Federated Block-Term Tensor Regression|Topic|Heart Disease Prediction|Topic|RELATED_TO
1582|Axel Faes|Author|Federated Block-Term Tensor Regression|Topic|AUTHORED
1582|Ashkan Pirmani|Author|Federated Block-Term Tensor Regression|Topic|AUTHORED
1582|Yves Moreau|Author|Federated Block-Term Tensor Regression|Topic|AUTHORED
1582|Liesbet M. Peeters|Author|Federated Block-Term Tensor Regression|Topic|AUTHORED
1583|Brain Dynamics|Topic|Fractal Geometry|Topic|RELATED_TO
1583|Fractal Geometry|Topic|Eeg|Topic|RELATED_TO
1583|Lucas G. S. França|Author|Fractal Geometry|Topic|AUTHORED
1583|José G. V. Miranda|Author|Fractal Geometry|Topic|AUTHORED
1583|Marco Leite|Author|Fractal Geometry|Topic|AUTHORED
1583|Niraj K. Sharma|Author|Fractal Geometry|Topic|AUTHORED
1583|Matthew C. Walker|Author|Fractal Geometry|Topic|AUTHORED
1583|Louis Lemieux|Author|Fractal Geometry|Topic|AUTHORED
1583|Yujiang Wang|Author|Fractal Geometry|Topic|AUTHORED
1583|Chhabra-Jensen Algorithm|Topic|Fractal Geometry|Topic|RELATED_TO
1584|Fmri Data Collection And Analysis|Topic|Functional Brain Imaging|Topic|RELATED_TO
1584|Functional Brain Imaging|Topic|Quality Control (Qc) Process|Topic|RELATED_TO
1584|Quality Control (Qc) Process|Topic|Flag-Qc|Topic|RELATED_TO
1584|Flag-Qc|Topic|Matthew Kollada|Author|AUTHORED
1584|Flag-Qc|Topic|Qingzhu Gao|Author|AUTHORED
1584|Flag-Qc|Topic|Monika S Mellem|Author|AUTHORED
1584|Flag-Qc|Topic|Tathagata Banerjee|Author|AUTHORED
1584|Flag-Qc|Topic|William J Martin|Author|AUTHORED
1585|Major Depressive Disorder|Topic|Neuroimaging Modalities|Topic|DISCUSSES
1585|Major Depressive Disorder|Topic|Healthy Controls|Topic|DISCUSSES
1585|Major Depressive Disorder|Topic|Participants|Topic|DISCUSSES
1585|Major Depressive Disorder|Topic|Polygenic Risk Score|Topic|DISCUSSES
1585|Major Depressive Disorder|Topic|Environmental Variables|Topic|DISCUSSES
1585|Major Depressive Disorder|Topic|Biological Psychiatry|Topic|DISCUSSES
1585|Major Depressive Disorder|Topic|Computational Psychiatry|Topic|DISCUSSES
1585|Major Depressive Disorder|Topic|Multivariate Machine Learning|Topic|DISCUSSES
1585|Major Depressive Disorder|Topic|Ecologically Valid Phenotyping|Topic|DISCUSSES
1585|Nils R. Winter|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Ramona Leenings|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Jan Ernsting|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Kelvin Sarink|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Lukas Fisch|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Daniel Emden|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Julian Blanke|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Janik Goltermann|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Nils Opel|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Carlotta Barkhau|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Susanne Meinert|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Katharina Dohm|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Jonathan Repple|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Marco Mauritz|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Marius Gruber|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Elisabeth J. Leehr|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Dominik Grotegerd|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Ronny Redlich|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Andreas Jansen|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Igor Nenadic|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Markus Nöthen|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Andreas Forstner|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Marcella Rietschel|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Joachim Groß|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Jochen Bauer|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Walter Heindel|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Till Andlauer|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Simon Eickhoff|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Tilo Kircher|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Udo Dannlowski|Author|Major Depressive Disorder|Topic|AUTHORED
1585|Tim Hahn|Author|Major Depressive Disorder|Topic|AUTHORED
1586|Magnetic Resonance Imaging|Topic|Radiofrequency Excitation|Topic|RELATED_TO
1586|Clinical Diagnosis|Topic|Biophysical Data|Topic|DISCUSSES
1586|Biophysical Data|Topic|Mri Contrasts|Topic|DISCUSSES
1586|Mri Contrasts|Topic|Rf Sequences|Topic|DISCUSSES
1586|Vision Transformer-Based Framework|Topic|Spatiotemporal Magnetic Signal Evolution|Topic|AUTHORED
1586|Vision Transformer-Based Framework|Topic|Brain Tissue Response|Topic|AUTHORED
1586|Vision Transformer-Based Framework|Topic|Mri On A Chip|Topic|AUTHORED
1586|Calibration Scan|Topic|Image Contrasts|Topic|DISCUSSES
1586|Image Contrasts|Topic|Molecular Composition|Topic|DISCUSSES
1586|Human Brain Tissue|Topic|Molecular Composition|Topic|DISCUSSES
1586|Deepmonc|Topic|Human Brain Tissue|Topic|AUTHORED
1586|Deepmonc|Topic|Cancer Patient|Topic|AUTHORED
1586|Deepmonc|Topic|Healthy Subjects|Topic|AUTHORED
1586|Deepmonc|Topic|Imaging Sites|Topic|AUTHORED
1586|Deepmonc|Topic|Alternative Protocols|Topic|DISCUSSES
1586|Dinor Nagar|Author|Deepmonc|Topic|AUTHORED
1586|Moritz Zaiss|Author|Deepmonc|Topic|AUTHORED
1586|Or Perlman|Author|Deepmonc|Topic|AUTHORED
1587|Three New Textbooks|Paper|Teaching Computational Neuroscience|Topic|DISCUSSES
1587|Three New Textbooks|Paper|Péter Érdi|Author|AUTHORED
1588|Fabian|Topic|Hélène Lajous|Author|AUTHORED
1588|Fabian|Topic|Christopher W. Roy|Author|AUTHORED
1588|Fabian|Topic|Tom Hilbert|Author|AUTHORED
1588|Fabian|Topic|Priscille De Dumast|Author|AUTHORED
1588|Fabian|Topic|Sébastien Tourbier|Author|AUTHORED
1588|Fabian|Topic|Yasser Alemán-Gómez|Author|AUTHORED
1588|Fabian|Topic|Jérôme Yerly|Author|AUTHORED
1588|Fabian|Topic|Thomas Yu|Author|AUTHORED
1588|Fabian|Topic|Hamza Kebiri|Author|AUTHORED
1588|Fabian|Topic|Kelly Payette|Author|AUTHORED
1588|Fabian|Topic|Jean-Baptiste Ledoux|Author|AUTHORED
1588|Fabian|Topic|Reto Meuli|Author|AUTHORED
1588|Fabian|Topic|Patric Hagmann|Author|AUTHORED
1588|Fabian|Topic|Andras Jakab|Author|AUTHORED
1588|Fabian|Topic|Vincent Dunet|Author|AUTHORED
1588|Fabian|Topic|Mériam Koob|Author|AUTHORED
1588|Fabian|Topic|Tobias Kober|Author|AUTHORED
1588|Fabian|Topic|Matthias Stuber|Author|AUTHORED
1588|Fabian|Topic|Meritxell Bach Cuadra|Author|AUTHORED
1589|Tailored Patient Information: Some Issues And Questions|Paper|Ehud Reiter|Author|AUTHORED
1589|Tailored Patient Information: Some Issues And Questions|Paper|Liesl Osman|Author|AUTHORED
1589|Tailored Patient Information (Tpi) Systems|Topic|Natural-Language Generation (Nlg) Community|Topic|RELATED_TO
1589|Tailored Patient Information (Tpi) Systems|Topic|Medical Community|Topic|RELATED_TO
1589|Tailored Patient Information (Tpi) Systems|Topic|Asthma-Information Booklets|Topic|RELATED_TO
1589|Tailored Patient Information (Tpi) Systems|Topic|Smoking-Cessation Letters|Topic|RELATED_TO
1590|Generalized Pólya Urn|Topic|Sequential Estimation-Adjusted Urn Model|Topic|RELATED_TO
1590|Li-X. Zhang|Author|Sequential Estimation-Adjusted Urn Model|Topic|AUTHORED
1590|Feifang Hu|Author|Sequential Estimation-Adjusted Urn Model|Topic|AUTHORED
1590|Siu Hung Cheung|Author|Sequential Estimation-Adjusted Urn Model|Topic|AUTHORED
1591|Bayesian Transformation Hazard Models|Topic|Gousheng Yin|Author|AUTHORED
1591|Bayesian Transformation Hazard Models|Topic|Joseph G. Ibrahim|Author|AUTHORED
1592|Fatigue, Sleepiness And Disturbed Sleep|Topic|Electrophysiology|Topic|RELATED_TO
1592|Electrophysiology|Topic|Enobio|Topic|RELATED_TO
1592|Enobio|Topic|G. Ruffini|Author|AUTHORED
1592|Enobio|Topic|S. Dunne|Author|AUTHORED
1592|Enobio|Topic|L. Fuentemilla|Author|AUTHORED
1592|Enobio|Topic|C. Grau|Author|AUTHORED
1592|Enobio|Topic|E. Farres|Author|AUTHORED
1592|Enobio|Topic|J. Marco-Pallares|Author|AUTHORED
1592|Enobio|Topic|P. C. P. Watts|Author|AUTHORED
1592|Enobio|Topic|S. R. P. Silva|Author|AUTHORED
1593|Cell Cycling Models Of Carcinogenesis: A Complex Systems Analysis|Paper|V. I. Prisecaru|Author|AUTHORED
1593|Cell Cycling Models Of Carcinogenesis: A Complex Systems Analysis|Paper|I. C. Baianu|Author|AUTHORED
1593|Cell Cycling Models Of Carcinogenesis: A Complex Systems Analysis|Paper|Carcinogenesis|Topic|DISCUSSES
1593|Cell Cycling Models Of Carcinogenesis: A Complex Systems Analysis|Paper|Cyclins|Topic|DISCUSSES
1593|Cyclins|Topic|Tp53|Topic|RELATED_TO
1593|Cyclins|Topic|Thomsen-Friedenreich Antigen|Topic|RELATED_TO
1593|Cyclins|Topic|Rb|Topic|RELATED_TO
1593|Cyclins|Topic|Mdm2|Topic|RELATED_TO
1593|Cyclins|Topic|C-Myc|Topic|RELATED_TO
1593|Cyclins|Topic|P21|Topic|RELATED_TO
1593|Cyclins|Topic|P27|Topic|RELATED_TO
1593|Cyclins|Topic|Bax|Topic|RELATED_TO
1593|Cyclins|Topic|Bad|Topic|RELATED_TO
1593|Cyclins|Topic|Bcl-2|Topic|RELATED_TO
1594|Drug Effectiveness|Topic|Patient Compliance|Topic|RELATED_TO
1594|Patient Compliance|Topic|Latent Factors|Topic|RELATED_TO
1594|Latent Factors|Topic|Quantum Processes|Topic|RELATED_TO
1594|Quantum Processes|Topic|Dominik Janzing|Author|AUTHORED
1594|Quantum Processes|Topic|Thomas Beth|Author|AUTHORED
1595|Biology As An Emergent Science|Paper|Biological System|Topic|DISCUSSES
1595|Biological System|Topic|Young'S Model|Topic|RELATED_TO
1595|Young'S Model|Topic|Cancer Cachexia|Topic|RELATED_TO
1596|Neural Networks In 3D Medical Scan Visualization|Paper|Andreas Elsner|Author|AUTHORED
1596|Neural Networks In 3D Medical Scan Visualization|Paper|Gitta Domik|Author|AUTHORED
1597|Gaussian Approximation For Multi-Color Generalized Friedman'S Urn Model|Paper|Friedman'S Urn Model|Topic|RELATED_TO
1597|Gaussian Approximation For Multi-Color Generalized Friedman'S Urn Model|Paper|Multi-Dimensional Gaussian Process|Topic|DISCUSSES
1597|Gaussian Approximation For Multi-Color Generalized Friedman'S Urn Model|Paper|Stochastic Differential Equation|Topic|DISCUSSES
1597|Gaussian Approximation For Multi-Color Generalized Friedman'S Urn Model|Paper|Asymptotic Normality|Topic|DISCUSSES
1597|Gaussian Approximation For Multi-Color Generalized Friedman'S Urn Model|Paper|Law Of The Iterated Logarithm|Topic|DISCUSSES
1597|Gaussian Approximation For Multi-Color Generalized Friedman'S Urn Model|Paper|Randomized-Play-The-Winner Rule|Topic|DISCUSSES
1597|Gaussian Approximation For Multi-Color Generalized Friedman'S Urn Model|Paper|Li-Xin Zhang|Author|AUTHORED
1597|Gaussian Approximation For Multi-Color Generalized Friedman'S Urn Model|Paper|Feifang Hu|Author|AUTHORED
1599|Spatio-Temporal Structuring Of Brain Activity - Description Of Interictal Eeg In Paediatric Frontal Lobe Epilepsy|Paper|W. Bunk|Author|AUTHORED
1599|Spatio-Temporal Structuring Of Brain Activity - Description Of Interictal Eeg In Paediatric Frontal Lobe Epilepsy|Paper|T. Aschenbrenner|Author|AUTHORED
1599|Spatio-Temporal Structuring Of Brain Activity - Description Of Interictal Eeg In Paediatric Frontal Lobe Epilepsy|Paper|G. Kluger|Author|AUTHORED
1599|Spatio-Temporal Structuring Of Brain Activity - Description Of Interictal Eeg In Paediatric Frontal Lobe Epilepsy|Paper|S. Springer|Author|AUTHORED
1600|Nonparametric Methodology For The Time-Dependent Partial Area Under The Roc Curve|Paper|Roc Curve|Topic|DISCUSSES
1600|Nonparametric Methodology For The Time-Dependent Partial Area Under The Roc Curve|Paper|Pauc|Topic|DISCUSSES
1600|Nonparametric Methodology For The Time-Dependent Partial Area Under The Roc Curve|Paper|Biomarker|Topic|DISCUSSES
1600|Nonparametric Methodology For The Time-Dependent Partial Area Under The Roc Curve|Paper|Aids Clinical Trials Group (Actg) 175 Study|Topic|DISCUSSES
1600|Hung Hung|Author|Nonparametric Methodology For The Time-Dependent Partial Area Under The Roc Curve|Paper|AUTHORED
1600|Chin-Tsang Chiang|Author|Nonparametric Methodology For The Time-Dependent Partial Area Under The Roc Curve|Paper|AUTHORED
1601|Clinical Trial Data|Topic|Individualized Treatment Rule|Topic|RELATED_TO
1601|Individualized Treatment Rule|Topic|L_1-Penalized Least Squares|Topic|RELATED_TO
1601|Min Qian|Author|L_1-Penalized Least Squares|Topic|AUTHORED
1601|Susan A. Murphy|Author|L_1-Penalized Least Squares|Topic|AUTHORED
1603|Sequential Monitoring In Clinical Trials|Topic|Randomization-Based Context|Topic|RELATED_TO
1603|Randomization-Based Context|Topic|Conditional Tests|Topic|RELATED_TO
1603|Randomization-Based Context|Topic|Information Fraction|Topic|RELATED_TO
1603|Randomization-Based Context|Topic|Efron'S Biased Coin Design|Topic|RELATED_TO
1603|Victoria Plamadeala|Author|Randomization-Based Context|Topic|AUTHORED
1603|William F. Rosenberger|Author|Randomization-Based Context|Topic|AUTHORED
1604|Multi-Objective Optimal Designs In Comparative Clinical Trials With Covariates: The Reinforced Doubly Adaptive Biased Coin Design|Paper|Alessandro Baldi Antognini|Author|AUTHORED
1604|Multi-Objective Optimal Designs In Comparative Clinical Trials With Covariates: The Reinforced Doubly Adaptive Biased Coin Design|Paper|Maroussa Zagoraiou|Author|AUTHORED
1605|A Dual-Beam Irradiation Facility For A Novel Hybrid Cancer Therapy|Paper|Svilen Sabchevski|Author|AUTHORED
1605|A Dual-Beam Irradiation Facility For A Novel Hybrid Cancer Therapy|Paper|Toshitaka Idehara|Author|AUTHORED
1605|A Dual-Beam Irradiation Facility For A Novel Hybrid Cancer Therapy|Paper|Shintaro Ishiyama|Author|AUTHORED
1605|A Dual-Beam Irradiation Facility For A Novel Hybrid Cancer Therapy|Paper|Norio Miyoshi|Author|AUTHORED
1605|A Dual-Beam Irradiation Facility For A Novel Hybrid Cancer Therapy|Paper|Toshiaki Tatsukawa|Author|AUTHORED
1606|Decision-Making Model|Topic|Alzheimer'S Disease|Topic|RELATED_TO
1606|Athanasios Alexiou|Author|Decision-Making Model|Topic|AUTHORED
1606|Panayiotis Vlamos|Author|Decision-Making Model|Topic|AUTHORED
1607|Balancing Treatment Allocation For Influential Covariates|Topic|Clinical Trials|Topic|RELATED_TO
1607|Biomarkers|Topic|Translational Research|Topic|RELATED_TO
1607|Translational Research|Topic|Genomics|Topic|RELATED_TO
1607|Translational Research|Topic|Proteomics|Topic|RELATED_TO
1607|Translational Research|Topic|Metabolomics|Topic|RELATED_TO
1607|Stratified Permuted Block Randomization|Topic|Minimization Methods|Topic|RELATED_TO
1607|Covariate-Adaptive Design|Topic|Yanqing Hu|Author|AUTHORED
1607|Covariate-Adaptive Design|Topic|Feifang Hu|Author|AUTHORED
1609|Influence Diagrams|Topic|Bayesian Statistical Models|Topic|RELATED_TO
1609|User-Based Architecture|Topic|Influence Diagrams|Topic|DISCUSSES
1609|User-Based Architecture|Topic|Physicians|Topic|DISCUSSES
1609|User-Based Architecture|Topic|Two-Arm Parallel Randomized Clinical Trials (Taprct)|Topic|DISCUSSES
1609|Patient-Flow Diagram|Topic|Two-Arm Parallel Randomized Clinical Trials (Taprct)|Topic|RELATED_TO
1609|Cohort-State Diagram|Topic|Two-Arm Parallel Randomized Clinical Trials (Taprct)|Topic|RELATED_TO
1609|Construction Steps|Topic|Thomas|Topic|AUTHORED
1609|Thomas|Topic|Physicians|Topic|DISCUSSES
1609|Harold P. Lehmann|Author|End-User Construction Of Influence Diagrams For Bayesian Statistics|Paper|AUTHORED
1609|Ross D. Shachter|Author|End-User Construction Of Influence Diagrams For Bayesian Statistics|Paper|AUTHORED
1610|Cost Effectiveness Statistic: A Proposal To Take Into Account The Patient Stratification Factors|Paper|Randomized Clinical Trials|Topic|DISCUSSES
1610|Cost Effectiveness Statistic: A Proposal To Take Into Account The Patient Stratification Factors|Paper|Incremental Cost-Effective Ratio (Icer)|Topic|DISCUSSES
1610|Cost Effectiveness Statistic: A Proposal To Take Into Account The Patient Stratification Factors|Paper|Cancer Therapy|Topic|DISCUSSES
1610|Cost Effectiveness Statistic: A Proposal To Take Into Account The Patient Stratification Factors|Paper|Cluster Analysis|Topic|DISCUSSES
1610|Cost Effectiveness Statistic: A Proposal To Take Into Account The Patient Stratification Factors|Paper|Patient Stratification Factors|Topic|DISCUSSES
1610|Cost Effectiveness Statistic: A Proposal To Take Into Account The Patient Stratification Factors|Paper|Age|Topic|DISCUSSES
1610|Cost Effectiveness Statistic: A Proposal To Take Into Account The Patient Stratification Factors|Paper|Gender|Topic|DISCUSSES
1610|Cost Effectiveness Statistic: A Proposal To Take Into Account The Patient Stratification Factors|Paper|Disease Severity|Topic|DISCUSSES
1611|Scarf|Paper|Combinatorial Biomarkers|Topic|DISCUSSES
1611|Scarf|Paper|Alzheimer'S Disease|Topic|DISCUSSES
1611|Scarf|Paper|Dementia|Topic|DISCUSSES
1612|Identifiability Of Subgroup Causal Effects In Randomized Experiments With Nonignorable Missing Covariates|Paper|Peng Ding|Author|AUTHORED
1612|Identifiability Of Subgroup Causal Effects In Randomized Experiments With Nonignorable Missing Covariates|Paper|Zhi Geng|Author|AUTHORED
1613|Da-Crm|Topic|Toxicity Outcome|Topic|RELATED_TO
1613|Da-Crm|Topic|Bayesian Data Augmentation|Topic|RELATED_TO
1613|Da-Crm|Topic|Phase I Cancer Clinical Trials|Topic|RELATED_TO
1613|Suyu Liu|Author|Da-Crm|Topic|AUTHORED
1613|Guosheng Yin|Author|Da-Crm|Topic|AUTHORED
1613|Ying Yuan|Author|Da-Crm|Topic|AUTHORED
1614|Survregcenscov|Topic|Stanislas Hubeaux|Author|AUTHORED
1614|Survregcenscov|Topic|Kaspar Rufibach|Author|AUTHORED
1615|Biased-Coin Designs|Topic|Treatment Allocation|Topic|RELATED_TO
1615|Efron'S Biased-Coin Rule|Topic|Biased-Coin Designs|Topic|DISCUSSES
1615|Anthony C. Atkinson|Author|Biased-Coin Designs|Topic|AUTHORED
1615|Loss Of Information|Topic|Imbalance|Topic|RELATED_TO
1615|Selection Bias|Topic|Imbalance|Topic|RELATED_TO
1615|Bayesian Rule|Topic|Selection Bias|Topic|RELATED_TO
1615|Large Sample|Topic|Small-Sample Simulations|Topic|RELATED_TO
1616|Sharp Bounds On The Variance|Topic|Difference-In-Means Estimator|Topic|RELATED_TO
1616|Sharp Bounds On The Variance|Topic|Completely Randomized Experiments|Topic|RELATED_TO
1616|Identification Problem In Causal Inference|Topic|Sharp Bounds On The Variance|Topic|DISCUSSES
1616|Wald-Type Confidence Intervals|Topic|Sharp Bounds On The Variance|Topic|DISCUSSES
1616|Randomized Controlled Trials|Topic|Sharp Bounds On The Variance|Topic|RELATED_TO
1616|Randomized Clinical Trials|Topic|Sharp Bounds On The Variance|Topic|RELATED_TO
1616|Peter M. Aronow|Author|Sharp Bounds On The Variance|Topic|AUTHORED
1616|Donald P. Green|Author|Sharp Bounds On The Variance|Topic|AUTHORED
1616|Donald K. K. Lee|Author|Sharp Bounds On The Variance|Topic|AUTHORED
1617|Two-Stage Adaptive Dose-Response Study Designs|Topic|Maximum Likelihood Estimate|Topic|RELATED_TO
1617|Two-Stage Adaptive Dose-Response Study Designs|Topic|Bayesian Optimal Design|Topic|RELATED_TO
1617|Two-Stage Adaptive Dose-Response Study Designs|Topic|Parameter Uncertainty|Topic|RELATED_TO
1617|Two-Stage Adaptive Dose-Response Study Designs|Topic|Sigmoid Emax Dose-Response Model|Topic|RELATED_TO
1617|Two-Stage Adaptive Dose-Response Study Designs|Topic|D-Optimality Criterion|Topic|RELATED_TO
1617|Emma Mccallum|Author|Two-Stage Adaptive Dose-Response Study Designs|Topic|AUTHORED
1617|Björn Bornkamp|Author|Two-Stage Adaptive Dose-Response Study Designs|Topic|AUTHORED
1618|Breast Imaging|Topic|Numerical Observers|Topic|RELATED_TO
1618|Numerical Observers|Topic|Human Observer|Topic|RELATED_TO
1618|Spatiotemporal Contrast Sensitivity Function|Topic|Multi-Slice Channelized Hotelling Observer|Topic|RELATED_TO
1618|Contrast Masking|Topic|Numerical Observers|Topic|RELATED_TO
1618|Ali R. N. Avanaki|Author|Numerical Observers|Topic|AUTHORED
1618|Kathryn S. Espig|Author|Numerical Observers|Topic|AUTHORED
1618|Albert Xthona|Author|Numerical Observers|Topic|AUTHORED
1618|Tom R. L. Kimpe|Author|Numerical Observers|Topic|AUTHORED
1618|Predrag R. Bakic|Author|Numerical Observers|Topic|AUTHORED
1618|Andrew D. A. Maidment|Author|Numerical Observers|Topic|AUTHORED
1619|Multgee|Topic|Anestis Touloumis|Author|AUTHORED
1620|A Stochastic Evolutionary Model For Capturing Human Dynamics|Paper|Trevor Fenner|Author|AUTHORED
1620|A Stochastic Evolutionary Model For Capturing Human Dynamics|Paper|Mark Levene|Author|AUTHORED
1620|A Stochastic Evolutionary Model For Capturing Human Dynamics|Paper|George Loizou|Author|AUTHORED
1621|Funnel Plot|Topic|Meta-Analysis|Topic|RELATED_TO
1621|Jack Bowden|Author|Funnel Plot|Topic|AUTHORED
1621|Chris Jackson|Author|Funnel Plot|Topic|AUTHORED
1621|Cambridge Science Festival|Topic|Funnel Plot|Topic|RELATED_TO
1622|A Heteroscedastic Accelerated Failure Time Model For Survival Analysis|Paper|Yifan Wang|Author|AUTHORED
1622|A Heteroscedastic Accelerated Failure Time Model For Survival Analysis|Paper|Tian You|Author|AUTHORED
1622|A Heteroscedastic Accelerated Failure Time Model For Survival Analysis|Paper|Martin Lysy|Author|AUTHORED
1622|A Heteroscedastic Accelerated Failure Time Model For Survival Analysis|Paper|Survival Analysis|Topic|RELATED_TO
1622|A Heteroscedastic Accelerated Failure Time Model For Survival Analysis|Paper|Parametric Likelihood-Based Estimators|Topic|RELATED_TO
1622|A Heteroscedastic Accelerated Failure Time Model For Survival Analysis|Paper|Expectation-Conditional-Maximization (Ecm) Algorithm|Topic|RELATED_TO
1622|A Heteroscedastic Accelerated Failure Time Model For Survival Analysis|Paper|Colon Cancer Clinical Trial|Topic|RELATED_TO
1622|A Heteroscedastic Accelerated Failure Time Model For Survival Analysis|Paper|Haft Maximum Likelihood Estimator|Topic|RELATED_TO
1622|A Heteroscedastic Accelerated Failure Time Model For Survival Analysis|Paper|Homoscedastic Model|Topic|RELATED_TO
1622|A Heteroscedastic Accelerated Failure Time Model For Survival Analysis|Paper|Heteroscedasticity|Topic|RELATED_TO
1623|Modeling Long-Term Outcomes And Treatment Effects After Androgen Deprivation Therapy For Prostate Cancer|Paper|Yolanda Hagar|Author|AUTHORED
1623|Modeling Long-Term Outcomes And Treatment Effects After Androgen Deprivation Therapy For Prostate Cancer|Paper|James J. Dignam|Author|AUTHORED
1623|Modeling Long-Term Outcomes And Treatment Effects After Androgen Deprivation Therapy For Prostate Cancer|Paper|Vanja Dukic|Author|AUTHORED
1624|Differentially Private Algorithms For Stochastic Multi-Armed Bandit Problem|Topic|Aristide Tossou|Author|AUTHORED
1624|Differentially Private Algorithms For Stochastic Multi-Armed Bandit Problem|Topic|Christos Dimitrakakis|Author|AUTHORED
1625|Stochastic Processes|Topic|Human Behaviour|Topic|RELATED_TO
1625|Human Behaviour|Topic|Mobile Phone Networks|Topic|RELATED_TO
1625|Human Behaviour|Topic|Social Media|Topic|RELATED_TO
1625|Stochastic Urn-Based Model|Topic|Mixture Models|Topic|RELATED_TO
1625|Mixture Models|Topic|Exponential Distributions|Topic|RELATED_TO
1625|Survival Analysis|Topic|Clinical Trials|Topic|RELATED_TO
1625|Survival Analysis|Topic|Reliability Analysis|Topic|RELATED_TO
1625|Survival Analysis|Topic|Large Data Sets|Topic|RELATED_TO
1625|Heterogeneity In Data|Topic|Mixture Models|Topic|RELATED_TO
1625|Search Engine Queries|Topic|Mixture Models|Topic|RELATED_TO
1625|Trevor Fenner|Author|Stochastic Urn-Based Model|Topic|AUTHORED
1625|Mark Levene|Author|Stochastic Urn-Based Model|Topic|AUTHORED
1625|George Loizou|Author|Stochastic Urn-Based Model|Topic|AUTHORED
1626|Conditional Estimation In Two-Stage Adaptive Designs|Paper|Bias|Topic|DISCUSSES
1626|Conditional Estimation In Two-Stage Adaptive Designs|Paper|Estimators|Topic|DISCUSSES
1626|Conditional Estimation In Two-Stage Adaptive Designs|Paper|Simulation Study|Topic|DISCUSSES
1626|Conditional Estimation In Two-Stage Adaptive Designs|Paper|Clinical Trial Setting|Topic|DISCUSSES
1627|Control Of Directional Errors In Fixed Sequence Multiple Testing|Paper|Mixed Directional Familywise Error Rate|Topic|DISCUSSES
1627|Control Of Directional Errors In Fixed Sequence Multiple Testing|Paper|R-Package Fixseqmtp|Topic|RELATED_TO
1628|An Innovative Imputation And Classification Approach For Accurate Disease Prediction|Paper|Yelipe Usharani|Author|AUTHORED
1628|An Innovative Imputation And Classification Approach For Accurate Disease Prediction|Paper|P. Sammulal|Author|AUTHORED
1628|An Innovative Imputation And Classification Approach For Accurate Disease Prediction|Paper|Imputation Of Missing Attribute Values In Medical Datasets|Topic|DISCUSSES
1629|Phase Ii Clinical Trials|Topic|Dose Response Curves|Topic|RELATED_TO
1629|Dose Response Curves|Topic|Parametric Regression Models|Topic|RELATED_TO
1629|Parametric Regression Models|Topic|Treatment Groups|Topic|RELATED_TO
1629|Optimal Design Theory|Topic|D-Optimal Designs|Topic|RELATED_TO
1629|Dose-Finding Study|Topic|Optimal Design Theory|Topic|DISCUSSES
1629|Chrystel Feller|Author|Optimal Design Theory|Topic|AUTHORED
1629|Kirsten Schorning|Author|Optimal Design Theory|Topic|AUTHORED
1629|Holger Dette|Author|Optimal Design Theory|Topic|AUTHORED
1629|Georgina Bermann|Author|Optimal Design Theory|Topic|AUTHORED
1629|Björn Bornkamp|Author|Optimal Design Theory|Topic|AUTHORED
1630|Cox Model|Topic|Additive Hazard Model|Topic|RELATED_TO
1630|Cox Model|Topic|Accelerated Failure Time Model|Topic|RELATED_TO
1630|Cox Model|Topic|Transformation Model|Topic|RELATED_TO
1630|Shape-Invariant Hazard Regression Model|Topic|Moment-Based Inference Procedures|Topic|RELATED_TO
1630|Shape-Invariant Hazard Regression Model|Topic|Risk Prediction|Topic|RELATED_TO
1630|Shape-Invariant Hazard Regression Model|Topic|Goodness Of Fit Test|Topic|RELATED_TO
1630|Shape-Invariant Hazard Regression Model|Topic|Veteran'S Administration Lung Cancer Data|Topic|RELATED_TO
1630|Shape-Invariant Hazard Regression Model|Topic|Hivnet 012 Data|Topic|RELATED_TO
1630|Hivnet 012 Data|Topic|Nevirapine Treatment|Topic|RELATED_TO
1630|Cheng Zheng|Author|Shape-Invariant Hazard Regression Model|Topic|AUTHORED
1630|Ying Qing Chen|Author|Shape-Invariant Hazard Regression Model|Topic|AUTHORED
1631|An Approach To Find Missing Values In Medical Datasets|Paper|B. Mathura Bai|Author|AUTHORED
1631|An Approach To Find Missing Values In Medical Datasets|Paper|N. Mangathayaru|Author|AUTHORED
1631|An Approach To Find Missing Values In Medical Datasets|Paper|B. Padmaja Rani|Author|AUTHORED
1632|Weighted Parametric Multiple Test Procedures|Topic|Closure Principle|Topic|RELATED_TO
1632|Weighted Parametric Multiple Test Procedures|Topic|Adjusted Significance Levels|Topic|RELATED_TO
1632|Weighted Parametric Multiple Test Procedures|Topic|Adjusted P-Values|Topic|RELATED_TO
1632|Weighted Parametric Multiple Test Procedures|Topic|Intersection Hypotheses|Topic|RELATED_TO
1632|Weighted Parametric Multiple Test Procedures|Topic|Exact Alpha-Level Parametric Tests|Topic|RELATED_TO
1632|Exact Alpha-Level Parametric Tests|Topic|Consonance Property|Topic|RELATED_TO
1632|Weighted Parametric Multiple Test Procedures|Topic|Clinical Trial Example|Topic|RELATED_TO
1632|Clinical Trial Example|Topic|Dong Xi|Author|AUTHORED
1632|Clinical Trial Example|Topic|Ekkehard Glimm|Author|AUTHORED
1632|Clinical Trial Example|Topic|Willi Maurer|Author|AUTHORED
1632|Clinical Trial Example|Topic|Frank Bretz|Author|AUTHORED
1633|Bayesian Index|Topic|Kawasaki And Miyaoka (2012B)|Author|DISCUSSES
1634|Assessing The Similarity Of Dose Response And Target Doses In Two Non-Overlapping Subgroups|Paper|Frank Bretz|Author|AUTHORED
1634|Assessing The Similarity Of Dose Response And Target Doses In Two Non-Overlapping Subgroups|Paper|Kathrin Möllenhoff|Author|AUTHORED
1634|Assessing The Similarity Of Dose Response And Target Doses In Two Non-Overlapping Subgroups|Paper|Holger Dette|Author|AUTHORED
1634|Assessing The Similarity Of Dose Response And Target Doses In Two Non-Overlapping Subgroups|Paper|Wei Liu|Author|AUTHORED
1634|Assessing The Similarity Of Dose Response And Target Doses In Two Non-Overlapping Subgroups|Paper|Matthias Trampisch|Author|AUTHORED
1635|L0 Regularisation For The Estimation Of Piecewise Constant Hazard Rates In Survival Analysis|Paper|O Bouaziz|Author|AUTHORED
1635|L0 Regularisation For The Estimation Of Piecewise Constant Hazard Rates In Survival Analysis|Paper|G Nuel|Author|AUTHORED
1636|Mtpi|Topic|Mtpi-2|Topic|RELATED_TO
1636|Mtpi-2|Topic|Wentian Guo|Author|AUTHORED
1636|Mtpi-2|Topic|Sue-Jane Wang|Author|AUTHORED
1636|Mtpi-2|Topic|Shengjie Yang|Author|AUTHORED
1636|Mtpi-2|Topic|Suiheng Lin|Author|AUTHORED
1636|Mtpi-2|Topic|Yuan Ji|Author|AUTHORED
1637|Rank Verification For Exponential Families|Paper|Statistical Experiments|Topic|DISCUSSES
1637|Rank Verification For Exponential Families|Paper|Public Opinion Poll|Topic|RELATED_TO
1637|Rank Verification For Exponential Families|Paper|Social Scientific Survey|Topic|RELATED_TO
1637|Rank Verification For Exponential Families|Paper|Clinical Trial|Topic|RELATED_TO
1638|Bonferroni Based Multiple Testing Procedure|Topic|Complex Clinical Trials|Topic|RELATED_TO
1638|Zhiying Qiu|Author|Bonferroni Based Multiple Testing Procedure|Topic|AUTHORED
1638|Wenge Guo|Author|Bonferroni Based Multiple Testing Procedure|Topic|AUTHORED
1638|Sanat Sarkar|Author|Bonferroni Based Multiple Testing Procedure|Topic|AUTHORED
1639|A Noise-Filtering Approach For Cancer Drug Sensitivity Prediction|Paper|Turki Turki|Author|AUTHORED
1639|A Noise-Filtering Approach For Cancer Drug Sensitivity Prediction|Paper|Zhi Wei|Author|AUTHORED
1639|A Noise-Filtering Approach For Cancer Drug Sensitivity Prediction|Paper|Cancer|Topic|RELATED_TO
1640|Ranking Biomarkers Through Mutual Information|Paper|Konstantinos Sechidis|Author|AUTHORED
1640|Ranking Biomarkers Through Mutual Information|Paper|Emily Turner|Author|AUTHORED
1640|Ranking Biomarkers Through Mutual Information|Paper|Paul D. Metcalfe|Author|AUTHORED
1640|Ranking Biomarkers Through Mutual Information|Paper|James Weatherall|Author|AUTHORED
1640|Ranking Biomarkers Through Mutual Information|Paper|Gavin Brown|Author|AUTHORED
1641|Meboost|Topic|Box Lunch Study|Topic|DISCUSSES
1641|Meboost|Topic|Convex Conditioned Lasso|Topic|RELATED_TO
1641|Meboost|Topic|Lasso|Topic|RELATED_TO
1641|Benjamin Brown|Author|Meboost|Topic|AUTHORED
1641|Timothy Weaver|Author|Meboost|Topic|AUTHORED
1641|Julian Wolfson|Author|Meboost|Topic|AUTHORED
1642|Wald-Type Tests|Topic|Two Independent Samples|Topic|RELATED_TO
1642|Minimum Density Power Divergence Estimators|Topic|Wald-Type Tests|Topic|RELATED_TO
1642|Simple Two-Sample Hypothesis|Topic|Wald-Type Tests|Topic|RELATED_TO
1642|General Two-Sample Hypotheses|Topic|Wald-Type Tests|Topic|RELATED_TO
1642|Nuisance Parameters|Topic|General Two-Sample Hypotheses|Topic|RELATED_TO
1642|Asymptotic Properties|Topic|Wald-Type Tests|Topic|RELATED_TO
1642|Theoretical Robustness Properties|Topic|Wald-Type Tests|Topic|RELATED_TO
1642|One-Sided Alternatives|Topic|Wald-Type Tests|Topic|RELATED_TO
1642|Treatment Effectiveness|Topic|Clinical Trials|Topic|RELATED_TO
1642|Real Data Examples|Topic|Wald-Type Tests|Topic|RELATED_TO
1642|Abhik Ghosh|Author|Wald-Type Tests|Topic|AUTHORED
1642|Nirian Martin|Author|Wald-Type Tests|Topic|AUTHORED
1642|Ayanendranath Basu|Author|Wald-Type Tests|Topic|AUTHORED
1642|Leandro Pardo|Author|Wald-Type Tests|Topic|AUTHORED
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Multi-Armed Bandit Model|Topic|DISCUSSES
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Contextual Bandit With Restricted Context|Topic|DISCUSSES
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Thompson Sampling|Topic|DISCUSSES
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Thompson Sampling With Restricted Context|Topic|DISCUSSES
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Windows Thompson Sampling With Restricted Context|Topic|DISCUSSES
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Stationary Environments|Topic|DISCUSSES
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Nonstationary Environments|Topic|DISCUSSES
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Clinical Trials|Topic|DISCUSSES
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Recommender Systems|Topic|DISCUSSES
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Attention Modeling|Topic|DISCUSSES
1643|Context Attentive Bandits: Contextual Bandit With Restricted Context|Paper|Real-Life Datasets|Topic|DISCUSSES
1644|Tree Based Weighted Learning For Estimating Individualized Treatment Rules With Censored Data|Paper|Yifan Cui|Author|AUTHORED
1644|Tree Based Weighted Learning For Estimating Individualized Treatment Rules With Censored Data|Paper|Ruoqing Zhu|Author|AUTHORED
1644|Tree Based Weighted Learning For Estimating Individualized Treatment Rules With Censored Data|Paper|Michael Kosorok|Author|AUTHORED
1644|Estimating Individualized Treatment Rules|Topic|Tree Based Weighted Learning For Estimating Individualized Treatment Rules With Censored Data|Paper|RELATED_TO
1645|Subgroup Analysis Of Treatment Effects For Misclassified Biomarkers With Time-To-Event Data|Paper|Fang Wan|Author|AUTHORED
1645|Subgroup Analysis Of Treatment Effects For Misclassified Biomarkers With Time-To-Event Data|Paper|Andrew C. Titman|Author|AUTHORED
1645|Subgroup Analysis Of Treatment Effects For Misclassified Biomarkers With Time-To-Event Data|Paper|Thomas F. Jaki|Author|AUTHORED
1646|Why Adaptively Collected Data Have Negative Bias And How To Correct For It|Paper|Xinkun Nie|Author|AUTHORED
1646|Why Adaptively Collected Data Have Negative Bias And How To Correct For It|Paper|Xiaoying Tian|Author|AUTHORED
1646|Why Adaptively Collected Data Have Negative Bias And How To Correct For It|Paper|Jonathan Taylor|Author|AUTHORED
1646|Why Adaptively Collected Data Have Negative Bias And How To Correct For It|Paper|James Zou|Author|AUTHORED
1647|Global Hypothesis Tests|Topic|Clinical Trials|Topic|RELATED_TO
1647|Global Hypothesis Tests|Topic|Genetic Studies|Topic|RELATED_TO
1647|Global Hypothesis Tests|Topic|Meta Analyses|Topic|RELATED_TO
1647|Global Null Hypothesis|Topic|Combinations Tests|Topic|RELATED_TO
1647|Global Null Hypothesis|Topic|Bonferroni Test|Topic|RELATED_TO
1647|Global Null Hypothesis|Topic|Simes Test|Topic|RELATED_TO
1647|Omnibus Test|Topic|R-Package Omnibus|Topic|RELATED_TO
1647|Omnibus Test|Topic|Andreas Futschik|Author|AUTHORED
1647|Omnibus Test|Topic|Thomas Taus|Author|AUTHORED
1647|Omnibus Test|Topic|Sonja Zehetmayer|Author|AUTHORED
1648|Likelihood Methods For Measuring Statistical Evidence|Topic|Sequential Study Designs|Topic|RELATED_TO
1648|Sequential Study Designs|Topic|Sample Size Projections|Topic|RELATED_TO
1648|Sample Size Projections|Topic|Time-To-Event Outcomes|Topic|RELATED_TO
1648|Time-To-Event Outcomes|Topic|Efficacy And Futility|Topic|RELATED_TO
1648|Efficacy And Futility|Topic|Phase Ii Cancer Clinical Trial|Topic|RELATED_TO
1648|Jeffrey D Blume|Author|Likelihood Based Study Designs For Time-To-Event Endpoints|Paper|AUTHORED
1648|Leena Choi|Author|Likelihood Based Study Designs For Time-To-Event Endpoints|Paper|AUTHORED
1649|Dasgupta Et Al. (2015)|Author|Randomized Controlled $2^2$ Factorial Design|Topic|DISCUSSES
1649|Dasgupta Et Al. (2015)|Author|Binary Outcome|Topic|DISCUSSES
1649|Dasgupta Et Al. (2015)|Author|Randomization-Based Causal Inference Framework|Topic|DISCUSSES
1649|Dasgupta Et Al. (2015)|Author|Sampling Variance Of The Randomization-Based Factorial Effect Estimator|Topic|DISCUSSES
1649|Jiannan Lu|Author|New Variance Estimator|Topic|AUTHORED
1649|Jiannan Lu|Author|Real-Life Datasets From Randomized Clinical Trials|Topic|AUTHORED
1651|3D Fully Convolutional Network|Topic|Pancreas Segmentation In Computed Tomography Imaging|Topic|RELATED_TO
1651|Holger Roth|Author|3D Fully Convolutional Network|Topic|AUTHORED
1651|Masahiro Oda|Author|3D Fully Convolutional Network|Topic|AUTHORED
1651|Natsuki Shimizu|Author|3D Fully Convolutional Network|Topic|AUTHORED
1651|Hirohisa Oda|Author|3D Fully Convolutional Network|Topic|AUTHORED
1651|Yuichiro Hayashi|Author|3D Fully Convolutional Network|Topic|AUTHORED
1651|Takayuki Kitasaka|Author|3D Fully Convolutional Network|Topic|AUTHORED
1651|Michitaka Fujiwara|Author|3D Fully Convolutional Network|Topic|AUTHORED
1651|Kazunari Misawa|Author|3D Fully Convolutional Network|Topic|AUTHORED
1651|Kensaku Mori|Author|3D Fully Convolutional Network|Topic|AUTHORED
1651|147 Contrast Enhanced Abdominal Ct Scans|Topic|Gastric Cancer Patients|Topic|RELATED_TO
1651|3D Fully Convolutional Network|Topic|Dice Score Of 89.7 ± 3.8|Topic|RELATED_TO
1651|3D Fully Convolutional Network|Topic|State-Of-The-Art Performance In Pancreas Segmentation|Topic|RELATED_TO
1652|Causal K-Nearest Neighbor Method|Topic|Optimal Treatment Regimes|Topic|RELATED_TO
1652|Causal K-Nearest Neighbor Method|Topic|Causal Inference Framework|Topic|RELATED_TO
1652|Causal K-Nearest Neighbor Regime|Topic|Optimal Treatment Regimes|Topic|RELATED_TO
1652|Causal K-Nearest Neighbor Regime|Topic|Curse Of Dimensionality|Topic|RELATED_TO
1652|Adaptive Causal K-Nearest Neighbor Method|Topic|Curse Of Dimensionality|Topic|RELATED_TO
1652|Xin Zhou|Author|Causal K-Nearest Neighbor Method|Topic|AUTHORED
1652|Michael R. Kosorok|Author|Causal K-Nearest Neighbor Method|Topic|AUTHORED
1652|Causal K-Nearest Neighbor Method|Topic|Chronic Depression Clinical Trial|Topic|RELATED_TO
1652|Causal K-Nearest Neighbor Method|Topic|Simulation Studies|Topic|RELATED_TO
1653|Two-Stage Fisher Exact Test For Multi-Arm Studies With Binary Outcome Variables|Paper|Fisher'S Exact Test|Topic|DISCUSSES
1653|Two-Stage Fisher Exact Test For Multi-Arm Studies With Binary Outcome Variables|Paper|Exact Binomial Tests|Topic|RELATED_TO
1654|Computational Analysis For The Rational Design Of Anti-Amyloid Beta (Abeta) Antibodies|Paper|Alzheimer'S Disease|Topic|DISCUSSES
1654|Computational Analysis For The Rational Design Of Anti-Amyloid Beta (Abeta) Antibodies|Paper|Anti-Amyloid Beta Antibodies|Topic|DISCUSSES
1654|Computational Analysis For The Rational Design Of Anti-Amyloid Beta (Abeta) Antibodies|Paper|D'Artagnan Greene|Author|AUTHORED
1654|Computational Analysis For The Rational Design Of Anti-Amyloid Beta (Abeta) Antibodies|Paper|Theodora Po|Author|AUTHORED
1654|Computational Analysis For The Rational Design Of Anti-Amyloid Beta (Abeta) Antibodies|Paper|Jennifer Pan|Author|AUTHORED
1654|Computational Analysis For The Rational Design Of Anti-Amyloid Beta (Abeta) Antibodies|Paper|Tanya Tabibian|Author|AUTHORED
1654|Computational Analysis For The Rational Design Of Anti-Amyloid Beta (Abeta) Antibodies|Paper|Ray Luo|Author|AUTHORED
1655|Monte Carlo Modified Profile Likelihood In Models For Clustered Data|Paper|Clustered Data|Topic|RELATED_TO
1655|Monte Carlo Modified Profile Likelihood In Models For Clustered Data|Paper|Monte Carlo Simulation|Topic|RELATED_TO
1655|Monte Carlo Modified Profile Likelihood In Models For Clustered Data|Paper|Modified Profile Likelihood|Topic|RELATED_TO
1655|Monte Carlo Modified Profile Likelihood In Models For Clustered Data|Paper|Missing-Data Models|Topic|RELATED_TO
1655|Monte Carlo Modified Profile Likelihood In Models For Clustered Data|Paper|Survival Models|Topic|RELATED_TO
1655|Monte Carlo Modified Profile Likelihood In Models For Clustered Data|Paper|Clinical Trial Applications|Topic|RELATED_TO
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|R. Arboretti|Author|AUTHORED
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|E. Carrozzo|Author|AUTHORED
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|F. Pesarin|Author|AUTHORED
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|L. Salmaso|Author|AUTHORED
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|Clinical Trials|Topic|RELATED_TO
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|Pharmaceutical Experiments|Topic|RELATED_TO
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|Bioequivalence|Topic|RELATED_TO
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|Quality Control|Topic|RELATED_TO
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|Intersection-Union Principle|Topic|RELATED_TO
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|Likelihood Techniques|Topic|RELATED_TO
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|Nonparametric Setting|Topic|RELATED_TO
1656|Testing For Equivalence: An Intersection-Union Permutation Solution|Paper|Iu Permutation Test|Topic|RELATED_TO
1657|Deep Learning For Segmentation And Counting Within Microscopy Data|Paper|Carlos X. Hernández|Author|AUTHORED
1657|Deep Learning For Segmentation And Counting Within Microscopy Data|Paper|Mohammad M. Sultan|Author|AUTHORED
1657|Deep Learning For Segmentation And Counting Within Microscopy Data|Paper|Vijay S. Pande|Author|AUTHORED
1657|Cell Counting|Topic|Convolutional Neural Network|Topic|RELATED_TO
1657|Convolutional Neural Network|Topic|Feature Pyramid Network|Topic|RELATED_TO
1657|Convolutional Neural Network|Topic|Vgg-Style Neural Network|Topic|RELATED_TO
1657|Microscopy Image|Topic|Cell Counting|Topic|RELATED_TO
1658|Using Survival Information In Truncation By Death Problems Without The Monotonicity Assumption|Paper|Truncation By Death Problem|Topic|RELATED_TO
1658|Using Survival Information In Truncation By Death Problems Without The Monotonicity Assumption|Paper|Potential Outcomes Framework|Topic|RELATED_TO
1658|Using Survival Information In Truncation By Death Problems Without The Monotonicity Assumption|Paper|Survival Information|Topic|RELATED_TO
1658|Using Survival Information In Truncation By Death Problems Without The Monotonicity Assumption|Paper|Fan Yang|Author|AUTHORED
1658|Using Survival Information In Truncation By Death Problems Without The Monotonicity Assumption|Paper|Peng Ding|Author|AUTHORED
1659|Lgbtq Health Issues|Topic|Public Health Policy|Topic|RELATED_TO
1659|Public Health Policy|Topic|Computational Approach|Topic|RELATED_TO
1659|Computational Approach|Topic|Men Who Have Sex With Men|Topic|RELATED_TO
1659|Men Who Have Sex With Men|Topic|Diseases And Disorders|Topic|RELATED_TO
1659|Diseases And Disorders|Topic|Frank Webb|Author|AUTHORED
1659|Diseases And Disorders|Topic|Amir Karami|Author|AUTHORED
1659|Diseases And Disorders|Topic|Vanessa Kitzie|Author|AUTHORED
1660|Respiratory Rate Estimation Algorithm|Topic|Pressure-Sensitive Mat (Psm) Technology|Topic|RELATED_TO
1660|Pressure-Sensitive Mat (Psm) Technology|Topic|Neonatal Intensive Care Units (Nicu)|Topic|RELATED_TO
1660|S. Nizami|Author|Respiratory Rate Estimation Algorithm|Topic|AUTHORED
1660|A. Bekele|Author|Respiratory Rate Estimation Algorithm|Topic|AUTHORED
1660|M. Hozayen|Author|Respiratory Rate Estimation Algorithm|Topic|AUTHORED
1660|K. Greenwood|Author|Respiratory Rate Estimation Algorithm|Topic|AUTHORED
1660|J. Harrold|Author|Respiratory Rate Estimation Algorithm|Topic|AUTHORED
1660|J. R. Green|Author|Respiratory Rate Estimation Algorithm|Topic|AUTHORED
1661|Crossing Survival Curves|Topic|Clinical Trial'S Primary Endpoint|Topic|DISCUSSES
1661|Crossing Point|Topic|Individual Survival Curves|Topic|RELATED_TO
1661|Survival Curve Errors|Topic|Crossing Point Errors|Topic|RELATED_TO
1661|Crossing Point|Topic|System Conditions|Topic|RELATED_TO
1661|Thomas Mcandrew|Author|Crossing Point|Topic|AUTHORED
1661|Bjorn Redfors|Author|Crossing Point|Topic|AUTHORED
1661|Yiran Zhang|Author|Crossing Point|Topic|AUTHORED
1661|Aaron Crowley|Author|Crossing Point|Topic|AUTHORED
1661|Shmuel Chen|Author|Crossing Point|Topic|AUTHORED
1661|Gregg Stone|Author|Crossing Point|Topic|AUTHORED
1661|Paul Jenkins|Author|Crossing Point|Topic|AUTHORED
1662|Digital Science'S Dimensions|Topic|Cascading Citation Expansion|Topic|RELATED_TO
1662|Cascading Citation Expansion|Topic|Chaomei Chen|Author|DISCUSSES
1663|A Corpus With Multi-Level Annotations Of Patients, Interventions And Outcomes To Support Language Processing For Medical Literature|Paper|Benjamin Nye|Author|AUTHORED
1663|A Corpus With Multi-Level Annotations Of Patients, Interventions And Outcomes To Support Language Processing For Medical Literature|Paper|Junyi Jessy Li|Author|AUTHORED
1663|A Corpus With Multi-Level Annotations Of Patients, Interventions And Outcomes To Support Language Processing For Medical Literature|Paper|Roma Patel|Author|AUTHORED
1663|A Corpus With Multi-Level Annotations Of Patients, Interventions And Outcomes To Support Language Processing For Medical Literature|Paper|Yinfei Yang|Author|AUTHORED
1663|A Corpus With Multi-Level Annotations Of Patients, Interventions And Outcomes To Support Language Processing For Medical Literature|Paper|Iain J. Marshall|Author|AUTHORED
1663|A Corpus With Multi-Level Annotations Of Patients, Interventions And Outcomes To Support Language Processing For Medical Literature|Paper|Ani Nenkova|Author|AUTHORED
1663|A Corpus With Multi-Level Annotations Of Patients, Interventions And Outcomes To Support Language Processing For Medical Literature|Paper|Byron C. Wallace|Author|AUTHORED
1664|Protein Design Algorithms|Topic|Mark A. Hallen|Author|AUTHORED
1664|Protein Design Algorithms|Topic|Bruce R. Donald|Author|AUTHORED
1664|Protein Design Algorithms|Topic|Computer Science Classes|Topic|RELATED_TO
1664|Protein Design Algorithms|Topic|Molecular Therapies|Topic|RELATED_TO
1664|Protein Design Algorithms|Topic|Therapeutics Development|Topic|RELATED_TO
1665|Matching Algorithms For Causal Inference With Multiple Treatments|Paper|Anthony D. Scotina|Author|AUTHORED
1665|Matching Algorithms For Causal Inference With Multiple Treatments|Paper|Roee Gutman|Author|AUTHORED
1665|Randomized Clinical Trials|Topic|Causal Effects|Topic|RELATED_TO
1665|Observational Data|Topic|Matching|Topic|RELATED_TO
1665|Matching Algorithms|Topic|Causal Effects|Topic|RELATED_TO
1666|Interval Estimation Of Individual-Level Causal Effects Under Unobserved Confounding|Paper|Nathan Kallus|Author|AUTHORED
1666|Interval Estimation Of Individual-Level Causal Effects Under Unobserved Confounding|Paper|Xiaojie Mao|Author|AUTHORED
1666|Interval Estimation Of Individual-Level Causal Effects Under Unobserved Confounding|Paper|Angela Zhou|Author|AUTHORED
1667|Online Learning Procedures|Topic|Cost Minimizing Algorithms|Topic|RELATED_TO
1667|Cost Minimizing Algorithms|Topic|Ucb-Algorithms|Topic|DISCUSSES
1667|Cost Minimizing Algorithms|Topic|Non-Iid Case|Topic|RELATED_TO
1667|Adaptive Tests|Topic|A/B Tests|Topic|RELATED_TO
1667|Rémy Degenne|Author|Cost Minimizing Algorithms|Topic|AUTHORED
1667|Thomas Nedelec|Author|Cost Minimizing Algorithms|Topic|AUTHORED
1667|Clément Calauzènes|Author|Cost Minimizing Algorithms|Topic|AUTHORED
1667|Vianney Perchet|Author|Cost Minimizing Algorithms|Topic|AUTHORED
1668|Kernel-Based Goodness-Of-Fit Test For Censored Data|Topic|Tamara Fernández|Author|AUTHORED
1668|Kernel-Based Goodness-Of-Fit Test For Censored Data|Topic|Arthur Gretton|Author|AUTHORED
1668|Kernel-Based Goodness-Of-Fit Test For Censored Data|Topic|Log-Rank Test|Topic|DISCUSSES
1668|Kernel-Based Goodness-Of-Fit Test For Censored Data|Topic|Periodic And Weibull Hazard Functions|Topic|RELATED_TO
1668|Kernel-Based Goodness-Of-Fit Test For Censored Data|Topic|Classical Tests|Topic|RELATED_TO
1669|Model Selection Based On Experimental Data|Topic|Biological Data Science|Topic|RELATED_TO
1669|Geometric Properties Of Input Data|Topic|Algebraic Model|Topic|RELATED_TO
1669|Staircase|Topic|Unique Reduced Gröbner Basis|Topic|RELATED_TO
1669|Linear Shift Of A Staircase|Topic|Unique Reduced Gröbner Basis|Topic|RELATED_TO
1669|Boolean Model Of The Lac Operon|Topic|E. Coli|Topic|RELATED_TO
1669|Elena S. Dimitrova|Author|Geometric Characterization Of Data Sets With Unique Reduced Gröbner Bases|Topic|AUTHORED
1669|Qijun He|Author|Geometric Characterization Of Data Sets With Unique Reduced Gröbner Bases|Topic|AUTHORED
1669|Brandilyn Stigler|Author|Geometric Characterization Of Data Sets With Unique Reduced Gröbner Bases|Topic|AUTHORED
1669|Anyu Zhang|Author|Geometric Characterization Of Data Sets With Unique Reduced Gröbner Bases|Topic|AUTHORED
1670|Contextual|Topic|Robin Van Emden|Author|AUTHORED
1670|Contextual|Topic|Maurits Kaptein|Author|AUTHORED
1671|Vaccine Dose Optimization|Topic|Immunostimulation/Immunodynamic Modelling|Topic|RELATED_TO
1671|Sophie J. Rhodes|Author|Immunostimulation/Immunodynamic Modelling|Topic|AUTHORED
1671|Gwenan M. Knight|Author|Immunostimulation/Immunodynamic Modelling|Topic|AUTHORED
1671|Denise E. Kirschner|Author|Immunostimulation/Immunodynamic Modelling|Topic|AUTHORED
1671|Richard G. White|Author|Immunostimulation/Immunodynamic Modelling|Topic|AUTHORED
1671|Thomas G. Evans|Author|Immunostimulation/Immunodynamic Modelling|Topic|AUTHORED
1672|Quantile Regression Modeling Of Recurrent Event Risk|Paper|Huijuan Ma|Author|AUTHORED
1672|Quantile Regression Modeling Of Recurrent Event Risk|Paper|Limin Peng|Author|AUTHORED
1672|Quantile Regression Modeling Of Recurrent Event Risk|Paper|Chiung-Yu Huang|Author|AUTHORED
1672|Quantile Regression Modeling Of Recurrent Event Risk|Paper|Haoda Fu|Author|AUTHORED
1672|Quantile Regression Modeling Of Recurrent Event Risk|Paper|Recurrent Event Risk|Topic|DISCUSSES
1673|Evaluating And Optimizing Network Sampling Designs: Decision Theory And Information Theory Perspectives|Paper|Simón Lunagómez|Author|AUTHORED
1673|Evaluating And Optimizing Network Sampling Designs: Decision Theory And Information Theory Perspectives|Paper|Marios Papamichalis|Author|AUTHORED
1673|Evaluating And Optimizing Network Sampling Designs: Decision Theory And Information Theory Perspectives|Paper|Patrick J. Wolfe|Author|AUTHORED
1673|Evaluating And Optimizing Network Sampling Designs: Decision Theory And Information Theory Perspectives|Paper|Edoardo M. Airoldi|Author|AUTHORED
1673|Evaluating And Optimizing Network Sampling Designs: Decision Theory And Information Theory Perspectives|Paper|Respondent-Driven Sampling|Topic|RELATED_TO
1673|Evaluating And Optimizing Network Sampling Designs: Decision Theory And Information Theory Perspectives|Paper|Decision Theory|Topic|RELATED_TO
1673|Evaluating And Optimizing Network Sampling Designs: Decision Theory And Information Theory Perspectives|Paper|Information Theory|Topic|RELATED_TO
1673|Evaluating And Optimizing Network Sampling Designs: Decision Theory And Information Theory Perspectives|Paper|Sufficiency|Topic|RELATED_TO
1673|Evaluating And Optimizing Network Sampling Designs: Decision Theory And Information Theory Perspectives|Paper|Goel-Degroot Criterion|Topic|RELATED_TO
1674|Quantification Of Sulfated Polysaccharides In Urine Samples|Topic|Heparin Red Kit|Topic|RELATED_TO
1674|Heparin Red Kit|Topic|Inorganic Sulfate|Topic|RELATED_TO
1674|Inorganic Sulfate|Topic|Hydrochloric Acid|Topic|RELATED_TO
1674|Inorganic Sulfate|Topic|Magnesium Chloride|Topic|RELATED_TO
1674|Heparin Red Kit|Topic|Ulrich Warttinger|Author|AUTHORED
1674|Heparin Red Kit|Topic|Roland Krämer|Author|AUTHORED
1675|Applications Of Blockchain In Healthcare: Current Landscape & Challenges|Paper|Healthcare|Topic|DISCUSSES
1675|Applications Of Blockchain In Healthcare: Current Landscape & Challenges|Paper|Blockchain|Topic|DISCUSSES
1676|A Sequential Significance Test For Treatment By Covariate Interactions|Paper|Min Qian|Author|AUTHORED
1676|A Sequential Significance Test For Treatment By Covariate Interactions|Paper|Bibhas Chakraborty|Author|AUTHORED
1676|A Sequential Significance Test For Treatment By Covariate Interactions|Paper|Raju Maiti|Author|AUTHORED
1676|A Sequential Significance Test For Treatment By Covariate Interactions|Paper|Ying Kuen Cheung|Author|AUTHORED
1677|Robust Kernel Association Test|Topic|Kara Martinez|Author|AUTHORED
1677|Robust Kernel Association Test|Topic|Arnab Maity|Author|AUTHORED
1677|Robust Kernel Association Test|Topic|Robert Yolken|Author|AUTHORED
1677|Robust Kernel Association Test|Topic|Patrick Sullivan|Author|AUTHORED
1677|Robust Kernel Association Test|Topic|Jung-Ying Tzeng|Author|AUTHORED
1677|Robust Kernel Association Test|Topic|Catie Clinical Trial|Topic|RELATED_TO
1677|Snp-Sets|Topic|Robust Kernel Association Test|Topic|RELATED_TO
1678|Separable Effects For Causal Inference In The Presence Of Competing Events|Paper|Mats J. Stensrud|Author|AUTHORED
1678|Separable Effects For Causal Inference In The Presence Of Competing Events|Paper|Jessica G. Young|Author|AUTHORED
1678|Separable Effects For Causal Inference In The Presence Of Competing Events|Paper|Vanessa Didelez|Author|AUTHORED
1678|Separable Effects For Causal Inference In The Presence Of Competing Events|Paper|James M. Robins|Author|AUTHORED
1678|Separable Effects For Causal Inference In The Presence Of Competing Events|Paper|Miguel A. Hernán|Author|AUTHORED
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Tissue Classification|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Magnetic Resonance Imaging (Mri)|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Brain Tissue Classification|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Surgical Planning|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Monitoring Therapy|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Clinical Drug Trials|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Image Registration|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Stereotactic Neurosurgery|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Radiotherapy|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Unsupervised Classification Algorithms|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Itk|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|White Matter|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Gray Matter|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Cerebrospinal Fluid (Csf)|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Background Of The Human Brain|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|5 Grayscale Head Mri Scans|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Otsu Thresholding|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Bayesian Classification|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Bayesian Classification With Gaussian Smoothing|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Results And Discussion Section|Topic|DISCUSSES
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Shadman Sakib|Author|AUTHORED
1679|Unsupervised Segmentation Algorithms' Implementation In Itk For Tissue Classification Via Human Head Mri Scans|Paper|Md. Abu Bakr Siddique|Author|AUTHORED
1680|Lakens Et Al (2018)|Paper|Interval Null Hypothesis Testing|Topic|DISCUSSES
1680|Lakens And Harms (2017)|Paper|Interval Null Hypothesis Testing|Topic|DISCUSSES
1680|Bayes Factor|Topic|Region Of Practical Equivalence (Rope)|Topic|RELATED_TO
1680|J. G. Liao|Author|Lakens Et Al (2018)|Paper|AUTHORED
1680|Vishal Midya|Author|Lakens Et Al (2018)|Paper|AUTHORED
1680|Arthur Berg|Author|Lakens Et Al (2018)|Paper|AUTHORED
1681|Admet|Topic|Cheminformatics|Topic|RELATED_TO
1681|Admet|Topic|Medicinal Chemistry|Topic|RELATED_TO
1681|Potentialnet|Paper|Admet|Topic|DISCUSSES
1682|Multicompartment Mathematical Model|Topic|Dose-Dense Protocols|Topic|RELATED_TO
1682|Dose-Dense Protocols|Topic|Combination Cancer Chemotherapy|Topic|RELATED_TO
1682|Álvaro G. López|Author|Multicompartment Mathematical Model|Topic|AUTHORED
1682|Kelly C. Iarosz|Author|Multicompartment Mathematical Model|Topic|AUTHORED
1682|Antonio M. Batista|Author|Multicompartment Mathematical Model|Topic|AUTHORED
1682|Jesús M. Seoane|Author|Multicompartment Mathematical Model|Topic|AUTHORED
1682|Ricardo L. Viana|Author|Multicompartment Mathematical Model|Topic|AUTHORED
1682|Miguel A. F. Sanjuán|Author|Multicompartment Mathematical Model|Topic|AUTHORED
1683|Robust Blocked Response-Adaptive Randomization Designs|Paper|Response-Adaptive Randomization|Topic|DISCUSSES
1683|Robust Blocked Response-Adaptive Randomization Designs|Paper|Type-I Error|Topic|DISCUSSES
1684|Two-Stage Adaptive Optimal Design|Topic|Clinical Trials|Topic|RELATED_TO
1684|Maximum Likelihood Estimator (Mle)|Topic|Nonlinear Regression Models|Topic|RELATED_TO
1684|Maximum Likelihood Estimator (Mle)|Topic|Independent Normal Errors|Topic|RELATED_TO
1684|Maximum Likelihood Estimator (Mle)|Topic|Pilot Study|Topic|RELATED_TO
1684|Fisher Information|Topic|Maximum Likelihood Estimator (Mle)|Topic|RELATED_TO
1684|Random Information Measures|Topic|Maximum Likelihood Estimator (Mle)|Topic|RELATED_TO
1684|Observed Information|Topic|Random Information Measures|Topic|RELATED_TO
1684|Zhantao Lin|Author|Random Norming Aids Analysis Of Non-Linear Regression Models With Sequential Informative Dose Selection|Paper|AUTHORED
1684|Nancy Flournoy|Author|Random Norming Aids Analysis Of Non-Linear Regression Models With Sequential Informative Dose Selection|Paper|AUTHORED
1684|William F. Rosenberger|Author|Random Norming Aids Analysis Of Non-Linear Regression Models With Sequential Informative Dose Selection|Paper|AUTHORED
1685|A Deep Framework For Bone Age Assessment Based On Finger Joint Localization|Paper|Bone Age Assessment|Topic|DISCUSSES
1685|A Deep Framework For Bone Age Assessment Based On Finger Joint Localization|Paper|Tanner-Whitehouse|Topic|RELATED_TO
1685|A Deep Framework For Bone Age Assessment Based On Finger Joint Localization|Paper|Greulich And Pyle|Topic|RELATED_TO
1685|A Deep Framework For Bone Age Assessment Based On Finger Joint Localization|Paper|Finger Joint Localization Strategy|Topic|DISCUSSES
1685|A Deep Framework For Bone Age Assessment Based On Finger Joint Localization|Paper|Deep Neural Network|Topic|DISCUSSES
1686|Frailty Models|Topic|Heterogeneous Survival Data|Topic|RELATED_TO
1686|Frailty Models|Topic|Random Effects|Topic|RELATED_TO
1686|Frailty Models|Topic|Fixed Effects|Topic|RELATED_TO
1686|Cox Model|Topic|Fixed Effects|Topic|RELATED_TO
1686|Maximisation Of The Integrated Partial Likelihood|Topic|Random Effects|Topic|RELATED_TO
1686|Stochastic Estimation Procedure|Topic|Random Effects|Topic|RELATED_TO
1686|Cancer Clinical Trial Data|Topic|Stochastic Estimation Procedure|Topic|RELATED_TO
1686|Oodally Ajmal|Author|Maximisation Of The Integrated Partial Likelihood|Topic|AUTHORED
1686|Luc Duchateau|Author|Maximisation Of The Integrated Partial Likelihood|Topic|AUTHORED
1686|Estelle Kuhn|Author|Maximisation Of The Integrated Partial Likelihood|Topic|AUTHORED
1687|Robust Inference For Skewed Data In Health Sciences|Paper|Skew-Normal Distributions|Topic|DISCUSSES
1687|Robust Inference For Skewed Data In Health Sciences|Paper|Health Data|Topic|DISCUSSES
1687|Robust Inference For Skewed Data In Health Sciences|Paper|Robust Methodology|Topic|DISCUSSES
1687|Robust Inference For Skewed Data In Health Sciences|Paper|Outliers|Topic|DISCUSSES
1687|Robust Inference For Skewed Data In Health Sciences|Paper|Australian Institute Of Sports|Topic|RELATED_TO
1687|Robust Inference For Skewed Data In Health Sciences|Paper|Aids Clinical Trial Data|Topic|RELATED_TO
1688|Random Interaction Forest (Rif)|Topic|Precision Medicine|Topic|RELATED_TO
1688|Random Interaction Forest (Rif)|Topic|Clostridium Difficile|Topic|RELATED_TO
1688|Zhen Zeng|Author|Random Interaction Forest (Rif)|Topic|AUTHORED
1688|Yuefeng Lu|Author|Random Interaction Forest (Rif)|Topic|AUTHORED
1688|Judong Shen|Author|Random Interaction Forest (Rif)|Topic|AUTHORED
1688|Wei Zheng|Author|Random Interaction Forest (Rif)|Topic|AUTHORED
1688|Peter Shaw|Author|Random Interaction Forest (Rif)|Topic|AUTHORED
1688|Mary Beth Dorr|Author|Random Interaction Forest (Rif)|Topic|AUTHORED
1689|Yp Model|Topic|Proportional Hazards Model|Topic|RELATED_TO
1689|Yp Model|Topic|Proportional Odds Model|Topic|RELATED_TO
1689|Yp Model|Topic|Accelerated Failure Time Model|Topic|RELATED_TO
1689|Fabio N. Demarqui|Author|Yp Model|Topic|AUTHORED
1689|Vinicius D. Mayrink|Author|Yp Model|Topic|AUTHORED
1689|Yp Model|Topic|Survival Data|Topic|RELATED_TO
1689|Yp Model|Topic|Piecewise Exponential Distribution|Topic|RELATED_TO
1689|Yp Model|Topic|Cancer Clinical Trial|Topic|RELATED_TO
1689|Yp Model|Topic|Simulation Study|Topic|RELATED_TO
1690|Equivalence Tests For Binary Efficacy-Toxicity Responses|Paper|Efficacy And Toxicity|Topic|DISCUSSES
1690|Equivalence Tests For Binary Efficacy-Toxicity Responses|Paper|Clinical Trials|Topic|RELATED_TO
1690|Equivalence Tests For Binary Efficacy-Toxicity Responses|Paper|Parametric Bootstrap|Topic|DISCUSSES
1690|Equivalence Tests For Binary Efficacy-Toxicity Responses|Paper|2-Dimensional Gumbel Model|Topic|DISCUSSES
1690|Equivalence Tests For Binary Efficacy-Toxicity Responses|Paper|Simulation Study|Topic|DISCUSSES
1690|Equivalence Tests For Binary Efficacy-Toxicity Responses|Paper|Case Study|Topic|DISCUSSES
1691|Baymedr|Topic|Maximilian Linde|Author|AUTHORED
1691|Baymedr|Topic|Don Van Ravenzwaaij|Author|AUTHORED
1691|Frequentist Statistical Methods|Topic|Bayesian Inference|Topic|RELATED_TO
1692|Electroencephalogram (Eeg)|Topic|Eeg Applications|Topic|RELATED_TO
1692|Electroencephalogram (Eeg)|Topic|Eeg Artifacts|Topic|RELATED_TO
1692|Electroencephalogram (Eeg)|Topic|Eeg Techniques|Topic|RELATED_TO
1692|Ibrahim Kaya|Author|A Brief Summary Of Eeg Artifact Handling|Paper|AUTHORED
1693|Boosting Algorithms For Estimating Optimal Individualized Treatment Rules|Paper|Xgboost|Topic|RELATED_TO
1693|Boosting Algorithms For Estimating Optimal Individualized Treatment Rules|Paper|Additive Regression Trees|Topic|RELATED_TO
1693|Boosting Algorithms For Estimating Optimal Individualized Treatment Rules|Paper|Boosting Technique|Topic|RELATED_TO
1693|Boosting Algorithms For Estimating Optimal Individualized Treatment Rules|Paper|Parametric Methods|Topic|RELATED_TO
1693|Boosting Algorithms For Estimating Optimal Individualized Treatment Rules|Paper|Diabetes Phase Iii Trial|Topic|RELATED_TO
1694|Beta-Stacy Bootstrap|Topic|Beta-Stacy Process|Topic|RELATED_TO
1694|Beta-Stacy Bootstrap|Topic|Survival Data From A Real Clinical Trial|Topic|DISCUSSES
1694|Andrea Arfè|Author|Beta-Stacy Bootstrap|Topic|AUTHORED
1694|Pietro Muliere|Author|Beta-Stacy Bootstrap|Topic|AUTHORED
1695|Online Batch Decision-Making With High-Dimensional Covariates|Paper|Teamwork Lasso Bandit Algorithm|Topic|DISCUSSES
1695|Online Batch Decision-Making With High-Dimensional Covariates|Paper|Sequential Decision Making|Topic|DISCUSSES
1695|Online Batch Decision-Making With High-Dimensional Covariates|Paper|Batch Models|Topic|DISCUSSES
1695|Online Batch Decision-Making With High-Dimensional Covariates|Paper|Interactive Marketing|Topic|DISCUSSES
1695|Online Batch Decision-Making With High-Dimensional Covariates|Paper|Clinical Trial|Topic|DISCUSSES
1695|Online Batch Decision-Making With High-Dimensional Covariates|Paper|Treatment Efficacy|Topic|DISCUSSES
1695|Online Batch Decision-Making With High-Dimensional Covariates|Paper|High-Dimensional User Covariates|Topic|DISCUSSES
1695|Online Batch Decision-Making With High-Dimensional Covariates|Paper|Explore-Exploit Dilemma|Topic|DISCUSSES
1695|Online Batch Decision-Making With High-Dimensional Covariates|Paper|Lasso Estimate|Topic|DISCUSSES
1695|Online Batch Decision-Making With High-Dimensional Covariates|Paper|Cumulative Regret|Topic|DISCUSSES
1696|Intelligentpooling|Topic|Mobile Health|Topic|RELATED_TO
1696|Sabina Tomkins|Author|Rapidly Personalizing Mobile Health Treatment Policies With Limited Data|Paper|AUTHORED
1696|Peng Liao|Author|Rapidly Personalizing Mobile Health Treatment Policies With Limited Data|Paper|AUTHORED
1696|Predrag Klasnja|Author|Rapidly Personalizing Mobile Health Treatment Policies With Limited Data|Paper|AUTHORED
1696|Serena Yeung|Author|Rapidly Personalizing Mobile Health Treatment Policies With Limited Data|Paper|AUTHORED
1696|Susan Murphy|Author|Rapidly Personalizing Mobile Health Treatment Policies With Limited Data|Paper|AUTHORED
1697|Linecospar|Topic|Optimizing Lower-Body Exoskeleton Walking Gaits For User Comfort|Topic|RELATED_TO
1697|Maegan Tucker|Author|Human Preference-Based Learning For High-Dimensional Optimization Of Exoskeleton Walking Gaits|Paper|AUTHORED
1697|Myra Cheng|Author|Human Preference-Based Learning For High-Dimensional Optimization Of Exoskeleton Walking Gaits|Paper|AUTHORED
1697|Ellen Novoseller|Author|Human Preference-Based Learning For High-Dimensional Optimization Of Exoskeleton Walking Gaits|Paper|AUTHORED
1697|Richard Cheng|Author|Human Preference-Based Learning For High-Dimensional Optimization Of Exoskeleton Walking Gaits|Paper|AUTHORED
1697|Yisong Yue|Author|Human Preference-Based Learning For High-Dimensional Optimization Of Exoskeleton Walking Gaits|Paper|AUTHORED
1697|Joel W. Burdick|Author|Human Preference-Based Learning For High-Dimensional Optimization Of Exoskeleton Walking Gaits|Paper|AUTHORED
1697|Aaron D. Ames|Author|Human Preference-Based Learning For High-Dimensional Optimization Of Exoskeleton Walking Gaits|Paper|AUTHORED
1698|Covid-19|Topic|China|Topic|RELATED_TO
1698|China|Topic|Imported Cases|Topic|RELATED_TO
1698|Imported Cases|Topic|Epidemic Control|Topic|RELATED_TO
1698|Clinical Trials|Topic|Covid-19|Topic|RELATED_TO
1698|Control Strategies|Topic|Epidemic Trends|Topic|RELATED_TO
1698|Epidemic Trends|Topic|Medical Burden|Topic|RELATED_TO
1698|Jiwei Jia|Author|Covid-19|Topic|AUTHORED
1698|Siyu Liu|Author|Covid-19|Topic|AUTHORED
1698|Jing Ding|Author|Covid-19|Topic|AUTHORED
1698|Guidong Liao|Author|Covid-19|Topic|AUTHORED
1698|Lihua Zhang|Author|Covid-19|Topic|AUTHORED
1698|Ran Zhang|Author|Covid-19|Topic|AUTHORED
1699|Shrinkage Estimation In A Meta-Analysis Framework|Topic|Dynamical Borrowing Of Information|Topic|RELATED_TO
1699|Shrinkage Estimation In A Meta-Analysis Framework|Topic|Randomized Controlled Trial (Rct)|Topic|RELATED_TO
1699|Shrinkage Estimation In A Meta-Analysis Framework|Topic|Clinical Registry|Topic|RELATED_TO
1699|Shrinkage Estimation In A Meta-Analysis Framework|Topic|Bayesian Meta-Analysis|Topic|RELATED_TO
1699|Shrinkage Estimation In A Meta-Analysis Framework|Topic|Creutzfeldt-Jakob Disease|Topic|RELATED_TO
1699|Shrinkage Estimation In A Meta-Analysis Framework|Topic|Fetal Monitoring|Topic|RELATED_TO
1699|Shrinkage Estimation In A Meta-Analysis Framework|Topic|Metabolic Acidosis|Topic|RELATED_TO
1699|Christian Röver|Author|Shrinkage Estimation In A Meta-Analysis Framework|Topic|AUTHORED
1699|Tim Friede|Author|Shrinkage Estimation In A Meta-Analysis Framework|Topic|AUTHORED
1700|Inactivity Time|Topic|Mortality Data|Topic|RELATED_TO
1700|Quantile Inactivity Time|Topic|Regression Method|Topic|AUTHORED
1700|Variance-Covariance Matrix|Topic|Regression Method|Topic|RELATED_TO
1700|Breast Cancer Clinical Trial|Topic|Regression Method|Topic|RELATED_TO
1700|Lauren C. Balmert|Author|Quantile Inactivity Time|Topic|AUTHORED
1700|Ruosha Li|Author|Quantile Inactivity Time|Topic|AUTHORED
1700|Limin Peng|Author|Quantile Inactivity Time|Topic|AUTHORED
1700|Jong-Hyeon Jeong|Author|Quantile Inactivity Time|Topic|AUTHORED
1701|Power Constrained Bandits|Paper|Jiayu Yao|Author|AUTHORED
1701|Power Constrained Bandits|Paper|Emma Brunskill|Author|AUTHORED
1701|Power Constrained Bandits|Paper|Weiwei Pan|Author|AUTHORED
1701|Power Constrained Bandits|Paper|Susan Murphy|Author|AUTHORED
1701|Power Constrained Bandits|Paper|Finale Doshi-Velez|Author|AUTHORED
1701|Contextual Bandits|Topic|Mobile Health|Topic|RELATED_TO
1701|Contextual Bandits|Topic|Clinical Trial|Topic|RELATED_TO
1702|Covid-19|Topic|Rna-Dependent Rna Polymerase|Topic|RELATED_TO
1702|Covid-19|Topic|Angiotensin-Converting Enzyme 2|Topic|RELATED_TO
1702|Covid-19|Topic|Spike Glycoprotein|Topic|RELATED_TO
1702|Molecular Docking|Topic|Rna-Dependent Rna Polymerase|Topic|DISCUSSES
1702|Molecular Docking|Topic|Angiotensin-Converting Enzyme 2|Topic|DISCUSSES
1702|Molecular Docking|Topic|Spike Glycoprotein|Topic|DISCUSSES
1702|Limonin|Topic|Covid-19|Topic|RELATED_TO
1702|Scopadulcic Acid B|Topic|Covid-19|Topic|RELATED_TO
1702|Paracetamol|Topic|Covid-19|Topic|RELATED_TO
1702|Hydroxychloroquine|Topic|Covid-19|Topic|RELATED_TO
1702|Seshu Vardhan|Author|Molecular Docking|Topic|AUTHORED
1702|Suban K Sahoo|Author|Molecular Docking|Topic|AUTHORED
1703|Covid-19|Topic|Sars-Cov-2|Topic|RELATED_TO
1703|Sars-Cov-2|Topic|Fda-Approved Drugs|Topic|RELATED_TO
1703|Fda-Approved Drugs|Topic|Clinical Trials|Topic|RELATED_TO
1703|Tyrphostin-Ag-1478|Topic|Influenza A Virus|Topic|DISCUSSES
1703|Brefeldin-A|Topic|Influenza A Virus|Topic|DISCUSSES
1703|Zhihan Wang|Author|Identification Of Repurposable Drugs And Adverse Drug Reactions For Various Courses Of Covid-19 Based On Single-Cell Rna Sequencing Data|Paper|AUTHORED
1703|Kai Guo|Author|Identification Of Repurposable Drugs And Adverse Drug Reactions For Various Courses Of Covid-19 Based On Single-Cell Rna Sequencing Data|Paper|AUTHORED
1703|Pan Gao|Author|Identification Of Repurposable Drugs And Adverse Drug Reactions For Various Courses Of Covid-19 Based On Single-Cell Rna Sequencing Data|Paper|AUTHORED
1703|Qinqin Pu|Author|Identification Of Repurposable Drugs And Adverse Drug Reactions For Various Courses Of Covid-19 Based On Single-Cell Rna Sequencing Data|Paper|AUTHORED
1703|Min Wu|Author|Identification Of Repurposable Drugs And Adverse Drug Reactions For Various Courses Of Covid-19 Based On Single-Cell Rna Sequencing Data|Paper|AUTHORED
1703|Changlong Li|Author|Identification Of Repurposable Drugs And Adverse Drug Reactions For Various Courses Of Covid-19 Based On Single-Cell Rna Sequencing Data|Paper|AUTHORED
1703|Junguk Hur|Author|Identification Of Repurposable Drugs And Adverse Drug Reactions For Various Courses Of Covid-19 Based On Single-Cell Rna Sequencing Data|Paper|AUTHORED
1704|Best Arm Identification|Topic|Bandit Models|Topic|RELATED_TO
1704|Best Arm Identification|Topic|Graph Smoothness Constraint|Topic|RELATED_TO
1704|Best Arm Identification|Topic|Gradient Ascent Algorithm|Topic|RELATED_TO
1704|Best Arm Identification|Topic|Sample Complexity|Topic|RELATED_TO
1704|Best Arm Identification|Topic|Non-Smooth Max-Min Problem|Topic|RELATED_TO
1704|Best Arm Identification|Topic|Asymptotically Optimal Strategy|Topic|RELATED_TO
1704|Best Arm Identification|Topic|Numerical Experiments|Topic|RELATED_TO
1704|Tomá Kocák|Author|Best Arm Identification|Topic|AUTHORED
1704|Aurélien Garivier|Author|Best Arm Identification|Topic|AUTHORED
1705|Sparse Additive Modeling|Topic|Treatment Effect-Modification|Topic|RELATED_TO
1705|Hyung Park|Author|Constrained Sparse Additive Model|Topic|AUTHORED
1705|Eva Petkova|Author|Constrained Sparse Additive Model|Topic|AUTHORED
1705|Thaddeus Tarpey|Author|Constrained Sparse Additive Model|Topic|AUTHORED
1705|R. Todd Ogden|Author|Constrained Sparse Additive Model|Topic|AUTHORED
1705|Constrained Sparse Additive Model|Topic|Randomized Clinical Trial|Topic|RELATED_TO
1706|Text Retrieval Conference|Topic|Precision Medicine|Topic|RELATED_TO
1706|Precision Medicine|Topic|Pubmed|Topic|RELATED_TO
1706|Precision Medicine|Topic|Clinical Trials|Topic|RELATED_TO
1706|Sequential Model-Based Algorithm Configuration|Topic|Bm25-Based Search Engine|Topic|RELATED_TO
1706|Bm25-Based Search Engine|Topic|Gold Standard Data|Topic|RELATED_TO
1706|Gold Standard Data|Topic|Infndcg Metric|Topic|RELATED_TO
1706|Erik Faessler|Author|What Makes A Top-Performing Precision Medicine Search Engine? Tracing Main System Features In A Systematic Way|Paper|AUTHORED
1706|Michel Oleynik|Author|What Makes A Top-Performing Precision Medicine Search Engine? Tracing Main System Features In A Systematic Way|Paper|AUTHORED
1706|Udo Hahn|Author|What Makes A Top-Performing Precision Medicine Search Engine? Tracing Main System Features In A Systematic Way|Paper|AUTHORED
1707|Balanced Representation Learning Methods|Topic|Counterfactual Inference|Topic|RELATED_TO
1707|Counterfactual Inference|Topic|Survival Outcomes|Topic|RELATED_TO
1707|Survival Outcomes|Topic|Survival Data|Topic|RELATED_TO
1707|Survival Data|Topic|Medical Applications|Topic|RELATED_TO
1707|Medical Applications|Topic|Drug Development|Topic|RELATED_TO
1707|Medical Applications|Topic|Risk Profiling|Topic|RELATED_TO
1707|Medical Applications|Topic|Clinical Trials|Topic|RELATED_TO
1707|Survival Outcomes|Topic|Censored Events|Topic|RELATED_TO
1707|Counterfactual Inference|Topic|Hazard Ratio Metric|Topic|RELATED_TO
1707|Hazard Ratio Metric|Topic|Treatment Effects|Topic|RELATED_TO
1707|Paidamoyo Chapfuwa|Author|Enabling Counterfactual Survival Analysis With Balanced Representations|Paper|AUTHORED
1707|Serge Assaad|Author|Enabling Counterfactual Survival Analysis With Balanced Representations|Paper|AUTHORED
1707|Shuxi Zeng|Author|Enabling Counterfactual Survival Analysis With Balanced Representations|Paper|AUTHORED
1707|Michael J. Pencina|Author|Enabling Counterfactual Survival Analysis With Balanced Representations|Paper|AUTHORED
1707|Lawrence Carin|Author|Enabling Counterfactual Survival Analysis With Balanced Representations|Paper|AUTHORED
1707|Ricardo Henao|Author|Enabling Counterfactual Survival Analysis With Balanced Representations|Paper|AUTHORED
1708|Covid-19|Topic|Antibody Therapies|Topic|RELATED_TO
1708|Sars-Cov-2|Topic|Antibody Therapies|Topic|RELATED_TO
1708|Sars-Cov|Topic|Antibody Therapies|Topic|RELATED_TO
1708|Jiahui Chen|Author|Review Of Covid-19 Antibody Therapies|Paper|AUTHORED
1708|Kaifu Gao|Author|Review Of Covid-19 Antibody Therapies|Paper|AUTHORED
1708|Rui Wang|Author|Review Of Covid-19 Antibody Therapies|Paper|AUTHORED
1708|Duc Duy Nguyen|Author|Review Of Covid-19 Antibody Therapies|Paper|AUTHORED
1708|Guo-Wei Wei|Author|Review Of Covid-19 Antibody Therapies|Paper|AUTHORED
1708|Protein Data Bank|Topic|Antibody Therapies|Topic|RELATED_TO
1708|Topological Data Analysis (Tda)|Topic|Binding Affinities|Topic|RELATED_TO
1708|Angiotensin-Converting Enzyme 2 (Ace2)|Topic|Sars-Cov-2|Topic|RELATED_TO
1708|Covid-19 Antibody Clinical Trials|Topic|Antibody Therapies|Topic|RELATED_TO
1709|Causal Relationships In Health Sciences|Topic|Randomized Controlled Trials|Topic|RELATED_TO
1709|Causal Relationships In Health Sciences|Topic|Causal Inference Theory|Topic|RELATED_TO
1709|Causal Relationships In Health Sciences|Topic|Survival Analysis|Topic|RELATED_TO
1709|Survival Analysis|Topic|Hazard Ratio|Topic|RELATED_TO
1709|Hazard Ratio|Topic|Observational Studies|Topic|RELATED_TO
1709|Observational Studies|Topic|Novel Approach For Hazard Ratios|Topic|RELATED_TO
1709|Novel Approach For Hazard Ratios|Topic|Ewing'S Sarcoma|Topic|RELATED_TO
1709|Riddhiman Adib|Author|A Causally Formulated Hazard Ratio Estimation Through Backdoor Adjustment On Structural Causal Model|Paper|AUTHORED
1709|Paul Griffin|Author|A Causally Formulated Hazard Ratio Estimation Through Backdoor Adjustment On Structural Causal Model|Paper|AUTHORED
1709|Sheikh Iqbal Ahamed|Author|A Causally Formulated Hazard Ratio Estimation Through Backdoor Adjustment On Structural Causal Model|Paper|AUTHORED
1709|Mohammad Adibuzzaman|Author|A Causally Formulated Hazard Ratio Estimation Through Backdoor Adjustment On Structural Causal Model|Paper|AUTHORED
1710|Stratified Clinical Trial Design|Topic|Log-Rank Test|Topic|RELATED_TO
1710|Stratified Clinical Trial Design|Topic|Cox Regression Analyses|Topic|RELATED_TO
1710|Madan G. Kundu|Author|Time To Event Analyses|Topic|AUTHORED
1710|Shoubhik Mondal|Author|Time To Event Analyses|Topic|AUTHORED
1710|Stratification Factors|Topic|Power Of The Stratified Log-Rank Test|Topic|RELATED_TO
1710|Stratification Factors|Topic|Hr Estimate|Topic|RELATED_TO
1710|Power Of The Stratified Log-Rank Test|Topic|Bias And Standard Error|Topic|RELATED_TO
1710|Multivariate Cox Analysis|Topic|Hr Estimate|Topic|RELATED_TO
1710|Stratified Cox Analysis|Topic|Hr Estimate|Topic|RELATED_TO
1710|Simulation|Topic|Bias And Standard Error|Topic|RELATED_TO
1710|Study Design|Topic|Stratification Factors|Topic|RELATED_TO
1711|Nlnde|Topic|Natural Language Processing|Topic|RELATED_TO
1711|Nlnde|Topic|Meddocan|Topic|RELATED_TO
1712|On Second Order Correctness Of Bootstrap In Logistic Regression|Paper|Debraj Das|Author|AUTHORED
1712|On Second Order Correctness Of Bootstrap In Logistic Regression|Paper|Priyam Das|Author|AUTHORED
1713|Contextual Bandit With Missing Rewards|Paper|Djallel Bouneffouf|Author|AUTHORED
1713|Contextual Bandit With Missing Rewards|Paper|Sohini Upadhyay|Author|AUTHORED
1713|Contextual Bandit With Missing Rewards|Paper|Yasaman Khazaeni|Author|AUTHORED
1714|Covariate-Adaptive Randomization Schemes|Topic|Clinical Trials|Topic|RELATED_TO
1714|Covariate-Adaptive Randomization Schemes|Topic|Treatment Assignments|Topic|RELATED_TO
1714|Covariate-Adaptive Randomization Schemes|Topic|Prognostic Factors|Topic|RELATED_TO
1714|Inference After Covariate-Adaptive Randomization|Topic|Average Treatment Effect|Topic|RELATED_TO
1714|Ting Ye|Author|Inference After Covariate-Adaptive Randomization|Topic|AUTHORED
1714|Yanyao Yi|Author|Inference After Covariate-Adaptive Randomization|Topic|AUTHORED
1714|Jun Shao|Author|Inference After Covariate-Adaptive Randomization|Topic|AUTHORED
1714|Estimators|Topic|Asymptotic Normality|Topic|RELATED_TO
1714|Minimization|Topic|Asymptotic Normality|Topic|RELATED_TO
1714|Variance Estimators|Topic|Asymptotic Inference|Topic|RELATED_TO
1714|Asymptotic Relative Efficiencies|Topic|Estimators|Topic|RELATED_TO
1714|Finite Sample Properties|Topic|Estimators|Topic|RELATED_TO
1714|Valid And Model Free Inference|Topic|Estimators|Topic|RELATED_TO
1715|Predicting Interactions Among Heterogenous Graph Structured Data|Topic|Knowledge Graph Completion|Topic|RELATED_TO
1715|Predicting Interactions Among Heterogenous Graph Structured Data|Topic|Recommendation Systems|Topic|RELATED_TO
1715|Predicting Interactions Among Heterogenous Graph Structured Data|Topic|Drug Discovery|Topic|RELATED_TO
1715|Drug Discovery|Topic|Few-Shot Link Prediction|Topic|RELATED_TO
1715|Few-Shot Link Prediction|Topic|Inductive Rgcn|Paper|DISCUSSES
1715|Inductive Rgcn|Paper|Drug-Repurposing Knowledge Graph (Drkg)|Topic|DISCUSSES
1715|Inductive Rgcn|Paper|Covid-19|Topic|DISCUSSES
1715|Inductive Rgcn|Paper|Biological Entities|Topic|DISCUSSES
1715|Drug-Repurposing Knowledge Graph (Drkg)|Topic|Drugs Used In Clinical Trials|Topic|RELATED_TO
1715|Drugs Used In Clinical Trials|Topic|Drug Candidates|Topic|RELATED_TO
1716|Drug Discovery|Topic|Deep Graph Generative Models|Topic|RELATED_TO
1716|Deep Graph Generative Models|Topic|Visualization Framework|Topic|RELATED_TO
1716|Karan Yang|Author|Visualization Framework|Topic|AUTHORED
1716|Chengxi Zang|Author|Visualization Framework|Topic|AUTHORED
1716|Fei Wang|Author|Visualization Framework|Topic|AUTHORED
1717|Panrep|Topic|Node Classification|Topic|RELATED_TO
1717|Panrep|Topic|Link Prediction|Topic|RELATED_TO
1717|Panrep|Topic|Drug Repurposing|Topic|RELATED_TO
1717|Panrep|Topic|Covid-19|Topic|RELATED_TO
1717|Vassilis N. Ioannidis|Author|Panrep|Topic|AUTHORED
1717|Da Zheng|Author|Panrep|Topic|AUTHORED
1717|George Karypis|Author|Panrep|Topic|AUTHORED
1718|Seenet|Topic|Deeplesion|Topic|RELATED_TO
1718|Youbao Tang|Author|Seenet|Topic|AUTHORED
1718|Ke Yan|Author|Seenet|Topic|AUTHORED
1718|Jing Xiao|Author|Seenet|Topic|AUTHORED
1718|Ranold M. Summers|Author|Seenet|Topic|AUTHORED
1719|On The Programmatic Generation Of Reproducible Documents|Paper|R Markdown|Topic|DISCUSSES
1719|On The Programmatic Generation Of Reproducible Documents|Paper|Listdown Package|Topic|RELATED_TO
1720|Lee, Boone, Et Al (2020)|Author|Application Of Dynamic Linear Models To Random Allocation Clinical Trials With Covariates|Paper|AUTHORED
1720|Dynamic Linear Models|Topic|Application Of Dynamic Linear Models To Random Allocation Clinical Trials With Covariates|Paper|RELATED_TO
1720|Random Allocation Models|Topic|Application Of Dynamic Linear Models To Random Allocation Clinical Trials With Covariates|Paper|RELATED_TO
1720|Bayesian Adaptive Allocation Models|Topic|Application Of Dynamic Linear Models To Random Allocation Clinical Trials With Covariates|Paper|RELATED_TO
1720|Sensitivity Analysis|Topic|Application Of Dynamic Linear Models To Random Allocation Clinical Trials With Covariates|Paper|RELATED_TO
1720|Power Analysis|Topic|Application Of Dynamic Linear Models To Random Allocation Clinical Trials With Covariates|Paper|RELATED_TO
1721|Sars-Cov-2|Topic|Covid-19|Topic|RELATED_TO
1721|Sars-Cov-2|Topic|Spike Protein|Topic|RELATED_TO
1721|Sars-Cov-2|Topic|Rdrp|Topic|RELATED_TO
1721|Sars-Cov-2|Topic|Hemoglobin|Topic|RELATED_TO
1721|Sars-Cov-2|Topic|Orthocoronavirinae|Topic|RELATED_TO
1721|Lokesh Agrawal|Author|Sars-Cov-2|Topic|AUTHORED
1721|Thanasis Poullikkas|Author|Sars-Cov-2|Topic|AUTHORED
1721|Scott Eisenhower|Author|Sars-Cov-2|Topic|AUTHORED
1721|Carlo Monsanto|Author|Sars-Cov-2|Topic|AUTHORED
1721|Ranjith Kumar Bakku|Author|Sars-Cov-2|Topic|AUTHORED
1722|A General Bayesian Model For Heteroskedastic Data With Fully Conjugate Full-Conditional Distributions|Paper|Paul A. Parker|Author|AUTHORED
1722|A General Bayesian Model For Heteroskedastic Data With Fully Conjugate Full-Conditional Distributions|Paper|Scott H. Holan|Author|AUTHORED
1722|A General Bayesian Model For Heteroskedastic Data With Fully Conjugate Full-Conditional Distributions|Paper|Skye A. Wills|Author|AUTHORED
1722|A General Bayesian Model For Heteroskedastic Data With Fully Conjugate Full-Conditional Distributions|Paper|Financial Time Series|Topic|RELATED_TO
1722|A General Bayesian Model For Heteroskedastic Data With Fully Conjugate Full-Conditional Distributions|Paper|Environmental Statistics|Topic|RELATED_TO
1722|A General Bayesian Model For Heteroskedastic Data With Fully Conjugate Full-Conditional Distributions|Paper|High Dimensional Soil Dataset|Topic|RELATED_TO
1722|A General Bayesian Model For Heteroskedastic Data With Fully Conjugate Full-Conditional Distributions|Paper|Asset Volatility|Topic|RELATED_TO
1722|A General Bayesian Model For Heteroskedastic Data With Fully Conjugate Full-Conditional Distributions|Paper|Clinical Trial Data For Creatinine|Topic|RELATED_TO
1723|Biomedical Knowledge Graph|Topic|Identification Of Disease Genes|Topic|RELATED_TO
1723|Machine Learning Method|Topic|Biomedical Knowledge Graph|Topic|RELATED_TO
1723|Relation Types|Topic|Machine Learning Method|Topic|RELATED_TO
1723|Disease Gene Identification|Topic|Relation Types|Topic|RELATED_TO
1723|Open Targets|Topic|Disease Gene Identification|Topic|RELATED_TO
1723|Parkinson'S Disease|Topic|Open Targets|Topic|RELATED_TO
1723|Srivamshi Pittala|Author|Disease Gene Identification|Topic|AUTHORED
1723|William Koehler|Author|Disease Gene Identification|Topic|AUTHORED
1723|Jonathan Deans|Author|Disease Gene Identification|Topic|AUTHORED
1723|Daniel Salinas|Author|Disease Gene Identification|Topic|AUTHORED
1723|Martin Bringmann|Author|Disease Gene Identification|Topic|AUTHORED
1723|Katharina Sophia Volz|Author|Disease Gene Identification|Topic|AUTHORED
1723|Berk Kapicioglu|Author|Disease Gene Identification|Topic|AUTHORED
1724|Systemic Lupus Erythematosus|Topic|Aditi Deokar|Author|AUTHORED
1724|Gene Expression Data|Topic|Systemic Lupus Erythematosus|Topic|RELATED_TO
1724|Immune Pathways|Topic|Systemic Lupus Erythematosus|Topic|RELATED_TO
1724|High Interferon Levels|Topic|Immune Pathways|Topic|RELATED_TO
1724|High Autoantibody Levels|Topic|Immune Pathways|Topic|RELATED_TO
1724|Dysregulation Of The Mitochondrial Apoptosis Pathway|Topic|Immune Pathways|Topic|RELATED_TO
1724|K-Means Clustering|Topic|Gene Expression Data|Topic|RELATED_TO
1724|Pca|Topic|Gene Expression Data|Topic|RELATED_TO
1724|Umap|Topic|Gene Expression Data|Topic|RELATED_TO
1724|Six Clusters|Topic|K-Means Clustering|Topic|RELATED_TO
1724|Therapeutic Targets For Sle|Topic|Dysregulation Of The Mitochondrial Apoptosis Pathway|Topic|RELATED_TO
1725|Explainable Artificial Intelligence Recommendation System|Paper|Adverse Childhood Experiences|Topic|RELATED_TO
1725|Explainable Artificial Intelligence Recommendation System|Paper|Knowledge Graph Generation|Topic|RELATED_TO
1725|Explainable Artificial Intelligence Recommendation System|Paper|Question-Answering Agent|Topic|RELATED_TO
1725|Question-Answering Agent|Topic|Google Dialogflow|Topic|RELATED_TO
1725|Explainable Artificial Intelligence Recommendation System|Paper|Children Hospital In Memphis, Tennessee|Topic|RELATED_TO
1725|Explainable Artificial Intelligence Recommendation System|Paper|Optimization Algorithm|Topic|RELATED_TO
1725|Explainable Artificial Intelligence Recommendation System|Paper|Privacy Layer|Topic|RELATED_TO
1725|Explainable Artificial Intelligence Recommendation System|Paper|Clinical Trial|Topic|RELATED_TO
1725|Explainable Artificial Intelligence Recommendation System|Paper|Health Care Practitioners|Topic|RELATED_TO
1726|A General Theory Of Regression Adjustment For Covariate-Adaptive Randomization: Ols, Lasso, And Beyond|Paper|Hanzhong Liu|Author|AUTHORED
1726|A General Theory Of Regression Adjustment For Covariate-Adaptive Randomization: Ols, Lasso, And Beyond|Paper|Fuyi Tu|Author|AUTHORED
1726|A General Theory Of Regression Adjustment For Covariate-Adaptive Randomization: Ols, Lasso, And Beyond|Paper|Wei Ma|Author|AUTHORED
1726|A General Theory Of Regression Adjustment For Covariate-Adaptive Randomization: Ols, Lasso, And Beyond|Paper|Treatment Effects|Topic|DISCUSSES
1726|A General Theory Of Regression Adjustment For Covariate-Adaptive Randomization: Ols, Lasso, And Beyond|Paper|Covariate-Adaptive Randomization|Topic|DISCUSSES
1726|A General Theory Of Regression Adjustment For Covariate-Adaptive Randomization: Ols, Lasso, And Beyond|Paper|Lasso-Adjusted Treatment Effect Estimators|Topic|DISCUSSES
1727|Sars-Cov-2|Topic|Covid-19|Topic|RELATED_TO
1727|Artificial Intelligence|Topic|Natural Language Processing|Topic|RELATED_TO
1727|Clinical Trial Information|Topic|Text Mining|Topic|RELATED_TO
1727|Preclinical Studies|Topic|Text Mining|Topic|RELATED_TO
1727|Text Mining|Topic|Covid-19|Topic|RELATED_TO
1727|Yutong Jin|Author|Covid-19|Topic|AUTHORED
1727|Jie Li|Author|Covid-19|Topic|AUTHORED
1727|Xinyu Wang|Author|Covid-19|Topic|AUTHORED
1727|Peiyao Li|Author|Covid-19|Topic|AUTHORED
1727|Jinjiang Guo|Author|Covid-19|Topic|AUTHORED
1727|Junfeng Wu|Author|Covid-19|Topic|AUTHORED
1727|Dawei Leng|Author|Covid-19|Topic|AUTHORED
1727|Lurong Pan|Author|Covid-19|Topic|AUTHORED
1728|Sharp Inference On Selected Subgroups In Observational Studies|Paper|Xinzhou Guo|Author|AUTHORED
1728|Sharp Inference On Selected Subgroups In Observational Studies|Paper|Linqing Wei|Author|AUTHORED
1728|Sharp Inference On Selected Subgroups In Observational Studies|Paper|Chong Wu|Author|AUTHORED
1728|Sharp Inference On Selected Subgroups In Observational Studies|Paper|Jingshen Wang|Author|AUTHORED
1728|Sharp Inference On Selected Subgroups In Observational Studies|Paper|Observational Data|Topic|RELATED_TO
1728|Sharp Inference On Selected Subgroups In Observational Studies|Paper|Subgroup Selection Bias|Topic|RELATED_TO
1728|Sharp Inference On Selected Subgroups In Observational Studies|Paper|Uk Biobank Data|Topic|RELATED_TO
1729|Batched Neural Bandits|Paper|Batchneuralucb|Topic|DISCUSSES
1730|Simultaneous Inference For Partial Areas Under Receiver Operating Curves -- With A View Towards Efficiency|Paper|Maximilian Wechsung|Author|AUTHORED
1730|Simultaneous Inference For Partial Areas Under Receiver Operating Curves -- With A View Towards Efficiency|Paper|Frank Konietschke|Author|AUTHORED
1731|Surrogate Endpoint|Topic|True Outcome|Topic|RELATED_TO
1731|Causal Inference Approaches|Topic|Surrogate Endpoint|Topic|DISCUSSES
1731|Treatment Effect|Topic|Surrogate Endpoint|Topic|DISCUSSES
1731|Treatment Effect|Topic|True Outcome|Topic|DISCUSSES
1731|Principal Surrogacy Criteria|Topic|Treatment Effect|Topic|DISCUSSES
1731|Bayesian Methods|Topic|Surrogate Endpoint|Topic|DISCUSSES
1731|Muscular Dystrophy Gene Therapy|Topic|Surrogate Endpoint|Topic|RELATED_TO
1731|Emily Roberts|Author|Muscular Dystrophy Gene Therapy|Topic|AUTHORED
1731|Michael Elliott|Author|Muscular Dystrophy Gene Therapy|Topic|AUTHORED
1731|Jeremy M. G. Taylor|Author|Muscular Dystrophy Gene Therapy|Topic|AUTHORED
1732|Multiple Hypothesis Testing|Topic|Economic Foundation For Practices|Topic|RELATED_TO
1732|Economic Foundation For Practices|Topic|Regulatory Approval|Topic|RELATED_TO
1732|Regulatory Approval|Topic|Clinical Trials|Topic|RELATED_TO
1732|Davide Viviano|Author|Multiple Hypothesis Testing|Topic|AUTHORED
1732|Kaspar Wuthrich|Author|Multiple Hypothesis Testing|Topic|AUTHORED
1732|Paul Niehaus|Author|Multiple Hypothesis Testing|Topic|AUTHORED
1733|Reference Based Multiple Imputation|Topic|Randomised Clinical Trials|Topic|RELATED_TO
1733|Rubin'S Variance Estimator|Topic|Repeated Sampling Variance|Topic|RELATED_TO
1733|Rubin'S Variance Estimator|Topic|Variance Estimators|Topic|RELATED_TO
1733|Frequentist Variance|Topic|Bootstrapping|Topic|RELATED_TO
1733|Jonathan W. Bartlett|Author|Reference Based Multiple Imputation|Topic|AUTHORED
1733|Multiple Imputation|Topic|Missing Data|Topic|RELATED_TO
1734|Hepatitis B Virus|Topic|World Health Organisation|Author|RELATED_TO
1734|World Health Organisation|Author|Age-Structured Model|Topic|DISCUSSES
1734|Age-Structured Model|Topic|Immune Response|Topic|DISCUSSES
1734|Immune Response|Topic|Viral Life Cycle|Topic|DISCUSSES
1734|Immune Response|Topic|Immune Response Exhaustion|Topic|DISCUSSES
1734|Immune Response|Topic|Non-Infectious Subviral Particles|Topic|DISCUSSES
1734|Treatment Options|Topic|Antiviral Treatment|Topic|DISCUSSES
1734|Antiviral Treatment|Topic|Viral Load|Topic|DISCUSSES
1734|Viral Load|Topic|Viral Clearance|Topic|DISCUSSES
1734|Antibody Therapies|Topic|Clinical Trials|Topic|RELATED_TO
1734|Farzad Fatehi|Author|Age-Structured Model|Topic|AUTHORED
1734|Richard J. Bingham|Author|Age-Structured Model|Topic|AUTHORED
1734|Eric C. Dykeman|Author|Age-Structured Model|Topic|AUTHORED
1734|Peter G. Stockley|Author|Age-Structured Model|Topic|AUTHORED
1734|Reidun Twarock|Author|Age-Structured Model|Topic|AUTHORED
1735|Improving The Power Of Economic Experiments Using Adaptive Designs|Paper|Sebastian Jobjörnsson|Author|AUTHORED
1735|Improving The Power Of Economic Experiments Using Adaptive Designs|Paper|Henning Schaak|Author|AUTHORED
1735|Improving The Power Of Economic Experiments Using Adaptive Designs|Paper|Oliver Mußhoff|Author|AUTHORED
1735|Improving The Power Of Economic Experiments Using Adaptive Designs|Paper|Tim Friede|Author|AUTHORED
1735|Improving The Power Of Economic Experiments Using Adaptive Designs|Paper|Adaptive Designs|Topic|RELATED_TO
1735|Improving The Power Of Economic Experiments Using Adaptive Designs|Paper|Economic Experiments|Topic|RELATED_TO
1735|Improving The Power Of Economic Experiments Using Adaptive Designs|Paper|Type I Error Probability|Topic|RELATED_TO
1736|Operational Learning-Based Boundary Estimation In Electromagnetic Medical Imaging|Paper|A. Al-Saffar|Author|AUTHORED
1736|Operational Learning-Based Boundary Estimation In Electromagnetic Medical Imaging|Paper|A. Stancombe|Author|AUTHORED
1736|Operational Learning-Based Boundary Estimation In Electromagnetic Medical Imaging|Paper|A. Zamani|Author|AUTHORED
1736|Operational Learning-Based Boundary Estimation In Electromagnetic Medical Imaging|Paper|A. Abbosh|Author|AUTHORED
1736|Operational Learning-Based Boundary Estimation In Electromagnetic Medical Imaging|Paper|Electromagnetic Medical Imaging|Topic|RELATED_TO
1736|Operational Learning-Based Boundary Estimation In Electromagnetic Medical Imaging|Paper|Boundary Detection|Topic|RELATED_TO
1736|Operational Learning-Based Boundary Estimation In Electromagnetic Medical Imaging|Paper|Head Imaging System|Topic|RELATED_TO
1736|Operational Learning-Based Boundary Estimation In Electromagnetic Medical Imaging|Paper|16-Element Antenna Array|Topic|RELATED_TO
1736|Operational Learning-Based Boundary Estimation In Electromagnetic Medical Imaging|Paper|0.7-1.6 Ghz|Topic|RELATED_TO
1737|Periodontitis And Preeclampsia In Pregnancy: A Systematic Review And Meta-Analysis|Paper|Periodontitis|Topic|DISCUSSES
1737|Periodontitis And Preeclampsia In Pregnancy: A Systematic Review And Meta-Analysis|Paper|Preeclampsia|Topic|DISCUSSES
1737|Periodontitis|Topic|Preeclampsia|Topic|RELATED_TO
1739|Linear Transformation Model|Topic|Proportional Hazards Model|Topic|RELATED_TO
1739|Linear Transformation Model|Topic|Proportional Odds Model|Topic|RELATED_TO
1739|Linear Transformation Model|Topic|Measurement Error In Covariates|Topic|RELATED_TO
1739|Linear Transformation Model|Topic|Estimators Of Regression Coefficients|Topic|RELATED_TO
1739|Estimators Of Regression Coefficients|Topic|Instrumental Variables|Topic|RELATED_TO
1739|Estimators Of Regression Coefficients|Topic|Counting Process Based Estimating Equations|Topic|RELATED_TO
1739|Estimators Of Regression Coefficients|Topic|Martingale Representation|Topic|RELATED_TO
1739|Estimators Of Regression Coefficients|Topic|Monte Carlo Simulation Study|Topic|RELATED_TO
1739|Monte Carlo Simulation Study|Topic|Aids Clinical Trial (Actg 175)|Topic|RELATED_TO
1739|Sudheesh K. K.|Author|Estimators Of Regression Coefficients|Topic|AUTHORED
1739|Deemat C. Mathew|Author|Estimators Of Regression Coefficients|Topic|AUTHORED
1739|Litty Mathew|Author|Estimators Of Regression Coefficients|Topic|AUTHORED
1739|Min Xie|Author|Estimators Of Regression Coefficients|Topic|AUTHORED
1740|Effect Size Measures And Visualization Techniques|Topic|Common Mathematical Setting|Topic|RELATED_TO
1740|Common Mathematical Setting|Topic|Formal Framework|Topic|RELATED_TO
1740|Formal Framework|Topic|Parametric Regression|Topic|RELATED_TO
1740|Hannah Kümpel|Author|Formal Framework|Topic|AUTHORED
1740|Sabine Hoffmann|Author|Formal Framework|Topic|AUTHORED
1740|Bayesian Approach|Topic|Frequentist Inference|Topic|RELATED_TO
1740|Formal Framework|Topic|Clinical Trial|Topic|RELATED_TO
1740|Formal Framework|Topic|Multi-Analyst Study|Topic|RELATED_TO
1741|Mrsa Colonization|Topic|Decolonization Protocols|Topic|RELATED_TO
1741|Decolonization Protocols|Topic|Machine Learning Model|Topic|RELATED_TO
1741|Machine Learning Model|Topic|Randomized Controlled Trial (Rct)|Topic|RELATED_TO
1741|Machine Learning Model|Topic|Onur Poyraz|Author|AUTHORED
1741|Machine Learning Model|Topic|Mohamad R. A. Sater|Author|AUTHORED
1741|Machine Learning Model|Topic|Loren G. Miller|Author|AUTHORED
1741|Machine Learning Model|Topic|James A. Mckinnell|Author|AUTHORED
1741|Machine Learning Model|Topic|Susan S. Huang|Author|AUTHORED
1741|Machine Learning Model|Topic|Yonatan H. Grad|Author|AUTHORED
1741|Machine Learning Model|Topic|Pekka Marttinen|Author|AUTHORED
1742|Semi-Competing Risks Data|Topic|Medical Research|Topic|RELATED_TO
1742|Semi-Competing Risks Data|Topic|Clinical Trials|Topic|RELATED_TO
1742|Broken Adaptive Ridge (Bar) Penalty|Topic|Illness-Death Model|Topic|RELATED_TO
1742|Broken Adaptive Ridge (Bar) Penalty|Topic|Shared Frailty|Topic|RELATED_TO
1742|Fatemeh Mahmoudi|Author|Penalized Variable Selection With Broken Adaptive Ridge Regression For Semi-Competing Risks Data|Paper|AUTHORED
1742|Xuewen Lu|Author|Penalized Variable Selection With Broken Adaptive Ridge Regression For Semi-Competing Risks Data|Paper|AUTHORED
1742|Penalized Variable Selection With Broken Adaptive Ridge Regression For Semi-Competing Risks Data|Paper|Colon Cancer Study|Topic|RELATED_TO
1743|Homogeneity Tests And Interval Estimations Of Risk Differences For Stratified Bilateral And Unilateral Correlated Data|Paper|Shuyi Liang|Author|AUTHORED
1743|Homogeneity Tests And Interval Estimations Of Risk Differences For Stratified Bilateral And Unilateral Correlated Data|Paper|Kai-Tai Fang|Author|AUTHORED
1743|Homogeneity Tests And Interval Estimations Of Risk Differences For Stratified Bilateral And Unilateral Correlated Data|Paper|Xin-Wei Huang|Author|AUTHORED
1743|Homogeneity Tests And Interval Estimations Of Risk Differences For Stratified Bilateral And Unilateral Correlated Data|Paper|Yijing Xin|Author|AUTHORED
1743|Homogeneity Tests And Interval Estimations Of Risk Differences For Stratified Bilateral And Unilateral Correlated Data|Paper|Chang-Xing Ma|Author|AUTHORED
1744|Experimentation Platforms Meet Reinforcement Learning: Bayesian Sequential Decision-Making For Continuous Monitoring|Paper|Runzhe Wan|Author|AUTHORED
1744|Experimentation Platforms Meet Reinforcement Learning: Bayesian Sequential Decision-Making For Continuous Monitoring|Paper|Yu Liu|Author|AUTHORED
1744|Experimentation Platforms Meet Reinforcement Learning: Bayesian Sequential Decision-Making For Continuous Monitoring|Paper|James Mcqueen|Author|AUTHORED
1744|Experimentation Platforms Meet Reinforcement Learning: Bayesian Sequential Decision-Making For Continuous Monitoring|Paper|Doug Hains|Author|AUTHORED
1744|Experimentation Platforms Meet Reinforcement Learning: Bayesian Sequential Decision-Making For Continuous Monitoring|Paper|Rui Song|Author|AUTHORED
1745|Hiv Dynamical Models|Topic|Non-Linear Systems Of Ordinary Differential Equations|Topic|RELATED_TO
1745|Hierarchical Likelihood|Topic|Maximum H-Likelihood Estimators|Topic|RELATED_TO
1745|Maximum H-Likelihood Estimators|Topic|D. Commenges|Author|AUTHORED
1745|Maximum H-Likelihood Estimators|Topic|D. Jolly|Author|AUTHORED
1745|Maximum H-Likelihood Estimators|Topic|H. Putter|Author|AUTHORED
1745|Maximum H-Likelihood Estimators|Topic|R. Thiebaut|Author|AUTHORED
1745|Maximum H-Likelihood Estimators|Topic|Clinical Trial|Topic|RELATED_TO
1745|Maximum H-Likelihood Estimators|Topic|Simulation Study|Topic|RELATED_TO
1745|Parametric Bootstrap Procedure|Topic|Maximum H-Likelihood Estimators|Topic|RELATED_TO
1746|Hands-Free Evolution Of 3D-Printable Objects Via Eye Tracking|Paper|Interactive Evolution|Topic|DISCUSSES
1746|Hands-Free Evolution Of 3D-Printable Objects Via Eye Tracking|Paper|Eye Tracking|Topic|DISCUSSES
1746|Hands-Free Evolution Of 3D-Printable Objects Via Eye Tracking|Paper|Nick Cheney|Author|AUTHORED
1746|Hands-Free Evolution Of 3D-Printable Objects Via Eye Tracking|Paper|Jeff Clune|Author|AUTHORED
1746|Hands-Free Evolution Of 3D-Printable Objects Via Eye Tracking|Paper|Jason Yosinski|Author|AUTHORED
1746|Hands-Free Evolution Of 3D-Printable Objects Via Eye Tracking|Paper|Hod Lipson|Author|AUTHORED
1747|Subgroup Mixable Inference In Personalized Medicine, With An Application To Time-To-Event Outcomes|Paper|Ying Ding|Author|AUTHORED
1747|Subgroup Mixable Inference In Personalized Medicine, With An Application To Time-To-Event Outcomes|Paper|Hui-Min Lin|Author|AUTHORED
1747|Subgroup Mixable Inference In Personalized Medicine, With An Application To Time-To-Event Outcomes|Paper|Jason C. Hsu|Author|AUTHORED
1747|Subgroup Mixable Inference In Personalized Medicine, With An Application To Time-To-Event Outcomes|Paper|Personalized Medicine|Topic|RELATED_TO
1747|Subgroup Mixable Inference In Personalized Medicine, With An Application To Time-To-Event Outcomes|Paper|Mixture Population|Topic|RELATED_TO
1747|Subgroup Mixable Inference In Personalized Medicine, With An Application To Time-To-Event Outcomes|Paper|Subgroup Mixable Estimation|Topic|RELATED_TO
1747|Subgroup Mixable Inference In Personalized Medicine, With An Application To Time-To-Event Outcomes|Paper|Hazard Ratio|Topic|RELATED_TO
1748|On Prediction And Tolerance Intervals For Dynamic Treatment Regimes|Paper|Daniel J. Lizotte|Author|AUTHORED
1748|On Prediction And Tolerance Intervals For Dynamic Treatment Regimes|Paper|Arezoo Tahmasebi|Author|AUTHORED
1749|Abcd Multi-Arm Multi-Stage Experiment|Topic|Drug Development Process|Topic|RELATED_TO
1749|Abcd Multi-Arm Multi-Stage Experiment|Topic|Generalised Error-Rates|Topic|RELATED_TO
1749|Abcd Multi-Arm Multi-Stage Experiment|Topic|Statistical Operating Characteristics|Topic|RELATED_TO
1749|Abcd Multi-Arm Multi-Stage Experiment|Topic|Multi-Arm Multi-Stage Experiments|Topic|RELATED_TO
1749|Abcd Multi-Arm Multi-Stage Experiment|Topic|Type-I Familywise Error-Rate|Topic|RELATED_TO
1749|Abcd Multi-Arm Multi-Stage Experiment|Topic|Type-Ii Familywise Error-Rate|Topic|RELATED_TO
1749|Abcd Multi-Arm Multi-Stage Experiment|Topic|Clinical Trial|Topic|RELATED_TO
1749|Michael Grayling|Author|Abcd Multi-Arm Multi-Stage Experiment|Topic|AUTHORED
1749|James Wason|Author|Abcd Multi-Arm Multi-Stage Experiment|Topic|AUTHORED
1749|Adrian Mander|Author|Abcd Multi-Arm Multi-Stage Experiment|Topic|AUTHORED
1750|Mild Cognitive Impairment|Topic|Alzheimer'S Dementia|Topic|RELATED_TO
1750|Brain Signature|Topic|Alzheimer'S Dementia|Topic|RELATED_TO
1750|Machine Learning Model|Topic|Brain Signature|Topic|RELATED_TO
1750|Brain Atrophy|Topic|Brain Signature|Topic|RELATED_TO
1750|Functional Dysconnectivity|Topic|Brain Signature|Topic|RELATED_TO
1750|Christian Dansereau|Author|Brain Signature|Topic|AUTHORED
1750|Angela Tam|Author|Brain Signature|Topic|AUTHORED
1750|Amanpreet Badhwar|Author|Brain Signature|Topic|AUTHORED
1750|Sebastian Urchs|Author|Brain Signature|Topic|AUTHORED
1750|Pierre Orban|Author|Brain Signature|Topic|AUTHORED
1750|Pedro Rosa-Neto|Author|Brain Signature|Topic|AUTHORED
1750|Pierre Bellec|Author|Brain Signature|Topic|AUTHORED
1750|Mci Subpopulation|Topic|Alzheimer'S Dementia|Topic|RELATED_TO
1751|Equivalence Test|Topic|Frequentist Tool|Topic|RELATED_TO
1751|Equivalence Test|Topic|Equivalence Margin|Topic|RELATED_TO
1751|Harlan Campbell|Author|Equivalence Test|Topic|AUTHORED
1751|Paul Gustafson|Author|Equivalence Test|Topic|AUTHORED
1751|Equivalence Test|Topic|Clinical Trials Research|Topic|DISCUSSES
1752|Endovascular Technique|Topic|Robotically Steerable Catheters|Topic|RELATED_TO
1752|Robotically Steerable Catheters|Topic|Shape Memory Alloys (Sma) Actuators|Topic|RELATED_TO
1752|Shape Memory Alloys (Sma) Actuators|Topic|Active Sma-Based Catheters|Topic|RELATED_TO
1752|Active Sma-Based Catheters|Topic|Thibault Couture|Author|AUTHORED
1752|Active Sma-Based Catheters|Topic|Jérome Szewczyk|Author|AUTHORED
1752|Active Sma-Based Catheters|Topic|Silicon-Based Arterial Model|Topic|RELATED_TO
1752|Active Sma-Based Catheters|Topic|23-Kg Pig|Topic|RELATED_TO
1752|Active Sma-Based Catheters|Topic|Supra-Aortic Trunks|Topic|RELATED_TO
1752|Active Sma-Based Catheters|Topic|Renal Arteries|Topic|RELATED_TO
1752|Active Sma-Based Catheters|Topic|6F Catheter|Topic|RELATED_TO
1752|Active Sma-Based Catheters|Topic|70 Different Prototypes|Topic|RELATED_TO
1752|70 Different Prototypes|Topic|Core Body|Topic|RELATED_TO
1752|Core Body|Topic|Metallic Beams|Topic|RELATED_TO
1752|Core Body|Topic|Sma Actuators|Topic|RELATED_TO
1752|Active Sma-Based Catheters|Topic|Anatomical Constraints|Topic|RELATED_TO
1752|Active Sma-Based Catheters|Topic|Trial-Error Campaign|Topic|RELATED_TO
1752|Trial-Error Campaign|Topic|Best Dimensions|Topic|RELATED_TO
1752|Best Dimensions|Topic|Final Prototype|Topic|RELATED_TO
1752|Final Prototype|Topic|Design And Experimental Validation|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Schizophrenia|Topic|RELATED_TO
1753|David Calhas|Author|Brain Signal Classification|Topic|AUTHORED
1753|Enrique Romero|Author|Brain Signal Classification|Topic|AUTHORED
1753|Rui Henriques|Author|Brain Signal Classification|Topic|AUTHORED
1753|Brain Signal Classification|Topic|Siamese Neural Network Architecture|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Electroencephalography|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Cosine Contrastive Loss|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Multivariate Order Of The Signal|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Spectral Features|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Neuronal Diseases|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Electrophysiological Brain Activity|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Data Augmentation|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Convolutional Layers|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Case-Control Population|Topic|RELATED_TO
1753|Brain Signal Classification|Topic|Improved Schizophrenia Diagnosis|Topic|RELATED_TO
1754|Bayesian Two-Sample T-Test|Topic|Effect Size|Topic|RELATED_TO
1754|Bayesian Two-Sample T-Test|Topic|Gibbs Sampler|Topic|RELATED_TO
1754|Bayesian Two-Sample T-Test|Topic|Region Of Practical Equivalence (Rope)|Topic|RELATED_TO
1754|Bayesian Two-Sample T-Test|Topic|R Package Bayest|Topic|RELATED_TO
1755|Optimal Experimental Designs For Treatment Contrasts In Heteroscedastic Models With Covariates|Paper|Samuel Rosa|Author|AUTHORED
1755|Optimal Experimental Designs For Treatment Contrasts In Heteroscedastic Models With Covariates|Paper|Treatment|Topic|RELATED_TO
1755|Optimal Experimental Designs For Treatment Contrasts In Heteroscedastic Models With Covariates|Paper|Covariates|Topic|RELATED_TO
1755|Optimal Experimental Designs For Treatment Contrasts In Heteroscedastic Models With Covariates|Paper|Heteroscedasticity|Topic|RELATED_TO
1755|Optimal Experimental Designs For Treatment Contrasts In Heteroscedastic Models With Covariates|Paper|D-Optimality|Topic|RELATED_TO
1755|Optimal Experimental Designs For Treatment Contrasts In Heteroscedastic Models With Covariates|Paper|A-Optimality|Topic|RELATED_TO
1755|Optimal Experimental Designs For Treatment Contrasts In Heteroscedastic Models With Covariates|Paper|E-Optimality|Topic|RELATED_TO
1755|Optimal Experimental Designs For Treatment Contrasts In Heteroscedastic Models With Covariates|Paper|Linear Programming|Topic|RELATED_TO
1755|Optimal Experimental Designs For Treatment Contrasts In Heteroscedastic Models With Covariates|Paper|Sparsification Method|Topic|RELATED_TO
1756|Bispatial Inference|Topic|Bayesian Method|Topic|RELATED_TO
1756|Bispatial Inference|Topic|P Values|Topic|RELATED_TO
1756|Bispatial Inference|Topic|Post-Data Density Function|Topic|RELATED_TO
1756|Bispatial Inference|Topic|Post-Data Opinion Curves|Topic|RELATED_TO
1756|Bispatial Inference|Topic|Fiducial Inference|Topic|RELATED_TO
1756|Bispatial Inference|Topic|Clinical Trial Data|Topic|RELATED_TO
1756|Bispatial Inference|Topic|Sharp Hypotheses|Topic|RELATED_TO
1756|Russell J. Bowater|Author|Bispatial Inference|Topic|AUTHORED
1757|Modeling Variables With A Detection Limit Using A Truncated Normal Distribution With Censoring|Paper|Tcensreg|Topic|DISCUSSES
1757|Modeling Variables With A Detection Limit Using A Truncated Normal Distribution With Censoring|Paper|Tobit Regression|Topic|RELATED_TO
1757|Modeling Variables With A Detection Limit Using A Truncated Normal Distribution With Censoring|Paper|Single Imputation|Topic|RELATED_TO
1757|Modeling Variables With A Detection Limit Using A Truncated Normal Distribution With Censoring|Paper|Vision Quality Data|Topic|DISCUSSES
1757|Justin R. Williams|Author|Modeling Variables With A Detection Limit Using A Truncated Normal Distribution With Censoring|Paper|AUTHORED
1757|Hyung-Woo Kim|Author|Modeling Variables With A Detection Limit Using A Truncated Normal Distribution With Censoring|Paper|AUTHORED
1757|Catherine M. Crespi|Author|Modeling Variables With A Detection Limit Using A Truncated Normal Distribution With Censoring|Paper|AUTHORED
1758|Hiv-1|Topic|Broadly Neutralizing Antibodies|Topic|RELATED_TO
1758|Broadly Neutralizing Antibodies|Topic|Fitness Landscape|Topic|DISCUSSES
1758|Fitness Landscape|Topic|Viral Load|Topic|RELATED_TO
1758|Fitness Landscape|Topic|Antibody Dosage|Topic|RELATED_TO
1758|Broadly Neutralizing Antibodies|Topic|Escape Dynamics|Topic|DISCUSSES
1758|Escape Dynamics|Topic|Resistance-Cost Tradeoff Curves|Topic|DISCUSSES
1758|Matthijs Meijers|Author|Hiv-1|Topic|AUTHORED
1758|Kanika Vanshylla|Author|Hiv-1|Topic|AUTHORED
1758|Henning Gruell|Author|Hiv-1|Topic|AUTHORED
1758|Florian Klein|Author|Hiv-1|Topic|AUTHORED
1758|Michael Laessig|Author|Hiv-1|Topic|AUTHORED
1759|Retrofitting Vector Representations Of Adverse Event Reporting Data To Structured Knowledge To Improve Pharmacovigilance Signal Detection|Paper|Adverse Drug Events|Topic|DISCUSSES
1759|Retrofitting Vector Representations Of Adverse Event Reporting Data To Structured Knowledge To Improve Pharmacovigilance Signal Detection|Paper|Spontaneous Reporting Systems|Topic|DISCUSSES
1759|Retrofitting Vector Representations Of Adverse Event Reporting Data To Structured Knowledge To Improve Pharmacovigilance Signal Detection|Paper|Aer2Vec|Topic|DISCUSSES
1759|Retrofitting Vector Representations Of Adverse Event Reporting Data To Structured Knowledge To Improve Pharmacovigilance Signal Detection|Paper|Rxnorm|Topic|DISCUSSES
1759|Retrofitting Vector Representations Of Adverse Event Reporting Data To Structured Knowledge To Improve Pharmacovigilance Signal Detection|Paper|Pharmacovigilance Signal Detection|Topic|DISCUSSES
1759|Xiruo Ding|Author|Retrofitting Vector Representations Of Adverse Event Reporting Data To Structured Knowledge To Improve Pharmacovigilance Signal Detection|Paper|AUTHORED
1759|Trevor Cohen|Author|Retrofitting Vector Representations Of Adverse Event Reporting Data To Structured Knowledge To Improve Pharmacovigilance Signal Detection|Paper|AUTHORED
1760|Performing Company Valuations Within The Domain Of Biotechnology, Pharmacy And Medical Technology|Topic|Automated Knowledge Discovery, Extraction And Data Fusion|Topic|RELATED_TO
1760|Automated Knowledge Discovery, Extraction And Data Fusion|Topic|Clinical Trials|Topic|RELATED_TO
1760|Automated Knowledge Discovery, Extraction And Data Fusion|Topic|Company Valuation Ontology|Topic|RELATED_TO
1760|Albert Weichselbraun|Author|Performing Company Valuations Within The Domain Of Biotechnology, Pharmacy And Medical Technology|Topic|AUTHORED
1760|Philipp Kuntschik|Author|Performing Company Valuations Within The Domain Of Biotechnology, Pharmacy And Medical Technology|Topic|AUTHORED
1760|Sandro Hörler|Author|Performing Company Valuations Within The Domain Of Biotechnology, Pharmacy And Medical Technology|Topic|AUTHORED
1761|Bayesian Multivariate Probability Of Success Using Historical Data With Strict Control Of Family-Wise Error Rate|Paper|Ethan M. Alt|Author|AUTHORED
1761|Bayesian Multivariate Probability Of Success Using Historical Data With Strict Control Of Family-Wise Error Rate|Paper|Matthew A. Psioda|Author|AUTHORED
1761|Bayesian Multivariate Probability Of Success Using Historical Data With Strict Control Of Family-Wise Error Rate|Paper|Joseph G. Ibrahim|Author|AUTHORED
1762|Automatic Segmentation Of Brain Glioma From Multimodal Mri Scans|Topic|End-To-End Deep-Learning-Based Segmentation Method|Topic|RELATED_TO
1762|End-To-End Deep-Learning-Based Segmentation Method|Topic|Multi-Decoder Architecture|Topic|RELATED_TO
1762|End-To-End Deep-Learning-Based Segmentation Method|Topic|Smoothing Methods|Topic|RELATED_TO
1762|End-To-End Deep-Learning-Based Segmentation Method|Topic|Validation Performance|Topic|RELATED_TO
1762|End-To-End Deep-Learning-Based Segmentation Method|Topic|Denoised Versions|Topic|RELATED_TO
1762|End-To-End Deep-Learning-Based Segmentation Method|Topic|Segmentation|Topic|RELATED_TO
1762|Proposed Method|Topic|Quantification Of Uncertainty In Segmentation In The Brain Tumors In Multimodal Magnetic Resonance Imaging Challenge 2020|Topic|RELATED_TO
1762|Minh H. Vu|Author|Proposed Method|Topic|AUTHORED
1762|Tufve Nyholm|Author|Proposed Method|Topic|AUTHORED
1762|Tommy Löfstedt|Author|Proposed Method|Topic|AUTHORED
1763|Kaplan-Meier Survival Analysis|Topic|Treatment Efficacy|Topic|RELATED_TO
1763|Kaplan-Meier Survival Analysis|Topic|Oncology|Topic|RELATED_TO
1763|Kaplan-Meier Survival Analysis|Topic|Precision Medicine|Topic|RELATED_TO
1763|Patient Censoring|Topic|Incomplete Observation|Topic|RELATED_TO
1763|Overall Survival|Topic|Right-Censoring|Topic|RELATED_TO
1763|Surrogate Of Patient Lost To Follow-Up|Topic|Kaplan-Meier Survival Analysis|Topic|DISCUSSES
1763|Bias Indexes|Topic|Public Available Datasets|Topic|RELATED_TO
1763|Enrique Barrajón|Author|Effect Of Right Censoring Bias On Survival Analysis|Paper|AUTHORED
1763|Laura Barrajón|Author|Effect Of Right Censoring Bias On Survival Analysis|Paper|AUTHORED
1764|Multi-Armed Bandit|Topic|Clinical Trials|Topic|RELATED_TO
1764|Multi-Armed Bandit|Topic|Adaptive Routing|Topic|RELATED_TO
1764|Multi-Armed Bandit|Topic|Epsilon-Greedy|Topic|RELATED_TO
1764|Multi-Armed Bandit|Topic|Upper Confident Bound (Ucb)|Topic|RELATED_TO
1764|Multi-Armed Bandit|Topic|Thompson Sampling (Ts)|Topic|RELATED_TO
1764|Djallel Bouneffouf|Author|Multi-Armed Bandit|Topic|AUTHORED
1765|Us Food And Drug Administration|Topic|Real-World Data|Topic|RELATED_TO
1765|Real-World Data|Topic|Drug Development|Topic|RELATED_TO
1765|Artificial Intelligence|Topic|Drug Development|Topic|RELATED_TO
1765|Machine- And Deep-Learning Methods|Topic|Drug Development|Topic|RELATED_TO
1765|Drug Development|Topic|Adverse Event Detection|Topic|RELATED_TO
1765|Drug Development|Topic|Trial Recruitment|Topic|RELATED_TO
1765|Drug Development|Topic|Drug Repurposing|Topic|RELATED_TO
1765|Zhaoyi Chen|Author|Drug Development|Topic|AUTHORED
1765|Xiong Liu|Author|Drug Development|Topic|AUTHORED
1765|William Hogan|Author|Drug Development|Topic|AUTHORED
1765|Elizabeth Shenkman|Author|Drug Development|Topic|AUTHORED
1765|Jiang Bian|Author|Drug Development|Topic|AUTHORED
1766|Health And Demographic Surveillance System|Topic|2030 Agenda|Topic|RELATED_TO
1766|Samuel J. Clark|Author|Health And Demographic Surveillance System|Topic|AUTHORED
1767|Contextual Bandit|Topic|Recommendation Systems|Topic|RELATED_TO
1767|Contextual Bandit|Topic|Online Advertising|Topic|RELATED_TO
1767|Contextual Bandit|Topic|Clinical Trials|Topic|RELATED_TO
1767|Privacy-Preserving Bandit Framework|Topic|Homomorphic Encryption|Topic|RELATED_TO
1767|Linear Contextual Bandits|Topic|Homomorphic Encryption|Topic|RELATED_TO
1767|Evrard Garcelon|Author|Privacy-Preserving Bandit Framework|Topic|AUTHORED
1767|Vianney Perchet|Author|Privacy-Preserving Bandit Framework|Topic|AUTHORED
1767|Matteo Pirotta|Author|Privacy-Preserving Bandit Framework|Topic|AUTHORED
1768|Distance Assisted Recursive Testing|Topic|Xuechan Li|Author|AUTHORED
1768|Distance Assisted Recursive Testing|Topic|Anthony Sung|Author|AUTHORED
1768|Distance Assisted Recursive Testing|Topic|Jichun Xie|Author|AUTHORED
1769|Pair-Switching Rerandomization|Topic|Fisher Randomization Tests|Topic|RELATED_TO
1769|Pair-Switching Rerandomization|Topic|Difference-In-Means Estimator|Topic|RELATED_TO
1769|Pair-Switching Rerandomization|Topic|Ke Zhu|Author|AUTHORED
1769|Pair-Switching Rerandomization|Topic|Hanzhong Liu|Author|AUTHORED
1769|Pair-Switching Rerandomization|Topic|Clinical Trial Datasets|Topic|RELATED_TO
1769|Pair-Switching Rerandomization|Topic|Classical Rerandomization|Topic|RELATED_TO
1770|Ict Revolution|Topic|Digital Traces|Topic|RELATED_TO
1770|Knowledge-Driven Domains|Topic|Science|Topic|RELATED_TO
1770|Interdisciplinary Innovations|Topic|Social Sciences|Topic|RELATED_TO
1770|Interdisciplinary Innovations|Topic|Computational Sciences|Topic|RELATED_TO
1770|Complex Systems Approaches|Topic|Phylomemies|Topic|RELATED_TO
1770|Phylomemies|Topic|Knowledge|Topic|RELATED_TO
1770|Phylomemy Reconstruction Process|Topic|Synchronic Approaches|Topic|RELATED_TO
1770|Phylomemy Reconstruction Process|Topic|Diachronic Approaches|Topic|RELATED_TO
1770|Phylomemetic Networks|Topic|Graphical Projections|Topic|RELATED_TO
1770|Phylomemetic Networks|Topic|Interactive Visualizations|Topic|RELATED_TO
1770|Seabed Views|Topic|Kinship Views|Topic|RELATED_TO
1770|Macro-To-Micro Methodology|Topic|Memiescape|Topic|RELATED_TO
1770|Memiescape|Topic|Scientific Publications|Topic|RELATED_TO
1770|Memiescape|Topic|Clinical Trials|Topic|RELATED_TO
1770|Quentin Lobbé|Author|Phylomemy Reconstruction Process|Topic|AUTHORED
1770|Alexandre Delanoë|Author|Phylomemy Reconstruction Process|Topic|AUTHORED
1770|David Chavalarias|Author|Phylomemy Reconstruction Process|Topic|AUTHORED
1771|Exploration|Topic|Online Learning|Topic|RELATED_TO
1771|Exploration|Topic|Long-Term Reward|Topic|RELATED_TO
1771|Exploration|Topic|Short-Term Regret|Topic|RELATED_TO
1771|Clinical Trial Setting|Topic|Sub-Optimal Treatment|Topic|RELATED_TO
1771|Natural Groups|Topic|Race|Topic|RELATED_TO
1771|Natural Groups|Topic|Age|Topic|RELATED_TO
1771|Grouped Bandit Model|Topic|Axiomatic Bargaining|Topic|RELATED_TO
1771|Grouped Bandit Model|Topic|Nash Bargaining Solution|Topic|RELATED_TO
1771|Regret-Optimal Policy|Topic|Disadvantaged Groups|Topic|RELATED_TO
1771|Optimally Fair Policies|Topic|Price Of Fairness|Topic|RELATED_TO
1771|Algorithmic Framework|Topic|Contextual Bandits|Topic|RELATED_TO
1771|Contextual Bandits|Topic|Warfarin Dosing|Topic|RELATED_TO
1771|Jackie Baek|Author|Fair Exploration Via Axiomatic Bargaining|Paper|AUTHORED
1771|Vivek F. Farias|Author|Fair Exploration Via Axiomatic Bargaining|Paper|AUTHORED
1772|Robust Stochastic Linear Contextual Bandits Under Adversarial Attacks|Paper|Stochastic Linear Contextual Bandit Algorithms|Topic|DISCUSSES
1772|Robust Stochastic Linear Contextual Bandits Under Adversarial Attacks|Paper|Adversarial Attacks|Topic|DISCUSSES
1772|Robust Stochastic Linear Contextual Bandits Under Adversarial Attacks|Paper|Robust Bandit Algorithms|Topic|DISCUSSES
1773|Multi-Armed Bandit Requiring Monotone Arm Sequences|Paper|Ningyuan Chen|Author|AUTHORED
1773|Multi-Armed Bandit Requiring Monotone Arm Sequences|Paper|Monotone Arm Sequences|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Hristo Sariev|Author|AUTHORED
1774|Dominant Pólya Sequences|Topic|Sandra Fortini|Author|AUTHORED
1774|Dominant Pólya Sequences|Topic|Sonia Petrone|Author|AUTHORED
1774|Dominant Pólya Sequences|Topic|Randomized Clinical Trials|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Species Sampling|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Bayesian Inference|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Random Probability Measure|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Set Of Dominant Colors|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Predictive Probabilities|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Empirical Frequencies|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Total Variation|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Expected Reinforcement|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Color-Specific Random Weights|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|Unbounded Number Of Possible Colors|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|$	Ilde{P}$|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|$	Ilde{P}(	Ext{D})=1$|Topic|RELATED_TO
1774|Dominant Pólya Sequences|Topic|$	Ext{D}$|Topic|RELATED_TO
1775|Multi-Type Recurrent Events|Topic|Medical Applications|Topic|RELATED_TO
1775|Nonmelanoma Skin Cancers|Topic|Clinical Trial For Skin Cancer Prevention|Topic|RELATED_TO
1775|Copula-Frailty Models|Topic|Monte Carlo Expectation-Maximization (Mcem) Algorithm|Topic|RELATED_TO
1775|Khaled F. Bedair|Author|Copula-Frailty Models For Recurrent Event Data Based On Monte Carlo Em Algorithm|Paper|AUTHORED
1775|Yili Hong|Author|Copula-Frailty Models For Recurrent Event Data Based On Monte Carlo Em Algorithm|Paper|AUTHORED
1775|Hussein R. Al-Khalidi|Author|Copula-Frailty Models For Recurrent Event Data Based On Monte Carlo Em Algorithm|Paper|AUTHORED
1775|Recurrences Of Skin Cancer|Topic|Copula-Frailty Models|Topic|RELATED_TO
1776|A Nonmyopic Approach To Cost-Constrained Bayesian Optimization|Paper|Eric Hans Lee|Author|AUTHORED
1776|A Nonmyopic Approach To Cost-Constrained Bayesian Optimization|Paper|David Eriksson|Author|AUTHORED
1776|A Nonmyopic Approach To Cost-Constrained Bayesian Optimization|Paper|Valerio Perrone|Author|AUTHORED
1776|A Nonmyopic Approach To Cost-Constrained Bayesian Optimization|Paper|Matthias Seeger|Author|AUTHORED
1776|Bayesian Optimization|Topic|Cost-Constrained Bayesian Optimization|Topic|RELATED_TO
1777|Reversible Covalent Kinase Inhibitors|Topic|Pemphigus|Topic|RELATED_TO
1777|Zheng Zhao|Author|Reversible Covalent Kinase Inhibitors|Topic|AUTHORED
1777|Philip E. Bourne|Author|Reversible Covalent Kinase Inhibitors|Topic|AUTHORED
1778|Covid-19|Topic|Human Coronaviruses|Topic|RELATED_TO
1778|Covid-19|Topic|Shuting Jin|Author|AUTHORED
1778|Covid-19|Topic|Xiangxiang Zeng|Author|AUTHORED
1778|Covid-19|Topic|Wei Huang|Author|AUTHORED
1778|Covid-19|Topic|Feng Xia|Author|AUTHORED
1778|Covid-19|Topic|Changzhi Jiang|Author|AUTHORED
1778|Covid-19|Topic|Xiangrong Liu|Author|AUTHORED
1778|Covid-19|Topic|Shaoliang Peng|Author|AUTHORED
1779|Matching-Adjusted Indirect Comparison|Topic|Calibration Estimation|Topic|RELATED_TO
1779|Calibration Estimation|Topic|Entropy Balancing Approach|Topic|RELATED_TO
1779|Jixian Wang|Author|Matching-Adjusted Indirect Comparison|Topic|AUTHORED
1779|Matching-Adjusted Indirect Comparison|Topic|Health Technology Assessment|Topic|RELATED_TO
1779|Matching-Adjusted Indirect Comparison|Topic|Drug Regulatory Submissions|Topic|RELATED_TO
1779|Standard Error Estimation|Topic|Simulation|Topic|RELATED_TO
1780|Missing Data|Topic|Hidden Markov Models|Topic|RELATED_TO
1780|Mnar|Topic|Missing Data|Topic|RELATED_TO
1780|Mar|Topic|Missing Data|Topic|RELATED_TO
1780|State-Dependent Missingness|Topic|Missing Data|Topic|RELATED_TO
1780|Time-Dependent Missingness|Topic|Missing Data|Topic|RELATED_TO
1780|Maarten Speekenbrink|Author|Hidden Markov Models|Topic|AUTHORED
1780|Ingmar Visser|Author|Hidden Markov Models|Topic|AUTHORED
1780|Severity Of Schizophrenic Symptoms|Topic|Clinical Trial|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Scopus Database|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Covid-19|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Teriflunomide|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Clinical Trial|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Microglia|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|B Cells|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Myelin|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Brain|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|White Matter|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Functional Connectivity|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Pain|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Employment|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Health-Related Quality Of Life|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Meta-Analysis|Topic|RELATED_TO
1781|Multiple Sclerosis|Topic|Comorbidity|Topic|RELATED_TO
1781|Nazlahshaniza Shafina|Author|Multiple Sclerosis|Topic|AUTHORED
1781|Che Aishah Nazariah Ismaila|Author|Multiple Sclerosis|Topic|AUTHORED
1781|Mohd Zulkifli Mustafa|Author|Multiple Sclerosis|Topic|AUTHORED
1781|Nurhafizah Ghani|Author|Multiple Sclerosis|Topic|AUTHORED
1781|Asma Hayati Ahmad|Author|Multiple Sclerosis|Topic|AUTHORED
1781|Zahiruddin Othman|Author|Multiple Sclerosis|Topic|AUTHORED
1781|Adi Wijaya|Author|Multiple Sclerosis|Topic|AUTHORED
1781|Rahimah Zakaria|Author|Multiple Sclerosis|Topic|AUTHORED
1782|Extended Rayleigh Lomax Distribution|Topic|Rayleigh Lomax Distribution|Topic|RELATED_TO
1782|Extended Rayleigh Lomax Distribution|Topic|Jones (2004)|Author|DISCUSSES
1782|N. I. Badmus|Author|Covid-19 Death Cases Data|Topic|AUTHORED
1782|O. Faweya|Author|Covid-19 Death Cases Data|Topic|AUTHORED
1782|S. A. Ige|Author|Covid-19 Death Cases Data|Topic|AUTHORED
1782|Covid-19 Death Cases Data|Topic|Better Distribution|Topic|RELATED_TO
1782|Goodness Of Fit|Topic|Model Selection Criteria|Topic|RELATED_TO
1782|Anderson Darling (Ad)|Topic|Model Selection Criteria|Topic|RELATED_TO
1782|Cramervon Misses (Cvm)|Topic|Model Selection Criteria|Topic|RELATED_TO
1782|Kolmogorov Smirnov (Ks)|Topic|Model Selection Criteria|Topic|RELATED_TO
1782|Akaike Information Criterion (Aic)|Topic|Model Selection Criteria|Topic|RELATED_TO
1782|Bayesian Information Criterion (Bic)|Topic|Model Selection Criteria|Topic|RELATED_TO
1782|Consistent Akaike Information Criterion (Caic)|Topic|Model Selection Criteria|Topic|RELATED_TO
1782|Skewness|Topic|Extended Rayleigh Lomax Distribution|Topic|RELATED_TO
1782|Kurtosis|Topic|Extended Rayleigh Lomax Distribution|Topic|RELATED_TO
1782|Coefficient Of Variation|Topic|Extended Rayleigh Lomax Distribution|Topic|RELATED_TO
1782|Hazard Rate|Topic|Extended Rayleigh Lomax Distribution|Topic|RELATED_TO
1782|Reverse Hazard Rate|Topic|Extended Rayleigh Lomax Distribution|Topic|RELATED_TO
1782|Likelihood Functions|Topic|Extended Rayleigh Lomax Distribution|Topic|RELATED_TO
1782|Moment Generating Functions|Topic|Extended Rayleigh Lomax Distribution|Topic|RELATED_TO
1782|Probability Density Function|Topic|Extended Rayleigh Lomax Distribution|Topic|RELATED_TO
1782|Cumulative Density Function|Topic|Extended Rayleigh Lomax Distribution|Topic|RELATED_TO
1782|Reliability Rate|Topic|Extended Rayleigh Lomax Distribution|Topic|RELATED_TO
1783|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|Linear Mixed Models (Lmms)|Topic|RELATED_TO
1783|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|Gaussian Assumptions|Topic|RELATED_TO
1783|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|Skewness|Topic|RELATED_TO
1783|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|Heavy-Tails|Topic|RELATED_TO
1783|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|Outliers|Topic|RELATED_TO
1783|Fernanda L. Schumacher|Author|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|AUTHORED
1783|Larissa A. Matos|Author|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|AUTHORED
1783|Celso R. B. Cabral|Author|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|AUTHORED
1783|Clinical Trials|Topic|Longitudinal Data|Topic|RELATED_TO
1783|Clinical Trials|Topic|Clustered Data|Topic|RELATED_TO
1783|Parameter Estimation|Topic|Maximum Likelihood|Topic|RELATED_TO
1783|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|Standard Errors|Topic|RELATED_TO
1783|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|Random Effects|Topic|RELATED_TO
1783|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|Schizophrenia Data|Topic|RELATED_TO
1783|Canonical Fundamental Skew-T Linear Mixed Model (St-Lmm)|Topic|Simulation Studies|Topic|RELATED_TO
1784|Survtrace|Topic|Zifeng Wang|Author|AUTHORED
1784|Survtrace|Topic|Jimeng Sun|Author|AUTHORED
1784|Survtrace|Topic|Survival Analysis|Topic|RELATED_TO
1784|Survtrace|Topic|Competing Events|Topic|RELATED_TO
1784|Survtrace|Topic|Metabric|Topic|RELATED_TO
1784|Survtrace|Topic|Support|Topic|RELATED_TO
1784|Survtrace|Topic|Seer|Topic|RELATED_TO
1785|Interval Estimation Of Relative Risks For Combined Unilateral And Bilateral Correlated Data|Paper|Relative Risk|Topic|DISCUSSES
1785|Interval Estimation Of Relative Risks For Combined Unilateral And Bilateral Correlated Data|Paper|Confidence Intervals|Topic|DISCUSSES
1785|Interval Estimation Of Relative Risks For Combined Unilateral And Bilateral Correlated Data|Paper|Fisher Scoring Method|Topic|DISCUSSES
1785|Interval Estimation Of Relative Risks For Combined Unilateral And Bilateral Correlated Data|Paper|Simulation Studies|Topic|DISCUSSES
1786|Covid-19 Clinical Decision Support Systems|Topic|Algorithmic Bias|Topic|DISCUSSES
1786|Logistic Regression Models|Topic|Covid-19 Mortality|Topic|DISCUSSES
1786|Logistic Regression Models|Topic|Ventilator Status|Topic|DISCUSSES
1786|Logistic Regression Models|Topic|Inpatient Status|Topic|DISCUSSES
1786|New York City|Topic|Real-World Dataset|Topic|RELATED_TO
1786|Yifan Li|Author|Covid-19 Clinical Decision Support Systems|Topic|AUTHORED
1786|Garrett Yoon|Author|Covid-19 Clinical Decision Support Systems|Topic|AUTHORED
1786|Mustafa Nasir-Moin|Author|Covid-19 Clinical Decision Support Systems|Topic|AUTHORED
1786|David Rosenberg|Author|Covid-19 Clinical Decision Support Systems|Topic|AUTHORED
1786|Sean Neifert|Author|Covid-19 Clinical Decision Support Systems|Topic|AUTHORED
1786|Douglas Kondziolka|Author|Covid-19 Clinical Decision Support Systems|Topic|AUTHORED
1786|Eric Karl Oermann|Author|Covid-19 Clinical Decision Support Systems|Topic|AUTHORED
1787|Prediction Method For Imaging Data|Topic|Steatosis Prediction|Topic|RELATED_TO
1787|Matthias Perkonigg|Author|Prediction Method For Imaging Data|Topic|AUTHORED
1787|Peter Mesenbrink|Author|Prediction Method For Imaging Data|Topic|AUTHORED
1787|Alexander Goehler|Author|Prediction Method For Imaging Data|Topic|AUTHORED
1787|Miljen Martic|Author|Prediction Method For Imaging Data|Topic|AUTHORED
1787|Ahmed Ba-Ssalamah|Author|Prediction Method For Imaging Data|Topic|AUTHORED
1787|Georg Langs|Author|Prediction Method For Imaging Data|Topic|AUTHORED
1788|Model-Assisted Complier Average Treatment Effect Estimates In Randomized Experiments With Non-Compliance And A Binary Outcome|Paper|Jiyang Ren|Author|AUTHORED
1788|Model-Assisted Complier Average Treatment Effect Estimates In Randomized Experiments With Non-Compliance And A Binary Outcome|Paper|Complier Average Treatment Effect|Topic|RELATED_TO
1788|Model-Assisted Complier Average Treatment Effect Estimates In Randomized Experiments With Non-Compliance And A Binary Outcome|Paper|Randomized Experiments|Topic|RELATED_TO
1788|Model-Assisted Complier Average Treatment Effect Estimates In Randomized Experiments With Non-Compliance And A Binary Outcome|Paper|Non-Compliance|Topic|RELATED_TO
1788|Model-Assisted Complier Average Treatment Effect Estimates In Randomized Experiments With Non-Compliance And A Binary Outcome|Paper|Binary Outcome|Topic|RELATED_TO
1788|Model-Assisted Complier Average Treatment Effect Estimates In Randomized Experiments With Non-Compliance And A Binary Outcome|Paper|Wald Estimator|Topic|RELATED_TO
1788|Model-Assisted Complier Average Treatment Effect Estimates In Randomized Experiments With Non-Compliance And A Binary Outcome|Paper|Neyman-Type Conservative Variance Estimators|Topic|RELATED_TO
1788|Model-Assisted Complier Average Treatment Effect Estimates In Randomized Experiments With Non-Compliance And A Binary Outcome|Paper|Academic Services|Topic|RELATED_TO
1788|Model-Assisted Complier Average Treatment Effect Estimates In Randomized Experiments With Non-Compliance And A Binary Outcome|Paper|Academic Performance|Topic|RELATED_TO
1789|Personal Health Navigation (Phn)|Topic|Cardiology|Topic|RELATED_TO
1789|Personal Health Navigation (Phn)|Topic|Health Trajectory|Topic|RELATED_TO
1789|Personal Health Navigation (Phn)|Topic|Health Computing Challenges|Topic|RELATED_TO
1789|Cardiology|Topic|Cardiovascular Exercise Response Variability|Topic|RELATED_TO
1789|Cardiovascular Exercise Response Variability|Topic|Smartwatch Data-Set|Topic|RELATED_TO
1789|Nitish Nag|Author|Personal Health Navigation (Phn)|Topic|AUTHORED
1789|Hyungik Oh|Author|Personal Health Navigation (Phn)|Topic|AUTHORED
1789|Mengfan Tang|Author|Personal Health Navigation (Phn)|Topic|AUTHORED
1789|Mingshu Shi|Author|Personal Health Navigation (Phn)|Topic|AUTHORED
1789|Ramesh Jain|Author|Personal Health Navigation (Phn)|Topic|AUTHORED
1790|Phase I Dose-Finding Clinical Trial|Topic|Dose-Finding Designs|Topic|RELATED_TO
1790|Dose-Finding Designs|Topic|Decision Framework|Topic|RELATED_TO
1790|Decision Framework|Topic|Mtpi|Topic|RELATED_TO
1790|Decision Framework|Topic|Boin|Topic|RELATED_TO
1790|Decision Framework|Topic|Crm|Topic|RELATED_TO
1790|Yunshan Duan|Author|Decision Framework|Topic|AUTHORED
1790|Shijie Yuan|Author|Decision Framework|Topic|AUTHORED
1790|Yuan Ji|Author|Decision Framework|Topic|AUTHORED
1790|Peter Mueller|Author|Decision Framework|Topic|AUTHORED
1791|Learning Personalized Decision Policies|Topic|Target Population|Topic|RELATED_TO
1791|Training Data|Topic|Standard Policy Learning Methods|Topic|RELATED_TO
1791|Novel Framework|Topic|Sample Selection Bias|Topic|RELATED_TO
1791|Sample Selection Bias|Topic|Selection Variable|Topic|RELATED_TO
1791|Uncertainty Set|Topic|Minimax Value|Topic|RELATED_TO
1791|Convex-Concave Procedure|Topic|Logistic Policies|Topic|RELATED_TO
1791|Tobias Hatt|Author|Novel Framework|Topic|AUTHORED
1791|Daniel Tschernutter|Author|Novel Framework|Topic|AUTHORED
1791|Stefan Feuerriegel|Author|Novel Framework|Topic|AUTHORED
1792|Power And Sample Size Analysis|Topic|Clinical Trial Study Design|Topic|RELATED_TO
1792|Bayesian Paradigm|Topic|General Bayesian Framework|Topic|RELATED_TO
1792|O'Hagan And Stevens (2001)|Author|General Bayesian Framework|Topic|AUTHORED
1792|General Bayesian Framework|Topic|Simulation-Based Sample Size Determination|Topic|RELATED_TO
1792|Conjugate Bayesian Linear Regression Models|Topic|General Bayesian Framework|Topic|RELATED_TO
1792|Frequentist Solutions|Topic|General Bayesian Framework|Topic|RELATED_TO
1792|Jane Pan|Author|A Unifying Bayesian Approach For Sample Size Determination Using Design And Analysis Priors|Paper|AUTHORED
1792|Sudipto Banerjee|Author|A Unifying Bayesian Approach For Sample Size Determination Using Design And Analysis Priors|Paper|AUTHORED
1793|Longitudinal Studies|Topic|Missing Data|Topic|RELATED_TO
1793|Ich E9(R1) Addendum|Topic|Treatment Effect Estimand|Topic|DISCUSSES
1793|Treatment Effect Estimand|Topic|Intercurrent Events|Topic|RELATED_TO
1793|Jump-To-Reference (J2R)|Topic|Treatment Effect Evaluation|Topic|DISCUSSES
1793|Jump-To-Reference (J2R)|Topic|Average Treatment Effect|Topic|RELATED_TO
1793|Average Treatment Effect|Topic|Potential Outcomes Framework|Topic|DISCUSSES
1793|Nuisance Functions|Topic|Multiple Robustness|Topic|DISCUSSES
1793|Simulation Studies|Topic|Proposed Estimators|Topic|DISCUSSES
1793|Antidepressant Clinical Trial|Topic|Proposed Estimators|Topic|DISCUSSES
1793|Siyi Liu|Author|Proposed Estimators|Topic|AUTHORED
1793|Shu Yang|Author|Proposed Estimators|Topic|AUTHORED
1793|Yilong Zhang|Author|Proposed Estimators|Topic|AUTHORED
1793|Guanghan|Author|Proposed Estimators|Topic|AUTHORED
1793|Liu|Author|Proposed Estimators|Topic|AUTHORED
1794|Delayed Separation Of Survival Curves|Topic|Immuno-Oncology|Topic|RELATED_TO
1794|Statistical Methods|Topic|Weighted Log-Rank Tests|Topic|RELATED_TO
1794|Weighted Log-Rank Tests|Topic|Baseline Variable|Topic|RELATED_TO
1794|Dominic Magirr|Author|Stratified Modestly-Weighted Log-Rank Tests|Topic|AUTHORED
1794|José L. Jiménez|Author|Stratified Modestly-Weighted Log-Rank Tests|Topic|AUTHORED
1794|Stratified Modestly-Weighted Log-Rank Tests|Topic|Randomized Clinical Trials|Topic|RELATED_TO
1794|Simulation Study|Topic|Stratified Modestly-Weighted Log-Rank Tests|Topic|RELATED_TO
1795|Covariate-Adjusted Log-Rank Test: Guaranteed Efficiency Gain And Universal Applicability|Paper|Ting Ye|Author|AUTHORED
1795|Covariate-Adjusted Log-Rank Test: Guaranteed Efficiency Gain And Universal Applicability|Paper|Jun Shao|Author|AUTHORED
1795|Covariate-Adjusted Log-Rank Test: Guaranteed Efficiency Gain And Universal Applicability|Paper|Yanyao Yi|Author|AUTHORED
1796|Warfarin|Topic|Deep Reinforcement Learning-Based Dosing Model|Topic|RELATED_TO
1796|Deep Reinforcement Learning-Based Dosing Model|Topic|Pharmacokinetic/Pharmacodynamic Model|Topic|RELATED_TO
1796|Sadjad Anzabi Zadeh|Author|Deep Reinforcement Learning-Based Dosing Model|Topic|AUTHORED
1796|W. Nick Street|Author|Deep Reinforcement Learning-Based Dosing Model|Topic|AUTHORED
1796|Barrett W. Thomas|Author|Deep Reinforcement Learning-Based Dosing Model|Topic|AUTHORED
1797|Automated Architecture Search For Brain-Inspired Hyperdimensional Computing|Paper|Hyperdimensional Computing|Topic|RELATED_TO
1798|Quantile Regression Models|Topic|Clustered Data|Topic|RELATED_TO
1798|Random Effects|Topic|Quantile Regression Models|Topic|RELATED_TO
1798|Small Clusters|Topic|Clustered Data|Topic|RELATED_TO
1798|Bias-Adjusted Estimator|Topic|Quantile Regression Models|Topic|RELATED_TO
1798|Aids Clinical Trial Group (Actg) Study|Topic|Bias-Adjusted Estimator|Topic|RELATED_TO
1798|Maria Laura Battagliola|Author|Two-Step Estimation Methodology|Topic|AUTHORED
1798|Helle Sørensen|Author|Two-Step Estimation Methodology|Topic|AUTHORED
1798|Anders Tolver|Author|Two-Step Estimation Methodology|Topic|AUTHORED
1798|Ana-Maria Staicu|Author|Two-Step Estimation Methodology|Topic|AUTHORED
1798|Two-Step Estimation Methodology|Topic|Pseudo Likelihood Approach (Lqmm Method)|Topic|RELATED_TO
1798|Two-Step Estimation Methodology|Topic|Bootstrap Sampling Procedure|Topic|RELATED_TO
1798|Simulation Studies|Topic|Two-Step Estimation Methodology|Topic|RELATED_TO
1799|Ensemble Method For Estimating Individualized Treatment Effects|Paper|Kevin Wu Han|Author|AUTHORED
1799|Ensemble Method For Estimating Individualized Treatment Effects|Paper|Han Wu|Author|AUTHORED
1799|Ensemble Method For Estimating Individualized Treatment Effects|Paper|Individualized Treatment Effects|Topic|RELATED_TO
1799|Ensemble Method For Estimating Individualized Treatment Effects|Paper|Machine Learning Models|Topic|RELATED_TO
1799|Ensemble Method For Estimating Individualized Treatment Effects|Paper|Randomized Experiment|Topic|RELATED_TO
1799|Ensemble Method For Estimating Individualized Treatment Effects|Paper|Clinical Trials|Topic|RELATED_TO
1799|Ensemble Method For Estimating Individualized Treatment Effects|Paper|A/B Testing|Topic|RELATED_TO
1799|Ensemble Method For Estimating Individualized Treatment Effects|Paper|Model Selection|Topic|RELATED_TO
1799|Ensemble Method For Estimating Individualized Treatment Effects|Paper|Ensembling|Topic|RELATED_TO
1799|Ensemble Method For Estimating Individualized Treatment Effects|Paper|Benchmark Datasets|Topic|RELATED_TO
1800|Model-Free Artificial Pancreas|Topic|Type 1 Diabetes|Topic|RELATED_TO
1800|Model-Free Artificial Pancreas|Topic|Tobias K. S. Ritschel|Author|AUTHORED
1800|Model-Free Artificial Pancreas|Topic|Asbjørn Thode Reenberg|Author|AUTHORED
1800|Model-Free Artificial Pancreas|Topic|Emilie B. Lindkvist|Author|AUTHORED
1800|Model-Free Artificial Pancreas|Topic|Christian Laugesen|Author|AUTHORED
1800|Model-Free Artificial Pancreas|Topic|Jannet Svensson|Author|AUTHORED
1800|Model-Free Artificial Pancreas|Topic|Ajenthen G. Ranjan|Author|AUTHORED
1800|Model-Free Artificial Pancreas|Topic|Kirsten Nørgaard|Author|AUTHORED
1800|Model-Free Artificial Pancreas|Topic|Bernd Dammann|Author|AUTHORED
1800|Model-Free Artificial Pancreas|Topic|John Bagterp Jørgensen|Author|AUTHORED
1801|Learning Conditional Variational Autoencoders With Missing Covariates|Paper|Siddharth Ramchandran|Author|AUTHORED
1801|Learning Conditional Variational Autoencoders With Missing Covariates|Paper|Gleb Tikhonov|Author|AUTHORED
1801|Learning Conditional Variational Autoencoders With Missing Covariates|Paper|Otto Lönnroth|Author|AUTHORED
1801|Learning Conditional Variational Autoencoders With Missing Covariates|Paper|Pekka Tiikkainen|Author|AUTHORED
1801|Learning Conditional Variational Autoencoders With Missing Covariates|Paper|Harri Lähdesmäki|Author|AUTHORED
1801|Learning Conditional Variational Autoencoders With Missing Covariates|Paper|Conditional Variational Autoencoders|Topic|RELATED_TO
1802|A Single Index Model For Longitudinal Outcomes To Optimize Individual Treatment Decision Rules|Paper|Precision Medicine|Topic|DISCUSSES
1802|A Single Index Model For Longitudinal Outcomes To Optimize Individual Treatment Decision Rules|Paper|Longitudinal Data|Topic|DISCUSSES
1802|A Single Index Model For Longitudinal Outcomes To Optimize Individual Treatment Decision Rules|Paper|Kullback-Leibler Divergence|Topic|DISCUSSES
1802|A Single Index Model For Longitudinal Outcomes To Optimize Individual Treatment Decision Rules|Paper|Biosignatures|Topic|DISCUSSES
1803|Bayesassurance|Topic|Jane Pan|Author|AUTHORED
1803|Bayesassurance|Topic|Sudipto Banerjee|Author|AUTHORED
1804|Digital Therapeutics (Dtx)|Topic|Software As A Medical Device (Samd)|Topic|RELATED_TO
1804|Software As A Medical Device (Samd)|Topic|Mobile And Wearable Devices|Topic|RELATED_TO
1804|Randomized Clinical Trials|Topic|Digital Therapeutics (Dtx)|Topic|RELATED_TO
1804|Data-Driven Dtx Analytics|Topic|Dtx Engagement|Topic|RELATED_TO
1804|Data-Driven Dtx Analytics|Topic|Behavioral Adherence|Topic|RELATED_TO
1804|Data-Driven Dtx Analytics|Topic|Contextual Patterns|Topic|RELATED_TO
1804|Data-Driven Dtx Analytics|Topic|Mobile Sensor And Interaction Datasets|Topic|RELATED_TO
1804|Data-Driven Dtx Analytics|Topic|Receptivity Of Existing Dtx|Topic|RELATED_TO
1804|Uichin Lee|Author|Data-Driven Dtx Analytics|Topic|AUTHORED
1804|Gyuwon Jung|Author|Data-Driven Dtx Analytics|Topic|AUTHORED
1804|Eun-Yeol Ma|Author|Data-Driven Dtx Analytics|Topic|AUTHORED
1804|Jin San Kim|Author|Data-Driven Dtx Analytics|Topic|AUTHORED
1804|Heepyung Kim|Author|Data-Driven Dtx Analytics|Topic|AUTHORED
1804|Jumabek Alikhanov|Author|Data-Driven Dtx Analytics|Topic|AUTHORED
1804|Youngtae Noh|Author|Data-Driven Dtx Analytics|Topic|AUTHORED
1804|Heeyoung Kim|Author|Data-Driven Dtx Analytics|Topic|AUTHORED
1805|A Deep Bayesian Bandits Approach For Anticancer Therapy: Exploration Via Functional Prior|Paper|Mingyu Lu|Author|AUTHORED
1805|A Deep Bayesian Bandits Approach For Anticancer Therapy: Exploration Via Functional Prior|Paper|Yifang Chen|Author|AUTHORED
1805|A Deep Bayesian Bandits Approach For Anticancer Therapy: Exploration Via Functional Prior|Paper|Su-In Lee|Author|AUTHORED
1805|Learning Personalized Cancer Treatment With Machine Learning|Topic|A Deep Bayesian Bandits Approach For Anticancer Therapy: Exploration Via Functional Prior|Paper|RELATED_TO
1806|Reinforcement Learning|Topic|Bayesian Sequential Design|Topic|RELATED_TO
1806|Healthcare Applications|Topic|Reinforcement Learning|Topic|RELATED_TO
1806|Mauricio Tec|Author|A Comparative Tutorial Of Bayesian Sequential Design And Reinforcement Learning|Paper|AUTHORED
1806|Yunshan Duan|Author|A Comparative Tutorial Of Bayesian Sequential Design And Reinforcement Learning|Paper|AUTHORED
1806|Peter Müller|Author|A Comparative Tutorial Of Bayesian Sequential Design And Reinforcement Learning|Paper|AUTHORED
1807|A Survey Of Risk-Aware Multi-Armed Bandits|Paper|Vincent Y. F. Tan|Author|AUTHORED
1807|A Survey Of Risk-Aware Multi-Armed Bandits|Paper|Prashanth L. A.|Author|AUTHORED
1807|A Survey Of Risk-Aware Multi-Armed Bandits|Paper|Krishna Jagannathan|Author|AUTHORED
1808|Value Of Information (Voi) Analysis|Topic|Unit Normal Loss Integral (Unli)|Topic|RELATED_TO
1808|Unit Normal Loss Integral (Unli)|Topic|Closed-Form Solution|Topic|RELATED_TO
1808|Closed-Form Solution|Topic|Two-Dimensional Unli|Topic|RELATED_TO
1808|Two-Dimensional Unli|Topic|Three-Arm Clinical Trial|Topic|RELATED_TO
1808|Three-Arm Clinical Trial|Topic|Predtools Package|Topic|RELATED_TO
1808|Tae Yoon Lee|Author|Closed-Form Solution|Topic|AUTHORED
1808|Paul Gustafson|Author|Closed-Form Solution|Topic|AUTHORED
1808|Mohsen Sadatsafavi|Author|Closed-Form Solution|Topic|AUTHORED
1809|Markov Decision Process|Topic|Model Uncertainty|Topic|RELATED_TO
1809|Model Uncertainty|Topic|Bayesian Framework|Topic|RELATED_TO
1809|State Process|Topic|Controls|Topic|RELATED_TO
1809|Cost|Topic|Risk Measures|Topic|RELATED_TO
1809|Risk Measures|Topic|Risk Filters|Topic|RELATED_TO
1809|Risk Filters|Topic|Bellman Principle Of Optimality|Topic|RELATED_TO
1809|Optimal Investment|Topic|Clinical Trials|Topic|RELATED_TO
1809|Tomasz R. Bielecki|Author|Risk Filtering And Risk-Averse Control Of Markovian Systems Subject To Model Uncertainty|Paper|AUTHORED
1809|Igor Cialenco|Author|Risk Filtering And Risk-Averse Control Of Markovian Systems Subject To Model Uncertainty|Paper|AUTHORED
1810|Bayesian Optimization Under Stochastic Delayed Feedback|Paper|Arun Verma|Author|AUTHORED
1810|Bayesian Optimization Under Stochastic Delayed Feedback|Paper|Zhongxiang Dai|Author|AUTHORED
1810|Bayesian Optimization Under Stochastic Delayed Feedback|Paper|Bryan Kian Hsiang Low|Author|AUTHORED
1810|Bayesian Optimization Under Stochastic Delayed Feedback|Paper|Bayesian Optimization|Topic|RELATED_TO
1810|Bayesian Optimization Under Stochastic Delayed Feedback|Paper|Stochastic Delayed Feedback|Topic|RELATED_TO
1810|Bayesian Optimization Under Stochastic Delayed Feedback|Paper|Function Evaluation|Topic|RELATED_TO
1810|Bayesian Optimization Under Stochastic Delayed Feedback|Paper|Sub-Linear Regret Guarantees|Topic|RELATED_TO
1810|Bayesian Optimization Under Stochastic Delayed Feedback|Paper|Batch Bo|Topic|RELATED_TO
1810|Bayesian Optimization Under Stochastic Delayed Feedback|Paper|Contextual Gaussian Process Bandits|Topic|RELATED_TO
1811|Constrained D-Optimal Design For Paid Research Study|Paper|Yifei Huang|Author|AUTHORED
1811|Constrained D-Optimal Design For Paid Research Study|Paper|Liping Tong|Author|AUTHORED
1811|Constrained D-Optimal Design For Paid Research Study|Paper|Jie Yang|Author|AUTHORED
1812|Human-Centered Ai-Assisted Colonoscopy System|Paper|Ai-Assisted Colonoscopy|Topic|RELATED_TO
1812|Human-Centered Ai-Assisted Colonoscopy System|Paper|Hsiang-Ting Chen|Author|AUTHORED
1812|Human-Centered Ai-Assisted Colonoscopy System|Paper|Yuan Zhang|Author|AUTHORED
1812|Human-Centered Ai-Assisted Colonoscopy System|Paper|Gustavo Carneiro|Author|AUTHORED
1812|Human-Centered Ai-Assisted Colonoscopy System|Paper|Seon Ho Shin|Author|AUTHORED
1812|Human-Centered Ai-Assisted Colonoscopy System|Paper|Rajvinder Singh|Author|AUTHORED
1813|Comparing Results Of Thermographic Images Based Diagnosis For Breast Diseases|Paper|Infrared Imaging|Topic|DISCUSSES
1813|Comparing Results Of Thermographic Images Based Diagnosis For Breast Diseases|Paper|Support Vector Machine|Topic|DISCUSSES
1813|Comparing Results Of Thermographic Images Based Diagnosis For Breast Diseases|Paper|Pro Engenharia Public Database|Topic|RELATED_TO
1813|Pro Engenharia Public Database|Topic|Universidade Federal De Pernambuco|Topic|RELATED_TO
1814|An Empathetic Ai Coach For Self-Attachment Therapy|Paper|Self-Attachment Therapy|Topic|DISCUSSES
1814|An Empathetic Ai Coach For Self-Attachment Therapy|Paper|Digital Coach|Topic|DISCUSSES
1814|An Empathetic Ai Coach For Self-Attachment Therapy|Paper|Deep-Learning Classifier|Topic|DISCUSSES
1814|An Empathetic Ai Coach For Self-Attachment Therapy|Paper|Rule-Based Conversational Agent|Topic|DISCUSSES
1814|An Empathetic Ai Coach For Self-Attachment Therapy|Paper|Human-Like Personas|Topic|DISCUSSES
1814|An Empathetic Ai Coach For Self-Attachment Therapy|Paper|User Engagement|Topic|DISCUSSES
1814|An Empathetic Ai Coach For Self-Attachment Therapy|Paper|Empathy|Topic|DISCUSSES
1814|An Empathetic Ai Coach For Self-Attachment Therapy|Paper|Usefulness|Topic|DISCUSSES
1814|An Empathetic Ai Coach For Self-Attachment Therapy|Paper|Non-Clinical Trial|Topic|DISCUSSES
1814|An Empathetic Ai Coach For Self-Attachment Therapy|Paper|Participants|Topic|DISCUSSES
1815|Pocock And Simon'S Minimization Method|Topic|Limiting Covariance Matrix|Topic|RELATED_TO
1815|Limiting Covariance Matrix|Topic|Bootstrap-Based Estimator|Topic|DISCUSSES
1815|Bootstrap-Based Estimator|Topic|Le Cam'S Third Lemma|Topic|DISCUSSES
1815|Bootstrap-Based Estimator|Topic|Robust Tests|Topic|DISCUSSES
1815|Robust Tests|Topic|Consistent Covariance Estimation For Stratum Imbalances Under Minimization Method For Covariate-Adaptive Randomization|Paper|RELATED_TO
1815|Zixuan Zhao|Author|Consistent Covariance Estimation For Stratum Imbalances Under Minimization Method For Covariate-Adaptive Randomization|Paper|AUTHORED
1815|Yanglei Song|Author|Consistent Covariance Estimation For Stratum Imbalances Under Minimization Method For Covariate-Adaptive Randomization|Paper|AUTHORED
1815|Wenyu Jiang|Author|Consistent Covariance Estimation For Stratum Imbalances Under Minimization Method For Covariate-Adaptive Randomization|Paper|AUTHORED
1815|Dongsheng Tu|Author|Consistent Covariance Estimation For Stratum Imbalances Under Minimization Method For Covariate-Adaptive Randomization|Paper|AUTHORED
1816|Optimal Personalized Treatment Selection|Topic|Chathura Siriwardhana|Author|AUTHORED
1816|Optimal Personalized Treatment Selection|Topic|K. B. Kulasekera|Author|AUTHORED
1816|Optimal Personalized Treatment Selection|Topic|Somnath Datta|Author|AUTHORED
1817|Feature Selection With Respect To Time-To-Event Outcomes|Topic|Clinical Trials|Topic|RELATED_TO
1817|Feature Selection With Respect To Time-To-Event Outcomes|Topic|Biomarker Discovery Studies|Topic|RELATED_TO
1817|Statistical Methods|Topic|Sample Size|Topic|RELATED_TO
1817|Simulation Study|Topic|Cox Proportional Hazards Models|Topic|RELATED_TO
1817|Cox Proportional Hazards Models|Topic|Covariates|Topic|RELATED_TO
1817|Gaussian Regression|Topic|Cox Regression|Topic|RELATED_TO
1817|Rong Lu|Author|Gaussian Regression|Topic|AUTHORED
1818|Deep Conditional Transformation Models For Survival Analysis|Paper|Gabriele Campanella|Author|AUTHORED
1818|Deep Conditional Transformation Models For Survival Analysis|Paper|Lucas Kook|Author|AUTHORED
1818|Deep Conditional Transformation Models For Survival Analysis|Paper|Ida Häggström|Author|AUTHORED
1818|Deep Conditional Transformation Models For Survival Analysis|Paper|Torsten Hothorn|Author|AUTHORED
1818|Deep Conditional Transformation Models For Survival Analysis|Paper|Thomas J. Fuchs|Author|AUTHORED
1819|Hybrid Censored Quantile Regression Forest (Hcqrf)|Topic|Censored Response Variable|Topic|RELATED_TO
1819|Hybrid Censored Quantile Regression Forest (Hcqrf)|Topic|Treatment Effects|Topic|RELATED_TO
1819|Hybrid Censored Quantile Regression Forest (Hcqrf)|Topic|Quantiles|Topic|RELATED_TO
1819|Hybrid Censored Quantile Regression Forest (Hcqrf)|Topic|Variable Importance Decomposition|Topic|RELATED_TO
1819|Huichen Zhu|Author|Hybrid Censored Quantile Regression Forest (Hcqrf)|Topic|AUTHORED
1819|Yifei Sun|Author|Hybrid Censored Quantile Regression Forest (Hcqrf)|Topic|AUTHORED
1819|Ying Wei|Author|Hybrid Censored Quantile Regression Forest (Hcqrf)|Topic|AUTHORED
1819|Hybrid Censored Quantile Regression Forest (Hcqrf)|Topic|Colorectal Cancer Clinical Trial|Topic|RELATED_TO
1819|Hybrid Censored Quantile Regression Forest (Hcqrf)|Topic|Simulation Studies|Topic|RELATED_TO
1820|Stratified Medicine|Topic|Predictive Biomarkers|Topic|RELATED_TO
1820|Predictive Biomarkers|Topic|Randomized Data|Topic|RELATED_TO
1820|Rare Cancers|Topic|Clinical Registries|Topic|RELATED_TO
1820|Rare Cancers|Topic|Observational Studies|Topic|RELATED_TO
1820|Average Treatment Effect|Topic|Confounder Adjustment|Topic|RELATED_TO
1820|Confounder Adjustment|Topic|Regression Modelling|Topic|RELATED_TO
1820|Predmob|Paper|Covariate Adjustment|Topic|DISCUSSES
1820|Predmob|Paper|Matching|Topic|DISCUSSES
1820|Predmob|Paper|Inverse Probability Of Treatment Weighting (Iptw)|Topic|DISCUSSES
1820|German Breast Cancer Study Group (Gbsg) Trial 2|Paper|Predmob|Paper|AUTHORED
1820|Julia Krzykalla|Author|Predmob|Paper|AUTHORED
1820|Axel Benner|Author|Predmob|Paper|AUTHORED
1820|Annette Kopp-Schneider|Author|Predmob|Paper|AUTHORED
1821|Frailty Model With Change Point For Survival Analysis|Paper|Cox Proportional Hazard Model|Topic|RELATED_TO
1821|Frailty Model With Change Point For Survival Analysis|Paper|Expectation-Maximization Algorithm|Topic|RELATED_TO
1821|Frailty Model With Change Point For Survival Analysis|Paper|R Package|Topic|RELATED_TO
1821|Frailty Model With Change Point For Survival Analysis|Paper|Simulation Studies|Topic|RELATED_TO
1821|Frailty Model With Change Point For Survival Analysis|Paper|Clinical Trials|Topic|RELATED_TO
1821|Frailty Model With Change Point For Survival Analysis|Paper|Random Effects|Topic|RELATED_TO
1821|Frailty Model With Change Point For Survival Analysis|Paper|Heterogeneity|Topic|RELATED_TO
1821|Frailty Model With Change Point For Survival Analysis|Paper|Change Points|Topic|RELATED_TO
1821|Frailty Model With Change Point For Survival Analysis|Paper|Accuracy|Topic|RELATED_TO
1822|Mild Cognitive Impairment|Topic|Dementia|Topic|RELATED_TO
1822|Mild Cognitive Impairment|Topic|Psychiatric Disorders|Topic|RELATED_TO
1822|Psychiatric Disorders|Topic|Depression|Topic|RELATED_TO
1822|Psychiatric Disorders|Topic|Mood Disorders|Topic|RELATED_TO
1822|Psychiatric Disorders|Topic|Schizophrenia|Topic|RELATED_TO
1822|Mild Cognitive Impairment|Topic|Disability-Adjusted Life-Years|Topic|RELATED_TO
1822|Mild Cognitive Impairment|Topic|Healthcare Burden|Topic|RELATED_TO
1822|Mild Cognitive Impairment|Topic|Drug Trials|Topic|RELATED_TO
1822|Drug Trials|Topic|Alzheimer'S Disease|Topic|RELATED_TO
1822|Mild Cognitive Impairment|Topic|Non-Drug-Based Therapies|Topic|RELATED_TO
1822|Non-Drug-Based Therapies|Topic|Ultrasound Ablation Of Amyloid Plaques|Topic|RELATED_TO
1822|Mild Cognitive Impairment|Topic|Neurofeedback Therapy|Topic|RELATED_TO
1822|Neurofeedback Therapy|Topic|Neuroplasticity|Topic|RELATED_TO
1822|Mild Cognitive Impairment|Topic|Pathophysiological Aspects|Topic|RELATED_TO
1822|Mild Cognitive Impairment|Topic|Non-Pharmacological Interventions|Topic|RELATED_TO
1822|Sheng Mai|Author|Pathophysiological Aspects|Topic|AUTHORED
1823|Black Box Optimisation|Topic|Kernel Based Bandit Problem|Topic|RELATED_TO
1823|Kernel Based Bandit Problem|Topic|Bayesian Optimisation|Topic|RELATED_TO
1823|Stochastically Delayed Feedback|Topic|Kernel Based Bandit Problem|Topic|RELATED_TO
1823|Algorithm|Topic|$	Ilde{	Ext{O}}(	Ext{Sqrt}(	Ext{Gamma}_K(T)T)+	Ext{E}[	Au])$ Regret|Topic|RELATED_TO
1823|$	Ilde{	Ext{O}}(	Ext{Sqrt}(	Ext{Gamma}_K(T)T)+	Ext{E}[	Au])$ Regret|Topic|$	Ilde{	Ext{O}}(	Ext{Gamma}_K(T)	Ext{Sqrt}(T)+	Ext{E}[	Au]	Ext{Gamma}_K(T))$|Topic|RELATED_TO
1823|Verma Et Al. (2022)|Paper|$	Ilde{	Ext{O}}(	Ext{Gamma}_K(T)	Ext{Sqrt}(T)+	Ext{E}[	Au]	Ext{Gamma}_K(T))$|Topic|DISCUSSES
1823|Sattar Vakili|Author|Algorithm|Topic|AUTHORED
1823|Danyal Ahmed|Author|Algorithm|Topic|AUTHORED
1823|Alberto Bernacchia|Author|Algorithm|Topic|AUTHORED
1823|Ciara Pike-Burke|Author|Algorithm|Topic|AUTHORED
1823|Algorithm|Topic|Simulations|Topic|DISCUSSES
1824|Factorial Survival Analysis For Treatment Effects Under Dependent Censoring|Paper|Takeshi Emura|Author|AUTHORED
1824|Factorial Survival Analysis For Treatment Effects Under Dependent Censoring|Paper|Marc Ditzhaus|Author|AUTHORED
1824|Factorial Survival Analysis For Treatment Effects Under Dependent Censoring|Paper|Dennis Dobler|Author|AUTHORED
1824|Factorial Survival Analysis For Treatment Effects Under Dependent Censoring|Paper|Kenta Murotani|Author|AUTHORED
1824|Surv.Factorial|Topic|Factorial Survival Analysis For Treatment Effects Under Dependent Censoring|Paper|RELATED_TO
1825|Multi-Task Representation Learning For Pure Exploration In Linear Bandits|Paper|Yihan Du|Author|AUTHORED
1825|Multi-Task Representation Learning For Pure Exploration In Linear Bandits|Paper|Longbo Huang|Author|AUTHORED
1825|Multi-Task Representation Learning For Pure Exploration In Linear Bandits|Paper|Wen Sun|Author|AUTHORED
1825|Multi-Task Representation Learning For Pure Exploration In Linear Bandits|Paper|Linear Bandits|Topic|RELATED_TO
1825|Multi-Task Representation Learning For Pure Exploration In Linear Bandits|Paper|Contextual Linear Bandits|Topic|RELATED_TO
1825|Multi-Task Representation Learning For Pure Exploration In Linear Bandits|Paper|Best Arm Identification|Topic|RELATED_TO
1825|Multi-Task Representation Learning For Pure Exploration In Linear Bandits|Paper|Best Policy Identification|Topic|RELATED_TO
1825|Multi-Task Representation Learning For Pure Exploration In Linear Bandits|Paper|Douexpdes|Topic|RELATED_TO
1825|Multi-Task Representation Learning For Pure Exploration In Linear Bandits|Paper|C-Douexpdes|Topic|RELATED_TO
1826|Number Of Repetitions In Re-Randomization Tests|Paper|Yilong Zhang|Author|AUTHORED
1826|Number Of Repetitions In Re-Randomization Tests|Paper|Yujie Zhao|Author|AUTHORED
1826|Number Of Repetitions In Re-Randomization Tests|Paper|Yiwen Luo|Author|AUTHORED
1827|Is Calendar Time The True Clock Of Innovation?|Paper|Martin Ho|Author|AUTHORED
1827|Is Calendar Time The True Clock Of Innovation?|Paper|Henry Cw Price|Author|AUTHORED
1827|Is Calendar Time The True Clock Of Innovation?|Paper|Tim S Evans|Author|AUTHORED
1827|Is Calendar Time The True Clock Of Innovation?|Paper|Eoin O'Sullivan|Author|AUTHORED
1828|An Efficient Data Integration Scheme For Synthesizing Information From Multiple Secondary Datasets For The Parameter Inference Of The Main Analysis|Paper|Multiple Information Borrowing (Minbo)|Topic|DISCUSSES
1828|An Efficient Data Integration Scheme For Synthesizing Information From Multiple Secondary Datasets For The Parameter Inference Of The Main Analysis|Paper|Atherosclerosis Risk In Communities Study|Topic|RELATED_TO
1828|An Efficient Data Integration Scheme For Synthesizing Information From Multiple Secondary Datasets For The Parameter Inference Of The Main Analysis|Paper|Chixiang Chen|Author|AUTHORED
1828|An Efficient Data Integration Scheme For Synthesizing Information From Multiple Secondary Datasets For The Parameter Inference Of The Main Analysis|Paper|Ming Wang|Author|AUTHORED
1828|An Efficient Data Integration Scheme For Synthesizing Information From Multiple Secondary Datasets For The Parameter Inference Of The Main Analysis|Paper|Shuo Chen|Author|AUTHORED
1829|Latent Exchangeability Prior|Topic|Historical Data|Topic|RELATED_TO
1829|Latent Exchangeability Prior|Topic|Propensity Score Approaches|Topic|RELATED_TO
1829|Latent Exchangeability Prior|Topic|Phase 3 Clinical Trial|Topic|RELATED_TO
1829|Latent Exchangeability Prior|Topic|Plaque Psoriasis|Topic|RELATED_TO
1829|Ethan M. Alt|Author|Latent Exchangeability Prior|Topic|AUTHORED
1829|Xiuya Chang|Author|Latent Exchangeability Prior|Topic|AUTHORED
1829|Xun Jiang|Author|Latent Exchangeability Prior|Topic|AUTHORED
1829|Qing Liu|Author|Latent Exchangeability Prior|Topic|AUTHORED
1829|May Mo|Author|Latent Exchangeability Prior|Topic|AUTHORED
1829|H. Amy Xia|Author|Latent Exchangeability Prior|Topic|AUTHORED
1829|Joseph G. Ibrahim|Author|Latent Exchangeability Prior|Topic|AUTHORED
1830|Smartstate|Topic|Samuel E. Armstrong|Author|AUTHORED
1830|Smartstate|Topic|Mitchell A. Klusty|Author|AUTHORED
1830|Smartstate|Topic|Aaron D. Mullen|Author|AUTHORED
1830|Smartstate|Topic|Jeffery C. Talbert|Author|AUTHORED
1830|Smartstate|Topic|V. K. Cody Bumgardner|Author|AUTHORED
1831|Dirichlet Process Mixture Models For The Analysis Of Repeated Attempt Designs|Paper|Michael J. Daniels|Author|AUTHORED
1831|Dirichlet Process Mixture Models For The Analysis Of Repeated Attempt Designs|Paper|Minji Lee|Author|AUTHORED
1831|Dirichlet Process Mixture Models For The Analysis Of Repeated Attempt Designs|Paper|Wei Feng|Author|AUTHORED
1832|An Ensemble Learning Approach For Exercise Detection In Type 1 Diabetes Patients|Paper|Ke Ma|Author|AUTHORED
1832|An Ensemble Learning Approach For Exercise Detection In Type 1 Diabetes Patients|Paper|Hongkai Chen|Author|AUTHORED
1832|An Ensemble Learning Approach For Exercise Detection In Type 1 Diabetes Patients|Paper|Shan Lin|Author|AUTHORED
1832|Type 1 Diabetes|Topic|Artificial Pancreas Systems|Topic|RELATED_TO
1832|Type 1 Diabetes|Topic|Exercise-Induced Glucose Intake|Topic|RELATED_TO
1832|Exercise-Induced Glucose Intake|Topic|Hypoglycemia|Topic|RELATED_TO
1832|Existing Exercise Detection Methods|Topic|Ensemble Learning Framework|Topic|RELATED_TO
1832|Public Dataset|Topic|An Ensemble Learning Approach For Exercise Detection In Type 1 Diabetes Patients|Paper|RELATED_TO
1832|True Positive Rate|Topic|An Ensemble Learning Approach For Exercise Detection In Type 1 Diabetes Patients|Paper|RELATED_TO
1832|True Negative Rate|Topic|An Ensemble Learning Approach For Exercise Detection In Type 1 Diabetes Patients|Paper|RELATED_TO
1833|Covariance Adaptive Best Arm Identification|Paper|Best Arm Identification|Topic|DISCUSSES
1833|Covariance Adaptive Best Arm Identification|Paper|Multi-Armed Bandit Model|Topic|DISCUSSES
1833|El Mehdi Saad|Author|Covariance Adaptive Best Arm Identification|Paper|AUTHORED
1833|Gilles Blanchard|Author|Covariance Adaptive Best Arm Identification|Paper|AUTHORED
1833|Nicolas Verzelen|Author|Covariance Adaptive Best Arm Identification|Paper|AUTHORED
1834|Should I Stop Or Should I Go: Early Stopping With Heterogeneous Populations|Paper|Hammaad Adam|Author|AUTHORED
1834|Should I Stop Or Should I Go: Early Stopping With Heterogeneous Populations|Paper|Fan Yin|Author|AUTHORED
1834|Should I Stop Or Should I Go: Early Stopping With Heterogeneous Populations|Paper|Huibin|Author|AUTHORED
1834|Should I Stop Or Should I Go: Early Stopping With Heterogeneous Populations|Paper|Hu|Author|AUTHORED
1834|Should I Stop Or Should I Go: Early Stopping With Heterogeneous Populations|Paper|Neil Tenenholtz|Author|AUTHORED
1834|Should I Stop Or Should I Go: Early Stopping With Heterogeneous Populations|Paper|Lorin Crawford|Author|AUTHORED
1834|Should I Stop Or Should I Go: Early Stopping With Heterogeneous Populations|Paper|Lester Mackey|Author|AUTHORED
1834|Should I Stop Or Should I Go: Early Stopping With Heterogeneous Populations|Paper|Allison Koenecke|Author|AUTHORED
1835|Web Scraping|Topic|Medicine|Topic|RELATED_TO
1835|Web Scraping|Topic|Medical Ministrations|Topic|RELATED_TO
1835|Medical Ministrations|Topic|Medicine|Topic|RELATED_TO
1835|Niketha Sabesan|Author|Medical Ministrations|Topic|AUTHORED
1835|Nivethitha|Author|Medical Ministrations|Topic|AUTHORED
1835|J. N Shreyah|Author|Medical Ministrations|Topic|AUTHORED
1835|Pranauv A J|Author|Medical Ministrations|Topic|AUTHORED
1835|Shyam R|Author|Medical Ministrations|Topic|AUTHORED
1836|A Direct Approach To Simultaneous Tests Of Superiority And Noninferiority With Multiple Endpoints|Paper|Wenfeng Chen|Author|AUTHORED
1836|A Direct Approach To Simultaneous Tests Of Superiority And Noninferiority With Multiple Endpoints|Paper|Naiqing Zhao|Author|AUTHORED
1836|A Direct Approach To Simultaneous Tests Of Superiority And Noninferiority With Multiple Endpoints|Paper|Guoyou Qin|Author|AUTHORED
1836|A Direct Approach To Simultaneous Tests Of Superiority And Noninferiority With Multiple Endpoints|Paper|Jie Chen|Author|AUTHORED
1836|A Direct Approach To Simultaneous Tests Of Superiority And Noninferiority With Multiple Endpoints|Paper|Clinical Trials|Topic|RELATED_TO
1836|A Direct Approach To Simultaneous Tests Of Superiority And Noninferiority With Multiple Endpoints|Paper|Superiority Hypothesis|Topic|RELATED_TO
1836|A Direct Approach To Simultaneous Tests Of Superiority And Noninferiority With Multiple Endpoints|Paper|Non-Inferiority Hypothesis|Topic|RELATED_TO
1836|A Direct Approach To Simultaneous Tests Of Superiority And Noninferiority With Multiple Endpoints|Paper|Type I Error Rate|Topic|RELATED_TO
1836|A Direct Approach To Simultaneous Tests Of Superiority And Noninferiority With Multiple Endpoints|Paper|Simulations|Topic|RELATED_TO
1836|A Direct Approach To Simultaneous Tests Of Superiority And Noninferiority With Multiple Endpoints|Paper|Confidence Intervals|Topic|RELATED_TO
1837|Medical Image Analysis Challenges|Topic|Clinical Trials|Topic|RELATED_TO
1837|Reproducibility Of Methods|Topic|2019 Robust Medical Image Segmentation Challenge|Topic|RELATED_TO
1837|2019 Robust Medical Image Segmentation Challenge|Topic|Annika Reinke|Author|AUTHORED
1837|2019 Robust Medical Image Segmentation Challenge|Topic|Georg Grab|Author|AUTHORED
1837|2019 Robust Medical Image Segmentation Challenge|Topic|Lena Maier-Hein|Author|AUTHORED
1838|Parkinson'S Disease|Topic|Subgroups|Topic|RELATED_TO
1838|Subgroups|Topic|Clinical Trials|Topic|RELATED_TO
1838|Subgroups|Topic|Biomarkers|Topic|RELATED_TO
1838|Cluster Analysis|Topic|Subgroups|Topic|DISCUSSES
1838|Longitudinal Data|Topic|Cluster Analysis|Topic|RELATED_TO
1838|Time-To-Event Data|Topic|Cluster Analysis|Topic|RELATED_TO
1838|Divisive Hierarchical Bayesian Clustering|Topic|Idiopathic Pd|Topic|AUTHORED
1838|Idiopathic Pd|Topic|Parkinson'S Progression Markers Initiative|Topic|RELATED_TO
1838|Elliot Burghardt|Author|Divisive Hierarchical Bayesian Clustering|Topic|AUTHORED
1838|Daniel Sewell|Author|Divisive Hierarchical Bayesian Clustering|Topic|AUTHORED
1838|Joseph Cavanaugh|Author|Divisive Hierarchical Bayesian Clustering|Topic|AUTHORED
1839|Vertxgradenet|Topic|Msasss|Topic|RELATED_TO
1839|Vertxgradenet|Topic|Vertxnet|Topic|RELATED_TO
1839|Yuanhan Mo|Author|Vertxgradenet|Topic|AUTHORED
1839|Yao Chen|Author|Vertxgradenet|Topic|AUTHORED
1839|Aimee Readie|Author|Vertxgradenet|Topic|AUTHORED
1839|Gregory Ligozio|Author|Vertxgradenet|Topic|AUTHORED
1839|Thibaud Coroller|Author|Vertxgradenet|Topic|AUTHORED
1839|Axial Spondylarthritis|Topic|Msasss|Topic|RELATED_TO
1840|Drugchat|Topic|Youwei Liang|Author|AUTHORED
1840|Drugchat|Topic|Ruiyi Zhang|Author|AUTHORED
1840|Drugchat|Topic|Li Zhang|Author|AUTHORED
1840|Drugchat|Topic|Pengtao Xie|Author|AUTHORED
1840|Drugchat|Topic|Drug Discovery|Topic|RELATED_TO
1840|Drugchat|Topic|Structure-Activity Relationships|Topic|RELATED_TO
1840|Drugchat|Topic|Lead Optimization|Topic|RELATED_TO
1840|Drugchat|Topic|Drug Repurposing|Topic|RELATED_TO
1840|Drugchat|Topic|Clinical Trials|Topic|RELATED_TO
1840|Drugchat|Topic|Graph Neural Network|Topic|RELATED_TO
1840|Drugchat|Topic|Large Language Model|Topic|RELATED_TO
1840|Drugchat|Topic|Adaptor|Topic|RELATED_TO
1840|Drugchat|Topic|Instruction Tuning Datasets|Topic|RELATED_TO
1840|Instruction Tuning Datasets|Topic|Drug Compounds|Topic|RELATED_TO
1840|Instruction Tuning Datasets|Topic|Question-Answer Pairs|Topic|RELATED_TO
1841|Healthfc|Topic|Juraj Vladika|Author|AUTHORED
1841|Healthfc|Topic|Phillip Schneider|Author|AUTHORED
1841|Healthfc|Topic|Florian Matthes|Author|AUTHORED
1842|Neyman Allocation|Topic|Multi-Stage Experimental Design|Topic|RELATED_TO
1842|Multi-Stage Experimental Design|Topic|Adaptive Neyman Allocation Algorithm|Topic|RELATED_TO
1842|Adaptive Neyman Allocation Algorithm|Topic|Online A/B Testing|Topic|DISCUSSES
1842|Adaptive Neyman Allocation Algorithm|Topic|Jinglong Zhao|Author|AUTHORED
1843|Heterogeneous Treatment Effect Estimation Method|Topic|Rulefit|Topic|RELATED_TO
1843|Heterogeneous Treatment Effect Estimation Method|Topic|Aids Clinical Trials Group Protocol 175 Dataset|Topic|RELATED_TO
1843|Heterogeneous Treatment Effect Estimation Method|Topic|Ke Wan|Author|AUTHORED
1843|Heterogeneous Treatment Effect Estimation Method|Topic|Kensuke Tanioka|Author|AUTHORED
1843|Heterogeneous Treatment Effect Estimation Method|Topic|Toshio Shimokawa|Author|AUTHORED
1844|Physical Experiments In National Security|Topic|Test Engineers|Topic|RELATED_TO
1844|Test Engineers|Topic|Bayesian Adaptive Designs|Topic|RELATED_TO
1844|Bayesian Adaptive Designs|Topic|Predictive Probability|Topic|RELATED_TO
1844|Predictive Probability|Topic|Measuring The Robustness Of Predictive Probability For Early Stopping In Experimental Design|Paper|DISCUSSES
1844|Measuring The Robustness Of Predictive Probability For Early Stopping In Experimental Design|Paper|Daniel Ries|Author|AUTHORED
1844|Measuring The Robustness Of Predictive Probability For Early Stopping In Experimental Design|Paper|Victoria R. C. Sieck|Author|AUTHORED
1844|Measuring The Robustness Of Predictive Probability For Early Stopping In Experimental Design|Paper|Philip Jones|Author|AUTHORED
1844|Measuring The Robustness Of Predictive Probability For Early Stopping In Experimental Design|Paper|Julie Shaffer|Author|AUTHORED
1845|Human Genetic Diseases|Topic|Point Mutations|Topic|RELATED_TO
1845|Point Mutations|Topic|Genome Editing Techniques|Topic|RELATED_TO
1845|Genome Editing Techniques|Topic|Base Editing|Topic|RELATED_TO
1845|Base Editing|Topic|Editing Efficiency|Topic|RELATED_TO
1845|Base Editing|Topic|Unintended Mutations|Topic|RELATED_TO
1845|Base Editing|Topic|Trial-And-Error Experimentation|Topic|RELATED_TO
1845|Attention-Based Two-Stage Machine Learning Model|Paper|Genomic Target Sequence|Topic|RELATED_TO
1845|Attention-Based Two-Stage Machine Learning Model|Paper|Multi-Task Learning Schema|Topic|RELATED_TO
1845|Multi-Task Learning Schema|Topic|Base Editors|Topic|RELATED_TO
1845|Attention-Based Two-Stage Machine Learning Model|Paper|Predictions|Topic|RELATED_TO
1845|Predictions|Topic|Experimental Results|Topic|RELATED_TO
1845|Experimental Results|Topic|Datasets|Topic|RELATED_TO
1845|Experimental Results|Topic|Base Editor Variants|Topic|RELATED_TO
1845|Models' Capacity|Topic|Base Editing Designs|Topic|RELATED_TO
1846|Reference Based Imputation|Topic|Conditional Mean Imputation|Topic|RELATED_TO
1846|Conditional Mean Imputation|Topic|Mixed Model For Repeated Measures|Topic|RELATED_TO
1846|Sequential Linear Regression|Topic|Mixed Model For Repeated Measures|Topic|RELATED_TO
1846|Sean Yiu|Author|Sequential Linear Regression|Topic|AUTHORED
1847|Contextual Bandit Algorithms|Topic|Recommender Systems|Topic|RELATED_TO
1847|Contextual Bandit Algorithms|Topic|Clinical Trials|Topic|RELATED_TO
1847|Contextual Bandit Algorithms|Topic|Optimal Portfolio Selection|Topic|RELATED_TO
1848|Accurate Cancer Risk Estimation|Topic|Clinical Decision-Making|Topic|RELATED_TO
1848|Clinical Decision-Making|Topic|High-Risk People For Screening|Topic|RELATED_TO
1848|Cancer Risk Models|Topic|Epidemiologic Studies|Topic|RELATED_TO
1848|Population-Based Health Surveys|Topic|Time-To-Cancer Incidence Data|Topic|RELATED_TO
1848|Time-To-Cancer Specific Mortality|Topic|Vital Statistics|Topic|RELATED_TO
1848|Calibrated Pseudoweighting Methods|Topic|Individual-Level Data|Topic|RELATED_TO
1848|Individual-Level Data|Topic|Cohort|Topic|RELATED_TO
1848|Summary Statistics Of Cancer Incidence|Topic|National Cancer Registries|Topic|RELATED_TO
1848|Cox Regression|Topic|Inverse-Propensity Pseudoweighting Method|Topic|RELATED_TO
1848|Lung Cancer Incidence Pure Risk Model|Topic|Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial|Topic|RELATED_TO
1848|Lung Cancer Incidence Pure Risk Model|Topic|National Health Interview Survey|Topic|RELATED_TO
1848|Lung Cancer Incidence Pure Risk Model|Topic|Cancer Registries|Topic|RELATED_TO
1848|Lingxiao Wang|Author|Lung Cancer Incidence Pure Risk Model|Topic|AUTHORED
1848|Yan Li|Author|Lung Cancer Incidence Pure Risk Model|Topic|AUTHORED
1848|Barry Graubard|Author|Lung Cancer Incidence Pure Risk Model|Topic|AUTHORED
1848|Hormuzd Katki|Author|Lung Cancer Incidence Pure Risk Model|Topic|AUTHORED
1850|Translation|Topic|Biomedical Translation|Topic|DISCUSSES
1850|Nih|Author|Biomedical Translation|Topic|AUTHORED
1850|Darpa|Author|Biomedical Translation|Topic|AUTHORED
1850|Martin Ho|Author|Biomedical Translation|Topic|AUTHORED
1850|Henry Cw Price|Author|Biomedical Translation|Topic|AUTHORED
1850|Tim S Evans|Author|Biomedical Translation|Topic|AUTHORED
1850|Eoin O'Sullivan|Author|Biomedical Translation|Topic|AUTHORED
1851|A Multilingual Virtual Guide For Self-Attachment Technique|Paper|Self-Attachment Technique|Topic|RELATED_TO
1852|Coronary Artery Disease|Topic|Stenting|Topic|RELATED_TO
1852|Stenting|Topic|Bypass Surgery|Topic|RELATED_TO
1852|Angioplasty|Topic|Forssmann|Author|RELATED_TO
1852|Angioplasty|Topic|Dotter|Author|RELATED_TO
1852|Angioplasty|Topic|Gruentzig|Author|RELATED_TO
1852|Bare Metal Stents|Topic|Drug-Eluting Stents|Topic|RELATED_TO
1852|Drug-Eluting Stents|Topic|Bioresorbable Vascular Scaffolds|Topic|RELATED_TO
1852|Clinical Trials|Topic|Drug-Eluting Stents|Topic|RELATED_TO
1852|Personalized Stenting|Topic|Stenting|Topic|RELATED_TO
1852|Umme Hafsa Momy|Author|Stenting|Topic|AUTHORED
1853|Human Genetic Diseases|Topic|Point Mutations|Topic|RELATED_TO
1853|Point Mutations|Topic|Genome Editing Techniques|Topic|RELATED_TO
1853|Genome Editing Techniques|Topic|Base Editing|Topic|RELATED_TO
1853|Base Editing|Topic|Editing Efficiency|Topic|RELATED_TO
1853|Base Editing|Topic|Unintended Mutations|Topic|RELATED_TO
1853|Base Editing|Topic|Trial-And-Error Experimentation|Topic|RELATED_TO
1853|Attention-Based Two-Stage Machine Learning Model|Paper|Genomic Target Sequence|Topic|RELATED_TO
1853|Attention-Based Two-Stage Machine Learning Model|Paper|Multi-Task Learning Schema|Topic|RELATED_TO
1853|Multi-Task Learning Schema|Topic|Base Editors|Topic|RELATED_TO
1853|Attention-Based Two-Stage Machine Learning Model|Paper|Predictions|Topic|RELATED_TO
1853|Predictions|Topic|Experimental Results|Topic|RELATED_TO
1853|Experimental Results|Topic|Datasets|Topic|RELATED_TO
1853|Experimental Results|Topic|Base Editor Variants|Topic|RELATED_TO
1853|Models' Capacity|Topic|Base Editing Designs|Topic|RELATED_TO
1854|Incremental Cost-Effectiveness Statistical Inference: Calculations And Communications|Paper|Robert L. Obenchain|Author|AUTHORED
1854|Incremental Cost-Effectiveness Statistical Inference: Calculations And Communications|Paper|Nonparametric Statistical Methods|Topic|DISCUSSES
1854|Incremental Cost-Effectiveness Statistical Inference: Calculations And Communications|Paper|Incremental Cost Effectiveness (Ice) Methods|Topic|DISCUSSES
1854|Incremental Cost-Effectiveness Statistical Inference: Calculations And Communications|Paper|Bootstrapping|Topic|DISCUSSES
1854|Incremental Cost-Effectiveness Statistical Inference: Calculations And Communications|Paper|Shadow Price Of Health|Topic|DISCUSSES
1854|Incremental Cost-Effectiveness Statistical Inference: Calculations And Communications|Paper|Iceinfer R-Package|Topic|DISCUSSES
1854|Incremental Cost-Effectiveness Statistical Inference: Calculations And Communications|Paper|Qaly|Topic|DISCUSSES
1854|Incremental Cost-Effectiveness Statistical Inference: Calculations And Communications|Paper|Histograms|Topic|DISCUSSES
1854|Incremental Cost-Effectiveness Statistical Inference: Calculations And Communications|Paper|Health-Care Stakeholders|Topic|DISCUSSES
1855|Survtimesurvival: Survival Analysis On Patients With Multiple Visits/Records|Paper|Hung Le|Author|AUTHORED
1855|Survtimesurvival: Survival Analysis On Patients With Multiple Visits/Records|Paper|Ong Eng-Jon|Author|AUTHORED
1855|Survtimesurvival: Survival Analysis On Patients With Multiple Visits/Records|Paper|Bober Miroslaw|Author|AUTHORED
1856|Mobile Health Interventions|Topic|Contextual Bandits|Topic|RELATED_TO
1856|Contextual Bandits|Topic|Count Data Models|Topic|RELATED_TO
1856|Count Data Models|Topic|Thompson Sampling|Topic|RELATED_TO
1856|Thompson Sampling|Topic|Drink Less Trial|Topic|RELATED_TO
1856|Drink Less Trial|Topic|Xueqing Liu|Author|AUTHORED
1856|Drink Less Trial|Topic|Nina Deliu|Author|AUTHORED
1856|Drink Less Trial|Topic|Tanujit Chakraborty|Author|AUTHORED
1856|Drink Less Trial|Topic|Lauren Bell|Author|AUTHORED
1856|Drink Less Trial|Topic|Bibhas Chakraborty|Author|AUTHORED
1857|Treatment-Covariate Interaction Tests|Topic|Covariate-Adaptive Randomization|Topic|RELATED_TO
1857|Covariate-Adaptive Randomization|Topic|Interaction Tests|Topic|RELATED_TO
1857|Interaction Tests|Topic|Personalized Medicine|Topic|RELATED_TO
1857|Likun Zhang|Author|Interaction Tests|Topic|AUTHORED
1857|Wei Ma|Author|Interaction Tests|Topic|AUTHORED
1858|Aids Clinical Trials Group Protocol 175|Paper|Kai Chen|Author|AUTHORED
1858|Aids Clinical Trials Group Protocol 175|Paper|Yuqian Zhang|Author|AUTHORED
1858|Semi-Supervised Learning|Topic|Linear Parameters|Topic|RELATED_TO
1858|Linear Parameters|Topic|Model Misspecification|Topic|RELATED_TO
1858|Model Misspecification|Topic|High Dimensions|Topic|RELATED_TO
1858|Robust Semi-Supervised Estimators|Topic|Regression Coefficient|Topic|RELATED_TO
1858|Sparse Structures|Topic|Large-Scale Unlabeled Data|Topic|RELATED_TO
1858|Estimation Accuracy|Topic|Inference Robustness|Topic|RELATED_TO
1858|Sparse Linear Slope|Topic|Covariate Shift|Topic|RELATED_TO
1858|Numerical Studies|Topic|Simulations|Topic|RELATED_TO
1859|Experimental And Observational Studies|Topic|Spurious Association|Topic|RELATED_TO
1859|Spurious Association|Topic|Outcome|Topic|RELATED_TO
1859|Spurious Association|Topic|Independent Variables|Topic|RELATED_TO
1859|Independent Variables|Topic|Intervention|Topic|RELATED_TO
1859|Confounding|Topic|Third-Party Factors|Topic|RELATED_TO
1859|Randomized Clinical Trials|Topic|Confounding|Topic|RELATED_TO
1859|Small Sample Sizes|Topic|Confounding|Topic|RELATED_TO
1859|New Study|Topic|Ethical Concerns|Topic|RELATED_TO
1859|Hypothetical Studies|Topic|Dependencies|Topic|RELATED_TO
1859|Observed Confounders|Topic|Independent Variables|Topic|RELATED_TO
1859|Historic Studies|Topic|Effect Size|Topic|RELATED_TO
1859|Orestis Loukas|Author|Hypothetical Studies|Topic|AUTHORED
1859|Ho Ryun Chung|Author|Hypothetical Studies|Topic|AUTHORED
1860|A Class Of Computational Methods To Reduce Selection Bias When Designing Phase 3 Clinical Trials|Paper|Phase 3 Studies|Topic|DISCUSSES
1860|A Class Of Computational Methods To Reduce Selection Bias When Designing Phase 3 Clinical Trials|Paper|Treatment Effect|Topic|DISCUSSES
1860|A Class Of Computational Methods To Reduce Selection Bias When Designing Phase 3 Clinical Trials|Paper|Estimation Bias|Topic|DISCUSSES
1860|A Class Of Computational Methods To Reduce Selection Bias When Designing Phase 3 Clinical Trials|Paper|Mean Squared Error|Topic|DISCUSSES
1860|A Class Of Computational Methods To Reduce Selection Bias When Designing Phase 3 Clinical Trials|Paper|Computational Methods|Topic|DISCUSSES
1860|A Class Of Computational Methods To Reduce Selection Bias When Designing Phase 3 Clinical Trials|Paper|Selection Problems|Topic|DISCUSSES
1861|Maximum Likelihood Estimation Under The Emax Model: Existence, Geometry And Efficiency|Paper|Emax Dose-Response Model|Topic|DISCUSSES
1861|Maximum Likelihood Estimation Under The Emax Model: Existence, Geometry And Efficiency|Paper|Giacomo Aletti|Author|AUTHORED
1861|Maximum Likelihood Estimation Under The Emax Model: Existence, Geometry And Efficiency|Paper|Nancy Flournoy|Author|AUTHORED
1861|Maximum Likelihood Estimation Under The Emax Model: Existence, Geometry And Efficiency|Paper|Caterina May|Author|AUTHORED
1861|Maximum Likelihood Estimation Under The Emax Model: Existence, Geometry And Efficiency|Paper|Chiara Tommasi|Author|AUTHORED
1862|Cure Rate Models|Topic|Cancer Clinical Trials|Topic|RELATED_TO
1862|Cure Rate Models|Topic|Infectious Diseases|Topic|RELATED_TO
1862|Tournoud And Ecochard|Author|2008|Topic|AUTHORED
1862|Tournoud And Ecochard|Author|Poisson Distribution|Topic|AUTHORED
1862|New Cure Rate Model|Topic|Infectious Diseases|Topic|RELATED_TO
1862|New Cure Rate Model|Topic|Expectation Maximization Algorithm|Topic|RELATED_TO
1862|New Cure Rate Model|Topic|Monte Carlo Simulation Study|Topic|RELATED_TO
1862|New Cure Rate Model|Topic|Likelihood Ratio Test|Topic|RELATED_TO
1862|New Cure Rate Model|Topic|Information-Based Criteria|Topic|RELATED_TO
1862|New Cure Rate Model|Topic|Covid-19|Topic|RELATED_TO
1862|Suvra Pal|Author|New Cure Rate Model|Topic|AUTHORED
1863|Testing For Similarity Of Multivariate Mixed Outcomes Using Generalised Joint Regression Models With Application To Efficacy-Toxicity Responses|Paper|Gaussian Copula|Topic|RELATED_TO
1863|Testing For Similarity Of Multivariate Mixed Outcomes Using Generalised Joint Regression Models With Application To Efficacy-Toxicity Responses|Paper|Multivariate Outcomes|Topic|RELATED_TO
1863|Testing For Similarity Of Multivariate Mixed Outcomes Using Generalised Joint Regression Models With Application To Efficacy-Toxicity Responses|Paper|Efficacy-Toxicity Case Study|Topic|RELATED_TO
1864|Posterior Shrinkage Towards Linear Subspaces|Paper|Prior Beliefs|Topic|DISCUSSES
1864|Posterior Shrinkage Towards Linear Subspaces|Paper|Exponential Tilting|Topic|DISCUSSES
1864|Posterior Shrinkage Towards Linear Subspaces|Paper|Antihypertensive Clinical Trial Dataset|Topic|DISCUSSES
1864|Posterior Shrinkage Towards Linear Subspaces|Paper|Monthly Influenza And Pneumonia Data|Topic|DISCUSSES
1864|Posterior Shrinkage Towards Linear Subspaces|Paper|R Package Subset|Topic|DISCUSSES
1865|Effect Size Estimates|Topic|Intervention/Exposure|Topic|RELATED_TO
1865|Effect Size Estimates|Topic|Confounders|Topic|RELATED_TO
1865|Effect Size Estimates|Topic|Outcome|Topic|RELATED_TO
1865|Causal Inference|Topic|Observational Studies|Topic|RELATED_TO
1865|Causal Inference|Topic|Randomized Clinical Trials|Topic|RELATED_TO
1865|Combinatorics|Topic|Information Theory|Topic|RELATED_TO
1865|Logistic Regression|Topic|Three-Way Stratified Analysis|Topic|DISCUSSES
1865|Mantel-Haenszel Estimator|Topic|Two-Way Effect|Topic|DISCUSSES
1865|Orestis Loukas|Author|On The Estimation And Interpretation Of Effect Size Metrics|Paper|AUTHORED
1865|Ho Ryun Chung|Author|On The Estimation And Interpretation Of Effect Size Metrics|Paper|AUTHORED
1866|Individualized Treatment Effects Estimation|Topic|Ghadeer O. Ghosheh|Author|AUTHORED
1866|Individualized Treatment Effects Estimation|Topic|Moritz Gögl|Author|AUTHORED
1866|Individualized Treatment Effects Estimation|Topic|Tingting Zhu|Author|AUTHORED
1867|Federated Learning For Estimating Heterogeneous Treatment Effects|Paper|Disha Makhija|Author|AUTHORED
1867|Federated Learning For Estimating Heterogeneous Treatment Effects|Paper|Joydeep Ghosh|Author|AUTHORED
1867|Federated Learning For Estimating Heterogeneous Treatment Effects|Paper|Yejin Kim|Author|AUTHORED
1867|Machine Learning Methods For Estimating Heterogeneous Treatment Effects (Hte)|Topic|Federated Learning For Estimating Heterogeneous Treatment Effects|Paper|RELATED_TO
1868|Vqsynergy|Topic|Drug Synergy|Topic|RELATED_TO
1868|Vqsynergy|Topic|Cancer Treatment|Topic|RELATED_TO
1868|Jiawei Wu|Author|Vqsynergy|Topic|AUTHORED
1868|Mingyuan Yan|Author|Vqsynergy|Topic|AUTHORED
1868|Dianbo Liu|Author|Vqsynergy|Topic|AUTHORED
1869|Using Smartphones To Study Vaccination Decisions In The Wild|Paper|Vaccination|Topic|RELATED_TO
1869|Using Smartphones To Study Vaccination Decisions In The Wild|Paper|Nicolò Alessandro Girardini|Author|AUTHORED
1869|Using Smartphones To Study Vaccination Decisions In The Wild|Paper|Arkadiusz Stopczynski|Author|AUTHORED
1869|Using Smartphones To Study Vaccination Decisions In The Wild|Paper|Olga Baranov|Author|AUTHORED
1869|Using Smartphones To Study Vaccination Decisions In The Wild|Paper|Cornelia Betsch|Author|AUTHORED
1869|Using Smartphones To Study Vaccination Decisions In The Wild|Paper|Dirk Brockmann|Author|AUTHORED
1869|Using Smartphones To Study Vaccination Decisions In The Wild|Paper|Sune Lehmann|Author|AUTHORED
1869|Using Smartphones To Study Vaccination Decisions In The Wild|Paper|Robert Böhm|Author|AUTHORED
1870|Kg-Treat|Paper|Treatment Effect Estimation|Topic|DISCUSSES
1870|Kg-Treat|Paper|Biomedical Knowledge Graphs|Topic|RELATED_TO
1870|Kg-Treat|Paper|Patient Outcomes|Topic|RELATED_TO
1870|Kg-Treat|Paper|Treatment-Covariate Relationships|Topic|RELATED_TO
1870|Kg-Treat|Paper|Outcome-Covariate Relationships|Topic|RELATED_TO
1870|Kg-Treat|Paper|Area Under The Roc Curve|Topic|RELATED_TO
1870|Kg-Treat|Paper|Influence Function-Based Precision Of Estimating Heterogeneous Effects|Topic|RELATED_TO
1870|Kg-Treat|Paper|Randomized Clinical Trial Findings|Topic|RELATED_TO
1871|Generative Modelling For Shapes|Topic|In-Silico Clinical Trials (Iscts)|Topic|RELATED_TO
1871|In-Silico Clinical Trials (Iscts)|Topic|Synthetic Anatomical Shapes|Topic|RELATED_TO
1871|Synthetic Anatomical Shapes|Topic|3D Surface Meshes|Topic|RELATED_TO
1871|Ai Models|Topic|3D Surface Meshes|Topic|RELATED_TO
1871|Graph Representations For Meshes|Topic|Unsupervised Geometric Deep-Learning Model|Topic|RELATED_TO
1871|Unsupervised Geometric Deep-Learning Model|Topic|Shape Correspondences|Topic|RELATED_TO
1871|Unsupervised Geometric Deep-Learning Model|Topic|Population-Derived Atlas|Topic|RELATED_TO
1871|Unsupervised Geometric Deep-Learning Model|Topic|Realistic Synthetic Shapes|Topic|RELATED_TO
1871|Joint Shape Generative-Clustering Multi-Atlas Framework|Topic|Realistic Synthetic Shapes|Topic|RELATED_TO
1871|Liver Models|Topic|Computational Medicine|Topic|RELATED_TO
1871|Left-Ventricular Models|Topic|Computational Medicine|Topic|RELATED_TO
1871|End-To-End Deep Learning Generative Framework For Refinable Shape Matching And Generation|Paper|Soodeh Kalaie|Author|AUTHORED
1871|End-To-End Deep Learning Generative Framework For Refinable Shape Matching And Generation|Paper|Andy Bulpitt|Author|AUTHORED
1871|End-To-End Deep Learning Generative Framework For Refinable Shape Matching And Generation|Paper|Alejandro F. Frangi|Author|AUTHORED
1871|End-To-End Deep Learning Generative Framework For Refinable Shape Matching And Generation|Paper|Ali Gooya|Author|AUTHORED
1872|Copula Based Dependent Censoring In Cure Models|Paper|Morine Delhelle|Author|AUTHORED
1872|Copula Based Dependent Censoring In Cure Models|Paper|Ingrid Van Keilegom|Author|AUTHORED
1872|Copula Based Dependent Censoring In Cure Models|Paper|Time-To-Event Variable|Topic|RELATED_TO
1872|Copula Based Dependent Censoring In Cure Models|Paper|Random Right Censoring|Topic|RELATED_TO
1872|Copula Based Dependent Censoring In Cure Models|Paper|Bivariate Distribution|Topic|RELATED_TO
1872|Copula Based Dependent Censoring In Cure Models|Paper|Parametric Copula|Topic|RELATED_TO
1872|Copula Based Dependent Censoring In Cure Models|Paper|Marginal Distributions|Topic|RELATED_TO
1872|Copula Based Dependent Censoring In Cure Models|Paper|Survival Function|Topic|RELATED_TO
1872|Copula Based Dependent Censoring In Cure Models|Paper|Breast Cancer Data|Topic|RELATED_TO
1873|Clinical Trial|Topic|Survival Times|Topic|RELATED_TO
1873|Treatment Group|Topic|Control Group|Topic|RELATED_TO
1873|Propensity Score Methods|Topic|Logistic Regression Model|Topic|RELATED_TO
1873|Confounders|Topic|Propensity Score Methods|Topic|RELATED_TO
1873|Coarsened Exact Matching (Cem)|Topic|Weighted Log-Rank Statistic|Topic|RELATED_TO
1873|Asymptotic Properties|Topic|Weighted Log-Rank Statistic|Topic|RELATED_TO
1873|Gaussian Process|Topic|Asymptotic Properties|Topic|RELATED_TO
1873|Asymptotic Normality|Topic|Null Hypothesis|Topic|RELATED_TO
1873|Log-Rank Test|Topic|Coarsened Exact Matching (Cem)|Topic|RELATED_TO
1873|Tomoya Baba|Author|Log-Rank Test|Topic|AUTHORED
1873|Nakahiro Yoshida|Author|Log-Rank Test|Topic|AUTHORED
1874|Bayesppdsurv|Topic|Yueqi Shen|Author|AUTHORED
1874|Bayesppdsurv|Topic|Matthew A. Psioda|Author|AUTHORED
1874|Bayesppdsurv|Topic|Joseph G. Ibrahim|Author|AUTHORED
1875|Quantitative Systems Pharmacology|Topic|Chemotherapy Pharmacodynamics|Topic|RELATED_TO
1875|Universal Physics-Informed Neural Networks|Topic|Chemotherapy Pharmacodynamics|Topic|RELATED_TO
1875|Doxorubicin|Topic|Chemotherapy Pharmacodynamics|Topic|RELATED_TO
1875|Lena Podina|Author|Learning Chemotherapy Drug Action Via Universal Physics-Informed Neural Networks|Paper|AUTHORED
1875|Ali Ghodsi|Author|Learning Chemotherapy Drug Action Via Universal Physics-Informed Neural Networks|Paper|AUTHORED
1875|Mohammad Kohandel|Author|Learning Chemotherapy Drug Action Via Universal Physics-Informed Neural Networks|Paper|AUTHORED
1876|Unlocking Insights: Enhanced Analysis Of Covariance In General Factorial Designs Through Multiple Contrast Tests Under Variance Heteroscedasticity|Paper|Analysis Of Covariance (Ancova)|Topic|DISCUSSES
1876|Unlocking Insights: Enhanced Analysis Of Covariance In General Factorial Designs Through Multiple Contrast Tests Under Variance Heteroscedasticity|Paper|Multiple Contrast Test Procedure (Mctp)|Topic|DISCUSSES
1876|Unlocking Insights: Enhanced Analysis Of Covariance In General Factorial Designs Through Multiple Contrast Tests Under Variance Heteroscedasticity|Paper|Wild-Bootstrap Method|Topic|DISCUSSES
1876|Matthias Becher|Author|Unlocking Insights: Enhanced Analysis Of Covariance In General Factorial Designs Through Multiple Contrast Tests Under Variance Heteroscedasticity|Paper|AUTHORED
1876|Ludwig A. Hothorn|Author|Unlocking Insights: Enhanced Analysis Of Covariance In General Factorial Designs Through Multiple Contrast Tests Under Variance Heteroscedasticity|Paper|AUTHORED
1876|Frank Konietschke|Author|Unlocking Insights: Enhanced Analysis Of Covariance In General Factorial Designs Through Multiple Contrast Tests Under Variance Heteroscedasticity|Paper|AUTHORED
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Retinal Implants|Topic|RELATED_TO
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Degenerative Retinal Disease|Topic|RELATED_TO
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Phosphenes|Topic|RELATED_TO
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Argus Ii Retinal Prosthesis System|Topic|RELATED_TO
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Yuchen Hou|Author|AUTHORED
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Laya Pullela|Author|AUTHORED
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Jiaxin Su|Author|AUTHORED
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Sriya Aluru|Author|AUTHORED
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Shivani Sista|Author|AUTHORED
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Xiankun Lu|Author|AUTHORED
1877|Predicting The Temporal Dynamics Of Prosthetic Vision|Paper|Michael Beyeler|Author|AUTHORED
1878|Preliminary Study|Paper|Christos Sardianos|Author|AUTHORED
1878|Preliminary Study|Paper|Chrysostomos Symvoulidis|Author|AUTHORED
1878|Preliminary Study|Paper|Matthias Schlögl|Author|AUTHORED
1878|Preliminary Study|Paper|Iraklis Varlamis|Author|AUTHORED
1878|Preliminary Study|Paper|Georgios Th. Papadopoulos|Author|AUTHORED
1878|Enhanced Diagnostic Techniques|Topic|Gas Chromatography-Ion Mobility Spectrometry (Gc-Ims)|Topic|RELATED_TO
1878|Enhanced Diagnostic Techniques|Topic|Machine Learning Algorithms|Topic|RELATED_TO
1878|Gas Chromatography-Ion Mobility Spectrometry (Gc-Ims)|Topic|Laboratory Information Management System (Lims)|Topic|RELATED_TO
1879|Investigating The Causal Effects Of Multiple Treatments Using Longitudinal Data: A Simulation Study|Paper|Robins Generalised Methods|Topic|DISCUSSES
1879|Investigating The Causal Effects Of Multiple Treatments Using Longitudinal Data: A Simulation Study|Paper|G-Methods|Topic|DISCUSSES
1879|Investigating The Causal Effects Of Multiple Treatments Using Longitudinal Data: A Simulation Study|Paper|Uk Cf Registry|Topic|RELATED_TO
1880|Vascularpilot3D|Topic|Jingwei Song|Author|AUTHORED
1880|Vascularpilot3D|Topic|Keke Yang|Author|AUTHORED
1880|Vascularpilot3D|Topic|Han Chen|Author|AUTHORED
1880|Vascularpilot3D|Topic|Jiayi Liu|Author|AUTHORED
1880|Vascularpilot3D|Topic|Yinan Gu|Author|AUTHORED
1880|Vascularpilot3D|Topic|Qianxin Hui|Author|AUTHORED
1880|Vascularpilot3D|Topic|Yanqi Huang|Author|AUTHORED
1880|Vascularpilot3D|Topic|Meng Li|Author|AUTHORED
1880|Vascularpilot3D|Topic|Zheng Zhang|Author|AUTHORED
1880|Vascularpilot3D|Topic|Tuoyu Cao|Author|AUTHORED
1880|Vascularpilot3D|Topic|Maani Ghaffari|Author|AUTHORED
1881|Graph Feedback Bandits With Similar Arms|Paper|Stochastic Multi-Armed Bandit Problem|Topic|DISCUSSES
1881|Graph Feedback Bandits With Similar Arms|Paper|Graph Feedback|Topic|DISCUSSES
1881|Graph Feedback Bandits With Similar Arms|Paper|Clinical Trials|Topic|DISCUSSES
1881|Graph Feedback Bandits With Similar Arms|Paper|Recommendation Problem|Topic|DISCUSSES
1881|Graph Feedback Bandits With Similar Arms|Paper|D-Ucb|Topic|DISCUSSES
1881|Graph Feedback Bandits With Similar Arms|Paper|C-Ucb|Topic|DISCUSSES
1881|Graph Feedback Bandits With Similar Arms|Paper|Q&A Platforms|Topic|DISCUSSES
1881|Graph Feedback Bandits With Similar Arms|Paper|Product Reviews|Topic|DISCUSSES
1881|Q&A Platforms|Topic|Reddit|Topic|RELATED_TO
1881|Q&A Platforms|Topic|Stack Overflow|Topic|RELATED_TO
1881|Q&A Platforms|Topic|Quora|Topic|RELATED_TO
1881|Product Reviews|Topic|Amazon|Topic|RELATED_TO
1881|Product Reviews|Topic|Flipkart|Topic|RELATED_TO
1882|Marc Harary|Author|Pearson Correlation Coefficient|Topic|AUTHORED
1882|Marc Harary|Author|Welford'S Online Algorithm|Topic|AUTHORED
1882|Marc Harary|Author|Bivariate Data|Topic|AUTHORED
1882|Marc Harary|Author|Time-Series Analysis|Topic|AUTHORED
1882|Marc Harary|Author|Sensitivity Algorithms|Topic|AUTHORED
1882|Marc Harary|Author|Cython-Wrapped C|Topic|AUTHORED
1882|Marc Harary|Author|Econometrics|Topic|AUTHORED
1882|Marc Harary|Author|Operations Research|Topic|AUTHORED
1882|Marc Harary|Author|Clinical Trials|Topic|AUTHORED
1882|Marc Harary|Author|Climatology|Topic|AUTHORED
1882|Marc Harary|Author|Differential Privacy|Topic|AUTHORED
1882|Marc Harary|Author|Bioinformatics|Topic|AUTHORED
1882|Sensitivity Algorithms|Topic|Https://Github.Com/Marc-Harary/Sensitivity|Topic|RELATED_TO
1883|Ai/Ml Evaluations Using An Estimands Framework|Paper|Olivier Binette|Author|AUTHORED
1883|Ai/Ml Evaluations Using An Estimands Framework|Paper|Jerome P. Reiter|Author|AUTHORED
1883|Ai/Ml Evaluations Using An Estimands Framework|Paper|Estimands Framework|Topic|DISCUSSES
1883|Ai/Ml Evaluations Using An Estimands Framework|Paper|Benchmark Performance|Topic|DISCUSSES
1883|Ai/Ml Evaluations Using An Estimands Framework|Paper|Evaluation Methodologies|Topic|DISCUSSES
1884|Causal Inference With Outcomes Truncated By Death And Missing Not At Random|Paper|Wei Li|Author|AUTHORED
1884|Causal Inference With Outcomes Truncated By Death And Missing Not At Random|Paper|Yuan Liu|Author|AUTHORED
1884|Causal Inference With Outcomes Truncated By Death And Missing Not At Random|Paper|Shanshan Luo|Author|AUTHORED
1884|Causal Inference With Outcomes Truncated By Death And Missing Not At Random|Paper|Zhi Geng|Author|AUTHORED
1884|Causal Inference With Outcomes Truncated By Death And Missing Not At Random|Paper|Principal Stratification Analysis|Topic|RELATED_TO
1884|Causal Inference With Outcomes Truncated By Death And Missing Not At Random|Paper|Truncation By Death|Topic|RELATED_TO
1884|Causal Inference With Outcomes Truncated By Death And Missing Not At Random|Paper|Average Treatment Effect|Topic|RELATED_TO
1884|Causal Inference With Outcomes Truncated By Death And Missing Not At Random|Paper|Proxy Variable|Topic|RELATED_TO
1884|Causal Inference With Outcomes Truncated By Death And Missing Not At Random|Paper|Causal Parameters|Topic|RELATED_TO
1884|Causal Inference With Outcomes Truncated By Death And Missing Not At Random|Paper|Human Immunodeficiency Virus (Hiv) Study|Topic|RELATED_TO
1885|Dental Disease|Topic|Oralytics|Paper|RELATED_TO
1886|Medical Imaging Datasets|Topic|Annotations|Topic|RELATED_TO
1886|Artificial Intelligence|Topic|Annotations|Topic|RELATED_TO
1886|Totalsegmentator Method|Topic|National Lung Screening Trial|Topic|RELATED_TO
1886|Cloudsegmentatorresults|Paper|Deepa Krishnaswamy|Author|AUTHORED
1886|Cloudsegmentatorresults|Paper|Vamsi Krishna Thiriveedhi|Author|AUTHORED
1886|Cloudsegmentatorresults|Paper|Cosmin Ciausu|Author|AUTHORED
1886|Cloudsegmentatorresults|Paper|David Clunie|Author|AUTHORED
1886|Cloudsegmentatorresults|Paper|Steve Pieper|Author|AUTHORED
1886|Cloudsegmentatorresults|Paper|Ron Kikinis|Author|AUTHORED
1886|Cloudsegmentatorresults|Paper|Andrey Fedorov|Author|AUTHORED
1887|Acr: A Benchmark For Automatic Cohort Retrieval|Paper|Automatic Cohort Retrieval|Topic|RELATED_TO
1887|Acr: A Benchmark For Automatic Cohort Retrieval|Paper|Dung Ngoc Thai|Author|AUTHORED
1887|Acr: A Benchmark For Automatic Cohort Retrieval|Paper|Victor Ardulov|Author|AUTHORED
1887|Acr: A Benchmark For Automatic Cohort Retrieval|Paper|Jose Ulises Mena|Author|AUTHORED
1887|Acr: A Benchmark For Automatic Cohort Retrieval|Paper|Simran Tiwari|Author|AUTHORED
1887|Acr: A Benchmark For Automatic Cohort Retrieval|Paper|Gleb Erofeev|Author|AUTHORED
1887|Acr: A Benchmark For Automatic Cohort Retrieval|Paper|Ramy Eskander|Author|AUTHORED
1887|Acr: A Benchmark For Automatic Cohort Retrieval|Paper|Karim Tarabishy|Author|AUTHORED
1887|Acr: A Benchmark For Automatic Cohort Retrieval|Paper|Ravi B Parikh|Author|AUTHORED
1887|Acr: A Benchmark For Automatic Cohort Retrieval|Paper|Wael Salloum|Author|AUTHORED
1888|Functional Linear Regression Models|Topic|Partial Shape Constraints|Topic|RELATED_TO
1888|Partial Shape Constraints|Topic|Kernel- And Spline-Based Methods|Topic|RELATED_TO
1888|Kernel- And Spline-Based Methods|Topic|L^2-Distance|Topic|RELATED_TO
1888|Large-Sample Analysis|Topic|Finite-Sample Analysis|Topic|RELATED_TO
1888|Neurobloc|Topic|Type A-Resistant Cervical Dystonia|Topic|RELATED_TO
1888|National Institute Of Mental Health Schizophrenia Study|Topic|Partial Shape Constraints|Topic|RELATED_TO
1888|Kyunghee Han|Author|Functional Linear Regression Models|Topic|AUTHORED
1888|Yeonjoo Park|Author|Functional Linear Regression Models|Topic|AUTHORED
1888|Soo-Young Kim|Author|Functional Linear Regression Models|Topic|AUTHORED
1889|Drugclip|Topic|Drug Repurposing|Topic|RELATED_TO
1889|Yingzhou Lu|Author|Drugclip|Topic|AUTHORED
1889|Yaojun Hu|Author|Drugclip|Topic|AUTHORED
1889|Chenhao Li|Author|Drugclip|Topic|AUTHORED
1890|Mrex|Topic|Rex|Topic|RELATED_TO
1890|Mrex|Topic|D-Optimality|Topic|RELATED_TO
1890|Pál Somogyi|Author|Mrex|Topic|AUTHORED
1890|Samuel Rosa|Author|Mrex|Topic|AUTHORED
1890|Radoslav Harman|Author|Mrex|Topic|AUTHORED
1891|Preference-Based Abstract Argumentation For Case-Based Reasoning|Topic|Adam Gould|Author|AUTHORED
1891|Preference-Based Abstract Argumentation For Case-Based Reasoning|Topic|Guilherme Paulino-Passos|Author|AUTHORED
1891|Preference-Based Abstract Argumentation For Case-Based Reasoning|Topic|Seema Dadhania|Author|AUTHORED
1891|Preference-Based Abstract Argumentation For Case-Based Reasoning|Topic|Matthew Williams|Author|AUTHORED
1891|Preference-Based Abstract Argumentation For Case-Based Reasoning|Topic|Francesca Toni|Author|AUTHORED
1891|Preference-Based Abstract Argumentation For Case-Based Reasoning|Topic|Real-World Medical Dataset|Topic|RELATED_TO
1891|Real-World Medical Dataset|Topic|Clinical Trial|Topic|RELATED_TO
1891|Clinical Trial|Topic|Primary Brain Tumour|Topic|RELATED_TO
1891|Real-World Medical Dataset|Topic|Interpretable Machine Learning Models|Topic|RELATED_TO
1892|Upper Confidence Bound Approach To Estimating The Maximum Mean|Paper|Estimating The Maximum Mean|Topic|DISCUSSES
1893|Causal Inference Methods For Observational Data|Topic|Randomized Clinical Trials (Rcts)|Topic|RELATED_TO
1893|Causal Inference Methods For Observational Data|Topic|Causal Directed Acyclic Graphs (Dags)|Topic|RELATED_TO
1893|Observational Studies In Medicine|Topic|Midway Insights|Topic|RELATED_TO
1893|Midway Insights|Topic|Identification And Positivity|Topic|RELATED_TO
1893|Aneurysmal Subarachnoid Hemorrhage (Asah)|Topic|External Ventricular Drain (Evd)|Topic|RELATED_TO
1893|Multicenter Studies|Topic|Instrumental Variable (Iv) Inference|Topic|RELATED_TO
1893|Carlo Berzuini|Author|Causal Inference Methods For Observational Data|Topic|AUTHORED
1893|Davide Luciani|Author|Causal Inference Methods For Observational Data|Topic|AUTHORED
1893|Hiren C. Patel|Author|Causal Inference Methods For Observational Data|Topic|AUTHORED
1894|Aligned Nanofibers|Topic|Tissue Engineering|Topic|RELATED_TO
1894|Gayatri Patel|Author|Aligned Nanofibers|Topic|AUTHORED
1894|Louis-S. Bouchard|Author|Aligned Nanofibers|Topic|AUTHORED
1895|Learning Robust Treatment Rules For Censored Data|Paper|Yifan Cui|Author|AUTHORED
1895|Learning Robust Treatment Rules For Censored Data|Paper|Junyi Liu|Author|AUTHORED
1895|Learning Robust Treatment Rules For Censored Data|Paper|Tao Shen|Author|AUTHORED
1895|Learning Robust Treatment Rules For Censored Data|Paper|Zhengling Qi|Author|AUTHORED
1895|Learning Robust Treatment Rules For Censored Data|Paper|Xi Chen|Author|AUTHORED
1895|Learning Robust Treatment Rules For Censored Data|Paper|Censored Survival Outcomes|Topic|RELATED_TO
1895|Learning Robust Treatment Rules For Censored Data|Paper|Optimal Treatment Rules|Topic|RELATED_TO
1895|Learning Robust Treatment Rules For Censored Data|Paper|Restricted Mean Survival Time|Topic|RELATED_TO
1895|Learning Robust Treatment Rules For Censored Data|Paper|Buffered Survival Probabilities|Topic|RELATED_TO
1895|Learning Robust Treatment Rules For Censored Data|Paper|Aids Clinical Trial Data|Topic|RELATED_TO
1896|Randomized Controlled Trials|Topic|Observational Studies|Topic|RELATED_TO
1896|Randomized Controlled Trials|Topic|Analysis Of Covariance|Topic|RELATED_TO
1896|Spillover Time Series Causal|Paper|Real-World Budget-Control Experiment|Topic|DISCUSSES
1896|Real-World Budget-Control Experiment|Topic|5% Live Experiment|Topic|RELATED_TO
1896|Real-World Budget-Control Experiment|Topic|50% Live Experiment|Topic|RELATED_TO
1896|Spillover Time Series Causal|Paper|Treatment Effect|Topic|DISCUSSES
1896|Treatment Effect|Topic|Vanilla Estimation|Topic|RELATED_TO
1896|Treatment Effect|Topic|Robust Estimation|Topic|RELATED_TO
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Drug Discovery And Development|Topic|DISCUSSES
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Quantum Computing|Topic|DISCUSSES
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Yidong Zhou|Author|AUTHORED
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Jintai Chen|Author|AUTHORED
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Jinglei Cheng|Author|AUTHORED
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Gopal Karemore|Author|AUTHORED
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Marinka Zitnik|Author|AUTHORED
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Frederic T. Chong|Author|AUTHORED
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Junyu Liu|Author|AUTHORED
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Tianfan Fu|Author|AUTHORED
1897|Quantum-Machine-Assisted Drug Discovery: Survey And Perspective|Paper|Zhiding Liang|Author|AUTHORED
1898|Miwaves Reinforcement Learning Algorithm|Topic|Cannabis Use|Topic|RELATED_TO
1898|Miwaves Reinforcement Learning Algorithm|Topic|Emerging Adults|Topic|RELATED_TO
1898|Miwaves Reinforcement Learning Algorithm|Topic|Public Health Challenge|Topic|RELATED_TO
1898|Miwaves Reinforcement Learning Algorithm|Topic|Reinforcement Learning Algorithm|Topic|RELATED_TO
1898|Miwaves Reinforcement Learning Algorithm|Topic|Clinical Trial|Topic|RELATED_TO
1898|Clinical Trial|Topic|March 2024|Topic|RELATED_TO
1898|Clinical Trial|Topic|May 2024|Topic|RELATED_TO
1898|Susobhan Ghosh|Author|Miwaves Reinforcement Learning Algorithm|Topic|AUTHORED
1898|Yongyi Guo|Author|Miwaves Reinforcement Learning Algorithm|Topic|AUTHORED
1898|Pei-Yao Hung|Author|Miwaves Reinforcement Learning Algorithm|Topic|AUTHORED
1898|Lara Coughlin|Author|Miwaves Reinforcement Learning Algorithm|Topic|AUTHORED
1898|Erin Bonar|Author|Miwaves Reinforcement Learning Algorithm|Topic|AUTHORED
1898|Inbal Nahum-Shani|Author|Miwaves Reinforcement Learning Algorithm|Topic|AUTHORED
1898|Maureen Walton|Author|Miwaves Reinforcement Learning Algorithm|Topic|AUTHORED
1898|Susan Murphy|Author|Miwaves Reinforcement Learning Algorithm|Topic|AUTHORED
1899|Chasing Shadows: How Implausible Assumptions Skew Our Understanding Of Causal Estimands|Paper|Ich E9 (R1) Addendum|Topic|DISCUSSES
1899|Chasing Shadows: How Implausible Assumptions Skew Our Understanding Of Causal Estimands|Paper|Model-Free Treatment Effect Estimands|Topic|DISCUSSES
1899|Chasing Shadows: How Implausible Assumptions Skew Our Understanding Of Causal Estimands|Paper|Traditional Model-Dependent Approaches|Topic|DISCUSSES
1899|Chasing Shadows: How Implausible Assumptions Skew Our Understanding Of Causal Estimands|Paper|Stijn Vansteelandt|Author|AUTHORED
1899|Chasing Shadows: How Implausible Assumptions Skew Our Understanding Of Causal Estimands|Paper|Kelly Van Lancker|Author|AUTHORED
1900|Alzheimer'S Disease|Topic|Dementia|Topic|RELATED_TO
1900|Convolutional Neural Networks|Topic|Mri Scans|Topic|DISCUSSES
1900|Synthetic Minority Oversampling Technique|Topic|Class Imbalance|Topic|DISCUSSES
1900|Demned Dementia Network|Topic|Alzheimer'S Disease|Topic|DISCUSSES
1900|Sajjad Aghasi Javid|Author|Deep Learning Model|Topic|AUTHORED
1900|Mahmood Mohassel Feghhi|Author|Deep Learning Model|Topic|AUTHORED
1900|Deep Learning Model|Topic|Accuracy Of 98.67%|Topic|DISCUSSES
1901|Estimating Interpretable Heterogeneous Treatment Effect With Causal Subgroup Discovery In Survival Outcomes|Paper|Na Bo|Author|AUTHORED
1901|Estimating Interpretable Heterogeneous Treatment Effect With Causal Subgroup Discovery In Survival Outcomes|Paper|Ying Ding|Author|AUTHORED
1901|Estimating Interpretable Heterogeneous Treatment Effect With Causal Subgroup Discovery In Survival Outcomes|Paper|Heterogeneous Treatment Effect|Topic|DISCUSSES
1901|Estimating Interpretable Heterogeneous Treatment Effect With Causal Subgroup Discovery In Survival Outcomes|Paper|Survival Outcomes|Topic|DISCUSSES
1901|Estimating Interpretable Heterogeneous Treatment Effect With Causal Subgroup Discovery In Survival Outcomes|Paper|Age-Related Macular Degeneration|Topic|DISCUSSES
1902|Binary Emax Model|Topic|Dose-Response Analysis|Topic|RELATED_TO
1902|Dose-Response Analysis|Topic|Drug Development|Topic|RELATED_TO
1902|Nonignorable Missing Binary Responses|Topic|Non-Responder Imputation|Topic|RELATED_TO
1902|Nonignorable Missing Binary Responses|Topic|Separation|Topic|RELATED_TO
1902|Penalized Likelihood-Based Method|Topic|Expectation-Maximization Algorithm|Topic|RELATED_TO
1902|Penalized Likelihood-Based Method|Topic|Noninformative Jeffreys Prior|Topic|RELATED_TO
1902|Penalized Likelihood-Based Method|Topic|Parameter Estimation|Topic|RELATED_TO
1902|Penalized Likelihood-Based Method|Topic|Nri|Topic|RELATED_TO
1902|Penalized Likelihood-Based Method|Topic|Phase Ii Clinical Trial|Topic|RELATED_TO
1902|Ememax|Topic|Penalized Likelihood-Based Method|Topic|RELATED_TO
1902|Jiangshan Zhang|Author|Penalized Likelihood-Based Method|Topic|AUTHORED
1902|Vivek Pradhan|Author|Penalized Likelihood-Based Method|Topic|AUTHORED
1902|Yuxi Zhao|Author|Penalized Likelihood-Based Method|Topic|AUTHORED
1903|Nonparametric Tests Of Treatment Effect Homogeneity For Policy-Makers|Paper|Oliver Dukes|Author|AUTHORED
1903|Nonparametric Tests Of Treatment Effect Homogeneity For Policy-Makers|Paper|Mats J. Stensrud|Author|AUTHORED
1903|Nonparametric Tests Of Treatment Effect Homogeneity For Policy-Makers|Paper|Riccardo Brioschi|Author|AUTHORED
1903|Nonparametric Tests Of Treatment Effect Homogeneity For Policy-Makers|Paper|Aaron Hudson|Author|AUTHORED
1904|Digital Twins In Healthcare|Topic|Hugo Chenel|Author|AUTHORED
1904|Digital Twins In Healthcare|Topic|Malvina Marku|Author|AUTHORED
1904|Digital Twins In Healthcare|Topic|Tim James|Author|AUTHORED
1904|Digital Twins In Healthcare|Topic|Andrei Zinovyev|Author|AUTHORED
1904|Digital Twins In Healthcare|Topic|Vera Pancaldi|Author|AUTHORED
1905|Crossover Design|Topic|Salil Koner|Author|AUTHORED
1905|Crossover Design|Topic|Clinical Trials|Topic|RELATED_TO
1905|Crossover Design|Topic|Ab-Ba Design|Topic|RELATED_TO
1905|Crossover Design|Topic|Higher-Order Designs|Topic|RELATED_TO
1905|Crossover Design|Topic|Statistical Inference Methods|Topic|RELATED_TO
1905|Crossover Design|Topic|Multivariate And Categorical Responses|Topic|RELATED_TO
1905|Crossover Design|Topic|Open Problems|Topic|RELATED_TO
1907|Cdsampling|Topic|Yifei Huang|Author|AUTHORED
1907|Cdsampling|Topic|Liping Tong|Author|AUTHORED
1907|Cdsampling|Topic|Jie Yang|Author|AUTHORED
1908|Rapiddock|Topic|Molecular Docking|Topic|RELATED_TO
1908|Rapiddock|Topic|Drug Discovery|Topic|RELATED_TO
1908|Rapiddock|Topic|Posebusters|Topic|RELATED_TO
1908|Rapiddock|Topic|Dockgen|Topic|RELATED_TO
1908|Bazyli Klockiewicz|Author|Rapiddock|Topic|AUTHORED
1908|Bartosz Topolski|Author|Rapiddock|Topic|AUTHORED
1908|Dariusz Plewczynski|Author|Rapiddock|Topic|AUTHORED
1909|Anti-Tuberculosis Drugs|Topic|Degree-Based Topological Indices|Topic|RELATED_TO
1909|Anti-Tuberculosis Drugs|Topic|Distance Based Indices|Topic|RELATED_TO
1909|Anti-Tuberculosis Drugs|Topic|Molecular Graph|Topic|RELATED_TO
1909|Anti-Tuberculosis Drugs|Topic|Quantitative Structure-Property Relationship (Qspr)|Topic|RELATED_TO
1909|D. C. Gunawardhana|Author|Novel Approach For Computing Distance Based Indices Of Anti-Tuberculosis Drugs|Paper|AUTHORED
1909|G. H. J. Lanel|Author|Novel Approach For Computing Distance Based Indices Of Anti-Tuberculosis Drugs|Paper|AUTHORED
1909|K. K. K. R. Perera|Author|Novel Approach For Computing Distance Based Indices Of Anti-Tuberculosis Drugs|Paper|AUTHORED
1909|A. G. M. J. Gunaratna|Author|Novel Approach For Computing Distance Based Indices Of Anti-Tuberculosis Drugs|Paper|AUTHORED
1910|Antibody Drug|Topic|Biotechnology|Topic|RELATED_TO
1910|Monoclonal Antibody|Topic|Energy-Based Generative Models|Topic|RELATED_TO
1910|Paul Pereira|Author|Energy-Based Generative Models|Topic|AUTHORED
1910|Hervé Minoux|Author|Energy-Based Generative Models|Topic|AUTHORED
1910|Aleksandra M. Walczak|Author|Energy-Based Generative Models|Topic|AUTHORED
1910|Thierry Mora|Author|Energy-Based Generative Models|Topic|AUTHORED
1911|Multi-Regional Clinical Trial (Mrct)|Topic|Fda Guidance "Demonstrating Substantial Evidence Of Effectiveness For Human Drug And Biological Products Guidance For Industry"|Topic|RELATED_TO
1911|Kunhai Qing|Author|Multi-Regional Clinical Trial (Mrct)|Topic|AUTHORED
1911|Xinru Ren|Author|Multi-Regional Clinical Trial (Mrct)|Topic|AUTHORED
1911|Jin Xu|Author|Multi-Regional Clinical Trial (Mrct)|Topic|AUTHORED
1912|Storm: Strategic Orchestration Of Modalities For Rare Event Classification|Paper|Biomedical|Topic|RELATED_TO
1912|Storm: Strategic Orchestration Of Modalities For Rare Event Classification|Paper|Artificial Intelligence|Topic|RELATED_TO
1912|Storm: Strategic Orchestration Of Modalities For Rare Event Classification|Paper|Multi-Modal Learning|Topic|RELATED_TO
1912|Storm: Strategic Orchestration Of Modalities For Rare Event Classification|Paper|Entropy-Based Algorithm|Topic|RELATED_TO
1912|Storm: Strategic Orchestration Of Modalities For Rare Event Classification|Paper|Seizure Onset Zone Detection|Topic|RELATED_TO
1913|Patient Weighted While-Alive Estimand|Topic|Alessandra Ragni|Author|AUTHORED
1913|Patient Weighted While-Alive Estimand|Topic|Torben Martinussen|Author|AUTHORED
1913|Patient Weighted While-Alive Estimand|Topic|Thomas Scheike|Author|AUTHORED
1914|Aspire|Topic|Information Retrieval|Topic|RELATED_TO
1914|Aspire|Topic|Trec Clinical Trials|Topic|RELATED_TO
1914|Georgios Peikos|Author|Aspire|Topic|AUTHORED
1914|Wojciech Kusa|Author|Aspire|Topic|AUTHORED
1914|Symeon Symeonidis|Author|Aspire|Topic|AUTHORED
1915|Denoising Data With Measurement Error Using A Reproducing Kernel-Based Diffusion Model|Paper|Mingyang Yi|Author|AUTHORED
1915|Denoising Data With Measurement Error Using A Reproducing Kernel-Based Diffusion Model|Paper|Marcos Matabuena|Author|AUTHORED
1915|Denoising Data With Measurement Error Using A Reproducing Kernel-Based Diffusion Model|Paper|Ruoyu Wang|Author|AUTHORED
1916|Eog Communication Interface For Quadriplegics: Prototype & Signal Processing|Paper|Aniket Raj|Author|AUTHORED
1916|Eog Communication Interface For Quadriplegics: Prototype & Signal Processing|Paper|Amit Kumar|Author|AUTHORED
1916|Electrooculography|Topic|Human Tracking Interfaces|Topic|RELATED_TO
1916|Eog Communication Interface For Quadriplegics: Prototype & Signal Processing|Paper|Quadriplegic Patients|Topic|RELATED_TO
1916|Eog Communication Interface For Quadriplegics: Prototype & Signal Processing|Paper|Assistive Technology|Topic|RELATED_TO
1916|Esp32 Board|Topic|Eog Communication Interface For Quadriplegics: Prototype & Signal Processing|Paper|RELATED_TO
1917|Contextual Bandit Problem|Topic|Private Context Misreporting|Topic|RELATED_TO
1917|Yiting Hu|Author|Private Context Misreporting|Topic|AUTHORED
1917|Lingjie Duan|Author|Private Context Misreporting|Topic|AUTHORED
1917|Adaptive Clinical Trials|Topic|Private Context Misreporting|Topic|RELATED_TO
1917|Ucb Family Algorithms|Topic|Private Context Misreporting|Topic|RELATED_TO
1917|Thompson Sampling|Topic|Private Context Misreporting|Topic|RELATED_TO
1917|Explore-Then-Commit (Etc)|Topic|Private Context Misreporting|Topic|RELATED_TO
1917|Epsilon-Greedy Algorithm|Topic|Private Context Misreporting|Topic|RELATED_TO
1917|Linear Program|Topic|Private Context Misreporting|Topic|RELATED_TO
1917|Frequentist Regret|Topic|Private Context Misreporting|Topic|RELATED_TO
1917|Numerical Experiments|Topic|Private Context Misreporting|Topic|RELATED_TO
1918|Interpretable Model|Topic|Interpretability|Topic|RELATED_TO
1918|Interpretability|Topic|Functional Skeleton|Topic|RELATED_TO
1918|Functional Skeleton|Topic|Mallows'S C_P-Statistic|Topic|RELATED_TO
1918|Mallows'S C_P-Statistic|Topic|Adaptive Clinical Trial Designs|Topic|RELATED_TO
1918|Adaptive Clinical Trial Designs|Topic|Bayesian Go/No-Go Paradigm|Topic|RELATED_TO
1918|Bayesian Go/No-Go Paradigm|Topic|Fisher'S Exact Test|Topic|RELATED_TO
1918|Fisher'S Exact Test|Topic|Nhanes|Topic|RELATED_TO
1918|Tianyu Zhan|Author|Functional Skeleton|Topic|AUTHORED
1918|Jian Kang|Author|Functional Skeleton|Topic|AUTHORED
1919|Randomized Controlled Trials|Topic|Causal Inference|Topic|RELATED_TO
1919|Observational Studies|Topic|Causal Inference|Topic|RELATED_TO
1919|Estimand Of Interest|Topic|Ideal Trial|Topic|RELATED_TO
1919|Target Trial Framework|Topic|Observational Studies|Topic|RELATED_TO
1919|Respiratory Epidemiology|Topic|Target Trial Framework|Topic|RELATED_TO
1919|Margarita Moreno-Betancur|Author|Ideal Trial|Topic|AUTHORED
1919|Rushani Wijesuriya|Author|Ideal Trial|Topic|AUTHORED
1919|John B. Carlin|Author|Ideal Trial|Topic|AUTHORED
1920|Overtreatment Of Early-Stage Low-Risk Prostate Cancer Patients|Topic|Genetic And Molecular Markers|Topic|RELATED_TO
1920|Genetic And Molecular Markers|Topic|Gene Expression Signature|Topic|RELATED_TO
1920|Gene Expression Signature|Topic|Lethal Prostate Cancer|Topic|RELATED_TO
1920|Lethal Prostate Cancer|Topic|Biopsy Specimens|Topic|RELATED_TO
1920|Gleason 6 Tumors|Topic|98-Genes Ges|Topic|RELATED_TO
1920|Gleason 7 Tumors|Topic|98-Genes Ges|Topic|RELATED_TO
1920|Swedish Watchful Waiting Cohort|Topic|98-Genes Ges|Topic|RELATED_TO
1920|98-Genes Ges|Topic|Death Events|Topic|RELATED_TO
1920|98-Genes Ges|Topic|Malignant Field Effect|Topic|RELATED_TO
1920|Clinical Trial|Topic|Diagnostic And Prognostic Tests|Topic|RELATED_TO
1920|Diagnostic And Prognostic Tests|Topic|Active Surveillance Programs|Topic|RELATED_TO
1920|Gennadi Glinsky|Author|98-Genes Ges|Topic|AUTHORED
1921|Patient-Specific 3D Volumetric Reconstruction Of Bioresorbable Stents: A Method To Generate 3D Geometries For Computational Analysis Of Coronaries Treated With Bioresorbable Stents|Paper|Boyi Yang|Author|AUTHORED
1921|Patient-Specific 3D Volumetric Reconstruction Of Bioresorbable Stents: A Method To Generate 3D Geometries For Computational Analysis Of Coronaries Treated With Bioresorbable Stents|Paper|Marina Piccinelli|Author|AUTHORED
1921|Patient-Specific 3D Volumetric Reconstruction Of Bioresorbable Stents: A Method To Generate 3D Geometries For Computational Analysis Of Coronaries Treated With Bioresorbable Stents|Paper|Gaetano Esposito|Author|AUTHORED
1921|Patient-Specific 3D Volumetric Reconstruction Of Bioresorbable Stents: A Method To Generate 3D Geometries For Computational Analysis Of Coronaries Treated With Bioresorbable Stents|Paper|Tianli Han|Author|AUTHORED
1921|Patient-Specific 3D Volumetric Reconstruction Of Bioresorbable Stents: A Method To Generate 3D Geometries For Computational Analysis Of Coronaries Treated With Bioresorbable Stents|Paper|Yasir Bouchi|Author|AUTHORED
1921|Patient-Specific 3D Volumetric Reconstruction Of Bioresorbable Stents: A Method To Generate 3D Geometries For Computational Analysis Of Coronaries Treated With Bioresorbable Stents|Paper|Bill Gogas|Author|AUTHORED
1921|Patient-Specific 3D Volumetric Reconstruction Of Bioresorbable Stents: A Method To Generate 3D Geometries For Computational Analysis Of Coronaries Treated With Bioresorbable Stents|Paper|Don Giddens|Author|AUTHORED
1921|Patient-Specific 3D Volumetric Reconstruction Of Bioresorbable Stents: A Method To Generate 3D Geometries For Computational Analysis Of Coronaries Treated With Bioresorbable Stents|Paper|Habib Samady|Author|AUTHORED
1921|Patient-Specific 3D Volumetric Reconstruction Of Bioresorbable Stents: A Method To Generate 3D Geometries For Computational Analysis Of Coronaries Treated With Bioresorbable Stents|Paper|Alessandro Veneziani|Author|AUTHORED
1921|Computational Fluid Dynamics|Topic|Bioresorbable Vascular Stents|Topic|RELATED_TO
1922|Pico|Topic|Clinical Question|Topic|RELATED_TO
1922|Deep Learning Model|Topic|Pico|Topic|RELATED_TO
1922|Deep Learning Model|Topic|Biomedical Abstracts|Topic|RELATED_TO
1922|Bidirectional Long-Short Term Memory|Topic|Deep Learning Model|Topic|RELATED_TO
1922|Conditional Random Field|Topic|Deep Learning Model|Topic|RELATED_TO
1922|Adversarial Training|Topic|Deep Learning Model|Topic|RELATED_TO
1922|Unsupervised Pre-Training|Topic|Deep Learning Model|Topic|RELATED_TO
1922|Pubmed-Pico Dataset|Topic|Deep Learning Model|Topic|RELATED_TO
1922|Nicta-Piboso|Topic|Deep Learning Model|Topic|RELATED_TO
1922|Di Jin|Author|Deep Learning Model|Topic|AUTHORED
1922|Peter Szolovits|Author|Deep Learning Model|Topic|AUTHORED
1923|Lung Nodule Detection And Cancer Prediction|Topic|Long Short-Term Memory (Lstm)|Topic|RELATED_TO
1923|Long Short-Term Memory (Lstm)|Topic|Distanced Lstm (Dlstm)|Topic|RELATED_TO
1923|Distanced Lstm (Dlstm)|Topic|Temporal Emphasis Model (Tem)|Topic|RELATED_TO
1923|Distanced Lstm (Dlstm)|Topic|National Lung Screening Trial (Nlst)|Topic|RELATED_TO
1923|Distanced Lstm (Dlstm)|Topic|Riqiang Gao|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Yuankai Huo|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Shunxing Bao|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Yucheng Tang|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Sanja L. Antic|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Emily S. Epstein|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Aneri B. Balar|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Steve Deppen|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Alexis B. Paulson|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Kim L. Sandler|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Pierre P. Massion|Author|AUTHORED
1923|Distanced Lstm (Dlstm)|Topic|Bennett A. Landman|Author|AUTHORED
1924|A Precision Medicine Approach To Develop And Internally Validate Optimal Exercise And Weight Loss Treatments For Overweight And Obese Adults With Knee Osteoarthritis|Paper|Idea|Topic|DISCUSSES
1924|Idea|Topic|Knee Osteoarthritis|Topic|RELATED_TO
1925|Fetal Heart Rate (Fhr) Temporal Dynamics|Topic|Cardiovascular Decompensation (Cvd)|Topic|RELATED_TO
1925|Animal Model Of Human Labor|Topic|Near-Term Ovine Fetuses|Topic|RELATED_TO
1925|Near-Term Ovine Fetuses|Topic|Umbilical Cord Occlusions (Uco)|Topic|RELATED_TO
1925|Umbilical Cord Occlusions (Uco)|Topic|Metabolites|Topic|RELATED_TO
1925|Umbilical Cord Occlusions (Uco)|Topic|Ph|Topic|RELATED_TO
1925|Umbilical Cord Occlusions (Uco)|Topic|Electrocardiogram (Ecg)|Topic|RELATED_TO
1925|Umbilical Cord Occlusions (Uco)|Topic|Systemic Arterial Blood Pressure|Topic|RELATED_TO
1925|Fhr Variability Features|Topic|Cardiovascular Decompensation (Cvd)|Topic|RELATED_TO
1925|Self-Referencing Metric|Topic|Cardiovascular Decompensation (Cvd)|Topic|RELATED_TO
1925|Stéphane G. Roux|Author|Cardiovascular Decompensation (Cvd)|Topic|AUTHORED
1925|Nicolas B. Garnier|Author|Cardiovascular Decompensation (Cvd)|Topic|AUTHORED
1925|Patrice Abry|Author|Cardiovascular Decompensation (Cvd)|Topic|AUTHORED
1925|Nathan Gold|Author|Cardiovascular Decompensation (Cvd)|Topic|AUTHORED
1925|Martin G. Frasch|Author|Cardiovascular Decompensation (Cvd)|Topic|AUTHORED
1926|Chatgpt-4|Topic|Radiation Oncology|Topic|RELATED_TO
1926|Chatgpt-3.5|Topic|Radiation Oncology|Topic|RELATED_TO
1926|Chatgpt-4|Topic|Acr Radiation Oncology In-Training Exam|Topic|DISCUSSES
1926|Chatgpt-4|Topic|Red Journal Gray Zone Cases|Topic|DISCUSSES
1926|Yixing Huang|Author|Chatgpt-4|Topic|AUTHORED
1926|Ahmed Gomaa|Author|Chatgpt-4|Topic|AUTHORED
1926|Sabine Semrau|Author|Chatgpt-4|Topic|AUTHORED
1926|Marlen Haderlein|Author|Chatgpt-4|Topic|AUTHORED
1926|Sebastian Lettmaier|Author|Chatgpt-4|Topic|AUTHORED
1926|Thomas Weissmann|Author|Chatgpt-4|Topic|AUTHORED
1926|Johanna Grigo|Author|Chatgpt-4|Topic|AUTHORED
1926|Hassen Ben Tkhayat|Author|Chatgpt-4|Topic|AUTHORED
1926|Benjamin Frey|Author|Chatgpt-4|Topic|AUTHORED
1926|Udo S. Gaipl|Author|Chatgpt-4|Topic|AUTHORED
1926|Luitpold V. Distel|Author|Chatgpt-4|Topic|AUTHORED
1926|Andreas Maier|Author|Chatgpt-4|Topic|AUTHORED
1926|Rainer Fietkau|Author|Chatgpt-4|Topic|AUTHORED
1926|Christoph Bert|Author|Chatgpt-4|Topic|AUTHORED
1926|Florian Putz|Author|Chatgpt-4|Topic|AUTHORED
1927|Theia|Topic|Diabetic Retinopathy|Topic|RELATED_TO
1927|Theia|Topic|New Zealand Diabetic Screening Programme|Topic|RELATED_TO
1927|Multi-Center Prospective Study|Topic|Theia|Topic|AUTHORED
1927|Ehsan Vaghefi|Author|Multi-Center Prospective Study|Topic|AUTHORED
1927|Song Yang|Author|Multi-Center Prospective Study|Topic|AUTHORED
1927|Li Xie|Author|Multi-Center Prospective Study|Topic|AUTHORED
1927|David Han|Author|Multi-Center Prospective Study|Topic|AUTHORED
1927|David Squirrell|Author|Multi-Center Prospective Study|Topic|AUTHORED
1928|Decision Curve Analysis|Topic|Personalized Model|Topic|DISCUSSES
1928|Personalized Model|Topic|Treatment Options|Topic|DISCUSSES
1928|Treatment Options|Topic|Network Meta-Analysis (Nma)|Topic|DISCUSSES
1928|Network Meta-Analysis (Nma)|Topic|Relapsing-Remitting Multiple Sclerosis|Topic|DISCUSSES
1928|Relapsing-Remitting Multiple Sclerosis|Topic|Natalizumab|Topic|RELATED_TO
1928|Relapsing-Remitting Multiple Sclerosis|Topic|Dimethyl Fumarate|Topic|RELATED_TO
1928|Relapsing-Remitting Multiple Sclerosis|Topic|Glatiramer Acetate|Topic|RELATED_TO
1928|Relapsing-Remitting Multiple Sclerosis|Topic|Placebo|Topic|RELATED_TO
1928|Konstantina Chalkou|Author|Decision Curve Analysis|Topic|AUTHORED
1928|Andrew J. Vickers|Author|Decision Curve Analysis|Topic|AUTHORED
1928|Fabio Pellegrini|Author|Decision Curve Analysis|Topic|AUTHORED
1928|Andrea Manca|Author|Decision Curve Analysis|Topic|AUTHORED
1928|Georgia Salanti|Author|Decision Curve Analysis|Topic|AUTHORED
1929|Traumatic Brain Injury|Topic|Neuroinflammation|Topic|RELATED_TO
1929|Traumatic Brain Injury|Topic|Neurodegeneration|Topic|RELATED_TO
1929|64 Adult Patients|Paper|Neuroimaging Biomarker Of Extracellular Free Water Content|Topic|DISCUSSES
1929|64 Adult Patients|Paper|Chronic Neurological Complications|Topic|DISCUSSES
1929|64 Adult Patients|Paper|Long-Term Disability|Topic|DISCUSSES
1929|64 Adult Patients|Paper|Biomarkers|Topic|DISCUSSES
1929|64 Adult Patients|Paper|Clinical Trials Of Neuroprotective Therapies|Topic|DISCUSSES
1930|Large Medical Imaging Data Sets|Topic|Sample Quality|Topic|RELATED_TO
1930|Sample Quality|Topic|Artefacts|Topic|RELATED_TO
1930|Machine Learning Models|Topic|Clinical Research|Topic|RELATED_TO
1930|Framework|Topic|Artefact Generators|Topic|RELATED_TO
1930|Artefact Generators|Topic|Brain Mri Scans|Topic|RELATED_TO
1930|Brain Mri Scans|Topic|Training Dataset|Topic|RELATED_TO
1930|Abstract And Engineered Features|Topic|Images|Topic|RELATED_TO
1930|Feature Selection Process|Topic|Artefact Class|Topic|RELATED_TO
1930|Svm Classifiers|Topic|Artefacts|Topic|RELATED_TO
1930|Synthetic Brain Mri Scans|Topic|Data Augmentation|Topic|RELATED_TO
1930|Multiple Sclerosis Clinical Trial|Topic|Real Artefacts|Topic|RELATED_TO
1930|Daniele Ravi|Author|Framework|Topic|AUTHORED
1930|Frederik Barkhof|Author|Framework|Topic|AUTHORED
1930|Daniel C. Alexander|Author|Framework|Topic|AUTHORED
1930|Lemuel Puglisi|Author|Framework|Topic|AUTHORED
1930|Geoffrey Jm Parker|Author|Framework|Topic|AUTHORED
1930|Arman Eshaghi|Author|Framework|Topic|AUTHORED
1931|Qdm Methods|Topic|Study Level|Topic|RELATED_TO
1931|Qdm Methods|Topic|Project Level|Topic|RELATED_TO
1931|Qdm Methods|Topic|Portfolio Level|Topic|RELATED_TO
1931|Special Interest Group On Qdm|Topic|Qdm Methods|Topic|RELATED_TO
1931|Implementation And Practical Aspects Of Quantitative Decision-Making In Clinical Drug Development|Paper|Juan J. Abellan|Author|AUTHORED
1931|Implementation And Practical Aspects Of Quantitative Decision-Making In Clinical Drug Development|Paper|Nicolas Bonnet|Author|AUTHORED
1931|Implementation And Practical Aspects Of Quantitative Decision-Making In Clinical Drug Development|Paper|Alex Carlton|Author|AUTHORED
1931|Implementation And Practical Aspects Of Quantitative Decision-Making In Clinical Drug Development|Paper|Paul Frewer|Author|AUTHORED
1931|Implementation And Practical Aspects Of Quantitative Decision-Making In Clinical Drug Development|Paper|Heiko Götte|Author|AUTHORED
1931|Implementation And Practical Aspects Of Quantitative Decision-Making In Clinical Drug Development|Paper|John-Philip Lawo|Author|AUTHORED
1931|Implementation And Practical Aspects Of Quantitative Decision-Making In Clinical Drug Development|Paper|Jesper Madsen|Author|AUTHORED
1931|Implementation And Practical Aspects Of Quantitative Decision-Making In Clinical Drug Development|Paper|Oliver Sailer|Author|AUTHORED
1931|Implementation And Practical Aspects Of Quantitative Decision-Making In Clinical Drug Development|Paper|Guido Thömmes|Author|AUTHORED
1931|Implementation And Practical Aspects Of Quantitative Decision-Making In Clinical Drug Development|Paper|Gaëlle Saint-Hilary|Author|AUTHORED
1932|Thorium-227-Based Alpha-Particle Radiopharmaceutical Therapies|Topic|Thorium-227|Topic|RELATED_TO
1932|Thorium-227-Based Alpha-Particle Radiopharmaceutical Therapies|Topic|Radium-223|Topic|RELATED_TO
1932|Spect|Topic|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|DISCUSSES
1932|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|Thorium-227|Topic|DISCUSSES
1932|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|Radium-223|Topic|DISCUSSES
1932|Zekun Li|Author|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|AUTHORED
1932|Nadia Benabdallah|Author|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|AUTHORED
1932|Richard Laforest|Author|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|AUTHORED
1932|Richard L. Wahl|Author|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|AUTHORED
1932|Daniel L. J. Thorek|Author|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|AUTHORED
1932|Abhinav K. Jha|Author|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|AUTHORED
1932|Prostate Cancer|Topic|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|DISCUSSES
1932|Bone Metastases|Topic|Multiple-Energy-Window Projection-Domain Quantification (Mew-Pdq) Method|Topic|DISCUSSES
1933|Flash Or Ultra-High Dose Rate (Uhdr) Radiation Therapy|Topic|Conventional Dose Rate (Cdr) Rt|Topic|RELATED_TO
1933|Electron Flash Units|Topic|Allison Palmiero|Author|AUTHORED
1933|Electron Flash Units|Topic|Kevin Liu|Author|AUTHORED
1933|Electron Flash Units|Topic|Julie Colnot|Author|AUTHORED
1933|Electron Flash Units|Topic|Nitish Chopra|Author|AUTHORED
1933|Electron Flash Units|Topic|Denae Neill|Author|AUTHORED
1933|Electron Flash Units|Topic|Luke Connell|Author|AUTHORED
1933|Electron Flash Units|Topic|Brett Velasquez|Author|AUTHORED
1933|Electron Flash Units|Topic|Albert C. Koong|Author|AUTHORED
1933|Electron Flash Units|Topic|Steven H. Lin|Author|AUTHORED
1933|Electron Flash Units|Topic|Peter Balter|Author|AUTHORED
1933|Electron Flash Units|Topic|Ramesh Tailor|Author|AUTHORED
1933|Electron Flash Units|Topic|Charlotte Robert|Author|AUTHORED
1933|Electron Flash Units|Topic|Jean-François Germond|Author|AUTHORED
1933|Electron Flash Units|Topic|Patrik Gonçalves Jorge|Author|AUTHORED
1933|Electron Flash Units|Topic|Reiner Geyer|Author|AUTHORED
1933|Electron Flash Units|Topic|Sam Beddar|Author|AUTHORED
1933|Electron Flash Units|Topic|Raphael Moeckli|Author|AUTHORED
1933|Electron Flash Units|Topic|Emil Schüler|Author|AUTHORED
1934|Abdomenatlas|Topic|Wenxuan Li|Author|AUTHORED
1934|Abdomenatlas|Topic|Chongyu Qu|Author|AUTHORED
1934|Abdomenatlas|Topic|Xiaoxi Chen|Author|AUTHORED
1934|Abdomenatlas|Topic|Pedro R. A. S. Bassi|Author|AUTHORED
1934|Abdomenatlas|Topic|Yijia Shi|Author|AUTHORED
1934|Abdomenatlas|Topic|Yuxiang Lai|Author|AUTHORED
1934|Abdomenatlas|Topic|Qian Yu|Author|AUTHORED
1934|Abdomenatlas|Topic|Huimin Xue|Author|AUTHORED
1934|Abdomenatlas|Topic|Yixiong Chen|Author|AUTHORED
1934|Abdomenatlas|Topic|Xiaorui Lin|Author|AUTHORED
1934|Abdomenatlas|Topic|Yutong Tang|Author|AUTHORED
1934|Abdomenatlas|Topic|Yining Cao|Author|AUTHORED
1934|Abdomenatlas|Topic|Haoqi Han|Author|AUTHORED
1934|Abdomenatlas|Topic|Zheyuan Zhang|Author|AUTHORED
1934|Abdomenatlas|Topic|Jiawei Liu|Author|AUTHORED
1934|Abdomenatlas|Topic|Tiezheng Zhang|Author|AUTHORED
1934|Abdomenatlas|Topic|Yujiu Ma|Author|AUTHORED
1934|Abdomenatlas|Topic|Jincheng Wang|Author|AUTHORED
1934|Abdomenatlas|Topic|Guang Zhang|Author|AUTHORED
1934|Abdomenatlas|Topic|Alan Yuille|Author|AUTHORED
1934|Abdomenatlas|Topic|Zongwei Zhou|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Qiao Jin|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Nicholas Wan|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Robert Leaman|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Shubo Tian|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Zhizheng Wang|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Yifan Yang|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Zifeng Wang|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Guangzhi Xiong|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Po-Ting Lai|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Qingqing Zhu|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Benjamin Hou|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Maame Sarfo-Gyamfi|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Gongbo Zhang|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Aidan Gilson|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Balu Bhasuran|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Zhe He|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Aidong Zhang|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Jimeng Sun|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Chunhua Weng|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Ronald M. Summers|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Qingyu Chen|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Yifan Peng|Author|AUTHORED
1935|Demystifying Large Language Models For Medicine: A Primer|Paper|Zhiyong Lu|Author|AUTHORED
1936|A Paradigm Shift In Neuroscience Driven By Big Data: State Of Art, Challenges, And Proof Of Concept|Paper|Zi-Xuan Zhou|Author|AUTHORED
1936|A Paradigm Shift In Neuroscience Driven By Big Data: State Of Art, Challenges, And Proof Of Concept|Paper|Xi-Nian Zuo|Author|AUTHORED
1936|Cognitive Neuroscience|Topic|Population Neuroscience|Topic|RELATED_TO
1937|Computer Systems|Topic|Computer Security|Topic|RELATED_TO
1937|Human Immune System|Topic|Computer Security|Topic|RELATED_TO
1937|Danger Theory|Topic|Artificial Immune Systems|Topic|RELATED_TO
1937|Danger Theory|Topic|Intrusion Detection Systems|Topic|RELATED_TO
1937|Intrusion Detection Systems|Topic|Computer Security|Topic|RELATED_TO
1937|Detecting Danger: Applying A Novel Immunological Concept To Intrusion Detection Systems|Paper|Julie Greensmith|Author|AUTHORED
1937|Detecting Danger: Applying A Novel Immunological Concept To Intrusion Detection Systems|Paper|Uwe Aickelin|Author|AUTHORED
1937|Detecting Danger: Applying A Novel Immunological Concept To Intrusion Detection Systems|Paper|Jamie Twycross|Author|AUTHORED
1938|Simple Derivation Of The Gompertz Law For Human Mortality|Topic|Gompertz Law Of Dependence Of Human Mortality Rate On Age|Topic|RELATED_TO
1938|B. I. Shklovskii|Author|Simple Derivation Of The Gompertz Law For Human Mortality|Topic|AUTHORED
1938|Model Of Death As A Result Of The Exponentially Rare Escape Of Abnormal Cells From Immunological Response|Topic|Gompertz Law Of Dependence Of Human Mortality Rate On Age|Topic|DISCUSSES
1939|An Immune System Inspired Approach To Automated Program Verification|Paper|Artificial Immune System (Ais)|Topic|DISCUSSES
1939|An Immune System Inspired Approach To Automated Program Verification|Paper|Automated Program Verification|Topic|DISCUSSES
1939|An Immune System Inspired Approach To Automated Program Verification|Paper|Program Invariants|Topic|DISCUSSES
1939|An Immune System Inspired Approach To Automated Program Verification|Paper|Benchmark Programs|Topic|DISCUSSES
1940|Pathogen|Topic|N|Topic|RELATED_TO
1940|Biological Parameters|Topic|Partial Order|Topic|RELATED_TO
1940|Partial Order|Topic|Immune Regulation|Topic|RELATED_TO
1940|Immune Regulation|Topic|Asymptotically Stable Fixed Point|Topic|RELATED_TO
1940|Host Response|Topic|Pathogen|Topic|RELATED_TO
1940|Edgar Delgado-Eckert|Author|Host Response|Topic|AUTHORED
1940|Michael Shapiro|Author|Host Response|Topic|AUTHORED
1941|Additive, Multiplicative, And Odd Ratio Neutral Models|Topic|Jorge Fernandez-De-Cossio|Author|AUTHORED
1941|Additive, Multiplicative, And Odd Ratio Neutral Models|Topic|Jorge Fernandez-De-Cossio-Diaz|Author|AUTHORED
1941|Additive, Multiplicative, And Odd Ratio Neutral Models|Topic|Toshifumi Takao|Author|AUTHORED
1941|Additive, Multiplicative, And Odd Ratio Neutral Models|Topic|Yasser Perera|Author|AUTHORED
1942|Ectil|Topic|Computational Til Assessment (Cta)|Topic|RELATED_TO
1942|Ectil|Topic|Triple-Negative Breast Cancer (Bc)|Topic|RELATED_TO
1942|Yoni Schirris|Author|Ectil|Topic|AUTHORED
1942|Rosie Voorthuis|Author|Ectil|Topic|AUTHORED
1942|Mark Opdam|Author|Ectil|Topic|AUTHORED
1942|Marte Liefaard|Author|Ectil|Topic|AUTHORED
1942|Gabe S Sonke|Author|Ectil|Topic|AUTHORED
1942|Gwen Dackus|Author|Ectil|Topic|AUTHORED
1942|Vincent De Jong|Author|Ectil|Topic|AUTHORED
1942|Yuwei Wang|Author|Ectil|Topic|AUTHORED
1942|Annelot Van Rossum|Author|Ectil|Topic|AUTHORED
1942|Tessa G Steenbruggen|Author|Ectil|Topic|AUTHORED
1942|Lars C Steggink|Author|Ectil|Topic|AUTHORED
1942|Liesbeth G. E. De Vries|Author|Ectil|Topic|AUTHORED
1942|Marc Van De Vijver|Author|Ectil|Topic|AUTHORED
1942|Roberto Salgado|Author|Ectil|Topic|AUTHORED
1942|Efstratios Gavves|Author|Ectil|Topic|AUTHORED
1942|Paul J Van Diest|Author|Ectil|Topic|AUTHORED
1942|Sabine C Linn|Author|Ectil|Topic|AUTHORED
1942|Jonas Teuwen|Author|Ectil|Topic|AUTHORED
1942|Renee Menezes|Author|Ectil|Topic|AUTHORED
1942|Marleen Kok|Author|Ectil|Topic|AUTHORED
1942|Hugo Horlings|Author|Ectil|Topic|AUTHORED
1943|Prostate Biopsies|Topic|Artificial Intelligence|Topic|RELATED_TO
1943|Artificial Intelligence|Topic|Sthlm3 Diagnostic Study|Topic|RELATED_TO
1943|Peter Ström|Author|Prostate Biopsies|Topic|AUTHORED
1943|Kimmo Kartasalo|Author|Prostate Biopsies|Topic|AUTHORED
1943|Henrik Olsson|Author|Prostate Biopsies|Topic|AUTHORED
1943|Leslie Solorzano|Author|Prostate Biopsies|Topic|AUTHORED
1943|Brett Delahunt|Author|Prostate Biopsies|Topic|AUTHORED
1943|Daniel M. Berney|Author|Prostate Biopsies|Topic|AUTHORED
1943|David G. Bostwick|Author|Prostate Biopsies|Topic|AUTHORED
1943|Andrew J. Evans|Author|Prostate Biopsies|Topic|AUTHORED
1943|David J. Grignon|Author|Prostate Biopsies|Topic|AUTHORED
1943|Peter A. Humphrey|Author|Prostate Biopsies|Topic|AUTHORED
1943|Kenneth A. Iczkowski|Author|Prostate Biopsies|Topic|AUTHORED
1943|James G. Kench|Author|Prostate Biopsies|Topic|AUTHORED
1943|Glen Kristiansen|Author|Prostate Biopsies|Topic|AUTHORED
1943|Theodorus H. Van Der Kwast|Author|Prostate Biopsies|Topic|AUTHORED
1943|Katia R. M. Leite|Author|Prostate Biopsies|Topic|AUTHORED
1943|Jesse K. Mckenney|Author|Prostate Biopsies|Topic|AUTHORED
1943|Jon Oxley|Author|Prostate Biopsies|Topic|AUTHORED
1943|Chin-Chen Pan|Author|Prostate Biopsies|Topic|AUTHORED
1943|Hemamali Samaratunga|Author|Prostate Biopsies|Topic|AUTHORED
1943|John R. Srigley|Author|Prostate Biopsies|Topic|AUTHORED
1943|Hiroyuki Takahashi|Author|Prostate Biopsies|Topic|AUTHORED
1943|Toyonori Tsuzuki|Author|Prostate Biopsies|Topic|AUTHORED
1943|Murali Varma|Author|Prostate Biopsies|Topic|AUTHORED
1943|Ming Zhou|Author|Prostate Biopsies|Topic|AUTHORED
1943|Johan Lindberg|Author|Prostate Biopsies|Topic|AUTHORED
1943|Cecilia Bergström|Author|Prostate Biopsies|Topic|AUTHORED
1943|Pekka Ruusuvuori|Author|Prostate Biopsies|Topic|AUTHORED
1943|Carolina Wählby|Author|Prostate Biopsies|Topic|AUTHORED
1943|Henrik Grönberg|Author|Prostate Biopsies|Topic|AUTHORED
1943|Mattias Rantalainen|Author|Prostate Biopsies|Topic|AUTHORED
1943|Lars Egevad|Author|Prostate Biopsies|Topic|AUTHORED
1943|Martin Eklund|Author|Prostate Biopsies|Topic|AUTHORED
1944|Support Surface Translation Study|Paper|Vision|Topic|DISCUSSES
1944|Support Surface Translation Study|Paper|Low-Frequency Range|Topic|RELATED_TO
1944|Support Surface Translation Study|Paper|Mid-Frequency Range|Topic|RELATED_TO
1944|Support Surface Translation Study|Paper|High-Frequency Range|Topic|RELATED_TO
1944|Support Surface Translation Study|Paper|Single Inverted Pendulum Model|Topic|RELATED_TO
1944|Support Surface Translation Study|Paper|Double Inverted Pendulum Model|Topic|RELATED_TO
1944|Support Surface Translation Study|Paper|Eyes Closed Condition|Topic|RELATED_TO
1944|Support Surface Translation Study|Paper|Stroboscopic Illumination Condition|Topic|RELATED_TO
1944|Support Surface Translation Study|Paper|Eyes Open Continuous Illumination Condition|Topic|RELATED_TO
1945|Recurrent Neural Networks|Topic|Time-Series Data|Topic|RELATED_TO
1945|Recurrent Neural Networks|Topic|Machine Learning Community|Topic|RELATED_TO
1945|Recurrent Neural Networks|Topic|Neuroscience Community|Topic|RELATED_TO
1945|Recurrent Neural Networks|Topic|Switching Linear Dynamical System|Topic|RELATED_TO
1945|Switching Linear Dynamical System|Topic|First-Order Taylor Series Expansion|Topic|RELATED_TO
1945|Switching Linear Dynamical System|Topic|Auxiliary Function|Topic|RELATED_TO
1945|Recurrent Neural Networks|Topic|Synthetic Tasks|Topic|RELATED_TO
1945|Recurrent Neural Networks|Topic|Lfads|Topic|RELATED_TO
1945|Jimmy T. H. Smith|Author|Recurrent Neural Networks|Topic|AUTHORED
1945|Scott W. Linderman|Author|Recurrent Neural Networks|Topic|AUTHORED
1945|David Sussillo|Author|Recurrent Neural Networks|Topic|AUTHORED
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Rabia Gondur|Author|AUTHORED
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Usama Bin Sikandar|Author|AUTHORED
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Evan Schaffer|Author|AUTHORED
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Mikio Christian Aoi|Author|AUTHORED
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Stephen L Keeley|Author|AUTHORED
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Gaussian Process Factor Analysis|Topic|RELATED_TO
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Gaussian Process Variational Autoencoders|Topic|RELATED_TO
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Drosophila Whole-Brain Calcium Imaging|Topic|RELATED_TO
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Manduca Sexta Spike Train Measurements|Topic|RELATED_TO
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Poisson Spike Counts|Topic|RELATED_TO
1946|Multi-Modal Gaussian Process Variational Autoencoders For Neural And Behavioral Data|Paper|Mnist Images|Topic|RELATED_TO
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|Pressure Ulcers|Topic|DISCUSSES
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|Tongue Display Unit-Tdu|Topic|DISCUSSES
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|Spinal Cord Injuries|Topic|DISCUSSES
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|A. Moreau-Gaudry|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|O. Chenu|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|M. Dang|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|J. L. Bosson|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|M. Hommel|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|J. Demongeot|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|F. Cannard|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|B. Diot|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|A. Prince|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|C. Hughes|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|Nicolas Vuillerme|Author|AUTHORED
1947|Reduction Of Prolonged Excessive Pressure In Seated Persons With Paraplegia Using Wireless Lingual Tactile Feedback: A Randomized Controlled Trial|Paper|Yohan Payan|Author|AUTHORED
1948|Precision Medicine|Topic|Individualized Treatment Regime (Itr)|Topic|RELATED_TO
1948|Crossover Study Design|Topic|Individualized Treatment Regime (Itr)|Topic|RELATED_TO
1948|Estimating Individualized Treatment Regimes From Crossover Designs|Paper|Crossover Study Design|Topic|DISCUSSES
1948|Estimating Individualized Treatment Regimes From Crossover Designs|Paper|Precision Medicine|Topic|DISCUSSES
1949|Concentration Of Benefit Index|Topic|Mohsen Sadatsafavi|Author|AUTHORED
1949|Concentration Of Benefit Index|Topic|Mohammad Ali Mansournia|Author|AUTHORED
1949|Concentration Of Benefit Index|Topic|Paul Gustafson|Author|AUTHORED
1950|Drug Development Programs|Topic|Early Stage Clinical Trials|Topic|RELATED_TO
1950|Expert Judgements|Topic|Sheffield Elicitation Framework (Shelf)|Topic|RELATED_TO
1950|Sheffield Elicitation Framework (Shelf)|Topic|Asthma Drug|Topic|RELATED_TO
1950|Björn Holzhauer|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1950|Lisa V. Hampson|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1950|John Paul Gosling|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1950|Björn Bornkamp|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1950|Joseph Kahn|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1950|Markus R. Lange|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1950|Wen-Lin Luo|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1950|Caterina Brindicci|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1950|David Lawrence|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1950|Steffen Ballerstedt|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1950|Anthony O'Hagan|Author|Eliciting Judgements About Dependent Quantities Of Interest: The Shelf Extension And Copula Methods Illustrated Using An Asthma Case Study|Paper|AUTHORED
1951|Large Language Models|Topic|Radiation Oncology Physics|Topic|RELATED_TO
1951|Radiation Oncology Physics|Topic|Mayo Clinic|Topic|RELATED_TO
1951|Chatgpt (Gpt-3.5)|Author|Radiation Oncology Physics|Topic|RELATED_TO
1951|Chatgpt (Gpt-4)|Author|Radiation Oncology Physics|Topic|RELATED_TO
1951|Bard (Lamda)|Author|Radiation Oncology Physics|Topic|RELATED_TO
1951|Bloomz|Author|Radiation Oncology Physics|Topic|RELATED_TO
1951|Jason Holmes|Author|Large Language Models|Topic|AUTHORED
1951|Zhengliang Liu|Author|Large Language Models|Topic|AUTHORED
1951|Lian Zhang|Author|Large Language Models|Topic|AUTHORED
1951|Yuzhen Ding|Author|Large Language Models|Topic|AUTHORED
1951|Terence T. Sio|Author|Large Language Models|Topic|AUTHORED
1951|Lisa A. Mcgee|Author|Large Language Models|Topic|AUTHORED
1951|Jonathan B. Ashman|Author|Large Language Models|Topic|AUTHORED
1951|Xiang Li|Author|Large Language Models|Topic|AUTHORED
1951|Tianming Liu|Author|Large Language Models|Topic|AUTHORED
1951|Jiajian Shen|Author|Large Language Models|Topic|AUTHORED
1951|Wei Liu|Author|Large Language Models|Topic|AUTHORED
1952|Adaptive Resistance To Genetic-Based Targeted Therapies|Topic|Solid Malignancies|Topic|RELATED_TO
1952|Braf-Mutated Melanoma|Topic|Braf Inhibition|Topic|RELATED_TO
1952|Single-Cell Proteomic Level|Topic|Co-Targeted Hub/Pathways|Topic|RELATED_TO
1952|Hur|Topic|Perk|Topic|RELATED_TO
1952|Hur|Topic|Egfr|Topic|RELATED_TO
1952|Aurore Bugi-Marteyn|Author|Mutual Information (Mi)|Topic|AUTHORED
1952|Fanny Noulet|Author|Mutual Information (Mi)|Topic|AUTHORED
1952|Nicolas Liaudet|Author|Mutual Information (Mi)|Topic|AUTHORED
1952|Rastine Merat|Author|Mutual Information (Mi)|Topic|AUTHORED
1953|Cluster Randomized Trials|Topic|Causal Effects|Topic|RELATED_TO
1953|Causal Effects|Topic|Estimators|Topic|RELATED_TO
1953|Estimators|Topic|Tmle|Topic|RELATED_TO
1953|Preterm Birth Initiative|Topic|Estimators|Topic|RELATED_TO
1953|Alejandra Benitez|Author|Defining And Estimating Effects In Cluster Randomized Trials: A Methods Comparison|Paper|AUTHORED
1953|Maya L. Petersen|Author|Defining And Estimating Effects In Cluster Randomized Trials: A Methods Comparison|Paper|AUTHORED
1953|Mark J. Van Der Laan|Author|Defining And Estimating Effects In Cluster Randomized Trials: A Methods Comparison|Paper|AUTHORED
1953|Nicole Santos|Author|Defining And Estimating Effects In Cluster Randomized Trials: A Methods Comparison|Paper|AUTHORED
1953|Elizabeth Butrick|Author|Defining And Estimating Effects In Cluster Randomized Trials: A Methods Comparison|Paper|AUTHORED
1953|Dilys Walker|Author|Defining And Estimating Effects In Cluster Randomized Trials: A Methods Comparison|Paper|AUTHORED
1953|Rakesh Ghosh|Author|Defining And Estimating Effects In Cluster Randomized Trials: A Methods Comparison|Paper|AUTHORED
1953|Phelgona Otieno|Author|Defining And Estimating Effects In Cluster Randomized Trials: A Methods Comparison|Paper|AUTHORED
1953|Peter Waiswa|Author|Defining And Estimating Effects In Cluster Randomized Trials: A Methods Comparison|Paper|AUTHORED
1953|Laura B. Balzer|Author|Defining And Estimating Effects In Cluster Randomized Trials: A Methods Comparison|Paper|AUTHORED
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Elizabeth A. Handorf|Author|AUTHORED
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|J. Robert Beck|Author|AUTHORED
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Andres Correa|Author|AUTHORED
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Chethan Ramamurthy|Author|AUTHORED
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Daniel M. Geynisman|Author|AUTHORED
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Metastatic Prostate Cancer|Topic|RELATED_TO
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Microsimulation Framework|Topic|RELATED_TO
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Discrete-Time State Transition Model|Topic|RELATED_TO
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Docetaxel|Topic|RELATED_TO
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Abiraterone Acetate|Topic|RELATED_TO
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Quality-Adjusted Life Years|Topic|RELATED_TO
1954|Cost-Effectiveness Analysis For Therapy Sequence In Advanced Cancer: A Microsimulation Approach With Application To Metastatic Prostate Cancer|Paper|Incremental Cost Effectiveness Ratio|Topic|RELATED_TO
1955|Diagnostic Errors In Radiology|Topic|Radiologists|Topic|RELATED_TO
1955|Eye-Tracking Technology|Topic|Suspicious Pulmonary Nodules|Topic|RELATED_TO
1955|Automated Feedback-Driven Educational Framework|Topic|Suspicious Pulmonary Nodules|Topic|RELATED_TO
1955|Carolina Ramirez-Tamayo|Author|Automated Feedback-Driven Educational Framework|Topic|AUTHORED
1955|Syed Hasib Akhter Faruqui|Author|Automated Feedback-Driven Educational Framework|Topic|AUTHORED
1955|Stanford Martinez|Author|Automated Feedback-Driven Educational Framework|Topic|AUTHORED
1955|Angel Brisco|Author|Automated Feedback-Driven Educational Framework|Topic|AUTHORED
1955|Nicholas Czarnek|Author|Automated Feedback-Driven Educational Framework|Topic|AUTHORED
1955|Adel Alaeddini|Author|Automated Feedback-Driven Educational Framework|Topic|AUTHORED
1955|Jeffrey R. Mock|Author|Automated Feedback-Driven Educational Framework|Topic|AUTHORED
1955|Edward J. Golob|Author|Automated Feedback-Driven Educational Framework|Topic|AUTHORED
1955|Kal L. Clark|Author|Automated Feedback-Driven Educational Framework|Topic|AUTHORED
1956|Item-Level Heterogeneous Treatment Effects Of Selective Serotonin Reuptake Inhibitors (Ssris) On Depression: Implications For Inference, Generalizability, And Identification|Paper|Item Response Theory (Irt)|Topic|DISCUSSES
1956|Item-Level Heterogeneous Treatment Effects Of Selective Serotonin Reuptake Inhibitors (Ssris) On Depression: Implications For Inference, Generalizability, And Identification|Paper|Selective Serotonin Reuptake Inhibitors (Ssris)|Topic|DISCUSSES
1956|Item-Level Heterogeneous Treatment Effects Of Selective Serotonin Reuptake Inhibitors (Ssris) On Depression: Implications For Inference, Generalizability, And Identification|Paper|Depression|Topic|DISCUSSES
1956|Item-Level Heterogeneous Treatment Effects Of Selective Serotonin Reuptake Inhibitors (Ssris) On Depression: Implications For Inference, Generalizability, And Identification|Paper|Monte Carlo Simulation|Topic|DISCUSSES
1956|Item-Level Heterogeneous Treatment Effects Of Selective Serotonin Reuptake Inhibitors (Ssris) On Depression: Implications For Inference, Generalizability, And Identification|Paper|17-Item Hamilton Depression Rating Scale (Hdrs-17)|Topic|DISCUSSES
1956|Item-Level Heterogeneous Treatment Effects Of Selective Serotonin Reuptake Inhibitors (Ssris) On Depression: Implications For Inference, Generalizability, And Identification|Paper|Hdrs-6|Topic|DISCUSSES
1957|Alzheimer'S Disease|Topic|Cognitive Decline|Topic|RELATED_TO
1957|Predictive Models|Topic|Cognitive Test Scores|Topic|RELATED_TO
1957|Hiroyuki Sato|Author|Japanese Alzheimer'S Disease Neuroimaging Initiative|Author|AUTHORED
1957|Keisuke Suzuki|Author|Japanese Alzheimer'S Disease Neuroimaging Initiative|Author|AUTHORED
1957|Atsushi Hashizume|Author|Japanese Alzheimer'S Disease Neuroimaging Initiative|Author|AUTHORED
1957|Ryoichi Hanazawa|Author|Japanese Alzheimer'S Disease Neuroimaging Initiative|Author|AUTHORED
1957|Masanao Sasaki|Author|Japanese Alzheimer'S Disease Neuroimaging Initiative|Author|AUTHORED
1957|Akihiro Hirakawa|Author|Japanese Alzheimer'S Disease Neuroimaging Initiative|Author|AUTHORED
1957|Alzheimer'S Disease Neuroimaging Initiative|Author|Longitudinal Disease Progression|Topic|RELATED_TO
1957|Randomized Controlled Trial Design|Topic|Longitudinal Disease Progression|Topic|RELATED_TO
1958|Data Format Standardization And Dicom Integration For Hyperpolarized 13C Mri|Paper|Hyperpolarized 13C Mri|Topic|DISCUSSES
1959|Octcube-M|Topic|Octcube|Topic|RELATED_TO
1959|Octcube-M|Topic|Coep|Topic|RELATED_TO
1959|Octcube-M|Topic|Octcube-Ir|Topic|RELATED_TO
1959|Octcube-M|Topic|Octcube-Ef|Topic|RELATED_TO
1959|Octcube-M|Topic|Zixuan Liu|Author|AUTHORED
1959|Octcube-M|Topic|Hanwen Xu|Author|AUTHORED
1959|Octcube-M|Topic|Addie Woicik|Author|AUTHORED
1959|Octcube-M|Topic|Linda G. Shapiro|Author|AUTHORED
1959|Octcube-M|Topic|Marian Blazes|Author|AUTHORED
1959|Octcube-M|Topic|Yue Wu|Author|AUTHORED
1959|Octcube-M|Topic|Verena Steffen|Author|AUTHORED
1959|Octcube-M|Topic|Catherine Cukras|Author|AUTHORED
1959|Octcube-M|Topic|Cecilia S. Lee|Author|AUTHORED
1959|Octcube-M|Topic|Miao Zhang|Author|AUTHORED
1959|Octcube-M|Topic|Aaron Y. Lee|Author|AUTHORED
1959|Octcube-M|Topic|Sheng Wang|Author|AUTHORED
1960|Immuno-Inspired Robotic Applications|Paper|Ali Raza|Author|AUTHORED
1960|Immuno-Inspired Robotic Applications|Paper|Benito R. Fernandez|Author|AUTHORED
1960|Artificial Immune Systems|Topic|Biological Immune Functions|Topic|RELATED_TO
1960|Artificial Immune Systems|Topic|Robotic Applications|Topic|RELATED_TO
1960|Ais-Based Robotic Applications|Topic|Antigen|Topic|RELATED_TO
1960|Ais-Based Robotic Applications|Topic|Co-Stimulatory Signal|Topic|RELATED_TO
1960|Ais-Based Robotic Applications|Topic|Immune Functions|Topic|RELATED_TO
1960|Immune Functions|Topic|Evolved Antibodies|Topic|RELATED_TO
1960|Immune Functions|Topic|Maturity Of Dendritic Cells|Topic|RELATED_TO
1960|Maturity Of Dendritic Cells|Topic|Actuation Signals|Topic|RELATED_TO
1960|Immuno-Inspired Robotic Applications|Paper|Innate Immunity|Topic|RELATED_TO
1960|Immuno-Inspired Robotic Applications|Paper|Robot Embodiment|Topic|RELATED_TO
1960|Immuno-Inspired Robotic Applications|Paper|Modern Trends|Topic|RELATED_TO
1961|Immunological Self/Not-Self Discrimination|Topic|T Cells|Topic|RELATED_TO
1961|Immunological Self/Not-Self Discrimination|Topic|Major Histocompatibility Complex Proteins|Topic|RELATED_TO
1961|Immunological Self/Not-Self Discrimination|Topic|Pmhcs|Topic|RELATED_TO
1961|Donald R. Forsdyke|Author|Lymphocyte Repertoire Selection|Topic|AUTHORED
1961|Donald R. Forsdyke|Author|Intracellular Self/Not-Self Discrimination|Topic|AUTHORED
1961|Immunological Self/Not-Self Discrimination|Topic|Pyrexia|Topic|RELATED_TO
1961|Immunological Self/Not-Self Discrimination|Topic|Female Susceptibility To Autoimmune Disease|Topic|RELATED_TO
1962|Muscular Dystrophy|Topic|Mathematical Models Of Md|Topic|DISCUSSES
1962|Mathematical Models Of Md|Topic|Systems Biology Approach|Topic|RELATED_TO
1962|Amanda N. Cameron|Author|Mathematical Models Of Md|Topic|AUTHORED
1962|Matthew T. Houston|Author|Mathematical Models Of Md|Topic|AUTHORED
1962|Juan B. Gutierrez|Author|Mathematical Models Of Md|Topic|AUTHORED
1963|Immunological Systems|Topic|Computer Scientists|Topic|RELATED_TO
1963|Computer Scientists|Topic|Monroy, Saab, Godinez, 2004|Paper|DISCUSSES
1963|Immune Memory|Topic|Vaccines|Topic|RELATED_TO
1963|Immune Memory|Topic|Antigenic Mutation|Topic|RELATED_TO
1963|Alexandre De Castro|Author|Lundegaard, Lund, Kesmir, Brunak, Nielsen, 2007|Paper|AUTHORED
1963|Carlos Frederico Fronza|Author|Lundegaard, Lund, Kesmir, Brunak, Nielsen, 2007|Paper|AUTHORED
1963|Domingos Alves|Author|Lundegaard, Lund, Kesmir, Brunak, Nielsen, 2007|Paper|AUTHORED
1964|The Human Body|Topic|Immune System|Topic|RELATED_TO
1964|Immune System|Topic|Immunology|Topic|RELATED_TO
1964|Immunology|Topic|Computer Network Security|Topic|RELATED_TO
1964|Computer Network Security|Topic|New Network Security Model|Topic|RELATED_TO
1964|New Network Security Model|Topic|Lans|Topic|RELATED_TO
1964|New Network Security Model|Topic|Datalink Layer|Topic|RELATED_TO
1964|New Network Security Model|Topic|Foreign Frames|Topic|RELATED_TO
1964|Almotasem Bellah Alajlouni|Author|Exploring The Potential Of The Innate Immune System For Computers Network Security|Paper|AUTHORED
1965|Adaptive Immune System|Topic|Antigens|Topic|RELATED_TO
1965|Adaptive Immune System|Topic|Antigen-Binding Antibodies|Topic|RELATED_TO
1965|Adaptive Immune System|Topic|T-Cell Receptors|Topic|RELATED_TO
1965|Adaptive Immune System|Topic|Immune Repertoire|Topic|RELATED_TO
1965|Immune Repertoire|Topic|Disease|Topic|RELATED_TO
1965|Immune Repertoire|Topic|Infection|Topic|RELATED_TO
1965|Immune Repertoire|Topic|Autoimmunity|Topic|RELATED_TO
1965|Immune Repertoire|Topic|Cancer|Topic|RELATED_TO
1965|Immune Repertoire|Topic|Hiv|Topic|RELATED_TO
1965|Airr-Seq|Topic|Immune Receptor Sequence Landscape|Topic|RELATED_TO
1965|Airr-Seq|Topic|Computational And Statistical Analysis|Topic|RELATED_TO
1965|Airr-Seq|Topic|Large-Scale Airr-Seq Data|Topic|RELATED_TO
1965|Adaptive Immunity|Topic|Diversity|Topic|RELATED_TO
1965|Adaptive Immunity|Topic|Clustering And Network|Topic|RELATED_TO
1965|Adaptive Immunity|Topic|Phylogenetic Methods|Topic|RELATED_TO
1965|Adaptive Immunity|Topic|Machine Learning Methods|Topic|RELATED_TO
1965|Computational Immunology|Topic|Systems Immunology|Topic|RELATED_TO
1965|Systems Immunology|Topic|Immunotherapeutics|Topic|RELATED_TO
1965|Systems Immunology|Topic|Vaccines|Topic|RELATED_TO
1965|Systems Immunology|Topic|Immunodiagnostics|Topic|RELATED_TO
1965|Enkelejda Miho|Author|Adaptive Immune System|Topic|AUTHORED
1965|Alexander Yermanos|Author|Adaptive Immune System|Topic|AUTHORED
1965|Cédric R. Weber|Author|Adaptive Immune System|Topic|AUTHORED
1965|Christoph T. Berger|Author|Adaptive Immune System|Topic|AUTHORED
1965|Sai T. Reddy|Author|Adaptive Immune System|Topic|AUTHORED
1965|Victor Greiff|Author|Adaptive Immune System|Topic|AUTHORED
1966|Computational Implementation Of Clonal Selection Principle|Paper|Clonal Selection Principle|Topic|DISCUSSES
1966|Computational Implementation Of Clonal Selection Principle|Paper|Adaptive Immune Response|Topic|DISCUSSES
1966|Computational Implementation Of Clonal Selection Principle|Paper|Affinity Maturation|Topic|DISCUSSES
1966|Computational Implementation Of Clonal Selection Principle|Paper|Immunological Memory Cells|Topic|DISCUSSES
1966|Computational Implementation Of Clonal Selection Principle|Paper|Coronary Heart Disease Database|Topic|DISCUSSES
1966|Computational Implementation Of Clonal Selection Principle|Paper|Takumi Ichimura|Author|AUTHORED
1966|Computational Implementation Of Clonal Selection Principle|Paper|Shin Kamada|Author|AUTHORED
1967|Dengue Virus|Topic|Dengue Hemorrhagic Fever (Dhf)|Topic|RELATED_TO
1967|Cross-Reactive Antibodies|Topic|Dengue Hemorrhagic Fever (Dhf)|Topic|RELATED_TO
1967|Multi-Scale Modeling Approach|Topic|Within-Host Model|Topic|RELATED_TO
1967|Within-Host Model|Topic|Epidemiological Spread|Topic|RELATED_TO
1967|Vector-Host Partial Differential Equation Model|Topic|Epidemiological Spread|Topic|RELATED_TO
1967|Primary Infection|Topic|Secondary Infections|Topic|RELATED_TO
1967|Immunological Variables|Topic|Epidemiological Spread|Topic|RELATED_TO
1967|Hayriye Gulbudak|Author|Multi-Scale Modeling Approach|Topic|AUTHORED
1967|Cameron J. Browne|Author|Multi-Scale Modeling Approach|Topic|AUTHORED
1968|Computational And Systems Biology Advances To Enable Bioagent-Agnostic Signatures|Paper|Andy Lin|Author|AUTHORED
1968|Computational And Systems Biology Advances To Enable Bioagent-Agnostic Signatures|Paper|Cameron Torres|Author|AUTHORED
1968|Computational And Systems Biology Advances To Enable Bioagent-Agnostic Signatures|Paper|Errett C. Hobbs|Author|AUTHORED
1968|Computational And Systems Biology Advances To Enable Bioagent-Agnostic Signatures|Paper|Jaydeep Bardhan|Author|AUTHORED
1968|Computational And Systems Biology Advances To Enable Bioagent-Agnostic Signatures|Paper|Stephen B. Aley|Author|AUTHORED
1968|Computational And Systems Biology Advances To Enable Bioagent-Agnostic Signatures|Paper|Charles T. Spencer|Author|AUTHORED
1968|Computational And Systems Biology Advances To Enable Bioagent-Agnostic Signatures|Paper|Karen L. Taylor|Author|AUTHORED
1968|Computational And Systems Biology Advances To Enable Bioagent-Agnostic Signatures|Paper|Tony Chiang|Author|AUTHORED
1969|Cognitive Tasks|Topic|Interference|Topic|RELATED_TO
1969|Visual Working Memory Tasks|Topic|Interference|Topic|RELATED_TO
1969|Probabilistic Inference Model|Topic|Interference|Topic|RELATED_TO
1969|Recurrent Network|Topic|Probabilistic Inference Model|Topic|RELATED_TO
1969|Zachary P Kilpatrick|Author|Probabilistic Inference Model|Topic|AUTHORED
1970|Necrotizing Enterocolitis Surgery Trial|Paper|Generalizability Analyses With A Partially Nested Trial Design|Topic|DISCUSSES
1970|Necrotizing Enterocolitis Surgery Trial|Paper|Partially Nested Trial Design|Topic|RELATED_TO
1970|Necrotizing Enterocolitis Surgery Trial|Paper|Randomized Individuals|Topic|RELATED_TO
1970|Necrotizing Enterocolitis Surgery Trial|Paper|Non-Randomized Individuals|Topic|RELATED_TO
1971|Trial Engagement Effects|Topic|Randomized Trial|Topic|RELATED_TO
1971|Trial Engagement Effects|Topic|Generalizability|Topic|RELATED_TO
1971|Trial Engagement Effects|Topic|Transportability|Topic|RELATED_TO
1971|Average Treatment Effects|Topic|Randomized Trial|Topic|RELATED_TO
1971|Lawson Ung|Author|Randomized Trial|Topic|AUTHORED
1971|Tyler J. Vanderweele|Author|Randomized Trial|Topic|AUTHORED
1971|Issa J. Dahabreh|Author|Randomized Trial|Topic|AUTHORED
1972|Radiomics|Topic|Framework|Topic|RELATED_TO
1972|Automated Machine Learning|Topic|Framework|Topic|RELATED_TO
1972|Clinical Applications|Topic|Framework|Topic|RELATED_TO
1972|Framework|Topic|Authors|Author|AUTHORED
1972|Liposarcoma|Topic|Clinical Applications|Topic|RELATED_TO
1972|Desmoid-Type Fibromatosis|Topic|Clinical Applications|Topic|RELATED_TO
1972|Primary Liver Tumors|Topic|Clinical Applications|Topic|RELATED_TO
1972|Gastrointestinal Stromal Tumors|Topic|Clinical Applications|Topic|RELATED_TO
1972|Colorectal Liver Metastases|Topic|Clinical Applications|Topic|RELATED_TO
1972|Melanoma Metastases|Topic|Clinical Applications|Topic|RELATED_TO
1972|Hepatocellular Carcinoma|Topic|Clinical Applications|Topic|RELATED_TO
1972|Mesenteric Fibrosis|Topic|Clinical Applications|Topic|RELATED_TO
1972|Prostate Cancer|Topic|Clinical Applications|Topic|RELATED_TO
1972|Glioma|Topic|Clinical Applications|Topic|RELATED_TO
1972|Alzheimer'S Disease|Topic|Clinical Applications|Topic|RELATED_TO
1972|Head And Neck Cancer|Topic|Clinical Applications|Topic|RELATED_TO
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Alzheimer'S Disease|Topic|RELATED_TO
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Razvan V. Marinescu|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Neil P. Oxtoby|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Alexandra L. Young|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Esther E. Bron|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Arthur W. Toga|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Michael W. Weiner|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Frederik Barkhof|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Nick C. Fox|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Arman Eshaghi|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Tina Toni|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Marcin Salaterski|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Veronika Lunina|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Manon Ansart|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Stanley Durrleman|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Pascal Lu|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Samuel Iddi|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Dan Li|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Wesley K. Thompson|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Michael C. Donohue|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Aviv Nahon|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Yarden Levy|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Dan Halbersberg|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Mariya Cohen|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Huiling Liao|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Tengfei Li|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Kaixian Yu|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Hongtu Zhu|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Jose G. Tamez-Pena|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Aya Ismail|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Timothy Wood|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Hector Corrada Bravo|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Minh Nguyen|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Nanbo Sun|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Jiashi Feng|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|B. T. Thomas Yeo|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Gang Chen|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Ke Qi|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Shiyang Chen|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Deqiang Qiu|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Ionut Buciuman|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Alex Kelner|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Raluca Pop|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Denisa Rimocea|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Mostafa M. Ghazi|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Mads Nielsen|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Sebastien Ourselin|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Lauge Sorensen|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Vikram Venkatraghavan|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Keli Liu|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Christina Rabe|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Paul Manser|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Steven M. Hill|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|James Howlett|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Zhiyue Huang|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Steven Kiddle|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Sach Mukherjee|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Anais Rouanet|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Bernd Taschler|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Brian D. M. Tom|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Simon R. White|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Noel Faux|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Suman Sedai|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Javier De Velasco Oriol|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Edgar E. V. Clemente|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Karol Estrada|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Leon Aksman|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Andre Altmann|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Cynthia M. Stonnington|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Yalin Wang|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Jianfeng Wu|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Vivek Devadas|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Clementine Fourrier|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Lars Lau Raket|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Aristeidis Sotiras|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Guray Erus|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Jimit Doshi|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Christos Davatzikos|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Jacob Vogel|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Andrew Doyle|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Angela Tam|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Alex Diaz-Papkovich|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Emmanuel Jammeh|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Igor Koval|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Paul Moore|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Terry J. Lyons|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|John Gallacher|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Jussi Tohka|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Robert Ciszek|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Bruno Jedynak|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Kruti Pandya|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Murat Bilgel|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|William Engels|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Joseph Cole|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Polina Golland|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Stefan Klein|Author|AUTHORED
1973|The Alzheimer'S Disease Prediction Of Longitudinal Evolution Challenge|Topic|Daniel C. Alexander|Author|AUTHORED
1974|Radiotherapy For Head And Neck Cancer|Topic|Dysphagia|Topic|RELATED_TO
1974|Dysphagia|Topic|Pharyngeal Mucosa|Topic|RELATED_TO
1974|3D Dose Distributions|Topic|Pharyngeal Mucosa|Topic|RELATED_TO
1974|Predictive Modelling|Topic|Dysphagia|Topic|RELATED_TO
1974|Support Vector Classification Model|Topic|Dysphagia|Topic|RELATED_TO
1974|Dicom Data|Topic|3D Dose Distributions|Topic|RELATED_TO
1974|Numpy|Topic|3D Dose Distributions|Topic|RELATED_TO
1974|Scipy|Topic|3D Dose Distributions|Topic|RELATED_TO
1974|Pandas|Topic|Predictive Modelling|Topic|RELATED_TO
1974|Scikit-Learn|Topic|Predictive Modelling|Topic|RELATED_TO
1974|Matplotlib|Topic|3D Dose Distributions|Topic|RELATED_TO
1974|Mayavi|Topic|3D Dose Distributions|Topic|RELATED_TO
1974|Jamie A. Dean|Author|Predictive Modelling|Topic|AUTHORED
1974|Liam C. Welsh|Author|Predictive Modelling|Topic|AUTHORED
1974|Kevin J. Harrington|Author|Predictive Modelling|Topic|AUTHORED
1974|Christopher M. Nutting|Author|Predictive Modelling|Topic|AUTHORED
1974|Sarah L. Gulliford|Author|Predictive Modelling|Topic|AUTHORED
1975|Monte Carlo-Based Biological Dose Optimization|Topic|H. Wan Chan Tseung|Author|AUTHORED
1975|Monte Carlo-Based Biological Dose Optimization|Topic|J. Ma|Author|AUTHORED
1975|Monte Carlo-Based Biological Dose Optimization|Topic|C. R. Kreofsky|Author|AUTHORED
1975|Monte Carlo-Based Biological Dose Optimization|Topic|D. Ma|Author|AUTHORED
1975|Monte Carlo-Based Biological Dose Optimization|Topic|C. Beltran|Author|AUTHORED
1976|Artemisinin Resistance|Topic|Malaria|Topic|RELATED_TO
1976|Artemisinin-Based Drugs|Topic|Malaria|Topic|RELATED_TO
1976|Dihydroartemisinin (Dha)|Topic|Artemisinin-Based Drugs|Topic|RELATED_TO
1976|Plasmodium Falciparum|Topic|Artemisinin-Based Drugs|Topic|RELATED_TO
1976|Pengxing Cao|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1976|Nectarios Klonis|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1976|Sophie Zaloumis|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1976|Con Dogovski|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1976|Stanley C. Xie|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1976|Sompob Saralamba|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1976|Lisa J. White|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1976|Freya J. I. Fowkes|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1976|Leann Tilley|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1976|Julie A. Simpson|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1976|James M. Mccaw|Author|A Dynamic Stress Model Explains The Delayed Drug Effect In Artemisinin Treatment Of Plasmodium Falciparum|Paper|AUTHORED
1977|Gynaecologists And Obstetricians|Topic|Cardiotocography (Ctg)|Topic|DISCUSSES
1977|Cardiotocography (Ctg)|Topic|International Federation Of Gynaecology And Obstetrics (Figo)|Topic|RELATED_TO
1977|Machine Learning Models|Topic|Positive Predictive Value|Topic|DISCUSSES
1977|Synthetic Data|Topic|Machine Learning Models|Topic|RELATED_TO
1977|One Dimensional Convolutional Neural Network (1Dcnn)|Topic|Multilayer Perceptron (Mlp) Ensemble|Topic|RELATED_TO
1977|Modelling Segmented Cardiotocography Time-Series Signals Using One-Dimensional Convolutional Neural Networks For The Early Detection Of Abnormal Birth Outcomes|Paper|Gynaecologists And Obstetricians|Topic|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Deisy Morselli Gysi|Author|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Ítalo Do Valle|Author|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Marinka Zitnik|Author|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Asher Ameli|Author|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Xiao Gan|Author|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Onur Varol|Author|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Susan Dina Ghiassian|Author|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Jj Patten|Author|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Robert Davey|Author|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Joseph Loscalzo|Author|AUTHORED
1978|Network Medicine Framework For Identifying Drug Repurposing Opportunities For Covid-19|Paper|Albert-László Barabási|Author|AUTHORED
1979|Optimism Corrections|Topic|Prediction Accuracy Measures|Topic|RELATED_TO
1979|Bootstrap-Based Correction Methods|Topic|Prediction Accuracy Measures|Topic|RELATED_TO
1979|Delong'S Confidence Interval|Topic|C-Statistic|Topic|RELATED_TO
1979|Location-Shifted Bootstrap Confidence Intervals|Topic|Bootstrap-Based Correction Methods|Topic|RELATED_TO
1979|Two-Stage Bootstrap Confidence Intervals|Topic|Bootstrap-Based Correction Methods|Topic|RELATED_TO
1979|Harrell'S Bias Correction|Topic|Bootstrap-Based Correction Methods|Topic|RELATED_TO
1979|0.632 Method|Topic|Bootstrap-Based Correction Methods|Topic|RELATED_TO
1979|0.632+ Method|Topic|Bootstrap-Based Correction Methods|Topic|RELATED_TO
1979|Ridge Regression|Topic|Multivariable Prediction Models|Topic|RELATED_TO
1979|Lasso Regression|Topic|Multivariable Prediction Models|Topic|RELATED_TO
1979|R Package Predboot|Topic|Bootstrap-Based Correction Methods|Topic|RELATED_TO
1979|Gusto-I Clinical Trial|Topic|Prediction Accuracy Measures|Topic|RELATED_TO
1979|Hisashi Noma|Author|R Package Predboot|Topic|AUTHORED
1979|Tomohiro Shinozaki|Author|R Package Predboot|Topic|AUTHORED
1979|Katsuhiro Iba|Author|R Package Predboot|Topic|AUTHORED
1979|Satoshi Teramukai|Author|R Package Predboot|Topic|AUTHORED
1979|Toshi A. Furukawa|Author|R Package Predboot|Topic|AUTHORED
1980|Cox Proportional Hazards (Coxph) Models|Topic|Hazard Ratio (Hr)|Topic|RELATED_TO
1980|Tree-Based Machine Learning (Ml) Models|Topic|Hazard Ratio (Hr)|Topic|RELATED_TO
1980|Shapley Additive Explanation (Shap) Values|Topic|Hazard Ratio (Hr)|Topic|RELATED_TO
1980|Xgboost|Topic|Hazard Ratio (Hr)|Topic|RELATED_TO
1980|Survival Data|Topic|Xgboost|Topic|RELATED_TO
1980|Sameer Sundrani|Author|Cox Proportional Hazards (Coxph) Models|Topic|AUTHORED
1980|James Lu|Author|Cox Proportional Hazards (Coxph) Models|Topic|AUTHORED
1980|Colon Cancer Data Set|Topic|Xgboost|Topic|RELATED_TO
1980|Breast Cancer Data Set|Topic|Xgboost|Topic|RELATED_TO
1980|Pan-Cancer Dataset|Topic|Xgboost|Topic|RELATED_TO
1980|Kaplan-Meier Plots|Topic|Xgboost|Topic|RELATED_TO
1980|Open-Source Libraries In Python And R|Topic|Survival Data|Topic|RELATED_TO
1981|Coronary Computed Tomography Angiography (Ccta)|Topic|Emergency Department (Ed)|Topic|RELATED_TO
1981|Artificial Intelligence (Ai) Algorithm|Topic|Coronary Computed Tomography Angiography (Ccta)|Topic|RELATED_TO
1981|Phase 1|Topic|Artificial Intelligence (Ai) Algorithm|Topic|RELATED_TO
1981|Phase 2|Topic|Artificial Intelligence (Ai) Algorithm|Topic|RELATED_TO
1981|Area Under The Receiver-Operating-Characteristic Curve (Auc-Roc)|Topic|Artificial Intelligence (Ai) Algorithm|Topic|RELATED_TO
1981|Richard D. White|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Barbaros S. Erdal|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Mutlu Demirer|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Vikash Gupta|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Matthew T. Bigelow|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Engin Dikici|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Sema Candemir|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Mauricio S. Galizia|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Jessica L. Carpenter|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Thomas P. O Donnell|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Abdul H. Halabi|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1981|Luciano M. Prevedello|Author|Artificial Intelligence (Ai) Algorithm|Topic|AUTHORED
1982|A Randomized Trial|Topic|Intercurrent Events|Topic|RELATED_TO
1982|Intercurrent Events|Topic|Principal Stratum Strategy|Topic|RELATED_TO
1982|Principal Stratum Strategy|Topic|Björn Bornkamp|Author|AUTHORED
1982|Principal Stratum Strategy|Topic|Kaspar Rufibach|Author|AUTHORED
1982|Principal Stratum Strategy|Topic|Jianchang Lin|Author|AUTHORED
1982|Principal Stratum Strategy|Topic|Yi Liu|Author|AUTHORED
1982|Principal Stratum Strategy|Topic|Devan V. Mehrotra|Author|AUTHORED
1982|Principal Stratum Strategy|Topic|Satrajit Roychoudhury|Author|AUTHORED
1982|Principal Stratum Strategy|Topic|Heinz Schmidli|Author|AUTHORED
1982|Principal Stratum Strategy|Topic|Yue Shentu|Author|AUTHORED
1982|Principal Stratum Strategy|Topic|Marcel Wolbers|Author|AUTHORED
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Rui Zhang|Author|AUTHORED
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Dimitar Hristovski|Author|AUTHORED
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Dalton Schutte|Author|AUTHORED
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Andrej Kastrin|Author|AUTHORED
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Marcelo Fiszman|Author|AUTHORED
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Halil Kilicoglu|Author|AUTHORED
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Pubmed|Topic|RELATED_TO
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Covid-19|Topic|RELATED_TO
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Bert|Topic|RELATED_TO
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Transe|Topic|RELATED_TO
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Paclitaxel|Topic|RELATED_TO
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Sb 203580|Topic|RELATED_TO
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Alpha 2-Antiplasmin|Topic|RELATED_TO
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Pyrrolidine Dithiocarbamate|Topic|RELATED_TO
1983|Drug Repurposing For Covid-19 Via Knowledge Graph Completion|Paper|Butylated Hydroxytoluene|Topic|RELATED_TO
1984|Machine Learning For Real-World Evidence Analysis Of Covid-19 Pharmacotherapy|Paper|Covid-19|Topic|DISCUSSES
1984|Machine Learning For Real-World Evidence Analysis Of Covid-19 Pharmacotherapy|Paper|Real-World Evidence|Topic|DISCUSSES
1984|Machine Learning For Real-World Evidence Analysis Of Covid-19 Pharmacotherapy|Paper|Machine Learning|Topic|DISCUSSES
1984|Machine Learning For Real-World Evidence Analysis Of Covid-19 Pharmacotherapy|Paper|Valencian Region|Topic|DISCUSSES
1984|Machine Learning For Real-World Evidence Analysis Of Covid-19 Pharmacotherapy|Paper|Remdesivir|Topic|DISCUSSES
1984|Machine Learning For Real-World Evidence Analysis Of Covid-19 Pharmacotherapy|Paper|Tocilizumab|Topic|DISCUSSES
1984|Machine Learning For Real-World Evidence Analysis Of Covid-19 Pharmacotherapy|Paper|Corticosteroids|Topic|DISCUSSES
1984|Machine Learning For Real-World Evidence Analysis Of Covid-19 Pharmacotherapy|Paper|Lopinavir-Ritonavir|Topic|DISCUSSES
1984|Machine Learning For Real-World Evidence Analysis Of Covid-19 Pharmacotherapy|Paper|Azithromycin|Topic|DISCUSSES
1984|Machine Learning For Real-World Evidence Analysis Of Covid-19 Pharmacotherapy|Paper|Chloroquine/Hydroxychloroquine|Topic|DISCUSSES
1985|Fast Image Search For Histopathology (Fish)|Topic|Chengkuan Chen|Author|AUTHORED
1985|Fast Image Search For Histopathology (Fish)|Topic|Ming Y. Lu|Author|AUTHORED
1985|Fast Image Search For Histopathology (Fish)|Topic|Drew F. K. Williamson|Author|AUTHORED
1985|Fast Image Search For Histopathology (Fish)|Topic|Tiffany Y. Chen|Author|AUTHORED
1985|Fast Image Search For Histopathology (Fish)|Topic|Andrew J. Schaumberg|Author|AUTHORED
1985|Fast Image Search For Histopathology (Fish)|Topic|Faisal Mahmood|Author|AUTHORED
1986|Systemic Lupus Erythematosus|Topic|Lupus Nephritis|Topic|RELATED_TO
1986|Lupus Nephritis|Topic|Electronic Health Records|Topic|RELATED_TO
1986|Lupus Nephritis|Topic|Vanderbilt University Medical Center|Topic|RELATED_TO
1986|Yu Deng|Author|Lupus Nephritis|Topic|AUTHORED
1986|Jennifer A. Pacheco|Author|Lupus Nephritis|Topic|AUTHORED
1986|Anh Chung|Author|Lupus Nephritis|Topic|AUTHORED
1986|Chengsheng Mao|Author|Lupus Nephritis|Topic|AUTHORED
1986|Joshua C. Smith|Author|Lupus Nephritis|Topic|AUTHORED
1986|Juan Zhao|Author|Lupus Nephritis|Topic|AUTHORED
1986|Wei-Qi Wei|Author|Lupus Nephritis|Topic|AUTHORED
1986|April Barnado|Author|Lupus Nephritis|Topic|AUTHORED
1986|Chunhua Weng|Author|Lupus Nephritis|Topic|AUTHORED
1986|Cong Liu|Author|Lupus Nephritis|Topic|AUTHORED
1986|Adam Cordon|Author|Lupus Nephritis|Topic|AUTHORED
1986|Jingzhi Yu|Author|Lupus Nephritis|Topic|AUTHORED
1986|Yacob Tedla|Author|Lupus Nephritis|Topic|AUTHORED
1986|Abel Kho|Author|Lupus Nephritis|Topic|AUTHORED
1986|Rosalind Ramsey-Goldman|Author|Lupus Nephritis|Topic|AUTHORED
1986|Theresa Walunas|Author|Lupus Nephritis|Topic|AUTHORED
1986|Yuan Luo|Author|Lupus Nephritis|Topic|AUTHORED
1987|Reproduction Of Pre-Clinical Results|Topic|Medical Sciences|Topic|RELATED_TO
1987|Reproduction Of Pre-Clinical Results|Topic|Plant Sciences|Topic|RELATED_TO
1987|Reproduction Of Pre-Clinical Results|Topic|Protocols|Topic|RELATED_TO
1987|Jeremy S. C. Clark|Author|Reproduction Of Pre-Clinical Results|Topic|AUTHORED
1987|Anna Salacka|Author|Reproduction Of Pre-Clinical Results|Topic|AUTHORED
1987|Agnieszka Boron|Author|Reproduction Of Pre-Clinical Results|Topic|AUTHORED
1987|Thierry Van De Wetering|Author|Reproduction Of Pre-Clinical Results|Topic|AUTHORED
1987|Konrad Podsiadlo|Author|Reproduction Of Pre-Clinical Results|Topic|AUTHORED
1987|Kamila Rydzewska|Author|Reproduction Of Pre-Clinical Results|Topic|AUTHORED
1987|Krzysztof Safranow|Author|Reproduction Of Pre-Clinical Results|Topic|AUTHORED
1987|Kazimierz Ciechanowski|Author|Reproduction Of Pre-Clinical Results|Topic|AUTHORED
1987|Leszek Domanski|Author|Reproduction Of Pre-Clinical Results|Topic|AUTHORED
1987|Andrzej Ciechanowicz|Author|Reproduction Of Pre-Clinical Results|Topic|AUTHORED
1987|2017|Topic|Triple-Result Protocols|Topic|RELATED_TO
1987|2019|Topic|Triple-Result Protocols|Topic|RELATED_TO
1987|2017|Topic|Replication-Error Protocol|Topic|RELATED_TO
1987|2019|Topic|Replication-Error Protocol|Topic|RELATED_TO
1987|2017|Topic|Meta-Analyses|Topic|RELATED_TO
1987|2019|Topic|Meta-Analyses|Topic|RELATED_TO
1987|2017|Topic|Non-Replicated|Topic|RELATED_TO
1987|2019|Topic|Non-Replicated|Topic|RELATED_TO
1987|2017|Topic|Global|Topic|RELATED_TO
1987|2019|Topic|Global|Topic|RELATED_TO
1988|Observational Studies|Topic|Causal Inference Methods|Topic|RELATED_TO
1988|Clinical Trial|Topic|Observational Studies|Topic|RELATED_TO
1988|Instrumental Variable Method|Topic|Causal Inference Methods|Topic|RELATED_TO
1988|Heterogeneity Statistic|Topic|Causal Inference Methods|Topic|RELATED_TO
1988|Sodium-Glucose Co-Transporter-2 Inhibitors|Topic|Type 2 Diabetes|Topic|RELATED_TO
1988|Dipeptidyl Peptidase-4 Inhibitors|Topic|Type 2 Diabetes|Topic|RELATED_TO
1988|Laura Güdemann|Author|Triangulating Instrumental Variable, Confounder Adjustment And Difference-In-Difference Methods For Comparative Effectiveness Research In Observational Data|Paper|AUTHORED
1988|John M. Dennis|Author|Triangulating Instrumental Variable, Confounder Adjustment And Difference-In-Difference Methods For Comparative Effectiveness Research In Observational Data|Paper|AUTHORED
1988|Andrew P. Mcgovern|Author|Triangulating Instrumental Variable, Confounder Adjustment And Difference-In-Difference Methods For Comparative Effectiveness Research In Observational Data|Paper|AUTHORED
1988|Lauren R. Rodgers|Author|Triangulating Instrumental Variable, Confounder Adjustment And Difference-In-Difference Methods For Comparative Effectiveness Research In Observational Data|Paper|AUTHORED
1988|Beverley M. Shields|Author|Triangulating Instrumental Variable, Confounder Adjustment And Difference-In-Difference Methods For Comparative Effectiveness Research In Observational Data|Paper|AUTHORED
1988|William Henley|Author|Triangulating Instrumental Variable, Confounder Adjustment And Difference-In-Difference Methods For Comparative Effectiveness Research In Observational Data|Paper|AUTHORED
1988|Jack Bowden|Author|Triangulating Instrumental Variable, Confounder Adjustment And Difference-In-Difference Methods For Comparative Effectiveness Research In Observational Data|Paper|AUTHORED
1989|Lung Cancer|Topic|Lung Cancer Screening|Topic|RELATED_TO
1989|Lung Cancer Screening|Topic|Low-Dose Computed Tomography|Topic|RELATED_TO
1989|Low-Dose Computed Tomography|Topic|Machine/Deep Learning Algorithms|Topic|RELATED_TO
1989|Machine/Deep Learning Algorithms|Topic|Deepcad-Nlm-L|Paper|RELATED_TO
1990|A Scalable Workflow To Build Machine Learning Classifiers With Clinician-In-The-Loop To Identify Patients In Specific Diseases|Paper|International Classification Of Diseases (Icd)|Topic|DISCUSSES
1990|A Scalable Workflow To Build Machine Learning Classifiers With Clinician-In-The-Loop To Identify Patients In Specific Diseases|Paper|Electronic Health Records (Ehrs)|Topic|DISCUSSES
1990|A Scalable Workflow To Build Machine Learning Classifiers With Clinician-In-The-Loop To Identify Patients In Specific Diseases|Paper|Mimic-Iii Dataset|Topic|DISCUSSES
1990|A Scalable Workflow To Build Machine Learning Classifiers With Clinician-In-The-Loop To Identify Patients In Specific Diseases|Paper|Nlp|Topic|DISCUSSES
1990|A Scalable Workflow To Build Machine Learning Classifiers With Clinician-In-The-Loop To Identify Patients In Specific Diseases|Paper|Automl|Topic|DISCUSSES
1990|A Scalable Workflow To Build Machine Learning Classifiers With Clinician-In-The-Loop To Identify Patients In Specific Diseases|Paper|Clinician-In-The-Loop Mechanism|Topic|DISCUSSES
1990|A Scalable Workflow To Build Machine Learning Classifiers With Clinician-In-The-Loop To Identify Patients In Specific Diseases|Paper|Ovarian Cancer|Topic|RELATED_TO
1990|A Scalable Workflow To Build Machine Learning Classifiers With Clinician-In-The-Loop To Identify Patients In Specific Diseases|Paper|Lung Cancer|Topic|RELATED_TO
1990|A Scalable Workflow To Build Machine Learning Classifiers With Clinician-In-The-Loop To Identify Patients In Specific Diseases|Paper|Cancer Cachexia|Topic|RELATED_TO
1990|A Scalable Workflow To Build Machine Learning Classifiers With Clinician-In-The-Loop To Identify Patients In Specific Diseases|Paper|Lupus Nephritis|Topic|RELATED_TO
1991|Nlstt|Topic|Lung Nodules|Topic|RELATED_TO
1991|Siamese Encoder|Topic|Lung Nodules|Topic|RELATED_TO
1991|Spatial-Temporal Mixer|Topic|Lung Nodules|Topic|RELATED_TO
1991|Jiansheng Fang|Author|Siamese Encoder|Topic|AUTHORED
1991|Jingwen Wang|Author|Siamese Encoder|Topic|AUTHORED
1991|Anwei Li|Author|Siamese Encoder|Topic|AUTHORED
1991|Yuguang Yan|Author|Siamese Encoder|Topic|AUTHORED
1991|Yonghe Hou|Author|Siamese Encoder|Topic|AUTHORED
1991|Chao Song|Author|Siamese Encoder|Topic|AUTHORED
1991|Hongbo Liu|Author|Siamese Encoder|Topic|AUTHORED
1991|Jiang Liu|Author|Siamese Encoder|Topic|AUTHORED
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Mohsen Sadatsafavi|Author|AUTHORED
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Tae Yoon Lee|Author|AUTHORED
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Laure Wynants|Author|AUTHORED
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Andrew Vickers|Author|AUTHORED
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Paul Gustafson|Author|AUTHORED
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Expected Value Of Perfect Information (Evpi)|Topic|RELATED_TO
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Net Benefit (Nb)|Topic|RELATED_TO
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Myocardial Infarction|Topic|RELATED_TO
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Simulation Studies|Topic|RELATED_TO
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Clinical Trial|Topic|RELATED_TO
1992|Value Of Information Analysis For External Validation Of Risk Prediction Models|Paper|Heart Attacks In The Us|Topic|RELATED_TO
1993|Freezing Of Gait (Fog)|Topic|Parkinson'S Disease|Topic|RELATED_TO
1993|Adversarial Spatio-Temporal Network (Astn)|Topic|Freezing Of Gait (Fog)|Topic|DISCUSSES
1993|Kun Hu|Author|Multi-Level Adversarial Spatio-Temporal Learning For Footstep Pressure Based Fog Detection|Paper|AUTHORED
1993|Shaohui Mei|Author|Multi-Level Adversarial Spatio-Temporal Learning For Footstep Pressure Based Fog Detection|Paper|AUTHORED
1993|Wei Wang|Author|Multi-Level Adversarial Spatio-Temporal Learning For Footstep Pressure Based Fog Detection|Paper|AUTHORED
1993|Kaylena A. Ehgoetz Martens|Author|Multi-Level Adversarial Spatio-Temporal Learning For Footstep Pressure Based Fog Detection|Paper|AUTHORED
1993|Liang Wang|Author|Multi-Level Adversarial Spatio-Temporal Learning For Footstep Pressure Based Fog Detection|Paper|AUTHORED
1993|Simon J. G. Lewis|Author|Multi-Level Adversarial Spatio-Temporal Learning For Footstep Pressure Based Fog Detection|Paper|AUTHORED
1993|David D. Feng|Author|Multi-Level Adversarial Spatio-Temporal Learning For Footstep Pressure Based Fog Detection|Paper|AUTHORED
1993|Zhiyong Wang|Author|Multi-Level Adversarial Spatio-Temporal Learning For Footstep Pressure Based Fog Detection|Paper|AUTHORED
1994|Proton Vertebral Body Sparing Craniospinal Irradiation (Vbs Csi)|Topic|Radiation Damage Quantification Method|Topic|RELATED_TO
1994|Pediatric Patients|Topic|Proton Vertebral Body Sparing Craniospinal Irradiation (Vbs Csi)|Topic|RELATED_TO
1994|Monte Carlo Robust Planning|Topic|Proton Vertebral Body Sparing Craniospinal Irradiation (Vbs Csi)|Topic|RELATED_TO
1994|Magnetic Resonance (Mr) Scans|Topic|Radiation Damage Quantification Method|Topic|RELATED_TO
1994|Fatty Marrow Filtration|Topic|Magnetic Resonance (Mr) Scans|Topic|RELATED_TO
1994|Radiation-Induced Marrow Damage|Topic|Fatty Marrow Filtration|Topic|RELATED_TO
1994|Early Vertebral Marrow Damage Identification|Topic|Radiation-Induced Marrow Damage|Topic|RELATED_TO
1994|Chih-Wei Chang|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1994|Matt Goette|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1994|Nadja Kadom|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1994|Yinan Wang|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1994|Jacob Wynne|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1994|Tonghe Wang|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1994|Tian Liu|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1994|Natia Esiashvili|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1994|Jun Zhou|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1994|Bree R. Eaton|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1994|Xiaofeng Yang|Author|Early Vertebral Marrow Damage Identification|Topic|AUTHORED
1995|Foresight|Paper|Electronic Health Records|Topic|RELATED_TO
1995|Foresight|Paper|King'S College Hospital|Topic|RELATED_TO
1995|Foresight|Paper|South London And Maudsley|Topic|RELATED_TO
1995|Foresight|Paper|Mimic-Iii|Topic|RELATED_TO
1995|Foresight|Paper|Zeljko Kraljevic|Author|AUTHORED
1995|Foresight|Paper|Dan Bean|Author|AUTHORED
1995|Foresight|Paper|Anthony Shek|Author|AUTHORED
1995|Foresight|Paper|Rebecca Bendayan|Author|AUTHORED
1995|Foresight|Paper|Harry Hemingway|Author|AUTHORED
1995|Foresight|Paper|Joshua Au Yeung|Author|AUTHORED
1995|Foresight|Paper|Alexander Deng|Author|AUTHORED
1995|Foresight|Paper|Alfie Baston|Author|AUTHORED
1995|Foresight|Paper|Jack Ross|Author|AUTHORED
1995|Foresight|Paper|Esther Idowu|Author|AUTHORED
1995|Foresight|Paper|James T Teo|Author|AUTHORED
1995|Foresight|Paper|Richard J Dobson|Author|AUTHORED
1996|Proton Flash Therapy|Topic|Chang Gung Memorial Hospital|Topic|RELATED_TO
1996|Chang Gung Memorial Hospital|Topic|Tung-Yuan Hsiao|Author|AUTHORED
1996|Chang Gung Memorial Hospital|Topic|Lu-Kai Wang|Author|AUTHORED
1996|Chang Gung Memorial Hospital|Topic|Tzung-Yuang Chen|Author|AUTHORED
1996|Chang Gung Memorial Hospital|Topic|Ching-Fang Yu|Author|AUTHORED
1996|Chang Gung Memorial Hospital|Topic|Pan|Author|AUTHORED
1996|Chang Gung Memorial Hospital|Topic|Cheng-Ya|Author|AUTHORED
1996|Chang Gung Memorial Hospital|Topic|Chun-Chieh Wang|Author|AUTHORED
1996|Chang Gung Memorial Hospital|Topic|Chien-Yu Lin|Author|AUTHORED
1996|Chang Gung Memorial Hospital|Topic|I-Chun Cho|Author|AUTHORED
1996|Chang Gung Memorial Hospital|Topic|Huan Niu|Author|AUTHORED
1996|Chang Gung Memorial Hospital|Topic|Chien-Hsu Chen|Author|AUTHORED
1997|Lung Cancer|Topic|National Lung Screening Trial|Topic|RELATED_TO
1997|National Lung Screening Trial|Topic|Penalized Deep Partially Linear Cox Model|Topic|RELATED_TO
1997|Penalized Deep Partially Linear Cox Model|Topic|Yuming Sun|Author|AUTHORED
1997|Penalized Deep Partially Linear Cox Model|Topic|Jian Kang|Author|AUTHORED
1997|Penalized Deep Partially Linear Cox Model|Topic|Chinmay Haridas|Author|AUTHORED
1997|Penalized Deep Partially Linear Cox Model|Topic|Nicholas R. Mayne|Author|AUTHORED
1997|Penalized Deep Partially Linear Cox Model|Topic|Alexandra L. Potter|Author|AUTHORED
1997|Penalized Deep Partially Linear Cox Model|Topic|Chi-Fu Jeffrey Yang|Author|AUTHORED
1997|Penalized Deep Partially Linear Cox Model|Topic|David C. Christiani|Author|AUTHORED
1997|Penalized Deep Partially Linear Cox Model|Topic|Yi Li|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Lauren E Dang|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Susan Gruber|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Hana Lee|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Issa Dahabreh|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Elizabeth A Stuart|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Brian D Williamson|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Richard Wyss|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Iván Díaz|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Debashis Ghosh|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Demissie Alemayehu|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Katherine L Hoffman|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Carla Y Vossen|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Raymond A Huml|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Henrik Ravn|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Kajsa Kvist|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Richard Pratley|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Mei-Chiung Shih|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Gene Pennello|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|David Martin|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Salina P Waddy|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Charles E Barr|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Mouna Akacha|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|John B Buse|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Mark Van Der Laan|Author|AUTHORED
1998|Causal Roadmap For Generating High-Quality Real-World Evidence|Paper|Maya Petersen|Author|AUTHORED
1999|Flash Radiotherapy|Topic|Flash Beam Scintillator Monitor|Topic|RELATED_TO
1999|Flash Beam Scintillator Monitor|Topic|Daniel S. Levin|Author|AUTHORED
1999|Flash Beam Scintillator Monitor|Topic|Peter S. Friedman|Author|AUTHORED
1999|Flash Beam Scintillator Monitor|Topic|Claudio Ferretti|Author|AUTHORED
1999|Flash Beam Scintillator Monitor|Topic|Nicholas Ristow|Author|AUTHORED
1999|Flash Beam Scintillator Monitor|Topic|Monica Tecchio|Author|AUTHORED
1999|Flash Beam Scintillator Monitor|Topic|Dale W. Litzenberg|Author|AUTHORED
1999|Flash Beam Scintillator Monitor|Topic|Vladimir Bashkirov|Author|AUTHORED
1999|Flash Beam Scintillator Monitor|Topic|Reinhard Schulte|Author|AUTHORED
